Drug;Gene;Allele;Genotype;Outcome;Variation;Effect
NIFEDIPINE;CYP3A4;*17;CYP3A4*1, CYP3A4*17;OTHER;DECREASED_METABOLISM;nan
NIFEDIPINE;CYP3A4;*17;CYP3A4*1, CYP3A4*17;LADME_PK;DECREASED_METABOLISM;nan
SITAGLIPTIN;DPP4;TT;rs2909451;EFFICACY;DECREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
SITAGLIPTIN;KCNJ11;GG;rs2285676;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
WARFARIN;CYP2C9;*11/*11;CYP2C9*11;DOSAGE;DECREASED_DOSE;nan
SITAGLIPTIN;KCNQ1;GG;rs163184;EFFICACY;DECREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
EFAVIRENZ;CYP2B6;*1/*18;CYP2B6*1, CYP2B6*18;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
SITAGLIPTIN;DPP4;GG;rs4664443;EFFICACY;DECREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
CODEINE;CYP2D6;*1xN;CYP2D6*1xN;LADME_PK;INCREASED_METABOLISM;nan
SITAGLIPTIN;CYP2C9;TT;rs1799853;EFFICACY;DECREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
SITAGLIPTIN;GLP1R;AG;rs3765467;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
FLUOXETINE;CYP2C19;INTERMEDIATE_METABOLIZER;CYP2C19;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
PAROXETINE;CYP2C19;ULTRARAPID_METABOLIZER;CYP2C19;EFFICACY;DECREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
SITAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
CODEINE;CYP2D6;*2/*2xN;CYP2D6*2, CYP2D6*2xN;LADME_PK;INCREASED_METABOLISM;nan
EXENATIDE;GLP1R;GG;rs3765467;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
LIRAGLUTIDE;GLP1R;GG;rs3765467;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
IVACAFTOR;CFTR;del;rs113993960;EFFICACY;RESPONSE;nan
LUMACAFTOR;CFTR;del;rs113993960;EFFICACY;RESPONSE;nan
CITALOPRAM;CYP2C19;POOR_METABOLIZER;CYP2C19;EFFICACY;DECREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
FLUOXETINE;CYP2C19;POOR_METABOLIZER;CYP2C19;EFFICACY;DECREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
PAROXETINE;CYP2C19;POOR_METABOLIZER;CYP2C19;EFFICACY;DECREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
SERTRALINE;CYP2C19;POOR_METABOLIZER;CYP2C19;EFFICACY;DECREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
ALBIGLUTIDE;GLP1R;A;rs6923761;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
DULAGLUTIDE;GLP1R;A;rs6923761;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
GLP-1 RECEPTOR AGONISTS;GLP1R;A;rs6923761;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
EXENATIDE;TCF7L2;CT + TT;rs7903146;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
RIFAPENTINE;NAT2;slow_acetylator;NAT2;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;POOR_METABOLIZER;CYP2B6;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1;LADME_PK;DECREASED_EXPOSURE;OTHER:HISTORY_OF_GASTRIC_BYPASS_SURGERY
ALBIGLUTIDE;ARRB1;A;rs140226575;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
DULAGLUTIDE;ARRB1;A;rs140226575;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
GLP-1 RECEPTOR AGONISTS;ARRB1;A;rs140226575;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
EFAVIRENZ;NAT2;slow_acetylator;NAT2;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
PROPAFENONE;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:CARDIAC_RHYTHM_DISEASE
PROPAFENONE;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;EFFICACY;INCREASED_RESPONSE;DISEASE:CARDIAC_RHYTHM_DISEASE
DEXTROMETHORPHAN;CYP2D6;*4/*6;CYP2D6*4, CYP2D6*6;LADME_PK;DECREASED_METABOLISM;nan
NEVIRAPINE;NAT2;slow_acetylator;NAT2;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
ALBIGLUTIDE;ARRB1;A;rs78979036;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
DULAGLUTIDE;ARRB1;A;rs78979036;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
GLP-1 RECEPTOR AGONISTS;ARRB1;A;rs78979036;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*1, CYP2D6*2, CYP2D6*2xN;EFFICACY;INCREASED_RESPONSE;OTHER:OPIOID-RELATED_DISORDERS
LURBINECTEDIN;CYP3A4;*1/*1;CYP3A4*1, CYP3A4*22;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:NEOPLASMS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
ALBIGLUTIDE;ARRB1;T;rs78052828;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
DULAGLUTIDE;ARRB1;T;rs78052828;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
GLP-1 RECEPTOR AGONISTS;ARRB1;T;rs78052828;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
METHYLMERCAPTOPURINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:INFLAMMATORY_BOWEL_DISEASES
PHENYTOIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ALBIGLUTIDE;ARRB1;C;rs58428187;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
DULAGLUTIDE;ARRB1;C;rs58428187;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
GLP-1 RECEPTOR AGONISTS;ARRB1;C;rs58428187;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
TAMOXIFEN;CYP2D6;*10/*36;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*36;DOSAGE;INCREASED_DOSE;OTHER:BREAST_NEOPLASMS
RALOXIFENE 6-GLUCURONIDE;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OSTEOPOROSIS
RALOXIFENE-4â€²-GLUCURONIDE;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OSTEOPOROSIS
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
TRAMADOL;CYP2D6;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*17;LADME_PK;DECREASED_CLEARANCE;nan
CLOZAPINE;CYP1A2;*35;CYP1A2*35;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
N-DESMETHYLCLOZAPINE;CYP1A2;*35;CYP1A2*35;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
VENLAFAXINE;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;INCREASED_EXPOSURE;OTHER:LACTATION
LURBINECTEDIN;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CLEARANCE;OTHER:NEOPLASMS
LURBINECTEDIN;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:NEOPLASMS
LEFLUNOMIDE;PON1;GG;rs705379;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;DOSAGE;DECREASED_DOSE;DISEASE:COLORECTAL_NEOPLASMS
LETROZOLE;CYP2A6;T;rs56113850;nan;INCREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
TRAMADOL;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;INCREASED_EXPOSURE;nan
(S)-METHADONE;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7;LADME_PK;INCREASED_CONCENTRATIONS;nan
ANTIEPILEPTICS;SCN1A;C;rs2298771;EFFICACY;INCREASED_RESISTANCE;OTHER:EPILEPSY
ANTIEPILEPTICS;SCN1A;T;rs10167228;EFFICACY;INCREASED_RESISTANCE;OTHER:EPILEPSY
O-DESMETHYLTRAMADOL;CYP2D6;*3/*4 + *4/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10;LADME_PK;DECREASED_CONCENTRATIONS;nan
WARFARIN;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;nan
CODEINE;CYP2D6;*2/*2xN;CYP2D6*2, CYP2D6*2xN;LADME_PK;INCREASED_METABOLISM;nan
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*1/*5;CYP2C9*1, CYP2C9*5;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*1/*11;CYP2C9*1, CYP2C9*11;DOSAGE;DECREASED_DOSE;nan
METHADONE;nan;nan;low activity;LADME_PK;INCREASED_TROUGH CONCENTRATION;nan
SN-38;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;LADME_PK;DECREASED_METABOLISM;OTHER:NEOPLASMS
BILIRUBIN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;OTHER;INCREASED;DISEASE:NEOPLASMS
SN-38;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;LADME_PK;DECREASED_METABOLISM;OTHER:NEOPLASMS
CARVEDILOL;UGT1A1;*28;UGT1A1*1, UGT1A1*28;LADME_PK;INCREASED_METABOLISM;OTHER:ANGINA_PECTORIS
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;RESPONSE;nan
ACENOCOUMAROL;VKORC1;A;rs9934438;DOSAGE;DOSE;OTHER:A_STABLE_MAINTENANCE_DOSE
WARFARIN;CYP2C9;*3/*3 + *1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
LIRAGLUTIDE;CNR1;CT + TT;rs1049353;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2 | OTHER:OBESITY
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;DECREASED_CONCENTRATIONS;nan
FLUVOXAMINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;C;rs104894542;DOSAGE;INCREASED_DOSE;nan
CLONIDINE;ADRA2C;GGGGAGCTTTCCCAGAGACCC/del + del/del;rs11269124;EFFICACY;INCREASED_RESPONSE;DISEASE:LIVER_CIRRHOSIS
SIMVASTATIN ACID;SLCO1B1;CC + CT;rs4149056;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:CARDIOVASCULAR_DISEASE | OTHER:DYSLIPIDAEMIA
SIMVASTATIN ACID;SLCO1B1;AG + GG;rs2306283;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:CARDIOVASCULAR_DISEASE | OTHER:DYSLIPIDAEMIA
DEXTROMETHORPHAN;CYP2D6;*4/*2xN;CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5;LADME_PK;INCREASED_METABOLISM;OTHER:HYPERCHOLESTEROLEMIA
ASPIRIN;P2RY1;T;rs1371097;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:STROKE
ASPIRIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:STROKE
SN-38;UGT1A1;*28;UGT1A1*1, UGT1A1*28;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:COLONIC_NEOPLASMS
DEXTROMETHORPHAN;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;DECREASED_METABOLISM;nan
SIROLIMUS;CYP3A4;*8/*20;CYP3A4*8, CYP3A4*20;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SEIZURES | OTHER:INTESTINAL_DISEASES | OTHER:CONGENITAL_ABNORMALITIES
DEXTROMETHORPHAN;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;DECREASED_METABOLISM;nan
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;OTHER:CHRONIC_HEPATITIS_C
SOFOSBUVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;OTHER:CHRONIC_HEPATITIS_C
RIFAMPIN;SLCO1B1;TT;rs4149032;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:TUBERCULOSIS
MODAFINIL;COMT;GG;rs4680;EFFICACY;INCREASED_RESPONSE;OTHER:METHAMPHETAMINE_DEPENDENCE
ISONIAZID;nan;AA;rs1495741;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:TUBERCULOSIS
VALSARTAN;AGT;GG;rs699;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:HYPERTENSION
NALTREXONE;OPRM1;G;rs1799971;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ALCOHOL_ABUSE
IVACAFTOR;CFTR;del;rs113993960;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
IVACAFTOR;CFTR;del;rs113993960;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
IVACAFTOR;CFTR;del;rs113993960;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
IVACAFTOR;CFTR;del;rs113993960;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
ELEXACAFTOR;CFTR;nan;CFTR deficiency;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:CYSTIC_FIBROSIS
REMIFENTANIL;ADRA2A;CG + GG;rs1800544;DOSAGE;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
WARFARIN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;DOSAGE;INCREASED_DOSE;OTHER:THROMBOEMBOLISM
REMIFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
ELIGLUSTAT;CYP2D6;ULTRARAPID_METABOLIZER;CYP2D6;DOSAGE;INCREASED_DOSE;OTHER:GAUCHER_DISEASE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CLEARANCE;OTHER:LIVER_TRANSPLANTATION
POSACONAZOLE;ABCB1;GG;rs1045642;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;ABCB1;GG;rs1045642;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*6;CYP3A5*1, CYP3A5*6;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:EPILEPSY
TACROLIMUS;CYP3A5;*3;CYP3A5*3;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*7;CYP3A5*1, CYP3A5*7;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE;DISEASE:ORGAN_TRANSPLANTATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:ULCERATIVE_COLITIS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;CONCENTRATIONS;nan
COUMARIN;CYP2A6;*4/*4 + *4/*10;CYP2A6*1, CYP2A6*4, CYP2A6*10;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;*1/*2 + *2/*2;CYP2A6*1, CYP2A6*2;DOSAGE;DECREASED_DOSE;DISEASE:TOBACCO_USE_DISORDER
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
BELINOSTAT;UGT1A1;*28/*28 + *1/*60 + *60/*60;UGT1A1*1, UGT1A1*28, UGT1A1*60;DOSAGE;DECREASED_DOSE;OTHER:NEOPLASMS
MOXIFLOXACIN;UGT1A1;*1/*36;UGT1A1*1, UGT1A1*28, UGT1A1*36, UGT1A1*37;LADME_PK;DECREASED_CLEARANCE;DISEASE:TUBERCULOSIS
DEXTROMETHORPHAN;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;DECREASED_METABOLISM;OTHER:BREAST_NEOPLASMS
NICOTINE;CYP2A6;*46/*46;CYP2A6*1, CYP2A6*46;LADME_PK;INCREASED_CLEARANCE;nan
BUPRENORPHINE;SLC39A10;C;rs149319538;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:OPIOID-RELATED_DISORDERS
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;LADME_PK;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*2/*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;DISEASE:HEART_DISEASES
WARFARIN;CYP2C9;*2/*2;CYP2C9*1, CYP2C9*2;EFFICACY;DECREASED_DOSE;DISEASE:HEART_DISEASES
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;DISEASE:VENOUS_THROMBOEMBOLISM
SIMVASTATIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
SIMVASTATIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
DEXTROMETHORPHAN;CYP2D6;*4;CYP2D6*1, CYP2D6*4;LADME_PK;DECREASED_METABOLISM;nan
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DOSE;nan
WARFARIN;CYP2C9;*2;CYP2C9*2;LADME_PK;DOSE;nan
LETROZOLE;CYP2A6;*1/*1;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
LETROZOLE;CYP2A6;*1/*46 + *1/*46 + *46/*46;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*46;LADME_PK;INCREASED_CLEARANCE;nan
WARFARIN;CYP4F2;*3;CYP4F2*3;DOSAGE;DOSE;nan
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT | OTHER:ATRIAL_FIBRILLATION | OTHER:STROKE | OTHER:PULMONARY_EMBOLISM | OTHER:VENOUS_THROMBOSIS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT | OTHER:ATRIAL_FIBRILLATION | OTHER:STROKE | OTHER:PULMONARY_EMBOLISM | OTHER:VENOUS_THROMBOSIS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
ARIPIPRAZOLE;DRD2;G/del;rs1799732;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOAFFECTIVE_DISORDER
RIVAROXABAN;ABCB1;CC;rs4148738;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
RIVAROXABAN;ABCB1;AA;rs1128503;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
METHOTREXATE;TYMS;GG;rs2853542;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*1, TPMT*2, TPMT*3A;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*33, TPMT*34;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*33, TPMT*34;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE;ATIC;TT;rs4673993;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
FLUOXETINE;HTR1A;GG;rs6295;EFFICACY;INCREASED_RESPONSE;EFFICACY:MAJOR_DEPRESSIVE_DISORDER
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED_DISCONTINUATION;OTHER:SCHIZOPHRENIA | OTHER:SCHIZOAFFECTIVE_DISORDER | OTHER:BIPOLAR_DISORDER | OTHER:DEPRESSIVE_DISORDER
SN-38;UGT1A1;*6/*60 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28, UGT1A1*60;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
TAMOXIFEN;CYP2D6;A;rs16947;EFFICACY;INCREASED_DISCONTINUATION;OTHER:BREAST_NEOPLASMS
TAMOXIFEN;CYP2D6;A;rs16947;TOXICITY;INCREASED_DISCONTINUATION;OTHER:BREAST_NEOPLASMS
DIHYDROPYRIDINE DERIVATIVES;NUMA1;AA + AG;rs10898815;OTHER;INCREASED_DISCONTINUATION;nan
TAMOXIFEN;ABCC2;G;rs3740065;EFFICACY;INCREASED_DISCONTINUATION;OTHER:BREAST_NEOPLASMS
TAMOXIFEN;ABCC2;G;rs3740065;TOXICITY;INCREASED_DISCONTINUATION;OTHER:BREAST_NEOPLASMS
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
WARFARIN;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;nan
HYDRALAZINE;NAT2;rapid_acetylator;NAT2;DOSAGE;INCREASED_DOSE;OTHER:HYPERTENSION
HYDRALAZINE;NAT2;rapid_acetylator;NAT2;EFFICACY;INCREASED_DOSE;OTHER:HYPERTENSION
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:GASTROESOPHAGEAL_REFLUX
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_METABOLISM;DISEASE:HEART_TRANSPLANTATION
LANSOPRAZOLE;CYP2C19;POOR_METABOLIZER;CYP2C19;LADME_PK;DECREASED_CLEARANCE;OTHER:GASTROESOPHAGEAL_REFLUX
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;LADME_PK;DECREASED_METABOLISM;DISEASE:FUNGAL_INFECTIOUS_DISEASE
SULFONAMIDES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
UREA DERIVATIVES;CYP2C19;*2/*2  + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
CORTICOSTEROIDS;NR3C1;GG;rs10482634;EFFICACY;INCREASED_RESISTANCE;OTHER:NEPHROTIC_SYNDROME
WARFARIN;CYP2C9;*11 + *2 + *3 + *5 + *6;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*10, CYP2C9*11;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE;DISEASE:HEART_TRANSPLANTATION
VALPROIC ACID;UGT1A6;TT;rs6759892;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:EPILEPSY
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
METHYLPHENIDATE;SYT1;AA + AG;rs2251214;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ADHD
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*17;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:SEVERE_COMBINED_IMMUNODEFICIENCY
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
HYDRALAZINE;NAT2;slow_acetylator;NAT2;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HYPERTENSION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION
CHOP;CBR3;AA + AG;rs8133052;EFFICACY;DECREASED_RESPONSE;OTHER:NON-HODGKIN_LYMPHOMA
RITUXIMAB;CBR3;AA + AG;rs8133052;EFFICACY;DECREASED_RESPONSE;OTHER:NON-HODGKIN_LYMPHOMA
CHOP;ABCC2;AA + AG;rs8187710;EFFICACY;DECREASED_RESPONSE;OTHER:NON-HODGKIN_LYMPHOMA
RITUXIMAB;ABCC2;AA + AG;rs8187710;EFFICACY;DECREASED_RESPONSE;OTHER:NON-HODGKIN_LYMPHOMA
N-DESMETHYLTAMOXIFEN;SEPTIN3;AG;rs11914200;LADME_PK;DECREASED_METABOLISM;nan
FENTANYL;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:NEOPLASMS | DISEASE:PAIN
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;A;rs34130495;EFFICACY;DECREASED_RESPONSE;nan
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;A;rs34130495;LADME_PK;DECREASED_RESPONSE;nan
N-DESMETHYLTAMOXIFEN;SREBF2;AC;rs133290;LADME_PK;DECREASED_METABOLISM;nan
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;DISEASE:VENOUS_THROMBOEMBOLISM
N-DESMETHYLTAMOXIFEN;TCF20;GG;rs5751251;LADME_PK;INCREASED_METABOLISM;nan
N-DESMETHYLTAMOXIFEN;SREBF2;TT;rs2267439;LADME_PK;INCREASED_METABOLISM;nan
N-DESMETHYLTAMOXIFEN;SREBF2;TT;rs9607850;LADME_PK;INCREASED_METABOLISM;nan
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
N-DESMETHYLTAMOXIFEN;CENPM;AG;rs8140869;LADME_PK;DECREASED_METABOLISM;nan
N-DESMETHYLTAMOXIFEN;SMIM45;AG;rs8140869;LADME_PK;DECREASED_METABOLISM;nan
RIBAVIRIN;IFNL4;GG;rs11322783;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
SOFOSBUVIR;IFNL4;GG;rs11322783;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
VARENICLINE;CYP2A6;nan;CYP2A6 high activity;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
WARFARIN;CYP2C9;*2/*24;CYP2C9*1, CYP2C9*2, CYP2C9*24;DOSAGE;DECREASED_CLEARANCE;OTHER:CARDIOMYOPATHIES
ETOPOSIDE;nan;AA;rs446112;OTHER;INCREASED_RESISTANCE;nan
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;LADME_PK;INCREASED_EXPOSURE;OTHER:DIABETES_MELLITUS | OTHER:HYPERCHOLESTEROLEMIA
FLUVOXAMINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PAROXETINE;CYP2D6;*2/*2;CYP2D6*2;LADME_PK;INCREASED_CLEARANCE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
OPIOIDS;CYP2D6;nan;CYP2D6 poor and ultrarapid metabolizers;EFFICACY;DECREASED_RESPONSE;DISEASE:PAIN
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*2/*24;CYP2C9*1, CYP2C9*2, CYP2C9*24;DOSAGE;DECREASED_DOSE;OTHER:CARDIOMYOPATHIES
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:PANIC_DISORDER
IVACAFTOR;CFTR;del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
LUMACAFTOR;CFTR;del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
AFATINIB;EGFR;GG;rs28929495;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA
HYDROMORPHONE;CYP2D6;*5/*17;CYP2D6*5, CYP2D6*17;LADME_PK;DECREASED_CONCENTRATIONS;nan
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
3-AMINOISOBUTYRATE;DPYD;TT;rs3918290;LADME_PK;DECREASED_CONCENTRATIONS;nan
HYDRALAZINE;NAT2;rapid_acetylator;NAT2;DOSAGE;INCREASED_DOSE;OTHER:HYPERTENSION
HYDRALAZINE;NAT2;rapid_acetylator;NAT2;EFFICACY;INCREASED_DOSE;OTHER:HYPERTENSION
MEXILETINE;CYP2D6;*41;CYP2D6*41;EFFICACY;DECREASED_RESPONSE;OTHER:MYOTONIC_DYSTROPHY | OTHER:NONDYSTROPHIC_MYOTONIA
HYDROCODONE;CYP2D6;*5/*17;CYP2D6*5, CYP2D6*17;EFFICACY;DECREASED_RESPONSE;nan
TRAMADOL;CYP2D6;*5/*17;CYP2D6*5, CYP2D6*17;EFFICACY;DECREASED_RESPONSE;nan
3-AMINOISOBUTYRATE;UPB1;AA;rs143493067;LADME_PK;DECREASED_CONCENTRATIONS;nan
3-AMINOISOBUTYRATE;AGXT2;TT;rs114286107;LADME_PK;INCREASED_CONCENTRATIONS;nan
FENTANYL;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:POSTOPERATIVE_PAIN
URACIL;DPYD;TT;rs3918290;LADME_PK;INCREASED_CONCENTRATIONS;nan
2-AMINOHEPTANOATE;ACAD11;AA;rs41272317;LADME_PK;INCREASED_CONCENTRATIONS;nan
2-AMINOOCTANOIC ACID;ACAD11;AA;rs41272317;LADME_PK;INCREASED_CONCENTRATIONS;nan
2-HYDROXYLAURATE;ACAD11;AA;rs41272317;LADME_PK;INCREASED_CONCENTRATIONS;nan
CYSTEINE-S-SULFATE;NPC2;TT;rs140130028;LADME_PK;INCREASED_CONCENTRATIONS;nan
L-ORNITHINE;NPC2;TT;rs140130028;LADME_PK;INCREASED_CONCENTRATIONS;nan
HYDRALAZINE;NAT2;slow_acetylator;NAT2;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
5;UPB1;AA;rs143493067;LADME_PK;INCREASED_CONCENTRATIONS;nan
6-DIHYDROTHYMINE;UPB1;AA;rs143493067;LADME_PK;INCREASED_CONCENTRATIONS;nan
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
HYDRALAZINE;NAT2;slow_acetylator;NAT2;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HYPERTENSION
10-MONOHYDROXY OXCARBAZEPINE;ABCC2;G;rs2273697;LADME_PK;INCREASED_CLEARANCE;OTHER:EPILEPSY
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;nan
RIVAROXABAN;CYP3A5;TT;rs776746;TOXICITY;DECREASED_CONCENTRATIONS;OTHER:VENOUS_THROMBOEMBOLISM
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
CYTARABINE;SLC29A1;T;rs2396243;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MYELOID_ACUTE_LEUKEMIA
CYTARABINE;NME4;CT + TT;rs5841;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MYELOID_ACUTE_LEUKEMIA
PRAZIQUANTEL;CYP1A2;*1/*30 + *30/*30;CYP1A2*1, CYP1A2*30;LADME_PK;INCREASED_METABOLISM;OTHER:SCHISTOSOMIASIS
PRAZIQUANTEL;CYP2C9;*1/*9 + *9/*9;CYP2C9*1, CYP2C9*9;LADME_PK;INCREASED_METABOLISM;OTHER:SCHISTOSOMIASIS
CYTARABINE;CDA;AG + GG;rs10916819;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MYELOID_ACUTE_LEUKEMIA
CYTARABINE;CMPK1;AG + GG;rs17103168;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MYELOID_ACUTE_LEUKEMIA
EFAVIRENZ;CYP2B6;*6;CYP2B6*1, CYP2B6*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CYTARABINE;CTPS1;A;rs12067645;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MYELOID_ACUTE_LEUKEMIA
CYTARABINE;RRM1;CC;rs11030918;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MYELOID_ACUTE_LEUKEMIA
CYTARABINE;DCK;C;rs4643786;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MYELOID_ACUTE_LEUKEMIA
CYTARABINE;RRM2;AG + GG;rs1138729;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MYELOID_ACUTE_LEUKEMIA
CYTARABINE;CMPK1;CT + TT;rs1044457;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MYELOID_ACUTE_LEUKEMIA
CYTARABINE;SLC28A3;AA;rs17343066;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MYELOID_ACUTE_LEUKEMIA
ARIPIPRAZOLE;CYP2D6;AA + AG;rs1065852;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:TIC_DISORDERS
ARIPIPRAZOLE;CYP2D6;CT + TT;rs1080989;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:TIC_DISORDERS
QUINAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
ARIPIPRAZOLE;CYP2D6;CT + TT;rs1080989;EFFICACY;DECREASED_CLEARANCE;OTHER:TIC_DISORDERS
CYCLOPHOSPHAMIDE;CYP3A4;CC + CT;rs2740574;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:LEUKEMIA | LYMPHOCYTIC | CHRONIC | B-CELL
CYCLOPHOSPHAMIDE;CYP3A5;*3;CYP3A5*1, CYP3A5*3;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:LEUKEMIA | LYMPHOCYTIC | CHRONIC | B-CELL
WARFARIN;CYP2C9;A;rs72558189;DOSAGE;DOSE;nan
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;DOSAGE;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;EFFICACY;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;DOSAGE;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;EFFICACY;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
PURINE ANALOGUES;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;DOSAGE;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
PURINE ANALOGUES;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;EFFICACY;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
PURINE ANALOGUES;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
WARFARIN;CYP2C9;C;rs28371686;DOSAGE;DOSE;nan
WARFARIN;CYP2C9;A;rs1057910;DOSAGE;DOSE;nan
WARFARIN;CYP4F2;C;rs2108622;DOSAGE;DOSE;nan
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
TACROLIMUS;UGT1A4;TT;rs2011425;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A4;GG;rs35599367;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;LADME_PK;INCREASED_EXPOSURE;OTHER:DIABETES_MELLITUS | OTHER:HYPERCHOLESTEROLEMIA
TACROLIMUS;CYP3A4;*22;CYP3A4*1, CYP3A4*22;DOSAGE;DECREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
WARFARIN;CYP2C9;*2/*3;CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
EFAVIRENZ;CYP2B6;*28;CYP2B6*1, CYP2B6*28;LADME_PK;INCREASED_EXPOSURE;DISEASE:HIV_INFECTIOUS_DISEASE
ALOGLIPTIN;PNPLA3;CG + GG;rs738409;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2 | OTHER:FATTY_LIVER_DISEASE | OTHER:BODY_WEIGHT_CHANGES
AMLODIPINE;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:HYPERTENSION
IVACAFTOR;CFTR;CTT/del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
LUMACAFTOR;CFTR;CTT/del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
SERTRALINE;DRD3;AG;rs167770;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:OBSESSIVE-COMPULSIVE_DISORDER
SERTRALINE;DRD3;AG;rs11721264;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:OBSESSIVE-COMPULSIVE_DISORDER
ILOPERIDONE;CYP2D6;AA;rs1065852;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
ILOPERIDONE METABOLITE P88;CYP2D6;AA;rs1065852;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
ASPIRIN;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;nan
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;nan
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
EFAVIRENZ;CYP2B6;*1/*4;CYP2B6*1, CYP2B6*4;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
VALPROIC ACID;CACNA1H;T;rs3751664;EFFICACY;INCREASED_RESISTANCE;OTHER:EPILEPSY
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
PENICILLIN G;IFNG;CC;rs1861494;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:SYPHILIS
ASPIRIN;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED_RESPONSE;nan
PENICILLIN G;IFNG;TT;rs2430561;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:SYPHILIS
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
IMIPRAMINE;CYP2D6;*1/*1xN + *1/*2xN;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN;DOSAGE;INCREASED_DOSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ISONIAZID;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*5, NAT2*6, NAT2*7;LADME_PK;DECREASED_METABOLISM;OTHER:TUBERCULOSIS
SIMVASTATIN;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HYPERCHOLESTEROLEMIA
FLUVOXAMINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED_METABOLISM;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_METABOLISM;DISEASE:LIVER_TRANSPLANTATION
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_METABOLISM;nan
WARFARIN;CYP2C9;*3 + *5 + *2 + *1;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5;DOSAGE;DOSE;nan
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
VENETOCLAX;CYP3A5;CC;rs776746;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:MYELOID_ACUTE_LEUKEMIA
CLOZAPINE;NFIB;CT;rs28379954;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:SCHIZOPHRENIA
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A4;TT;rs2740574;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_METABOLISM;DISEASE:GASTROESOPHAGEAL_REFLUX
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_METABOLISM;DISEASE:GASTROESOPHAGEAL_REFLUX
METHYLPHENIDATE;SLC6A2;GG;rs998424;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ADHD
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;DECREASED_METABOLISM;nan
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:LUPUS_NEPHRITIS
LITHIUM;nan;T;rs7405404;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
NICOTINE;CYP2A6;CT + TT;rs28399454;LADME_PK;DECREASED_METABOLISM;nan
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;nan
EFAVIRENZ;CYP2B6;C;rs28399499;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;del;rs35167514;EFFICACY;DECREASED_RESPONSE;nan
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;del;rs35167514;LADME_PK;DECREASED_RESPONSE;nan
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
FENTANYL;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;DOSAGE;INCREASED_DOSE;OTHER:GASTROINTESTINAL_NEOPLASMS | OTHER:POSTOPERATIVE_PAIN
VARENICLINE;HYKK;CT + TT;rs7164594;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
SIROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*17;EFFICACY;DECREASED_RESPONSE;DISEASE:FUNGAL_INFECTIOUS_DISEASE
4-HYDROXYTAMOXIFEN;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*41;LADME_PK;DECREASED_METABOLISM;nan
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*41;LADME_PK;DECREASED_METABOLISM;nan
MERCAPTOPURINE;NUDT15;*1/*1;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5;LADME_PK;INCREASED_METABOLISM;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
EFAVIRENZ;CYP2B6;T;rs3745274;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
VENLAFAXINE;CYP2D6;*4/*5;CYP2D6*4, CYP2D6*5;LADME_PK;DECREASED_METABOLISM;nan
ENALAPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_DISEASE
LOSARTAN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_DISEASE
VENLAFAXINE;CYP2C19;*2/*2;CYP2C19*2;LADME_PK;DECREASED_METABOLISM;nan
TACROLIMUS;CYP3A5;*1;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
BENAZEPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
BUPROPION;CYP2B6;GG;rs8109525;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
MERCAPTOPURINE;NUDT15;*1/*1;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5;DOSAGE;INCREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CLEARANCE;DISEASE:NEPHROTIC_SYNDROME
ENDOXIFEN;CYP2D6;*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*41;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
MESALAZINE;NAT1;*10;NAT1*3, NAT1*4, NAT1*10;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ULCERATIVE_COLITIS | DISEASE:CROHN_DISEASE | DISEASE:INFLAMMATORY_BOWEL_DISEASES
THIOGUANINE;NAT1;*10;NAT1*3, NAT1*4, NAT1*10;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ULCERATIVE_COLITIS | DISEASE:CROHN_DISEASE | DISEASE:INFLAMMATORY_BOWEL_DISEASES
PIOGLITAZONE;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;LADME_PK;INCREASED_METABOLISM;nan
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:ULCERATIVE_COLITIS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:ORGAN_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:ORGAN_TRANSPLANTATION
EXEMESTANE;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
WARFARIN;CYP4F2;*3;CYP4F2*1, CYP4F2*3;DOSAGE;INCREASED_DOSE;nan
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_METABOLISM;DISEASE:HEART_TRANSPLANTATION
RISPERIDONE;CYP2D6;*4 + *5;CYP2D6*1, CYP2D6*4, CYP2D6*5;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
RISPERIDONE;CYP2D6;*4 + *5 + *10 +*14;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
METOPROLOL;CYP2D6;*4;CYP2D6*4;DOSAGE;DECREASED_DOSE;DISEASE:HEART_FAILURE
CETUXIMAB;VEGFA;del/del;rs144854329;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
SN-38;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;LADME_PK;DECREASED_METABOLISM;OTHER:NEOPLASMS
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:RHEUMATOID_ARTHRITIS | DISEASE:ULCERATIVE_COLITIS
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;INCREASED_TROUGH CONCENTRATION;DISEASE:ULCERATIVE_COLITIS
SN-38;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;LADME_PK;DECREASED_CLEARANCE;OTHER:NEOPLASMS
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
WARFARIN;CYP2C9;*1/*6;CYP2C9*1, CYP2C9*6;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2, CYP2C9*3;DOSAGE;DOSE;DISEASE:STROKE
VENLAFAXINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;LADME_PK;DECREASED_METABOLISM;nan
LETROZOLE;nan;C;rs7937;nan;INCREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;OTHER:TOTAL_KNEE_OR_HIP_ARTHROPLASTY
PROPOFOL;CYP2C9;*1/*1 + *1/*2;CYP2C9*1, CYP2C9*2;LADME_PK;DECREASED_CONCENTRATIONS;nan
WARFARIN;VKORC1;G;rs104894540;DOSAGE;INCREASED_DOSE;nan
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;LADME_PK;CLEARANCE;DISEASE:HEART_DISEASES
CODEINE;CYP2D6;nan;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;EFFICACY;DECREASED_RESPONSE;OTHER:PAIN
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
NOROXYCODONE;CYP2D6;nan;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;LADME_PK;INCREASED_CONCENTRATIONS;nan
OXYCODONE;CYP2D6;nan;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;LADME_PK;INCREASED_CONCENTRATIONS;nan
CITALOPRAM;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;DOSAGE;DECREASED_DOSE;DISEASE:DEPRESSION
CITALOPRAM;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
ESCITALOPRAM;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;DOSAGE;DECREASED_DOSE;DISEASE:DEPRESSION
ESCITALOPRAM;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
FLUOXETINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;DOSAGE;DECREASED_DOSE;DISEASE:DEPRESSION
FLUOXETINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
FLUVOXAMINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;DOSAGE;DECREASED_DOSE;DISEASE:DEPRESSION
FLUVOXAMINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
PAROXETINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;DOSAGE;DECREASED_DOSE;DISEASE:DEPRESSION
PAROXETINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
SERTRALINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;DOSAGE;DECREASED_DOSE;DISEASE:DEPRESSION
SERTRALINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION
DISULFIRAM;SLC6A3;GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT/GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT;rs28363170;EFFICACY;INCREASED_RESPONSE;OTHER:COCAINE_DEPENDENCE
WARFARIN;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;DOSAGE;INCREASED_DOSE;nan
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;OTHER:TOTAL_KNEE_OR_HIP_ARTHROPLASTY
BENAZEPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
PERINDOPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;LADME_PK;DECREASED_CLEARANCE;DISEASE:PSYCHOTIC_DISORDER
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;nan
THIOGUANINE;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:CROHN_DISEASE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CLEARANCE;OTHER:HUMAN_LIVER_MICROSOMES
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED_DOSE;DISEASE:ULCERATIVE_COLITIS
PROGUANIL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;DECREASED_METABOLISM;DISEASE:MALARIA
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*1, TPMT*3A, TPMT*3C;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CITALOPRAM;CYP2C19;*17/*17;CYP2C19*17;EFFICACY;DECREASED_RESPONSE;DISEASE:OBSESSIVE-COMPULSIVE_DISORDER
N-DESMETHYLCLOZAPINE;CYP2C19;*17;CYP2C19*1, CYP2C19*17;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:SCHIZOAFFECTIVE_DISORDER | DISEASE:SCHIZOPHRENIA
CLOZAPINE;CYP2C19;*17/*17;CYP2C19*17;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOAFFECTIVE_DISORDER | DISEASE:SCHIZOPHRENIA
WARFARIN;VKORC1;C;rs104894541;DOSAGE;INCREASED_DOSE;nan
EFAVIRENZ;CYP2B6;GG;rs36118214;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;VKORC1;A;rs104894539;DOSAGE;INCREASED_DOSE;nan
CYCLOPHOSPHAMIDE;CYP2B6;*6;CYP2B6*1, CYP2B6*6;LADME_PK;DECREASED_METABOLISM;DISEASE:NON-HODGKIN_LYMPHOMA
CYCLOPHOSPHAMIDE;CYP2B6;*1/*30;CYP2B6*1, CYP2B6*30;LADME_PK;DECREASED_METABOLISM;DISEASE:NON-HODGKIN_LYMPHOMA
CYCLOPHOSPHAMIDE;CYP2B6;*1/*29;CYP2B6*1, CYP2B6*29;LADME_PK;DECREASED_METABOLISM;DISEASE:NON-HODGKIN_LYMPHOMA
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
CYCLOPHOSPHAMIDE;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_METABOLISM;DISEASE:NON-HODGKIN_LYMPHOMA
QUINAPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del;rs1799752;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
CYCLOPHOSPHAMIDE;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-HODGKIN_LYMPHOMA
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION | DISEASE:VENOUS_THROMBOEMBOLISM
TESTOSTERONE;UGT1A4;*3a;UGT1A4*1a, UGT1A4*3a;EFFICACY;INCREASED_CLEARANCE;nan
TESTOSTERONE;UGT1A4;*3a;UGT1A4*1a, UGT1A4*3a;LADME_PK;INCREASED_CLEARANCE;nan
CYCLOPHOSPHAMIDE;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-HODGKIN_LYMPHOMA
HYDRALAZINE;NAT2;slow_acetylator;NAT2;LADME_PK;DECREASED_METABOLISM;OTHER:HYPERTENSION
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*2, CYP2C9*3;DOSAGE;DOSE;nan
LAMOTRIGINE;UGT1A4;*2 + *3a;UGT1A4*1a, UGT1A4*2, UGT1A4*3a;EFFICACY;DECREASED_CLEARANCE;nan
LAMOTRIGINE;UGT1A4;*2 + *3a;UGT1A4*1a, UGT1A4*2, UGT1A4*3a;LADME_PK;DECREASED_CLEARANCE;nan
CURCUMIN;CFTR;AA + AG;rs77010898;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;AA + AG;rs77010898;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
AMITRIPTYLINE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MENTAL_DISORDERS
3-HYDROXYCOTININE;CYP2A6;*1/*12;CYP2A6*1, CYP2A6*12;LADME_PK;DECREASED_CONCENTRATIONS;nan
TACROLIMUS;CYP3A5;*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
AMITRIPTYLINE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_METABOLISM;DISEASE:MENTAL_DISORDERS
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;EFFICACY;DECREASED_RESPONSE;DISEASE:LIVER_TRANSPLANTATION
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;DOSAGE;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:NEOPLASMS
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:NEOPLASMS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*45, CYP2D6*46;TOXICITY;DECREASED_METABOLISM;DISEASE:HYPERTENSION
METOPROLOL;CYP2D6;*9 + *29 + *45 + *46 + *17 + *10;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*45, CYP2D6*46;LADME_PK;DECREASED_METABOLISM;DISEASE:HYPERTENSION
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_RESISTANCE;OTHER:CORONARY_DISEASE
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;LADME_PK;DECREASED_CLEARANCE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*17;DOSAGE;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:NEOPLASMS
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*17;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:NEOPLASMS
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
METHOTREXATE;HLA-G;del/del;rs371194629;EFFICACY;INCREASED_RESPONSE;EFFICACY:RHEUMATOID_ARTHRITIS
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;TOXICITY;DECREASED_METABOLISM;DISEASE:HYPERTENSION
METOPROLOL;CYP2D6;*4 + *3 + *5  + *6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;LADME_PK;DECREASED_METABOLISM;DISEASE:HYPERTENSION
SN-38;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
ESOMEPRAZOLE;CYP2C19;*17;CYP2C19*1, CYP2C19*17;EFFICACY;DECREASED_RESPONSE;OTHER:EOSINOPHILIC_ESOPHAGITIS
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;DOSAGE;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:NEOPLASMS
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:NEOPLASMS
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;DOSAGE;DECREASED_DOSE;DISEASE:NEOPLASMS
CAPTOPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
TEZACAFTOR;CFTR;del/del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
TRAMADOL;CYP2D6;*1/*1xN;CYP2D6*1, CYP2D6*1xN;LADME_PK;INCREASED_METABOLISM;nan
WARFARIN;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;nan
LOSARTAN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:HYPERTENSION
CHIGLITAZAR;PPARA;CC + CT;rs1800234;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
LAMOTRIGINE;UGT1A4;*1b;UGT1A4*1a, UGT1A4*1b;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:EPILEPSY
HALOPERIDOL;CYP2D6;*5 + *10;CYP2D6*1, CYP2D6*5, CYP2D6*10;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
HALOPERIDOL;CYP2D6;*3 + *4;CYP2D6*1, CYP2D6*3, CYP2D6*4;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
ZUCLOPENTHIXOL;CYP2D6;*1/*4 + *3/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4;LADME_PK;DECREASED_METABOLISM;OTHER:SCHIZOPHRENIA
AZATHIOPRINE;TPMT;nan;TPMT low activity;LADME_PK;DECREASED_METABOLISM;nan
MERCAPTOPURINE;TPMT;nan;TPMT low activity;LADME_PK;DECREASED_METABOLISM;nan
O-DESMETHYLTRAMADOL;SLC22A1;nan;SLC22A1 deficiency;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:PAIN
MERCAPTOPURINE;TPMT;nan;TPMT intermediate activity;EFFICACY;INCREASED_RESPONSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
SULFASALAZINE;NAT2;slow_acetylator;NAT2;OTHER;INCREASED_DISCONTINUATION;DISEASE:RHEUMATOID_ARTHRITIS
FENTANYL;CYP3A4;T/T;rs2242480;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:POSTOPERATIVE_PAIN
ETHANOL;OPRM1;G;rs1799971;DOSAGE;INCREASED_DOSE;nan
SUFENTANIL;CYP3A4;T/T;rs2242480;EFFICACY;INCREASED_RESPONSE;OTHER:POSTOPERATIVE_PAIN
SUFENTANIL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
SUFENTANIL;CYP3A4;T/T;rs2242480;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:PAIN
TACROLIMUS;CYP3A4;C/C;rs2242480;OTHER;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;C/C;rs2242480;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
SUFENTANIL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
BETA BLOCKING AGENTS;GRK5;T;rs4752292;EFFICACY;DECREASED_RESPONSE;OTHER:CORONARY_ARTERY_DISEASE
INTERFERON BETA-1A;HLA-B;*15:01;HLA-B*15:01;EFFICACY;DECREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DOSE;DISEASE:HEART_DISEASES
RUBELLA VACCINES;HLA-B;*35:03;HLA-B*35:03;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
PEGINTERFERON ALFA-2A;HLA-B;*38:01;HLA-B*38:01;EFFICACY;DECREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;HLA-B;*38:01;HLA-B*38:01;EFFICACY;DECREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;HLA-B;*38:01;HLA-B*38:01;EFFICACY;DECREASED_RESPONSE;DISEASE:HEPATITIS_C
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);OPRM1;GG;rs671531;EFFICACY;DECREASED_RESPONSE;OTHER:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A4;*1/*18;CYP3A4*1, CYP3A4*18;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
CYCLOSPORINE;CYP3A4;*18/*18;CYP3A4*1, CYP3A4*18;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
USTEKINUMAB;HLA-C;*06:02;HLA-C*06:02;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
METHOTREXATE;HLA-C;*06:02;HLA-C*06:02;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
FENTANYL;CYP3A4;*18/*18;CYP3A4*1, CYP3A4*18;DOSAGE;DECREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
FENTANYL;CYP3A4;*18/*18;CYP3A4*1, CYP3A4*18;EFFICACY;DECREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
RUBELLA VACCINES;HLA-C;*15:02;HLA-C*15:02;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
PEGINTERFERON ALFA-2B;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*01:02, HLA-C*02:02, HLA-C*03:02, HLA-C*04:01, HLA-C*05:01, HLA-C*06:02, HLA-C*07:01, HLA-C*08:01, HLA-C*12:02, HLA-C*14:02, HLA-C*15:02, HLA-C*16:01, HLA-C*17:01;EFFICACY;DECREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;HLA-C;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;HLA-C*01:02, HLA-C*02:02, HLA-C*03:02, HLA-C*04:01, HLA-C*05:01, HLA-C*06:02, HLA-C*07:01, HLA-C*08:01, HLA-C*12:02, HLA-C*14:02, HLA-C*15:02, HLA-C*16:01, HLA-C*17:01;EFFICACY;DECREASED_RESPONSE;DISEASE:HEPATITIS_C
MEASLES VACCINES;HLA-DQA1;*01:04;HLA-DQA1*01:04;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
MEASLES VACCINES;HLA-DRB1;*01:01;HLA-DRB1*01:01;EFFICACY;RESPONSE;nan
CYCLOSPORINE;CYP3A4;*1/*1;CYP3A4*1, CYP3A4*18;LADME_PK;INCREASED_CONCENTRATIONS;nan
INTERFERON BETA-1A;HLA-DRB1;*04:01;HLA-DRB1*04:01;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
ADALIMUMAB;HLA-DRB1;*04:01;HLA-DRB1*04:01;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
ETANERCEPT;HLA-DRB1;*04:01;HLA-DRB1*04:01;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
INFLIXIMAB;HLA-DRB1;*04:01;HLA-DRB1*04:01;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
HEPATITIS VACCINES;HLA-DRB1;*07:01;HLA-DRB1*07:01;EFFICACY;DECREASED_RESPONSE;nan
INFLUENZA VACCINES;HLA-DRB1;*07:01;HLA-DRB1*07:01;EFFICACY;DECREASED_RESPONSE;nan
MEASLES VACCINES;HLA-DRB1;*08:01;HLA-DRB1*08:01;EFFICACY;RESPONSE;nan
INFLUENZA VACCINES;HLA-DRB1;*13:01;HLA-DRB1*13:01;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
TACROLIMUS;CYP2C8;*1/*3 + *3/*3;CYP2C8*1, CYP2C8*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
METHOTREXATE;GGH;AA + AG;rs11545078;TOXICITY;INCREASED_DISCONTINUATION;SIDE_EFFECT:RHEUMATOID_ARTHRITIS
IBUPROFEN;CYP2C8;*1/*3;CYP2C8*1, CYP2C8*3;DOSAGE;DECREASED_DOSE;nan
METHADONE;CYP2B6;*1/*6 + *1/*18 + *6/*6 + *6/*18;CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7, CYP2B6*18;LADME_PK;DECREASED_METABOLISM;OTHER:OPIOID-RELATED_DISORDERS
DISULFIRAM;SLC6A4;HTTLPR short form (S allele) / HTTLPR short form (S allele) + HTTLPR short form (S allele) / L allele-rs25531C + L allele-rs25531C / L allele-rs25531C;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;EFFICACY;INCREASED_RESPONSE;OTHER:COCAINE_DEPENDENCE
SERTRALINE;CYP2B6;*1/*4 + *4/*4;CYP2B6*1, CYP2B6*4;LADME_PK;DECREASED_CONCENTRATIONS;nan
SERTRALINE;CYP2B6;*6 + *9;CYP2B6*1, CYP2B6*6, CYP2B6*9;LADME_PK;INCREASED_CONCENTRATIONS;nan
SERTRALINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;LADME_PK;DECREASED_CONCENTRATIONS;nan
SERTRALINE;CYP2C19;*2 + *3 + *4;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4;LADME_PK;INCREASED_CONCENTRATIONS;nan
SERTRALINE;CYP2B6;*9/*9;CYP2B6*1, CYP2B6*9;LADME_PK;INCREASED_HALF_LIFE TIME;nan
PRAVASTATIN;SLCO1B1;*1/*15;SLCO1B1*1, SLCO1B1*15;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERCHOLESTEROLEMIA
RIFAMPIN;CYP2C9;*2 + *3 + *11;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*11;EFFICACY;INCREASED_RESPONSE;OTHER:TUBERCULOSIS
WARFARIN;CYP2C9;*2 + *3 + *11;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*11;EFFICACY;INCREASED_RESPONSE;OTHER:TUBERCULOSIS
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
TACROLIMUS;ABCB1;GG;rs1045642;LADME_PK;INCREASED_METABOLISM;DISEASE:LIVER_TRANSPLANTATION
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
FLUVASTATIN;SLCO1B1;*14;SLCO1B1*1, SLCO1B1*14;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED_DOSE;nan
METHADONE;CYP2B6;*6/*6;CYP2B6*6;TOXICITY;DECREASED_METABOLISM;OTHER:POSTOPERATIVE_PAIN | OTHER:SCOLIOSIS
METHOTREXATE;SLCO1B1;*31;SLCO1B1*1, SLCO1B1*31, SLCO1B1*37;LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE;SLCO1B1;*20;SLCO1B1*1, SLCO1B1*20, SLCO1B1*37;LADME_PK;INCREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CONJUGATED ESTROGENS;SLCO1B1;TT;rs4149056;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:MENOPAUSE
METHOTREXATE;SLCO1B1;*23;SLCO1B1*1, SLCO1B1*23, SLCO1B1*37;LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ACENOCOUMAROL;CYP2C18;GG;rs1998591;DOSAGE;INCREASED_DOSE;nan
ACENOCOUMAROL;VKORC1;AA;rs9934438;DOSAGE;DECREASED_DOSE;nan
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESISTANCE;OTHER:STROKE
METHOTREXATE;SLCO1B1;*15;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HYPERCHOLESTEROLEMIA
ATRASENTAN;SLCO1B1;*15/*15 + *1/*15 + *15/*37 + *14/*37;SLCO1B1*1, SLCO1B1*14, SLCO1B1*15, SLCO1B1*37;LADME_PK;INCREASED_CONCENTRATIONS;nan
ESCITALOPRAM;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;LADME_PK;DECREASED_CONCENTRATIONS;nan
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_STEADY_STATE CONCENTRATION;OTHER:TRANSPLANTATION
3;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:CEREBRAL_INFARCTION
4-DEHYDROCILOSTAZOL;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:CEREBRAL_INFARCTION
BETA BLOCKING AGENTS;ADRA2C;del;rs61767072;EFFICACY;INCREASED_RESPONSE;OTHER:CARDIOMYOPATHY | DILATED
ARIPIPRAZOLE;CYP2D6;*3 + *4 + *4xN + *5 + *6 + *10 + *41;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;LADME_PK;INCREASED_CONCENTRATIONS;nan
ATOMOXETINE;CYP2D6;nan;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ADHD
DOCETAXEL;SULT1C4;G;rs1402467;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
THALIDOMIDE;SULT1C4;G;rs1402467;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
ATOMOXETINE;CYP2D6;nan;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;DOSAGE;DECREASED_DOSE;OTHER:ADHD
ATOMOXETINE;CYP2C19;*2;CYP2C19*1, CYP2C19*2;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ADHD
AMITRIPTYLINE;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*17;OTHER;INCREASED_DISCONTINUATION;OTHER:BIPOLAR_DISORDER
CLOMIPRAMINE;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*17;OTHER;INCREASED_DISCONTINUATION;OTHER:BIPOLAR_DISORDER
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;DOSAGE;DECREASED_DOSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
TACROLIMUS;CYP3A5;*1;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;DOSAGE;INCREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
BREXPIPRAZOLE;CYP2D6;*2;CYP2D6*1, CYP2D6*2;LADME_PK;DECREASED_METABOLISM;nan
BREXPIPRAZOLE;CYP2D6;*9 +*10 + *14 + *17 + *29 + *41;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*14, CYP2D6*17, CYP2D6*29, CYP2D6*41;LADME_PK;DECREASED_METABOLISM;nan
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
N-DESMETHYLTRAMADOL;CYP2D6;*1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HEAD_AND_NECK_NEOPLASMS
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED_DOSE;nan
VENLAFAXINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
VENLAFAXINE;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 L allele-rs25531T;EFFICACY;INCREASED_RESPONSE;OTHER:ANXIETY_DISORDERS
VENLAFAXINE;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 L allele-rs25531T;EFFICACY;DECREASED_RESPONSE;OTHER:DEPRESSION
METHOTREXATE;ABCC2;CT + TT;rs717620;TOXICITY;DECREASED_DISCONTINUATION;SIDE_EFFECT:RHEUMATOID_ARTHRITIS
KETOROLAC;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;INCREASED_RESPONSE;OTHER:POSTOPERATIVE_PAIN
TRAMADOL;CYP2D6;*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED_RESPONSE;OTHER:POSTOPERATIVE_PAIN
FLUOROURACIL;ERCC1;C;rs3212948;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
LEUCOVORIN;ERCC1;C;rs3212948;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
OXALIPLATIN;ERCC1;C;rs3212948;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
SERTRALINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;OTHER:PANIC_DISORDER
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
ENDOXIFEN;CYP3A4;*22/*22;CYP3A4*1, CYP3A4*22;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
TACROLIMUS;CYP3A4;*22;CYP3A4*1, CYP3A4*22;DOSAGE;DECREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
MIDAZOLAM;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CLEARANCE;OTHER:NEOPLASMS
ENDOXIFEN;CYP2D6;*17/*29 + *17/*17;CYP2D6*1, CYP2D6*2, CYP2D6*17, CYP2D6*29;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
LIRAGLUTIDE;GLP1R;TT;rs10305420;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
TAMOXIFEN;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_METABOLISM;nan
N-DESMETHYLTAMOXIFEN;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;LADME_PK;DECREASED_METABOLISM;nan
TAMOXIFEN;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;LADME_PK;DECREASED_METABOLISM;nan
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
OXYCODONE;CYP2C19;nan;CYP2C19 poor metabolizers and intermediate metabolizers;LADME_PK;DECREASED_METABOLISM;nan
OXYCODONE;CYP2D6;nan;CYP2D6 poor metabolizers and intermediate metabolizers;LADME_PK;DECREASED_METABOLISM;nan
OXYCODONE;CYP3A4;*22;CYP3A4*1, CYP3A4*22;LADME_PK;DECREASED_METABOLISM;nan
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CLEARANCE;OTHER:LUNG_TRANSPLANTATION
BEVACIZUMAB;CXCL8;AA + AT;rs4073;EFFICACY;DECREASED_RESPONSE;DISEASE:OVARIAN_NEOPLASMS
CYCLOPHOSPHAMIDE;CXCL8;AA + AT;rs4073;EFFICACY;DECREASED_RESPONSE;DISEASE:OVARIAN_NEOPLASMS
NICOTINE;CYP2A6;*4/*4;CYP2A6*1, CYP2A6*4;LADME_PK;DECREASED_METABOLISM;nan
DULOXETINE;CYP2D6;*4/*4;CYP2D6*4;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEPRESSIVE_DISORDER
N-DESMETHYLCLOZAPINE;CYP3A4;nan;CYP3A4 low activity;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
DIHYDROPYRIDINE DERIVATIVES;CYP3A5;TT;rs776746;OTHER;INCREASED_DISCONTINUATION;nan
DESVENLAFAXINE;CYP2D6;*4/*4;CYP2D6*4;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:DEPRESSIVE_DISORDER
N-DESMETHYLCLOZAPINE;CYP1A2;nan;CYP1A2 low activity;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
DESVENLAFAXINE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:DEPRESSIVE_DISORDER
NICOTINE;CYP2A6;*1/*35 + *9/*35 + *17/*35;CYP2A6*1, CYP2A6*9, CYP2A6*17, CYP2A6*35;LADME_PK;DECREASED_METABOLISM;nan
DISULFIRAM;ALDH2;nan;ALDH2 deficiency;EFFICACY;INCREASED_RESPONSE;OTHER:ALCOHOL_ABUSE
NICOTINE;CYP2A6;*1/*46 + *46/*46;CYP2A6*1, CYP2A6*46;LADME_PK;INCREASED_METABOLISM;nan
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*24, CYP2A6*25, CYP2A6*26, CYP2A6*27, CYP2A6*28, CYP2A6*35;LADME_PK;DECREASED_METABOLISM;nan
EFAVIRENZ;CYP2B6;*6;CYP2B6*6;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
NICOTINE;CYP2A6;A;rs137904044;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;*35/*35;CYP2A6*1, CYP2A6*35;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;A;rs571335587;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;T;rs28399454;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;T;rs140471703;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;A;rs199515342;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;T;rs61605570;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;T;rs768416963;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;C;rs1302192284;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;A;rs111869995;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;A;rs200554095;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;G;rs772964366;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;T;rs145308399;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;T;rs758479488;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;T;rs145157460;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;G;rs148693084;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;T;rs1303839356;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;T;rs374515279;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;G;rs777098658;LADME_PK;DECREASED_METABOLISM;nan
WARFARIN;VKORC1;C;rs11150606;DOSAGE;DECREASED_DOSE;nan
NICOTINE;CYP2A6;G;rs5031016;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;*1 + *46 + *9 + *14 + *38;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*14, CYP2A6*38, CYP2A6*46;LADME_PK;INCREASED_METABOLISM;nan
NICOTINE;CYP2A6;*1 + *9 + *12 + *38;CYP2A6*1, CYP2A6*9, CYP2A6*12, CYP2A6*38, CYP2A6*46;LADME_PK;DECREASED_METABOLISM;nan
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED_DOSE;nan
OXALIPLATIN;MTHFR;GG + GT;rs1801131;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
ALPRAZOLAM;CYP3A4;nan;CYP3A4 low activity;EFFICACY;INCREASED_RESPONSE;OTHER:ALCOHOL_ABUSE | OTHER:ANXIETY_DISORDERS
TACROLIMUS;CYP3A4;C/C;rs2242480;LADME_PK;DECREASED_METABOLISM;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A4;C/C;rs2242480;LADME_PK;DECREASED_METABOLISM;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A4;C/T + T/T;rs2242480;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;C/C;rs2242480;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
FENTANYL;CYP3A4;T/T;rs2242480;DOSAGE;DECREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
ENDOXIFEN;CYP2D6;INTERMEDIATE_METABOLIZER;CYP2D6;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
TACROLIMUS;CYP3A5;nan;CYP3A5 intermediate metabolizer and normal metabolizer;DOSAGE;INCREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
CLOZAPINE;ABCG2;GT + TT;rs2231142;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:SCHIZOPHRENIA
DOLUTEGRAVIR;UGT1A1;*28/*28 + *6/*6;UGT1A1*1, UGT1A1*6, UGT1A1*28;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
ASPIRIN;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED_RESPONSE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTIONS_AND_DRUG-ELUTING_STENTS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED_RESPONSE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTIONS_AND_DRUG-ELUTING_STENTS
(S)-METHADONE;CYP2B6;*6 + *7 + *9 + *18;CYP2B6*1, CYP2B6*6, CYP2B6*7, CYP2B6*9, CYP2B6*18;LADME_PK;DECREASED_CLEARANCE;OTHER:SCOLIOSIS
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*1, TPMT*3C;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
THIOGUANINE;TPMT;*1/*3C;TPMT*1, TPMT*3C;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
THIOGUANINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
NICOTINE;CYP2A6;*4/*4 + *4/*7;CYP2A6*1, CYP2A6*4, CYP2A6*7;OTHER;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;*4/*4 + *4/*7;CYP2A6*1, CYP2A6*4, CYP2A6*7;LADME_PK;DECREASED_METABOLISM;nan
HYDRALAZINE;NAT2;rapid_acetylator;NAT2;DOSAGE;INCREASED_DOSE;OTHER:HYPERTENSION
HYDRALAZINE;NAT2;rapid_acetylator;NAT2;EFFICACY;INCREASED_DOSE;OTHER:HYPERTENSION
WARFARIN;CYP2C9;*1/*13;CYP2C9*1, CYP2C9*13;DOSAGE;DECREASED_DOSE;OTHER:ATRIAL_FIBRILLATION
L-METHYLFOLATE;MTHFR;AG;rs1801133;EFFICACY;INCREASED_RESPONSE;OTHER:BIPOLAR_DISORDER | OTHER:DEPRESSION | OTHER:OBSESSIVE-COMPULSIVE_DISORDER
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA | OTHER:LYMPHOMA | OTHER:MYELOID_ACUTE_LEUKEMIA
HYDRALAZINE;NAT2;slow_acetylator;NAT2;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HYPERTENSION
VENLAFAXINE;CYP2D6;INTERMEDIATE_METABOLIZER;CYP2D6;LADME_PK;DECREASED_METABOLISM;OTHER:ELDERLY_ADULT
ESCITALOPRAM;CYP2C19;INTERMEDIATE_METABOLIZER;CYP2C19;LADME_PK;DECREASED_METABOLISM;OTHER:ELDERLY_ADULT
SOMATROPIN RECOMBINANT;COL1A1;AA;rs1800012;DOSAGE;DECREASED_DOSE;OTHER:GROWTH_HORMONE_DEFICIENCY
NICOTINE;CYP2A6;*2 + *4 + *7 + *9 + *10 + *11 + *13 + *15 + *17 + *19 + *20;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10, CYP2A6*11, CYP2A6*13, CYP2A6*15, CYP2A6*17, CYP2A6*19, CYP2A6*20;LADME_PK;DECREASED_METABOLISM;nan
TEGAFUR;CYP2A6;*11/*4;CYP2A6*1, CYP2A6*4, CYP2A6*11;LADME_PK;DECREASED_METABOLISM;OTHER:STOMACH_NEOPLASMS
LETROZOLE;CYP2A6;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*35;LADME_PK;DECREASED_CLEARANCE;DISEASE:BREAST_NEOPLASMS
L-METHYLFOLATE;MTHFR;GT;rs1801131;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
NICOTINE;CYP2A6;*1/*46;CYP2A6*1, CYP2A6*46;LADME_PK;INCREASED_CLEARANCE;nan
COUMARIN;CYP2A6;*5/*47;CYP2A6*5, CYP2A6*47;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*24, CYP2A6*25, CYP2A6*26, CYP2A6*27, CYP2A6*28, CYP2A6*35, CYP2A6*46;LADME_PK;DECREASED_METABOLISM;nan
VITAMIN B-COMPLEX;MTHFR;A;rs1801133;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
INCL. COMBINATIONS;MTHFR;A;rs1801133;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;A;rs2359612;DOSAGE;DECREASED_DOSE;nan
VITAMIN B-COMPLEX;MTHFR;G;rs1801131;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
INCL. COMBINATIONS;MTHFR;G;rs1801131;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;G;rs9923231;DOSAGE;DOSE;DISEASE:HEART_DISEASES
ATOMOXETINE;SLC6A2;A;rs12708954;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
CYCLOSPORINE;CYP3A4;C;rs2740574;LADME_PK;DECREASED_CONCENTRATIONS;SIDE_EFFECT:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;C;rs2740574;LADME_PK;DECREASED_CONCENTRATIONS;SIDE_EFFECT:KIDNEY_TRANSPLANTATION
MERCAPTOPURINE;NUDT15;del;rs746071566;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MERCAPTOPURINE;NUDT15;del;rs746071566;TOXICITY;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED_DOSE;nan
RIZATRIPTAN;DRD2;AA + AG;rs6275;EFFICACY;DECREASED_RESPONSE;OTHER:MIGRAINE_WITHOUT_AURA
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;CYP2C9;C;rs1799853;DOSAGE;DOSE;nan
WARFARIN;VKORC1;G;rs61162043;DOSAGE;INCREASED_DOSE;nan
SULFONAMIDES;CYP2C9;CC;rs1057910;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
UREA DERIVATIVES;CYP2C9;CC;rs1057910;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
NICOTINE;OPRM1;AG + GG;rs1799971;EFFICACY;DECREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
RISPERIDONE;DRD3;CC + CT;rs6280;EFFICACY;INCREASED_RESPONSE;DISEASE:AUTISM
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED_DOSE;nan
SIROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CONCENTRATIONS;nan
WARFARIN;CYP2C9;*2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
CYSTEAMINE;CFTR;CTT/del + del/del;rs113993960;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;DISEASE:PANIC_DISORDER
WARFARIN;CYP2C9;*3/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*2/*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;nan
HYDRALAZINE;NAT2;slow_acetylator;NAT2;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HYPERTENSION
FLUOROURACIL;DPYD;nan;DPYD deficiency;LADME_PK;DECREASED_METABOLISM;DISEASE:BREAST_NEOPLASMS
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;DOSAGE;DECREASED_DOSE;DISEASE:TRANSPLANTATION
EFAVIRENZ;CYP2B6;*6;CYP2B6*1, CYP2B6*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:MYOCARDIAL_INFARCTION
HYDRALAZINE;NAT2;slow_acetylator;NAT2;LADME_PK;DECREASED_METABOLISM;OTHER:HYPERTENSION
CODEINE;CYP2D6;*17;CYP2D6*17;LADME_PK;DECREASED_METABOLISM;DISEASE:SICKLE_CELL_ANEMIA
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
VORICONAZOLE;CYP2C19;*1/*17 + *1/*2 + *17/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;DOSAGE;DOSE;DISEASE:CYSTIC_FIBROSIS | DISEASE:LUNG_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;EFFICACY;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
ARIPIPRAZOLE;CYP2D6;*4 + *5 + *6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6;LADME_PK;DECREASED_METABOLISM;nan
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;DISEASE:GASTROESOPHAGEAL_REFLUX
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17 + *1/*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;DOSAGE;DOSE;DISEASE:CYSTIC_FIBROSIS | DISEASE:LUNG_TRANSPLANTATION
PANTOPRAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;LADME_PK;INCREASED_METABOLISM;nan
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTM1;nan;GSTM1 non-null, GSTM1 null;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
CAPECITABINE;GSTM1;nan;GSTM1 non-null, GSTM1 null;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
CYCLOPHOSPHAMIDE;GSTM1;nan;GSTM1 non-null, GSTM1 null;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
FLUOROURACIL;GSTM1;nan;GSTM1 non-null, GSTM1 null;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
TAXANES;GSTM1;nan;GSTM1 non-null, GSTM1 null;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;DISEASE:GASTROESOPHAGEAL_REFLUX
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_METABOLISM;DISEASE:GASTROESOPHAGEAL_REFLUX
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_METABOLISM;DISEASE:GASTROESOPHAGEAL_REFLUX
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;LADME_PK;DECREASED_CLEARANCE;nan
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CLEARANCE;DISEASE:LIVER_TRANSPLANTATION
MIANSERIN;CYP2D6;*1/*10 + *5/*10;CYP2D6*1, CYP2D6*5, CYP2D6*10;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:DEPRESSION
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
SALVIANOLIC ACID B;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED_RESPONSE;OTHER:CORONARY_DISEASE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
VALPROIC ACID;UGT1A6;*1a;UGT1A6*1a, UGT1A6*2a, UGT1A6*3a, UGT1A6*4a, UGT1A6*8;LADME_PK;METABOLISM;DISEASE:EPILEPSY
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:MYASTHENIA_GRAVIS
VALPROIC ACID;UGT1A6;*1a;UGT1A6*1a, UGT1A6*2a, UGT1A6*3a, UGT1A6*4a, UGT1A6*8;DOSAGE;DECREASED_DOSE;DISEASE:EPILEPSY
WARFARIN;CYP2C9;*8/*8;CYP2C9*1, CYP2C9*8;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
CYCLOSPORINE;CYP3A4;*1/*1;CYP3A4*1, CYP3A4*22;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
CAPECITABINE;DPYD;C;rs55886062;DOSAGE;DECREASED_DOSE;nan
FLUOROURACIL;DPYD;C;rs55886062;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
SIROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;DOSAGE;DECREASED_DOSE;DISEASE:DEPRESSION
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A4;*18;CYP3A4*1, CYP3A4*18;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;DOSAGE;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;EFFICACY;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*17;EFFICACY;DECREASED_RESPONSE;DISEASE:FUNGAL_INFECTIOUS_DISEASE
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;LADME_PK;DECREASED_METABOLISM;nan
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*17;EFFICACY;DECREASED_RESPONSE;DISEASE:FUNGAL_INFECTIOUS_DISEASE
ENDOXIFEN;CYP2D6;nan;CYP2D6 normal metabolizer and ultrarapid metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
IMIPRAMINE;CYP2C19;*2;CYP2C19*1, CYP2C19*2;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
O-DESMETHYLTRAMADOL;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:LOW_BACK_PAIN | DISEASE:OSTEOARTHRITIS
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
ISONIAZID;NAT2;slow_acetylator;NAT2;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:TUBERCULOSIS
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;DOSAGE;DECREASED_DOSE;DISEASE:COLORECTAL_NEOPLASMS
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;DOSAGE;DECREASED_DOSE;DISEASE:COLORECTAL_NEOPLASMS
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:FUNGAL_INFECTIOUS_DISEASE
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;LADME_PK;DECREASED_METABOLISM;nan
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;LADME_PK;DECREASED_METABOLISM;nan
RABEPRAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;LADME_PK;DECREASED_METABOLISM;nan
CORTICOSTEROIDS;NR1I2;del/del;rs3842689;EFFICACY;INCREASED_RESISTANCE;nan
PEGINTERFERON ALFA-2B;IFNL4;GG;rs11322783;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;GG;rs11322783;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
IRINOTECAN;UGT1A1;*1/*28;UGT1A1*1, UGT1A1*28;DOSAGE;DECREASED_DOSE;DISEASE:COLORECTAL_NEOPLASMS
VORICONAZOLE;CYP2C19;nan;CYP2C19 poor metabolizers and intermediate metabolizers;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:FUNGAL_INFECTIOUS_DISEASE
MEPHENYTOIN;CYP2C19;*26;CYP2C19*1, CYP2C19*26;LADME_PK;DECREASED_METABOLISM;nan
OMEPRAZOLE;CYP2C19;*26;CYP2C19*1, CYP2C19*26;LADME_PK;DECREASED_METABOLISM;nan
IRBESARTAN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
ESCITALOPRAM;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;LADME_PK;DECREASED_EXPOSURE;nan
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
ESCITALOPRAM;CYP2C19;*2 + *3 + *4;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4;LADME_PK;INCREASED_EXPOSURE;nan
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;DISEASE:CARDIOVASCULAR_DISEASE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CLEARANCE;DISEASE:LIVER_TRANSPLANTATION
SIPOGLITAZAR;UGT2B15;*2/*2;UGT2B15*1, UGT2B15*2;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
SIPOGLITAZAR;UGT2B15;*2/*2;UGT2B15*1, UGT2B15*2;LADME_PK;INCREASED_RESPONSE;nan
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
SERTRALINE;CYP2B6;*6/*9 + *1/*6 + *6/*6;CYP2B6*1, CYP2B6*6, CYP2B6*9;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
CLOMIPRAMINE;CYP2D6;*1/*1xN;CYP2D6*1, CYP2D6*1xN;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:DEPRESSION
TAMOXIFEN;CYP2D6;*10/*10 + *1/*10;CYP2D6*1, CYP2D6*10;DOSAGE;INCREASED_DOSE;DISEASE:BREAST_NEOPLASMS
TAMOXIFEN;CYP2D6;*10/*10 + *1/*10;CYP2D6*1, CYP2D6*10;LADME_PK;INCREASED_DOSE;DISEASE:BREAST_NEOPLASMS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_RESISTANCE;DISEASE:STROKE
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
NORTRIPTYLINE;CYP2D6;*2/*1xN;CYP2D6*1xN, CYP2D6*2;LADME_PK;INCREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;DISEASE:CEREBRAL_SINOVENOUS_THROMBOSIS
EFAVIRENZ;CYP2B6;*1/*26 + *6/*6 + *6/*26;CYP2B6*1, CYP2B6*6, CYP2B6*26;DOSAGE;DECREASED_DOSE;DISEASE:HIV_INFECTIOUS_DISEASE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;DISEASE:CEREBRAL_SINOVENOUS_THROMBOSIS
NORTRIPTYLINE;CYP2D6;*2/*1xN;CYP2D6*1xN, CYP2D6*2;DOSAGE;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
NORTRIPTYLINE;CYP2D6;*2/*1xN;CYP2D6*1xN, CYP2D6*2;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;*1;CYP3A5*1;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;RESPONSE;DISEASE:MYOCARDIAL_INFARCTION
PRASUGREL;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;RESPONSE;DISEASE:MYOCARDIAL_INFARCTION
CLOPIDOGREL;CYP2C19;*2 + *3 + *17;CYP2C19*2, CYP2C19*3, CYP2C19*17;DOSAGE;DOSE;nan
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
CLOMIPRAMINE;CYP2D6;*2/*1xN;CYP2D6*1xN, CYP2D6*2;DOSAGE;DECREASED_RESPONSE;DISEASE:AGORAPHOBIA
CLOMIPRAMINE;CYP2D6;*2/*1xN;CYP2D6*1xN, CYP2D6*2;EFFICACY;DECREASED_RESPONSE;DISEASE:AGORAPHOBIA
SERTRALINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;DECREASED_METABOLISM;nan
SERTRALINE;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*17;LADME_PK;INCREASED_METABOLISM;nan
NICOTINE;CYP2A6;*4/*17 + *9/*26;CYP2A6*4, CYP2A6*9, CYP2A6*17, CYP2A6*26;LADME_PK;DECREASED_METABOLISM;nan
SERTRALINE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;DECREASED_METABOLISM;nan
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_RESISTANCE;DISEASE:STROKE
ENDOXIFEN;CYP2D6;*3/*4 + *4/*4;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*41;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ENDOXIFEN;CYP2D6;*4/*4 + *3/*4 + *4/*5 + *4/*6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
MORPHINE;SLC22A1;GAT/del + del/del;rs72552763;LADME_PK;DECREASED_CLEARANCE;nan
ENDOXIFEN;CYP2D6;*4/*41 + *4/*10 + *4/*17 + *5/*41;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*17, CYP2D6*41;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ENDOXIFEN;CYP2D6;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
IMATINIB;GSTT1;null/null;GSTT1 non-null, GSTT1 null;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
GLUCOCORTICOIDS;HSD3B1;AA + AC;rs1047303;EFFICACY;INCREASED_RESISTANCE;OTHER:ASTHMA
DEXTROMETHORPHAN;CYP2D6;*12/*84 + *4xN/*29;CYP2D6*4xN, CYP2D6*12, CYP2D6*29, CYP2D6*84;LADME_PK;DECREASED_METABOLISM;nan
LANSOPRAZOLE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_METABOLISM;nan
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*17;LADME_PK;INCREASED_METABOLISM;nan
VORICONAZOLE;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_METABOLISM;nan
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:FUNGAL_INFECTIOUS_DISEASE
VORICONAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*1, CYP2C19*17;LADME_PK;INCREASED_METABOLISM;nan
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;nan
ENDOXIFEN;CYP2D6;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
SIMVASTATIN;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;LADME_PK;CONCENTRATIONS;nan
MORPHINE;SLC22A1;del/del;rs72552763;LADME_PK;DECREASED_CLEARANCE;OTHER:ADENOTONSILLECTOMY
METHOTREXATE;SLCO1B1;*5;SLCO1B1*1, SLCO1B1*5, SLCO1B1*37;LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_METABOLISM;DISEASE:ACUTE_CORONARY_SYNDROME
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;DISEASE:MOOD_DISORDER
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;DISEASE:MOOD_DISORDER
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
SILDENAFIL;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEART_FAILURE
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
SN-38;UGT1A1;*28/*28 + *1/*28;UGT1A1*1, UGT1A1*28;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
EFAVIRENZ;CYP2B6;*6;CYP2B6*6;LADME_PK;METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;C;rs55918055;EFFICACY;DECREASED_RESPONSE;nan
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;C;rs55918055;LADME_PK;DECREASED_RESPONSE;nan
FLUOROURACIL;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;rs45445694;EFFICACY;INCREASED_RESPONSE;DISEASE:RECTAL_NEOPLASMS
BILIRUBIN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1, UGT1A1*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:NEOPLASMS
METHADONE;CYP2C9;*1/*2 + *1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;LADME_PK;INCREASED_CONCENTRATIONS;nan
BILIRUBIN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:NEOPLASMS
METHADONE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CONCENTRATIONS;nan
METHADONE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_CONCENTRATIONS;nan
METHOTREXATE;SLCO1B1;*14;SLCO1B1*1, SLCO1B1*14, SLCO1B1*37;LADME_PK;INCREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
WARFARIN;CYP2C9;*1/*1;CYP2C9*1;DOSAGE;INCREASED_DOSE;nan
WARFARIN;CYP2C9;*1/*1;CYP2C9*1;LADME_PK;INCREASED_DOSE;nan
SN-38;UGT1A1;*6/*6 + *1/*6;UGT1A1*1, UGT1A1*6;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
PAROXETINE;CYP2D6;*1/*1;CYP2D6*1, CYP2D6*1xN;LADME_PK;INCREASED_CLEARANCE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
EFAVIRENZ;CYP2B6;*1/*1;CYP2B6*1, CYP2B6*6;LADME_PK;INCREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
VENLAFAXINE;CYP2D6;*3/*9 + *4/*17 +  *4/*41 + *4/*10;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41;DOSAGE;DECREASED_DOSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PACLITAXEL;CYP2C8;*3;CYP2C8*3;LADME_PK;DECREASED_EXPOSURE;DISEASE:BREAST_NEOPLASMS
PANTOPRAZOLE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_CLEARANCE;nan
CLOBAZAM;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;METABOLISM;nan
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DOSE;nan
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
GLATIRAMER ACETATE;CCR5;del;rs333;EFFICACY;DECREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
WARFARIN;CYP2C9;*1/*13 + *1/*16 + *1/*60;CYP2C9*1, CYP2C9*3, CYP2C9*13, CYP2C9*16, CYP2C9*60;DOSAGE;DECREASED_DOSE;OTHER:ATRIAL_FIBRILLATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;*1/*1;CYP3A4*1, CYP3A4*22;LADME_PK;DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
AZATHIOPRINE;TPMT;*3A/*3C;TPMT*1, TPMT*3A, TPMT*3C;DOSAGE;DECREASED_DOSE;DISEASE:CROHN_DISEASE
AZATHIOPRINE;TPMT;*3A/*3C;TPMT*1, TPMT*3A, TPMT*3C;EFFICACY;DECREASED_DOSE;DISEASE:CROHN_DISEASE
AZATHIOPRINE;TPMT;*3A/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;DECREASED_DOSE;DISEASE:CROHN_DISEASE
AZATHIOPRINE;TPMT;*3A/*3A;TPMT*1, TPMT*3A;DOSAGE;DECREASED_DOSE;DISEASE:CROHN_DISEASE
AZATHIOPRINE;TPMT;*3A/*3A;TPMT*1, TPMT*3A;EFFICACY;DECREASED_DOSE;DISEASE:CROHN_DISEASE
AZATHIOPRINE;TPMT;*3A/*3A;TPMT*1, TPMT*3A;TOXICITY;DECREASED_DOSE;DISEASE:CROHN_DISEASE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2, CYP2C9*3;DOSAGE;DOSE;nan
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*9;LADME_PK;DECREASED_METABOLISM;DISEASE:ASTHMA
GLIPIZIDE;TCF7L2;T;rs7903146;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*17;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;nan
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED_RESPONSE;DISEASE:CAROTID_ARTERY_DISEASES
CLOPIDOGREL;SLC14A2;T;rs12456693;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_B_VIRUS_INFECTION
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_B_VIRUS_INFECTION
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_B_VIRUS_INFECTION
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
CISPLATIN;TPMT;*3C;TPMT*3C;EFFICACY;DECREASED_RESPONSE;DISEASE:HEAD_AND_NECK_NEOPLASMS
FLUOROURACIL;TPMT;*3C;TPMT*3C;EFFICACY;DECREASED_RESPONSE;DISEASE:HEAD_AND_NECK_NEOPLASMS
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
CAVOSONSTAT;CFTR;del/del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
BUPROPION;CYP2B6;*6;CYP2B6*6;LADME_PK;DECREASED_METABOLISM;nan
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;LADME_PK;DECREASED_METABOLISM;DISEASE:CORONARY_ARTERY_DISEASE
RISPERIDONE;CYP2D6;*10 + *5;CYP2D6*5, CYP2D6*10;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:SCHIZOPHRENIA
VORICONAZOLE;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;LADME_PK;INCREASED_TROUGH CONCENTRATION;nan
ZUCLOPENTHIXOL;CYP2D6;*4;CYP2D6*1, CYP2D6*4;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
NEVIRAPINE;NR1I2;GAGAAG/del + del/del;rs3842689;DOSAGE;INCREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
NEVIRAPINE;NR1I2;GAGAAG/del + del/del;rs3842689;LADME_PK;INCREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:FUNGAL_INFECTIOUS_DISEASE
MIDAZOLAM;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
SN-38;UGT1A1;*6 + *28;UGT1A1*1, UGT1A1*6, UGT1A1*28;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:COLORECTAL_NEOPLASMS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;DOSAGE;DECREASED_DOSE;DISEASE:TRANSPLANTATION
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
HALOPERIDOL;CYP2D6;*5;CYP2D6*1, CYP2D6*5;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_METABOLISM;DISEASE:ULCERATIVE_COLITIS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*17;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:FUNGAL_INFECTIOUS_DISEASE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;LADME_PK;DECREASED_METABOLISM;DISEASE:CORONARY_ARTERY_DISEASE
MEASLES VACCINES;HLA-B;*51:01;HLA-B*51:01;EFFICACY;DECREASED_RESPONSE;nan
BUCINDOLOL;ADRA2C;GGGGCGGGGCCG/GGGGCGGGGCCG;rs61767072;EFFICACY;INCREASED_RESPONSE;DISEASE:HEART_FAILURE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
RISPERIDONE;CYP2D6;nan;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;DOSAGE;DECREASED_DOSE;DISEASE:PSYCHOTIC_DISORDER
MEASLES VACCINES;HLA-B;*07:02;HLA-B*07:02;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
MEASLES VACCINES;HLA-B;*13:01;HLA-B*13:01;EFFICACY;DECREASED_RESPONSE;nan
MEASLES VACCINES;HLA-B;*08:01;HLA-B*08:01;EFFICACY;DECREASED_RESPONSE;nan
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
INFLUENZA VACCINES;HLA-DQB1;*03:03;HLA-DQB1*03:03;EFFICACY;DECREASED_RESPONSE;nan
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
MEASLES VACCINES;HLA-DQA1;*02:01;HLA-DQA1*02:01;EFFICACY;DECREASED_RESPONSE;nan
MEASLES VACCINES;HLA-DRB1;*03:01;HLA-DRB1*03:01;EFFICACY;DECREASED_RESPONSE;nan
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;*1/*20;CYP3A4*1, CYP3A4*20;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;nan
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;nan
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
FLUOROURACIL;DPYD;POOR_METABOLIZER;DPYD;DOSAGE;DECREASED_DOSE;DISEASE:COLORECTAL_NEOPLASMS | DISEASE:GASTROINTESTINAL_NEOPLASMS | DISEASE:RECTAL_NEOPLASMS
EFAVIRENZ;CYP2B6;*6;CYP2B6*1, CYP2B6*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
ESOMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;OTHER:HEART_TRANSPLANTATION
CISPLATIN;TPMT;*3B;TPMT*3B;EFFICACY;DECREASED_RESPONSE;DISEASE:HEAD_AND_NECK_NEOPLASMS
FLUOROURACIL;TPMT;*3B;TPMT*3B;EFFICACY;DECREASED_RESPONSE;DISEASE:HEAD_AND_NECK_NEOPLASMS
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;OTHER:HEART_TRANSPLANTATION
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_METABOLISM;DISEASE:ULCERATIVE_COLITIS
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
AMITRIPTYLINE;CYP2D6;*4/*5 + *4/*4;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10;LADME_PK;DECREASED_METABOLISM;nan
SIROLIMUS;ABCB1;GG;rs1128503;LADME_PK;DECREASED_EXPOSURE;DISEASE:URINARY_BLADDER_NEOPLASMS
TEMSIROLIMUS;ABCB1;GG;rs1128503;LADME_PK;DECREASED_EXPOSURE;DISEASE:URINARY_BLADDER_NEOPLASMS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CLEARANCE;OTHER:LUNG_TRANSPLANTATION
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*4;LADME_PK;INCREASED_CONCENTRATIONS;nan
PHENPROCOUMON;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
WARFARIN;CYP2C9;*1/*59;CYP2C9*1, CYP2C9*59;DOSAGE;DECREASED_DOSE;nan
METHADONE;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;LADME_PK;INCREASED_CONCENTRATIONS;nan
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
GRANISETRON;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CLEARANCE;nan
CODEINE;CYP2D6;*40;CYP2D6*1, CYP2D6*40;EFFICACY;DECREASED_RESPONSE;DISEASE:SICKLE_CELL_ANEMIA
CODEINE;CYP2D6;*17;CYP2D6*1, CYP2D6*17;EFFICACY;DECREASED_RESPONSE;DISEASE:SICKLE_CELL_ANEMIA
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;OTHER;INCREASED_DISCONTINUATION;DISEASE:RHEUMATOID_ARTHRITIS
CODEINE;CYP2D6;*6;CYP2D6*1, CYP2D6*6;EFFICACY;DECREASED_RESPONSE;DISEASE:SICKLE_CELL_ANEMIA
CODEINE;CYP2D6;*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED_RESPONSE;DISEASE:SICKLE_CELL_ANEMIA
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;EFFICACY;DECREASED_RESPONSE;DISEASE:STROKE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;EFFICACY;DECREASED_RESPONSE;DISEASE:STROKE
CODEINE;CYP2D6;*5;CYP2D6*1, CYP2D6*5;EFFICACY;DECREASED_RESPONSE;DISEASE:SICKLE_CELL_ANEMIA
GRANISETRON;CYP1A1;*2A;CYP1A1*1, CYP1A1*2A;LADME_PK;INCREASED_CLEARANCE;nan
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:RHEUMATOID_ARTHRITIS
CLOMIPRAMINE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_METABOLISM;DISEASE:MENTAL_DISORDERS
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
HMG COA REDUCTASE INHIBITORS;UGT1A1;*28;UGT1A1*28;TOXICITY;DECREASED_DISCONTINUATION;DISEASE:HYPERLIPIDEMIAS
ROCURONIUM;SLCO1A2;CC;rs7967354;DOSAGE;DECREASED_DOSE;nan
PHENPROCOUMON;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
NORTRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MENTAL_DISORDERS
AMITRIPTYLINE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MENTAL_DISORDERS
EFAVIRENZ;CYP2B6;*11;CYP2B6*1, CYP2B6*11;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:HIV_INFECTIOUS_DISEASE | DISEASE:TUBERCULOSIS
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;T;rs12208357;EFFICACY;DECREASED_RESPONSE;nan
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;T;rs12208357;LADME_PK;DECREASED_RESPONSE;nan
EFAVIRENZ;CYP2B6;*6;CYP2B6*1, CYP2B6*6;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:HIV_INFECTIOUS_DISEASE | DISEASE:TUBERCULOSIS
ACENOCOUMAROL;CYP2C9;*3 + *2;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RESPONSE;DISEASE:RECTAL_NEOPLASMS
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RESPONSE;DISEASE:RECTAL_NEOPLASMS
AMITRIPTYLINE;CYP2C19;*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_METABOLISM;DISEASE:MENTAL_DISORDERS
ACENOCOUMAROL;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_CLEARANCE;nan
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
CARVEDILOL;CYP2D6;*3/*10 + *4/*4;CYP2D6*3, CYP2D6*4, CYP2D6*10;DOSAGE;INCREASED_DOSE;DISEASE:HEART_FAILURE
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
WARFARIN;CYP2C9;*3/*3 + *1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
RABEPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
WARFARIN;CYP2C9;*58;CYP2C9*1, CYP2C9*58;DOSAGE;DECREASED_DOSE;nan
VORICONAZOLE;CYP3A4;*22;CYP3A4*1, CYP3A4*22;LADME_PK;INCREASED_EXPOSURE;nan
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*17;DOSAGE;INCREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS
AMITRIPTYLINE;CYP2C19;*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_METABOLISM;DISEASE:MENTAL_DISORDERS
IMIPRAMINE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
ACENOCOUMAROL;CYP2C9;*1/*3 + *2/*3 + *2/*2;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
VARENICLINE;CYP2A6;nan;CYP2A6 normal metabolizer;EFFICACY;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
AZATHIOPRINE;GSTM1;nan;GSTM1 non-null, GSTM1 null;LADME_PK;INCREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*1/*12;CYP2C9*1, CYP2C9*12;DOSAGE;DECREASED_DOSE;nan
RALOXIFENE;UGT1A8;*1a/*3;UGT1A8*1a, UGT1A8*2, UGT1A8*3;LADME_PK;INCREASED_METABOLISM;nan
PHENAZEPAM;CYP2C19;*17;CYP2C19*1, CYP2C19*17;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ALCOHOL_ABUSE | OTHER:ANXIETY_DISORDERS
DAUNORUBICIN;G6PD;Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham;G6PD Mediterranean, Dallas, Panama, Sassari, Cagliari, Birmingham;LADME_PK;DECREASED_METABOLISM;nan
WARFARIN;CYP2C9;*5 + *6 + *11;CYP2C9*1, CYP2C9*5, CYP2C9*6, CYP2C9*11;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
DOLUTEGRAVIR;UGT1A1;*28/*28 + *28/*37 + *1/*6 + *1/*28 + *1/*37 + *28/*36 + *36/*37;UGT1A1*1, UGT1A1*6, UGT1A1*28, UGT1A1*36, UGT1A1*37;LADME_PK;DECREASED_CLEARANCE;nan
NICOTINE;CYP2B6;*6;CYP2B6*1, CYP2B6*6;LADME_PK;DECREASED_METABOLISM;nan
MERCAPTOPURINE;TPMT;*3A/*3C;TPMT*3A, TPMT*3C;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MERCAPTOPURINE;TPMT;*3A/*3C;TPMT*3A, TPMT*3C;EFFICACY;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MERCAPTOPURINE;TPMT;*3A/*3C;TPMT*3A, TPMT*3C;TOXICITY;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
DIMETHYL FUMARATE;GSTP1;GG;rs1695;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
MERCAPTOPURINE;TPMT;*3A/*3A;TPMT*3A;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MERCAPTOPURINE;TPMT;*3A/*3A;TPMT*3A;EFFICACY;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MERCAPTOPURINE;TPMT;*3A/*3A;TPMT*3A;TOXICITY;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
VENLAFAXINE;CYP2D6;*1/*3 + *1/*4 + *1/*5;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;LADME_PK;DECREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_METABOLISM;DISEASE:ULCERATIVE_COLITIS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*1, TPMT*3A, TPMT*3C;OTHER;INCREASED_DISCONTINUATION;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
WARFARIN;CYP2C9;*2 + *3 + *5 + *8 + *11;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*8, CYP2C9*11;DOSAGE;DECREASED_DOSE;nan
O-DESMETHYLTRAMADOL;CYP2D6;ULTRARAPID_METABOLIZER;CYP2D6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:LOW_BACK_PAIN | DISEASE:OSTEOARTHRITIS
TOREMIFENE;CYP2D6;*10;CYP2D6*10;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BREAST_NEOPLASMS
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;EFFICACY;DECREASED_RESPONSE;DISEASE:MALARIA
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED_RESPONSE;nan
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;nan
TAMOXIFEN;CYP2C19;*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_METABOLISM;DISEASE:BREAST_NEOPLASMS
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;A;rs34059508;EFFICACY;DECREASED_RESPONSE;nan
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;A;rs34059508;LADME_PK;DECREASED_RESPONSE;nan
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;OTHER;INCREASED_RESISTANCE;DISEASE:CORONARY_ARTERY_DISEASE
CAPECITABINE;TYMP;AA + AG;rs11479;DOSAGE;DOSE;DISEASE:COLORECTAL_NEOPLASMS
FLUOROURACIL;TYMP;AA + AG;rs11479;DOSAGE;DOSE;DISEASE:COLORECTAL_NEOPLASMS
USTEKINUMAB;HLA-C;*06:02;HLA-C*06:02;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DOSE;DISEASE:ATRIAL_FIBRILLATION | DISEASE:PULMONARY_EMBOLISM | DISEASE:STROKE | DISEASE:VENOUS_THROMBOSIS
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DOSE;nan
DOXEPIN;CYP2D6;*3/*4;CYP2D6*3, CYP2D6*4;LADME_PK;DECREASED_METABOLISM;nan
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PHENYTOIN;CYP2C19;*2 + *3;CYP2C19*2, CYP2C19*3;DOSAGE;DOSE;DISEASE:EPILEPSY
CLOZAPINE;SLC6A4;HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
PHENYTOIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DOSE;DISEASE:EPILEPSY
ANTIPSYCHOTICS;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
HALOPERIDOL;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
OLANZAPINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
RISPERIDONE;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
FOLIC ACID;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
FOLIC ACID;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
HYDROXYCHLOROQUINE;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
HYDROXYCHLOROQUINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
SULFASALAZINE;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
SULFASALAZINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_METABOLISM;DISEASE:CORONARY_ARTERY_DISEASE
FLUVASTATIN;ACE;del/del;rs1799752;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
ONDANSETRON;CYP2D6;*1/*1xN;CYP2D6*1, CYP2D6*1xN;LADME_PK;INCREASED_METABOLISM;nan
INTERFERON ALFA-2A;HLA-B;*44:02;HLA-B*44:02;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RECOMBINANT;HLA-B;*44:02;HLA-B*44:02;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;HLA-B;*44:02;HLA-B*44:02;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
ONDANSETRON;CYP2D6;*1/*1xN;CYP2D6*1, CYP2D6*1xN;EFFICACY;DECREASED_RESPONSE;DISEASE:NEOPLASMS
TROPISETRON;CYP2D6;*1/*1xN;CYP2D6*1, CYP2D6*1xN;EFFICACY;DECREASED_RESPONSE;DISEASE:NEOPLASMS
CYCLOSPORINE;CYP3A5;*1;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
PRAVASTATIN;ACE;del/del;rs1799752;EFFICACY;RESPONSE;OTHER:NON-HYPERCHOLESTEROLAEMIC_PATIENTS_SCHEDULED_FOR_ANGIOPLASTY
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*6;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;*1/*18;CYP2B6*1, CYP2B6*18;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;*1/*9;CYP2B6*1, CYP2B6*9;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
SERTRALINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
CAPECITABINE;DPYD;CT;rs3918290;DOSAGE;DOSE;DISEASE:COLORECTAL_NEOPLASMS
FLUOROURACIL;DPYD;CT;rs3918290;DOSAGE;DOSE;DISEASE:COLORECTAL_NEOPLASMS
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;EFFICACY;DECREASED_RESPONSE;nan
4-HYDROXYTAMOXIFEN;CYP2D6;*10;CYP2D6*1, CYP2D6*10;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ENDOXIFEN;CYP2D6;*10;CYP2D6*1, CYP2D6*10;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
(S)-METHADONE;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
METOPROLOL;ADRA2C;del;rs61767072;EFFICACY;INCREASED_RESPONSE;DISEASE:HEART_FAILURE
ENDOXIFEN;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
IMATINIB;ABCG2;GT + TT;rs2231142;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:GASTROINTESTINAL_STROMAL_TUMORS
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
CAPECITABINE;DPYD;AT;rs67376798;DOSAGE;DOSE;DISEASE:COLORECTAL_NEOPLASMS
FLUOROURACIL;DPYD;AT;rs67376798;DOSAGE;DOSE;DISEASE:COLORECTAL_NEOPLASMS
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_METABOLISM;nan
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;LADME_PK;DECREASED_METABOLISM;OTHER:LUNG_TRANSPLANTATION
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
GEFITINIB;EGFR;GT;rs121434568;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
VINCRISTINE;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_METABOLISM;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ENDOXIFEN;CYP2D6;*9/*4;CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ENDOXIFEN;CYP2D6;*9/*41 + *10/*10 + *41/*41;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*41;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
ENDOXIFEN;CYP2D6;*1/*9 + *1/*10 + *1/*41;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*41;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
NORTRIPTYLINE;CYP2D6;*1/*81;CYP2D6*1, CYP2D6*81;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
CAPECITABINE;DPYD;CG;rs75017182;DOSAGE;DOSE;DISEASE:COLORECTAL_NEOPLASMS
FLUOROURACIL;DPYD;CG;rs75017182;DOSAGE;DOSE;DISEASE:COLORECTAL_NEOPLASMS
SIROLIMUS;NR1I2;GG;rs6785049;LADME_PK;INCREASED_EXPOSURE;DISEASE:URINARY_BLADDER_NEOPLASMS
TEMSIROLIMUS;NR1I2;GG;rs6785049;LADME_PK;INCREASED_EXPOSURE;DISEASE:URINARY_BLADDER_NEOPLASMS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CLEARANCE;DISEASE:LAPAROSCOPIC_SLEEVE_GASTRECTOMY
TACROLIMUS;nan;G;rs4646458;DOSAGE;DOSE;DISEASE:KIDNEY_TRANSPLANTATION
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10;DOSAGE;DECREASED_DOSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ROCURONIUM;IAPP;CC;rs11045995;DOSAGE;DECREASED_DOSE;nan
ROCURONIUM;SLCO1A2;CC;rs11045995;DOSAGE;DECREASED_DOSE;nan
MEASLES VACCINES;HLA-B;*44:02;HLA-B*44:02;EFFICACY;RESPONSE;nan
ENDOXIFEN;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
NORTRIPTYLINE;CYP2D6;*2/*1xN;CYP2D6*1xN, CYP2D6*2;LADME_PK;INCREASED_DOSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:LAPAROSCOPIC_SLEEVE_GASTRECTOMY
METOPROLOL;CYP2D6;del/del;rs5030655;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
AMOXICILLIN;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;RESPONSE;nan
AMOXICILLIN;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
MERCAPTOPURINE;NUDT15;*2/*3;NUDT15*1, NUDT15*2, NUDT15*3;TOXICITY;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5;TOXICITY;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
ESTRONE SULFATE;SLCO1B1;*5;SLCO1B1*1, SLCO1B1*5;LADME_PK;INCREASED;OTHER:BREAST_NEOPLASMS
HMG COA REDUCTASE INHIBITORS;CXCL5;CC;rs352046;EFFICACY;INCREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
AMOXICILLIN;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;DISEASE:VENOUS_THROMBOEMBOLISM
DEBRISOQUINE;CYP2D6;*4/*5 + *4/*15 + *4/*6 + *3/*4 + *4/*4 + *3/*5;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*15;LADME_PK;DECREASED_METABOLISM;nan
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:LEUKEMIA
DEXTROMETHORPHAN;CYP2D6;*4/*5 + *4/*15 + *4/*6 + *3/*4 + *4/*4 + *3/*5;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*15;LADME_PK;DECREASED_METABOLISM;nan
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
ATAZANAVIR;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28, UGT1A1*36;TOXICITY;INCREASED_DISCONTINUATION;DISEASE:HIV_INFECTIOUS_DISEASE
RITONAVIR;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28, UGT1A1*36;TOXICITY;INCREASED_DISCONTINUATION;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*1, CYP2C9*2, CYP2C9*5, CYP2C9*6, CYP2C9*11;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*2 + *6 + *5 + *11;CYP2C9*1, CYP2C9*2, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*9, CYP2C9*11;DOSAGE;DECREASED_DOSE;nan
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED_RESPONSE;nan
CYCLOSPORINE;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CONCENTRATIONS;nan
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DOSE;nan
ENDOXIFEN;CYP2D6;*4 + *6 + *8;CYP2D6*1, CYP2D6*4, CYP2D6*6, CYP2D6*8;LADME_PK;DECREASED_CONCENTRATIONS;nan
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
TELAPREVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DOSE;nan
METFORMIN;CSMD1;CT + TT;rs2954625;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
ATAZANAVIR;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_DISCONTINUATION;OTHER:HIV_INFECTIOUS_DISEASE
RITONAVIR;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_DISCONTINUATION;OTHER:HIV_INFECTIOUS_DISEASE
ESTRONE;SLCO1B1;*5/*5;SLCO1B1*1, SLCO1B1*5;EFFICACY;INCREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED_RESPONSE;nan
VORICONAZOLE;ABCB1;AA;rs1045642;LADME_PK;DECREASED_TROUGH CONCENTRATION;nan
MERCAPTOPURINE;NT5C2;AA + AG;rs72846714;LADME_PK;DECREASED_METABOLISM;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
HALOPERIDOL;CYP2D6;*2/*2;CYP2D6*1, CYP2D6*2;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:SCHIZOPHRENIA
CYCLOSPORINE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED_DOSE;nan
IRINOTECAN;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
OXALIPLATIN;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
TEGAFUR;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
GIMERACIL;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
OTERACIL;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
WARFARIN;CYP2C9;*1/*8 + *8/*8;CYP2C9*1, CYP2C9*8;LADME_PK;DECREASED_CLEARANCE;nan
WARFARIN;VKORC1;T;rs7294;DOSAGE;INCREASED_DOSE;nan
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2, CYP2C9*3;DOSAGE;DOSE;nan
ENDOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;CYP2D6*1, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
AZATHIOPRINE;TPMT;*2 + *3A + *3B + *3C;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C;DOSAGE;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C;DOSAGE;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
PURINE ANALOGUES;TPMT;*2 + *3A + *3B + *3C;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C;DOSAGE;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
SERTRALINE;CYP2C18;GG;rs11188059;LADME_PK;DECREASED_CONCENTRATIONS;nan
IRINOTECAN;CYP2A6;*4 + *7 + *9;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
OXALIPLATIN;CYP2A6;*4 + *7 + *9;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
TEGAFUR;CYP2A6;*4 + *7 + *9;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
GIMERACIL;CYP2A6;*4 + *7 + *9;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
OTERACIL;CYP2A6;*4 + *7 + *9;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
DONEPEZIL;CYP2D6;*4/*4 + *4/*5;CYP2D6*4, CYP2D6*5;LADME_PK;DECREASED_CLEARANCE;DISEASE:ALZHEIMER_DISEASE
DEBRISOQUINE;CYP2D6;*4/*17;CYP2D6*4, CYP2D6*17;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;nan;CYP2A6 high activity;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A;TPMT*1, TPMT*2, TPMT*3A;DOSAGE;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*1, TPMT*2, TPMT*3A;DOSAGE;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
PURINE ANALOGUES;TPMT;*1/*2 + *1/*3A;TPMT*1, TPMT*2, TPMT*3A;DOSAGE;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
FENTANYL;CYP2D6;*29;CYP2D6*1, CYP2D6*29;LADME_PK;DECREASED_CLEARANCE;OTHER:BURNS
ENDOXIFEN;CYP2D6;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*41;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
DEXTROMETHORPHAN;CYP2D6;*4xN/*56;CYP2D6*4xN, CYP2D6*56;LADME_PK;DECREASED_METABOLISM;nan
LEVONORGESTREL;CYP2B6;GT + TT;rs3745274;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
ADALIMUMAB;nan;T;rs9828223;EFFICACY;DECREASED_RESPONSE;OTHER:CROHN_DISEASE
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED_RESPONSE;OTHER:COLORECTAL_NEOPLASMS
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PROGESTERONE;CYP2C19;*1/*2 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;LADME_PK;INCREASED_EXPOSURE;nan
TACROLIMUS;CYP3A5;*3 + *6 + *7;CYP3A5*3, CYP3A5*6, CYP3A5*7;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
DONEPEZIL;CYP2D6;*1/*1xN + *1xN/*1xN;CYP2D6*1, CYP2D6*1xN;LADME_PK;INCREASED_CLEARANCE;DISEASE:ALZHEIMER_DISEASE
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1, CYP2B6*6;EFFICACY;DECREASED_RESPONSE;DISEASE:LEUKEMIA | LYMPHOCYTIC | CHRONIC | B-CELL
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1, CYP2B6*6;EFFICACY;DECREASED_RESPONSE;DISEASE:LEUKEMIA | LYMPHOCYTIC | CHRONIC | B-CELL
LEVONORGESTREL;CYP2B6;CT;rs4803419;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
MERCAPTOPURINE;TPMT;POOR_METABOLIZER;TPMT;LADME_PK;INCREASED_CONCENTRATIONS;nan
ATORVASTATIN;IFNL3;CC;rs12979860;EFFICACY;DECREASED_CLEARANCE;nan
ATORVASTATIN;IFNL4;CC;rs12979860;EFFICACY;DECREASED_CLEARANCE;nan
SORAFENIB;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;LADME_PK;INCREASED_EXPOSURE;DISEASE:NEOPLASMS
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B;TOXICITY;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
CLOBAZAM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;DECREASED_DOSE;DISEASE:EPILEPSY
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;METABOLISM;DISEASE:EPILEPSY
OMEPRAZOLE;CYP2C19;*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;LADME_PK;DECREASED_CLEARANCE;DISEASE:GASTROESOPHAGEAL_REFLUX
ATENOLOL;ACE;del/del;rs1799752;EFFICACY;INCREASED_RESISTANCE;DISEASE:KIDNEY_DISORDER
ENALAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED_RESISTANCE;DISEASE:KIDNEY_DISORDER
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;LADME_PK;INCREASED_CONCENTRATIONS;nan
MERCAPTOPURINE;TPMT;*1/*3C + *1/*2 + *1/*3A;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;METABOLISM;DISEASE:EPILEPSY
BREXPIPRAZOLE;CYP2D6;INTERMEDIATE_METABOLIZER;CYP2D6;LADME_PK;DECREASED_METABOLISM;OTHER:SCHIZOPHRENIA
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESISTANCE;DISEASE:EPILEPSY
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
LOPINAVIR;CYP3A4;*22/*22;CYP3A4*1, CYP3A4*22;LADME_PK;DECREASED_CLEARANCE;OTHER:HIV_INFECTIOUS_DISEASE
CLOBAZAM;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;METABOLISM;DISEASE:EPILEPSY
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
CLOBAZAM;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;LADME_PK;METABOLISM;DISEASE:EPILEPSY
NICOTINE;CYP2A6;*4/*9 + *9/*9;CYP2A6*1, CYP2A6*4, CYP2A6*9;LADME_PK;DECREASED_METABOLISM;nan
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
CLOBAZAM;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;LADME_PK;METABOLISM;DISEASE:EPILEPSY
EFAVIRENZ;ABCB1;C;rs3842;LADME_PK;METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
CLOBAZAM;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;LADME_PK;METABOLISM;DISEASE:EPILEPSY
CITALOPRAM;SERPINE1;G;rs2227631;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
FLUOXETINE;SERPINE1;G;rs2227631;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PHENYTOIN;CYP2C9;AG;rs12782374;OTHER;INCREASED_METABOLISM;nan
PHENYTOIN;CYP2C9;AG;rs12782374;LADME_PK;INCREASED_METABOLISM;nan
PHENYTOIN;CYP2C9;GT/del + del/del;rs71486745;DOSAGE;DECREASED_DOSE;DISEASE:EPILEPSY
PHENYTOIN;CYP2C9;GT/del + del/del;rs71486745;LADME_PK;DECREASED_DOSE;DISEASE:EPILEPSY
ATENOLOL;SLC25A31;TTA/del;rs201279313;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
HYDROCHLOROTHIAZIDE;SLC25A31;TTA/del;rs201279313;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
METOPROLOL;SLC25A31;TTA/del;rs201279313;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
CAPTOPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
IRINOTECAN;UGT1A1;*28;UGT1A1*1, UGT1A1*28;DOSAGE;DECREASED_DOSE;OTHER:ADENOCARCINOMA | OTHER:GASTROINTESTINAL_NEOPLASMS
TEGAFUR;CYP2A6;*1/*1;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;LADME_PK;INCREASED_METABOLISM;DISEASE:BILIARY_TRACT_NEOPLASM
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TAMOXIFEN;CYP2C19;*17;CYP2C19*1, CYP2C19*17;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
TAMOXIFEN;CYP2C19;*17;CYP2C19*1, CYP2C19*17;LADME_PK;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
WARFARIN;CYP2C9;*1/*1;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;INCREASED_DOSE;nan
TAMOXIFEN;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
TAMOXIFEN;CYP2C19;*2;CYP2C19*1, CYP2C19*2;LADME_PK;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED_RESPONSE;DISEASE:HEART_FAILURE
MERCAPTOPURINE;CNNM2;CC + CT;rs58700372;LADME_PK;DECREASED_METABOLISM;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
OXYCODONE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:NEOPLASMS
VORICONAZOLE;CYP2C19;*1/*1 + *1/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:HEMATOLOGIC_DISORDER
PHENYTOIN;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;LADME_PK;INCREASED_CONCENTRATIONS;nan
FLUOROURACIL;TYMS;TTAAAGTTA/del;rs11280056;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
PRIMAQUINE;CYP2D6;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41;EFFICACY;DECREASED_RESPONSE;DISEASE:MALARIA
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;LADME_PK;INCREASED_CONCENTRATIONS;nan
SERTRALINE;ACE;del/del;rs1799752;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;LADME_PK;DECREASED_CLEARANCE;DISEASE:MALARIA
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*1, TPMT*3C;DOSAGE;INCREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*1, TPMT*3C;TOXICITY;INCREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;TOXICITY;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
O-DESMETHYLTRAMADOL;CYP2D6;nan;CYP2D6 deficiency;LADME_PK;DECREASED_EXPOSURE;DISEASE:PAIN
ENDOXIFEN;CYP2D6;*10/*10 + *5/*10;CYP2D6*1, CYP2D6*5, CYP2D6*10;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
ESOMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
TACROLIMUS;CYP3A7;*1A/*1A;CYP3A7*1A, CYP3A7*1C;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
KETAMINE;CYP2B6;*6;CYP2B6*1, CYP2B6*6;LADME_PK;DECREASED_CLEARANCE;DISEASE:NEOPLASMS | DISEASE:PAIN
ESOMEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
PANTOPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
ESOMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
PANTOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
ESOMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED_DOSE;nan
CLOMIPRAMINE;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*17;LADME_PK;INCREASED_METABOLISM;DISEASE:CHRONIC_GRANULOMATOUS_DISEASE
CLOMIPRAMINE;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*17;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
CAPECITABINE;DPYD;T;rs3918290;DOSAGE;DECREASED_DOSE;nan
FLUOROURACIL;DPYD;T;rs3918290;DOSAGE;DECREASED_DOSE;nan
ETHANOL;DRD2;A;rs1800497;DOSAGE;INCREASED_DOSE;nan
VARDENAFIL;CYP3A5;TT;rs776746;OTHER;INCREASED_CLEARANCE;nan
VARDENAFIL;CYP3A5;TT;rs776746;LADME_PK;INCREASED_CLEARANCE;nan
ETHANOL;OPRM1;G;rs1799971;DOSAGE;INCREASED_DOSE;nan
IMATINIB;SLC22A1;CC;rs683369;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:GASTROINTESTINAL_STROMAL_TUMORS
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESISTANCE;DISEASE:GASTROESOPHAGEAL_REFLUX
CAPECITABINE;DPYD;T;rs56038477;DOSAGE;DECREASED_DOSE;nan
FLUOROURACIL;DPYD;T;rs56038477;DOSAGE;DECREASED_DOSE;nan
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESISTANCE;DISEASE:GASTROESOPHAGEAL_REFLUX
ACETAMINOPHEN;UGT1A6;*2a;UGT1A6*1a, UGT1A6*2a;LADME_PK;INCREASED_CLEARANCE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
CAPECITABINE;DPYD;A;rs67376798;DOSAGE;DECREASED_DOSE;nan
FLUOROURACIL;DPYD;A;rs67376798;DOSAGE;DECREASED_DOSE;nan
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION | DISEASE:ATRIAL_FLUTTER | DISEASE:VENOUS_THROMBOSIS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
HALOPERIDOL;CYP2D6;*10;CYP2D6*1, CYP2D6*10;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
METHADONE;OPRK1;TT;rs3802281;DOSAGE;DECREASED_DOSE;OTHER:HEROIN_DEPENDENCE
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
AZATHIOPRINE;TPMT;CT;rs1142345;DOSAGE;DECREASED_DOSE;OTHER:ULCERATIVE_COLITIS | OTHER:CROHN_DISEASE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
DEBRISOQUINE;CYP2D6;*17/*17;CYP2D6*17;LADME_PK;DECREASED_METABOLISM;nan
TOLTERODINE;CYP2D6;*3 + *4;CYP2D6*1, CYP2D6*3, CYP2D6*4;LADME_PK;DECREASED_METABOLISM;nan
CITALOPRAM;CYP2D6;*1xN + *2xN;CYP2D6*1xN, CYP2D6*2xN;EFFICACY;DECREASED_RESPONSE;DISEASE:MOOD_DISORDER
MIANSERIN;CYP2D6;*1xN + *2xN;CYP2D6*1xN, CYP2D6*2xN;EFFICACY;DECREASED_RESPONSE;DISEASE:MOOD_DISORDER
MIRTAZAPINE;CYP2D6;*1xN + *2xN;CYP2D6*1xN, CYP2D6*2xN;EFFICACY;DECREASED_RESPONSE;DISEASE:MOOD_DISORDER
NORTRIPTYLINE;CYP2D6;*1xN + *2xN;CYP2D6*1xN, CYP2D6*2xN;EFFICACY;DECREASED_RESPONSE;DISEASE:MOOD_DISORDER
PAROXETINE;CYP2D6;*1xN + *2xN;CYP2D6*1xN, CYP2D6*2xN;EFFICACY;DECREASED_RESPONSE;DISEASE:MOOD_DISORDER
VENLAFAXINE;CYP2D6;*1xN + *2xN;CYP2D6*1xN, CYP2D6*2xN;EFFICACY;DECREASED_RESPONSE;DISEASE:MOOD_DISORDER
SPARTEINE;CYP2D6;*10/*10 + *4/*10;CYP2D6*1, CYP2D6*4, CYP2D6*10;LADME_PK;DECREASED_METABOLISM;nan
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:AUTOIMMUNE_DISEASES
HYDROXYUREA;SIN3A;GG;rs7166737;EFFICACY;DECREASED_RESPONSE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
RABEPRAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;DECREASED_CLEARANCE;DISEASE:HELICOBACTER_INFECTIONS
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
HYDRALAZINE;NAT2;slow_acetylator;NAT2;LADME_PK;DECREASED_METABOLISM;OTHER:HYPERTENSION
EFAVIRENZ;CYP2B6;*1/*6;CYP2B6*1, CYP2B6*6;LADME_PK;INCREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;TT;rs1799964;EFFICACY;INCREASED_RESPONSE;DISEASE:SPONDYLITIS | ANKYLOSING
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
VENLAFAXINE;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;DECREASED_METABOLISM;nan
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
RALTITREXED;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
WARFARIN;CYP2C9;*1/*1;CYP2C9*1, CYP2C9*3;DOSAGE;INCREASED_DOSE;nan
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
VENLAFAXINE;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;DECREASED_METABOLISM;OTHER:ELDERLY_ADULT
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2, CYP2C9*3;DOSAGE;DOSE;DISEASE:ATRIAL_FIBRILLATION | DISEASE:VENOUS_THROMBOEMBOLISM
PEGINTERFERON ALFA-2A;IFNL4;G/TT + TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;G/TT + TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
VENLAFAXINE;CYP2D6;nan;CYP2D6 normal metabolizer;LADME_PK;DECREASED_METABOLISM;OTHER:ELDERLY_ADULT
DEBRISOQUINE;CYP2D6;*4/*4 + *3/*4;CYP2D6*3, CYP2D6*4;LADME_PK;DECREASED_METABOLISM;nan
SPARTEINE;CYP2D6;*4/*4 + *3/*4;CYP2D6*3, CYP2D6*4;LADME_PK;DECREASED_METABOLISM;nan
ESCITALOPRAM;CYP2C19;nan;CYP2C19 normal metabolizer;LADME_PK;DECREASED_METABOLISM;OTHER:ELDERLY_ADULT
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*17;LADME_PK;DECREASED_CONCENTRATIONS;nan
PHENYTOIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;LADME_PK;INCREASED_CONCENTRATIONS;nan
CYCLOPHOSPHAMIDE;CYP2B6;*6;CYP2B6*1, CYP2B6*6;LADME_PK;DECREASED_CLEARANCE;DISEASE:B-CELL_LYMPHOMA
SERTRALINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;OTHER:POSTTRAUMATIC_STRESS_DISORDER
MIDAZOLAM;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CLEARANCE;DISEASE:GASTROINTESTINAL_NEOPLASMS
BUPROPION;HTR2A;CC;rs2770296;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
CAPECITABINE;HLA-G;ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del;rs371194629;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
FLUOROURACIL;HLA-G;ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del;rs371194629;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
VORICONAZOLE;CYP2C19;ULTRARAPID_METABOLIZER;CYP2C19;LADME_PK;DECREASED_CONCENTRATIONS;nan
VORICONAZOLE;CYP2C19;POOR_METABOLIZER;CYP2C19;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:FUNGAL_INFECTIOUS_DISEASE
HYDRALAZINE;NAT2;slow_acetylator;NAT2;LADME_PK;DECREASED_METABOLISM;OTHER:NEOPLASMS
HYDRALAZINE;NAT2;slow_acetylator;NAT2;LADME_PK;DECREASED_METABOLISM;OTHER:NEOPLASMS
PRAVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;INCREASED_RESPONSE;DISEASE:MYOCARDIAL_INFARCTION
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;*2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
DONEPEZIL;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;DECREASED_METABOLISM;DISEASE:ALZHEIMER_DISEASE
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
FLUOXETINE;ABCB1;A;rs2032582;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
4-HYDROXYTAMOXIFEN;CYP2D6;*4/*4 + *4/*5;CYP2D6*1, CYP2D6*4, CYP2D6*5;LADME_PK;DECREASED_CONCENTRATIONS;nan
ENDOXIFEN;CYP2D6;*4/*4 + *4/*5;CYP2D6*1, CYP2D6*4, CYP2D6*5;LADME_PK;DECREASED_CONCENTRATIONS;nan
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_EXPOSURE;OTHER:KIDNEY_TRANSPLANTATION
BUPROPION;CYP2B6;*1/*6 + *6/*6;CYP2B6*1, CYP2B6*6;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
COLCHICINE;CYP2D6;*1/*1;CYP2D6*1, CYP2D6*4;EFFICACY;INCREASED_RESPONSE;DISEASE:FAMILIAL_MEDITERRANEAN_FEVER
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
SERTRALINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TEGAFUR;CYP2A6;*1/*4 + *4/*4 + *4/*7 + *4/*9;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;LADME_PK;DECREASED_METABOLISM;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
ESCITALOPRAM;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
AZATHIOPRINE;GSTM1;nan;GSTM1 non-null, GSTM1 null;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ULCERATIVE_COLITIS | OTHER:CROHN_DISEASE
RISPERIDONE;CYP2D6;*4/*10 + *5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10;LADME_PK;DECREASED_METABOLISM;nan
OXYCODONE;CYP2D6;*4;CYP2D6*4;LADME_PK;INCREASED_CONCENTRATIONS;nan
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*27, UGT1A1*28;DOSAGE;DECREASED_DOSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5;DOSAGE;DECREASED_DOSE;nan
METHADONE;CYP2B6;*6;CYP2B6*1, CYP2B6*6;LADME_PK;DECREASED_CLEARANCE;DISEASE:OPIOID-RELATED_DISORDERS
BUPROPION;DBH;CC;rs2873804;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:RHEUMATOID_ARTHRITIS | DISEASE:SYSTEMIC_LUPUS_ERYTHEMATOSUS
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED_RESPONSE;DISEASE:NEOPLASM_OF_ESOPHAGUS | DISEASE:STOMACH_NEOPLASMS
LEUCOVORIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED_RESPONSE;DISEASE:NEOPLASM_OF_ESOPHAGUS | DISEASE:STOMACH_NEOPLASMS
OXALIPLATIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED_RESPONSE;DISEASE:NEOPLASM_OF_ESOPHAGUS | DISEASE:STOMACH_NEOPLASMS
HYDRALAZINE;NAT2;slow_acetylator;NAT2;LADME_PK;DECREASED_METABOLISM;OTHER:HYPERTENSION
PACLITAXEL;GSTM1;non-null;GSTM1 non-null, GSTM1 null;EFFICACY;DECREASED_RESPONSE;DISEASE:OVARIAN_NEOPLASMS
PLATINUM COMPOUNDS;GSTM1;non-null;GSTM1 non-null, GSTM1 null;EFFICACY;DECREASED_RESPONSE;DISEASE:OVARIAN_NEOPLASMS
WARFARIN;CYP2C9;*3/*13;CYP2C9*1, CYP2C9*3, CYP2C9*13;DOSAGE;DECREASED_DOSE;nan
BLEOMYCIN;GSTM1;non-null/non-null;GSTM1 non-null, GSTM1 null;EFFICACY;INCREASED_RESPONSE;DISEASE:HODGKIN_DISEASE
DACARBAZINE;GSTM1;non-null/non-null;GSTM1 non-null, GSTM1 null;EFFICACY;INCREASED_RESPONSE;DISEASE:HODGKIN_DISEASE
DOXORUBICIN;GSTM1;non-null/non-null;GSTM1 non-null, GSTM1 null;EFFICACY;INCREASED_RESPONSE;DISEASE:HODGKIN_DISEASE
VINBLASTINE;GSTM1;non-null/non-null;GSTM1 non-null, GSTM1 null;EFFICACY;INCREASED_RESPONSE;DISEASE:HODGKIN_DISEASE
METHADONE;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CONCENTRATIONS;nan
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2, CYP2C9*3;DOSAGE;DOSE;nan
S-EDDP;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CONCENTRATIONS;nan
CITALOPRAM;CYP2C19;*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ENALAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HYPERTENSION
LISINOPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HYPERTENSION
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
BUPROPION;SLC18A2;CC;rs363225;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
RALTEGRAVIR;UGT1A9;*3a;UGT1A9*3a;LADME_PK;INCREASED_EXPOSURE;DISEASE:HIV_INFECTIOUS_DISEASE
NICOTINE;CYP2A6;*1/*2 + *1/*9;CYP2A6*1, CYP2A6*2, CYP2A6*9;LADME_PK;DECREASED_METABOLISM;nan
SERTRALINE;CYP2C18;TT;rs2860840;LADME_PK;DECREASED_CONCENTRATIONS;nan
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DOSE;DISEASE:HEART_DISEASES
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;DISEASE:RHEUMATIC_HEART_DISEASE
ARIPIPRAZOLE;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOAFFECTIVE_DISORDER | DISEASE:SCHIZOPHRENIA
4-HYDROXYTAMOXIFEN;CYP3A4;*22;CYP3A4*1, CYP3A4*22;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
TAMOXIFEN;CYP3A4;*22;CYP3A4*1, CYP3A4*22;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RESPONSE;OTHER:RECTAL_NEOPLASMS
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;LADME_PK;INCREASED_CONCENTRATIONS;nan
WARFARIN;CYP2C9;*1/*14;CYP2C9*1, CYP2C9*14;DOSAGE;DECREASED_DOSE;nan
VORICONAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:FUNGAL_INFECTIOUS_DISEASE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;CC;rs1799724;EFFICACY;INCREASED_RESPONSE;DISEASE:SPONDYLITIS | ANKYLOSING
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED_DOSE;nan
ACETYLCYSTEINE;EPHX1;POOR_METABOLIZER;EPHX1;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE
BUPROPION;SLC18A2;GG;rs363226;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;nan
METHOTREXATE;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ISONIAZID;NAT2;*4;NAT2*4;LADME_PK;INCREASED_METABOLISM;DISEASE:TUBERCULOSIS
LEVODOPA;SLC6A3;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;rs3836790;EFFICACY;INCREASED_RESPONSE;DISEASE:PARKINSON_DISEASE
METHYLPHENIDATE;SLC6A3;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;rs3836790;EFFICACY;INCREASED_RESPONSE;DISEASE:PARKINSON_DISEASE
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*29, CYP2D6*41;LADME_PK;DECREASED_CLEARANCE;DISEASE:ADHD
WARFARIN;CYP2C9;*3/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;DISEASE:HEART_DISEASES
WARFARIN;CYP2C9;*3/*3;CYP2C9*1, CYP2C9*3;EFFICACY;DECREASED_DOSE;DISEASE:HEART_DISEASES
LEVODOPA;SLC6A3;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;rs3836790;EFFICACY;INCREASED_RESPONSE;DISEASE:PARKINSON_DISEASE
WARFARIN;CYP2C9;*2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;DISEASE:HEART_DISEASES
WARFARIN;CYP2C9;*2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED_DOSE;DISEASE:HEART_DISEASES
FLUOROURACIL;DPYD;nan;DPYD deficiency;LADME_PK;CLEARANCE;DISEASE:HEAD_AND_NECK_NEOPLASMS
ATOMOXETINE;CYP2D6;*4/*4xN + *4/*4;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*41;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:ADHD
BUPROPION;FKBP5;TT;rs17614642;EFFICACY;DECREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;DISEASE:HEART_DISEASES
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;EFFICACY;DECREASED_DOSE;DISEASE:HEART_DISEASES
WARFARIN;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;DISEASE:HEART_DISEASES
WARFARIN;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;EFFICACY;DECREASED_DOSE;DISEASE:HEART_DISEASES
INTERFERON BETA-1A;ACE;del/del;rs1799752;EFFICACY;DECREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
ETHANOL;OPRM1;AG;rs1799971;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
WARFARIN;EPHX1;CG;rs2260863;DOSAGE;INCREASED_DOSE;nan
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LUNG_TRANSPLANTATION
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;DISEASE:ESOPHAGITIS | DISEASE:GASTROESOPHAGEAL_REFLUX
LOSARTAN;ACE;del/del;rs1799752;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
TACROLIMUS;CYP3A4;GG;rs35599367;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
THALIDOMIDE;CYP2C19;*2;CYP2C19*1, CYP2C19*2;DOSAGE;INCREASED_DOSE;DISEASE:ERYTHEMA_NODOSUM | DISEASE:LEPROSY
CARVEDILOL;CYP2D6;*10;CYP2D6*10;LADME_PK;DECREASED_METABOLISM;DISEASE:ANGINA_PECTORIS
EFAVIRENZ;CYP2B6;*1/*1;CYP2B6*1;LADME_PK;INCREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DOSE;nan
WARFARIN;CYP2C9;*3;CYP2C9*3;LADME_PK;DOSE;nan
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;OTHER:ATRIAL_FIBRILLATION | OTHER:PULMONARY_EMBOLISM | OTHER:VENOUS_THROMBOSIS
WARFARIN;CYP2C9;*8;CYP2C9*8;DOSAGE;DOSE;nan
WARFARIN;CYP2C9;*8;CYP2C9*8;LADME_PK;DOSE;nan
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;LADME_PK;INCREASED_METABOLISM;DISEASE:FUNGAL_INFECTIOUS_DISEASE
DIHYDROCODEINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;LADME_PK;DECREASED_METABOLISM;nan
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6;CYP3A5*1, CYP3A5*3, CYP3A5*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
NICOTINE;CYP2A6;nan;CYP2A6 low activity;DOSAGE;DECREASED_DOSE;DISEASE:TOBACCO_USE_DISORDER
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_METABOLISM;DISEASE:FUNGAL_INFECTIOUS_DISEASE
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:FUNGAL_INFECTIOUS_DISEASE
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;nan
IMATINIB;CYP3A5;CC;rs776746;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:GASTROESOPHAGEAL_REFLUX
PACLITAXEL;SLCO1B1;*5 + *15;SLCO1B1*5, SLCO1B1*15;LADME_PK;INCREASED_EXPOSURE;DISEASE:BREAST_NEOPLASMS
IMIPRAMINE;CYP2C19;*2/*3 + *2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;DECREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_METABOLISM;DISEASE:GASTROESOPHAGEAL_REFLUX
LAMOTRIGINE;UGT2B7;CC;rs7668258;DOSAGE;INCREASED_CLEARANCE;nan
LAMOTRIGINE;UGT2B7;CC;rs7668258;LADME_PK;INCREASED_CLEARANCE;nan
RABEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_METABOLISM;DISEASE:GASTROESOPHAGEAL_REFLUX
BUPRENORPHINE;UGT2B7;*2;UGT2B7;EFFICACY;DECREASED_RESPONSE;DISEASE:PAIN
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;DOSAGE;INCREASED_DOSE;DISEASE:FUNGAL_INFECTIOUS_DISEASE
VORICONAZOLE;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:FUNGAL_INFECTIOUS_DISEASE
IMATINIB;ABCB1;AG;rs1045642;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:FUNGAL_INFECTIOUS_DISEASE
ENDOXIFEN;CYP2D6;nan;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;LADME_PK;CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEPATITIS_C | DISEASE:LYMPHOMA | DISEASE:SHOCK | SEPTIC
NELFINAVIR;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_METABOLISM;nan
HYDROXYBUPROPION;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;LADME_PK;DECREASED_CONCENTRATIONS;nan
NELFINAVIR;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:PANCREATIC_NEOPLASMS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
BUPROPION;CYP2B6;*1/*6 + *1/*18;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*18, CYP2B6*22;LADME_PK;DECREASED_METABOLISM;DISEASE:TOBACCO_USE_DISORDER
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
TEZACAFTOR;CFTR;del/del;rs113993960;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
TELAPREVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
BUPROPION;CYP2B6;*6/*6 + *6/*18;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*18, CYP2B6*22;LADME_PK;DECREASED_METABOLISM;DISEASE:TOBACCO_USE_DISORDER
IVACAFTOR;CFTR;CTT/del;rs113993960;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
TEZACAFTOR;CFTR;CTT/del;rs113993960;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
WARFARIN;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;DOSAGE;INCREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION
WARFARIN;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;DOSAGE;INCREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6;CYP3A5*1, CYP3A5*3, CYP3A5*6;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
ATOMOXETINE;CYP2D6;POOR_METABOLIZER;CYP2D6;DOSAGE;DECREASED_DOSE;DISEASE:ADHD
GEMCITABINE;CDA;A;rs60369023;OTHER;DECREASED_METABOLISM;DISEASE:NEOPLASMS
GEMCITABINE;CDA;A;rs60369023;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
APIXABAN;ABCB1;GG;rs1045642;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:THROMBOEMBOLISM
DABIGATRAN;ABCB1;GG;rs1045642;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:THROMBOEMBOLISM
EDOXABAN;ABCB1;GG;rs1045642;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:THROMBOEMBOLISM
RIVAROXABAN;ABCB1;GG;rs1045642;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:THROMBOEMBOLISM
ATAZANAVIR;NR1I2;TT;rs2472677;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
IMATINIB;ABCB1;A;rs2032582;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
ANTIDEPRESSANTS;FKBP5;CC;rs1360780;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
IMATINIB;ABCB1;A;rs1128503;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
TACROLIMUS;CYP3A5;TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:LIVER_TRANSPLANTATION
ANTIDEPRESSANTS;GNB3;CC + CT;rs5443;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
IMATINIB;ABCB1;A;rs1045642;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
ANTIDEPRESSANTS;FKBP5;AC + CC;rs3800373;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;nan
METHADONE;OPRK1;CC;rs963549;DOSAGE;DECREASED_DOSE;OTHER:HEROIN_DEPENDENCE
ANTIPSYCHOTICS;ABCB1;AA;rs1128503;DOSAGE;INCREASED_DOSE;DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;ABCB1;AA;rs1128503;LADME_PK;INCREASED_DOSE;DISEASE:SCHIZOPHRENIA
IMATINIB;ABCG2;T;rs2231142;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;EFFICACY;DECREASED_RESISTANCE;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;PPARA;G;rs4823613;LADME_PK;DECREASED_METABOLISM;OTHER:KIDNEY_TRANSPLANTATION
INFLIXIMAB;SLCO1C1;G;rs3794271;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;POR;T;rs1057868;LADME_PK;INCREASED_METABOLISM;OTHER:KIDNEY_TRANSPLANTATION
DALCETRAPIB;ADCY9;AA;rs1967309;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
ANTIDEPRESSANTS;BDNF;CT;rs6265;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
BETA BLOCKING AGENTS;ADRB1;G;rs1801253;EFFICACY;DECREASED_RESPONSE;DISEASE:TACHYCARDIA
FLECAINIDE;ADRB1;G;rs1801253;EFFICACY;DECREASED_RESPONSE;DISEASE:TACHYCARDIA
METHOTREXATE;ABCC2;T;rs717620;LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
RITUXIMAB;FCGR3A;AA;rs396991;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:NEUROMYELITIS_OPTICA
EFAVIRENZ;CYP2B6;*18;CYP2B6*1, CYP2B6*18;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
DRUGS USED IN ALCOHOL DEPENDENCE;GATA4;CC;rs13273672;EFFICACY;DECREASED_CLINICAL BENEFIT;DISEASE:ALCOHOL_ABUSE
CHORIONIC GONADOTROPIN;FSHR;CC;rs6166;DOSAGE;INCREASED_DOSE;nan
BEPRIDIL;CYP2D6;*10;CYP2D6*10;LADME_PK;INCREASED_CLEARANCE;DISEASE:CARDIAC_RHYTHM_DISEASE
TACROLIMUS;CYP3A4;GG;rs35599367;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
NICARDIPINE;CACNA1B;AG + GG;rs2739260;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BIPOLAR_DISORDER
NIMODIPINE;CACNA1B;AG + GG;rs2739260;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BIPOLAR_DISORDER
CITALOPRAM;GLDC;G;rs10975641;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ESCITALOPRAM;GLDC;G;rs10975641;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DOSE;OTHER:A_STABLE_MAINTENANCE_DOSE
CORTISONE ACETATE;CYP3A7;*1C;CYP3A7*1A, CYP3A7*1C;DOSAGE;DECREASED_DOSE;DISEASE:ADRENAL_HYPERPLASIA | CONGENITAL
DAUNORUBICIN;G6PD;A-202A_376G;G6PD A- 202A_376G;LADME_PK;DECREASED_METABOLISM;nan
TEGAFUR;CYP2A6;*4/*4 + *4/*7 + *7/*7;CYP2A6*1, CYP2A6*4, CYP2A6*7;LADME_PK;DECREASED_CLEARANCE;DISEASE:NEOPLASMS
EFAVIRENZ;CYP2A6;*2;CYP2A6*2;OTHER;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2A6;*2;CYP2A6*2;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;OTHER:MECHANICAL_HEART_VALVE_REPLACEMENT
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;EFFICACY;DECREASED_DOSE;OTHER:MECHANICAL_HEART_VALVE_REPLACEMENT
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DOSE;OTHER:A_STABLE_MAINTENANCE_DOSE
METFORMIN;HNF1B;AA + AG;rs11868513;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED_DOSE;nan
ATORVASTATIN;CYP3A4;C/C;rs2242480;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERLIPIDEMIAS
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
GLATIRAMER ACETATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;EFFICACY;DECREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
ACENOCOUMAROL;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_CLEARANCE;DISEASE:CARDIOVASCULAR_DISEASE
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_CLEARANCE;DISEASE:CARDIOVASCULAR_DISEASE
WARFARIN;CYP2C9;*1/*1;CYP2C9*1;DOSAGE;INCREASED_DOSE;nan
WARFARIN;CYP2C9;*1/*1;CYP2C9*1;LADME_PK;INCREASED_DOSE;nan
WARFARIN;CYP2C9;*3;CYP2C9*3;LADME_PK;DECREASED_DOSE;DISEASE:CARDIOVASCULAR_DISEASE
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *2/*17 + *3/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;EFFICACY;INCREASED_RESPONSE;DISEASE:ANGINA_PECTORIS
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
ATORVASTATIN;CYP3A4;C/C;rs2242480;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERLIPIDEMIAS
DIAZEPAM;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;OTHER;DECREASED_METABOLISM;nan
DIAZEPAM;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;DECREASED_METABOLISM;nan
INTERFERON ALFA-2A;IL18;T;rs1946518;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RECOMBINANT;IL18;T;rs1946518;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
INTERFERON ALFA-2B;IL18;T;rs1946518;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RECOMBINANT;IL18;T;rs1946518;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
INTERFERONS;IL18;T;rs1946518;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IL18;T;rs1946518;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IL18;T;rs1946518;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IL18;T;rs1946518;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
FLUOXETINE;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;rs57098334;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSION
PAROXETINE;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;rs57098334;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSION
VENLAFAXINE;CYP2D6;*4/*4;CYP2D6*4;LADME_PK;DECREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
THIOGUANOSINE DIPHOSPHATE;TPMT;POOR_METABOLIZER;TPMT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:INFLAMMATORY_BOWEL_DISEASES
THIOGUANOSINE MONOPHOSPHATE;TPMT;POOR_METABOLIZER;TPMT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:INFLAMMATORY_BOWEL_DISEASES
THIOGUANOSINE TRIPHOSPHATE;TPMT;POOR_METABOLIZER;TPMT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:INFLAMMATORY_BOWEL_DISEASES
COUMARIN;CYP2A6;*12;CYP2A6*1, CYP2A6*12;OTHER;DECREASED_METABOLISM;nan
COUMARIN;CYP2A6;*12;CYP2A6*1, CYP2A6*12;LADME_PK;DECREASED_METABOLISM;nan
VALPROIC ACID;CYP2A6;*4;CYP2A6*1, CYP2A6*4;LADME_PK;DECREASED_METABOLISM;DISEASE:EPILEPSY
TEGAFUR;CYP2A6;*4;CYP2A6*4;LADME_PK;DECREASED_METABOLISM;DISEASE:STOMACH_NEOPLASMS
TEGAFUR;CYP2A6;*4;CYP2A6*1, CYP2A6*4;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;*1/*7;CYP2A6*1, CYP2A6*7;LADME_PK;DECREASED_METABOLISM;nan
WARFARIN;CYP2C9;*3/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;OTHER:STABLE_INR = [2-3]
WARFARIN;CYP2C9;*2/*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;OTHER:STABLE_INR = [2-3]
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
WARFARIN;CYP4F2;*3/*3;CYP4F2*1, CYP4F2*3;DOSAGE;INCREASED_DOSE;OTHER:STABLE_INR = [2-3]
WARFARIN;CYP2C9;*2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;OTHER:STABLE_INR = [2-3]
PACLITAXEL;CYP2C8;*1/*3 + *3/*3;CYP2C8*1, CYP2C8*3;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
CAFFEINE;CYP2A6;*7 + *10 + *11;CYP2A6*1, CYP2A6*7, CYP2A6*10, CYP2A6*11;OTHER;DECREASED_METABOLISM;nan
CAFFEINE;CYP2A6;*7 + *10 + *11;CYP2A6*1, CYP2A6*7, CYP2A6*10, CYP2A6*11;LADME_PK;DECREASED_METABOLISM;nan
CAFFEINE;CYP2A6;*1/*4 + *1/*9 + *4/*4 + *4/*9;CYP2A6*1, CYP2A6*4, CYP2A6*9;OTHER;DECREASED_METABOLISM;nan
CAFFEINE;CYP2A6;*1/*4 + *1/*9 + *4/*4 + *4/*9;CYP2A6*1, CYP2A6*4, CYP2A6*9;LADME_PK;DECREASED_METABOLISM;nan
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;DISEASE:THROMBOEMBOLISM
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_DOSE;DISEASE:THROMBOEMBOLISM
TOCILIZUMAB;IL6R;CT + TT;rs4845625;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
ATORVASTATIN;CYP3A4;T/T;rs2242480;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERLIPIDEMIAS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED_RESPONSE;DISEASE:CARDIOVASCULAR_DISEASE
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;OTHER;DECREASED_CLEARANCE;nan
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_CLEARANCE;nan
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;OTHER;DECREASED_CLEARANCE;nan
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;LADME_PK;DECREASED_CLEARANCE;nan
LETROZOLE;CYP2A6;*1/*26;CYP2A6*1, CYP2A6*26;LADME_PK;METABOLISM;DISEASE:BREAST_NEOPLASMS
LETROZOLE;CYP2A6;*1/*35;CYP2A6*1, CYP2A6*35;nan;METABOLISM;DISEASE:BREAST_NEOPLASMS
MIRTAZAPINE;CYP2B6;*6/*6;CYP2B6*6;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSION
METHOTREXATE;SLC19A1;CT;rs1051266;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_CLEARANCE;DISEASE:CARDIOVASCULAR_DISEASE
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;LADME_PK;DECREASED_CLEARANCE;DISEASE:CARDIOVASCULAR_DISEASE
WARFARIN;CYP2C9;*2;CYP2C9*2;LADME_PK;DECREASED_DOSE;DISEASE:CARDIOVASCULAR_DISEASE
INTERFERON ALFA-2A;IL18;C;rs187238;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RECOMBINANT;IL18;C;rs187238;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
INTERFERON ALFA-2B;IL18;C;rs187238;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RECOMBINANT;IL18;C;rs187238;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
INTERFERONS;IL18;C;rs187238;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IL18;C;rs187238;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IL18;C;rs187238;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IL18;C;rs187238;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
EFAVIRENZ;CYP2B6;*6;CYP2B6*1, CYP2B6*6;LADME_PK;DECREASED_METABOLISM;OTHER:HUMAN_LIVER_MICROSOMES
ACENOCOUMAROL;CYP2C9;*1/*1;CYP2C9*1;DOSAGE;INCREASED_DOSE;nan
ISONIAZID;NAT2;*4/*4;NAT2*4;LADME_PK;INCREASED_METABOLISM;DISEASE:TUBERCULOSIS
ISONIAZID;NAT2;*4/*4;NAT2*4;LADME_PK;INCREASED_METABOLISM;DISEASE:TUBERCULOSIS
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED_DOSE;nan
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED_DOSE;nan
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
ACENOCOUMAROL;CYP2C9;*1/*1;CYP2C9*1;DOSAGE;INCREASED_DOSE;nan
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*17;LADME_PK;TROUGH CONCENTRATION;nan
LOSARTAN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED_RESPONSE;DISEASE:KIDNEY_DISORDER
TROPISETRON;CYP2D6;*3/*3;CYP2D6*3;EFFICACY;DECREASED_METABOLISM;DISEASE:NEOPLASMS
LOSARTAN;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED_RESPONSE;DISEASE:KIDNEY_DISORDER
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;DECREASED_RESPONSE;DISEASE:MYOCARDIAL_ISCHEMIA
TACROLIMUS;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
METOPROLOL;CYP2D6;*10;CYP2D6*10;LADME_PK;DECREASED_CLEARANCE;nan
SIMVASTATIN;CYP3A4;*1/*4;CYP3A4*1, CYP3A4*4;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERLIPIDEMIAS
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;LADME_PK;DECREASED_METABOLISM;nan
ONDANSETRON;CYP2D6;*1xN + *2xN;CYP2D6*1, CYP2D6*1xN, CYP2D6*2xN;EFFICACY;DECREASED_RESPONSE;nan
PHENPROCOUMON;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
RISPERIDONE;CYP2D6;*10;CYP2D6*1, CYP2D6*10;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
DEBRISOQUINE;CYP2D6;*2xN;CYP2D6*2xN;LADME_PK;INCREASED_METABOLISM;nan
HALOPERIDOL;CYP2D6;*10;CYP2D6*1, CYP2D6*10;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
CARVEDILOL;CYP2D6;*1/*4;CYP2D6*1, CYP2D6*4;LADME_PK;DECREASED_CLEARANCE;DISEASE:HEART_DISEASES
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*17;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:GASTROESOPHAGEAL_REFLUX
CARVEDILOL;CYP2D6;*4/*5 + *4/*6;CYP2D6*4, CYP2D6*5, CYP2D6*6;DOSAGE;INCREASED_DOSE;DISEASE:HEART_FAILURE
CLOPIDOGREL;CYP2C19;*1/*1;CYP2C19*1;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
PANTOPRAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
CARVEDILOL;CYP2D6;*10/*10;CYP2D6*10;LADME_PK;DECREASED_CLEARANCE;DISEASE:HEART_DISEASES
CARVEDILOL;CYP2D6;*1/*5;CYP2D6*1, CYP2D6*5;LADME_PK;DECREASED_CLEARANCE;DISEASE:HEART_DISEASES
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
ZUCLOPENTHIXOL;CYP2D6;*3;CYP2D6*1, CYP2D6*3;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
FLUOXETINE;CYP2D6;CC;rs3892097;EFFICACY;INCREASED_RESPONSE;EFFICACY:ALCOHOL_ABUSE | EFFICACY:MAJOR_DEPRESSIVE_DISORDER
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;DOSAGE;DECREASED_DOSE;DISEASE:DEPRESSION
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
CLOMIPRAMINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;DOSAGE;DECREASED_DOSE;DISEASE:DEPRESSION
CLOMIPRAMINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
DOXEPIN;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;DOSAGE;DECREASED_DOSE;DISEASE:DEPRESSION
DOXEPIN;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
IMIPRAMINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;DOSAGE;DECREASED_DOSE;DISEASE:DEPRESSION
IMIPRAMINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
MAPROTILINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;DOSAGE;DECREASED_DOSE;DISEASE:DEPRESSION
MAPROTILINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
NORTRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;DOSAGE;DECREASED_DOSE;DISEASE:DEPRESSION
NORTRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
OPIPRAMOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;DOSAGE;DECREASED_DOSE;DISEASE:DEPRESSION
OPIPRAMOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
SUFENTANIL;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
METFORMIN;nan;CG;rs6719578;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
RISPERIDONE;CYP2D6;*10;CYP2D6*1, CYP2D6*10;EFFICACY;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
RISPERIDONE;CYP2D6;*10;CYP2D6*1, CYP2D6*10;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*4;TOXICITY;DECREASED_CLEARANCE;OTHER:ONE_SUICIDE_CASE
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*4;LADME_PK;DECREASED_CLEARANCE;OTHER:ONE_SUICIDE_CASE
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
HALOPERIDOL;CYP2D6;*10;CYP2D6*1, CYP2D6*10;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
RISPERIDONE;CYP2D6;*4;CYP2D6*1, CYP2D6*4;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
METHOTREXATE;ATIC;CC;rs4673993;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCER
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:CARDIOVASCULAR_DISEASE
LANSOPRAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_METABOLISM;nan
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED_DOSE;nan
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*1/*2 + *2/*2 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
HYDROMORPHONE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED_RESPONSE;nan
KETOROLAC;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED_RESPONSE;nan
MORPHINE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED_RESPONSE;nan
OPIOIDS;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED_RESPONSE;nan
OXYCODONE;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED_RESPONSE;nan
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
BUPROPION;CYP2B6;*1/*22;CYP2B6*1, CYP2B6*22;LADME_PK;INCREASED_METABOLISM;nan
LANSOPRAZOLE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_METABOLISM;nan
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C9;*1/*1;CYP2C9*1;DOSAGE;INCREASED_DOSE;nan
WARFARIN;CYP2C9;*1/*1;CYP2C9*1;LADME_PK;INCREASED_DOSE;nan
VORICONAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;DOSAGE;DECREASED_DOSE;DISEASE:CYSTIC_FIBROSIS | DISEASE:LUNG_TRANSPLANTATION
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:PANIC_DISORDER
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;nan
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
HYDRALAZINE;NAT2;slow_acetylator;NAT2;LADME_PK;DECREASED_METABOLISM;OTHER:HYPERTENSION
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;DECREASED_RESPONSE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION
PEGINTERFERON ALFA-2A;HLA-A;*01:01;HLA-A*01:01;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;HLA-A;*01:01;HLA-A*01:01;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;HLA-A;*01:01;HLA-A*01:01;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PAROXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
ACENOCOUMAROL;VKORC1;AC + CC;rs104894542;DOSAGE;INCREASED_DOSE;nan
ASPIRIN;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
MEPHENYTOIN;CYP2C19;G;rs28399504;LADME_PK;DECREASED_METABOLISM;nan
ACENOCOUMAROL;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
4-HYDROXYTAMOXIFEN;CYP2D6;*10/*10 + *5/*5;CYP2D6*1, CYP2D6*5, CYP2D6*10;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ENDOXIFEN;CYP2D6;*10/*10 + *5/*5;CYP2D6*1, CYP2D6*5, CYP2D6*10;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
WARFARIN;CYP2C9;*1/*3 + *2/*3 + *3/*3 + *2/*2;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
CLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;DECREASED_CLEARANCE;DISEASE:EPILEPSY
WARFARIN;CYP2C9;*1/*2 + *2/*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;nan
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
LAMIVUDINE;HLA-B;*40:01;HLA-B*40:01;EFFICACY;RESPONSE;DISEASE:HIV_INFECTIOUS_DISEASE
NEVIRAPINE;HLA-B;*40:01;HLA-B*40:01;EFFICACY;RESPONSE;DISEASE:HIV_INFECTIOUS_DISEASE
STAVUDINE;HLA-B;*40:01;HLA-B*40:01;EFFICACY;RESPONSE;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;LADME_PK;INCREASED_CONCENTRATIONS;nan
BELINOSTAT;UGT1A1;*1/*60 + *60/*60;UGT1A1*1, UGT1A1*60;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:NEOPLASMS
BELINOSTAT;UGT1A1;*1/*60 + *60/*60;UGT1A1*1, UGT1A1*60;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
NORTRIPTYLINE;CYP2D6;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
BOCEPREVIR;IFNL4;TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
TELAPREVIR;IFNL4;TT;rs11322783;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*11;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
ACENOCOUMAROL;CYP2C19;*2 + *3;CYP2C19*2, CYP2C19*3;DOSAGE;DOSE;nan
PHENPROCOUMON;CYP2C19;*2 + *3;CYP2C19*2, CYP2C19*3;DOSAGE;DOSE;nan
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DOSE;DISEASE:STROKE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*2, CYP2C9*3;DOSAGE;DOSE;nan
COUMARIN;CYP2A6;*6;CYP2A6*1, CYP2A6*6;LADME_PK;DECREASED_METABOLISM;nan
ECULIZUMAB;C5;CT;rs56040400;EFFICACY;DECREASED_RESPONSE;OTHER:PAROXYSMAL_NOCTURNAL_HEMOGLOBINURIA
DEFERASIROX;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ANEMIA
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DOSE;nan
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
PRASUGREL;CYP2C19;A;rs4244285;EFFICACY;RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
TICAGRELOR;CYP2C19;A;rs4244285;EFFICACY;RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
WARFARIN;CYP2C9;A;rs9332131;DOSAGE;DOSE;nan
WARFARIN;CYP2C9;C;rs28371685;DOSAGE;DOSE;nan
EFAVIRENZ;CYP2B6;*6;CYP2B6*1, CYP2B6*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_RESISTANCE;DISEASE:ACUTE_CORONARY_SYNDROME | DISEASE:STROKE
VALPROIC ACID;CYP2C9;*1/*2 + *1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;DISEASE:BIPOLAR_DISORDER | DISEASE:PSYCHOTIC_DISORDER
WARFARIN;POR;CT + TT;rs41301394;DOSAGE;INCREASED_DOSE;nan
METHADONE;DRD2;AA + AG;rs6275;nan;INCREASED_DOSE;OTHER:TREATMENT_FOR_HEROIN_ADDICTION
CARBOPLATIN;GSTP1;G;rs1695;TOXICITY;DECREASED_RESPONSE;OTHER:OVARIAN_NEOPLASMS
PACLITAXEL;GSTP1;G;rs1695;TOXICITY;DECREASED_RESPONSE;OTHER:OVARIAN_NEOPLASMS
VORICONAZOLE;CYP2C19;ULTRARAPID_METABOLIZER;CYP2C19;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:FUNGAL_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;*1/*6 + *6/*6;CYP2B6*1, CYP2B6*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
IRINOTECAN;UGT1A1;*1/*28;UGT1A1*1, UGT1A1*28;DOSAGE;DECREASED_DOSE;DISEASE:COLORECTAL_NEOPLASMS
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;DECREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION
TACROLIMUS;CYP3A4;*1/*1;CYP3A4*1, CYP3A4*18;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
CISPLATIN;MIR335;AA + AG;rs3807348;EFFICACY;INCREASED_RESPONSE;OTHER:MESOTHELIOMA
HYDROCODONE;CYP2D6;*2/*41;CYP2D6*2, CYP2D6*41;LADME_PK;INCREASED_CONCENTRATIONS;nan
CYCLOPHOSPHAMIDE;ALDH1A1;CTGGTGAGGAGAGAACC/del;rs6151031;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
DOXORUBICIN;ALDH1A1;CTGGTGAGGAGAGAACC/del;rs6151031;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
BUPRENORPHINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
METHADONE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
DESVENLAFAXINE;CYP2D6;nan;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;nan;VKORC1 low activity;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;EFFICACY;DECREASED_RESPONSE;nan
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;LADME_PK;DECREASED_METABOLISM;DISEASE:FUNGAL_INFECTIOUS_DISEASE
CLOMIPRAMINE;CYP2D6;*4/*5;CYP2D6*4, CYP2D6*5;LADME_PK;DECREASED_METABOLISM;nan
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:LIVER_TRANSPLANTATION
CLOZAPINE;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED_CONCENTRATIONS;DISEASE:SCHIZOAFFECTIVE_DISORDER | DISEASE:SCHIZOPHRENIA
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED_DOSE;OTHER:HEART_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED_TROUGH CONCENTRATION;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
SIROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;nan
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CLEARANCE;DISEASE:HEART_TRANSPLANTATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:ULCERATIVE_COLITIS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
CARBAMAZEPINE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CLEARANCE;DISEASE:EPILEPSY
FENTANYL;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:NEOPLASMS | DISEASE:PAIN
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
FENTANYL;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CLEARANCE;DISEASE:POSTOPERATIVE_PAIN
MIDAZOLAM;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_METABOLISM;DISEASE:NEOPLASMS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_METABOLISM;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
CYCLOSPORINE;CYP3A5;*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
FENTANYL;CYP2D6;*9;CYP2D6*1, CYP2D6*9;LADME_PK;DECREASED_CLEARANCE;OTHER:BURNS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
SIMVASTATIN;F3;CT;rs3917643;EFFICACY;INCREASED_RESPONSE;DISEASE:MYOCARDIAL_ISCHEMIA
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
FLUVASTATIN;ACE;del/del;rs1799752;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
IVACAFTOR;CFTR;CTT/del;rs113993960;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
ENALAPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del;rs1799752;EFFICACY;INCREASED_RESPONSE;DISEASE:ARTERIOSCLEROSIS
BEVACIZUMAB;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
CISPLATIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
DOCETAXEL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
EPIRUBICIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
OXALIPLATIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
TRASTUZUMAB;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
IMATINIB;CYP3A5;C;rs776746;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;DOSAGE;DECREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
FENTANYL;CYP3A5;POOR_METABOLIZER;CYP3A5;LADME_PK;DECREASED_DOSE;OTHER:SEDATION
MEPERIDINE;CYP3A5;POOR_METABOLIZER;CYP3A5;LADME_PK;DECREASED_DOSE;OTHER:SEDATION
MIDAZOLAM;CYP3A5;POOR_METABOLIZER;CYP3A5;LADME_PK;DECREASED_DOSE;OTHER:SEDATION
FENTANYL;CYP2C19;nan;CYP2C19 poor metabolizers and intermediate metabolizers;LADME_PK;DECREASED_DOSE;OTHER:SEDATION
MEPERIDINE;CYP2C19;nan;CYP2C19 poor metabolizers and intermediate metabolizers;LADME_PK;DECREASED_DOSE;OTHER:SEDATION
MIDAZOLAM;CYP2C19;nan;CYP2C19 poor metabolizers and intermediate metabolizers;LADME_PK;DECREASED_DOSE;OTHER:SEDATION
FENTANYL;UGT1A1;POOR_METABOLIZER;UGT1A1;LADME_PK;DECREASED_DOSE;OTHER:SEDATION
MEPERIDINE;UGT1A1;POOR_METABOLIZER;UGT1A1;LADME_PK;DECREASED_DOSE;OTHER:SEDATION
MIDAZOLAM;UGT1A1;POOR_METABOLIZER;UGT1A1;LADME_PK;DECREASED_DOSE;OTHER:SEDATION
BELZUTIFAN;UGT2B17;POOR_METABOLIZER;UGT2B17;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:VON_HIPPEL-LINDAU_DISEASE | OTHER:RENAL_CELL_CARCINOMA
BELZUTIFAN;CYP2C19;POOR_METABOLIZER;CYP2C19;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:VON_HIPPEL-LINDAU_DISEASE | OTHER:RENAL_CELL_CARCINOMA
TACROLIMUS;CYP3A4;AG;rs35599367;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
O-DESMETHYLTRAMADOL;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:PAIN
4-HYDROXYTAMOXIFEN;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
TAMSULOSIN;CYP2D6;*1/*4 + *4/*10;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED_CLINICAL BENEFIT;nan
IMATINIB;CYP3A4;C;rs2242480;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
FULVESTRANT;CYP2C9;POOR_METABOLIZER;CYP2C9;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS | OTHER:METASTATIC_NEOPLASM
ANASTROZOLE;CYP2C9;INTERMEDIATE_METABOLIZER;CYP2C9;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS | OTHER:METASTATIC_NEOPLASM
ANASTROZOLE;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS | OTHER:METASTATIC_NEOPLASM
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LEUKEMIA
ABATACEPT;HLA-DRB1;*04:05;HLA-DRB1*04:05;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
ETANERCEPT;SLCO1C1;G;rs3794271;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
APATINIB;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CLEARANCE;OTHER:NEOPLASMS
ESCITALOPRAM;CYP2C19;rapid_metabolizer;CYP2C19;LADME_PK;INCREASED_CLEARANCE;nan
ESCITALOPRAM;CYP2C19;POOR_METABOLIZER;CYP2C19;LADME_PK;DECREASED_CLEARANCE;nan
SERTRALINE;CYP2C19;POOR_METABOLIZER;CYP2C19;LADME_PK;DECREASED_CLEARANCE;nan
DULOXETINE;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;nan
AMOXICILLIN;VDR;A;rs7975232;EFFICACY;INCREASED_RESPONSE;OTHER:HELICOBACTER_INFECTIONS
CLARITHROMYCIN;VDR;A;rs7975232;EFFICACY;INCREASED_RESPONSE;OTHER:HELICOBACTER_INFECTIONS
OMEPRAZOLE;VDR;A;rs7975232;EFFICACY;INCREASED_RESPONSE;OTHER:HELICOBACTER_INFECTIONS
AMOXICILLIN;VDR;A;rs2228570;EFFICACY;INCREASED_RESPONSE;OTHER:HELICOBACTER_INFECTIONS
CLARITHROMYCIN;VDR;A;rs2228570;EFFICACY;INCREASED_RESPONSE;OTHER:HELICOBACTER_INFECTIONS
OMEPRAZOLE;VDR;A;rs2228570;EFFICACY;INCREASED_RESPONSE;OTHER:HELICOBACTER_INFECTIONS
BUPROPION;ANKK1;AA + AG;rs1800497;EFFICACY;INCREASED_RESPONSE;OTHER:OBESITY
BUPROPION;DRD2;AA + AG;rs1800497;EFFICACY;INCREASED_RESPONSE;OTHER:OBESITY
NALTREXONE;ANKK1;AA + AG;rs1800497;EFFICACY;INCREASED_RESPONSE;OTHER:OBESITY
NALTREXONE;DRD2;AA + AG;rs1800497;EFFICACY;INCREASED_RESPONSE;OTHER:OBESITY
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CLEARANCE;OTHER:HEART_TRANSPLANTATION
RISPERIDONE;CYP2D6;INTERMEDIATE_METABOLIZER;CYP2D6;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:AUTISM_SPECTRUM_DISORDER
TACROLIMUS;CYP3A4;*1/*1;CYP3A4*1, CYP3A4*22;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
DOCETAXEL;PPARD;G;rs6922548;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
THALIDOMIDE;PPARD;G;rs6922548;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
SN-38;UGT1A1;*6;UGT1A1*1, UGT1A1*6;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:RECTAL_NEOPLASMS
TACROLIMUS;CYP3A5;*1;CYP3A5*1;LADME_PK;INCREASED_TIME TO RESPONSE;OTHER:KIDNEY_TRANSPLANTATION
O-DESMETHYLTRAMADOL;CYP2D6;INTERMEDIATE_METABOLIZER;CYP2D6;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:POSTOPERATIVE_PAIN
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
NALDEMEDINE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:NEOPLASMS | OTHER:PAIN | OTHER:CONSTIPATION
METHADONE;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;nan
RISPERIDONE;CYP2D6;*10/*10 + *10/*65 + *10/*41;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*41, CYP2D6*65;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
DOCETAXEL;PPARD;G;rs7769719;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
THALIDOMIDE;PPARD;G;rs7769719;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
TACROLIMUS;CYP3A5;TT;rs776746;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;NEDD4;G;rs2288344;DOSAGE;INCREASED_DOSE;nan
QUETIAPINE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CLEARANCE;OTHER:BIPOLAR_DISORDER
TACROLIMUS;CYP3A5;TT;rs776746;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;DDHD1;G;rs17126068;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;INTERMEDIATE_METABOLIZER;CYP3A5;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LUNG_TRANSPLANTATION
CISPLATIN;UGT1A1;AA;rs4148323;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
IRINOTECAN;UGT1A1;AA;rs4148323;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
DESVENLAFAXINE;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;INCREASED_EXPOSURE;OTHER:MAJOR_DEPRESSIVE_DISORDER
VENLAFAXINE;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;INCREASED_EXPOSURE;OTHER:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;CT;rs776746;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
TACROLIMUS;CYP3A4;*22;CYP3A4*1, CYP3A4*22;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
SALBUTAMOL;nan;T;rs7903366;EFFICACY;DECREASED_RESPONSE;OTHER:ASTHMA
PRAZIQUANTEL;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;LADME_PK;INCREASED_EXPOSURE;OTHER:SCHISTOSOMIASIS
LOSARTAN;CYP2C9;C;rs1057910;LADME_PK;DECREASED_METABOLISM;PK:NO_DISEASE
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:STROKE
RISPERIDONE;CYP2D6;nan;CYP2D6 poor metabolizer genotype;LADME_PK;INCREASED_EXPOSURE;DISEASE:BIPOLAR_DISORDER | DISEASE:DEPRESSION | DISEASE:PSYCHOTIC_DISORDER | DISEASE:SUBSTANCE-RELATED_DISORDERS
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;LADME_PK;DECREASED_METABOLISM;DISEASE:SYSTEMIC_LUPUS_ERYTHEMATOSUS
ISONIAZID;NAT2;*16/*16 + *16/*6 + *6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;LADME_PK;DECREASED_METABOLISM;DISEASE:TUBERCULOSIS
SALBUTAMOL;nan;A;rs7081864;EFFICACY;DECREASED_RESPONSE;OTHER:ASTHMA
SULFINPYRAZONE;UGT1A9;T;rs72551330;LADME_PK;INCREASED_METABOLISM;nan
SULFAMETHOXAZOLE;NAT2;*4/*4;NAT2*4, NAT2*6, NAT2*7, NAT2*16;LADME_PK;INCREASED_METABOLISM;OTHER:KIDNEY_TRANSPLANTATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;AA;rs1051792;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:SPONDYLARTHROPATHIES
WARFARIN;VKORC1;GG;rs9923231;DOSAGE;INCREASED_DOSE;OTHER:ATRIAL_FIBRILLATION | OTHER:PULMONARY_EMBOLISM | OTHER:VENOUS_THROMBOSIS
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*1, CYP2D6*2, CYP2D6*2xN;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:OPIOID-RELATED_DISORDERS
LITHIUM;GSK3B;GG;rs6438552;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
TACROLIMUS;ABCB1;AA;rs1045642;DOSAGE;DECREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
LITHIUM;NR1D1;TT;rs2071427;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
LITHIUM;THRA;TT;rs2071427;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
TACROLIMUS;CYP3A5;nan;CYP3A5 poor metabolizers;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
MORPHINE;CYP2D6;nan;CYP2D6 poor metabolizer phenotype;LADME_PK;DECREASED_EXPOSURE;nan
ENDOXIFEN;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ARIPIPRAZOLE;CYP2D6;nan;CYP2D6 poor metabolizer genotype;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:PSYCHOTIC_DISORDER
ATOMOXETINE;CYP2C19;nan;CYP2C19 poor metabolizers;LADME_PK;INCREASED_CONCENTRATIONS;nan
CAFFEINE;NAT2;*4/*5 + *1/*16 + *4/*6 + *4/*7;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*16;LADME_PK;INCREASED_METABOLISM;nan
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:HEART_TRANSPLANTATION
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*7G, NAT2*39;LADME_PK;DECREASED_CLEARANCE;DISEASE:TUBERCULOSIS
TACROLIMUS;ABCB1;GG;rs1045642;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
INFLIXIMAB;HLA-DQA1;*05;HLA-DQA1*05;EFFICACY;INCREASED_DISCONTINUATION;EFFICACY:CROHN_DISEASE
TACROLIMUS;ABCB1;AA;rs1045642;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
ENZYME INHIBITORS;CYP19A1;CC;rs700518;OTHER;RESPONSE;DISEASE:BREAST_NEOPLASMS
TACROLIMUS;ABCB1;AA;rs1128503;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
CORTICOSTEROIDS;FCER2;G;rs28364072;DOSAGE;INCREASED_DOSE;DISEASE:ASTHMA
TACROLIMUS;ABCB1;AA;rs2032582;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
ISONIAZID;NAT2;*16 + *6 + *7 + *14;NAT2*1, NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;ABCB1;AG + GG;rs1045642;LADME_PK;INCREASED_CLEARANCE;DISEASE:LIVER_TRANSPLANTATION
HYDRALAZINE;NAT2;*4/*16 + *4/*6 + *4/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;LADME_PK;INCREASED_METABOLISM;OTHER:HYPERTENSION | OTHER:PREGNANCY
DEXTROMETHORPHAN;CYP2D6;*4/*59;CYP2D6*4, CYP2D6*59;LADME_PK;DECREASED_METABOLISM;nan
HALOPERIDOL;CYP2D6;nan;CYP2D6 poor metabolizer genotype;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:PSYCHOTIC_DISORDER
ESCITALOPRAM;nan;G;rs12154537;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
MORPHINE;ABCB1;AG + GG;rs1128503;LADME_PK;DECREASED_CONCENTRATIONS;nan
ISONIAZID;NAT2;*4/*4;NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16, NAT2*19;DOSAGE;INCREASED_DOSE;DISEASE:TUBERCULOSIS
ISONIAZID;NAT2;*4/*4;NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16, NAT2*19;LADME_PK;INCREASED_DOSE;DISEASE:TUBERCULOSIS
DOCETAXEL;SLCO1B3;G;rs11045585;OTHER;DECREASED_CLEARANCE;DISEASE:NASOPHARYNGEAL_NEOPLASMS
DOCETAXEL;SLCO1B3;G;rs11045585;LADME_PK;DECREASED_CLEARANCE;DISEASE:NASOPHARYNGEAL_NEOPLASMS
DOCETAXEL;SLCO1B3;A;rs7311358;OTHER;DECREASED_CLEARANCE;DISEASE:NASOPHARYNGEAL_NEOPLASMS
DOCETAXEL;SLCO1B3;A;rs7311358;LADME_PK;DECREASED_CLEARANCE;DISEASE:NASOPHARYNGEAL_NEOPLASMS
DOCETAXEL;SLCO1B3;G;rs4149118;OTHER;DECREASED_CLEARANCE;DISEASE:NASOPHARYNGEAL_NEOPLASMS
DOCETAXEL;SLCO1B3;G;rs4149118;LADME_PK;DECREASED_CLEARANCE;DISEASE:NASOPHARYNGEAL_NEOPLASMS
CAFFEINE;NAT2;*16/*5 + *5/*5 + *5/*6 + *5/*34 + *5/*7 + *6/*6 + *6/*7;NAT2*5, NAT2*6, NAT2*7, NAT2*16, NAT2*34;LADME_PK;DECREASED_METABOLISM;nan
ISONIAZID;NAT2;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;NAT2*4, NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*7G;LADME_PK;DECREASED_METABOLISM;DISEASE:TUBERCULOSIS
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;A;rs9934438;LADME_PK;DECREASED_DOSE;nan
TACROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:HEART_TRANSPLANTATION
MIDAZOLAM;VDR;C;rs1544410;LADME_PK;INCREASED_CLEARANCE;nan
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;KLRC4;GG;rs1154831;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SPONDYLARTHROPATHIES
TACROLIMUS;CYP3A5;*1;CYP3A5*1;DOSAGE;INCREASED_DOSE;OTHER:LUNG_TRANSPLANTATION
ESCITALOPRAM;CYP2C19;INTERMEDIATE_METABOLIZER;CYP2C19;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:DEPRESSION | OTHER:ANXIETY_DISORDERS
METHADONE;CYP2D6;nan;CYP2D6 ultrarapid metabolizer genotype;EFFICACY;DECREASED_RESPONSE;OTHER:HEROIN_DEPENDENCE
FLUOXETINE;CYP2D6;ULTRARAPID_METABOLIZER;CYP2D6;EFFICACY;DECREASED_CLINICAL BENEFIT;EFFICACY:MAJOR_DEPRESSIVE_DISORDER | EFFICACY:OBSESSIVE-COMPULSIVE_DISORDER
HYDRALAZINE;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *7/*6;NAT2*6, NAT2*7, NAT2*14, NAT2*16;EFFICACY;INCREASED_RESPONSE;OTHER:RESISTANT_HYPERTENSION
ISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:TUBERCULOSIS
ACETYLISONIAZID;NAT2;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:TUBERCULOSIS
ACETAMINOPHEN;CYP2D6;*10;CYP2D6*10;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PATENT_DUCTUS_ARTERIOSUS
BUPROPION;CYP2B6;*6;CYP2B6*6;LADME_PK;INCREASED_EXPOSURE;OTHER:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;T;rs7294;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;T;rs7294;LADME_PK;INCREASED_DOSE;nan
PARAMETHOXYMETHAMPHETAMINE;CYP2D6;nan;CYP2D6 normal metabolizer genotype;LADME_PK;INCREASED_METABOLISM;DISEASE:SUBSTANCE-RELATED_DISORDERS
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*17;CYP2C19 intermediate metabolizers;LADME_PK;INCREASED_CONCENTRATIONS;nan
MARAVIROC;CYP3A5;nan;CYP3A5 intermediate metabolizers;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CLOPIDOGREL;CYP2C19;nan;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;EFFICACY;DECREASED_RESPONSE;nan
ENDOXIFEN;CYP2D6;nan;CYP2D6 poor metabolizer phenotype;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
ENDOXIFEN;CYP2D6;nan;CYP2D6 poor metabolizer phenotype;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:FUNGAL_INFECTIOUS_DISEASE
CITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;LADME_PK;INCREASED_EXPOSURE;nan
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;LADME_PK;INCREASED_EXPOSURE;nan
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
NORTRIPTYLINE;CYP2D6;nan;CYP2D6 ultrarapid metabolizer phenotype;LADME_PK;INCREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
HALOPERIDOL;DRD2;C;rs1799978;EFFICACY;INCREASED_RESISTANCE;OTHER:SCHIZOPHRENIA
OLANZAPINE;DRD2;C;rs1799978;EFFICACY;INCREASED_RESISTANCE;OTHER:SCHIZOPHRENIA
PERPHENAZINE;DRD2;C;rs1799978;EFFICACY;INCREASED_RESISTANCE;OTHER:SCHIZOPHRENIA
QUETIAPINE;DRD2;C;rs1799978;EFFICACY;INCREASED_RESISTANCE;OTHER:SCHIZOPHRENIA
RISPERIDONE;DRD2;C;rs1799978;EFFICACY;INCREASED_RESISTANCE;OTHER:SCHIZOPHRENIA
MARAVIROC;CYP3A5;nan;CYP3A5 poor metabolizers;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CITALOPRAM;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*17;LADME_PK;DECREASED_EXPOSURE;nan
ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*17;LADME_PK;DECREASED_EXPOSURE;nan
TACROLIMUS;CYP3A5;nan;CYP3A5 intermediate metabolizer and normal metabolizer;DOSAGE;INCREASED_TIME TO RESPONSE;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;nan;CYP3A5 intermediate metabolizer and normal metabolizer;LADME_PK;INCREASED_TIME TO RESPONSE;OTHER:KIDNEY_TRANSPLANTATION
RISPERIDONE;CYP2D6;ULTRARAPID_METABOLIZER;CYP2D6;LADME_PK;INCREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
RISPERIDONE;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
NORTRIPTYLINE;CYP2D6;nan;CYP2D6 intermediate metabolizers;LADME_PK;DECREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
IMIPRAMINE;CYP2D6;nan;CYP2D6 poor metabolizers;DOSAGE;DECREASED_DOSE;DISEASE:DIABETIC_NEUROPATHIES
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
HYDROCODONE;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;DECREASED_METABOLISM;nan
ATOMOXETINE;CYP2C19;nan;CYP2C19 poor metabolizers;LADME_PK;DECREASED_CLEARANCE;nan
IMIPRAMINE;CYP2C19;nan;CYP2C19 poor metabolizers;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ENDOXIFEN;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
RISPERIDONE;CYP2D6;nan;CYP2D6 poor metabolizer genotype;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:PSYCHOTIC_DISORDER
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*8, CYP2C19*17;EFFICACY;DECREASED_METABOLISM;DISEASE:CORONARY_ARTERY_DISEASE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*8, CYP2C19*17;LADME_PK;DECREASED_METABOLISM;DISEASE:CORONARY_ARTERY_DISEASE
TAMOXIFEN;CYP2D6;nan;CYP2D6 intermediate metabolizers;LADME_PK;INCREASED_DOSE;DISEASE:BREAST_NEOPLASMS
PROPAFENONE;CYP2D6;*1/*5 + *2/*36 + *5/*10 + *5/*5;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*36;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:TACHYCARDIA
IMIPRAMINE;CYP2D6;*4/*4 + *4/*5;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5;DOSAGE;DECREASED_DOSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
CITALOPRAM;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*17;LADME_PK;DECREASED_EXPOSURE;nan
ESCITALOPRAM;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*17;LADME_PK;DECREASED_EXPOSURE;nan
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*8, CYP2C19*17;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*8 + *2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*8, CYP2C19*17;LADME_PK;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
METHAMPHETAMINE;CYP2D6;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*18, CYP2D6*36;LADME_PK;INCREASED_CONCENTRATIONS;nan
ENDOXIFEN;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
RISPERIDONE;CYP2D6;nan;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;LADME_PK;INCREASED_EXPOSURE;OTHER:PSYCHOTIC_DISORDER | OTHER:SCHIZOPHRENIA
NORTRIPTYLINE;CYP2D6;nan;CYP2D6 ultrarapid metabolizer phenotype;DOSAGE;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
NORTRIPTYLINE;CYP2D6;nan;CYP2D6 ultrarapid metabolizer phenotype;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
4-HYDROXYTAMOXIFEN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ENDOXIFEN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
DESVENLAFAXINE;CYP2D6;*99;CYP2D6*99;LADME_PK;DECREASED_CONCENTRATIONS;nan
DEXTROMETHORPHAN;CYP2D6;*4/*36 + *4x2/*36;CYP2D6*4, CYP2D6*4x2, CYP2D6*36;LADME_PK;DECREASED_METABOLISM;nan
RISPERIDONE;CYP2D6;*5/*10 + *4/*10 + *10/*10 + *10/*41;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;LADME_PK;DECREASED_METABOLISM;nan
VENLAFAXINE;CYP2D6;nan;CYP2D6 poor metabolizer phenotype;LADME_PK;DECREASED_METABOLISM;nan
METHADONE;CYP2D6;*1/*2xN + *2/*2xN;CYP2D6*1, CYP2D6*2, CYP2D6*2xN;DOSAGE;INCREASED_DOSE;OTHER:OPIOID-RELATED_DISORDERS
VENLAFAXINE;CYP2D6;nan;CYP2D6 ultrarapid metabolizer phenotype;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
DESIPRAMINE;CYP2D6;*4/*4 + *4/*5;CYP2D6*4, CYP2D6*5;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
IMIPRAMINE;CYP2D6;*4/*4 + *4/*5;CYP2D6*4, CYP2D6*5;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TRANS 4-HYDROXYPRAZIQUANTEL;CYP2J2;AA + AC;rs890293;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHISTOSOMIASIS
VENLAFAXINE;CYP2D6;nan;CYP2D6 poor metabolizer phenotype;LADME_PK;DECREASED_METABOLISM;nan
PERPHENAZINE;CYP2D6;nan;CYP2D6 poor metabolizer genotype;LADME_PK;INCREASED_CONCENTRATIONS;nan
TACROLIMUS;CYP2C19;*1/*2 + *1/*3 + *2/*2 +*2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;DOSAGE;DECREASED_DOSE;OTHER:HEART_TRANSPLANTATION
TACROLIMUS;CYP2C19;*1/*2 + *1/*3 + *2/*2 +*2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;DECREASED_DOSE;OTHER:HEART_TRANSPLANTATION
VORTIOXETINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED_DISCONTINUATION;nan
DEBRISOQUINE;CYP2D6;*4/*38;CYP2D6*4, CYP2D6*38;LADME_PK;DECREASED_METABOLISM;nan
NORTRIPTYLINE;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
FENTANYL;nan;nan;poor metabolizers;LADME_PK;DECREASED_METABOLISM;DISEASE:PAIN
ESCITALOPRAM;CYP2C19;nan;CYP2C19 ultrarapid metabolizer phenotype;LADME_PK;INCREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
NORTRIPTYLINE;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;DECREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ESCITALOPRAM;CYP2C19;nan;CYP2C19 poor metabolizers;LADME_PK;DECREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ETHANOL;OPRM1;G;rs2075572;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
PROTON PUMP INHIBITORS;CYP2C19;nan;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HELICOBACTER_INFECTIONS
DEXAMETHASONE;CHRM3;AA;rs2165870;EFFICACY;INCREASED_RESPONSE;DISEASE:POSTOPERATIVE_NAUSEA_AND_VOMITING
METOPROLOL;CYP2D6;nan;CYP2D6 poor metabolizers;DOSAGE;DECREASED_DOSE;nan
ETHANOL;OPRM1;T;rs548646;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
GLICLAZIDE;KCNQ1;T;rs2237892;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
DEXTROMETHORPHAN;CYP2D6;*4/*31;CYP2D6*4, CYP2D6*31;LADME_PK;DECREASED_METABOLISM;nan
NORTRIPTYLINE;CYP2D6;nan;CYP2D6 ultrarapid metabolizer phenotype;LADME_PK;INCREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
NICOTINE;DRD2;G/del + del/del;rs1799732;EFFICACY;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
LINAGLIPTIN;TCF7L2;CC + CT;rs7903146;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
DEXTROMETHORPHAN;CYP2D6;*5/*13;CYP2D6*5, CYP2D6*13;LADME_PK;DECREASED_METABOLISM;nan
CITALOPRAM;CYP2C19;nan;CYP2C19 poor metabolizer phenotype;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ESCITALOPRAM;CYP2C19;nan;CYP2C19 poor metabolizer phenotype;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PAROXETINE;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;DECREASED_CLEARANCE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ETHANOL;OPRM1;T;rs681243;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
DEXTROMETHORPHAN;CYP2D6;nan;CYP2D6 normal metabolizer genotype;LADME_PK;INCREASED_METABOLISM;nan
AMOXICILLIN;CYP2C19;nan;CYP2C19 normal metabolizer genotype;EFFICACY;DECREASED_RESPONSE;DISEASE:GASTRITIS
CLARITHROMYCIN;CYP2C19;nan;CYP2C19 normal metabolizer genotype;EFFICACY;DECREASED_RESPONSE;DISEASE:GASTRITIS
ESOMEPRAZOLE;CYP2C19;nan;CYP2C19 normal metabolizer genotype;EFFICACY;DECREASED_RESPONSE;DISEASE:GASTRITIS
ESCITALOPRAM;CYP2C19;nan;CYP2C19 poor metabolizers;LADME_PK;DECREASED_METABOLISM;nan
VENLAFAXINE;CYP2D6;nan;CYP2D6 poor metabolizers;EFFICACY;DECREASED_RESPONSE;EFFICACY:MAJOR_DEPRESSIVE_DISORDER
BUPROPION;COMT;AG + GG;rs4680;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
ARIPIPRAZOLE;CYP2D6;nan;CYP2D6 intermediate metabolizer phenotype;LADME_PK;DECREASED_METABOLISM;nan
CODEINE;CYP2D6;nan;CYP2D6 poor metabolizers and intermediate metabolizers;EFFICACY;DECREASED_RESPONSE;OTHER:NEOPLASMS | OTHER:PAIN
FENTANYL;CYP2D6;nan;CYP2D6 poor metabolizers and intermediate metabolizers;EFFICACY;DECREASED_RESPONSE;OTHER:NEOPLASMS | OTHER:PAIN
HYDROCODONE;CYP2D6;nan;CYP2D6 poor metabolizers and intermediate metabolizers;EFFICACY;DECREASED_RESPONSE;OTHER:NEOPLASMS | OTHER:PAIN
HYDROMORPHONE;CYP2D6;nan;CYP2D6 poor metabolizers and intermediate metabolizers;EFFICACY;DECREASED_RESPONSE;OTHER:NEOPLASMS | OTHER:PAIN
METHADONE;CYP2D6;nan;CYP2D6 poor metabolizers and intermediate metabolizers;EFFICACY;DECREASED_RESPONSE;OTHER:NEOPLASMS | OTHER:PAIN
MORPHINE;CYP2D6;nan;CYP2D6 poor metabolizers and intermediate metabolizers;EFFICACY;DECREASED_RESPONSE;OTHER:NEOPLASMS | OTHER:PAIN
OXYCODONE;CYP2D6;nan;CYP2D6 poor metabolizers and intermediate metabolizers;EFFICACY;DECREASED_RESPONSE;OTHER:NEOPLASMS | OTHER:PAIN
TRAMADOL;CYP2D6;nan;CYP2D6 poor metabolizers and intermediate metabolizers;EFFICACY;DECREASED_RESPONSE;OTHER:NEOPLASMS | OTHER:PAIN
TRIMIPRAMINE;CYP2C19;nan;CYP2C19 poor metabolizers;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
VENLAFAXINE;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;DECREASED_METABOLISM;OTHER:MAJOR_DEPRESSIVE_DISORDER
ETHANOL;OPRM1;A;rs1461773;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
3;CYP2D6;*4/*4 + *3/*5;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;*4/*4 + *3/*5;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
ENDOXIFEN;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ETHANOL;OPRM1;T;rs3778148;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
AMOXICILLIN;CYP2C19;nan;CYP2C19 normal metabolizer genotype;EFFICACY;DECREASED_CLINICAL BENEFIT;EFFICACY:HELICOBACTER_INFECTIONS
CLARITHROMYCIN;CYP2C19;nan;CYP2C19 normal metabolizer genotype;EFFICACY;DECREASED_CLINICAL BENEFIT;EFFICACY:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;nan;CYP2C19 normal metabolizer genotype;EFFICACY;DECREASED_CLINICAL BENEFIT;EFFICACY:HELICOBACTER_INFECTIONS
AMOXICILLIN;CYP2C19;nan;CYP2C19 normal metabolizer genotype;EFFICACY;DECREASED_CLINICAL BENEFIT;EFFICACY:HELICOBACTER_INFECTIONS
CLARITHROMYCIN;CYP2C19;nan;CYP2C19 normal metabolizer genotype;EFFICACY;DECREASED_CLINICAL BENEFIT;EFFICACY:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;nan;CYP2C19 normal metabolizer genotype;EFFICACY;DECREASED_CLINICAL BENEFIT;EFFICACY:HELICOBACTER_INFECTIONS
MIDAZOLAM;VDR;T;rs4516035;LADME_PK;INCREASED_CLEARANCE;nan
DESIPRAMINE;CYP2D6;nan;CYP2D6 poor metabolizers;DOSAGE;DECREASED_DOSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
AMITRIPTYLINE;CYP2D6;nan;CYP2D6 poor metabolizer phenotype;EFFICACY;DECREASED_RESPONSE;OTHER:PHANTOM_LIMB_SYNDROME
TRAMADOL;CYP2D6;nan;CYP2D6 poor metabolizer phenotype;EFFICACY;INCREASED_RESPONSE;OTHER:PHANTOM_LIMB_SYNDROME
MORPHINE;COMT;A;rs4680;EFFICACY;INCREASED_RESPONSE;DISEASE:LOW_BACK_PAIN
VORICONAZOLE;CYP2C19;nan;CYP2C19 poor metabolizers;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
ANTIDEPRESSANTS;FKBP5;AC + CC;rs3800373;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
VENLAFAXINE;CYP2D6;nan;CYP2D6 poor metabolizer phenotype;LADME_PK;DECREASED_CLEARANCE;nan
DESIPRAMINE;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
VORICONAZOLE;CYP2C19;nan;CYP2C19 poor metabolizers and intermediate metabolizers;LADME_PK;INCREASED_TROUGH CONCENTRATION;nan
TRIMIPRAMINE;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
OPIOIDS;COMT;GG;rs4680;DOSAGE;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
ATENOLOL;ADRB2;CC;rs1042714;EFFICACY;INCREASED_RESPONSE;OTHER:TACHYCARDIA
METOPROLOL;ADRB2;CC;rs1042714;EFFICACY;INCREASED_RESPONSE;OTHER:TACHYCARDIA
GLICLAZIDE;KCNQ1;C;rs2237895;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
WARFARIN;CYP2C9;nan;CYP2C9 normal metabolizers;DOSAGE;INCREASED_DOSE;nan
SOLANIDINE;CYP2D6;nan;CYP2D6 poor metabolizer genotype;LADME_PK;DECREASED_METABOLISM;OTHER:DEPRESSION
FLECAINIDE;CYP2D6;nan;CYP2D6 normal metabolizer genotype;LADME_PK;CONCENTRATIONS;DISEASE:TACHYCARDIA | SUPRAVENTRICULAR
NOROXYCODONE;CYP2D6;nan;CYP2D6 poor metabolizer phenotype;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:NEOPLASMS | OTHER:PAIN
OXYCODONE;CYP2D6;nan;CYP2D6 poor metabolizer phenotype;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:NEOPLASMS | OTHER:PAIN
OXYCODONE;CYP2D6;nan;CYP2D6 poor metabolizer phenotype;EFFICACY;DECREASED_RESPONSE;OTHER:NEOPLASMS | OTHER:PAIN
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19 poor metabolizers;LADME_PK;DECREASED_METABOLISM;DISEASE:FUNGAL_INFECTIOUS_DISEASE
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*2;LADME_PK;INCREASED_CONCENTRATIONS;nan
PIMOZIDE;CYP2D6;nan;CYP2D6 poor metabolizers;DOSAGE;DECREASED_DOSE;nan
PERPHENAZINE;CYP2D6;nan;CYP2D6 normal metabolizer genotype;LADME_PK;INCREASED_CLEARANCE;nan
BUPROPION;CYP2C19;*2 + *3;CYP2C19*2, CYP2C19*3, CYP2C19*17;LADME_PK;DECREASED_METABOLISM;DISEASE:PREGNANCY
(R)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:HEROIN_DEPENDENCE
(S)-METHADONE;CYP2D6;*1/*1xN;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:HEROIN_DEPENDENCE
METHADONE;OPRM1;AA;rs1799971;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:OPIOID-RELATED_DISORDERS
ARSENIC COMPOUNDS;CBS;AA + AG;rs4920037;TOXICITY;INCREASED_METABOLISM;nan
ARSENIC COMPOUNDS;CBS;AA + AG;rs4920037;LADME_PK;INCREASED_METABOLISM;nan
(R)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HEROIN_DEPENDENCE
(S)-METHADONE;CYP2D6;*3/*4 + *4/*4 + *4/*6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HEROIN_DEPENDENCE
VORICONAZOLE;CYP2C19;*2/*2;CYP2C19*2;LADME_PK;INCREASED_CONCENTRATIONS;nan
MORPHINE;CYP2D6;nan;CYP2D6 ultrarapid metabolizer phenotype;DOSAGE;DECREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
MORPHINE;CYP2D6;nan;CYP2D6 ultrarapid metabolizer phenotype;EFFICACY;DECREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
CODEINE;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;DECREASED_METABOLISM;nan
O-DESMETHYLTRAMADOL;CYP2D6;nan;CYP2D6 poor metabolizers and intermediate metabolizers;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:NEOPLASMS | OTHER:PAIN
(S)-METHADONE;CYP2D6;nan;CYP2D6 ultrarapid metabolizer genotype;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
WARFARIN;VKORC1;GG;rs9934438;DOSAGE;INCREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
VORICONAZOLE;CYP2C19;nan;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;EFFICACY;INCREASED_CLINICAL BENEFIT;nan
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*9;LADME_PK;DECREASED_METABOLISM;nan
METHOTREXATE;FOXP3;G;rs3761548;OTHER;DECREASED_RESPONSE;DISEASE:PSORIASIS
ATENOLOL;ADRB2;AA;rs1042713;EFFICACY;INCREASED_RESPONSE;OTHER:TACHYCARDIA
METOPROLOL;ADRB2;AA;rs1042713;EFFICACY;INCREASED_RESPONSE;OTHER:TACHYCARDIA
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:FUNGAL_INFECTIOUS_DISEASE
N-DESMETHYLTRAMADOL;CYP2D6;nan;CYP2D6 poor metabolizers and intermediate metabolizers;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:NEOPLASMS | OTHER:PAIN
4-HYDROXYTAMOXIFEN;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ENDOXIFEN;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
GEMCITABINE;NT5C2;TT;rs11598702;LADME_PK;DECREASED_CLEARANCE;nan
GEMCITABINE;CDA;TT;rs1048977;LADME_PK;DECREASED_METABOLISM;nan
VORICONAZOLE;CYP2C19;*17/*17;CYP2C19*17;LADME_PK;DECREASED_CONCENTRATIONS;nan
METHADONE;ABCB1;AG;rs1045642;LADME_PK;DECREASED_CONCENTRATIONS;nan
CLOMIPRAMINE;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;DECREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
OXYMORPHONE;CYP2D6;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*17, CYP2D6*41;LADME_PK;INCREASED_EXPOSURE;nan
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CTRB1;GG + GT;rs7202877;EFFICACY;DECREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CTRB2;GG + GT;rs7202877;EFFICACY;DECREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
LANSOPRAZOLE;CYP2C19;nan;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;nan;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HELICOBACTER_INFECTIONS
SERTRALINE;CYP2B6;*6/*6 + *6/*9;CYP2B6*1, CYP2B6*6, CYP2B6*9;LADME_PK;INCREASED_CONCENTRATIONS;nan
ENDOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *9 + *10 + *17 + *29 + *41;CYP2D6 poor metabolizers and intermediate metabolizers;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ARSENIC COMPOUNDS;CBS;CT + TT;rs234709;TOXICITY;INCREASED_METABOLISM;nan
ARSENIC COMPOUNDS;CBS;CT + TT;rs234709;LADME_PK;INCREASED_METABOLISM;nan
3-HYDROXYCOTININE;CYP2A6;*1 + *2;CYP2A6*1, CYP2A6*2, CYP2A6*9, CYP2A6*10;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:TOBACCO_USE_DISORDER
3-HYDROXYCOTININE GLUCURONIDE;CYP2A6;*1 + *2;CYP2A6*1, CYP2A6*2, CYP2A6*9, CYP2A6*10;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:TOBACCO_USE_DISORDER
RISPERIDONE;CYP2D6;nan;CYP2D6 ultrarapid metabolizer phenotype;LADME_PK;INCREASED_CLEARANCE;DISEASE:PSYCHOTIC_DISORDER
RISPERIDONE;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;DECREASED_METABOLISM;nan
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;VDR;C;rs2239179;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
ENDOXIFEN;CYP2D6;*1/*1 + *2/*2 + *1/*2;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
AMITRIPTYLINE;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;DECREASED_METABOLISM;DISEASE:DEPRESSION
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;VDR;C;rs1540339;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
ENDOXIFEN;CYP2C9;nan;CYP2C9 poor metabolizers;LADME_PK;DECREASED_CONCENTRATIONS;nan
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;DOSAGE;INCREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;EFFICACY;INCREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:HEMATOLOGIC_DISORDER | DISEASE:INFECTIOUS_DISEASE
ENDOXIFEN;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
IMIPRAMINE;CYP2C19;nan;CYP2C19 poor metabolizers;LADME_PK;DECREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DEBRISOQUINE;CYP2D6;*21/*36xN;CYP2D6*21, CYP2D6*36xN;LADME_PK;DECREASED_METABOLISM;nan
GEMIGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
LINAGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
SAXAGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
SITAGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
VILDAGLIPTIN;GLP1R;AA + AG;rs3765467;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
METHADONE;ABCB1;AA;rs1045642;LADME_PK;INCREASED_CONCENTRATIONS;nan
FENTANYL;CYP3A5;*1/*3 + *1/*6 + *3/*3 + *3/*6 + *6/*6;CYP3A5*1, CYP3A5*3, CYP3A5*6;LADME_PK;DECREASED_CLEARANCE;nan
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
NORQUETIAPINE;CYP2D6;nan;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;LADME_PK;INCREASED_EXPOSURE;nan
CODEINE;CYP2D6;nan;CYP2D6 normal metabolizers;EFFICACY;INCREASED_RESPONSE;OTHER:PAIN
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19 intermediate metabolizers;LADME_PK;DECREASED_METABOLISM;DISEASE:FUNGAL_INFECTIOUS_DISEASE
CITALOPRAM;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_EXPOSURE;nan
ESCITALOPRAM;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_EXPOSURE;nan
INDOMETHACIN;CYP2C9;G;rs2153628;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
GEMCITABINE;CDA;AA;rs2072671;LADME_PK;DECREASED_METABOLISM;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
TACROLIMUS;CYP3A5;nan;CYP3A5 poor metabolizer genotype;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
VENLAFAXINE;SLC6A4;TT;rs25531;EFFICACY;INCREASED_CLINICAL BENEFIT;DISEASE:ANXIETY_DISORDERS
ENDOXIFEN;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ENDOXIFEN;CYP2D6;nan;CYP2D6 intermediate metabolizers;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
TRAMADOL;CYP2D6;nan;CYP2D6 ultrarapid metabolizer genotype;LADME_PK;INCREASED_METABOLISM;nan
CODEINE;CYP2D6;nan;CYP2D6 normal metabolizers;EFFICACY;INCREASED_RESPONSE;OTHER:PAIN
MARAVIROC;CYP3A5;nan;CYP3A5 poor metabolizers;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
VENLAFAXINE;GABRQ;AA + AT;rs3810651;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
METOPROLOL;CYP2D6;nan;CYP2D6 normal metabolizers;LADME_PK;INCREASED_CLEARANCE;OTHER:PREGNANCY
CYTARABINE;DCK;G;rs80143932;EFFICACY;INCREASED_RESPONSE;DISEASE:MYELOID_ACUTE_LEUKEMIA
IDARUBICIN;DCK;G;rs80143932;EFFICACY;INCREASED_RESPONSE;DISEASE:MYELOID_ACUTE_LEUKEMIA
CLOMIPRAMINE;CYP1A2;AA;rs762551;EFFICACY;INCREASED_DOSE;DISEASE:DEPRESSION
FENTANYL;CYP2D6;ULTRARAPID_METABOLIZER;CYP2D6;DOSAGE;INCREASED_DOSE;OTHER:SURGERY
HYDROMORPHONE;CYP2D6;ULTRARAPID_METABOLIZER;CYP2D6;DOSAGE;INCREASED_DOSE;OTHER:SURGERY
OPIOIDS;CYP2D6;ULTRARAPID_METABOLIZER;CYP2D6;DOSAGE;INCREASED_DOSE;OTHER:SURGERY
OXYCODONE;CYP2D6;ULTRARAPID_METABOLIZER;CYP2D6;DOSAGE;INCREASED_DOSE;OTHER:SURGERY
TRAMADOL;CYP2D6;ULTRARAPID_METABOLIZER;CYP2D6;DOSAGE;INCREASED_DOSE;OTHER:SURGERY
CLOZAPINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
N-DESMETHYLCLOZAPINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
IBOGAINE;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;DECREASED_CLEARANCE;OTHER:OPIOID-RELATED_DISORDERS
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*10;LADME_PK;INCREASED_EXPOSURE;OTHER:ADHD
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ADHD
AMPHETAMINE;CYP2D6;POOR_METABOLIZER;CYP2D6;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ADHD
LISDEXAMFETAMINE;CYP2D6;POOR_METABOLIZER;CYP2D6;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ADHD
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GRIA3;CC;rs502434;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
VENLAFAXINE;GRIA3;CC;rs502434;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
NICOTINE;CYP2A6;*41;CYP2A6*1, CYP2A6*41;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;*55;CYP2A6*1, CYP2A6*55;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CYP2A6;*39;CYP2A6*1, CYP2A6*39;LADME_PK;DECREASED_METABOLISM;nan
ISONIAZID;NAT2;slow_acetylator;NAT2;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:TUBERCULOSIS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_EXPOSURE;OTHER:KIDNEY_TRANSPLANTATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;HLA-DQA1;*05;HLA-DQA1*05;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:INFLAMMATORY_BOWEL_DISEASES | OTHER:INFLAMMATION
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;DOSAGE;DOSE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DOSE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*17;LADME_PK;DECREASED_CONCENTRATIONS;nan
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GRIA3;TT;rs3761554;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
VENLAFAXINE;GRIA3;TT;rs3761554;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CALU;G;rs339097;DOSAGE;INCREASED_DOSE;nan
ISONIAZID;NAT2;intermediate_acetylator;NAT2;LADME_PK;INCREASED_CLEARANCE;OTHER:TUBERCULOSIS
OPIOIDS;OPRM1;GG;rs1799971;DOSAGE;INCREASED_DOSE;OTHER:PAIN
DIHYDROARTEMISININ;CYP2B6;*6/*6 + *18/*18 + *1/*6;CYP2B6*1, CYP2B6*6, CYP2B6*18;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:MALARIA | FALCIPARUM
DESBUTYL LUMEFANTRINE;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3, CYP3A5*6;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:MALARIA | FALCIPARUM
SERTRALINE;CYP2D6;*2;CYP2D6*1, CYP2D6*2;LADME_PK;DECREASED_CLEARANCE;OTHER:SUBSTANCE-RELATED_DISORDERS | OTHER:MAJOR_DEPRESSIVE_DISORDER | OTHER:ANXIETY_DISORDERS | OTHER:BORDERLINE_PERSONALITY_DISORDER
SERTRALINE;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;LADME_PK;DECREASED_CLEARANCE;OTHER:SUBSTANCE-RELATED_DISORDERS | OTHER:MAJOR_DEPRESSIVE_DISORDER | OTHER:ANXIETY_DISORDERS | OTHER:BORDERLINE_PERSONALITY_DISORDER
TACROLIMUS;ABCC2;TT;rs3740066;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
LEVONORGESTREL;CYP2B6;POOR_METABOLIZER;CYP2B6;LADME_PK;INCREASED_CLEARANCE;OTHER:HIV_INFECTIOUS_DISEASE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GRIA3;TT;rs3761555;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
VENLAFAXINE;GRIA3;TT;rs3761555;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;NKX2-6;AG + GG;rs310279;DOSAGE;INCREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
CYTARABINE;DCK;T;rs2306744;EFFICACY;INCREASED_RESPONSE;DISEASE:MYELOID_ACUTE_LEUKEMIA
IDARUBICIN;DCK;T;rs2306744;EFFICACY;INCREASED_RESPONSE;DISEASE:MYELOID_ACUTE_LEUKEMIA
VENLAFAXINE;HTR2A;AG + GG;rs7997012;EFFICACY;INCREASED_CLINICAL BENEFIT;DISEASE:ANXIETY_DISORDERS
VORICONAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:THERAPEUTIC_DRUG_MONITORING_ANALYSES
ANTIEPILEPTICS;nan;CC + CT;rs16935279;LADME_PK;DECREASED_METABOLISM;DISEASE:BIPOLAR_DISORDER | DISEASE:PSYCHOTIC_DISORDER
FOLLITROPIN BETA;FSHR;CC + CT;rs6166;DOSAGE;INCREASED_DOSE;nan
UROFOLLITROPIN;FSHR;CC + CT;rs6166;DOSAGE;INCREASED_DOSE;nan
PAROXETINE;CYP2D6;ULTRARAPID_METABOLIZER;CYP2D6;LADME_PK;DECREASED_STEADY_STATE CONCENTRATION;OTHER:MAJOR_DEPRESSIVE_DISORDER | OTHER:ANXIETY_DISORDERS | OTHER:PANIC_DISORDER
PAROXETINE;CYP2D6;ULTRARAPID_METABOLIZER;CYP2D6;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
CLOMIPRAMINE;CYP2D6;*2/*1xN;CYP2D6*1xN, CYP2D6*2;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:AGORAPHOBIA
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
CLOMIPRAMINE;CYP2D6;*4/*6;CYP2D6*4, CYP2D6*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;LADME_PK;INCREASED_CLEARANCE;nan
ATORVASTATIN;CYP2C19;*2 + *4 + *8;CYP2C19*1, CYP2C19*2, CYP2C19*4, CYP2C19*8, CYP2C19*11;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CARDIOVASCULAR_DISEASE
CISPLATIN;UBE2I;CG;rs9597;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
IRINOTECAN;UBE2I;CG;rs9597;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
WARFARIN;FRAS1;AA + AG;rs4386623;DOSAGE;INCREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:GASTROESOPHAGEAL_REFLUX
WARFARIN;FAM201A;AG + GG;rs1890109;DOSAGE;INCREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
VALPROIC ACID;SCN1A;T;rs3812718;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
PANTOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCER
PANTOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCER
CAPECITABINE;DPYD;CC + CT;rs1801159;EFFICACY;INCREASED_RESPONSE;DISEASE:GASTROESOPHAGEAL_CANCER
NICOTINE;DRD2;A;rs6277;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
CAPTOPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED_RESISTANCE;DISEASE:DIABETES_MELLITUS
APIXABAN;CYP3A5;CC;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:THROMBOEMBOLISM
DABIGATRAN;CYP3A5;CC;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:THROMBOEMBOLISM
EDOXABAN;CYP3A5;CC;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:THROMBOEMBOLISM
RIVAROXABAN;CYP3A5;CC;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:THROMBOEMBOLISM
BUPROPION;SLC6A4;HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
ETHANOL;OPRM1;A;rs648007;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
MIDAZOLAM;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
CLOZAPINE;NFIB;CT;rs28379954;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:TOBACCO_USE_DISORDER
ETHANOL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;INCREASED_EXPOSURE;DISEASE:KIDNEY_TRANSPLANTATION
PRIMAQUINE;CYP2D6;*4/*41 + *5/*6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MALARIA
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED_DOSE;nan
NICOTINE;UGT2B10;T;rs61750900;OTHER;DECREASED_METABOLISM;nan
NICOTINE;UGT2B10;T;rs61750900;LADME_PK;DECREASED_METABOLISM;nan
NICOTINE;CHRNA7;CC;rs2337980;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
BUPROPION;DRD2;GG;rs1799732;EFFICACY;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
WARFARIN;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED_DOSE;nan
CLOZAPINE;CYP1A1;CT;rs2472297;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:TOBACCO_USE_DISORDER
SIMVASTATIN;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;LADME_PK;CONCENTRATIONS;nan
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
VORICONAZOLE;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:FUNGAL_INFECTIOUS_DISEASE
QUETIAPINE;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:PSYCHOTIC_DISORDER
WARFARIN;EPHX1;A;rs1131873;DOSAGE;DECREASED_DOSE;nan
CLOZAPINE;CYP1A1;CT;rs2472297;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;nan
METFORMIN;SLC2A2;C;rs8192675;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
WARFARIN;CYP2C9;G;rs28371686;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:CONNECTIVE_TISSUE_DISEASES
WARFARIN;CYP2C9;T;rs28371685;DOSAGE;DECREASED_DOSE;nan
DULOXETINE;CYP2D6;CC;rs3892097;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ALCOHOL_ABUSE | OTHER:DEPRESSIVE_DISORDER
SN-38;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:NEOPLASMS
WARFARIN;CYP2C9;del;rs9332131;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CONCENTRATIONS;nan
CLOZAPINE;NFIB;CT;rs28379954;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;nan
HYDROXYUREA;BCL11A;A;rs4671393;EFFICACY;INCREASED_RESPONSE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
WARFARIN;CYP2C9;A;rs7900194;DOSAGE;DECREASED_DOSE;nan
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*1, CYP2C8*3;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
BETA BLOCKING AGENTS;KL;A/del + del/del;rs36217263;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
EFAVIRENZ;CYP2B6;*6/*6 + *1/*6;CYP2B6*1, CYP2B6*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
VORICONAZOLE;CYP2C19;*2/*2 + *1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:FUNGAL_INFECTIOUS_DISEASE
GEMCITABINE;RRM1;AC;rs12806698;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
FLUOXETINE;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;rs57098334;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
SERTRALINE;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;rs57098334;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
BUPROPION;ACE;TT;rs8075924;EFFICACY;DECREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;DECREASED_METABOLISM;OTHER:KIDNEY_TRANSPLANTATION
SERTRALINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
SUNITINIB;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;LADME_PK;DECREASED_CLEARANCE;nan
HYDROXYCHLOROQUINE;CYP3A4;CC;rs3735451;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:RHEUMATOID_ARTHRITIS | OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS
FLUOROURACIL;XRCC1;CC;rs25487;EFFICACY;INCREASED_RESPONSE;DISEASE:RECTAL_NEOPLASMS
MIRTAZAPINE;CYP2B6;*6/*6;CYP2B6*6;LADME_PK;INCREASED_METABOLISM;DISEASE:DEPRESSION
CLOBAZAM;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
GEMCITABINE;RRM1;CT;rs11030918;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
TACROLIMUS;ABCB1;AG + GG;rs1045642;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
ACENOCOUMAROL;CYP2C9;*1/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;LADME_PK;DECREASED_CLEARANCE;nan
RISPERIDONE;CYP2D6;nan;CYP2D6 intermediate metabolizer phenotype;LADME_PK;DECREASED_METABOLISM;nan
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;DOSAGE;DECREASED_RESPONSE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED_RESPONSE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION
PACLITAXEL;CYP2C8;T;rs11572080;OTHER;DECREASED_METABOLISM;nan
PACLITAXEL;CYP2C8;T;rs11572080;LADME_PK;DECREASED_METABOLISM;nan
PACLITAXEL;CYP2C8;C;rs10509681;OTHER;DECREASED_METABOLISM;nan
PACLITAXEL;CYP2C8;C;rs10509681;LADME_PK;DECREASED_METABOLISM;nan
CYCLOSPORINE;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_CONCENTRATIONS;nan
CYCLOSPORINE;CYP3A4;A;rs35599367;LADME_PK;DECREASED_METABOLISM;OTHER:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
FLUOXETINE;CYP2D6;*1/*1 + *10/*10 + *1/*4 + *1/*10;CYP2D6*1, CYP2D6*4, CYP2D6*10;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ANXIETY_DISORDERS | OTHER:DEPRESSION | OTHER:MAJOR_DEPRESSIVE_DISORDER
CODEINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;LADME_PK;DECREASED_METABOLISM;DISEASE:CHRONIC_KIDNEY_FAILURE
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;LADME_PK;INCREASED_METABOLISM;OTHER:PATIENTS_WITH_DECREASED_CONCENTRATIONS_OF_VORICONAZOLE
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
DOCETAXEL;PPARD;T;rs3734254;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
THALIDOMIDE;PPARD;T;rs3734254;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
ATENOLOL;OR10P1;G;rs17117817;LADME_PD;DECREASED_RESPONSE;OTHER:HYPERTENSION
METOPROLOL;OR10P1;G;rs17117817;LADME_PD;DECREASED_RESPONSE;OTHER:HYPERTENSION
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_DOSE;nan
CARBOPLATIN;RRM1;AC;rs12806698;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
GEMCITABINE;RRM1;AC;rs12806698;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
METFORMIN;C11orf65;C;rs11212617;EFFICACY;INCREASED_CLINICAL BENEFIT;DISEASE:DIABETES_MELLITUS_TYPE2
ABATACEPT;HLA-DRB1;*04:01 + *04:04 + *04:05 + *04:10 + *10:01;HLA-DRB1*04:01, HLA-DRB1*04:04, HLA-DRB1*04:05, HLA-DRB1*04:10, HLA-DRB1*10:01;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
METHADONE;nan;AG + GG;rs17180299;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
WARFARIN;CALU;G;rs339097;DOSAGE;INCREASED_DOSE;nan
VINCRISTINE;nan;G;rs1247117;LADME_PD;INCREASED_RESISTANCE;nan
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
ATENOLOL;SNX9;A;rs2364349;LADME_PD;DECREASED_RESPONSE;OTHER:HYPERTENSION
METOPROLOL;SNX9;A;rs2364349;LADME_PD;DECREASED_RESPONSE;OTHER:HYPERTENSION
TACROLIMUS;nan;GT + TT;rs11265572;LADME_PK;DECREASED_METABOLISM;DISEASE:LIVER_TRANSPLANTATION
WARFARIN;STX4;T;rs10871454;DOSAGE;DECREASED_DOSE;nan
SIROLIMUS;CYP3A5;CT;rs776746;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:URINARY_BLADDER_NEOPLASMS
TEMSIROLIMUS;CYP3A5;CT;rs776746;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:URINARY_BLADDER_NEOPLASMS
PERAMPANEL;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;nan;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:EPILEPSY
VORICONAZOLE;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
VORICONAZOLE;CYP2C19;*17;CYP2C19*17;LADME_PK;DECREASED_CONCENTRATIONS;nan
ENALAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
URACIL;DPYD;c.295_298delTCAT (*7);DPYD c.295_298delTCAT (*7), DPYD Reference;LADME_PK;INCREASED_CONCENTRATIONS;nan
URACIL;DPYD;c.2846A>T;DPYD c.2846A>T, DPYD Reference;LADME_PK;INCREASED_CONCENTRATIONS;nan
URACIL;DPYD;c.1679T>G (*13);DPYD c.1679T>G (*13), DPYD Reference;LADME_PK;INCREASED_CONCENTRATIONS;nan
URACIL;DPYD;c.1905+1G>A (*2A);DPYD c.1905+1G>A (*2A), DPYD Reference;LADME_PK;INCREASED_CONCENTRATIONS;nan
N-DESMETHYLTAMOXIFEN;CYP2D6;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*29, CYP2D6*35, CYP2D6*41;LADME_PK;DECREASED_METABOLISM;DISEASE:BREAST_NEOPLASMS
N-DESMETHYLTAMOXIFEN;CYP2D6;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41;LADME_PK;DECREASED_METABOLISM;DISEASE:BREAST_NEOPLASMS
ATORVASTATIN;CYP3A5;*3/*3;CYP3A5*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
N-DESMETHYLTAMOXIFEN;CYP2D6;*10/*10 + *1/*10;CYP2D6*1, CYP2D6*10;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ESCITALOPRAM;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;INCREASED_CONCENTRATIONS;nan
ESCITALOPRAM;CYP2D6;INTERMEDIATE_METABOLIZER;CYP2D6;LADME_PK;INCREASED_CONCENTRATIONS;nan
AMITRIPTYLINE;CYP2C19;*2/*2 + *1/*2;CYP2C19*1, CYP2C19*2;TOXICITY;DECREASED_METABOLISM;SIDE_EFFECT:POSTMORTEM_TOXICOLOGY_CASES
AMITRIPTYLINE;CYP2C19;*2/*2 + *1/*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_METABOLISM;SIDE_EFFECT:POSTMORTEM_TOXICOLOGY_CASES
EFAVIRENZ;CYP2B6;POOR_METABOLIZER;CYP2B6;LADME_PK;INCREASED_EXPOSURE;nan
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;*03:01;HLA-A*03:01;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;*23:17;HLA-A*23:17;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-B;*57:03;HLA-B*57:03;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3, CYP3A5*7;LADME_PK;INCREASED_CLEARANCE;OTHER:KIDNEY_TRANSPLANTATION
RISPERIDONE;CYP2D6;*2 + *9 + *10 + *35 + *41;CYP2D6*1, CYP2D6*2, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*41;LADME_PK;DECREASED_CLEARANCE;nan
ANTIDEPRESSANTS;CYP2C19;POOR_METABOLIZER;CYP2C19;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
SUMATRIPTAN;SLC22A1;TAAGTTGT/TAAGTTGT;rs1349294037;OTHER;INCREASED_CONCENTRATIONS;nan
METHADONE;CYP2B6;*6 + *18;CYP2B6*1, CYP2B6*6, CYP2B6*18;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:OPIOID-RELATED_DISORDERS
LAMOTRIGINE;UGT1A4;*3b;UGT1A4*3b;EFFICACY;DECREASED_CLINICAL BENEFIT;nan
DOCETAXEL;PPARD;C;rs2016520;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
THALIDOMIDE;PPARD;C;rs2016520;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1;DOSAGE;INCREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
INFLIXIMAB;HLA-DQA1;*05;HLA-DQA1*05;EFFICACY;DECREASED_RESPONSE;OTHER:CROHN_DISEASE
CLOPIDOGREL;CYP2C19;*2 + *4;CYP2C19*1, CYP2C19*2, CYP2C19*4, CYP2C19*17;EFFICACY;DECREASED_RESPONSE;nan
DOCETAXEL;CHST3;A;rs1871450;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
THALIDOMIDE;CHST3;A;rs1871450;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;T;rs9923231;LADME_PK;DECREASED_DOSE;nan
PROPOFOL;CYP2B6;*6;CYP2B6*1, CYP2B6*6;TOXICITY;DECREASED_RESPONSE;OTHER:BRAIN_INJURY
TILDRAKIZUMAB;PDE4D;CT/CT;rs10556657;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
BUPRENORPHINE;ABCB1;A;rs1045642;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
DIHYDROCODEINE;ABCB1;A;rs1045642;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
FENTANYL;ABCB1;A;rs1045642;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
HYDROMORPHONE;ABCB1;A;rs1045642;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
METHADONE;ABCB1;A;rs1045642;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
MORPHINE;ABCB1;A;rs1045642;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
OXYCODONE;ABCB1;A;rs1045642;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
PIRITRAMIDE;ABCB1;A;rs1045642;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
TILIDINE;ABCB1;A;rs1045642;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
TRAMADOL;ABCB1;A;rs1045642;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
TACROLIMUS;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;LADME_PK;DECREASED_CLEARANCE;OTHER:KIDNEY_TRANSPLANTATION
SIROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
DOCETAXEL;PPARD;C;rs1883322;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
THALIDOMIDE;PPARD;C;rs1883322;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
PHENYTOIN;CYP2C19;INTERMEDIATE_METABOLIZER;CYP2C19;LADME_PK;INCREASED_CONCENTRATIONS;nan
VALPROIC ACID;CYP2C19;INTERMEDIATE_METABOLIZER;CYP2C19;LADME_PK;INCREASED_CONCENTRATIONS;nan
CARBAMAZEPINE;CYP3A5;POOR_METABOLIZER;CYP3A5;LADME_PK;INCREASED_CONCENTRATIONS;nan
VALPROIC ACID;CYP2C9;INTERMEDIATE_METABOLIZER;CYP2C9;LADME_PK;INCREASED_CONCENTRATIONS;nan
VALPROIC ACID;UGT1A6;*2a;UGT1A6*1a, UGT1A6*2a;LADME_PK;DECREASED_CONCENTRATIONS;nan
PHENYTOIN;CYP2C9;INTERMEDIATE_METABOLIZER;CYP2C9;LADME_PK;INCREASED_CONCENTRATIONS;nan
SN-38;UGT1A1;*1/*28;UGT1A1*1, UGT1A1*28;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:COLORECTAL_NEOPLASMS | OTHER:METASTATIC_NEOPLASM
DOCETAXEL;CHST3;A;rs12418;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
THALIDOMIDE;CHST3;A;rs12418;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
FOLFIRI;UGT1A1;*28 + *60;UGT1A1*1, UGT1A1*28, UGT1A1*60;DOSAGE;DECREASED_DOSE;OTHER:COLORECTAL_NEOPLASMS
IRINOTECAN;UGT1A1;*28 + *60;UGT1A1*1, UGT1A1*28, UGT1A1*60;DOSAGE;DECREASED_DOSE;OTHER:COLORECTAL_NEOPLASMS
IRINOTECAN;UGT1A1;*28/*28 + *1/*28;UGT1A1*1, UGT1A1*28;DOSAGE;DECREASED_DOSE;OTHER:COLORECTAL_NEOPLASMS | OTHER:METASTATIC_NEOPLASM
OMEPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_METABOLISM;OTHER:PEPTIC_ULCER_DISEASE | OTHER:GASTROESOPHAGEAL_REFLUX | OTHER:ESOPHAGITIS
MERCAPTOPURINE;TPMT;*1/*8;TPMT*1, TPMT*8;LADME_PK;DECREASED_METABOLISM;nan
ABROCITINIB;CYP2C19;POOR_METABOLIZER;CYP2C19;LADME_PK;INCREASED_EXPOSURE;nan
WARFARIN;CYP2C9;*1/*1;CYP2C9*1;DOSAGE;INCREASED_DOSE;nan
WARFARIN;CYP2C9;*2 + *3 + *8;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*8;DOSAGE;DECREASED_DOSE;nan
OPIOIDS;OPRM1;GG;rs1799971;DOSAGE;INCREASED_DOSE;OTHER:CAESARIAN_SECTION | OTHER:PAIN
DULOXETINE;DRD3;GG;rs963468;EFFICACY;DECREASED_RESPONSE;DISEASE:ANXIETY_DISORDERS
SIMVASTATIN;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;LADME_PK;INCREASED_EXPOSURE;nan
METFORMIN;C11orf65;C;rs11212617;EFFICACY;INCREASED_CLINICAL BENEFIT;DISEASE:DIABETES_MELLITUS_TYPE2
CYCLOSPORINE;CYP3A5;CC;rs776746;DOSAGE;DECREASED_DOSE;nan
CYCLOSPORINE;CYP3A5;CC;rs776746;LADME_PK;DECREASED_DOSE;nan
EFAVIRENZ;NR1I3;AA + AG;rs2307424;EFFICACY;INCREASED_RESPONSE;EFFICACY:HIV_INFECTIOUS_DISEASE
NEVIRAPINE;NR1I3;AA + AG;rs2307424;EFFICACY;INCREASED_RESPONSE;EFFICACY:HIV_INFECTIOUS_DISEASE
VORICONAZOLE;CYP2C19;*1/*1 + *1/*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:HEMATOLOGIC_NEOPLASMS | OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
ARIPIPRAZOLE;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;LADME_PK;INCREASED_CONCENTRATIONS;nan
ARIPIPRAZOLE;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;INCREASED_CONCENTRATIONS;nan
DEHYDROARIPIPRAZOLE;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;INCREASED_CONCENTRATIONS;nan
PIMOZIDE;CYP3A4;*22;CYP3A4*1, CYP3A4*22;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:PSYCHOTIC_DISORDER
DOCETAXEL;CHST3;C;rs4148943;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
THALIDOMIDE;CHST3;C;rs4148943;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
RISPERIDONE;CYP2D6;ULTRARAPID_METABOLIZER;CYP2D6;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
DOCETAXEL;CHST3;C;rs4148945;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
THALIDOMIDE;CHST3;C;rs4148945;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
ELEXACAFTOR;CFTR;CG;rs80034486;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
TEZACAFTOR;CFTR;CG;rs80034486;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;CG;rs80034486;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
GLYBURIDE;ABCB11;G;rs4148776;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
IMATINIB;SLCO1B3;AA + AG;rs7311358;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
IMATINIB;SLCO1B3;GG + GT;rs4149117;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
PRAZIQUANTEL;CYP2C19;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHISTOSOMIASIS
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA | OTHER:LYMPHOMA | OTHER:MYELOID_ACUTE_LEUKEMIA
GLYBURIDE;CHST13;C;rs1054097;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
LACOSAMIDE;CYP2C19;nan;CYP2C19 normal metabolizer;LADME_PK;DECREASED_EXPOSURE;OTHER:EPILEPSY
LACOSAMIDE;ABCC2;T;rs717620;LADME_PK;DECREASED_EXPOSURE;OTHER:EPILEPSY
ZUCLOPENTHIXOL;CYP2D6;*1/*3 + *1/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4;LADME_PK;INCREASED_CONCENTRATIONS;nan
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4;LADME_PK;INCREASED_CONCENTRATIONS;nan
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1, CYP2C9*2, CYP2C9*3;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SURGERY
CLOZAPINE;CYP2D6;nan;CYP2D6 normal metabolizer;DOSAGE;INCREASED_DOSE;OTHER:SCHIZOPHRENIA | OTHER:PSYCHOTIC_DISORDER
EFAVIRENZ;CYP2B6;INTERMEDIATE_METABOLIZER;CYP2B6;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
MERCAPTOPURINE;TPMT;nan;TPMT deficiency;DOSAGE;DECREASED_DOSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
THIOGUANOSINE DIPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:INFLAMMATORY_BOWEL_DISEASES
THIOGUANOSINE MONOPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:INFLAMMATORY_BOWEL_DISEASES
THIOGUANOSINE TRIPHOSPHATE;TPMT;*3A + *3B + *3C;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:INFLAMMATORY_BOWEL_DISEASES
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
TOLTERODINE;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;INCREASED_CONCENTRATIONS;nan
METOPROLOL;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;DECREASED_METABOLISM;nan
CLOZAPINE;ITIH3;AA;rs2535629;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ATOMOXETINE;CYP2D6;POOR_METABOLIZER;CYP2D6;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
EFAVIRENZ;CYP2B6;POOR_METABOLIZER;CYP2B6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE | DISEASE:TUBERCULOSIS
EFAVIRENZ;NAT2;slow_acetylator;NAT2;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE | DISEASE:TUBERCULOSIS
COTININE;CYP2A6;nan;CYP2A6 low activity;LADME_PK;INCREASED_METABOLISM;OTHER:TOBACCO_USE_DISORDER
COTININE;CYP2A6;nan;CYP2A6 low activity;LADME_PK;INCREASED_CONCENTRATIONS;nan
NICOTINE;CYP2A6;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*24, CYP2A6*25, CYP2A6*26, CYP2A6*27, CYP2A6*28, CYP2A6*35;LADME_PK;DECREASED_METABOLISM;nan
ESCITALOPRAM;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
DEOXY-THIOGUANOSINE TRIPHOSPHATE;TPMT;nan;TPMT deficiency;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
THIOGUANOSINE TRIPHOSPHATE;TPMT;nan;TPMT deficiency;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ENDOXIFEN;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
CAFFEINE;ADORA1;CC;rs10920573;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:APNEA_OF_PREMATURITY
NORQUETIAPINE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CONCENTRATIONS;nan
QUETIAPINE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_CONCENTRATIONS;nan
AMLODIPINE;CACNA1D;GG;rs312481;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HYPERTENSION
PEGINTERFERON ALFA-2A;ZHX2;C;rs17289471;EFFICACY;INCREASED_RESPONSE;OTHER:HEPATITIS_B_VIRUS_INFECTION
BERBERINE;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;DECREASED_METABOLISM;nan
CLOPIDOGREL;CYP2C19;T;rs12248560;EFFICACY;RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
CLOPIDOGREL;CYP2C19;T;rs12248560;OTHER;RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
RANIBIZUMAB;VEGFA;CC + CT;rs833069;EFFICACY;INCREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
TACROLIMUS;CYP3A5;CC;rs4646449;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
ONDANSETRON;CYP2D6;POOR_METABOLIZER;CYP2D6;DOSAGE;INCREASED_DOSE;OTHER:SURGERY
IMATINIB;ABCA3;GG + GT;rs150929;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
METFORMIN;CBARP;TT;rs2301759;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
METFORMIN;STK11;TT;rs2301759;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
METFORMIN;SLC22A3;T;rs3127602;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
METFORMIN;PRKAA1;A;rs11749180;EFFICACY;DECREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
METFORMIN;SLC29A4;A;rs10234709;EFFICACY;DECREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
METFORMIN;PRKAG2;T;rs4725434;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
METFORMIN;SLC47A1;A;rs2120274;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
METFORMIN;STK11;C;rs2301759;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
METFORMIN;SLC47A2;C;rs4621031;EFFICACY;DECREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
ELEXACAFTOR;CFTR;3849+10kbC->T;CFTR 3849+10kbC->T;nan;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
TEZACAFTOR;CFTR;3849+10kbC->T;CFTR 3849+10kbC->T;nan;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;3849+10kbC->T;CFTR 3849+10kbC->T;nan;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
ALECTINIB;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA
METFORMIN;TCF7L2;T;rs7903146;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
METHADONE;OPRK1;CC;rs3802279;DOSAGE;DECREASED_DOSE;OTHER:HEROIN_DEPENDENCE
ELEXACAFTOR;CFTR;GG;rs80034486;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
TEZACAFTOR;CFTR;GG;rs80034486;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;GG;rs80034486;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:EPILEPSY
N-DESMETHYLTRAMADOL;SLC22A1;AG;rs41267797;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
O-DESMETHYLTRAMADOL;SLC22A1;AG;rs41267797;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
N;CYP2D6;*4/*6 + *4/*5;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*41, CYP2D6*45;LADME_PK;INCREASED_CONCENTRATIONS;nan
N-DIDESMETHYLTRAMADOL;CYP2D6;*4/*6 + *4/*5;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*41, CYP2D6*45;LADME_PK;INCREASED_CONCENTRATIONS;nan
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:IMMUNOGLOBULIN_A_VASCULITIS
ELEXACAFTOR;CFTR;AA;rs75961395;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
TEZACAFTOR;CFTR;AA;rs75961395;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;AA;rs75961395;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
TOCILIZUMAB;IL6R;AG + GG;rs35717427;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
N-DESMETHYLTRAMADOL;ABCC2;CT;rs17216317;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
O-DESMETHYLTRAMADOL;ABCC2;CT;rs17216317;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
TOCILIZUMAB;IL6R;CG + GG;rs6690230;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
TOCILIZUMAB;IL6R;AA + AG;rs11265621;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
TOCILIZUMAB;nan;AA;rs10108210;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
TOCILIZUMAB;CLEC2D;GG;rs1560011;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
TOCILIZUMAB;KCNMB1;AA + AG;rs703505;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:ELDERLY_ADULT | OTHER:MAJOR_DEPRESSIVE_DISORDER
MORPHINE;CCL11;AA;rs17809012;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:NEOPLASMS | OTHER:PAIN
MORPHINE;IL16;TT;rs4778889;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:NEOPLASMS | OTHER:PAIN
N-DESMETHYLTRAMADOL;SLC22A1;CT;rs35235578;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
O-DESMETHYLTRAMADOL;SLC22A1;CT;rs35235578;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
VALPROIC ACID;SLC16A1;GG;rs7169;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
N-DESMETHYLTRAMADOL;SLC22A1;C;rs9457841;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
O-DESMETHYLTRAMADOL;SLC22A1;C;rs9457841;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
N-DESMETHYLTRAMADOL;SLC22A1;CC;rs34134157;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:DEATH
O-DESMETHYLTRAMADOL;SLC22A1;CC;rs34134157;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:DEATH
TENOFOVIR;ABCC4;AC + CC;rs3742106;TOXICITY;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
ANTIDEPRESSANTS;FKBP5;CT + TT;rs1360780;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ACETAMINOPHEN SULFATE;CYP2E1;*1/*5B;CYP2E1*1, CYP2E1*5B;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:PATENT_DUCTUS_ARTERIOSUS | OTHER:PREMATURE_BIRTH
FENTANYL;ABCC1;(A)14;rs58572178;LADME_PK;INCREASED_CLEARANCE;OTHER:PAIN | OTHER:PREMATURE_BIRTH
VORICONAZOLE;CYP2C19;*2 + *17;CYP2C19*2, CYP2C19*17;DOSAGE;DOSE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
ACETAMINOPHEN;CYP1A2;A;rs2069514;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PATENT_DUCTUS_ARTERIOSUS
DOXORUBICIN;CBR1;T;rs20572;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
SUNITINIB;KDR;AG;rs34231037;EFFICACY;INCREASED_CLINICAL BENEFIT;nan
ANTIDEPRESSANTS;FKBP5;CC;rs3800373;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
GLICLAZIDE;KCNQ1;GT + TT;rs163184;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
GLIMEPIRIDE;KCNQ1;GT + TT;rs163184;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
GLIPIZIDE;KCNQ1;GT + TT;rs163184;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
GLYBURIDE;KCNQ1;GT + TT;rs163184;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
ISONIAZID;NAT2;slow_acetylator;NAT2;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:TUBERCULOSIS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
MORPHINE;CYP2D6;*41;CYP2D6*10, CYP2D6*41;LADME_PK;INCREASED_EXPOSURE;OTHER:POSTOPERATIVE_PAIN
DULOXETINE;DRD3;CC + CT;rs324026;EFFICACY;DECREASED_RESPONSE;DISEASE:ANXIETY_DISORDERS
CYTARABINE;RAD50;AA + AC;rs2299014;EFFICACY;INCREASED_RESISTANCE;OTHER:MYELOID_ACUTE_LEUKEMIA
DAUNORUBICIN;RAD50;AA + AC;rs2299014;EFFICACY;INCREASED_RESISTANCE;OTHER:MYELOID_ACUTE_LEUKEMIA
TENOFOVIR;ABCC4;TT;rs1751034;TOXICITY;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
DULOXETINE;DRD3;CT;rs324023;EFFICACY;DECREASED_RESPONSE;DISEASE:ANXIETY_DISORDERS
EFAVIRENZ;NR1I2;AA + AC;rs1523127;EFFICACY;DECREASED_RESPONSE;EFFICACY:HIV_INFECTIOUS_DISEASE
NEVIRAPINE;NR1I2;AA + AC;rs1523127;EFFICACY;DECREASED_RESPONSE;EFFICACY:HIV_INFECTIOUS_DISEASE
EZETIMIBE;ABCG8;nan;ABCG8 deficiency;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:FAMILIAL_HYPERCHOLESTEROLEMIA
EZETIMIBE;ABCG5;nan;ABCG5 deficiency;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:FAMILIAL_HYPERCHOLESTEROLEMIA
RABEPRAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
DULOXETINE;DRD3;AG;rs167770;EFFICACY;DECREASED_RESPONSE;DISEASE:ANXIETY_DISORDERS
RISPERIDONE;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BIPOLAR_DISORDER | DISEASE:SCHIZOAFFECTIVE_DISORDER | DISEASE:SCHIZOPHRENIA
TAMSULOSIN;CYP2D6;*10 + *41;CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PROSTATIC_HYPERPLASIA
HYDROXYUREA;HBG2;AG;rs7482144;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES | OTHER:ALPHA-THALASSEMIA
HYDROXYUREA;HBG2;AA + AG;rs7482144;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
HYDROXYUREA;HBG2;AA;rs7482144;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
HYDROXYUREA;BCL11A;C;rs766432;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
IMATINIB;PDGFRB;CT;rs201866603;EFFICACY;DECREASED_RESPONSE;EFFICACY:INFANTILE_MYOFIBROMATOSIS
FLUOROURACIL;MTHFR;A;rs1801133;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
LEUCOVORIN;MTHFR;A;rs1801133;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
OXALIPLATIN;MTHFR;A;rs1801133;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
VORTIOXETINE;CYP2D6;*4/*4 + *4/*10;CYP2D6*1, CYP2D6*4, CYP2D6*10;LADME_PK;INCREASED_CONCENTRATIONS;nan
ANTIEPILEPTICS;SCN1A;AA + AT;rs121917953;EFFICACY;INCREASED_RESISTANCE;OTHER:EPILEPSY
NICOTINE;CYP2A6;G;rs778019189;LADME_PK;DECREASED_METABOLISM;nan
METHOTREXATE;ENG;G;rs1800956;LADME_PK;DECREASED_CLEARANCE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE;PKD1L2;A;rs16954698;LADME_PK;DECREASED_CLEARANCE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *2/*4 + *3/*3;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4;DOSAGE;DECREASED_DOSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ANTIDEPRESSANTS;FKBP5;TT;rs1360780;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;TOXICITY;INCREASED_CONCENTRATIONS;SIDE_EFFECT:ADVERSE_EVENTS | SIDE_EFFECT:CHOLESTASIS | SIDE_EFFECT:THROMBOCYTOPENIA
VORICONAZOLE;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;LADME_PK;INCREASED_CONCENTRATIONS;SIDE_EFFECT:ADVERSE_EVENTS | SIDE_EFFECT:CHOLESTASIS | SIDE_EFFECT:THROMBOCYTOPENIA
EFAVIRENZ;NR1I3;AG + GG;rs3003596;EFFICACY;DECREASED_RESPONSE;EFFICACY:HIV_INFECTIOUS_DISEASE
NEVIRAPINE;NR1I3;AG + GG;rs3003596;EFFICACY;DECREASED_RESPONSE;EFFICACY:HIV_INFECTIOUS_DISEASE
ANTIDEPRESSANTS;FKBP5;AA;rs4713916;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
ENDOXIFEN;CYP2D6;*10/*10 + *2/*10;CYP2D6*1, CYP2D6*2, CYP2D6*10;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
ENDOXIFEN;CYP2D6;nan;CYP2D6 normal metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
DEXTROMETHORPHAN;CYP2D6;*4/*4;CYP2D6*4;LADME_PK;DECREASED_METABOLISM;nan
CLOZAPINE;CYP2D6;C;rs202102799;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA | OTHER:PSYCHOTIC_DISORDER
CLOZAPINE;CYP2D6;G;rs28371726;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA | OTHER:PSYCHOTIC_DISORDER
CLOZAPINE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA | OTHER:PSYCHOTIC_DISORDER
N-DESMETHYLCLOZAPINE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA | OTHER:PSYCHOTIC_DISORDER
CLOZAPINE;DRD4;C;rs762502;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA | OTHER:PSYCHOTIC_DISORDER
NIFEDIPINE;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:PREGNANCY
CLOZAPINE;DRD4;del;rs2133251840;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA | OTHER:PSYCHOTIC_DISORDER
CLOZAPINE;CYP1A2;ULTRARAPID_METABOLIZER;CYP1A2;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA | OTHER:PSYCHOTIC_DISORDER
N-DESMETHYLCLOZAPINE;CYP1A2;ULTRARAPID_METABOLIZER;CYP1A2;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA | OTHER:PSYCHOTIC_DISORDER
EXENATIDE;SORCS1;GG;rs1416406;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
LINAGLIPTIN;KCNJ11;GG;rs2285676;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
SITAGLIPTIN;KCNJ11;GG;rs2285676;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
VILDAGLIPTIN;KCNJ11;GG;rs2285676;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
LINAGLIPTIN;PRKD1;G;rs57803087;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
SAXAGLIPTIN;PRKD1;G;rs57803087;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
SITAGLIPTIN;PRKD1;G;rs57803087;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
VILDAGLIPTIN;PRKD1;G;rs57803087;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
CLOZAPINE;CYP1A2;T;rs72547516;nan;DECREASED_METABOLISM;nan
CLOZAPINE;CYP1A2;*8;CYP1A2*8;LADME_PK;DECREASED_METABOLISM;nan
MIDAZOLAM;NR1I2;CC;rs2461817;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:RESPIRATORY_FAILURE_REQUIRING_ASSISTED_VENTILATION
METHADONE;CYP2D6;INTERMEDIATE_METABOLIZER;CYP2D6;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
R-EDDP;CYP2D6;INTERMEDIATE_METABOLIZER;CYP2D6;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
S-EDDP;CYP2D6;INTERMEDIATE_METABOLIZER;CYP2D6;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
FLUOROURACIL;MTHFR;G;rs1801131;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
LEUCOVORIN;MTHFR;G;rs1801131;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
OXALIPLATIN;MTHFR;G;rs1801131;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED_DOSE;DISEASE:ULCERATIVE_COLITIS | DISEASE:CROHN_DISEASE | DISEASE:AUTOIMMUNE_HEPATITIS
WARFARIN;CYP2C9;AA;rs1057910;DOSAGE;INCREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
WARFARIN;APOE;CC;rs7412;DOSAGE;INCREASED_DOSE;OTHER:ATRIAL_FIBRILLATION | OTHER:PULMONARY_EMBOLISM | OTHER:VENOUS_THROMBOSIS
METHACHOLINE;ADRB2;AA;rs1042713;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
NALTREXONE;OPRM1;AG + GG;rs1799971;EFFICACY;DECREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
ACENOCOUMAROL;VKORC1;CT;rs9923231;DOSAGE;DECREASED_DOSE;nan
TEMSIROLIMUS;NR1I2;TT;rs3814055;LADME_PK;DECREASED_METABOLISM;DISEASE:URINARY_BLADDER_NEOPLASMS
TEMSIROLIMUS;ABCB1;CC;rs2032582;LADME_PK;INCREASED_METABOLISM;DISEASE:URINARY_BLADDER_NEOPLASMS
TACROLIMUS;CYP3A5;TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;nan;C;rs4646457;DOSAGE;DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;G;rs15524;DOSAGE;DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;A;rs12333983;DOSAGE;DOSE;DISEASE:KIDNEY_TRANSPLANTATION
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;DISEASE:RHEUMATIC_HEART_DISEASE
FLECAINIDE;SCN4A;T;rs80338792;EFFICACY;INCREASED_RESPONSE;DISEASE:MYOTONIA
ATENOLOL;nan;A;rs294610;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
METOPROLOL;nan;A;rs294610;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
ATENOLOL;SLC4A1;CC + CT;rs45545233;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
METOPROLOL;SLC4A1;CC + CT;rs45545233;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;G;rs3794271;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CAPECITABINE;DPYD;CT;rs56038477;DOSAGE;DOSE;DISEASE:COLORECTAL_NEOPLASMS
FLUOROURACIL;DPYD;CT;rs56038477;DOSAGE;DOSE;DISEASE:COLORECTAL_NEOPLASMS
SUNITINIB;ABCB1;AA;rs2032582;EFFICACY;DECREASED_RESPONSE;DISEASE:RENAL_CELL_CARCINOMA
FLUOROURACIL;DPYD;AG + GG;rs17376848;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:COLORECTAL_NEOPLASMS
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED_DOSE;nan
HYDROCHLOROTHIAZIDE;nan;AA + AG;rs11065987;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
METHADONE;ABCB1;AA;rs1128503;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
ETHANOL;OPRM1;T;rs553202;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
ETHANOL;OPRM1;A;rs524731;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
S-EDDP;ABCB1;AG;rs1128503;LADME_PK;INCREASED_CONCENTRATIONS;nan
NICOTINE;HINT1;CT + TT;rs3852209;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
S-EDDP;ABCB1;AG;rs1045642;LADME_PK;INCREASED_CONCENTRATIONS;nan
OPIOIDS;OPRM1;AG;rs1799971;EFFICACY;DECREASED_RESPONSE;DISEASE:POSTOPERATIVE_PAIN
METHADONE;ABCB1;AG;rs1128503;LADME_PK;DECREASED_CONCENTRATIONS;nan
PHENPROCOUMON;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
FLUOXETINE;CYP2D6;CT;rs3892097;EFFICACY;INCREASED_CONCENTRATIONS;EFFICACY:ALCOHOL_ABUSE | EFFICACY:MAJOR_DEPRESSIVE_DISORDER
LEVODOPA;DBH;CT + TT;rs1611115;EFFICACY;INCREASED_RESPONSE;DISEASE:COCAINE_DEPENDENCE
VENLAFAXINE;COMT;GG;rs4680;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
AXITINIB;OR2B11;A;rs35305980;LADME_PK;CONCENTRATIONS;DISEASE:RENAL_CELL_CARCINOMA
SULFONAMIDES;KCNJ11;CT;rs5219;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
UREA DERIVATIVES;KCNJ11;CT;rs5219;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
WARFARIN;VKORC1;T;rs7294;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;T;rs7294;LADME_PK;INCREASED_DOSE;nan
SULFONAMIDES;ABCC8;AA + CC;rs757110;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
UREA DERIVATIVES;ABCC8;AA + CC;rs757110;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
TIPIRACIL HYDROCHLORIDE;SLC29A1;CT + TT;rs9394992;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
TRIFLURIDINE;SLC29A1;CT + TT;rs9394992;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
ANTIDEPRESSANTS;BDNF;GG;rs61888800;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DESIPRAMINE;BDNF;GG;rs61888800;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
FLUOXETINE;BDNF;GG;rs61888800;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
AXITINIB;UGT1A10;del;rs3832043;LADME_PK;CONCENTRATIONS;DISEASE:RENAL_CELL_CARCINOMA
AXITINIB;UGT1A8;del;rs3832043;LADME_PK;CONCENTRATIONS;DISEASE:RENAL_CELL_CARCINOMA
AXITINIB;UGT1A9;del;rs3832043;LADME_PK;CONCENTRATIONS;DISEASE:RENAL_CELL_CARCINOMA
AXITINIB;UGT1A7;G;rs17868323;LADME_PK;CONCENTRATIONS;DISEASE:RENAL_CELL_CARCINOMA
RISPERIDONE;HTR2C;A;rs3813928;EFFICACY;DECREASED_RESPONSE;DISEASE:AUTISM
METHOTREXATE;MTRR;CT + TT;rs1532268;LADME_PK;INCREASED_EXPOSURE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
RISPERIDONE;HTR2A;CT + TT;rs6311;EFFICACY;INCREASED_RESPONSE;DISEASE:AUTISM
AXITINIB;ABCB1;A;rs1045642;LADME_PK;CONCENTRATIONS;DISEASE:RENAL_CELL_CARCINOMA
AXITINIB;ABCG2;T;rs2231142;LADME_PK;CONCENTRATIONS;DISEASE:RENAL_CELL_CARCINOMA
AXITINIB;ABCB1;T;rs2032582;LADME_PK;CONCENTRATIONS;DISEASE:RENAL_CELL_CARCINOMA
VORICONAZOLE;CYP2C19;AA + AG;rs4244285;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;nan
ERLOTINIB;EGFR;GT + TT;rs121434568;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
METHOTREXATE;ABCB1;AA;rs1045642;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CYTARABINE;SLC29A1;A;rs3734703;EFFICACY;INCREASED_RESPONSE;DISEASE:MYELOID_ACUTE_LEUKEMIA
SUNITINIB;ABCB1;AA + AG;rs1045642;LADME_PK;INCREASED_CLEARANCE;DISEASE:RENAL_CELL_CARCINOMA | DISEASE:METASTATIC_NEOPLASM
METHOTREXATE;SLC19A1;CC + TT;rs1051266;EFFICACY;DECREASED_RESPONSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
SN-38;UGT1A9;TT;rs3832043;DOSAGE;INCREASED_METABOLISM;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
EFAVIRENZ;CYP2B6;CC + CT;rs2279345;LADME_PK;INCREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
RISPERIDONE;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED_RESPONSE;DISEASE:AUTISM
EFAVIRENZ;CYP2B6;CT;rs2279345;LADME_PK;INCREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
GLUCOCORTICOIDS;CRHR1;T;rs1876828;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
ANTIDEPRESSANTS;ERICH3;C;rs11580409;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
SN-38;SLCO1B1;CC + CT;rs4149056;DOSAGE;INCREASED_DOSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
SALMETEROL;ADRB2;AA;rs1042713;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
(S)-METHADONE;CYP3A4;CT;rs2740574;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
VORICONAZOLE;CYP2C19;AA + AG;rs4986893;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;nan
METHYLPHENIDATE;GRIN2B;CC;rs2284411;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
WARFARIN;VKORC1;A;rs17708472;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;A;rs17708472;LADME_PK;INCREASED_DOSE;nan
FENTANYL;CYP3A4;C;rs2740574;LADME_PK;DECREASED_CLEARANCE;OTHER:BURNS
METHOTREXATE;SLC19A1;TT;rs1051266;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
SALBUTAMOL;CRHR2;T;rs7793837;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;CRHR2;T;rs7793837;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
ATORVASTATIN;ABCA1;T;rs2230806;EFFICACY;DECREASED_RESPONSE;nan
ROSUVASTATIN;ABCA1;T;rs2230806;EFFICACY;DECREASED_RESPONSE;nan
SIMVASTATIN;ABCA1;T;rs2230806;EFFICACY;DECREASED_RESPONSE;nan
SALBUTAMOL;CRHR2;T;rs7793837;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;CRHR2;T;rs7793837;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
ATORVASTATIN;CYP2D6;T;rs3892097;EFFICACY;DECREASED_RESPONSE;nan
ROSUVASTATIN;CYP2D6;T;rs3892097;EFFICACY;DECREASED_RESPONSE;nan
SIMVASTATIN;CYP2D6;T;rs3892097;EFFICACY;DECREASED_RESPONSE;nan
NICARDIPINE;CACNA1B;AG + GG;rs2739258;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BIPOLAR_DISORDER
NIMODIPINE;CACNA1B;AG + GG;rs2739258;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BIPOLAR_DISORDER
METHOTREXATE;MTHFR;TT;rs1801131;EFFICACY;DECREASED_RESPONSE;OTHER:NON-HODGKIN_LYMPHOMA | OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
IMATINIB;CYP3A5;C;rs776746;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
IMATINIB;SLC22A1;CG + GG;rs683369;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
SIMVASTATIN;APOA5;AA;rs662799;EFFICACY;INCREASED_RESPONSE;DISEASE:DYSLIPIDAEMIA
IRBESARTAN;APOB;AG;rs1367117;EFFICACY;RESPONSE;DISEASE:HYPERTENSION
IRBESARTAN;APOB;AG;rs1367117;LADME_PK;RESPONSE;DISEASE:HYPERTENSION
IRBESARTAN;APOB;GG;rs1367117;EFFICACY;RESPONSE;DISEASE:HYPERTENSION
ATORVASTATIN;APOA5;AA;rs662799;EFFICACY;INCREASED_RESPONSE;DISEASE:DYSLIPIDAEMIA
EFAVIRENZ;CYP2A6;C;rs28399433;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;INCREASED_RESPONSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
BENAZEPRIL;PRCP;GG + GT;rs2229437;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
EFAVIRENZ;UGT2B7;GG;rs28365062;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;C;rs28399499;LADME_PK;METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
CLOPIDOGREL;CYP2C19;A;rs4244285;OTHER;RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
EFAVIRENZ;CYP2B6;AG + GG;rs2279343;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HIV_INFECTIOUS_DISEASE
LAMIVUDINE;CYP2B6;AG + GG;rs2279343;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HIV_INFECTIOUS_DISEASE
TENOFOVIR;CYP2B6;AG + GG;rs2279343;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HIV_INFECTIOUS_DISEASE
METHOTREXATE;MTHFR;GG;rs1801131;EFFICACY;INCREASED_RESPONSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CLOPIDOGREL;ABCB1;G;rs1045642;EFFICACY;RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
CLOPIDOGREL;ABCB1;G;rs1045642;OTHER;RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
QUETIAPINE;RGS4;TT;rs951439;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ZIPRASIDONE;RGS4;TT;rs951439;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
MIDAZOLAM;VDR;CT + TT;rs11568820;LADME_PK;INCREASED_CLEARANCE;nan
METHYLDOPA;ARG2;G;rs3742879;EFFICACY;INCREASED_RESPONSE;OTHER:PREGNANCY | OTHER:PRE-ECLAMPSIA
FLUOROURACIL;MTHFR;AA + AG;rs1801133;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
ARIPIPRAZOLE;ABCB1;AA;rs1128503;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:MAJOR_DEPRESSIVE_DISORDER
OMEPRAZOLE;CYP2C19;TT;rs12248560;DOSAGE;INCREASED_METABOLISM;OTHER:NO_DISEASE
OMEPRAZOLE;CYP2C19;TT;rs12248560;LADME_PK;INCREASED_METABOLISM;OTHER:NO_DISEASE
MEPHENYTOIN;CYP2C19;TT;rs12248560;DOSAGE;INCREASED_METABOLISM;OTHER:NO_DISEASE
MEPHENYTOIN;CYP2C19;TT;rs12248560;LADME_PK;INCREASED_METABOLISM;OTHER:NO_DISEASE
OMEPRAZOLE;CYP2C19;TT;rs11188072;DOSAGE;INCREASED_METABOLISM;OTHER:NO_DISEASE
OMEPRAZOLE;CYP2C19;TT;rs11188072;LADME_PK;INCREASED_METABOLISM;OTHER:NO_DISEASE
MEPHENYTOIN;CYP2C19;TT;rs11188072;DOSAGE;INCREASED_METABOLISM;OTHER:NO_DISEASE
MEPHENYTOIN;CYP2C19;TT;rs11188072;LADME_PK;INCREASED_METABOLISM;OTHER:NO_DISEASE
METHADONE;CYP2B6;TT;rs3211371;LADME_PK;INCREASED_CONCENTRATIONS;nan
MERCAPTOPURINE;SLCO1B1;CC + CT;rs4149056;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
GEMCITABINE;CMPK1;CC;rs1044457;EFFICACY;INCREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
DEXMEDETOMIDINE;ADRA2A;CG + GG;rs1800035;EFFICACY;DECREASED_RESPONSE;OTHER:POSTOPERATIVE_PAIN
BUDESONIDE;IL10;CC + CT;rs3024498;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ASTHMA
FLUTICASONE;IL10;CC + CT;rs3024498;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ASTHMA
SALMETEROL;IL10;CC + CT;rs3024498;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ASTHMA
FORMOTEROL;IL10;CC + CT;rs3024498;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ASTHMA
OMALIZUMAB;IL10;CC + CT;rs3024498;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ASTHMA
DEXMEDETOMIDINE;ADRA2A;CT + TT;rs775887911;EFFICACY;DECREASED_RESPONSE;OTHER:POSTOPERATIVE_PAIN
DEXMEDETOMIDINE;ADRA2A;CT + TT;rs201376588;EFFICACY;DECREASED_RESPONSE;OTHER:POSTOPERATIVE_PAIN
GEMCITABINE;CMPK1;GG;rs35687416;EFFICACY;INCREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
GEMCITABINE;DCTD;CC;rs12507552;EFFICACY;INCREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
BETA BLOCKING AGENTS;nan;T;rs139945292;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
ROSUVASTATIN;APOA5;AA;rs662799;EFFICACY;INCREASED_RESPONSE;DISEASE:DYSLIPIDAEMIA
GEMCITABINE;TENT4A;GG;rs274713;EFFICACY;INCREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
METHOTREXATE;FPGS;CT + TT;rs1544105;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
GEMCITABINE;CDC5L;CT + TT;rs992160;EFFICACY;INCREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
METHOTREXATE;TYMS;AA;rs2853539;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ATORVASTATIN;APOA5;AA;rs662799;OTHER;RESPONSE;DISEASE:DYSLIPIDAEMIA
ROSUVASTATIN;APOA5;AA;rs662799;OTHER;RESPONSE;DISEASE:DYSLIPIDAEMIA
SIMVASTATIN;APOA5;AA;rs662799;OTHER;RESPONSE;DISEASE:DYSLIPIDAEMIA
BUDESONIDE;IL17A;AG + GG;rs3819024;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ASTHMA
FLUTICASONE;IL17A;AG + GG;rs3819024;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ASTHMA
SALMETEROL;IL17A;AG + GG;rs3819024;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ASTHMA
FORMOTEROL;IL17A;AG + GG;rs3819024;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ASTHMA
OMALIZUMAB;IL17A;AG + GG;rs3819024;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ASTHMA
GEMCITABINE;SH2D5;GT + TT;rs10916852;EFFICACY;INCREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
ROSUVASTATIN;CETP;A;rs708272;EFFICACY;DECREASED_RESPONSE;nan
ATORVASTATIN;ABCB1;AA;rs1045642;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CORONARY_ARTERY_DISEASE
ATORVASTATIN;SLCO1B1;AA;rs2306283;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CORONARY_ARTERY_DISEASE
PHENPROCOUMON;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
PHENPROCOUMON;VKORC1;TT;rs9923231;TOXICITY;DECREASED_DOSE;nan
AZATHIOPRINE;TPMT;CT;rs1142345;LADME_PK;DECREASED_METABOLISM;DISEASE:INFLAMMATORY_BOWEL_DISEASES
AZATHIOPRINE;ITPA;AC;rs1127354;LADME_PK;INCREASED_METABOLISM;DISEASE:INFLAMMATORY_BOWEL_DISEASES
BUPRENORPHINE;CYP3A4;TT;rs2740574;EFFICACY;INCREASED_RESPONSE;DISEASE:ISCHEMIA | DISEASE:PAIN
PERINDOPRIL;AGTR1;AA;rs5186;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
NITRENDIPINE;AGTR1;AA;rs5186;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
LAMOTRIGINE;HNF4A;AA;rs2071197;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:EPILEPSY
LAMOTRIGINE;ABCG2;GT + TT;rs2231142;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
LAMOTRIGINE;ABCG2;CC + CT;rs3114020;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
CYCLOSPORINE;TSPYL1;AG + GG;rs3828743;LADME_PK;INCREASED_CLEARANCE;OTHER:KIDNEY_TRANSPLANTATION
GEMCITABINE;CMPK1;CC;rs7543016;EFFICACY;INCREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
GEMCITABINE;ESR2;TT;rs944050;EFFICACY;INCREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
RISPERIDONE;DRD2;TT;rs1799978;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
IRINOTECAN;ABCC2;AA + AG;rs2273697;LADME_PK;INCREASED_METABOLISM;DISEASE:COLORECTAL_NEOPLASMS
RISPERIDONE;DRD2;T;rs1799978;OTHER;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
LETROZOLE;CYP19A1;A;rs4646;EFFICACY;INCREASED_CLINICAL BENEFIT;DISEASE:BREAST_NEOPLASMS
ANTIEPILEPTICS;ABCC2;CT + TT;rs717620;EFFICACY;INCREASED_RESISTANCE;DISEASE:EPILEPSY
WARFARIN;nan;A;rs12777823;DOSAGE;DOSE;nan
METHOTREXATE;SLCO1B1;AA + AG;rs2306283;LADME_PK;INCREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
IVACAFTOR;CFTR;AA + AG;rs75527207;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CONJUGATED ESTROGENS;SLCO1B1;CT;rs4149056;EFFICACY;INCREASED_RESPONSE;DISEASE:MENOPAUSE
CISPLATIN;ERCC1;A;rs3212986;EFFICACY;DECREASED_RESPONSE;OTHER:OVARIAN_NEOPLASMS
ANTIPSYCHOTICS;ABCB1;GG;rs1045642;DOSAGE;INCREASED_DOSE;DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;ABCB1;GG;rs1045642;LADME_PK;INCREASED_DOSE;DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;ABCB1;AA;rs2032582;DOSAGE;INCREASED_DOSE;DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;ABCB1;AA;rs2032582;LADME_PK;INCREASED_DOSE;DISEASE:SCHIZOPHRENIA
DIAZEPAM;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ALCOHOL_ABUSE
ALPRAZOLAM;CYP3A4;AG;rs35599367;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ALCOHOL_ABUSE | OTHER:ANXIETY_DISORDERS
DIAZEPAM;CYP2C19;CT + TT;rs12248560;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ALCOHOL_ABUSE
CLOZAPINE;POR;CT + TT;rs1057868;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:SCHIZOPHRENIA | OTHER:TOBACCO_USE_DISORDER
SALBUTAMOL;IGF2R;AG;rs8191725;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
SALBUTAMOL;SLC24A4;AG;rs77441273;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
ALPRAZOLAM;CYP3A4;AG;rs35599367;EFFICACY;DECREASED_RESPONSE;OTHER:ALCOHOL_ABUSE | OTHER:ANXIETY_DISORDERS
LANSOPRAZOLE;IL1B;AG;rs16944;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;IL1B;AG;rs16944;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
RABEPRAZOLE;IL1B;AG;rs16944;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;IL1B;AA;rs16944;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;IL1B;AA;rs16944;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
RABEPRAZOLE;IL1B;AA;rs16944;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
METHOTREXATE;AHRR;G;rs2292596;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
WARFARIN;VKORC1;AA;rs2359612;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
PLATINUM COMPOUNDS;ERCC1;AG + GG;rs11615;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:OVARIAN_NEOPLASMS | OTHER:NEOPLASM_OF_ESOPHAGUS | OTHER:NEOPLASMS
ULINASTATIN;MMP2;T;rs243865;EFFICACY;DECREASED_RESPONSE;OTHER:PANCREATITIS
ANTIPSYCHOTICS;ABCB1;G;rs1128503;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ULINASTATIN;MMP9;T;rs3918242;EFFICACY;INCREASED_RESPONSE;OTHER:PANCREATITIS
TACROLIMUS;CYP3A4;AA + AG;rs35599367;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;NR1I2;CT + TT;rs2276707;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
ANTIPSYCHOTICS;ABCB1;G;rs1045642;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
IRINOTECAN;NR1I2;AA;rs10934498;TOXICITY;DECREASED_EXPOSURE;DISEASE:COLONIC_NEOPLASMS
IRINOTECAN;NR1I2;AA;rs10934498;LADME_PK;DECREASED_EXPOSURE;DISEASE:COLONIC_NEOPLASMS
TACROLIMUS;IL10;CC;rs1800896;DOSAGE;DECREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
OLANZAPINE;RGS4;TT;rs2842030;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
PERPHENAZINE;RGS4;TT;rs2842030;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
OLANZAPINE;DRD3;C;rs324026;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA
CYTARABINE;ADH1A;A;rs6811453;EFFICACY;INCREASED_RESISTANCE;DISEASE:MYELOID_ACUTE_LEUKEMIA
FLUDARABINE;ADH1A;A;rs6811453;EFFICACY;INCREASED_RESISTANCE;DISEASE:MYELOID_ACUTE_LEUKEMIA
GEMTUZUMAB OZOGAMICIN;ADH1A;A;rs6811453;EFFICACY;INCREASED_RESISTANCE;DISEASE:MYELOID_ACUTE_LEUKEMIA
IDARUBICIN;ADH1A;A;rs6811453;EFFICACY;INCREASED_RESISTANCE;DISEASE:MYELOID_ACUTE_LEUKEMIA
RISPERIDONE;RGS4;GG;rs2842030;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
MEASLES VACCINES;TLR3;CT;rs3775291;EFFICACY;DECREASED_RESPONSE;nan
CYTARABINE;ADH1A;T;rs1826909;EFFICACY;INCREASED_RESISTANCE;DISEASE:MYELOID_ACUTE_LEUKEMIA
FLUDARABINE;ADH1A;T;rs1826909;EFFICACY;INCREASED_RESISTANCE;DISEASE:MYELOID_ACUTE_LEUKEMIA
GEMTUZUMAB OZOGAMICIN;ADH1A;T;rs1826909;EFFICACY;INCREASED_RESISTANCE;DISEASE:MYELOID_ACUTE_LEUKEMIA
IDARUBICIN;ADH1A;T;rs1826909;EFFICACY;INCREASED_RESISTANCE;DISEASE:MYELOID_ACUTE_LEUKEMIA
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED_DOSE;nan
TAMOXIFEN;ABCC2;CT;rs717620;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
SALBUTAMOL;nan;CT;rs77149876;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
ETANERCEPT;TNF;A;rs1800629;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
INFLIXIMAB;TNF;A;rs1800629;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;A;rs1800629;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CARBAMAZEPINE;SCN1A;TT;rs3812718;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
SALBUTAMOL;PAPPA2;CT;rs77977790;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
NORBUPRENORPHINE;OPRD1;GG;rs569356;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:OPIOID-RELATED_DISORDERS
TACROLIMUS;CYP3A4;CT;rs2740574;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
SALMETEROL;ADRB2;G;rs1042713;EFFICACY;INCREASED_RESPONSE;OTHER:ASTHMA
SALBUTAMOL;nan;AG;rs116551936;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
SALBUTAMOL;NCOA3;CT;rs115501901;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
LITHIUM;CACNG2;C;rs2284017;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
SALBUTAMOL;nan;AG;rs74973995;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
SALBUTAMOL;CRHR2;CT;rs73294475;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
PHENPROCOUMON;CYP3A4;C;rs2740574;DOSAGE;DECREASED_DOSE;nan
SALBUTAMOL;ADCY9;AG;rs144315541;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
PERPHENAZINE;MCPH1;A;rs17570753;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
PERPHENAZINE;CDH13;G;rs2116971;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
PERPHENAZINE;SKOR2;G;rs9952628;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
METFORMIN;SLC47A2;AA;rs12943590;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
METFORMIN;SLC47A2;AA;rs12943590;LADME_PK;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
QUETIAPINE;KCNMA1;G;rs35793;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
PERPHENAZINE;MAML3;A;rs11100483;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
VALPROIC ACID;UGT2B7;CC + CT;rs7668258;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
METHACHOLINE;RUNX1;AA;rs11702779;OTHER;INCREASED_RESPONSE;DISEASE:ASTHMA
RISPERIDONE;LRP1B;G;rs874295;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
BEVACIZUMAB;HTRA1;AA;rs11200638;EFFICACY;DECREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
RISPERIDONE;PSMD14;A;rs9713;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
RISPERIDONE;AGAP1;C;rs1869295;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
BEVACIZUMAB;ARMS2;TT;rs10490924;EFFICACY;DECREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
VALPROIC ACID;APEH;CC;rs3816877;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
RISPERIDONE;NPAS3;G;rs1315115;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
RISPERIDONE;TMEFF2;G;rs3738883;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
METFORMIN;PCK1;CT + TT;rs4810083;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
ZIPRASIDONE;CDH4;A;rs4925300;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
ZIPRASIDONE;LYN;G;rs1546519;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
BEVACIZUMAB;CFH;GG;rs800292;EFFICACY;DECREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
WARFARIN;CYP2C9;CT;rs1799853;DOSAGE;DECREASED_DOSE;nan
ZIPRASIDONE;NALCN;C;rs9585618;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
ZIPRASIDONE;CNTN4;A;rs17194378;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
OPIOIDS;COMT;GG;rs4680;DOSAGE;INCREASED_DOSE;DISEASE:NEOPLASMS | DISEASE:PAIN
IMATINIB;SLCO1A2;CT + TT;rs4148978;TOXICITY;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:GASTROINTESTINAL_STROMAL_TUMORS
IMATINIB;SLCO1A2;CT + TT;rs4148978;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:GASTROINTESTINAL_STROMAL_TUMORS
IMATINIB;SLCO1B3;GG;rs4149117;TOXICITY;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:GASTROINTESTINAL_STROMAL_TUMORS
IMATINIB;SLCO1B3;GG;rs4149117;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:GASTROINTESTINAL_STROMAL_TUMORS
HYDROCHLOROTHIAZIDE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
WARFARIN;CALU;AA;rs2290228;DOSAGE;DECREASED_DOSE;nan
OLANZAPINE;nan;T;rs12610827;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA
REMIFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED_DOSE;OTHER:SURGERY
FENOFIBRATE;APOB;AA;rs676210;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
METHACHOLINE;RUNX1;AG + GG;rs11702779;OTHER;INCREASED_RESPONSE;DISEASE:ASTHMA
CITALOPRAM;SERPINE1;G;rs1799889;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
FLUOXETINE;SERPINE1;G;rs1799889;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
METHOTREXATE;MTR;G;rs1805087;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:NON-HODGKIN_LYMPHOMA | OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CITALOPRAM;FKBP5;A;rs4713916;EFFICACY;INCREASED_RESPONSE;DISEASE:MOOD_DISORDER
FLUOXETINE;FKBP5;A;rs4713916;EFFICACY;INCREASED_RESPONSE;DISEASE:MOOD_DISORDER
MIRTAZAPINE;FKBP5;A;rs4713916;EFFICACY;INCREASED_RESPONSE;DISEASE:MOOD_DISORDER
PAROXETINE;FKBP5;A;rs4713916;EFFICACY;INCREASED_RESPONSE;DISEASE:MOOD_DISORDER
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;FKBP5;A;rs4713916;EFFICACY;INCREASED_RESPONSE;DISEASE:MOOD_DISORDER
VENLAFAXINE;FKBP5;A;rs4713916;EFFICACY;INCREASED_RESPONSE;DISEASE:MOOD_DISORDER
OLANZAPINE;CSMD1;A;rs17070785;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
OLANZAPINE;PLAGL1;C;rs2247408;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
SIROLIMUS;CYP3A5;AA;rs15524;LADME_PK;INCREASED_TROUGH CONCENTRATION;OTHER:KIDNEY_TRANSPLANTATION
OLANZAPINE;PLAGL1;A;rs3819811;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
SIROLIMUS;CYP3A5;CC;rs4646453;LADME_PK;INCREASED_TROUGH CONCENTRATION;OTHER:KIDNEY_TRANSPLANTATION
ACETAMINOPHEN;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED_DOSE;nan
OLANZAPINE;PTPRN2;C;rs221253;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
IMATINIB;SLC22A1;AA + AG;rs628031;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
WARFARIN;NQO1;AA + AG;rs1800566;DOSAGE;INCREASED_DOSE;nan
PERPHENAZINE;PRKCE;C;rs2278773;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
PERPHENAZINE;nan;C;rs11774231;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
HYDROCHLOROTHIAZIDE;DOT1L;CT + TT;rs2269879;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
PAROXETINE;ADM;CC;rs11042725;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED_DOSE;nan
TILDRAKIZUMAB;ATG5;CT;rs9373839;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
TILDRAKIZUMAB;IL17RC;CC;rs708567;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
CITALOPRAM;BDNF;TT;rs7124442;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ARIPIPRAZOLE;ABCB1;AA;rs2032582;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;nan
CLOZAPINE;OXT;T;rs2740204;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
DIAZEPAM;CYP3A4;GG;rs35599367;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ALCOHOL_ABUSE
METHOTREXATE;MTHFR;G;rs1801133;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CROHN_DISEASE
METHOTREXATE;DHFR;C;rs408626;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CROHN_DISEASE
REPAGLINIDE;NOS1AP;T;rs10494366;DOSAGE;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
REPAGLINIDE;NOS1AP;T;rs10494366;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
CITALOPRAM;BDNF;TT;rs7103411;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED_RESISTANCE;DISEASE:HIV_INFECTIOUS_DISEASE
CITALOPRAM;BDNF;CC;rs6265;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
LAMIVUDINE;ABCC1;CC + CT;rs212091;EFFICACY;INCREASED_RESISTANCE;DISEASE:HIV_INFECTIOUS_DISEASE
LOPINAVIR;ABCC1;CC + CT;rs212091;EFFICACY;INCREASED_RESISTANCE;DISEASE:HIV_INFECTIOUS_DISEASE
RITONAVIR;ABCC1;CC + CT;rs212091;EFFICACY;INCREASED_RESISTANCE;DISEASE:HIV_INFECTIOUS_DISEASE
ZIDOVUDINE;ABCC1;CC + CT;rs212091;EFFICACY;INCREASED_RESISTANCE;DISEASE:HIV_INFECTIOUS_DISEASE
FLUOXETINE;BDNF;CT;rs6265;EFFICACY;INCREASED_CLINICAL BENEFIT;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TILDRAKIZUMAB;TNFAIP3;GG;rs610604;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
ANTIDEPRESSANTS;ERICH3;CC;rs11580409;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
CLOPIDOGREL;CYP2C19;CT;rs12248560;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
ARIPIPRAZOLE;ABCB1;AA;rs1045642;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;nan
IVACAFTOR;CFTR;A;rs77932196;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
PAROXETINE;DRD3;CC + CT;rs6280;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ENTACAPONE;COMT;GG;rs4680;EFFICACY;INCREASED_RESPONSE;DISEASE:PARKINSON_DISEASE
CLOZAPINE;CYP2D6;AA;rs1065852;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
CLOZAPINE;CYP2D6;GG;rs16947;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
ATORVASTATIN;ABCG8;CC + CG;rs11887534;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:DYSLIPIDAEMIA
SIMVASTATIN;ABCG8;CC + CG;rs11887534;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:DYSLIPIDAEMIA
IVACAFTOR;CFTR;C;rs121909011;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
IMATINIB;ULK3;GG;rs2290573;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
CLOZAPINE;DRD1;GT;rs265976;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
IVACAFTOR;CFTR;AA + AG;rs75527207;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
INTERFERONS;STAT3;GG;rs4796793;EFFICACY;INCREASED_RESPONSE;DISEASE:RENAL_CELL_CARCINOMA
TAMOXIFEN;SLCO2B1;AA + AG;rs12422149;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
ACENOCOUMAROL;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;AA + AG;rs2359612;DOSAGE;DECREASED_DOSE;nan
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;DOSAGE;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;DOSAGE;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;DOSAGE;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;DOSAGE;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;DOSAGE;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;DOSAGE;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
WARFARIN;VKORC1;CG + GG;rs8050894;DOSAGE;DECREASED_DOSE;nan
RISPERIDONE;HRH3;TT;rs3787430;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
WARFARIN;nan;AA + AG;rs12777823;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;AC + CC;rs2884737;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED_DOSE;nan
RISPERIDONE;HRH3;TT;rs3787429;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ACENOCOUMAROL;VKORC1;AA + AG;rs17708472;DOSAGE;INCREASED_DOSE;nan
ARIPIPRAZOLE;TAAR6;AA + AG;rs4305746;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
PEGINTERFERON ALFA-2A;IL6;G;rs1800795;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IL6;G;rs1800796;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IL6;G;rs1800797;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
WARFARIN;VKORC1;G;rs104894540;DOSAGE;INCREASED_DOSE;nan
ROSUVASTATIN;ABCG2;AA + AG;rs2199936;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
WARFARIN;VKORC1;C;rs104894542;DOSAGE;INCREASED_DOSE;nan
ILOPERIDONE;CNTF;GG;rs1800169;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ILOPERIDONE;ZFP91-CNTF;GG;rs1800169;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED_DOSE;nan
DISULFIRAM;OPRD1;CC;rs678849;EFFICACY;INCREASED_RESPONSE;OTHER:COCAINE_DEPENDENCE
ERYTHROPOIETIN;STIM1;AG + GG;rs1561876;EFFICACY;INCREASED_RESISTANCE;OTHER:KIDNEY_DISORDER | OTHER:ANEMIA
LATANOPROST;PTGFR;CC;rs3753380;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
RANIBIZUMAB;VEGFA;AC + CC;rs699947;EFFICACY;INCREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
FUROSEMIDE;ABCC4;T;rs17268282;EFFICACY;INCREASED_RESPONSE;DISEASE:HEART_FAILURE
METFORMIN;SLC22A1;CC;rs622342;EFFICACY;RESPONSE;OTHER:GENETIC_VARIATION_AT_RS2289669
MORPHINE;COMT;T;rs737866;DOSAGE;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;COMT;T;rs737866;EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;COMT;G;rs2075507;DOSAGE;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;COMT;G;rs2075507;EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
ANTIEPILEPTICS;CYP1A1;AA;rs2606345;EFFICACY;DECREASED_RESPONSE;DISEASE:EPILEPSY
MORPHINE;COMT;A;rs5746849;DOSAGE;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;COMT;A;rs5746849;EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;COMT;C;rs7287550;DOSAGE;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;COMT;C;rs7287550;EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;TXNRD2;C;rs7287550;DOSAGE;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;TXNRD2;C;rs7287550;EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;COMT;A;rs6269;DOSAGE;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;COMT;A;rs6269;EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
CARBAMAZEPINE;CYP3A4;TT;rs2740574;LADME_PK;INCREASED_CLEARANCE;DISEASE:EPILEPSY
MORPHINE;COMT;A;rs740603;DOSAGE;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;COMT;A;rs740603;EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;ABCC3;T;rs4793665;LADME_PK;DECREASED_CLEARANCE;nan
TACROLIMUS;POR;T;rs1057868;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
N-DESMETHYLTRAMADOL;CYP2D6;DELT/T;rs35742686;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
O-DESMETHYLTRAMADOL;CYP2D6;DELT/T;rs35742686;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
N-DESMETHYLTRAMADOL;CYP3A4;AG;rs35599367;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
TRAMADOL;CYP3A4;AG;rs35599367;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
CLOPIDOGREL;CYP2C19;AA;rs4244285;EFFICACY;DECREASED_RESPONSE;OTHER:CORONARY_ARTERY_DISEASE
CLOPIDOGREL;CYP2C19;AG;rs4986893;EFFICACY;DECREASED_RESPONSE;OTHER:CORONARY_ARTERY_DISEASE
CLOPIDOGREL;ABCC2;CC;rs717620;EFFICACY;DECREASED_RESPONSE;OTHER:CORONARY_ARTERY_DISEASE
ATAZANAVIR;SORCS2;A;rs73208473;LADME_PK;DECREASED_EXPOSURE;OTHER:HIV_INFECTIOUS_DISEASE
WARFARIN;VKORC1;A;rs104894539;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;C;rs104894541;DOSAGE;INCREASED_DOSE;nan
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;ZNF816;CC;rs9304742;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
CARBAMAZEPINE;UGT2B7;AA;rs28365063;LADME_PK;DECREASED_CLEARANCE;DISEASE:EPILEPSY
CARBAMAZEPINE;NR1I2;T;rs3814055;LADME_PK;DECREASED_CLEARANCE;DISEASE:EPILEPSY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PGLYRP4;CC + CT;rs2916205;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
METHOTREXATE;MTHFR;AA + AG;rs1801133;LADME_PK;INCREASED_EXPOSURE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
SULFONAMIDES;CYP2C9;TT;rs1799853;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
UREA DERIVATIVES;CYP2C9;TT;rs1799853;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
SUMATRIPTAN;GNB3;CT;rs5443;EFFICACY;INCREASED_RESPONSE;DISEASE:CLUSTER_HEADACHE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;AG + GG;rs2546890;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
DESETHYL HYDROXYCHLOROQUINE;CYP2D6;G;rs1135840;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS
CANNABINOIDS;TRPV1;CC;rs8065080;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PAIN
RIVAROXABAN;ABCB1;AA + AG;rs4728709;LADME_PK;INCREASED_CLEARANCE;OTHER:ATRIAL_FIBRILLATION
CANNABINOIDS;UGT2B7;AA;rs7438135;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PAIN
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CTNNA2;AA;rs11126740;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
IMATINIB;ABCG2;GT;rs2231142;OTHER;DECREASED_METABOLISM;DISEASE:NEOPLASMS
IMATINIB;ABCG2;GT;rs2231142;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
DESETHYL HYDROXYCHLOROQUINE;CYP2D6;AA;rs1065852;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS
REPAGLINIDE;KCNJ11;T;rs5219;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
TRAMADOL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED_RESPONSE;OTHER:POSTOPERATIVE_PAIN
REPAGLINIDE;TCF7L2;TT;rs290487;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
MORPHINE;COMT;A;rs4680;DOSAGE;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;COMT;A;rs4680;EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
CARBAMAZEPINE;EPHX1;TT;rs1051740;LADME_PK;DECREASED_METABOLISM;DISEASE:EPILEPSY
MORPHINE;COMT;C;rs4818;DOSAGE;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;COMT;C;rs4818;EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
ERYTHROPOIETIN;ORAI1;GG + GT;rs12320939;EFFICACY;INCREASED_RESISTANCE;OTHER:KIDNEY_DISORDER | OTHER:ANEMIA
CARBAMAZEPINE;ABCB1;AA + AG;rs1128503;LADME_PK;INCREASED_CLEARANCE;DISEASE:EPILEPSY
MORPHINE;COMT;A;rs2239393;DOSAGE;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;COMT;A;rs2239393;EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
MERCAPTOPURINE;NUDT15;CT;rs116855232;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MORPHINE;ARVCF;T;rs165728;DOSAGE;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;ARVCF;T;rs165728;EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;COMT;T;rs165728;DOSAGE;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;COMT;T;rs165728;EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
CARBAMAZEPINE;ABCB1;AG;rs4148740;LADME_PK;INCREASED_METABOLISM;DISEASE:EPILEPSY
CARBAMAZEPINE;ABCB1;TT;rs4148739;LADME_PK;DECREASED_METABOLISM;DISEASE:EPILEPSY
MORPHINE;ARVCF;T;rs174699;DOSAGE;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;ARVCF;T;rs174699;EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;COMT;T;rs174699;DOSAGE;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;COMT;T;rs174699;EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
ANTIPSYCHOTICS;DRD2;del;rs1799732;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
HMG COA REDUCTASE INHIBITORS;CETP;AA;rs1532624;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERLIPIDEMIAS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CDKAL1;CT + TT;rs6908425;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
CARBAMAZEPINE;ABCC2;AA + AG;rs2273697;LADME_PK;INCREASED_CLEARANCE;DISEASE:EPILEPSY
HMG COA REDUCTASE INHIBITORS;SIK3;AA;rs533556;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERLIPIDEMIAS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;HLA-C;CT + TT;rs12191877;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
RITODRINE;KCNMB2;TT;rs7624046;EFFICACY;DECREASED_RESPONSE;nan
CARBAMAZEPINE;ABCC2;AA + AG;rs4148386;LADME_PK;INCREASED_CLEARANCE;DISEASE:EPILEPSY
WARFARIN;VKORC1;AA + AC;rs61742245;DOSAGE;INCREASED_DOSE;nan
CARBAMAZEPINE;ABCC2;CT + TT;rs3740066;LADME_PK;DECREASED_METABOLISM;DISEASE:EPILEPSY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAP3K1;AG + GG;rs96844;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
RITODRINE;KCNMB2;CC;rs9839376;EFFICACY;DECREASED_RESPONSE;nan
WARFARIN;GGCX;G;rs11676382;DOSAGE;DECREASED_DOSE;nan
CARBAMAZEPINE;NR1I2;G;rs7643645;LADME_PK;INCREASED_METABOLISM;DISEASE:EPILEPSY
MORPHINE;METTL21A;CC;rs2952768;DOSAGE;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
CARBAMAZEPINE;NR1I2;T;rs4688040;LADME_PK;INCREASED_METABOLISM;DISEASE:EPILEPSY
CANNABINOIDS;ABCB1;AG + GG;rs1045642;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PAIN
MORPHINE;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
CARBAMAZEPINE;NR1I2;C;rs2461817;LADME_PK;INCREASED_METABOLISM;DISEASE:EPILEPSY
METOPROLOL;ADRB1;AA;rs1801252;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;CC;rs2884737;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
CITALOPRAM;SRP19;G;rs495794;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
FLUOXETINE;SRP19;G;rs495794;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PAROXETINE;SRP19;G;rs495794;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
SERTRALINE;SRP19;G;rs495794;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED_DOSE;nan
CITALOPRAM;REEP5;G;rs153560;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
FLUOXETINE;REEP5;G;rs153560;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PAROXETINE;REEP5;G;rs153560;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
SERTRALINE;REEP5;G;rs153560;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;GG;rs8050894;DOSAGE;DECREASED_DOSE;nan
CITALOPRAM;REEP5;A;rs153549;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
FLUOXETINE;REEP5;A;rs153549;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PAROXETINE;REEP5;A;rs153549;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
SERTRALINE;REEP5;A;rs153549;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ATAZANAVIR;ABCB1;AA + AG;rs1045642;DOSAGE;DOSE;DISEASE:HIV_INFECTIOUS_DISEASE
ATAZANAVIR;SLCO1B1;TT;rs4149056;DOSAGE;DOSE;DISEASE:HIV_INFECTIOUS_DISEASE
FLUOROURACIL;DPYD;CT;rs3918290;OTHER;DECREASED_METABOLISM;DISEASE:NEOPLASMS
FLUOROURACIL;DPYD;CT;rs3918290;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
ATAZANAVIR;NR1I2;TT;rs2472677;DOSAGE;DOSE;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;VKORC1;AC;rs61742245;DOSAGE;INCREASED_DOSE;OTHER:WARFARIN_MAINTENANCE_TREATMENT
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
ACENOCOUMAROL;VKORC1;CT;rs9923231;DOSAGE;DECREASED_DOSE;nan
DOCETAXEL;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
GEMCITABINE;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
PACLITAXEL;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
PLATINUM COMPOUNDS;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
VINORELBINE;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
DOCETAXEL;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
GEMCITABINE;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
PACLITAXEL;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
PLATINUM COMPOUNDS;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
VINORELBINE;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
DOCETAXEL;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
GEMCITABINE;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
PACLITAXEL;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
PLATINUM COMPOUNDS;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
VINORELBINE;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
DOCETAXEL;CASP7;CT;rs7921977;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
GEMCITABINE;CASP7;CT;rs7921977;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
PACLITAXEL;CASP7;CT;rs7921977;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
PLATINUM COMPOUNDS;CASP7;CT;rs7921977;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
VINORELBINE;CASP7;CT;rs7921977;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
OLANZAPINE;SLC26A9;A;rs11240594;DOSAGE;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
OLANZAPINE;SLC26A9;A;rs11240594;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
SOLANIDINE;NFIB;CC + CT;rs28379954;LADME_PK;INCREASED_METABOLISM;nan
ZIPRASIDONE;EHF;A;rs286913;DOSAGE;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ZIPRASIDONE;EHF;A;rs286913;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CLOZAPINE;SLC6A3;A;rs2975226;DOSAGE;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CLOZAPINE;SLC6A3;A;rs2975226;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
OLANZAPINE;IL1A;C;rs11677416;DOSAGE;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
OLANZAPINE;IL1A;C;rs11677416;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CYCLOSPORINE;POR;TT;rs1057868;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
CARBAMAZEPINE;EPHX1;C;rs1051740;DOSAGE;INCREASED_METABOLISM;DISEASE:EPILEPSY
CARBAMAZEPINE;EPHX1;C;rs1051740;LADME_PK;INCREASED_METABOLISM;DISEASE:EPILEPSY
PIOGLITAZONE;PTPRD;CC;rs17584499;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
ACENOCOUMAROL;VKORC1;CC + CT;rs9923231;EFFICACY;INCREASED_DOSE;nan
WARFARIN;VKORC1;CC + CT;rs9923231;EFFICACY;INCREASED_DOSE;nan
ETHANOL;OPRM1;G;rs1799971;TOXICITY;INCREASED_RESPONSE;OTHER:ALCOHOL_ABUSE
ACAMPROSATE;GRIN2B;A;rs2058878;EFFICACY;INCREASED_RESPONSE;DISEASE:ALCOHOL_ABUSE
OLANZAPINE;ATP1A2;T;rs6688363;EFFICACY;DECREASED_RESPONSE;OTHER:SCHIZOPHRENIA
RISPERIDONE;nan;T;rs8050896;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
RISPERIDONE;TNFRSF11A;A;rs2980976;EFFICACY;DECREASED_RESPONSE;OTHER:SCHIZOPHRENIA
RISPERIDONE;PPA2;G;rs2636697;EFFICACY;DECREASED_RESPONSE;OTHER:SCHIZOPHRENIA
METHOTREXATE;nan;A;rs1232027;EFFICACY;INCREASED_RESPONSE;DISEASE:ARTHRITIS | PSORIATIC
FENTANYL;OPRM1;AA;rs1799971;DOSAGE;INCREASED_DOSE;OTHER:SURGERY
HYDROMORPHONE;OPRM1;AA;rs1799971;DOSAGE;INCREASED_DOSE;OTHER:SURGERY
OPIOIDS;OPRM1;AA;rs1799971;DOSAGE;INCREASED_DOSE;OTHER:SURGERY
OXYCODONE;OPRM1;AA;rs1799971;DOSAGE;INCREASED_DOSE;OTHER:SURGERY
TRAMADOL;OPRM1;AA;rs1799971;DOSAGE;INCREASED_DOSE;OTHER:SURGERY
RISPERIDONE;PPA2;A;rs2636719;EFFICACY;DECREASED_RESPONSE;OTHER:SCHIZOPHRENIA
REPAGLINIDE;IGF2BP2;GT + TT;rs4402960;DOSAGE;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
REPAGLINIDE;IGF2BP2;GT + TT;rs4402960;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
REPAGLINIDE;IGF2BP2;AC + CC;rs1470579;DOSAGE;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
REPAGLINIDE;IGF2BP2;AC + CC;rs1470579;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
DISULFIRAM;MTHFR;AA + AG;rs1801133;EFFICACY;INCREASED_RESPONSE;DISEASE:COCAINE_DEPENDENCE
IVACAFTOR;CFTR;A;rs78655421;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED_RESPONSE;DISEASE:ARTHRITIS | PSORIATIC | DISEASE:CROHN_DISEASE | DISEASE:PSORIASIS | DISEASE:SPONDYLITIS | ANKYLOSING
ISONIAZID;NAT2;AT;rs4646244;TOXICITY;DECREASED_CLEARANCE;DISEASE:TUBERCULOSIS
ISONIAZID;NAT2;AT;rs4646244;LADME_PK;DECREASED_CLEARANCE;DISEASE:TUBERCULOSIS
PLATINUM COMPOUNDS;ERCC1;AA;rs11615;EFFICACY;DECREASED_RESPONSE;DISEASE:OVARIAN_NEOPLASMS
ISONIAZID;NAT2;AA;rs1799930;TOXICITY;DECREASED_CLEARANCE;DISEASE:TUBERCULOSIS
ISONIAZID;NAT2;AA;rs1799930;LADME_PK;DECREASED_CLEARANCE;DISEASE:TUBERCULOSIS
HYDROCHLOROTHIAZIDE;BEST3;AA + AG;rs61747221;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
DEFERIPRONE;UGT1A6;AA;rs2070959;EFFICACY;INCREASED_RESPONSE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;C;rs396991;EFFICACY;INCREASED_RESPONSE;DISEASE:ARTHRITIS | PSORIATIC | DISEASE:CROHN_DISEASE | DISEASE:PSORIASIS | DISEASE:SPONDYLITIS | ANKYLOSING
NIFEDIPINE;ADRA1A;AA + AG;rs1048101;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
DEFERIPRONE;UGT1A6;AA;rs2070959;EFFICACY;INCREASED_RESPONSE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
DEFERIPRONE;UGT1A6;GG;rs6759892;EFFICACY;INCREASED_RESPONSE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
PIOGLITAZONE;PPARG;CG;rs1801282;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
PACLITAXEL;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
PLATINUM COMPOUNDS;CASP7;CC + CT;rs4353229;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
OPIOIDS;TNF;GG;rs1800629;DOSAGE;INCREASED_DOSE;OTHER:NEOPLASMS | OTHER:PAIN
CARBAMAZEPINE;SCN1A;CT;rs3812718;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
CARBAMAZEPINE;SCN1A;CT;rs3812718;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
PACLITAXEL;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
PLATINUM COMPOUNDS;CASP7;CG + GG;rs2227310;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
RISPERIDONE;TJP1;T;rs813676;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
OPIOIDS;IL6;A;rs1800797;DOSAGE;DECREASED_DOSE;OTHER:NEOPLASMS | OTHER:PAIN
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED_DOSE;DISEASE:MYOCARDIAL_INFARCTION
WARFARIN;VKORC1;AA + AG;rs9934438;EFFICACY;DECREASED_DOSE;DISEASE:MYOCARDIAL_INFARCTION
METHYLPHENIDATE;ADGRL3;CC + CT;rs734644;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
PACLITAXEL;CASP7;AA + AG;rs1127687;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
PLATINUM COMPOUNDS;CASP7;AA + AG;rs1127687;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
FLUTICASONE PROPIONATE;CA10;CC + CT;rs967676;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
MONTELUKAST;CA10;CC + CT;rs967676;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
CARBAMAZEPINE;EPHX1;CT;rs1051740;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
CARBAMAZEPINE;EPHX1;CT;rs1051740;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
CARBAMAZEPINE;EPHX1;CC;rs1051740;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
CARBAMAZEPINE;EPHX1;CC;rs1051740;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
GEMCITABINE;CASP7;AA + AG;rs1127687;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
PLATINUM COMPOUNDS;CASP7;AA + AG;rs1127687;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
FLUTICASONE PROPIONATE;nan;AA + AG;rs1786929;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
MONTELUKAST;nan;AA + AG;rs1786929;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
CYTARABINE;CDA;CC;rs2072671;TOXICITY;DECREASED_CLEARANCE;DISEASE:LYMPHOMA | T-CELL
CYTARABINE;CDA;CC;rs2072671;LADME_PK;DECREASED_CLEARANCE;DISEASE:LYMPHOMA | T-CELL
TACROLIMUS;ABCB1;AA;rs2032582;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
CARBAMAZEPINE;SCN1A;TT;rs3812718;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
CARBAMAZEPINE;SCN1A;TT;rs3812718;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;LADME_PK;INCREASED_CONCENTRATIONS;nan
METHYLPHENIDATE;ADGRL3;AG + GG;rs1355368;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
METHYLPHENIDATE;ADGRL3;CC + CG;rs6813183;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
RISPERIDONE;nan;C;rs7395555;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
RANIBIZUMAB;CFH;TT;rs1061170;EFFICACY;INCREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
OLANZAPINE;SPOPL;C;rs10170310;EFFICACY;DECREASED_RESPONSE;OTHER:SCHIZOPHRENIA
QUETIAPINE;PDE4D;T;rs17382202;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
ACENOCOUMAROL;VKORC1;T;rs9923231;DOSAGE;DOSE;nan
ACENOCOUMAROL;CYP4F2;T;rs2108622;DOSAGE;DOSE;nan
QUETIAPINE;PDE4D;G;rs17742120;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
QUETIAPINE;PDE4D;A;rs2164660;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
ACENOCOUMAROL;VKORC1;CC;rs9923231;DOSAGE;INCREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION | DISEASE:VENOUS_THROMBOEMBOLISM
PERINDOPRIL;AGTR1;CC + CT;rs5182;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
RISPERIDONE;TJP1;T;rs711355;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
RISPERIDONE;TJP1;A;rs785423;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
TENOFOVIR ALAFENAMIDE;ABCB1;CT;rs3842;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEPATITIS_B_VIRUS_INFECTION | DISEASE:HIV_INFECTIOUS_DISEASE
CLOZAPINE;SLC6A4;T;rs25531;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
RALOXIFENE;UGT1A8;CC;rs1042597;EFFICACY;INCREASED_RESPONSE;DISEASE:MENOPAUSE | DISEASE:SCHIZOPHRENIA
ACENOCOUMAROL;VKORC1;T;rs9923231;DOSAGE;DOSE;nan
PHENPROCOUMON;VKORC1;T;rs9923231;DOSAGE;DOSE;nan
ESOMEPRAZOLE;STAT6;CC + CT;rs1059513;EFFICACY;INCREASED_RESPONSE;OTHER:EOSINOPHILIC_ESOPHAGITIS
RISPERIDONE;WBP2NL;A;rs5758550;LADME_PK;DECREASED_CLEARANCE;nan
PACLITAXEL;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
PLATINUM COMPOUNDS;CASP7;AA + AC;rs12415607;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
ADALIMUMAB;CD40LG;T;rs1126535;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
RALOXIFENE;ESR1;CC;rs11543791;EFFICACY;DECREASED_RESPONSE;DISEASE:MENOPAUSE | DISEASE:SCHIZOPHRENIA
PERINDOPRIL;AGTR1;AA + AT;rs275651;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
LITHIUM;MYO1H;C;rs7959663;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
INFLIXIMAB;FCGR2A;G;rs1801274;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
LITHIUM;EPHX2;T;rs59724122;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
LITHIUM;GRAMD1B;A;rs61123830;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
WARFARIN;VKORC1;T;rs7294;DOSAGE;DECREASED_DOSE;nan
LITHIUM;nan;A;rs66486766;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
LITHIUM;nan;A;rs324899;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
LITHIUM;nan;T;rs1611259;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
LITHIUM;nan;A;rs6942227;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
NEVIRAPINE;CYP2D6;AA + AG;rs28371706;DOSAGE;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
NEVIRAPINE;CYP2D6;AA + AG;rs28371706;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
NEVIRAPINE;CYP2B6;GT + TT;rs3745274;DOSAGE;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
NEVIRAPINE;CYP2B6;GT + TT;rs3745274;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
CATECHOLAMINES;ADRB1;CC;rs1801253;DOSAGE;DECREASED_DOSE;DISEASE:CORONARY_ARTERY_DISEASE
ACENOCOUMAROL;APOE;CC;rs429358;DOSAGE;INCREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION | DISEASE:VENOUS_THROMBOEMBOLISM
PERINDOPRIL;BDKRB1;AA + AG;rs12050217;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
WARFARIN;VKORC1;A;rs17708472;DOSAGE;INCREASED_DOSE;nan
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;C;rs680244;OTHER;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
ADALIMUMAB;NFATC2;CC + CT;rs3787186;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
ETANERCEPT;NFATC2;CC + CT;rs3787186;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
INFLIXIMAB;NFATC2;CC + CT;rs3787186;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3;G;rs16969968;OTHER;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;G;rs16969968;OTHER;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;T;rs680244;OTHER;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
ALLOPURINOL;ABCG2;T;rs2231142;EFFICACY;DECREASED_RESPONSE;OTHER:GOUT
LITHIUM;FAM177A1;T;rs79403677;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
CLOPIDOGREL;nan;A;rs2487032;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
WARFARIN;VKORC1;A;rs9923231;DOSAGE;DECREASED_DOSE;OTHER:TOTAL_KNEE_OR_HIP_ARTHROPLASTY
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED_DOSE;nan
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CHUK;G;rs11591741;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED_DOSE;nan
LITHIUM;ADCY1;A;rs1521470;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
WARFARIN;VKORC1;CC;rs9923231;DOSAGE;INCREASED_DOSE;nan
REPAGLINIDE;KCNQ1;CT + TT;rs2237892;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
LITHIUM;nan;A;rs7588746;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
LITHIUM;FAM178B;A;rs6728642;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
BETA BLOCKING AGENTS;GRK5;AT + TT;rs2230345;EFFICACY;INCREASED_RESPONSE;OTHER:HEART_FAILURE
ZILEUTON;PRORP;AA;rs12436663;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
LITHIUM;ZNF804A;T;rs62200793;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
LITHIUM;nan;A;rs1611255;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
LITHIUM;nan;A;rs209474;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
REPAGLINIDE;KCNQ1;AC + CC;rs2237895;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
LITHIUM;nan;A;rs3919583;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
PLATINUM COMPOUNDS;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
GLATIRAMER ACETATE;TGFB1;A;rs1800469;EFFICACY;DECREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
ANTIEPILEPTICS;ABCC2;CT + TT;rs3740066;EFFICACY;INCREASED_RESISTANCE;DISEASE:EPILEPSY
N-DESMETHYLTAMOXIFEN;ABCG2;GT + TT;rs2231142;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
GLUCOCORTICOIDS;GLCCI1;G;rs37973;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED_DOSE;nan
ANTIEPILEPTICS;ABCC2;CT + TT;rs717620;EFFICACY;INCREASED_RESISTANCE;DISEASE:EPILEPSY
AMLODIPINE;CYP3A4;AG + GG;rs2246709;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
NICOTINE;CYP2B6;G;rs2279343;LADME_PK;INCREASED_METABOLISM;DISEASE:TOBACCO_USE_DISORDER
TENELIGLIPTIN;FMO3;AG + GG;rs2266780;LADME_PK;DECREASED_CLEARANCE;nan
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3;A;rs16969968;OTHER;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;A;rs16969968;OTHER;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
QUETIAPINE;COMT;C;rs4818;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
HYDROCHLOROTHIAZIDE;GPR83;GG;rs3758785;EFFICACY;DECREASED_RESPONSE;EFFICACY:ESSENTIAL_HYPERTENSION
QUETIAPINE;COMT;T;rs5993883;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
TENELIGLIPTIN;FMO3;CT + TT;rs909530;LADME_PK;DECREASED_CLEARANCE;nan
MENOTROPINS;FSHR;CT;rs6166;nan;DECREASED_DOSE;nan
QUETIAPINE;COMT;A;rs6269;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CANDESARTAN;GPR83;GG;rs3758785;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
TACROLIMUS;IL6;GG;rs1800795;DOSAGE;INCREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
TENELIGLIPTIN;FMO3;AG + GG;rs2266782;LADME_PK;DECREASED_CLEARANCE;nan
PACLITAXEL;ABCB1;CT;rs2032582;LADME_PK;INCREASED_METABOLISM;DISEASE:OVARIAN_NEOPLASMS
HYDROCHLOROTHIAZIDE;HSD3B1;CC + CT;rs7553527;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
HYDROCHLOROTHIAZIDE;TTC6;CC + CT;rs177852;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
TENELIGLIPTIN;CYP3A4;CT + TT;rs2242480;LADME_PK;DECREASED_CONCENTRATIONS;nan
GLATIRAMER ACETATE;IFNAR1;G;rs1012335;EFFICACY;DECREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
DARUNAVIR;SLCO3A1;GT + TT;rs8027174;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED_DOSE;nan
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
ATORVASTATIN;CYP3A4;CC;rs2740574;EFFICACY;DECREASED_RESPONSE;OTHER:CARDIOVASCULAR_DISEASE | OTHER:HYPERLIPIDEMIAS
ELEXACAFTOR;CFTR;A;rs121909047;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
TEZACAFTOR;CFTR;A;rs121909047;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;A;rs121909047;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
ELEXACAFTOR;CFTR;AA + AG;rs75961395;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
TEZACAFTOR;CFTR;AA + AG;rs75961395;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;AA + AG;rs75961395;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
6-HYDROXY S-WARFARIN;nan;A;rs368245720;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION | OTHER:VENOUS_THROMBOEMBOLISM | OTHER:HEART_VALVE_DISEASES
ATORVASTATIN;CYP3A5;CC;rs776746;EFFICACY;INCREASED_RESPONSE;OTHER:CARDIOVASCULAR_DISEASE | OTHER:HYPERLIPIDEMIAS
CITALOPRAM;BDNF;CC;rs6265;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
ESCITALOPRAM;BDNF;CC;rs6265;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
FLUOXETINE;BDNF;CC;rs6265;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
SERTRALINE;BDNF;CC;rs6265;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
6-HYDROXY S-WARFARIN;PARP14;A;rs10433340;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION | OTHER:VENOUS_THROMBOEMBOLISM | OTHER:HEART_VALVE_DISEASES
METOPROLOL;ADRB1;C;rs1801253;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
ELEXACAFTOR;CFTR;T;rs121909019;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
TEZACAFTOR;CFTR;T;rs121909019;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;T;rs121909019;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
ELEXACAFTOR;CFTR;T;rs121909011;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
TEZACAFTOR;CFTR;T;rs121909011;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;T;rs121909011;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
ELEXACAFTOR;CFTR;A;rs75549581;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
TEZACAFTOR;CFTR;A;rs75549581;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;A;rs75549581;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
EFAVIRENZ;NR1I3;GG;rs3003596;LADME_PK;INCREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
IMATINIB;ABCG2;G;rs12505410;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
IMATINIB;ABCG2;GG + GT;rs12505410;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
TAMOXIFEN;CYP19A1;AA + AC;rs4646;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
6-HYDROXY R-WARFARIN;GRID2;G;rs558364281;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION | OTHER:VENOUS_THROMBOEMBOLISM | OTHER:HEART_VALVE_DISEASES
6-HYDROXY S-WARFARIN;GRID2;G;rs558364281;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION | OTHER:VENOUS_THROMBOEMBOLISM | OTHER:HEART_VALVE_DISEASES
IMATINIB;ABCG2;CC + CT;rs13120400;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
METHOTREXATE;SLCO1B1;CT + TT;rs10841753;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
IMATINIB;ABCG2;AC + CC;rs2725252;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
LACIDIPINE;CACNA1C;TT;rs2238032;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
NIFEDIPINE;CACNA1C;TT;rs2238032;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
NITRENDIPINE;CACNA1C;TT;rs2238032;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
LUMEFANTRINE;CYP3A4;C;rs2740574;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MALARIA | OTHER:PREGNANCY
QUETIAPINE;HTR1A;TT;rs10042486;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
AMITRIPTYLINE;BDNF;CT + TT;rs6265;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
CLOMIPRAMINE;BDNF;CT + TT;rs6265;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;BDNF;CT + TT;rs6265;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
IMIPRAMINE;BDNF;CT + TT;rs6265;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
MILNACIPRAN;BDNF;CT + TT;rs6265;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
VENLAFAXINE;BDNF;CT + TT;rs6265;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
CHLORPROMAZINE;EPM2A;C;rs1415744;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CLOZAPINE;EPM2A;C;rs1415744;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
HALOPERIDOL;EPM2A;C;rs1415744;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
OLANZAPINE;EPM2A;C;rs1415744;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
QUETIAPINE;EPM2A;C;rs1415744;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
RISPERIDONE;EPM2A;C;rs1415744;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
TRIFLUOPERAZINE;EPM2A;C;rs1415744;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
AMLODIPINE;CACNA1C;GG;rs2239050;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
FELODIPINE;CACNA1C;GG;rs2239050;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
WARFARIN;CYP2C18;A;rs41291550;LADME_PK;DECREASED_METABOLISM;OTHER:ATRIAL_FIBRILLATION | OTHER:VENOUS_THROMBOEMBOLISM | OTHER:HEART_VALVE_DISEASES
ATORVASTATIN;CYP3A4;TT;rs2740574;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:CARDIOVASCULAR_DISEASE | OTHER:HYPERLIPIDEMIAS
CITALOPRAM;GSK3B;GG;rs334558;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
FLUOXETINE;GSK3B;GG;rs334558;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C9;T;rs9332241;LADME_PK;DECREASED_METABOLISM;OTHER:ATRIAL_FIBRILLATION | OTHER:VENOUS_THROMBOEMBOLISM | OTHER:HEART_VALVE_DISEASES
LUMEFANTRINE;CYP3A5;T;rs10264272;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MALARIA | OTHER:PREGNANCY
ATORVASTATIN;CYP3A5;CC;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:CARDIOVASCULAR_DISEASE | OTHER:HYPERLIPIDEMIAS
WARFARIN;FPGS;G;rs7856096;DOSAGE;DECREASED_DOSE;nan
WARFARIN;FPGS;G;rs7856096;DOSAGE;DECREASED_DOSE;nan
LUMEFANTRINE;CYP3A5;C;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MALARIA | OTHER:PREGNANCY
INFLIXIMAB;FCGR3A;A;rs396991;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CETUXIMAB;FCGR3A;A;rs396991;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
NALTREXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED_RESPONSE;DISEASE:ALCOHOL_ABUSE
ELEXACAFTOR;CFTR;CG + GG;rs80034486;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
TEZACAFTOR;CFTR;CG + GG;rs80034486;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;CG + GG;rs80034486;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
AMLODIPINE;CACNA1C;C;rs2239128;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
FELODIPINE;CACNA1C;C;rs2239128;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;DECREASED_CLEARANCE;DISEASE:COLORECTAL_NEOPLASMS
FLUOROURACIL;DPYD;CT;rs3918290;LADME_PK;DECREASED_CLEARANCE;DISEASE:COLORECTAL_NEOPLASMS
SUNITINIB;CYP3A5;T;rs776746;DOSAGE;DECREASED_DOSE;DISEASE:RENAL_CELL_CARCINOMA
N-DESMETHYLCLOZAPINE;UGT2B10;GT;rs61750900;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
LUMEFANTRINE;CYP3A4;T;rs2740574;EFFICACY;DECREASED_RESPONSE;DISEASE:MALARIA | DISEASE:PREGNANCY
CLOPIDOGREL;N6AMT1;G;rs2254638;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
VALPROIC ACID;UGT1A6;TT;rs6759892;LADME_PK;INCREASED_EXPOSURE;OTHER:EPILEPSY
FENTANYL;ASTN2;CT + TT;rs7858836;DOSAGE;DECREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
BENAZEPRIL;CYP11B2;AA + AG;rs1799998;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
IMIDAPRIL;CYP11B2;AA + AG;rs1799998;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
FENTANYL;ASTN2;CC + CT;rs958804;DOSAGE;DECREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
VALPROIC ACID;UGT1A6;AA;rs1105879;LADME_PK;INCREASED_EXPOSURE;OTHER:EPILEPSY
VALPROIC ACID;UGT1A6;AA;rs2070959;LADME_PK;INCREASED_EXPOSURE;OTHER:EPILEPSY
TACROLIMUS;CYP3A4;AA + AG;rs35599367;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL3;CC + CT;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC + CT;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;CC + CT;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;CC + CT;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
ETIDRONIC ACID;COL1A1;AA + AC;rs1800012;EFFICACY;DECREASED_RESPONSE;DISEASE:METABOLIC_BONE_DISORDER
VORICONAZOLE;ABCG2;CC;rs13120400;LADME_PK;INCREASED_TROUGH CONCENTRATION;nan
MORPHINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED_RESPONSE;OTHER:PAIN
NORTRIPTYLINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED_RESPONSE;OTHER:PAIN
RISPERIDONE;HTR1A;CG + GG;rs6295;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
DULOXETINE;nan;G;rs4858478;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;DECREASED_CLEARANCE;DISEASE:COLORECTAL_NEOPLASMS
FLUOROURACIL;DPYD;AT;rs67376798;LADME_PK;DECREASED_CLEARANCE;DISEASE:COLORECTAL_NEOPLASMS
VALPROIC ACID;UGT1A6;GG;rs6759892;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:EPILEPSY
DULOXETINE;ZNF385D;T;rs13093500;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ESCITALOPRAM;BDNF;CC;rs6265;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
FLUOXETINE;BDNF;CC;rs6265;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
PAROXETINE;BDNF;CC;rs6265;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
SERTRALINE;BDNF;CC;rs6265;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
FOLIC ACID;SLC19A1;T;rs1051266;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
HYDROXYCHLOROQUINE;SLC19A1;T;rs1051266;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;SLC19A1;T;rs1051266;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
SULFASALAZINE;SLC19A1;T;rs1051266;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
DULOXETINE;ZNF385D;T;rs4334661;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
FOLIC ACID;MTR;A;rs1805087;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
HYDROXYCHLOROQUINE;MTR;A;rs1805087;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;MTR;A;rs1805087;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
SULFASALAZINE;MTR;A;rs1805087;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
DULOXETINE;nan;G;rs7625956;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;CC;rs4646453;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
TAMOXIFEN;SULT1A1;TT;rs1042028;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
DULOXETINE;ZNF385D;G;rs7616119;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;nan;T;rs2933304;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;CT;rs9923231;DOSAGE;INCREASED_DOSE;DISEASE:THROMBOEMBOLISM
METHOTREXATE;SLC19A1;T;rs1051266;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
DULOXETINE;NRXN1;T;rs4971678;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TRAMADOL;RGL4;A;rs184199168;LADME_PK;DECREASED_METABOLISM;nan
DULOXETINE;ZNF385D;G;rs12630569;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TRAMADOL;nan;T;rs72732317;LADME_PK;DECREASED_METABOLISM;nan
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED_DOSE;DISEASE:THROMBOEMBOLISM
BEVACIZUMAB;VEGFA;CC;rs699947;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
CAPECITABINE;VEGFA;CC;rs699947;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
FLUOROURACIL;VEGFA;CC;rs699947;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
IRINOTECAN;VEGFA;CC;rs699947;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
LEUCOVORIN;VEGFA;CC;rs699947;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
OXALIPLATIN;VEGFA;CC;rs699947;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
TRAMADOL;HCN1;C;rs79983226;LADME_PK;DECREASED_METABOLISM;nan
TRAMADOL;ICA1;A;rs62435418;LADME_PK;DECREASED_METABOLISM;nan
ERYTHROPOIETIN;HFE;A;rs1800562;DOSAGE;DECREASED_DOSE;OTHER:HEMODIALYSIS_TREATMENT
ERYTHROPOIETIN;HFE;A;rs1800562;LADME_PK;DECREASED_DOSE;OTHER:HEMODIALYSIS_TREATMENT
DULOXETINE;nan;C;rs6700741;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ENALAPRIL;ADRB2;CG + GG;rs1042714;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTROPHY | LEFT_VENTRICULAR
ATENOLOL;ADRB2;CG + GG;rs1042714;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTROPHY | LEFT_VENTRICULAR
ENALAPRIL;ADRB2;CG + GG;rs1042714;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTROPHY | LEFT_VENTRICULAR
BEVACIZUMAB;VEGFA;TT;rs3025039;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
CAPECITABINE;VEGFA;TT;rs3025039;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
FLUOROURACIL;VEGFA;TT;rs3025039;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
IRINOTECAN;VEGFA;TT;rs3025039;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
LEUCOVORIN;VEGFA;TT;rs3025039;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
OXALIPLATIN;VEGFA;TT;rs3025039;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
ERYTHROPOIETIN;HFE;G;rs1799945;DOSAGE;DECREASED_DOSE;OTHER:HEMODIALYSIS_TREATMENT
ERYTHROPOIETIN;HFE;G;rs1799945;LADME_PK;DECREASED_DOSE;OTHER:HEMODIALYSIS_TREATMENT
TRAMADOL;RFPL4B;T;rs9384825;LADME_PK;DECREASED_METABOLISM;nan
DULOXETINE;TEX10;C;rs6479008;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;AA;rs15524;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
DULOXETINE;TEX10;A;rs7035619;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;TEX10;T;rs10989064;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DIGOXIN;ABCB1;GG;rs1045642;LADME_PK;INCREASED_METABOLISM;nan
DULOXETINE;ATP10A;G;rs12595802;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;TEX10;G;rs7472;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
MYCOPHENOLIC ACID;IMPDH2;G;rs11706052;EFFICACY;DECREASED_RESPONSE;nan
DULOXETINE;nan;G;rs56229625;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DIGOXIN;ABCB1;CC;rs2032582;LADME_PK;INCREASED_METABOLISM;nan
DULOXETINE;nan;G;rs61692318;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;nan;A;rs62319299;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
DULOXETINE;TEX10;G;rs10124893;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;INVS;G;rs10123866;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ABEMACICLIB;ABCB1;A;rs1045642;DOSAGE;DECREASED_DOSE;OTHER:BREAST_NEOPLASMS
ABEMACICLIB;ABCB1;A;rs1045642;TOXICITY;DECREASED_DOSE;OTHER:BREAST_NEOPLASMS
PALBOCICLIB;ABCB1;A;rs1045642;DOSAGE;DECREASED_DOSE;OTHER:BREAST_NEOPLASMS
PALBOCICLIB;ABCB1;A;rs1045642;TOXICITY;DECREASED_DOSE;OTHER:BREAST_NEOPLASMS
RIBOCICLIB;ABCB1;A;rs1045642;DOSAGE;DECREASED_DOSE;OTHER:BREAST_NEOPLASMS
RIBOCICLIB;ABCB1;A;rs1045642;TOXICITY;DECREASED_DOSE;OTHER:BREAST_NEOPLASMS
DULOXETINE;nan;C;rs10007051;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
DULOXETINE;ZNF385D;C;rs9879065;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;nan;C;rs55881666;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
INFLIXIMAB;nan;CC + CT;rs2097432;EFFICACY;DECREASED_RESPONSE;OTHER:CROHN_DISEASE
VALPROIC ACID;CYP2C9;CC + CT;rs4918758;LADME_PK;INCREASED_EXPOSURE;OTHER:EPILEPSY
DULOXETINE;nan;A;rs11933890;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
VALPROIC ACID;CYP2C19;AA + AG;rs4244285;LADME_PK;INCREASED_EXPOSURE;OTHER:EPILEPSY
DULOXETINE;ZNF385D;C;rs9310658;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ZNF385D;A;rs7653345;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
VALPROIC ACID;ABAT;GG;rs1731017;LADME_PK;INCREASED_EXPOSURE;OTHER:EPILEPSY
DULOXETINE;ZNF385D;T;rs9310657;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ZNF385D;G;rs9824595;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ZNF385D;C;rs9873889;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ZNF385D;G;rs9819548;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED_DOSE;nan
CAPECITABINE;CDA;CC;rs532545;EFFICACY;DECREASED_RESPONSE;OTHER:BREAST_NEOPLASMS
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
HYDRALAZINE;NOS3;GG;rs1799983;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HEART_FAILURE
ISOSORBIDE DINITRATE;NOS3;GG;rs1799983;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HEART_FAILURE
WARFARIN;CYP2C9;C;rs56165452;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;ABCB1;AA;rs1045642;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
PEGINTERFERON ALFA-2A;IFNL3;GG + GT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;GG + GT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED_DOSE;nan
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
ADALIMUMAB;CRP;AG + GG;rs1130864;EFFICACY;INCREASED_RESPONSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
OLANZAPINE;CYP3A43;AA;rs472660;DOSAGE;INCREASED_CLEARANCE;DISEASE:SCHIZOPHRENIA
OLANZAPINE;CYP3A43;AA;rs472660;EFFICACY;INCREASED_CLEARANCE;DISEASE:SCHIZOPHRENIA
OLANZAPINE;CYP3A43;AA;rs472660;TOXICITY;INCREASED_CLEARANCE;DISEASE:SCHIZOPHRENIA
OLANZAPINE;CYP3A43;AA;rs472660;LADME_PK;INCREASED_CLEARANCE;DISEASE:SCHIZOPHRENIA
GLATIRAMER ACETATE;EOMES;T;rs2371108;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
CARVEDILOL;UGT1A1;A;rs4148323;LADME_PK;DECREASED_METABOLISM;DISEASE:ANGINA_PECTORIS
ETOPOSIDE;ABCB1;GG;rs1045642;LADME_PK;INCREASED_METABOLISM;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ADALIMUMAB;ATG5;CC + CT;rs9373839;EFFICACY;INCREASED_RESPONSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
DULOXETINE;MIEF2;G;rs56355515;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;MIEF2;G;rs12603700;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
EFAVIRENZ;CYP2B6;C;rs28399499;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
ADALIMUMAB;ATG5;CT + TT;rs510432;EFFICACY;INCREASED_RESPONSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
TACROLIMUS;ABCB1;GG;rs1045642;LADME_PK;INCREASED_DOSE;DISEASE:TRANSPLANTATION
DULOXETINE;MIEF2;G;rs3889402;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
AZATHIOPRINE;AOX1;G;rs55754655;EFFICACY;DECREASED_RESPONSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
AZATHIOPRINE;AOX1;AG + GG;rs55754655;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
HYDRALAZINE;CYP11B2;AA;rs1799998;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HEART_FAILURE
ISOSORBIDE DINITRATE;CYP11B2;AA;rs1799998;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HEART_FAILURE
DULOXETINE;nan;G;rs58042962;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A4;C;rs2740574;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
DULOXETINE;nan;T;rs10771997;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
FENOFIBRATE;LPL;GG;rs320;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
DULOXETINE;FCN2;T;rs3124955;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
FENOFIBRATE;APOA1;CG;rs2727786;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
DULOXETINE;FCN2;A;rs3128624;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;nan;A;rs7306991;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
GLATIRAMER ACETATE;CLEC16A;A;rs6498169;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
TACROLIMUS;CYP3A4;C;rs2740574;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
DIGOXIN;ABCB1;AA;rs1045642;LADME_PK;DECREASED_METABOLISM;nan
DULOXETINE;nan;C;rs10771999;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;nan;A;rs10771998;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;SKIC3;G;rs12657120;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ETHOSUXIMIDE;CACNA1H;T;rs61734410;EFFICACY;DECREASED_CLINICAL BENEFIT;EFFICACY:EPILEPSY
DULOXETINE;SKIC3;G;rs4639250;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;nan;A;rs4437856;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ETHOSUXIMIDE;CACNA1I;T;rs3747178;EFFICACY;DECREASED_CLINICAL BENEFIT;EFFICACY:EPILEPSY
DULOXETINE;TREML4;A;rs9369266;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
AZATHIOPRINE;MOCOS;AA + AC;rs594445;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
DULOXETINE;TREML4;G;rs13204353;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
LAMOTRIGINE;ABCB1;A;rs2032582;EFFICACY;DECREASED_CLINICAL BENEFIT;EFFICACY:EPILEPSY
CYCLOSPORINE;CALM1;T;rs12885713;EFFICACY;INCREASED_RESPONSE;OTHER:PSORIASIS
IRBESARTAN;AGT;GG;rs699;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTROPHY | LEFT_VENTRICULAR
DULOXETINE;nan;C;rs2419128;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
METHOTREXATE;SLC19A1;T;rs1051266;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
DULOXETINE;nan;G;rs12502866;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
METHOTREXATE;GGH;AA + AG;rs3758149;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
DULOXETINE;nan;T;rs12094644;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
CAPECITABINE;CDA;AA + AC;rs2072671;EFFICACY;DECREASED_RESPONSE;OTHER:BREAST_NEOPLASMS
LAMOTRIGINE;CACNA1H;A;rs2753326;EFFICACY;INCREASED_CLINICAL BENEFIT;EFFICACY:EPILEPSY
RIVAROXABAN;ABCB1;GG;rs4728709;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
ATENOLOL;ADRA2A;GG;rs1800545;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTROPHY | LEFT_VENTRICULAR
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
CYCLOSPORINE;nan;G;rs2874116;EFFICACY;INCREASED_RESPONSE;OTHER:PSORIASIS
IRBESARTAN;APOB;CC;rs1801701;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTROPHY | LEFT_VENTRICULAR
RIVAROXABAN;ABCB1;CC;rs4148738;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
EFAVIRENZ;CYP2B6;C;rs28399499;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
MEPHENYTOIN;CYP2C19;T;rs183701923;LADME_PK;DECREASED_CLEARANCE;nan
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
MEPHENYTOIN;CYP2C19;A;rs140278421;LADME_PK;DECREASED_CLEARANCE;nan
EFAVIRENZ;CYP2B6;T;rs4803419;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CLOZAPINE;CYP1A2;A;rs34067076;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
N-DESMETHYLCLOZAPINE;CYP1A2;A;rs34067076;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
CHLORPROMAZINE;DRD2;GG;rs1799732;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CLOZAPINE;CYP1A2;A;rs59410695;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
N-DESMETHYLCLOZAPINE;CYP1A2;A;rs59410695;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
WARFARIN;CYP2C9;G;rs28371686;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;T;rs28371685;DOSAGE;DECREASED_DOSE;nan
METHOTREXATE;AMPD1;AA + AG;rs17602729;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
WARFARIN;CYP2C9;G;rs28371686;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;C;rs56165452;DOSAGE;DECREASED_DOSE;nan
BENAZEPRIL;AGT;TT;rs7079;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
PLATINUM COMPOUNDS;XRCC3;A;rs861539;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
CLOZAPINE;CYP1A2;C;rs200571120;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
N-DESMETHYLCLOZAPINE;CYP1A2;C;rs200571120;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
EFAVIRENZ;CYP2B6;T;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
OMEPRAZOLE;ABCB1;AA + AG;rs1045642;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:GASTROESOPHAGEAL_REFLUX
OPIOIDS;OPRM1;AA;rs1799971;DOSAGE;DECREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
OPIOIDS;OPRM1;AA;rs1799971;EFFICACY;DECREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
NELFINAVIR;CYP2C19;AA;rs4244285;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
TOLBUTAMIDE;CYP2C9;C;rs771237265;LADME_PK;DECREASED_CLEARANCE;nan
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED_DOSE;nan
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
TOLBUTAMIDE;CYP2C9;T;rs762081829;LADME_PK;DECREASED_CLEARANCE;nan
METFORMIN;SLC22A1;A;rs628031;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
MEPHENYTOIN;CYP2C19;A;rs145119820;LADME_PK;DECREASED_CLEARANCE;nan
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED_DOSE;nan
TOLBUTAMIDE;CYP2C9;C;rs761895497;LADME_PK;DECREASED_CLEARANCE;nan
WARFARIN;F7;AA + AG;rs510317;DOSAGE;INCREASED_DOSE;nan
FLUOXETINE;HTR1A;GG;rs6295;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
MEPHENYTOIN;CYP2C19;T;rs61311738;LADME_PK;DECREASED_CLEARANCE;nan
SULFONAMIDES;TCF7L2;TT;rs7903146;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
UREA DERIVATIVES;TCF7L2;TT;rs7903146;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
BENAZEPRIL;AGT;G;rs4762;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
BENAZEPRIL;AGT;A;rs699;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
FLUOROURACIL;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
OXALIPLATIN;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED_DOSE;nan
BENAZEPRIL;AGT;T;rs7079;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED_DOSE;nan
FENOFIBRATE;APOA5;CG + GG;rs3135506;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
PRAVASTATIN;RHOA;A;rs11716445;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
SIMVASTATIN;RHOA;A;rs11716445;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
SULFONAMIDES;KCNJ11;T;rs587783672;EFFICACY;RESPONSE;nan
UREA DERIVATIVES;KCNJ11;T;rs587783672;EFFICACY;RESPONSE;nan
EFAVIRENZ;CYP2B6;AG;rs35303484;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
CLOZAPINE;CYP1A2;G;rs72547516;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
N-DESMETHYLCLOZAPINE;CYP1A2;G;rs72547516;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED_DOSE;nan
CITALOPRAM;nan;CT;rs585719;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSION
WARFARIN;GGCX;CG + GG;rs11676382;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
CLOZAPINE;CYP1A2;T;rs566851431;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
N-DESMETHYLCLOZAPINE;CYP1A2;T;rs566851431;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
WARFARIN;nan;A;rs12777823;LADME_PK;DECREASED_METABOLISM;OTHER:ATRIAL_FIBRILLATION | OTHER:VENOUS_THROMBOEMBOLISM | OTHER:HEART_VALVE_DISEASES
WARFARIN;CYP2C9;A;rs7900194;LADME_PK;DECREASED_METABOLISM;OTHER:ATRIAL_FIBRILLATION | OTHER:VENOUS_THROMBOEMBOLISM | OTHER:HEART_VALVE_DISEASES
ISONIAZID;CYP2E1;A;rs6413432;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:TUBERCULOSIS
EFAVIRENZ;CYP2B6;TT;rs4803419;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED_DOSE;nan
WARFARIN;GATA4;TT;rs2645400;DOSAGE;INCREASED_DOSE;nan
WARFARIN;CYP2C9;T;rs28371685;LADME_PK;DECREASED_METABOLISM;OTHER:ATRIAL_FIBRILLATION | OTHER:VENOUS_THROMBOEMBOLISM | OTHER:HEART_VALVE_DISEASES
WARFARIN;GATA4;TT;rs4841588;DOSAGE;INCREASED_DOSE;nan
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;GG;rs7662029;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
BUPRENORPHINE;UGT2B7;CC;rs7439366;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:OPIOID-RELATED_DISORDERS
METHOTREXATE;SLCO1B1;CC;rs4149056;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;CC;rs7439366;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
METHOTREXATE;SLC19A1;AA;rs2838958;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;AC + CC;rs1057910;LADME_PK;DECREASED_DOSE;nan
SILDENAFIL;VEGFA;AA;rs1570360;EFFICACY;DECREASED_RESPONSE;DISEASE:ERECTILE_DYSFUNCTION
SILDENAFIL;VEGFA;AA + AC;rs699947;EFFICACY;DECREASED_RESPONSE;DISEASE:ERECTILE_DYSFUNCTION
CAPTOPRIL;ACE2;GG;rs2106809;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
CYCLOPHOSPHAMIDE;FCGR2A;AA;rs1801274;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
DOXORUBICIN;FCGR2A;AA;rs1801274;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
PACLITAXEL;FCGR2A;AA;rs1801274;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
TRASTUZUMAB;FCGR2A;AA;rs1801274;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
TRASTUZUMAB;FCGR3A;CC;rs396991;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
BUPRENORPHINE;UGT2B7;GG;rs7662029;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:OPIOID-RELATED_DISORDERS
ECULIZUMAB;CR1;AG + GG;rs2274567;EFFICACY;DECREASED_RESPONSE;DISEASE:PAROXYSMAL_NOCTURNAL_HEMOGLOBINURIA
TACROLIMUS;NR1I2;TT;rs3814055;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;CT;rs2740574;LADME_PK;INCREASED_EXPOSURE;OTHER:KIDNEY_TRANSPLANTATION
MYCOPHENOLIC ACID;UGT1A1;AG;rs4148323;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
PHENPROCOUMON;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
CLOZAPINE;DRD1;G;rs686;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;AA;rs7438135;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
CLOZAPINE;DRD3;TT;rs6280;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
FOLLITROPIN BETA;FSHR;CT;rs6166;EFFICACY;DECREASED_RESPONSE;OTHER:INFERTILITY_DISORDER
MENOTROPINS;FSHR;CT;rs6166;EFFICACY;DECREASED_RESPONSE;OTHER:INFERTILITY_DISORDER
THYROTROPIN ALFA;FSHR;CT;rs6166;EFFICACY;DECREASED_RESPONSE;OTHER:INFERTILITY_DISORDER
UROFOLLITROPIN;FSHR;CT;rs6166;EFFICACY;DECREASED_RESPONSE;OTHER:INFERTILITY_DISORDER
MERCAPTOPURINE;TPMT;G;rs12199316;DOSAGE;INCREASED_DOSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
TICAGRELOR;CYP3A4;CC;rs56324128;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ACUTE_CORONARY_SYNDROME
CANDESARTAN;AGTR1;AA;rs5186;EFFICACY;INCREASED_RESPONSE;DISEASE:HEART_FAILURE
IRBESARTAN;AGTR1;AC;rs5186;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTROPHY | LEFT_VENTRICULAR
WARFARIN;CYP2C9;G;rs2256871;LADME_PK;DECREASED_METABOLISM;OTHER:ATRIAL_FIBRILLATION | OTHER:VENOUS_THROMBOEMBOLISM | OTHER:HEART_VALVE_DISEASES
DOCETAXEL;CYP3A5;CC;rs776746;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
PACLITAXEL;CYP3A5;CC;rs776746;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
CAPECITABINE;DPYD;CC + CT;rs1801159;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
FLUOROURACIL;DPYD;CC + CT;rs1801159;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
TEGAFUR;DPYD;CC + CT;rs1801159;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
GIMERACIL;DPYD;CC + CT;rs1801159;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
OTERACIL;DPYD;CC + CT;rs1801159;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
CANDESARTAN;AGTR1;AC;rs5186;EFFICACY;INCREASED_RESPONSE;DISEASE:HEART_FAILURE
TICAGRELOR;SLCO1B1;C;rs113681054;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:ACUTE_CORONARY_SYNDROME
TICAGRELOR;SLCO1B1;T;rs4149056;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ACUTE_CORONARY_SYNDROME
GEMCITABINE;SLC29A1;A;rs760370;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
PACLITAXEL;SLC29A1;A;rs760370;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
CITALOPRAM;BDNF;CC;rs6265;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
ESCITALOPRAM;BDNF;CC;rs6265;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
FLUOXETINE;BDNF;CC;rs6265;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
FLUVOXAMINE;BDNF;CC;rs6265;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
PAROXETINE;BDNF;CC;rs6265;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
SERTRALINE;BDNF;CC;rs6265;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C19;T;rs11188082;LADME_PK;DECREASED_METABOLISM;OTHER:ATRIAL_FIBRILLATION | OTHER:VENOUS_THROMBOEMBOLISM | OTHER:HEART_VALVE_DISEASES
METHYLPHENIDATE;CES1;CT;rs71647871;DOSAGE;DECREASED_DOSE;DISEASE:ADHD
METHYLPHENIDATE;CES1;CT;rs71647871;LADME_PK;DECREASED_DOSE;DISEASE:ADHD
TICAGRELOR;UGT2B7;TT;rs61361928;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ACUTE_CORONARY_SYNDROME
QUETIAPINE;HTR1A;GG;rs6295;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
TICAGRELOR;CYP3A43;G;rs62471956;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ACUTE_CORONARY_SYNDROME
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
SIMVASTATIN;LEPR;GG;rs1137101;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERLIPIDEMIAS
LAMOTRIGINE;ABCG2;T;rs2231142;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
OPIOIDS;IL2;AA;rs2069762;DOSAGE;INCREASED_DOSE;OTHER:PAIN | OTHER:NEOPLASMS
OPIOIDS;BDNF;CC;rs6265;DOSAGE;INCREASED_DOSE;OTHER:PAIN | OTHER:NEOPLASMS
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
VORICONAZOLE;CYP3A4;AG;rs4646437;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:FUNGAL_INFECTIOUS_DISEASE
OPIOIDS;IL6;CC;rs1800795;DOSAGE;INCREASED_DOSE;OTHER:PAIN | OTHER:NEOPLASMS
ATENOLOL;AGT;AG;rs4762;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTROPHY | LEFT_VENTRICULAR
IRBESARTAN;AGT;AG;rs4762;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTROPHY | LEFT_VENTRICULAR
TENOFOVIR;ABCC4;AA + AG;rs1059751;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:HEPATITIS_B | CHRONIC
CAFFEINE;CYP1A1;T;rs2472297;LADME_PK;INCREASED_METABOLISM;nan
DOCETAXEL;VEGFA;GG;rs1570360;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
OPIOIDS;IL1B;AA + AG;rs1143634;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PAIN | OTHER:NEOPLASMS
FENOFIBRATE;SCARB1;CT + TT;rs4238001;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
TENOFOVIR;SLC22A6;TT;rs4149170;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HEPATITIS_B | CHRONIC
NEVIRAPINE;CYP2B6;TT;rs3745274;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
OPIOIDS;OPRD1;CC;rs678849;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PAIN | OTHER:NEOPLASMS
ACENOCOUMAROL;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
IRBESARTAN;AGT;AG + GG;rs699;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTROPHY | LEFT_VENTRICULAR
PEGINTERFERON ALFA-2A;CXCL10;CT + TT;rs56061981;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;CXCL10;CT + TT;rs56061981;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
ATORVASTATIN;ABCB1;T;rs2032582;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
ATORVASTATIN;ABCB1;T;rs2032582;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
ATALUREN;CFTR;T;rs113993959;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
FOLIC ACID;MTHFR;G;rs1801131;LADME_PK;DECREASED_METABOLISM;nan
ATALUREN;CFTR;T;rs75039782;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
FOLIC ACID;MTHFR;A;rs1801133;LADME_PK;DECREASED_METABOLISM;nan
ATALUREN;CFTR;A;rs77010898;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
PLATINUM COMPOUNDS;ERCC2;AA + AG;rs1052555;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
FENOFIBRATE;APOA5;CC + CG;rs3135506;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
METHYLPHENIDATE;DRD1;CT + TT;rs5326;EFFICACY;INCREASED_RESPONSE;DISEASE:AUTISM_SPECTRUM_DISORDER
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
FENTANYL;ABCB1;GG;rs1045642;DOSAGE;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
FENTANYL;ABCB1;GG;rs1045642;EFFICACY;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
FOLIC ACID;ATIC;CC;rs2372536;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;ATIC;CC;rs2372536;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CORTICOSTEROIDS;ADAM33;AA;rs2853209;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ASTHMA
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ADAM33;AA;rs2853209;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ASTHMA
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
LITHIUM;GADL1;T;rs17026688;EFFICACY;INCREASED_RESPONSE;OTHER:BIPOLAR_DISORDER
TACROLIMUS;POR;CC;rs1057868;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
FOLIC ACID;ITPA;CC;rs1127354;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;ITPA;CC;rs1127354;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;ATIC;C;rs4673993;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;TT;rs9923231;LADME_PK;DECREASED_DOSE;nan
WARFARIN;GGCX;C;rs12714145;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED_DOSE;nan
METHOTREXATE;ADA;C;rs244076;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;ADORA2A;T;rs5751876;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
FOLIC ACID;AMPD1;A;rs17602729;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;AMPD1;A;rs17602729;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
RITUXIMAB;FCGR3A;CC;rs396991;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED_DOSE;nan
FLUOROURACIL;EGFR;CC;rs2293347;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED_DOSE;nan
ANTIDEPRESSANTS;TGFBR3;TT;rs12082710;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSION
WARFARIN;VKORC1;C;rs7294;DOSAGE;DECREASED_DOSE;nan
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
ALLOPURINOL;ABCG2;T;rs2231142;DOSAGE;INCREASED_DOSE;DISEASE:GOUT
WARFARIN;VKORC1;C;rs2884737;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;A;rs2359612;DOSAGE;DECREASED_DOSE;nan
RIFAMPIN;AADAC;GG;rs1803155;LADME_PK;DECREASED_EXPOSURE;OTHER:TUBERCULOSIS
CETUXIMAB;AREG;AA;rs9996584;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
PANITUMUMAB;AREG;AA;rs9996584;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
NEVIRAPINE;CYP2B6;CT;rs28399499;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
CETUXIMAB;AREG;GG;rs1353295;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
PANITUMUMAB;AREG;GG;rs1353295;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
NEVIRAPINE;CYP2B6;CT;rs28399499;TOXICITY;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
NEVIRAPINE;CYP2B6;CT;rs28399499;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
METHOTREXATE;MTHFR;AA + AG;rs1801133;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BURKITT_LYMPHOMA | DISEASE:LYMPHOMA | T-CELL | DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
RIFAMPIN;ABCB1;CC;rs3842;LADME_PK;INCREASED_EXPOSURE;OTHER:TUBERCULOSIS
NEVIRAPINE;CYP2B6;GT + TT;rs3745274;TOXICITY;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
NEVIRAPINE;CYP2B6;GT + TT;rs3745274;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
METHOTREXATE;ABCB1;AA;rs1045642;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BURKITT_LYMPHOMA | DISEASE:LYMPHOMA | T-CELL | DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CLOPIDOGREL;CYP2C19;AG;rs4986893;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HYPERTENSION | OTHER:ACUTE_CORONARY_SYNDROME
FENTANYL;P2RX7;CT + TT;rs1718125;DOSAGE;INCREASED_DOSE;OTHER:LUNG_NEOPLASMS | OTHER:POSTOPERATIVE_PAIN
METHYLPHENIDATE;DRD1;CC + CT;rs4867798;EFFICACY;INCREASED_RESPONSE;DISEASE:AUTISM_SPECTRUM_DISORDER
METHYLPHENIDATE;DRD3;TT;rs6280;EFFICACY;INCREASED_RESPONSE;DISEASE:AUTISM_SPECTRUM_DISORDER
METHYLPHENIDATE;DRD4;AA;rs11246226;EFFICACY;INCREASED_RESPONSE;DISEASE:AUTISM_SPECTRUM_DISORDER
PLATINUM COMPOUNDS;XRCC1;CT + TT;rs25487;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
METHYLPHENIDATE;ADRA2A;CC;rs1800544;EFFICACY;INCREASED_RESPONSE;DISEASE:AUTISM_SPECTRUM_DISORDER
METHYLPHENIDATE;COMT;AA + AG;rs4680;EFFICACY;INCREASED_RESPONSE;DISEASE:AUTISM_SPECTRUM_DISORDER
ESTRONE SULFATE;SLCO1B1;C;rs10841753;EFFICACY;DECREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
ESTRONE SULFATE;SLCO1B1;C;rs10841753;LADME_PK;DECREASED;OTHER:BREAST_NEOPLASMS
WARFARIN;GGCX;TT;rs12714145;DOSAGE;INCREASED_DOSE;nan
NEVIRAPINE;CYP2B6;GT + TT;rs3745274;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
CETUXIMAB;AREG;GG;rs13104811;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
PANITUMUMAB;AREG;GG;rs13104811;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
CETUXIMAB;AREG;AA;rs11942466;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
PANITUMUMAB;AREG;AA;rs11942466;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
ANTIDEPRESSANTS;CRHR1;AA + AG;rs28364032;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TOPIRAMATE;UGT1A1;GG + GT;rs4148324;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:EPILEPSY
TOPIRAMATE;UGT1A10;GG + GT;rs4148324;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:EPILEPSY
TOPIRAMATE;UGT1A3;GG + GT;rs4148324;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:EPILEPSY
TOPIRAMATE;UGT1A4;GG + GT;rs4148324;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:EPILEPSY
TOPIRAMATE;UGT1A5;GG + GT;rs4148324;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:EPILEPSY
TOPIRAMATE;UGT1A6;GG + GT;rs4148324;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:EPILEPSY
TOPIRAMATE;UGT1A7;GG + GT;rs4148324;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:EPILEPSY
TOPIRAMATE;UGT1A8;GG + GT;rs4148324;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:EPILEPSY
TOPIRAMATE;UGT1A9;GG + GT;rs4148324;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:EPILEPSY
CAPECITABINE;EXO1;A;rs1047840;EFFICACY;INCREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM
FLUOROURACIL;EXO1;A;rs1047840;EFFICACY;INCREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM
CAPECITABINE;CYP19A1;G;rs2236722;EFFICACY;DECREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM
FLUOROURACIL;CYP19A1;G;rs2236722;EFFICACY;DECREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM
CAPECITABINE;PTEN;C;rs17431184;EFFICACY;INCREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM
FLUOROURACIL;PTEN;C;rs17431184;EFFICACY;INCREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM
CYCLOSPORINE;POR;T;rs1057868;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
CAPECITABINE;DLG5;T;rs2289310;EFFICACY;INCREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM
FLUOROURACIL;DLG5;T;rs2289310;EFFICACY;INCREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM
PEGINTERFERON ALFA-2A;SLC29A1;GG;rs760370;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;SLC29A1;GG;rs760370;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;SLC29A1;GG;rs760370;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
METHOTREXATE;MTHFR;AA + AG;rs1801133;LADME_PK;DECREASED_CLEARANCE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
TIPIRACIL HYDROCHLORIDE;SLC29A1;AG + GG;rs760370;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
TRIFLURIDINE;SLC29A1;AG + GG;rs760370;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
ETHANOL;ADH1B;A;rs2018417;TOXICITY;METABOLISM;nan
ETHANOL;ADH1B;A;rs2018417;LADME_PK;METABOLISM;nan
ETHANOL;ADH1B;C;rs17033;TOXICITY;METABOLISM;nan
ETHANOL;ADH1B;C;rs17033;LADME_PK;METABOLISM;nan
ETHANOL;ADH1B;G;rs1229985;TOXICITY;METABOLISM;nan
ETHANOL;ADH1B;G;rs1229985;LADME_PK;METABOLISM;nan
PHENPROCOUMON;PPARA;A;rs4253728;DOSAGE;INCREASED_DOSE;nan
ETHANOL;ADH1A;A;rs931635;TOXICITY;METABOLISM;nan
ETHANOL;ADH1A;A;rs931635;LADME_PK;METABOLISM;nan
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
METHADONE;KCNJ6;TT;rs2070995;nan;INCREASED_DOSE;DISEASE:SUBSTANCE-RELATED_DISORDERS
ETHANOL;ADH1C;A;rs283416;TOXICITY;METABOLISM;nan
ETHANOL;ADH1C;A;rs283416;LADME_PK;METABOLISM;nan
CAPECITABINE;ABCB1;T;rs17160359;EFFICACY;INCREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM
FLUOROURACIL;ABCB1;T;rs17160359;EFFICACY;INCREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM
ROSIGLITAZONE;PPARG;CG;rs1801282;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
ETHANOL;ADH1C;A;rs283411;TOXICITY;METABOLISM;nan
ETHANOL;ADH1C;A;rs283411;LADME_PK;METABOLISM;nan
ETHANOL;ADH1C;C;rs1662060;TOXICITY;METABOLISM;nan
ETHANOL;ADH1C;C;rs1662060;LADME_PK;METABOLISM;nan
TACROLIMUS;SUMO4;AA;rs237025;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
ACENOCOUMAROL;VKORC1;TT;rs17878544;DOSAGE;DECREASED_DOSE;nan
HMG COA REDUCTASE INHIBITORS;LPA;G;rs10455872;EFFICACY;DECREASED_RESPONSE;nan
ACENOCOUMAROL;VKORC1;AA + AG;rs7200749;DOSAGE;INCREASED_DOSE;nan
HMG COA REDUCTASE INHIBITORS;ABCG2;G;rs2231142;EFFICACY;DECREASED_RESPONSE;nan
ACENOCOUMAROL;VKORC1;AA + AC;rs61742245;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;A;rs7200749;DOSAGE;INCREASED_DOSE;nan
ACENOCOUMAROL;VKORC1;CC;rs9923231;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;T;rs7294;DOSAGE;INCREASED_DOSE;nan
CITALOPRAM;NEDD4L;A;rs520210;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSION
HMG COA REDUCTASE INHIBITORS;TOMM40;G;rs2075650;EFFICACY;DECREASED_RESPONSE;nan
ACENOCOUMAROL;VKORC1;CT + TT;rs55894764;DOSAGE;INCREASED_DOSE;nan
VALPROIC ACID;UGT1A10;G;rs28898617;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A3;G;rs28898617;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A4;G;rs28898617;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A5;G;rs28898617;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A6;G;rs28898617;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A7;G;rs28898617;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A8;G;rs28898617;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A9;G;rs28898617;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
IVACAFTOR;CFTR;AA + AG;rs78655421;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
METHYLPHENIDATE;PEBP4;T;rs17685420;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;DISEASE:CARDIOVASCULAR_DISEASE
VERAPAMIL;ITGAL;C;rs2230433;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MIGRAINE_DISORDER
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HYPERCHOLESTEROLEMIA
PAZOPANIB;KDR;AG;rs34231037;EFFICACY;INCREASED_RESPONSE;DISEASE:RENAL_CELL_CARCINOMA
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
ETHANOL;ADH7;C;rs1154461;TOXICITY;METABOLISM;nan
ETHANOL;ADH7;C;rs1154461;LADME_PK;METABOLISM;nan
HEPATITIS VACCINES;IL4R;C;rs1805015;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;DECREASED_METABOLISM;OTHER:HIV_INFECTIOUS_DISEASE
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
ETHANOL;ADH1A;C;rs1229967;TOXICITY;METABOLISM;nan
ETHANOL;ADH1A;C;rs1229967;LADME_PK;METABOLISM;nan
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
ETHANOL;ADH1A;C;rs2276332;TOXICITY;METABOLISM;nan
ETHANOL;ADH1A;C;rs2276332;LADME_PK;METABOLISM;nan
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
BENAZEPRIL;AGT;CC;rs5051;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
IMIDAPRIL;AGT;CC;rs5051;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
ETHANOL;ADH1A;C;rs1229976;TOXICITY;METABOLISM;nan
ETHANOL;ADH1A;C;rs1229976;LADME_PK;METABOLISM;nan
URSODEOXYCHOLIC ACID;MGAT5;TT;rs661899;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CHOLANGITIS
CLOPIDOGREL THIOL METABOLITE H4;CYP2C19;A;rs4244285;LADME_PK;EXPOSURE;nan
HEPATITIS VACCINES;IL13;T;rs1295686;EFFICACY;DECREASED_RESPONSE;nan
PHENPROCOUMON;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED_DOSE;nan
PHENPROCOUMON;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED_DOSE;nan
TACROLIMUS;ABCB1;AA;rs1045642;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:RHEUMATOID_ARTHRITIS
PEGINTERFERON ALFA-2B;CYP27B1;GT + TT;rs10877012;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;CYP27B1;GT + TT;rs10877012;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
DABIGATRAN;CES1;AA + AG;rs8192935;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
IRINOTECAN;VDR;TT;rs11574077;LADME_PK;INCREASED_METABOLISM;DISEASE:COLORECTAL_NEOPLASMS
METHYLPHENIDATE;ADGRL3;AA;rs1868790;EFFICACY;DECREASED_RESPONSE;DISEASE:ADHD
METHYLPHENIDATE;SNAP25;GG + GT;rs3746544;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
METHYLPHENIDATE;SLC6A3;CC + CT;rs2550948;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
PHENPROCOUMON;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
ATORVASTATIN;SLCO1B1;C;rs4149056;LADME_PK;INCREASED_EXPOSURE;nan
INTERFERONS;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
INTERFERONS;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
MORPHINE;SLC22A1;AA + AG;rs34059508;LADME_PK;DECREASED_CLEARANCE;nan
METHYLPHENIDATE;ADRA2A;G;rs1800544;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
PLATINUM;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;nan;A;rs10514475;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSION
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;PLCB1;A;rs6108160;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSION
WARFARIN;LRP1;TT;rs1800139;DOSAGE;INCREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
METHYLPHENIDATE;ADRA2A;GG;rs1800544;EFFICACY;DECREASED_RESPONSE;DISEASE:ADHD
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED_DOSE;nan
WARFARIN;CYP4F2;T;rs2108622;EFFICACY;INCREASED_DOSE;nan
WARFARIN;LRP1;CC;rs1800154;DOSAGE;INCREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
NICOTINE;CYP2A6;T;rs56113850;LADME_PK;DECREASED_CLEARANCE;nan
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
INTERFERONS;IFNL3;GG;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;GG;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PHENPROCOUMON;VKORC1;AA + AG;rs2359612;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
METHYLPHENIDATE;COMT;GG;rs4680;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED_DOSE;nan
WARFARIN;CYP4F2;T;rs2108622;EFFICACY;INCREASED_DOSE;nan
PLATINUM COMPOUNDS;XRCC1;G;rs1799782;EFFICACY;DECREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
MORPHINE;SLC22A1;TT;rs12208357;LADME_PK;DECREASED_CLEARANCE;OTHER:ADENOTONSILLECTOMY
PHENPROCOUMON;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
METHYLPHENIDATE;ADRA2A;GG;rs1800544;EFFICACY;DECREASED_RESPONSE;DISEASE:ADHD
FLUOROURACIL;LGR5;CC + CT;rs17109924;EFFICACY;INCREASED_RESPONSE;DISEASE:COLONIC_NEOPLASMS
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;LADME_PK;INCREASED_CONCENTRATIONS;nan
MORPHINE;SLC22A1;AA;rs34059508;LADME_PK;DECREASED_CLEARANCE;OTHER:ADENOTONSILLECTOMY
METHYLPHENIDATE;COMT;AA + AG;rs4680;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
MORPHINE;SLC22A1;AA;rs34130495;LADME_PK;DECREASED_CLEARANCE;OTHER:ADENOTONSILLECTOMY
ATORVASTATIN;KIF6;AA + AC;rs9462535;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
PRAVASTATIN;KIF6;AA + AC;rs9462535;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
CAPECITABINE;MTHFR;AA + AG;rs1801133;DOSAGE;DECREASED_DOSE;OTHER:NEOPLASMS
FLUOROURACIL;MTHFR;AA + AG;rs1801133;DOSAGE;DECREASED_DOSE;OTHER:NEOPLASMS
ROSUVASTATIN;ABCG2;AG + GG;rs1481012;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
SOMATROPIN RECOMBINANT;CDK4;CC;rs2069502;EFFICACY;DECREASED_RESPONSE;DISEASE:TURNER_SYNDROME
ATORVASTATIN;KIF6;AG + GG;rs9471077;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
PRAVASTATIN;KIF6;AG + GG;rs9471077;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
METFORMIN;FMO5;A;rs7541245;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
METHYLPHENIDATE;ADGRL3;A;rs6858066;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
METHYLPHENIDATE;ADGRL3;C;rs1947274;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;DECREASED_RESPONSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ROSUVASTATIN;USP24;CC + CT;rs17111584;EFFICACY;DECREASED_RESPONSE;nan
METHYLPHENIDATE;ADGRL3;G;rs6551665;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
METHYLPHENIDATE;ADGRL3;G;rs2345039;EFFICACY;DECREASED_RESPONSE;DISEASE:ADHD
METHYLPHENIDATE;ADGRL3;G;rs6858066;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
METHYLPHENIDATE;ADGRL3;C;rs1947274;EFFICACY;DECREASED_RESPONSE;DISEASE:ADHD
METHYLPHENIDATE;SLC6A2;GG;rs5569;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
INTERFERON BETA-1A;RORA;TT;rs4774388;EFFICACY;INCREASED_RESPONSE;OTHER:MULTIPLE_SCLEROSIS
METHYLPHENIDATE;SLC6A2;AT + TT;rs28386840;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
METHYLPHENIDATE;ADGRL3;G;rs6551665;EFFICACY;DECREASED_RESPONSE;DISEASE:ADHD
REMIMAZOLAM;CES1;CT + TT;rs71647871;LADME_PK;DECREASED_METABOLISM;nan
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
NICOTINE;nan;T;rs113288603;LADME_PK;DECREASED_CLEARANCE;nan
ROSUVASTATIN;APOE;CC + CT;rs71352238;EFFICACY;DECREASED_RESPONSE;nan
METHYLPHENIDATE;ADRA2A;GG;rs1800544;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
NICOTINE;nan;A;rs12461964;LADME_PK;DECREASED_CLEARANCE;nan
ROSUVASTATIN;APOE;CT + TT;rs7412;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
METHYLPHENIDATE;ADRA2A;CG + GG;rs1800544;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
IDARUBICIN;NCF4;AA;rs1883112;EFFICACY;INCREASED_RESPONSE;DISEASE:MYELOID_ACUTE_LEUKEMIA
SIMVASTATIN;ABCC2;CT + TT;rs717620;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
IDARUBICIN;RAC2;AT;rs13058338;EFFICACY;INCREASED_RESPONSE;DISEASE:MYELOID_ACUTE_LEUKEMIA
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:MYELOPROLIFERATIVE_DISORDER
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:MYELOPROLIFERATIVE_DISORDER
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:MYELOPROLIFERATIVE_DISORDER
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:MYELOPROLIFERATIVE_DISORDER
ROSUVASTATIN;LPA;AG + GG;rs10455872;EFFICACY;DECREASED_RESPONSE;nan
ATORVASTATIN;UGT1A1;T;rs887829;LADME_PK;INCREASED_METABOLISM;nan
ATORVASTATIN;UGT1A10;T;rs887829;LADME_PK;INCREASED_METABOLISM;nan
ATORVASTATIN;UGT1A3;T;rs887829;LADME_PK;INCREASED_METABOLISM;nan
ATORVASTATIN;UGT1A4;T;rs887829;LADME_PK;INCREASED_METABOLISM;nan
ATORVASTATIN;UGT1A5;T;rs887829;LADME_PK;INCREASED_METABOLISM;nan
ATORVASTATIN;UGT1A6;T;rs887829;LADME_PK;INCREASED_METABOLISM;nan
ATORVASTATIN;UGT1A7;T;rs887829;LADME_PK;INCREASED_METABOLISM;nan
ATORVASTATIN;UGT1A8;T;rs887829;LADME_PK;INCREASED_METABOLISM;nan
ATORVASTATIN;UGT1A9;T;rs887829;LADME_PK;INCREASED_METABOLISM;nan
METHYLPHENIDATE;BDNF;CC;rs6265;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
EFAVIRENZ;CYP2B6;GG + GT;rs3745274;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
IVACAFTOR;CFTR;AA + AG;rs78655421;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
ATORVASTATIN;CYP3A7;G;rs45446698;LADME_PK;INCREASED_METABOLISM;nan
ATALUREN;CFTR;A;rs77010898;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
METHYLPHENIDATE;GRM7;CT;rs3792452;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
CLOZAPINE;CYP1A2;AA;rs762551;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:SCHIZOPHRENIA | OTHER:TOBACCO_USE_DISORDER
EFAVIRENZ;CYP2B6;G;rs2279343;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;T;rs2279345;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
ATORVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
PRAVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
METHYLPHENIDATE;ADGRL3;AG + GG;rs6551665;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
ATALUREN;CFTR;T;rs113993959;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
METHYLPHENIDATE;COMT;GG;rs4680;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
EFAVIRENZ;ABCB1;AG;rs1045642;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
SOMATROPIN RECOMBINANT;CDK4;TT;rs2270777;EFFICACY;INCREASED_RESPONSE;DISEASE:GROWTH_HORMONE_DEFICIENCY
IVACAFTOR;CFTR;AG;rs78655421;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
METHYLPHENIDATE;ADRA2A;G;rs1800544;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
ATALUREN;CFTR;T;rs75039782;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
ACENOCOUMAROL;VKORC1;CT;rs9923231;DOSAGE;DECREASED_DOSE;nan
METFORMIN;PRPF31;C;rs254271;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
GABAPENTIN;SLC7A5;AG;rs4240803;DOSAGE;INCREASED_DOSE;OTHER:NEUROPATHIC_PAIN
ATALUREN;CFTR;A;rs77010898;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
METFORMIN;NBEA;C;rs57081354;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
METFORMIN;SLC22A1;AA + AG;rs628031;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
CYCLOPHOSPHAMIDE;CYP2B6;GT + TT;rs3745274;EFFICACY;INCREASED_RESPONSE;OTHER:LUPUS_NEPHRITIS
DRUGS USED IN DIABETES;IRS1;CT + TT;rs1801278;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
FLUOROURACIL;XRCC1;CC;rs25487;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
LEUCOVORIN;XRCC1;CC;rs25487;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
OXALIPLATIN;XRCC1;CC;rs25487;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
METHOTREXATE;MTRR;A;rs1801394;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
SALBUTAMOL;DUSP1;G;rs881152;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
FLUOROURACIL;ERCC1;GG;rs11615;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
LEUCOVORIN;ERCC1;GG;rs11615;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
OXALIPLATIN;ERCC1;GG;rs11615;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
HYDROCHLOROTHIAZIDE;NEDD4L;A;rs4149601;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
METFORMIN;SLC22A1;AC + CC;rs622342;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
WARFARIN;CYP4F2;CT;rs2108622;DOSAGE;INCREASED_DOSE;nan
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED_RESPONSE;DISEASE:MYELOPROLIFERATIVE_DISORDER
PEGINTERFERON ALFA-2B;IFNL3;AA;rs12980275;EFFICACY;INCREASED_RESPONSE;DISEASE:MYELOPROLIFERATIVE_DISORDER
EMTRICITABINE;ABCC2;TT;rs2273897;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE | OTHER:PREGNANCY
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
ATALUREN;CFTR;T;rs113993959;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
GABAPENTIN;SLC7A5;AG;rs4240803;EFFICACY;DECREASED_RESPONSE;OTHER:NEUROPATHIC_PAIN
PREGABALIN;SLC7A5;AG;rs4240803;EFFICACY;DECREASED_RESPONSE;OTHER:NEUROPATHIC_PAIN
METHOTREXATE;SLC19A1;CT + TT;rs1051266;TOXICITY;DECREASED_DISCONTINUATION;DISEASE:RHEUMATOID_ARTHRITIS
MORPHINE;COMT;AA;rs4680;DOSAGE;DECREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
MORPHINE;COMT;AA;rs4680;EFFICACY;DECREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
METFORMIN;CPA6;T;rs2162145;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
SALBUTAMOL;DUSP1;G;rs881152;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
IVACAFTOR;CFTR;AA + AG;rs75527207;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
MIGALASTAT;GLA;T;rs372966991;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
TACROLIMUS;CYP3A4;CC;rs2242480;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LUNG_TRANSPLANTATION
MIGALASTAT;GLA;T;rs869312146;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
WARFARIN;VKORC1;AA + AC;rs61742245;DOSAGE;INCREASED_DOSE;nan
TRAMADOL;SLC22A1;A;rs34059508;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
TACROLIMUS;SLCO1B3;GG + GT;rs4149117;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LUNG_TRANSPLANTATION
MIGALASTAT;GLA;G;rs397515870;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
ESCITALOPRAM;IL11;CT + TT;rs1126757;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSION
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED_DOSE;nan
CLOPIDOGREL;CES1;CT + TT;rs2307240;EFFICACY;INCREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
MIGALASTAT;GLA;G;rs398123223;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
MIGALASTAT;GLA;A;rs190347120;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
TACROLIMUS;SLC2A2;CC;rs1499821;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LUNG_TRANSPLANTATION
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED_DOSE;nan
MIGALASTAT;GLA;T;rs28935490;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
ABIRATERONE;YBX1;AC + CC;rs10493112;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PROSTATIC_NEOPLASMS
TACROLIMUS;NFATC4;CC + CT;rs1955915;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LUNG_TRANSPLANTATION
GRAZOPREVIR;SLCO1B1;C;rs4149056;LADME_PD;INCREASED_EXPOSURE;OTHER:CHRONIC_HEPATITIS_C
BISOPROLOL;CYP2D6;CC;rs1080985;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:CARDIOVASCULAR_DISEASE
GRAZOPREVIR;SLCO1B1;A;rs11045819;LADME_PD;INCREASED_EXPOSURE;OTHER:CHRONIC_HEPATITIS_C
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;C;rs9923231;LADME_PK;INCREASED_STEADY_STATE CONCENTRATION;nan
WARFARIN;VKORC1;C;rs9923231;LADME_PK;INCREASED_DOSE;nan
MIGALASTAT;GLA;T;rs398123212;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
WARFARIN;nan;AA + AG;rs12777823;DOSAGE;DECREASED_DOSE;nan
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
MIGALASTAT;GLA;C;rs398123217;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
METHADONE;BDNF;C;rs7127507;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
METHADONE;BDNF-AS;C;rs7127507;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
O-DESMETHYLTRAMADOL;SLC22A1;T;rs12208357;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:PAIN
MIGALASTAT;GLA;G;rs397515874;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
MIGALASTAT;GLA;G;rs727505292;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
ENALAPRIL;NOS3;CC + CT;rs2070744;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
METHADONE;BDNF;G;rs11030118;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
METHADONE;BDNF-AS;G;rs11030118;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
MIGALASTAT;GLA;C;rs869312399;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
WARFARIN;VKORC1;AG + GG;rs2359612;DOSAGE;INCREASED_DOSE;nan
WARFARIN;CYP2C9;T;rs7089580;DOSAGE;DECREASED_DOSE;nan
MIGALASTAT;GLA;T;rs104894828;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED_DOSE;nan
METHADONE;BDNF;C;rs1967554;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
METHADONE;BDNF-AS;C;rs1967554;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
WARFARIN;VKORC1;CG + GG;rs8050894;DOSAGE;DECREASED_DOSE;nan
BISOPROLOL;CYP2D6;G;rs1080985;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_CORONARY_SYNDROME
MIGALASTAT;GLA;T;rs398123226;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
MIGALASTAT;GLA;C;rs398123226;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED_DOSE;nan
METHADONE;BDNF;G;rs2030324;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
MIGALASTAT;GLA;T;rs727504348;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
BISOPROLOL;CYP2D6;CT + TT;rs3892097;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_CORONARY_SYNDROME
BUSULFAN;GSTA1;AA;rs3957357;LADME_PK;INCREASED_CLEARANCE;DISEASE:TRANSPLANTATION
O-DESMETHYLTRAMADOL;SLC22A1;A;rs34130495;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:PAIN
O-DESMETHYLTRAMADOL;SLC22A1;A;rs34059508;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:PAIN
ENALAPRIL;BDKRB2;TT;rs1799722;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
METHADONE;BDNF;C;rs988748;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
O-DESMETHYLTRAMADOL;SLC22A1;C;rs55918055;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:PAIN
WARFARIN;VKORC1;A;rs61742245;DOSAGE;INCREASED_DOSE;nan
MIGALASTAT;GLA;C;rs869312136;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
TRAMADOL;SLC22A1;C;rs55918055;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
MIGALASTAT;GLA;T;rs28935195;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
METHADONE;BDNF;G;rs11030119;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LUNG_TRANSPLANTATION
TRAMADOL;SLC22A1;T;rs12208357;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
MIGALASTAT;GLA;A;rs104894827;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
FENTANYL;CYP3A4;T;rs2242480;DOSAGE;DECREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
FENTANYL;CYP3A4;T;rs2242480;EFFICACY;DECREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
MIGALASTAT;GLA;C;rs869312138;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
CELECOXIB;CYP2C9;CC;rs1057910;LADME_PK;DECREASED_METABOLISM;nan
BISOPROLOL;CYP3A5;TT;rs776746;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ACUTE_CORONARY_SYNDROME
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED_DOSE;nan
TRAMADOL;SLC22A1;A;rs34130495;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
MIGALASTAT;GLA;T;rs1569304898;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1A;AA;rs4149570;EFFICACY;INCREASED_RESPONSE;DISEASE:CROHN_DISEASE | DISEASE:INFLAMMATORY_BOWEL_DISEASES
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR4;AA + AG;rs5030728;EFFICACY;INCREASED_RESPONSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
METFORMIN;SLC47A1;CT + TT;rs8065082;EFFICACY;INCREASED_RESPONSE;OTHER:GLUCOSE_INTOLERANCE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;TT;rs4696480;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED_DOSE;nan
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNG;AA + AT;rs2430561;EFFICACY;INCREASED_RESPONSE;DISEASE:CROHN_DISEASE | DISEASE:INFLAMMATORY_BOWEL_DISEASES
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;TT;rs352139;EFFICACY;DECREASED_RESPONSE;DISEASE:CROHN_DISEASE | DISEASE:INFLAMMATORY_BOWEL_DISEASES
WARFARIN;VKORC1L1;AA;rs4072879;DOSAGE;DECREASED_DOSE;nan
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;CC + CT;rs3804099;EFFICACY;INCREASED_RESPONSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;CT + TT;rs1816702;EFFICACY;INCREASED_RESPONSE;DISEASE:CROHN_DISEASE
TACROLIMUS;CYP3A4;A;rs35599367;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
SUFENTANIL;OPRM1;G;rs1799971;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
OPIOIDS;ENPP2;AA;rs2249015;DOSAGE;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
DONEPEZIL;APOE;CC + CT;rs429358;EFFICACY;DECREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
GALANTAMINE;APOE;CC + CT;rs429358;EFFICACY;DECREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
RIVASTIGMINE;APOE;CC + CT;rs429358;EFFICACY;DECREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
ROSIGLITAZONE;PAX4;AA + AG;rs6467136;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
ROSIGLITAZONE;PAX4;AA + AG;rs6467136;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
ATORVASTATIN;APOE;CT;rs429358;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
OPIOIDS;ABCB1;AA;rs1045642;DOSAGE;DECREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
OPIOIDS;ABCB1;AA;rs1045642;EFFICACY;DECREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL6;CC + CT;rs10499563;EFFICACY;INCREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS | DISEASE:INFLAMMATORY_BOWEL_DISEASES
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL17A;AA + AG;rs2275913;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS | DISEASE:INFLAMMATORY_BOWEL_DISEASES
LATANOPROST;ABCC4;AC;rs11568658;EFFICACY;DECREASED_RESPONSE;DISEASE:OPEN-ANGLE_GLAUCOMA
ADALIMUMAB;TNFRSF1B;GG + GT;rs1061622;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
ETANERCEPT;TNFRSF1B;GG + GT;rs1061622;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
INFLIXIMAB;TNFRSF1B;GG + GT;rs1061622;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
USTEKINUMAB;TNFRSF1B;GG + GT;rs1061622;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CNPY4;CC + CT;rs1554973;EFFICACY;DECREASED_RESPONSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
BOTULINUM TOXIN TYPE A;CALCA;G;rs3781719;EFFICACY;DECREASED_RESPONSE;OTHER:MIGRAINE_DISORDER
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CD14;AA + AG;rs2569190;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;AA + AC;rs11938228;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS | DISEASE:INFLAMMATORY_BOWEL_DISEASES
BOTULINUM TOXIN TYPE A;TRPV1;A;rs222749;EFFICACY;DECREASED_RESPONSE;OTHER:MIGRAINE_DISORDER
OPIOIDS;ENPP2;AA;rs7832704;DOSAGE;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1B;AA + AG;rs4848306;EFFICACY;INCREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS | DISEASE:INFLAMMATORY_BOWEL_DISEASES
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1RN;CC + CT;rs4251961;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;CG + GG;rs6927172;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS | DISEASE:INFLAMMATORY_BOWEL_DISEASES
HMG COA REDUCTASE INHIBITORS;APOE;CC;rs429358;EFFICACY;INCREASED_RESPONSE;OTHER:ALZHEIMER_DISEASE
LOSARTAN;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
PEMETREXED;FOLR3;CT + TT;rs61734430;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA | DISEASE:MESOTHELIOMA
PEGINTERFERON ALFA-2A;IFNL3;AC + CC;rs4803217;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;AC + CC;rs4803217;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
METOPROLOL;GRK4;CT;rs1801058;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSIVE_NEPHROSCLEROSIS
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HIV_INFECTIOUS_DISEASE
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HIV_INFECTIOUS_DISEASE
FLUOXETINE;HTR2A;GG;rs7997012;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;GG;rs1800629;EFFICACY;INCREASED_RESPONSE;DISEASE:INFLAMMATION
DIRECT ACTING ANTIVIRALS;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CHRONIC_HEPATITIS_C
DIRECT ACTING ANTIVIRALS;IFNL4;GG + GT;rs8099917;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CHRONIC_HEPATITIS_C
ELBASVIR;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CHRONIC_HEPATITIS_C
ELBASVIR;IFNL4;GG + GT;rs8099917;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CHRONIC_HEPATITIS_C
GRAZOPREVIR;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CHRONIC_HEPATITIS_C
GRAZOPREVIR;IFNL4;GG + GT;rs8099917;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CHRONIC_HEPATITIS_C
LEDIPASVIR;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CHRONIC_HEPATITIS_C
LEDIPASVIR;IFNL4;GG + GT;rs8099917;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CHRONIC_HEPATITIS_C
SOFOSBUVIR;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CHRONIC_HEPATITIS_C
SOFOSBUVIR;IFNL4;GG + GT;rs8099917;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CHRONIC_HEPATITIS_C
METOPROLOL;GRK4;GT + TT;rs2960306;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSIVE_NEPHROSCLEROSIS
TACROLIMUS;ABCC2;CT + TT;rs3740066;LADME_PK;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;ABCC2;CT + TT;rs3740066;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
METHOTREXATE;ABCC2;CT + TT;rs717620;LADME_PK;INCREASED_CLEARANCE;DISEASE:LYMPHOMA
TACROLIMUS;ABCC2;CT + TT;rs717620;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
METOPROLOL;GRK4;CC;rs1024323;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSIVE_NEPHROSCLEROSIS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;CC;rs1799724;EFFICACY;INCREASED_RESPONSE;DISEASE:INFLAMMATION
WARFARIN;CYP2C19;T;rs3814637;OTHER;DECREASED_CLEARANCE;nan
WARFARIN;CYP2C19;T;rs3814637;LADME_PK;DECREASED_CLEARANCE;nan
METHADONE;GAD1;G;rs3762556;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
WARFARIN;CYP3A4;CT;rs2242480;OTHER;INCREASED_CLEARANCE;nan
WARFARIN;CYP3A4;CT;rs2242480;LADME_PK;INCREASED_CLEARANCE;nan
INFLIXIMAB;IL1B;GG;rs1143634;EFFICACY;DECREASED_RESPONSE;DISEASE:CROHN_DISEASE
METHADONE;GAD1;TT;rs769404;DOSAGE;DECREASED_DOSE;OTHER:HEROIN_DEPENDENCE
CLOZAPINE;CYP1A2;AA + AC;rs762551;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
ACENOCOUMAROL;VKORC1;GG;rs9934438;DOSAGE;INCREASED_DOSE;nan
CAPECITABINE;DPYD;AT;rs67376798;DOSAGE;DECREASED_DOSE;DISEASE:COLORECTAL_NEOPLASMS
CLOZAPINE;UGT1A4;C;rs2011404;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA | OTHER:PSYCHOTIC_DISORDER
CAPECITABINE;DPYD;CT;rs3918290;DOSAGE;DECREASED_DOSE;DISEASE:COLORECTAL_NEOPLASMS
URIC ACID;VEGFC;C;rs1002976;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HYPERTENSION
LETERMOVIR;SLCO1B1;TT;rs4149032;LADME_PK;DECREASED_EXPOSURE;nan
CLOZAPINE;UGT1A1;T;rs34946978;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA | OTHER:PSYCHOTIC_DISORDER
METFORMIN;CAPN10;G;rs3792269;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
LETERMOVIR;SLCO1B1;CC + CT;rs4149056;LADME_PK;INCREASED_EXPOSURE;nan
LETERMOVIR;UGT1A1;AA + AG;rs4148323;LADME_PK;INCREASED_EXPOSURE;nan
INTERFERON BETA-1A;FHIT;C;rs760316;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
INTERFERON BETA-1B;FHIT;C;rs760316;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
GLYBURIDE;FMO2;T;rs7512785;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
METHOTREXATE;MTRR;AG + GG;rs1801394;EFFICACY;INCREASED_RESPONSE;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS
PROPRANOLOL;ADRB2;GG;rs1042713;EFFICACY;INCREASED_RESPONSE;DISEASE:LIVER_CIRRHOSIS
METHOTREXATE;ABCB1;AA;rs1128503;EFFICACY;INCREASED_RESPONSE;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS
METHOTREXATE;ABCB1;AA;rs1045642;EFFICACY;INCREASED_RESPONSE;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS
CLOZAPINE;ABCB1;G;rs10248420;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA | OTHER:PSYCHOTIC_DISORDER
METHOTREXATE;SLC16A7;A;rs3763980;EFFICACY;DECREASED_RESPONSE;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS
PEGINTERFERON ALFA-2A;IFNL3;C;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_B | CHRONIC
PEGINTERFERON ALFA-2A;IFNL4;C;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_B | CHRONIC
PEGINTERFERON ALFA-2B;IFNL3;C;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_B | CHRONIC
PEGINTERFERON ALFA-2B;IFNL4;C;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_B | CHRONIC
METHOTREXATE;SLC16A7;T;rs12231740;EFFICACY;DECREASED_RESPONSE;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS
METHOTREXATE;ARID5B;CC;rs4948496;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CLOZAPINE;UGT1A1;A;rs4148323;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA | OTHER:PSYCHOTIC_DISORDER
FENOFIBRATE;APOE;CT + TT;rs7412;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
METHOTREXATE;SLCO1B1;TT;rs4149056;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
PEGINTERFERON ALFA-2A;IFNL3;T;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_B | CHRONIC
PEGINTERFERON ALFA-2A;IFNL4;T;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_B | CHRONIC
PEGINTERFERON ALFA-2B;IFNL3;T;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_B | CHRONIC
PEGINTERFERON ALFA-2B;IFNL4;T;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_B | CHRONIC
METHADONE;GAD1;G;rs3762555;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;DECREASED_RESPONSE;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS
METHADONE;GAD1;G;rs3749034;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
CLOZAPINE;ABCB1;A;rs7787082;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA | OTHER:PSYCHOTIC_DISORDER
IGURATIMOD;NAT2;AG + GG;rs1495741;EFFICACY;DECREASED_CLINICAL BENEFIT;DISEASE:RHEUMATOID_ARTHRITIS
INTERFERON BETA-1A;nan;T;rs4278350;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
INTERFERON BETA-1B;nan;T;rs4278350;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
SITAGLIPTIN;KCNQ1;GG + GT;rs163184;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
VILDAGLIPTIN;KCNQ1;GG + GT;rs163184;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
IGURATIMOD;ABCG2;GT + TT;rs2231142;EFFICACY;INCREASED_CLINICAL BENEFIT;DISEASE:RHEUMATOID_ARTHRITIS
INTERFERON BETA-1A;GAPVD1;G;rs2291858;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
INTERFERON BETA-1B;GAPVD1;G;rs2291858;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
METHADONE;OPRD1;GG;rs204047;DOSAGE;INCREASED_DOSE;nan
METHADONE;OPRD1;AA;rs797397;LADME_PK;INCREASED_CONCENTRATIONS;nan
METHADONE;OPRD1;GG;rs204047;LADME_PK;INCREASED_CONCENTRATIONS;nan
ANTIPSYCHOTICS;ZNF804A;AA;rs1344706;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
PLATINUM COMPOUNDS;XRCC1;CC + CT;rs25487;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
INTERFERON BETA-1A;GAPVD1;T;rs10819043;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
INTERFERON BETA-1B;GAPVD1;T;rs10819043;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
INTERFERON BETA-1A;nan;A;rs3133084;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
INTERFERON BETA-1B;nan;A;rs3133084;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
CAPECITABINE;CYP1A1;AG + GG;rs1048943;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
DOCETAXEL;CYP1A1;AG + GG;rs1048943;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
GLYBURIDE;CYP51A1;G;rs7793861;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
INTERFERON BETA-1A;nan;G;rs1448673;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
INTERFERON BETA-1B;nan;G;rs1448673;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
GLYBURIDE;FMO2;T;rs7515157;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
ANASTROZOLE;ABCB1;AA;rs2032582;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
AMISULPRIDE;HTR1A;TT;rs10042486;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;HTR1A;TT;rs10042486;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
OLANZAPINE;HTR1A;TT;rs10042486;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
QUETIAPINE;HTR1A;TT;rs10042486;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
RISPERIDONE;HTR1A;TT;rs10042486;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
URIC ACID;BRINP3;T;rs950569;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HYPERTENSION
GLYBURIDE;UGT2B15;G;rs4148269;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
INTERFERON BETA-1A;GAPVD1;C;rs10760397;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
INTERFERON BETA-1B;GAPVD1;C;rs10760397;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
URIC ACID;PADI4;G;rs2477134;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HYPERTENSION
INTERFERON BETA-1A;ZNF697;A;rs10494227;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
INTERFERON BETA-1B;ZNF697;A;rs10494227;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
DOXORUBICIN;ABCC5;TT;rs1533682;LADME_PK;INCREASED_CLEARANCE;DISEASE:BREAST_NEOPLASMS
PLATINUM COMPOUNDS;XRCC3;AA + AG;rs861539;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
GLYBURIDE;MAPK1;A;rs1803545;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
GLYBURIDE;ABCC5;A;rs3749442;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
GLYBURIDE;SPINK5;T;rs2303070;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
GLYBURIDE;BDKRB2;A;rs5224;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
GLYBURIDE;MAPK1;G;rs3729910;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
IGURATIMOD;ABCB1;CT + TT;rs2032582;EFFICACY;INCREASED_CLINICAL BENEFIT;DISEASE:RHEUMATOID_ARTHRITIS
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED_DOSE;nan
ETHANOL;KLB;A;rs11940694;TOXICITY;DECREASED_DOSE;nan
PLATINUM COMPOUNDS;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
GLYBURIDE;ESR1;T;rs2077647;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs1800629;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS | OTHER:AUTOIMMUNE_DISEASES | OTHER:PSORIASIS
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
ANTIDEPRESSANTS;BDNF;C;rs6265;EFFICACY;INCREASED_RESISTANCE;nan
FLUNISOLIDE;TBXT;TT;rs2305089;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
GRANISETRON;ERCC1;AC + CC;rs3212986;EFFICACY;INCREASED_RESPONSE;SIDE_EFFECT:NAUSEA | SIDE_EFFECT:VOMITING
PALONOSETRON;ERCC1;AC + CC;rs3212986;EFFICACY;INCREASED_RESPONSE;SIDE_EFFECT:NAUSEA | SIDE_EFFECT:VOMITING
TACROLIMUS;IL6;GG;rs1800795;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:KIDNEY_TRANSPLANTATION
VALPROIC ACID;CYP2D6;CT + TT;rs3892097;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;T;rs1061622;EFFICACY;INCREASED_RESPONSE;OTHER:PSORIASIS
TACROLIMUS;IL6;GG;rs1800795;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;C;rs1799724;EFFICACY;INCREASED_RESPONSE;OTHER:PSORIASIS
TACROLIMUS;CYP3A4;GG;rs4646437;LADME_PK;INCREASED_EXPOSURE;DISEASE:KIDNEY_TRANSPLANTATION
RASAGILINE;DRD2;CC;rs1076560;EFFICACY;INCREASED_RESPONSE;DISEASE:PARKINSON_DISEASE
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_EXPOSURE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;CC;rs2242480;LADME_PK;INCREASED_EXPOSURE;DISEASE:KIDNEY_TRANSPLANTATION
RASAGILINE;DRD2;CC;rs2283265;EFFICACY;INCREASED_RESPONSE;DISEASE:PARKINSON_DISEASE
TACROLIMUS;CYP3A4;GG;rs4646437;LADME_PK;INCREASED_EXPOSURE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CTLA4;AG + GG;rs4553808;LADME_PK;INCREASED_EXPOSURE;DISEASE:KIDNEY_TRANSPLANTATION
ANTIDEPRESSANTS;BDNF-AS;T;rs10501087;EFFICACY;INCREASED_RESISTANCE;nan
TACROLIMUS;IL3;AA;rs181781;LADME_PK;INCREASED_EXPOSURE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:LIVER_TRANSPLANTATION
LAMOTRIGINE;UGT1A4;CC;rs6755571;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:EPILEPSY
WARFARIN;CYP2C9;C;rs4917639;DOSAGE;DECREASED_DOSE;nan
TELAPREVIR;CYP24A1;C;rs2585428;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:HEPATITIS_C
TACROLIMUS;CTLA4;AA;rs4553808;LADME_PK;INCREASED_EXPOSURE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;CC;rs2242480;LADME_PK;INCREASED_EXPOSURE;DISEASE:KIDNEY_TRANSPLANTATION
VARENICLINE;CHRNA4;GG;rs1044396;EFFICACY;DECREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
ESCITALOPRAM;CYP1A2;T;rs4646425;LADME_PK;INCREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ESCITALOPRAM;CYP1A2;G;rs2069526;LADME_PK;INCREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ESCITALOPRAM;CYP1A2;C;rs4646427;LADME_PK;INCREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PLATINUM COMPOUNDS;HSPA5;TT;rs430397;EFFICACY;INCREASED_RESISTANCE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;A;rs1801274;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;C;rs396991;EFFICACY;INCREASED_RESPONSE;OTHER:SPONDYLARTHROPATHIES
EFAVIRENZ;CYP2B6;GG;rs2279343;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
MORPHINE;ABCB1;AA;rs1045642;LADME_PK;INCREASED_METABOLISM;nan
CLOPIDOGREL;P2RY12;AA + AG;rs6785930;EFFICACY;INCREASED_RESISTANCE;nan
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;GT;rs3745274;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
CLOPIDOGREL;P2RY12;AA + AC;rs6809699;EFFICACY;INCREASED_RESISTANCE;nan
EFAVIRENZ;CYP2B6;AG;rs2279343;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs361525;EFFICACY;INCREASED_RESPONSE;OTHER:PSORIASIS
FLUTICASONE PROPIONATE;ORMDL3;AA + AG;rs2872507;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED_DOSE;nan
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
RITUXIMAB;FCGR3A;AC + CC;rs396991;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
ABATACEPT;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
RITUXIMAB;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
TOCILIZUMAB;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;AG + GG;rs1801274;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
VALPROIC ACID;CYP2C9;AC;rs1057910;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:EPILEPSY
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CALU;G;rs339097;DOSAGE;INCREASED_DOSE;nan
ATAZANAVIR;SLCO1B1;CC + CT;rs4149056;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
RITONAVIR;SLCO1B1;CC + CT;rs4149056;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
DEFERASIROX;ABCG2;CT + TT;rs13120400;LADME_PK;INCREASED_EXPOSURE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
ATAZANAVIR;CYP3A5;CC;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
RITONAVIR;CYP3A5;CC;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;CYP2C9;T;rs10509680;DOSAGE;DECREASED_DOSE;nan
ADALIMUMAB;VDR;AA + AC;rs7975232;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
CERTOLIZUMAB PEGOL;VDR;AA + AC;rs7975232;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
ETANERCEPT;VDR;AA + AC;rs7975232;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
GOLIMUMAB;VDR;AA + AC;rs7975232;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
INFLIXIMAB;VDR;AA + AC;rs7975232;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
ANTIEPILEPTICS;NR3C1;GG;rs41423247;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
TACROLIMUS;CYP3A5;CT;rs776746;EFFICACY;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT;rs776746;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
DEFERASIROX;ABCC2;AG;rs2273697;LADME_PK;INCREASED_EXPOSURE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;DECREASED_METABOLISM;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
FLUVASTATIN;APOE;CT;rs7412;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
METFORMIN;SLC47A1;A;rs2289669;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
LAMOTRIGINE;UGT2B7;TT;rs7439366;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:EPILEPSY
TACROLIMUS;CYP3A4;CC + CT;rs2740574;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;CC + CT;rs2740574;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
RITODRINE;PDE4B;AA;rs598961;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PREMATURE_BIRTH
TACROLIMUS;CYP3A4;G;rs4986910;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;G;rs4986910;LADME_PK;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED_DOSE;nan
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED_DOSE;nan
LAMOTRIGINE;UGT2B15;AA;rs1902023;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:EPILEPSY
PLATINUM COMPOUNDS;XPA;CC;rs1800975;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
ARIPIPRAZOLE;ABCB1;CC;rs2032582;LADME_PK;INCREASED_CONCENTRATIONS;nan
DEHYDROARIPIPRAZOLE;ABCB1;CC;rs2032582;LADME_PK;INCREASED_CONCENTRATIONS;nan
ARIPIPRAZOLE;ABCB1;GG;rs1045642;LADME_PK;INCREASED_CONCENTRATIONS;nan
DEHYDROARIPIPRAZOLE;ABCB1;GG;rs1045642;LADME_PK;INCREASED_CONCENTRATIONS;nan
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
ARIPIPRAZOLE;ABCB1;GG;rs1128503;LADME_PK;INCREASED_CONCENTRATIONS;nan
DEHYDROARIPIPRAZOLE;ABCB1;GG;rs1128503;LADME_PK;INCREASED_CONCENTRATIONS;nan
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;IL10;AA;rs1800871;LADME_PK;DECREASED_METABOLISM;OTHER:KIDNEY_TRANSPLANTATION
ANTIHYPERTENSIVES;MMP9;CT;rs3918242;EFFICACY;DECREASED_RESPONSE;DISEASE:GESTATIONAL_HYPERTENSION
HYDRALAZINE;MMP9;CT;rs3918242;EFFICACY;DECREASED_RESPONSE;DISEASE:GESTATIONAL_HYPERTENSION
METHYLDOPA;MMP9;CT;rs3918242;EFFICACY;DECREASED_RESPONSE;DISEASE:GESTATIONAL_HYPERTENSION
NIFEDIPINE;MMP9;CT;rs3918242;EFFICACY;DECREASED_RESPONSE;DISEASE:GESTATIONAL_HYPERTENSION
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;T;rs1799853;EFFICACY;DECREASED_DOSE;nan
WARFARIN;CYP2C9;T;rs1799853;TOXICITY;DECREASED_DOSE;nan
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DOSE;nan
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;DOSE;nan
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;C;rs1057910;EFFICACY;DECREASED_DOSE;nan
WARFARIN;CYP2C9;C;rs1057910;TOXICITY;DECREASED_DOSE;nan
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED_DOSE;OTHER:RHEUMATIC_HEART_DISEASE | OTHER:ATRIAL_FIBRILLATION | OTHER:HEART_VALVE_DISEASES | OTHER:CORONARY_ARTERY_DISEASE
DACLATASVIR;VDR;TT;rs11568820;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:HEPATITIS_C
MORPHINE;COMT;AG + GG;rs4680;EFFICACY;INCREASED_DOSE;nan
CLOMIPRAMINE;CYP2D6;CG;rs1080985;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
METHYLDOPA;MMP9;CT + TT;rs3918242;EFFICACY;DECREASED_RESPONSE;DISEASE:GESTATIONAL_HYPERTENSION
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DOSE;nan
DACLATASVIR;CYP24A1;CT + TT;rs2248359;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEPATITIS_C
WARFARIN;VKORC1;A;rs9923231;DOSAGE;DOSE;nan
TACROLIMUS;ABCB1;AG + GG;rs1045642;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
CARBAMAZEPINE;SCN1A;TT;rs3812718;EFFICACY;RESISTANCE;DISEASE:EPILEPSY
OXCARBAZEPINE;SCN1A;TT;rs3812718;EFFICACY;RESISTANCE;DISEASE:EPILEPSY
METOPROLOL;ADRB1;AA;rs1801252;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
METOPROLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
ELEXACAFTOR;CFTR;C;rs139304906;EFFICACY;INCREASED_CLINICAL BENEFIT;nan
TEZACAFTOR;CFTR;C;rs139304906;EFFICACY;INCREASED_CLINICAL BENEFIT;nan
IVACAFTOR;CFTR;C;rs139304906;EFFICACY;INCREASED_CLINICAL BENEFIT;nan
CALCIUM CHANNEL BLOCKERS;NUMA1;GG;rs10898815;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
CARBAMAZEPINE;SCN1A;TT;rs3812718;EFFICACY;RESISTANCE;DISEASE:EPILEPSY
OXCARBAZEPINE;SCN1A;TT;rs3812718;EFFICACY;RESISTANCE;DISEASE:EPILEPSY
CALCIUM CHANNEL BLOCKERS;TANC2;GG;rs2429427;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
SIBUTRAMINE;GNB3;CC;rs5443;EFFICACY;INCREASED_RESPONSE;OTHER:OBESITY
CARBAMAZEPINE;ABCC2;AG;rs2273697;EFFICACY;RESISTANCE;DISEASE:EPILEPSY
OXCARBAZEPINE;ABCC2;AG;rs2273697;EFFICACY;RESISTANCE;DISEASE:EPILEPSY
METHOTREXATE;ABCC2;AG;rs765027508;LADME_PK;INCREASED_EXPOSURE;OTHER:B-CELL_LYMPHOMA
BUSULFAN;GSTA1;T;rs3957356;LADME_PK;DECREASED_CLEARANCE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
S-EDDP;CYP2B6;CT;rs8192709;LADME_PK;INCREASED_CONCENTRATIONS;nan
BUSULFAN;GSTA1;A;rs3957357;LADME_PK;DECREASED_CLEARANCE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
SIMVASTATIN;UGT1A9;T;rs12052787;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
SIMVASTATIN;UGT1A9;A;rs2003569;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
PLATINUM COMPOUNDS;ERCC4;TT;rs1799801;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
PLATINUM COMPOUNDS;ERCC1;AA + AG;rs11615;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
AMITRIPTYLINE;CYP2D6;TT;rs3892097;DOSAGE;DECREASED_DOSE;DISEASE:DEPRESSION
AMITRIPTYLINE;CYP2D6;TT;rs3892097;EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
CLOMIPRAMINE;CYP2D6;TT;rs3892097;DOSAGE;DECREASED_DOSE;DISEASE:DEPRESSION
CLOMIPRAMINE;CYP2D6;TT;rs3892097;EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
DOXEPIN;CYP2D6;TT;rs3892097;DOSAGE;DECREASED_DOSE;DISEASE:DEPRESSION
DOXEPIN;CYP2D6;TT;rs3892097;EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
IMIPRAMINE;CYP2D6;TT;rs3892097;DOSAGE;DECREASED_DOSE;DISEASE:DEPRESSION
IMIPRAMINE;CYP2D6;TT;rs3892097;EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
MAPROTILINE;CYP2D6;TT;rs3892097;DOSAGE;DECREASED_DOSE;DISEASE:DEPRESSION
MAPROTILINE;CYP2D6;TT;rs3892097;EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
NORTRIPTYLINE;CYP2D6;TT;rs3892097;DOSAGE;DECREASED_DOSE;DISEASE:DEPRESSION
NORTRIPTYLINE;CYP2D6;TT;rs3892097;EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
OPIPRAMOL;CYP2D6;TT;rs3892097;DOSAGE;DECREASED_DOSE;DISEASE:DEPRESSION
OPIPRAMOL;CYP2D6;TT;rs3892097;EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
PLATINUM COMPOUNDS;ERCC3;AG + GG;rs3738948;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
TEGAFUR;CYP2A6;AA + AG;rs8192720;LADME_PK;INCREASED_METABOLISM;nan
ANTIPSYCHOTICS;MTHFR;AG;rs1801133;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA
CHLORPROMAZINE;MTHFR;AG;rs1801133;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA
CLOZAPINE;MTHFR;AG;rs1801133;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA
HALOPERIDOL;MTHFR;AG;rs1801133;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA
OLANZAPINE;MTHFR;AG;rs1801133;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA
QUETIAPINE;MTHFR;AG;rs1801133;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA
RISPERIDONE;MTHFR;AG;rs1801133;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA
OXYCODONE;UGT2B7;TT;rs7439366;EFFICACY;DECREASED_RESPONSE;DISEASE:NEOPLASMS | DISEASE:PAIN
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED_DOSE;nan
BUPROPION;CYP2B6;T;rs3745274;LADME_PK;INCREASED_EXPOSURE;OTHER:MAJOR_DEPRESSIVE_DISORDER
RISPERIDONE;HRH4;TT;rs4483927;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ATENOLOL;GRK4;T;rs2960306;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
ATENOLOL;GRK4;T;rs1024323;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
CALCIUM CHANNEL BLOCKERS;PICALM;GG;rs588076;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
DELEOBUVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
DELEOBUVIR;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
FALDAPREVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
FALDAPREVIR;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
WARFARIN;CYP2C9;del;rs9332131;DOSAGE;DECREASED_DOSE;DISEASE:PULMONARY_EMBOLISM
WARFARIN;CYP2C9;del;rs9332131;EFFICACY;DECREASED_DOSE;DISEASE:PULMONARY_EMBOLISM
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;G;rs28371686;DOSAGE;DECREASED_DOSE;DISEASE:PULMONARY_EMBOLISM
WARFARIN;CYP2C9;G;rs28371686;EFFICACY;DECREASED_DOSE;DISEASE:PULMONARY_EMBOLISM
PROPOFOL;GABRA2;CC;rs11503014;OTHER;DECREASED_RESPONSE;nan
WARFARIN;HNF4A;T;rs3212198;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
CODEINE;CYP1B1;C;rs1056836;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PAIN
TRAMADOL;CYP1B1;C;rs1056836;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PAIN
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
GEFITINIB;EGFR;G;rs121434568;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
WARFARIN;NR1I3;TT;rs2501873;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
VERAPAMIL;PCDHB8;G;rs3733694;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MIGRAINE_DISORDER
RIVAROXABAN;POR;TT;rs1057868;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
VERAPAMIL;PCDHB6;A;rs17844444;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MIGRAINE_DISORDER
WARFARIN;VKORC1;T;rs72547529;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;T;rs72547529;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;T;rs72547529;DOSAGE;INCREASED_DOSE;nan
CAPECITABINE;KRAS;AC;rs61764370;EFFICACY;INCREASED_RESPONSE;DISEASE:RECTAL_NEOPLASMS
CETUXIMAB;KRAS;AC;rs61764370;EFFICACY;INCREASED_RESPONSE;DISEASE:RECTAL_NEOPLASMS
OXALIPLATIN;KRAS;AC;rs61764370;EFFICACY;INCREASED_RESPONSE;DISEASE:RECTAL_NEOPLASMS
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
SIMVASTATIN ACID;SLCO1B1;CT;rs4149056;LADME_PK;INCREASED_EXPOSURE;nan
LOSARTAN;AGTR1;AA;rs5186;EFFICACY;INCREASED_RESPONSE;DISEASE:LIVER_CIRRHOSIS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
HEROIN;OPRM1;AG;rs9479757;DOSAGE;INCREASED_DOSE;DISEASE:HEROIN_DEPENDENCE
5-HYDROXYINDOLE-3-ACETIC ACID;MAOB;T;rs1799836;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:MAJOR_DEPRESSIVE_DISORDER
SEROTONIN;MAOB;T;rs1799836;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:MAJOR_DEPRESSIVE_DISORDER
ANTIDEPRESSANTS;GRIK4;CC;rs1954787;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
RIVAROXABAN;ABCB1;CT;rs4148738;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
5-HYDROXYINDOLE-3-ACETIC ACID;MAOB;TT;rs1799836;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:MAJOR_DEPRESSIVE_DISORDER
SEROTONIN;MAOB;TT;rs1799836;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:MAJOR_DEPRESSIVE_DISORDER
APIXABAN;POR;T;rs1057868;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
OXCARBAZEPINE;UGT1A9;CC;rs2741049;EFFICACY;INCREASED_RESPONSE;DISEASE:SEIZURES
CODEINE;CYP1B1;A;rs1056837;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PAIN
TRAMADOL;CYP1B1;A;rs1056837;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PAIN
CANDESARTAN;CYP11B2;GG;rs1799998;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
3-HYDROXYCOTININE;nan;CC + CT;rs4105144;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:TOBACCO_USE_DISORDER
HYDROCODONE;CYP2D6;DELT;rs35742686;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PAIN
OXYCODONE;CYP2D6;DELT;rs35742686;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PAIN
3-HYDROXYCOTININE;EGLN2;AA + AG;rs3733829;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:TOBACCO_USE_DISORDER
HYDROCODONE;MACROD2;G;rs76026520;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PAIN
OXYCODONE;MACROD2;G;rs76026520;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PAIN
MERCAPTOPURINE;NUDT15;CT;rs116855232;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
BENAZEPRIL;MTHFR;AA;rs1801133;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
DEFERASIROX;CYP1A1;AC + CC;rs2606345;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
PITRAKINRA;IL4R;GG;rs1029489;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:LIVER_TRANSPLANTATION
CIPROFLOXACIN;CYP1A2;AA + AC;rs762551;nan;INCREASED_CLEARANCE;OTHER:INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
RADIOTHERAPY;CACNA2D3;AG + GG;rs11130424;EFFICACY;INCREASED_RESISTANCE;OTHER:NASOPHARYNGEAL_NEOPLASMS
HYDROXYUREA;MAP3K5;CC;rs9483947;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
ANTIHYPERTENSIVES;CLNK;G;rs13144136;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
HYDROXYUREA;MAP3K5;CC;rs9376230;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
IMATINIB;ABCB1;GG;rs1128503;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
IMATINIB;ABCB1;AA;rs1045642;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
ATORVASTATIN;ABCC2;CT + TT;rs717620;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
LENALIDOMIDE;FGF2;CG + GG;rs308395;EFFICACY;DECREASED_RESPONSE;DISEASE:MULTIPLE_MYELOMA
THALIDOMIDE;FGF2;CG + GG;rs308395;EFFICACY;DECREASED_RESPONSE;DISEASE:MULTIPLE_MYELOMA
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
METHOTREXATE;ABCC2;CT + TT;rs717620;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ANTIDEPRESSANTS;MAOA;AA;rs979605;LADME_PK;DECREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
METHOTREXATE;ABCB1;GG;rs1045642;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ANTIDEPRESSANTS;GRIK4;C;rs1954787;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ETHANOL;ALDH2;AG;rs671;OTHER;INCREASED_EXPOSURE;nan
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
HYDROCHLOROTHIAZIDE;NEDD4L;CC + CG;rs292449;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
PITRAKINRA;IL4R;GG;rs8832;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
TACROLIMUS;CYP3A5;T;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
PITRAKINRA;IL4R;AA;rs3024530;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
PITRAKINRA;IL4R;AA;rs1110470;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
PITRAKINRA;IL4R;AA;rs2239347;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
BENAZEPRIL;MTR;AG + GG;rs1805087;EFFICACY;DECREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
PITRAKINRA;IL4R;AA;rs1805010;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
VORICONAZOLE;ABCC2;CT + TT;rs717620;LADME_PK;INCREASED_TROUGH CONCENTRATION;nan
ACENOCOUMAROL;VKORC1;GG;rs9934438;DOSAGE;INCREASED_DOSE;nan
ACENOCOUMAROL;VKORC1;GG;rs9934438;TOXICITY;INCREASED_DOSE;nan
PHENPROCOUMON;VKORC1;GG;rs9934438;DOSAGE;INCREASED_DOSE;nan
PHENPROCOUMON;VKORC1;GG;rs9934438;TOXICITY;INCREASED_DOSE;nan
MYCOPHENOLATE MOFETIL;SLCO1B3;A;rs7311358;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
MORPHINE;ABCC3;CC;rs4793665;LADME_PK;INCREASED_METABOLISM;nan
PEGINTERFERON ALFA-2A;IFNL3;C;rs8105790;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;C;rs8105790;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
ATORVASTATIN;SLCO1B1;CT;rs4149056;LADME_PK;INCREASED_EXPOSURE;nan
PEGINTERFERON ALFA-2A;IFNL3;C;rs8103142;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;C;rs8103142;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
MEMANTINE;NR1I2;CT + TT;rs1523130;LADME_PK;DECREASED_CLEARANCE;DISEASE:DEMENTIA
BENAZEPRIL;ADRB2;AG + GG;rs1042713;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
PEGINTERFERON ALFA-2A;IFNL3;G;rs11881222;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;G;rs11881222;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL3;A;rs7248668;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;A;rs7248668;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
AMISULPRIDE;ANKS1B;CC;rs7968606;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
PEGINTERFERON ALFA-2A;IFNL3;C;rs28416813;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;C;rs28416813;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL3;C;rs4803219;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;C;rs4803219;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
MORPHINE;OPRM1;AG;rs1799971;DOSAGE;INCREASED_DOSE;DISEASE:NEOPLASMS
ESCITALOPRAM;nan;A;rs2069521;LADME_PK;INCREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
IMATINIB;CYP3A5;CC;rs776746;LADME_PK;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
ROSUVASTATIN;SCARB1;CC;rs4238001;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MYOCARDIAL_ISCHEMIA
IMATINIB;ABCB1;AA;rs1045642;LADME_PK;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
IMATINIB;CYP3A5;CC;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
LACOSAMIDE;ABCC2;GG;rs2273697;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:EPILEPSY
IMATINIB;ABCB1;AA;rs1045642;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED_RESPONSE;DISEASE:DYSLIPIDAEMIA
OLANZAPINE;SV2C;TT;rs11960832;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CORTICOSTEROIDS;TBX21;CG;rs2240017;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
METHOTREXATE;ABCC1;GG;rs2238476;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
ANTIDEPRESSANTS;HTR2A;AG + GG;rs6314;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
CARBAMAZEPINE;CYP2D6;A;rs1065852;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
LAMOTRIGINE;CYP2D6;A;rs1065852;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
PHENYTOIN;CYP2D6;A;rs1065852;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
PRIMIDONE;CYP2D6;A;rs1065852;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
VALPROIC ACID;CYP2D6;A;rs1065852;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
CARBAMAZEPINE;CYP2C9;C;rs9332120;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
LAMOTRIGINE;CYP2C9;C;rs9332120;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
PHENYTOIN;CYP2C9;C;rs9332120;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
PRIMIDONE;CYP2C9;C;rs9332120;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
VALPROIC ACID;CYP2C9;C;rs9332120;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
TACROLIMUS;CYP3A5;C;rs776746;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
CARBAMAZEPINE;CYP2D6;C;rs3892097;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
LAMOTRIGINE;CYP2D6;C;rs3892097;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
PHENYTOIN;CYP2D6;C;rs3892097;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
PRIMIDONE;CYP2D6;C;rs3892097;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
VALPROIC ACID;CYP2D6;C;rs3892097;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
CARBAMAZEPINE;CYP3A4;C;rs2740574;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
LAMOTRIGINE;CYP3A4;C;rs2740574;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
PHENYTOIN;CYP3A4;C;rs2740574;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
PRIMIDONE;CYP3A4;C;rs2740574;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
VALPROIC ACID;CYP3A4;C;rs2740574;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:LIVER_TRANSPLANTATION
CARBAMAZEPINE;CYP3A4;C;rs2687116;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
LAMOTRIGINE;CYP3A4;C;rs2687116;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
PHENYTOIN;CYP3A4;C;rs2687116;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
PRIMIDONE;CYP3A4;C;rs2687116;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
VALPROIC ACID;CYP3A4;C;rs2687116;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
DULOXETINE;ANO2;C;rs61908411;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;C;rs61908409;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;T;rs61908410;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;A;rs78615940;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;G;rs78482393;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;C;rs61908405;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;G;rs61908406;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ARG1;A;rs2781659;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
DULOXETINE;ANO2;C;rs61908404;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;A;rs61908408;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;A;rs61908407;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;G;rs17786412;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
DULOXETINE;ANO2;A;rs17786400;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
METHADONE;ABCB1;C;rs9282564;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
DULOXETINE;ANO2;G;rs61908403;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;T;rs61908402;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;C;rs17724452;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
GLATIRAMER ACETATE;PVT1;A;rs2114358;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
DULOXETINE;nan;G;rs7316769;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;C;rs17724494;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C9;CT;rs56165452;DOSAGE;DECREASED_DOSE;nan
METHADONE;ABCB1;A;rs1045642;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
DULOXETINE;ANO2;T;rs17786394;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;G;rs17724464;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
METHADONE;UGT2B7;CT;rs7439366;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
TENOFOVIR;ABCC4;TT;rs1751034;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED_DOSE;nan
PEMETREXED;CCND1;A;rs9344;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:LUNG_NEOPLASMS
PLATINUM COMPOUNDS;CCND1;A;rs9344;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:LUNG_NEOPLASMS
WARFARIN;VKORC1;A;rs2359612;DOSAGE;DECREASED_DOSE;nan
METOPROLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED_RESPONSE;DISEASE:HEART_FAILURE
WARFARIN;VKORC1;T;rs7294;DOSAGE;INCREASED_DOSE;nan
LIRAGLUTIDE;GLP1R;CT + TT;rs10305420;EFFICACY;DECREASED_RESPONSE;DISEASE:OBESITY | DISEASE:POLYCYSTIC_OVARY_SYNDROME
LAMOTRIGINE;CACNA1H;A;rs2753325;EFFICACY;INCREASED_CLINICAL BENEFIT;EFFICACY:EPILEPSY
AZATHIOPRINE;TPMT;nan;TPMT low activity;LADME_PK;DECREASED_DOSE;nan
FLUOROURACIL;DPYD;CT;rs3918290;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
FLUOROURACIL;DPYD;CC + CT;rs2297595;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
ASPIRIN;GP1BA;CT + TT;rs6065;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
FLUOROURACIL;DPYD;CT + TT;rs1801160;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
FLUOROURACIL;DPYD;GG;rs1801265;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
LACOSAMIDE;ABCC2;CC;rs717620;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:EPILEPSY
ANASTROZOLE;nan;G;rs11648166;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
LACOSAMIDE;ABCC2;A;rs2273697;EFFICACY;INCREASED_RESISTANCE;OTHER:EPILEPSY
LACOSAMIDE;ABCC2;T;rs717620;EFFICACY;INCREASED_RESISTANCE;OTHER:EPILEPSY
ANASTROZOLE;nan;T;rs28845026;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
CYCLOPHOSPHAMIDE;CYP2B6;C;rs4802101;LADME_PK;DECREASED_METABOLISM;DISEASE:LUPUS_ERYTHEMATOSUS
APIXABAN;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:ATRIAL_FIBRILLATION
METHOTREXATE;ARID5B;A;rs10994982;LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
OXYCODONE;OPRM1;AG + GG;rs1799971;EFFICACY;DECREASED_RESPONSE;OTHER:POSTOPERATIVE_PAIN
CYCLOPHOSPHAMIDE;CYP2C19;A;rs4244285;LADME_PK;DECREASED_METABOLISM;DISEASE:LUPUS_ERYTHEMATOSUS
IMATINIB;ABCB1;AG + GG;rs1045642;LADME_PK;INCREASED_TROUGH CONCENTRATION;OTHER:GASTROINTESTINAL_STROMAL_TUMORS
FENOFIBRATE;PPARA;GG;rs4253778;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
METHOTREXATE;SLC22A11;AT + TT;rs11231809;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;ABCC1;AG + GG;rs246240;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
HMG COA REDUCTASE INHIBITORS;HMGCR;AA;rs3846662;EFFICACY;DECREASED_RESPONSE;DISEASE:FAMILIAL_HYPERCHOLESTEROLEMIA
METHOTREXATE;ABCC1;AG + GG;rs3784864;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CYCLOPHOSPHAMIDE;CYP2C19;AG + GG;rs4244285;EFFICACY;DECREASED_RESPONSE;DISEASE:LUPUS_NEPHRITIS
4-HYDROXYCYCLOPHOSPHAMIDE;CYP3A5;CC + CT;rs776746;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:LUPUS_NEPHRITIS
CYCLOPHOSPHAMIDE;CYP2B6;C;rs7254579;LADME_PK;METABOLISM;DISEASE:LUPUS_ERYTHEMATOSUS
HMG COA REDUCTASE INHIBITORS;nan;A;rs445925;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;GT;rs3745274;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
HMG COA REDUCTASE INHIBITORS;LPA;G;rs10455872;EFFICACY;DECREASED_RESPONSE;nan
FENOFIBRATE;IL6;CC + CG;rs1800795;EFFICACY;INCREASED_RESPONSE;OTHER:PATIENTS_WITH_A_HIGH_RISK_OF_CARDIOVASCULAR_DISEASE
RANIBIZUMAB;NRP1;T;rs2070296;EFFICACY;DECREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
ATORVASTATIN;CETP;GG;rs708272;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
PEGINTERFERON ALFA-2A;MICB;CC;rs3828913;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;MICB;CC;rs3828913;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;MICB;CC;rs3828913;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
METHOTREXATE;ABCG2;CC;rs13120400;EFFICACY;INCREASED_RESPONSE;SIDE_EFFECT:PSORIASIS
NICOTINE;DBH;GG;rs77905;DOSAGE;DECREASED_DOSE;DISEASE:TOBACCO_USE_DISORDER
WARFARIN;VKORC1;CC + CT;rs9923231;DOSAGE;INCREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
NICOTINE;MAOA;TT;rs1137070;DOSAGE;INCREASED_DOSE;DISEASE:TOBACCO_USE_DISORDER
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED_DOSE;nan
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED_DOSE;nan
OMEPRAZOLE;ABCB1;AA;rs1045642;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
PANTOPRAZOLE;ABCB1;AA;rs1045642;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
DEFERASIROX;CYP24A1;TT;rs2248359;LADME_PK;METABOLISM;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
DEFERASIROX;VDR;AA;rs7975232;LADME_PK;METABOLISM;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
FLUVOXAMINE;HTR1A;TT;rs1364043;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
MILNACIPRAN;HTR1A;TT;rs1364043;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PAROXETINE;HTR1A;TT;rs1364043;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DEFERASIROX;VDR;G;rs2228570;LADME_PK;METABOLISM;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
ANTIPSYCHOTICS;GRM3;AA;rs6465084;TOXICITY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
METFORMIN;SLC47A1;AA;rs2289669;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
WARFARIN;CYP4F2;CC + CT;rs2108622;DOSAGE;DECREASED_DOSE;nan
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
METFORMIN;SLC47A1;AA;rs2289669;LADME_PK;DECREASED_CLEARANCE;DISEASE:DIABETES_MELLITUS_TYPE2
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED_DOSE;nan
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
BETA BLOCKING AGENTS;GRK5;AA + AT;rs2230345;EFFICACY;RESPONSE;DISEASE:HEART_FAILURE
EFAVIRENZ;CYP2B6;T;rs3745274;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;NR1I3;G;rs2307424;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;NR1I3;AG;rs2307424;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
ANTIHYPERTENSIVES;ATP2B1;CT + TT;rs12817819;EFFICACY;INCREASED_RESISTANCE;DISEASE:CORONARY_ARTERY_DISEASE | DISEASE:HYPERTENSION
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
WARFARIN;EPHX1;CT;rs1051741;DOSAGE;DECREASED_DOSE;nan
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8103142;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8103142;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8103142;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;AA;rs12980275;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED_DOSE;nan
PEGINTERFERON ALFA-2A;IFNL3;AA;rs11881222;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;AA;rs11881222;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;AA;rs11881222;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED_DOSE;nan
ISONIAZID;NAT2;AA;rs1799930;LADME_PK;INCREASED_EXPOSURE;DISEASE:HIV_INFECTIOUS_DISEASE | DISEASE:TUBERCULOSIS
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED_DOSE;nan
MERCAPTOPURINE;NUDT15;T;rs73189762;DOSAGE;DECREASED_DOSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
WARFARIN;PRSS53;CT;rs7294;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;CT;rs7294;DOSAGE;INCREASED_DOSE;nan
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
ISONIAZID;NR1I2;TT;rs2472677;LADME_PK;INCREASED_EXPOSURE;DISEASE:HIV_INFECTIOUS_DISEASE | DISEASE:TUBERCULOSIS
AMLODIPINE;CACNA1C;TT;rs2238032;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
FELODIPINE;CACNA1C;TT;rs2238032;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
ISONIAZID;SLCO1B1;CC;rs4149032;LADME_PK;DECREASED_EXPOSURE;DISEASE:HIV_INFECTIOUS_DISEASE | DISEASE:TUBERCULOSIS
CALCIUM CHANNEL BLOCKERS;CACNA1C;C;rs2239128;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
MORPHINE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED_DOSE;nan
GEFITINIB;EGFR;G;rs121434568;EFFICACY;RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
HMG COA REDUCTASE INHIBITORS;SLCO1B1;A;rs2900478;EFFICACY;DECREASED_RESPONSE;nan
CALCIUM CHANNEL BLOCKERS;CACNA1C;GG;rs2239050;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
HMG COA REDUCTASE INHIBITORS;CELSR2;C;rs646776;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
VALPROIC ACID;UGT2B7;GG;rs12233719;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
EFAVIRENZ;CYP2A6;T;rs28399454;LADME_PK;METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;T;rs3745274;LADME_PK;METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;C;rs28399499;LADME_PK;METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
CALCIUM CHANNEL BLOCKERS;CACNA1C;TT;rs2238032;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
EFAVIRENZ;CYP2B6;GT;rs3745274;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;DISEASE:VENOUS_THROMBOEMBOLISM
PHENPROCOUMON;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
EFAVIRENZ;CYP2B6;GG;rs2279343;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
ATAZANAVIR;ABCB1;GG;rs1045642;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;A;rs7900194;DOSAGE;DECREASED_DOSE;nan
EFAVIRENZ;CYP2B6;AG;rs2279343;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
VALPROIC ACID;UGT2B7;CT;rs7668258;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;G;rs28371686;DOSAGE;DECREASED_DOSE;nan
WARFARIN;APOC1;T;rs429358;DOSAGE;DECREASED_DOSE;OTHER:HAPLOTYPE_EPSILON2
WARFARIN;APOE;T;rs429358;DOSAGE;DECREASED_DOSE;OTHER:HAPLOTYPE_EPSILON2
VALPROIC ACID;UGT2B7;TT;rs7668258;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
WARFARIN;APOC1;T;rs7412;DOSAGE;DECREASED_DOSE;OTHER:HAPLOTYPE_EPSILON2
WARFARIN;APOE;T;rs7412;DOSAGE;DECREASED_DOSE;OTHER:HAPLOTYPE_EPSILON2
INFLIXIMAB;nan;CC + CT;rs2097432;EFFICACY;INCREASED_DISCONTINUATION;EFFICACY:CROHN_DISEASE
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED_DOSE;nan
PHOTODYNAMIC THERAPY;CFH;TT;rs1061170;EFFICACY;DECREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
VALPROIC ACID;UGT2B7;TT;rs7439366;LADME_PK;CONCENTRATIONS;DISEASE:EPILEPSY
RISPERIDONE;ABCG2;GT + TT;rs2231142;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;nan
FLUOXETINE;HTR1B;CC + TT;rs9361233;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
EFAVIRENZ;CYP2B6;CC;rs8192709;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
INFLIXIMAB;nan;T;rs73277969;EFFICACY;INCREASED_DISCONTINUATION;EFFICACY:CROHN_DISEASE
IVACAFTOR;CFTR;C;rs121908757;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;G;rs121909005;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
ASPIRIN;CYP2C19;A;rs4244285;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
ASPIRIN;CYP2C19;T;rs12248560;nan;INCREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
CLOPIDOGREL;CYP2C19;T;rs12248560;nan;INCREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
IVACAFTOR;CFTR;A;rs121908755;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
ASPIRIN;PEAR1;AC + CC;rs2768759;EFFICACY;DECREASED_RESPONSE;nan
PRASUGREL;PEAR1;AC + CC;rs2768759;EFFICACY;DECREASED_RESPONSE;nan
CYCLOSPORINE;ABCB1;AC + CC;rs2032582;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
ASPIRIN;PEAR1;AA + AG;rs12041331;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
CLOPIDOGREL;PEAR1;AA + AG;rs12041331;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
PRASUGREL;PEAR1;AA + AG;rs12041331;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
CYCLOSPORINE;CYP3A4;AG + GG;rs4646437;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
HYDRALAZINE;GNB3;TT;rs5443;EFFICACY;INCREASED_RESPONSE;DISEASE:HEART_FAILURE
ISOSORBIDE DINITRATE;GNB3;TT;rs5443;EFFICACY;INCREASED_RESPONSE;DISEASE:HEART_FAILURE
IVACAFTOR;CFTR;C;rs397508453;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
WARFARIN;VKORC1;T;rs72547529;EFFICACY;DECREASED_RESPONSE;nan
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;INCREASED_CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
IVACAFTOR;CFTR;A;rs121909013;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;C;rs121909041;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
TACROLIMUS;CYP3A4;T;rs2242480;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
ASPIRIN;CYP2C19;A;rs4244285;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
IVACAFTOR;CFTR;A;rs74503330;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
NEVIRAPINE;CYP1A2;CC;rs762551;EFFICACY;INCREASED_RESPONSE;DISEASE:HIV_INFECTIOUS_DISEASE
FENTANYL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED_RESPONSE;DISEASE:PAIN
ANASTROZOLE;CYP19A1;AA;rs4646;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS | DISEASE:MENOPAUSE
LETROZOLE;CYP19A1;AA;rs4646;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS | DISEASE:MENOPAUSE
TAMOXIFEN;CYP19A1;AA;rs4646;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS | DISEASE:MENOPAUSE
IVACAFTOR;CFTR;A;rs267606723;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
SEROTONIN;ERICH3;T;rs696692;OTHER;DECREASED_CONCENTRATIONS;DISEASE:DEPRESSIVE_DISORDER
IVACAFTOR;CFTR;A;rs80282562;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
TACROLIMUS;ABCB1;AG + GG;rs1045642;DOSAGE;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
CYCLOSPORINE;CYP3A4;AG + GG;rs4646437;EFFICACY;INCREASED_RESPONSE;DISEASE:KIDNEY_TRANSPLANTATION
ANASTROZOLE;CYP19A1;AA;rs4646;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
LETROZOLE;CYP19A1;AA;rs4646;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
TAMOXIFEN;CYP19A1;AA;rs4646;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
PLATINUM COMPOUNDS;ERCC2;CT + TT;rs1799793;EFFICACY;INCREASED_RESISTANCE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA
SEROTONIN;TSPAN5;G;rs11947402;OTHER;DECREASED_CONCENTRATIONS;DISEASE:DEPRESSIVE_DISORDER
NEVIRAPINE;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED_DOSE;nan
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TRAF1;G;rs3761847;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
THALIDOMIDE;CTNNB1;AA;rs4533622;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_MYELOMA
WARFARIN;VKORC1;AG;rs9934438;DOSAGE;INCREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION | DISEASE:CARDIOMYOPATHIES | DISEASE:HEART_VALVE_REPLACEMENT | DISEASE:PERIPHERAL_VASCULAR_DISEASES | DISEASE:PULMONARY_EMBOLISM | DISEASE:VENOUS_THROMBOSIS
FENTANYL;OPRM1;AG + GG;rs1799971;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
IVACAFTOR;CFTR;A;rs193922525;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
CYCLOPHOSPHAMIDE;CTNNB1;AA;rs4135385;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_MYELOMA
DEXAMETHASONE;CTNNB1;AA;rs4135385;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_MYELOMA
THALIDOMIDE;CTNNB1;AA;rs4135385;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_MYELOMA
OPIOIDS;IL17A;A;rs2275913;DOSAGE;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
OPIOIDS;IL17A;A;rs2275913;EFFICACY;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
PLATINUM COMPOUNDS;CYP1A1;CC + CT;rs1048943;EFFICACY;INCREASED_RESISTANCE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA
WARFARIN;CYP4F2;C;rs2108622;DOSAGE;DECREASED_DOSE;DISEASE:VENOUS_THROMBOEMBOLISM
TACROLIMUS;ABCB1;AC + CC;rs2032582;DOSAGE;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;DISEASE:VENOUS_THROMBOEMBOLISM
ANTIDEPRESSANTS;ERICH3;C;rs11580409;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
CITALOPRAM;ERICH3;C;rs11580409;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
ESCITALOPRAM;ERICH3;C;rs11580409;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
ETHANOL;OPRM1;AG + GG;rs1799971;OTHER;DECREASED_DOSE;nan
CYCLOSPORINE;ABCB1;AC + CC;rs2032582;DOSAGE;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A7;TT;rs10211;LADME_PK;INCREASED_CONCENTRATIONS;OTHER
WARFARIN;VKORC1;C;rs9923231;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;C;rs9923231;EFFICACY;INCREASED_DOSE;nan
WARFARIN;VKORC1;T;rs9923231;DOSAGE;INCREASED_RESPONSE;nan
WARFARIN;VKORC1;T;rs9923231;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
TACROLIMUS;ABCB1;GG;rs1045642;LADME_PK;INCREASED_DOSE;OTHER:LIVER_TRANSPLANTATION
ACETAMINOPHEN;OPRM1;AA;rs1799971;EFFICACY;INCREASED_RESPONSE;DISEASE:NEUROPATHIC_PAIN
TRAMADOL;OPRM1;AA;rs1799971;EFFICACY;INCREASED_RESPONSE;DISEASE:NEUROPATHIC_PAIN
RITUXIMAB;FCGR2A;AA;rs1801274;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHADONE;CYP2B6;T;rs3745274;LADME_PK;DECREASED_CLEARANCE;DISEASE:OPIOID-RELATED_DISORDERS
COTININE;UGT2B10;CC;rs2942857;LADME_PK;DECREASED_CLEARANCE;DISEASE:TOBACCO_USE_DISORDER
FENTANYL;nan;GG;rs6961071;EFFICACY;INCREASED_RESPONSE;DISEASE:POSTOPERATIVE_PAIN
RITUXIMAB;FCGR3A;AC + CC;rs396991;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
WARFARIN;VKORC1;G;rs2359612;DOSAGE;INCREASED_DOSE;nan
CYCLOPHOSPHAMIDE;ALDH1A1;AG + GG;rs13959;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BREAST_NEOPLASMS
DOXORUBICIN;ALDH1A1;AG + GG;rs13959;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BREAST_NEOPLASMS
FEC100;ALDH1A1;AG + GG;rs13959;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BREAST_NEOPLASMS
FLUOROURACIL;ALDH1A1;AG + GG;rs13959;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BREAST_NEOPLASMS
TACROLIMUS;POR;CC;rs1057868;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
COUMARIN;CYP2A6;TT;rs1801272;OTHER;DECREASED_METABOLISM;nan
COUMARIN;CYP2A6;TT;rs1801272;LADME_PK;DECREASED_METABOLISM;nan
COUMARIN;CYP2A6;TT;rs1801272;LADME_PK;DECREASED_METABOLISM;nan
METHADONE;ABCB1;CC;rs2032582;LADME_PK;DECREASED_CLEARANCE;DISEASE:OPIOID-RELATED_DISORDERS
NICOTINE;CYP2A6;G;rs5031016;LADME_PK;DECREASED_METABOLISM;nan
TOCILIZUMAB;FCGR3A;AA;rs396991;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CARVEDILOL;ADRB2;GG;rs1042714;EFFICACY;INCREASED_RESPONSE;DISEASE:HEART_FAILURE
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
FENTANYL;nan;GG;rs13093031;EFFICACY;INCREASED_RESPONSE;DISEASE:POSTOPERATIVE_PAIN
ATORVASTATIN;CYP3A5;CC;rs776746;EFFICACY;INCREASED_RESPONSE;DISEASE:ARTERIOSCLEROSIS
LOVASTATIN;CYP3A5;CC;rs776746;EFFICACY;INCREASED_RESPONSE;DISEASE:ARTERIOSCLEROSIS
SIMVASTATIN;CYP3A5;CC;rs776746;EFFICACY;INCREASED_RESPONSE;DISEASE:ARTERIOSCLEROSIS
COTININE;UGT2B10;CC;rs2942857;LADME_PK;INCREASED_EXPOSURE;DISEASE:TOBACCO_USE_DISORDER
CLOPIDOGREL;ABCB1;A;rs1045642;EFFICACY;INCREASED_RESPONSE;OTHER:ACUTE_CORONARY_SYNDROME
CISPLATIN;ERCC1;A;rs11615;EFFICACY;DECREASED_RESPONSE;OTHER:OVARIAN_NEOPLASMS
WARFARIN;VKORC1;C;rs2884737;DOSAGE;DECREASED_DOSE;nan
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
WARFARIN;PRSS53;TT;rs7294;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;TT;rs7294;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED_DOSE;nan
PHENOBARBITAL;ABCB1;GG;rs1045642;EFFICACY;INCREASED_RESISTANCE;DISEASE:EPILEPSY
TACROLIMUS;FMO3;CC;rs1800822;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
FENOFIBRATE;CRP;TT;rs1417938;EFFICACY;INCREASED_RESPONSE;DISEASE:METABOLIC_SYNDROME
PRAVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED_RESPONSE;DISEASE:DYSLIPIDAEMIA
IVACAFTOR;CFTR;T;rs397508442;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
FLUOXETINE;HTR1B;CC + TT;rs9361235;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
N-DESMETHYLCLOZAPINE;UGT2B10;T;rs61750900;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
WARFARIN;NQO1;GG;rs10517;DOSAGE;DECREASED_DOSE;nan
FENOFIBRATE;CRP;AG + GG;rs3091244;EFFICACY;INCREASED_RESPONSE;DISEASE:METABOLIC_SYNDROME
PRAVASTATIN;MMP3;A/del + AA;rs35068180;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
N-DESMETHYLCLOZAPINE;UGT1A4;G;rs2011425;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
FENOFIBRATE;CRP;GG + GT;rs3091244;EFFICACY;INCREASED_RESPONSE;DISEASE:METABOLIC_SYNDROME
FENTANYL;ABCB1;AA;rs1128503;EFFICACY;DECREASED_RESPONSE;DISEASE:NEOPLASMS | DISEASE:PAIN
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED_DOSE;DISEASE:CARDIOVASCULAR_DISEASE
CLOZAPINE;CYP2C18;T;rs1126545;LADME_PK;DECREASED_METABOLISM;OTHER:SCHIZOPHRENIA
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED_DOSE;nan
SIMVASTATIN;SLCO1B1;C;rs4149056;EFFICACY;DECREASED_RESPONSE;nan
DESLORATADINE;FCER1A;AA;rs2298805;EFFICACY;INCREASED_RESPONSE;DISEASE:URTICARIA
MIZOLASTINE;FCER1A;AA;rs2298805;EFFICACY;INCREASED_RESPONSE;DISEASE:URTICARIA
ATORVASTATIN;CYP3A5;TT;rs17161788;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
PEGINTERFERON ALFA-2B;IFNL3;G;rs8099917;EFFICACY;DECREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;G;rs8099917;EFFICACY;DECREASED_RESPONSE;DISEASE:HEPATITIS_C
CAPECITABINE;SELE;CC;rs3917412;EFFICACY;DECREASED_RESPONSE;DISEASE:COLONIC_NEOPLASMS
FLUOROURACIL;SELE;CC;rs3917412;EFFICACY;DECREASED_RESPONSE;DISEASE:COLONIC_NEOPLASMS
LEUCOVORIN;SELE;CC;rs3917412;EFFICACY;DECREASED_RESPONSE;DISEASE:COLONIC_NEOPLASMS
OXALIPLATIN;SELE;CC;rs3917412;EFFICACY;DECREASED_RESPONSE;DISEASE:COLONIC_NEOPLASMS
ATORVASTATIN;CYP3A5;CC;rs776746;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
OPIOIDS;nan;CC;rs2952768;EFFICACY;DECREASED_RESPONSE;OTHER:POSTOPERATIVE_PAIN
HMG COA REDUCTASE INHIBITORS;PCSK9;T;rs11591147;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
IMATINIB;CYP3A4;AG;rs28371759;EFFICACY;INCREASED_RESPONSE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
DIGOXIN;ABCB1;CC;rs2032582;LADME_PK;INCREASED_CLEARANCE;DISEASE:HEART_FAILURE
CAPECITABINE;MTHFR;AA;rs1801133;EFFICACY;DECREASED_RESPONSE;DISEASE:COLONIC_NEOPLASMS
FLUOROURACIL;MTHFR;AA;rs1801133;EFFICACY;DECREASED_RESPONSE;DISEASE:COLONIC_NEOPLASMS
LEUCOVORIN;MTHFR;AA;rs1801133;EFFICACY;DECREASED_RESPONSE;DISEASE:COLONIC_NEOPLASMS
OXALIPLATIN;MTHFR;AA;rs1801133;EFFICACY;DECREASED_RESPONSE;DISEASE:COLONIC_NEOPLASMS
PLATINUM;ERCC5;GG;rs17655;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
ELEXACAFTOR;CFTR;AG + GG;rs75389940;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
TEZACAFTOR;CFTR;AG + GG;rs75389940;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;AG + GG;rs75389940;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;AG + GG;rs75389940;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
TEZACAFTOR;CFTR;AG + GG;rs75389940;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
CARVEDILOL;UGT2B7;T;rs12233719;LADME_PK;DECREASED_CLEARANCE;DISEASE:HEART_DISEASES
BUPROPION;CHRNA5;AA + AG;rs2036527;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
NICOTINE;CHRNA5;AA + AG;rs2036527;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
VARENICLINE;CHRNA5;AA + AG;rs2036527;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
BUPROPION;CHRNA5;AA + AG;rs16969968;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
NICOTINE;CHRNA5;AA + AG;rs16969968;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
VARENICLINE;CHRNA5;AA + AG;rs16969968;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
CARVEDILOL;UGT2B7;G;rs28365063;LADME_PK;DECREASED_CLEARANCE;DISEASE:HEART_DISEASES
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;FMO3;CC;rs909530;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
DIGOXIN;ABCB1;AA + AT;rs2032582;LADME_PK;DECREASED_CLEARANCE;DISEASE:HEART_FAILURE
LUMACAFTOR;CFTR;AA;rs121909047;EFFICACY;RESPONSE;nan
METHADONE;CDH2;AA;rs8094439;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
PERTUSSIS VACCINES;TLR4;AA;rs4986790;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
TACROLIMUS;POR;CT + TT;rs1057868;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED_RESPONSE;nan
METHADONE;CDH2;CC;rs17446819;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED_DOSE;nan
SORAFENIB;ABCG2;CT;rs2231137;LADME_PK;CONCENTRATIONS;DISEASE:HEPATOCELLULAR_CARCINOMA
NICOTINE;CYP2A6;CT + TT;rs376817657;LADME_PK;DECREASED_METABOLISM;nan
SORAFENIB;ABCG2;GT;rs2231142;LADME_PK;CONCENTRATIONS;DISEASE:HEPATOCELLULAR_CARCINOMA
IVACAFTOR;CFTR;A;rs397508602;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
IMATINIB;SLC22A1;CC;rs683369;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
FENOFIBRATE;GCKR;CT + TT;rs780094;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
IVACAFTOR;CFTR;T;rs121909011;EFFICACY;RESPONSE;nan
LUMACAFTOR;CFTR;T;rs121909011;EFFICACY;RESPONSE;nan
IMATINIB;ABCB1;GG;rs1045642;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED_RESPONSE;nan
FENTANYL;OPRM1;GG;rs1799971;DOSAGE;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
FENTANYL;OPRM1;GG;rs1799971;EFFICACY;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
IVACAFTOR;CFTR;A;rs74551128;EFFICACY;RESPONSE;nan
LUMACAFTOR;CFTR;A;rs74551128;EFFICACY;RESPONSE;nan
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED_DOSE;nan
BILIRUBIN;UGT1A1;TT;rs887829;LADME_PK;INCREASED_CONCENTRATIONS;nan
WARFARIN;CYP2C9;CT;rs1799853;DOSAGE;DECREASED_DOSE;nan
METHOTREXATE;GGH;AA + AG;rs3758149;EFFICACY;INCREASED_RESPONSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MERCAPTOPURINE;NUDT15;A;rs186364861;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
FENOFIBRATE;APOA5;AG + GG;rs662799;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
IMIQUIMOD;TLR7;A;rs179008;EFFICACY;INCREASED_RESPONSE;DISEASE:BASAL_CELL_CARCINOMA
MERCAPTOPURINE;NUDT15;T;rs116855232;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
METHOTREXATE;GGH;CC + CT;rs11545077;EFFICACY;INCREASED_RESPONSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;T;rs9923231;OTHER;DECREASED_DOSE;nan
FENOFIBRATE;APOA5;CG + GG;rs3135506;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
CLONIDINE;GNB3;CT + TT;rs5443;EFFICACY;INCREASED_RESPONSE;DISEASE:LIVER_CIRRHOSIS
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
CLOZAPINE;UGT2B10;T;rs61750900;LADME_PK;DECREASED_METABOLISM;OTHER:SCHIZOPHRENIA
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
OPIOIDS;TAOK3;AG + GG;rs1277441;DOSAGE;INCREASED_DOSE;OTHER:NEOPLASMS | OTHER:PAIN
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
OPIOIDS;TAOK3;TT;rs795484;DOSAGE;DECREASED_RESPONSE;OTHER:NEOPLASMS | OTHER:PAIN
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
FENTANYL;OPRM1;GG;rs1799971;DOSAGE;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
WARFARIN;CYP2C9;T;rs1799853;LADME_PK;DECREASED_METABOLISM;nan
IVACAFTOR;CFTR;G;rs121909005;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
OPIOIDS;TAOK3;CT + TT;rs795484;DOSAGE;INCREASED_DOSE;OTHER:NEOPLASMS | OTHER:PAIN
FENTANYL;ABCB1;AA;rs1128503;DOSAGE;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
IVACAFTOR;CFTR;C;rs121908757;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
TENOFOVIR;ABCC4;AC + CC;rs3742106;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
VITAMIN B12 AND FOLIC ACID;MTHFR;A;rs1801133;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:HYPERHOMOCYSTEINEMIA | OTHER:STROKE
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_EXPOSURE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE;MTHFR;AA + AG;rs1801133;LADME_PK;INCREASED_EXPOSURE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CAPTOPRIL;AGTR1;AC + CC;rs5186;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTP1;A;rs1695;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED_RESPONSE;nan
DAUNORUBICIN;CBR1;CC;rs25678;LADME_PK;DECREASED_EXPOSURE;DISEASE:MYELOID_ACUTE_LEUKEMIA
IVACAFTOR;CFTR;A;rs78655421;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
MERCAPTOPURINE;TPMT;CC;rs1142345;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CITALOPRAM;CYP2C19;AG;rs4244285;EFFICACY;DECREASED_RESPONSE;OTHER:ALCOHOL_ABUSE | OTHER:MAJOR_DEPRESSIVE_DISORDER
BILIRUBIN;SLCO1B1;C;rs1910167;LADME_PK;INCREASED_CONCENTRATIONS;nan
BILIRUBIN;SLCO1B3;C;rs1910167;LADME_PK;INCREASED_CONCENTRATIONS;nan
BILIRUBIN;SLCO1B7;C;rs1910167;LADME_PK;INCREASED_CONCENTRATIONS;nan
CITALOPRAM;CYP2C19;AG;rs4244285;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ALCOHOL_ABUSE | OTHER:MAJOR_DEPRESSIVE_DISORDER
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
ATENOLOL;GNB3;CC;rs5443;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
ETANERCEPT;PSORS1C1;C;rs2233945;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
TACROLIMUS;POR;CT + TT;rs1057868;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
MERCAPTOPURINE;ABCC4;AA;rs2274407;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE | DISEASE:TUBERCULOSIS
DISULFIRAM;TPH2;AA + AT;rs4290270;EFFICACY;INCREASED_RESPONSE;OTHER:COCAINE_DEPENDENCE
ATENOLOL;GNB3;AA;rs11064426;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
ENALAPRIL;NR3C2;TT;rs5522;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
ATENOLOL;GNB3;GG;rs2301339;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
ATENOLOL;GNB3;CC;rs5443;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
MERCAPTOPURINE;NUDT15;TT;rs116855232;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ATENOLOL;GNB3;AA;rs11064426;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
ACENOCOUMAROL;CYP2C9;T;rs4086116;DOSAGE;DECREASED_DOSE;nan
ATENOLOL;GNB3;AA;rs11064426;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
ETANERCEPT;STAT4;T;rs7574865;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ATENOLOL;GNB3;GG;rs2301339;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
METHOTREXATE;GGH;AC + CC;rs11545076;EFFICACY;INCREASED_RESPONSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ALLOPURINOL;ABCG2;T;rs2231142;EFFICACY;DECREASED_RESPONSE;DISEASE:GOUT
PRAVASTATIN;SLCO1B1;AG;rs4149015;EFFICACY;DECREASED_RESPONSE;nan
PRAVASTATIN;SLCO1B1;AG;rs4149015;LADME_PK;DECREASED_RESPONSE;nan
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
TEZACAFTOR;CFTR;A;rs75527207;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERLIPIDEMIAS
HMG COA REDUCTASE INHIBITORS;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERLIPIDEMIAS
PRAVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERLIPIDEMIAS
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERLIPIDEMIAS
FENOFIBRATE;ABCA1;CT;rs2230806;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
SERTRALINE;HTR2A;AA + AG;rs6313;DOSAGE;INCREASED_DOSE;OTHER:DEPRESSION | OTHER:ANXIETY_DISORDERS
FENOFIBRATE;ABCA1;CC;rs2230808;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
PLATINUM COMPOUNDS;NUP107;C;rs79419059;EFFICACY;INCREASED_RESISTANCE;DISEASE:OVARIAN_NEOPLASMS
FENOFIBRATE;ABCA1;TT;rs2230806;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
VENLAFAXINE;COMT;AA + AG;rs4680;EFFICACY;INCREASED_RESPONSE;DISEASE:ANXIETY_DISORDERS
WARFARIN;NQO1;AA;rs1800566;DOSAGE;DECREASED_DOSE;nan
KETOPROFEN;CYP2C9;CC;rs1799853;EFFICACY;INCREASED_RESPONSE;OTHER:POSTOPERATIVE_PAIN
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION
ETANERCEPT;TNF;AG + GG;rs1800629;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ANTIDEPRESSANTS;CHL1;TT;rs1516338;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER | DISEASE:DEPRESSIVE_DISORDER | DISEASE:MAJOR_DEPRESSIVE_DISORDER
ADALIMUMAB;TANK;CC;rs1267067;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;AA;rs15524;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
ADALIMUMAB;VEGFA;T;rs25648;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
DACLATASVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
DACLATASVIR;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
CARVEDILOL;ADRB1;GG;rs1801253;DOSAGE;INCREASED_DOSE;DISEASE:HEART_FAILURE
TACROLIMUS;CYP3A5;GG;rs4646450;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
INFLIXIMAB;TNF;GG;rs361525;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;SLCO1B1;CC + CT;rs11045879;LADME_PK;INCREASED_EXPOSURE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A4;GG;rs4646437;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
HYDROCHLOROTHIAZIDE;VASP;AG + GG;rs10995;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
ADALIMUMAB;TNFAIP3;T;rs2230926;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
METHOTREXATE;SLC19A1;AA + AG;rs2838958;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
SIMVASTATIN;SLCO1B1;C;rs4149056;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HYPERCHOLESTEROLEMIA
SIMVASTATIN ACID;SLCO1B1;C;rs4149056;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HYPERCHOLESTEROLEMIA
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED_DOSE;nan
IVACAFTOR;CFTR;C;rs121908757;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
METHOTREXATE;SLC19A1;AG + GG;rs3788200;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
LITHIUM;NR1D1;T;rs2314339;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
LITHIUM;THRA;T;rs2314339;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED_DOSE;nan
NALTREXONE;OPRM1;AG;rs1799971;EFFICACY;INCREASED_RESPONSE;OTHER:AMPLIFICATION_OF_SEXUAL_BEHAVIOR | OTHER:PARKINSON_DISEASE
TACROLIMUS;CYP3A5;CT;rs776746;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED_DOSE;DISEASE:VENOUS_THROMBOEMBOLISM
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
ATENOLOL;GNB3;GG;rs2301339;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
BEVACIZUMAB;ERCC2;GG;rs13181;EFFICACY;INCREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
CAPECITABINE;ERCC2;GG;rs13181;EFFICACY;INCREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
CISPLATIN;ERCC2;GG;rs13181;EFFICACY;INCREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
DOCETAXEL;ERCC2;GG;rs13181;EFFICACY;INCREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
EPIRUBICIN;ERCC2;GG;rs13181;EFFICACY;INCREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
OXALIPLATIN;ERCC2;GG;rs13181;EFFICACY;INCREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
TRASTUZUMAB;ERCC2;GG;rs13181;EFFICACY;INCREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
ACENOCOUMAROL;APOE;C;rs429358;DOSAGE;DECREASED_DOSE;DISEASE:VENOUS_THROMBOEMBOLISM
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;CG + GG;rs8050894;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;AA + AG;rs2359612;DOSAGE;DECREASED_DOSE;nan
ATAZANAVIR;SORCS2;A;rs73208473;LADME_PK;DECREASED_EXPOSURE;DISEASE:HIV_INFECTIOUS_DISEASE
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;LADME_PK;INCREASED_CONCENTRATIONS;nan
BEVACIZUMAB;ERCC1;GG;rs11615;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
CAPECITABINE;ERCC1;GG;rs11615;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
CISPLATIN;ERCC1;GG;rs11615;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
DOCETAXEL;ERCC1;GG;rs11615;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
EPIRUBICIN;ERCC1;GG;rs11615;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
OXALIPLATIN;ERCC1;GG;rs11615;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
TRASTUZUMAB;ERCC1;GG;rs11615;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
BEVACIZUMAB;MTHFR;AA;rs1801133;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
CAPECITABINE;MTHFR;AA;rs1801133;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
CISPLATIN;MTHFR;AA;rs1801133;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
DOCETAXEL;MTHFR;AA;rs1801133;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
EPIRUBICIN;MTHFR;AA;rs1801133;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
OXALIPLATIN;MTHFR;AA;rs1801133;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
TRASTUZUMAB;MTHFR;AA;rs1801133;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
METHADONE;CNR1;CT + TT;rs806368;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
METHADONE;TPH2;GG;rs1386493;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
MORPHINE;UGT2B7;CT + TT;rs7439366;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:NEOPLASMS | OTHER:PAIN
ATORVASTATIN;KIF6;GG;rs20455;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
SIMVASTATIN;KIF6;GG;rs20455;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
EFAVIRENZ;CYP2B6;GG;rs35303484;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
METHADONE;CYP2B6;CT;rs16974799;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
LAMIVUDINE;ABCB1;A;rs1045642;EFFICACY;RESPONSE;DISEASE:HIV_INFECTIOUS_DISEASE
NEVIRAPINE;ABCB1;A;rs1045642;EFFICACY;RESPONSE;DISEASE:HIV_INFECTIOUS_DISEASE
METHADONE;OPRL1;CT;rs2229205;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
ROSUVASTATIN;KIF6;GG;rs20455;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
ADRENERGICS;nan;T;rs34548976;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
INHALANTS;nan;T;rs34548976;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
TOPIRAMATE;GRIK1;AA + AC;rs2832407;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:ALCOHOL-RELATED_DISORDERS
CISPLATIN;CDA;AA;rs2072671;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
GEMCITABINE;CDA;AA;rs2072671;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
TOPIRAMATE;GRIK1;AA + AC;rs2832407;EFFICACY;DECREASED_RESPONSE;DISEASE:ALCOHOL-RELATED_DISORDERS
LAMIVUDINE;ABCB1;A;rs2032582;EFFICACY;RESPONSE;DISEASE:HIV_INFECTIOUS_DISEASE
NEVIRAPINE;ABCB1;A;rs2032582;EFFICACY;RESPONSE;DISEASE:HIV_INFECTIOUS_DISEASE
ZIDOVUDINE;ABCB1;A;rs2032582;EFFICACY;RESPONSE;DISEASE:HIV_INFECTIOUS_DISEASE
ATORVASTATIN;KIF6;GG;rs20455;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
CISPLATIN;ERCC1;AA;rs11615;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
GEMCITABINE;ERCC1;AA;rs11615;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
FLUVASTATIN;ABCB1;AA;rs1922242;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
GLICLAZIDE;KCNQ1;CT + TT;rs2237897;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
WARFARIN;CYP4F11;G;rs1060467;DOSAGE;DECREASED_DOSE;nan
CARBOPLATIN;VEGFA;CC + CT;rs9369421;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
TAXANES;VEGFA;CC + CT;rs9369421;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
TACROLIMUS;CYP3A4;AA + AG;rs35599367;LADME_PK;DECREASED_CLEARANCE;OTHER:KIDNEY_TRANSPLANTATION
EFAVIRENZ;CYP2A6;AC;rs28399433;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
FLUVASTATIN;CETP;GG;rs4783961;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_CLEARANCE;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;ABCB1;CC + CT;rs9282564;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
METHOTREXATE;MTRR;AG + GG;rs1801394;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
TENOFOVIR;IFNL3;C;rs12979860;LADME_PK;INCREASED_CLEARANCE;OTHER:HIV_INFECTIOUS_DISEASE
TENOFOVIR;IFNL4;C;rs12979860;LADME_PK;INCREASED_CLEARANCE;OTHER:HIV_INFECTIOUS_DISEASE
GLUCOCORTICOIDS;ABCB1;GG;rs1128503;EFFICACY;DECREASED_RESPONSE;DISEASE:CROHN_DISEASE
METFORMIN;SLC22A1;A;rs622342;EFFICACY;INCREASED_RESPONSE;EFFICACY:DIABETES_MELLITUS
GLUCOCORTICOIDS;ABCB1;GG;rs1045642;EFFICACY;DECREASED_RESPONSE;DISEASE:CROHN_DISEASE
HYDROXYUREA;BCL11A;T;rs1427407;EFFICACY;INCREASED_RESPONSE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
HYDROXYUREA;BCL11A;C;rs766432;EFFICACY;INCREASED_RESPONSE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
WARFARIN;CYP2C9;A;rs2860905;DOSAGE;DECREASED_DOSE;nan
FENTANYL;UGT2B7;TT;rs7439366;EFFICACY;DECREASED_RESPONSE;DISEASE:POSTOPERATIVE_PAIN
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;AC + CC;rs1057910;EFFICACY;DECREASED_DOSE;nan
TIOTROPIUM;ADRB2;AA;rs1042713;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
LUMEFANTRINE;ABCC2;AA;rs8187710;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:MALARIA
ELEXACAFTOR;CFTR;G;rs80034486;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
TEZACAFTOR;CFTR;G;rs80034486;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;G;rs80034486;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
ATORVASTATIN;APOE;CT;rs7412;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
METHADONE;ABCB1;AG;rs1045642;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED_DOSE;nan
CLOPIDOGREL;ABCB1;GG;rs1045642;EFFICACY;INCREASED_RESISTANCE;DISEASE:HYPERTENSION
MORPHINE;UGT2B7;CT + TT;rs7439366;EFFICACY;DECREASED_RESPONSE;OTHER:NEOPLASMS | OTHER:PAIN
VALPROIC ACID;UGT1A6;AG + GG;rs2070959;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:EPILEPSY
VALPROIC ACID;UGT1A6;AC + CC;rs1105879;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:EPILEPSY
CLOZAPINE;HTR2A;AA + AG;rs6314;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA
FLUVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
PRAVASTATIN;ACE;CG + GG;rs4341;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
PRAVASTATIN;LPL;GG;rs328;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
LOVASTATIN;CETP;AG;rs708272;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
FENTANYL;UGT2B7;CC;rs10028494;EFFICACY;DECREASED_RESPONSE;DISEASE:POSTOPERATIVE_PAIN
METHOTREXATE;MTHFR;AA;rs1801133;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
NICOTINE;CHRNA3;A;rs1051730;LADME_PK;INCREASED_DOSE;nan
FLUVASTATIN;LIPC;CC + CT;rs1800588;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
CLOZAPINE;CYP1A1;T;rs2472297;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
METHYLPHENIDATE;CES1;CG;rs114119971;DOSAGE;DECREASED_DOSE;OTHER:ADHD
SIMVASTATIN;LIPC;CT;rs1800588;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
CISPLATIN;VEGFA;CT + TT;rs25648;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
FLUOROURACIL;VEGFA;CT + TT;rs25648;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
OXALIPLATIN;VEGFA;CT + TT;rs25648;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED_DOSE;DISEASE:CARDIOVASCULAR_DISEASE
ATORVASTATIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
ATORVASTATIN;SLCO1B1;AC + CC;rs4149036;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
ATORVASTATIN;CYP3A5;CC + CT;rs776746;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
PERTUSSIS VACCINES;TLR4;GG;rs2770150;EFFICACY;DECREASED_RESPONSE;nan
CISPLATIN;nan;CC + TT;rs6025211;EFFICACY;INCREASED_RESPONSE;OTHER:LIVER_CANCER
FLUOROURACIL;nan;CC + TT;rs6025211;EFFICACY;INCREASED_RESPONSE;OTHER:LIVER_CANCER
MITOXANTRONE;nan;CC + TT;rs6025211;EFFICACY;INCREASED_RESPONSE;OTHER:LIVER_CANCER
TACROLIMUS;ABCB1;AA + TT;rs2032582;EFFICACY;INCREASED_RESPONSE;DISEASE:NEPHROTIC_SYNDROME
LOVASTATIN;SLCO1B1;GT + TT;rs2291073;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
SUFENTANIL;CYP3A4;CT + TT;rs2242480;DOSAGE;DECREASED_DOSE;OTHER:PAIN
TACROLIMUS;ABCB1;AA;rs1128503;EFFICACY;INCREASED_RESPONSE;DISEASE:NEPHROTIC_SYNDROME
CATECHOLAMINES;SLC22A3;T;rs8187725;OTHER;DECREASED_METABOLISM;nan
CATECHOLAMINES;SLC22A3;T;rs8187725;LADME_PK;DECREASED_METABOLISM;nan
METFORMIN;SLC22A3;T;rs8187725;OTHER;DECREASED_METABOLISM;nan
METFORMIN;SLC22A3;T;rs8187725;LADME_PK;DECREASED_METABOLISM;nan
LOVASTATIN;LDLR;TT;rs688;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
AMLODIPINE;CACNA1C;GG;rs2239050;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HYPERTENSION
FLUVASTATIN;CYP3A4;AG;rs4986910;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
NALTREXONE;ADH1C;C;rs698;EFFICACY;INCREASED_RESPONSE;OTHER:ALCOHOL_ABUSE
NALTREXONE;ADH1B;A;rs2066702;EFFICACY;DECREASED_RESPONSE;OTHER:ALCOHOL_ABUSE
LOVASTATIN;LDLR;CC;rs5925;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
CISPLATIN;GALNT14;TT;rs9679162;EFFICACY;INCREASED_RESPONSE;OTHER:LIVER_CANCER
FLUOROURACIL;GALNT14;TT;rs9679162;EFFICACY;INCREASED_RESPONSE;OTHER:LIVER_CANCER
MITOXANTRONE;GALNT14;TT;rs9679162;EFFICACY;INCREASED_RESPONSE;OTHER:LIVER_CANCER
FLUOXETINE;HTR2A;GG;rs6313;EFFICACY;DECREASED_TIME TO RESPONSE;OTHER:DEPRESSION | OTHER:ANXIETY_DISORDERS
NALTREXONE;ALDH2;G;rs671;EFFICACY;INCREASED_RESPONSE;OTHER:ALCOHOL_ABUSE
VARENICLINE;CYP2B6;AG + GG;rs8109525;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
TACROLIMUS;ABCB1;AG;rs1128503;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;T;rs7089580;DOSAGE;INCREASED_DOSE;nan
CLOPIDOGREL;P2RY12;AA;rs2046934;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_DISEASE
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;OTHER
TACROLIMUS;ABCB1;AA;rs1045642;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C19;C;rs3814637;DOSAGE;DOSE;nan
TACROLIMUS;ABCB1;AA;rs2032582;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;A;rs4917639;DOSAGE;DOSE;nan
WARFARIN;VKORC1;A;rs2359612;DOSAGE;DOSE;nan
TACROLIMUS;CYP3A7;CG + GG;rs2257401;LADME_PK;DECREASED_CONCENTRATIONS;OTHER
CLOPIDOGREL;P2RY12;GG;rs3732759;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_DISEASE
ANTIBIOTICS;ABCB1;AA;rs1045642;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:HELICOBACTER_INFECTIONS
ESOMEPRAZOLE;ABCB1;AA;rs1045642;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:HELICOBACTER_INFECTIONS
CARFILZOMIB;VEGFA;CT + TT;rs833061;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_MYELOMA
DEXAMETHASONE;VEGFA;CT + TT;rs833061;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_MYELOMA
LENALIDOMIDE;VEGFA;CT + TT;rs833061;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_MYELOMA
DOLUTEGRAVIR;ABCG2;TT;rs2231142;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CLOPIDOGREL;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED_RESISTANCE;nan
CISPLATIN;GALNT14;GG;rs9679162;EFFICACY;INCREASED_RESPONSE;OTHER:LIVER_CANCER
FLUOROURACIL;GALNT14;GG;rs9679162;EFFICACY;INCREASED_RESPONSE;OTHER:LIVER_CANCER
CARFILZOMIB;KDR;CT + TT;rs2305948;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_MYELOMA
DEXAMETHASONE;KDR;CT + TT;rs2305948;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_MYELOMA
LENALIDOMIDE;KDR;CT + TT;rs2305948;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_MYELOMA
CARFILZOMIB;KDR;AT + TT;rs1870377;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_MYELOMA
DEXAMETHASONE;KDR;AT + TT;rs1870377;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_MYELOMA
LENALIDOMIDE;KDR;AT + TT;rs1870377;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_MYELOMA
MORPHINE;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED_DOSE;OTHER:LIVER_CANCER | OTHER:PAIN
SORAFENIB;GALNT14;GG;rs9679162;EFFICACY;INCREASED_RESPONSE;OTHER:HEPATITIS_C | OTHER:LIVER_CANCER
MYCOPHENOLIC ACID;ABCC2;A;rs2273697;LADME_PK;DECREASED_EXPOSURE;nan
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED_DOSE;OTHER:LIVER_TRANSPLANTATION
MYCOPHENOLIC ACID;ABCC2;T;rs717620;LADME_PK;EXPOSURE;OTHER:KIDNEY_TRANSPLANTATION
FENTANYL;ATF2;A;rs7583431;EFFICACY;INCREASED_RESPONSE;DISEASE:POSTOPERATIVE_PAIN
MYCOPHENOLIC ACID;ABCC2;T;rs717620;LADME_PK;EXPOSURE;OTHER:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;NR1I2;CT + TT;rs3814055;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
AFLIBERCEPT;ANO2;TT;rs2110166;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MACULAR_DEGENERATION
RANIBIZUMAB;ANO2;TT;rs2110166;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MACULAR_DEGENERATION
TACROLIMUS;NR1I2;CT + TT;rs3814055;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
VENLAFAXINE;SLC6A2;CC;rs2242446;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
MYCOPHENOLIC ACID;ABCC2;A;rs2273697;LADME_PK;DECREASED_EXPOSURE;OTHER:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
BOCEPREVIR;IFNL3;C;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
BOCEPREVIR;IFNL4;C;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL3;C;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;C;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;C;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;C;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;C;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;C;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
TELAPREVIR;IFNL3;C;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
TELAPREVIR;IFNL4;C;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;TT;rs1799724;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
DONEPEZIL;CHRNA7;T;rs6494223;EFFICACY;INCREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
GALANTAMINE;CHRNA7;T;rs6494223;EFFICACY;INCREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
RIVASTIGMINE;CHRNA7;T;rs6494223;EFFICACY;INCREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
ADALIMUMAB;FCGR2A;A;rs1801274;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
FLUOROURACIL;ENOSF1;CC;rs2612091;EFFICACY;INCREASED_RESPONSE;OTHER:STOMACH_NEOPLASMS
ALLOPURINOL;SLC22A12;T;rs505802;DOSAGE;INCREASED_DOSE;OTHER:GOUT
ALLOPURINOL;PDZK1;C;rs12129861;DOSAGE;INCREASED_DOSE;OTHER:GOUT
DACLATASVIR;HINT1;CT + TT;rs7728773;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CHRONIC_HEPATITIS_C
SOFOSBUVIR;HINT1;CT + TT;rs7728773;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CHRONIC_HEPATITIS_C
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ADALIMUMAB;IL6;G;rs1800795;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ETANERCEPT;IL6;G;rs1800795;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
INFLIXIMAB;IL6;G;rs1800795;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
LITHIUM;nan;T;rs78015114;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
BUPRENORPHINE;OPRD1;CC;rs678849;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
CARBAMAZEPINE;SCN2A;A;rs17183814;EFFICACY;RESISTANCE;nan
PHENOBARBITAL;SCN2A;A;rs17183814;EFFICACY;RESISTANCE;nan
PHENYTOIN;SCN2A;A;rs17183814;EFFICACY;RESISTANCE;nan
VALPROIC ACID;SCN2A;A;rs17183814;EFFICACY;RESISTANCE;nan
LITHIUM;nan;T;rs79663003;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
APREMILAST;CYP3A4;C;rs1203844;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
APREMILAST;TMEM130;C;rs1203844;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
APREMILAST;CYP3A4;A;rs35599367;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
ATORVASTATIN;MYLIP;AA;rs9370867;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
LITHIUM;nan;T;rs75222709;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
LITHIUM;nan;G;rs74795342;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
APREMILAST;PDE4D;T;rs295943;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
METHYLPHENIDATE;ADRA2A;CG + GG;rs1800544;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
SIMVASTATIN;SCAP;TT;rs12487736;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED_DOSE;OTHER:TOTAL_KNEE_OR_HIP_ARTHROPLASTY
CAFFEINE;CYP1A2;AA + AG;rs2069514;OTHER;DECREASED_METABOLISM;nan
CAFFEINE;CYP1A2;AA + AG;rs2069514;LADME_PK;DECREASED_METABOLISM;nan
APREMILAST;CDKN2B;G;rs1063192;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
APREMILAST;CDKN2B-AS1;G;rs1063192;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
PRAVASTATIN;LIPC;CT + TT;rs1800588;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED_DOSE;OTHER:TOTAL_KNEE_OR_HIP_ARTHROPLASTY
EFAVIRENZ;CYP2B6;CT;rs28399499;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
(R)-METHADONE;NR1I3;GG;rs2307424;LADME_PK;INCREASED_CLEARANCE;OTHER:HIV_INFECTIOUS_DISEASE
OLANZAPINE;HTR2A;GG;rs6314;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
(S)-METHADONE;CYP2B6;G;rs2279343;LADME_PK;DECREASED_CLEARANCE;OTHER:HIV_INFECTIOUS_DISEASE
SIMVASTATIN;ABCB1;GG;rs1128503;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
AZATHIOPRINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED_DISCONTINUATION;DISEASE:INFLAMMATORY_BOWEL_DISEASES
MERCAPTOPURINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED_DISCONTINUATION;DISEASE:INFLAMMATORY_BOWEL_DISEASES
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
(R)-METHADONE;NR1I3;GG;rs3003596;LADME_PK;INCREASED_CLEARANCE;OTHER:HIV_INFECTIOUS_DISEASE
BEVACIZUMAB;CFH;CT;rs1061170;DOSAGE;INCREASED_DOSE;DISEASE:MACULAR_DEGENERATION
METHADONE;OPRD1;CC;rs678849;EFFICACY;INCREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
AZATHIOPRINE;NUDT15;CT;rs116855232;DOSAGE;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
MERCAPTOPURINE;NUDT15;CT;rs116855232;DOSAGE;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
BEVACIZUMAB;ARMS2;GT + TT;rs10490924;EFFICACY;INCREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
SIMVASTATIN;ABCB1;CC;rs2032582;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
WARFARIN;NQO1;AA + AG;rs1800566;DOSAGE;INCREASED_DOSE;nan
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;LADME_PK;INCREASED_CONCENTRATIONS;nan
DEFERASIROX;ABCC2;AG;rs2273697;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
BUDESONIDE;nan;AG + GG;rs2392165;EFFICACY;INCREASED_RESPONSE;OTHER:ASTHMA
THIORIDAZINE;CYP2D6;CC + CG;rs1080985;LADME_PK;DECREASED_METABOLISM;nan
DEFERASIROX;CYP1A2;CC + CT;rs2470890;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
DEFERASIROX;CYP1A2;AC + CC;rs762551;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
OLANZAPINE;DRD2;AA + AC;rs1076560;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
DEFERASIROX;CYP1A1;AC + CC;rs2606345;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
DEFERASIROX;UGT1A1;TT;rs887829;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
CARBAMAZEPINE;ABCB1;A;rs1128503;LADME_PK;INCREASED_CLEARANCE;OTHER:EPILEPSY
ADALIMUMAB;FCGR2A;GG;rs1801274;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
ETANERCEPT;FCGR2A;GG;rs1801274;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
INFLIXIMAB;FCGR2A;GG;rs1801274;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
CAPECITABINE;MTHFR;GG;rs1801133;LADME_PK;INCREASED_EXPOSURE;DISEASE:NEOPLASMS
DACLATASVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CHRONIC_HEPATITIS_C
SOFOSBUVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CHRONIC_HEPATITIS_C
BUPRENORPHINE;nan;T;rs6973474;EFFICACY;INCREASED_RESPONSE;OTHER:OPIOID-RELATED_DISORDERS
CARBAMAZEPINE;ABCB1;A;rs2032582;LADME_PK;INCREASED_CLEARANCE;OTHER:EPILEPSY
METHOTREXATE;SLC19A1;A;rs2838958;LADME_PK;DECREASED_CLEARANCE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
BUPRENORPHINE;nan;T;rs13169373;EFFICACY;INCREASED_RESPONSE;OTHER:OPIOID-RELATED_DISORDERS
HALOPERIDOL;CYP2D6;CC;rs3892097;EFFICACY;DECREASED_RESPONSE;DISEASE:ALCOHOLIC_PSYCHOSIS | DISEASE:ALCOHOL_ABUSE | DISEASE:ALCOHOL-RELATED_DISORDERS
CARBAMAZEPINE;ABCB1;A;rs1045642;LADME_PK;INCREASED_CLEARANCE;OTHER:EPILEPSY
NEVIRAPINE;CYP2B6;C;rs28399499;LADME_PK;INCREASED_CONCENTRATIONS;nan
IMATINIB;SLC22A1;GG;rs628031;LADME_PK;DECREASED_CLEARANCE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
NICOTINE;CHRNA5;A;rs16969968;DOSAGE;INCREASED_DOSE;DISEASE:TOBACCO_USE_DISORDER
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
BUPRENORPHINE;nan;G;rs62368105;EFFICACY;INCREASED_RESPONSE;OTHER:OPIOID-RELATED_DISORDERS
BUPRENORPHINE;nan;T;rs11782370;EFFICACY;INCREASED_RESPONSE;OTHER:OPIOID-RELATED_DISORDERS
METHOTREXATE;ABCC4;G;rs7317112;LADME_PK;DECREASED_CLEARANCE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ADALIMUMAB;FCGR3A;AA;rs396991;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
ETANERCEPT;FCGR3A;AA;rs396991;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
INFLIXIMAB;FCGR3A;AA;rs396991;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
METHOTREXATE;SLCO1B1;G;rs2306283;LADME_PK;INCREASED_CLEARANCE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
BUPRENORPHINE;nan;T;rs7205113;EFFICACY;INCREASED_RESPONSE;OTHER:OPIOID-RELATED_DISORDERS
ETANERCEPT;IL10;CC;rs1800896;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
BUPRENORPHINE;ADAMTSL2;A;rs756770;EFFICACY;INCREASED_RESPONSE;OTHER:OPIOID-RELATED_DISORDERS
(R)-METHADONE;ABCB1;AA;rs2032582;LADME_PK;DECREASED_CLEARANCE;OTHER:HIV_INFECTIOUS_DISEASE
ETANERCEPT;TGFB1;CG;rs1800471;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ATORVASTATIN;SLCO1B1;AG + GG;rs2306283;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
EFAVIRENZ;CYP2B6;T;rs3745274;EFFICACY;INCREASED_RESPONSE;DISEASE:HIV_INFECTIOUS_DISEASE
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS;CYP2B6;T;rs3745274;EFFICACY;INCREASED_RESPONSE;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;CC + CT;rs2279345;LADME_PK;INCREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;TT;rs3745274;EFFICACY;INCREASED_RESPONSE;DISEASE:HIV_INFECTIOUS_DISEASE | DISEASE:TUBERCULOSIS
METHOTREXATE;SLCO1B1;TT;rs4149056;LADME_PK;INCREASED_EXPOSURE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
XK469;AOX1;G;rs10931910;LADME_PK;DECREASED_CLEARANCE;DISEASE:NEOPLASMS
SIMVASTATIN;PON1;CC;rs662;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_DISEASE
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE | DISEASE:TUBERCULOSIS
MERCAPTOPURINE;NUDT15;T;rs116855232;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ETANERCEPT;TNF;GG;rs1800629;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
MERCAPTOPURINE;TPMT;CT;rs1142345;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
NEVIRAPINE;CYP2B6;T;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;nan
BUCINDOLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED_RESPONSE;DISEASE:HEART_FAILURE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A4;CT;rs4986907;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
NEVIRAPINE;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
PHENPROCOUMON;VKORC1;CC;rs9923231;DOSAGE;INCREASED_DOSE;nan
WARFARIN;CYP4F2;AG + GG;rs2189784;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
PHENPROCOUMON;EPHX1;CC;rs1051740;DOSAGE;DECREASED_DOSE;nan
PHENPROCOUMON;EPHX1;CC;rs1051740;LADME_PK;DECREASED_DOSE;nan
ASPIRIN;TNF;A;rs1800629;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MIGRAINE_WITHOUT_AURA
DICLOFENAC;TNF;A;rs1800629;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MIGRAINE_WITHOUT_AURA
IBUPROFEN;TNF;A;rs1800629;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MIGRAINE_WITHOUT_AURA
INDOMETHACIN;TNF;A;rs1800629;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MIGRAINE_WITHOUT_AURA
KETOROLAC;TNF;A;rs1800629;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MIGRAINE_WITHOUT_AURA
NAPROXEN;TNF;A;rs1800629;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MIGRAINE_WITHOUT_AURA
PHENPROCOUMON;PROC;CC;rs1799808;DOSAGE;INCREASED_DOSE;nan
PHENPROCOUMON;PROC;CC;rs1799808;LADME_PK;INCREASED_DOSE;nan
LAMOTRIGINE;UGT2B7;CT + TT;rs7668258;LADME_PK;INCREASED_STEADY_STATE CONCENTRATION;DISEASE:EPILEPSY
INFLIXIMAB;TNF;GG;rs1800629;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
IMATINIB;SLC22A4;TT;rs1050152;EFFICACY;DECREASED_RESPONSE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
IMATINIB;SLC22A5;CG + GG;rs2631367;EFFICACY;INCREASED_RESPONSE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS
IMATINIB;SLC22A5;CG + GG;rs2631372;EFFICACY;INCREASED_RESPONSE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS
ETANERCEPT;TNF;CT + TT;rs1799724;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
WARFARIN;EPHX1;CG;rs2260863;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
WARFARIN;APOE;CC;rs7412;DOSAGE;DECREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
CYCLOPHOSPHAMIDE;CYP2B6;AG + GG;rs2279343;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-HODGKIN_LYMPHOMA
WARFARIN;CYP3A4;AA;rs28371759;DOSAGE;DECREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;DECREASED_RESPONSE;nan
WARFARIN;CYP1A2;GG;rs2069514;DOSAGE;DECREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
IMATINIB;ABCC4;AG;rs9561765;EFFICACY;INCREASED_RESPONSE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS
WARFARIN;VKORC1;CC;rs9923231;DOSAGE;INCREASED_DOSE;nan
WARFARIN;SLC15A2;TT;rs1143671;DOSAGE;DECREASED_DOSE;nan
LAMOTRIGINE;UGT1A4;GG + GT;rs2011425;LADME_PK;DECREASED_STEADY_STATE CONCENTRATION;DISEASE:EPILEPSY
WARFARIN;EPHX1;CC;rs2260863;DOSAGE;DECREASED_DOSE;OTHER:ATRIAL_FIBRILLATION
RITONAVIR;NR1I2;CC + CT;rs1523130;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
L-TRYPTOPHAN;SLC22A2;CC;rs316019;LADME_PK;INCREASED_CLEARANCE;nan
WARFARIN;VKORC1;AA;rs9923231;DOSAGE;INCREASED_DOSE;OTHER:ATRIAL_FIBRILLATION
PHENPROCOUMON;VKORC1;A;rs9934438;DOSAGE;DECREASED_DOSE;nan
RITONAVIR;SLCO1B1;CC + CT;rs4149056;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
RITONAVIR;ABCB1;AC + CC;rs2032582;LADME_PK;CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
ERENUMAB;RAMP1;A;rs13386048;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MIGRAINE_WITH_AURA | OTHER:MIGRAINE_WITHOUT_AURA
ADALIMUMAB;TNF;GG;rs1800629;EFFICACY;INCREASED_RESPONSE;OTHER:SPONDYLITIS | ANKYLOSING
INFLIXIMAB;TNF;GG;rs1800629;EFFICACY;INCREASED_RESPONSE;OTHER:SPONDYLITIS | ANKYLOSING
SIROLIMUS;POR;CT + TT;rs1057868;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED_DOSE;OTHER:ATRIAL_FIBRILLATION
OLANZAPINE;BDNF;CC;rs6265;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
RITONAVIR;NR1I2;AA + AG;rs6785049;LADME_PK;CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
ERENUMAB;RAMP1;G;rs6431564;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MIGRAINE_WITH_AURA | OTHER:MIGRAINE_WITHOUT_AURA
INFLIXIMAB;TNF;GG;rs1800629;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
LOSARTAN;SLC22A12;CC + CT;rs1529909;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION | DISEASE:HYPERURICEMIA
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED_DOSE;nan
ERENUMAB;RAMP1;G;rs12465864;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MIGRAINE_WITH_AURA | OTHER:MIGRAINE_WITHOUT_AURA
ADALIMUMAB;TNF;GG;rs1800629;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ETANERCEPT;TNF;GG;rs1800629;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
INFLIXIMAB;TNF;GG;rs1800629;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
LOSARTAN;SLC22A12;CT + TT;rs3825016;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION | DISEASE:HYPERURICEMIA
ADALIMUMAB;TNF;GG;rs1800629;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
SIROLIMUS;IL10;CC;rs1800896;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
CYCLOSPORINE;ABCB1;CT;rs9282564;TOXICITY;INCREASED_CONCENTRATIONS;OTHER:HEART_TRANSPLANTATION
CYCLOSPORINE;ABCB1;CT;rs9282564;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HEART_TRANSPLANTATION
CLADRIBINE;RRM1;AT;rs1042919;EFFICACY;DECREASED_RESPONSE;DISEASE:MYELOID_ACUTE_LEUKEMIA
CYTARABINE;RRM1;AT;rs1042919;EFFICACY;DECREASED_RESPONSE;DISEASE:MYELOID_ACUTE_LEUKEMIA
CLADRIBINE;RRM2B;AA;rs1265138;EFFICACY;INCREASED_RESPONSE;DISEASE:MYELOID_ACUTE_LEUKEMIA
CYTARABINE;RRM2B;AA;rs1265138;EFFICACY;INCREASED_RESPONSE;DISEASE:MYELOID_ACUTE_LEUKEMIA
FLUOROURACIL;DPYD;AA;rs1801265;EFFICACY;INCREASED_RESPONSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED_EXPOSURE;DISEASE:COLONIC_NEOPLASMS
CLADRIBINE;RRM1;AC + CC;rs2898950;EFFICACY;INCREASED_RESPONSE;DISEASE:MYELOID_ACUTE_LEUKEMIA
CYTARABINE;RRM1;AC + CC;rs2898950;EFFICACY;INCREASED_RESPONSE;DISEASE:MYELOID_ACUTE_LEUKEMIA
INTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
INTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RECOMBINANT;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RECOMBINANT;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
INTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
INTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RECOMBINANT;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RECOMBINANT;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
BUPROPION;CYP2B6;AA;rs2279343;EFFICACY;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
INTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RECOMBINANT;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
INTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RECOMBINANT;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
CLADRIBINE;RRM1;GG;rs1561876;EFFICACY;DECREASED_RESPONSE;DISEASE:MYELOID_ACUTE_LEUKEMIA
CYTARABINE;RRM1;GG;rs1561876;EFFICACY;DECREASED_RESPONSE;DISEASE:MYELOID_ACUTE_LEUKEMIA
COTININE;PSMA4;A;rs57064725;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:TOBACCO_USE_DISORDER
METHOTREXATE;ATIC;GG;rs16853826;TOXICITY;INCREASED_DISCONTINUATION;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;ABCC1;TT;rs35592;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
COTININE;CHRNA5;A;rs16969968;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:TOBACCO_USE_DISORDER
INFLIXIMAB;TNFRSF10A;CC;rs20575;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CLADRIBINE;RRM2;GT + TT;rs1130609;EFFICACY;DECREASED_RESPONSE;DISEASE:MYELOID_ACUTE_LEUKEMIA
CYTARABINE;RRM2;GT + TT;rs1130609;EFFICACY;DECREASED_RESPONSE;DISEASE:MYELOID_ACUTE_LEUKEMIA
INTERFERON ALFA-2A;FTO;AA + AT;rs9939609;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
RECOMBINANT;FTO;AA + AT;rs9939609;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
INTERFERON ALFA-2B;FTO;AA + AT;rs9939609;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
RECOMBINANT;FTO;AA + AT;rs9939609;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
RIBAVIRIN;FTO;AA + AT;rs9939609;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
VITAMIN K AND ANALOGUES;CYP4F2;T;rs2108622;LADME_PK;DECREASED_METABOLISM;nan
COTININE;nan;G;rs77107237;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:TOBACCO_USE_DISORDER
CLOZAPINE;DTNBP1;CT + TT;rs742105;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CLADRIBINE;RRM2;CG + GG;rs5030743;EFFICACY;DECREASED_RESPONSE;DISEASE:MYELOID_ACUTE_LEUKEMIA
CYTARABINE;RRM2;CG + GG;rs5030743;EFFICACY;DECREASED_RESPONSE;DISEASE:MYELOID_ACUTE_LEUKEMIA
COTININE;CHRNB4;A;rs10851907;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:TOBACCO_USE_DISORDER
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
SIMEPREVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
SIMEPREVIR;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
SIROLIMUS;ABCB1;AA + AG;rs1045642;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;SLCO1B3;AA;rs7311358;DOSAGE;DECREASED_DOSE;nan
WARFARIN;SLC15A2;AA;rs1143672;DOSAGE;DECREASED_DOSE;nan
INTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
INTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RECOMBINANT;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RECOMBINANT;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
INTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
INTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RECOMBINANT;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RECOMBINANT;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
WARFARIN;SLCO1B3;GG;rs4149117;DOSAGE;DECREASED_DOSE;nan
ETANERCEPT;TNF;GG;rs1800629;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
COTININE;CHRNA3;A;rs7170068;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:TOBACCO_USE_DISORDER
SUNITINIB;ABCB1;AA;rs1045642;EFFICACY;DECREASED_RESPONSE;DISEASE:RENAL_CELL_CARCINOMA
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP4F2;CC;rs2108622;EFFICACY;DECREASED_DOSE;nan
INTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RECOMBINANT;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
INTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RECOMBINANT;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
SIMEPREVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
SIMEPREVIR;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
FLUPENTHIXOL;NFKB1;CT + TT;rs230504;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
MONTELUKAST;SLCO2B1;AG;rs12422149;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
MONTELUKAST;SLCO2B1;AG;rs12422149;LADME_PK;DECREASED_RESPONSE;DISEASE:ASTHMA
DEFERASIROX;CYP24A1;CT + TT;rs927650;LADME_PK;DECREASED_METABOLISM;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED_DOSE;nan
DEFERASIROX;CYP24A1;CT + TT;rs2585428;LADME_PK;DECREASED_METABOLISM;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
FLUPENTHIXOL;NFKB1;AG;rs3774959;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ANTIDEPRESSANTS;TPH2;C;rs10879346;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
METHOTREXATE POLYGLUTAMATE;IMPDH1;GG;rs4731448;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CARBOPLATIN;EIF3A;AA + AG;rs3740556;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
CISPLATIN;EIF3A;AA + AG;rs3740556;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
METHOTREXATE POLYGLUTAMATE;CEP72;TT;rs924607;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
TACROLIMUS;IL10;TT;rs1800896;DOSAGE;DECREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
MIRTAZAPINE;TPH2;C;rs1487278;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSION
VENLAFAXINE;TPH2;C;rs1487278;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSION
TACROLIMUS;ABCB1;GG;rs1045642;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
BILIRUBIN;UGT1A1;GG + GT;rs4124874;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:NEOPLASMS
CARBOPLATIN;EIF3A;AA + AG;rs3740556;EFFICACY;INCREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
CISPLATIN;EIF3A;AA + AG;rs3740556;EFFICACY;INCREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
DEFERASIROX;CYP24A1;CT + TT;rs2248359;LADME_PK;DECREASED_METABOLISM;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
FLUPENTHIXOL;NFKB1;AT;rs230493;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
METHOTREXATE POLYGLUTAMATE;SLCO1B3;AA + AG;rs7311358;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
NICOTINE;FMO3;AA;rs2266780;LADME_PK;INCREASED_METABOLISM;nan
PAZOPANIB;VEGFA;A;rs699947;EFFICACY;DECREASED_RESPONSE;DISEASE:RENAL_CELL_CARCINOMA
METHOTREXATE POLYGLUTAMATE;FSTL5;AA + AC;rs3749598;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE POLYGLUTAMATE;ATG16L1;AG + GG;rs2241880;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
FLUOROURACIL;DPYD;CC;rs3918290;EFFICACY;INCREASED_RESPONSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
TACROLIMUS;CYP3A5;CT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
THEOPHYLLINE;CYP1A2;AA + AG;rs2069514;OTHER;DECREASED_METABOLISM;DISEASE:ASTHMA
THEOPHYLLINE;CYP1A2;AA + AG;rs2069514;LADME_PK;DECREASED_METABOLISM;DISEASE:ASTHMA
INFLIXIMAB;TNFRSF10A;CC;rs20575;EFFICACY;INCREASED_RESPONSE;DISEASE:ARTHRITIS | PSORIATIC
ADALIMUMAB;TNFRSF1A;TT;rs767455;EFFICACY;INCREASED_RESPONSE;DISEASE:ARTHRITIS | PSORIATIC
ETANERCEPT;TNFRSF1A;TT;rs767455;EFFICACY;INCREASED_RESPONSE;DISEASE:ARTHRITIS | PSORIATIC
INFLIXIMAB;TNFRSF1A;TT;rs767455;EFFICACY;INCREASED_RESPONSE;DISEASE:ARTHRITIS | PSORIATIC
PAZOPANIB;VEGFA;G;rs2010963;EFFICACY;DECREASED_RESPONSE;DISEASE:RENAL_CELL_CARCINOMA
ADALIMUMAB;TNFRSF10A;CC;rs20575;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ETANERCEPT;TNFRSF10A;CC;rs20575;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
INFLIXIMAB;TNFRSF10A;CC;rs20575;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ADALIMUMAB;TNFRSF1A;TT;rs767455;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ETANERCEPT;TNFRSF1A;TT;rs767455;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
INFLIXIMAB;TNFRSF1A;TT;rs767455;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
PAZOPANIB;VEGFA;T;rs833061;EFFICACY;DECREASED_RESPONSE;DISEASE:RENAL_CELL_CARCINOMA
ETANERCEPT;PTTG1;CC + CT;rs2431697;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
CISPLATIN;CMPK1;CC;rs4492666;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
GEMCITABINE;CMPK1;CC;rs4492666;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
BUPROPION;CHRNA5;A;rs503464;EFFICACY;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
NICOTINE;CHRNA5;A;rs503464;EFFICACY;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
VARENICLINE;CHRNA5;A;rs503464;EFFICACY;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
VORICONAZOLE;NR1I2;GG;rs6785049;LADME_PK;INCREASED_CONCENTRATIONS;nan
ETANERCEPT;HLA-B;TT;rs13437088;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
ETANERCEPT;MAP3K1;AG + GG;rs96844;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
CLOZAPINE;COMT;GG;rs4680;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CLOZAPINE;HTR1A;GG;rs6295;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ETANERCEPT;GBP6;AG + GG;rs928655;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
ATORVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;DECREASED_RESPONSE;nan
ETANERCEPT;IL12B;AG + GG;rs2546890;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
TEMOZOLOMIDE;ABCB1;AA + AG;rs1128503;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:GLIOMA
IVACAFTOR;SLC26A9;CC + CT;rs7512462;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
GEMCITABINE;DCK;AG + GG;rs66878317;LADME_PK;INCREASED_CLEARANCE;nan
VORICONAZOLE;NR1I2;CC;rs3814057;LADME_PK;INCREASED_CONCENTRATIONS;nan
NICOTINE;COMT;GG;rs4680;EFFICACY;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
MILNACIPRAN;ADRA2A;CC + CG;rs1800544;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
PLATINUM COMPOUNDS;IGF2;GG;rs4244809;EFFICACY;DECREASED_RESISTANCE;DISEASE:OVARIAN_NEOPLASMS
PLATINUM COMPOUNDS;IGF2-AS;GG;rs4244809;EFFICACY;DECREASED_RESISTANCE;DISEASE:OVARIAN_NEOPLASMS
PLATINUM COMPOUNDS;INS-IGF2;GG;rs4244809;EFFICACY;DECREASED_RESISTANCE;DISEASE:OVARIAN_NEOPLASMS
VORICONAZOLE;FMO3;AA;rs2266780;LADME_PK;INCREASED_CONCENTRATIONS;nan
HMG COA REDUCTASE INHIBITORS;SLCO1B1;GG;rs2306283;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
FLUVOXAMINE;FGF2;CC + CT;rs1449683;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
VORICONAZOLE;POR;GG;rs10954732;LADME_PK;INCREASED_CONCENTRATIONS;nan
PLATINUM COMPOUNDS;INS-IGF2;GG;rs3842761;EFFICACY;DECREASED_RESISTANCE;DISEASE:OVARIAN_NEOPLASMS
MILNACIPRAN;HTR1A;CC + CG;rs6295;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
VALPROIC ACID;SCN2A;AA + AG;rs17183814;EFFICACY;INCREASED_RESISTANCE;OTHER:EPILEPSY
VALPROIC ACID;SCN1A;TT;rs2298771;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
VORICONAZOLE;NR1I2;AA;rs2461817;LADME_PK;DECREASED_CONCENTRATIONS;nan
VORICONAZOLE;NR1I2;GG;rs3732359;LADME_PK;INCREASED_CONCENTRATIONS;nan
METHOTREXATE;ABCC2;TT;rs3740066;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:OSTEOSARCOMA
CISPLATIN;RRM1;TT;rs720106;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
GEMCITABINE;RRM1;TT;rs720106;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
VORICONAZOLE;NR1I2;AA;rs7643645;LADME_PK;INCREASED_CONCENTRATIONS;nan
SIMVASTATIN;SLCO1B1;AA;rs2306283;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
CISPLATIN;RRM1;AA;rs232043;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
GEMCITABINE;RRM1;AA;rs232043;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
CISPLATIN;CMPK1;CC;rs11211524;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
GEMCITABINE;CMPK1;CC;rs11211524;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
SIMVASTATIN;SLCO1B1;GG;rs2306283;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
CISPLATIN;RRM1;TT;rs2284449;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
GEMCITABINE;RRM1;TT;rs2284449;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
ACENOCOUMAROL;GGCX;G;rs11676382;DOSAGE;DECREASED_DOSE;nan
ACENOCOUMAROL;CYP4F2;T;rs2108622;DOSAGE;INCREASED_DOSE;nan
ACENOCOUMAROL;VKORC1;T;rs7294;DOSAGE;INCREASED_DOSE;nan
METHOTREXATE;NR1I2;G;rs6785049;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OSTEOSARCOMA
RITUXIMAB;TGFB1;AG;rs1800470;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
RITUXIMAB;TGFB1;CG;rs1800471;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
PEGINTERFERON ALFA-2A;IFNL3;A;rs12980275;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;A;rs12980275;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;A;rs12980275;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL3;T;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;T;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;T;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
SIMVASTATIN;CYP3A4;A;rs35599367;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERCHOLESTEROLEMIA
PIOGLITAZONE;ADIPOQ;GT;rs2241766;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
MORPHINE;OPRM1;GG;rs1799971;DOSAGE;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
MORPHINE;OPRM1;GG;rs1799971;EFFICACY;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
MORPHINE;OPRM1;GG;rs1799971;DOSAGE;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
MORPHINE;OPRM1;GG;rs1799971;EFFICACY;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
ACENOCOUMAROL;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
ROSUVASTATIN;CYP3A5;C;rs776746;EFFICACY;INCREASED_RESPONSE;DISEASE:MYOCARDIAL_INFARCTION
METHOTREXATE;GSK3B;A;rs3732361;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OSTEOSARCOMA
NALOXONE;OPRM1;AG + GG;rs1799971;OTHER;INCREASED_RESPONSE;nan
TIPIFARNIB;ABCB1;AA;rs1128503;OTHER;DECREASED_METABOLISM;nan
TIPIFARNIB;ABCB1;AA;rs1128503;LADME_PK;DECREASED_METABOLISM;nan
ETANERCEPT;ZNF816;CC;rs9304742;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
ROSUVASTATIN;ABCG2;T;rs2231142;EFFICACY;INCREASED_RESPONSE;DISEASE:MYOCARDIAL_INFARCTION
EFAVIRENZ;CYP2B6;GG;rs3745274;DOSAGE;INCREASED_DOSE;DISEASE:HIV_INFECTIOUS_DISEASE
NALTREXONE;OPRM1;G;rs1799971;EFFICACY;INCREASED_RESPONSE;DISEASE:ALCOHOL_ABUSE
ANTIPSYCHOTICS;NRG1;G;rs13250975;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED_DOSE;DISEASE:HEART_DISEASES
METHOTREXATE;SLCO1A2;CC + CT;rs4149009;LADME_PK;DECREASED_CLEARANCE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ANTIPSYCHOTICS;nan;A;rs2513265;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;ADCY2;C;rs1544938;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;NRG1;A;rs17716295;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
NICOTINE;CHRNA5;GG;rs16969968;OTHER;DECREASED_DOSE;DISEASE:TOBACCO_USE_DISORDER
METHADONE;DAO;TT;rs55944529;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
ANTIPSYCHOTICS;CCL2;G;rs4795893;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;CCL2;T;rs4586;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
METHADONE;DAO;TT;rs55944529;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HEROIN_DEPENDENCE
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
ESCITALOPRAM;HTR2A;GG + GT;rs3803189;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
FLUOXETINE;HTR2A;GG + GT;rs3803189;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
FLUVOXAMINE;HTR2A;GG + GT;rs3803189;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
SERTRALINE;HTR2A;GG + GT;rs3803189;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
EFAVIRENZ;CYP2B6;T;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE | OTHER:MALARIA
IVACAFTOR;CFTR;A;rs121908755;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
METHADONE;DRD1;TT;rs5326;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
IVACAFTOR;CFTR;C;rs121908757;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
IVACAFTOR;CFTR;A;rs80282562;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
RIFAMPIN;SLCO1B1;CT;rs4149056;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:TUBERCULOSIS
METHYLPHENIDATE;CYP2D6;GG;rs1065852;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ADHD
HMG COA REDUCTASE INHIBITORS;SLCO1B1;CC;rs11045819;EFFICACY;DECREASED_RESPONSE;nan
METHYLPHENIDATE;CYP2D6;CG;rs1135840;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ADHD
IVACAFTOR;CFTR;C;rs121909041;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
PRAVASTATIN;SLCO1B1;GG;rs2306283;EFFICACY;DECREASED_RESPONSE;nan
WARFARIN;CYP2C9;AA;rs1057910;DOSAGE;INCREASED_DOSE;nan
IVACAFTOR;CFTR;A;rs193922525;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
WARFARIN;VKORC1;AA + AG;rs7196161;DOSAGE;INCREASED_DOSE;nan
IVACAFTOR;CFTR;A;rs267606723;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED_DOSE;nan
IVACAFTOR;CFTR;A;rs74503330;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
IVACAFTOR;CFTR;G;rs121909005;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
IVACAFTOR;CFTR;A;rs121909013;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
SUNITINIB;GLP1R;A;rs6923761;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:RENAL_CELL_CARCINOMA | OTHER:GASTROINTESTINAL_STROMAL_TUMORS
DOXORUBICIN;ABCB1;AA;rs1128503;LADME_PK;DECREASED_METABOLISM;DISEASE:BREAST_NEOPLASMS
ATOMOXETINE;CYP2D6;CC;rs1135840;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ADHD
BETA BLOCKING AGENTS;GRK5;A;rs3740563;EFFICACY;DECREASED_RESPONSE;OTHER:CORONARY_ARTERY_DISEASE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNG;G;rs2069705;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
MONTELUKAST;MLLT3;AA;rs6475448;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
BETA BLOCKING AGENTS;GRK5;A;rs10787959;EFFICACY;DECREASED_RESPONSE;OTHER:CORONARY_ARTERY_DISEASE
BUPROPION;nan;C;rs1908557;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
BETA BLOCKING AGENTS;GRK5;A;rs11198893;EFFICACY;DECREASED_RESPONSE;OTHER:CORONARY_ARTERY_DISEASE
RIFAMPIN;CYP27B1;AG + GG;rs4646536;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:TUBERCULOSIS
CORTICOSTEROIDS;ST13;G;rs138335;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
RIFAMPIN;VDR;TT;rs1544410;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:TUBERCULOSIS
DOCETAXEL;CYP3A4;C;rs2740574;LADME_PK;INCREASED_CLEARANCE;DISEASE:NEOPLASMS
BETA BLOCKING AGENTS;ADRB1;GG;rs1801253;EFFICACY;DECREASED_RESPONSE;OTHER:HEART_FAILURE
METHADONE;CYP2B6;GG + GT;rs3745274;DOSAGE;INCREASED_DOSE;DISEASE:HEROIN_DEPENDENCE
DOCETAXEL;CYP3A5;T;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:NEOPLASMS
HMG COA REDUCTASE INHIBITORS;SLCO1B1;C;rs4149056;EFFICACY;DECREASED_RESPONSE;DISEASE:CARDIOVASCULAR_DISEASE
RAMIPRIL;ADRB2;AA + AG;rs2053044;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
OPIOIDS;COMT;GG;rs4680;DOSAGE;INCREASED_DOSE;OTHER:BREAST_NEOPLASMS | OTHER:POSTOPERATIVE_PAIN
METHADONE;NGF;AA;rs2239622;DOSAGE;DECREASED_DOSE;DISEASE:OPIOID-RELATED_DISORDERS
NICOTINE;CYP1A2;T/del + del/del;rs35694136;EFFICACY;INCREASED_EXPOSURE;OTHER:URINARY_BLADDER_NEOPLASMS
METHADONE;CYP2B6;AA + AG;rs2279343;DOSAGE;INCREASED_DOSE;DISEASE:HEROIN_DEPENDENCE
GEMCITABINE;NT5C3A;AA;rs3750117;OTHER;INCREASED_CLEARANCE;DISEASE:NEOPLASMS
GEMCITABINE;NT5C3A;AA;rs3750117;LADME_PK;INCREASED_CLEARANCE;DISEASE:NEOPLASMS
GEMCITABINE;NT5C2;TT;rs11598702;OTHER;DECREASED_CLEARANCE;DISEASE:NEOPLASMS
GEMCITABINE;NT5C2;TT;rs11598702;LADME_PK;DECREASED_CLEARANCE;DISEASE:NEOPLASMS
FENTANYL;PGAP6;T;rs199670311;EFFICACY;INCREASED_DOSE;DISEASE:PAIN
REMIFENTANIL;PGAP6;T;rs199670311;EFFICACY;INCREASED_DOSE;DISEASE:PAIN
OLANZAPINE;UGT1A4;GT;rs2011425;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:SCHIZOPHRENIA
ANTIDEPRESSANTS;ADCY9;CC;rs2230739;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
DABIGATRAN;CES1;GG + GT;rs2244613;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:STROKE
ANTIPSYCHOTICS;PI4KA;AG + GG;rs165854;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;GRM3;AA + AT;rs1468412;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
BUDESONIDE;ZNF432;TT;rs3752120;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
CORTICOSTEROIDS;ZNF432;TT;rs3752120;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
FLUTICASONE;ZNF432;TT;rs3752120;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
SALMETEROL;ZNF432;TT;rs3752120;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
FLUTICASONE PROPIONATE;ZNF432;TT;rs3752120;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
AZATHIOPRINE;ITPA;AA + AC;rs1127354;EFFICACY;INCREASED_RESPONSE;DISEASE:SYSTEMIC_LUPUS_ERYTHEMATOSUS
CARBOPLATIN;ERBB2;G;rs1136201;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
DOCETAXEL;ERBB2;G;rs1136201;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
TRASTUZUMAB;ERBB2;G;rs1136201;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
ANTIPSYCHOTICS;SLC1A3;AA + AG;rs1529461;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;GRM3;CC;rs2299214;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CARBOPLATIN;RNF8;A;rs2284922;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
DOCETAXEL;RNF8;A;rs2284922;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
TRASTUZUMAB;RNF8;A;rs2284922;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
ANTIPSYCHOTICS;GRM3;AG + GG;rs6465084;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CARBOPLATIN;BARD1;A;rs2070096;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
DOCETAXEL;BARD1;A;rs2070096;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
TRASTUZUMAB;BARD1;A;rs2070096;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
GEMCITABINE;CDA;CC;rs1048977;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
CARBOPLATIN;ERBB3;C;rs2229046;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
DOCETAXEL;ERBB3;C;rs2229046;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
TRASTUZUMAB;ERBB3;C;rs2229046;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
CORTICOSTEROIDS;ST13;G;rs138337;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
CARBOPLATIN;ERBB3;A;rs773123;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
DOCETAXEL;ERBB3;A;rs773123;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
TRASTUZUMAB;ERBB3;A;rs773123;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
ANTIPSYCHOTICS;SLC1A4;AA;rs10211524;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
RISPERIDONE;GRM3;CC + CT;rs2299214;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
EFAVIRENZ;CYP2B6;GT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;nan
PRAVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED_RESPONSE;nan
SUFENTANIL;COMT;AA;rs4680;DOSAGE;DECREASED_DOSE;nan
SUFENTANIL;COMT;AA;rs4680;EFFICACY;DECREASED_DOSE;nan
FLUINDIONE;VKORC1;TT;rs9923231;LADME_PK;DOSE;nan
APREMILAST;LEPR;AA + AG;rs1045895;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
APREMILAST;LEPROT;AA + AG;rs1045895;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED_DOSE;nan
OPIOIDS;ABCB1;AA;rs1045642;DOSAGE;DECREASED_DOSE;DISEASE:NEOPLASMS | DISEASE:PAIN
OPIOIDS;ABCB1;AA;rs1045642;EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS | DISEASE:PAIN
CARBOPLATIN;AKT1;AG;rs2494752;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
CISPLATIN;AKT1;AG;rs2494752;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
QUINAPRIL;AGT;GG;rs699;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
OPIOIDS;KCNJ6;CC;rs6517442;DOSAGE;INCREASED_DOSE;OTHER:LOW_BACK_PAIN
OLANZAPINE;CYP1A2;T/del;rs35694136;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:SCHIZOPHRENIA
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED_DOSE;DISEASE:NEOPLASMS | DISEASE:PAIN
OPIOIDS;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED_DOSE;DISEASE:NEOPLASMS | DISEASE:PAIN
OLANZAPINE;CYP1A2;AA;rs762551;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:SCHIZOPHRENIA
FENTANYL;OPRM1;GG;rs1799971;DOSAGE;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
FENTANYL;OPRM1;GG;rs1799971;EFFICACY;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
PHENPROCOUMON;CYP4F2;TT;rs2108622;DOSAGE;INCREASED_DOSE;nan
CAPECITABINE;TYMS;C;rs183205964;TOXICITY;INCREASED_DISCONTINUATION;DISEASE:NEOPLASMS
FLUOROURACIL;TYMS;C;rs183205964;TOXICITY;INCREASED_DISCONTINUATION;DISEASE:NEOPLASMS
TEGAFUR;TYMS;C;rs183205964;TOXICITY;INCREASED_DISCONTINUATION;DISEASE:NEOPLASMS
KETOPROFEN;CYP2C9;AC;rs1057910;EFFICACY;INCREASED_RESPONSE;OTHER:POSTOPERATIVE_PAIN
ATORVASTATIN;ABCB1;GG;rs1045642;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
IMATINIB;SLC22A1;CC;rs683369;LADME_PK;INCREASED_CLEARANCE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
CAFFEINE;CYP1A2;AA;rs762551;OTHER;INCREASED_METABOLISM;nan
CAFFEINE;CYP1A2;AA;rs762551;LADME_PK;INCREASED_METABOLISM;nan
IMATINIB;SLC22A1;CC;rs683369;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
ETANERCEPT;TNFRSF1B;GT;rs1061622;EFFICACY;DECREASED_RESPONSE;DISEASE:SPONDYLITIS | ANKYLOSING
FENTANYL;SLC9A9;GG;rs4839603;EFFICACY;DECREASED_DOSE;DISEASE:PAIN
REMIFENTANIL;SLC9A9;GG;rs4839603;EFFICACY;DECREASED_DOSE;DISEASE:PAIN
EFAVIRENZ;ABCB1;GG;rs1045642;EFFICACY;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;ABCB1;GG;rs1045642;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;T;rs3745274;EFFICACY;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;ABCB1;AA;rs1045642;EFFICACY;INCREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;ABCB1;AA;rs1045642;LADME_PK;INCREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
APREMILAST;PDE4B;T;rs12745871;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
ATORVASTATIN;SCARB1;AA;rs5888;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
APREMILAST;TSPAN16;C;rs322144;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
PRAVASTATIN;FCAR;AA + AG;rs11666735;EFFICACY;INCREASED_RESPONSE;DISEASE:MYOCARDIAL_INFARCTION
CYCLOPHOSPHAMIDE;GSTP1;AA + AG;rs1695;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
EPIRUBICIN;GSTP1;AA + AG;rs1695;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
FENOFIBRATE;APOA1;G;rs964184;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
ANTIEPILEPTICS;SCN1A;CT;rs10188577;EFFICACY;INCREASED_RESISTANCE;DISEASE:EPILEPSY
APREMILAST;DOCK6;G;rs12979813;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
DAPTOMYCIN;ABCB1;AA;rs1045642;LADME_PK;INCREASED_CONCENTRATIONS;nan
DAPTOMYCIN;ABCB1;AA;rs1045642;LADME_PK;DECREASED_CLEARANCE;nan
NALTREXONE;DBH;CT + TT;rs1611115;EFFICACY;INCREASED_RESPONSE;DISEASE:ALCOHOL_ABUSE
GEMCITABINE;SLC28A2;CC;rs11854484;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
ANTINEOPLASTIC AGENTS;ABCG2;GG;rs2231142;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
GEMCITABINE;SLC28A2;CC;rs1060896;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
APREMILAST;EIF3G;G;rs2305795;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
APREMILAST;P2RY11;G;rs2305795;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
APREMILAST;PPAN-P2RY11;G;rs2305795;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1A;TT;rs767455;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OSTEOSARCOMA
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL3;GG;rs1139130;EFFICACY;INCREASED_RESISTANCE;OTHER:TUBERCULOSIS
METHOTREXATE;SLCO1B1;CC + CT;rs11045879;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OSTEOSARCOMA
SUFENTANIL;OPRM1;AG;rs1799971;DOSAGE;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
APREMILAST;ILF3;T;rs76966440;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED_DOSE;nan
CYCLOPHOSPHAMIDE;GSTP1;A;rs1695;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
EPIRUBICIN;GSTP1;A;rs1695;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
FLUOROURACIL;GSTP1;A;rs1695;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
SULFASALAZINE;ABCG2;GT + TT;rs2231142;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
PEGINTERFERON ALFA-2A;IFNL3;T;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;T;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;T;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
WARFARIN;VKORC1;CC + CT;rs9923231;DOSAGE;INCREASED_DOSE;nan
TACROLIMUS;ABCB1;AG + GG;rs1128503;EFFICACY;INCREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED_DOSE;nan
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
WARFARIN;PRSS53;AA + AG;rs9934438;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED_DOSE;nan
PEGINTERFERON ALFA-2B;IFNL3;T;rs12979860;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;T;rs12979860;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;T;rs12979860;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;T;rs12979860;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;VDR;A;rs2228570;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;VDR;A;rs2228570;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
NORTRIPTYLINE;NOS3;TT;rs1799983;EFFICACY;INCREASED_RESPONSE;OTHER:MIGRAINE_WITHOUT_AURA | OTHER:MIGRAINE_WITH_AURA
ALLOPURINOL;GREM2;T;rs1934341;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
COTININE;NAT1;AG + GG;rs13253389;LADME_PK;INCREASED_CONCENTRATIONS;nan
ALLOPURINOL;GREM2;G;rs77567654;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
TACROLIMUS;ABCB1;CC;rs2032582;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
ALLOPURINOL;ABCG2;C;rs45499402;EFFICACY;DECREASED_RESPONSE;nan
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
ALLOPURINOL;ABCG2;T;rs2231142;EFFICACY;DECREASED_RESPONSE;nan
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
EXENATIDE;GLP1R;T;rs10305420;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
TOPIRAMATE;ABCB1;AA;rs1045642;EFFICACY;INCREASED_RESPONSE;OTHER:MIGRAINE_WITHOUT_AURA | OTHER:MIGRAINE_WITH_AURA
LAMOTRIGINE;UGT2B7;TT;rs7668258;LADME_PK;DECREASED_CLEARANCE;DISEASE:EPILEPSY
WARFARIN;VKORC1;TT;rs7294;DOSAGE;INCREASED_DOSE;nan
BENAZEPRIL;AGT;GG;rs4762;EFFICACY;RESPONSE;DISEASE:HYPERTENSION
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
IMATINIB;ABCB1;GG;rs1128503;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
LAMOTRIGINE;UGT2B7;GG;rs28365063;LADME_PK;INCREASED_CLEARANCE;DISEASE:EPILEPSY
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
METHOTREXATE;ABCC4;GG;rs7317112;LADME_PK;INCREASED_CLEARANCE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
BENAZEPRIL;AGTR1;GG;rs2640543;EFFICACY;RESPONSE;DISEASE:HYPERTENSION
ALENDRONATE;MVK;GG;rs10161126;EFFICACY;INCREASED_RESPONSE;DISEASE:BONE_DISEASES
PEGINTERFERON ALFA-2B;ITPA;A;rs1127354;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;ITPA;A;rs1127354;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
ELEXACAFTOR;CFTR;G;rs80034486;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
TEZACAFTOR;CFTR;G;rs80034486;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;G;rs80034486;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
SARILUMAB;IL6R;CC;rs11265618;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
PEGINTERFERON ALFA-2A;LDLR;GG;rs14158;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
PEGINTERFERON ALFA-2B;LDLR;GG;rs14158;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
RIBAVIRIN;LDLR;GG;rs14158;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
BENAZEPRIL;SPTA1;G;rs2106089;EFFICACY;RESPONSE;DISEASE:HYPERTENSION
IMATINIB;ABCB1;GG;rs1045642;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
TACROLIMUS;CYP3A5;TT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
SARILUMAB;IL6R;TT;rs4329505;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
IMATINIB;ABCB1;C;rs2032582;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
BUPRENORPHINE;OPRD1;CC;rs678849;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
EFAVIRENZ;CYP2B6;GT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
PHENPROCOUMON;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
ADALIMUMAB;NCR3;AT + TT;rs1052248;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
CERTOLIZUMAB PEGOL;NCR3;AT + TT;rs1052248;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
ETANERCEPT;NCR3;AT + TT;rs1052248;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
INFLIXIMAB;NCR3;AT + TT;rs1052248;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;NCR3;AT + TT;rs1052248;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
SALBUTAMOL;COL2A1;GT + TT;rs3809324;LADME_PD;DECREASED_RESPONSE;OTHER:ASTHMA
ANTIPSYCHOTICS;CACNA1C;CC;rs2238087;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
DIURETICS;PRKCA;T;rs4791040;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
HYDROCHLOROTHIAZIDE;PRKCA;T;rs4791040;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
THIAZIDES;PRKCA;T;rs4791040;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
PLAIN;PRKCA;T;rs4791040;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
ANTIPSYCHOTICS;CACNA1B;CC;rs2229949;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ACENOCOUMAROL;STX4;T;rs10871454;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED_DOSE;nan
WARFARIN;nan;AA + AG;rs12777823;DOSAGE;DECREASED_DOSE;nan
CORTICOSTEROIDS;GLCCI1;GG;rs37973;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:RHINITIS
DEFERASIROX;GC;AA;rs7041;EFFICACY;INCREASED_RESPONSE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED_DOSE;nan
PEGINTERFERON ALFA-2A;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED_RESPONSE;DISEASE:HEPATITIS_C
ASPIRIN;CYP4F2;CC + CT;rs2108622;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
CLOPIDOGREL;CYP4F2;CC + CT;rs2108622;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
ACENOCOUMAROL;CYP4F2;T;rs2108622;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED_DOSE;DISEASE:CARDIOVASCULAR_DISEASE
WARFARIN;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED_DOSE;DISEASE:CARDIOVASCULAR_DISEASE
INTERFERON BETA-1A;CD58;CC;rs12044852;EFFICACY;DECREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
INTERFERON BETA-1B;CD58;CC;rs12044852;EFFICACY;DECREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;GG + GT;rs610604;EFFICACY;INCREASED_RESPONSE;OTHER:ARTHRITIS | PSORIATIC | OTHER:PSORIASIS
MORPHINE;OPRM1;AG + GG;rs1799971;EFFICACY;DECREASED_RESPONSE;nan
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;DISEASE:CARDIOVASCULAR_DISEASE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;AA;rs6920220;EFFICACY;DECREASED_RESPONSE;OTHER:ARTHRITIS | PSORIATIC | OTHER:PSORIASIS
WARFARIN;CYP4F2;CC + CT;rs2108622;DOSAGE;DECREASED_DOSE;DISEASE:CARDIOVASCULAR_DISEASE
ANTIPSYCHOTICS;CACNB2;TT;rs12245847;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
TACROLIMUS;CYP3A7;C;rs2257401;LADME_PK;TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION | DISEASE:TRANSPLANTATION
DEFERASIROX;UGT1A1;CC;rs887829;EFFICACY;DECREASED_RESPONSE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
ANTIPSYCHOTICS;CACNG3;TT;rs1859204;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
TACROLIMUS;CYP3A5;C;rs776746;LADME_PK;TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION | DISEASE:TRANSPLANTATION
DEFERASIROX;UGT1A3;TT;rs1983023;EFFICACY;INCREASED_RESPONSE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
DEFERASIROX;CYP27B1;GG;rs10877012;EFFICACY;INCREASED_RESPONSE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
TACROLIMUS;CYP3A4;A;rs4646437;LADME_PK;TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION | DISEASE:TRANSPLANTATION
ADALIMUMAB;ATG16L1;CT + TT;rs10210302;EFFICACY;INCREASED_RESPONSE;DISEASE:CROHN_DISEASE
ANTIPSYCHOTICS;CACNB2;CC;rs982003;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
TACROLIMUS;CYP3A4;T;rs2242480;LADME_PK;TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION | DISEASE:TRANSPLANTATION
DEFERASIROX;VDR;GG;rs731236;EFFICACY;INCREASED_RESPONSE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
DEFERASIROX;VDR;TT;rs1544410;EFFICACY;INCREASED_RESPONSE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
TACROLIMUS;CYP3A5;A;rs41303343;LADME_PK;TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION | DISEASE:TRANSPLANTATION
CAPECITABINE;SLC19A1;CC;rs1051266;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
FLUOROURACIL;SLC19A1;CC;rs1051266;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
IRINOTECAN;SLC19A1;CC;rs1051266;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
LEUCOVORIN;SLC19A1;CC;rs1051266;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
CAPECITABINE;SLCO1B1;AA + AG;rs2306283;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
FLUOROURACIL;SLCO1B1;AA + AG;rs2306283;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
IRINOTECAN;SLCO1B1;AA + AG;rs2306283;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
LEUCOVORIN;SLCO1B1;AA + AG;rs2306283;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
TACROLIMUS;CYP3A5;A;rs4646450;LADME_PK;TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION | DISEASE:TRANSPLANTATION
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
SIMVASTATIN ACID;SLCO1B1;CC + CT;rs4149056;LADME_PK;INCREASED_CONCENTRATIONS;nan
DIURETICS;nan;A;rs2776546;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
HYDROCHLOROTHIAZIDE;nan;A;rs2776546;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
THIAZIDES;nan;A;rs2776546;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
PLAIN;nan;A;rs2776546;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
WARFARIN;CYP2C9;CG;rs28371686;DOSAGE;DECREASED_DOSE;nan
ANTIPSYCHOTICS;CACNB2;TT;rs10741058;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ATAZANAVIR;UGT1A1;TT;rs887829;TOXICITY;INCREASED_DISCONTINUATION;DISEASE:HIV_INFECTIOUS_DISEASE
DIURETICS;nan;A;rs238;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
HYDROCHLOROTHIAZIDE;nan;A;rs238;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
THIAZIDES;nan;A;rs238;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
PLAIN;nan;A;rs238;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
ANTIPSYCHOTICS;CACNA2D3;AA;rs4505744;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
DIURETICS;nan;T;rs4815273;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
HYDROCHLOROTHIAZIDE;nan;T;rs4815273;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
THIAZIDES;nan;T;rs4815273;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
PLAIN;nan;T;rs4815273;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
IBUPROFEN;CYP2C9;AC;rs1057910;EFFICACY;DECREASED_TIME TO RESPONSE;OTHER:PATENT_DUCTUS_ARTERIOSUS
ANTIPSYCHOTICS;CACNA1E;TT;rs12060765;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CORTICOSTEROIDS;TAAR6;GG;rs7772821;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
SALBUTAMOL;VEGFA;CT + TT;rs3025039;LADME_PD;DECREASED_RESPONSE;OTHER:ASTHMA
BEVACIZUMAB;CFH;CC;rs1061170;EFFICACY;DECREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
RANIBIZUMAB;CFH;CC;rs1061170;EFFICACY;DECREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED_DOSE;nan
MORPHINE;TAOK3;TT;rs795484;DOSAGE;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
MORPHINE;TAOK3;TT;rs795484;EFFICACY;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
PREDNISONE;NR3C1;G;rs6196;EFFICACY;DECREASED_RESISTANCE;DISEASE:NEPHROTIC_SYNDROME
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
SN-38;UGT1A1;AA;rs4148323;LADME_PK;DECREASED_METABOLISM;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
DOCETAXEL;nan;G;rs4842198;LADME_PK;INCREASED_METABOLISM;DISEASE:NASOPHARYNGEAL_NEOPLASMS
FLUVOXAMINE;HTR2A;CC;rs6311;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;AG + GG;rs3794271;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED_DOSE;nan
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;EFFICACY;DECREASED_DOSE;nan
PREDNISONE;NR3C1;A;rs258751;EFFICACY;DECREASED_RESISTANCE;DISEASE:NEPHROTIC_SYNDROME
LEDIPASVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
LEDIPASVIR;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
SOFOSBUVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
SOFOSBUVIR;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
SN-38;UGT1A9;del/del;rs3832043;LADME_PK;DECREASED_METABOLISM;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
PHENYTOIN;CYP2C9;G;rs28371686;OTHER;DECREASED_METABOLISM;OTHER:NO_DISEASE
PHENYTOIN;CYP2C9;G;rs28371686;LADME_PK;DECREASED_METABOLISM;OTHER:NO_DISEASE
IMATINIB;ABCG2;CT + TT;rs2231137;DOSAGE;DECREASED_DOSE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS
PREDNISONE;NR3C1;A;rs10052957;EFFICACY;DECREASED_RESISTANCE;DISEASE:NEPHROTIC_SYNDROME
IMATINIB;CYP1A2;CC;rs762551;DOSAGE;DECREASED_DOSE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS
PHENYTOIN;CYP2C9;A;rs7900194;OTHER;DECREASED_METABOLISM;OTHER:NO_DISEASE
PHENYTOIN;CYP2C9;A;rs7900194;LADME_PK;DECREASED_METABOLISM;OTHER:NO_DISEASE
LURASIDONE;HTR1A;CG + GG;rs6295;EFFICACY;DECREASED_RESPONSE;OTHER:SCHIZOPHRENIA
PHENYTOIN;CYP2C9;T;rs28371685;OTHER;INCREASED_METABOLISM;PK:NO_DISEASE
PHENYTOIN;CYP2C9;T;rs28371685;LADME_PK;INCREASED_METABOLISM;PK:NO_DISEASE
PHENYTOIN;CYP2C9;del;rs9332131;OTHER;DECREASED_METABOLISM;PK:NO_DISEASE
PHENYTOIN;CYP2C9;del;rs9332131;LADME_PK;DECREASED_METABOLISM;PK:NO_DISEASE
DOCETAXEL;RXRA;A;rs3132291;LADME_PK;INCREASED_METABOLISM;DISEASE:NASOPHARYNGEAL_NEOPLASMS
INFLIXIMAB;TNFRSF1B;G;rs1061622;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
CODEINE;OPRM1;AA;rs1799971;DOSAGE;DECREASED_DOSE;nan
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
CODEINE;UGT2B7;TT;rs7439366;DOSAGE;DECREASED_DOSE;nan
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
ANTIPSYCHOTICS;CACNB2;CC;rs4237348;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
TACROLIMUS;CYP3A4;T;rs2740574;LADME_PK;TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION | DISEASE:TRANSPLANTATION
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
ANTIPSYCHOTICS;CACNB4;AA + AC;rs3768652;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
TACROLIMUS;CYP3A4;A;rs35599367;LADME_PK;TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION | DISEASE:TRANSPLANTATION
ANTIPSYCHOTICS;CACNA2D3;CC;rs7427395;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;CACNB2;TT;rs1277733;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
SOFOSBUVIR;CES1;A;rs4513095;EFFICACY;DECREASED_RESPONSE;OTHER:CHRONIC_HEPATITIS_C
TACROLIMUS;CYP3A5;CT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
PROPOFOL;SCN9A;AA + AG;rs6746030;OTHER;INCREASED_RESPONSE;nan
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED_DOSE;DISEASE:TRANSPLANTATION
SALBUTAMOL;PRKG1;A;rs7081864;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ASTHMA
TACROLIMUS;CYP3A5;C;rs776746;DOSAGE;DECREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
TOCILIZUMAB;IL6R;AA;rs12083537;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ANTIPSYCHOTICS;BDNF;AG + GG;rs11030104;EFFICACY;INCREASED_RESISTANCE;DISEASE:SCHIZOPHRENIA
SUNITINIB;ABCB1;GG;rs1045642;LADME_PK;INCREASED_EXPOSURE;DISEASE:RENAL_CELL_CARCINOMA
PROPOFOL;HTR2A;AA;rs6313;DOSAGE;DECREASED_DOSE;nan
ANTIPSYCHOTICS;BDNF-AS;CC + CT;rs10501087;EFFICACY;INCREASED_RESISTANCE;DISEASE:SCHIZOPHRENIA
PROPOFOL;GABRA1;GG;rs2279020;OTHER;INCREASED_RESPONSE;nan
SUNITINIB;ABCB1;GG;rs1045642;EFFICACY;DECREASED_RESPONSE;DISEASE:RENAL_CELL_CARCINOMA
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
OPIOIDS;COMT;AA + AG;rs4680;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
TACROLIMUS;CYP3A5;CT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
DOXORUBICIN;ABCB1;AA;rs1045642;EFFICACY;DECREASED_RESISTANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE;ABCB1;AA;rs1045642;EFFICACY;DECREASED_RESISTANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
PREDNISOLONE;ABCB1;AA;rs1045642;EFFICACY;DECREASED_RESISTANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
VINCRISTINE;ABCB1;AA;rs1045642;EFFICACY;DECREASED_RESISTANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ANTIPSYCHOTICS;BDNF;CT + TT;rs6265;EFFICACY;INCREASED_RESISTANCE;DISEASE:SCHIZOPHRENIA
OPIOIDS;COMT;AG;rs4680;DOSAGE;DECREASED_DOSE;nan
METFORMIN;ABCC8;CT + TT;rs5219;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
METFORMIN;KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
SULFONAMIDES;ABCC8;CT + TT;rs5219;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
SULFONAMIDES;KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
UREA DERIVATIVES;ABCC8;CT + TT;rs5219;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
UREA DERIVATIVES;KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
PALIPERIDONE;NFIB;CT;rs28379954;LADME_PK;INCREASED_CONCENTRATIONS;nan
RISPERIDONE;NFIB;CT;rs28379954;LADME_PK;INCREASED_CONCENTRATIONS;nan
REMIFENTANIL;ABCB1;GG;rs1128503;EFFICACY;INCREASED_RESPONSE;OTHER:TONSILLECTOMY
SEVOFLURANE;ABCB1;GG;rs1128503;EFFICACY;INCREASED_RESPONSE;OTHER:TONSILLECTOMY
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
MORPHINE;TAOK3;GG;rs1277441;DOSAGE;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
MORPHINE;TAOK3;GG;rs1277441;EFFICACY;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
DOXORUBICIN;ABCB1;CT;rs2229109;EFFICACY;INCREASED_RESISTANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE;ABCB1;CT;rs2229109;EFFICACY;INCREASED_RESISTANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
PREDNISOLONE;ABCB1;CT;rs2229109;EFFICACY;INCREASED_RESISTANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
VINCRISTINE;ABCB1;CT;rs2229109;EFFICACY;INCREASED_RESISTANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
HYDROXYUREA;KLF4;C;rs2236599;EFFICACY;INCREASED_RESPONSE;OTHER:SICKLE_CELL_ANEMIA | OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
OXYCODONE;OPRM1;GG;rs1799971;DOSAGE;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
TACROLIMUS;CYP3A4;CT + TT;rs2242480;LADME_PK;INCREASED_CLEARANCE;OTHER:HEART_TRANSPLANTATION
METHOTREXATE;SLCO1B1;A;rs11045821;EFFICACY;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE;SLCO1B1;A;rs11045821;TOXICITY;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE;SLCO1B1;A;rs11045821;LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHYLPHENIDATE;SLC6A2;AT + TT;rs28386840;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
BILIRUBIN;UGT1A;AG + GG;rs11563250;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:COLORECTAL_NEOPLASMS
DEFERASIROX;UGT1A3;CT + TT;rs1983023;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
ADALIMUMAB;CERS6;A;rs13393173;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
CERTOLIZUMAB PEGOL;CERS6;A;rs13393173;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
ETANERCEPT;CERS6;A;rs13393173;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
INFLIXIMAB;CERS6;A;rs13393173;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CERS6;A;rs13393173;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
MORPHINE;SLC22A1;CT + TT;rs12208357;LADME_PK;DECREASED_CLEARANCE;nan
MIDAZOLAM;CYP3A4;AG;rs35599367;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
MORPHINE;SLC22A1;CC + CT;rs55918055;LADME_PK;DECREASED_CLEARANCE;nan
BUPROPION;CYP2A6;T;rs4803381;EFFICACY;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
DRUGS USED IN NICOTINE DEPENDENCE;CYP2A6;T;rs4803381;EFFICACY;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
METFORMIN;SRR;CC + CT;rs391300;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
METHYLPHENIDATE;SLC6A2;AG + GG;rs5569;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
ERYTHROMYCIN;CYP3A4;AG;rs35599367;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
NICOTINE;CYP2A6;T;rs4803381;LADME_PK;DECREASED_METABOLISM;nan
CLOZAPINE;ABCB1;G;rs7787082;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CAFFEINE;CYP1A2;AA + AC;rs762551;LADME_PK;INCREASED_METABOLISM;nan
ATENOLOL;nan;AA + AC;rs12346562;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
HYDROCHLOROTHIAZIDE;nan;AA + AC;rs12346562;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
ATENOLOL;nan;AA + AG;rs1104514;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
IVACAFTOR;CFTR;A;rs121908755;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
MORPHINE;SLC22A1;AA + AG;rs34130495;LADME_PK;DECREASED_CLEARANCE;nan
ATENOLOL;nan;GG + GT;rs10739150;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
CLOZAPINE;ABCB1;A;rs10248420;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
DEFERASIROX;UGT1A3;CC;rs3806596;EFFICACY;INCREASED_RESPONSE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
DEFERASIROX;UGT1A3;CC;rs3806596;LADME_PK;INCREASED_RESPONSE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
TRANDOLAPRIL;PTPRD;T;rs4742610;EFFICACY;RESISTANCE;DISEASE:HYPERTENSION
VERAPAMIL;PTPRD;T;rs4742610;EFFICACY;RESISTANCE;DISEASE:HYPERTENSION
DEFERASIROX;ABCG2;CC;rs13120400;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
EFAVIRENZ;ABCB1;CC + CT;rs3842;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:HIV_INFECTIOUS_DISEASE | DISEASE:TUBERCULOSIS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
METFORMIN;SLC47A1;A;rs2289669;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
SULFONAMIDES;SLC47A1;A;rs2289669;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
UREA DERIVATIVES;SLC47A1;A;rs2289669;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
SUNITINIB;ABCG2;GT + TT;rs2231142;LADME_PK;INCREASED_EXPOSURE;DISEASE:NEOPLASMS
WARFARIN;VDR;GG;rs11168292;DOSAGE;INCREASED_DOSE;nan
4-HYDROXYTAMOXIFEN;SULT1A2;AA;rs1136703;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ENDOXIFEN;SULT1A2;AA;rs1136703;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ARA-CTP;SLC28A3;AA;rs17343066;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MYELOID_ACUTE_LEUKEMIA
WARFARIN;VDR;GG;rs4760658;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VDR;TT;rs11168293;DOSAGE;INCREASED_DOSE;nan
ADALIMUMAB;ALPL;T;rs885814;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
CERTOLIZUMAB PEGOL;ALPL;T;rs885814;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
ETANERCEPT;ALPL;T;rs885814;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
INFLIXIMAB;ALPL;T;rs885814;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;ALPL;T;rs885814;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
ETOPOSIDE;SLIT1;AA;rs2784917;LADME_PK;DECREASED_INHIBITION;nan
METHOTREXATE;SLCO1B1;C;rs4149056;EFFICACY;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE;SLCO1B1;C;rs4149056;TOXICITY;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE;SLCO1B1;C;rs4149056;LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHYLPHENIDATE;SLC6A2;GG;rs5569;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
METHOTREXATE;SLCO1B1;A;rs2306283;EFFICACY;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE;SLCO1B1;A;rs2306283;TOXICITY;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE;SLCO1B1;A;rs2306283;LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ADALIMUMAB;nan;A;rs1350948;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
CERTOLIZUMAB PEGOL;nan;A;rs1350948;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
ETANERCEPT;nan;A;rs1350948;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
INFLIXIMAB;nan;A;rs1350948;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;nan;A;rs1350948;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
4-HYDROXYTAMOXIFEN;SULT1A2;TT;rs1059491;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ENDOXIFEN;SULT1A2;TT;rs1059491;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
METHYLPHENIDATE;SLC6A2;AT + TT;rs28386840;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
METHOTREXATE;SLCO1B1;A;rs4149081;EFFICACY;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE;SLCO1B1;A;rs4149081;TOXICITY;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE;SLCO1B1;A;rs4149081;LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ADALIMUMAB;EYA4;C;rs17301249;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
CERTOLIZUMAB PEGOL;EYA4;C;rs17301249;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
ETANERCEPT;EYA4;C;rs17301249;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
INFLIXIMAB;EYA4;C;rs17301249;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;EYA4;C;rs17301249;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
METHYLPHENIDATE;SLC6A2;AT + TT;rs28386840;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED_DOSE;nan
ADALIMUMAB;nan;G;rs12081765;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
CERTOLIZUMAB PEGOL;nan;G;rs12081765;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
ETANERCEPT;nan;G;rs12081765;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
INFLIXIMAB;nan;G;rs12081765;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;nan;G;rs12081765;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
METHOTREXATE;SLCO1B1;C;rs11045879;EFFICACY;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE;SLCO1B1;C;rs11045879;TOXICITY;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE;SLCO1B1;C;rs11045879;LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
PHENYLEPHRINE;ADRB2;AA;rs1042713;DOSAGE;INCREASED_DOSE;nan
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED_DOSE;OTHER:MECHANICAL_HEART_VALVE_REPLACEMENT
WARFARIN;CYP4F2;CT + TT;rs2108622;EFFICACY;INCREASED_DOSE;OTHER:MECHANICAL_HEART_VALVE_REPLACEMENT
ANASTROZOLE;CSMD1;G;rs6990851;EFFICACY;INCREASED_RESPONSE;OTHER:BREAST_NEOPLASMS
N-DESMETHYLTRAMADOL;ABCC2;AA;rs2273697;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
O-DESMETHYLTRAMADOL;ABCC2;AA;rs2273697;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
PEGINTERFERON ALFA-2B;nan;C;rs6806020;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;nan;C;rs6806020;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
NICOTINE;CYP2A6;C;rs28399433;LADME_PK;DECREASED_METABOLISM;nan
ATORVASTATIN;ABCB1;AA + AC;rs2032582;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
WARFARIN;VKORC1;CT + TT;rs7294;DOSAGE;INCREASED_DOSE;OTHER:MECHANICAL_HEART_VALVE_REPLACEMENT
WARFARIN;VKORC1;CT + TT;rs7294;EFFICACY;INCREASED_DOSE;OTHER:MECHANICAL_HEART_VALVE_REPLACEMENT
PEGINTERFERON ALFA-2B;nan;A;rs1931704;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;nan;A;rs1931704;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
ACAMPROSATE;CHDH;A;rs6801605;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ALCOHOL_ABUSE
ACAMPROSATE;IL17RB;A;rs6801605;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ALCOHOL_ABUSE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;OTHER:MECHANICAL_HEART_VALVE_REPLACEMENT
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;DECREASED_DOSE;OTHER:MECHANICAL_HEART_VALVE_REPLACEMENT
PEGINTERFERON ALFA-2B;IFNL3;GG;rs8099917;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;GG;rs8099917;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
CYCLOPHOSPHAMIDE;CYP2B6;GG;rs3745274;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:LEUKEMIA | LYMPHOCYTIC | CHRONIC | B-CELL
PRAVASTATIN;MTTP;GT + TT;rs1800591;EFFICACY;RESPONSE;nan
TACROLIMUS;CYP3A5;CT;rs776746;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED_DOSE;nan
COUMARIN;CYP2A6;C;rs28399433;LADME_PK;DECREASED_METABOLISM;nan
PEGINTERFERON ALFA-2B;IL21R;C;rs3093390;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IL21R;C;rs3093390;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
BEVACIZUMAB;VEGFA;GG;rs1570360;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
IRINOTECAN;VEGFA;GG;rs1570360;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
PEGINTERFERON ALFA-2B;nan;A;rs7512595;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;nan;A;rs7512595;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;CARD16;C;rs1792774;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;CARD16;C;rs1792774;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
WARFARIN;CYP2C19;CC;rs3814637;DOSAGE;INCREASED_DOSE;nan
WARFARIN;CYP2C9;AA + AC;rs1057910;DOSAGE;INCREASED_DOSE;nan
N-DESMETHYLTRAMADOL;ABCC2;TT;rs3740066;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
PEGINTERFERON ALFA-2B;nan;G;rs7750468;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;nan;G;rs7750468;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
WARFARIN;GGCX;CT + TT;rs699664;DOSAGE;INCREASED_DOSE;nan
IVACAFTOR;CFTR;AG;rs75527207;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
ATORVASTATIN;SLCO1B1;AA;rs2306283;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
FENTANYL;ABCC3;C;rs11079921;LADME_PK;INCREASED_CLEARANCE;OTHER:PAIN | OTHER:PREMATURE_BIRTH
PEGINTERFERON ALFA-2B;CARD16;A;rs1503391;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;CARD16;A;rs1503391;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;CASP1;T;rs557905;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;CASP1;T;rs557905;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;nan;A;rs2066911;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;nan;A;rs2066911;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
HMG COA REDUCTASE INHIBITORS;CFAP44;G;rs13064411;EFFICACY;DECREASED_RESPONSE;nan
ATORVASTATIN;CYP7A1;TT;rs3808607;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
PEGINTERFERON ALFA-2B;CASP1;A;rs568910;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;CASP1;A;rs568910;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
CODEINE;CYP2D6;TT;rs3892097;LADME_PK;DECREASED_METABOLISM;DISEASE:CHRONIC_KIDNEY_FAILURE
NICOTINE;CHRNB2;AG;rs2072658;OTHER;INCREASED_RESPONSE;OTHER:DAILY_SMOKING
METFORMIN;SLC22A1;AC + CC;rs622342;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
N-DESMETHYLTRAMADOL;UGT1A8;CC;rs8330;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:DEATH
PEGINTERFERON ALFA-2B;IFNL3;CC + CT;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC + CT;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;CC + CT;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;CC + CT;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC + CT;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC + CT;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;CC + CT;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;CC + CT;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
NICOTINE;CHRNA4;C;rs2229959;OTHER;INCREASED_RESPONSE;OTHER:DAILY_SMOKING
PEGINTERFERON ALFA-2B;TUT7;C;rs17461620;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;TUT7;C;rs17461620;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
ACETYLCYSTEINE;TOLLIP;TT;rs3750920;EFFICACY;INCREASED_RESPONSE;DISEASE:PULMONARY_FIBROSIS
OXCARBAZEPINE;ABCB1;A;rs1045642;EFFICACY;DECREASED_RESPONSE;DISEASE:EPILEPSY
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
TELAPREVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
TELAPREVIR;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
OXCARBAZEPINE;UGT2B7;C;rs7439366;EFFICACY;DECREASED_RESPONSE;DISEASE:EPILEPSY
ARA-CTP;CDA;AG + GG;rs12404655;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MYELOID_ACUTE_LEUKEMIA
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
ARA-CTP;RRM1;CT + TT;rs11030918;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:MYELOID_ACUTE_LEUKEMIA
CLOZAPINE;CYP1A2;AA;rs762551;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
CLOPIDOGREL;CYP3A5;CC + CT;rs776746;EFFICACY;INCREASED_RESISTANCE;DISEASE:STROKE
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
ARA-CTP;CTPS1;AG;rs11577910;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MYELOID_ACUTE_LEUKEMIA
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
ARA-CTP;CTPS1;AA + AG;rs12067645;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MYELOID_ACUTE_LEUKEMIA
ARA-CTP;CTPS1;CT + TT;rs4364871;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:MYELOID_ACUTE_LEUKEMIA
N-DESMETHYLTRAMADOL;UGT1A8;CC;rs10929303;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:DEATH
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
N-DESMETHYLTRAMADOL;UGT1A8;CC;rs34650714;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:DEATH
O-DESMETHYLTRAMADOL;UGT1A8;CC;rs34650714;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:DEATH
ARA-CTP;SLC28A1;TT;rs11853372;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:MYELOID_ACUTE_LEUKEMIA
ARA-CTP;DCTD;GG;rs4742;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:MYELOID_ACUTE_LEUKEMIA
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
ALLOPURINOL;ABCG2;GT + TT;rs2231142;EFFICACY;DECREASED_RESPONSE;DISEASE:GOUT
OXCARBAZEPINE;ABCB1;GG;rs1045642;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
AMANTADINE;SLC22A1;C;rs622342;DOSAGE;INCREASED_DOSE;DISEASE:PARKINSON_DISEASE
AMANTADINE;SLC22A1;C;rs622342;EFFICACY;INCREASED_DOSE;DISEASE:PARKINSON_DISEASE
ANTICHOLINERGICS;SLC22A1;C;rs622342;DOSAGE;INCREASED_DOSE;DISEASE:PARKINSON_DISEASE
ANTICHOLINERGICS;SLC22A1;C;rs622342;EFFICACY;INCREASED_DOSE;DISEASE:PARKINSON_DISEASE
LEVODOPA;SLC22A1;C;rs622342;DOSAGE;INCREASED_DOSE;DISEASE:PARKINSON_DISEASE
LEVODOPA;SLC22A1;C;rs622342;EFFICACY;INCREASED_DOSE;DISEASE:PARKINSON_DISEASE
SELEGILINE;SLC22A1;C;rs622342;DOSAGE;INCREASED_DOSE;DISEASE:PARKINSON_DISEASE
SELEGILINE;SLC22A1;C;rs622342;EFFICACY;INCREASED_DOSE;DISEASE:PARKINSON_DISEASE
ARA-CTP;DCK;CC + CT;rs4643786;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:MYELOID_ACUTE_LEUKEMIA
CLOZAPINE;CYP1A2;AA;rs762551;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA | OTHER:TOBACCO_USE_DISORDER
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
MORPHINE-3-GLUCURONIDE;ABCC3;CC;rs4793665;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:SCOLIOSIS | DISEASE:TONSILLECTOMY
MORPHINE-6-GLUCURONIDE;ABCC3;CC;rs4793665;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:SCOLIOSIS | DISEASE:TONSILLECTOMY
TACROLIMUS;ABCB1;GG;rs1128503;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
MORPHINE-3-GLUCURONIDE;ABCC3;TT;rs4148412;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:TONSILLECTOMY
GLUCOSE;CRTC2;AA + AG;rs8450;TOXICITY;INCREASED_CONCENTRATIONS;DISEASE:TRANSPLANTATION
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED_DOSE;nan
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;AG + GG;rs3794271;EFFICACY;DECREASED_RESPONSE;DISEASE:ARTHRITIS | PSORIATIC
TACROLIMUS;ABCB1;GG;rs1128503;LADME_PK;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
SERTRALINE;GNB3;GG;rs5441;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
FENTANYL;CYP3A4;TT;rs2242480;EFFICACY;INCREASED_RESPONSE;OTHER:POSTOPERATIVE_PAIN
SUFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED_DOSE;OTHER:LUNG_NEOPLASMS | OTHER:POSTOPERATIVE_PAIN
SUFENTANIL;OPRM1;AG + GG;rs1323040;DOSAGE;INCREASED_DOSE;OTHER:LUNG_NEOPLASMS | OTHER:POSTOPERATIVE_PAIN
SUFENTANIL;ABCB1;AA + AG;rs1128503;DOSAGE;INCREASED_DOSE;OTHER:LUNG_NEOPLASMS | OTHER:POSTOPERATIVE_PAIN
CYCLOSPORINE;ABCB1;A;rs1045642;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
SUFENTANIL;ABCB1;AA + AC;rs2032582;DOSAGE;INCREASED_DOSE;OTHER:LUNG_NEOPLASMS | OTHER:POSTOPERATIVE_PAIN
MORPHINE;OPRM1;GG;rs1799971;DOSAGE;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
HDL CHOLESTEROL;CRTC2;AA;rs8450;TOXICITY;DECREASED_CONCENTRATIONS;DISEASE:TRANSPLANTATION
O-DESMETHYLTRAMADOL;SLC22A1;GG;rs34130495;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:DEATH
MYCOPHENOLIC ACID;ABCC2;TT;rs717620;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
METHYLPHENIDATE;COMT;GG;rs4680;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
METHYLPHENIDATE;COMT;GG;rs4680;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
N-DESMETHYLTRAMADOL;SLC22A1;TT;rs1867351;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:DEATH
O-DESMETHYLTRAMADOL;SLC22A1;TT;rs1867351;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:DEATH
PHENYTOIN;CYP2C9;AA + AG;rs12782374;DOSAGE;DECREASED_DOSE;DISEASE:EPILEPSY
PHENYTOIN;CYP2C9;AA + AG;rs12782374;LADME_PK;DECREASED_DOSE;DISEASE:EPILEPSY
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;C;rs1057910;LADME_PK;DECREASED_DOSE;nan
FENTANYL;ABCC3;T;rs8077268;LADME_PK;INCREASED_CLEARANCE;OTHER:PAIN | OTHER:PREMATURE_BIRTH
METHYLPHENIDATE;COMT;G;rs4680;EFFICACY;INCREASED_CLEARANCE;DISEASE:ADHD
WARFARIN;CYP2C9;T;rs1799853;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;T;rs1799853;LADME_PK;DECREASED_DOSE;nan
PLATINUM COMPOUNDS;XRCC1;CC;rs25487;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;INCREASED_DOSE;nan
CYCLOSPORINE;ABCB1;GG;rs1045642;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
NICOTINE;CYP1A2;T/del + del/del;rs35694136;EFFICACY;DECREASED_EXPOSURE;nan
SIROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED_METABOLISM;DISEASE:TRANSPLANTATION
SIROLIMUS;CYP3A5;CC;rs776746;LADME_PK;DECREASED_METABOLISM;DISEASE:TRANSPLANTATION
PLATINUM COMPOUNDS;ERCC1;CC;rs3212986;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
MYCOPHENOLIC ACID;UGT2B7;G;rs7662029;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
METHYLPHENIDATE;TH;GG;rs2070762;EFFICACY;DECREASED_RESPONSE;DISEASE:ADHD
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED_RESPONSE;nan
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
TACROLIMUS;IL18;CC + CG;rs5744247;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
SIROLIMUS;CYP3A4;CC + CT;rs2740574;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
SIROLIMUS;CYP3A4;CC + CT;rs2740574;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
SIROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
SIROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
CETUXIMAB;FCGR2A;AA;rs1801274;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
CARBAMAZEPINE;CYP3A4;CC;rs2242480;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
RISPERIDONE;HTR2C;CC;rs518147;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CARBAMAZEPINE;CYP3A5;CC;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
SITAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
VILDAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
DESETHYLCHLOROQUINE;CYP2C8;C;rs7910936;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS
HYDROXYCHLOROQUINE;CYP2C8;C;rs7910936;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS
CARBAMAZEPINE;ABCB1;GG;rs1045642;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
CARBAMAZEPINE;EPHX1;CG;rs3738046;LADME_PK;CONCENTRATIONS;DISEASE:EPILEPSY
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HYPERCHOLESTEROLEMIA
PHENYTOIN;CYP2C9;AC;rs1057910;OTHER;DECREASED_METABOLISM;DISEASE:EPILEPSY
PHENYTOIN;CYP2C9;AC;rs1057910;LADME_PK;DECREASED_METABOLISM;DISEASE:EPILEPSY
PHENYTOIN;CYP2C9;CT;rs1799853;LADME_PK;DECREASED_METABOLISM;DISEASE:EPILEPSY
PHENYTOIN;CYP2C19;AG;rs4244285;OTHER;DECREASED_METABOLISM;DISEASE:EPILEPSY
PHENYTOIN;CYP2C19;AG;rs4244285;LADME_PK;DECREASED_METABOLISM;DISEASE:EPILEPSY
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
CLOZAPINE;HTR2C;C;rs6318;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CARBAMAZEPINE;EPHX1;AG + GG;rs2234922;LADME_PK;CONCENTRATIONS;DISEASE:EPILEPSY
CARBAMAZEPINE;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
SULFONAMIDES;TCF7L2;TT;rs12255372;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
UREA DERIVATIVES;TCF7L2;TT;rs12255372;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
SIMVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERCHOLESTEROLEMIA
CARBOPLATIN;XRCC1;T;rs25487;EFFICACY;DECREASED_RESPONSE;DISEASE:UTERINE_CERVICAL_NEOPLASM
CISPLATIN;XRCC1;T;rs25487;EFFICACY;DECREASED_RESPONSE;DISEASE:UTERINE_CERVICAL_NEOPLASM
FLUOROURACIL;XRCC1;T;rs25487;EFFICACY;DECREASED_RESPONSE;DISEASE:UTERINE_CERVICAL_NEOPLASM
TRAMADOL;ABCB1;AA;rs2032582;LADME_PK;INCREASED_EXPOSURE;nan
TRAMADOL;ABCB1;AA;rs1045642;LADME_PK;INCREASED_EXPOSURE;nan
CARBOPLATIN;SLC19A1;A;rs12659;EFFICACY;DECREASED_RESPONSE;DISEASE:UTERINE_CERVICAL_NEOPLASM
CISPLATIN;SLC19A1;A;rs12659;EFFICACY;DECREASED_RESPONSE;DISEASE:UTERINE_CERVICAL_NEOPLASM
FLUOROURACIL;SLC19A1;A;rs12659;EFFICACY;DECREASED_RESPONSE;DISEASE:UTERINE_CERVICAL_NEOPLASM
TRAMADOL;ABCB1;AA;rs1128503;LADME_PK;INCREASED_EXPOSURE;nan
TOCILIZUMAB;IL6R;AA;rs12083537;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CAFFEINE;ADORA1;CC;rs16851030;EFFICACY;INCREASED_RESPONSE;OTHER:APNEA_OF_PREMATURITY
TOCILIZUMAB;IL6R;CC + CT;rs4329505;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
RISPERIDONE;HTR2C;CC;rs1023574;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
RISPERIDONE;HTR2C;TT;rs9698290;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
DIURETICS;PRKCA;A;rs16960228;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
HYDROCHLOROTHIAZIDE;PRKCA;A;rs16960228;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
THIAZIDES;PRKCA;A;rs16960228;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
PLAIN;PRKCA;A;rs16960228;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
ANTIDEPRESSANTS;RGS17;A;rs672170;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
LITHIUM;NTRK2;AA;rs1387923;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
WARFARIN;CYP2C9;AT;rs7089580;DOSAGE;INCREASED_DOSE;nan
WARFARIN;CYP2C9;AT;rs7089580;DOSAGE;INCREASED_CLEARANCE;nan
VORICONAZOLE;SLCO1B3;GT + TT;rs4149117;LADME_PK;DECREASED_TROUGH CONCENTRATION;nan
LITHIUM;GSK3B;G;rs334558;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
OXALIPLATIN;TP53;CG + GG;rs1042522;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
ANTIDEPRESSANTS;NBEA;T;rs9315310;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ANTIDEPRESSANTS;CRH;C;rs4737771;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
ANTIDEPRESSANTS;FHIT;C;rs49411;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ANTIDEPRESSANTS;PARP11;G;rs2532560;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ANTIDEPRESSANTS;nan;T;rs2831440;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
SILDENAFIL;GNB3;TT;rs5443;EFFICACY;INCREASED_RESPONSE;DISEASE:ERECTILE_DYSFUNCTION
ANTIDEPRESSANTS;MTRF1L;G;rs766127;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ATORVASTATIN;POR;CT + TT;rs1057868;EFFICACY;DECREASED_RESPONSE;DISEASE:FAMILIAL_HYPERCHOLESTEROLEMIA
TACROLIMUS;HSD11B1;AA;rs846908;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
SARILUMAB;IL6R;CC;rs4845625;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
SALVIANOLIC ACID B;NOS3;GG;rs1799983;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_DISEASE
BUPROPION;COMT;AA + AG;rs165599;EFFICACY;INCREASED_RESPONSE;OTHER:SMOKERS
LITHIUM;TPH1;TT;rs1799913;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
BUPROPION;COMT;AA;rs737865;EFFICACY;DECREASED_RESPONSE;OTHER:SMOKERS
LITHIUM;TPH1;TT;rs1800532;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
LITHIUM;CACNG2;CC;rs2284017;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
SALBUTAMOL;CRHR2;G;rs2267715;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
DESETHYLCHLOROQUINE;CYP2C8;T;rs10882521;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS
HYDROXYCHLOROQUINE;CYP2C8;T;rs10882521;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS
LITHIUM;BCR;A;rs140504;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
SALMETEROL;ADRB2;AA;rs1042713;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
WARFARIN;STX1B;AG + GG;rs4889606;DOSAGE;INCREASED_DOSE;nan
ADALIMUMAB;HFE;CC + CT;rs2071303;EFFICACY;INCREASED_RESPONSE;DISEASE:CROHN_DISEASE
ROSIGLITAZONE;LPIN1;G;rs10192566;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
TACROLIMUS;HSD11B1;AA;rs4844880;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
DESETHYLCHLOROQUINE;CYP2D6;AA;rs1065852;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS
HYDROXYCHLOROQUINE;CYP2D6;AA;rs1065852;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS
TACROLIMUS;HSD11B1;AA;rs846910;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
ACENOCOUMAROL;GATA4;AG + GG;rs3735814;DOSAGE;DECREASED_DOSE;nan
BETA BLOCKING AGENTS;NEDD4L;AG + GG;rs4149601;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
SELECTIVE;NEDD4L;AG + GG;rs4149601;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
DIURETICS;NEDD4L;AG + GG;rs4149601;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
ANTIDEPRESSANTS;CTNNA3;C;rs10997242;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ALDOSTERONE ANTAGONISTS;NEDD4L;G;rs4149601;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
AMILORIDE;NEDD4L;G;rs4149601;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
LITHIUM;DRD1;C;rs4532;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
ANTIDEPRESSANTS;HTR2A;AG + GG;rs7997012;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
SALBUTAMOL;CRHR2;A;rs255100;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
ANTIDEPRESSANTS;HTR2A;GG;rs6313;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ANTIDEPRESSANTS;CACNA1A;A;rs2112460;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
SALBUTAMOL;CRHR2;G;rs2284220;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
WARFARIN;ORM1;AG + GG;rs17650;DOSAGE;DECREASED_DOSE;nan
ANTIDEPRESSANTS;nan;T;rs521093;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
MORPHINE;UGT2B7;CC;rs7439366;DOSAGE;DECREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
WARFARIN;VKORC1;C;rs7294;DOSAGE;DECREASED_DOSE;nan
ANTIDEPRESSANTS;RAPGEF5;C;rs16873129;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
VALPROIC ACID;ABCB1;AA;rs1128503;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
ANTIDEPRESSANTS;PON2;G;rs2299267;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;C;rs776746;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;C;rs776746;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
CISPLATIN;GALNT18;GG;rs7937567;EFFICACY;INCREASED_RESPONSE;DISEASE:URINARY_BLADDER_NEOPLASMS
EFAVIRENZ;CYP2B6;AG + GG;rs2279343;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
RITUXIMAB;nan;CC;rs3759467;EFFICACY;DECREASED_RESPONSE;DISEASE:VASCULITIS
ANTIPSYCHOTICS;CYP3A43;CG;rs680055;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOAFFECTIVE_DISORDER | DISEASE:SCHIZOPHRENIA
ARIPIPRAZOLE;CYP3A43;CG;rs680055;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOAFFECTIVE_DISORDER | DISEASE:SCHIZOPHRENIA
CLOZAPINE;CYP3A43;CG;rs680055;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOAFFECTIVE_DISORDER | DISEASE:SCHIZOPHRENIA
HALOPERIDOL;CYP3A43;CG;rs680055;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOAFFECTIVE_DISORDER | DISEASE:SCHIZOPHRENIA
OLANZAPINE;CYP3A43;CG;rs680055;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOAFFECTIVE_DISORDER | DISEASE:SCHIZOPHRENIA
QUETIAPINE;CYP3A43;CG;rs680055;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOAFFECTIVE_DISORDER | DISEASE:SCHIZOPHRENIA
RISPERIDONE;CYP3A43;CG;rs680055;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOAFFECTIVE_DISORDER | DISEASE:SCHIZOPHRENIA
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_STEADY_STATE CONCENTRATION;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;A;rs9923231;DOSAGE;DOSE;nan
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
CORTICOSTEROIDS;HDAC1;CC;rs1741981;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
VINCRISTINE;MTNR1B;AG;rs8192552;LADME_PK;INCREASED_EXPOSURE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA | OTHER:HODGKIN_DISEASE | OTHER:RHABDOMYOSARCOMA | OTHER:MEDULLOBLASTOMA | OTHER:GLIOMA
MORPHINE;TLR2;CC + CT;rs3804100;DOSAGE;DECREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
MORPHINE;TLR2;CC + CT;rs3804100;EFFICACY;DECREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;CT;rs776746;OTHER;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
DOCETAXEL;CHST3;T;rs4148947;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
THALIDOMIDE;CHST3;T;rs4148947;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
MORPHINE;IL1B;A;rs1143634;DOSAGE;DECREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
MORPHINE;IL1B;A;rs1143634;EFFICACY;DECREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CISPLATIN;MLLT3;AA + AC;rs10964552;EFFICACY;DECREASED_RESPONSE;DISEASE:URINARY_BLADDER_NEOPLASMS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;T;rs776746;DOSAGE;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;T;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
MORPHINE;IL1B;A;rs1143634;DOSAGE;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
MORPHINE;IL1B;A;rs1143634;EFFICACY;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
EFAVIRENZ;CYP2B6;CT;rs28399499;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
DOCETAXEL;CHST3;A;rs4148950;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
THALIDOMIDE;CHST3;A;rs4148950;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;TT;rs776746;DOSAGE;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;TT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
ATORVASTATIN;MTTP;TT;rs1800591;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERLIPOPROTEINEMIA_TYPE_II
NITROGLYCERIN;ALDH2;AA + AG;rs671;EFFICACY;DECREASED_RESPONSE;DISEASE:CONGENITAL_HEART_DEFECTS
TOCILIZUMAB;GALNT18;CC;rs4910008;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CISPLATIN;RARS1;TT;rs244898;EFFICACY;INCREASED_RESPONSE;DISEASE:URINARY_BLADDER_NEOPLASMS
TACROLIMUS;CYP3A5;CT;rs776746;DOSAGE;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DOSE;DISEASE:STROKE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
RISPERIDONE;ABCB1;AG + GG;rs2235048;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
TACROLIMUS;CYP3A5;CT;rs776746;LADME_PK;INCREASED_DOSE;OTHER:HEART_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
NITROGLYCERIN;ALDH2;AA + AG;rs671;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:CONGENITAL_HEART_DEFECTS | DISEASE:PULMONARY_HYPERTENSION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TOCILIZUMAB;CD69;A;rs11052877;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
PHENAZEPAM;CYP2C19;CC + CT;rs12248560;EFFICACY;INCREASED_RESPONSE;DISEASE:ALCOHOL-RELATED_DISORDERS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;TT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
VINCRISTINE;SNU13;G;rs6519270;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA | OTHER:HODGKIN_DISEASE | OTHER:RHABDOMYOSARCOMA | OTHER:MEDULLOBLASTOMA | OTHER:GLIOMA
ATENOLOL;nan;A;rs7184292;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
ATENOLOL;XIRP2;C;rs7606603;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
CYCLOSPORINE;CYP3A7;TT;rs10211;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DOSE;nan
CYCLOSPORINE;CYP3A7;CC;rs2257401;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;JAK2;CC;rs12343867;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS
NILOTINIB;GSTP1;A;rs1695;EFFICACY;INCREASED_RESPONSE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
HYDROCHLOROTHIAZIDE;nan;C;rs16872401;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;GG;rs3212217;EFFICACY;INCREASED_RESPONSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
CYCLOSPORINE;CYP3A4;GG;rs4646437;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
PAROXETINE;ABCB1;CC + CT;rs2032582;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
NILOTINIB;CYP1A1;CT + TT;rs1048943;EFFICACY;INCREASED_RESPONSE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;NLRP3;CG + GG;rs10754558;EFFICACY;INCREASED_RESPONSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
ATENOLOL;nan;GG;rs7184292;DOSAGE;DECREASED_DOSE;OTHER:HYPERTENSION
ATORVASTATIN;SLCO1B1;GG;rs2306283;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:HYPERLIPIDEMIAS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL18;GT + TT;rs1946518;EFFICACY;INCREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS
RISPERIDONE;AKT1;CT;rs3803300;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
RISPERIDONE;AKT1;TT;rs2494732;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR1;AG;rs2234711;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS
IMATINIB;CYP2B6;GG + TT;rs3745274;EFFICACY;INCREASED_RESISTANCE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
WARFARIN;CYP2C19;AA + AG;rs4986893;DOSAGE;DECREASED_DOSE;nan
CYCLOSPORINE;CYP3A5;CC;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C19;CT + TT;rs3814637;DOSAGE;DECREASED_DOSE;nan
CANNABIDIOL;AOC1;CT + TT;rs12539;EFFICACY;INCREASED_RESPONSE;OTHER:EPILEPSY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TBX21;CC;rs17250932;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS
VINCRISTINE;RAB7A;CT;rs4548;LADME_PK;INCREASED_EXPOSURE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA | OTHER:HODGKIN_DISEASE | OTHER:RHABDOMYOSARCOMA | OTHER:MEDULLOBLASTOMA | OTHER:GLIOMA
DOCETAXEL;CHST3;C;rs730720;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
THALIDOMIDE;CHST3;C;rs730720;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR2;CC;rs8126756;EFFICACY;DECREASED_RESPONSE;DISEASE:CROHN_DISEASE
CANNABIDIOL;SLC15A1;TT;rs1339067;EFFICACY;DECREASED_RESPONSE;OTHER:EPILEPSY
WARFARIN;nan;T;rs12772169;DOSAGE;DOSE;nan
ROSIGLITAZONE;SLCO1B1;C;rs4149056;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;CG + GG;rs3212217;EFFICACY;DECREASED_RESPONSE;DISEASE:CROHN_DISEASE
CORTICOSTEROIDS FOR SYSTEMIC USE;HDAC1;CC;rs1741981;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
WARFARIN;NQO1;A;rs1800566;EFFICACY;DECREASED_RESPONSE;DISEASE:THROMBOTIC_DISEASE
RISPERIDONE;COMT;G;rs165599;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
WARFARIN;VKORC1;A;rs9923231;DOSAGE;DOSE;nan
RISPERIDONE;GRM3;G;rs724226;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;DOSE;nan
ATENOLOL;KCNH2;GG;rs1137617;EFFICACY;RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
BISOPROLOL;KCNH2;GG;rs1137617;EFFICACY;RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
CELIPROLOL;KCNH2;GG;rs1137617;EFFICACY;RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
DOXAZOSIN;KCNH2;GG;rs1137617;EFFICACY;RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR5;AG;rs5744174;EFFICACY;DECREASED_RESPONSE;DISEASE:CROHN_DISEASE
MORPHINE;KCNJ6;CC;rs6517442;EFFICACY;INCREASED_RESPONSE;DISEASE:PAIN
METHOTREXATE;ABCG2;GT;rs2231142;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;POR;CT + TT;rs1057868;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION
MORPHINE;KCNJ6;TT;rs6517442;EFFICACY;DECREASED_RESPONSE;DISEASE:PAIN
REMIFENTANIL;KCNJ6;TT;rs6517442;EFFICACY;DECREASED_RESPONSE;DISEASE:PAIN
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
LOW DENSITY LIPOPROTEIN;SH2B1;CC;rs3888190;OTHER;INCREASED_CONCENTRATIONS;DISEASE:BIPOLAR_DISORDER | DISEASE:DEPRESSIVE_DISORDER | DISEASE:PSYCHOTIC_DISORDER | DISEASE:SCHIZOAFFECTIVE_DISORDER
TACROLIMUS;CYP3A5;T;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
ENALAPRIL;VEGFA;AA + AC;rs699947;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
LITHIUM;CACNG2;TT;rs2284018;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
EFAVIRENZ;ABCB1;GG;rs1045642;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;nan
ANASTROZOLE;nan;T;rs1437153;EFFICACY;DECREASED_RESPONSE;OTHER:BREAST_NEOPLASMS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
DOCETAXEL;ORM2;AA;rs2250242;LADME_PK;INCREASED_CLEARANCE;DISEASE:PROSTATIC_NEOPLASMS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
ETANERCEPT;CARD8;TT;rs2043211;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
INFLIXIMAB;CARD8;TT;rs2043211;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
METHOTREXATE;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED_RESPONSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
TELAPREVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
TELAPREVIR;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
TACROLIMUS;CYP3A5;TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;TT;rs776746;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR1;AG;rs2234711;EFFICACY;DECREASED_RESPONSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
ETANERCEPT;NLRP3;TT;rs4612666;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
INFLIXIMAB;NLRP3;TT;rs4612666;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
ANASTROZOLE;DLG2;T;rs2449598;EFFICACY;DECREASED_RESPONSE;OTHER:BREAST_NEOPLASMS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;T;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:NEPHROTIC_SYNDROME
EFAVIRENZ;CYP2B6;GG;rs2279343;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;CC;rs2242480;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:NEPHROTIC_SYNDROME
METHOTREXATE;MTHFR;AA;rs1801133;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
PEGINTERFERON ALFA-2B;HLA-DPA1;GG;rs3077;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_B | CHRONIC
RIVASTIGMINE;BCHE;CC;rs1803274;EFFICACY;INCREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED_DOSE;nan
METHOTREXATE;ABCB1;AG;rs1045642;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ADALIMUMAB;TNF;A;rs1800629;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ETANERCEPT;TNF;A;rs1800629;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
INFLIXIMAB;TNF;A;rs1800629;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;A;rs1800629;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
PRAVASTATIN;LDLR;TT;rs1433099;EFFICACY;INCREASED_RESPONSE;DISEASE:VASCULAR_DISEASES
PRAVASTATIN;LDLR;GG;rs2738466;EFFICACY;INCREASED_RESPONSE;DISEASE:VASCULAR_DISEASES
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
CANNABIDIOL;ABCC5;AA + AG;rs3749442;EFFICACY;DECREASED_RESPONSE;OTHER:EPILEPSY
PEGINTERFERON ALFA-2B;IFNL3;CC;rs4803217;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
RIBAVIRIN;IFNL3;CC;rs4803217;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:LIVER_TRANSPLANTATION
SUFENTANIL;NFKBIA;TT;rs696;DOSAGE;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
PEGINTERFERON ALFA-2B;IFNL3;AA;rs11881222;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
RIBAVIRIN;IFNL3;AA;rs11881222;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
GLUCOSE;RABEP1;AG + GG;rs1000940;OTHER;DECREASED_CONCENTRATIONS;DISEASE:BIPOLAR_DISORDER | DISEASE:DEPRESSIVE_DISORDER | DISEASE:PSYCHOTIC_DISORDER | DISEASE:SCHIZOAFFECTIVE_DISORDER
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
PAROXETINE;BDNF;TT;rs6265;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
REMIFENTANIL;COMT;AA;rs4680;EFFICACY;INCREASED_RESPONSE;DISEASE:PAIN
TACROLIMUS;CYP3A5;CT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:LIVER_TRANSPLANTATION
MORPHINE;COMT;GG;rs4680;EFFICACY;DECREASED_RESPONSE;DISEASE:PAIN
MORPHINE;COMT;AA + AG;rs4680;EFFICACY;INCREASED_RESPONSE;DISEASE:PAIN
REMIFENTANIL;COMT;AA + AG;rs4680;EFFICACY;INCREASED_RESPONSE;DISEASE:PAIN
TACROLIMUS;CYP3A5;CT;rs776746;DOSAGE;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
ANTIPSYCHOTICS;ABCB1;CC;rs2032582;DOSAGE;INCREASED_DOSE;DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;ABCB1;CC;rs2032582;LADME_PK;INCREASED_DOSE;DISEASE:SCHIZOPHRENIA
ADALIMUMAB;TLR2;T;rs3804099;EFFICACY;DECREASED_RESPONSE;OTHER:CROHN_DISEASE
INFLIXIMAB;TLR2;T;rs3804099;EFFICACY;DECREASED_RESPONSE;OTHER:CROHN_DISEASE
ANTIPSYCHOTICS;ABCB1;C;rs2032582;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
INTERFERON ALFA-N1;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
INTERFERON ALFA-N1;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
MORPHINE;COMT;G;rs4680;DOSAGE;INCREASED_DOSE;OTHER:CORONARY_ARTERY_DISEASE | EFFICACY:POSTOPERATIVE_PAIN
MORPHINE;COMT;G;rs4680;EFFICACY;INCREASED_DOSE;OTHER:CORONARY_ARTERY_DISEASE | EFFICACY:POSTOPERATIVE_PAIN
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_EXPOSURE;DISEASE:HIV_INFECTIOUS_DISEASE
INTERFERON ALFA-N1;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8103142;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
RIBAVIRIN;IFNL3;TT;rs8103142;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;T;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_CLEARANCE;OTHER:HSCT
PEGINTERFERON ALFA-2B;IFNL3;CC;rs28416813;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
RIBAVIRIN;IFNL3;CC;rs28416813;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;OTHER:KIDNEY_DISEASE
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
IMATINIB;ABCG2;GT;rs2231142;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
PEGINTERFERON ALFA-2B;nan;AA;rs8113007;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
RIBAVIRIN;nan;AA;rs8113007;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
CLOZAPINE;CHRM1;CC;rs2075748;DOSAGE;DECREASED_DOSE;OTHER:SCHIZOPHRENIA
CYCLOPHOSPHAMIDE;CYP1B1;CC;rs1056836;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
EPIRUBICIN;CYP1B1;CC;rs1056836;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
FLUOROURACIL;CYP1B1;CC;rs1056836;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_EXPOSURE;DISEASE:HIV_INFECTIOUS_DISEASE
PEGINTERFERON ALFA-2A;IFNL3;G;rs28416813;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;G;rs28416813;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;G;rs28416813;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
INTERFERON ALFA-N1;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
INTERFERON ALFA-N1;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
INTERFERON ALFA-N1;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
ERENUMAB;nan;G;rs12615320;EFFICACY;DECREASED_RESPONSE;OTHER:MIGRAINE_WITHOUT_AURA | OTHER:MIGRAINE_WITH_AURA
FREMANEZUMAB;nan;G;rs12615320;EFFICACY;DECREASED_RESPONSE;OTHER:MIGRAINE_WITHOUT_AURA | OTHER:MIGRAINE_WITH_AURA
GALCANEZUMAB;nan;G;rs12615320;EFFICACY;DECREASED_RESPONSE;OTHER:MIGRAINE_WITHOUT_AURA | OTHER:MIGRAINE_WITH_AURA
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED_RESPONSE;nan
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED_DOSE;nan
HYDROXYUREA;ASS1;T;rs10901080;EFFICACY;INCREASED_RESPONSE;DISEASE:SICKLE_CELL_ANEMIA | DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
ANASTROZOLE;CSMD1;T;rs6981827;EFFICACY;DECREASED_RESPONSE;OTHER:BREAST_NEOPLASMS
HYDROXYUREA;ASS1;T;rs10793902;EFFICACY;INCREASED_RESPONSE;DISEASE:SICKLE_CELL_ANEMIA | DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
PEGINTERFERON ALFA-2B;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED_RESPONSE;DISEASE:HEPATITIS_C
DOXORUBICIN;ABCB1;AA;rs2032582;LADME_PK;DECREASED_METABOLISM;DISEASE:BREAST_NEOPLASMS
PEGINTERFERON ALFA-2B;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL3;T;rs8103142;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;T;rs8103142;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;T;rs8103142;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
TACROLIMUS;CYP3A5;CT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
EPIRUBICIN;NQO1;AA;rs1800566;EFFICACY;DECREASED_RESPONSE;OTHER:BREAST_CANCER_CELL_LINES
EPIRUBICIN;NQO1;AA;rs1800566;TOXICITY;DECREASED_RESPONSE;OTHER:BREAST_CANCER_CELL_LINES
DOCETAXEL;MDM4;AA;rs1563828;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
EPIRUBICIN;MDM4;AA;rs1563828;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
GEMCITABINE;CDA;C;rs2072671;LADME_PK;DECREASED_CLEARANCE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
HYDROCHLOROTHIAZIDE;NEDD4L;AG + GG;rs75982813;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
GLICLAZIDE;KCNJ11;TT;rs5219;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
WARFARIN;nan;AA + AG;rs12777823;DOSAGE;DECREASED_DOSE;nan
DOXORUBICIN;ABCB1;AA;rs1045642;LADME_PK;DECREASED_METABOLISM;DISEASE:BREAST_NEOPLASMS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
ARIPIPRAZOLE;DRD2;GG;rs6277;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
CAPECITABINE;AREG;AA + AC;rs11942466;EFFICACY;DECREASED_RESPONSE;DISEASE:RECTAL_NEOPLASMS
RADIOTHERAPY;AREG;AA + AC;rs11942466;EFFICACY;DECREASED_RESPONSE;DISEASE:RECTAL_NEOPLASMS
(S)-METHADONE;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
(R)-METHADONE;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
CAPECITABINE;ERCC1;AG + GG;rs11615;EFFICACY;DECREASED_RESPONSE;DISEASE:RECTAL_NEOPLASMS
RADIOTHERAPY;ERCC1;AG + GG;rs11615;EFFICACY;DECREASED_RESPONSE;DISEASE:RECTAL_NEOPLASMS
CAPECITABINE;VEGFA;CG;rs2010963;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
OXALIPLATIN;VEGFA;CG;rs2010963;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
ARIPIPRAZOLE;ANKK1;AA + AG;rs1800497;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
MORPHINE;COMT;C;rs4633;DOSAGE;INCREASED_DOSE;OTHER:CORONARY_ARTERY_DISEASE | EFFICACY:POSTOPERATIVE_PAIN
MORPHINE;COMT;C;rs4633;EFFICACY;INCREASED_DOSE;OTHER:CORONARY_ARTERY_DISEASE | EFFICACY:POSTOPERATIVE_PAIN
CLOZAPINE;HTR3A;G;rs1150226;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
RISPERIDONE;GRM7;CC;rs2069062;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
CLOZAPINE;HTR3A;A;rs2276302;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
GLUCOSE;COMT;AA + AG;rs4680;TOXICITY;INCREASED_CONCENTRATIONS;nan
CLOZAPINE;HTR3A;C;rs1062613;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;LADME_PK;DECREASED_METABOLISM;DISEASE:ACUTE_CORONARY_SYNDROME
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
ADALIMUMAB;PTPRC;G;rs10919563;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ETANERCEPT;PTPRC;G;rs10919563;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
INFLIXIMAB;PTPRC;G;rs10919563;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_DISCONTINUATION;DISEASE:KIDNEY_DISORDER
RISPERIDONE;GRID2;GG;rs1875705;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
PACLITAXEL;ABCB1;CC;rs2032582;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
TACROLIMUS;NR1I2;CC;rs2276707;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT;rs776746;DOSAGE;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
CAPECITABINE;VEGFA;AC;rs699947;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
OXALIPLATIN;VEGFA;AC;rs699947;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
WARFARIN;PRSS53;A;rs17886199;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;A;rs17886199;DOSAGE;DECREASED_DOSE;nan
4-HYDROXYATORVASTATIN;SLCO2B1;AG;rs12422149;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:CORONARY_DISEASE
4-HYDROXYATORVASTATIN LACTONE;SLCO2B1;AG;rs12422149;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:CORONARY_DISEASE
PACLITAXEL;ABCB1;AA + AT;rs2032582;EFFICACY;INCREASED_RESPONSE;DISEASE:OVARIAN_NEOPLASMS
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
PEGINTERFERON ALFA-2B;IFNL3;AG + GG;rs11881222;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;AG + GG;rs11881222;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
2-HYDROXYATORVASTATIN LACTONE;UGT1A1;CC;rs887829;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:CORONARY_DISEASE
4-HYDROXYATORVASTATIN LACTONE;UGT1A1;CC;rs887829;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:CORONARY_DISEASE
ATORVASTATIN LACTONE;UGT1A1;CC;rs887829;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:CORONARY_DISEASE
BEVACIZUMAB;RGS5;TT;rs1056515;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
FLUOROURACIL;RGS5;TT;rs1056515;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
IRINOTECAN;RGS5;TT;rs1056515;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
LEUCOVORIN;RGS5;TT;rs1056515;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
SN-38;UGT1A1;AA;rs4148323;DOSAGE;DECREASED_METABOLISM;DISEASE:NEOPLASMS
PEGINTERFERON ALFA-2B;IFNL3;CC + CT;rs8105790;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC + CT;rs8105790;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;AG + GG;rs12980275;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;AG + GG;rs12980275;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
VALPROIC ACID;GABRA1;AA + AG;rs10068980;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
PEGINTERFERON ALFA-2B;IFNL3;CT + TT;rs12979860;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CT + TT;rs12979860;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CT + TT;rs12979860;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CT + TT;rs12979860;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
CLOZAPINE;CHRM1;GG;rs1942499;DOSAGE;DECREASED_DOSE;OTHER:SCHIZOPHRENIA
PEGINTERFERON ALFA-2B;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
ROSUVASTATIN;SCAP;C;rs12487736;EFFICACY;INCREASED_RESPONSE;DISEASE:METABOLIC_SYNDROME
PEGINTERFERON ALFA-2B;IFNL3;CT;rs4803219;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CT;rs4803219;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
BEVACIZUMAB;RALBP1;GG;rs329007;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
FLUOROURACIL;RALBP1;GG;rs329007;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
IRINOTECAN;RALBP1;GG;rs329007;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
LEUCOVORIN;RALBP1;GG;rs329007;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
ROCURONIUM;ABCB1;AA;rs1128503;EFFICACY;DECREASED_RESPONSE;nan
MYCOPHENOLIC ACID;UGT1A9;AA + AT;rs6714486;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
ACENOCOUMAROL;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;DECREASED_CLEARANCE;DISEASE:LIVER_TRANSPLANTATION
ROCURONIUM;SLCO1B1;AA;rs2306283;EFFICACY;DECREASED_RESPONSE;nan
PEGINTERFERON ALFA-2B;IFNL3;G;rs8099917;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;G;rs8099917;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PERAMPANEL;CYP3A5;C;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:EPILEPSY
PERAMPANEL;ZSCAN25;C;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:EPILEPSY
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:LIVER_TRANSPLANTATION
MORPHINE;UGT2B7;AA + AG;rs7438135;LADME_PK;DECREASED_CONCENTRATIONS;nan
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;DECREASED_CLEARANCE;DISEASE:LIVER_TRANSPLANTATION
PEGINTERFERON ALFA-2B;IFNL3;GT;rs8099917;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;GT;rs8099917;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;AA + AG;rs7248668;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;AA + AG;rs7248668;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;nan;GG;rs10853728;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;nan;GG;rs10853728;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PRAVASTATIN;SLCO1B1;CC + CT;rs4149056;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HYPERCHOLESTEROLEMIA
PEGINTERFERON ALFA-2B;nan;CG + GG;rs10853728;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;nan;CG + GG;rs10853728;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
ACENOCOUMAROL;CYP4F2;TT;rs2108622;DOSAGE;INCREASED_DOSE;nan
IMATINIB;ABCG2;C;rs2725252;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
PHENPROCOUMON;CYP4F2;T;rs2108622;DOSAGE;INCREASED_DOSE;OTHER:MAINTENANCE_DOSAGE_BY_1.5_MG/WEEK
ATENOLOL;EDN1;GT;rs5370;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
IRBESARTAN;EDN1;GT;rs5370;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
PAROXETINE;HTR2A;CC;rs6311;EFFICACY;INCREASED_RESPONSE;OTHER:OBSESSIVE-COMPULSIVE_DISORDER
PHENPROCOUMON;CYP2C9;T;rs4086116;DOSAGE;DECREASED_DOSE;OTHER:MAINTENANCE_DOSAGE_BY_2.2_MG/WEEK
ATORVASTATIN;APOE;C;rs7412;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERLIPIDEMIAS
PRAVASTATIN;APOE;C;rs7412;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERLIPIDEMIAS
SIMVASTATIN;APOE;C;rs7412;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERLIPIDEMIAS
IMATINIB;ABCG2;C;rs2725252;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
ATAZANAVIR;NR1I2;CT;rs2472677;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
PRAVASTATIN;SLCO1B1;AG;rs4149015;LADME_PK;INCREASED_METABOLISM;DISEASE:HYPERLIPOPROTEINEMIA_TYPE_II
APIXABAN;CYP3A5;CC + CT;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:ATRIAL_FIBRILLATION
IMATINIB;ABCG2;G;rs12505410;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
NIACIN;HCAR2;CT + TT;rs2454727;EFFICACY;DECREASED_RESPONSE;nan
ATORVASTATIN;ABCA1;C;rs12003906;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERLIPIDEMIAS
PRAVASTATIN;ABCA1;C;rs12003906;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERLIPIDEMIAS
SIMVASTATIN;ABCA1;C;rs12003906;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERLIPIDEMIAS
CEFTRIAXONE;ABCG2;TT;rs13120400;LADME_PK;CONCENTRATIONS;DISEASE:CENTRAL_NERVOUS_SYSTEM_INFECTIOUS_DISORDER
RIBAVIRIN;ITPA;CC;rs1127354;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;CT;rs776746;LADME_PK;DECREASED_EXPOSURE;DISEASE:KIDNEY_TRANSPLANTATION
PRAVASTATIN;SLCO1B1;AG;rs4149015;LADME_PK;INCREASED_RESPONSE;DISEASE:HYPERLIPOPROTEINEMIA_TYPE_II
CREATINE;MOBP;AA + AG;rs616147;EFFICACY;INCREASED_RESPONSE;OTHER:AMYOTROPHIC_LATERAL_SCLEROSIS
PEMETREXED;EXO1;AA + AG;rs1047840;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:LUNG_NEOPLASMS
PRAVASTATIN;SLCO1B1;CT;rs4149056;EFFICACY;INCREASED_RESPONSE;DISEASE:TRANSPLANTATION
PHENPROCOUMON;STX4;T;rs10871454;DOSAGE;DECREASED_DOSE;OTHER:MAINTENANCE_DOSAGE_BY_4.8_MG/WEEK
PRAVASTATIN;SLCO1B1;CT;rs4149056;LADME_PK;INCREASED_METABOLISM;DISEASE:TRANSPLANTATION
PROPOFOL;CYP2B6;GT + TT;rs3745274;DOSAGE;DECREASED_DOSE;nan
ADALIMUMAB;TLR9;CT + TT;rs352139;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
ETANERCEPT;TLR9;CT + TT;rs352139;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
INFLIXIMAB;TLR9;CT + TT;rs352139;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;CT + TT;rs352139;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
VALPROIC ACID;CYP2C19;AA + AG;rs4244285;DOSAGE;INCREASED_DOSE;DISEASE:MYELODYSPLASTIC_SYNDROMES
VALPROIC ACID;CYP2C19;AA + AG;rs4244285;LADME_PK;INCREASED_DOSE;DISEASE:MYELODYSPLASTIC_SYNDROMES
APIXABAN;ABCG2;TT;rs2231142;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:ATRIAL_FIBRILLATION
IVACAFTOR;CFTR;A;rs121908755;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
3;SLC6A2;TT;rs2242446;OTHER;DECREASED_RESPONSE;nan
4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;TT;rs2242446;OTHER;DECREASED_RESPONSE;nan
ATENOLOL;AGT;AG + GG;rs699;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
3;SLC6A2;GG;rs1861647;OTHER;INCREASED_RESPONSE;nan
4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;GG;rs1861647;OTHER;INCREASED_RESPONSE;nan
3;SLC6A2;AA;rs36029;OTHER;INCREASED_RESPONSE;nan
4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;AA;rs36029;OTHER;INCREASED_RESPONSE;nan
ATENOLOL;AGT;CT + TT;rs5051;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
TEMOZOLOMIDE;ABCB1;CT;rs2229109;EFFICACY;DECREASED_RESPONSE;OTHER:GLIOMA
FOLLITROPIN BETA;FSHR;T;rs6166;TOXICITY;INCREASED_RESPONSE;nan
UROFOLLITROPIN;FSHR;T;rs6166;TOXICITY;INCREASED_RESPONSE;nan
ADALIMUMAB;HLA-E;AA;rs1264457;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CERTOLIZUMAB PEGOL;HLA-E;AA;rs1264457;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ETANERCEPT;HLA-E;AA;rs1264457;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
GLUCOCORTICOIDS;HLA-E;AA;rs1264457;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
INFLIXIMAB;HLA-E;AA;rs1264457;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;HLA-E;AA;rs1264457;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
REPAGLINIDE;SLC30A8;CT + TT;rs13266634;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
DISULFIRAM;ADRA1A;AA + AG;rs1048101;EFFICACY;INCREASED_RESPONSE;OTHER:COCAINE_DEPENDENCE
ADALIMUMAB;ATP5F1E;GG;rs1059150;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CERTOLIZUMAB PEGOL;ATP5F1E;GG;rs1059150;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ETANERCEPT;ATP5F1E;GG;rs1059150;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
GLUCOCORTICOIDS;ATP5F1E;GG;rs1059150;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
INFLIXIMAB;ATP5F1E;GG;rs1059150;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;ATP5F1E;GG;rs1059150;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
SIROLIMUS;ABCB1;AG;rs1045642;LADME_PK;INCREASED_CONCENTRATIONS;nan
MERCAPTOPURINE;NUDT15;TT;rs116855232;DOSAGE;DECREASED_DOSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
DEXMEDETOMIDINE;CYP2A6;C;rs28399433;LADME_PK;DECREASED_CLEARANCE;nan
IRBESARTAN;CYP2C9;CT;rs1799853;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
FENTANYL;CALCA;GG;rs145837941;DOSAGE;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
NITRIC OXIDE;NAMPT;TT;rs1319501;EFFICACY;INCREASED_CONCENTRATIONS;OTHER:PRE-ECLAMPSIA
TOCILIZUMAB;GALNT18;CC + CT;rs4910008;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
BUPRENORPHINE;OPRD1;AA;rs529520;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
NICOTINE;nan;C;rs12459249;LADME_PK;DECREASED_METABOLISM;nan
WARFARIN;GGCX;AA + AG;rs2592551;DOSAGE;INCREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR7;TT;rs7905446;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
ESCITALOPRAM;HTR7;TT;rs7905446;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
ATOMOXETINE;HTR7;TT;rs7905446;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
DESVENLAFAXINE;HTR7;TT;rs7905446;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
DULOXETINE;HTR7;TT;rs7905446;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR7;TT;rs7905446;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
VENLAFAXINE;HTR7;TT;rs7905446;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
TOCILIZUMAB;IL6;CC;rs2069840;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
ANTIDEPRESSANTS;HTR7;TT;rs7905446;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
BENAZEPRIL;MTHFR;G;rs1801131;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
FLUOXETINE;HTR7;TT;rs7905446;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
PAROXETINE;HTR7;TT;rs7905446;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
BENAZEPRIL;MTHFR;G;rs1801133;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
IRBESARTAN;CYP2C9;AC;rs1057910;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:ESSENTIAL_HYPERTENSION
PAROXETINE;HTR7;TT;rs7905446;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
FENTANYL;CALCA;AG + GG;rs145837941;DOSAGE;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN | OTHER:CAESARIAN_SECTION
EFAVIRENZ;CYP2B6;CC + CT;rs28399499;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
PEMETREXED;CAMKK2;GT;rs1653586;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:LUNG_NEOPLASMS
ABIRATERONE;SRD5A2;CC;rs523349;EFFICACY;INCREASED_RESPONSE;OTHER:PROSTATIC_NEOPLASMS
BUPRENORPHINE;OPRD1;AA + AG;rs581111;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
CARBOPLATIN;FNTB;GG;rs11623866;EFFICACY;RESPONSE;DISEASE:OVARIAN_NEOPLASMS
LONAFARNIB;FNTB;GG;rs11623866;EFFICACY;RESPONSE;DISEASE:OVARIAN_NEOPLASMS
PACLITAXEL;FNTB;GG;rs11623866;EFFICACY;RESPONSE;DISEASE:OVARIAN_NEOPLASMS
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
METHOTREXATE;ABCG2;GG;rs12505410;LADME_PK;INCREASED_CLEARANCE;DISEASE:OSTEOSARCOMA
ESCITALOPRAM;BMP5;A;rs41271330;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ESCITALOPRAM;BMP5;AA + AG;rs41271330;EFFICACY;INCREASED_DOSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
METHOTREXATE;ABCG2;GT + TT;rs13137622;LADME_PK;INCREASED_CLEARANCE;DISEASE:OSTEOSARCOMA
METHOTREXATE;ABCG2;CC;rs13120400;LADME_PK;INCREASED_CLEARANCE;DISEASE:OSTEOSARCOMA
AMLODIPINE;CYP3A4;CT + TT;rs2740574;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
TACROLIMUS;IL18;GG + GT;rs1946518;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LUNG_TRANSPLANTATION
TACROLIMUS;IL10;TT;rs1800896;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LUNG_TRANSPLANTATION
RIVASTIGMINE;BCHE;CT + TT;rs1803274;EFFICACY;DECREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;G;rs35303484;LADME_PK;CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
VALPROIC ACID;CYP2C9;C;rs1057910;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:EPILEPSY
METHOTREXATE;MTHFR;AG + GG;rs1801133;LADME_PK;INCREASED_STEADY_STATE CONCENTRATION;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
AZATHIOPRINE;NUDT15;TT;rs116855232;TOXICITY;DECREASED_DOSE;DISEASE:LEUKOPENIA
CLOZAPINE;NFIB;CT;rs28379954;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LUNG_TRANSPLANTATION
METFORMIN;SLC22A1;AA + AG;rs594709;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
IRINOTECAN;TDP1;GG;rs2401863;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
METFORMIN;SLC47A1;GG;rs2289669;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
TACROLIMUS;IL18;CC + CG;rs5744247;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LUNG_TRANSPLANTATION
METHOTREXATE;SLC19A1;TT;rs1051266;LADME_PK;INCREASED_STEADY_STATE CONCENTRATION;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
DEXMEDETOMIDINE;CYP2D6;GG;rs16947;DOSAGE;INCREASED_DOSE;OTHER:SURGERY
CARBAMAZEPINE;CYP1A2;AA;rs762551;LADME_PK;INCREASED_CLEARANCE;DISEASE:EPILEPSY
RIVAROXABAN;CYP3A4;T;rs2242480;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
CYCLOSPORINE;CYP3A5;CC;rs776746;DOSAGE;INCREASED_CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
CYCLOSPORINE;CYP3A5;CC;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;INCREASED_CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
METHOTREXATE;UGT1A1;GG + GT;rs4148324;LADME_PK;DECREASED_CLEARANCE;DISEASE:OSTEOSARCOMA
METHOTREXATE;UGT1A10;GG + GT;rs4148324;LADME_PK;DECREASED_CLEARANCE;DISEASE:OSTEOSARCOMA
METHOTREXATE;UGT1A3;GG + GT;rs4148324;LADME_PK;DECREASED_CLEARANCE;DISEASE:OSTEOSARCOMA
METHOTREXATE;UGT1A4;GG + GT;rs4148324;LADME_PK;DECREASED_CLEARANCE;DISEASE:OSTEOSARCOMA
METHOTREXATE;UGT1A5;GG + GT;rs4148324;LADME_PK;DECREASED_CLEARANCE;DISEASE:OSTEOSARCOMA
METHOTREXATE;UGT1A6;GG + GT;rs4148324;LADME_PK;DECREASED_CLEARANCE;DISEASE:OSTEOSARCOMA
METHOTREXATE;UGT1A7;GG + GT;rs4148324;LADME_PK;DECREASED_CLEARANCE;DISEASE:OSTEOSARCOMA
METHOTREXATE;UGT1A8;GG + GT;rs4148324;LADME_PK;DECREASED_CLEARANCE;DISEASE:OSTEOSARCOMA
METHOTREXATE;UGT1A9;GG + GT;rs4148324;LADME_PK;DECREASED_CLEARANCE;DISEASE:OSTEOSARCOMA
EFAVIRENZ;ABCB1;C;rs3842;LADME_PK;CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CYCLOSPORINE;CYP3A5;CC;rs776746;DOSAGE;DECREASED_DOSE;OTHER:LIVER_TRANSPLANTATION
CYCLOSPORINE;CYP3A5;CC;rs776746;LADME_PK;DECREASED_DOSE;OTHER:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED_DOSE;OTHER:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;DECREASED_DOSE;OTHER:LIVER_TRANSPLANTATION
DEXMEDETOMIDINE;WBP2NL;AG + GG;rs5758550;TOXICITY;INCREASED_RESPONSE;OTHER:SURGERY
MEMANTINE;BCHE;CT + TT;rs1803274;EFFICACY;DECREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
RIVASTIGMINE;BCHE;CT + TT;rs1803274;EFFICACY;DECREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
IVACAFTOR;CFTR;AA;rs75527207;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED_DOSE;nan
WARFARIN;GGCX;CC;rs699664;DOSAGE;INCREASED_DOSE;nan
METHOTREXATE;MTHFR;GT;rs1801131;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CLOPIDOGREL;ABCB1;AA;rs1045642;LADME_PK;DECREASED_EXPOSURE;nan
TACROLIMUS;POR;CT + TT;rs1057868;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;GG;rs9934438;DOSAGE;INCREASED_DOSE;nan
RIVASTIGMINE;BCHE;CT;rs1803274;EFFICACY;INCREASED_RESPONSE;DISEASE:LEWY_BODY_DISEASE
FENTANYL;CALCA;GG;rs145837941;DOSAGE;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
APIXABAN;ABCG2;G;rs2231142;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;GG;rs1061622;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
DEXMEDETOMIDINE;CYP1A2;AC + CC;rs762551;LADME_PK;INCREASED_CLEARANCE;OTHER:SEDATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;CC;rs3397;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
LATANOPROST;PTGFR;CC;rs3766355;EFFICACY;INCREASED_RESPONSE;DISEASE:GLAUCOMA | DISEASE:OCULAR_HYPERTENSION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;AA;rs1061631;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;MTHFR;AG;rs1801133;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;C;rs3397;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHADONE;NECTIN4;AA;rs11265549;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:OPIOID-RELATED_DISORDERS
OPIOID ANESTHETICS;OPRM1;GG;rs1799971;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
OTHER GENERAL ANESTHETICS;OPRM1;GG;rs1799971;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
VOLATILE ANESTHETICS;OPRM1;GG;rs1799971;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
OPIOID ANESTHETICS;ABCG2;TT;rs2231142;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
OTHER GENERAL ANESTHETICS;ABCG2;TT;rs2231142;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
VOLATILE ANESTHETICS;ABCG2;TT;rs2231142;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
METHADONE;NECTIN4;AA;rs11265549;DOSAGE;DECREASED_DOSE;OTHER:OPIOID-RELATED_DISORDERS
DEXMEDETOMIDINE;KCNMA1;AA + AG;rs16934182;DOSAGE;DECREASED_DOSE;OTHER:SURGERY
DABIGATRAN;CES1;GG + GT;rs2244613;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
ATORVASTATIN;ABCG8;CC + CG;rs11887534;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
CAPECITABINE;DPYD;CT;rs3918290;DOSAGE;DOSE;DISEASE:NEOPLASMS
CAPECITABINE;DPYD;CT;rs56038477;DOSAGE;DOSE;DISEASE:NEOPLASMS
CAPECITABINE;DPYD;AT;rs67376798;DOSAGE;DOSE;DISEASE:NEOPLASMS
DEXMEDETOMIDINE;ADRA2A;GG;rs1800544;DOSAGE;DECREASED_DOSE;OTHER:SURGERY
TAMOXIFEN-N-GLUCURONIDE;UGT1A4;GG + GT;rs2011425;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
IMATINIB;CYP2B6;GG + GT;rs3745274;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
ATORVASTATIN;CYP7A1;GG;rs3808607;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
METHOTREXATE;ATIC;CC;rs4673993;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
BENAZEPRIL;AGT;GG;rs7079;EFFICACY;RESPONSE;DISEASE:HYPERTENSION
WARFARIN;CYP2C9;GG;rs9332098;DOSAGE;INCREASED_DOSE;nan
CANNABIDIOL;nan;CC;rs6729738;EFFICACY;INCREASED_RESPONSE;OTHER:EPILEPSY
METHOTREXATE;MTHFR;AG + GG;rs1801133;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
DEXMEDETOMIDINE;ADRB2;AA;rs1042713;EFFICACY;INCREASED_RESPONSE;OTHER:SURGERY
WARFARIN;CYP2C9;TT;rs9332092;DOSAGE;INCREASED_DOSE;nan
HYDROCHLOROTHIAZIDE;TXNDC11;G;rs3784921;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
WARFARIN;CYP2C9;CC;rs1057910;LADME_PK;DECREASED_CLEARANCE;nan
PAROXETINE;CYP1A2;A;rs762551;LADME_PK;INCREASED_DOSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C9;TT;rs1799853;LADME_PK;DECREASED_CLEARANCE;nan
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
DEXMEDETOMIDINE;KCNMA1;AA + AG;rs16934182;TOXICITY;INCREASED_RESPONSE;OTHER:SURGERY
TOPOTECAN;ABCG2;AA + AG;rs4148157;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BRAIN_NEOPLASMS
EFAVIRENZ;CYP2B6;CC + CT;rs28399499;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
RIVAROXABAN;CYP3A4;G;rs2246709;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
DULOXETINE;KMT2E;GG;rs117986340;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
RIVASTIGMINE;ACHE;TT;rs2571598;EFFICACY;INCREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
MORPHINE;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
MORPHINE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
DULOXETINE;NCAM1;TT;rs2303377;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
RIVAROXABAN;CYP3A5;T;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:HEART_TRANSPLANTATION
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
DULOXETINE;ZNF385D;TT;rs4261893;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
EFAVIRENZ;CYP2B6;AG + GG;rs2279343;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
RIVAROXABAN;CYP3A4;C;rs3735451;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
WARFARIN;VKORC1;GG;rs2359612;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;TT;rs7294;DOSAGE;INCREASED_DOSE;nan
DEXMEDETOMIDINE;nan;CC;rs141294036;TOXICITY;INCREASED_RESPONSE;OTHER:SURGERY
AMPHETAMINE;CDH13;AG + GG;rs3784943;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
EVEROLIMUS;CYP3A4;AG;rs35599367;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
PRAVASTATIN;SLCO1B1;CT;rs4149056;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_STENOSIS
DEXMEDETOMIDINE;KCNMB1;CC + CT;rs11739136;EFFICACY;INCREASED_RESPONSE;OTHER:SURGERY
MORPHINE;UGT2B7;CC + CT;rs7668282;LADME_PK;DECREASED_METABOLISM;DISEASE:SICKLE_CELL_ANEMIA
MIVACURIUM;BCHE;AG;rs755648929;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
SUCCINYLCHOLINE;BCHE;CT;rs772583466;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
EFAVIRENZ;CYP2A7P1;T;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:PREGNANCY
EFAVIRENZ;CYP2B6;T;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:PREGNANCY
DABIGATRAN;CES1;GG;rs8192935;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
ETHANOL;OPRM1;AG + GG;rs1799971;DOSAGE;DECREASED_DOSE;nan
METHOTREXATE;CLCN6;AA;rs1801133;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;C1orf167;TT;rs1801131;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;CLCN6;TT;rs1801131;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;MTHFR;TT;rs1801131;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;MTR;AA;rs1805087;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
RANIBIZUMAB;CXCL8;AA;rs4073;EFFICACY;DECREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
ETHANOL;OPRM1;AA;rs10485057;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED_DOSE;nan
OPIOIDS;COMT;AA + AG;rs4680;DOSAGE;DECREASED_DOSE;OTHER:PAIN | OTHER:NEOPLASMS
METHOTREXATE;BIRC5;CG;rs9904341;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ACENOCOUMAROL;VKORC1;GG;rs9934438;EFFICACY;DECREASED_RESPONSE;nan
SALBUTAMOL;nan;A;rs17834628;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
NICOTINE;CHRNA3;A;rs1051730;DOSAGE;DECREASED_DOSE;OTHER:TOBACCO_USE_DISORDER
ABIRATERONE;TSPYL1;A;rs3828743;EFFICACY;DECREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
PREDNISOLONE;TSPYL1;A;rs3828743;EFFICACY;DECREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
PLATINUM;RICTOR;GG;rs6878291;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
EFAVIRENZ;CYP2B6;GT;rs3745274;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
CLOZAPINE;DRD2;T;rs2514218;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
METHOTREXATE;FASTKD3;AA + AG;rs1801394;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;MTRR;AA + AG;rs1801394;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
RANIBIZUMAB;KDR;AA + AG;rs2071559;EFFICACY;DECREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
ETHANOL;OPRM1;AG;rs1799971;OTHER;INCREASED_RESPONSE;OTHER:ALCOHOL_ABUSE
BUSULFAN;GSTA1;CT;rs3957356;LADME_PK;DECREASED_CLEARANCE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
METHOTREXATE;ATIC;CT + TT;rs12995526;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CLOZAPINE;HTR3A;T;rs1062613;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
METHOTREXATE;ATIC;CT + TT;rs7563206;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
WARFARIN;CYP4F2;CC;rs2108622;DOSAGE;DECREASED_DOSE;nan
METHOTREXATE;ATIC;CC + CG;rs2372536;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;ATIC;CT + TT;rs4673993;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CANDESARTAN;KCNK3;C;rs1275988;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
RISPERIDONE;NR1I2;CC;rs1523130;LADME_PK;DECREASED_CLEARANCE;DISEASE:BIPOLAR_DISORDER | DISEASE:DEPRESSION | DISEASE:SUBSTANCE-RELATED_DISORDERS
SUFENTANIL;ABCB1;GG;rs1045642;DOSAGE;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
ADALIMUMAB;IL17F;TT;rs763780;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
IMMUNOGLOBULINS;CASP3;CT + TT;rs113420705;EFFICACY;DECREASED_RESPONSE;DISEASE:MUCOCUTANEOUS_LYMPH_NODE_SYNDROME
IMMUNOGLOBULINS;PRIMPOL;CT + TT;rs113420705;EFFICACY;DECREASED_RESPONSE;DISEASE:MUCOCUTANEOUS_LYMPH_NODE_SYNDROME
SUFENTANIL;COMT;AA;rs4680;DOSAGE;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
WARFARIN;VKORC1;CC;rs7294;DOSAGE;DECREASED_CONCENTRATIONS;OTHER:HEART_VALVE_REPLACEMENT
IMMUNOGLOBULINS;COQ8B;CC + CG;rs28493229;EFFICACY;DECREASED_RESPONSE;DISEASE:MUCOCUTANEOUS_LYMPH_NODE_SYNDROME
IMMUNOGLOBULINS;ITPKC;CC + CG;rs28493229;EFFICACY;DECREASED_RESPONSE;DISEASE:MUCOCUTANEOUS_LYMPH_NODE_SYNDROME
USTEKINUMAB;IL17F;TT;rs763780;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
WARFARIN;CYP2C9;AA;rs1057910;DOSAGE;INCREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
INFLIXIMAB;IL17F;CT;rs763780;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
EFAVIRENZ;CYP2B6;TT;rs3745274;DOSAGE;DECREASED_DOSE;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;DECREASED_DOSE;DISEASE:HIV_INFECTIOUS_DISEASE
HYDROCHLOROTHIAZIDE;CSK;C;rs1378942;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
SALBUTAMOL;nan;G;rs35661809;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
ANTIPSYCHOTICS;DRD3;CT + TT;rs6280;EFFICACY;INCREASED_RESISTANCE;OTHER:MOOD_DISORDER | OTHER:SCHIZOPHRENIA
HYDROCHLOROTHIAZIDE;PDE3A;C;rs12579720;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
CANDESARTAN;SULT1C3;T;rs6722745;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
ATENOLOL;STN1;A;rs4387287;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
METFORMIN;nan;TT;rs10783050;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
METFORMIN;IL1B;GG;rs1143623;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;TT;rs9923231;LADME_PK;DECREASED_CONCENTRATIONS;nan
CISPLATIN;TP53;CG + GG;rs1042522;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
PACLITAXEL;TP53;CG + GG;rs1042522;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
RIFAPENTINE;ABCB1;AA + AG;rs1045642;LADME_PK;INCREASED_CLEARANCE;nan
BEVACIZUMAB;VEGFA;CC;rs2010963;EFFICACY;DECREASED_RESPONSE;DISEASE:CHOROIDAL_NEOVASCULARIZATION
PEGAPTANIB;VEGFA;CC;rs2010963;EFFICACY;DECREASED_RESPONSE;DISEASE:CHOROIDAL_NEOVASCULARIZATION
RANIBIZUMAB;VEGFA;CC;rs2010963;EFFICACY;DECREASED_RESPONSE;DISEASE:CHOROIDAL_NEOVASCULARIZATION
EPIRUBICIN;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM | DISEASE:STOMACH_NEOPLASMS
FLUOROURACIL;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM | DISEASE:STOMACH_NEOPLASMS
OXALIPLATIN;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM | DISEASE:STOMACH_NEOPLASMS
WARFARIN;VKORC1;CT;rs9923231;EFFICACY;INCREASED_DOSE;OTHER:LEFT_VENTRICULAR_DYSFUNCTION
EPIRUBICIN;PON1;CC;rs662;EFFICACY;INCREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM | DISEASE:STOMACH_NEOPLASMS
FLUOROURACIL;PON1;CC;rs662;EFFICACY;INCREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM | DISEASE:STOMACH_NEOPLASMS
OXALIPLATIN;PON1;CC;rs662;EFFICACY;INCREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM | DISEASE:STOMACH_NEOPLASMS
RISPERIDONE;NR1I2;CC;rs2276707;LADME_PK;DECREASED_CLEARANCE;DISEASE:BIPOLAR_DISORDER | DISEASE:DEPRESSION | DISEASE:SUBSTANCE-RELATED_DISORDERS
EFAVIRENZ;CYP2B6;C;rs28399499;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
WARFARIN;VKORC1;CT;rs9923231;EFFICACY;DECREASED_RESPONSE;OTHER:LEFT_VENTRICULAR_DYSFUNCTION
RITUXIMAB;FCGR3A;C;rs396991;EFFICACY;INCREASED_RESPONSE;OTHER:AUTOIMMUNE_DISEASES
NICOTINE;CHRNA3;AA + AG;rs16969968;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
NICOTINE;CHRNA5;AA + AG;rs16969968;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
CLOZAPINE;HTR3A;G;rs2276302;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
IMATINIB;ABCB1;AT + TT;rs2032582;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
IMATINIB;ABCG2;T;rs2231142;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
TELMISARTAN;GNB3;TT;rs5443;EFFICACY;DECREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
EFAVIRENZ;CYP2B6;T;rs8192719;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
LITHIUM;nan;CC;rs2769605;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
VALPROIC ACID;nan;CC;rs2769605;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
CISPLATIN;GNAS;CC;rs7121;EFFICACY;INCREASED_RESPONSE;DISEASE:NEOPLASM_OF_ESOPHAGUS
FLUOROURACIL;GNAS;CC;rs7121;EFFICACY;INCREASED_RESPONSE;DISEASE:NEOPLASM_OF_ESOPHAGUS
ATENOLOL;ZMAT4;T;rs1367094;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
METOPROLOL;ZMAT4;T;rs1367094;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
EFAVIRENZ;CYP2B6;T;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
ATENOLOL;LRRC15;del;rs11313667;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
HYDROCHLOROTHIAZIDE;LRRC15;del;rs11313667;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
METOPROLOL;LRRC15;del;rs11313667;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
ONDANSETRON;CYP3A5;CC;rs776746;LADME_PK;DECREASED_METABOLISM;nan
LITHIUM;DRD2;GG;rs1800497;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BIPOLAR_DISORDER
OLANZAPINE;DRD2;GG;rs1800497;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BIPOLAR_DISORDER
HMG COA REDUCTASE INHIBITORS;nan;T;rs247616;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
BOCEPREVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
BOCEPREVIR;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
TELAPREVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
TELAPREVIR;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
ADALIMUMAB;KLRC1;CC;rs7301582;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CERTOLIZUMAB PEGOL;KLRC1;CC;rs7301582;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ETANERCEPT;KLRC1;CC;rs7301582;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
GLUCOCORTICOIDS;KLRC1;CC;rs7301582;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
INFLIXIMAB;KLRC1;CC;rs7301582;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;KLRC1;CC;rs7301582;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
HYDROCHLOROTHIAZIDE;PRKAG2;A;rs10224002;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
AGOMELATINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
MELATONIN RECEPTOR AGONISTS;ABCB1;GG;rs1045642;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;ABCB1;GG;rs1045642;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
VENLAFAXINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
ADALIMUMAB;KLRD1;TT;rs2302489;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CERTOLIZUMAB PEGOL;KLRD1;TT;rs2302489;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ETANERCEPT;KLRD1;TT;rs2302489;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
GLUCOCORTICOIDS;KLRD1;TT;rs2302489;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
INFLIXIMAB;KLRD1;TT;rs2302489;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;KLRD1;TT;rs2302489;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
HYDROCHLOROTHIAZIDE;PLCE1;A;rs932764;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
SIMEPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
METOPROLOL;nan;T;rs1446468;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
ATENOLOL;RRP1B;T;rs9306160;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
ATENOLOL;TBX2;C;rs8068318;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
AMISULPRIDE;DRD2;C;rs1079597;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
USTEKINUMAB;NFKBIA;CC;rs2145623;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
HYDROCHLOROTHIAZIDE;ADO;C;rs10995311;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
PLATINUM COMPOUNDS;XBP1;CC;rs2269577;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
CANDESARTAN;DOT1L;A;rs740406;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
CANDESARTAN;PLEKHJ1;A;rs740406;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
USTEKINUMAB;ADAM33;CC;rs2787094;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
HYDROCHLOROTHIAZIDE;NUCB2;C;rs757081;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
USTEKINUMAB;nan;AG + GG;rs1975974;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
EXENATIDE;KCNQ1;G;rs163184;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE | DISEASE:TUBERCULOSIS
USTEKINUMAB;AGBL4;CC + CT;rs191190;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
NORTRIPTYLINE;SLC39A14;C;rs17060812;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSION
ACENOCOUMAROL;VKORC1;CC;rs9923231;DOSAGE;INCREASED_DOSE;nan
USTEKINUMAB;CHUK;CC + CG;rs11591741;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
USTEKINUMAB;HTR2A;CT + TT;rs6311;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
WARFARIN;VKORC1;CC + CT;rs9923231;DOSAGE;INCREASED_DOSE;nan
HYDROCHLOROTHIAZIDE;C5orf56;G;rs12521868;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
CANDESARTAN;SH2B3;T;rs3184504;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
CARBAMAZEPINE;CYP3A5;CC;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
APIXABAN;ABCG2;GG + GT;rs2231142;LADME_PK;INCREASED_CLEARANCE;DISEASE:ATRIAL_FIBRILLATION
CARBAMAZEPINE;CYP3A5;AA;rs15524;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
PAROXETINE;COMT;A;rs4680;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
CAPECITABINE;TP53;GG;rs1042522;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
PACLITAXEL;TP53;GG;rs1042522;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
SUFENTANIL;CYP3A4;CC;rs2242480;DOSAGE;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
TRIGLYCERIDES;CYP19A1;A;rs749292;OTHER;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS | DISEASE:MENOPAUSE
HDL CHOLESTEROL;CYP19A1;G;rs1062033;OTHER;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS | DISEASE:MENOPAUSE
EFAVIRENZ;CYP2B6;C;rs28399499;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
CLOBAZAM;POR;TT;rs1057868;LADME_PK;INCREASED_CLEARANCE;DISEASE:EPILEPSY
WARFARIN;CYP2C9;AA;rs1057910;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_DISEASES
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
EFAVIRENZ;CYP2B6;T;rs3745274;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
NORTRIPTYLINE;PPM1A;AA;rs2273623;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
AMILORIDE;CYP4A11;GG;rs1126742;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
SPIRONOLACTONE;CYP4A11;GG;rs1126742;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
AZATHIOPRINE;NUDT15;TT;rs116855232;DOSAGE;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
MERCAPTOPURINE;NUDT15;TT;rs116855232;DOSAGE;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
DEFERASIROX;UGT1A3;CC;rs3806596;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
LOPINAVIR;CYP3A5;C;rs776746;LADME_PK;INCREASED_TROUGH CONCENTRATION;OTHER:HIV_INFECTIOUS_DISEASE
PROPOFOL;CYP2B6;AA + AG;rs2279343;LADME_PK;DECREASED_CLEARANCE;nan
SPIRONOLACTONE;CYP4A11;CC;rs3890011;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
OPIOIDS;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
ATAZANAVIR;NR1I2;TT;rs2472677;LADME_PK;INCREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
RIFAMPIN;AADAC;AA;rs1803155;LADME_PK;DECREASED_CLEARANCE;OTHER:TUBERCULOSIS
APATINIB;CYP2C9;GG;rs1934968;LADME_PK;INCREASED_EXPOSURE;OTHER:NEOPLASMS
APATINIB METABOLITE M1-1;CYP2C9;GG;rs1934968;LADME_PK;INCREASED_EXPOSURE;OTHER:NEOPLASMS
PD-1;FTO;AT + TT;rs11075995;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:NEOPLASMS
PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1;FTO;AT + TT;rs11075995;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:NEOPLASMS
DEATH LIGAND 1) INHIBITORS;FTO;AT + TT;rs11075995;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:NEOPLASMS
AMPRENAVIR;SLCO1B1;C;rs4149056;LADME_PK;DECREASED_TROUGH CONCENTRATION;OTHER:HIV_INFECTIOUS_DISEASE
ACAMPROSATE;nan;G;rs77583603;EFFICACY;DECREASED_RESPONSE;OTHER:ALCOHOL_ABUSE
EVEROLIMUS;CYP3A5;CC + CT;rs776746;LADME_PK;DECREASED_CLEARANCE;DISEASE:HEART_TRANSPLANTATION
NALTREXONE;nan;A;rs12749274;EFFICACY;DECREASED_RESPONSE;OTHER:ALCOHOL_ABUSE
DEFERASIROX;ABCG2;CC;rs13120400;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
FLUVASTATIN;SLCO1B1;CC + CT;rs4149056;EFFICACY;INCREASED_CLINICAL BENEFIT;nan
FLUVASTATIN;APOE;CC;rs429358;EFFICACY;INCREASED_CLINICAL BENEFIT;nan
DOXORUBICIN;CBR1;CC;rs20572;LADME_PK;INCREASED_CLEARANCE;DISEASE:BREAST_NEOPLASMS
DEHYDROARIPIPRAZOLE;CYP1A2;AA;rs762551;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
CLOZAPINE;CYP1A2;AA;rs762551;LADME_PK;DECREASED_EXPOSURE;OTHER:SCHIZOPHRENIA | OTHER:TOBACCO_USE_DISORDER
ETHANOL;OPRM1;AA;rs1799971;DOSAGE;INCREASED_DOSE;nan
PREDNISOLONE;GATA3;AA;rs3824662;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
TACROLIMUS;GSTM3;TT;rs7483;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;AG;rs1051792;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
ADALIMUMAB;TNF;CC;rs1799724;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;GG;rs1051792;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
FLUOXETINE;HTR1B;AA + TT;rs130058;EFFICACY;INCREASED_RESPONSE;DISEASE:MENTAL_DISORDERS
ADALIMUMAB;TNF;GG;rs1800629;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CLOZAPINE;CYP1A2;AA;rs762551;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA
FLUVASTATIN;APOE;TT;rs7412;EFFICACY;INCREASED_CLINICAL BENEFIT;nan
ADALIMUMAB;TNF;GG;rs361525;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CARBAMAZEPINE;CYP1A2;AA;rs762551;LADME_PK;INCREASED_CLEARANCE;OTHER:EPILEPSY
MORPHINE;SLC6A4;CC;rs1042173;DOSAGE;DECREASED_DOSE;OTHER:LUNG_NEOPLASMS | OTHER:PAIN
FLUOROURACIL;ABCA2;G;rs2271862;LADME_PK;INCREASED_CLEARANCE;OTHER:COLORECTAL_NEOPLASMS
FLUOXETINE;TPH2;TT;rs4570625;EFFICACY;INCREASED_RESPONSE;DISEASE:MENTAL_DISORDERS
5'-DEOXY-5-FLUOROURIDINE;ABCG5;C;rs6720173;LADME_PK;INCREASED_CLEARANCE;OTHER:COLORECTAL_NEOPLASMS
METHOTREXATE;ADORA2A-AS1;CT + TT;rs17004921;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
ANTIEPILEPTICS;ABCB1;AA;rs2032582;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
ANTIEPILEPTICS;ABCB1;AA;rs1045642;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
ATENOLOL;nan;C;rs35123024;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
HYDROCHLOROTHIAZIDE;nan;C;rs35123024;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
ATENOLOL;ALDH1A2;T;rs261316;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
HYDROCHLOROTHIAZIDE;ALDH1A2;T;rs261316;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
CISPLATIN;REV3L;AG + GG;rs462779;EFFICACY;DECREASED_RESPONSE;DISEASE:OSTEOSARCOMA
CISPLATIN;REV1;CT + TT;rs3087403;EFFICACY;INCREASED_RESPONSE;DISEASE:OSTEOSARCOMA
ANTIEPILEPTICS;SCN1A;CC + CT;rs2298771;EFFICACY;INCREASED_RESISTANCE;OTHER:EPILEPSY
LOPINAVIR;SLCO1B1;C;rs4149056;LADME_PK;INCREASED_TROUGH CONCENTRATION;OTHER:HIV_INFECTIOUS_DISEASE
FENTANYL;OPRM1;AA;rs9384179;DOSAGE;INCREASED_DOSE;SIDE_EFFECT:POSTOPERATIVE_PAIN
FENTANYL;OPRM1;AA;rs9384179;EFFICACY;INCREASED_DOSE;SIDE_EFFECT:POSTOPERATIVE_PAIN
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
FLUVASTATIN;CYP2C9;AC;rs1057910;LADME_PK;INCREASED_CONCENTRATIONS;nan
FENTANYL;KCNJ6;TT;rs2835859;DOSAGE;INCREASED_DOSE;SIDE_EFFECT:POSTOPERATIVE_PAIN
FENTANYL;KCNJ6;TT;rs2835859;EFFICACY;INCREASED_DOSE;SIDE_EFFECT:POSTOPERATIVE_PAIN
ABIRATERONE;HSD3B1;AC;rs1047303;LADME_PK;INCREASED_METABOLISM;OTHER:PROSTATIC_NEOPLASMS
FENTANYL;nan;CC;rs2952768;DOSAGE;INCREASED_DOSE;SIDE_EFFECT:POSTOPERATIVE_PAIN
FENTANYL;nan;CC;rs2952768;EFFICACY;INCREASED_DOSE;SIDE_EFFECT:POSTOPERATIVE_PAIN
FENTANYL;nan;AA;rs11959113;DOSAGE;INCREASED_DOSE;SIDE_EFFECT:POSTOPERATIVE_PAIN
FENTANYL;nan;AA;rs11959113;EFFICACY;INCREASED_DOSE;SIDE_EFFECT:POSTOPERATIVE_PAIN
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:HEART_TRANSPLANTATION
CYCLOPHOSPHAMIDE;GSTA1;CT;rs3957356;EFFICACY;DECREASED_RESPONSE;DISEASE:LUPUS_NEPHRITIS
CYCLOPHOSPHAMIDE;GSTA1;CT;rs3957356;TOXICITY;DECREASED_RESPONSE;DISEASE:LUPUS_NEPHRITIS
CYCLOPHOSPHAMIDE;GSTA1;CT;rs3957356;LADME_PK;DECREASED_RESPONSE;DISEASE:LUPUS_NEPHRITIS
EFAVIRENZ;CYP2B6;T;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
BILIRUBIN;SOD2;GG;rs4880;TOXICITY;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:HEART_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
METHYLPHENIDATE;SLC6A2;GG;rs5569;EFFICACY;INCREASED_RESPONSE;DISEASE:ADHD
TACROLIMUS;POR;CT + TT;rs1057868;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:HEART_TRANSPLANTATION
IVACAFTOR;CFTR;AA;rs77010898;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
DOCETAXEL;AKR1C3;GG;rs1937840;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
DOXORUBICIN;AKR1C3;GG;rs1937840;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
CYCLOPHOSPHAMIDE;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
ANTIDEPRESSANTS;GRIK4;TT;rs1954787;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
ANTIDEPRESSANTS;GRIK4;C;rs1954787;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED_DOSE;OTHER:AN_INTERNATIONAL_NORMALIZED_RATIO_(INR)_OF_2.0-3.0
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;T;rs7294;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
WARFARIN;CYP2C9;A;rs1057910;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED_DOSE;nan
BUPRENORPHINE;OPRM1;CC + CG;rs2075572;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:OPIOID-RELATED_DISORDERS
SELECTIVE SEROTONIN (5HT1) AGONISTS;PRDM16;C;rs2651899;EFFICACY;INCREASED_RESPONSE;OTHER:MIGRAINE_WITH_AURA | OTHER:MIGRAINE_WITHOUT_AURA
AFATINIB;NR1I2;AA + AG;rs6785049;LADME_PK;DECREASED_CLEARANCE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA
WARFARIN;CYP2C9;C;rs4917639;DOSAGE;DECREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
LOPINAVIR;SLCO1B1;CT;rs4149056;LADME_PK;INCREASED_EXPOSURE;OTHER:HIV_INFECTIOUS_DISEASE
NALTREXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED_RESPONSE;DISEASE:ALCOHOL_ABUSE
ANTIDEPRESSANTS;ABCB1;A;rs1128503;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
METHADONE;COMT;CC + CT;rs933271;EFFICACY;INCREASED_RESPONSE;OTHER:OPIOID-RELATED_DISORDERS
VALPROIC ACID;UGT1A10;AG;rs2070959;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A10;AG;rs2070959;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A6;AG;rs2070959;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A6;AG;rs2070959;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A7;AG;rs2070959;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A7;AG;rs2070959;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A8;AG;rs2070959;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A8;AG;rs2070959;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A9;AG;rs2070959;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A9;AG;rs2070959;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
METHOTREXATE;MTHFR;GT + TT;rs1801131;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
VALPROIC ACID;GRIN2B;AC;rs1019385;DOSAGE;DECREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;GRIN2B;AC;rs1019385;LADME_PK;DECREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;GRIN2B;CC;rs1019385;DOSAGE;DECREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;GRIN2B;CC;rs1019385;LADME_PK;DECREASED_DOSE;DISEASE:EPILEPSY
METHOTREXATE;SLC19A1;CT + TT;rs1051266;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CARBAMAZEPINE;SCN1A;C;rs2298771;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
CLOBAZAM;SCN1A;C;rs2298771;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
ETHOSUXIMIDE;SCN1A;C;rs2298771;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
LAMOTRIGINE;SCN1A;C;rs2298771;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
LEVETIRACETAM;SCN1A;C;rs2298771;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
OXCARBAZEPINE;SCN1A;C;rs2298771;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
VALPROIC ACID;SCN1A;C;rs2298771;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
LOPINAVIR;SLCO1B1;C;rs4149056;LADME_PK;INCREASED_TROUGH CONCENTRATION;OTHER:HIV_INFECTIOUS_DISEASE
VALPROIC ACID;UGT1A6;AC;rs1105879;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A6;AC;rs1105879;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
FLUVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
EVEROLIMUS;CYP3A5;CT;rs776746;LADME_PK;DECREASED_TROUGH CONCENTRATION;OTHER:BREAST_NEOPLASMS | OTHER:KIDNEY_NEOPLASMS | OTHER:NEUROENDOCRINE_TUMORS
WARFARIN;CYP4F2;C;rs2108622;DOSAGE;DECREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
AMISULPRIDE;SNAP25;CT;rs8636;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CLOPIDOGREL;ABCA1;A;rs2487032;LADME_PK;INCREASED_METABOLISM;nan
CLOPIDOGREL;N6AMT1;G;rs2254638;LADME_PK;DECREASED_METABOLISM;nan
TENOFOVIR;ABCG2;GT + TT;rs2231142;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
SIROLIMUS;ABCB1;A;rs2032582;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
ANTIPSYCHOTICS;NRXN1;AA;rs12467557;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;NRXN1;TT;rs10490162;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CLOPIDOGREL;CYP2C19;AA;rs4986893;EFFICACY;DECREASED_RESPONSE;nan
DABIGATRAN;CES1;GG;rs8192935;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:ATRIAL_FIBRILLATION
ADALIMUMAB;TNF;GG;rs1800629;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BEHCET_SYNDROME
CERTOLIZUMAB PEGOL;TNF;GG;rs1800629;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BEHCET_SYNDROME
GOLIMUMAB;TNF;GG;rs1800629;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BEHCET_SYNDROME
INFLIXIMAB;TNF;GG;rs1800629;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BEHCET_SYNDROME
CLOPIDOGREL;CYP2C19;AA;rs4244285;EFFICACY;DECREASED_RESPONSE;nan
TACROLIMUS;CYP3A5;CC;rs776746;OTHER;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
BEVACIZUMAB;CFH;CC;rs1061170;EFFICACY;DECREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
VALPROIC ACID;UGT1A10;GG;rs2070959;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A10;GG;rs2070959;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A6;GG;rs2070959;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A6;GG;rs2070959;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A7;GG;rs2070959;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A7;GG;rs2070959;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A8;GG;rs2070959;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A8;GG;rs2070959;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A9;GG;rs2070959;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A9;GG;rs2070959;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
CISPLATIN;DPYD;CT;rs3918290;EFFICACY;DECREASED_RESPONSE;DISEASE:HEAD_AND_NECK_NEOPLASMS
FLUOROURACIL;DPYD;CT;rs3918290;EFFICACY;DECREASED_RESPONSE;DISEASE:HEAD_AND_NECK_NEOPLASMS
CISPLATIN;XRCC3;AA;rs861539;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
DOCETAXEL;XRCC3;AA;rs861539;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
IRINOTECAN;XRCC3;AA;rs861539;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
VALPROIC ACID;UGT1A10;GG;rs6759892;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A10;GG;rs6759892;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A6;GG;rs6759892;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A6;GG;rs6759892;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A7;GG;rs6759892;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A7;GG;rs6759892;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A8;GG;rs6759892;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A8;GG;rs6759892;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A9;GG;rs6759892;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A9;GG;rs6759892;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A10;GT;rs6759892;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A10;GT;rs6759892;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A6;GT;rs6759892;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A6;GT;rs6759892;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A7;GT;rs6759892;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A7;GT;rs6759892;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A8;GT;rs6759892;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A8;GT;rs6759892;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A9;GT;rs6759892;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A9;GT;rs6759892;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
VALPROIC ACID;UGT1A6;CC;rs1105879;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A6;CC;rs1105879;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
10-MONOHYDROXY OXCARBAZEPINE;INSR;C;rs2396185;LADME_PK;DECREASED_CLEARANCE;OTHER:EPILEPSY
ETHANOL;OPRM1;AG;rs1799971;EFFICACY;INCREASED_RESPONSE;OTHER:ALCOHOL_ABUSE
RISPERIDONE;HTR1A;GG;rs6295;DOSAGE;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
RISPERIDONE;HTR1A;GG;rs6295;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
FENTANYL;CACNA1E;CC + CT;rs3845446;DOSAGE;DECREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
FENTANYL;LAMB3;G;rs2076222;DOSAGE;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
FENTANYL;LAMB3;G;rs2076222;EFFICACY;INCREASED_DOSE;DISEASE:POSTOPERATIVE_PAIN
CETUXIMAB;VEGFA;TT;rs833061;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
CETUXIMAB;VEGFA;GG;rs1570360;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
CISPLATIN;MECP2;A;rs1734791;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
FLUOROURACIL;MECP2;A;rs1734791;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
MITOXANTRONE;MECP2;A;rs1734791;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
CISPLATIN;MECP2;A;rs1734787;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
FLUOROURACIL;MECP2;A;rs1734787;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
MITOXANTRONE;MECP2;A;rs1734787;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
CISPLATIN;MECP2;A;rs17435;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
FLUOROURACIL;MECP2;A;rs17435;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
MITOXANTRONE;MECP2;A;rs17435;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
CISPLATIN;nan;T;rs5906072;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
FLUOROURACIL;nan;T;rs5906072;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
MITOXANTRONE;nan;T;rs5906072;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
PROCHLORPERAZINE;ANKK1;AA + AG;rs1800497;EFFICACY;DECREASED_RESPONSE;OTHER:NAUSEA
PROCHLORPERAZINE;DRD2;AA + AG;rs1800497;EFFICACY;DECREASED_RESPONSE;OTHER:NAUSEA
PROCHLORPERAZINE;DRD2;CT + TT;rs1079597;EFFICACY;DECREASED_RESPONSE;OTHER:NAUSEA
METFORMIN;ATM;AC;rs11212617;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
MORPHINE;OPRK1;A;rs1051660;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
MORPHINE;OPRK1;A;rs1051660;EFFICACY;DECREASED_DOSE;DISEASE:PAIN
CISPLATIN;GALNT14;G;rs12613732;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
FLUOROURACIL;GALNT14;G;rs12613732;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
MITOXANTRONE;GALNT14;G;rs12613732;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
CISPLATIN;GALNT14;C;rs5009910;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
FLUOROURACIL;GALNT14;C;rs5009910;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
MITOXANTRONE;GALNT14;C;rs5009910;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
ATORVASTATIN;HMGCR;CT + TT;rs17671591;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
ESCITALOPRAM;TPH1;GT + TT;rs1800532;EFFICACY;DECREASED_RESPONSE;OTHER:DEPRESSION
CISPLATIN;GALNT14;C;rs6752303;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
FLUOROURACIL;GALNT14;C;rs6752303;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
MITOXANTRONE;GALNT14;C;rs6752303;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
CISPLATIN;GALNT14;C;rs10209881;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
FLUOROURACIL;GALNT14;C;rs10209881;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
MITOXANTRONE;GALNT14;C;rs10209881;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
DABIGATRAN;CES1;GG;rs2244613;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ATRIAL_FIBRILLATION
CISPLATIN;GALNT14;A;rs12999804;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
FLUOROURACIL;GALNT14;A;rs12999804;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
MITOXANTRONE;GALNT14;A;rs12999804;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
TACROLIMUS;CYP3A4;TT;rs2740574;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
APATINIB;CYP2C9;TT;rs34532201;LADME_PK;INCREASED_EXPOSURE;OTHER:NEOPLASMS
APATINIB METABOLITE M1-1;CYP2C9;TT;rs34532201;LADME_PK;INCREASED_EXPOSURE;OTHER:NEOPLASMS
CISPLATIN;nan;C;rs5934731;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
FLUOROURACIL;nan;C;rs5934731;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
MITOXANTRONE;nan;C;rs5934731;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
CISPLATIN;nan;C;rs715171;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
FLUOROURACIL;nan;C;rs715171;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
MITOXANTRONE;nan;C;rs715171;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
CISPLATIN;nan;C;rs4932551;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
FLUOROURACIL;nan;C;rs4932551;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
MITOXANTRONE;nan;C;rs4932551;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
CISPLATIN;nan;T;rs7170769;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
FLUOROURACIL;nan;T;rs7170769;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
MITOXANTRONE;nan;T;rs7170769;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
CISPLATIN;nan;C;rs6458232;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
FLUOROURACIL;nan;C;rs6458232;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
MITOXANTRONE;nan;C;rs6458232;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
CISPLATIN;GALNT14;C;rs7608731;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
FLUOROURACIL;GALNT14;C;rs7608731;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
MITOXANTRONE;GALNT14;C;rs7608731;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
ELEXACAFTOR;CFTR;A;rs758900656;LADME_PD;INCREASED_CLINICAL BENEFIT;nan
TEZACAFTOR;CFTR;A;rs758900656;LADME_PD;INCREASED_CLINICAL BENEFIT;nan
IVACAFTOR;CFTR;A;rs758900656;LADME_PD;INCREASED_CLINICAL BENEFIT;nan
ALLOPURINOL;AOX1;G;rs3731722;DOSAGE;DOSE;DISEASE:GOUT
FEBUXOSTAT;AOX1;G;rs3731722;DOSAGE;DOSE;DISEASE:GOUT
PAZOPANIB;CYP3A4;AG;rs35599367;LADME_PK;DECREASED_CLEARANCE;OTHER:NEOPLASMS
RITUXIMAB;IL2;GG;rs6822844;EFFICACY;INCREASED_RESPONSE;DISEASE:AUTOIMMUNE_DISEASES
TACROLIMUS;CYP3A5;TT;rs776746;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
RITUXIMAB;IL2;GG;rs6822844;EFFICACY;INCREASED_RESPONSE;DISEASE:SYSTEMIC_LUPUS_ERYTHEMATOSUS
ALLOPURINOL;AOX1;T;rs11678615;DOSAGE;DOSE;DISEASE:GOUT
FEBUXOSTAT;AOX1;T;rs11678615;DOSAGE;DOSE;DISEASE:GOUT
METHOTREXATE;MTHFR;GG;rs1801131;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ALLOPURINOL;UGT1A1;T;rs34650714;DOSAGE;DECREASED_DOSE;DISEASE:GOUT
ALLOPURINOL;UGT1A10;T;rs34650714;DOSAGE;DECREASED_DOSE;DISEASE:GOUT
ALLOPURINOL;UGT1A3;T;rs34650714;DOSAGE;DECREASED_DOSE;DISEASE:GOUT
ALLOPURINOL;UGT1A4;T;rs34650714;DOSAGE;DECREASED_DOSE;DISEASE:GOUT
ALLOPURINOL;UGT1A5;T;rs34650714;DOSAGE;DECREASED_DOSE;DISEASE:GOUT
ALLOPURINOL;UGT1A6;T;rs34650714;DOSAGE;DECREASED_DOSE;DISEASE:GOUT
ALLOPURINOL;UGT1A7;T;rs34650714;DOSAGE;DECREASED_DOSE;DISEASE:GOUT
ALLOPURINOL;UGT1A8;T;rs34650714;DOSAGE;DECREASED_DOSE;DISEASE:GOUT
ALLOPURINOL;UGT1A9;T;rs34650714;DOSAGE;DECREASED_DOSE;DISEASE:GOUT
FEBUXOSTAT;UGT1A1;T;rs34650714;DOSAGE;DECREASED_DOSE;DISEASE:GOUT
FEBUXOSTAT;UGT1A10;T;rs34650714;DOSAGE;DECREASED_DOSE;DISEASE:GOUT
FEBUXOSTAT;UGT1A3;T;rs34650714;DOSAGE;DECREASED_DOSE;DISEASE:GOUT
FEBUXOSTAT;UGT1A4;T;rs34650714;DOSAGE;DECREASED_DOSE;DISEASE:GOUT
FEBUXOSTAT;UGT1A5;T;rs34650714;DOSAGE;DECREASED_DOSE;DISEASE:GOUT
FEBUXOSTAT;UGT1A6;T;rs34650714;DOSAGE;DECREASED_DOSE;DISEASE:GOUT
FEBUXOSTAT;UGT1A7;T;rs34650714;DOSAGE;DECREASED_DOSE;DISEASE:GOUT
FEBUXOSTAT;UGT1A8;T;rs34650714;DOSAGE;DECREASED_DOSE;DISEASE:GOUT
FEBUXOSTAT;UGT1A9;T;rs34650714;DOSAGE;DECREASED_DOSE;DISEASE:GOUT
ALLOPURINOL;XDH;G;rs1884725;DOSAGE;DECREASED_DOSE;DISEASE:GOUT
FEBUXOSTAT;XDH;G;rs1884725;DOSAGE;DECREASED_DOSE;DISEASE:GOUT
ALLOPURINOL;AOX1;T;rs75995567;DOSAGE;INCREASED_DOSE;DISEASE:GOUT
FEBUXOSTAT;AOX1;T;rs75995567;DOSAGE;INCREASED_DOSE;DISEASE:GOUT
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;DOSE;nan
WARFARIN;CYP4F2;T;rs2108622;LADME_PK;DOSE;nan
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DOSE;nan
WARFARIN;VKORC1;T;rs9923231;LADME_PK;DOSE;nan
WARFARIN;GGCX;T;rs699664;DOSAGE;DOSE;nan
WARFARIN;GGCX;T;rs699664;LADME_PK;DOSE;nan
METFORMIN;SLC22A1;AC;rs622342;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
PROPOFOL;ABCB1;GG;rs1128503;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
REMIFENTANIL;ABCB1;GG;rs1128503;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
METHOTREXATE;ABCC3;TT;rs4148416;LADME_PK;INCREASED_CLEARANCE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
TACROLIMUS;CYP3A4;TT;rs2740574;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
METHOTREXATE;SLC19A1;CG;rs17004785;LADME_PK;INCREASED_CLEARANCE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
DONEPEZIL;BCHE;T;rs1803274;EFFICACY;INCREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
CISPLATIN;MTHFD1;AA + AG;rs2236225;EFFICACY;INCREASED_RESPONSE;OTHER:OSTEOSARCOMA
DOXORUBICIN;MTHFD1;AA + AG;rs2236225;EFFICACY;INCREASED_RESPONSE;OTHER:OSTEOSARCOMA
METHOTREXATE;MTHFD1;AA + AG;rs2236225;EFFICACY;INCREASED_RESPONSE;OTHER:OSTEOSARCOMA
CISPLATIN;GALNT14;TT;rs9679162;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
FLUOROURACIL;GALNT14;TT;rs9679162;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
MITOXANTRONE;GALNT14;TT;rs9679162;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
PAROXETINE;GDNF;CT + TT;rs2973049;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PAROXETINE;GDNF;AA + AG;rs2216711;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL17RA;AA;rs4819554;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
ATOMOXETINE;SLC6A2;T;rs3785143;EFFICACY;DECREASED_RESPONSE;DISEASE:ADHD
PAROXETINE;BDNF;CC + CT;rs6265;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;AC + CC;rs396991;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
ROSUVASTATIN;CETP;G;rs5882;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
DISULFIRAM;DBH;CC;rs1611115;EFFICACY;INCREASED_RESPONSE;DISEASE:ALCOHOL_ABUSE
RIVAROXABAN;CYP3A5;TT;rs776746;LADME_PK;INCREASED_STEADY_STATE CONCENTRATION;OTHER:ATRIAL_FIBRILLATION
RISPERIDONE;COMT;GG;rs9606186;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
RIVAROXABAN;ABCB1;AA + AG;rs1045642;LADME_PK;INCREASED_CLEARANCE;OTHER:ATRIAL_FIBRILLATION
TACROLIMUS;C6;CC + TT;rs10052999;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
WARFARIN;VKORC1;GG;rs9934438;DOSAGE;INCREASED_DOSE;nan
TACROLIMUS;C6;CC + CT;rs9200;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
CISPLATIN;ABCC2;CT + TT;rs717620;EFFICACY;DECREASED_RESPONSE;OTHER:OSTEOSARCOMA
DOXORUBICIN;ABCC2;CT + TT;rs717620;EFFICACY;DECREASED_RESPONSE;OTHER:OSTEOSARCOMA
METHOTREXATE;ABCC2;CT + TT;rs717620;EFFICACY;DECREASED_RESPONSE;OTHER:OSTEOSARCOMA
RISPERIDONE;RGS4;C;rs2661319;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
LAMOTRIGINE;SLC22A1;AA + AG;rs628031;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
RISPERIDONE;ANKK1;A;rs1800497;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
TACROLIMUS;CYP3A4;CT;rs2740574;LADME_PK;INCREASED_DOSE;OTHER:TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
CISPLATIN;GSTP1;AG + GG;rs1695;EFFICACY;DECREASED_RESPONSE;OTHER:OSTEOSARCOMA
DOXORUBICIN;GSTP1;AG + GG;rs1695;EFFICACY;DECREASED_RESPONSE;OTHER:OSTEOSARCOMA
METHOTREXATE;GSTP1;AG + GG;rs1695;EFFICACY;DECREASED_RESPONSE;OTHER:OSTEOSARCOMA
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
PHENYTOIN;CYP2C9;C;rs1057910;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
PHENYTOIN;CYP2C9;C;rs1057910;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
CARBAMAZEPINE;SCN1A;TT;rs3812718;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
PHENYTOIN;SCN1A;T;rs3812718;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
INDINAVIR;CYP3A4;CC;rs2740574;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;ABCB1;T;rs2032582;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
ALPHA-HYDROXYMETOPROLOL;CYP2D6;A;rs28371738;LADME_PK;INCREASED_CONCENTRATIONS;nan
RIVAROXABAN;ABCB1;AG + GG;rs1128503;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
FLUVOXAMINE;HTR1A;GG;rs6295;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
MILNACIPRAN;HTR1A;GG;rs6295;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PAROXETINE;HTR1A;GG;rs6295;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
LANSOPRAZOLE;ABCB1;G;rs1045642;OTHER;INCREASED_METABOLISM;nan
LANSOPRAZOLE;ABCB1;G;rs1045642;LADME_PK;INCREASED_METABOLISM;nan
FLUVOXAMINE;HTR1A;CC;rs10042486;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
MILNACIPRAN;HTR1A;CC;rs10042486;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PAROXETINE;HTR1A;CC;rs10042486;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
LAMOTRIGINE;ABCG2;TT;rs2231142;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
RIVAROXABAN;ABCB1;AG + GG;rs1045642;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
RIVAROXABAN;ABCB1;T;rs4148738;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
PHENYTOIN;CYP2C9;AT + TT;rs1934969;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:EPILEPSY
DEXAMETHASONE;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED_RESPONSE;DISEASE:HEAD_AND_NECK_NEOPLASMS
DIPHENHYDRAMINE;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED_RESPONSE;DISEASE:HEAD_AND_NECK_NEOPLASMS
PACLITAXEL;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED_RESPONSE;DISEASE:HEAD_AND_NECK_NEOPLASMS
RANITIDINE;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED_RESPONSE;DISEASE:HEAD_AND_NECK_NEOPLASMS
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION | DISEASE:HEART_VALVE_REPLACEMENT | DISEASE:PULMONARY_HYPERTENSION | DISEASE:PULMONARY_EMBOLISM | DISEASE:VENOUS_THROMBOSIS
HMG COA REDUCTASE INHIBITORS;APOC1;G;rs4420638;EFFICACY;DECREASED_RESPONSE;DISEASE:CARDIOVASCULAR_DISEASE | DISEASE:HYPERCHOLESTEROLEMIA
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;DECREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION | DISEASE:HEART_VALVE_REPLACEMENT | DISEASE:PULMONARY_HYPERTENSION | DISEASE:PULMONARY_EMBOLISM | DISEASE:VENOUS_THROMBOSIS
PHOTODYNAMIC THERAPY;F13A1;AA + AC;rs5985;EFFICACY;DECREASED_RESPONSE;DISEASE:CHOROIDAL_NEOVASCULARIZATION
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION | DISEASE:HEART_VALVE_REPLACEMENT | DISEASE:PULMONARY_HYPERTENSION | DISEASE:PULMONARY_EMBOLISM | DISEASE:VENOUS_THROMBOSIS
CITALOPRAM;TPH1;GT + TT;rs1800532;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
HMG COA REDUCTASE INHIBITORS;NPC1L1;G;rs2072183;EFFICACY;DECREASED_RESPONSE;DISEASE:CARDIOVASCULAR_DISEASE | DISEASE:HYPERCHOLESTEROLEMIA
HMG COA REDUCTASE INHIBITORS;SORT1;T;rs629301;EFFICACY;DECREASED_RESPONSE;DISEASE:CARDIOVASCULAR_DISEASE | DISEASE:HYPERCHOLESTEROLEMIA
MERCAPTOPURINE;NUDT15;CT;rs116855232;DOSAGE;DECREASED_DOSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MYCOPHENOLIC ACID;UGT1A9;del;rs3832043;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
BISOPROLOL;ACY3;T;rs2514036;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
MYCOPHENOLIC ACID;SLCO1B1;AA + AG;rs2306283;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
IMATINIB;BCL2L11;T;rs724710;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
FLUOROURACIL;DPYD;CT;rs3918290;LADME_PK;DECREASED_CLEARANCE;DISEASE:COLORECTAL_NEOPLASMS
METOPROLOL;SEPTIN3;G;rs56234624;LADME_PK;INCREASED_CONCENTRATIONS;nan
ALEMTUZUMAB;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED_RESPONSE;DISEASE:LEUKEMIA | LYMPHOCYTIC | CHRONIC | B-CELL
CHLORAMBUCIL;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED_RESPONSE;DISEASE:LEUKEMIA | LYMPHOCYTIC | CHRONIC | B-CELL
CYCLOPHOSPHAMIDE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED_RESPONSE;DISEASE:LEUKEMIA | LYMPHOCYTIC | CHRONIC | B-CELL
FLUDARABINE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED_RESPONSE;DISEASE:LEUKEMIA | LYMPHOCYTIC | CHRONIC | B-CELL
PREDNISONE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED_RESPONSE;DISEASE:LEUKEMIA | LYMPHOCYTIC | CHRONIC | B-CELL
RITUXIMAB;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED_RESPONSE;DISEASE:LEUKEMIA | LYMPHOCYTIC | CHRONIC | B-CELL
VINCRISTINE;CXCL12;CT + TT;rs1801157;EFFICACY;DECREASED_RESPONSE;DISEASE:LEUKEMIA | LYMPHOCYTIC | CHRONIC | B-CELL
MYCOPHENOLIC ACID;ABCC2;CT;rs3740066;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:LUNG_TRANSPLANTATION
GEMCITABINE;RRM1;AA;rs9937;EFFICACY;DECREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
TACROLIMUS;ABCB1;AA + AG;rs1045642;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:LUNG_TRANSPLANTATION
BEVACIZUMAB;CXCL8;AA;rs4073;EFFICACY;DECREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
GEMCITABINE;RRM1;AC;rs183484;EFFICACY;DECREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
GEMCITABINE;RRM1;AC;rs183484;TOXICITY;DECREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
HYDROCHLOROTHIAZIDE;NEDD4L;AG + GG;rs4149601;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
SN-38;UGT1A1;AA;rs4148323;DOSAGE;INCREASED_CONCENTRATIONS;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA
COTININE GLUCURONIDE;UGT1A9;CT;rs12471326;LADME_PK;INCREASED_CONCENTRATIONS;nan
NICOTINE;CYP2A6;GT;rs145014075;LADME_PK;INCREASED_CONCENTRATIONS;nan
BEVACIZUMAB;VEGFA;CT + TT;rs3025000;EFFICACY;INCREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
RANIBIZUMAB;VEGFA;CT + TT;rs3025000;EFFICACY;INCREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
GRANISETRON;ABCB1;AA;rs1045642;EFFICACY;INCREASED_RESPONSE;SIDE_EFFECT:NAUSEA | SIDE_EFFECT:VOMITING
WARFARIN;VKORC1;CC + CT;rs9923231;DOSAGE;INCREASED_DOSE;OTHER:HEART_FAILURE
CARBAMAZEPINE;SCN1A;CC + CT;rs3812718;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
BEVACIZUMAB;VEGFA;CT + TT;rs3025000;EFFICACY;INCREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
RANIBIZUMAB;VEGFA;CT + TT;rs3025000;EFFICACY;INCREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
CARBAMAZEPINE;SCN1A;TT;rs3812718;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
ETANERCEPT;CD84;AG;rs6427528;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
LOPINAVIR;SLCO1B1;CC + CT;rs4149056;LADME_PK;INCREASED_TROUGH CONCENTRATION;OTHER:HIV_INFECTIOUS_DISEASE
CARBAMAZEPINE;SCN1A;TT;rs2298771;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
METHADONE;OPRM1;AA;rs10485058;EFFICACY;INCREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
CARBAMAZEPINE;GABRA1;AA + AG;rs2290732;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
USTEKINUMAB;IL12B;CT;rs3213094;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
GEMCITABINE;CDA;AA;rs2072671;EFFICACY;INCREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
TOCILIZUMAB;IL6R;CC;rs11265618;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
TOCILIZUMAB;IL6R;AA;rs12083537;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
EFAVIRENZ;ABCB1;AA;rs2032582;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
ALFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED_DOSE;DISEASE:PAIN
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;ABCB1;AA;rs1045642;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CETUXIMAB;FCGR3A;AA;rs396991;EFFICACY;INCREASED_RESPONSE;DISEASE:HEAD_AND_NECK_NEOPLASMS
CETUXIMAB;FCGR2A;GG;rs1801274;EFFICACY;INCREASED_RESPONSE;DISEASE:HEAD_AND_NECK_NEOPLASMS
EFAVIRENZ;HNF4A;CC;rs1884613;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
METHADONE;ALDH5A1;CT + TT;rs2760118;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
ATAZANAVIR;UGT1A1;TT;rs887829;TOXICITY;INCREASED_DISCONTINUATION;nan
PLATINUM COMPOUNDS;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS | DISEASE:STOMACH_NEOPLASMS
OLANZAPINE;CHAT;A;rs1880676;DOSAGE;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
OLANZAPINE;CHAT;A;rs1880676;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
RAMIPRIL;ACE;CC + TT;rs4359;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
RAMIPRIL;ACE;AA + GG;rs4344;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;DOSE;nan
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:GLOMERULONEPHRITIS | MEMBRANOUS
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
OXYCODONE;OPRD1;AA + AG;rs581111;EFFICACY;DECREASED_RESPONSE;nan
PEGINTERFERON ALFA-2B;KLRK1;GG;rs1049174;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;KLRK1;GG;rs1049174;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
CITALOPRAM;CRHR2;CC + CG;rs2270007;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
RIFAMPIN;NR1I2;AA + AG;rs3732357;LADME_PK;DECREASED_EXPOSURE;OTHER:TUBERCULOSIS
METHOTREXATE;SLC19A1;CT + TT;rs1051266;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:OSTEOSARCOMA
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
TELAPREVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
TELAPREVIR;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
OXYCODONE;nan;CT;rs6848893;EFFICACY;DECREASED_RESPONSE;nan
PLATINUM COMPOUNDS;ATP7B;G;rs9535826;EFFICACY;INCREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
DEXAMETHASONE;NR3C1;CC;rs6198;EFFICACY;INCREASED_TIME TO RESPONSE;OTHER:COVID-19
ANTIDEPRESSANTS;HTR2A;AA + AG;rs6313;EFFICACY;INCREASED_RESPONSE;OTHER:BIPOLAR_DISORDER | OTHER:DEPRESSION | OTHER:MAJOR_DEPRESSIVE_DISORDER
PLATINUM COMPOUNDS;ATP7B;A;rs9535828;EFFICACY;INCREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
DEXAMETHASONE;NR3C1;AA;rs33388;EFFICACY;INCREASED_TIME TO RESPONSE;OTHER:COVID-19
RISPERIDONE;CCL2;AA + AG;rs4795893;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
RISPERIDONE;CCL2;CC + CT;rs4586;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
METHOTREXATE;FPGS;TT;rs1544105;EFFICACY;INCREASED_RESPONSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ACENOCOUMAROL;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
METHOTREXATE;FPGS;TT;rs1544105;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
DEXAMETHASONE;NR3C1;TT;rs33389;EFFICACY;INCREASED_TIME TO RESPONSE;OTHER:COVID-19
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
ATORVASTATIN;ABCA1;AAAA;rs769705621;EFFICACY;DECREASED_RESPONSE;OTHER:FAMILIAL_HYPERCHOLESTEROLEMIA
ROSUVASTATIN;ABCA1;AAAA;rs769705621;EFFICACY;DECREASED_RESPONSE;OTHER:FAMILIAL_HYPERCHOLESTEROLEMIA
SIMVASTATIN;ABCA1;AAAA;rs769705621;EFFICACY;DECREASED_RESPONSE;OTHER:FAMILIAL_HYPERCHOLESTEROLEMIA
CORTICOSTEROIDS;ADRB2;A;rs1042713;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ADRB2;A;rs1042713;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
RISPERIDONE;CCL2;GG;rs2857657;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
LAMOTRIGINE;UGT1A4;TT;rs2011425;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
MERCAPTOPURINE;ITPA;A;rs1127354;LADME_PK;METABOLISM;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
LAMOTRIGINE;UGT1A4;TT;rs2011425;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
WARFARIN;CYP2C9;C;rs1057910;DOSAGE;DECREASED_DOSE;nan
EFAVIRENZ;CYP2B6;CC;rs28399499;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
NICOTINE;CHRNB3;G;rs4950;EFFICACY;INCREASED_RESPONSE;OTHER:SMOKERS
NICOTINE;CHRNB3;G;rs4950;OTHER;INCREASED_RESPONSE;OTHER:SMOKERS
EFAVIRENZ;CYP2B6;T;rs3745274;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
PLATINUM COMPOUNDS;HMGB1;CC;rs1412125;EFFICACY;INCREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;CT + TT;rs352139;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
NICOTINE;CHRNB3;G;rs13280604;EFFICACY;INCREASED_RESPONSE;OTHER:SMOKERS
NICOTINE;CHRNB3;G;rs13280604;OTHER;INCREASED_RESPONSE;OTHER:SMOKERS
WARFARIN;VKORC1;G;rs749671;DOSAGE;INCREASED_DOSE;nan
DEXAMETHASONE;CYP3A4;AG;rs35599367;EFFICACY;INCREASED_TIME TO RESPONSE;OTHER:COVID-19
PLATINUM COMPOUNDS;HMGB1;GG;rs2249825;EFFICACY;INCREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
EFAVIRENZ;CYP2B6;T;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;G;rs2279343;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CISPLATIN;XRCC1;TT;rs25487;EFFICACY;DECREASED_RESPONSE;DISEASE:NASOPHARYNGEAL_NEOPLASMS | DISEASE:TOBACCO_USE_DISORDER
RADIOTHERAPY;XRCC1;TT;rs25487;EFFICACY;DECREASED_RESPONSE;DISEASE:NASOPHARYNGEAL_NEOPLASMS | DISEASE:TOBACCO_USE_DISORDER
LOSARTAN;ACE;AT + TT;rs4291;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HYPERTENSION
VEGF;VEGFA;AC + CC;rs699947;EFFICACY;INCREASED_RESPONSE;OTHER:MACULAR_DEGENERATION
VEGFR (VASCULAR ENDOTHELIAL GROWTH FACTOR) INHIBITORS;VEGFA;AC + CC;rs699947;EFFICACY;INCREASED_RESPONSE;OTHER:MACULAR_DEGENERATION
ACENOCOUMAROL;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
OXYCODONE;COMT;AA + AG;rs4680;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
ADALIMUMAB;IL12B;AA + AG;rs2546890;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
INFLIXIMAB;IL12B;AA + AG;rs2546890;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
TACROLIMUS;CYP3A4;T;rs2740574;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
ADALIMUMAB;IVL;CT + TT;rs6661932;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
INFLIXIMAB;IVL;CT + TT;rs6661932;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
OPIOIDS;COMT;AA + AG;rs4680;DOSAGE;INCREASED_DOSE;OTHER:PAIN
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
USTEKINUMAB;TIRAP;CT + TT;rs8177374;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
NICOTINE;OPRM1;AG + GG;rs1799971;OTHER;INCREASED_EXPOSURE;OTHER:SCHIZOPHRENIA
USTEKINUMAB;TLR5;AG + GG;rs5744174;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;AA + AC;rs11938228;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;LY96;CG + GG;rs11465996;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;AT + TT;rs4696480;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
TACROLIMUS;CYP3A5;C;rs776746;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1B;CG + GG;rs1143623;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
USTEKINUMAB;IL1B;CG + GG;rs1143623;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
WARFARIN;ABCB1;A;rs1045642;DOSAGE;INCREASED_DOSE;nan
WARFARIN;APOE;CC + CT;rs429358;DOSAGE;DECREASED_DOSE;nan
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1B;AG + GG;rs1143627;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
USTEKINUMAB;IL1B;AG + GG;rs1143627;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
REPAGLINIDE;NR1I2;GG;rs2276706;LADME_PK;DECREASED_METABOLISM;nan
COTININE;OPRM1;T;rs510769;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
RISPERIDONE;COMT;C;rs9606186;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
REPAGLINIDE;NR1I2;CC;rs3814058;LADME_PK;DECREASED_METABOLISM;nan
ATEZOLIZUMAB;IL7;AA;rs16906115;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:HEPATOCELLULAR_CARCINOMA
BEVACIZUMAB;IL7;AA;rs16906115;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:HEPATOCELLULAR_CARCINOMA
COTININE;OPRM1;T;rs12209447;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
RISPERIDONE;COMT;C;rs2020917;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
COTININE;OPRM1;T;rs3798676;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
WARFARIN;VKORC1;A;rs2359612;DOSAGE;DECREASED_DOSE;nan
FENTANYL;ABCB1;AA;rs1045642;DOSAGE;DECREASED_DOSE;nan
RISPERIDONE;COMT;C;rs933271;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
COTININE;OPRM1;T;rs553202;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
COTININE;OPRM1;G;rs1074287;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
METHADONE;OPRD1;AA + AC;rs529520;DOSAGE;INCREASED_DOSE;DISEASE:HEROIN_DEPENDENCE
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C
COTININE;OPRM1;A;rs1799971;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
COTININE;OPRM1;T;rs6912029;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
PREDNISONE;EDNRA;CC + CT;rs5333;EFFICACY;INCREASED_RESISTANCE;DISEASE:NEPHROTIC_SYNDROME
REPAGLINIDE;NR1I2;CC;rs3814058;LADME_PK;INCREASED_METABOLISM;nan
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;TLR4;CC;rs1927907;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
PAZOPANIB;NR1I2;T;rs3814055;EFFICACY;DECREASED_RESPONSE;DISEASE:RENAL_CELL_CARCINOMA
ACENOCOUMAROL;CYP4F2;T;rs2108622;DOSAGE;INCREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION
ADALIMUMAB;ZNF816;CC + CT;rs9304742;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
INFLIXIMAB;ZNF816;CC + CT;rs9304742;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
ACENOCOUMAROL;CALU;G;rs1043550;DOSAGE;INCREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;IL18;GG + GT;rs1946518;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
ADALIMUMAB;NFKBIA;CC + CG;rs2145623;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
INFLIXIMAB;NFKBIA;CC + CG;rs2145623;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
ADALIMUMAB;TNFRSF1B;AG + GG;rs1061624;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
INFLIXIMAB;TNFRSF1B;AG + GG;rs1061624;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
REPAGLINIDE;NR1I2;GG;rs2276706;LADME_PK;INCREASED_METABOLISM;nan
ADALIMUMAB;SLC9A8;GG;rs645544;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
INFLIXIMAB;SLC9A8;GG;rs645544;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
FLUOROURACIL;XRCC4;G;rs10040363;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
PLATINUM COMPOUNDS;XRCC4;G;rs10040363;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
RADIOTHERAPY;XRCC4;G;rs10040363;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
FENTANYL;OPRM1;TT;rs79910351;EFFICACY;DECREASED_RESPONSE;nan
REMIFENTANIL;OPRM1;TT;rs79910351;EFFICACY;DECREASED_RESPONSE;nan
FLUOROURACIL;XRCC4;T;rs2075685;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
PLATINUM COMPOUNDS;XRCC4;T;rs2075685;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
RADIOTHERAPY;XRCC4;T;rs2075685;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
MYCOPHENOLIC ACID;SLCO1B1;TT;rs4149056;LADME_PK;INCREASED_EXPOSURE;OTHER:KIDNEY_TRANSPLANTATION
HMG COA REDUCTASE INHIBITORS;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
SIMVASTATIN;PPARA;AA + AG;rs4253728;LADME_PK;DECREASED_CLEARANCE;nan
FLUOROURACIL;ERCC1;A;rs2298881;EFFICACY;INCREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
PLATINUM COMPOUNDS;ERCC1;A;rs2298881;EFFICACY;INCREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
RADIOTHERAPY;ERCC1;A;rs2298881;EFFICACY;INCREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
COTININE;OPRM1;T;rs563649;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
COTININE;OPRM1;G;rs2075572;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
SIMVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
COTININE;OPRM1;G;rs7748401;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
COTININE;OPRM1;G;rs495491;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
COTININE;OPRM1;G;rs10457090;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
COTININE;OPRM1;G;rs3778152;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
PRAVASTATIN;SLCO1B1;TT;rs4149056;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
COTININE;OPRM1;T;rs589046;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
METHOTREXATE;NR1I2;T;rs3814055;LADME_PK;DECREASED_METABOLISM;DISEASE:OSTEOSARCOMA
METHOTREXATE;SLCO1B1;AA + AG;rs2306283;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE;ABCC3;C;rs4793665;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:OSTEOSARCOMA
METHOTREXATE;NR1I2;G;rs7643038;LADME_PK;DECREASED_METABOLISM;DISEASE:OSTEOSARCOMA
METHOTREXATE;ABCB1;C;rs9282564;LADME_PK;INCREASED_CONCENTRATIONS;nan
METHOTREXATE;ABCG2;T;rs2231142;LADME_PK;DECREASED_METABOLISM;DISEASE:OSTEOSARCOMA
GLUCOCORTICOIDS;nan;AA;rs17446593;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:THROMBOCYTOPENIA
SUNITINIB;CYP3A5;CC;rs776746;LADME_PK;DECREASED_CLEARANCE;nan
CLOZAPINE;NTRK2;CC;rs10465180;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
SIMVASTATIN;CYP3A5;TT;rs776746;LADME_PK;INCREASED_CLEARANCE;nan
SIMVASTATIN ACID;SLCO1B1;CT;rs4149056;LADME_PK;DECREASED_CLEARANCE;nan
SIMVASTATIN;SLCO2B1;AA;rs12422149;LADME_PK;INCREASED_CLEARANCE;nan
WARFARIN;CYP2C9;G;rs9332238;DOSAGE;INCREASED_DOSE;nan
CLOPIDOGREL;P2RY12;AA + AC;rs6809699;EFFICACY;INCREASED_RESISTANCE;OTHER:CORONARY_DISEASE
EFAVIRENZ;CYP2B6;T;rs3745274;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
DOXORUBICIN;CBR1;CC;rs20572;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;ADRA2A;CG;rs1800544;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ERLOTINIB;ABCB1;AA;rs1045642;TOXICITY;DECREASED_CLEARANCE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
ERLOTINIB;ABCB1;AA;rs1045642;LADME_PK;DECREASED_CLEARANCE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
ERLOTINIB;ABCB1;AA;rs1128503;TOXICITY;DECREASED_CLEARANCE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
ERLOTINIB;ABCB1;AA;rs1128503;LADME_PK;DECREASED_CLEARANCE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
NICOTINE;CYP2A6;A;rs28399468;LADME_PK;DECREASED_METABOLISM;nan
METHOTREXATE;ABCC1;GG;rs28364006;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
DOLUTEGRAVIR;NR1I2;TT;rs2472677;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
ERLOTINIB;ABCB1;AA;rs2032582;TOXICITY;DECREASED_CLEARANCE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
ERLOTINIB;ABCB1;AA;rs2032582;LADME_PK;DECREASED_CLEARANCE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
LOSARTAN;AGTR1;CC;rs5186;EFFICACY;DECREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
CLOPIDOGREL;KDR;T;rs2305948;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_DISEASE
LAMOTRIGINE;UGT2B7;CT + TT;rs7668258;DOSAGE;INCREASED_DOSE;OTHER:EPILEPSY
MERCAPTOPURINE;NUDT15;T;rs73189762;DOSAGE;DECREASED_DOSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METFORMIN;ARFGEF3;AC;rs143276236;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
TRASTUZUMAB;ERBB2;G;rs1136201;TOXICITY;RESPONSE;nan
DOXORUBICIN;CBR1;GG;rs9024;LADME_PK;INCREASED_CLEARANCE;DISEASE:BREAST_NEOPLASMS
METFORMIN;PRKAB2;A;rs7541245;EFFICACY;DECREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;DOSAGE;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES | DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;POR;CT + TT;rs1057868;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;POR;CT + TT;rs1057868;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
DOXORUBICIN;CBR1;GG;rs9024;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
DOXORUBICIN;CBR1;GG;rs9024;LADME_PK;DECREASED_EXPOSURE;DISEASE:BREAST_NEOPLASMS
PRAMIPEXOLE;DRD3;T;rs6280;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;GG;rs7196161;DOSAGE;DECREASED_DOSE;nan
ANTIDEPRESSANTS;GAL;C;rs948854;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
BENZODIAZEPINE DERIVATIVES;GAL;C;rs948854;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
MIRTAZAPINE;GAL;C;rs948854;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GAL;C;rs948854;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;GG;rs9934438;DOSAGE;INCREASED_DOSE;nan
SUFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED_DOSE;OTHER:PREGNANCY
WARFARIN;VKORC1;CC;rs9923231;DOSAGE;INCREASED_DOSE;nan
TACROLIMUS;CYP3A5;A;rs41303343;DOSAGE;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;A;rs41303343;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
METFORMIN;SLC22A1;GG;rs628031;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
TACROLIMUS;CYP3A5;T;rs10264272;DOSAGE;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;T;rs10264272;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;AA;rs2884737;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;A;rs61742245;DOSAGE;INCREASED_DOSE;nan
TACROLIMUS;CYP3A5;C;rs776746;DOSAGE;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;C;rs776746;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
MYCOPHENOLIC ACID;ABCC2;CC;rs717620;LADME_PK;INCREASED_EXPOSURE;OTHER:KIDNEY_TRANSPLANTATION
WARFARIN;PRSS53;A;rs2359612;DOSAGE;DECREASED_DOSE;nan
WARFARIN;VKORC1;A;rs2359612;DOSAGE;DECREASED_DOSE;nan
CAFFEINE;CYP1A2;AA;rs762551;OTHER;INCREASED_METABOLISM;DISEASE:TOBACCO_USE_DISORDER
CAFFEINE;CYP1A2;AA;rs762551;LADME_PK;INCREASED_METABOLISM;DISEASE:TOBACCO_USE_DISORDER
DOXORUBICIN;CBR1;CC;rs20572;LADME_PK;DECREASED_EXPOSURE;DISEASE:BREAST_NEOPLASMS
WARFARIN;GGCX;CG;rs11676382;DOSAGE;DECREASED_DOSE;nan
CAFFEINE;CYP1A2;AA;rs762551;OTHER;INCREASED_METABOLISM;OTHER:HEAVY_COFFEE_CONSUMPTION
CAFFEINE;CYP1A2;AA;rs762551;LADME_PK;INCREASED_METABOLISM;OTHER:HEAVY_COFFEE_CONSUMPTION
METHOTREXATE;ATIC;GG;rs2372536;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
TACROLIMUS;CYP3A4;AA + AG;rs35599367;LADME_PK;DECREASED_CLEARANCE;OTHER:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A4;C;rs2740574;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;A;rs35599367;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_CLEARANCE;OTHER:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_CLEARANCE;OTHER:LIVER_TRANSPLANTATION
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
WARFARIN;PRSS53;T;rs7294;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;T;rs7294;DOSAGE;INCREASED_DOSE;nan
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL9;AA + AG;rs2069885;EFFICACY;INCREASED_RESPONSE;OTHER:SPONDYLITIS | ANKYLOSING
RITUXIMAB;FCGR3A;AA;rs396991;EFFICACY;DECREASED_RESPONSE;DISEASE:NEUROMYELITIS_OPTICA
PREDNISOLONE;CD40;CC;rs1883832;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:THROMBOCYTOPENIA
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_METABOLISM;OTHER:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_METABOLISM;OTHER:LIVER_TRANSPLANTATION
METFORMIN;SLC47A1;AA;rs2289669;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
ERENUMAB;CALCRL;G;rs6710852;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MIGRAINE_WITH_AURA | OTHER:MIGRAINE_WITHOUT_AURA
TACROLIMUS;ABCB1;AA + TT;rs2032582;DOSAGE;DECREASED_CLEARANCE;OTHER:LIVER_TRANSPLANTATION
TACROLIMUS;ABCB1;AA + TT;rs2032582;LADME_PK;DECREASED_CLEARANCE;OTHER:LIVER_TRANSPLANTATION
WARFARIN;VKORC1;CC;rs7294;DOSAGE;DECREASED_DOSE;nan
HALOTHANE;RYR1;T;rs118192161;OTHER;INCREASED_RESPONSE;nan
WARFARIN;VKORC1;CC;rs8050894;DOSAGE;INCREASED_DOSE;nan
WARFARIN;VKORC1;GG;rs2359612;DOSAGE;INCREASED_DOSE;nan
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL5;AA + AG;rs2069812;EFFICACY;INCREASED_RESPONSE;OTHER:SPONDYLITIS | ANKYLOSING
BETA BLOCKING AGENTS;BST1;A;rs28404156;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
SELECTIVE;BST1;A;rs28404156;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C | DISEASE:HIV_INFECTIOUS_DISEASE
TAMOXIFEN;CYP19A1;AA;rs4646;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS | DISEASE:MENOPAUSE
BISPHOSPHONATES;FDPS;T;rs2297480;EFFICACY;INCREASED_RESPONSE;DISEASE:OSTEOPOROSIS
SIMVASTATIN;CETP;A;rs5882;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;APOE;TT;rs405509;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
METHOTREXATE;ABCG2;GG;rs17731538;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;C;rs1799724;EFFICACY;INCREASED_RESPONSE;DISEASE:CROHN_DISEASE | DISEASE:INFLAMMATORY_BOWEL_DISEASES | DISEASE:PSORIASIS | DISEASE:SPONDYLARTHROPATHIES
CYCLOSPORINE;UMOD;GT + TT;rs12917707;EFFICACY;INCREASED_RESPONSE;DISEASE:KIDNEY_TRANSPLANTATION
MODAFINIL;ABCB1;AC + CT;rs2032582;EFFICACY;INCREASED_RESPONSE;DISEASE:NARCOLEPSY
MODAFINIL;ABCB1;AG;rs1045642;EFFICACY;INCREASED_RESPONSE;DISEASE:NARCOLEPSY
WARFARIN;MYC;CT;rs4645962;DOSAGE;DECREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
WARFARIN;MYC;CT + TT;rs4645943;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
CARBAMAZEPINE;EPHX1;G;rs2234922;DOSAGE;DECREASED_METABOLISM;DISEASE:EPILEPSY
CARBAMAZEPINE;EPHX1;G;rs2234922;LADME_PK;DECREASED_METABOLISM;DISEASE:EPILEPSY
MODAFINIL;ABCB1;AG;rs1128503;EFFICACY;INCREASED_RESPONSE;DISEASE:NARCOLEPSY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs361525;EFFICACY;INCREASED_RESPONSE;DISEASE:CROHN_DISEASE | DISEASE:INFLAMMATORY_BOWEL_DISEASES | DISEASE:PSORIASIS | DISEASE:SPONDYLARTHROPATHIES
BISPHOSPHONATES;FDPS;A;rs11264359;EFFICACY;INCREASED_RESPONSE;DISEASE:OSTEOPOROSIS
WARFARIN;MYC;CC;rs4645974;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;G;rs1800629;EFFICACY;INCREASED_RESPONSE;DISEASE:CROHN_DISEASE | DISEASE:INFLAMMATORY_BOWEL_DISEASES | DISEASE:PSORIASIS | DISEASE:SPONDYLARTHROPATHIES
ATORVASTATIN;ABCC2;T;rs717620;EFFICACY;DECREASED_DOSE;nan
SIMVASTATIN;ABCC2;T;rs717620;EFFICACY;DECREASED_DOSE;nan
LEFLUNOMIDE;DHODH;CC;rs3213422;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
ANTIPSYCHOTICS;DRD2;G;rs1799732;EFFICACY;INCREASED_RESISTANCE;OTHER:MOOD_DISORDER | OTHER:SCHIZOPHRENIA
IMATINIB;SLC22A4;TT;rs1050152;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
RISPERIDONE;HTR2A;AA + AG;rs6313;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
ANTIPSYCHOTICS;HTR2A;AG;rs7997012;EFFICACY;INCREASED_RESISTANCE;OTHER:MOOD_DISORDER | OTHER:SCHIZOPHRENIA
METHADONE;CYP2B6;TT;rs3745274;DOSAGE;DECREASED_DOSE;DISEASE:HEROIN_DEPENDENCE
METHADONE;CYP2B6;TT;rs3745274;LADME_PK;DECREASED_DOSE;DISEASE:HEROIN_DEPENDENCE
METHADONE;ABCB1;AA + AG;rs1045642;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:OPIOID-RELATED_DISORDERS
OLANZAPINE;HTR2A;AG + GG;rs6313;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DOSE;nan
OLANZAPINE;HTR2A;AA + AG;rs6313;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
CARBAMAZEPINE;EPHX1;CC;rs1051740;LADME_PK;INCREASED_METABOLISM;DISEASE:EPILEPSY
EFAVIRENZ;CYP2B6;GG;rs3745274;LADME_PK;INCREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
CARBAMAZEPINE;EPHX1;GG;rs2234922;LADME_PK;INCREASED_METABOLISM;DISEASE:EPILEPSY
AZATHIOPRINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED_METABOLISM;DISEASE:INFLAMMATORY_BOWEL_DISEASES | DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
AZATHIOPRINE;ITPA;AC + CC;rs7270101;LADME_PK;INCREASED_METABOLISM;DISEASE:INFLAMMATORY_BOWEL_DISEASES | DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MERCAPTOPURINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED_METABOLISM;DISEASE:INFLAMMATORY_BOWEL_DISEASES | DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MERCAPTOPURINE;ITPA;AC + CC;rs7270101;LADME_PK;INCREASED_METABOLISM;DISEASE:INFLAMMATORY_BOWEL_DISEASES | DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
IMATINIB;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
IMATINIB;SLC22A4;TT;rs1050152;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA_POSITIVE_(BCR-ABL1)
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
ETHANOL;OPRM1;CC + CT;rs3778150;nan;DECREASED_RESPONSE;nan
CARBAMAZEPINE;ABCB1;AG;rs1045642;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
ANTIEPILEPTICS;ABCB1;AG;rs1045642;EFFICACY;INCREASED_RESISTANCE;DISEASE:EPILEPSY
RALOXIFENE;COMT;AG;rs737865;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA | OTHER:SCHIZOAFFECTIVE_DISORDER
PACLITAXEL;ABCC2;CT;rs717620;TOXICITY;DECREASED_DOSE;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
RALOXIFENE;COMT;AA;rs737865;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA | OTHER:SCHIZOAFFECTIVE_DISORDER
BUPRENORPHINE;OPRD1;CT + TT;rs678849;EFFICACY;INCREASED_RESPONSE;OTHER:OPIOID-RELATED_DISORDERS
METHADONE;ABCB1;AC;rs2032582;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
ETHANOL;OPRM1;AG + GG;rs1799971;OTHER;INCREASED_EXPOSURE;nan
ANTIEPILEPTICS;ABCB1;AA;rs1045642;EFFICACY;INCREASED_RESISTANCE;DISEASE:EPILEPSY
RISPERIDONE;TNIK;CC;rs7627954;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
RALOXIFENE;COMT;CG;rs4818;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA | OTHER:SCHIZOAFFECTIVE_DISORDER
METHADONE;CYP3A4;AG;rs35599367;LADME_PK;DECREASED_CLEARANCE;DISEASE:OPIOID-RELATED_DISORDERS
SUNITINIB;ABCB1;AA + AT;rs2032582;DOSAGE;INCREASED_DOSE;DISEASE:RENAL_CELL_CARCINOMA
SUNITINIB;ABCB1;AA + AT;rs2032582;TOXICITY;INCREASED_DOSE;DISEASE:RENAL_CELL_CARCINOMA
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_DOSE;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS
ADALIMUMAB;TNF;AG + GG;rs1800629;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ETANERCEPT;TNF;AG + GG;rs1800629;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
INFLIXIMAB;TNF;AG + GG;rs1800629;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
SUNITINIB;ABCB1;AA;rs1128503;DOSAGE;INCREASED_DOSE;DISEASE:RENAL_CELL_CARCINOMA
SUNITINIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED_DOSE;DISEASE:RENAL_CELL_CARCINOMA
METHADONE;ABCB1;AA;rs1045642;LADME_PK;INCREASED_CLEARANCE;DISEASE:OPIOID-RELATED_DISORDERS
METHADONE;ABCB1;AG;rs1128503;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
METHADONE;POR;CT + TT;rs1057868;LADME_PK;INCREASED_CLEARANCE;DISEASE:OPIOID-RELATED_DISORDERS
METHADONE;CYP2B6;AA;rs2279343;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
DOLUTEGRAVIR;ABCG2;TT;rs2231142;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
METHADONE;CYP2B6;GG;rs3745274;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
PREDNISOLONE;TLR4;T;rs4986791;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:THROMBOCYTOPENIA
PERAMPANEL;CYP3A4;CG;rs4986908;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
TELBIVUDINE;TK2;CC + CT;rs3826160;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HEPATITIS_B | CHRONIC
WARFARIN;EPHX1;TT;rs1877724;DOSAGE;DECREASED_DOSE;nan
NEVIRAPINE;CYP2B6;TT;rs3745274;TOXICITY;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
NEVIRAPINE;CYP2B6;TT;rs3745274;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
IVACAFTOR;CFTR;AA + AG;rs75527207;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
ETHANOL;OPRM1;CC + CT;rs3778150;DOSAGE;INCREASED_DOSE;nan
IVACAFTOR;CFTR;AA + AG;rs75527207;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
NEVIRAPINE;CYP2B6;T;rs3745274;OTHER;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
NEVIRAPINE;CYP2B6;T;rs3745274;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
NEVIRAPINE;CYP2C19;AA;rs12768009;OTHER;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
NEVIRAPINE;CYP2C19;AA;rs12768009;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
ESCITALOPRAM;CYP2C18;G;rs11188059;LADME_PK;DECREASED_CONCENTRATIONS;nan
DONEPEZIL;PRKCE;T;rs6720975;EFFICACY;INCREASED_RESPONSE;OTHER:ALZHEIMER_DISEASE
GALANTAMINE;PRKCE;T;rs6720975;EFFICACY;INCREASED_RESPONSE;OTHER:ALZHEIMER_DISEASE
RIVASTIGMINE;PRKCE;T;rs6720975;EFFICACY;INCREASED_RESPONSE;OTHER:ALZHEIMER_DISEASE
ESCITALOPRAM;CYP2C18;T;rs2860840;LADME_PK;DECREASED_CONCENTRATIONS;nan
EFAVIRENZ;CYP2B6;TT;rs2279345;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
PERAMPANEL;CYP3A4;CT + TT;rs2242480;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
DONEPEZIL;nan;T;rs17798800;EFFICACY;DECREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
GALANTAMINE;nan;T;rs17798800;EFFICACY;DECREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
RIVASTIGMINE;nan;T;rs17798800;EFFICACY;DECREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED_DOSE;nan
PREDNISOLONE;TLR4;G;rs4986790;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:THROMBOCYTOPENIA
METHADONE;ABCB1;CC;rs2032582;DOSAGE;DECREASED_DOSE;OTHER:HEROIN_DEPENDENCE
METHADONE;ABCB1;AA;rs1045642;DOSAGE;INCREASED_DOSE;DISEASE:HEROIN_DEPENDENCE
METHADONE;ABCB1;AA;rs1045642;LADME_PK;INCREASED_DOSE;DISEASE:HEROIN_DEPENDENCE
SN-38;ABCB1;AC + CC;rs12720066;LADME_PK;DECREASED_EXPOSURE;DISEASE:COLORECTAL_NEOPLASMS
ANTIPSYCHOTICS;GABRB1;T;rs4627835;DOSAGE;INCREASED_DOSE;DISEASE:SCHIZOAFFECTIVE_DISORDER | DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;GABRB1;A;rs16860087;DOSAGE;INCREASED_DOSE;DISEASE:SCHIZOAFFECTIVE_DISORDER | DISEASE:SCHIZOPHRENIA
WARFARIN;VKORC1;CC;rs9923231;DOSAGE;INCREASED_DOSE;OTHER:STABLE_INR = [2-3]
SN-38;ABCC1;CT + TT;rs35621;LADME_PK;INCREASED_EXPOSURE;DISEASE:COLORECTAL_NEOPLASMS
CARBAMAZEPINE;ABCB1;AA;rs1045642;DOSAGE;INCREASED_DOSE;OTHER:EPILEPSY
LITHIUM;ASIC2;CC;rs11869731;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
SN-38;ABCC1;AT + TT;rs6498588;LADME_PK;INCREASED_EXPOSURE;DISEASE:COLORECTAL_NEOPLASMS
CAPECITABINE;HLA-G;GG;rs9380142;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
FLUOROURACIL;HLA-G;GG;rs9380142;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
ANTIDEPRESSANTS;MAPK1;AG;rs8136867;EFFICACY;INCREASED_RESPONSE;DISEASE:MENTAL_DISORDERS
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED_DOSE;nan
CAPECITABINE;HLA-G;CT;rs17179108;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
FLUOROURACIL;HLA-G;CT;rs17179108;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
WARFARIN;VKORC1;CC;rs9923231;DOSAGE;INCREASED_DOSE;DISEASE:HEART_DISEASES
WARFARIN;VKORC1;CC;rs9923231;EFFICACY;INCREASED_DOSE;DISEASE:HEART_DISEASES
PHENYTOIN;CYP2C9;A;rs9332238;LADME_PK;INCREASED_CONCENTRATIONS;nan
DONEPEZIL;CHAT;G;rs3793790;EFFICACY;INCREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
GALANTAMINE;CHAT;G;rs3793790;EFFICACY;INCREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
RIVASTIGMINE;CHAT;G;rs3793790;EFFICACY;INCREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
FLUVOXAMINE;COMT;GG;rs4680;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
LITHIUM;OR52E2;TT;rs16909440;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
LITHIUM;OR52J3;GG;rs2499984;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
ANTIDEPRESSANTS;CREB1;GG;rs889895;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DOLUTEGRAVIR;UGT1A1;CT + TT;rs887829;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE | OTHER:TUBERCULOSIS
LITHIUM;nan;CC;rs16973410;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
MERCAPTOPURINE;TPMT;C;rs1142345;EFFICACY;EXPOSURE;DISEASE:LEUKEMIA
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;INCREASED_RESPONSE;NO_RISK | NO_SIDE_EFFECT
DOLUTEGRAVIR;AADAC;AG + GG;rs1803155;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE | OTHER:TUBERCULOSIS
DONEPEZIL;CHAT;A;rs2177370;EFFICACY;INCREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
GALANTAMINE;CHAT;A;rs2177370;EFFICACY;INCREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
RIVASTIGMINE;CHAT;A;rs2177370;EFFICACY;INCREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
METHOTREXATE;ATIC;GG;rs2372536;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ZIDOVUDINE;UGT2B7;G;rs28365062;LADME_PK;INCREASED_METABOLISM;nan
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DOSE;DISEASE:ATRIAL_FIBRILLATION | DISEASE:VENOUS_THROMBOEMBOLISM
CHOLESTEROL;APOE;TT;rs429358;TOXICITY;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHADONE;DRD2;AA;rs6275;DOSAGE;DECREASED_DOSE;DISEASE:HEROIN_DEPENDENCE
METHADONE;DRD2;AA;rs6275;LADME_PK;DECREASED_DOSE;DISEASE:HEROIN_DEPENDENCE
METFORMIN;SLC47A2;AA + AG;rs12943590;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
ATENOLOL;ADRB1;CG + GG;rs1801253;EFFICACY;INCREASED_RESPONSE;DISEASE:ATRIAL_FIBRILLATION
CARVEDILOL;ADRB1;CG + GG;rs1801253;EFFICACY;INCREASED_RESPONSE;DISEASE:ATRIAL_FIBRILLATION
DILTIAZEM;ADRB1;CG + GG;rs1801253;EFFICACY;INCREASED_RESPONSE;DISEASE:ATRIAL_FIBRILLATION
METOPROLOL;ADRB1;CG + GG;rs1801253;EFFICACY;INCREASED_RESPONSE;DISEASE:ATRIAL_FIBRILLATION
VERAPAMIL;ADRB1;CG + GG;rs1801253;EFFICACY;INCREASED_RESPONSE;DISEASE:ATRIAL_FIBRILLATION
METHADONE;DRD2;CC;rs1799978;DOSAGE;DECREASED_DOSE;DISEASE:HEROIN_DEPENDENCE
METHADONE;DRD2;CC;rs1799978;LADME_PK;DECREASED_DOSE;DISEASE:HEROIN_DEPENDENCE
METFORMIN;SLC22A2;AA + AC;rs316019;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
CARBAMAZEPINE;ABCB1;AA + AG;rs1128503;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
CARBAMAZEPINE;ABCB1;AA + AC;rs2032582;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
ERYTHROMYCIN;ABCC2;TT;rs717620;OTHER;INCREASED_METABOLISM;nan
ERYTHROMYCIN;ABCC2;TT;rs717620;LADME_PK;INCREASED_METABOLISM;nan
WARFARIN;GGCX;CG + GG;rs11676382;DOSAGE;DECREASED_DOSE;nan
CARBAMAZEPINE;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
ABIRATERONE;HSD3B1;AC;rs1047303;EFFICACY;DECREASED_RESPONSE;OTHER:PROSTATIC_NEOPLASMS
DUTASTERIDE;HSD3B1;AC;rs1047303;EFFICACY;DECREASED_RESPONSE;OTHER:PROSTATIC_NEOPLASMS
AZATHIOPRINE;PACSIN2;CT + TT;rs2413739;EFFICACY;DECREASED_RESPONSE;OTHER:IRRITABLE_BOWEL_SYNDROME
SILDENAFIL;NOS3;CC + CT;rs2070744;EFFICACY;INCREASED_RESPONSE;DISEASE:ERECTILE_DYSFUNCTION
NEVIRAPINE;CYP2B6;TT;rs3745274;TOXICITY;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
NEVIRAPINE;CYP2B6;TT;rs3745274;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
ABIRATERONE;SRD5A2;CC;rs523349;LADME_PK;INCREASED_METABOLISM;OTHER:PROSTATIC_NEOPLASMS
TRIGLYCERIDES;CYP19A1;A;rs10046;OTHER;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS | DISEASE:MENOPAUSE
TRIGLYCERIDES;CYP19A1;C;rs3759811;OTHER;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS | DISEASE:MENOPAUSE
WARFARIN;VKORC1;A;rs7196161;DOSAGE;DOSE;DISEASE:ATRIAL_FIBRILLATION | DISEASE:PULMONARY_EMBOLISM | DISEASE:STROKE | DISEASE:VENOUS_THROMBOSIS
HDL CHOLESTEROL;CYP19A1;G;rs1008805;OTHER;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS | DISEASE:MENOPAUSE
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
TRIGLYCERIDES;CYP19A1;C;rs2289105;OTHER;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS | DISEASE:MENOPAUSE
WARFARIN;VKORC1;G;rs7196161;DOSAGE;DOSE;nan
METHOTREXATE;SLC19A1;AC + CC;rs1051296;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
HDL CHOLESTEROL;CYP19A1;G;rs10046;OTHER;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS | DISEASE:MENOPAUSE
FENTANYL;CYP3A4;T;rs2242480;DOSAGE;DECREASED_DOSE;OTHER:POSTOPERATIVE_PAIN
HDL CHOLESTEROL;CYP19A1;T;rs2289105;OTHER;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS | DISEASE:MENOPAUSE
LEFLUNOMIDE;ESR1;TT;rs2234693;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
NEVIRAPINE;CYP2B6;GT;rs3745274;TOXICITY;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
NEVIRAPINE;CYP2B6;GT;rs3745274;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
LEFLUNOMIDE;ESR1;AA;rs9340799;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
USTEKINUMAB;C9orf72;CC + CT;rs774359;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
METHOTREXATE;GGH;GG;rs3758149;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
HDL CHOLESTEROL;CYP19A1;A;rs4646;OTHER;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS | DISEASE:MENOPAUSE
USTEKINUMAB;IL13;AA + AC;rs848;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
TRIGLYCERIDES;CYP19A1;C;rs700518;OTHER;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS | DISEASE:MENOPAUSE
USTEKINUMAB;ZNF816;CC + CT;rs9304742;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
TRIGLYCERIDES;CYP19A1;C;rs4775936;OTHER;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS | DISEASE:MENOPAUSE
WARFARIN;GGCX;CG + GG;rs11676382;DOSAGE;DECREASED_DOSE;nan
USTEKINUMAB;STAT4;GT + TT;rs7574865;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
USTEKINUMAB;SLC22A4;CT;rs1050152;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
ETHANOL;OPRM1;AG + GG;rs1799971;OTHER;INCREASED_RESPONSE;OTHER:ALCOHOL_ABUSE
NICOTINE;CHRNA5;GG;rs16969968;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
WARFARIN;STX1B;AA + AG;rs72800847;DOSAGE;DECREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
WARFARIN;CYP1A1;CC;rs3826041;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
VARENICLINE;CHRNA5;AA + AG;rs16969968;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
WARFARIN;DNMT3A;TT;rs2304429;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
WARFARIN;NQO1;AA;rs10517;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
RALOXIFENE;ESR1;TT;rs2234693;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA | OTHER:SCHIZOAFFECTIVE_DISORDER
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED_DOSE;nan
PHENPROCOUMON;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED_DOSE;nan
FENTANYL;DRD1;AG + GG;rs966775;EFFICACY;INCREASED_CONCENTRATIONS;OTHER:POSTOPERATIVE_PAIN
FLUTICASONE;CHRM2;A;rs8191992;EFFICACY;RESPONSE;DISEASE:ASTHMA
SALMETEROL;CHRM2;A;rs8191992;EFFICACY;RESPONSE;DISEASE:ASTHMA
METHOTREXATE;MTHFR;AA + AG;rs1801133;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:NON-HODGKIN_LYMPHOMA
WARFARIN;VKORC1;A;rs9923231;DOSAGE;DOSE;nan
PHENPROCOUMON;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;nan
WARFARIN;CYP2C9;AA;rs1057910;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
ARIPIPRAZOLE;DRD2;CC;rs2514218;EFFICACY;INCREASED_RESPONSE;OTHER:PSYCHOTIC_DISORDER | OTHER:SCHIZOAFFECTIVE_DISORDER | OTHER:SCHIZOPHRENIA
RISPERIDONE;DRD2;CC;rs2514218;EFFICACY;INCREASED_RESPONSE;OTHER:PSYCHOTIC_DISORDER | OTHER:SCHIZOAFFECTIVE_DISORDER | OTHER:SCHIZOPHRENIA
VORICONAZOLE;ABCG2;GT + TT;rs2231142;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LEUKEMIA | OTHER:LYMPHOMA | OTHER:MYELODYSPLASTIC_SYNDROMES
WARFARIN;STX1B;AG + GG;rs4889606;DOSAGE;DECREASED_DOSE;nan
WARFARIN;UGT1A1;CC;rs887829;DOSAGE;DECREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
WARFARIN;CYP4F2;CC + CT;rs2108622;DOSAGE;DECREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
AZATHIOPRINE;ITPA;AA + AC;rs1127354;LADME_PK;DECREASED_METABOLISM;DISEASE:INFLAMMATORY_BOWEL_DISEASES
MERCAPTOPURINE;ITPA;AA + AC;rs1127354;LADME_PK;DECREASED_METABOLISM;DISEASE:INFLAMMATORY_BOWEL_DISEASES
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED_DOSE;OTHER:ATRIAL_FIBRILLATION | OTHER:HEART_VALVE_REPLACEMENT | OTHER:PULMONARY_EMBOLISM
BEVACIZUMAB;SHMT1;A;rs1979277;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
FLUOROURACIL;SHMT1;A;rs1979277;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
IRINOTECAN;SHMT1;A;rs1979277;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
LEUCOVORIN;SHMT1;A;rs1979277;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL6;G;rs1800795;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
WARFARIN;CYP2C9;AC + CC;rs1057910;DOSAGE;INCREASED_DOSE;OTHER:ATRIAL_FIBRILLATION | OTHER:HEART_VALVE_REPLACEMENT | OTHER:PULMONARY_EMBOLISM
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;INCREASED_DOSE;OTHER:ATRIAL_FIBRILLATION | OTHER:HEART_VALVE_REPLACEMENT | OTHER:PULMONARY_EMBOLISM
PLATINUM COMPOUNDS;nan;GG + GT;rs6983267;EFFICACY;INCREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
METFORMIN;SLC22A2;TT;rs316009;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED_DOSE;OTHER:PAIN | OTHER:POSTOPERATIVE_PAIN
OPIOIDS;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED_DOSE;OTHER:PAIN | OTHER:POSTOPERATIVE_PAIN
ATORVASTATIN;SLCO1B1;C;rs4149056;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:HYPERCHOLESTEROLEMIA
CYCLOSPORINE;CYP3A4;AA + AG;rs35599367;TOXICITY;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
CYCLOSPORINE;CYP3A4;AA + AG;rs35599367;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
PLATINUM COMPOUNDS;MALAT1;AG + GG;rs619586;EFFICACY;DECREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
PLATINUM COMPOUNDS;HOTAIR;CC + CG;rs7958904;EFFICACY;DECREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
PLATINUM COMPOUNDS;H19;AA + AG;rs2839698;EFFICACY;INCREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
TACROLIMUS;CYP3A4;AG;rs35599367;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
CARBAMAZEPINE;EPHX1;C;rs1051740;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
CARBAMAZEPINE;EPHX1;C;rs1051740;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED_DOSE;nan
FLUTICASONE;CHRM2;A;rs6962027;EFFICACY;RESPONSE;DISEASE:ASTHMA
SALMETEROL;CHRM2;A;rs6962027;EFFICACY;RESPONSE;DISEASE:ASTHMA
NICOTINE;OPRM1;AG + GG;rs1799971;OTHER;INCREASED_EXPOSURE;nan
BETA BLOCKING AGENTS;ADRB1;C;rs1801253;EFFICACY;INCREASED_RESPONSE;OTHER:CARDIOMYOPATHY | DILATED
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED_DOSE;DISEASE:STROKE
BETA BLOCKING AGENTS;ADRB2;A;rs1042713;EFFICACY;INCREASED_RESPONSE;OTHER:CARDIOMYOPATHY | DILATED
FLUTICASONE;CHRM2;A;rs6962027;EFFICACY;RESPONSE;DISEASE:ASTHMA
SALMETEROL;CHRM2;A;rs6962027;EFFICACY;RESPONSE;DISEASE:ASTHMA
CARBAMAZEPINE;EPHX1;G;rs2234922;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
CARBAMAZEPINE;EPHX1;G;rs2234922;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
FLUTICASONE PROPIONATE;CRHR1;T;rs1876831;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
RISPERIDONE;TNIK;AA;rs2088885;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
FLUTICASONE PROPIONATE;CRHR1;T;rs1876828;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
METFORMIN;CSMD1;AC + CC;rs2617102;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
FLUTICASONE PROPIONATE;CRHR1;C;rs1876829;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
FLUTICASONE PROPIONATE;CRHR1;G;rs739645;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DOSE;nan
NEVIRAPINE;CYP2B6;T;rs3745274;TOXICITY;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
NEVIRAPINE;CYP2B6;T;rs3745274;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
NICOTINE;POR;CT + TT;rs1057868;LADME_PK;INCREASED_METABOLISM;PK:CYP2A6_NORMAL | BUT_NOT_REDUCED | METABOLIZERS
CARBAMAZEPINE;SCN1A;TT;rs3812718;LADME_PK;INCREASED_METABOLISM;DISEASE:EPILEPSY
WARFARIN;CYP4F2;TT;rs2108622;DOSAGE;INCREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION
VORICONAZOLE;CYP2C18;T;rs2860840;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LEUKEMIA | OTHER:LYMPHOMA | OTHER:MYELODYSPLASTIC_SYNDROMES
VORICONAZOLE;CYP2C18;G;rs11188059;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LEUKEMIA | OTHER:LYMPHOMA | OTHER:MYELODYSPLASTIC_SYNDROMES
REMIFENTANIL;ABCB1;GG;rs1045642;DOSAGE;INCREASED_DOSE;nan
WARFARIN;GGCX;CT + TT;rs12714145;DOSAGE;DECREASED_DOSE;OTHER:ATRIAL_FIBRILLATION | OTHER:HEART_VALVE_REPLACEMENT | OTHER:PULMONARY_EMBOLISM
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION
REMIFENTANIL;ABCB1;GG;rs1045642;EFFICACY;DECREASED_RESPONSE;nan
FLUOROURACIL;DPYD;CC + CT;rs1801159;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:COLORECTAL_NEOPLASMS
WARFARIN;VKORC1;AA;rs9934438;DOSAGE;DECREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C
CARBAMAZEPINE;SCN1A;TT;rs3812718;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
NALTREXONE;OPRM1;AA;rs1799971;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:OPIOID-RELATED_DISORDERS
ASPIRIN;P2RY1;T;rs1371097;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:STROKE
GEMCITABINE;CMPK1;TT;rs1044457;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA
TACROLIMUS;SLC7A8;AC + CC;rs7141505;LADME_PK;DECREASED_METABOLISM;OTHER:LIVER_TRANSPLANTATION
MERCAPTOPURINE;NUDT15;CC;rs55713253;DOSAGE;INCREASED_DOSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CYCLOPHOSPHAMIDE;ABCC2;AA;rs145008610;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:BREAST_NEOPLASMS
DOXORUBICIN;ABCC2;AA;rs145008610;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:BREAST_NEOPLASMS
PACLITAXEL;ABCC2;AA;rs145008610;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:BREAST_NEOPLASMS
DEOXY-THIOGUANOSINE TRIPHOSPHATE;TPMT;CT;rs1142345;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:INFLAMMATORY_BOWEL_DISEASES
THIOGUANOSINE TRIPHOSPHATE;TPMT;CT;rs1142345;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:INFLAMMATORY_BOWEL_DISEASES
AZATHIOPRINE;PACSIN2;CC + CT;rs2413739;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:INFLAMMATORY_BOWEL_DISEASES
CLOPIDOGREL CARBOXYLIC ACID;ABCB1;AA + AG;rs1045642;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:CARDIOVASCULAR_DISEASE
BREXPIPRAZOLE;CYP2D6;INTERMEDIATE_METABOLIZER;CYP2D6;LADME_PK;DECREASED_METABOLISM;OTHER:SCHIZOPHRENIA
BREXPIPRAZOLE;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
THIORIDAZINE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:MENTAL_DISORDERS
PRIMAQUINE;CYP2D6;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*17, CYP2D6*29, CYP2D6*34, CYP2D6*39, CYP2D6*41;EFFICACY;INCREASED_CONCENTRATIONS;OTHER:MALARIA | VIVAX
CYCLOSPORINE;CYP3A5;CT;rs776746;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
RISPERIDONE;CYP2D6;*17;CYP2D6*17;LADME_PK;INCREASED_METABOLISM;OTHER:SCHIZOPHRENIA | OTHER:ADHD | OTHER:AUTISM | OTHER:BIPOLAR_DISORDER
RISPERIDONE;CYP2D6;*29;CYP2D6*29;LADME_PK;DECREASED_METABOLISM;OTHER:SCHIZOPHRENIA | OTHER:ADHD | OTHER:AUTISM | OTHER:BIPOLAR_DISORDER
DULAGLUTIDE;GLP1R;GG;rs6923761;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
LIRAGLUTIDE;GLP1R;GG;rs6923761;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
SEMAGLUTIDE;GLP1R;GG;rs6923761;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
N-DESMETHYLCLOZAPINE;SLCO1B1;CC + CT;rs4149056;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
NORCLOBAZAM;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;LADME_PK;DECREASED_CLEARANCE;OTHER:EPILEPSY
ARTEMETHER;CYP2B6;GT;rs3745274;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MALARIA
LUMEFANTRINE;CYP2B6;GT;rs3745274;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MALARIA
4-ENE VALPROIC ACID;CPT1A;GG;rs2228502;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:EPILEPSY
TACROLIMUS;SULT1E1;CC;rs3775770;LADME_PK;DECREASED_METABOLISM;OTHER:LIVER_TRANSPLANTATION
DEXTROMETHORPHAN;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;DECREASED_METABOLISM;nan
METHOTREXATE;ATIC;CC + CT;rs4673991;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
QUETIAPINE;CYP3A4;*22;CYP3A4*22;LADME_PK;INCREASED_EXPOSURE;OTHER:LIVER_CIRRHOSIS
METHOTREXATE;ATIC;CT + TT;rs4673993;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
METHOTREXATE;ADA;GT + TT;rs2057638;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
METHOTREXATE;ATIC;CC + CG;rs2372536;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
METHOTREXATE;ADA;CG + GG;rs6017375;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
METHOTREXATE;ADA;AA;rs371927;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
PROPOFOL;UGT1A9;CT;rs72551330;LADME_PK;DECREASED_CLEARANCE;nan
PROPOFOL;UGT1A9;CC;rs2741045;LADME_PK;INCREASED_CLEARANCE;nan
LOSARTAN;CYP2C9;*1/*1;CYP2C9*1, CYP2C9*2, CYP2C9*3;nan;INCREASED_CLINICAL BENEFIT;nan
CODEINE;CYP2D6;POOR_METABOLIZER;CYP2D6;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PAIN
HYDROCODONE;CYP2D6;POOR_METABOLIZER;CYP2D6;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PAIN
OXYCODONE;CYP2D6;POOR_METABOLIZER;CYP2D6;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PAIN
TRAMADOL;CYP2D6;POOR_METABOLIZER;CYP2D6;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PAIN
ZUCLOPENTHIXOL;CYP2D6;nan;CYP2D6 normal metabolizer;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;nan
SITAGLIPTIN;GLP1R;GG;rs6923761;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HYPERTENSION | OTHER:DIABETES_MELLITUS
SALBUTAMOL;ADRB2;AA;rs1042717;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ASTHMA
SALBUTAMOL;ADRB2;GG;rs1042714;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ASTHMA
THIORIDAZINE;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEPRESSION
ZUCLOPENTHIXOL;CYP2D6;INTERMEDIATE_METABOLIZER;CYP2D6;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:MENTAL_DISORDERS
PERPHENAZINE;CYP2D6;INTERMEDIATE_METABOLIZER;CYP2D6;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:MENTAL_DISORDERS
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CDKAL1;CC;rs7754840;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CDKAL1;GG;rs7756992;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
SITAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
VILDAGLIPTIN;GLP1R;AA;rs6923761;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
NORTRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ANTIDEPRESSANTS;CYP2C19;*17;CYP2C19*17;EFFICACY;INCREASED_RESISTANCE;OTHER:SCHIZOPHRENIA | OTHER:MENTAL_DISORDERS | OTHER:NEUROTIC_DISORDER | OTHER:PERSONALITY_DISORDER
ANTIPSYCHOTICS;CYP2C19;*17;CYP2C19*17;EFFICACY;INCREASED_RESISTANCE;OTHER:SCHIZOPHRENIA | OTHER:MENTAL_DISORDERS | OTHER:NEUROTIC_DISORDER | OTHER:PERSONALITY_DISORDER
AMITRIPTYLINE;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ANTIDEPRESSANTS;CYP2D6;*3;CYP2D6*3;EFFICACY;INCREASED_RESISTANCE;OTHER:SCHIZOPHRENIA | OTHER:MENTAL_DISORDERS | OTHER:NEUROTIC_DISORDER | OTHER:PERSONALITY_DISORDER
ANTIPSYCHOTICS;CYP2D6;*3;CYP2D6*3;EFFICACY;INCREASED_RESISTANCE;OTHER:SCHIZOPHRENIA | OTHER:MENTAL_DISORDERS | OTHER:NEUROTIC_DISORDER | OTHER:PERSONALITY_DISORDER
ANTIDEPRESSANTS;CYP1A2;*30;CYP1A2*30;EFFICACY;INCREASED_RESISTANCE;OTHER:SCHIZOPHRENIA | OTHER:MENTAL_DISORDERS | OTHER:NEUROTIC_DISORDER | OTHER:PERSONALITY_DISORDER
ANTIPSYCHOTICS;CYP1A2;*30;CYP1A2*30;EFFICACY;INCREASED_RESISTANCE;OTHER:SCHIZOPHRENIA | OTHER:MENTAL_DISORDERS | OTHER:NEUROTIC_DISORDER | OTHER:PERSONALITY_DISORDER
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;DOSAGE;INCREASED_DOSE;OTHER:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A4;AG;rs35599367;DOSAGE;DECREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;DOSAGE;INCREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;CC + CT;rs2740574;DOSAGE;INCREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
EFAVIRENZ;CYP2B6;C;rs4803419;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE | OTHER:MISSED_DOSE
ANTIDEPRESSANTS;SLC22A3;AG + GG;rs2292334;DOSAGE;INCREASED_DOSE;OTHER:DEPRESSION
KETANSERIN;HTR1B;C;rs130060;LADME_PD;DECREASED_AFFINITY;HTR1B
THIOXANTHINE;XDH;T;rs2295474;LADME_PK;DECREASED_CLEARANCE;XDH
PAROMOMYCIN;MT-RNR1;G;rs267606617;LADME_PD;DECREASED_ACTIVITY;MT-RNR1
THIOXANTHINE;XDH;T;rs45442092;LADME_PK;DECREASED_CLEARANCE;XDH
DIHYDROERGOTAMINE;HTR1B;C;rs130060;LADME_PD;INCREASED_AFFINITY;HTR1B
METHYSERGIDE;HTR1B;C;rs130060;LADME_PD;INCREASED_AFFINITY;HTR1B
SUMATRIPTAN;HTR1B;C;rs130060;LADME_PD;INCREASED_AFFINITY;HTR1B
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;LADME_PK;INCREASED_EXPRESSION;TYMS
CISPLATIN;UBE2I;CG;rs9597;LADME_PK;INCREASED_EXPRESSION;SAE1
IRINOTECAN;UBE2I;CG;rs9597;LADME_PK;INCREASED_EXPRESSION;SAE1
METHOTREXATE;SHMT1;AA;rs1979277;LADME_PK;INCREASED_CATALYTIC-ACTIVITY;TYMS
IVACAFTOR;CFTR;del;rs113993960;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;A;rs397508139;EFFICACY;ACTIVITY;CFTR
FLUOROURACIL;DPYD;C;rs1335150891;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;DPYD
IVACAFTOR;CFTR;T;rs141033578;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;T;rs121909011;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;T;rs77409459;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;C;rs397508510;EFFICACY;ACTIVITY;CFTR
PHENYTOIN;CYP2C9;A;rs12782374;nan;DECREASED_EXPRESSION;CYP2C9
IVACAFTOR;CFTR;C;rs397508435;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;A;rs77010898;EFFICACY;INCREASED_ACTIVITY;CFTR
ESTRADIOL;TCL1A;G;rs7158782;OTHER;INCREASED_EXPRESSION;IL17RA
IVACAFTOR;CFTR;G;rs397508328;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;A;rs77932196;EFFICACY;ACTIVITY;CFTR
NIMESULIDE;PTGS2;C;rs5272;LADME_PK;INCREASED_ENZYME_ACTIVITY;PTGS2
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;ASSOCIATED_PROTEIN-STABILITY;CFTR
IVACAFTOR;CFTR;C;rs1800111;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;A;rs74551128;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;A;rs186045772;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;A;rs78769542;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;A;rs397508537;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;A;rs397508256;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;A;rs121908751;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;ACTIVITY;CFTR
CISPLATIN;TPMT;*3A;TPMT*1, TPMT*3A;OTHER;INCREASED_EXPRESSION;TLR4
IVACAFTOR;CFTR;T;rs368505753;EFFICACY;ACTIVITY;CFTR
NIMESULIDE;PTGS2;G;rs5273;LADME_PK;INCREASED_ENZYME_ACTIVITY;PTGS2
IVACAFTOR;CFTR;T;rs115545701;EFFICACY;ACTIVITY;CFTR
SACUBITRIL;CES1;CT;rs71647871;EFFICACY;DECREASED_CATALYTIC-ACTIVITY;CES1
IVACAFTOR;CFTR;T;rs1800100;EFFICACY;ACTIVITY;CFTR
ESTRADIOL;TCL1A;A;rs7158782;OTHER;INCREASED_EXPRESSION;IL12RB2
ESTRADIOL;TCL1A;G;rs7158782;OTHER;INCREASED_EXPRESSION;TCL1A
ANASTROZOLE;CYP19A1;AG;rs6493497;OTHER;ACTIVITY;CYP19A1
EXEMESTANE;CYP19A1;AG;rs6493497;OTHER;ACTIVITY;CYP19A1
LETROZOLE;CYP19A1;AG;rs6493497;OTHER;ACTIVITY;CYP19A1
ANASTROZOLE;CYP19A1;CT;rs7176005;OTHER;ACTIVITY;CYP19A1
EXEMESTANE;CYP19A1;CT;rs7176005;OTHER;ACTIVITY;CYP19A1
LETROZOLE;CYP19A1;CT;rs7176005;OTHER;ACTIVITY;CYP19A1
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*32, TPMT*33, TPMT*34;LADME_PK;DECREASED_ACTIVITY;TPMT
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*32, TPMT*33, TPMT*34;LADME_PK;DECREASED_ACTIVITY;TPMT
SITAGLIPTIN;DPP4;CC;rs759717;LADME_PD;INCREASED_ACTIVITY;DPP4
SITAGLIPTIN;DPP4;TT;rs2909451;LADME_PD;INCREASED_ACTIVITY;DPP4
TAMOXIFEN;CYP2D6;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;CYP2D6*1, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*18, CYP2D6*21, CYP2D6*41;EFFICACY;INCREASED_EXPRESSION;MKI67
ESTRADIOL;TCL1A;A;rs7158782;OTHER;INCREASED_EXPRESSION;IL1R2
ESTRADIOL;TCL1A;A;rs7158782;OTHER;INCREASED_EXPRESSION;IL17A
ESTRADIOL;TCL1A;A;rs7159713;OTHER;INCREASED_EXPRESSION;IL1R2
ESTRADIOL;TCL1A;A;rs7159713;OTHER;INCREASED_EXPRESSION;IL12RB2
ESTRADIOL;TCL1A;A;rs7159713;OTHER;INCREASED_EXPRESSION;IL17A
ESTRADIOL;TCL1A;G;rs7159713;OTHER;INCREASED_EXPRESSION;TCL1A
IVACAFTOR;CFTR;A;rs78655421;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;A;rs397508759;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;G;rs150212784;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;G;rs34911792;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;C;rs397508513;EFFICACY;ACTIVITY;CFTR
ESTRADIOL;TCL1A;G;rs7159713;OTHER;INCREASED_EXPRESSION;IL17RA
METHOXSALEN;CYP2A6;*15 + *21 + *22;CYP2A6*15, CYP2A6*21, CYP2A6*22;OTHER;DECREASED_ENZYME_ACTIVITY;CYP2A6
ATORVASTATIN;SCAP;TT;rs12487736;OTHER;DECREASED_TRANSCRIPTION;SCAP
IVACAFTOR;CFTR;T;rs202179988;EFFICACY;ACTIVITY;CFTR
TAMOXIFEN;CYP2D6;*2;CYP2D6*1, CYP2D6*2;OTHER;DECREASED_ACTIVITY;CYP2D6
VITAMIN E;CYP4F2;C;rs3093105;LADME_PK;INCREASED_CATALYTIC-ACTIVITY;CYP4F2
ESTRADIOL;nan;C;rs11849538;OTHER;INCREASED_EXPRESSION;IL17A
ESTRADIOL;nan;C;rs11849538;OTHER;INCREASED_EXPRESSION;IL1R2
IVACAFTOR;CFTR;A;rs78655421;EFFICACY;INCREASED_ACTIVITY;CFTR
LUMACAFTOR;CFTR;A;rs78655421;EFFICACY;INCREASED_ACTIVITY;CFTR
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;INCREASED_ACTIVITY;CFTR
NPPB;CFTR;A;rs75527207;EFFICACY;INCREASED_ACTIVITY;CFTR
EFAVIRENZ;CYP2B6;*6;CYP2B6*6;LADME_PK;INCREASED_ACTIVITY;CYP3A4
FLUOROURACIL;DPYD;T;rs56005131;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;DPYD
ESTRADIOL;nan;G;rs2369049;OTHER;INCREASED_EXPRESSION;IL17RA
ESTRADIOL;nan;A;rs2369049;OTHER;INCREASED_EXPRESSION;IL12RB2
ESTRADIOL;nan;A;rs2369049;OTHER;INCREASED_EXPRESSION;IL17A
ELEXACAFTOR;CFTR;CG;rs80034486;LADME_PD;INCREASED_ACTIVITY;CFTR
TEZACAFTOR;CFTR;CG;rs80034486;LADME_PD;INCREASED_ACTIVITY;CFTR
IVACAFTOR;CFTR;CG;rs80034486;LADME_PD;INCREASED_ACTIVITY;CFTR
CORR-4A;CFTR;del/del;rs113993960;EFFICACY;INCREASED_ACTIVITY;CFTR
IVACAFTOR;CFTR;del/del;rs113993960;EFFICACY;INCREASED_ACTIVITY;CFTR
LUMACAFTOR;CFTR;del/del;rs113993960;EFFICACY;INCREASED_ACTIVITY;CFTR
ESTRADIOL;nan;A;rs2369049;OTHER;INCREASED_EXPRESSION;IL1R2
IVACAFTOR;CFTR;G;rs397508288;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;C;rs75541969;EFFICACY;ACTIVITY;CFTR
ESCITALOPRAM;IL11;CT + TT;rs1126757;OTHER;DECREASED_EXPRESSION;IL11
ESTRADIOL;nan;G;rs11849538;OTHER;INCREASED_EXPRESSION;TCL1A
METHOTREXATE;FASTKD3;AG + GG;rs1801394;nan;INCREASED_CATALYTIC-ACTIVITY;TYMS
METHOTREXATE;MTRR;AG + GG;rs1801394;nan;INCREASED_CATALYTIC-ACTIVITY;TYMS
ESTRADIOL;nan;G;rs11849538;OTHER;INCREASED_EXPRESSION;IL17RA
ESTRADIOL;nan;C;rs11849538;OTHER;INCREASED_EXPRESSION;IL12RB2
IVACAFTOR;CFTR;T;rs11971167;EFFICACY;ACTIVITY;CFTR
ESTRADIOL;nan;G;rs2369049;OTHER;INCREASED_EXPRESSION;TCL1A
IVACAFTOR;CFTR;A;rs121909019;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;A;rs121908753;EFFICACY;ACTIVITY;CFTR
PHENYTOIN;CYP2C9;del;rs71486745;nan;DECREASED_EXPRESSION;CYP2C9
METHOTREXATE;MTHFR;GT;rs1801131;nan;INCREASED_CATALYTIC-ACTIVITY;TYMS
IVACAFTOR;CFTR;T;rs77834169;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;T;rs397508442;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;A;rs121909047;EFFICACY;ACTIVITY;CFTR
GLYBURIDE;KCNJ11;T;rs5219;LADME_PK;DECREASED_ACTIVITY;KCNJ11
HYDROCHLOROTHIAZIDE;YEATS4;CC;rs7297610;LADME_PK;DECREASED_EXPRESSION;YEATS4
IVACAFTOR;CFTR;G;rs121908752;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;INCREASED_ACTIVITY;CFTR
VITAMIN E;CYP4F2;T;rs2108622;OTHER;DECREASED_ENZYME_ACTIVITY;CYP4F2
IVACAFTOR;CFTR;A;rs121909020;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;C;rs113993958;EFFICACY;ACTIVITY;CFTR
DISOPYRAMIDE;KCNH2;T;rs104894021;EFFICACY;DECREASED_INHIBITION;KCNH2
MEPHENYTOIN;CYP2C19;*10;CYP2C19*1, CYP2C19*10;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C19
QUINIDINE;KCNH2;T;rs104894021;EFFICACY;DECREASED_INHIBITION;KCNH2
CHLOROCRESOL;RYR1;T;rs193922803;OTHER;INCREASED_ACTIVITY;RYR1
TAMOXIFEN;NCOA1;T;rs1804645;nan;DECREASED_ACTIVITY;NCOA1
CYTARABINE;CDA;AA + AG;rs60369023;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CDA
GENTAMICIN;MT-RNR1;T;rs267606619;LADME_PD;DECREASED_ACTIVITY;MT-RNR1
QUINIDINE;KCNH2;C;rs104894021;EFFICACY;DECREASED_INHIBITION;KCNH2
BUPROPION;CYP2B6;*1/*30;CYP2B6*1, CYP2B6*30;OTHER;DECREASED_ACTIVITY;CYP2B6
GEMCITABINE;DCTD;C;rs35932500;LADME_PK;DECREASED_ENZYME_ACTIVITY;DCTD
BUPROPION;POR;AG + GG;rs2868177;LADME_PK;INCREASED_ACTIVITY;CYP2B6
GEMCITABINE;CDA;C;rs2072671;LADME_PK;DECREASED_ENZYME_ACTIVITY;CDA
ADALIMUMAB;TNF;AG;rs1800629;LADME_PK;DECREASED_STEADY_STATE_LEVEL;TNF
PAROMOMYCIN;MT-RNR1;G;rs267606617;LADME_PD;DECREASED_ACTIVITY;MT-RNR1
SIMVASTATIN;HLA-G;GG;rs1063320;OTHER;INCREASED_EXPRESSION;HLA-G
ACETAMINOPHEN;CYP2E1;T;rs2515641;OTHER;INCREASED_EXPRESSION;CYP2E1
MEPHENYTOIN;CYP2C19;*19;CYP2C19*1, CYP2C19*19;OTHER;DECREASED_CATALYTIC-ACTIVITY;CYP2C19
BUPRENORPHINE;OPRM1;G;rs1799971;EFFICACY;DECREASED_ACTIVITY;OPRM1
TAMOXIFEN;UGT1A4;CC;rs8330;LADME_PK;DECREASED_ACTIVITY;UGT1A4
OMEPRAZOLE;CYP2C19;*19;CYP2C19*1, CYP2C19*19;LADME_PK;INCREASED_CATALYTIC-ACTIVITY;CYP2C19
CLOPIDOGREL;CYP2C19;*28;CYP2C19*1, CYP2C19*28;LADME_PK;INCREASED_CATALYTIC-ACTIVITY;CYP2C19
GEMCITABINE;FKBP5;CT;rs73748206;OTHER;INCREASED_EXPRESSION;FKBP5
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*1, CYP2C19*10, CYP2C19*14, CYP2C19*19, CYP2C19*25, CYP2C19*26;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C19
CLOPIDOGREL;CYP2C19;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;CYP2C19*1, CYP2C19*10, CYP2C19*13, CYP2C19*14, CYP2C19*15, CYP2C19*18, CYP2C19*19, CYP2C19*23, CYP2C19*25, CYP2C19*26;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C19
MEPHENYTOIN;CYP2C19;*26;CYP2C19*1, CYP2C19*26;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;*26;CYP2C19*1, CYP2C19*26;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C19
ACETAMINOPHEN;UGT1A;CC;rs8330;LADME_PK;DECREASED_ACTIVITY;UGT1A
ETHANOL;ADH1B;CT + TT;rs1229984;LADME_PK;INCREASED_ENZYME_ACTIVITY;ADH1B
ELEXACAFTOR;CFTR;del/del;rs113993960;OTHER;INCREASED_TRANSPORT;CFTR
IVACAFTOR;CFTR;del/del;rs113993960;OTHER;INCREASED_TRANSPORT;CFTR
TEZACAFTOR;CFTR;del/del;rs113993960;OTHER;INCREASED_TRANSPORT;CFTR
ACETAMINOPHEN;UGT1A;CC;rs10929303;LADME_PK;DECREASED_ACTIVITY;UGT1A
XENOBIOTICS;AHR;A;rs2066853;LADME_PK;INCREASED_EXPRESSION;CYP1A1
OMEPRAZOLE;AHR;G;rs75519181;LADME_PK;DECREASED_EXPRESSION;CYP1A1
XENOBIOTICS;AHR;G;rs75519181;LADME_PK;DECREASED_EXPRESSION;CYP1A1
ACETAMINOPHEN;UGT1A;CC;rs1042640;LADME_PK;DECREASED_ACTIVITY;UGT1A
GEMCITABINE;FKBP5;CT;rs73748206;OTHER;INCREASED_EXPRESSION;NR3C1
ESTRADIOL;nan;GG;rs3802201;OTHER;INCREASED_EXPRESSION;MIR2052
ALDOSTERONE;SCNN1B;A;rs34241435;OTHER;INCREASED_TRANSCRIPTION;SCNN1B
INSULIN RECOMBINANT;SCNN1B;A;rs34241435;OTHER;INCREASED_TRANSCRIPTION;SCNN1B
ESTRADIOL;nan;CC;rs4476990;OTHER;INCREASED_EXPRESSION;MIR2052
MEPHENYTOIN;CYP2C19;*9;CYP2C19*1, CYP2C19*9;LADME_PK;DECREASED_ACTIVITY;CYP2C19
MEPHENYTOIN;CYP2C19;*10;CYP2C19*1, CYP2C19*10;LADME_PK;DECREASED_ACTIVITY;CYP2C19
BERBERINE;CYP2D6;*1/*1;CYP2D6*1;LADME_PK;INCREASED_INHIBITION;CYP2D6
COPTISINE;CYP2D6;*1/*1;CYP2D6*1;LADME_PK;INCREASED_INHIBITION;CYP2D6
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *10;CYP2C19*1, CYP2C19*8, CYP2C19*10;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C19
MEPHENYTOIN;CYP2C19;*23;CYP2C19*1, CYP2C19*23;LADME_PK;INCREASED_CATALYTIC-ACTIVITY;CYP2C19
BERBERINE;CYP2D6;*1/*10;CYP2D6*1, CYP2D6*10;LADME_PK;INCREASED_INHIBITION;CYP2D6
COPTISINE;CYP2D6;*1/*10;CYP2D6*1, CYP2D6*10;LADME_PK;INCREASED_INHIBITION;CYP2D6
DISOPYRAMIDE;KCNH2;C;rs104894021;EFFICACY;DECREASED_INHIBITION;KCNH2
IVACAFTOR;CFTR;A;rs74503330;OTHER;INCREASED_ACTIVITY;CFTR
FLUOROURACIL;DPYD;T;rs372307932;LADME_PK;DECREASED_ACTIVITY;DPYD
MIDAZOLAM;CYP3A4;AG;rs35599367;LADME_PK;DECREASED_ACTIVITY;CYP3A4
DEXTROMETHORPHAN;CYP3A4;AG;rs35599367;LADME_PK;DECREASED_ACTIVITY;CYP3A4
MEPHENYTOIN;CYP2C19;*10;CYP2C19*1, CYP2C19*10;LADME_PK;DECREASED_ACTIVITY;CYP2C19
MEPHENYTOIN;CYP2C19;*16;CYP2C19*1, CYP2C19*16;LADME_PK;DECREASED_ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;*16;CYP2C19*1, CYP2C19*16;LADME_PK;DECREASED_ACTIVITY;CYP2C19
MEPHENYTOIN;CYP2C19;*19;CYP2C19*1, CYP2C19*19;LADME_PK;DECREASED_ACTIVITY;CYP2C19
MEPHENYTOIN;CYP2C19;*18;CYP2C19*1, CYP2C19*18;LADME_PK;DECREASED_ACTIVITY;CYP2C19
FLUOROURACIL;DPYD;T;rs376073289;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;G;rs374527058;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;A;rs538336580;LADME_PK;DECREASED_ACTIVITY;DPYD
MEPHENYTOIN;CYP2C19;*9;CYP2C19*1, CYP2C19*9;LADME_PK;DECREASED_ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;*9;CYP2C19*1, CYP2C19*9;LADME_PK;DECREASED_ACTIVITY;CYP2C19
FLUOROURACIL;DPYD;A;rs568367673;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;A;rs558354142;LADME_PK;DECREASED_ACTIVITY;DPYD
MEPHENYTOIN;CYP2C19;A;rs770829708;LADME_PK;DECREASED_ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;A;rs770829708;LADME_PK;DECREASED_ACTIVITY;CYP2C19
FLUOROURACIL;DPYD;T;rs374825099;LADME_PK;DECREASED_ACTIVITY;DPYD
ESTRONE SULFATE;SLCO2B1;T;rs199654337;LADME_PK;DECREASED_TRANSPORT;SLCO2B1
ROSUVASTATIN;SLCO2B1;T;rs199654337;LADME_PK;DECREASED_TRANSPORT;SLCO2B1
MEPHENYTOIN;CYP2C19;*9 + *10 + *16;CYP2C19*1, CYP2C19*9, CYP2C19*10, CYP2C19*16;LADME_PK;DECREASED_CLEARANCE;CYP2C19
OMEPRAZOLE;CYP2C19;*9 + *10 + *16;CYP2C19*1, CYP2C19*9, CYP2C19*10, CYP2C19*16;LADME_PK;DECREASED_CLEARANCE;CYP2C19
OMEPRAZOLE;CYP2C19;*19;CYP2C19*1, CYP2C19*19;LADME_PK;DECREASED_CLEARANCE;CYP2C19
ESTRONE SULFATE;SLCO2B1;C;rs1009122956;LADME_PK;DECREASED_TRANSPORT;SLCO2B1
ROSUVASTATIN;SLCO2B1;C;rs1009122956;LADME_PK;DECREASED_TRANSPORT;SLCO2B1
ESTRONE SULFATE;SLCO2B1;T;rs1621378;LADME_PK;DECREASED_TRANSPORT;SLCO2B1
ROSUVASTATIN;SLCO2B1;T;rs1621378;LADME_PK;DECREASED_TRANSPORT;SLCO2B1
ESTRONE SULFATE;SLCO2B1;T;rs2306168;LADME_PK;DECREASED_TRANSPORT;SLCO2B1
FLUOROURACIL;DPYD;T;rs548783838;LADME_PK;DECREASED_ACTIVITY;DPYD
NO_DRUG_RELATED;CYP2B6;*1/*1;CYP2B6*1, CYP2B6*6;EFFICACY;INCREASED_ACTIVITY;CYP2B6
BUPROPION;CYP2B6;*1/*1;CYP2B6*1, CYP2B6*6;EFFICACY;INCREASED_ACTIVITY;CYP2B6
FLUOROURACIL;DPYD;G;rs140989814;LADME_PK;DECREASED_ACTIVITY;DPYD
MEPHENYTOIN;CYP2C19;*8;CYP2C19*1, CYP2C19*8;LADME_PK;DECREASED_ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;*8;CYP2C19*1, CYP2C19*8;LADME_PK;DECREASED_ACTIVITY;CYP2C19
MEPHENYTOIN;CYP2C19;*13;CYP2C19*1, CYP2C19*13;LADME_PK;DECREASED_ACTIVITY;CYP2C19
BLONANSERIN;CYP3A4;*29;CYP3A4*1, CYP3A4*29;LADME_PK;INCREASED_ACTIVITY;CYP3A4
TESTOSTERONE;CYP3A4;AG;rs35599367;LADME_PK;DECREASED_ACTIVITY;CYP3A4
ACALABRUTINIB;CYP3A4;*2 + *3 + *11 + *29 + *33;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*11, CYP3A4*29, CYP3A4*33;LADME_PK;INCREASED_CATALYTIC-ACTIVITY;CYP3A4
ACALABRUTINIB;CYP3A4;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;CYP3A4*1, CYP3A4*9, CYP3A4*14, CYP3A4*16, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*32;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP3A4
VANDETANIB;CYP3A4;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*9, CYP3A4*15, CYP3A4*16, CYP3A4*29, CYP3A4*32, CYP3A4*33;LADME_PK;INCREASED_CLEARANCE;CYP3A4
MEPHENYTOIN;CYP2C19;*10;CYP2C19*1, CYP2C19*10;LADME_PK;DECREASED_ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;*10;CYP2C19*1, CYP2C19*10;LADME_PK;DECREASED_ACTIVITY;CYP2C19
FLUOROURACIL;DPYD;A;rs1801266;LADME_PK;DECREASED_ACTIVITY;DPYD
DEXTROMETHORPHAN;SEPTIN3;G;rs1062753;LADME_PK;INCREASED_ENZYME_ACTIVITY;CYP2D6
DEXTROMETHORPHAN;WBP2NL;G;rs1062753;LADME_PK;INCREASED_ENZYME_ACTIVITY;CYP2D6
BUMETANIDE;SLC17A3;A;rs34376145;LADME_PK;DECREASED_TRANSPORT;SLC17A3
BUMETANIDE;SLC17A3;A;rs34902660;LADME_PK;DECREASED_TRANSPORT;SLC17A3
BUMETANIDE;SLC17A3;A;rs11966370;LADME_PK;DECREASED_TRANSPORT;SLC17A3
BUMETANIDE;SLC17A3;T;rs56027330;LADME_PK;DECREASED_TRANSPORT;SLC17A3
OMEPRAZOLE;CYP2C19;G;rs148247410;LADME_PK;DECREASED_ACTIVITY;CYP2C19
FLUOROURACIL;DPYD;A;rs528152707;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;A;rs570122671;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;T;rs201268750;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;C;rs527580106;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;C;rs55886062;LADME_PK;DECREASED_ACTIVITY;DPYD
MEPHENYTOIN;CYP2C19;T;rs550527959;LADME_PK;DECREASED_ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;T;rs550527959;LADME_PK;DECREASED_ACTIVITY;CYP2C19
FLUOROURACIL;DPYD;A;rs538703919;LADME_PK;DECREASED_ACTIVITY;DPYD
IBUPROFEN;CYP3A4;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;CYP3A4*1, CYP3A4*4, CYP3A4*5, CYP3A4*18, CYP3A4*23, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;OTHER;DECREASED_CLEARANCE;CYP3A4
BLONANSERIN;CYP3A4;*20;CYP3A4*1, CYP3A4*20;LADME_PK;DECREASED_ACTIVITY;CYP3A4
MEPHENYTOIN;CYP2C19;A;rs763625282;LADME_PK;DECREASED_ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;A;rs763625282;LADME_PK;DECREASED_ACTIVITY;CYP2C19
BLONANSERIN;CYP3A4;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;CYP3A4*1, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*31, CYP3A4*33, CYP3A4*34;LADME_PK;DECREASED_ACTIVITY;CYP3A4
REGORAFENIB;CYP3A4;*20;CYP3A4*1, CYP3A4*20;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP3A4
FLUOROURACIL;DPYD;C;rs72549307;LADME_PK;DECREASED_ACTIVITY;DPYD
OMEPRAZOLE;CYP2C19;T;rs1431015009;LADME_PK;DECREASED_ACTIVITY;CYP2C19
BUFURALOL;CYP2D6;T;rs1058171;LADME_PK;DECREASED_ACTIVITY;CYP2D6
DICLOFENAC;CYP2C9;*72;CYP2C9*1, CYP2C9*72;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
LOSARTAN;CYP2C9;*72;CYP2C9*1, CYP2C9*72;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
TOLBUTAMIDE;CYP2C9;*72;CYP2C9*1, CYP2C9*72;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
SUMATRIPTAN;HTR1B;C;rs130060;LADME_PD;INCREASED_CONCENTRATIONS;AMPc
BUFURALOL;CYP2D6;A;rs1230912765;LADME_PK;DECREASED_ACTIVITY;CYP2D6
PURINE ANALOGUES;PACSIN2;C;rs2413739;OTHER;INCREASED_ACTIVITY;TPMT
PURINE ANALOGUES;PACSIN2;C;rs2413739;LADME_PK;INCREASED_ACTIVITY;TPMT
L-PHENYLALANINE;PAH;A;rs76394784;LADME_PK;DECREASED_ACTIVITY;PAH
CARBOCISTEINE;PAH;T;rs62516101;LADME_PK;DECREASED_ACTIVITY;PAH
CARBOCISTEINE;PAH;G;rs75193786;LADME_PK;DECREASED_ACTIVITY;PAH
DICLOFENAC;CYP2C9;*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
LOSARTAN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
TOLBUTAMIDE;CYP2C9;*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
LOSARTAN;CYP2C9;*75;CYP2C9*1, CYP2C9*75;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
L-PHENYLALANINE;PAH;T;rs62516101;LADME_PK;DECREASED_ACTIVITY;PAH
CARBOCISTEINE;PAH;C;rs5030860;LADME_PK;DECREASED_ACTIVITY;PAH
L-PHENYLALANINE;PAH;T;rs5030849;LADME_PK;DECREASED_ACTIVITY;PAH
CARBOCISTEINE;PAH;A;rs76394784;LADME_PK;DECREASED_ACTIVITY;PAH
DICLOFENAC;CYP2C9;*3;CYP2C9*3;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C9
WARFARIN;CYP2C9;*60;CYP2C9*1, CYP2C9*60;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;*37;CYP2C9*37;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;*46;CYP2C9*46;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C9
CARBOCISTEINE;PAH;T;rs5030849;LADME_PK;DECREASED_ACTIVITY;PAH
L-PHENYLALANINE;PAH;C;rs5030860;LADME_PK;DECREASED_ACTIVITY;PAH
DICLOFENAC;CYP2C9;*54;CYP2C9*54;LADME_PK;INCREASED_CATALYTIC-ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;*74;CYP2C9*1, CYP2C9*74;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
LOSARTAN;CYP2C9;*74;CYP2C9*1, CYP2C9*74;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
TOLBUTAMIDE;CYP2C9;*74;CYP2C9*1, CYP2C9*74;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
TOLBUTAMIDE;CYP2C9;T;rs9332239;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C9
BUFURALOL;CYP2D6;*49 + *55;CYP2D6*1, CYP2D6*49, CYP2D6*55;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2D6
TOLTERODINE;CYP2D6;*92 + *96;CYP2D6*92, CYP2D6*96;LADME_PK;DECREASED_ACTIVITY;CYP2D6
GEFITINIB;CYP2D6;*92 + *96;CYP2D6*92, CYP2D6*96;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2D6
DEXTROMETHORPHAN;CYP2D6;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;CYP2D6*1, CYP2D6*10, CYP2D6*18, CYP2D6*36, CYP2D6*47, CYP2D6*49, CYP2D6*50, CYP2D6*51, CYP2D6*54, CYP2D6*55, CYP2D6*114;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2D6
BUFURALOL;CYP2D6;*18;CYP2D6*1, CYP2D6*18;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2D6
HYDRALAZINE;NAT2;*4/*5 + *4/*6;NAT2*4, NAT2*5, NAT2*6, NAT2*7;OTHER;INCREASED_ACTIVITY;NAT2
HYDRALAZINE;NAT2;*4/*4;NAT2*4, NAT2*5, NAT2*6;OTHER;INCREASED_ACTIVITY;NAT2
BUFURALOL;CYP2D6;*36;CYP2D6*1, CYP2D6*36;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2D6
DICLOFENAC;CYP2C9;*73;CYP2C9*1, CYP2C9*73;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
LOSARTAN;CYP2C9;*73;CYP2C9*1, CYP2C9*73;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
BUFURALOL;CYP2D6;*36;CYP2D6*1, CYP2D6*36;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2D6
FLUOXETINE;CYP2D6;*10 + *92 + *93 + *96 + *87 + *2;CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*92, CYP2D6*93, CYP2D6*96;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2D6
BUFURALOL;CYP2D6;*2 + *10 + *89 + *92 + *93 + *96;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*89, CYP2D6*92, CYP2D6*93, CYP2D6*96;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2D6
TOLBUTAMIDE;CYP2C9;*60;CYP2C9*1, CYP2C9*60;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
TOLBUTAMIDE;CYP2C9;*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;*60;CYP2C9*1, CYP2C9*60;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
DEXTROMETHORPHAN;CYP2D6;*10;CYP2D6*1, CYP2D6*10;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2D6
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
BUFURALOL;CYP2D6;*50;CYP2D6*1, CYP2D6*50;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2D6
DICLOFENAC;CYP2C9;*44;CYP2C9*44;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;*42;CYP2C9*42;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;*40;CYP2C9*40;LADME_PK;INCREASED_CATALYTIC-ACTIVITY;CYP2C9
MEPHENYTOIN;CYP2C19;A;rs200346442;LADME_PK;DECREASED_ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;A;rs200346442;LADME_PK;DECREASED_ACTIVITY;CYP2C19
MEPHENYTOIN;CYP2C19;G;rs200150287;LADME_PK;DECREASED_ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;G;rs200150287;LADME_PK;DECREASED_ACTIVITY;CYP2C19
MEPHENYTOIN;CYP2C19;T;rs150152656;LADME_PK;DECREASED_ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;T;rs150152656;LADME_PK;DECREASED_ACTIVITY;CYP2C19
BUPROPION;POR;AA;rs2868177;OTHER;DECREASED_ENZYME_ACTIVITY;CYP2B6
BUPROPION;POR;AA;rs2868177;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2B6
BUPROPION;POR;GG;rs2868177;OTHER;INCREASED_ACTIVITY;CYP2B6
BUPROPION;POR;GG;rs2868177;LADME_PK;INCREASED_ACTIVITY;CYP2B6
BUFURALOL;CYP2D6;*51;CYP2D6*1, CYP2D6*51;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2D6
MEPHENYTOIN;CYP2C19;*32;CYP2C19*1, CYP2C19*32;LADME_PK;DECREASED_ACTIVITY;CYP2C19
MEPHENYTOIN;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*1, CYP2C19*29, CYP2C19*30, CYP2C19*31, CYP2C19*33;LADME_PK;DECREASED_ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;*29 + *30 + *31 + *33;CYP2C19*1, CYP2C19*29, CYP2C19*30, CYP2C19*31, CYP2C19*33;LADME_PK;DECREASED_ACTIVITY;CYP2C19
NO_DRUG_RELATED;POR;AA;rs2868177;OTHER;DECREASED_ACTIVITY;CYP2B6
NO_DRUG_RELATED;POR;AA;rs2868177;LADME_PK;DECREASED_ACTIVITY;CYP2B6
CLOPIDOGREL;CYP2C19;*10;CYP2C19*1, CYP2C19*10;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;A;rs140278421;LADME_PK;DECREASED_ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;G;rs1361528097;LADME_PK;DECREASED_ACTIVITY;CYP2C19
MEPHENYTOIN;CYP2C19;*3;CYP2C19*1, CYP2C19*3;LADME_PK;DECREASED_ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;*3;CYP2C19*1, CYP2C19*3;LADME_PK;DECREASED_ACTIVITY;CYP2C19
FLUOROURACIL;DPYD;C;rs536577604;LADME_PK;DECREASED_ACTIVITY;DPYD
DEBRISOQUINE;CYP2D6;*10;CYP2D6*1, CYP2D6*10;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2D6
MEPHENYTOIN;CYP2C19;C;rs1267723490;LADME_PK;DECREASED_ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;C;rs1267723490;LADME_PK;DECREASED_ACTIVITY;CYP2C19
BUFURALOL;CYP2D6;*54;CYP2D6*1, CYP2D6*54;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2D6
BUFURALOL;CYP2D6;*29;CYP2D6*1, CYP2D6*29;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2D6
DEBRISOQUINE;CYP2D6;*29;CYP2D6*1, CYP2D6*29;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2D6
BUFURALOL;CYP2D6;*47;CYP2D6*1, CYP2D6*47;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2D6
MEPHENYTOIN;CYP2C19;T;rs764137538;LADME_PK;DECREASED_ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;T;rs764137538;LADME_PK;DECREASED_ACTIVITY;CYP2C19
IBUPROFEN;CYP2C19;*3 + *35;CYP2C19*1, CYP2C19*3, CYP2C19*35;OTHER;DECREASED_CATALYTIC-ACTIVITY;CYP2C19
IBUPROFEN;CYP2C19;*33 + *30 + *31 + *32;CYP2C19*1, CYP2C19*30, CYP2C19*31, CYP2C19*32, CYP2C19*33;OTHER;DECREASED_CATALYTIC-ACTIVITY;CYP2C19
DEXTROMETHORPHAN;PHETA2;G;rs1807493;LADME_PK;INCREASED_ENZYME_ACTIVITY;CYP2D6
DEXTROMETHORPHAN;SMDT1;G;rs1807493;LADME_PK;INCREASED_ENZYME_ACTIVITY;CYP2D6
BUFURALOL;CYP2D6;*10;CYP2D6*1, CYP2D6*10;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2D6
DICLOFENAC;CYP2C9;*52;CYP2C9*52;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;*43;CYP2C9*43;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;*45;CYP2C9*45;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;*36;CYP2C9*36;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;*55;CYP2C9*55;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;*39;CYP2C9*39;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;*50;CYP2C9*50;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;*47;CYP2C9*47;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;*53;CYP2C9*53;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;*38;CYP2C9*38;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;*48;CYP2C9*48;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2C9
MEPHENYTOIN;CYP2C19;T;rs1463550071;LADME_PK;DECREASED_ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;T;rs1463550071;LADME_PK;DECREASED_ACTIVITY;CYP2C19
MEPHENYTOIN;CYP2C19;A;rs1349931378;LADME_PK;DECREASED_ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;A;rs1349931378;LADME_PK;DECREASED_ACTIVITY;CYP2C19
DEBRISOQUINE;CYP2D6;*75;CYP2D6*1, CYP2D6*75;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2D6
OMEPRAZOLE;CYP2C19;T;rs1393133490;LADME_PK;DECREASED_ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;G;rs1466428833;LADME_PK;DECREASED_ACTIVITY;CYP2C19
MEPHENYTOIN;CYP2C19;C;rs749678783;LADME_PK;DECREASED_ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;C;rs749678783;LADME_PK;DECREASED_ACTIVITY;CYP2C19
IBRUTINIB;CYP3A4;*17 + *24;CYP3A4*1, CYP3A4*17, CYP3A4*24;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP3A4
EFAVIRENZ;CYP2B6;A;rs58871670;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2B6
FLUOROURACIL;DPYD;C;rs72547601;LADME_PK;DECREASED_ACTIVITY;DPYD
BUPROPION;CYP2B6;C;rs201500445;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2B6
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B;TPMT*1, TPMT*3A, TPMT*3B;LADME_PK;DECREASED_ENZYME_ACTIVITY;TPMT
FLUOROURACIL;DPYD;C;rs188052243;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;DPYD
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1, TPMT*3A, TPMT*3C;LADME_PK;DECREASED_ENZYME_ACTIVITY;TPMT
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*1, TPMT*3C;LADME_PK;DECREASED_ENZYME_ACTIVITY;TPMT
DAUNORUBICIN;AKR7A2;T;rs1043657;LADME_PK;DECREASED_ENZYME_ACTIVITY;AKR7A2
DOXORUBICIN;AKR7A2;T;rs1043657;LADME_PK;DECREASED_ENZYME_ACTIVITY;AKR7A2
DAUNORUBICIN;AKR1C4;G;rs17134592;LADME_PK;DECREASED_ENZYME_ACTIVITY;AKR1C4
MERCAPTOPURINE;TPMT;*1/*1;TPMT*1, TPMT*3A, TPMT*3C;LADME_PK;INCREASED_ENZYME_ACTIVITY;TPMT
MERCAPTOPURINE;TPMT;AT;rs3931660;LADME_PK;DECREASED_ENZYME_ACTIVITY;TPMT
MERCAPTOPURINE;TPMT;CT;rs1142345;LADME_PK;DECREASED_ENZYME_ACTIVITY;TPMT
DAUNORUBICIN;AKR1C3;A;rs4987102;LADME_PK;DECREASED_ENZYME_ACTIVITY;AKR1C3
DAUNORUBICIN;AKR1C3;T;rs35575889;LADME_PK;DECREASED_ENZYME_ACTIVITY;AKR1C3
DOXORUBICIN;AKR1C3;T;rs35575889;LADME_PK;DECREASED_ENZYME_ACTIVITY;AKR1C3
DAUNORUBICIN;AKR1C3;T;rs34186955;LADME_PK;DECREASED_ENZYME_ACTIVITY;AKR1C3
DOXORUBICIN;AKR1C3;T;rs34186955;LADME_PK;DECREASED_ENZYME_ACTIVITY;AKR1C3
NO_DRUG_RELATED;TPMT;*2 + *3A + *5 + *12 + *14 + *18 + *22;TPMT*1, TPMT*2, TPMT*3A, TPMT*5, TPMT*12, TPMT*14, TPMT*18, TPMT*22;LADME_PK;DECREASED_EXPRESSION;TPMT
FLUOROURACIL;DPYD;A;rs72549306;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;DPYD
SN-38;UGT1A1;*1/*28 + *28/*28 + *1/*37;UGT1A1*1, UGT1A1*28, UGT1A1*37;LADME_PK;DECREASED_ENZYME_ACTIVITY;UGT1A1
SN-38;UGT1A1;A;rs4148323;LADME_PK;DECREASED_ENZYME_ACTIVITY;UGT1A1
FLUOROURACIL;DPYD;T;rs137999090;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;T;rs145773863;LADME_PK;DECREASED_ACTIVITY;DPYD
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;T;rs200858900;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;ABCC4
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;LADME_PK;DECREASED_ACTIVITY;TPMT
FLUOROURACIL;DPYD;A;rs59086055;LADME_PK;DECREASED_ACTIVITY;DPYD
MERCAPTOPURINE;TPMT;*3B/*3C;TPMT*1, TPMT*3B, TPMT*3C;LADME_PK;DECREASED_ENZYME_ACTIVITY;TPMT
PURINE ANALOGUES;TPMT;CT;rs1142345;OTHER;DECREASED_ACTIVITY;TPMT
PURINE ANALOGUES;TPMT;CT;rs1142345;LADME_PK;DECREASED_ACTIVITY;TPMT
ELEXACAFTOR;CFTR;T;rs1792306355;EFFICACY;INCREASED_ACTIVITY;CFTR
TEZACAFTOR;CFTR;T;rs1792306355;EFFICACY;INCREASED_ACTIVITY;CFTR
ELEXACAFTOR;CFTR;CT;rs186089140;LADME_PD;INCREASED_ACTIVITY;CFTR
TEZACAFTOR;CFTR;CT;rs186089140;LADME_PD;INCREASED_ACTIVITY;CFTR
IVACAFTOR;CFTR;CT;rs186089140;LADME_PD;INCREASED_ACTIVITY;CFTR
ELEXACAFTOR;CFTR;A;rs35516286;LADME_PD;INCREASED_ACTIVITY;CFTR
TEZACAFTOR;CFTR;A;rs35516286;LADME_PD;INCREASED_ACTIVITY;CFTR
IVACAFTOR;CFTR;A;rs35516286;LADME_PD;INCREASED_ACTIVITY;CFTR
IVACAFTOR;CFTR;A;rs35516286;LADME_PD;INCREASED_ACTIVITY;CFTR
TEZACAFTOR;CFTR;A;rs35516286;LADME_PD;INCREASED_ACTIVITY;CFTR
CLOPIDOGREL;CES1;G;rs143718310;LADME_PK;DECREASED_METABOLISM;nan
ENALAPRIL;CES1;G;rs143718310;LADME_PK;DECREASED_METABOLISM;nan
SACUBITRIL;CES1;G;rs143718310;LADME_PK;DECREASED_METABOLISM;nan
ENALAPRIL;CES1;C;rs202121317;LADME_PK;DECREASED_ENZYME_ACTIVITY;nan
REMIMAZOLAM;CES1;T;rs2307240;LADME_PK;INCREASED_CATALYTIC-ACTIVITY;CES1
CLOPIDOGREL;CES1;A;rs202001817;LADME_PK;DECREASED_ENZYME_ACTIVITY;nan
REMIMAZOLAM;CES1;T;rs71647871;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CES1
REMIMAZOLAM;CES1;C;rs151291296;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CES1
CLOPIDOGREL;CES1;C;rs151291296;LADME_PK;DECREASED_ENZYME_ACTIVITY;nan
ENALAPRIL;CES1;C;rs151291296;LADME_PK;DECREASED_ENZYME_ACTIVITY;nan
SACUBITRIL;CES1;C;rs151291296;LADME_PK;DECREASED_ENZYME_ACTIVITY;nan
CLOPIDOGREL;CES1;A;rs146456965;LADME_PK;DECREASED_METABOLISM;nan
ENALAPRIL;CES1;A;rs146456965;LADME_PK;DECREASED_METABOLISM;nan
SACUBITRIL;CES1;A;rs146456965;LADME_PK;DECREASED_METABOLISM;nan
REMIMAZOLAM;CES1;G;rs143718310;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CES1
CLOPIDOGREL;CES1;C;rs200707504;LADME_PK;DECREASED_ENZYME_ACTIVITY;nan
ENALAPRIL;CES1;C;rs200707504;LADME_PK;DECREASED_ENZYME_ACTIVITY;nan
SACUBITRIL;CES1;C;rs200707504;LADME_PK;DECREASED_ENZYME_ACTIVITY;nan
ENALAPRIL;CES1;T;rs2307243;LADME_PK;DECREASED_ENZYME_ACTIVITY;nan
REMIMAZOLAM;CES1;C;rs200707504;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CES1
BUPROPION;CYP2B6;A;rs58871670;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2B6
FLUOROURACIL;DPYD;G;rs755692084;LADME_PK;DECREASED_ACTIVITY;DPYD
MERCAPTOPURINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, TPMT*5, TPMT*6, TPMT*8, TPMT*10, TPMT*11, TPMT*12, TPMT*13;LADME_PK;DECREASED_ENZYME_ACTIVITY;TPMT
THIOGUANINE;TPMT;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, TPMT*5, TPMT*6, TPMT*7, TPMT*9, TPMT*10, TPMT*12, TPMT*14, TPMT*17, TPMT*18, TPMT*19, TPMT*20, TPMT*21, TPMT*22, TPMT*23, TPMT*30;LADME_PK;DECREASED_ENZYME_ACTIVITY;TPMT
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;LADME_PK;DECREASED_ENZYME_ACTIVITY;TPMT
ELEXACAFTOR;CFTR;T;rs758900656;EFFICACY;INCREASED_ACTIVITY;CFTR
TEZACAFTOR;CFTR;T;rs758900656;EFFICACY;INCREASED_ACTIVITY;CFTR
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;T;rs11568681;LADME_PK;INCREASED_CATALYTIC-ACTIVITY;ABCC4
FLUOROURACIL;DPYD;T;rs183385770;LADME_PK;DECREASED_ACTIVITY;DPYD
ESLICARBAZEPINE;AADAC;A;rs35084477;LADME_PK;INCREASED_CATALYTIC-ACTIVITY;AADAC
ESLICARBAZEPINE;AADAC;A;rs1803155;LADME_PK;INCREASED_CATALYTIC-ACTIVITY;AADAC
ESLICARBAZEPINE;AADAC;C;rs61733692;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;AADAC
FLUOROURACIL;DPYD;T;rs114096998;LADME_PK;INCREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;C;rs60139309;LADME_PK;INCREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;C;rs143986398;LADME_PK;DECREASED_ACTIVITY;DPYD
SN-38;UGT1A9;C;rs11692021;LADME_PK;DECREASED_ENZYME_ACTIVITY;UGT1A1
SN-38;UGT1A9;G;rs72551344;LADME_PK;DECREASED_ENZYME_ACTIVITY;UGT1A1
SN-38;UGT1A9;G;rs34993780;LADME_PK;DECREASED_ENZYME_ACTIVITY;UGT1A1
FLUOROURACIL;DPYD;G;rs72549308;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;del;rs1184321568;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;DPYD
FLUOROURACIL;DPYD;A;rs143879757;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;DPYD
FLUOROURACIL;DPYD;A;rs59086055;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;DPYD
FLUOROURACIL;DPYD;T;rs148994843;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;DPYD
DEXTROMETHORPHAN;nan;GG;rs729559;LADME_PK;INCREASED_ENZYME_ACTIVITY;CYP2D6
FLUOROURACIL;DPYD;G;rs748620513;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;DPYD
DEXTROMETHORPHAN;nan;TT;rs4073010;LADME_PK;INCREASED_ENZYME_ACTIVITY;CYP2D6
FLUOROURACIL;DPYD;A;rs72549304;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;T;rs200687447;LADME_PK;INCREASED_ACTIVITY;DPYD
ESLICARBAZEPINE;AADAC;G;rs144650170;LADME_PK;INCREASED_CATALYTIC-ACTIVITY;AADAC
FLUOROURACIL;DPYD;C;rs146356975;LADME_PK;DECREASED_ACTIVITY;DPYD
ESLICARBAZEPINE;AADAC;G;rs140197497;LADME_PK;INCREASED_CATALYTIC-ACTIVITY;AADAC
FLUOROURACIL;DPYD;C;rs2297595;LADME_PK;INCREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;G;rs183105782;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;C;rs190577302;LADME_PK;DECREASED_ACTIVITY;DPYD
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;A;rs11568644;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;ABCC4
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;T;rs142211148;LADME_PK;INCREASED_CATALYTIC-ACTIVITY;ABCC4
FLUOROURACIL;DPYD;C;rs186169810;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;A;rs143154602;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;G;rs368146607;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;T;rs371258350;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;T;rs575853463;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;G;rs569661196;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;T;rs138616379;LADME_PK;DECREASED_ACTIVITY;DPYD
AMISULPRIDE;ABCB1;T;rs2229109;LADME_PK;DECREASED_TRANSPORT;ABCB1
ARIPIPRAZOLE;ABCB1;T;rs2229109;LADME_PK;DECREASED_TRANSPORT;ABCB1
OLANZAPINE;ABCB1;T;rs2229109;LADME_PK;DECREASED_TRANSPORT;ABCB1
RISPERIDONE;ABCB1;T;rs2229109;LADME_PK;DECREASED_TRANSPORT;ABCB1
FLUOROURACIL;DPYD;C;rs115232898;LADME_PK;DECREASED_ACTIVITY;DPYD
CLOZAPINE;UGT1A4;G;rs2011425;LADME_PK;INCREASED_CATALYTIC-ACTIVITY;UGT1A4
FLUOROURACIL;DPYD;C;rs111858276;LADME_PK;DECREASED_ACTIVITY;DPYD
ACETAMINOPHEN;UGT1A6;*2a;UGT1A6*1a, UGT1A6*2a;LADME_PK;INCREASED_ACTIVITY;UGT1A6
FLUOROURACIL;DPYD;G;rs140039091;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;G;rs187713395;LADME_PK;DECREASED_ACTIVITY;DPYD
SN-38;UGT1A9;A;rs35350960;LADME_PK;DECREASED_ENZYME_ACTIVITY;UGT1A1
ESLICARBAZEPINE;AADAC;T;rs186388618;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;AADAC
ELEXACAFTOR;CFTR;A;rs397508139;EFFICACY;INCREASED_ACTIVITY;CFTR
TEZACAFTOR;CFTR;A;rs397508139;EFFICACY;INCREASED_ACTIVITY;CFTR
FLUOROURACIL;MIR27A;C;rs895819;LADME_PK;DECREASED_ENZYME_ACTIVITY;DPYD
ELEXACAFTOR;CFTR;A;rs397508609;EFFICACY;INCREASED_ACTIVITY;CFTR
TEZACAFTOR;CFTR;A;rs397508609;EFFICACY;INCREASED_ACTIVITY;CFTR
FLUOROURACIL;DPYD;C;rs141044036;LADME_PK;DECREASED_ACTIVITY;DPYD
ARACHIDONIC ACID;CYP4F2;G;rs753169154;LADME_PD;DECREASED_CATALYTIC-ACTIVITY;CYP4F2
EFAVIRENZ;CYP2B6;C;rs201500445;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2B6
BUPROPION;CYP2B6;T;rs535039125;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2B6
EFAVIRENZ;CYP2B6;A;rs117872433;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2B6
BUPROPION;CYP2B6;A;rs200238771;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2B6
ARACHIDONIC ACID;CYP4F2;A;rs114396708;LADME_PD;DECREASED_CATALYTIC-ACTIVITY;CYP4F2
COUMARIN;CYP2A6;*7 + *19;CYP2A6*1, CYP2A6*7, CYP2A6*19;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2A6
NICOTINE;CYP2A6;*7 + *19;CYP2A6*1, CYP2A6*7, CYP2A6*19;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2A6
TEGAFUR;CYP2A6;*7 + *19;CYP2A6*1, CYP2A6*7, CYP2A6*19;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2A6
BUPROPION;CYP2B6;*47;CYP2B6*47;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2B6
NICOTINE;CYP2A6;CC + CT;rs4803381;LADME_PK;INCREASED_ACTIVITY;CYP2A6
EFAVIRENZ;CYP2B6;*47;CYP2B6*47;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2B6
NICOTINE;CYP2A6;AG + GG;rs57837628;LADME_PK;INCREASED_ACTIVITY;CYP2A6
COUMARIN;CYP2A6;*18;CYP2A6*1, CYP2A6*18;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2A6
TEGAFUR;CYP2A6;*18;CYP2A6*1, CYP2A6*18;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2A6
FLUOROURACIL;DPYD;A;rs67376798;LADME_PK;DECREASED_ACTIVITY;DPYD
EFAVIRENZ;CYP2B6;*46;CYP2B6*46;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2B6
NICOTINE;CYP2A6;C;rs72549435;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2A6
EFAVIRENZ;CYP2B6;T;rs535039125;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2B6
PREGNENOLONE;SULT2B1;T;rs746398875;LADME_PK;DECREASED_ENZYME_ACTIVITY;SULT2B1
PREGNENOLONE;SULT2B1;A;rs762765702;LADME_PK;DECREASED_ENZYME_ACTIVITY;SULT2B1
COUMARIN;CYP2A6;*4/*9;CYP2A6*4, CYP2A6*9;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2A6
BUPROPION;CYP2B6;A;rs374099483;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2B6
BUPROPION;CYP2B6;A;rs764288403;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2B6
BUPROPION;CYP2B6;*46;CYP2B6*46;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2B6
EFAVIRENZ;CYP2B6;A;rs374099483;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2B6
BUPROPION;CYP2B6;A;rs117872433;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2B6
FLUOROURACIL;DPYD;A;rs112766203;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;TT;rs1801158;OTHER;INCREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;C;rs188052243;LADME_PK;DECREASED_ACTIVITY;DPYD
PREGNENOLONE;SULT2B1;T;rs527454384;LADME_PK;DECREASED_ENZYME_ACTIVITY;SULT2B1
FLUOROURACIL;DPYD;A;rs61757362;LADME_PK;DECREASED_ACTIVITY;DPYD
ARACHIDONIC ACID;CYP4F2;T;rs2108622;LADME_PD;DECREASED_CATALYTIC-ACTIVITY;CYP4F2
NICOTINE;CYP2A6;*17 + *35;CYP2A6*1, CYP2A6*17, CYP2A6*35;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2A6
BUPROPION;CYP2B6;A;rs148009906;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2B6
ELEXACAFTOR;CFTR;T;rs397508293;EFFICACY;INCREASED_ACTIVITY;CFTR
TEZACAFTOR;CFTR;T;rs397508293;EFFICACY;INCREASED_ACTIVITY;CFTR
FLUOROURACIL;DPYD;A;rs1801268;LADME_PK;DECREASED_ACTIVITY;DPYD
BUPROPION;CYP2B6;A;rs200458614;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2B6
EFAVIRENZ;CYP2B6;A;rs764288403;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2B6
EFAVIRENZ;CYP2B6;A;rs200238771;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2B6
FLUOROURACIL;DPYD;C;rs367619008;LADME_PK;DECREASED_ACTIVITY;DPYD
EFAVIRENZ;CYP2B6;A;rs200458614;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2B6
NICOTINE;CYP2A6;CC + CT;rs56113850;LADME_PK;INCREASED_ACTIVITY;CYP2A6
FLUOROURACIL;DPYD;T;rs758649719;LADME_PK;DECREASED_ACTIVITY;DPYD
NICOTINE;CYP2A6;TT;rs7259706;LADME_PK;INCREASED_ACTIVITY;CYP2A6
FLUOROURACIL;DPYD;G;rs369103276;LADME_PK;DECREASED_ACTIVITY;DPYD
VANDETANIB;CYP3A4;*6 + *30;CYP3A4*1, CYP3A4*6, CYP3A4*30;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP3A4
NICOTINE;CYP2A6;AA + AG;rs28399453;LADME_PK;INCREASED_ACTIVITY;CYP2A6
NICOTINE;CYP2A6;CC + CG;rs8192733;LADME_PK;INCREASED_ACTIVITY;CYP2A6
EFAVIRENZ;CYP2B6;A;rs148009906;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2B6
PREGNENOLONE;SULT2B1;G;rs777924668;LADME_PK;DECREASED_ENZYME_ACTIVITY;SULT2B1
FLUOROURACIL;DPYD;A;rs55674432;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;CC;rs55886062;OTHER;DECREASED_ACTIVITY;DPYD
LETROZOLE;CYP2A6;*1/*4 + *1/*7 + *4/*4 + *4/*9;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2A6
NICOTINE;CYP2A6;GG;rs7260629;LADME_PK;INCREASED_ACTIVITY;CYP2A6
FLUOROURACIL;DPYD;GG;rs1801265;OTHER;INCREASED_ACTIVITY;DPYD
DEXTROMETHORPHAN;CYP2D6;*89 + *92 + *93 + *96;CYP2D6*1, CYP2D6*89, CYP2D6*92, CYP2D6*93, CYP2D6*96;LADME_PK;DECREASED_CATALYTIC-ACTIVITY;CYP2D6
PREGNENOLONE;SULT2B1;A;rs777140014;LADME_PK;DECREASED_ENZYME_ACTIVITY;SULT2B1
TESTOSTERONE;CYP3A5;A;rs55817950;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP3A5
NIFEDIPINE;CYP3A5;C;rs72552791;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP3A5
PREGNENOLONE;SULT2B1;T;rs774212320;LADME_PK;DECREASED_ENZYME_ACTIVITY;SULT2B1
NO_DRUG_RELATED;CYP2C9;T;rs762081829;OTHER;DECREASED_EXPRESSION;CYP2C9protein
NO_DRUG_RELATED;SLCO1B1;*14;SLCO1B1*1, SLCO1B1*14;OTHER;INCREASED_EXPRESSION;SLCO1B1protein
NO_DRUG_RELATED;VDR;T;rs11568820;OTHER;INCREASED_STEADY_STATE_LEVEL;CYP3A4protein
NO_DRUG_RELATED;A2M;T;rs669;LADME_PK;INCREASED_STEADY_STATE_LEVEL;A2Mprotein
NO_DRUG_RELATED;SLCO1B1;*37;SLCO1B1*1, SLCO1B1*37;OTHER;INCREASED_EXPRESSION;SLCO1B1protein
NO_DRUG_RELATED;NAMPT;CC + CT;rs1319501;OTHER;DECREASED_STEADY_STATE_LEVEL;NAMPcTprotein
NO_DRUG_RELATED;DPYD;T;rs1801160;OTHER;INCREASED_EXPRESSION;DPYDprotein
NO_DRUG_RELATED;NAMPT;CC + CT;rs3801266;OTHER;INCREASED_STEADY_STATE_LEVEL;NAMPcTprotein
NO_DRUG_RELATED;SLCO1B1;*20;SLCO1B1*1, SLCO1B1*20;OTHER;INCREASED_EXPRESSION;SLCO1B1protein
NO_DRUG_RELATED;ABCC11;AA + AG;rs17822471;OTHER;DECREASED_EXPRESSION;ABCC11protein
NO_DRUG_RELATED;CYP2C9;C;rs771237265;OTHER;DECREASED_EXPRESSION;CYP2C9protein
NO_DRUG_RELATED;CYP2C9;C;rs761895497;OTHER;DECREASED_EXPRESSION;CYP2C9protein
NO_DRUG_RELATED;CYP2C19;T;rs183701923;OTHER;DECREASED_EXPRESSION;CYP2C19protein
NO_DRUG_RELATED;DPYD;G;rs748620513;OTHER;INCREASED_EXPRESSION;DPYDprotein
NO_DRUG_RELATED;CYP2C19;T;rs61311738;OTHER;DECREASED_EXPRESSION;CYP2C19protein
NO_DRUG_RELATED;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;nan;DECREASED_ENZYME_ACTIVITY;TPMTprotein
NO_DRUG_RELATED;DPYD;A;rs143879757;OTHER;INCREASED_EXPRESSION;DPYDprotein
NO_DRUG_RELATED;DPYD;T;rs1212037891;OTHER;INCREASED_EXPRESSION;DPYDprotein
NO_DRUG_RELATED;DPYD;A;rs72549306;OTHER;INCREASED_EXPRESSION;DPYDprotein
NO_DRUG_RELATED;CYP2C19;A;rs140278421;OTHER;DECREASED_EXPRESSION;CYP2C19protein
DOXORUBICIN;CBR1;GG;rs9024;LADME_PK;INCREASED_CATALYTIC-ACTIVITY;CBR1
DOXORUBICIN;CBR1;GG;rs9024;LADME_PK;INCREASED_CATALYTIC-ACTIVITY;CBR1
NO_DRUG_RELATED;ADRB2;G;rs1042713;OTHER;DECREASED_ACTIVITY;ADRB2
NO_DRUG_RELATED;NOS3;GT + TT;rs1799983;nan;DECREASED_EXPRESSION;NOS3mRNA
NO_DRUG_RELATED;IL18;CC + CG;rs5744247;OTHER;INCREASED_EXPRESSION;IL18mRNA
NO_DRUG_RELATED;IL18;GG + GT;rs1946518;OTHER;INCREASED_EXPRESSION;IL18mRNA
NO_DRUG_RELATED;CYP3A5;CC;rs776746;OTHER;DECREASED_EXPRESSION;CYP3A5mRNA
NO_DRUG_RELATED;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PD;DECREASED_EXPRESSION;HDAC2mRNA
NO_DRUG_RELATED;CYP3A5;TT;rs776746;OTHER;INCREASED_EXPRESSION;CYP3A5mRNA
NO_DRUG_RELATED;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PD;DECREASED_EXPRESSION;FKBP5mRNA
NO_DRUG_RELATED;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PD;DECREASED_EXPRESSION;NR3C1mRNA
NO_DRUG_RELATED;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PD;DECREASED_EXPRESSION;GLCCI1mRNA
NO_DRUG_RELATED;ERCC1;A;rs2298881;OTHER;DECREASED_EXPRESSION;ERCC1mRNA
NO_DRUG_RELATED;HSPA5;TT;rs430397;OTHER;INCREASED_EXPRESSION;HSPA5mRNA
NO_DRUG_RELATED;CCND1;AA + AG;rs9344;OTHER;INCREASED_TRANSCRIPTION;CCND1mRNA
NO_DRUG_RELATED;ABCC2;CG;rs113646094;OTHER;INCREASED_EXPRESSION;ABCC2mRNA
NO_DRUG_RELATED;ABCB1;GG;rs1128503;nan;INCREASED_EXPRESSION;ABCB1mRNA
NO_DRUG_RELATED;XRCC4;T;rs2075685;OTHER;INCREASED_EXPRESSION;XRCC4mRNA
NO_DRUG_RELATED;XRCC4;G;rs10040363;OTHER;INCREASED_EXPRESSION;ERCC1mRNA
NO_DRUG_RELATED;GCLC;CC;rs761142;OTHER;DECREASED_EXPRESSION;GCLCmRNA
NO_DRUG_RELATED;BCL2L11;T;rs724710;OTHER;DECREASED_EXPRESSION;BCL2L11mRNA
NO_DRUG_RELATED;EPO;AA;rs1617640;OTHER;INCREASED_EXPRESSION;EPOmRNA
NO_DRUG_RELATED;KDR;G;rs34231037;OTHER;DECREASED_STEADY_STATE_LEVEL;KDR
METHOTREXATE;GGH;A;rs11545078;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;DPYD;G;rs1801265;LADME_PK;INCREASED_ACTIVITY;DPYD
NO_DRUG_RELATED;FCER2;GG;rs28364072;nan;DECREASED_EXPRESSION;FCER2
NO_DRUG_RELATED;DPYD;T;rs114096998;OTHER;DECREASED_CATALYTIC-ACTIVITY;DPYD
NO_DRUG_RELATED;DPYD;AC;rs55886062;OTHER;DECREASED_ACTIVITY;DPYD
NO_DRUG_RELATED;MGMT;G;rs4751104;LADME_PK;INCREASED_TRANSCRIPTION;MGMT
NO_DRUG_RELATED;ERCC2;TT;rs1799793;nan;INCREASED_EXPRESSION;ERCC2
CISPLATIN;ERCC2;GG;rs13181;TOXICITY;DECREASED_SENSITIVITY;nan
NO_DRUG_RELATED;ERCC2;GG;rs13181;nan;INCREASED_EXPRESSION;ERCC2
NO_DRUG_RELATED;GSTT1;T;rs1007888;LADME_PK;INCREASED_TRANSCRIPTION;GSTT1
NO_DRUG_RELATED;KCNQ3;AA;rs7818112;OTHER;INCREASED_TRANSCRIPTION;ABCB1
NO_DRUG_RELATED;GSK3B;A;rs334558;nan;INCREASED_TRANSCRIPTION;GSK3B
CISPLATIN;GSTP1;AG;rs1695;TOXICITY;DECREASED_SENSITIVITY;nan
BUSULFAN;GSTM1;C;rs3754446;LADME_PK;INCREASED_CLEARANCE;nan
NO_DRUG_RELATED;DPYD;A;rs780025995;OTHER;DECREASED_CATALYTIC-ACTIVITY;DPYD
NO_DRUG_RELATED;F12;G;rs1801020;LADME_PK;INCREASED_ENZYME_ACTIVITY;F12
NO_DRUG_RELATED;ERCC1;GG;rs11615;nan;INCREASED_EXPRESSION;ERCC1
NO_DRUG_RELATED;IL7;AA + AG;rs16906115;OTHER;INCREASED_EXPRESSION;IL7
NO_DRUG_RELATED;F3;T;rs841698;nan;INCREASED_EXPRESSION;ABCD3
NO_DRUG_RELATED;DPYD;CT + TT;rs56038477;LADME_PK;DECREASED_ACTIVITY;DPYD
NO_DRUG_RELATED;DPYD;C;rs2297595;OTHER;DECREASED_ACTIVITY;DPYD
NO_DRUG_RELATED;DPYD;CT + TT;rs1801160;LADME_PK;DECREASED_ACTIVITY;DPYD
NO_DRUG_RELATED;DPYD;CC + CT;rs2297595;LADME_PK;DECREASED_ACTIVITY;DPYD
NO_DRUG_RELATED;HPR;G;rs2000999;OTHER;INCREASED_EXPRESSION;HP
FLUOROURACIL;DPYD;A;rs4294451;TOXICITY;INCREASED_SENSITIVITY;nan
NO_DRUG_RELATED;DPYD;CT;rs115232898;OTHER;DECREASED_ACTIVITY;DPYD
NO_DRUG_RELATED;DPYD;T;rs4294451;OTHER;INCREASED_EXPRESSION;DPYD
TAMOXIFEN;E2F7;CC;rs310786;OTHER;INCREASED_SENSITIVITY;nan
NO_DRUG_RELATED;ECHDC1;AA;rs6569487;OTHER;INCREASED_TRANSCRIPTION;ABCB1
NO_DRUG_RELATED;EGFR;TT;rs712829;nan;INCREASED_EXPRESSION;EGFR
NO_DRUG_RELATED;HLA-G;C;rs1063320;OTHER;INCREASED_EXPRESSION;HLA-G
CARBAMAZEPINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;OTHER;INCREASED_SENSITIVITY;nan
NO_DRUG_RELATED;DPYD;CT;rs3918290;OTHER;DECREASED_ACTIVITY;DPYD
NO_DRUG_RELATED;IFNL3;C;rs4803217;OTHER;INCREASED_EXPRESSION;IFNL3
NO_DRUG_RELATED;DPYD;CT;rs3918290;OTHER;DECREASED_ACTIVITY;DPYD
CISPLATIN;ERCC1;GG;rs11615;TOXICITY;DECREASED_SENSITIVITY;nan
NO_DRUG_RELATED;DPYD;G;rs748639205;OTHER;DECREASED_CATALYTIC-ACTIVITY;DPYD
NO_DRUG_RELATED;DPYD;CG;rs75017182;OTHER;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;CT;rs3918290;OTHER;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;IFNL4;TT/TT;rs11322783;OTHER;INCREASED_EXPRESSION;IFNAR1
NO_DRUG_RELATED;DPYD;C;rs75017182;LADME_PK;DECREASED_ACTIVITY;DPYD
NO_DRUG_RELATED;IMPDH2;A;rs121434586;OTHER;DECREASED_ENZYME_ACTIVITY;IMPDH2
NO_DRUG_RELATED;DPYD;A;rs67376798;OTHER;DECREASED_ACTIVITY;DPYD
CALCIUM;RYR1;AG;rs118192167;OTHER;INCREASED_STEADY_STATE_LEVEL;nan
NO_DRUG_RELATED;MIR6076;G;rs1463411;OTHER;DECREASED_EXPRESSION;P2RY12
DESMETHYLNAPROXEN;SULT1A1;G;rs28374453;LADME_PK;INCREASED_SULFATION;nan
ACETAMINOPHEN;SULT1A1;G;rs28374453;LADME_PK;INCREASED_SULFATION;nan
DESMETHYLNAPROXEN;SULT1A1;A;rs1042008;LADME_PK;DECREASED_SULFATION;nan
ACETAMINOPHEN;SULT1A1;A;rs1042008;LADME_PK;DECREASED_SULFATION;nan
DESMETHYLNAPROXEN;SULT1A1;T;rs758145522;LADME_PK;DECREASED_SULFATION;nan
DESMETHYLNAPROXEN;SULT1A1;C;rs767487725;LADME_PK;DECREASED_SULFATION;nan
ACETAMINOPHEN;SULT1A1;T;rs72547527;LADME_PK;DECREASED_SULFATION;nan
TAPENTADOL;SULT1A1;A;rs1042008;LADME_PK;DECREASED_SULFATION;nan
ACETAMINOPHEN;SULT1A1;C;rs767487725;LADME_PK;DECREASED_SULFATION;nan
DESMETHYLNAPROXEN;SULT1A1;T;rs1042028;LADME_PK;DECREASED_SULFATION;nan
ACETAMINOPHEN;SULT1A1;A;rs544820732;LADME_PK;DECREASED_SULFATION;nan
NO_DRUG_RELATED;TBXAS1;AA;rs6962291;OTHER;DECREASED_STEADY_STATE_LEVEL;TBX2
NO_DRUG_RELATED;TBXAS1;AA;rs6962291;OTHER;DECREASED_EXPRESSION;TBXAS1
NO_DRUG_RELATED;TMPRSS11E;T;rs2168047;nan;INCREASED_EXPRESSION;UGT2B4
NO_DRUG_RELATED;TNF;AA + AG;rs1800629;LADME_PK;INCREASED_ACTIVITY;TNF
NO_DRUG_RELATED;TPH2;AA;rs7305115;OTHER;INCREASED_EXPRESSION;TPH2
NO_DRUG_RELATED;TPH2;T;rs4290270;OTHER;INCREASED_EXPRESSION;TPH2
THIOGUANINE;TPMT;*7 + *10 + *12 + *13;TPMT*1, TPMT*7, TPMT*10, TPMT*12, TPMT*13;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;TPMT;*3A + *3C;TPMT*1, TPMT*3A, TPMT*3C;OTHER;DECREASED_ACTIVITY;TPMT
ACETAMINOPHEN;SULT1A1;T;rs765399160;LADME_PK;INCREASED_SULFATION;nan
NO_DRUG_RELATED;TPMT;*3A + *3C + *24;TPMT*1, TPMT*3A, TPMT*3C, TPMT*24;OTHER;DECREASED_EXPRESSION;TPMT
ACETAMINOPHEN;SULT1A1;G;rs552524124;LADME_PK;DECREASED_SULFATION;nan
TAPENTADOL;SULT1A1;T;rs1042028;LADME_PK;DECREASED_SULFATION;nan
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*1, SLCO1B1*15;LADME_PK;DECREASED_UPTAKE;nan
CERIVASTATIN;SLCO1B1;*15;SLCO1B1*1, SLCO1B1*15;LADME_PK;DECREASED_UPTAKE;nan
PRAVASTATIN;SLCO1B1;*15;SLCO1B1*1, SLCO1B1*15;LADME_PK;DECREASED_UPTAKE;nan
PACLITAXEL;SLCO1B3;A;rs7311358;OTHER;DECREASED_TRANSPORT;nan
ROSUVASTATIN;SLCO2B1;T;rs2306168;LADME_PK;DECREASED_UPTAKE;nan
ROSUVASTATIN;SLCO2B1;A;rs142693902;LADME_PK;DECREASED_UPTAKE;nan
ROSUVASTATIN;SLCO2B1;A;rs35199625;LADME_PK;DECREASED_UPTAKE;nan
METHOTREXATE;SOD2;G;rs4880;TOXICITY;DECREASED_SENSITIVITY;nan
NO_DRUG_RELATED;SPAG16;CC;rs35945601;OTHER;INCREASED_TRANSCRIPTION;ABCB1
NO_DRUG_RELATED;SQSTM1;C;rs10277;LADME_PK;INCREASED_TRANSCRIPTION;SQSTM1
NO_DRUG_RELATED;STXBP4;AA;rs9303363;OTHER;INCREASED_TRANSCRIPTION;ABCB1
DESMETHYLNAPROXEN;SULT1A1;G;rs552524124;LADME_PK;DECREASED_SULFATION;nan
TAPENTADOL;SULT1A1;T;rs758145522;LADME_PK;DECREASED_SULFATION;nan
TAPENTADOL;SULT1A1;T;rs72547527;LADME_PK;DECREASED_SULFATION;nan
TAPENTADOL;SULT1A1;A;rs544820732;LADME_PK;DECREASED_SULFATION;nan
TAPENTADOL;SULT1A1;C;rs767487725;LADME_PK;DECREASED_SULFATION;nan
DESMETHYLNAPROXEN;SULT1A1;A;rs544820732;LADME_PK;DECREASED_SULFATION;nan
ACETAMINOPHEN;SULT1A1;T;rs1042028;LADME_PK;DECREASED_SULFATION;nan
DESMETHYLNAPROXEN;SULT1A1;T;rs72547527;LADME_PK;DECREASED_SULFATION;nan
TAPENTADOL;SULT1A1;G;rs552524124;LADME_PK;DECREASED_SULFATION;nan
TAPENTADOL;SULT1A1;G;rs28374453;LADME_PK;INCREASED_SULFATION;nan
ACETAMINOPHEN;SULT1A1;T;rs758145522;LADME_PK;DECREASED_SULFATION;nan
ATORVASTATIN;SLCO1B1;*5;SLCO1B1*1, SLCO1B1*5;LADME_PK;DECREASED_UPTAKE;nan
CERIVASTATIN;SLCO1B1;*5;SLCO1B1*1, SLCO1B1*5;LADME_PK;DECREASED_UPTAKE;nan
PRAVASTATIN;SLCO1B1;*5;SLCO1B1*1, SLCO1B1*5;LADME_PK;DECREASED_UPTAKE;nan
MERCAPTOPURINE;TPMT;nan;TPMT deficiency;TOXICITY;INCREASED_CONCENTRATIONS;nan
MERCAPTOPURINE;TPMT;nan;TPMT deficiency;LADME_PK;INCREASED_CONCENTRATIONS;nan
CISPLATIN;TPMT;*3A;TPMT*1, TPMT*3A;TOXICITY;INCREASED_SENSITIVITY;nan
SN-38;UGT1A9;CT + TT;rs2741049;LADME_PK;INCREASED_CLEARANCE;nan
NO_DRUG_RELATED;UGT1A9;T/del + TT;rs3832043;LADME_PK;INCREASED_FORMATION;UGT1A9
NO_DRUG_RELATED;UGT1A9;TT;rs2741049;LADME_PK;INCREASED_FORMATION;UGT1A1
SN-38;UGT1A9;AA;rs3806598;LADME_PK;INCREASED_CLEARANCE;nan
NO_DRUG_RELATED;UGT1A9;T/del + TT;rs3832043;LADME_PK;INCREASED_FORMATION;UGT1A1
SN-38;UGT1A9;T/del + TT;rs3832043;LADME_PK;INCREASED_CLEARANCE;nan
NO_DRUG_RELATED;UGT1A9;CT + TT;rs2741049;LADME_PK;INCREASED_FORMATION;UGT1A9
OLANZAPINE;UGT2B10;GT + TT;rs61750900;LADME_PK;DECREASED_GLUCURONIDATION;nan
LORAZEPAM;UGT2B15;AA;rs1902023;LADME_PK;DECREASED_CLEARANCE;nan
OXAZEPAM;UGT2B15;A;rs1902023;OTHER;DECREASED_GLUCURONIDATION;nan
NO_DRUG_RELATED;UGT2B17;C;rs6817882;OTHER;INCREASED_EXPRESSION;UGT2B17
NO_DRUG_RELATED;UGT2B4;T;rs4557343;nan;INCREASED_EXPRESSION;UGT2B15
BUPRENORPHINE;UGT2B7;A;rs7438135;LADME_PK;INCREASED_GLUCURONIDATION;nan
NO_DRUG_RELATED;UMPS;C;rs1801019;LADME_PK;INCREASED_EXPRESSION;UMPS
NO_DRUG_RELATED;VKORC1;C;rs56314408;OTHER;INCREASED_TRANSCRIPTION;VKORC1
NO_DRUG_RELATED;VKORC1;T;rs9923231;nan;DECREASED_EXPRESSION;VKORC1
NO_DRUG_RELATED;WBP2NL;AG + GG;rs5758550;OTHER;INCREASED_EXPRESSION;CYP2D6
NO_DRUG_RELATED;YAP1;C;rs1820453;nan;DECREASED_TRANSCRIPTION;YAP1
NO_DRUG_RELATED;YEATS4;CC;rs7297610;LADME_PK;INCREASED_EXPRESSION;YEATS4
RALOXIFENE;UGT1A8;*2/*2;UGT1A8*1a, UGT1A8*2;LADME_PK;INCREASED_CLEARANCE;nan
THIOGUANINE;TPMT;*16;TPMT*1, TPMT*16;LADME_PK;DECREASED_CLEARANCE;nan
VALPROIC ACID;UGT1A6;C;rs1105879;LADME_PK;INCREASED_GLUCURONIDATION;nan
CLOZAPINE 5-N-GLUCURONIDE;UGT1A4;G;rs2011425;LADME_PK;INCREASED_FORMATION;nan
DESMETHYLCLOZAPINE GLUCURONIDE;UGT1A4;G;rs2011425;LADME_PK;INCREASED_FORMATION;nan
CISPLATIN;TPMT;*3A;TPMT*1, TPMT*3A;TOXICITY;INCREASED_SENSITIVITY;nan
NO_DRUG_RELATED;TXLNB;CC;rs9495425;OTHER;INCREASED_TRANSCRIPTION;ABCB1
NO_DRUG_RELATED;UGT1A1;GG + GT;rs4124874;LADME_PK;DECREASED_FORMATION;UGT1A1
SN-38;UGT1A1;GG + GT;rs4124874;LADME_PK;DECREASED_CLEARANCE;nan
OXAZEPAM;UGT1A1;A;rs10929302;OTHER;DECREASED_GLUCURONIDATION;nan
NO_DRUG_RELATED;UGT1A1;A;rs10929302;OTHER;DECREASED_CONCENTRATIONS;UGT1A1
NO_DRUG_RELATED;UGT1A1;A;rs28967009;OTHER;INCREASED_EXPRESSION;UGT1A1
SN-38;UGT1A1;AG;rs4148323;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;UGT1A1;AG;rs4148323;LADME_PK;DECREASED_FORMATION;UGT1A1
OXAZEPAM;UGT1A1;T;rs887829;OTHER;DECREASED_GLUCURONIDATION;nan
OXAZEPAM;UGT1A1;G;rs4124874;OTHER;ASSOCIATED_GLUCURONIDATION;nan
NO_DRUG_RELATED;UGT1A1;*28;UGT1A1*1, UGT1A1*28;OTHER;DECREASED_CONCENTRATIONS;UGT1A1
CLOZAPINE;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;LADME_PK;DECREASED_METABOLISM;nan
BELINOSTAT;UGT1A1;*28;UGT1A1*1, UGT1A1*28;LADME_PK;DECREASED_METABOLISM;nan
NO_DRUG_RELATED;UGT1A1;T;rs887829;OTHER;DECREASED_CONCENTRATIONS;UGT1A1
NO_DRUG_RELATED;UGT1A1;G;rs4124874;OTHER;DECREASED_CONCENTRATIONS;UGT1A1
RALOXIFENE 6-GLUCURONIDE;UGT1A1;*28;UGT1A1*1, UGT1A1*28;LADME_PK;DECREASED_FORMATION;nan
NO_DRUG_RELATED;UGT1A1;CG;rs11568319;LADME_PK;DECREASED_FORMATION;UGT1A1
NO_DRUG_RELATED;UGT1A3;T;rs7604115;OTHER;INCREASED_EXPRESSION;UGT1A3
OLANZAPINE;UGT1A4;*3a;UGT1A4*1a, UGT1A4*3a;LADME_PK;INCREASED_GLUCURONIDATION;nan
NO_DRUG_RELATED;SLCO1B1;*15;SLCO1B1*1, SLCO1B1*15;OTHER;DECREASED_EXPRESSION;SLCO1B1
ATRASENTAN;SLCO1B1;*14;SLCO1B1*1, SLCO1B1*14, SLCO1B1*37;LADME_PK;DECREASED_TRANSPORT;nan
ATRASENTAN;SLCO1B1;*9;SLCO1B1*1, SLCO1B1*9, SLCO1B1*37;LADME_PK;DECREASED_TRANSPORT;nan
NO_DRUG_RELATED;PACSIN2;CT + TT;rs2413739;LADME_PK;DECREASED_ACTIVITY;TPMT
NO_DRUG_RELATED;PHETA2;G;rs1807493;LADME_PK;INCREASED_EXPRESSION;CYP2D6
NO_DRUG_RELATED;SMDT1;G;rs1807493;LADME_PK;INCREASED_EXPRESSION;CYP2D6
NO_DRUG_RELATED;PITPNM2;C;rs12425009;nan;DECREASED_EXPRESSION;ABCB9
NO_DRUG_RELATED;PKNOX1;A;rs2839629;OTHER;INCREASED_EXPRESSION;PKNOX1
NO_DRUG_RELATED;PKNOX1;A;rs2839629;OTHER;INCREASED_EXPRESSION;CBS
NO_DRUG_RELATED;PLG;G;rs783145;LADME_PK;DECREASED_TRANSCRIPTION;PRSS55
NO_DRUG_RELATED;PLG;G;rs783145;LADME_PK;INCREASED_TRANSCRIPTION;PLG
NO_DRUG_RELATED;PLXNB3;A;rs4898439;nan;INCREASED_EXPRESSION;ABCD1
NO_DRUG_RELATED;POR;AG;rs2868177;EFFICACY;INCREASED_ENZYME_ACTIVITY;CYP2B6
NO_DRUG_RELATED;PPARA;AA;rs4253728;LADME_PK;DECREASED_CONCENTRATIONS;CYP3A4
NO_DRUG_RELATED;PROM1;CC;rs2286455;nan;DECREASED_EXPRESSION;PROM1
NO_DRUG_RELATED;PSMB8;T;rs2071543;nan;INCREASED_EXPRESSION;TAP2
NO_DRUG_RELATED;TAP1;T;rs2071543;nan;INCREASED_EXPRESSION;TAP2
NO_DRUG_RELATED;TAP2;T;rs2071543;nan;INCREASED_EXPRESSION;TAP2
NO_DRUG_RELATED;PSMB8;A;rs9357155;nan;INCREASED_EXPRESSION;TAP2
NO_DRUG_RELATED;TAP2;A;rs9357155;nan;INCREASED_EXPRESSION;TAP2
NO_DRUG_RELATED;RALGAPA2;GG;rs3827963;OTHER;INCREASED_TRANSCRIPTION;ABCB1
DOXORUBICIN;RARG;A;rs2229774;TOXICITY;INCREASED_SENSITIVITY;nan
NO_DRUG_RELATED;RARG;A;rs2229774;OTHER;DECREASED_PROTEIN-STABILITY;RARG
NO_DRUG_RELATED;REDIC1;T;rs10783969;nan;INCREASED_EXPRESSION;ABCD2
NO_DRUG_RELATED;RGMA;GG;rs7165938;OTHER;INCREASED_TRANSCRIPTION;ABCB1
CAFFEINE;RYR1;T;rs193922753;OTHER;INCREASED_SENSITIVITY;nan
NO_DRUG_RELATED;ORMDL3;AG + GG;rs2872507;LADME_PK;INCREASED_EXPRESSION;ORMDL3
CAFFEINE;RYR1;C;rs118204423;OTHER;INCREASED_SENSITIVITY;nan
CHLOROCRESOL;RYR1;C;rs118204423;OTHER;INCREASED_SENSITIVITY;nan
HALOTHANE;RYR1;C;rs118204423;OTHER;INCREASED_SENSITIVITY;nan
ETHANOL;OPRM1;GG;rs1799971;EFFICACY;DECREASED_SENSITIVITY;nan
NO_DRUG_RELATED;NT5C2;GG;rs11191612;LADME_PK;INCREASED_TRANSCRIPTION;NT5C2
PAROMOMYCIN;MT-RNR1;T;rs267606619;LADME_PD;INCREASED_SENSITIVITY;nan
GEMCITABINE;MTHFR;GG + GT;rs1801131;TOXICITY;INCREASED_SENSITIVITY;nan
NO_DRUG_RELATED;NAF1;AA;rs17571991;OTHER;INCREASED_TRANSCRIPTION;ABCC1
SOLITHROMYCIN;NAT2;*4;NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*14;LADME_PK;INCREASED_METABOLISM;nan
NO_DRUG_RELATED;NAT2;A;rs4646244;OTHER;DECREASED_TRANSCRIPTION;NAT2
NO_DRUG_RELATED;NCOA1;T;rs1804645;nan;INCREASED_HALF_LIFE;NCOA1
NO_DRUG_RELATED;NFATC2;T;rs6021191;OTHER;INCREASED_EXPRESSION;NFATC2
NO_DRUG_RELATED;NHLH1;T;rs11265375;OTHER;INCREASED_LUCIFERASE_ACTIVITY;nan
NO_DRUG_RELATED;NQO1;AA;rs1800566;nan;DECREASED_ENZYME_ACTIVITY;NQO1
NO_DRUG_RELATED;NQO1;A;rs1800566;nan;DECREASED_EXPRESSION;NQO1
MIDAZOLAM;NR1I2;G;rs1464602;LADME_PK;INCREASED_CLEARANCE;nan
MIDAZOLAM;NR1I2;G;rs1464603;LADME_PK;INCREASED_CLEARANCE;nan
NO_DRUG_RELATED;NRP2;C;rs10932125;nan;INCREASED_EXPRESSION;CYP1B1
CLADRIBINE;NT5C1A;G;rs201045130;OTHER;DECREASED_SENSITIVITY;nan
FLUOROURACIL;NT5C1A;G;rs201045130;OTHER;DECREASED_SENSITIVITY;nan
GEMCITABINE;NT5C1A;G;rs201045130;OTHER;DECREASED_SENSITIVITY;nan
CLADRIBINE;NT5C1A;T;rs370457585;OTHER;DECREASED_SENSITIVITY;nan
FLUOROURACIL;NT5C1A;T;rs370457585;OTHER;DECREASED_SENSITIVITY;nan
GEMCITABINE;NT5C1A;T;rs370457585;OTHER;DECREASED_SENSITIVITY;nan
CLADRIBINE;NT5C1A;A;rs374150125;OTHER;DECREASED_SENSITIVITY;nan
FLUOROURACIL;NT5C1A;A;rs374150125;OTHER;DECREASED_SENSITIVITY;nan
GEMCITABINE;NT5C1A;A;rs374150125;OTHER;DECREASED_SENSITIVITY;nan
CYTARABINE;NT5C2;G;rs1163075;EFFICACY;DECREASED_SENSITIVITY;nan
NO_DRUG_RELATED;NT5C2;G;rs1163075;LADME_PK;INCREASED_TRANSCRIPTION;NT5C2
CYTARABINE;NT5C2;GG;rs11191612;EFFICACY;DECREASED_SENSITIVITY;nan
NO_DRUG_RELATED;NT5E;A;rs9450278;nan;DECREASED_EXPRESSION;NT5E
CHLOROCRESOL;RYR1;del;rs121918596;OTHER;INCREASED_SENSITIVITY;nan
CAFFEINE;RYR1;T;rs193922843;DOSAGE;INCREASED_SENSITIVITY;nan
CAFFEINE;RYR1;T;rs193922816;OTHER;INCREASED_SENSITIVITY;nan
CAFFEINE;RYR1;A;rs118192176;OTHER;INCREASED_SENSITIVITY;nan
NO_DRUG_RELATED;SEMA6A;A;rs3806915;OTHER;INCREASED_LUCIFERASE_ACTIVITY;nan
NO_DRUG_RELATED;SEPTIN3;G;rs1062753;LADME_PK;INCREASED_EXPRESSION;CYP2D6
NO_DRUG_RELATED;WBP2NL;G;rs1062753;LADME_PK;INCREASED_EXPRESSION;CYP2D6
RANITIDINE;SLC22A1;T;rs12208357;LADME_PK;DECREASED_TRANSPORT;nan
RANITIDINE;SLC22A1;del;rs72552763;LADME_PK;DECREASED_TRANSPORT;nan
RANITIDINE;SLC22A1;A;rs34130495;LADME_PK;DECREASED_TRANSPORT;nan
NO_DRUG_RELATED;SLC22A3;G;rs2076828;OTHER;DECREASED_EXPRESSION;SLC22A3
NO_DRUG_RELATED;SLC22A3;C;rs884742;LADME_PK;INCREASED_TRANSCRIPTION;SLC22A3
NO_DRUG_RELATED;SLC22A3;AA;rs555754;nan;INCREASED_EXPRESSION;SLC22A3
ADEFOVIR DIPIVOXIL;SLC22A6;T;rs11568634;OTHER;DECREASED_UPTAKE;nan
CEFOTAXIME;SLC22A8;A;rs11568482;LADME_PK;DECREASED_TRANSPORT;nan
GEMCITABINE TRIPHOSPHATE;SLC28A3;CC;rs7867504;LADME_PK;INCREASED_FORMATION;nan
DOXORUBICIN;SLC28A3;AA;rs11140490;TOXICITY;INCREASED_SENSITIVITY;nan
NO_DRUG_RELATED;SLC29A1;G;rs731780;OTHER;INCREASED_EXPRESSION;SLC29A1
NO_DRUG_RELATED;SLC29A1;A;rs70914;nan;INCREASED_EXPRESSION;SLC29A1
NO_DRUG_RELATED;SLCO1A2;T;rs4148981;nan;DECREASED_EXPRESSION;SLCO1A2
ATRASENTAN;SLCO1B1;*15;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;LADME_PK;DECREASED_TRANSPORT;nan
NO_DRUG_RELATED;SLCO1B1;C;rs4149056;OTHER;DECREASED_EXPRESSION;SLCO1B1
ATRASENTAN;SLCO1B1;*5;SLCO1B1*1, SLCO1B1*5, SLCO1B1*37;LADME_PK;DECREASED_TRANSPORT;nan
CAFFEINE;RYR1;CT;rs28933397;OTHER;ASSOCIATED_SENSITIVITY;nan
HALOTHANE;RYR1;CT;rs28933397;OTHER;ASSOCIATED_SENSITIVITY;nan
CAFFEINE;RYR1;T;rs186983396;LADME_PK;INCREASED_SENSITIVITY;nan
CHLOROCRESOL;RYR1;T;rs186983396;LADME_PK;INCREASED_SENSITIVITY;nan
CAFFEINE;RYR1;T;rs118192178;OTHER;INCREASED_SENSITIVITY;nan
CHLOROCRESOL;RYR1;T;rs118192178;OTHER;INCREASED_SENSITIVITY;nan
CHLOROCRESOL;RYR1;T;rs118192124;OTHER;INCREASED_SENSITIVITY;nan
CAFFEINE;RYR1;G;rs118192167;OTHER;INCREASED_SENSITIVITY;nan
CAFFEINE;RYR1;T;rs193922803;DOSAGE;INCREASED_SENSITIVITY;nan
CAFFEINE;RYR1;A;rs118192122;OTHER;INCREASED_SENSITIVITY;nan
CAFFEINE;RYR1;A;rs193922809;OTHER;INCREASED_SENSITIVITY;nan
CAFFEINE;RYR1;A;rs118192168;DOSAGE;INCREASED_SENSITIVITY;nan
CAFFEINE;RYR1;A;rs193922832;DOSAGE;INCREASED_SENSITIVITY;nan
CAFFEINE;RYR1;A;rs112563513;DOSAGE;INCREASED_SENSITIVITY;nan
CAFFEINE;RYR1;A;rs121918594;OTHER;INCREASED_SENSITIVITY;nan
CHLOROCRESOL;RYR1;A;rs121918594;OTHER;INCREASED_SENSITIVITY;nan
HALOTHANE;RYR1;A;rs121918594;OTHER;INCREASED_SENSITIVITY;nan
CAFFEINE;RYR1;G;rs193922878;OTHER;INCREASED_SENSITIVITY;nan
NO_DRUG_RELATED;MIR27A;CC;rs895819;OTHER;INCREASED_EXPRESSION;MIR27A
CAFFEINE;RYR1;T;rs118192161;OTHER;INCREASED_SENSITIVITY;nan
CAFFEINE;RYR1;T;rs118192177;OTHER;INCREASED_SENSITIVITY;nan
CAFFEINE;RYR1;AG;rs118192167;OTHER;INCREASED_SENSITIVITY;nan
CAFFEINE;RYR1;CT;rs118192172;OTHER;ASSOCIATED_SENSITIVITY;nan
HALOTHANE;RYR1;CT;rs118192172;OTHER;ASSOCIATED_SENSITIVITY;nan
CAFFEINE;RYR1;GT;rs193922772;OTHER;ASSOCIATED_SENSITIVITY;nan
HALOTHANE;RYR1;GT;rs193922772;OTHER;ASSOCIATED_SENSITIVITY;nan
CAFFEINE;RYR1;CT;rs118192175;OTHER;ASSOCIATED_SENSITIVITY;nan
HALOTHANE;RYR1;CT;rs118192175;OTHER;ASSOCIATED_SENSITIVITY;nan
CAFFEINE;RYR1;CT;rs193922747;OTHER;ASSOCIATED_SENSITIVITY;nan
HALOTHANE;RYR1;CT;rs193922747;OTHER;ASSOCIATED_SENSITIVITY;nan
CAFFEINE;RYR1;AG;rs118192176;OTHER;ASSOCIATED_SENSITIVITY;nan
HALOTHANE;RYR1;AG;rs118192176;OTHER;ASSOCIATED_SENSITIVITY;nan
CHLOROCRESOL;RYR1;T;rs118192124;OTHER;INCREASED_SENSITIVITY;nan
CAFFEINE;RYR1;G;rs118192178;OTHER;INCREASED_SENSITIVITY;nan
CHLOROCRESOL;RYR1;G;rs118192178;OTHER;INCREASED_SENSITIVITY;nan
CAFFEINE;RYR1;A;rs193922818;OTHER;INCREASED_SENSITIVITY;nan
CHLOROCRESOL;RYR1;A;rs193922818;OTHER;INCREASED_SENSITIVITY;nan
NO_DRUG_RELATED;nan;G;rs2000068;nan;INCREASED_EXPRESSION;ABCA1
PRIMAQUINE;CYP2D6;*17 + *18 + *35 + *39 + *53;CYP2D6*1, CYP2D6*17, CYP2D6*18, CYP2D6*35, CYP2D6*39, CYP2D6*53;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;DPYD;T;rs1801158;OTHER;DECREASED_ACTIVITY;DPYD
EFAVIRENZ;CYP2B6;T;rs142421637;LADME_PK;DECREASED_CLEARANCE;nan
EFAVIRENZ;CYP2B6;A;rs373442191;LADME_PK;INCREASED_CLEARANCE;nan
PROPOFOL;CYP2B6;T;rs752695347;LADME_PK;DECREASED_CLEARANCE;nan
PROPOFOL;CYP2B6;T;rs142421637;LADME_PK;DECREASED_CLEARANCE;nan
PROPOFOL;CYP2B6;T;rs1282926098;LADME_PK;INCREASED_CLEARANCE;nan
PROPOFOL;CYP2B6;C;rs1969136524;LADME_PK;DECREASED_CLEARANCE;nan
EFAVIRENZ;CYP2B6;C;rs773494867;LADME_PK;DECREASED_CLEARANCE;nan
EFAVIRENZ;CYP2B6;T;rs1969376664;LADME_PK;DECREASED_CLEARANCE;nan
PROPOFOL;CYP2B6;T;rs138264188;LADME_PK;DECREASED_CLEARANCE;nan
PROPOFOL;CYP2B6;A;rs373442191;LADME_PK;INCREASED_CLEARANCE;nan
EFAVIRENZ;CYP2B6;T;rs1969255598;LADME_PK;INCREASED_CLEARANCE;nan
EFAVIRENZ;CYP2B6;G;rs1248477767;LADME_PK;INCREASED_CLEARANCE;nan
EFAVIRENZ;CYP2B6;G;rs750671397;LADME_PK;INCREASED_CLEARANCE;nan
EFAVIRENZ;CYP2B6;A;rs141666881;LADME_PK;INCREASED_CLEARANCE;nan
EFAVIRENZ;CYP2B6;G;rs1968919352;LADME_PK;INCREASED_CLEARANCE;nan
EFAVIRENZ;CYP2B6;T;rs1282926098;LADME_PK;INCREASED_CLEARANCE;nan
R-EDDP;CYP2B6;*4;CYP2B6*1, CYP2B6*4;LADME_PK;INCREASED_FORMATION;nan
S-EDDP;CYP2B6;*4;CYP2B6*1, CYP2B6*4;LADME_PK;INCREASED_FORMATION;nan
R-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7, CYP2B6*9, CYP2B6*17, CYP2B6*18, CYP2B6*19, CYP2B6*26;LADME_PK;DECREASED_FORMATION;nan
S-EDDP;CYP2B6;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7, CYP2B6*9, CYP2B6*17, CYP2B6*18, CYP2B6*19, CYP2B6*26;LADME_PK;DECREASED_FORMATION;nan
NO_DRUG_RELATED;CYP2B6;CA/CA;rs70950385;OTHER;DECREASED_ACTIVITY;CYP2B6
EFAVIRENZ;CYP2B6;C;rs1969136524;LADME_PK;DECREASED_CLEARANCE;nan
EFAVIRENZ;CYP2B6;A;rs772413158;LADME_PK;DECREASED_CLEARANCE;nan
EFAVIRENZ;CYP2B6;T;rs752695347;LADME_PK;DECREASED_CLEARANCE;nan
EFAVIRENZ;CYP2B6;T;rs553968231;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP1A2;A;rs762551;nan;INCREASED_ACTIVITY;CYP1A2
NO_DRUG_RELATED;CYP1A2;del;rs35694136;nan;DECREASED_ACTIVITY;CYP1A2
DACARBAZINE;CYP1A2;*11;CYP1A2*1, CYP1A2*11;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP1A2;AA + AC;rs762551;LADME_PK;INCREASED_TRANSCRIPTION;CYP1A2
DACARBAZINE;CYP1A2;*3;CYP1A2*1, CYP1A2*3;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP2A6;AA + AG;rs8192720;nan;INCREASED_EXPRESSION;CYP2A6
NO_DRUG_RELATED;CYP2A6;AG + GG;rs8192725;nan;INCREASED_EXPRESSION;CYP2A6
NO_DRUG_RELATED;CYP2A6;AC + CC;rs28399433;nan;DECREASED_EXPRESSION;CYP2A6
NO_DRUG_RELATED;CYP2A6;*4/*9;CYP2A6*4, CYP2A6*9;nan;DECREASED_EXPRESSION;CYP2A6
NO_DRUG_RELATED;CYP2B6;*27;CYP2B6*1, CYP2B6*27;nan;DECREASED_EXPRESSION;CYP2B6
COUMARIN;CYP2A6;T;rs28399454;LADME_PK;DECREASED_METABOLISM;nan
COUMARIN;CYP2A6;*1/*4;CYP2A6*1, CYP2A6*4;LADME_PK;DECREASED_CLEARANCE;nan
COUMARIN;CYP2A6;*1/*9;CYP2A6*1, CYP2A6*9;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP2A6;*46;CYP2A6*46;nan;INCREASED_EXPRESSION;CYP2A6
NO_DRUG_RELATED;CYP2A6;*4;CYP2A6*1, CYP2A6*4;nan;DECREASED_EXPRESSION;CYP2A6
NO_DRUG_RELATED;CYP2A6;*46;CYP2A6*46;nan;INCREASED_TRANSCRIPTION;CYP2A6
NO_DRUG_RELATED;CYP2B6;TT;rs3745274;OTHER;DECREASED_EXPRESSION;CYP2B6
PROPOFOL;CYP2B6;T;rs553968231;LADME_PK;DECREASED_CLEARANCE;nan
PROPOFOL;CYP2B6;T;rs1969376664;LADME_PK;DECREASED_CLEARANCE;nan
PROPOFOL;CYP2B6;C;rs773494867;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP2A6;*46;CYP2A6*46;nan;INCREASED_EXPRESSION;CYP2A6
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;*8 + *9 + *10 + *16 + *19;CYP2C19*1, CYP2C19*8, CYP2C19*9, CYP2C19*10, CYP2C19*16, CYP2C19*19;LADME_PK;DECREASED_CLEARANCE;nan
NEBIVOLOL;CYP2C19;*30 + *31 + *32 + *33 + *6 + *18;CYP2C19*1, CYP2C19*6, CYP2C19*18, CYP2C19*30, CYP2C19*31, CYP2C19*32, CYP2C19*33;LADME_PK;DECREASED_CLEARANCE;nan
MEPHENYTOIN;CYP2C19;*10 + *14 + *19 + *25 + *26;CYP2C19*1, CYP2C19*10, CYP2C19*14, CYP2C19*19, CYP2C19*25, CYP2C19*26;LADME_PK;DECREASED_CLEARANCE;nan
VORICONAZOLE;CYP2C19;*6;CYP2C19*1, CYP2C19*6;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;T;rs550527959;LADME_PK;DECREASED_CLEARANCE;nan
METHADONE;CYP2C19;T;rs1463550071;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;A;rs200346442;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;G;rs200150287;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;C;rs118203756;LADME_PK;DECREASED_CLEARANCE;nan
FLUVOXAMINE;CYP2C19;*15;CYP2C19*1, CYP2C19*15;LADME_PK;INCREASED_SENSITIVITY;nan
OMEPRAZOLE;CYP2C19;*15;CYP2C19*1, CYP2C19*15;LADME_PK;INCREASED_SENSITIVITY;nan
FLUVOXAMINE;CYP2C19;*18;CYP2C19*1, CYP2C19*18;LADME_PK;INCREASED_SENSITIVITY;nan
OMEPRAZOLE;CYP2C19;*18;CYP2C19*1, CYP2C19*18;LADME_PK;INCREASED_SENSITIVITY;nan
CELECOXIB;CYP2C19;*18;CYP2C19*1, CYP2C19*18;LADME_PK;DECREASED_SENSITIVITY;nan
FLUOXETINE;CYP2C19;*18;CYP2C19*1, CYP2C19*18;LADME_PK;DECREASED_SENSITIVITY;nan
KETOCONAZOLE;CYP2C19;*18;CYP2C19*1, CYP2C19*18;LADME_PK;DECREASED_SENSITIVITY;nan
TICLOPIDINE;CYP2C19;*18;CYP2C19*1, CYP2C19*18;LADME_PK;DECREASED_SENSITIVITY;nan
FLUOXETINE;CYP2C19;A;rs778258371;LADME_PK;DECREASED_CLEARANCE;nan
CELECOXIB;CYP2C19;*19;CYP2C19*1, CYP2C19*19;LADME_PK;INCREASED_SENSITIVITY;nan
CELECOXIB;CYP2C19;*16;CYP2C19*1, CYP2C19*16;LADME_PK;DECREASED_SENSITIVITY;nan
FLUOXETINE;CYP2C19;*16;CYP2C19*1, CYP2C19*16;LADME_PK;DECREASED_SENSITIVITY;nan
KETOCONAZOLE;CYP2C19;*16;CYP2C19*1, CYP2C19*16;LADME_PK;DECREASED_SENSITIVITY;nan
SERTRALINE;CYP2C19;*16;CYP2C19*1, CYP2C19*16;LADME_PK;DECREASED_SENSITIVITY;nan
TICLOPIDINE;CYP2C19;*16;CYP2C19*1, CYP2C19*16;LADME_PK;DECREASED_SENSITIVITY;nan
FLUOXETINE;CYP2C19;*19;CYP2C19*1, CYP2C19*19;LADME_PK;DECREASED_SENSITIVITY;nan
FLUVOXAMINE;CYP2C19;*19;CYP2C19*1, CYP2C19*19;LADME_PK;DECREASED_SENSITIVITY;nan
KETOCONAZOLE;CYP2C19;*19;CYP2C19*1, CYP2C19*19;LADME_PK;DECREASED_SENSITIVITY;nan
OMEPRAZOLE;CYP2C19;*19;CYP2C19*1, CYP2C19*19;LADME_PK;DECREASED_SENSITIVITY;nan
SERTRALINE;CYP2C19;*19;CYP2C19*1, CYP2C19*19;LADME_PK;DECREASED_SENSITIVITY;nan
TICLOPIDINE;CYP2C19;*19;CYP2C19*1, CYP2C19*19;LADME_PK;DECREASED_SENSITIVITY;nan
TRANYLCYPROMINE;CYP2C19;*19;CYP2C19*1, CYP2C19*19;LADME_PK;DECREASED_SENSITIVITY;nan
NO_DRUG_RELATED;CYP2C19;*16;CYP2C19*1, CYP2C19*16;OTHER;DECREASED_FORMATION;CYP2C19
FLUCONAZOLE;CYP2C19;*11;CYP2C19*1, CYP2C19*11;LADME_PK;INCREASED_SENSITIVITY;nan
FLUVOXAMINE;CYP2C19;*11;CYP2C19*1, CYP2C19*11;LADME_PK;INCREASED_SENSITIVITY;nan
SERTRALINE;CYP2C19;*11;CYP2C19*1, CYP2C19*11;LADME_PK;INCREASED_SENSITIVITY;nan
FLUOXETINE;CYP2C19;*10;CYP2C19*1, CYP2C19*10;LADME_PK;DECREASED_SENSITIVITY;nan
CELECOXIB;CYP2C19;*9;CYP2C19*1, CYP2C19*9;LADME_PK;DECREASED_SENSITIVITY;nan
FLUOXETINE;CYP2C19;*9;CYP2C19*1, CYP2C19*9;LADME_PK;DECREASED_SENSITIVITY;nan
KETOCONAZOLE;CYP2C19;*9;CYP2C19*1, CYP2C19*9;LADME_PK;DECREASED_SENSITIVITY;nan
SERTRALINE;CYP2C19;*9;CYP2C19*1, CYP2C19*9;LADME_PK;DECREASED_SENSITIVITY;nan
TROGLITAZONE;CYP2C19;*9;CYP2C19*1, CYP2C19*9;LADME_PK;DECREASED_SENSITIVITY;nan
FLUCONAZOLE;CYP2C19;*9;CYP2C19*1, CYP2C19*9;LADME_PK;INCREASED_SENSITIVITY;nan
FLUVOXAMINE;CYP2C19;*9;CYP2C19*1, CYP2C19*9;LADME_PK;INCREASED_SENSITIVITY;nan
OMEPRAZOLE;CYP2C19;*10;CYP2C19*1, CYP2C19*10;LADME_PK;DECREASED_CLEARANCE;nan
FLUCONAZOLE;CYP2C19;*8;CYP2C19*1, CYP2C19*8;LADME_PK;DECREASED_SENSITIVITY;nan
FLUOXETINE;CYP2C19;*8;CYP2C19*1, CYP2C19*8;LADME_PK;DECREASED_SENSITIVITY;nan
FLUVOXAMINE;CYP2C19;*8;CYP2C19*1, CYP2C19*8;LADME_PK;DECREASED_SENSITIVITY;nan
KETOCONAZOLE;CYP2C19;*8;CYP2C19*1, CYP2C19*8;LADME_PK;DECREASED_SENSITIVITY;nan
OMEPRAZOLE;CYP2C19;*8;CYP2C19*1, CYP2C19*8;LADME_PK;DECREASED_SENSITIVITY;nan
SERTRALINE;CYP2C19;*8;CYP2C19*1, CYP2C19*8;LADME_PK;DECREASED_SENSITIVITY;nan
TICLOPIDINE;CYP2C19;*8;CYP2C19*1, CYP2C19*8;LADME_PK;DECREASED_SENSITIVITY;nan
TRANYLCYPROMINE;CYP2C19;*8;CYP2C19*1, CYP2C19*8;LADME_PK;DECREASED_SENSITIVITY;nan
TROGLITAZONE;CYP2C19;*8;CYP2C19*1, CYP2C19*8;LADME_PK;DECREASED_SENSITIVITY;nan
FLUOXETINE;CYP2C19;*15;CYP2C19*1, CYP2C19*15;LADME_PK;DECREASED_SENSITIVITY;nan
TRANYLCYPROMINE;CYP2C19;*15;CYP2C19*1, CYP2C19*15;LADME_PK;DECREASED_SENSITIVITY;nan
NO_DRUG_RELATED;CYP1A2;A;rs2069514;nan;DECREASED_ACTIVITY;CYP1A2
MEPHENYTOIN;CYP2C19;*26;CYP2C19*1, CYP2C19*26;LADME_PK;DECREASED_CLEARANCE;nan
OMEPRAZOLE;CYP2C19;*26;CYP2C19*1, CYP2C19*26;LADME_PK;DECREASED_CLEARANCE;nan
VORICONAZOLE;CYP2C19;*23;CYP2C19*1, CYP2C19*23;LADME_PK;DECREASED_CLEARANCE;nan
CLOPIDOGREL;CYP2C19;*10 + *14 + *19 + *23 + *25 + *26;CYP2C19*1, CYP2C19*10, CYP2C19*14, CYP2C19*19, CYP2C19*23, CYP2C19*25, CYP2C19*26;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;A;rs370803989;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;T;rs145328984;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;A;rs763625282;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;T;rs147255955;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;G;rs3758581;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;A;rs559628884;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;T;rs764137538;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;A;rs1349931378;LADME_PK;DECREASED_CLEARANCE;nan
VORICONAZOLE;CYP2C19;*33;CYP2C19*1, CYP2C19*33;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;T;rs1463550071;LADME_PK;DECREASED_CLEARANCE;nan
METHADONE;CYP2C19;A;rs778258371;LADME_PK;DECREASED_CLEARANCE;nan
VORICONAZOLE;CYP2C19;*18;CYP2C19*1, CYP2C19*18;LADME_PK;DECREASED_CLEARANCE;nan
METHADONE;CYP2C19;A;rs72552267;LADME_PK;DECREASED_CLEARANCE;nan
METHADONE;CYP2C19;C;rs118203756;LADME_PK;DECREASED_CLEARANCE;nan
METHADONE;CYP2C19;T;rs764137538;LADME_PK;DECREASED_CLEARANCE;nan
METHADONE;CYP2C19;T;rs550527959;LADME_PK;DECREASED_CLEARANCE;nan
METHADONE;CYP2C19;A;rs1349931378;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;A;rs770829708;LADME_PK;DECREASED_CLEARANCE;nan
METHADONE;CYP2C19;C;rs1267723490;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;C;rs1267723490;LADME_PK;DECREASED_CLEARANCE;nan
DACARBAZINE;CYP1A1;*2C;CYP1A1*1, CYP1A1*2C;LADME_PK;DECREASED_CLEARANCE;nan
DACARBAZINE;CYP1A1;*4;CYP1A1*1, CYP1A1*4;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;CHD2;TT;rs28458425;OTHER;INCREASED_TRANSCRIPTION;ABCB1
OXAZEPAM;nan;G;rs1976391;OTHER;DECREASED_GLUCURONIDATION;nan
NO_DRUG_RELATED;nan;T;rs247616;OTHER;DECREASED_EXPRESSION;CETP
NO_DRUG_RELATED;ABCA1;G;rs2515629;nan;INCREASED_EXPRESSION;ABCA1
NO_DRUG_RELATED;ABCA1;G;rs4149297;nan;INCREASED_EXPRESSION;ABCA1
NO_DRUG_RELATED;ABCA1;C;rs2472507;nan;INCREASED_EXPRESSION;ABCA1
NO_DRUG_RELATED;ABCA12;C;rs10182702;nan;INCREASED_EXPRESSION;ABCA12
NO_DRUG_RELATED;ABCA12;A;rs2888327;nan;INCREASED_EXPRESSION;ABCA12
NO_DRUG_RELATED;ABCA8;T;rs11656365;nan;DECREASED_EXPRESSION;ABCA8
NO_DRUG_RELATED;ABCB1;AG + GG;rs1045642;LADME_PK;INCREASED_ACTIVITY;ABCB1
NO_DRUG_RELATED;nan;G;rs1976391;OTHER;DECREASED_CONCENTRATIONS;UGT1A1
NO_DRUG_RELATED;ABCB1;AG + GG;rs1128503;LADME_PK;INCREASED_ACTIVITY;ABCB1
NO_DRUG_RELATED;ABCB1;AA;rs1045642;OTHER;DECREASED_EXPRESSION;ABCB1
NO_DRUG_RELATED;ABCB1;AA;rs1128503;OTHER;DECREASED_EXPRESSION;ABCB1
NO_DRUG_RELATED;ABCB1;AA;rs2032582;OTHER;DECREASED_EXPRESSION;ABCB1
NO_DRUG_RELATED;ABCB9;T;rs4148866;nan;INCREASED_EXPRESSION;ABCB9
NO_DRUG_RELATED;ABCC10;A;rs2185631;nan;DECREASED_EXPRESSION;ABCC10
DOCETAXEL;ABCC10;TT;rs2125739;TOXICITY;INCREASED_SENSITIVITY;nan
NO_DRUG_RELATED;ABCC10;G;rs9394952;nan;DECREASED_EXPRESSION;ABCC10
NO_DRUG_RELATED;ABCC10;A;rs2487663;nan;DECREASED_EXPRESSION;ABCC10
NO_DRUG_RELATED;ABCC11;C;rs11861379;LADME_PK;INCREASED_TRANSCRIPTION;ABCC11
NO_DRUG_RELATED;ABCB1;AC + CC;rs2032582;LADME_PK;INCREASED_ACTIVITY;ABCB1
NO_DRUG_RELATED;ABCC2;T;rs717620;nan;INCREASED_TRANSCRIPTION;ABCC2
NO_DRUG_RELATED;nan;CC;rs6822259;nan;INCREASED_EXPRESSION;UGT2B17
NO_DRUG_RELATED;nan;GG;rs729559;LADME_PK;INCREASED_EXPRESSION;CYP2D6
NO_DRUG_RELATED;nan;GG;rs6539870;OTHER;INCREASED_EXPRESSION;IL1B
NO_DRUG_RELATED;nan;CC;rs478437;OTHER;INCREASED_EXPRESSION;USP7
NO_DRUG_RELATED;nan;C;rs9999111;OTHER;DECREASED_EXPRESSION;ABCG2
NO_DRUG_RELATED;nan;A;rs149713212;OTHER;DECREASED_EXPRESSION;ABCG2
NO_DRUG_RELATED;nan;G;rs12508471;OTHER;DECREASED_EXPRESSION;ABCG2
ENDOXIFEN;nan;C;rs4386686;TOXICITY;INCREASED_SENSITIVITY;nan
NO_DRUG_RELATED;nan;TT;rs4073010;LADME_PK;INCREASED_EXPRESSION;CYP2D6
NO_DRUG_RELATED;nan;G;rs35283911;OTHER;INCREASED_EXPRESSION;HP
NO_DRUG_RELATED;nan;C;rs4386686;TOXICITY;INCREASED_EXPRESSION;MIRLET7I
NO_DRUG_RELATED;nan;C;rs4386686;OTHER;INCREASED_EXPRESSION;MIRLET7I
TAMOXIFEN;nan;CC;rs478437;OTHER;INCREASED_SENSITIVITY;nan
NO_DRUG_RELATED;nan;AA;rs2784917;OTHER;INCREASED_EXPRESSION;WNT5B
NO_DRUG_RELATED;nan;C;rs9999111;OTHER;DECREASED_EXPRESSION;ABCG2
NO_DRUG_RELATED;nan;AG;rs10242455;LADME_PK;INCREASED_TRANSCRIPTION;CYP3A5
NO_DRUG_RELATED;nan;AA;rs446112;OTHER;INCREASED_EXPRESSION;AGPAT2
NO_DRUG_RELATED;nan;C;rs10871454;LADME_PK;INCREASED_TRANSCRIPTION;VKORC1
NO_DRUG_RELATED;nan;T;rs2487030;nan;INCREASED_EXPRESSION;ABCA1
NO_DRUG_RELATED;nan;G;rs4355801;nan;INCREASED_EXPRESSION;TNFRSF11B
NO_DRUG_RELATED;nan;G;rs4285917;nan;DECREASED_EXPRESSION;ABCD2
NO_DRUG_RELATED;nan;G;rs12195350;nan;DECREASED_EXPRESSION;ABCC10
NO_DRUG_RELATED;nan;C;rs4898437;nan;INCREASED_EXPRESSION;ABCD1
NO_DRUG_RELATED;nan;C;rs4386686;TOXICITY;DECREASED_EXPRESSION;TRAF1
NO_DRUG_RELATED;nan;C;rs4386686;OTHER;DECREASED_EXPRESSION;TRAF1
CLOPIDOGREL;CYP2C19;*28;CYP2C19*1, CYP2C19*28;LADME_PK;INCREASED_CLEARANCE;nan
NO_DRUG_RELATED;ABCC4;A;rs11568658;LADME_PK;INCREASED_CATALYTIC-ACTIVITY;ABCC4
MERCAPTOPURINE;ABCC4;TT;rs3765534;TOXICITY;INCREASED_SENSITIVITY;nan
MERCAPTOPURINE;ABCC4;TT;rs3765534;LADME_PK;INCREASED_SENSITIVITY;nan
NO_DRUG_RELATED;CACNA1S;T;rs1800559;OTHER;INCREASED_ACTIVITY;CACNA1S
CAFFEINE;CACNA1S;T;rs1800559;OTHER;INCREASED_SENSITIVITY;nan
HALOTHANE;CACNA1S;A;rs772226819;OTHER;INCREASED_SENSITIVITY;nan
ISOFLURANE;CACNA1S;A;rs772226819;OTHER;INCREASED_SENSITIVITY;nan
NO_DRUG_RELATED;CBR3;A;rs8133052;nan;DECREASED_EXPRESSION;CBR3
NO_DRUG_RELATED;CBR3;A;rs1056892;nan;INCREASED_EXPRESSION;CBR3
NO_DRUG_RELATED;CBS;C;rs915854;OTHER;INCREASED_EXPRESSION;PKNOX1
NO_DRUG_RELATED;CD38;T;rs1130169;nan;DECREASED_EXPRESSION;CD38
NO_DRUG_RELATED;CDA;C/del + del/del;rs3215400;OTHER;INCREASED_EXPRESSION;CDA
NO_DRUG_RELATED;CDA;CC;rs2072671;OTHER;INCREASED_EXPRESSION;CDA
DEXAMETHASONE;BCL2L11;AA;rs2241843;TOXICITY;INCREASED_SENSITIVITY;nan
NO_DRUG_RELATED;CDA;CC;rs532545;OTHER;DECREASED_ACTIVITY;CDA
NO_DRUG_RELATED;CDA;AA;rs2072671;OTHER;DECREASED_ACTIVITY;CDA
NO_DRUG_RELATED;CDA;TT;rs1048977;OTHER;INCREASED_EXPRESSION;CDA
NO_DRUG_RELATED;CDA;AA;rs602950;OTHER;DECREASED_ACTIVITY;CDA
NO_DRUG_RELATED;CDA;GG;rs602950;OTHER;INCREASED_EXPRESSION;CDA
NO_DRUG_RELATED;CDA;del/del;rs3215400;nan;INCREASED_EXPRESSION;CDA
PALBOCICLIB;CDKN2A;C;rs759922342;EFFICACY;INCREASED_SENSITIVITY;nan
REMIMAZOLAM;CES1;T;rs71647871;LADME_PK;DECREASED_METABOLISM;nan
CLOPIDOGREL;CES1;A;rs201065375;LADME_PK;DECREASED_METABOLISM;nan
ENALAPRIL;CES1;A;rs201065375;LADME_PK;DECREASED_METABOLISM;nan
SACUBITRIL;CES1;A;rs201065375;LADME_PK;DECREASED_METABOLISM;nan
NO_DRUG_RELATED;CETP;GG;rs708272;OTHER;INCREASED_EXPRESSION;CETP
NO_DRUG_RELATED;CDA;TT;rs532545;OTHER;INCREASED_EXPRESSION;CDA
MERCAPTOPURINE;ABCC4;nan;ABCC4 deficiency;TOXICITY;INCREASED_CONCENTRATIONS;nan
MERCAPTOPURINE;ABCC4;nan;ABCC4 deficiency;LADME_PK;INCREASED_CONCENTRATIONS;nan
DEXAMETHASONE;BCL2L11;CC;rs724710;TOXICITY;INCREASED_SENSITIVITY;nan
NO_DRUG_RELATED;ARNT;GG;rs2134688;LADME_PK;DECREASED_CONCENTRATIONS;CYP3A4
NO_DRUG_RELATED;ABCC4;C;rs11568684;LADME_PK;INCREASED_CATALYTIC-ACTIVITY;ABCC4
NO_DRUG_RELATED;ABCC4;T;rs4773866;nan;INCREASED_EXPRESSION;ABCC4
NO_DRUG_RELATED;ABCC9;T;rs704212;OTHER;INCREASED_EXPRESSION;ABCC9
NO_DRUG_RELATED;ABCD1;C;rs17091297;nan;INCREASED_EXPRESSION;ABCD1
NO_DRUG_RELATED;BCAP31;C;rs17091297;nan;INCREASED_EXPRESSION;ABCD1
NO_DRUG_RELATED;ABCD2;C;rs4284427;nan;DECREASED_EXPRESSION;ABCD2
NO_DRUG_RELATED;ABCG2;C;rs2725263;OTHER;INCREASED_EXPRESSION;ABCG2
NO_DRUG_RELATED;ACE;del;rs1799752;nan;INCREASED_ENZYME_ACTIVITY;ACE
NO_DRUG_RELATED;ADCYAP1;AA;rs304400;OTHER;INCREASED_TRANSCRIPTION;ABCB1
LOSARTAN;AGTR1;A;rs12721226;OTHER;DECREASED_AFFINITY;nan
NO_DRUG_RELATED;ATP2B1;CT + TT;rs12817819;nan;DECREASED_EXPRESSION;ATP2B1
DOXORUBICINOL;AKR1A1;G;rs2229540;LADME_PK;DECREASED_FORMATION;nan
DAUNORUBICINOL;AKR1A1;C;rs6690497;LADME_PK;DECREASED_FORMATION;nan
DAUNORUBICINOL;AKR1A1;G;rs2229540;LADME_PK;DECREASED_FORMATION;nan
EXEMESTANE;AKR1C3;T;rs62621365;LADME_PK;DECREASED_AFFINITY;nan
DOXORUBICIN;AKR1C3;T;rs62621365;LADME_PK;DECREASED_CLEARANCE;nan
DOXORUBICIN;AKR1C3;T;rs34186955;LADME_PK;DECREASED_CLEARANCE;nan
DOXORUBICIN;AKR1C3;A;rs28943579;LADME_PK;DECREASED_CLEARANCE;nan
EXEMESTANE;AKR1C4;A;rs11253043;LADME_PK;DECREASED_AFFINITY;nan
NO_DRUG_RELATED;ALDH1A2;AA + AG;rs12915901;OTHER;DECREASED_EXPRESSION;ALDH1A2
NO_DRUG_RELATED;AMPH;CC;rs12701634;OTHER;INCREASED_TRANSCRIPTION;ABCB1
DOXORUBICINOL;AKR1A1;C;rs6690497;LADME_PK;DECREASED_FORMATION;nan
NO_DRUG_RELATED;DPYD;C;rs2297595;LADME_PK;DECREASED_ACTIVITY;DPYD
NO_DRUG_RELATED;CYP2C19;*19;CYP2C19*1, CYP2C19*19;OTHER;DECREASED_EXPRESSION;CYP2C19
SERTRALINE;CYP2C19;*13;CYP2C19*1, CYP2C19*13;LADME_PK;DECREASED_SENSITIVITY;nan
EBASTINE;CYP2J2;A;rs201379188;LADME_PK;DECREASED_CLEARANCE;nan
TERFENADINE;CYP2J2;A;rs201379188;LADME_PK;DECREASED_CLEARANCE;nan
TERFENADINE;CYP2J2;A;rs199717190;LADME_PK;DECREASED_CLEARANCE;nan
OXYCODONE;CYP3A4;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;LADME_PK;DECREASED_CLEARANCE;nan
OXYCODONE;CYP3A4;*6 + *17 + *20 + *21 + *26 + *30;CYP3A4*1, CYP3A4*6, CYP3A4*17, CYP3A4*20, CYP3A4*21, CYP3A4*26, CYP3A4*30;LADME_PK;DECREASED_CLEARANCE;nan
SIROLIMUS;CYP3A4;*1/*22 + *22/*22;CYP3A4*1, CYP3A4*22;LADME_PK;DECREASED_CLEARANCE;nan
SILDENAFIL;CYP3A4;*3 + *10 + *14 + *32;CYP3A4*1, CYP3A4*3, CYP3A4*10, CYP3A4*14, CYP3A4*32;LADME_PK;INCREASED_CLEARANCE;nan
IBRUTINIB;CYP3A4;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;CYP3A4*1, CYP3A4*2, CYP3A4*5, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP3A4;TT;rs2242480;LADME_PK;DECREASED_ACTIVITY;CYP3A4
TESTOSTERONE;CYP3A4;*2 + *3 + *11 + *15 + *31;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*11, CYP3A4*15, CYP3A4*31;LADME_PK;INCREASED_CLEARANCE;nan
TESTOSTERONE;CYP3A4;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;CYP3A4*1, CYP3A4*5, CYP3A4*10, CYP3A4*14, CYP3A4*16, CYP3A4*17, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*32, CYP3A4*33, CYP3A4*34;LADME_PK;DECREASED_CLEARANCE;nan
LIDOCAINE;CYP3A4;*2 + *5 + *9 + *16 + *24;CYP3A4*1, CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16, CYP3A4*24;LADME_PK;DECREASED_CLEARANCE;nan
MIDAZOLAM;CYP3A4;C;rs12721627;LADME_PK;DECREASED_CLEARANCE;nan
FENTANYL;CYP3A4;T/T;rs2242480;LADME_PK;DECREASED_METABOLISM;nan
REGORAFENIB;CYP3A4;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*17, CYP3A4*18, CYP3A4*23, CYP3A4*32, CYP3A4*33, CYP3A4*34;LADME_PK;DECREASED_CLEARANCE;nan
TICAGRELOR;CYP3A4;*11 + *18 + *33;CYP3A4*1, CYP3A4*11, CYP3A4*18, CYP3A4*33;LADME_PK;INCREASED_CLEARANCE;nan
TICAGRELOR;CYP3A4;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*9, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*19, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31;LADME_PK;DECREASED_CLEARANCE;nan
LURASIDONE;CYP3A4;*12;CYP3A4*1, CYP3A4*12;LADME_PK;DECREASED_CLEARANCE;nan
LURASIDONE;CYP3A4;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;CYP3A4*1, CYP3A4*15, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*32, CYP3A4*33;LADME_PK;INCREASED_CLEARANCE;nan
SAXAGLIPTIN;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*20, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*34;LADME_PK;DECREASED_CLEARANCE;nan
EBASTINE;CYP2J2;A;rs759510111;LADME_PK;INCREASED_CLEARANCE;nan
TERFENADINE;CYP2J2;A;rs759510111;LADME_PK;INCREASED_CLEARANCE;nan
EBASTINE;CYP2J2;(CTC)1;rs757528200;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP2E1;*7B;CYP2E1*7A, CYP2E1*7B;LADME_PK;INCREASED_TRANSCRIPTION;CYP2E1
NO_DRUG_RELATED;CYP2E1;*7A;CYP2E1*7, CYP2E1*7A;LADME_PK;INCREASED_TRANSCRIPTION;CYP2E1
N-DESMETHYLTAMOXIFEN;CYP2D6;*2 + *28 + *35;CYP2D6*1, CYP2D6*2, CYP2D6*28, CYP2D6*35;LADME_PK;DECREASED_METABOLISM;nan
BUFURALOL;CYP2D6;*17;CYP2D6*1, CYP2D6*17;LADME_PK;DECREASED_CLEARANCE;nan
DEBRISOQUINE;CYP2D6;*17;CYP2D6*1, CYP2D6*17;LADME_PK;DECREASED_CLEARANCE;nan
DEXTROMETHORPHAN;CYP2D6;*17;CYP2D6*1, CYP2D6*17;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP2D6;*1/*4;CYP2D6*1, CYP2D6*4;LADME_PK;DECREASED_EXPRESSION;CYP2D6
DEXTROMETHORPHAN;CYP2D6;*169;CYP2D6*1, CYP2D6*169;LADME_PK;DECREASED_CLEARANCE;nan
DEXTROMETHORPHAN;CYP2D6;G;rs76187628;LADME_PK;INCREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP2D6;*169;CYP2D6*1, CYP2D6*169;LADME_PK;DECREASED_EXPRESSION;CYP2D6
NO_DRUG_RELATED;CYP2D6;G;rs76187628;LADME_PK;INCREASED_EXPRESSION;CYP2D6
DEXTROMETHORPHAN;CYP2D6;*2;CYP2D6*1, CYP2D6*2;LADME_PK;DECREASED_CLEARANCE;nan
DEXTROMETHORPHAN;CYP2D6;*10;CYP2D6*1, CYP2D6*10;LADME_PK;DECREASED_CLEARANCE;nan
IBRUTINIB;CYP3A4;*3 + *4 + *9 + *19 +*34;CYP3A4*1, CYP3A4*3, CYP3A4*4, CYP3A4*9, CYP3A4*19, CYP3A4*34;LADME_PK;INCREASED_CLEARANCE;nan
RISPERIDONE;CYP2D6;*2 + *28 + *35;CYP2D6*1, CYP2D6*2, CYP2D6*28, CYP2D6*35;LADME_PK;DECREASED_METABOLISM;nan
DEXTROMETHORPHAN;CYP2D6;*26;CYP2D6*1, CYP2D6*26;LADME_PK;DECREASED_CLEARANCE;nan
BUFURALOL;CYP2D6;T;rs750996195;LADME_PK;DECREASED_CLEARANCE;nan
DEXTROMETHORPHAN;CYP2D6;T;rs750996195;LADME_PK;DECREASED_CLEARANCE;nan
BUFURALOL;CYP2D6;*17;CYP2D6*1, CYP2D6*17;LADME_PK;DECREASED_CLEARANCE;nan
DEXTROMETHORPHAN;CYP2D6;*17;CYP2D6*1, CYP2D6*17;LADME_PK;DECREASED_CLEARANCE;nan
BUFURALOL;CYP2D6;*14;CYP2D6*1, CYP2D6*14;LADME_PK;DECREASED_CLEARANCE;nan
N-DESMETHYLTAMOXIFEN;CYP2D6;*53;CYP2D6*1, CYP2D6*53;LADME_PK;INCREASED_CLEARANCE;nan
DAPOXETINE;CYP2D6;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*97, CYP2D6*98;LADME_PK;DECREASED_CLEARANCE;nan
BUFURALOL;CYP2D6;*53;CYP2D6*1, CYP2D6*53;LADME_PK;INCREASED_CLEARANCE;nan
DEXTROMETHORPHAN;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP2E1;T;rs2515641;OTHER;DECREASED_EXPRESSION;CYP2E1
NO_DRUG_RELATED;ZBED5;GG;rs10840501;OTHER;INCREASED_TRANSCRIPTION;ABCB1
REGORAFENIB;CYP3A4;*14 + *15 + *28 + *31;CYP3A4*1, CYP3A4*14, CYP3A4*15, CYP3A4*28, CYP3A4*31;LADME_PK;INCREASED_CLEARANCE;nan
LIDOCAINE;CYP3A4;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*1, CYP3A4*11, CYP3A4*14, CYP3A4*15, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*34;LADME_PK;INCREASED_CLEARANCE;nan
CABOZANTINIB;CYP3A4;*14 + *15;CYP3A4*1, CYP3A4*14, CYP3A4*15;LADME_PK;INCREASED_CLEARANCE;nan
VITAMIN E;CYP4F2;T;rs2108622;LADME_PK;INCREASED_STEADY_STATE_LEVEL;nan
NO_DRUG_RELATED;CYP4F2;A;rs2189784;OTHER;INCREASED_EXPRESSION;CYP4F2
NO_DRUG_RELATED;CYP4F2;A;rs2189784;OTHER;DECREASED_EXPRESSION;CYP4F12
NO_DRUG_RELATED;CYP4F2;CT;rs2108622;OTHER;INCREASED_CONCENTRATIONS;CYP4F2
VITAMIN K AND ANALOGUES;CYP4F2;CT + TT;rs2108622;OTHER;INCREASED_CONCENTRATIONS;nan
VITAMIN K AND ANALOGUES;CYP4F2;CT + TT;rs2108622;LADME_PK;INCREASED_CONCENTRATIONS;nan
NO_DRUG_RELATED;CYP4F2;T;rs2108622;OTHER;INCREASED_EXPRESSION;CYP4F2
NO_DRUG_RELATED;CYP4F2;T;rs2108622;OTHER;INCREASED_EXPRESSION;CYP4F11
NO_DRUG_RELATED;DCK;T;rs2306744;OTHER;INCREASED_EXPRESSION;DCK
NO_DRUG_RELATED;DHRS4L1;GG;rs10147475;OTHER;INCREASED_TRANSCRIPTION;ABCB1
VITAMIN E;CYP4F2;T;rs2108622;LADME_PK;INCREASED_STEADY_STATE_LEVEL;nan
NO_DRUG_RELATED;DISP1;TT;rs61840266;OTHER;INCREASED_TRANSCRIPTION;ABCC1
NO_DRUG_RELATED;DPYD;A;rs568132506;OTHER;DECREASED_CATALYTIC-ACTIVITY;DPYD
NO_DRUG_RELATED;DPYD;A;rs760663364;OTHER;DECREASED_CATALYTIC-ACTIVITY;DPYD
FLUOROURACIL;DPYD;CC;rs1801159;TOXICITY;DECREASED_CLEARANCE;nan
FLUOROURACIL;DPYD;CC;rs1801159;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;DPYD;CT;rs3918290;OTHER;DECREASED_ACTIVITY;DPYD
NO_DRUG_RELATED;DPYD;CT;rs1801158;OTHER;DECREASED_CATALYTIC-ACTIVITY;DPYD
NO_DRUG_RELATED;DPYD;A;rs547099198;OTHER;DECREASED_CATALYTIC-ACTIVITY;DPYD
NO_DRUG_RELATED;DPYD;AT;rs67376798;OTHER;DECREASED_CATALYTIC-ACTIVITY;DPYD
NO_DRUG_RELATED;DPYD;G;rs1801265;OTHER;DECREASED_ACTIVITY;DPYD
NO_DRUG_RELATED;DPYD;T;rs1801160;OTHER;DECREASED_ACTIVITY;DPYD
NO_DRUG_RELATED;DISP1;GG;rs17535305;OTHER;INCREASED_TRANSCRIPTION;ABCB1
BUFURALOL;CYP2D6;A;rs777560972;LADME_PK;DECREASED_CLEARANCE;nan
DEXTROMETHORPHAN;CYP2D6;A;rs777560972;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP4F11;A;rs1060467;OTHER;INCREASED_EXPRESSION;CYP4F2
NO_DRUG_RELATED;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;OTHER;DECREASED_EXPRESSION;CYP3A5
BREXPIPRAZOLE;CYP3A4;*14 + *15;CYP3A4*1, CYP3A4*14, CYP3A4*15;LADME_PK;INCREASED_CLEARANCE;nan
ALECTINIB;CYP3A4;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;CYP3A4*1, CYP3A4*4, CYP3A4*7, CYP3A4*8, CYP3A4*12, CYP3A4*14, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*20, CYP3A4*23, CYP3A4*24;LADME_PK;DECREASED_METABOLISM;nan
METHADONE;CYP3A4;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*24, CYP3A4*29, CYP3A4*31;LADME_PK;DECREASED_CLEARANCE;nan
METHADONE;CYP3A4;*11 + *32 + *34;CYP3A4*1, CYP3A4*11, CYP3A4*32, CYP3A4*34;LADME_PK;INCREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP3A4;A;rs35599367;OTHER;DECREASED_EXPRESSION;CYP3A4
MIDAZOLAM;CYP3A4;*39 + *40 + *41 + *42 + *43 + *44 + *46;CYP3A4*1, CYP3A4*39, CYP3A4*40, CYP3A4*41, CYP3A4*42, CYP3A4*43, CYP3A4*44, CYP3A4*46;LADME_PK;DECREASED_CLEARANCE;nan
MACITENTAN;CYP3A4;*3 + *4 + *5 + *10 +*15 + *16;CYP3A4*1, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*10, CYP3A4*15, CYP3A4*16;LADME_PK;INCREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP3A4;A;rs4986909;nan;DECREASED_STEADY_STATE_LEVEL;CYP3A4
VANDETANIB;CYP3A4;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;CYP3A4*1, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*20, CYP3A4*23, CYP3A4*24, CYP3A4*31, CYP3A4*34;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;OTHER;DECREASED_EXPRESSION;CYP3A5
CABOZANTINIB;CYP3A4;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;LADME_PK;DECREASED_CLEARANCE;nan
AMIODARONE;CYP3A4;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;CYP3A4*1, CYP3A4*2, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*16, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*34;LADME_PK;INCREASED_CLEARANCE;nan
SILDENAFIL;CYP3A4;*2 + *5 + *24 + *28 + *29;CYP3A4*1, CYP3A4*2, CYP3A4*5, CYP3A4*24, CYP3A4*28, CYP3A4*29;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP3A4;*8;CYP3A4*8;nan;DECREASED_STEADY_STATE_LEVEL;CYP3A4
BREXPIPRAZOLE;CYP3A4;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;CYP3A4*1, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*16, CYP3A4*18, CYP3A4*23, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP3A4;*12;CYP3A4*12;nan;DECREASED_ENZYME_ACTIVITY;CYP3A4
BREXPIPRAZOLE;CYP3A4;*2 + *7 + *8 + *17 + *20;CYP3A4*1, CYP3A4*2, CYP3A4*7, CYP3A4*8, CYP3A4*17, CYP3A4*20;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP3A4;*11;CYP3A4*11;nan;DECREASED_STEADY_STATE_LEVEL;CYP3A4
AMIODARONE;CYP3A4;*17 + *24;CYP3A4*1, CYP3A4*17, CYP3A4*24;LADME_PK;DECREASED_CLEARANCE;nan
MIDAZOLAM;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_METABOLISM;nan
MACITENTAN;CYP3A4;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;CYP3A4*1, CYP3A4*9, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*17, CYP3A4*20, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*33, CYP3A4*34;LADME_PK;DECREASED_CLEARANCE;nan
BUFURALOL;CYP2D6;T;rs138417770;LADME_PK;DECREASED_CLEARANCE;nan
DEXTROMETHORPHAN;CYP2D6;T;rs138417770;LADME_PK;DECREASED_CLEARANCE;nan
BUFURALOL;CYP2D6;G;rs371793722;LADME_PK;DECREASED_CLEARANCE;nan
DEXTROMETHORPHAN;CYP2D6;G;rs371793722;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP2D6;G;rs1058164;OTHER;DECREASED_EXPRESSION;CYP2D6
METHADONE;CYP2C19;C;rs181297724;LADME_PK;DECREASED_CLEARANCE;nan
METHADONE;CYP2C19;*29 + *30 + *31 + *32 + *33;CYP2C19*1, CYP2C19*29, CYP2C19*30, CYP2C19*31, CYP2C19*32, CYP2C19*33;LADME_PK;DECREASED_CLEARANCE;nan
VORICONAZOLE;CYP2C19;A;rs778258371;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;*32;CYP2C19*1, CYP2C19*32;LADME_PK;DECREASED_CLEARANCE;nan
VORICONAZOLE;CYP2C19;*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_CLEARANCE;nan
VORICONAZOLE;CYP2C19;*3;CYP2C19*1, CYP2C19*3;LADME_PK;DECREASED_CLEARANCE;nan
METHADONE;CYP2C19;A;rs138142612;LADME_PK;DECREASED_CLEARANCE;nan
MEPHENYTOIN;CYP2C19;*24;CYP2C19*1, CYP2C19*24;LADME_PK;DECREASED_CLEARANCE;nan
OMEPRAZOLE;CYP2C19;*24;CYP2C19*1, CYP2C19*24;LADME_PK;DECREASED_CLEARANCE;nan
VORICONAZOLE;CYP2C19;*32;CYP2C19*1, CYP2C19*32;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;*31;CYP2C19*1, CYP2C19*31;LADME_PK;DECREASED_CLEARANCE;nan
16ALPHA-HYDROXYTESTOSTERONE;CYP2C19;*11 + *23;CYP2C19*1, CYP2C19*11, CYP2C19*23;LADME_PK;INCREASED_FORMATION;nan
11ALPHA-HYDROXYTESTOSTERONE;CYP2C19;*9 + *11 + *23;CYP2C19*1, CYP2C19*9, CYP2C19*11, CYP2C19*23;LADME_PK;INCREASED_FORMATION;nan
VORICONAZOLE;CYP2C19;*29;CYP2C19*1, CYP2C19*29;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;*29;CYP2C19*1, CYP2C19*29;LADME_PK;DECREASED_CLEARANCE;nan
VORICONAZOLE;CYP2C19;*31;CYP2C19*1, CYP2C19*31;LADME_PK;DECREASED_CLEARANCE;nan
VORICONAZOLE;CYP2C19;*30;CYP2C19*1, CYP2C19*30;LADME_PK;DECREASED_CLEARANCE;nan
SIPONIMOD;CYP2C9;*3/*3 + *2/*2;CYP2C9*1, CYP2C9*2, CYP2C9*3;LADME_PK;DECREASED_METABOLISM;nan
DICLOFENAC;CYP2C9;*13;CYP2C9*1, CYP2C9*13;LADME_PK;DECREASED_CLEARANCE;nan
DICLOFENAC;CYP2C9;*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_CLEARANCE;nan
TOLBUTAMIDE;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_CLEARANCE;nan
ANDROSTENEDIONE;CYP2C19;*9 + *11 + *23;CYP2C19*1, CYP2C19*9, CYP2C19*11, CYP2C19*23;LADME_PK;INCREASED_FORMATION;nan
PHENYTOIN;CYP2C9;*52;CYP2C9*1, CYP2C9*52;LADME_PK;DECREASED_CLEARANCE;nan
METHADONE;CYP2C19;C;rs749678783;LADME_PK;DECREASED_CLEARANCE;nan
METHADONE;CYP2C19;A;rs770829708;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;A;rs72552267;LADME_PK;DECREASED_CLEARANCE;nan
METHADONE;CYP2C19;G;rs200150287;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;C;rs749678783;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;A;rs138142612;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;C;rs181297724;LADME_PK;DECREASED_CLEARANCE;nan
FLUOXETINE;CYP2C19;C;rs181297724;LADME_PK;DECREASED_SENSITIVITY;nan
KETOCONAZOLE;CYP2C19;C;rs181297724;LADME_PK;DECREASED_SENSITIVITY;nan
SERTRALINE;CYP2C19;C;rs181297724;LADME_PK;DECREASED_SENSITIVITY;nan
TICLOPIDINE;CYP2C19;C;rs181297724;LADME_PK;DECREASED_SENSITIVITY;nan
FLUVOXAMINE;CYP2C19;C;rs181297724;LADME_PK;INCREASED_SENSITIVITY;nan
OMEPRAZOLE;CYP2C19;C;rs181297724;LADME_PK;INCREASED_SENSITIVITY;nan
FLUOXETINE;CYP2C19;C;rs17878459;LADME_PK;DECREASED_SENSITIVITY;nan
CELECOXIB;CYP2C19;C;rs17878459;LADME_PK;INCREASED_SENSITIVITY;nan
FLUCONAZOLE;CYP2C19;C;rs17878459;LADME_PK;INCREASED_SENSITIVITY;nan
FLUVOXAMINE;CYP2C19;C;rs17878459;LADME_PK;INCREASED_SENSITIVITY;nan
MEPHENYTOIN;CYP2C19;*23;CYP2C19*1, CYP2C19*23;LADME_PK;INCREASED_CLEARANCE;nan
FLUVOXAMINE;CYP2C19;G;rs3758581;LADME_PK;INCREASED_SENSITIVITY;nan
VORICONAZOLE;CYP2C19;A;rs763625282;LADME_PK;DECREASED_CLEARANCE;nan
VORICONAZOLE;CYP2C19;G;rs3758581;LADME_PK;DECREASED_CLEARANCE;nan
OMEPRAZOLE;CYP2C19;*19;CYP2C19*1, CYP2C19*19;LADME_PK;DECREASED_AFFINITY;nan
VORICONAZOLE;CYP2C19;A;rs770829708;LADME_PK;DECREASED_CLEARANCE;nan
CELECOXIB;CYP2C19;*14;CYP2C19*1, CYP2C19*14;LADME_PK;INCREASED_SENSITIVITY;nan
FLUCONAZOLE;CYP2C19;*14;CYP2C19*1, CYP2C19*14;LADME_PK;INCREASED_SENSITIVITY;nan
FLUOXETINE;CYP2C19;*14;CYP2C19*1, CYP2C19*14;LADME_PK;DECREASED_SENSITIVITY;nan
SERTRALINE;CYP2C19;*14;CYP2C19*1, CYP2C19*14;LADME_PK;DECREASED_SENSITIVITY;nan
FLUCONAZOLE;CYP2C19;*13;CYP2C19*1, CYP2C19*13;LADME_PK;INCREASED_SENSITIVITY;nan
FLUVOXAMINE;CYP2C19;*13;CYP2C19*1, CYP2C19*13;LADME_PK;INCREASED_SENSITIVITY;nan
VORICONAZOLE;CYP2C19;C;rs181297724;LADME_PK;DECREASED_CLEARANCE;nan
METHADONE;CYP2C19;A;rs200346442;LADME_PK;DECREASED_CLEARANCE;nan
VORICONAZOLE;CYP2C19;T;rs550527959;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP2C19;A;rs7902257;OTHER;DECREASED_EXPRESSION;CYP2C19
PHENYTOIN;CYP2C9;*51;CYP2C9*1, CYP2C9*51;LADME_PK;INCREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP2C9;C;rs4918758;OTHER;DECREASED_TRANSCRIPTION;CYP2C9
PHENYTOIN;CYP2C9;*33;CYP2C9*1, CYP2C9*33;LADME_PK;DECREASED_CLEARANCE;nan
PHENYTOIN;CYP2C9;*13;CYP2C9*1, CYP2C9*13;LADME_PK;DECREASED_CLEARANCE;nan
PHENYTOIN;CYP2C9;*16;CYP2C9*1, CYP2C9*16;LADME_PK;DECREASED_CLEARANCE;nan
PHENYTOIN;CYP2C9;*45;CYP2C9*1, CYP2C9*45;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP2D6;AA + AG;rs16947;OTHER;DECREASED_EXPRESSION;CYP2D6
PRIMAQUINE;CYP2D6;*22 + *48;CYP2D6*1, CYP2D6*22, CYP2D6*26, CYP2D6*48;LADME_PK;INCREASED_CLEARANCE;nan
METHADONE;CYP2D6;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*89, CYP2D6*90, CYP2D6*93, CYP2D6*95, CYP2D6*97, CYP2D6*98;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP2D6;*92 + *96;CYP2D6*1, CYP2D6*92, CYP2D6*96;LADME_PK;DECREASED_ACTIVITY;CYP2D6
VENLAFAXINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98;LADME_PK;DECREASED_CLEARANCE;nan
PHENYTOIN;CYP2C9;*36;CYP2C9*1, CYP2C9*36;LADME_PK;DECREASED_CLEARANCE;nan
GEFITINIB;CYP2D6;*10 + *87 + *90 + *93 + *95 + *98;CYP2D6*1, CYP2D6*10, CYP2D6*87, CYP2D6*90, CYP2D6*93, CYP2D6*95, CYP2D6*98;LADME_PK;DECREASED_CLEARANCE;nan
BUFURALOL;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98, CYP2D6*134, CYP2D6*153;LADME_PK;DECREASED_CLEARANCE;nan
RISPERIDONE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98;LADME_PK;DECREASED_CLEARANCE;nan
CITALOPRAM;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*98;LADME_PK;DECREASED_CLEARANCE;nan
ATOMOXETINE;CYP2D6;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*97;LADME_PK;DECREASED_CLEARANCE;nan
TAMOXIFEN;CYP2D6;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*98;LADME_PK;DECREASED_CLEARANCE;nan
TOLTERODINE;CYP2D6;*10 + *93 + *94 + *95;CYP2D6*1, CYP2D6*10, CYP2D6*93, CYP2D6*94, CYP2D6*95;LADME_PK;DECREASED_CLEARANCE;nan
DEXTROMETHORPHAN;CYP2D6;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;CYP2D6*1, CYP2D6*87, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98, CYP2D6*134, CYP2D6*153;LADME_PK;DECREASED_CLEARANCE;nan
AMITRIPTYLINE;CYP2D6;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98;LADME_PK;DECREASED_CLEARANCE;nan
BUFURALOL;CYP2D6;T;rs745746329;LADME_PK;DECREASED_CLEARANCE;nan
DEXTROMETHORPHAN;CYP2D6;T;rs745746329;LADME_PK;DECREASED_CLEARANCE;nan
OLANZAPINE;CYP2D6;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;CYP2D6*1, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*97;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP2C9;C;rs9332094;OTHER;DECREASED_TRANSCRIPTION;CYP2C9
PHENYTOIN;CYP2C9;*37;CYP2C9*1, CYP2C9*37;LADME_PK;DECREASED_CLEARANCE;nan
PHENYTOIN;CYP2C9;*42;CYP2C9*1, CYP2C9*42;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;CYP2C9;AT + TT;rs7089580;OTHER;INCREASED_EXPRESSION;CYP2C9
PHENYTOIN;CYP2C9;*55;CYP2C9*1, CYP2C9*55;LADME_PK;DECREASED_CLEARANCE;nan
PHENYTOIN;CYP2C9;*56;CYP2C9*1, CYP2C9*56;LADME_PK;INCREASED_CLEARANCE;nan
PHENYTOIN;CYP2C9;*53;CYP2C9*1, CYP2C9*53;LADME_PK;INCREASED_CLEARANCE;nan
PHENYTOIN;CYP2C9;*50;CYP2C9*1, CYP2C9*50;LADME_PK;DECREASED_CLEARANCE;nan
PHENYTOIN;CYP2C9;*54;CYP2C9*1, CYP2C9*54;LADME_PK;INCREASED_CLEARANCE;nan
PHENYTOIN;CYP2C9;*19;CYP2C9*1, CYP2C9*19;LADME_PK;DECREASED_CLEARANCE;nan
PHENYTOIN;CYP2C9;*31;CYP2C9*1, CYP2C9*31;LADME_PK;DECREASED_CLEARANCE;nan
LOSARTAN;CYP2C9;C;rs1057910;LADME_PK;DECREASED_CLEARANCE;nan
PHENYTOIN;CYP2C9;*41;CYP2C9*1, CYP2C9*41;LADME_PK;INCREASED_CLEARANCE;nan
PHENYTOIN;CYP2C9;*27;CYP2C9*1, CYP2C9*27;LADME_PK;INCREASED_CLEARANCE;nan
PHENYTOIN;CYP2C9;*14;CYP2C9*1, CYP2C9*14;LADME_PK;DECREASED_CLEARANCE;nan
DICLOFENAC;CYP2C9;*62;CYP2C9*1, CYP2C9*62;LADME_PK;DECREASED_CLEARANCE;nan
LOSARTAN;CYP2C9;*62;CYP2C9*1, CYP2C9*62;LADME_PK;DECREASED_CLEARANCE;nan
TOLBUTAMIDE;CYP2C9;*62;CYP2C9*1, CYP2C9*62;LADME_PK;DECREASED_CLEARANCE;nan
DICLOFENAC;CYP2C9;*2;CYP2C9*1, CYP2C9*2;LADME_PK;DECREASED_CLEARANCE;nan
LOSARTAN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;LADME_PK;DECREASED_CLEARANCE;nan
TOLBUTAMIDE;CYP2C9;*2;CYP2C9*1, CYP2C9*2;LADME_PK;DECREASED_CLEARANCE;nan
DICLOFENAC;CYP2C9;*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_CLEARANCE;nan
LOSARTAN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_CLEARANCE;nan
TOLBUTAMIDE;CYP2C9;*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_CLEARANCE;nan
PHENYTOIN;CYP2C9;*47;CYP2C9*1, CYP2C9*47;LADME_PK;INCREASED_CLEARANCE;nan
PHENYTOIN;CYP2C9;*49;CYP2C9*1, CYP2C9*49;LADME_PK;INCREASED_CLEARANCE;nan
PHENYTOIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_CLEARANCE;nan
PHENYTOIN;CYP2C9;*43;CYP2C9*1, CYP2C9*43;LADME_PK;DECREASED_CLEARANCE;nan
PHENYTOIN;CYP2C9;*39;CYP2C9*1, CYP2C9*39;LADME_PK;DECREASED_CLEARANCE;nan
PHENYTOIN;CYP2C9;*8;CYP2C9*1, CYP2C9*8;LADME_PK;DECREASED_CLEARANCE;nan
NO_DRUG_RELATED;ZNF890P;AA;rs62442010;OTHER;INCREASED_TRANSCRIPTION;ABCB1
NICOTINE;CYP2A6;AA + AT;rs1801272;TOXICITY;DECREASED_RISK;OTHER:TOBACCO_USE_DISORDER
SACITUZUMAB GOVITECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
TACROLIMUS;CYP3A4;T;rs2740574;LADME_PK;PK;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)
ARIPIPRAZOLE;CYP2D6;ULTRARAPID_METABOLIZER;CYP2D6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
SULFAMETHOXAZOLE;NAT2;A;rs1799930;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_REACTIONS
TRIMETHOPRIM;NAT2;A;rs1799930;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_REACTIONS
ATORVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*01:01, HLA-DRB1*04:06;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
FLUVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*01:01, HLA-DRB1*04:06;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
HMG COA REDUCTASE INHIBITORS;HLA-DRB1;*04:06;HLA-DRB1*01:01, HLA-DRB1*04:06;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
PITAVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*01:01, HLA-DRB1*04:06;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
PRAVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*01:01, HLA-DRB1*04:06;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
ROSUVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*01:01, HLA-DRB1*04:06;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
SIMVASTATIN;HLA-DRB1;*04:06;HLA-DRB1*01:01, HLA-DRB1*04:06;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
ETHANOL;CHRNA5;T;rs615470;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:ALCOHOL_ABUSE
ETHANOL;CHRNA5;T;rs615470;OTHER;DECREASED_LIKELIHOOD;DISEASE:ALCOHOL_ABUSE
LIRAGLUTIDE;GLP1R;AT + TT;rs2254336;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | VOMITING | DIARRHEA | GASTROINTESTINAL_TOXICITY
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SIMEPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SIMEPREVIR;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;T;rs1041983;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;A;rs1799931;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_PK;PK:DOSE-ADJUSTED_AUC24
GEFITINIB;ABCG2;GG;rs2231142;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
LIRAGLUTIDE;GLP1R;AA + AG;rs3765467;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | VOMITING | DIARRHEA | GASTROINTESTINAL_TOXICITY
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS | STEVENS-JOHNSON_SYNDROME
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:HEMORRHAGE
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
ATORVASTATIN;HTR3B;G;rs2276307;TOXICITY;INCREASED_RISK;DISEASE:MYALGIA
PRAVASTATIN;HTR3B;G;rs2276307;TOXICITY;INCREASED_RISK;DISEASE:MYALGIA
SIMVASTATIN;HTR3B;G;rs2276307;TOXICITY;INCREASED_RISK;DISEASE:MYALGIA
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_LIKELIHOODPK;PK:ACHIEVING_OPTIMAL_TROUGH_LEVEL
NORTRIPTYLINE;UST;A;rs2500535;EFFICACY;DECREASED_EFFICACY;EFFICACY:IMPROVEMENT_OF_DEPRESSION_SYMPTOMS
TACROLIMUS;CYP3A4;G;rs1851426;LADME_PK;PK;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
CLOPIDOGREL;CYP2C19;*17;CYP2C19*1, CYP2C19*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT:BLEEDING
OSIMERTINIB;IL6;CG + GG;rs1800796;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
FLUCLOXACILLIN;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RISPERIDONE;HTR2A;CT + TT;rs6311;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
TAMOXIFEN;CYP2D6;*6/*6;CYP2D6*6;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
TAMOXIFEN;CYP2D6;*5/*5;CYP2D6*5;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED_SEVERITY;OTHER:INTERSTITIAL_INFLAMMATORY_CELL_INFILTRATION
RISPERIDONE;HTR2A;AA + AG;rs6313;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
OXAZEPAM;UGT2B15;AA;rs1902023;LADME_PK;DECREASED_PK;PK:S-OXAZEPAM_GLUCURONIDATION_IN_HUMAN_LIVER_MICROSOMES
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
OXAZEPAM;UGT2B15;AA;rs1902023;LADME_PK;DECREASED_PK;PK:OXAZEPAM_ORAL_CLEARANCE
SULFAMETHOXAZOLE;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
TRIMETHOPRIM;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
EFAVIRENZ;CYP2B6;POOR_METABOLIZER;CYP2B6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERCHOLESTEROLEMIA
ISONIAZID;CYP2B6;POOR_METABOLIZER;CYP2B6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERCHOLESTEROLEMIA
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED_RISK;DISEASE:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
TACROLIMUS;PPARA;GG;rs4823613;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ACUTE_CELLULAR_REJECTION
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY | INFECTIOUS_DISEASE | STOMATITIS,
METHOTREXATE;TPMT;*1/*3A;TPMT*1, TPMT*3A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY | INFECTIOUS_DISEASE | STOMATITIS,
NITROUS OXIDE;MTHFR;AA;rs1801133;TOXICITY;INCREASED;SIDE_EFFECT:PLASMA_TOTAL_HOMOCYSTEINE_CONCENTRATIONS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:STROKE | MYOCARDIAL_INFARCTION | DEATH,
RISPERIDONE;DRD3;G;rs167771;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
ANTIPSYCHOTICS;CYP2D6;*1/*10 + *10/*10;CYP2D6*1, CYP2D6*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TARDIVE_DYSKINESIA
FLUCLOXACILLIN;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
FLUCLOXACILLIN;HLA-A;*01:01;HLA-A*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
AMOXICILLIN;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CISPLATIN;GGT1;CC;rs5751901;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA
PACLITAXEL;GGT1;CC;rs5751901;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA
ANTITHYROID PREPARATIONS;HLA-B;*27:05;HLA-B*27:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
FLUCLOXACILLIN;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
BUSULFAN;CYP2B6;*1/*1 + *1/*5 + *1/*9;CYP2B6*1, CYP2B6*5, CYP2B6*9;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
TAMOXIFEN;CYP2D6;POOR_METABOLIZER;CYP2D6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:UTERINE_DISORDER | LEIOMYOMA | ENDOMETRIAL_HYPERPLASIA | POLYPS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE
CAPECITABINE;ABCC11;AA + AG;rs17822471;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
FLUOROURACIL;ABCC11;AA + AG;rs17822471;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
SULFAMETHOXAZOLE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
TRIMETHOPRIM;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
ANTIPSYCHOTICS;CYP2D6;*1/*4 + *1/*5;CYP2D6*1, CYP2D6*4, CYP2D6*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TARDIVE_DYSKINESIA
FLUVOXAMINE;CYP2D6;*1/*10 + *1/*5 + *10/*10 + *5/*10;CYP2D6*1, CYP2D6*5, CYP2D6*10;LADME_PK;PK;PK:DIFFERENCES_IN_THE_FLUVOXAMINE_PLASMA_LEVEL_AT_50_MG/DAY
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQA1;*05;HLA-DQA1*05;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BULLOUS_PEMPHIGOID
PEGINTERFERON ALFA-2A;IDO1;CC;rs9657182;TOXICITY;INCREASED;SIDE_EFFECT:DEPRESSION
PEGINTERFERON ALFA-2B;IDO1;CC;rs9657182;TOXICITY;INCREASED;SIDE_EFFECT:DEPRESSION
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;nan;AA + AG;rs3129763;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BULLOUS_PEMPHIGOID
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQB1;*03:01;HLA-DQB1*03:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BULLOUS_PEMPHIGOID
NITROUS OXIDE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;SIDE_EFFECT:PLASMA_TOTAL_HOMOCYSTEINE_CONCENTRATIONS
CIPROFLOXACIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
LEVOFLOXACIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
MOXIFLOXACIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
OMEPRAZOLE;CYP2C19;TT;rs11188072;DOSAGE;DECREASED_PK;PK:AUC
OMEPRAZOLE;CYP2C19;TT;rs11188072;LADME_PK;DECREASED_PK;PK:AUC
METHADONE;CYP3A4;C;rs3735451;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SIDE_EFFECTS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
CARBOPLATIN;ABCB1;AA;rs2032582;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PACLITAXEL;ABCB1;AA;rs2032582;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
TAMOXIFEN;CYP2D6;*1/*1;CYP2D6*1, CYP2D6*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
SULFAMETHOXAZOLE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
TRIMETHOPRIM;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
ANTIPSYCHOTICS;CYP2D6;*10;CYP2D6*1, CYP2D6*10;TOXICITY;RISK;SIDE_EFFECT:TARDIVE_DYSKINESIA
ANTIDEPRESSANTS;CYP2D6;*2/*2xN;CYP2D6*2, CYP2D6*2xN;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
ASPARAGINASE;ATL2;T;rs59569490;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
AZATHIOPRINE;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PANCREATITIS
MERCAPTOPURINE;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PANCREATITIS
ASPIRIN;CYP2C19;*2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_EFFICACY;EFFICACY:MAXIMAL_PLATELET_AGGREGATION
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_EFFICACY;EFFICACY:MAXIMAL_PLATELET_AGGREGATION
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_EFFICACY;EFFICACY:MAXIMAL_PLATELET_AGGREGATION
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS_(ST)_AFTER_1_YEAR
ESCITALOPRAM;CYP2C19;A;rs4986893;DOSAGE;INCREASED_PK;PK:SERUM_CONCENTRATION
ESCITALOPRAM;CYP2C19;A;rs4986893;LADME_PK;INCREASED_PK;PK:SERUM_CONCENTRATION
PLATINUM COMPOUNDS;RETN;GG;rs1862513;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL | RECURRENCE_FREE_SURVIVAL
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
TAMOXIFEN;CYP2D6;*4/*4 + *1/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL | RECURRENCE_FREE_SURVIVAL
NILOTINIB;UGT1A1;*6/*6 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*27, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
PRIMAQUINE;MAOA;CC + CT;rs1137070;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
OMEPRAZOLE;CYP2C19;TT;rs12248560;DOSAGE;DECREASED_PK;PK:AUC
OMEPRAZOLE;CYP2C19;TT;rs12248560;LADME_PK;DECREASED_PK;PK:AUC
PRIMAQUINE;CYP2D6;NORMAL_METABOLIZER;CYP2D6 normal metabolizer;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
AZATHIOPRINE;NUDT15;GGAGTC;rs746071566;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:LEUKOPENIA
MERCAPTOPURINE;NUDT15;GGAGTC;rs746071566;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:LEUKOPENIA
PRIMAQUINE;CYP2D6;*4;CYP2D6*4;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
ESCITALOPRAM;CYP2C19;TT;rs11188072;DOSAGE;DECREASED_PK;PK:SERUM_CONCENTRATION
ESCITALOPRAM;CYP2C19;TT;rs11188072;LADME_PK;DECREASED_PK;PK:SERUM_CONCENTRATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_PK;PK:CONCENTRATION/DOSE_RATIO
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_PK;PK:CONCENTRATION/DOSE_RATIO
TENOFOVIR;ABCC10;C;rs2125739;TOXICITY;INCREASED;SIDE_EFFECT:KIDNEY_TUBULAR_DYSFUNCTION
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_PK;PK:BLOOD_CONCENTRATION/DOSAGE_RATIO
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_PK;PK:CONCENTRATION/DOSE_RATIO
CLOPIDOGREL;CYP2C19;*5;CYP2C19*1, CYP2C19*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
EFAVIRENZ;CYP2B6;POOR_METABOLIZER;CYP2B6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID;CYP2B6;POOR_METABOLIZER;CYP2B6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ROSUVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAEMATOLOGICAL_TOXICITY_OR_HEPATOTOXICITY
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
TACROLIMUS;CYP3A4;A;rs2687116;LADME_PK;PK;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)
CARBOPLATIN;ABCB1;AG + GG;rs1128503;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
PACLITAXEL;ABCB1;AG + GG;rs1128503;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
CARBOPLATIN;ABCB1;AG + GG;rs1128503;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VOMITING
PACLITAXEL;ABCB1;AG + GG;rs1128503;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VOMITING
ESCITALOPRAM;CYP2C19;A;rs4244285;DOSAGE;INCREASED_PK;PK:SERUM_CONCENTRATION
ESCITALOPRAM;CYP2C19;A;rs4244285;LADME_PK;INCREASED_PK;PK:SERUM_CONCENTRATION
NO_DRUG_RELATED;IFNL4;TT/TT;rs11322783;OTHER;INCREASED;OTHER:SPONTANEOUS_HCV_CLEARANCE
MERCAPTOPURINE;SLC22A1;del;rs72552763;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:INFECTIOUS_DISEASE
CARBOPLATIN;nan;AA + AG;rs6856089;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
CISPLATIN;nan;AA + AG;rs6856089;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;LADME_PK;DECREASED_PK;PK:6-MMPN_LEVELS
NO_DRUG_RELATED;SOD1;GCCCAGTAAAGCATGGGGCCTGGGGCCAGGGACCCCCTTGTTCAGGTGTG/del + del/del;rs36232792;OTHER;DECREASED_LIKELIHOOD;OTHER:OPIOID-RELATED_DISORDERS
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BONE_MARROW_TOXICITY
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BONE_MARROW_TOXICITY
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BONE_MARROW_TOXICITY
ETHAMBUTOL;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*1, NAT2*5, NAT2*6, NAT2*7, NAT2*14;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*1, NAT2*5, NAT2*6, NAT2*7, NAT2*14;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*1, NAT2*5, NAT2*6, NAT2*7, NAT2*14;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*1, NAT2*5, NAT2*6, NAT2*7, NAT2*14;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DISCONTINUATION
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DISCONTINUATION
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVERALL_ADRS
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVERALL_ADRS
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVERALL_ADRS
NO_DRUG_RELATED;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;OTHER;INCREASED_LIKELIHOOD;OTHER:DECREASED_GLOMERULAR_FILTRATION_RATE
ESCITALOPRAM;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;LADME_PK;INCREASED_LIKELIHOOD;OTHER:DISCONTINUATION | TREATMENT_MODIFICATION
PHENYTOIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;LADME_PK;INCREASED_LIKELIHOOD;OTHER:DISCONTINUATION | TREATMENT_MODIFICATION
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;TOXICITY;DECREASED;SIDE_EFFECT:HEMATOLOGICAL_INDICES
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CYCLOSPORINE;TPMT;*1/*3A + *1/*3B + *1/*3C;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;TOXICITY;INCREASED_PK;PK:PLASMA_LEVELS
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(RAPID_AND_SUSTAINED_VIROLOGICAL_RESPONSE)_FOR_PATIENTS_WITH_HEPATITIS_C_VIRUS_GENOTYPE_1
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(RAPID_AND_SUSTAINED_VIROLOGICAL_RESPONSE)_FOR_PATIENTS_WITH_HEPATITIS_C_VIRUS_GENOTYPE_1
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(RAPID_AND_SUSTAINED_VIROLOGICAL_RESPONSE)_FOR_PATIENTS_WITH_HEPATITIS_C_VIRUS_GENOTYPE_1
CISPLATIN;MTHFR;GG + GT;rs1801131;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PEMETREXED;MTHFR;GG + GT;rs1801131;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ESCITALOPRAM;CYP2C19;TT;rs12248560;DOSAGE;DECREASED_PK;PK:SERUM_CONCENTRATION
ESCITALOPRAM;CYP2C19;TT;rs12248560;LADME_PK;DECREASED_PK;PK:SERUM_CONCENTRATION
PHENYTOIN;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
SUFENTANIL;ADRB1;GG;rs1801253;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:POSTOPERATIVE_PAIN
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*35, CYP2D6*36, CYP2D6*41;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
TAMOXIFEN;CYP2D6;*10/*5 + *10/*10 + *10/*41;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*35, CYP2D6*36, CYP2D6*41;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
TENOFOVIR;ABCC10;G;rs9349256;TOXICITY;INCREASED;SIDE_EFFECT:KIDNEY_TUBULAR_DYSFUNCTION
CLOPIDOGREL;CYP2C19;*17;CYP2C19*1, CYP2C19*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MORTALITY
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
IMATINIB;ABCB1;A;rs1045642;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION
IMATINIB;NR1I2;TT;rs3814055;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_CLINICAL_EVENTS
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_CLINICAL_EVENTS
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR1A;C;rs6295;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
FLUOROURACIL;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;LADME_PK;DECREASED_PK;PK:AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
METHOTREXATE;MTRR;G;rs1801394;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
TEGAFUR;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL | OVERALL_SURVIVAL
GIMERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL | OVERALL_SURVIVAL
OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL | OVERALL_SURVIVAL
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_CLINICAL_EVENTS
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;OTHER;INCREASED;OTHER:P2Y12_REACTION_UNIT(PRU)_VALUES
ROSUVASTATIN;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;OTHER;INCREASED;OTHER:P2Y12_REACTION_UNIT(PRU)_VALUES
METHADONE;CYP3A4;A;rs4646437;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SIDE_EFFECTS
TEGAFUR;CYP2A6;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;LADME_PK;INCREASED_PK;PK:AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE
CLOPIDOGREL;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*17;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
ANTIPSYCHOTICS;CYP2D6;*3 + *4 + *5 + *6 + *7 + *14;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*14;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TARDIVE_DYSKINESIA
AZATHIOPRINE;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
AZATHIOPRINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
LAMOTRIGINE;HLA-C;*07:18;HLA-C*07:18;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
LAMOTRIGINE;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
RIVAROXABAN;ABCB1;CC;rs4148738;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
LAMOTRIGINE;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
RIVAROXABAN;ABCB1;AA;rs1045642;EFFICACY;INCREASED_RISK;SIDE_EFFECT:THROMBOEMBOLISM
TAMOXIFEN;CYP2D6;*10;CYP2D6*10;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ENDOMETRIAL_HYPERPLASIA
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CLOPIDOGREL_RESISTANCE
METHOTREXATE;MTHFD1;A;rs2236225;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
METHADONE;CYP3A4;T;rs2242480;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SIDE_EFFECTS
CARBOPLATIN;CD274;AG + GG;rs2297136;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CISPLATIN;CD274;AG + GG;rs2297136;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CLOPIDOGREL;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT:BLEEDING_EVENTS
CARBOPLATIN;CD274;CC + CG;rs822336;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CISPLATIN;CD274;CC + CG;rs822336;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CARBOPLATIN;CD274;GT + TT;rs2282055;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CISPLATIN;CD274;GT + TT;rs2282055;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
HYDROMORPHONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PRURITUS
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PRURITUS
ANTIPSYCHOTICS;CYP2D6;*2;CYP2D6*1, CYP2D6*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | SEVERE_CUTANEOUS_ADVERSE_REACTIONS | STEVENS-JOHNSON_SYNDROME,
DOXORUBICIN;NCF4;AA + AG;rs1883112;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
AZATHIOPRINE;NUDT15;*1/*2 + *1/*3;NUDT15*1, NUDT15*2, NUDT15*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DISCONTINUATION | MYELOSUPPRESSION
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*8, TPMT*9, TPMT*12, TPMT*24;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DISCONTINUATION | MYELOSUPPRESSION
DOXORUBICIN;CBR1;CT + TT;rs3787728;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL | OVERALL_SURVIVAL
INFLIXIMAB;HLA-DRB1;*04:04;HLA-DRB1*04:04;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
DOXORUBICIN;CBR1;CG + GG;rs1005695;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL | OVERALL_SURVIVAL
ATORVASTATIN;SLCO1B1;*1/*5 + *5/*5;SLCO1B1*1, SLCO1B1*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DISCONTINUATION | STATIN-RELATED_MYOPATHY
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;OTHER;INCREASED;OTHER:PLATELET_REACTIVITY_BY_P2Y12_REACTION_UNITS
DABIGATRAN;CES1;GG + GT;rs2244613;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
OLANZAPINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;DISEASE:DIZZINESS
QUETIAPINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;DISEASE:DIZZINESS
RISPERIDONE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;DISEASE:DIZZINESS
RIVAROXABAN;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOEMBOLISM
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
CAPECITABINE;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PLATINUM;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PLATINUM;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ONDANSETRON;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED;OTHER:PERCENTAGE_OF_DAYS_ABSTINENT_AND_LOWER_NUMBER_OF_DRINKS_PER_DRINKING_DAY
CHOP;CBR3;AA + AG;rs8133052;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
RITUXIMAB;CBR3;AA + AG;rs8133052;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
CHOP;ABCC2;AA + AG;rs8187710;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
RITUXIMAB;ABCC2;AA + AG;rs8187710;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CYCLOPHOSPHAMIDE;CYP2B6;*5/*6;CYP2B6*1, CYP2B6*5, CYP2B6*6;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
METHOTREXATE;SLC19A1;T;rs1051266;EFFICACY;EFFICACY;EFFICACY:WORSE_PROGNOSES
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEXUAL_DYSFUNCTION
WARFARIN;CYP2C9;*1/*11;CYP2C9*1, CYP2C9*11;EFFICACY;INCREASED_EFFICACY;EFFICACY:INTERNATIONAL_NORMALIZED_RATIO_VARIABILITY_(INR-VAR)
AZATHIOPRINE;TPMT;*1/*3C;TPMT*1, TPMT*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*1, TPMT*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
PURINE ANALOGUES;TPMT;*1/*3C;TPMT*1, TPMT*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
GEMCITABINE;RRM1;C;rs1042927;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_PROBABILITY
PLATINUM COMPOUNDS;RRM1;C;rs1042927;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_PROBABILITY
METHOTREXATE;SLC19A1;CC;rs1051266;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;CC + TT;rs6311;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:TREMOR | DIARRHEA
AMOXICILLIN;HLA-B;*15:18;HLA-B*15:18;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLAVULANATE;HLA-B;*15:18;HLA-B*15:18;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
IRINOTECAN;UGT1A1;*28/*28 + *28/*37;UGT1A1*1, UGT1A1*28, UGT1A1*37;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ASTHENIA | DIARRHEA | NEUTROPENIA,
CAPECITABINE;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PACLITAXEL;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
AZATHIOPRINE;PTPN2;C;rs11664064;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
MERCAPTOPURINE;PTPN2;C;rs11664064;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
ANTINEOPLASTIC AGENTS;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*41;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
TAMOXIFEN;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*41;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
BEVACIZUMAB;SHMT1;A;rs1979277;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_(P=0.00004)_AND_OVERALL_SURVIVAL_(OS)_(P=0.034)
FLUOROURACIL;SHMT1;A;rs1979277;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_(P=0.00004)_AND_OVERALL_SURVIVAL_(OS)_(P=0.034)
IRINOTECAN;SHMT1;A;rs1979277;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_(P=0.00004)_AND_OVERALL_SURVIVAL_(OS)_(P=0.034)
LEUCOVORIN;SHMT1;A;rs1979277;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_(P=0.00004)_AND_OVERALL_SURVIVAL_(OS)_(P=0.034)
METHOTREXATE;MTHFD1;AA;rs2236225;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
TAMOXIFEN;CYP2D6;CT + TT;rs3892097;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
METHOTREXATE;ABCB1;GG;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
METHOTREXATE;GSTP1;AA;rs1695;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION
MERCAPTOPURINE;TPMT;C;rs1142345;TOXICITY;INCREASED;SIDE_EFFECT:GI_TOXICITY
METHOTREXATE;TPMT;C;rs1142345;TOXICITY;INCREASED;SIDE_EFFECT:GI_TOXICITY
METHOTREXATE;SLCO1B1;T;rs11045879;TOXICITY;INCREASED_RISK;DISEASE:MUCOSITIS
AMOXICILLIN;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLAVULANATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
AMOXICILLIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLAVULANATE;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
AMOXICILLIN;ERAP1;G;rs1363907;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
AMOXICILLIN;ERAP2;G;rs1363907;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLAVULANATE;ERAP1;G;rs1363907;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLAVULANATE;ERAP2;G;rs1363907;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CYCLOPHOSPHAMIDE;GSTT1;nan;GSTT1 non-null, GSTT1 null;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
AMOXICILLIN;PTPN22;A;rs2476601;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLAVULANATE;PTPN22;A;rs2476601;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CYCLOPHOSPHAMIDE;GSTM1;nan;GSTM1 non-null, GSTM1 null;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CAPECITABINE;TYMS;G;rs3786362;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CAPECITABINE;TYMS;C;rs699517;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CAPECITABINE;ENOSF1;TTAAAGTTA;rs11280056;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CAPECITABINE;TYMS;TTAAAGTTA;rs11280056;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CAPECITABINE;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CAPECITABINE;ENOSF1;G;rs2790;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CAPECITABINE;TYMS;G;rs2790;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
NO_DRUG_RELATED;NME1;TT;rs2302254;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL | RECURRENCE_FREE_SURVIVAL
NO_DRUG_RELATED;NME1-NME2;TT;rs2302254;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL | RECURRENCE_FREE_SURVIVAL
IRINOTECAN;UGT1A7;*1a/*3 + *2/*3 + *3/*3;UGT1A7*1a, UGT1A7*2, UGT1A7*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
RIVAROXABAN;SUSD3;TT;rs76292544;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
NO_DRUG_RELATED;CYP3A5;CC;rs776746;nan;nan;SIDE_EFFECT:DRUG_TOXICITY
NO_DRUG_RELATED;ZSCAN25;CC;rs776746;nan;nan;SIDE_EFFECT:DRUG_TOXICITY
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
IRINOTECAN;UGT1A7;*1a/*3 + *2/*3 + *3/*3;UGT1A7*1a, UGT1A7*2, UGT1A7*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
METHOTREXATE;SLCO1B1;G;rs4149081;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GI_TOXICITY
SULFAMETHOXAZOLE;HLA-A;*02:07;HLA-A*02:07;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA | DRUG_HYPERSENSITIVITY
TRIMETHOPRIM;HLA-A;*02:07;HLA-A*02:07;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA | DRUG_HYPERSENSITIVITY
ASPIRIN;FCER1G;AA;rs11587213;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA
LAPATINIB;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TRANSPLANT_REJECTION
LAPATINIB;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
TACROLIMUS;CYP3A5;C;rs776746;LADME_PK;INCREASED_PK;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)
LAPATINIB;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
NO_DRUG_RELATED;MS4A2;AG + GG;rs569108;TOXICITY;INCREASED_LIKELIHOOD;OTHER:ATOPY_IN_PATIENTS_WITH_ASPIRIN-INTOLERANT_CHRONIC_URTICARIA
LAPATINIB;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PACLITAXEL;ABCB1;AA;rs2032582;EFFICACY;INCREASED_EFFICACY;EFFICACY:CHANCE_OF_POSITIVE_RESPONSE_TO_PACLITAXEL
ETHAMBUTOL;FECH;CC;rs536560;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ISONIAZID;FECH;CC;rs536560;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PYRAZINAMIDE;FECH;CC;rs536560;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RIFAMPIN;FECH;CC;rs536560;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NO_DRUG_RELATED;FCER1G;AG + GG;rs11587213;TOXICITY;INCREASED_LIKELIHOOD;OTHER:ATOPY_IN_PATIENTS_WITH_ASPIRIN-INTOLERANT_CHRONIC_URTICARIA
PHENYTOIN;CYP2C9;*1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1, CYP2C9*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
CISPLATIN;EPHX1;CT + TT;rs1051740;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY
RADIOTHERAPY;EPHX1;CT + TT;rs1051740;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY
CISPLATIN;ERCC2;GG + GT;rs13181;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
RADIOTHERAPY;ERCC2;GG + GT;rs13181;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN;ERCC2;CT + TT;rs1799793;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
RADIOTHERAPY;ERCC2;CT + TT;rs1799793;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
GEMCITABINE;CDA;C;rs2072671;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:NAUSEA
PLATINUM COMPOUNDS;CDA;C;rs2072671;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:NAUSEA
NO_DRUG_RELATED;CYP2A6;*4/*4;CYP2A6*4;OTHER;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
ANTHRACYCLINES AND RELATED SUBSTANCES;CYP3A5;AA;rs4646450;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*6 + *2/*2;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*6;TOXICITY;INCREASED;SIDE_EFFECT:NEUTROPENIA
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;AA;rs7853758;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
AZATHIOPRINE;TPMT;*1/*3C;TPMT*1, TPMT*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
OMEPRAZOLE;CYP2C19;*1/*1 + *1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;DISEASE:GASTRIC_PH
ETHAMBUTOL;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ISONIAZID;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PYRAZINAMIDE;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RIFAMPIN;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PHENPROCOUMON;VKORC1;TT;rs9923231;DOSAGE;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
PHENPROCOUMON;VKORC1;TT;rs9923231;OTHER;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
METHOTREXATE;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CARBOPLATIN;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:THROMBOCYTOPENIA
GEMCITABINE;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:THROMBOCYTOPENIA
METHOTREXATE;SLCO1B1;C;rs4149056;OTHER;DECREASED_PK;PK:CLEARANCE
METHOTREXATE;SLCO1B1;C;rs4149056;LADME_PK;DECREASED_PK;PK:CLEARANCE
ASPARAGINASE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ENALAPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED_LIKELIHOOD;DISEASE:CHRONIC_KIDNEY_FAILURE
SUCCINYLCHOLINE;RYR1;G;rs193922752;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MALIGNANT_HYPERTHERMIA
VOLATILE ANESTHETICS;RYR1;G;rs193922752;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MALIGNANT_HYPERTHERMIA
EGFR INHIBITORS;EGFR;GG;rs2227983;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:EXANTHEMA
GEMCITABINE;RRM1;A;rs12806698;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:NAUSEA
PLATINUM COMPOUNDS;RRM1;A;rs12806698;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:NAUSEA
GEMCITABINE;RRM1;C;rs11030918;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:NAUSEA
PLATINUM COMPOUNDS;RRM1;C;rs11030918;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:NAUSEA
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
VERAPAMIL;ADRB1;AA + AG;rs1801252;EFFICACY;INCREASED_RISK;DISEASE:DEATH
HEROIN;DRD2;G;rs12364283;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEROIN_DEPENDENCE
REPAGLINIDE;CYP2C8;*3;CYP2C8*3;LADME_PK;DECREASED_PK;PK:REPAGLINIDE_AUC
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
AZATHIOPRINE;TPMT;*1/*3C;TPMT*1, TPMT*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAEMATOPOIETIC_TOXICITY
SULFAMETHOXAZOLE;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TRIMETHOPRIM;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
AZATHIOPRINE;NUDT15;*3/*3;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
TACROLIMUS;CYP3A7;C;rs2257401;LADME_PK;PK;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)
SIMVASTATIN;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULAR_DISEASES
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
PHENYTOIN;CYP2C19;A;rs4986893;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
TRAMADOL;CYP2D6;*3/*5;CYP2D6*1, CYP2D6*3, CYP2D6*5;DOSAGE;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE
TRAMADOL;CYP2D6;*3/*5;CYP2D6*1, CYP2D6*3, CYP2D6*5;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;DOSAGE;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE
TACROLIMUS;CYP3A4;G;rs4646437;LADME_PK;PK;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)
ISONIAZID;NAT2;*4;NAT2*4;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*4;NAT2*4;LADME_PK;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*4;NAT2*4;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*4;NAT2*4;LADME_PK;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ASPARAGINASE;SOD2;GG;rs4880;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
NO_DRUG_RELATED;CYP1A2;AC + CC;rs762551;OTHER;INCREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
ANTITHYROID PREPARATIONS;HLA-B;*39:01;HLA-B*39:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
TRASTUZUMAB;ERBB2;AG + GG;rs1136201;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
SIMVASTATIN;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PHENYTOIN;CYP2C9;T;rs1799853;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:STEVENS-JOHNSON_SYNDROME
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
BETA BLOCKING AGENTS;ADRA2C;GGGGCGGGGCCG/GGGGCGGGGCCG;rs61767072;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
PACLITAXEL;FZD3;A;rs7001034;TOXICITY;DECREASED_RISK;SIDE_EFFECT:SENSORY_PERIPHERAL_NEUROPATHY
CAPECITABINE;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
FLUOROURACIL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
SERTRALINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER
CLOZAPINE;HLA-DRB1;*04:02;HLA-DRB1*04:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:AGRANULOCYTOSIS
DIRECT ACTING ANTIVIRALS;IFNL3;TT;rs12979860;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEPATOCELLULAR_CARCINOMA
DIRECT ACTING ANTIVIRALS;IFNL4;TT;rs12979860;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEPATOCELLULAR_CARCINOMA
GLICLAZIDE;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;OTHER;INCREASED_RISK;DISEASE:HYPOGLYCEMIA
GLIMEPIRIDE;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;OTHER;INCREASED_RISK;DISEASE:HYPOGLYCEMIA
GLIPIZIDE;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;OTHER;INCREASED_RISK;DISEASE:HYPOGLYCEMIA
GLIQUIDONE;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;OTHER;INCREASED_RISK;DISEASE:HYPOGLYCEMIA
GLYBURIDE;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;OTHER;INCREASED_RISK;DISEASE:HYPOGLYCEMIA
TRAMADOL;CYP2D6;*5/*5;CYP2D6*1, CYP2D6*5;DOSAGE;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE
TRAMADOL;CYP2D6;*5/*5;CYP2D6*1, CYP2D6*5;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE
ASPIRIN;NOS3;T;rs1799983;OTHER;INCREASED_RISK;OTHER:IN-STENT_RESTENOSIS
BETA BLOCKING AGENTS;NOS3;T;rs1799983;OTHER;INCREASED_RISK;OTHER:IN-STENT_RESTENOSIS
CLOPIDOGREL;NOS3;T;rs1799983;OTHER;INCREASED_RISK;OTHER:IN-STENT_RESTENOSIS
HMG COA REDUCTASE INHIBITORS;NOS3;T;rs1799983;OTHER;INCREASED_RISK;OTHER:IN-STENT_RESTENOSIS
CISPLATIN;UGT1A1;AA;rs4148323;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
IRINOTECAN;UGT1A1;AA;rs4148323;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ANTHRACYCLINES AND RELATED SUBSTANCES;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ASPIRIN;CYP2C9;AC + CC;rs1057910;EFFICACY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
CLOPIDOGREL;CYP2C9;AC + CC;rs1057910;EFFICACY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
TACROLIMUS;CYP3A4;C;rs6956344;LADME_PK;PK;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL | RECURRENCE_FREE_SURVIVAL
CISPLATIN;UGT1A1;AA;rs4148323;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IRINOTECAN;UGT1A1;AA;rs4148323;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IRINOTECAN;UGT1A1;*1/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
CARBAMAZEPINE;HLA-B;*15:21;HLA-B*15:21;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
FOLFIRI;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
PACLITAXEL;ABCB1;AG;rs1045642;EFFICACY;DECREASED_EFFICACY;EFFICACY:DISEASE_CONTROL_RATE_AND_LOWER_OVERALL_SURVIVAL_RATE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;LADME_PK;DECREASED_PK;PK:CLOPIDOGREL_ACTIVE_METABOLITE_LEVEL
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_LIKELIHOODPK;PK:ACHIEVING_TARGET_CONCENTRATIONS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:POST-TREATMENT_ADP-STIMULATED_PLATELET_AGGREGATION
PACLITAXEL;CYP3A5;C;rs776746;TOXICITY;DECREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HOT_FLASHES
INFLIXIMAB;HLA-DQB1;*02:01;HLA-DQB1*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
INFLIXIMAB;HLA-DPB1;*10:01;HLA-DPB1*10:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
INFLIXIMAB;HLA-DRB1;*03:01;HLA-DRB1*03:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TAMOXIFEN;CYP2D6;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;CYP2D6*1, CYP2D6*1xN, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*10x2, CYP2D6*14, CYP2D6*21, CYP2D6*36, CYP2D6*41;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
NO_DRUG_RELATED;HLA-DPB1;*03:01;HLA-DPB1*03:01;TOXICITY;INCREASED_RISK;DISEASE:ASPIRIN-INDUCED_ASTHMA
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *4/*10;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
TRAMADOL;CYP2D6;*6/*6;CYP2D6*1, CYP2D6*6;DOSAGE;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE
TRAMADOL;CYP2D6;*6/*6;CYP2D6*1, CYP2D6*6;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE
TRAMADOL;CYP2D6;*4/*5;CYP2D6*1, CYP2D6*4, CYP2D6*5;DOSAGE;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE
TRAMADOL;CYP2D6;*4/*5;CYP2D6*1, CYP2D6*4, CYP2D6*5;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:ANTIPLATELET_RESPONSE_AND_REDUCED_CLOPIDOGREL_ACTIVE_METABOLITE_FORMATION
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CYCLOPHOSPHAMIDE;CPT1A;T;rs12283870;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
CYCLOPHOSPHAMIDE;IGHMBP2;T;rs12283870;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
CYTARABINE;CPT1A;T;rs12283870;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
CYTARABINE;IGHMBP2;T;rs12283870;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
DAUNORUBICIN;CPT1A;T;rs12283870;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
DAUNORUBICIN;IGHMBP2;T;rs12283870;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
DOXORUBICIN;CPT1A;T;rs12283870;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
DOXORUBICIN;IGHMBP2;T;rs12283870;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
MERCAPTOPURINE;CPT1A;T;rs12283870;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
MERCAPTOPURINE;IGHMBP2;T;rs12283870;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
METHOTREXATE;CPT1A;T;rs12283870;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
METHOTREXATE;IGHMBP2;T;rs12283870;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
PEGASPARGASE;CPT1A;T;rs12283870;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
PEGASPARGASE;IGHMBP2;T;rs12283870;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
THIOGUANINE;CPT1A;T;rs12283870;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
THIOGUANINE;IGHMBP2;T;rs12283870;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
VINCRISTINE;CPT1A;T;rs12283870;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
VINCRISTINE;IGHMBP2;T;rs12283870;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
FOLFIRINOX;UGT1A1;*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:THROMBOCYTOPENIA
TAMOXIFEN;CYP2D6;*4 + *5 + *10 + *14 + *21 + *36 + *41;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*21, CYP2D6*36, CYP2D6*41;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_BLOOD_LEVELS
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_PK;PK:TROUGH_CONCENTRATION
TACROLIMUS;CYP3A4;C;rs2242480;LADME_PK;PK;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A;TPMT*1, TPMT*2, TPMT*3A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
METHAZOLAMIDE;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE_TO_PEGIFN-ALPHA/RBV_TREATMENT_AT_WEEK_20/24
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE_TO_PEGIFN-ALPHA/RBV_TREATMENT_AT_WEEK_20/24
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;OTHER;INCREASED;OTHER:CREATININE_CLEARANCE
FLECAINIDE;CYP2D6;*4 + *5 + *10 + *21 + *36;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*21, CYP2D6*36;LADME_PK;INCREASED_PK;PK:AGE-RELATED_DECLINE_IN_FLECAINIDE_CLEARANCE_PATIENTS_TREATED_WITH_ORAL_FLECAINIDE_FOR_SUPRAVENTRICULAR_TACHYARRHYTHMIAS
TRANILAST;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
NORTRIPTYLINE;CYP2D6;*3;CYP2D6*1, CYP2D6*3;LADME_PK;INCREASED_PK;PK:MEAN_NORTRIPTYLINE_CONCENTRATIONS_AND_NORTRIPTYLINE_CONCENTRATIONS_PER_UNIT_DOSE_OF_THE_MEDICATION
FLECAINIDE;CYP2D6;*5/*36 + *10/*10 + *10/*36 + *21/*36;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*21, CYP2D6*36;LADME_PK;DECREASED_PK;PK:ORAL_CLEARANCE_(CL/F)_OF_FLECAINIDE_IN_PATIENTS_WITH_SUPRAVENTRICULAR_TACHYARRHYTHMIA
ANTITHYROID PREPARATIONS;HLA-DRB1;*08:03;HLA-DRB1*08:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
ANTITHYROID PREPARATIONS;HLA-DQA1;*01:03;HLA-DQA1*01:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
ANTITHYROID PREPARATIONS;HLA-DQB1;*06:01;HLA-DQB1*06:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
ANTINEOPLASTIC AGENTS;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*20, CYP2D6*35, CYP2D6*41;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
TAMOXIFEN;CYP2D6;*4/*4 + *4/*41 + *1/*5 + *2/*5;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*20, CYP2D6*35, CYP2D6*41;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY | LEUKOPENIA | TOXIC_LIVER_DISEASE,
CYTARABINE;ABCB1;CC;rs2032582;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:3_YEAR_EVENT_FREE_SURVIVAL
IDARUBICIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:3_YEAR_EVENT_FREE_SURVIVAL
CLOPIDOGREL;CYP1A2;A;rs2069514;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
OPIOIDS;OPRM1;T;rs548646;TOXICITY;DECREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_PK;PK:TROUGH_CONCENTRATIONS
NORTRIPTYLINE;CYP2D6;*10;CYP2D6*1, CYP2D6*2, CYP2D6*10;LADME_PK;INCREASED_PK;PK:NORTRIPTYLINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT
TACROLIMUS;CYP3A4;C/T + T/T;rs2242480;TOXICITY;INCREASED_RISK;DISEASE:ACUTE_CELLULAR_REJECTION
RHODAMINE 123;ABCB1;GG;rs1045642;LADME_PK;INCREASED_PK;PK:EFFLUX_OF_RHODAMINE_FROM_CD56+_NATURAL_KILLER_CELLS
ASPIRIN;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;TOXICITY;nan;SIDE_EFFECT:NEUTROPENIA | THROMBOCYTOPENIA
THIOGUANINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;TOXICITY;nan;SIDE_EFFECT:NEUTROPENIA | THROMBOCYTOPENIA
ASPIRIN;PEAR1;AC;rs2768759;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
CLOPIDOGREL;PEAR1;AC;rs2768759;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
TICAGRELOR;PEAR1;AC;rs2768759;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
LAMOTRIGINE;HLA-A;*68:01;HLA-A*68:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CELECOXIB;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:PAIN
AZATHIOPRINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5, NUDT15*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
MERCAPTOPURINE;NUDT15;*2 + *3 + *4 + *5 + *6;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5, NUDT15*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
CARBAMAZEPINE;HLA-A;*01:01;HLA-A*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
TETANUS ANTITOXIN;HLA-A;*02:06;HLA-A*02:06;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
CARBAMAZEPINE;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ACETAMINOPHEN;HLA-A;*24:02;HLA-A*24:02;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS
CARBAMAZEPINE;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
INFLIXIMAB;HLA-B;*08:01;HLA-B*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
VANCOMYCIN;HLA-A;*32:01;HLA-A*32:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
PHENYTOIN;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
NEVIRAPINE;HLA-B;*14:02;HLA-B*14:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
PHENYTOIN;HLA-B;*15:01;HLA-B*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
ANTIEPILEPTICS;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ANTIEPILEPTICS;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
PHENYTOIN;HLA-B;*15:13;HLA-B*15:13;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS | TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME,
AZATHIOPRINE;TPMT;*3A + *3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
MERCAPTOPURINE;TPMT;*3A + *3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*4 + *1/*6;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
CLINDAMYCIN;HLA-B;*15:27;HLA-B*15:27;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
NEVIRAPINE;HLA-B;*35:01;HLA-B*35:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CLOZAPINE;HLA-B;*38:01;HLA-B*38:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
LAMOTRIGINE;HLA-B;*38:01;HLA-B*38:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
SULFAMETHOXAZOLE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
TRIMETHOPRIM;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
INFLIXIMAB;HLA-B;*39:01;HLA-B*39:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CARBAMAZEPINE;HLA-B;*40:01;HLA-B*40:01;TOXICITY;DECREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
OXCARBAZEPINE;HLA-B;*40:02;HLA-B*40:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
MIRTAZAPINE;CYP2D6;*3/*4 + *4/*6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6;LADME_PK;INCREASED_PK;PK:S-MIRTAZAPINE_PLASMA_LEVELS_IN_NON-SMOKERS_AT_DAY_14_OF_TREATMENT
PHENYTOIN;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
CARBAMAZEPINE;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
NILOTINIB;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
CLINDAMYCIN;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PHENYTOIN;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
PHENYTOIN;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
ISONIAZID;HLA-B;*52:01;HLA-B*52:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
METHAZOLAMIDE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
METHAZOLAMIDE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
MIRTAZAPINE;CYP2D6;*4 + *5;CYP2D6*1, CYP2D6*4, CYP2D6*5;LADME_PK;INCREASED_PK;PK:SERUM_CONCENTRATIONS_OF_S(+)-MIRTAZAPINE | MIRTAZAPINE_S(+)/R(-)_RATIOS_AND_S(+)-N-DESMETHYLMIRTAZAPINE
OPIOIDS;OPRM1;A;rs609148;TOXICITY;DECREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
ATAZANAVIR;UGT1A1;*1/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
METHAZOLAMIDE;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CYCLOSPORINE;CYP3A4;*1/*1 + *1/*18;CYP3A4*1, CYP3A4*18;LADME_PK;INCREASED_PK;PK:TROUGH_CONCENTRATIONS
SULFAMETHOXAZOLE;HLA-C;*07:27;HLA-C*07:27;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
TRIMETHOPRIM;HLA-C;*07:27;HLA-C*07:27;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
NEVIRAPINE;HLA-C;*08:02;HLA-C*08:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
INFLIXIMAB;HLA-C;*12:03;HLA-C*12:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NO_DRUG_RELATED;HLA-DPB1;*03:01;HLA-DPB1*03:01;TOXICITY;INCREASED_RISK;DISEASE:ASPIRIN-INDUCED_ASTHMA
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
PHENYTOIN;HLA-C;*15:02;HLA-C*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
TACROLIMUS;CYP2J2;AA + AC;rs890293;TOXICITY;INCREASED_RISK;DISEASE:NAUSEA | VOMITING
CARBAMAZEPINE;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ABACAVIR;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
NEVIRAPINE;HLA-DQB1;*05:01;HLA-DQB1*05:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
FLUPIRTINE;HLA-DQB1;*05:02;HLA-DQB1*05:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
AMOXICILLIN;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATITIS
CLAVULANATE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATITIS
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
NEVIRAPINE;HLA-DRB1;*01:02;HLA-DRB1*01:02;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
HYDRALAZINE;HLA-DRB1;*04:01;HLA-DRB1*04:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LUPUS_ERYTHEMATOSUS_DUE_TO_HYDRALAZINE
OXCARBAZEPINE;HLA-DRB1;*04:03;HLA-DRB1*04:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
ABACAVIR;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
ASPARAGINASE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERSENSITIVITY
LAPATINIB;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PEGINTERFERON ALFA-2A;nan;AA;rs4969170;TOXICITY;DECREASED_RISK;DISEASE:THROMBOCYTOPENIA
PEGINTERFERON ALFA-2B;nan;AA;rs4969170;TOXICITY;DECREASED_RISK;DISEASE:THROMBOCYTOPENIA
RIBAVIRIN;nan;AA;rs4969170;TOXICITY;DECREASED_RISK;DISEASE:THROMBOCYTOPENIA
PRAVASTATIN;LDLR;G;rs2738466;EFFICACY;INCREASED_RISK;DISEASE:CORONARY_DISEASE
LAMOTRIGINE;HLA-DRB1;*13:01;HLA-DRB1*13:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
FLUPIRTINE;HLA-DRB1;*16:01;HLA-DRB1*16:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
THALIDOMIDE;GSTT1;AA;rs4630;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY
MINOCYCLINE;HLA-B;*35:02;HLA-B*35:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PHENYTOIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;LADME_PK;DECREASED_PK;PK:DOSE
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROTHROMBIN_TIME_(PT)_AT_INDUCTION
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*1, CYP2C8*3;TOXICITY;DECREASED;SIDE_EFFECT:WEIGHT_GAIN
TACROLIMUS;CYP2C8;*3;CYP2C8*1, CYP2C8*3;TOXICITY;INCREASED_RISK;DISEASE:KIDNEY_DISORDER
CALCINEURIN INHIBITORS;CYP2C8;*3;CYP2C8*1, CYP2C8*3;TOXICITY;INCREASED_RISK;DISEASE:KIDNEY_DISORDER
CYCLOSPORINE;CYP2C8;*3;CYP2C8*1, CYP2C8*3;TOXICITY;INCREASED_RISK;DISEASE:KIDNEY_DISORDER
TACROLIMUS;CYP2C8;*3;CYP2C8*1, CYP2C8*3;TOXICITY;INCREASED_RISK;DISEASE:KIDNEY_DISORDER
ASPIRIN;CYP2C19;*2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
CILOSTAZOL;CYP2C19;*2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE | OVER-ANTICOAGULATION
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE | OVER-ANTICOAGULATION
WARFARIN;CYP2C9;*3/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
PACLITAXEL;NAT2;AA;rs1799931;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PLATINUM COMPOUNDS;NAT2;AA;rs1799931;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CAFFEINE;CYP1A2;nan;CYP1A2 low activity;OTHER;INCREASED;OTHER:INTAKE
HMG COA REDUCTASE INHIBITORS;GNB3;CT + TT;rs5443;EFFICACY;DECREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
NO_DRUG_RELATED;HMGCR;AA;rs3846662;OTHER;DECREASED;OTHER:HMGCRV_1_EXPRESSION_AND_AN_INCREASE_IN_THE_EXPRESSION_OF_THE_FULL-LENGTH_TRANSCRIPT
ATAZANAVIR;UGT1A1;*28;UGT1A1*28;LADME_PK;nan;DISEASE:HYPERBILIRUBINEMIA
RITONAVIR;UGT1A1;*28;UGT1A1*28;LADME_PK;nan;DISEASE:HYPERBILIRUBINEMIA
ACYCLOVIR;NUDT15;*2/*2 +*2/*3 +*3/*3 + *5/*5;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PRIMARY_GRAFT_FAILURE
METHOTREXATE;SLCO1B1;*15;SLCO1B1*15;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA
CAFFEINE;ADORA2A;T/del + TT;rs35320474;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:BRONCHOPULMONARY_DYSPLASIA
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;EFFICACY;EFFICACY;EFFICACY:HIGHER_MEAN_PEAK_INR_DURING_WEEK_1_OF_WARFARIN_THERAPY
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;EFFICACY;EFFICACY;EFFICACY:HIGHER_MEAN_PEAK_INR_DURING_WEEK_1_OF_WARFARIN_THERAPY
NO_DRUG_RELATED;DHFR;del/del;rs70991108;OTHER;INCREASED;OTHER:SERUM_AND_RED_BLOOD_CELL_FOLATE_CONCENTRATIONS
CISPLATIN;UGT1A1;AA;rs4148323;TOXICITY;INCREASED;DISEASE:NEUTROPENIA
IRINOTECAN;UGT1A1;AA;rs4148323;TOXICITY;INCREASED;DISEASE:NEUTROPENIA
FLUOXETINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:DEPRESSION
FLUOXETINE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ANXIETY_DISORDERS
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*1, CYP2A6*9, CYP2A6*17, CYP2A6*20, CYP2A6*24, CYP2A6*26, CYP2A6*27;OTHER;DECREASED_PK;PK:METABOLISM
NICOTINE;CYP2A6;*20 + *26 + *24+ *9 + *27 + *17;CYP2A6*1, CYP2A6*9, CYP2A6*17, CYP2A6*20, CYP2A6*24, CYP2A6*26, CYP2A6*27;LADME_PK;DECREASED_PK;PK:METABOLISM
COCAINE;OPRM1;A;rs3823010;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE | COCAINE_DEPENDENCE | OPIOID-RELATED_DISORDERS
ETHANOL;OPRM1;A;rs3823010;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE | COCAINE_DEPENDENCE | OPIOID-RELATED_DISORDERS
OPIOIDS;OPRM1;A;rs3823010;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE | COCAINE_DEPENDENCE | OPIOID-RELATED_DISORDERS
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
FOLFOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
XELOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
COCAINE;OPRM1;G;rs495491;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE | COCAINE_DEPENDENCE | OPIOID-RELATED_DISORDERS
ETHANOL;OPRM1;G;rs495491;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE | COCAINE_DEPENDENCE | OPIOID-RELATED_DISORDERS
OPIOIDS;OPRM1;G;rs495491;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE | COCAINE_DEPENDENCE | OPIOID-RELATED_DISORDERS
INTERFERON BETA-1A;HLA-DQA1;G;rs9272105;EFFICACY;INCREASED_EFFICACY;EFFICACY:ANTI-IFN-BETA_ANTIBODIES
INTERFERON BETA-1B;HLA-DQA1;G;rs9272105;EFFICACY;INCREASED_EFFICACY;EFFICACY:ANTI-IFN-BETA_ANTIBODIES
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
FOLFOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
XELOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
REPAGLINIDE;SLCO1B1;*37/*37;SLCO1B1*1, SLCO1B1*5, SLCO1B1*15, SLCO1B1*37;LADME_PK;DECREASED_PK;PK:REPAGLINIDE_EXPOSURE_(DECREASED_AUC_AND_INCREASED_CLEARANCE)
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
EGFR INHIBITORS;EGFR;A;rs2227983;EFFICACY;EFFICACY;EFFICACY:CYTOTOXICITY
ATAZANAVIR;UGT1A1;*28/*28 + *1/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
RITONAVIR;UGT1A1;*28/*28 + *1/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
NEVIRAPINE;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
INTERFERON BETA-1A;nan;G;rs4961252;EFFICACY;INCREASED_EFFICACY;EFFICACY:ANTI-IFN-BETA_ANTIBODIES
INTERFERON BETA-1B;nan;G;rs4961252;EFFICACY;INCREASED_EFFICACY;EFFICACY:ANTI-IFN-BETA_ANTIBODIES
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PEGASPARGASE;HLA-DRB1;*16:02;HLA-DRB1*16:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ASPARAGINASE;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CNS_RELAPSE | HEMATOLOGIC_RELAPSE
ASPARAGINASE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CNS_RELAPSE | HEMATOLOGIC_RELAPSE
CYTARABINE;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CNS_RELAPSE | HEMATOLOGIC_RELAPSE
CYTARABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CNS_RELAPSE | HEMATOLOGIC_RELAPSE
DAUNORUBICIN;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CNS_RELAPSE | HEMATOLOGIC_RELAPSE
DAUNORUBICIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CNS_RELAPSE | HEMATOLOGIC_RELAPSE
ETOPOSIDE;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CNS_RELAPSE | HEMATOLOGIC_RELAPSE
ETOPOSIDE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CNS_RELAPSE | HEMATOLOGIC_RELAPSE
MERCAPTOPURINE;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CNS_RELAPSE | HEMATOLOGIC_RELAPSE
MERCAPTOPURINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CNS_RELAPSE | HEMATOLOGIC_RELAPSE
METHOTREXATE;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CNS_RELAPSE | HEMATOLOGIC_RELAPSE
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CNS_RELAPSE | HEMATOLOGIC_RELAPSE
PREDNISONE;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CNS_RELAPSE | HEMATOLOGIC_RELAPSE
PREDNISONE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CNS_RELAPSE | HEMATOLOGIC_RELAPSE
VINCRISTINE;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CNS_RELAPSE | HEMATOLOGIC_RELAPSE
VINCRISTINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CNS_RELAPSE | HEMATOLOGIC_RELAPSE
METHOTREXATE;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
GEMCITABINE;RRM1;G;rs9937;TOXICITY;DECREASED_RISK;DISEASE:NEUTROPENIA
NO_DRUG_RELATED;ACE;del/del;rs1799752;OTHER;INCREASED_SEVERITY;OTHER:COVID-19
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;PD;DECREASED_LIKELIHOOD;OTHER:TIME_TO_THERAPEUTIC_INR
ETHANOL;OPRM1;T;rs1381376;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE
NEVIRAPINE;HLA-B;*35:01;HLA-B*35:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
PEGASPARGASE;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
PEGASPARGASE;HLA-DQB1;*02:02;HLA-DQB1*02:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
PEGASPARGASE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
METHOTREXATE;DHFR;TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;rs70991108;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:LEUKOPENIA
METHOTREXATE;MSH3;TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;rs70991108;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:LEUKOPENIA
METHOTREXATE;ENOSF1;TTA/TTA + TTA/TTAAAGTTA;rs11280056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
METHOTREXATE;TYMS;TTA/TTA + TTA/TTAAAGTTA;rs11280056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
NO_DRUG_RELATED;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED_LIKELIHOOD;OTHER:COVID-19
CYCLOSPORINE;ABCB1;GG;rs1128503;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TRANSPLANT_REJECTION
TACROLIMUS;ABCB1;GG;rs1128503;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TRANSPLANT_REJECTION
NO_DRUG_RELATED;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED_SEVERITY;OTHER:COVID-19
AMITRIPTYLINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_EMERGENT_MANIA
CLOMIPRAMINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_EMERGENT_MANIA
NO_DRUG_RELATED;ACE;del;rs1799752;OTHER;INCREASED_LIKELIHOOD;OTHER:COVID-19
ASPIRIN;nan;A;rs1050450;OTHER;INCREASED_RISK;OTHER:IN-STENT_RESTENOSIS
BETA BLOCKING AGENTS;nan;A;rs1050450;OTHER;INCREASED_RISK;OTHER:IN-STENT_RESTENOSIS
CLOPIDOGREL;nan;A;rs1050450;OTHER;INCREASED_RISK;OTHER:IN-STENT_RESTENOSIS
HMG COA REDUCTASE INHIBITORS;nan;A;rs1050450;OTHER;INCREASED_RISK;OTHER:IN-STENT_RESTENOSIS
NO_DRUG_RELATED;ACE;del/del;rs1799752;OTHER;INCREASED_RISK;OTHER:DEATH
SERTRALINE;CYP2C19;*2/*2 + *2/*1 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_EMERGENT_MANIA
MERCAPTOPURINE;NUDT15;*1/*2 + *1/*3 + *1/*5 + *1/*6;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
CLOPIDOGREL;CYP2C19;nan;CYP2C19 poor metabolizers and intermediate metabolizers;TOXICITY;DECREASED;SIDE_EFFECT:HEMORRHAGE
LEFLUNOMIDE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
ANAKINRA;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
CANAKINUMAB;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
RILONACEPT;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
TOCILIZUMAB;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
PEGINTERFERON ALFA-2A;IFNL4;GG;rs11322783;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_FAILURE_TO_PEGYLATED_INTERFERON-ALPHA/RIBAVIRIN_THERAPY_IN_HCV/HIV-1_COINFECTED_PATIENTS
PEGINTERFERON ALFA-2B;IFNL4;GG;rs11322783;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_FAILURE_TO_PEGYLATED_INTERFERON-ALPHA/RIBAVIRIN_THERAPY_IN_HCV/HIV-1_COINFECTED_PATIENTS
RIBAVIRIN;IFNL4;GG;rs11322783;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_FAILURE_TO_PEGYLATED_INTERFERON-ALPHA/RIBAVIRIN_THERAPY_IN_HCV/HIV-1_COINFECTED_PATIENTS
NORTRIPTYLINE;CYP2D6;*3;CYP2D6*1, CYP2D6*3;LADME_PK;INCREASED_PK;PK:APPARENT_TERMINAL_ELIMINATION_HALF-LIFE
FLUCLOXACILLIN;HLA-B;*57:03;HLA-B*57:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CISPLATIN;TPMT;*3B + *3C;TPMT*1, TPMT*3B, TPMT*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OTOTOXICITY
PREDNISONE;ABCB1;GG;rs1045642;EFFICACY;INCREASED_RISK;OTHER:REMAINING_ON_STEROIDS_AT_1_YEAR_AFTER_TRANSPLANTATION
TACROLIMUS;ABCB1;GG;rs1045642;EFFICACY;INCREASED_RISK;OTHER:REMAINING_ON_STEROIDS_AT_1_YEAR_AFTER_TRANSPLANTATION
CARBAMAZEPINE;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
FLUCLOXACILLIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
ATAZANAVIR;CYP3A5;*1/*3 + *1/*1;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_PK;PK:ORAL_CLEARANCE_(CL)_OF_ATAZANAVIR
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *1/*2;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:FEBRILE_NEUTROPENIA
ANTIINFLAMMATORY AGENTS;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_HEMORRHAGE
NON-STEROIDS;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_HEMORRHAGE
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
EGFR INHIBITORS;EGFR;T;rs712829;TOXICITY;EFFICACY;EFFICACY:CYTOTOXICITY
ANTINEOPLASTIC AGENTS;TYMS;TTA;rs11280056;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
CARBAMAZEPINE;HLA-A;*74:01;HLA-A*74:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;HLA-A;*24:07;HLA-A*24:07;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
AZATHIOPRINE;TPMT;*1/*3A;TPMT*1, TPMT*2, TPMT*3A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LOW_LEUKOCYTE_COUNTS
AZATHIOPRINE;TPMT;*1/*1;TPMT*1, TPMT*2, TPMT*3A;EFFICACY;INCREASED_EFFICACY;EFFICACY:TREATMENT_DURATION
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
CLOPIDOGREL;CYP2C19;*4;CYP2C19*1, CYP2C19*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
ATAZANAVIR;UGT1A1;*28;UGT1A1*28;TOXICITY;INCREASED_RISK;DISEASE:HYPERBILIRUBINEMIA
ATORVASTATIN;APOE;CC + CT;rs429358;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_C-REACTIVE_PROTEIN_(CRP)
PRAVASTATIN;APOE;CC + CT;rs429358;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_C-REACTIVE_PROTEIN_(CRP)
CLOZAPINE;GSTM1;null/null;GSTM1 non-null, GSTM1 null;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:THROMBOTIC_DISEASE | SUDDEN_CARDIAC_DEATH | MYOCARDIAL_INFARCTION,
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:THROMBOTIC_DISEASE | SUDDEN_CARDIAC_DEATH | MYOCARDIAL_INFARCTION,
OPIOIDS;OPRM1;AA;rs1799971;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
TAMOXIFEN;CYP2D6;*4/*5;CYP2D6*4, CYP2D6*5;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
TAMOXIFEN;CYP2D6;*4/*7;CYP2D6*4, CYP2D6*7;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
TRAMADOL;CYP2D6;POOR_METABOLIZER;CYP2D6;EFFICACY;DECREASED_EFFICACY;EFFICACY:METABOLISM_OF_TRAMADOL_AND_DECREASED_RESPONSE_TO_TRAMADOL
TRAMADOL;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;DECREASED_EFFICACY;EFFICACY:METABOLISM_OF_TRAMADOL_AND_DECREASED_RESPONSE_TO_TRAMADOL
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
TAMOXIFEN;CYP2D6;*4/*6;CYP2D6*4, CYP2D6*6;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CARBAMAZEPINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS
CARBAMAZEPINE;HLA-DRB1;*12:02;HLA-DRB1*12:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
CARBAMAZEPINE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;OTHER:INTRAGASTRIC_PH
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
CARBAMAZEPINE;HLA-B;*46:01;HLA-B*46:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
NORTRIPTYLINE;CYP2D6;*5;CYP2D6*1, CYP2D6*5;LADME_PK;INCREASED_PK;PK:APPARENT_TERMINAL_ELIMINATION_HALF-LIFE
CARBAMAZEPINE;HLA-DRB1;*09:01;HLA-DRB1*09:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
CARBAMAZEPINE;HLA-DQA1;*03:02;HLA-DQA1*03:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
TICAGRELOR;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION_INHIBITION
EFAVIRENZ;HLA-DRB1;*08:03;HLA-DRB1*08:03;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
EFAVIRENZ;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
NEVIRAPINE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
TAMOXIFEN;CYP2D6;*4/*11;CYP2D6*4, CYP2D6*11;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CYCLOSPORINE;ABCB1;AA;rs1128503;DOSAGE;INCREASED_PK;PK:TROUGH_BLOOD_CONCENTRATION
CYCLOSPORINE;ABCB1;AA;rs1128503;LADME_PK;INCREASED_PK;PK:TROUGH_BLOOD_CONCENTRATION
NO_DRUG_RELATED;TMPRSS2;CC;rs383510;OTHER;INCREASED_LIKELIHOOD;OTHER:COVID-19
LAPATINIB;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
TAMOXIFEN;CYP2D6;*3/*4;CYP2D6*3, CYP2D6*4;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
FLUVASTATIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
NORTRIPTYLINE;CYP2D6;*4;CYP2D6*1, CYP2D6*4;LADME_PK;INCREASED_PK;PK:APPARENT_TERMINAL_ELIMINATION_HALF-LIFE
TAMOXIFEN;CYP2D6;*3/*5;CYP2D6*3, CYP2D6*5;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
ATAZANAVIR;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28, UGT1A1*36;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
RITONAVIR;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28, UGT1A1*36;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
CYCLOSPORINE;ABCB1;AA;rs2032582;DOSAGE;INCREASED_PK;PK:TROUGH_BLOOD_CONCENTRATION
CYCLOSPORINE;ABCB1;AA;rs2032582;LADME_PK;INCREASED_PK;PK:TROUGH_BLOOD_CONCENTRATION
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
SERTRALINE;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;LADME_PK;INCREASED_PK;PK:MEAN_SERUM_CONCENTRATIONS_OF_SERTRALINE_AND_N-DESMETHYL_SERTRALINE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;INCREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
METHADONE;CYP3A4;G;rs2246709;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SIDE_EFFECTS
FLUVOXAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*1, CYP2D6*5, CYP2D6*10;LADME_PK;INCREASED_PK;PK:FLUVOXAMINE_PLASMA_CONCENTRATIONS
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*4;CYP2C19*1, CYP2C19*2, CYP2C19*4;LADME_PK;INCREASED_PK;PK:AREA_UNDER_THE_TIME-PLASMA_CONCENTRATION_CURVE_(AUC(0-24))
PRAVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;DECREASED_RISK;DISEASE:CORONARY_DISEASE
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
METHAZOLAMIDE;HLA-B;*55:02;HLA-B*55:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
METHAZOLAMIDE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
ACETAMINOPHEN;CYP2D6;*1/*1;CYP2D6*1;EFFICACY;PK;PK:INHIBITION_OF_METABOLISM
ACETAMINOPHEN;CYP2D6;*1/*1;CYP2D6*1;LADME_PK;PK;PK:INHIBITION_OF_METABOLISM
CODEINE;CYP2D6;*1/*1;CYP2D6*1;EFFICACY;PK;PK:INHIBITION_OF_METABOLISM
CODEINE;CYP2D6;*1/*1;CYP2D6*1;LADME_PK;PK;PK:INHIBITION_OF_METABOLISM
LEVOMEPROMAZINE;CYP2D6;*1/*1;CYP2D6*1;EFFICACY;PK;PK:INHIBITION_OF_METABOLISM
LEVOMEPROMAZINE;CYP2D6;*1/*1;CYP2D6*1;LADME_PK;PK;PK:INHIBITION_OF_METABOLISM
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS
METHADONE;CYP3A4;T;rs2242480;OTHER;INCREASED_SEVERITY;SIDE_EFFECT:OPIOID_WITHDRAWAL_SYMPTOMS
DOCETAXEL;RPL13;G;rs12960;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
DOCETAXEL;SNORD68;G;rs12960;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
DOCETAXEL;SPG7;G;rs12960;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
THALIDOMIDE;RPL13;G;rs12960;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
THALIDOMIDE;SNORD68;G;rs12960;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
THALIDOMIDE;SPG7;G;rs12960;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
DOCETAXEL;CHST3;A;rs1871450;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
THALIDOMIDE;CHST3;A;rs1871450;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
CLOPIDOGREL;CYP2C19;*1/*2+ *2/*2+ *1/*3 + *3/*3 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CITALOPRAM;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;LADME_PK;INCREASED_PK;PK:METABOLIC_RATIO_CIT/DCIT_VALUES_AND_MEAN_CITALOPRAM_DOSE
PEGINTERFERON ALFA-2B;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);TOXICITY;DECREASED_RISK;DISEASE:DEPRESSION
RIBAVIRIN;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);TOXICITY;DECREASED_RISK;DISEASE:DEPRESSION
METHADONE;CYP3A4;A;rs4646440;OTHER;INCREASED_SEVERITY;SIDE_EFFECT:OPIOID_WITHDRAWAL_SYMPTOMS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *1/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:ADVERSE_CARDIOVASCULAR_EVENTS
CARBAMAZEPINE;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ETHANOL;OPRM1;T;rs511435;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE | OPIOID-RELATED_DISORDERS
OPIOIDS;OPRM1;T;rs511435;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE | OPIOID-RELATED_DISORDERS
DOCETAXEL;NAT2;G;rs1799931;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
THALIDOMIDE;NAT2;G;rs1799931;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
ESCITALOPRAM;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*17;LADME_PK;DECREASED_PK;PK:MEAN_LOGARITHM_ESCITALOPRAM_CONCENTRATION
DOCETAXEL;CYP4B1;T;rs4646487;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
THALIDOMIDE;CYP4B1;T;rs4646487;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
SULFAMETHOXAZOLE;HLA-B;*07:02;HLA-B*07:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:RESPIRATORY_INSUFFICIENCY
TRIMETHOPRIM;HLA-B;*07:02;HLA-B*07:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:RESPIRATORY_INSUFFICIENCY
SULFAMETHOXAZOLE;HLA-C;*07:02;HLA-C*07:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:RESPIRATORY_INSUFFICIENCY
TRIMETHOPRIM;HLA-C;*07:02;HLA-C*07:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:RESPIRATORY_INSUFFICIENCY
SULFAMETHOXAZOLE;GSTM1;null/null;GSTM1 null;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
TRIMETHOPRIM;GSTM1;null/null;GSTM1 null;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
OLANZAPINE;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:FATIGUE
FOLFIRINOX;UGT1A1;*1/*6 + *1/*28 + *6/*28 + *6/*6 + *28/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:FEBRILE_NEUTROPENIA
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
METHOTREXATE;DHFR;GGGAGCTGG/del + del/del;rs3045983;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
OPIOIDS;OPRM1;CC;rs589046;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_PK;PK:METABOLIC_RATIO_(DEFINED_AS_RATIO_OF_OMEPRAZOLE_TO_ITS_METABOLITES)_OF_5-HYDROXYOMEPRAZOLE | R-5-HYDROXYOMEPRAZOLE_AND_S-5-HYDROXYOMEPRAZOLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_PK;PK:METABOLIC_RATIO_(DEFINED_AS_RATIO_OF_OMEPRAZOLE_TO_ITS_METABOLITES)_OF_5-HYDROXYOMEPRAZOLE | R-5-HYDROXYOMEPRAZOLE_AND_S-5-HYDROXYOMEPRAZOLE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;DECREASED;SIDE_EFFECT:LEUKOCYTES_AND_NEUTROPHILS
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_PK;PK:METABOLIC_RATIO_(DEFINED_AS_RATIO_OF_OMEPRAZOLE_TO_ITS_METABOLITES)_OF_5-HYDROXYOMEPRAZOLE_AND_R-5-HYDROXYOMEPRAZOLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_PK;PK:METABOLIC_RATIO_(DEFINED_AS_RATIO_OF_OMEPRAZOLE_TO_ITS_METABOLITES)_OF_5-HYDROXYOMEPRAZOLE_AND_R-5-HYDROXYOMEPRAZOLE
AMITRIPTYLINE;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;LADME_PK;INCREASED_PK;PK:AMITRIPTYLINE/NORTRIPTYLINE_RATIO_CORRECTED_FOR_DOSE_AND_WEIGHT
ALPRAZOLAM;CYP3A4;nan;CYP3A4 low activity;EFFICACY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
ASPIRIN;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
PACLITAXEL;CYP3A4;*1/*8 + *1/*20;CYP3A4*1, CYP3A4*8, CYP3A4*20;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES | TREATMENT_MODIFICATION
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CARBAMAZEPINE;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
DOCETAXEL;VEGFA;del/del;rs144854329;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
WARFARIN;CYP2C9;*3/*3 + *3/*2 + *2/*3;CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_PK;PK:UNBOUND_ORAL_CLEARANCE_FOR_S-WARFARIN
CITALOPRAM;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;TOXICITY;DECREASED;SIDE_EFFECT:ADVERSE_EFFECT_BURDEN
AZATHIOPRINE;NUDT15;*1/*3 + *3/*3 + *1/*6;NUDT15*1, NUDT15*3, NUDT15*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
MERCAPTOPURINE;NUDT15;*1/*3 + *3/*3 + *1/*6;NUDT15*1, NUDT15*3, NUDT15*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
WARFARIN;CYP2C9;*2/*3 + *3/*3 + *2/*2;CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
HALOPERIDOL;CYP2D6;*1/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
HMG COA REDUCTASE INHIBITORS;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
NO_DRUG_RELATED;HLA-DPB1;*04:01;HLA-DPB1*04:01;TOXICITY;DECREASED_RISK;DISEASE:ASPIRIN-INDUCED_ASTHMA
CARBOPLATIN;DPYD;Reference;DPYD Reference;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL | OVERALL_SURVIVAL
CISPLATIN;DPYD;Reference;DPYD Reference;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL | OVERALL_SURVIVAL
METHAMPHETAMINE;DAOA;T;rs947267;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
OXCARBAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
PHENOBARBITAL;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
TRAMADOL;CYP2D6;*10/*10 + *5/*10 + *36;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*10x2, CYP2D6*36;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_PK;PK:AREA_UNDER_CURVE_(AUC)_OF_OMEPRAZOLE_RACEMATE | OMEPRAZOLE_SULFONE | R-OMEPRAZOLE_AND_S-OMEPRAZOLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_PK;PK:AREA_UNDER_CURVE_(AUC)_OF_OMEPRAZOLE_RACEMATE | OMEPRAZOLE_SULFONE | R-OMEPRAZOLE_AND_S-OMEPRAZOLE
TACROLIMUS;CYP3A5;TT;rs776746;DOSAGE;nan;OTHER:HIGHER_STABLE_DOSE_LEVELS
TACROLIMUS;CYP3A5;TT;rs776746;LADME_PK;nan;OTHER:HIGHER_STABLE_DOSE_LEVELS
METHAMPHETAMINE;OPRM1;C;rs2075572;TOXICITY;DECREASED_RISK;OTHER:METHAMPHETAMINE_DEPENDENCE
ACETAMINOPHEN;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS
ACETAMINOPHEN;HLA-A;*02:06;HLA-A*02:06;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS
ACETAMINOPHEN;HLA-B;*44:03;HLA-B*44:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_PK;PK:AREA_UNDER_CURVE_(AUC)_OF_OMEPRAZOLE_RACEMATE | OMEPRAZOLE_SULFONE | R-OMEPRAZOLE_AND_S-OMEPRAZOLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_PK;PK:AREA_UNDER_CURVE_(AUC)_OF_OMEPRAZOLE_RACEMATE | OMEPRAZOLE_SULFONE | R-OMEPRAZOLE_AND_S-OMEPRAZOLE
ACETAMINOPHEN;HLA-C;*14:03;HLA-C*14:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED_RISK;DISEASE:THROMBOTIC_DISEASE
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;TOXICITY;INCREASED_RISK;DISEASE:THROMBOTIC_DISEASE
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
TAMOXIFEN;CYP2D6;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*33, TPMT*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA | THROMBOCYTOPENIA
THIOGUANINE;TPMT;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*33, TPMT*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA | THROMBOCYTOPENIA
METHADONE;CYP3A4;A;rs2246709;OTHER;DECREASED_SEVERITY;SIDE_EFFECT:OPIOID_WITHDRAWAL_SYMPTOMS
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED_EFFICACY;EFFICACY:CLOPI-H4_CONCENTRATIONS_AFTER_300_OR_900_MG_CLOPIDOGREL_LOADING_DOSE
ATORVASTATIN;APOE;CT + TT;rs7412;EFFICACY;INCREASED_EFFICACY;EFFICACY:PERCENT_REDUCTION_IN_LDL-CHOLESTEROL
PRAVASTATIN;APOE;CT + TT;rs7412;EFFICACY;INCREASED_EFFICACY;EFFICACY:PERCENT_REDUCTION_IN_LDL-CHOLESTEROL
ATORVASTATIN;SLCO1B1;*5;SLCO1B1*1, SLCO1B1*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PRAVASTATIN;SLCO1B1;*5;SLCO1B1*1, SLCO1B1*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
SIMVASTATIN;SLCO1B1;*5;SLCO1B1*1, SLCO1B1*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS;UGT1A1;*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
COMBINATIONS;UGT1A1;*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
ATENOLOL;GRK5;AT + TT;rs2230345;OTHER;DECREASED_RISK;OTHER:ADVERSE_CARDIOVASCULAR_OUTCOMES
HYDROCHLOROTHIAZIDE;GRK5;AT + TT;rs2230345;OTHER;DECREASED_RISK;OTHER:ADVERSE_CARDIOVASCULAR_OUTCOMES
TRANDOLAPRIL;GRK5;AT + TT;rs2230345;OTHER;DECREASED_RISK;OTHER:ADVERSE_CARDIOVASCULAR_OUTCOMES
VERAPAMIL;GRK5;AT + TT;rs2230345;OTHER;DECREASED_RISK;OTHER:ADVERSE_CARDIOVASCULAR_OUTCOMES
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_CARDIOVASCULAR_EVENTS
METHAMPHETAMINE;BDNF;CC;rs6265;TOXICITY;DECREASED_SEVERITY;OTHER:METHAMPHETAMINE_DEPENDENCE
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
TACROLIMUS;ABCB1;GG;rs1045642;EFFICACY;INCREASED_LIKELIHOOD;DISEASE:DELAYED_GRAFT_FUNCTION
TACROLIMUS;ABCB1;GG;rs1045642;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:DELAYED_GRAFT_FUNCTION
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*4;NAT2*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ANTICHOLINERGIC AGENTS;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;INCREASED_PK;PK:SERUM_ANTICHOLINERGIC_ACTIVITY
ANTIEPILEPTICS;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_PK;PK:FORMATION_OF_METABOLITES
AZATHIOPRINE;NUDT15;*2 + *3 + *5 + *6;NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA | DRUG_TOXICITY
NO_DRUG_RELATED;GSTT1;nan;GSTT1 non-null, GSTT1 null;OTHER;INCREASED_LIKELIHOOD;OTHER:ASTHMA
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
NO_DRUG_RELATED;GSTM1;nan;GSTM1 non-null, GSTM1 null;OTHER;INCREASED_LIKELIHOOD;OTHER:ASTHMA
METHAMPHETAMINE;DAOA;A;rs2391191;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6 + *4/*6 + *5/*6;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*22;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
CYCLOPHOSPHAMIDE;CYP2B6;*1/*1 + *1/*5 + *1/*4 + *1/*22;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*22;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION
IRINOTECAN;HLA-DQB3;C;rs2859101;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
CYCLOSPORINE;MTHFR;GG;rs3737967;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
METHOTREXATE;MTHFR;GG;rs3737967;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
ANTIDEPRESSANTS;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_PK;PK:PLASMA_CONCENTRATIONS
CYCLOPHOSPHAMIDE;PIK3R2;T;rs55633228;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;PIK3R2;T;rs55633228;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;PIK3R2;T;rs55633228;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
CARBOPLATIN;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
DEXAMETHASONE;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
ETOPOSIDE;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
IRINOTECAN;UGT1A1;*6;UGT1A1*6;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
SULFASALAZINE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
AZATHIOPRINE;NUDT15;GGAGTC;rs746071566;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PANCYTOPENIA | THROMBOCYTOPENIA
MERCAPTOPURINE;NUDT15;GGAGTC;rs746071566;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PANCYTOPENIA | THROMBOCYTOPENIA
CYCLOSPORINE;MTHFR;CC;rs2274976;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
METHOTREXATE;MTHFR;CC;rs2274976;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
NO_DRUG_RELATED;G6PD;T;rs1050828;nan;INCREASED;OTHER:PROTECTION_AGAINST_SEVERE_MALARIA
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*4;EFFICACY;INCREASED_LIKELIHOOD;DISEASE:BREAST_NEOPLASMS
CYCLOPHOSPHAMIDE;PERP;T;rs117101815;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;PERP;T;rs117101815;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;PERP;T;rs117101815;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
AZATHIOPRINE;TPMT;*3A + *3B + *3C;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
CISPLATIN;ERCC1;GG;rs11615;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:NEPHROTOXICITY
ATAZANAVIR;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28, UGT1A1*36;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:JAUNDICE
RITONAVIR;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28, UGT1A1*36;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:JAUNDICE
PRAVASTATIN;SLCO1B1;*15/*15;SLCO1B1*15, SLCO1B1*37;LADME_PK;INCREASED_PK;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)
CAPECITABINE;DPYD;nan;DPYD low activity;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY | TREATMENT_MODIFICATION
FLUOROURACIL;DPYD;nan;DPYD low activity;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY | TREATMENT_MODIFICATION
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1, CYP2C9*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
CISPLATIN;GSTM1;null/null;GSTM1 non-null, GSTM1 null;EFFICACY;DECREASED_LIKELIHOOD;OTHER:DEATH | RECURRENCE
RADIOTHERAPY;GSTM1;null/null;GSTM1 non-null, GSTM1 null;EFFICACY;DECREASED_LIKELIHOOD;OTHER:DEATH | RECURRENCE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*3 + *1/*3 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_IN_THERAPEUTIC_RANGE
ANTIDEPRESSANTS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;OTHER:USE
ANTIEPILEPTICS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;OTHER:USE
BETA BLOCKING AGENTS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;OTHER:USE
CALCIUM CHANNEL BLOCKERS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;OTHER:USE
ANTIDEPRESSANTS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;OTHER:USE
ANTIEPILEPTICS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;OTHER:USE
BETA BLOCKING AGENTS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;OTHER:USE
CALCIUM CHANNEL BLOCKERS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;DECREASED;OTHER:USE
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_PK;PK:C/D_RATIO
TACROLIMUS;CYP3A5;*1;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:ACUTE_CELLULAR_REJECTION
IRINOTECAN;DPYD;T;rs1042482;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
PAZOPANIB;UGT1A1;*28 + *37 + *6;UGT1A1*6, UGT1A1*28, UGT1A1*37;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
METHADONE;CYP3A4;A;rs4646440;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SIDE_EFFECTS
WARFARIN;VKORC1;CC;rs9923231;OTHER;INCREASED_LIKELIHOOD;OTHER:HAVING_WARFARIN_DOSE_GREATER_THAN_7.5_MG/DAY
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
CYCLOPHOSPHAMIDE;PPP2R5D;C;rs3805945;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;PPP2R5D;C;rs3805945;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;PPP2R5D;C;rs3805945;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:STROKE
ATAZANAVIR;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*1, UGT1A1*28, UGT1A1*36, UGT1A1*37;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:HYPERBILIRUBINEMIA
RITONAVIR;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*1, UGT1A1*28, UGT1A1*36, UGT1A1*37;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:HYPERBILIRUBINEMIA
LAMIVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*1, UGT1A1*28, UGT1A1*36, UGT1A1*37;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:HYPERBILIRUBINEMIA
ZIDOVUDINE;UGT1A1;*1/*36 + *28/*36 + *36/*37 + *1/*1;UGT1A1*1, UGT1A1*28, UGT1A1*36, UGT1A1*37;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:HYPERBILIRUBINEMIA
CYCLOPHOSPHAMIDE;CCNK;G;rs77769901;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;CCNK;G;rs77769901;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;CCNK;G;rs77769901;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CARBAMAZEPINE;SCN1A;TT;rs3812718;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DISCONTINUATION
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SIMEPREVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_BUT_NOT_MINOR_HEMORRHAGE
NO_DRUG_RELATED;CHRNB2;GG;rs2072661;nan;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_BUT_NOT_MINOR_HEMORRHAGE
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
ROSIGLITAZONE;PLIN1;CT + TT;rs894160;TOXICITY;DECREASED;SIDE_EFFECT:WEIGHT_GAIN
PLATINUM;nan;T;rs836554;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CYCLOSPORINE;ABCC1;GG + GT;rs17264736;EFFICACY;DECREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
METHOTREXATE;ABCC1;GG + GT;rs17264736;EFFICACY;DECREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
METHADONE;CYP2B6;*6;CYP2B6*6;TOXICITY;INCREASED_SEVERITY;DISEASE:PAIN
OXCARBAZEPINE;HLA-B;*15:01;HLA-B*15:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
NO_DRUG_RELATED;LRP5;T;rs3736228;nan;INCREASED_RISK;OTHER:OSTEOPOROTIC_FRACTURE
CYCLOPHOSPHAMIDE;PIK3R2;A;rs118129530;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;PIK3R2;A;rs118129530;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;PIK3R2;A;rs118129530;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CITALOPRAM;CYP2D6;*1/*4;CYP2D6*1, CYP2D6*4;LADME_PK;INCREASED_PK;PK:AUC_OF_CITALOPRAM
CYCLOPHOSPHAMIDE;PIK3R2;T;rs148013902;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;PIK3R2;T;rs148013902;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;PIK3R2;T;rs148013902;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
DRUGS USED IN NICOTINE DEPENDENCE;COMT;AA;rs4680;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:TRANSPLANT_REJECTION
NICOTINE;ANKK1;AA + AG;rs1800497;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
VALGANCICLOVIR;ABCC4;AC;rs11568658;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
CYCLOPHOSPHAMIDE;PIK3R2;T;rs145623321;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;PIK3R2;T;rs145623321;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;PIK3R2;T;rs145623321;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CYCLOSPORINE;NFATC1;CC;rs1017860;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
METHOTREXATE;NFATC1;CC;rs1017860;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
CYCLOPHOSPHAMIDE;CYP2C8;A;rs117458836;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;CYP2C8;A;rs117458836;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;CYP2C8;A;rs117458836;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
PRASUGREL;PEAR1;AA;rs822442;EFFICACY;DECREASED_EFFICACY;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION
TACROLIMUS;CYP2C8;*3;CYP2C8*1, CYP2C8*3;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:DELAYED_GRAFT_FUNCTION
CARBAMAZEPINE;HLA-B;*15:21;HLA-B*07:02, HLA-B*15:21;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
NICOTINE;COMT;G;rs4680;TOXICITY;DECREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
NICOTINE;COMT;G;rs4680;OTHER;DECREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
FLUOROURACIL;DPYD;nan;DPYD deficiency;TOXICITY;nan;SIDE_EFFECT:DRUG_TOXICITY
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
AMOXICILLIN;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLAVULANATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
RISPERIDONE;CYP2D6;*4/*4 + *4/*5 + *4/*6;CYP2D6*4, CYP2D6*5, CYP2D6*6;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_PSYCHOTIC_SYMPTOMS
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
PHENPROCOUMON;CYP2C9;*1/*2 + *2/*2 + *1/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
PHENYTOIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA | STEVENS-JOHNSON_SYNDROME
BOSENTAN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_PK;PK:BOSENTAN_METABOLISM_IN_VITRO
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *3/*3 + *1/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
CLOZAPINE;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
BOSENTAN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;LADME_PK;DECREASED_PK;PK:BOSENTAN_METABOLISM_IN_VITRO
CAPECITABINE;DPYD;CT;rs3918290;TOXICITY;INCREASED;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;SIDE_EFFECT:DRUG_TOXICITY
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;SIDE_EFFECT:NEUTROPENIA
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
ATORVASTATIN;TNF;GG;rs1800629;EFFICACY;INCREASED_EFFICACY;EFFICACY:BONE_MARROW_DENSITY_IN_THE_LUMBAR_SPINE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_IN_THERAPEUTIC_RANGE
ACENOCOUMAROL;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
LAMOTRIGINE;HLA-B;*44:03;HLA-B*44:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
PEGINTERFERON ALFA-2B;IFNL4;G/TT + GG;rs11322783;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_FAILURE_IN_JAPANESE_PATIENTS_WITH_WITH_CHRONIC_GENOTYPE_1_HCV_INFECTION
RIBAVIRIN;IFNL4;G/TT + GG;rs11322783;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_FAILURE_IN_JAPANESE_PATIENTS_WITH_WITH_CHRONIC_GENOTYPE_1_HCV_INFECTION
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(SVR_RATE)_TO_HCV_TRIPLE_THERAPY_(TELAPREVIR_(TVR) | PEG-INTERFERON_(PEG-IFN)_PLUS_RIBAVIRIN_(RBV)_COMBINATION_THERAPY)
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(SVR_RATE)_TO_HCV_TRIPLE_THERAPY_(TELAPREVIR_(TVR) | PEG-INTERFERON_(PEG-IFN)_PLUS_RIBAVIRIN_(RBV)_COMBINATION_THERAPY)
TELAPREVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(SVR_RATE)_TO_HCV_TRIPLE_THERAPY_(TELAPREVIR_(TVR) | PEG-INTERFERON_(PEG-IFN)_PLUS_RIBAVIRIN_(RBV)_COMBINATION_THERAPY)
IRINOTECAN;UGT1A1;*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
LAMOTRIGINE;HLA-A;*02:07;HLA-A*02:07;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA | SEVERE_CUTANEOUS_ADVERSE_REACTIONS | STEVENS-JOHNSON_SYNDROME,
FLUCLOXACILLIN;HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NICOTINE;CYP2A6;nan;CYP2A6 low activity;TOXICITY;DECREASED_RISK;OTHER:RECURRENCE
FLUVOXAMINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_EFFICACY;EFFICACY:IMPROVEMENT_BASED_ON_HAM-D_SCORE_PERCENTAGE_REDUCTION
PAROXETINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_EFFICACY;EFFICACY:IMPROVEMENT_BASED_ON_HAM-D_SCORE_PERCENTAGE_REDUCTION
NICOTINE;CYP2A6;nan;CYP2A6 low activity;TOXICITY;DECREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
PHENYTOIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA | SEVERE_CUTANEOUS_ADVERSE_REACTIONS
METHAZOLAMIDE;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
METHAZOLAMIDE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
WARFARIN;CYP2C9;*6;CYP2C9*1, CYP2C9*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_BUT_NOT_MINOR_HEMORRHAGE
METHOTREXATE;SLCO1B1;T;rs11045879;OTHER;INCREASED_PK;PK:CLEARANCE
METHOTREXATE;SLCO1B1;T;rs11045879;LADME_PK;INCREASED_PK;PK:CLEARANCE
CLOPIDOGREL;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
WARFARIN;CYP2C9;*11;CYP2C9*1, CYP2C9*11;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_BUT_NOT_MINOR_HEMORRHAGE
WARFARIN;CYP2C9;*5;CYP2C9*1, CYP2C9*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_BUT_NOT_MINOR_HEMORRHAGE
CODEINE;CYP2D6;POOR_METABOLIZER;CYP2D6;EFFICACY;INCREASED_LIKELIHOOD;DISEASE:PAIN
TRAMADOL;CYP2D6;POOR_METABOLIZER;CYP2D6;EFFICACY;INCREASED_LIKELIHOOD;DISEASE:PAIN
BOSENTAN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;TOXICITY;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED_SEVERITY;OTHER:TUBULAR_VACUOLAR_DEGENERATION
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_PK;PK:DOSE-ADJUSTED_TROUGH_LEVELS
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED_SEVERITY;DISEASE:INTERSTITIAL_FIBROSIS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_PK;PK:CONCENTRATION/DOSE_RATIO
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_PK;PK:C/D_RATIO
CLOPIDOGREL;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_LATE_REACTIVITY_(9MONTHS)
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED_RISKPK;PK:ACUTE_REJECTION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3 + *1/*6 + *1/*7;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DELAYED_GRAFT_FUNCTION
TACROLIMUS;CYP3A5;*1/*3 + *3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_PK;PK:BLOOD_CONCENTRATIONS
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2 + *2/*3 + *1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
ACE INHIBITORS;BDKRB2;(GGTGGGGAC)2/(GGTGGGGAC)2 + (GGTGGGGAC)2/GGTGGGGACGGTGGGGACGGTGGGGAC;rs71103505;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA | COUGH
PLAIN;BDKRB2;(GGTGGGGAC)2/(GGTGGGGAC)2 + (GGTGGGGAC)2/GGTGGGGACGGTGGGGACGGTGGGGAC;rs71103505;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA | COUGH
CODEINE;CYP2D6;nan;CYP2D6 poor and ultrarapid metabolizers;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
CODEINE;CYP2D6;nan;CYP2D6 poor and ultrarapid metabolizers;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
CODEINE;CYP2D6;nan;CYP2D6 poor and ultrarapid metabolizers;LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
TRAMADOL;CYP2D6;nan;CYP2D6 poor and ultrarapid metabolizers;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
TRAMADOL;CYP2D6;nan;CYP2D6 poor and ultrarapid metabolizers;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
TRAMADOL;CYP2D6;nan;CYP2D6 poor and ultrarapid metabolizers;LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
NO_DRUG_RELATED;KCNE1;T;rs727957;OTHER;INCREASED;OTHER:QT_INTERVAL
AMOXICILLIN;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLAVULANATE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
OXCARBAZEPINE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
HYDROCHLOROTHIAZIDE;ACE;del/del;rs1799752;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_SYSTOLIC_BLOOD_PRESSURE
METHOTREXATE;TYMS;del/del;rs11280056;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MUCOSITIS
PERINDOPRIL;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACEI-RELATED_COUGH
METHOTREXATE;TYMS;del/del;rs11280056;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
NO_DRUG_RELATED;RGS2;TC/del + del/del;rs34717272;OTHER;INCREASED_RISK;DISEASE:HYPERTENSION
CARBAMAZEPINE;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
METHOTREXATE;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
CARBAMAZEPINE;HLA-DRB1;*14:05;HLA-DRB1*14:05;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
CYCLOPHOSPHAMIDE;CBR3;T;rs74743371;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;CBR3;T;rs74743371;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;CBR3;T;rs74743371;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CARBAMAZEPINE;HLA-B;*58:01;HLA-B*58:01;TOXICITY;DECREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED_RISK;DISEASE:STOMATITIS
LAMOTRIGINE;HLA-A;*30:01;HLA-A*30:01;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
CARBAMAZEPINE;HLA-DRB1;*03:01;HLA-DRB1*03:01;TOXICITY;DECREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
OXCARBAZEPINE;HLA-B;*13:02;HLA-B*13:02;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
OXCARBAZEPINE;HLA-B;*15:27;HLA-B*15:27;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
OXCARBAZEPINE;HLA-B;*15:19;HLA-B*15:19;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
OXCARBAZEPINE;HLA-B;*48:04;HLA-B*48:04;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
RALOXIFENE;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;EFFICACY;INCREASED_EFFICACY;EFFICACY:BONE_MINERAL_DENSITY
ASPIRIN;HLA-DQB1;*03:02;HLA-DQB1*03:02;EFFICACY;DECREASED_SEVERITY;DISEASE:ASPIRIN-INDUCED_ASTHMA
ASPIRIN;HLA-DQB1;*03:02;HLA-DQB1*03:02;TOXICITY;DECREASED_SEVERITY;DISEASE:ASPIRIN-INDUCED_ASTHMA
OXCARBAZEPINE;HLA-B;*27:09;HLA-B*27:09;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
NEVIRAPINE;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
TAMOXIFEN;ABCB1;AG;rs1045642;OTHER;INCREASED_RISK;OTHER:DISEASE_RECURRENCE
NEVIRAPINE;HLA-B;*58:02;HLA-B*58:02;TOXICITY;DECREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;EFFICACY;EFFICACY:HIGHER_MEAN_BASELINE_HCV_RNA_LEVEL_AND_STEEPER_1ST_PHASE_HCV_RNA_DECLINE_IN_GENOTYPE_2_AND_3_HCV_INFECTED_PATIENTS
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;EFFICACY;EFFICACY:HIGHER_MEAN_BASELINE_HCV_RNA_LEVEL_AND_STEEPER_1ST_PHASE_HCV_RNA_DECLINE_IN_GENOTYPE_2_AND_3_HCV_INFECTED_PATIENTS
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;EFFICACY;EFFICACY:HIGHER_MEAN_BASELINE_HCV_RNA_LEVEL_AND_STEEPER_1ST_PHASE_HCV_RNA_DECLINE_IN_GENOTYPE_2_AND_3_HCV_INFECTED_PATIENTS
PRASUGREL;PEAR1;TT;rs3737224;EFFICACY;DECREASED_EFFICACY;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION
NEVIRAPINE;HLA-C;*02:10;HLA-C*02:10;TOXICITY;DECREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
CYCLOSPORINE;ABCC1;AA + AG;rs4781712;EFFICACY;DECREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
METHOTREXATE;ABCC1;AA + AG;rs4781712;EFFICACY;DECREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
CAPECITABINE;MIR27A;CT;rs895819;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;MIR27A;CT;rs895819;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
OLANZAPINE;ABCB1;GG;rs4728709;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ASTHENIA
BUPROPION;CYP2B6;TT;rs3211371;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
CYCLOPHOSPHAMIDE;TP53AIP1;T;rs118088833;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;TP53AIP1;T;rs118088833;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;TP53AIP1;T;rs118088833;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ASPIRIN;CYP2D6;*3 + *4;CYP2D6*3, CYP2D6*4, CYP2D6*5;DOSAGE;INCREASED_LIKELIHOOD;DISEASE:BRAIN_NEOPLASMS
ASPIRIN;CYP2D6;*3 + *4;CYP2D6*3, CYP2D6*4, CYP2D6*5;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:BRAIN_NEOPLASMS
SULFASALAZINE;CYP2D6;*3 + *4;CYP2D6*3, CYP2D6*4, CYP2D6*5;DOSAGE;INCREASED_LIKELIHOOD;DISEASE:BRAIN_NEOPLASMS
SULFASALAZINE;CYP2D6;*3 + *4;CYP2D6*3, CYP2D6*4, CYP2D6*5;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:BRAIN_NEOPLASMS
PRASUGREL;PEAR1;TT;rs41273215;EFFICACY;DECREASED_EFFICACY;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_IMPROVE_(BASED_ON_MEAN_REDUCTIONS_FROM_BASELINE_IN_HRSD)
TAMOXIFEN;ABCB1;AG;rs1045642;OTHER;INCREASED_RISK;OTHER:DISEASE_RECURRENCE
CYCLOPHOSPHAMIDE;GNL3;T;rs112242273;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;GNL3;T;rs112242273;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;GNL3;T;rs112242273;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;DOSAGE;nan;OTHER:SIGNIFICANTLY_HIGHER_TRAMADOL_CONSUMPTION_IN_CHINESE_GASTRIC_CANCER_PATIENTS_RECOVERING_FROM_GASTRECTOMY
PRASUGREL;PEAR1;CC;rs822441;EFFICACY;DECREASED_EFFICACY;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;LADME_PK;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
VORICONAZOLE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;TOXICITY;INCREASED_RISK;DISEASE:CARCINOMA | SQUAMOUS_CELL
CLOPIDOGREL;CYP2C9;*2;CYP2C9*1, CYP2C9*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_EVENTS
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
CYTARABINE;ABCB1;CC;rs2032582;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:COMPLETE_REMISSION
IDARUBICIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:COMPLETE_REMISSION
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;EFFICACY;EFFICACY:NON-RESPONSE
CAFFEINE;CYP1A2;nan;CYP1A2 high activity;TOXICITY;INCREASED_RISK;DISEASE:ABORTION | SPONTANEOUS
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE_IN_KOREAN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT_SINCE_DAY_7_OF_WARFARIN_THERAPY
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;EFFICACY;EFFICACY:NON-RESPONSE
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;EFFICACY;EFFICACY:NON-RESPONSE
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CYCLOPHOSPHAMIDE;TOP2A;A;rs181501757;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;TOP2A;A;rs181501757;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;TOP2A;A;rs181501757;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
LAMOTRIGINE;HLA-B;*13:02;HLA-B*13:02;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION_AFTER_SECOND_TREATMENT_SWITCH
LAMOTRIGINE;HLA-A;*33:03;HLA-A*33:03;TOXICITY;DECREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;EFFICACY;EFFICACY:IMPROVED_SECOND_TREATMENT_SWITCH_RESPONSE
BELINOSTAT;UGT1A1;*1/*60 + *60/*60;UGT1A1*1, UGT1A1*60;TOXICITY;INCREASED_RISK;SIDE_EFFECT:THROMBOCYTOPENIA
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE
CYCLOPHOSPHAMIDE;PERP;T;rs9402944;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;PERP;T;rs9402944;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;PERP;T;rs9402944;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;EFFICACY;EFFICACY:NON-REMISSION
PEGINTERFERON ALFA-2A;OAS1;AG;rs2660;TOXICITY;DECREASED_RISK;DISEASE:ANEMIA
PEGINTERFERON ALFA-2B;OAS1;AG;rs2660;TOXICITY;DECREASED_RISK;DISEASE:ANEMIA
RIBAVIRIN;OAS1;AG;rs2660;TOXICITY;DECREASED_RISK;DISEASE:ANEMIA
ANTIDEPRESSANTS;SLC6A4;HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;EFFICACY;EFFICACY:NON-RESPONSE
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
NO_DRUG_RELATED;VDR;A;rs731236;nan;INCREASED_RISK;DISEASE:ASTHMA
OLANZAPINE;ABCB1;CC;rs3842;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIAC_RHYTHM_DISEASE
IRINOTECAN;UGT1A1;A;rs10929302;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
CYCLOPHOSPHAMIDE;CBR3;T;rs112783657;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;CBR3;T;rs112783657;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;CBR3;T;rs112783657;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
BUPROPION;GALR1;CC + CT;rs2717162;EFFICACY;DECREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
CARBAMAZEPINE;HLA-B;*46:01;HLA-B*46:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
HEROIN;OPRM1;AG;rs1799971;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
CYCLOSPORINE;NFATC1;GG;rs8090560;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
METHOTREXATE;NFATC1;GG;rs8090560;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
VINCRISTINE;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ALLOPURINOL;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
AZATHIOPRINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA_AND_VOMITING
RISPERIDONE;LEP;A;rs7799039;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
BUPROPION;GALR1;CC + CT;rs2717162;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
PEGINTERFERON ALFA-2A;CTLA4;AG;rs231775;TOXICITY;DECREASED_RISK;DISEASE:ANEMIA
PEGINTERFERON ALFA-2B;CTLA4;AG;rs231775;TOXICITY;DECREASED_RISK;DISEASE:ANEMIA
RIBAVIRIN;CTLA4;AG;rs231775;TOXICITY;DECREASED_RISK;DISEASE:ANEMIA
CYCLOPHOSPHAMIDE;NOS1;G;rs149212925;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;NOS1;G;rs149212925;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;NOS1;G;rs149212925;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CYCLOSPORINE;DHFR;GG;rs34965641;EFFICACY;DECREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
METHOTREXATE;DHFR;GG;rs34965641;EFFICACY;DECREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
ETRAVIRINE;CYP2C19;AA + AG;rs4244285;LADME_PK;DECREASED_PK;PK:ETRAVIRINE_CLEARANCE
CISPLATIN;ERCC1;A;rs3212986;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL
ROSUVASTATIN;ABCG2;T;rs2231142;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_(LDL-C)_LEVEL | IN_A_GENE-DOSE-DEPENDENT_MANNER,
FLUOROURACIL;MTHFR;TT;rs1801131;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_EFFICACY;EFFICACY:IMPROVEMENT_BASED_ON_CHANGE_OF_HAM-D_SCORE_AFTER_ANTIDEPRESSANT_MEDICATION
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_EFFICACY;EFFICACY:IMPROVEMENT_BASED_ON_CHANGE_OF_HAM-D_SCORE_AFTER_ANTIDEPRESSANT_MEDICATION
CYCLOPHOSPHAMIDE;PIK3R2;T;rs58695150;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;PIK3R2;T;rs58695150;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;PIK3R2;T;rs58695150;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
PEMETREXED;GGH;A;rs11545078;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
METFORMIN;SLC22A1;GAT/del;rs72552763;OTHER;DECREASED_EFFICACY;EFFICACY:TROUGH_METFORMIN_STEADY-STATE_CONCENTRATION
METFORMIN;SLC22A1;GAT/del;rs72552763;LADME_PK;DECREASED_EFFICACY;EFFICACY:TROUGH_METFORMIN_STEADY-STATE_CONCENTRATION
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
PHENAZEPAM;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED;SIDE_EFFECT:DRUG_TOXICITY
CAPECITABINE;CDA;AG + GG;rs602950;TOXICITY;INCREASED_RISK;DISEASE:DEHYDRATION
METHOTREXATE;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
METHOTREXATE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
FLUOROURACIL;DPYD;nan;DPYD low activity;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
IRINOTECAN;DPYD;nan;DPYD low activity;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
LEUCOVORIN;DPYD;nan;DPYD low activity;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PHENYTOIN;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
FLUOROURACIL;DPYD;nan;DPYD deficiency;TOXICITY;nan;SIDE_EFFECT:DRUG_TOXICITY
CYCLOPHOSPHAMIDE;PIK3R2;G;rs150688309;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;PIK3R2;G;rs150688309;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;PIK3R2;G;rs150688309;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CAPECITABINE;CDA;AG + GG;rs602950;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
TAMOXIFEN;CYP2D6;*2;CYP2D6*2;EFFICACY;DECREASED_LIKELIHOOD;DISEASE:BREAST_NEOPLASMS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
TAMOXIFEN;CYP3A4;*22;CYP3A4*1, CYP3A4*22;TOXICITY;DECREASED;SIDE_EFFECT:HOT_FLASHES
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-A;*74:01;HLA-A*74:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOTAL_HEMORRHAGE_AND_MAJOR_HEMORRHAGE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:CORONARY_RESTENOSIS
CARBAMAZEPINE;HLA-A;*02:01;HLA-A*02:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
CODEINE;SLC22A1;nan;SLC22A1 low activity;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIZZINESS | DRUG_TOXICITY | HEADACHE | NAUSEA
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER_ANTI-COAGULATION
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED_RISK;DISEASE:LEUKOPENIA
OXCARBAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
ETHANOL;OPRM1;G;rs1799971;nan;INCREASED;OTHER:ALCOHOL_RESPONSE | CONSUMPTION | AND_PREFERENCE
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;OTHER:PLATELET_REACTIVITY
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;TOXICITY;INCREASED_RISK;DISEASE:TRANSPLANT_REJECTION
VENLAFAXINE;CYP2D6;*4/*4;CYP2D6*4;LADME_PK;INCREASED_PK;PK:VENLAFAXINE_LEVELS
CYCLOPHOSPHAMIDE;HMMR;T;rs299293;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;HMMR;T;rs299293;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;HMMR;T;rs299293;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EXEMESTANE;nan;AA;rs934635;TOXICITY;nan;SIDE_EFFECT:A_SIGNIFICANTLY_HIGHER_ODDS_OF_VASOMOTOR_SYMPTOMS_IN_POSTMENOPAUSAL_HORMONE_RECEPTOR_(HR)-POSITIVE_BREAST_CANCER_PATIENTS
CYCLOPHOSPHAMIDE;PERP;C;rs9389568;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;PERP;C;rs9389568;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;PERP;C;rs9389568;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;OTHER:PLATELET_REACTIVITY
CYCLOPHOSPHAMIDE;FOXO1;T;rs144991623;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;FOXO1;T;rs144991623;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;FOXO1;T;rs144991623;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
IRINOTECAN;UGT1A1;*1/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
PRASUGREL;PEAR1;AA;rs12407843;EFFICACY;DECREASED_EFFICACY;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION
DIGOXIN;ABCB1;AA;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SUDDEN_CARDIAC_DEATH
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PRASUGREL;PEAR1;AA;rs77235035;EFFICACY;DECREASED_EFFICACY;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION
VENLAFAXINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;LADME_PK;INCREASED_PK;PK:VENLAFAXINE_LEVELS
VENLAFAXINE;CYP2D6;*1/*4;CYP2D6*1, CYP2D6*4;LADME_PK;INCREASED_PK;PK:VENLAFAXINE_LEVELS
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2;CYP2C9*1, CYP2C9*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
CLOPIDOGREL;CYP2C19;*17/*17 + *1/*17;CYP2C19*1, CYP2C19*17;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION_INHIBITION
DIGOXIN;ABCB1;AA;rs2032582;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SUDDEN_CARDIAC_DEATH
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_DISEASE
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*6, UGT1A1*28;TOXICITY;RISK;DISEASE:NEUTROPENIA
DIGOXIN;ABCB1;AA;rs1128503;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SUDDEN_CARDIAC_DEATH
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;LADME_PK;DECREASED_PK;PK:CMAX_AND_AUC_OF_THIOL_METABOLITE
CAPECITABINE;MTHFR;GG;rs1801131;TOXICITY;INCREASED_RISK;DISEASE:HAND-FOOT_SYNDROME
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALL_AND_MINOR_HEMORRHAGE
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
CYCLOPHOSPHAMIDE;PIK3R2;A;rs8110364;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;PIK3R2;A;rs8110364;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;PIK3R2;A;rs8110364;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
OLANZAPINE;ABCB1;G;rs10248420;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
FLUOROURACIL;DPYD;AG + GG;rs56293913;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
FLUTICASONE PROPIONATE;CD14;AA;rs2569190;EFFICACY;INCREASED_EFFICACY;EFFICACY:PC20
FLUTICASONE PROPIONATE;TMCO6;AA;rs2569190;EFFICACY;INCREASED_EFFICACY;EFFICACY:PC20
CYCLOPHOSPHAMIDE;PIK3R2;T;rs117341846;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;PIK3R2;T;rs117341846;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;PIK3R2;T;rs117341846;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE_REQUIREMENT
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;EFFICACY;EFFICACY;EFFICACY:SIGNIFICANTLY_DELAYED_TIME_TO_INHIBITION_OF_PLATELET_AGGREGATION_(IPA)
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE
ESCITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
CYCLOPHOSPHAMIDE;IRS1;A;rs115457081;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;IRS1;A;rs115457081;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;IRS1;A;rs115457081;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CARBAMAZEPINE;HLA-B;*40:01;HLA-B*40:01;TOXICITY;DECREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;EFFICACY;EFFICACY;EFFICACY:SIGNIFICANTLY_DELAYED_TIME_TO_INHIBITION_OF_PLATELET_AGGREGATION_(IPA)
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
ESCITALOPRAM;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_FAILURE
CYCLOPHOSPHAMIDE;INSR;T;rs142244113;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;INSR;T;rs142244113;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;INSR;T;rs142244113;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
ASPIRIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
CLOPIDOGREL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CLOPIDOGREL;CYP2C19;*2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_AND_CEREBROVASCULAR_EVENTS
METHOTREXATE;ATIC;GG;rs2372536;EFFICACY;DECREASED_EFFICACY;EFFICACY:DISEASE_ACTIVITY_AS_ASSESSED_BY_THE_PHYSICIAN
DOXEPIN;CYP2D6;*4/*4;CYP2D6*4;LADME_PK;DECREASED_PK;PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN
CYCLOPHOSPHAMIDE;PIK3R2;T;rs79430272;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;PIK3R2;T;rs79430272;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;PIK3R2;T;rs79430272;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
OLANZAPINE;CYP2D6;*1/*3 + *1/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4;TOXICITY;INCREASED;DISEASE:WEIGHT_GAIN
CYCLOPHOSPHAMIDE;TP53;T;rs4968187;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;TP53;T;rs4968187;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;TP53;T;rs4968187;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
FLUOXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
PAROXETINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
CISPLATIN;ERCC1;AA;rs3212986;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:NEPHROTOXICITY
PALBOCICLIB;ABCG2;CT;rs2231137;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
CYCLOPHOSPHAMIDE;PIK3R2;T;rs117951771;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;PIK3R2;T;rs117951771;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;PIK3R2;T;rs117951771;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ACENOCOUMAROL;CYP2C9;*2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3 + *3/*3 + *4/*4 + *2/*4 + *3/*4;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_FAILURE
EXEMESTANE;nan;AA;rs934635;TOXICITY;nan;SIDE_EFFECT:A_SIGNIFICANTLY_HIGHER_ODDS_OF_MUSCULOSKELETAL_ADVERSE_EVENTS_(MSAES)_IN_POSTMENOPAUSAL_HORMONE_RECEPTOR_(HR)-POSITIVE_BREAST_CANCER_PATIENTS
PRIMAQUINE;G6PD;nan;G6PD deficiency;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DECREASED_HEMOCRIT_LEVELS
CYCLOPHOSPHAMIDE;PIK3R2;A;rs148235907;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;PIK3R2;A;rs148235907;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;PIK3R2;A;rs148235907;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
METHAMPHETAMINE;DAOA;C;rs3916965;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER
NO_DRUG_RELATED;UGT1A1;G;rs34993780;OTHER;INCREASED_LIKELIHOOD;OTHER:GILBERT_SYNDROME | CRIGLER-NAJJAR_SYNDROME
CYCLOPHOSPHAMIDE;CYP2C9;POOR_METABOLIZER;CYP2C9;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
DESIPRAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;LADME_PK;INCREASED_PK;PK:DESIPRAMINE/2-HYDROXY-DESIPRAMINE_RATIO
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;LADME_PK;INCREASED_PK;PK:THE_INTRINSIC_METABOLIC_ACTIVITY_(V(MAX)/K(M))
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;LADME_PK;INCREASED_PK;PK:THE_MEAN_MAXIMAL_ELIMINATION_RATES_(V(MAX))
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
ATAZANAVIR;UGT1A1;*28;UGT1A1*28;OTHER;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
RITONAVIR;UGT1A1;*28;UGT1A1*28;OTHER;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
ATAZANAVIR;UGT1A1;*28;UGT1A1*28;OTHER;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
IRINOTECAN;UGT1A1;*1/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
PALBOCICLIB;SULT2A1;CC;rs182420;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION | DISCONTINUATION
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*4 + *4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;INCREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
TAMOXIFEN;CYP2D6;*1/*4 + *4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;INCREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
IMIPRAMINE;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;LADME_PK;DECREASED_PK;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS
CYCLOPHOSPHAMIDE;HMMR;A;rs299313;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;HMMR;A;rs299313;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;HMMR;A;rs299313;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
PRIMAQUINE;G6PD;nan;G6PD deficiency;OTHER;INCREASED;OTHER:REDUCTIONS_IN_GLUTATHIONE_LEVELS
SULFANILAMIDE;G6PD;nan;G6PD deficiency;OTHER;INCREASED;OTHER:REDUCTIONS_IN_GLUTATHIONE_LEVELS
CHLORAMPHENICOL;G6PD;nan;G6PD deficiency;OTHER;INCREASED;OTHER:REDUCTIONS_IN_GLUTATHIONE_LEVELS
WARFARIN;CYP2C9;*1/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *1/*6 + *1/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
CODEINE;UGT2B7;A;rs73823859;EFFICACY;INCREASED_EFFICACY;EFFICACY:PAIN
MORPHINE;UGT2B7;A;rs73823859;EFFICACY;INCREASED_EFFICACY;EFFICACY:PAIN
TRAMADOL;UGT2B7;A;rs73823859;EFFICACY;INCREASED_EFFICACY;EFFICACY:PAIN
CISPLATIN;ALDH2;AA + AG;rs671;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | VOMITING
DOCETAXEL;ALDH2;AA + AG;rs671;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | VOMITING
CYCLOPHOSPHAMIDE;HMMR;C;rs299314;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;HMMR;C;rs299314;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;HMMR;C;rs299314;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
WARFARIN;CYP2C9;*8;CYP2C9*1, CYP2C9*8;LADME_PK;DECREASED_PK;PK:IN_VITRO_INTRINSIC_CLEARANCE_OF_S-WARFARIN_WITH_THE_CDNA-EXPRESSED_R150H_PROTEIN
IRINOTECAN;UGT1A1;*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
IRINOTECAN;UGT1A1;*28;UGT1A1*1, UGT1A1*28;LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;G;rs1056892;TOXICITY;INCREASED_RISK;DISEASE:HEART_FAILURE
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
CISPLATIN;ERCC2;G;rs13181;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL
ALLOPURINOL;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
ALLOPURINOL;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:STEVENS-JOHNSON_SYNDROME
ANTHRACYCLINES AND RELATED SUBSTANCES;CAT;CC;rs10836235;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIAC_DAMAGE
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
EXEMESTANE;UGT2B17;nan;UGT2B17 deficiency;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:FATIGUE
PAROXETINE;SLC6A4;HTTLPR short form (S allele) + L allele-rs25531C + L allele-rs25531T;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;TOXICITY;INCREASED;SIDE_EFFECT:BLEEDING_TIME
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
VALPROIC ACID;XBP1;G;rs2269577;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROPHYLACTIC_TREATMENT_RESPONSE
ACE INHIBITORS;ACE;del;rs1799752;TOXICITY;INCREASED;SIDE_EFFECT:MAJOR_CARDIOVASCULAR_EVENTS_(MACE)_RATE
PLAIN;ACE;del;rs1799752;TOXICITY;INCREASED;SIDE_EFFECT:MAJOR_CARDIOVASCULAR_EVENTS_(MACE)_RATE
PACLITAXEL;CYP1B1;GG;rs1056836;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
TAMOXIFEN;CYP2D6;*10/*10 + *4/*10 + *5/*10;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
DOCETAXEL;CYP1B1;CC;rs1056836;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
WARFARIN;CYP2C9;*8;CYP2C9*1, CYP2C9*8;DOSAGE;DECREASED_PK;PK:UNBOUND_ORAL_CLEARANCE_OF_S-WARFARIN_AND_LOWER_R-_TO_S-WARFARIN_PLASMA_CONCENTRATION_RATIO
WARFARIN;CYP2C9;*8;CYP2C9*1, CYP2C9*8;LADME_PK;DECREASED_PK;PK:UNBOUND_ORAL_CLEARANCE_OF_S-WARFARIN_AND_LOWER_R-_TO_S-WARFARIN_PLASMA_CONCENTRATION_RATIO
CYCLOPHOSPHAMIDE;ABCC4;T;rs9561778;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADR
CYCLOPHOSPHAMIDE;ABCC4;T;rs9561778;LADME_PK;INCREASED_RISK;SIDE_EFFECT:ADR
DOXORUBICIN;ABCC4;T;rs9561778;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADR
DOXORUBICIN;ABCC4;T;rs9561778;LADME_PK;INCREASED_RISK;SIDE_EFFECT:ADR
FLUOROURACIL;ABCC4;T;rs9561778;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADR
FLUOROURACIL;ABCC4;T;rs9561778;LADME_PK;INCREASED_RISK;SIDE_EFFECT:ADR
CYCLOPHOSPHAMIDE;ABCC4;T;rs9561778;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
CYCLOPHOSPHAMIDE;ABCC4;T;rs9561778;LADME_PK;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
CYCLOPHOSPHAMIDE;ABCC4;T;rs9561778;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
CYCLOPHOSPHAMIDE;ABCC4;T;rs9561778;LADME_PK;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION_(PA)
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*1, CYP2C19*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION_(PA)
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION_(PA)
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
HYDROCHLOROTHIAZIDE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;OTHER;INCREASED;OTHER:HYDROCHLOROTHIAZIDE_INDUCED_POTASSIUM_EXCRETION
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;T;rs6025;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:VENOUS_THROMBOEMBOLISM
ENALAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED_EFFICACY;EFFICACY:BONE_MINERAL_DENSITY_RESPONSE
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
CLOZAPINE;HLA-B;*38:01;HLA-B*38:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
PAROXETINE;CYP2D6;*1/*1xN;CYP2D6*1, CYP2D6*1xN;LADME_PK;DECREASED_PK;PK:PAROXETINE_SERUM_CONCENTRATION
FLUCLOXACILLIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
FLUCLOXACILLIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*4;NAT2*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CAPECITABINE;ANK3;T;rs143414470;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
GEFITINIB;CYP2D6;*10/*10 + *5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*14;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
LANSOPRAZOLE;CYP2C19;*2 + *3 + *8 + *9;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*9;OTHER;INCREASED_RISK;DISEASE:RESPIRATORY_TRACT_INFECTIONS
NEVIRAPINE;CCHCR1;T;rs130072;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEVIRAPINE-INDUCED_RASH
NEVIRAPINE;HLA-B;*35:05;HLA-B*35:05;TOXICITY;INCREASED_RISK;DISEASE:EXANTHEMA
RITONAVIR;APOC3;G;rs5128;TOXICITY;INCREASED;SIDE_EFFECT:TRIGLYCERIDE_LEVELS
EFAVIRENZ;CYP2B6;T;rs3745274;TOXICITY;INCREASED_PK;PK:PLASMA_CONCENTRATION
EFAVIRENZ;CYP2B6;T;rs3745274;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
METFORMIN;BDNF;C;rs6265;EFFICACY;INCREASED_LIKELIHOOD;OTHER:WEIGHT_REGAIN_AFTER_INTENTIONAL_WEIGHT_LOSS
EFAVIRENZ;CYP2B6;*1/*18;CYP2B6*1, CYP2B6*18;LADME_PK;INCREASED_PK;PK:PLASMA_EFAVIRENZ_LEVELS
LUMIRACOXIB;HLA-DRB1;*15:01;HLA-DRB1*01:01, HLA-DRB1*15:01;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
METHADONE;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;LADME_PK;INCREASED_PK;PK:TROUGH_(_R_ | S_)-METHADONE_PLASMA_CONCENTRATIONS
MERCAPTOPURINE;TPMT;*12;TPMT*1, TPMT*12;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
METHOTREXATE;TPMT;*12;TPMT*1, TPMT*12;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
MYCOPHENOLATE MOFETIL;IMPDH1;CT + TT;rs2278293;TOXICITY;DECREASED_RISK;SIDE_EFFECT:BIOPSY-PROVEN_ACUTE_REJECTION
MITOXANTRONE;ABCB1;AA;rs2032582;OTHER;INCREASED;OTHER:SENSITIVITY_IN_VITRO
LUMIRACOXIB;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*3;LADME_PK;INCREASED_RISK;OTHER:OVERANTICOAGULATION
ASPIRIN;PON1;CT + TT;rs662;EFFICACY;DECREASED_EFFICACY;EFFICACY:RELATIVE_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION
CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;DECREASED_EFFICACY;EFFICACY:RELATIVE_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*2;LADME_PK;INCREASED_RISK;OTHER:OVERANTICOAGULATION
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
METHADONE;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PROLONGED_QTC
METHADONE;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;LADME_PK;INCREASED_PK;PK:(S)-METHADONE_PLASMA_LEVELS
TRIMIPRAMINE;CYP2D6;*4/*4 + *3/*5 + *3/*3;CYP2D6*1, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5;TOXICITY;INCREASED;SIDE_EFFECT:SEDATION
CLOPIDOGREL;ABCB1;A;rs1045642;OTHER;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
NEVIRAPINE;HLA-C;T;rs9461684;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEVIRAPINE-INDUCED_RASH
ASPIRIN;IL1B;A;rs1143627;TOXICITY;nan;DISEASE:PEPTIC_ULCER_DISEASE
PACLITAXEL;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
CYCLOPHOSPHAMIDE;SLC22A16;CC + CT;rs714368;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
DOXORUBICIN;SLC22A16;CC + CT;rs714368;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
PHENYTOIN;EPHX1;G;rs2234922;TOXICITY;INCREASED_RISK;DISEASE:DISORDER_OF_FACIAL_SKELETON
PHENYTOIN;EPHX1;T;rs1051740;TOXICITY;INCREASED_RISK;DISEASE:DISORDER_OF_FACIAL_SKELETON
NEVIRAPINE;TCF19;T;rs2073724;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
RISPERIDONE;CYP2D6;*10;CYP2D6*1, CYP2D6*10;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
CARBOPLATIN;NRG3;G;rs1649942;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PACLITAXEL;NRG3;G;rs1649942;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PHENPROCOUMON;EPHX1;CC;rs1051740;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BEING_OVERANTICOAGULATED
NO_DRUG_RELATED;SLCO1B1;C;rs4149056;LADME_PK;INCREASED_PK;PK:STEROL/BILE_ACID_METABOLITES
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;LADME_PK;INCREASED_PK;PK:PLASMA_EFAVIRENZ_LEVELS
ASPIRIN;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:NON-RESPONSIVENESS
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:NON-RESPONSIVENESS
CYCLOPHOSPHAMIDE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
DOXORUBICIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CAFFEINE;ADORA2A;TT;rs5751876;TOXICITY;INCREASED;DISEASE:ANXIETY_DISORDERS
PACLITAXEL;NAT2;AG + GG;rs1208;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PLATINUM COMPOUNDS;NAT2;AG + GG;rs1208;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;*05:01 + *05:02 + *05:03;HLA-DQB1*05:01, HLA-DQB1*05:02, HLA-DQB1*05:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
VENLAFAXINE;CYP2D6;*5/*4 + *6/*6 + *6/*4;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
VENLAFAXINE;CYP2D6;*5/*4 + *6/*6 + *6/*4;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6;LADME_PK;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
FLUVOXAMINE;CYP2D6;*1/*5 + *10/*10 + *5/*10;CYP2D6*1, CYP2D6*5, CYP2D6*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_SIDE_EFFECTS
NEMONAPRIDE;ANKK1;A;rs1800497;TOXICITY;INCREASED;SIDE_EFFECT:PROLACTIN_CONCENTRATIONS
TAMOXIFEN;CYP2D6;*3/*3 + *4/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
METHOTREXATE;SLC19A1;TT;rs1051266;OTHER;INCREASED_PK;PK:METHOTREXATE_POLYGLUTAMATE_(MTXPG3-5)_LEVELS
METHOTREXATE;SLC19A1;TT;rs1051266;LADME_PK;INCREASED_PK;PK:METHOTREXATE_POLYGLUTAMATE_(MTXPG3-5)_LEVELS
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
FLUVOXAMINE;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;INCREASED_PK;PK:AREAS_UNDER_THE_SERUM_CONCENTRATION-TIME_CURVE
METHOTREXATE;GGH;AA;rs3758149;LADME_PK;DECREASED_PK;PK:METHOTREXATE_POLYGLUTAMATE_(MTXPG3-5)_LEVELS
RISPERIDONE;DRD2;C;rs1799978;TOXICITY;INCREASED_RISK;DISEASE:HYPERPROLACTINEMIA
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DEATH | MYOCARDIAL_INFARCTION | STROKE,
RISPERIDONE;ANKK1;AA + AG;rs1800497;TOXICITY;INCREASED_RISK;DISEASE:HYPERPROLACTINEMIA
MYCOPHENOLATE MOFETIL;IMPDH2;G;rs11706052;OTHER;INCREASED;OTHER:INOSINE_MONOPHOSPHATE_DEHYDROGENASE_ACTIVITY
MERCAPTOPURINE;XDH;CC + CT;rs2281547;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:TREATMENT_INTERRUPTION
ASPIRIN;CYP2C19;*2/*2 + *1/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:ADP-INDUCED_ON_TREATMENT_PLATELET_AGGREGATION_(OTPR)
CLOPIDOGREL;CYP2C19;*2/*2 + *1/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:ADP-INDUCED_ON_TREATMENT_PLATELET_AGGREGATION_(OTPR)
MYCOPHENOLATE MOFETIL;SLCO1B3;G;rs4149117;LADME_PK;DECREASED_PK;PK:DOSE-NORMALIZED_CMAX_AND_DOSE-NORMALIZED_AUC0TO12_H
ASPIRIN;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:RELATIVE_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:RELATIVE_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:ON-CLOPIDOGREL_PLATELET_REACTIVITY_(HPR)
INDINAVIR;UGT1A1;*6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
ANASTROZOLE;ABCB1;AA;rs1045642;OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT:ARTHRALGIA
METHOTREXATE;MTHFR;GG;rs1801131;EFFICACY;DECREASED;OTHER:EVENT-FREE_SURVIVAL
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HAVING_INR_ABOVE_TARGET_RANGE_IN_WEEK_1
NO_DRUG_RELATED;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED_RISK;OTHER:SUBSTANCE-RELATED_DISORDERS
MERCAPTOPURINE;ITPA;AC;rs1127354;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:FEBRILE_NEUTROPENIA
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY | NEPHROTOXICITY
FLECAINIDE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_PK;PK:SYSTEMIC_EXPOSURE_(AUC)_AND_LOWER_ORAL_CLEARANCE_OF_FLECAINIDE
ETHANOL;ALDH2;GG;rs671;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE
DIDANOSINE;XDH;AA;rs1429376;TOXICITY;INCREASED_RISK;DISEASE:HYPERTENSION | PORTAL
DAUNORUBICIN;SZRD1;T;rs6603859;OTHER;DECREASED_PK;PK:IC50
DAUNORUBICIN;SZRD1;T;rs6603859;LADME_PK;DECREASED_PK;PK:IC50
DIDANOSINE;NT5C2;CC + CT;rs11598702;TOXICITY;INCREASED_RISK;DISEASE:HYPERTENSION | PORTAL
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;EFFICACY;INCREASED;OTHER:PLATELET_REACTIVITY
DIDANOSINE;XDH;AA;rs1594160;TOXICITY;INCREASED_RISK;DISEASE:HYPERTENSION | PORTAL
CLOPIDOGREL;CYP2C19;*6;CYP2C19*1, CYP2C19*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS
DAUNORUBICIN;nan;GG;rs7929521;OTHER;INCREASED_PK;PK:IC50
DAUNORUBICIN;nan;GG;rs7929521;LADME_PK;INCREASED_PK;PK:IC50
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28, UGT1A1*37;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
AZACITIDINE;TYMS;del/del;rs11280056;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DAUNORUBICIN;MAN1B1;T;rs3750518;OTHER;INCREASED_PK;PK:IC50
DAUNORUBICIN;MAN1B1;T;rs3750518;LADME_PK;INCREASED_PK;PK:IC50
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7;LADME_PK;DECREASED_PK;PK:MEAN_OXYMORPHONE/OXYCODONE_RATIOS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;OTHER:PLATELET_REACTIVITY
DIDANOSINE;NT5C2;CG + GG;rs11191561;TOXICITY;INCREASED_RISK;DISEASE:HYPERTENSION | PORTAL
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQA1;*01:02;HLA-DQA1*01:02;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
IGURATIMOD;CYP2C19;A;rs4244285;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CYCLOSPORINE;CYP3A4;*1/*22;CYP3A4*1, CYP3A4*22;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TRANSPLANT_REJECTION
PHENYTOIN;HLA-C;*14:02;HLA-C*14:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
PHENYTOIN;HLA-B;*56:02;HLA-B*56:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
NICOTINE;CYP2A6;AT + TT;rs1801272;TOXICITY;INCREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
OLANZAPINE;CYP2C9;*1/*3 + *2/*3 + *3/*6;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*6;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:HYPOTENSIVE_DISORDER
DESIPRAMINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;LADME_PK;INCREASED_PK;PK:STEADY-STATE_PLASMA_CONCENTRATIONS_OF_DESIPRAMINE/DAILY_DOSE_OF_DESIPRAMINE/BODY_WEIGHT
GEFITINIB;EGFR;(CA)16/(CA)16;rs11568315;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
OLANZAPINE;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:FATIGUE
NO_DRUG_RELATED;NAT1;*11B/*4;NAT1*4, NAT1*11B;OTHER;INCREASED_RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*32, TPMT*33, TPMT*34;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
THIOGUANINE;TPMT;*1/*3C;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*32, TPMT*33, TPMT*34;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
OLANZAPINE;GSTM3;CCT/CCT;rs1799735;LADME_PK;DECREASED_PK;PK:AREA_UNDER_THE_CURVE
OLANZAPINE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_PK;PK:AREA_UNDER_THE_CURVE
MERCAPTOPURINE;XDH;CC + CT;rs2281547;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
ANASTROZOLE;CYP19A1;AA;rs727479;EFFICACY;INCREASED;OTHER:RECURRENCE_FREE_SURVIVAL
OXYCODONE;CYP2D6;*4/*4 + *4/*6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*6;LADME_PK;DECREASED_PK;PK:SERUM_CONCENTRATIONS_OF_OXYMORPHONE_AND_NOROXYMORPHONE_AND_OXYMORPHONE/OXYCODONE_RATIOS
FLUVASTATIN;SLCO1B1;CC;rs11045819;EFFICACY;DECREASED_EFFICACY;EFFICACY:LDL-C_REDUCTION
OXYCODONE;CYP2D6;*4/*4 + *3/*4;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4;LADME_PK;DECREASED_PK;PK:SERUM_CONCENTRATIONS_OF_OXYMORPHONE_AND_NOROXYMORPHONE_AND_OXYMORPHONE/OXYCODONE_RATIOS
EFAVIRENZ;CYP2B6;*18/*18;CYP2B6*18;LADME_PK;INCREASED_PK;PK:PLASMA_EFAVIRENZ_LEVELS
CYCLOPHOSPHAMIDE;NQO2;C;rs1143684;EFFICACY;EFFICACY;EFFICACY:WORSE_PROGNOSIS_(OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL)_IN_PATIENTS_WHO_WERE_ER-VE/PR-VE_NEGATIVE
DOXORUBICIN;NQO2;C;rs1143684;EFFICACY;EFFICACY;EFFICACY:WORSE_PROGNOSIS_(OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL)_IN_PATIENTS_WHO_WERE_ER-VE/PR-VE_NEGATIVE
PIOGLITAZONE;CYP2C8;*1/*2 + *2/*2;CYP2C8*1, CYP2C8*2;LADME_PK;DECREASED_PK;PK:M-III | PIOGLITAZONE_AUC0-48_RATIO_AND_M-III | M-IV_AUC0-48_RATIO_IN_HEALTHY_AFRICAN-AMERICAN_VOLUNTEERS,
PHENYTOIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
DICLOFENAC;UGT2B7;T;rs7668258;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;TOXICITY;INCREASED_RISK;DISEASE:HEMORRHAGE
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;EFFICACY;DECREASED_RISK;OTHER:NON-FATAL_MYOCARDIAL_INFARCTION,STROKE | REVASCULARIZATION_OR_DEATH
IBUPROFEN;CYP2C8;*1/*2;CYP2C8*1, CYP2C8*2;LADME_PK;INCREASED_PK;PK:R-IBUPROFEN_METABOLISM
CISPLATIN;GSTM3;TCCTC/TCCTC;rs36120609;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ANEMIA
CYCLOPHOSPHAMIDE;GSTM3;TCCTC/TCCTC;rs36120609;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ANEMIA
ASPIRIN;CYP2C19;A;rs4244285;TOXICITY;nan;SIDE_EFFECT:HIGHER_COMPOSITE_HAR_OUTCOME_(CARDIAC_DEATH | NON_FATAL_MYOCARDIAL_INFARCTION_AND_STENT_THROMBOSIS)_UP_TO_12_MONTHS'_FOLLOW_UP
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;nan;SIDE_EFFECT:HIGHER_COMPOSITE_HAR_OUTCOME_(CARDIAC_DEATH | NON_FATAL_MYOCARDIAL_INFARCTION_AND_STENT_THROMBOSIS)_UP_TO_12_MONTHS'_FOLLOW_UP
NO_DRUG_RELATED;IRS1;C;rs1801123;OTHER;nan;OTHER:LYMPH_NODE_INVOLVEMENT
ESTRADIOL;nan;A;rs1864729;OTHER;INCREASED;OTHER:PLASMA_LEVEL
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
GEFITINIB;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;rs11568315;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEDIAN_SURVIVAL_TIME
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE | STROKE
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE | STROKE
GEFITINIB;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;rs11568315;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE_(RR)
CARBIMAZOLE;HLA-DRB1;*08:03;HLA-DRB1*08:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
METHIMAZOLE;HLA-DRB1;*08:03;HLA-DRB1*08:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
PROPYLTHIOURACIL;HLA-DRB1;*08:03;HLA-DRB1*08:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTM1;nan;GSTM1 non-null, GSTM1 null;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOMYOPATHIES
NO_DRUG_RELATED;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;rs11568315;nan;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
ETHAMBUTOL;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ISONIAZID;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PYRAZINAMIDE;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RIFAMPIN;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CITALOPRAM;CYP2C19;*2;CYP2C19*1, CYP2C19*2;LADME_PK;DECREASED_PK;PK:CITALOPRAM_ORAL_CLEARANCES_OF_CITALOPRAM
DICLOFENAC;ABCC2;T;rs717620;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ANTIARRHYTHMICS;nan;GG;rs10033464;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUCCESSFUL_RHYTHM_CONTROL
CLASS I AND III;nan;GG;rs10033464;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUCCESSFUL_RHYTHM_CONTROL
CARBIMAZOLE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
METHIMAZOLE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
GEFITINIB;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;rs11568315;EFFICACY;INCREASED_EFFICACY;EFFICACY:SURVIVAL_TIME
HYDRALAZINE;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;EFFICACY;EFFICACY;EFFICACY:MORE_FREQUENT_HIGH_PLATELET_REACTIVITY_IN_JAPANESE_PATIENTS_IN_A_STEADY_STATE_RECEIVING_DUAL_ANTIPLATELET_THERAPY_AFTER_CORONARY_STENT_IMPLANTATION
GEFITINIB;EGFR;(CA)16/(CA)16 + (CA)16/(CA)17;rs11568315;EFFICACY;INCREASED_EFFICACY;EFFICACY:BETTER_CLINICAL_RESPONSE
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_PK;PK:UNBOUND_ORAL_CLEARANCE_FOR_S-WARFARIN
RIFAMPIN;SLCO1B1;*15;SLCO1B1*15;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;EFFICACY;EFFICACY:MORE_FREQUENT_HIGH_PLATELET_REACTIVITY_IN_JAPANESE_PATIENTS_IN_A_STEADY_STATE_RECEIVING_DUAL_ANTIPLATELET_THERAPY_AFTER_CORONARY_STENT_IMPLANTATION
FLUVOXAMINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;EFFICACY;DECREASED_EFFICACY;EFFICACY:HAM-D_SCORE_CHANGES_IN_FLUVOXAMINE-TREATED_PATIENTS_COMPARED_TO_PAROXETINE-TREATED_PATIENTS
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;EFFICACY;DECREASED_EFFICACY;EFFICACY:HAM-D_SCORE_CHANGES_IN_FLUVOXAMINE-TREATED_PATIENTS_COMPARED_TO_PAROXETINE-TREATED_PATIENTS
RISPERIDONE;CYP2D6;*4/*5 + *4/*6 + *3/*4 + *4/*4;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;OTHER;DECREASED;OTHER:WAKEFULNESS_ACTIVITY_LEVEL
NO_DRUG_RELATED;IGFBP3;T;rs2854744;OTHER;nan;OTHER:TUMOR_SIZE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CARBAMAZEPINE;HLA-A;*24:02;HLA-A*24:02;TOXICITY;DECREASED_RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME_AND_TOXIC_EPIDERMAL_NECROLYSIS-BULLOUS_LESIONS
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME_AND_TOXIC_EPIDERMAL_NECROLYSIS-BULLOUS_LESIONS
NEVIRAPINE;GSTM1;nan;GSTM1 non-null, GSTM1 null;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
CISPLATIN;GSTM3;TCCTC/TCCTC;rs36120609;TOXICITY;DECREASED_RISK;SIDE_EFFECT:THROMBOCYTOPENIA
CYCLOPHOSPHAMIDE;GSTM3;TCCTC/TCCTC;rs36120609;TOXICITY;DECREASED_RISK;SIDE_EFFECT:THROMBOCYTOPENIA
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME_AND_TOXIC_EPIDERMAL_NECROLYSIS-BULLOUS_LESIONS
CARBAMAZEPINE;HLA-B;*40:01;HLA-B*40:01;TOXICITY;DECREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CISPLATIN;GSTM3;TCCTC/TCCTC;rs36120609;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
CYCLOPHOSPHAMIDE;GSTM3;TCCTC/TCCTC;rs36120609;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
PAROXETINE;CYP2D6;*4/*5;CYP2D6*1, CYP2D6*4, CYP2D6*5;LADME_PK;INCREASED_PK;PK:PAROXETINE_PLASMA_CONCENTRATION
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
NO_DRUG_RELATED;GSTM3;TC/TC + TC/TCCTC;rs36120609;OTHER;INCREASED_LIKELIHOOD;OTHER:METASTATIC_NEOPLASM
FLUOXETINE;CYP2D6;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;LADME_PK;INCREASED_PK;PK:FLUOXETINE/(S)-NORFLUOXETINE_RATIO
PEGINTERFERON ALFA-2B;ITPA;CC;rs1127354;OTHER;nan;SIDE_EFFECT:REQUIREMENT_FOR_EARLIER_DOSE_REDUCTION_OF_RIBAVIRIN
RIBAVIRIN;ITPA;CC;rs1127354;OTHER;nan;SIDE_EFFECT:REQUIREMENT_FOR_EARLIER_DOSE_REDUCTION_OF_RIBAVIRIN
TELAPREVIR;ITPA;CC;rs1127354;OTHER;nan;SIDE_EFFECT:REQUIREMENT_FOR_EARLIER_DOSE_REDUCTION_OF_RIBAVIRIN
CARBOPLATIN;ALDH1A1;CTGGTGAGGAGAGAACC/del;rs6151031;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
CYCLOPHOSPHAMIDE;ALDH1A1;CTGGTGAGGAGAGAACC/del;rs6151031;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
THIOTEPA;ALDH1A1;CTGGTGAGGAGAGAACC/del;rs6151031;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
ANTITHYROID PREPARATIONS;HLA-B;*27:05;HLA-B*27:05;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:AGRANULOCYTOSIS
ASPIRIN;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_PLATELET_REACTIVITY
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_PLATELET_REACTIVITY
NO_DRUG_RELATED;IFNL3;TT;rs8099917;nan;INCREASED;OTHER:BASELINE_VIRAL_LOAD
IRINOTECAN;UGT1A1;*1/*28 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
PAROXETINE;CYP2D6;*1/*4 + *1/*5;CYP2D6*1, CYP2D6*4, CYP2D6*5;LADME_PK;INCREASED_PK;PK:PAROXETINE_PLASMA_CONCENTRATIONS_INCREASED_DURING_THE_COURSE_OF_PREGNANCY
DICLOFENAC;CYP2C8;*1/*3 + *3/*3;CYP2C8*1, CYP2C8*3;LADME_PK;INCREASED_PK;PK:DICLOFENAC/5-HYDROXYDICLOFENAC_URINARY_CONCENTRATION_RATIO
PAROXETINE;CYP2D6;*3/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4;LADME_PK;INCREASED_PK;PK:PAROXETINE_PLASMA_CONCENTRATION
HEPARIN;HLA-DRB3;*01:01;HLA-DRB3*01:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEPARIN-INDUCED_THROMBOCYTOPENIA
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
ACENOCOUMAROL;CYP2C9;*1/*2 + *2/*2;CYP2C9*1, CYP2C9*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;TOXICITY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;TT/TT;rs11322783;TOXICITY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SIMEPREVIR;IFNL4;TT/TT;rs11322783;TOXICITY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
CITALOPRAM;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-REMISSION
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
IBUPROFEN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;LADME_PK;DECREASED_PK;PK:RACEMIC | S-IBUPROFEN_AND_R-IBUPROFEN_METABOLISM | WITH_INCREASE_OF_AUC(0-INFINITY)_AND_REDUCTION_OF_CLEARANCE
TENOXICAM;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;LADME_PK;INCREASED_PK;PK:EXPOSURE_(AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_(AUC))_AND_DECREASED_ORAL_CLEARANCE
ASPIRIN;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
TENOXICAM;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;LADME_PK;INCREASED_PK;PK:EXPOSURE_(AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_(AUC))_AND_DECREASED_ORAL_CLEARANCE
EFAVIRENZ;CYP2B6;*6;CYP2B6*1, CYP2B6*6;LADME_PK;INCREASED_PK;PK:PLASMA_4BETA-OHC/CHOL_RATIO
LAMIVUDINE;CYP2B6;*6;CYP2B6*1, CYP2B6*6;LADME_PK;INCREASED_PK;PK:PLASMA_4BETA-OHC/CHOL_RATIO
STAVUDINE;CYP2B6;*6;CYP2B6*1, CYP2B6*6;LADME_PK;INCREASED_PK;PK:PLASMA_4BETA-OHC/CHOL_RATIO
ZIDOVUDINE;CYP2B6;*6;CYP2B6*1, CYP2B6*6;LADME_PK;INCREASED_PK;PK:PLASMA_4BETA-OHC/CHOL_RATIO
TAMOXIFEN;CYP2D6;nan;CYP2D6 low activity;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
PIROXICAM;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:INHIBITORY_EFFECT_ON_CYCLOOXYGENASE_1_ACTIVITY
NICOTINE;CYP2A6;*4 + *10 + *9;CYP2A6*1, CYP2A6*4, CYP2A6*9, CYP2A6*10;LADME_PK;DECREASED_PK;PK:PLASMA_AND_URINARY_RATIO_OF_METABOLITES_TRANS-3'-HYDROXYCOTININE_TO_COTININE_(3HC/COT)
ASPIRIN;CYP2C19;*17;CYP2C19*1, CYP2C19*17;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
CLOPIDOGREL;CYP2C19;*17;CYP2C19*1, CYP2C19*17;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
LUMIRACOXIB;HLA-DQA1;*01:02;HLA-DQA1*01:01, HLA-DQA1*01:02;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ASPIRIN;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
PAROXETINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;LADME_PK;INCREASED_PK;PK:PAROXETINE_LEVELS
IBUPROFEN;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;OTHER;DECREASED;OTHER:INOS_EXPRESSION
IRINOTECAN;UGT1A6;A;rs2070959;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
IBUPROFEN;CYP2C8;*1/*3;CYP2C8*1, CYP2C8*3;LADME_PK;INCREASED_PK;PK:R-IBUPROFEN_METABOLISM
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IMATINIB;EGFR;CC;rs2072454;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIORBITAL_EDEMA
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;rs45445694;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:SIDE_EFFECTS
KETOPROFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEDATION
TRAMADOL;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEDATION
PIROXICAM;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:INHIBITORY_EFFECT_ON_CYCLOOXYGENASE_1_ACTIVITY
PIROXICAM;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;LADME_PK;INCREASED_PK;PK:PIROXICAM'S_AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_AND_DECREASED_ORAL_CLEARANCE
PIROXICAM;CYP2C9;*1/*2;CYP2C9*1, CYP2C9*2;LADME_PK;INCREASED_PK;PK:PIROXICAM'S_AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_AND_DECREASED_ORAL_CLEARANCE
GEFITINIB;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*114;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
PEGINTERFERON ALFA-2A;IFNL4;G;rs11322783;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;G;rs11322783;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;G;rs11322783;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
CITALOPRAM;CYP2D6;A;rs1065852;OTHER;nan;OTHER:PLASMA_CONCENTRATION_OF_S-DIDESMETHYL-CITALOPRAM
ESCITALOPRAM;CYP2D6;A;rs1065852;OTHER;nan;OTHER:PLASMA_CONCENTRATION_OF_S-DIDESMETHYL-CITALOPRAM
HYDROCHLOROTHIAZIDE;ACE;del/del;rs1799752;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
ASPIRIN;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
CLOPIDOGREL;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
MIRTAZAPINE;CYP2D6;*1/*1xN;CYP2D6*1, CYP2D6*1xN;LADME_PK;INCREASED_PK;PK:CLEARANCE_OF_S(+)_MIRTAZAPINE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
NO_DRUG_RELATED;CYP2D6;*2xN;CYP2D6*2xN;OTHER;INCREASED_RISK;DISEASE:SUICIDE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_IN_THERAPEUTIC_RANGE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;INCREASED;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE
MIRTAZAPINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;LADME_PK;DECREASED_PK;PK:TOTAL_CLEARANCE_OF_RACEMIC_MIRTAZAPINE
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
NO_DRUG_RELATED;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;OTHER;DECREASED_SEVERITY;DISEASE:DEPRESSION
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
IRINOTECAN;UGT1A9;C;rs11692021;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
METOPROLOL;ADRB2;CG;rs1042714;TOXICITY;INCREASED;SIDE_EFFECT:TRIGLYCERIDES
LAMOTRIGINE;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:MACULOPAPULAR_EXANTHEMA
TAMOXIFEN;IGF1R;GG;rs2016347;EFFICACY;INCREASED_RISK;DISEASE:RECURRENCE
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
RALTITREXED;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
WARFARIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
NO_DRUG_RELATED;CYP2D6;*1xN;CYP2D6*1xN;OTHER;INCREASED_RISK;DISEASE:SUICIDE
ALLOPURINOL;HLA-B;*48:01;HLA-B*48:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
PACLITAXEL;CYP2C8;C;rs10509681;TOXICITY;INCREASED_RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VOMITING
RALTITREXED;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VOMITING
PAZOPANIB;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASTHENIA
RALTITREXED;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASTHENIA
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_PK;PK:TROUGH_CONCENTRATIONS
CITALOPRAM;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED;SIDE_EFFECT:INTOLERANCE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
QUETIAPINE;CYP2C19;*1/*2 + *2/*2 + *2/*4;CYP2C19*1, CYP2C19*2, CYP2C19*4;LADME_PK;INCREASED_SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA
CAFFEINE;ADORA2A;TTTTTTT/TTTTTTT;rs35060421;TOXICITY;INCREASED;SIDE_EFFECT:ANXIETY
ALLOPURINOL;HLA-DRB1;*14:01;HLA-DRB1*14:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
ALLOPURINOL;HLA-DRB1;*09:01;HLA-DRB1*09:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
ETHAMBUTOL;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ZONISAMIDE;HLA-A;*02:07;HLA-A*02:07;TOXICITY;nan;DISEASE:STEVENS-JOHNSON_SYNDROME
PHENOBARBITAL;HLA-B;*51:01;HLA-B*51:01;TOXICITY;nan;DISEASE:STEVENS-JOHNSON_SYNDROME
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*17;LADME_PK;DECREASED_PK;PK:MEAN_LOGARITHM_ESCITALOPRAM_CONCENTRATION_AND_HIGHER_MEAN_METABOLIC_RATIO
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;EFFICACY;INCREASED_SEVERITY;OTHER:PAIN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_PK;PK:TROUGH_CONCENTRATIONS
LAMIVUDINE;HLA-B;*35:05;HLA-B*35:05;TOXICITY;nan;SIDE_EFFECT:EXANTHEMA
NEVIRAPINE;HLA-B;*35:05;HLA-B*35:05;TOXICITY;nan;SIDE_EFFECT:EXANTHEMA
STAVUDINE;HLA-B;*35:05;HLA-B*35:05;TOXICITY;nan;SIDE_EFFECT:EXANTHEMA
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_PK;PK:TIME_TO_ACHIEVE_THERAPEUTIC_WINDOW
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;SIDE_EFFECT:DEATH
METHOTREXATE;ABCC2;AG + GG;rs3740065;LADME_PK;INCREASED_PK;PK:PLASMA_LEVEL
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
METOPROLOL;ADRB2;CC;rs1042714;TOXICITY;DECREASED;SIDE_EFFECT:TOTAL_CHOLESTEROL
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
METHOTREXATE;ABCC4;GG + GT;rs9516519;LADME_PK;DECREASED_PK;PK:PLASMA_LEVEL
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
AZATHIOPRINE;NUDT15;del;rs746071566;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MYELOSUPPRESSION
MERCAPTOPURINE;NUDT15;del;rs746071566;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MYELOSUPPRESSION
THIOGUANINE;NUDT15;del;rs746071566;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MYELOSUPPRESSION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_PK;PK:TROUGH_CONCENTRATIONS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_PK;PK:S-CIT_SERUM_CONCENTRATIONS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
ESCITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_PK;PK:MEAN_ESCITALOPRAM_CONCENTRATION
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;DECREASED_EFFICACY;EFFICACY:RESPONSE_WHEN_MEASURED_BY_THE_GERIATRIC_DEPRESSION_SCALE_AT_DAY_7_AND_DAY_28
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
PAROXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT:LOWER_FINAL_DAILY_DOSE | DECREASED_DOSING_COMPLIANCE_AND_LOWER_PLASMA_LEVELS_AT_DAY_28
ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*17;DOSAGE;DECREASED_PK;PK:SERUM_CONCENTRATION
ESCITALOPRAM;CYP2C19;*17/*17;CYP2C19*1, CYP2C19*17;LADME_PK;DECREASED_PK;PK:SERUM_CONCENTRATION
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_DISEASE
MIRTAZAPINE;SLC6A4;HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
ESCITALOPRAM;CYP2C19;*3;CYP2C19*1, CYP2C19*3;DOSAGE;INCREASED_PK;PK:SERUM_CONCENTRATION
ESCITALOPRAM;CYP2C19;*3;CYP2C19*1, CYP2C19*3;LADME_PK;INCREASED_PK;PK:SERUM_CONCENTRATION
LISINOPRIL;MMP3;del/del;rs35068180;EFFICACY;DECREASED_RISK;SIDE_EFFECT:STROKE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_RISK;DISEASE:INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;EFFICACY;EFFICACY:POSITIVE_CORRELATION_OF_PAROXETINE_CONCENTRATION_WITH_IMPROVEMENT_IN_HAMD_SCORES_AT_WEEK_2
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1, CYP2C9*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE | STROKE
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE | STROKE
ESCITALOPRAM;CYP2D6;*4/*41;CYP2D6*1, CYP2D6*4, CYP2D6*41;LADME_PK;INCREASED_PK;PK:MEAN_LOGARITHM_ESCITALOPRAM_CONCENTRATION
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
CLOPIDOGREL;CYP2C19;*1/*3 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_EFFICACY;EFFICACY:RISK_OF_RECURRENT_CARDIOVASCULAR_(CV)_EVENTS_1_YEAR_AFTER_PCI_IN_CHINESE_PATIENTS
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED_EFFICACY;EFFICACY:RISK_OF_RECURRENT_CARDIOVASCULAR_(CV)_EVENTS_1_YEAR_AFTER_PCI_IN_CHINESE_PATIENTS
FENTANYL;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
DIRECT ACTING ANTIVIRALS;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SOFOSBUVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
ESCITALOPRAM;CYP2C19;*2;CYP2C19*1, CYP2C19*2, CYP2C19*3;DOSAGE;INCREASED_PK;PK:SERUM_CONCENTRATION
ESCITALOPRAM;CYP2C19;*2;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_PK;PK:SERUM_CONCENTRATION
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;OTHER:PLATELET_REACTIVITY
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
CITALOPRAM;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;DECREASED_PK;PK:DEMETHYLATION_CLEARANCE_OF_DESMETHYLCITALOPRAM
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
EFAVIRENZ;CYP2B6;*6;CYP2B6*1, CYP2B6*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LONG_QT_SYNDROME
ALLOPURINOL;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
FOLFIRI;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:NEUTROPENIA
EFAVIRENZ;CYP2B6;*9;CYP2B6*1, CYP2B6*9;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DISCONTINUATION
CAPECITABINE;DPYD;CT;rs56038477;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
FLUOROURACIL;DPYD;CT;rs56038477;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
IRINOTECAN;UGT1A6;*2a;UGT1A6*2a;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:VOMITING
OXALIPLATIN;UGT1A6;*2a;UGT1A6*2a;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:VOMITING
TEGAFUR;UGT1A6;*2a;UGT1A6*2a;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:VOMITING
GIMERACIL;UGT1A6;*2a;UGT1A6*2a;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:VOMITING
OTERACIL;UGT1A6;*2a;UGT1A6*2a;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:VOMITING
IRINOTECAN;UGT1A1;*6/*6 + *28/*28 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
IRINOTECAN;UGT1A1;*28;UGT1A1*28;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
OXALIPLATIN;UGT1A1;*28;UGT1A1*28;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
TEGAFUR;UGT1A1;*28;UGT1A1*28;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
GIMERACIL;UGT1A1;*28;UGT1A1*28;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
OTERACIL;UGT1A1;*28;UGT1A1*28;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FOLFOX;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
IRINOTECAN;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
OXALIPLATIN;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
TEGAFUR;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
GIMERACIL;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
OTERACIL;UGT1A1;*60;UGT1A1*60;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ISONIAZID;NAT2;*4;NAT2*4;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*4;NAT2*4;LADME_PK;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*4;NAT2*4;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*4;NAT2*4;LADME_PK;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
WARFARIN;CYP2C9;*3/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
METHOTREXATE;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
EFAVIRENZ;CYP2B6;*9/*9 + *1/*9;CYP2B6*1, CYP2B6*9;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DISCONTINUATION
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:STROKE
FOLFOX;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ANEMIA
MERCAPTOPURINE;TPMT;*1/*2 + *1/*3A + *3A/*3B;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
METHOTREXATE;TPMT;*1/*2 + *1/*3A + *3A/*3B;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
EGFR INHIBITORS;HLA-A;*02:01;HLA-A*02:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:EXANTHEMA
CYCLOPHOSPHAMIDE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1, CYP2B6*6;TOXICITY;DECREASED_RISK;DISEASE:DRUG_TOXICITY
FLUDARABINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1, CYP2B6*6;TOXICITY;DECREASED_RISK;DISEASE:DRUG_TOXICITY
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
ANTINEOPLASTIC AGENTS;UGT2B15;*2/*2 + *1/*2;UGT2B15*1, UGT2B15*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
TAMOXIFEN;UGT2B15;*2/*2 + *1/*2;UGT2B15*1, UGT2B15*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
EGFR INHIBITORS;HLA-A;*03:01;HLA-A*03:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:EXANTHEMA
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED;SIDE_EFFECT:ASTHENIA
DOCETAXEL;SLCO1B3;A;rs3834935;OTHER;INCREASED_PK;PK:AUC
DOCETAXEL;SLCO1B3;A;rs3834935;LADME_PK;INCREASED_PK;PK:AUC
CARBAMAZEPINE;GABRA1;GG;rs2279020;EFFICACY;EFFICACY;EFFICACY:DRUG-RESISTANT_PHENOTYPE
PHENYTOIN;GABRA1;GG;rs2279020;EFFICACY;EFFICACY;EFFICACY:DRUG-RESISTANT_PHENOTYPE
VALPROIC ACID;GABRA1;GG;rs2279020;EFFICACY;EFFICACY;EFFICACY:DRUG-RESISTANT_PHENOTYPE
PACLITAXEL;CYP2C8;*2 + *3 + *4;CYP2C8*2, CYP2C8*3, CYP2C8*4;TOXICITY;INCREASED_RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
ETHAMBUTOL;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ISONIAZID;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PYRAZINAMIDE;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RIFAMPIN;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
AMOXICILLIN;HLA-A;*30:02;HLA-A*30:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLAVULANATE;HLA-A;*30:02;HLA-A*30:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CITALOPRAM;nan;A;rs1074145;OTHER;nan;OTHER:CONCENTRATIONS_OF_S-CITALOPRAM_AND_METABOLIC_RATIO_OF_OF_S-DESMETHYLCITALOPRAM/CITALOPRAM
ESCITALOPRAM;nan;A;rs1074145;OTHER;nan;OTHER:CONCENTRATIONS_OF_S-CITALOPRAM_AND_METABOLIC_RATIO_OF_OF_S-DESMETHYLCITALOPRAM/CITALOPRAM
NEVIRAPINE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
NEVIRAPINE;HLA-DQB1;*06:03;HLA-DQB1*06:03;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ANTINEOPLASTIC AGENTS;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
TAMOXIFEN;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
NEVIRAPINE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NEVIRAPINE;HLA-DRB1;*15:03;HLA-DRB1*15:03;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NEVIRAPINE;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
NEVIRAPINE;HLA-DQB1;*02:01;HLA-DQB1*02:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
IMATINIB;CYP1A2;AA;rs11636419;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIORBITAL_EDEMA
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;OTHER:PLATELET_REACTIVITY
NEVIRAPINE;HLA-DQB1;*02:01;HLA-DQB1*02:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
NEVIRAPINE;HLA-DQB1;*03:02;HLA-DQB1*03:02;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
NEVIRAPINE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
NEVIRAPINE;HLA-DQB1;*03:02;HLA-DQB1*03:02;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ETHANOL;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
CLOPIDOGREL;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*17;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION_INHIBITION
NEVIRAPINE;HLA-DQB1;*05:01;HLA-DQB1*05:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;GABRA1;G;rs2279020;EFFICACY;EFFICACY;EFFICACY:DRUG-RESISTANT_PHENOTYPE
PHENYTOIN;GABRA1;G;rs2279020;EFFICACY;EFFICACY;EFFICACY:DRUG-RESISTANT_PHENOTYPE
VALPROIC ACID;GABRA1;G;rs2279020;EFFICACY;EFFICACY;EFFICACY:DRUG-RESISTANT_PHENOTYPE
METOPROLOL;CYP2D6;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*41;OTHER;nan;OTHER:GREATER_HEART_RATE_(HR)_REDUCTION
BUCILLAMINE;HLA-DRB1;*08:02;HLA-DRB1*08:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PROTEINURIA
MERCAPTOPURINE;TPMT;nan;TPMT deficiency;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DEATH
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
CYCLOSPORINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
PREDNISONE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
BUCILLAMINE;HLA-DQB1;*04:02;HLA-DQB1*04:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PROTEINURIA
CYCLOPHOSPHAMIDE;CYP2B6;CT;rs3211371;EFFICACY;INCREASED_EFFICACY;EFFICACY:RECURRENCE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
WARFARIN;CYP2C9;*2 + *3 + *5 + *6 + *11;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*11;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
SULFAMETHOXAZOLE;HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
TRIMETHOPRIM;HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
DAPSONE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
LAPATINIB;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
DAPSONE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
LAPATINIB;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED_RISK;nan
MERCAPTOPURINE;ABCC4;nan;ABCC4 deficiency;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DEATH
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;nan;OTHER:HIGH_PLATELET_REACTIVITY_(HPR)
AMOXICILLIN;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLAVULANATE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLOZAPINE;HLA-DQB1;*05:02;HLA-DQB1*05:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
ASPIRIN;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
ASPIRIN;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED_RISK;SIDE_EFFECT:URTICARIA
ASPIRIN;CYP2C19;*3;CYP2C19*1, CYP2C19*3;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
ASPIRIN;HLA-DRB1;*13:02;HLA-DRB1*13:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:URTICARIA
SULFAMETHOXAZOLE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
TRIMETHOPRIM;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
CLOZAPINE;HLA-DQB1;*05:02;HLA-DQB1*05:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
CLOZAPINE;HLA-DPB1;*04:01;HLA-DPB1*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
CLOZAPINE;HLA-DRB5;*02:02;HLA-DRB5*02:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
SULFAMETHOXAZOLE;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
TRIMETHOPRIM;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
ASPIRIN;CYP2C19;*17/*17 + *1/*17;CYP2C19*1, CYP2C19*17;EFFICACY;DECREASED_LIKELIHOOD;DISEASE:INFLAMMATION
CLOPIDOGREL;CYP2C19;*17/*17 + *1/*17;CYP2C19*1, CYP2C19*17;EFFICACY;DECREASED_LIKELIHOOD;DISEASE:INFLAMMATION
PRASUGREL;CYP2C19;*17/*17 + *1/*17;CYP2C19*1, CYP2C19*17;EFFICACY;DECREASED_LIKELIHOOD;DISEASE:INFLAMMATION
OXCARBAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
AMOXICILLIN;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:JAUNDICE
CLAVULANATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:JAUNDICE
PAROXETINE;SLC6A4;L allele-rs25531T/L allele-rs25531T;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;OTHER;nan;OTHER:A_CORRELATION_OF_BRAIN_SERT_OCCUPANCY_WAS_ASSOCIATED_WITH_LARGER_PROPORTIONAL_HDRS17_DECREASES
AMOXICILLIN;HLA-DRB5;*01:01;HLA-DRB5*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATITIS
CLAVULANATE;HLA-DRB5;*01:01;HLA-DRB5*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATITIS
SORAFENIB;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
SORAFENIB;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTION
AMOXICILLIN;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATITIS
CLAVULANATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATITIS
SUNITINIB;ABCB1;AA + AG;rs1128503;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DIARRHEA
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA | SEVERE_CUTANEOUS_ADVERSE_REACTIONS
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
TICLOPIDINE;HLA-DRB1;*13:02;HLA-DRB1*13:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:EFFICACY
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:EFFICACY
AMITRIPTYLINE;CYP2D6;*41;CYP2D6*1, CYP2D6*41;OTHER;INCREASED_PK;PK:PLASMA_NORTRIPTYLINE
AMITRIPTYLINE;CYP2D6;*41;CYP2D6*1, CYP2D6*41;LADME_PK;INCREASED_PK;PK:PLASMA_NORTRIPTYLINE
TICLOPIDINE;HLA-C;*14:03;HLA-C*14:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CYCLOPHOSPHAMIDE;CYP2B6;CT;rs3211371;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ATORVASTATIN;LEPR;GG;rs1805094;OTHER;INCREASED;OTHER:BONE_MARROW_DENSITY_IN_THE_LUMBAR_SPINE
TICLOPIDINE;HLA-DQB1;*06:04;HLA-DQB1*06:04;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
TICLOPIDINE;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
BUSULFAN;ABCC3;G;rs4148405;EFFICACY;DECREASED;OTHER:DISEASE-FREE_SURVIVAL
BUSULFAN;ABCC3;G;rs4148405;TOXICITY;DECREASED;OTHER:DISEASE-FREE_SURVIVAL
CYTARABINE;ABCC3;G;rs4148405;EFFICACY;DECREASED;OTHER:DISEASE-FREE_SURVIVAL
CYTARABINE;ABCC3;G;rs4148405;TOXICITY;DECREASED;OTHER:DISEASE-FREE_SURVIVAL
ETOPOSIDE;ABCC3;G;rs4148405;EFFICACY;DECREASED;OTHER:DISEASE-FREE_SURVIVAL
ETOPOSIDE;ABCC3;G;rs4148405;TOXICITY;DECREASED;OTHER:DISEASE-FREE_SURVIVAL
TICLOPIDINE;HLA-B;*44:03;HLA-B*44:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
COCAINE;OPRM1;TT;rs1799972;TOXICITY;INCREASED_RISK;DISEASE:SUBSTANCE-RELATED_DISORDERS
ETHANOL;OPRM1;TT;rs1799972;TOXICITY;INCREASED_RISK;DISEASE:SUBSTANCE-RELATED_DISORDERS
NICOTINE;OPRM1;TT;rs1799972;TOXICITY;INCREASED_RISK;DISEASE:SUBSTANCE-RELATED_DISORDERS
NEVIRAPINE;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
ANTIPSYCHOTICS;COMT;A;rs4680;OTHER;INCREASED;OTHER:METHYLATION_AT_SITES_1_AND_2_IN_THE_COMT_PROMOTER
ISONIAZID;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ASPIRIN;HLA-DRB1;*09:01;HLA-DRB1*09:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:URTICARIA
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ASPIRIN;HLA-DPB1;*05:01;HLA-DPB1*05:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:URTICARIA
CLOPIDOGREL;CYP2C19;nan;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;*1A/*5B;CYP2E1*1A, CYP2E1*5B;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ASPIRIN;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;DECREASED_RISK;SIDE_EFFECT:URTICARIA
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ASPIRIN;HLA-DRB1;*13:02;HLA-DRB1*13:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:URTICARIA
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*1, TPMT*3C;TOXICITY;nan;SIDE_EFFECT:THROMBOCYTOPENIA
THIOGUANINE;TPMT;*1/*3C;TPMT*1, TPMT*3C;TOXICITY;nan;SIDE_EFFECT:THROMBOCYTOPENIA
ASPIRIN;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED_RISK;SIDE_EFFECT:URTICARIA
FLUTICASONE PROPIONATE;CD14;AA + AG;rs2569190;OTHER;DECREASED_EFFICACY;EFFICACY:FEV1/FVC_RATIO
FLUTICASONE PROPIONATE;TMCO6;AA + AG;rs2569190;OTHER;DECREASED_EFFICACY;EFFICACY:FEV1/FVC_RATIO
BLEOMYCIN;GSTM1;non-null/non-null;GSTM1 non-null, GSTM1 null;TOXICITY;DECREASED_RISK;DISEASE:DRUG_TOXICITY
DACARBAZINE;GSTM1;non-null/non-null;GSTM1 non-null, GSTM1 null;TOXICITY;DECREASED_RISK;DISEASE:DRUG_TOXICITY
DOXORUBICIN;GSTM1;non-null/non-null;GSTM1 non-null, GSTM1 null;TOXICITY;DECREASED_RISK;DISEASE:DRUG_TOXICITY
VINBLASTINE;GSTM1;non-null/non-null;GSTM1 non-null, GSTM1 null;TOXICITY;DECREASED_RISK;DISEASE:DRUG_TOXICITY
EFAVIRENZ;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
NEVIRAPINE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ETHANOL;ADH1B;T;rs1229984;TOXICITY;DECREASED_RISK;OTHER:ALCOHOL_ABUSE
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
ISONIAZID;GSTT1;nan;GSTT1 null;LADME_PK;DECREASED_PK;PK:SERUM_HYDRAZINE_CONCENTRATIONS
RIFAMPIN;GSTT1;nan;GSTT1 null;LADME_PK;DECREASED_PK;PK:SERUM_HYDRAZINE_CONCENTRATIONS
CAPECITABINE;DPYD;T;rs56038477;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;DPYD;T;rs56038477;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
TEGAFUR;DPYD;T;rs56038477;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ISONIAZID;GSTM1;nan;GSTM1 null;LADME_PK;INCREASED_PK;PK:SERUM_HYDRAZINE_CONCENTRATIONS
RIFAMPIN;GSTM1;nan;GSTM1 null;LADME_PK;INCREASED_PK;PK:SERUM_HYDRAZINE_CONCENTRATIONS
ALLOPURINOL;HLA-DQB1;*05:02;HLA-DQB1*05:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
ETHAMBUTOL;GSTM1;nan;GSTM1 null;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;GSTM1;nan;GSTM1 null;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;GSTM1;nan;GSTM1 null;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;GSTM1;nan;GSTM1 null;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMATOLOGIC_DISORDER
NEVIRAPINE;HLA-B;*35:01;HLA-B*35:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA | SEVERE_CUTANEOUS_ADVERSE_REACTIONS
METHADONE;CYP3A4;C;rs3735451;OTHER;INCREASED_SEVERITY;SIDE_EFFECT:OPIOID_WITHDRAWAL_SYMPTOMS
IRINOTECAN;UGT1A1;*1/*27;UGT1A1*1, UGT1A1*27;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:LEUKOPENIA
CLOZAPINE;CYP2C19;*17/*17;CYP2C19*17;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DIABETES_MELLITUS
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
CLOZAPINE;HLA-B;*59:01;HLA-B*59:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
IRINOTECAN;UGT1A1;*1/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:LEUKOPENIA
NEVIRAPINE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PHENYTOIN;HLA-B;*13:01;HLA-B*07:02, HLA-B*13:01;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
FLUOXETINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;LADME_PK;PK;PK:SIGNIFICANTLY_HIGHER_(S)-FLUOXETINE_AND_LOWER_AND_(S)-NORFLUOXETINE_CONCENTRATIONS
NO_DRUG_RELATED;TRPA1;CT + TT;rs920829;OTHER;INCREASED_LIKELIHOOD;DISEASE:PAIN
ETHANOL;ALDH2;A;rs671;TOXICITY;DECREASED_RISK;OTHER:ALCOHOL_ABUSE
NO_DRUG_RELATED;NAT2;nan;NAT2 deficiency;OTHER;nan;DISEASE:INSULIN_RESISTANCE
FLUOXETINE;CYP2C9;*1/*2 + *1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;LADME_PK;INCREASED_PK;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS_OF_FLUOXETINE_AND_THE_ACTIVE_MOIETY_IN_PATIENTS_WITH_TWO_FUNCTIONAL_CYP2D6_ALLELES
NORTRIPTYLINE;CYP2D6;*1/*4 + *1/*5;CYP2D6*1, CYP2D6*4, CYP2D6*5;LADME_PK;DECREASED_PK;PK:CONCENTRATIONS_OF_10-OH-NORTRIPTYLINE_AND_HIGHER_NORTRIPTYLINE/10-OH-NORTRIPTYLINE_RATIO
RITODRINE;CACNA1C;AA + AG;rs10774053;OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
SPIRONOLACTONE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del;rs1799752;EFFICACY;EFFICACY;EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR_EJECTION_FRACTION | END-SYSTOLIC_AND_END-DIASTOLIC_VOLUME
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
WARFARIN;APOE;TT;rs429358;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
WARFARIN;APOE;CC;rs7412;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
AMOXICILLIN;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLAVULANATE;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
FLUCLOXACILLIN;HLA-DQB1;*06:02;HLA-DQB1*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ATORVASTATIN;ACE;del/del;rs1799752;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_D-DIMER_LEVELS
QUINAPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_D-DIMER_LEVELS
TIMOLOL;CYP2D6;POOR_METABOLIZER;CYP2D6;EFFICACY;INCREASED_PK;PK:PLASMA_TIMOLOL_CONCENTRATION_AND_EXCERICE_HEART_RATE_REDUCTION
TIMOLOL;CYP2D6;POOR_METABOLIZER;CYP2D6;LADME_PK;INCREASED_PK;PK:PLASMA_TIMOLOL_CONCENTRATION_AND_EXCERICE_HEART_RATE_REDUCTION
LANSOPRAZOLE;CYP2C19;nan;CYP2C19 normal metabolizer;LADME_PK;DECREASED;OTHER:GASTRIC_PH
AMOXICILLIN;HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLAVULANATE;HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
FLUCLOXACILLIN;HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RABEPRAZOLE;CYP2C19;nan;CYP2C19 normal metabolizer;EFFICACY;DECREASED;OTHER:GASTRIC_PH
NO_DRUG_RELATED;AREG;A;rs1615111;OTHER;DECREASED;OTHER:OVERALL_SURVIVAL
CISPLATIN;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
EPIRUBICIN;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
EPIRUBICIN;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FLUOROURACIL;C18orf56;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FLUOROURACIL;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
ATORVASTATIN;ACE;del/del;rs1799752;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_IL-6_LEVELS
QUINAPRIL;ACE;del/del;rs1799752;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_IL-6_LEVELS
ATORVASTATIN;ACE;del/del;rs1799752;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_CRP_LEVELS
QUINAPRIL;ACE;del/del;rs1799752;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_CRP_LEVELS
AMOXICILLIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLAVULANATE;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
FLUCLOXACILLIN;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLOPIDOGREL;CYP2C9;*2/*2;CYP2C9*1, CYP2C9*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
VINCRISTINE;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;TOXICITY;DECREASED;SIDE_EFFECT:AVERAGE_CUMULATIVE_NEUROTOXICITY_GRADE
ASPIRIN;CYP2C19;*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2, CYP2C19*17;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
ETHANOL;CYP2E1;T;rs2031920;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE
CISPLATIN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1, CYP2C9*3;OTHER;INCREASED_LIKELIHOOD;OTHER:BLOOD_COAGULATION_DISORDERS
TOLTERODINE;CYP2D6;*10/*10 + *5/*10;CYP2D6*1, CYP2D6*5, CYP2D6*10;LADME_PK;INCREASED_PK;PK:TOLTERODINE_EXPOSURE_AND_INCREASED_ACTIVE_METABOLITE_(5-HM)_CONCENTRATIONS
AMOXICILLIN;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLAVULANATE;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
FLUCLOXACILLIN;HLA-DQB1;*03:03;HLA-DQB1*03:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PHENYTOIN;CYP2C9;*3;CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ANASTROZOLE;CYP19A1;GG;rs1008805;OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT:ARTHRALGIA
ACE INHIBITORS;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:COUGH
PLAIN;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:COUGH
OLANZAPINE;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE
CYCLOPHOSPHAMIDE;INSR;A;rs41412545;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;INSR;A;rs41412545;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;INSR;A;rs41412545;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CYCLOSPORINE;ATIC;AA;rs2177735;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
METHOTREXATE;ATIC;AA;rs2177735;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
LEVETIRACETAM;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
ALLOPURINOL;HLA-DRB1;*03:01;HLA-DRB1*03:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CYCLOPHOSPHAMIDE;PIK3R2;T;rs56022120;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;PIK3R2;T;rs56022120;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;PIK3R2;T;rs56022120;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
VALPROIC ACID;UGT1A10;G;rs6759892;DOSAGE;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A10;G;rs6759892;LADME_PK;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A6;G;rs6759892;DOSAGE;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A6;G;rs6759892;LADME_PK;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A7;G;rs6759892;DOSAGE;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A7;G;rs6759892;LADME_PK;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A8;G;rs6759892;DOSAGE;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A8;G;rs6759892;LADME_PK;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A9;G;rs6759892;DOSAGE;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A9;G;rs6759892;LADME_PK;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A10;G;rs2070959;DOSAGE;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A10;G;rs2070959;LADME_PK;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A6;G;rs2070959;DOSAGE;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A6;G;rs2070959;LADME_PK;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A7;G;rs2070959;DOSAGE;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A7;G;rs2070959;LADME_PK;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A8;G;rs2070959;DOSAGE;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A8;G;rs2070959;LADME_PK;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A9;G;rs2070959;DOSAGE;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A9;G;rs2070959;LADME_PK;INCREASED_PK;PK:GLUCURONIDATION
CYCLOPHOSPHAMIDE;PIK3R2;A;rs138602176;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;PIK3R2;A;rs138602176;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;PIK3R2;A;rs138602176;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
PHENYTOIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
NEVIRAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
CLOPIDOGREL;MED12L;T/del;rs5853517;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
CLOPIDOGREL;P2RY12;T/del;rs5853517;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
PHENYTOIN;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
EXEMESTANE;nan;TT;rs16964189;TOXICITY;nan;SIDE_EFFECT:A_SIGNIFICANTLY_HIGHER_ODDS_OF_VASOMOTOR_SYMPTOMS_IN_POSTMENOPAUSAL_HORMONE_RECEPTOR_(HR)-POSITIVE_BREAST_CANCER_PATIENTS
CYCLOPHOSPHAMIDE;PERP;A;rs78428806;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;PERP;A;rs78428806;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;PERP;A;rs78428806;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ASPIRIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;EFFICACY;INCREASED_LIKELIHOOD;DISEASE:INFLAMMATION
CLOPIDOGREL;CYP2C9;*2;CYP2C9*1, CYP2C9*2;EFFICACY;INCREASED_LIKELIHOOD;DISEASE:INFLAMMATION
PRASUGREL;CYP2C9;*2;CYP2C9*1, CYP2C9*2;EFFICACY;INCREASED_LIKELIHOOD;DISEASE:INFLAMMATION
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
FLUOROURACIL;DPYD;nan;DPYD deficiency;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
ANTIPSYCHOTICS;INSIG2;CC;rs11123469;EFFICACY;INCREASED_LIKELIHOOD;DISEASE:METABOLIC_SYNDROME
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_EVENTS
FENOFIBRATE;HLA-A;*33:01;HLA-A*33:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
SERTRALINE;HLA-A;*33:01;HLA-A*33:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TERBINAFINE;HLA-A;*33:01;HLA-A*33:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TICLOPIDINE;HLA-A;*33:01;HLA-A*33:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CARBAMAZEPINE;ABCB1;T;rs2032582;EFFICACY;EFFICACY;EFFICACY:DRUG-RESISTANT_PHENOTYPE
PHENYTOIN;ABCB1;T;rs2032582;EFFICACY;EFFICACY;EFFICACY:DRUG-RESISTANT_PHENOTYPE
VALPROIC ACID;ABCB1;T;rs2032582;EFFICACY;EFFICACY;EFFICACY:DRUG-RESISTANT_PHENOTYPE
FLUOROURACIL;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;rs45445694;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
LEUCOVORIN;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;rs45445694;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
OXALIPLATIN;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;rs45445694;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
WARFARIN;CYP4F2;*3;CYP4F2*1, CYP4F2*3;EFFICACY;EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
ASPIRIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTRITIS
CAPECITABINE;DPYD;A;rs67376798;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;DPYD;A;rs67376798;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
TEGAFUR;DPYD;A;rs67376798;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
METOPROLOL;CYP2D6;*1/*4 + *4/*4;CYP2D6*1, CYP2D6*4;LADME_PK;INCREASED_PK;PK:PLASMA_METOPROLOL_CONCENTRATIONS
FLUOROURACIL;DPYD;nan;DPYD deficiency;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ATAZANAVIR;UGT1A1;*28;UGT1A1*1, UGT1A1*28;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
NO_DRUG_RELATED;ACE2;C;rs2285666;OTHER;INCREASED_SEVERITY;OTHER:COVID-19
"""ACE INHIBITORS";ACE;del;rs1799752;EFFICACY;INCREASED_EFFICACY;EFFICACY:MORTALITY
"PLAIN""";ACE;del;rs1799752;EFFICACY;INCREASED_EFFICACY;EFFICACY:MORTALITY
"""BETA BLOCKING AGENTS""";ACE;del;rs1799752;EFFICACY;INCREASED_EFFICACY;EFFICACY:MORTALITY
"""CALCIUM CHANNEL BLOCKERS""";ACE;del;rs1799752;EFFICACY;INCREASED_EFFICACY;EFFICACY:MORTALITY
"""DIGOXIN""";ACE;del;rs1799752;EFFICACY;INCREASED_EFFICACY;EFFICACY:MORTALITY
"""DIURETICS""";ACE;del;rs1799752;EFFICACY;INCREASED_EFFICACY;EFFICACY:MORTALITY
IVACAFTOR;CFTR;del/del;rs113993960;OTHER;DECREASED;SIDE_EFFECT:CYSTIC_FIBROSIS_PULMONARY_EXACERBATION
TEZACAFTOR;CFTR;del/del;rs113993960;OTHER;DECREASED;SIDE_EFFECT:CYSTIC_FIBROSIS_PULMONARY_EXACERBATION
MERCAPTOPURINE;TPMT;*1/*3C;TPMT*1, TPMT*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_LEUKOPENIA
DESIPRAMINE;CYP2D6;*1/*1;CYP2D6*1, CYP2D6*4, CYP2D6*5;LADME_PK;DECREASED_PK;PK:METABOLIC_RATIOS_OF_DESIPAMINE
PAMAQUINE;G6PD;nan;G6PD deficiency;TOXICITY;nan;DISEASE:HEMOLYSIS
METOPROLOL;CYP2D6;*1/*4 + *4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;INCREASED;OTHER:HEART_RATE_(HR)_AND_DIASTOLIC_BLOOD_PRESSURE_(DBP)_REDUCTIONS_DURING_EARLY_TITRATION
METOPROLOL;CYP2D6;*1/*4 + *4/*4;CYP2D6*1, CYP2D6*4;OTHER;INCREASED;OTHER:HEART_RATE_(HR)_AND_DIASTOLIC_BLOOD_PRESSURE_(DBP)_REDUCTIONS_DURING_EARLY_TITRATION
PRIMAQUINE;G6PD;nan;G6PD deficiency;TOXICITY;nan;DISEASE:HEMOLYSIS
ITRACONAZOLE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;OTHER;DECREASED_SEVERITY;OTHER:INHIBITION_OF_CYP3A-CATALYZED_METABOLISM_OF_MIDAZOLAM_OR_TESTOSTERONE
ITRACONAZOLE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_SEVERITY;OTHER:INHIBITION_OF_CYP3A-CATALYZED_METABOLISM_OF_MIDAZOLAM_OR_TESTOSTERONE
KETOCONAZOLE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;OTHER;DECREASED_SEVERITY;OTHER:INHIBITION_OF_CYP3A-CATALYZED_METABOLISM_OF_MIDAZOLAM_OR_TESTOSTERONE
KETOCONAZOLE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;DECREASED_SEVERITY;OTHER:INHIBITION_OF_CYP3A-CATALYZED_METABOLISM_OF_MIDAZOLAM_OR_TESTOSTERONE
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
HMG COA REDUCTASE INHIBITORS;nan;A;rs3764261;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROTECTION_AGAINST_MYOCARDIAL_INFARCTION
CAPECITABINE;TYMS;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA | DRUG_TOXICITY | HAND-FOOT_SYNDROME,
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:ON-TREATMENT_PLATELET_ACTIVITY
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;EFFICACY;DECREASED;SIDE_EFFECT:TIME_BELOW_THERAPEUTIC_RANGE
OSIMERTINIB;CYP2A6;CC;rs28399433;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
AMITRIPTYLINE;CYP2D6;*1/*1xN + *2/*2xN;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
FLUOXETINE;CYP2D6;*1/*1xN + *2/*2xN;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
PAZOPANIB;VEGFA;CC + CT;rs833061;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
PEMETREXED;VEGFA;CC + CT;rs833061;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
WARFARIN;CYP2C9;*3/*3 + *1/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
PENICILLIN G;HLA-B;*55:01;HLA-B*55:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
PENICILLIN V;HLA-B;*55:01;HLA-B*55:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ETHANOL;GHSR;AG;rs2948694;OTHER;nan;OTHER:WEIGHT
OPIOIDS;OPRM1;AG + GG;rs495491;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
NICOTINE;CYP2A6;*46/*46;CYP2A6*1, CYP2A6*46;nan;INCREASED;OTHER:CIGARETTES_PER_DAY
OPIOIDS;OPRM1;AA + AG;rs10457090;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;LADME_PK;INCREASED_PK;PK:STEADY_STATE_CONCENTRATION_PER_DOSAGE
ALLOPURINOL;HLA-B;*58:01/*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EPIDERMAL_NECROLYSIS | TOXIC_OR_STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;SCN2A;A;rs17183814;EFFICACY;EFFICACY;EFFICACY:NON-RESPONSE
PHENYTOIN;SCN2A;A;rs17183814;EFFICACY;EFFICACY;EFFICACY:NON-RESPONSE
VALPROIC ACID;SCN2A;A;rs17183814;EFFICACY;EFFICACY;EFFICACY:NON-RESPONSE
WARFARIN;CYP2C9;*2;CYP2C9*2;EFFICACY;EFFICACY;EFFICACY:SHORTER_TIME_TO_THE_FIRST_INR_OF_MORE_THAN_4
ATORVASTATIN;HTR7;T;rs1935349;TOXICITY;INCREASED_RISK;DISEASE:MYALGIA
PRAVASTATIN;HTR7;T;rs1935349;TOXICITY;INCREASED_RISK;DISEASE:MYALGIA
SIMVASTATIN;HTR7;T;rs1935349;TOXICITY;INCREASED_RISK;DISEASE:MYALGIA
METHOTREXATE;TYMS;CCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTCGCCTGCCTCCGTCCCCC;rs45445694;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
NEVIRAPINE;CYP2B6;*6/*18;CYP2B6*1, CYP2B6*6, CYP2B6*18;TOXICITY;INCREASED_LIKELIHOODPK;PK:ELEVATED_PLASMA_CONCENTRATIONS
NEVIRAPINE;CYP2B6;*6/*18;CYP2B6*1, CYP2B6*6, CYP2B6*18;LADME_PK;INCREASED_LIKELIHOODPK;PK:ELEVATED_PLASMA_CONCENTRATIONS
DOCETAXEL;CYP2A6;*4/*4;CYP2A6*1, CYP2A6*4;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:EFFICACY
TEGAFUR;CYP2A6;*4/*4;CYP2A6*1, CYP2A6*4;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:EFFICACY
CISPLATIN;ERCC2;T;rs1799793;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL
CARBAMAZEPINE;HLA-B;*40:01;HLA-B*40:01;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:STEVENS-JOHNSON_SYNDROME
COCAINE;SLC6A3;CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA;rs3836790;TOXICITY;INCREASED_RISK;DISEASE:DEATH
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;DOSAGE;EFFICACY;EFFICACY:LOWER_WARFARIN_DOSE_REQUIREMENT
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS_IN_TAIWANESE_PATIENTS_RECEIVING_CLOPIDOGREL_AFTER_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI)
PHENYTOIN;HLA-DRB1;*16:02;HLA-DRB1*16:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EPIDERMAL_NECROLYSIS | TOXIC_OR_STEVENS-JOHNSON_SYNDROME
PAROXETINE;CYP2D6;*1/*4;CYP2D6*1, CYP2D6*4, CYP2D6*41;LADME_PK;INCREASED_PK;PK:PAROXETINE_SERUM_CONCENTRATIONS_(CMIN)
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIPHENYLHYDANTOIN-INDUCED_SKIN_RASH
IBUPROFEN;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:DURATION_OF_INHIBITION_OF_PROSTANOIDS
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;LADME_PK;DECREASED_PK;PK:PLASMA_CONCENTRATION
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;LADME_PK;INCREASED_PK;PK:THE_MAXIMAL_ELIMINATION_RATE_(VMAX)
ACETAMINOPHEN;CYP2E1;*1/*5B;CYP2E1*1, CYP2E1*5B;LADME_PK;INCREASED_PK;PK:ELIMINATION_RATE
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;TOXICITY;INCREASED_PK;PK:PLASMA_METHYLMERCAPTOPURINE_NUCLEOTIDES_LEVELS
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
WARFARIN;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE_IN_JAPANESE_PATIENTS
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;EFFICACY;EFFICACY:DECREASED_WARFARIN_DOSE_AND_INCREASED_RISK_OF_OVER-ANTICOAGULATION
WARFARIN;CYP2C9;*2;CYP2C9*2;EFFICACY;EFFICACY;EFFICACY:DECREASED_WARFARIN_DOSE_AND_INCREASED_RISK_OF_OVER-ANTICOAGULATION
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:ADP-INDUCED_MAXIMUM_PLATELET_AGGREGATION
WARFARIN;CYP2C9;*1/*3 + *1/*4;CYP2C9*1, CYP2C9*3, CYP2C9*4;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
MERCAPTOPURINE;CYP2A7;C;rs73032311;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESPONSE_TO_CLOPIDOGREL_AND_POORER_OUTCOMES_IN_CHINESE_PATIENTS_WITH_ACUTE_ISCHEMIC_STROKE
BUPROPION;CYP2B6;*18;CYP2B6*18;LADME_PK;DECREASED_PK;PK:HYDROXYBUPROPION_CONCENTRATIONS
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;LADME_PK;DECREASED_PK;PK:PLASMA_CONCENTRATION
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
PHENYTOIN;CYP2C9;*1/*1;CYP2C9*1;LADME_PK;DECREASED_PK;PK:PLASMA_CONCENTRATION
ANTIEPILEPTICS;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CUTANEOUS_REACTIONS
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CUTANEOUS_REACTIONS
AMITRIPTYLINE;CYP2C19;*2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_PK;PK:MEAN_AMITRIPTYLINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT
PHENYTOIN;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EPIDERMAL_NECROLYSIS | TOXIC_OR_STEVENS-JOHNSON_SYNDROME
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
NO_DRUG_RELATED;NAT1;*10/*11A;NAT1*10, NAT1*11A;OTHER;INCREASED_RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
NO_DRUG_RELATED;NAT1;*10/*4;NAT1*4, NAT1*10;OTHER;INCREASED_RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS
ISONIAZID;GSTT1;nan;GSTT1 null;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;GSTT1;nan;GSTT1 null;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;GSTT1;nan;GSTT1 null;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PACLITAXEL;CYP2C8;*3;CYP2C8*3;LADME_PK;DECREASED_PK;PK:CLERANCE_OF_PACLITAXEL
BUPROPION;CYP2B6;*6;CYP2B6*1, CYP2B6*6;LADME_PK;DECREASED_PK;PK:HYDROXYBUPROPION_CONCENTRATIONS_AND_HYDROXYBUPROPION/BUPROPION_RATIO
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;EFFICACY;EFFICACY:ADP-INDUCED_MAXIMUM_PLATELET_AGGREGATION_(MPA)_IN_CLOPIDOGREL-TREATED_PATIENTS_UNDERGOING_PE_RCUTANEOUS_CORONARY_INTERVENTION
IRINOTECAN;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;DECREASED_RISK;DISEASE:ASTHENIA
RALTITREXED;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;DECREASED_RISK;DISEASE:ASTHENIA
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;EFFICACY;EFFICACY:ADP-INDUCED_MAXIMUM_PLATELET_AGGREGATION_(MPA)_IN_CLOPIDOGREL-TREATED_PATIENTS_UNDERGOING_PE_RCUTANEOUS_CORONARY_INTERVENTION
TEMSIROLIMUS;NR1I2;AG + GG;rs6785049;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
TACROLIMUS;CYP3A4;C/C;rs2242480;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
NO_DRUG_RELATED;NAT1;*11B/*3;NAT1*3, NAT1*11B;OTHER;INCREASED_RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS
NO_DRUG_RELATED;NAT1;*10/*10;NAT1*10;OTHER;INCREASED_RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS
OXCARBAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
CALCINEURIN INHIBITORS;CYP2C8;*3;CYP2C8*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALLOGRAFT_DYSFUNCTION_IN_KIDNEY_TRANSPLANT_RECIPIENTS_TREATED_WITH_CALCINEURIN_INHIBITORS
CYCLOSPORINE;CYP2C8;*3;CYP2C8*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALLOGRAFT_DYSFUNCTION_IN_KIDNEY_TRANSPLANT_RECIPIENTS_TREATED_WITH_CALCINEURIN_INHIBITORS
TACROLIMUS;CYP2C8;*3;CYP2C8*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALLOGRAFT_DYSFUNCTION_IN_KIDNEY_TRANSPLANT_RECIPIENTS_TREATED_WITH_CALCINEURIN_INHIBITORS
DAUNORUBICIN;NRP2;C;rs10932125;DOSAGE;INCREASED_PK;PK:IC50
DAUNORUBICIN;NRP2;C;rs10932125;LADME_PK;INCREASED_PK;PK:IC50
CISPLATIN;GSTM3;CCT/CCT;rs1799735;TOXICITY;DECREASED_RISK;DISEASE:THROMBOCYTOPENIA
CISPLATIN;GSTM3;CCT/CCT;rs1799735;LADME_PK;DECREASED_RISK;DISEASE:THROMBOCYTOPENIA
CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;rs1799735;TOXICITY;DECREASED_RISK;DISEASE:THROMBOCYTOPENIA
CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;rs1799735;LADME_PK;DECREASED_RISK;DISEASE:THROMBOCYTOPENIA
CISPLATIN;GSTM3;CCT/CCT;rs1799735;TOXICITY;DECREASED_RISK;DISEASE:ANEMIA
CISPLATIN;GSTM3;CCT/CCT;rs1799735;LADME_PK;DECREASED_RISK;DISEASE:ANEMIA
CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;rs1799735;TOXICITY;DECREASED_RISK;DISEASE:ANEMIA
CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;rs1799735;LADME_PK;DECREASED_RISK;DISEASE:ANEMIA
CISPLATIN;GSTM3;CCT/CCT;rs1799735;TOXICITY;DECREASED_RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CISPLATIN;GSTM3;CCT/CCT;rs1799735;LADME_PK;DECREASED_RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;rs1799735;TOXICITY;DECREASED_RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CYCLOPHOSPHAMIDE;GSTM3;CCT/CCT;rs1799735;LADME_PK;DECREASED_RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
METOPROLOL;CYP2D6;del/del;rs5030655;OTHER;INCREASED_PK;PK:PLASMA_CONCENTRATIONS_OF_METOPROLOL
ANTIDEPRESSANTS;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;rs57098334;nan;EFFICACY;EFFICACY:LACK_OF_REMISSION_AND_LACK_OF_RESPONSE
ANTIDEPRESSANTS;SLC6A4;(CCCACCCGA)12/(CCCACCCGA)12;rs57098334;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_DRUG_REACTION_AFTER_THE_SECOND_SWITCH_IN_TREATMENT
VALPROIC ACID;UGT1A10;C;rs1105879;LADME_PK;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A6;C;rs1105879;LADME_PK;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A7;C;rs1105879;LADME_PK;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A8;C;rs1105879;LADME_PK;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A9;C;rs1105879;LADME_PK;INCREASED_PK;PK:GLUCURONIDATION
NEVIRAPINE;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;TOXICITY;INCREASED_LIKELIHOODPK;PK:ELEVATED_PLASMA_CONCENTRATIONS
NEVIRAPINE;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;LADME_PK;INCREASED_LIKELIHOODPK;PK:ELEVATED_PLASMA_CONCENTRATIONS
ISONIAZID;CYP2E1;*1A/*1A;CYP2E1*1A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
PYRIDOXAL PHOSPHATE;CYP2E1;*1A/*1A;CYP2E1*1A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ATENOLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;LADME_PK;INCREASED_PK;PK:AMITRIPTYLINE/(E)-10-_OH-AT_RATIO
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;LADME_PK;INCREASED_PK;PK:NORTRIPTYLINE/(E)-10-OH-NT_RATIO
REPAGLINIDE;SLCO1B1;*37/*37;SLCO1B1*1, SLCO1B1*37;LADME_PK;DECREASED_PK;PK:REPAGLINIDE_EXPOSURE_(DECREASED_AUC_AND_INCREASED_CLEARANCE)
PHENYTOIN;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EPIDERMAL_NECROLYSIS | TOXIC_OR_STEVENS-JOHNSON_SYNDROME
BENZENE;NQO1;AA;rs1800566;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMATOTOXICITY
ATAZANAVIR;TPH2;TT;rs4570625;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DEPRESSION
EFAVIRENZ;TPH2;TT;rs4570625;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DEPRESSION
METHOTREXATE;DHFR;TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;rs70991108;TOXICITY;INCREASED_RISK;DISEASE:THROMBOCYTOPENIA
ALLOPURINOL;HLA-C;*03:02;HLA-C*03:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
EFAVIRENZ;CYP2B6;*1;CYP2B6*1;EFFICACY;DECREASED_PK;PK:PLASMA_CONCENTRATION_OF_EFAVIRENZ
EFAVIRENZ;CYP2B6;*1;CYP2B6*1;LADME_PK;DECREASED_PK;PK:PLASMA_CONCENTRATION_OF_EFAVIRENZ
ANTITHYROID PREPARATIONS;HLA-B;*08:01;HLA-B*08:01;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:AGRANULOCYTOSIS
TEGAFUR;CYP2A6;*1;CYP2A6*1;OTHER;INCREASED_PK;PK:PLASMA_FLUOROURACIL
TEGAFUR;CYP2A6;*1;CYP2A6*1;LADME_PK;INCREASED_PK;PK:PLASMA_FLUOROURACIL
PHENYTOIN;CYP2C9;*1/*2 + *1/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED;SIDE_EFFECT:ADVERSE_DRUG_REACTIONS
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
CYCLOSPORINE;CYP3A4;*1/*1;CYP3A4*1, CYP3A4*18;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LIVER_INJURY
ANTIEPILEPTICS;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;EFFICACY;DECREASED_LIKELIHOOD;DISEASE:DRUG_RESISTANCE
ATORVASTATIN;UGT1A3;*2/*2;UGT1A3*1, UGT1A3*2;EFFICACY;INCREASED_PK;PK:ATORVASTATIN_LACTONIZATION
ATORVASTATIN;UGT1A3;*2/*2;UGT1A3*1, UGT1A3*2;LADME_PK;INCREASED_PK;PK:ATORVASTATIN_LACTONIZATION
ATORVASTATIN;UGT1A3;*2;UGT1A3*1, UGT1A3*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:TOTAL_AND_THE_LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_MAXIMUM_PERCENT_DECREASES_FROM_BASELINE
ATORVASTATIN;UGT1A3;*2;UGT1A3*1, UGT1A3*2;LADME_PK;DECREASED_EFFICACY;EFFICACY:TOTAL_AND_THE_LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_MAXIMUM_PERCENT_DECREASES_FROM_BASELINE
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
DOXEPIN;CYP2C9;*3/*3;CYP2C9*3;LADME_PK;DECREASED_PK;PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;DECREASED_PK;PK:ORAL_CLEARANCE_(CL/F)_OF_OMEPRAZOLE_RACEMATE | 5-HYDROXYOMEPRAZOLE | R-OMEPRAZOLE_AND_S-OMEPRAZOLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;DECREASED_PK;PK:ORAL_CLEARANCE_(CL/F)_OF_OMEPRAZOLE_RACEMATE | 5-HYDROXYOMEPRAZOLE | R-OMEPRAZOLE_AND_S-OMEPRAZOLE
TACROLIMUS;CYP2C19;*2/*2;CYP2C19*2;OTHER;INCREASED;OTHER:HOSPITAL_STAY
MERCAPTOPURINE;COMT;A;rs4680;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ROSIGLITAZONE;CYP2C8;*3;CYP2C8*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:MEAN_ABSOLUTE_DIFFERENCE_IN_HBA1C
NORTRIPTYLINE;CYP2D6;*1/*2xN;CYP2D6*1, CYP2D6*2xN;LADME_PK;INCREASED_PK;PK:MAXIMUM_PLASMA_CONCENTRATION_OF_10-HYDROXY_NORTRIPTYLINE
PRAVASTATIN;SLCO1B1;*15;SLCO1B1*1, SLCO1B1*15;LADME_PK;INCREASED_PK;PK:RELATIVE_BIOAVAILABILITY_OF_PRAVASTATIN
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_HYPERSENSITIVITY
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*1, CYP2C19*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:ANTIPLATELET_RESPONSE_AND_REDUCED_CLOPIDOGREL_ACTIVE_METABOLITE_FORMATION
AMITRIPTYLINE;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;LADME_PK;INCREASED_PK;PK:MEAN_AMITRIPTYLINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:CLOPIDOGREL_RESPONSE_IN_CHINESE_PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI)
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:CLOPIDOGREL_RESPONSE_IN_CHINESE_PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI)
NO_DRUG_RELATED;CYP2C19;*17;CYP2C19*1, CYP2C19*17;OTHER;RISK;DISEASE:PEPTIC_ULCER_DISEASE
CAFFEINE;ADORA2A;TT;rs5751876;OTHER;INCREASED;SIDE_EFFECT:ANXIETY
METHOTREXATE;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3;rs45445694;EFFICACY;INCREASED_SEVERITY;DISEASE:RHEUMATOID_ARTHRITIS
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:COMPOSITE_ISCHEMIC_EVENTS
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;TOXICITY;INCREASED_PK;PK:PLASMA_CONCENTRATION
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*6;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:COMPOSITE_ISCHEMIC_EVENTS
ATORVASTATIN;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED;SIDE_EFFECT:SERUM_CREATINE_KINASE_LEVELS_(INCREASED_RISK_OF_MYALGIA_AND_GREATER_DEGREE_OF_MUSCLE_DAMAGE)
NEVIRAPINE;ABCC10;CC;rs2125739;EFFICACY;INCREASED_LIKELIHOODPK;PK:LOWER_NEVIRAPINE_PLASMA_CONCENTRATIONS
NEVIRAPINE;ABCC10;CC;rs2125739;LADME_PK;INCREASED_LIKELIHOODPK;PK:LOWER_NEVIRAPINE_PLASMA_CONCENTRATIONS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARBAMAZEPINE-INDUCED_HYPERSENSITIVITY
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARBAMAZEPINE-INDUCED_STEVENS-JOHNSON_SYNDROME_(SJS)_AND_TOXIC_EPIDERMAL_NECROLYSIS_(TEN)
METFORMIN;SLC22A1;GTAAGTTG;rs36056065;TOXICITY;nan;SIDE_EFFECT:GASTROINTESTINAL_SIDE_EFFECTS
METFORMIN;SLC22A1;GTAAGTTG;rs36056065;LADME_PK;nan;SIDE_EFFECT:GASTROINTESTINAL_SIDE_EFFECTS
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:STEVENS-JOHNSON_SYNDROME
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;*1A/*1A;CYP2E1*1A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARBAMAZEPINE-INDUCED_HYPERSENSITIVITY_SYNDROME
CLOPIDOGREL;CYP2C19;*17;CYP2C19*17;EFFICACY;EFFICACY;EFFICACY:ENHANCED_RESPONSE_TO_CLOPIDOGREL_(AS_MEASURED_BY_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION)
PHENYTOIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PHENYTOIN_TOXICITY
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:ANTIPLATELET_RESPONSE_AND_REDUCED_CLOPIDOGREL_ACTIVE_METABOLITE_FORMATION
NO_DRUG_RELATED;NAT1;*10/*11B;NAT1*10, NAT1*11B;OTHER;INCREASED_RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS
EFAVIRENZ;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;DECREASED_PK;PK:ORAL_CLEARANCE_(CL/F)_OF_OMEPRAZOLE_RACEMATE | 5-HYDROXYOMEPRAZOLE | R-OMEPRAZOLE_AND_S-OMEPRAZOLE
OMEPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;DECREASED_PK;PK:ORAL_CLEARANCE_(CL/F)_OF_OMEPRAZOLE_RACEMATE | 5-HYDROXYOMEPRAZOLE | R-OMEPRAZOLE_AND_S-OMEPRAZOLE
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;*02:01;HLA-DQB1*02:01;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
NO_DRUG_RELATED;NAT1;*11A/*4;NAT1*4, NAT1*11A;OTHER;INCREASED_RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS
WARFARIN;CYP2C9;*3;CYP2C9*3;EFFICACY;EFFICACY;EFFICACY:SHORTER_TIME_TO_THE_FIRST_INR_OF_MORE_THAN_4
MERCAPTOPURINE;TPMT;*1/*3A;TPMT*1, TPMT*3A;TOXICITY;INCREASED_PK;PK:PLASMA_THIOGUANINE_NUCLEOTIDES_METABOLITES
PRAVASTATIN;SLCO1B1;*1/*15;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;LADME_PK;INCREASED_PK;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX
PRAVASTATIN;SLCO1B1;*1/*15;SLCO1B1*1, SLCO1B1*15;LADME_PK;INCREASED_PK;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX
WARFARIN;CYP2C9;*1/*13;CYP2C9*1, CYP2C9*13;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE_IN_KOREAN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT_SINCE_DAY_7_OF_WARFARIN_THERAPY
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;INCREASED_RISK;OTHER:COMPLICATIONS
PHENPROCOUMON;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;OTHER:COMPLICATIONS
CLOPIDOGREL;CYP2C19;*1/*3;CYP2C19*1, CYP2C19*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:ADP-INDUCED_MAXIMUM_PLATELET_AGGREGATION
METOPROLOL;CYP2D6;*4;CYP2D6*4;DOSAGE;INCREASED_RISK;DISEASE:BRADYCARDIA
METOPROLOL;CYP2D6;*4;CYP2D6*4;TOXICITY;INCREASED_RISK;DISEASE:BRADYCARDIA
PRAVASTATIN;SLCO1B1;*15/*15;SLCO1B1*1, SLCO1B1*15;LADME_PK;INCREASED_PK;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;nan;GSTM1 null;TOXICITY;DECREASED_SEVERITY;DISEASE:DRUG_TOXICITY
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
ASPIRIN;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
ASPIRIN;CYP2C19;*3;CYP2C19*3;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
CLOPIDOGREL;CYP2C19;*3;CYP2C19*3;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE_AFTER_ADJUSTMENT_FOR_VKORC1*1173
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
DOXEPIN;CYP2D6;*3/*5;CYP2D6*3, CYP2D6*5;LADME_PK;DECREASED_PK;PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN
HALOPERIDOL;COMT;AG;rs4680;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
ATORVASTATIN;CYP2D6;*4;CYP2D6*4;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCLE_EFFECTS
DOXEPIN;CYP2D6;*4/*5;CYP2D6*4, CYP2D6*5;LADME_PK;DECREASED_PK;PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN
WARFARIN;CYP2C9;*1/*13;CYP2C9*1, CYP2C9*13;EFFICACY;EFFICACY;EFFICACY:DELAYED_TIME_TO_REACH_STABLE_DOSE_AND_AND_TENDED_TO_HAVE_HIGH_RISK_FOR_THE_FIRST_INR_GREATER_THAN_3.5
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;EFFICACY;EFFICACY:DECREASED_WARFARIN_DOSE_AND_INCREASED_RISK_OF_OVER-ANTICOAGULATION
WARFARIN;CYP2C9;*3;CYP2C9*3;EFFICACY;EFFICACY;EFFICACY:DECREASED_WARFARIN_DOSE_AND_INCREASED_RISK_OF_OVER-ANTICOAGULATION
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
WARFARIN;CYP2C9;*1/*14;CYP2C9*1, CYP2C9*14;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE_IN_KOREAN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT_SINCE_DAY_7_OF_WARFARIN_THERAPY
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEAN_INR_VALUES_IN_PATIENTS_WITH_HEART_VALVE_REPLACEMENT
CLOPIDOGREL;CYP2B6;*5;CYP2B6*5;EFFICACY;EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY_IN_CYP2C19*1/*1_CARRIERS
VENLAFAXINE;CYP2D6;*10/*10;CYP2D6*10;LADME_PK;INCREASED_PK;PK:CMAX_AND_AUC_OF_VENLAFAXINE
WARFARIN;CYP2C9;*2/*3;CYP2C9*2, CYP2C9*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEAN_INR_VALUE
WARFARIN;CYP2C9;*2;CYP2C9*2;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
WARFARIN;CYP2C9;*3;CYP2C9*3;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
VENLAFAXINE;CYP2D6;*1/*10;CYP2D6*1, CYP2D6*10;LADME_PK;INCREASED_PK;PK:CMAX_AND_AUC_OF_VENLAFAXINE
WARFARIN;CYP2C9;*1/*14;CYP2C9*1, CYP2C9*14;EFFICACY;EFFICACY;EFFICACY:DELAYED_TIME_TO_REACH_STABLE_DOSE_AND_AND_TENDED_TO_HAVE_HIGH_RISK_FOR_THE_FIRST_INR_GREATER_THAN_3.5
WARFARIN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;EFFICACY;EFFICACY;EFFICACY:DELAYED_TIME_TO_REACH_STABLE_DOSE_AND_AND_TENDED_TO_HAVE_HIGH_RISK_FOR_THE_FIRST_INR_GREATER_THAN_3.5
PHENPROCOUMON;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
PHENPROCOUMON;CYP2C9;*3;CYP2C9*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:ACHIEVING_A_STABLE_DOSE
PHENPROCOUMON;CYP2C9;*2;CYP2C9*2;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:ACHIEVING_A_STABLE_DOSE
ESCITALOPRAM;CYP2D6;*4/*10;CYP2D6*1, CYP2D6*4, CYP2D6*10;EFFICACY;INCREASED_EFFICACY;EFFICACY:FREQUENCY_OF_REMITTERS
LANSOPRAZOLE;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;OTHER:INTRAGASTRIC_PH
LANSOPRAZOLE;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED;OTHER:INTRAGASTRIC_PH
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:ON-CLOPIDOGREL_PLATELET_AGGREGATION_(PA)_AND_HIGHER_PLATELET_REACTIVITY_INDEX_(PRI)_IN_PATIENTS_UNDERGOING_ELECTIVE_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI)
TRAMADOL;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;LADME_PK;DECREASED_PK;PK:TRAMADOL_CLEARANCE_IN_CHINESE_VOLUNTEERS
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED_EFFICACY;EFFICACY:TRAMADOL_METABOLISM_AND_RESPONSE
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;LADME_PK;DECREASED_EFFICACY;EFFICACY:TRAMADOL_METABOLISM_AND_RESPONSE
OMEPRAZOLE;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;OTHER:MEAL-STIMULATED_PLASMA_GASTRIN_CONCENTRATIONS
PAROXETINE;CYP2D6;*4/*4 + *3/*4;CYP2D6*3, CYP2D6*4;LADME_PK;INCREASED_PK;PK:PAROXETINE_PLASMA_CONCENTRATIONS_INCREASED_DURING_THE_COURSE_OF_PREGNANCY
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;DOSAGE;DECREASED_EFFICACY;EFFICACY:METABOLISM_AND_DECREASED_RESPONSE_TO_TRAMADOL
TRAMADOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;DECREASED_EFFICACY;EFFICACY:METABOLISM_AND_DECREASED_RESPONSE_TO_TRAMADOL
CLOPIDOGREL;CYP2C19;*1/*3 + *3/*3;CYP2C19*1, CYP2C19*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESPONSE_TO_CLOPIDOGREL_AND_POORER_OUTCOMES_IN_CHINESE_PATIENTS_WITH_ACUTE_ISCHEMIC_STROKE
TAMOXIFEN;CYP2D6;*6/*7;CYP2D6*6, CYP2D6*7;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
ESCITALOPRAM;CYP2D6;*5/*10;CYP2D6*1, CYP2D6*5, CYP2D6*10;EFFICACY;INCREASED_EFFICACY;EFFICACY:FREQUENCY_OF_REMITTERS
TAMOXIFEN;CYP2D6;*3/*6;CYP2D6*3, CYP2D6*6;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
TRAMADOL;CYP2D6;*3/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4;DOSAGE;DECREASED_EFFICACY;EFFICACY:METABOLISM_AND_DECREASED_RESPONSE_TO_TRAMADOL
TRAMADOL;CYP2D6;*3/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4;EFFICACY;DECREASED_EFFICACY;EFFICACY:METABOLISM_AND_DECREASED_RESPONSE_TO_TRAMADOL
CLOMIPRAMINE;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEAN_CLOMIPRAMINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT_AND_HIGHER_METABOLIC_RATIO_OF_CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE
NORTRIPTYLINE;CYP2D6;*4;CYP2D6*1, CYP2D6*4;LADME_PK;INCREASED_PK;PK:MEAN_NORTRIPTYLINE_CONCENTRATIONS_AND_NORTRIPTYLINE_CONCENTRATIONS_PER_UNIT_DOSE_OF_THE_MEDICATION
OXYCODONE;CYP2D6;*4/*4 + *3/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4;LADME_PK;PK;PK:MEAN_PLASMA_CONCENTRATION_OF_OXYMORPHONE_AND_LOWER_MEAN_OXYMORPHONE/OXYCODONE_RATIO
PAROXETINE;CYP2D6;*1/*1 + *1/*41;CYP2D6*1, CYP2D6*41;LADME_PK;DECREASED_PK;PK:PAROXETINE_PLASMA_CONCENTRATIONS_INCREASED_DURING_THE_COURSE_OF_PREGNANCY
NORTRIPTYLINE;CYP2D6;*5/*10;CYP2D6*1, CYP2D6*5, CYP2D6*10;LADME_PK;INCREASED_PK;PK:MEAN_NORTRIPTYLINE_CONCENTRATIONS_AND_NORTRIPTYLINE_CONCENTRATIONS_PER_UNIT_DOSE_OF_THE_MEDICATION
DESIPRAMINE;CYP2D6;*1/*1;CYP2D6*1, CYP2D6*3, CYP2D6*4;LADME_PK;DECREASED_PK;PK:METABOLIC_RATIOS_OF_DESIPAMINE
TRAMADOL;CYP2D6;*2/*10;CYP2D6*1, CYP2D6*2, CYP2D6*10;LADME_PK;DECREASED_PK;PK:TRAMADOL_CLEARANCE_IN_CHINESE_VOLUNTEERS
TRAMADOL;CYP2D6;*3/*5;CYP2D6*1, CYP2D6*3, CYP2D6*5;DOSAGE;DECREASED_EFFICACY;EFFICACY:METABOLISM_AND_DECREASED_RESPONSE_TO_TRAMADOL
TRAMADOL;CYP2D6;*3/*5;CYP2D6*1, CYP2D6*3, CYP2D6*5;EFFICACY;DECREASED_EFFICACY;EFFICACY:METABOLISM_AND_DECREASED_RESPONSE_TO_TRAMADOL
NORTRIPTYLINE;CYP2D6;*5;CYP2D6*1, CYP2D6*2, CYP2D6*5;LADME_PK;INCREASED_PK;PK:NORTRIPTYLINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT
PAROXETINE;CYP2D6;*1/*10 + *1/*5;CYP2D6*1, CYP2D6*5, CYP2D6*10;LADME_PK;INCREASED_PK;PK:PAROXETINE_PLASMA_CONCENTRATION_AT_AN_ADMINISTERED_DOSE_OF_30MG/DAY
COTININE;CYP2A6;*1/*1;CYP2A6*1, CYP2A6*2, CYP2A6*9, CYP2A6*17, CYP2A6*20;LADME_PK;PK;PK:SHORTER_CONTININ_HALF-LIFE
MIRTAZAPINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;LADME_PK;DECREASED_PK;PK:CLEARANCE_OF_S(+)_MIRTAZAPINE
PAROXETINE;CYP2D6;*1/*4;CYP2D6*1, CYP2D6*4;LADME_PK;INCREASED_PK;PK:PAROXETINE_LEVELS
CLOMIPRAMINE;CYP2C19;*3;CYP2C19*1, CYP2C19*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEAN_CLOMIPRAMINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT_AND_HIGHER_METABOLIC_RATIO_OF_CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;DECREASED_PK;PK:ORAL_CLEARANCE_OF_CITALOPRAM
PAROXETINE;CYP2D6;*10/*10 + *1/*10;CYP2D6*1, CYP2D6*10;LADME_PK;INCREASED_PK;PK:PLASMA_PAROXETINE_CONCENTRATIONS_AT_ADMINISTERED_DOSE_OF_10MG/DAY
MIRTAZAPINE;CYP2D6;*1/*1xN;CYP2D6*1, CYP2D6*1xN;LADME_PK;INCREASED_PK;PK:TOTAL_CLEARANCE_OF_RACEMIC_MIRTAZAPINE
CODEINE;CYP2D6;*36;CYP2D6*1, CYP2D6*36;LADME_PK;DECREASED_PK;PK:CODEINE_METABOLISM_AND_MORPHINE_AND_GLUCURONIDES_FORMATION
CODEINE;CYP2D6;*1/*1 + *1/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;LADME_PK;INCREASED_PK;PK:PLASMA_LEVEL_OF_MORPHINE
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:ON-TREATMENT_PLATELET_AGGREGATION
WARFARIN;CYP2C9;*2/*2 + *2/*3 + *3/*3;CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
NO_DRUG_RELATED;UGT1A1;T;rs34946978;OTHER;INCREASED_LIKELIHOOD;OTHER:GILBERT_SYNDROME | CRIGLER-NAJJAR_SYNDROME
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
FLURBIPROFEN;CYP2C9;*1/*3;CYP2C9*1, CYP2C9*3;LADME_PK;INCREASED_PK;PK:AUC | HIGHER_HALF-LIFE_AND_LOWER_FLURBIPROFEN_CLEARANCE
DICLOFENAC;CYP2C8;*1/*4 + *4/*4;CYP2C8*1, CYP2C8*4;LADME_PK;INCREASED_PK;PK:DICLOFENAC/5-HYDROXYDICLOFENAC_URINARY_CONCENTRATION_RATIO
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_AND_CEREBROVASCULAR_EVENTS
PYRIMIDINE ANALOGUES;MIR27A;CC + CT;rs895819;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_AND_CEREBROVASCULAR_EVENTS
CITALOPRAM;CYP2C19;POOR_METABOLIZER;CYP2C19;LADME_PK;INCREASED_PK;PK:PLASMA_RATIO_CITALOPRAM_(CIT)/N-DESMETHYLCIT_(DCIT)
TIMOLOL;CYP2D6;*3/*3 + *3/*4 + *4/*4 + *5/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;LADME_PK;INCREASED_PK;PK:EXPOSURE_TO_TIMOLOL_(HIGHER_AREA-UNDER-CURVE | LONGER_ELIMINATION_HALF-LIVES_)
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
CLOPIDOGREL;PON1;C;rs662;EFFICACY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOTAL_HEMORRHAGE_AND_MAJOR_HEMORRHAGE
TENOXICAM;CYP2C9;*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;LADME_PK;INCREASED_PK;PK:AUC_AND_HALF-LIFE_TIME_(T1/2)
IBUPROFEN;CYP2C8;*1/*3;CYP2C8*1, CYP2C8*3;TOXICITY;DECREASED;SIDE_EFFECT:INOS_EXPRESSION_AND_FEWER_ADVERSE_EVENTS
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CLOPIDOGREL;P2RY12;A;rs2046934;EFFICACY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
ANTIEPILEPTICS;HLA-B;*58:01;HLA-B*58:01;TOXICITY;DECREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
ASPIRIN;HLA-DPB1;*03:01;HLA-DPB1*03:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASTHMA
SULFONAMIDES;TCF7L2;CC;rs7903146;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(REDUCTIONS_IN_HAEMOGLOBIN_A1C_(HBA1C)_AND_FASTING_PLASMA_GLUCOSE_(FPG)_LEVELS)
UREA DERIVATIVES;TCF7L2;CC;rs7903146;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(REDUCTIONS_IN_HAEMOGLOBIN_A1C_(HBA1C)_AND_FASTING_PLASMA_GLUCOSE_(FPG)_LEVELS)
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
LUMACAFTOR;CFTR;del/del;rs113993960;TOXICITY;INCREASED_EFFICACY;EFFICACY:CHANGE_IN_SWEAT_CHLORIDE
CAFFEINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ABORTION | SPONTANEOUS
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
ACENOCOUMAROL;CYP2C9;*2/*2 + *2/*3 + *3/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;DOSAGE;DECREASED_EFFICACY;EFFICACY:ACENOCOUMAROL_DOSE
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:ON-CLOPIDOGREL_PLATELET_AGGREGATION_(PA)_AND_HIGHER_PLATELET_REACTIVITY_INDEX_(PRI)_IN_PATIENTS_UNDERGOING_ELECTIVE_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI)
CODEINE;CYP2D6;*1/*10 + *10/*10;CYP2D6*1, CYP2D6*10;LADME_PK;DECREASED_PK;PK:PLASMA_LEVELS_OF_MORPHINE | M3G_AND_M6G_LEVELS_BUT_NOT_THOSE_OF_CODEINE
AZATHIOPRINE;TPMT;*1/*2 + *1/*3A + *1/*3C;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;TOXICITY;INCREASED_RISK;DISEASE:TRANSPLANT_REJECTION
BOSENTAN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;TOXICITY;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
CODEINE;CYP2D6;*1/*1 + *1/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;OTHER;INCREASED;OTHER:OROCECCAL_TRANSIT_TIME
NO_DRUG_RELATED;CYP1B1;CC + CG;rs1056836;nan;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL | OVERALL_SURVIVAL
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_AND_CEREBROVASCULAR_EVENTS
TETRABENAZINE;CYP2D6;INTERMEDIATE_METABOLIZER;CYP2D6;EFFICACY;EFFICACY;EFFICACY:LESS_ROBUST_TREATMENT_RESPONSE
WARFARIN;CYP4F2;*3;CYP4F2*1, CYP4F2*3;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEMORRHAGE
CITALOPRAM;SLC6A4;HTTLPR short form (S allele)/L allele-rs25531C;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SIDE_EFFECTS
CITALOPRAM;CYP2C19;*1/*17;CYP2C19*1, CYP2C19*17;LADME_PK;DECREASED_PK;PK:METABOLIC_RATIO_CIT/DCIT_VALUES
CLOPIDOGREL;PTGS1;T;rs1330344;EFFICACY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CLOMIPRAMINE;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);TOXICITY;INCREASED;SIDE_EFFECT:CLOMIPRAMINE-INDUCED_PROLACTIN_RELEASE
CITALOPRAM;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;LADME_PK;INCREASED_PK;PK:AUC_OF_CITALOPRAM
PAROXETINE;SLC6A4;HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_EFFICACY;EFFICACY:PRESENTATION_IN_THE_NON-REPONDER_GROUP
PHENOBARBITAL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_DRUG_REACTIONS
OLANZAPINE;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DIZZINESS
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ISCHAEMIC_STROKE
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:PRU
CLOPIDOGREL;CYP2C19;*2/*2 + *1/*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS
CARBAMAZEPINE;HLA-B;*07:02;HLA-B*07:02, HLA-B*08:01;TOXICITY;DECREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
TRICHLOROETHYLENE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_CLINICAL_EVENTS
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_CLINICAL_EVENTS
AZATHIOPRINE;TPMT;*3A/*3C;TPMT*3A, TPMT*3C;TOXICITY;SEVERITY;SIDE_EFFECT:LEUKOPENIA
CYCLOSPORINE;TPMT;*3A/*3C;TPMT*3A, TPMT*3C;TOXICITY;SEVERITY;SIDE_EFFECT:LEUKOPENIA
PREDNISONE;TPMT;*3A/*3C;TPMT*3A, TPMT*3C;TOXICITY;SEVERITY;SIDE_EFFECT:LEUKOPENIA
ALLOPURINOL;HLA-A;*02:01;HLA-A*02:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
WARFARIN;CYP2C9;*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CARDIOVASCULAR_EVENT_OCCURRENCE
ALLOPURINOL;HLA-C;*08:01;HLA-C*08:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
IRINOTECAN;UGT1A7;*3;UGT1A7*3;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:VOMITING
OXALIPLATIN;UGT1A7;*3;UGT1A7*3;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:VOMITING
TEGAFUR;UGT1A7;*3;UGT1A7*3;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:VOMITING
GIMERACIL;UGT1A7;*3;UGT1A7*3;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:VOMITING
OTERACIL;UGT1A7;*3;UGT1A7*3;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:VOMITING
ASPIRIN;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
OSIMERTINIB;CYP2C9;CC;rs1057910;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS | EXANTHEMA
CITALOPRAM;SLC6A4;HTTLPR long form (L allele)/HTTLPR long form (L allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
MYCOPHENOLATE MOFETIL;CYP2C8;CC;rs11572076;TOXICITY;DECREASED_RISK;DISEASE:LEUKOPENIA
ALLOPURINOL;HLA-A;*33:03;HLA-A*33:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CLOZAPINE;HLA-DRB3;*02:02;HLA-DRB3*02:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
MERCAPTOPURINE;TPMT;C;rs1142345;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
MYCOPHENOLATE MOFETIL;UGT2B7;G;rs7438135;TOXICITY;INCREASED_RISK;DISEASE:ANEMIA
CLOZAPINE;HLA-C;*07:01;HLA-C*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
CLOZAPINE;HLA-DRB1;*01:01;HLA-DRB1*01:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
AZATHIOPRINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PANCREATITIS
MERCAPTOPURINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PANCREATITIS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED;OTHER:PLATELET_REACTIVITY
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
SULFASALAZINE;HLA-B;*39:01;HLA-B*39:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
METHAZOLAMIDE;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
CARBIMAZOLE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
METHIMAZOLE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
PROPYLTHIOURACIL;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
PLATINUM COMPOUNDS;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
PYRIMIDINE ANALOGUES;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CILOSTAZOL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
ACENOCOUMAROL;CYP2C9;*3;CYP2C9*1, CYP2C9*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
WARFARIN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | EXANTHEMA | STEVENS-JOHNSON_SYNDROME,
CAPECITABINE;DPYD;nan;DPYD deficiency;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;DPYD;nan;DPYD deficiency;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
DOLASETRON;CYP2D6;*1/*1xN;CYP2D6*1, CYP2D6*1xN;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
CYCLOSPORINE;NFATC2;AA;rs6123048;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
METHOTREXATE;NFATC2;AA;rs6123048;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
CYCLOPHOSPHAMIDE;CYP2C8;*4;CYP2C8*1, CYP2C8*4;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
EPIRUBICIN;CYP2C8;*4;CYP2C8*1, CYP2C8*4;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
PACLITAXEL;CYP2C8;*4;CYP2C8*1, CYP2C8*4;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
TAMOXIFEN;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ABACAVIR;HLA-B;*57:01;HLA-B*57:01;TOXICITY;nan;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
IFOSFAMIDE;ALDH1A1;AA;rs3764435;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ASPIRIN;CYP2C19;*17;CYP2C19*1, CYP2C19*17;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CLOPIDOGREL;CYP2C19;*17;CYP2C19*1, CYP2C19*17;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
DAPSONE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
CLOZAPINE;GSTT1;null/null;GSTT1 non-null, GSTT1 null;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CLOPIDOGREL;CYP2C19;*3;CYP2C19*1, CYP2C19*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:ACHIEVING_SVR_IN_OLDER_PATIENTS_WITH_GENOTYPE_1B_CHRONIC_HEPATITIS_C
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:ACHIEVING_SVR_IN_OLDER_PATIENTS_WITH_GENOTYPE_1B_CHRONIC_HEPATITIS_C
TELAPREVIR;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:ACHIEVING_SVR_IN_OLDER_PATIENTS_WITH_GENOTYPE_1B_CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
AZATHIOPRINE;NUDT15;del;rs746071566;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PANCYTOPENIA | THROMBOCYTOPENIA
MERCAPTOPURINE;NUDT15;del;rs746071566;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PANCYTOPENIA | THROMBOCYTOPENIA
HMG COA REDUCTASE INHIBITORS;ADAMTS1;CC;rs402007;EFFICACY;EFFICACY;EFFICACY:THE_MOST_BENEFIT_FROM_STATIN_TREATMENT_IN_REDUCING_THE_RISK_OF_MYOCARDIAL_INFARCTION
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NICOTINE;CYP2B6;*1/*4 + *4/*4;CYP2B6*1, CYP2B6*4;TOXICITY;INCREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
NICOTINE;CYP2A6;*1/*1;CYP2A6*1, CYP2A6*12;TOXICITY;DECREASED_RISK;OTHER:TOBACCO_USE_DISORDER
ANTITHYROID PREPARATIONS;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
ANTITHYROID PREPARATIONS;HLA-DRB1;*08:03;HLA-DRB1*08:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
AMOXICILLIN;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLAVULANATE;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
FLUCLOXACILLIN;HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED_RISK;DISEASE:VIRUS_DISEASES
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED_RISK;DISEASE:INFECTIOUS_DISEASE
GEFITINIB;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:ALLOGRAFT_REJECTION
CARBOPLATIN;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
PACLITAXEL;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
LAMOTRIGINE;SCN1A;C;rs3812718;EFFICACY;INCREASED_EFFICACY;EFFICACY:TONIC_BLOCK_OF_NA(V)_1.1_CHANNELS
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_PK;PK:FORMATION_OF_METABOLITES
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TRANSPLANT_REJECTION
PEMETREXED;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
METHOTREXATE;TYMS;del;rs11280056;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
NO_DRUG_RELATED;SLCO1B1;C;rs4149056;OTHER;DECREASED;OTHER:ERYTHROMYCIN_TRANSPORT
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
LEVOFLOXACIN;HLA-B;*13:01 + *13:02;HLA-B*13:01, HLA-B*13:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
PHENYTOIN;HLA-A;*03:01;HLA-A*03:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ASPIRIN;CYP2C19;INTERMEDIATE_METABOLIZER;CYP2C19;EFFICACY;INCREASED_RISK;SIDE_EFFECT:THROMBOTIC_DISEASE
CLOPIDOGREL;CYP2C19;INTERMEDIATE_METABOLIZER;CYP2C19;EFFICACY;INCREASED_RISK;SIDE_EFFECT:THROMBOTIC_DISEASE
BETA-LACTAM ANTIBACTERIALS;HLA-DRB1;*10:01;HLA-DRB1*10:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
PENICILLINS;HLA-DRB1;*10:01;HLA-DRB1*10:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_EVENTS
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_EVENTS
PROTON PUMP INHIBITORS;CYP2C19;*1/*1 + *1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_EVENTS
TAMOXIFEN;CYP2D6;*10/*10  + *1/*10;CYP2D6*1, CYP2D6*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
CLOPIDOGREL;CYP2C19;*1/*1 + *1/*17 + *17/*17;CYP2C19*1, CYP2C19*17;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEMORRHAGE
ASPIRIN;CYP2C19;POOR_METABOLIZER;CYP2C19;EFFICACY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CLOPIDOGREL;CYP2C19;POOR_METABOLIZER;CYP2C19;EFFICACY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CYCLOSPORINE;SLC19A1;TT;rs4818789;EFFICACY;DECREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
METHOTREXATE;SLC19A1;TT;rs4818789;EFFICACY;DECREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
ATENOLOL;ADRB2;GG;rs1042714;TOXICITY;INCREASED_RISK;DISEASE:HYPERTRIGLYCERIDEMIA
METOPROLOL;ADRB2;GG;rs1042714;TOXICITY;INCREASED_RISK;DISEASE:HYPERTRIGLYCERIDEMIA
ZOLEDRONATE;nan;CC;rs1152003;TOXICITY;INCREASED_RISK;DISEASE:OSTEONECROSIS
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ANTIDEPRESSANTS;CYP2C19;INTERMEDIATE_METABOLIZER;CYP2C19;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | VOMITING
ANTIPSYCHOTICS;CYP2C19;INTERMEDIATE_METABOLIZER;CYP2C19;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | VOMITING
ATORVASTATIN;HMGCR;T;rs17671591;EFFICACY;EFFICACY;EFFICACY:LDL-C_RESPONSE
ANTIDEPRESSANTS;CYP2D6;INTERMEDIATE_METABOLIZER;CYP2D6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DEPRESSION
ANTIPSYCHOTICS;CYP2D6;INTERMEDIATE_METABOLIZER;CYP2D6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DEPRESSION
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_SEVERITY;SIDE_EFFECT:DRUG-DRUG_PHARMACOKINETIC_INTERACTION
VORICONAZOLE;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;LADME_PK;INCREASED_SEVERITY;SIDE_EFFECT:DRUG-DRUG_PHARMACOKINETIC_INTERACTION
CARBOPLATIN;LIG3;T;rs1052536;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
PACLITAXEL;LIG3;T;rs1052536;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
CLOPIDOGREL;CYP1A2;A;rs2069514;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DEATH
CYCLOSPORINE;SLC19A1;TT;rs4819128;EFFICACY;DECREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
METHOTREXATE;SLC19A1;TT;rs4819128;EFFICACY;DECREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
ETHAMBUTOL;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ISONIAZID;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PYRAZINAMIDE;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RIFAMPIN;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ATORVASTATIN;HMGCR;T;rs10474433;EFFICACY;EFFICACY;EFFICACY:LDL-C_RESPONSE
VANCOMYCIN;HLA-A;*32:01;HLA-A*32:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS | DRUG-INDUCED_LIVER_INJURY
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
ATORVASTATIN;PCSK9;T;rs11591147;EFFICACY;EFFICACY;EFFICACY:LDL-C_RESPONSE
"""BETA-LACTAM ANTIBACTERIALS";HLA-A;*02:07;HLA-A*02:07;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
"PENICILLINS""";HLA-A;*02:07;HLA-A*02:07;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
"""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-A;*02:07;HLA-A*02:07;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
"""BETA-LACTAM ANTIBACTERIALS";HLA-A;*01:01;HLA-A*01:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
"PENICILLINS""";HLA-A;*01:01;HLA-A*01:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
"""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-A;*01:01;HLA-A*01:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
"""BETA-LACTAM ANTIBACTERIALS";HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
"PENICILLINS""";HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
"""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-C;*06:02;HLA-C*06:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
"""BETA-LACTAM ANTIBACTERIALS";HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
"PENICILLINS""";HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
"""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-DRB1;*15:01;HLA-DRB1*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
"""BETA-LACTAM ANTIBACTERIALS";HLA-DQB1;*03:02;HLA-DQB1*03:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
"PENICILLINS""";HLA-DQB1;*03:02;HLA-DQB1*03:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
"""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-DQB1;*03:02;HLA-DQB1*03:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CLOPIDOGREL;CYP2C19;POOR_METABOLIZER;CYP2C19;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
VALPROIC ACID;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
ATORVASTATIN;APOE;T;rs429358;EFFICACY;EFFICACY;EFFICACY:LDL-C_RESPONSE
ENALAPRIL;nan;TT;rs495828;TOXICITY;INCREASED_RISK;DISEASE:COUGH
RIBAVIRIN;ITPA;AC;rs1127354;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SOFOSBUVIR;ITPA;AC;rs1127354;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
ENALAPRIL;nan;TT;rs495828;TOXICITY;INCREASED_RISK;DISEASE:COUGH
ATORVASTATIN;APOE;T;rs7412;EFFICACY;EFFICACY;EFFICACY:LDL-C_RESPONSE
NO_DRUG_RELATED;GSTT1;nan;GSTT1 non-null, GSTT1 null;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TRANSPLANT_REJECTION
NO_DRUG_RELATED;GSTT1;nan;GSTT1 non-null, GSTT1 null;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TRANSPLANT_REJECTION
SIMVASTATIN;ABCG2;TT;rs2231142;LADME_PK;INCREASED_PK;PK:EXPOSURE_TO_DRUG
CISPLATIN;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPONATREMIA
DOCETAXEL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPONATREMIA
FLUOROURACIL;TYMS;TTA/TTA;rs11280056;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPONATREMIA
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS | MACULOPAPULAR_EXANTHEMA | DRUG_HYPERSENSITIVITY
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS
NO_DRUG_RELATED;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
EFAVIRENZ;CYP2B6;POOR_METABOLIZER;CYP2B6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
CAPECITABINE;DPYS;(T)7/(T)8;rs143004875;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;DPYS;(T)7/(T)8;rs143004875;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
FLUVASTATIN;ABCG2;TT;rs2231142;LADME_PK;INCREASED_PK;PK:EXPOSURE_TO_DRUG
CAPECITABINE;DPYD;c.1129-5923C>G, c.1236G>A (HapB3);DPYD c.1129-5923C>G, c.1236G>A (HapB3);TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;DPYD;c.1129-5923C>G, c.1236G>A (HapB3);DPYD c.1129-5923C>G, c.1236G>A (HapB3);TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
OSIMERTINIB;CYP2A6;*4;CYP2A6*4;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
OSIMERTINIB;ABCG2;TT;rs2622604;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
L-ASPARAGINE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
PREDNISONE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
VINCRISTINE;CYP3A5;*3/*3 + *3/*6 + *3/*7;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
L-ASPARAGINE;ASNS;(GCGGGGCGCAGGGC)3/(GCGGGGCGCAGGGC)3;rs3832526;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
PREDNISONE;ASNS;(GCGGGGCGCAGGGC)3/(GCGGGGCGCAGGGC)3;rs3832526;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
VINCRISTINE;ASNS;(GCGGGGCGCAGGGC)3/(GCGGGGCGCAGGGC)3;rs3832526;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
PRAVASTATIN;NPC1L1;CC;rs17655652;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_LDL-C
PRAVASTATIN;NPC1L1;CC;rs17655652;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_LDL-C
ETHAMBUTOL;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ISONIAZID;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PYRAZINAMIDE;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RIFAMPIN;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEMORRHAGE
CLOPIDOGREL;CYP2C19;*2;CYP2C19*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CLOPIDOGREL;CYP2C19;*17;CYP2C19*17;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
TRAMADOL;CYP2B6;POOR_METABOLIZER;CYP2B6;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:POSTOPERATIVE_PAIN
TRAMADOL;CYP3A4;POOR_METABOLIZER;CYP3A4;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIZZINESS | SOMNOLENCE
CITALOPRAM;CYP2C19;POOR_METABOLIZER;CYP2C19;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
ESCITALOPRAM;CYP2C19;POOR_METABOLIZER;CYP2C19;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
IRINOTECAN;HLA-B;C;rs9266271;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
ANTIINFLAMMATORY AGENTS;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
NON-STEROIDS;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ANTIINFLAMMATORY AGENTS;HLA-A;*34:01;HLA-A*34:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
NON-STEROIDS;HLA-A;*34:01;HLA-A*34:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ANTIINFLAMMATORY AGENTS;HLA-DRB1;*16:02;HLA-DRB1*16:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
NON-STEROIDS;HLA-DRB1;*16:02;HLA-DRB1*16:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ATORVASTATIN;HMGCR;GG;rs3846662;EFFICACY;INCREASED_EFFICACY;EFFICACY:LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_LEVEL_IN_BASAL_STATE_AND_POSSIBLY_IN_RESPONSE_TO_ATORVASTATIN.
CLOPIDOGREL;ABCB1;GG;rs1128503;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY | TREMOR | DIABETES_MELLITUS,
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*6;NAT2*4, NAT2*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:ACUTE_CELLULAR_REJECTION
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
BETA BLOCKING AGENTS;ADRB1;AG + GG;rs1801252;EFFICACY;INCREASED_EFFICACY;EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR(LV)_REMODELING
METOPROLOL;ADRB1;AG + GG;rs1801252;EFFICACY;INCREASED_EFFICACY;EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR(LV)_REMODELING
LANSOPRAZOLE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY
FOLFIRI;TYMS;del/del;rs11280056;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FOLFOX;TYMS;del/del;rs11280056;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
XELOX;TYMS;del/del;rs11280056;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IRINOTECAN;ALOX5;T;rs1051713;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
ETOPOSIDE;nan;GG;rs6539870;OTHER;INCREASED;OTHER:SENSITIVITY_TO_ETOPOSIDE
"""INTERFERON ALFA-2B";ITPA;CC;rs1127354;EFFICACY;DECREASED_EFFICACY;EFFICACY:FREQUENCY_OF_PATIENTS_WHO_RECEIVED_AT_LEAST_THE_RECOMMENDED_80%_OF_SCHEDULED_RIBAVIRIN
"RECOMBINANT""";ITPA;CC;rs1127354;EFFICACY;DECREASED_EFFICACY;EFFICACY:FREQUENCY_OF_PATIENTS_WHO_RECEIVED_AT_LEAST_THE_RECOMMENDED_80%_OF_SCHEDULED_RIBAVIRIN
"""RIBAVIRIN""";ITPA;CC;rs1127354;EFFICACY;DECREASED_EFFICACY;EFFICACY:FREQUENCY_OF_PATIENTS_WHO_RECEIVED_AT_LEAST_THE_RECOMMENDED_80%_OF_SCHEDULED_RIBAVIRIN
CLOPIDOGREL;CYP2C19;*2 + *3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:STROKE
"""INTERFERON ALFA-2B";ITPA;CC;rs1127354;EFFICACY;EFFICACY;EFFICACY:CUMULATIVE_REDUCTION_OF_RIBAVIRIN
"RECOMBINANT""";ITPA;CC;rs1127354;EFFICACY;EFFICACY;EFFICACY:CUMULATIVE_REDUCTION_OF_RIBAVIRIN
"""RIBAVIRIN""";ITPA;CC;rs1127354;EFFICACY;EFFICACY;EFFICACY:CUMULATIVE_REDUCTION_OF_RIBAVIRIN
ASPARAGINASE;F5;CT;rs6025;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOEMBOLISM
DABIGATRAN;CES1;GG + GT;rs2244613;LADME_PK;DECREASED_PK;PK:ADJUSTED_TROUGH_CONCENTRATIONS
DESIPRAMINE;MC1R;G;rs2228478;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
NO_DRUG_RELATED;ABCB1;A;rs1045642;nan;INCREASED;OTHER:LEVEL_OF_APOLIPOPROTEIN_A1
ACENOCOUMAROL;VKORC1;AA;rs9934438;DOSAGE;DECREASED_EFFICACY;EFFICACY:DOSE_REQUIREMENT
ACENOCOUMAROL;VKORC1;AA;rs9934438;EFFICACY;DECREASED_EFFICACY;EFFICACY:DOSE_REQUIREMENT
ACENOCOUMAROL;VKORC1;AA;rs9934438;TOXICITY;DECREASED_EFFICACY;EFFICACY:DOSE_REQUIREMENT
DESIPRAMINE;MC1R;A;rs2228479;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
ETHAMBUTOL;NAT2;*16/*7;NAT2*4, NAT2*7, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ETHAMBUTOL;NAT2;*16/*7;NAT2*4, NAT2*7, NAT2*16;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*16/*7;NAT2*4, NAT2*7, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*16/*7;NAT2*4, NAT2*7, NAT2*16;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*16/*7;NAT2*4, NAT2*7, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*16/*7;NAT2*4, NAT2*7, NAT2*16;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*16/*7;NAT2*4, NAT2*7, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*16/*7;NAT2*4, NAT2*7, NAT2*16;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
CARBAMAZEPINE;LTA;A;rs1800629;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SERIOUS_HYPERSENSITIVITY
CARBAMAZEPINE;TNF;A;rs1800629;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SERIOUS_HYPERSENSITIVITY
ASPARAGINASE;IL16;GG + GT;rs11556218;TOXICITY;INCREASED_RISK;SIDE_EFFECT:THROMBOTIC_DISEASE
MERCAPTOPURINE;PACSIN2;TT;rs2413739;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMATOLOGIC_DISORDER
GEMCITABINE;SLC29A1;CT + TT;rs9394992;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
DOCETAXEL;SPG7;A;rs2292954;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
THALIDOMIDE;SPG7;A;rs2292954;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
ANTINEOPLASTIC AGENTS;CTH;CC;rs648743;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
DOCETAXEL;ABCC6;C;rs2238472;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
THALIDOMIDE;ABCC6;C;rs2238472;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
DOCETAXEL;ATP7A;G;rs2227291;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
THALIDOMIDE;ATP7A;G;rs2227291;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
MERCAPTOPURINE;GNMT;CT + TT;rs10948059;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEMATOLOGIC_DISORDER
ACENOCOUMAROL;CYP4F2;CC;rs2108622;OTHER;DECREASED;OTHER:LEVELS_OF_VITAMIN_K-DEPENDENT_PROTEINS
ACENOCOUMAROL;CYP4F2;CC;rs2108622;LADME_PK;DECREASED;OTHER:LEVELS_OF_VITAMIN_K-DEPENDENT_PROTEINS
ACENOCOUMAROL;CYP4F2;CT;rs2108622;OTHER;DECREASED;OTHER:LEVELS_OF_VITAMIN_K-DEPENDENT_PROTEINS
ACENOCOUMAROL;CYP4F2;CT;rs2108622;LADME_PK;DECREASED;OTHER:LEVELS_OF_VITAMIN_K-DEPENDENT_PROTEINS
DABIGATRAN;CES1;GG + GT;rs2244613;TOXICITY;DECREASED_RISK;SIDE_EFFECT:BLEEDING_EVENTS
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENT
ACENOCOUMAROL;CYP4F2;CC;rs2108622;DOSAGE;DECREASED_EFFICACY;EFFICACY:DOSAGE_REQUIREMENT
ACENOCOUMAROL;CYP4F2;CC;rs2108622;EFFICACY;DECREASED_EFFICACY;EFFICACY:DOSAGE_REQUIREMENT
ACENOCOUMAROL;CYP4F2;CC;rs2108622;TOXICITY;DECREASED_EFFICACY;EFFICACY:DOSAGE_REQUIREMENT
CLOPIDOGREL;ABCB1;AA;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
TAMOXIFEN;CYP2D6;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
IRINOTECAN;SLCO1B1;AA + AG;rs4149015;TOXICITY;INCREASED;DISEASE:NEUTROPENIA
NO_DRUG_RELATED;CHRM3;AA + AG;rs2165870;nan;INCREASED_RISK;DISEASE:POSTOPERATIVE_NAUSEA_AND_VOMITING
ISONIAZID;NAT2;*16/*16;NAT2*4, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:A_MILD_INCREASE_OF_LIVER_ENZYMES
PYRAZINAMIDE;NAT2;*16/*16;NAT2*4, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:A_MILD_INCREASE_OF_LIVER_ENZYMES
RIFAMPIN;NAT2;*16/*16;NAT2*4, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:A_MILD_INCREASE_OF_LIVER_ENZYMES
SALBUTAMOL;ADRB2;AA;rs1042713;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:ASTHMA_EXACERBATIONS
SALMETEROL;ADRB2;AA;rs1042713;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:ASTHMA_EXACERBATIONS
IRINOTECAN;UGT1A9;del/del;rs3832043;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
ANTIPSYCHOTICS;HTR2C;C;rs1414334;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
ARIPIPRAZOLE;HTR2C;C;rs1414334;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
CLOZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
OLANZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
QUETIAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
CISPLATIN;SLC16A5;T;rs4788863;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY
ISONIAZID;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*1, NAT2*4, NAT2*5, NAT2*5G, NAT2*5J, NAT2*6, NAT2*7, NAT2*14, NAT2*16, NAT2*17, NAT2*30, NAT2*34;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_REACTIONS
RIFAMPIN;NAT2;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;NAT2*1, NAT2*4, NAT2*5, NAT2*5G, NAT2*5J, NAT2*6, NAT2*7, NAT2*14, NAT2*16, NAT2*17, NAT2*30, NAT2*34;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_REACTIONS
IRINOTECAN;ABCC2;CC;rs3740066;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
ETHAMBUTOL;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ISONIAZID;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PYRAZINAMIDE;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RIFAMPIN;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ENALAPRIL;BDKRB2;CT + TT;rs1799722;TOXICITY;INCREASED_RISK;DISEASE:COUGH
IMIDAPRIL;BDKRB2;CT + TT;rs1799722;TOXICITY;INCREASED_RISK;DISEASE:COUGH
LISINOPRIL;BDKRB2;CT + TT;rs1799722;TOXICITY;INCREASED_RISK;DISEASE:COUGH
IRINOTECAN;ABCG2;CT + TT;rs2231137;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
CLOZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED_RISK;SIDE_EFFECT:METABOLIC_SYNDROME
RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED_RISK;SIDE_EFFECT:METABOLIC_SYNDROME
HMG COA REDUCTASE INHIBITORS;SREBF1;AA + AG;rs11868035;OTHER;INCREASED;OTHER:TOTAL_CHOLESTEROL
OXYCODONE;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7;DOSAGE;INCREASED_PK;PK:OXYCODONE_CONSUMPTION_UP_TO_THE_12(TH)_HOUR_IN_POSTOPERATIVE_PATIENTS
CISPLATIN;GSTP1;G;rs1695;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY
ACE INHIBITORS;BDKRB2;T;rs1799722;TOXICITY;INCREASED_RISK;DISEASE:COUGH
PLAIN;BDKRB2;T;rs1799722;TOXICITY;INCREASED_RISK;DISEASE:COUGH
ATORVASTATIN;ABCG2;TT;rs2231142;DOSAGE;INCREASED_PK;PK:AUC
ATORVASTATIN;ABCG2;TT;rs2231142;LADME_PK;INCREASED_PK;PK:AUC
LANSOPRAZOLE;CYP2C19;nan;CYP2C19 intermediate metabolizers;LADME_PK;DECREASED;OTHER:GASTRIC_PH
ETHAMBUTOL;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5, NAT2*6, NAT2*7;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ETHAMBUTOL;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5, NAT2*6, NAT2*7;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5, NAT2*6, NAT2*7;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5, NAT2*6, NAT2*7;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5, NAT2*6, NAT2*7;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5, NAT2*6, NAT2*7;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5, NAT2*6, NAT2*7;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*5, NAT2*6, NAT2*7;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ETHAMBUTOL;NAT2;*6/*7;NAT2*6, NAT2*7;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*6/*7;NAT2*6, NAT2*7;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*6/*7;NAT2*6, NAT2*7;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*6/*7;NAT2*6, NAT2*7;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
IRBESARTAN;AGTR1;AC + CC;rs5186;EFFICACY;INCREASED_EFFICACY;EFFICACY:BLOOD_PRESSURE_RESPONSE
ETHAMBUTOL;NAT2;*6/*6;NAT2*6;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*6/*6;NAT2*6;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*6/*6;NAT2*6;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*6/*6;NAT2*6;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
OPIOIDS;PDE3A;A;rs12305038;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NAUSEA | VOMITING
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*7;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*7;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*7;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*5/*7 + *6/*6 + *6/*7;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*7;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
DEXMEDETOMIDINE;ADRA2A;G;rs1800544;EFFICACY;INCREASED_EFFICACY;EFFICACY:BISPECTRAL_INDEX_AND_RAMSAY_SEDATION_SCORES | INDICATING_A_LONGER_PERIOD_FOR_FALLING_ASLEEP
PACLITAXEL;CYP2C8;G;rs1113129;TOXICITY;DECREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES
OPIOIDS;MUC16;T;rs11882256;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NAUSEA | VOMITING
ISONIAZID;NAT2;*6;NAT2*6;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*6;NAT2*6;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*6;NAT2*6;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*6;NAT2*6;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ROSUVASTATIN;ABCG2;TT;rs2231142;DOSAGE;INCREASED_PK;PK:AUC
ROSUVASTATIN;ABCG2;TT;rs2231142;LADME_PK;INCREASED_PK;PK:AUC
ISONIAZID;NAT2;*6/*6;NAT2*6;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*6/*6;NAT2*6;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*6/*6;NAT2*6;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*6/*6;NAT2*6;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*6/*6;NAT2*6;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*6/*6;NAT2*6;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
SULFAMETHOXAZOLE;NAT2;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;NAT2*5, NAT2*6, NAT2*7, NAT2*14, NAT2*16;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
TRIMETHOPRIM;NAT2;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;NAT2*5, NAT2*6, NAT2*7, NAT2*14, NAT2*16;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
IRINOTECAN;UGT1A1;AA;rs4148323;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
ROSUVASTATIN;ABCG2;GG;rs2231142;DOSAGE;DECREASED_PK;PK:AUC
ROSUVASTATIN;ABCG2;GG;rs2231142;LADME_PK;DECREASED_PK;PK:AUC
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*6;NAT2*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*6/*7;NAT2*6, NAT2*7;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*6/*7;NAT2*6, NAT2*7;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*6/*7;NAT2*6, NAT2*7;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*6/*7;NAT2*6, NAT2*7;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
SORAFENIB;TNF;GG;rs1800629;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
OPIOIDS;PDE3A;A;rs12305038;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NAUSEA | VOMITING
IRINOTECAN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
ALFENTANIL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED_RISK;DISEASE:PAIN
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
"""INTERFERON ALFA-2B";ITPA;CC;rs1127354;TOXICITY;DECREASED;SIDE_EFFECT:HEMOGLOBIN_LEVELS
"RECOMBINANT""";ITPA;CC;rs1127354;TOXICITY;DECREASED;SIDE_EFFECT:HEMOGLOBIN_LEVELS
"""RIBAVIRIN""";ITPA;CC;rs1127354;TOXICITY;DECREASED;SIDE_EFFECT:HEMOGLOBIN_LEVELS
ETHAMBUTOL;NAT2;*6;NAT2*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*6;NAT2*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*6;NAT2*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*6;NAT2*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ALFENTANIL;OPRM1;AG + GG;rs1799971;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
SALMETEROL;ADRB2;AA;rs1042713;EFFICACY;INCREASED_RISK;OTHER:ASTHMA_EXACERBATIONS
PEGINTERFERON ALFA-2B;DNAAF9;C;rs6051702;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ANEMIA
PEGINTERFERON ALFA-2B;ITPA;C;rs6051702;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ANEMIA
RIBAVIRIN;DNAAF9;C;rs6051702;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ANEMIA
RIBAVIRIN;ITPA;C;rs6051702;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ANEMIA
CLOPIDOGREL;MIR6076;GG + GT;rs1463411;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
LANSOPRAZOLE;CYP2C19;nan;CYP2C19 intermediate metabolizers;LADME_PK;DECREASED;OTHER:GASTRIC_PH
TAMOXIFEN;LRMDA;C;rs10509373;EFFICACY;DECREASED;OTHER:RECURRENCE-FREE_SURVIVAL
OPIOIDS;CRYBG2;T;rs36024412;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NAUSEA | VOMITING
ETHAMBUTOL;NAT2;G;rs1799930;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;G;rs1799930;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;G;rs1799930;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;G;rs1799930;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ETHAMBUTOL;NAT2;*6/*7;NAT2*6, NAT2*7;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ETHAMBUTOL;NAT2;*6/*7;NAT2*6, NAT2*7;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*6/*7;NAT2*6, NAT2*7;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*6/*7;NAT2*6, NAT2*7;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*6/*7;NAT2*6, NAT2*7;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*6/*7;NAT2*6, NAT2*7;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*6/*7;NAT2*6, NAT2*7;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*6/*7;NAT2*6, NAT2*7;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
OPIOIDS;CLCC1;T;rs168107;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NAUSEA | VOMITING
CAPECITABINE;CDA;CT + TT;rs1048977;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
BOCEPREVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
BOCEPREVIR;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
TELAPREVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
TELAPREVIR;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PLATINUM COMPOUNDS;SLC31A1;AC;rs10759637;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
OPIOIDS;POM121L2;T;rs41269255;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NAUSEA | VOMITING
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*1, NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*1, NAT2*4, NAT2*6, NAT2*7, NAT2*16;LADME_PK;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
"COMBINATIONS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*1, NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
"COMBINATIONS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*1, NAT2*4, NAT2*6, NAT2*7, NAT2*16;LADME_PK;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*1, NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*1, NAT2*4, NAT2*6, NAT2*7, NAT2*16;LADME_PK;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
DIPYRONE;NAT2;*16 + *6 + *7 + *14;NAT2*6, NAT2*7, NAT2*14, NAT2*16;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
ETHAMBUTOL;NAT2;*16 + *6 + *7 + *14;NAT2*6, NAT2*7, NAT2*14, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ETHAMBUTOL;NAT2;*16 + *6 + *7 + *14;NAT2*6, NAT2*7, NAT2*14, NAT2*16;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*16 + *6 + *7 + *14;NAT2*6, NAT2*7, NAT2*14, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*16 + *6 + *7 + *14;NAT2*6, NAT2*7, NAT2*14, NAT2*16;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*16 + *6 + *7 + *14;NAT2*6, NAT2*7, NAT2*14, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*16 + *6 + *7 + *14;NAT2*6, NAT2*7, NAT2*14, NAT2*16;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*16 + *6 + *7 + *14;NAT2*6, NAT2*7, NAT2*14, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*16 + *6 + *7 + *14;NAT2*6, NAT2*7, NAT2*14, NAT2*16;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
METHOTREXATE;ABCC2;AG + GG;rs3740065;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
IRINOTECAN;NR3C1;A;rs61754806;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
IRINOTECAN;VKORC1;T;rs7294;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
PLATINUM COMPOUNDS;SLC31A1;AA;rs2233914;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
OPIOIDS;ZNF165;C;rs9393888;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NAUSEA | VOMITING
CISPLATIN;TPMT;CT;rs1142345;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CYCLOPHOSPHAMIDE;TPMT;CT;rs1142345;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
HMG COA REDUCTASE INHIBITORS;SLCO1B1;*5;SLCO1B1*5;TOXICITY;DECREASED_RISK;SIDE_EFFECT:CATARACT
GEMCITABINE;RRM1;AA;rs9937;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
OLANZAPINE;DRD2;C;rs1799978;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_UNTIL_RESPONSE
RISPERIDONE;DRD2;C;rs1799978;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_UNTIL_RESPONSE
PLATINUM COMPOUNDS;SLC31A1;AA;rs2233914;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;TOXICITY;INCREASED_RISK;SIDE_EFFECT:BLEEDING_EVENTS
ETHAMBUTOL;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ISONIAZID;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PYRAZINAMIDE;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RIFAMPIN;NAT2;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
METHOTREXATE;ABCC4;GG + GT;rs9516519;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXICITY
ESCITALOPRAM;CYP2D6;POOR_METABOLIZER;CYP2D6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PSYCHOMOTOR_AGITATION | HYPERKINESIS | IMPULSE_CONTROL_DISORDER,
RISPERIDONE;CYP2D6;nan;CYP2D6 normal metabolizer;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DISCONTINUATION
PALIPERIDONE;CYP2D6;POOR_METABOLIZER;CYP2D6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION | WEIGHT_GAIN
ETHAMBUTOL;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*6, NAT2*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ISONIAZID;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*6, NAT2*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PYRAZINAMIDE;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*6, NAT2*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RIFAMPIN;NAT2;*6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*6, NAT2*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TRAMADOL;CYP2D6;*10/*10;CYP2D6*10;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;EFFICACY;DECREASED_EFFICACY;EFFICACY:MAGNITUDE_OF_PLATELET_REACTIVITY
ISONIAZID;NAT2;*6 + *7;NAT2*6, NAT2*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ETHAMBUTOL;NAT2;*6 + *7;NAT2*4, NAT2*6, NAT2*7;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*6 + *7;NAT2*4, NAT2*6, NAT2*7;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*6 + *7;NAT2*4, NAT2*6, NAT2*7;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*6 + *7;NAT2*4, NAT2*6, NAT2*7;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATOTOXICITY
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATOTOXICITY
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATOTOXICITY
ETHAMBUTOL;NAT2;*16;NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*16;NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*16;NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*16;NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ETHAMBUTOL;NAT2;*6/*6 + *6/*7;NAT2*6, NAT2*7;TOXICITY;INCREASED_RISK;DISEASE:HEPATITIS
ETHAMBUTOL;NAT2;*6/*6 + *6/*7;NAT2*6, NAT2*7;LADME_PK;INCREASED_RISK;DISEASE:HEPATITIS
ISONIAZID;NAT2;*6/*6 + *6/*7;NAT2*6, NAT2*7;TOXICITY;INCREASED_RISK;DISEASE:HEPATITIS
ISONIAZID;NAT2;*6/*6 + *6/*7;NAT2*6, NAT2*7;LADME_PK;INCREASED_RISK;DISEASE:HEPATITIS
PYRAZINAMIDE;NAT2;*6/*6 + *6/*7;NAT2*6, NAT2*7;TOXICITY;INCREASED_RISK;DISEASE:HEPATITIS
PYRAZINAMIDE;NAT2;*6/*6 + *6/*7;NAT2*6, NAT2*7;LADME_PK;INCREASED_RISK;DISEASE:HEPATITIS
RIFAMPIN;NAT2;*6/*6 + *6/*7;NAT2*6, NAT2*7;TOXICITY;INCREASED_RISK;DISEASE:HEPATITIS
RIFAMPIN;NAT2;*6/*6 + *6/*7;NAT2*6, NAT2*7;LADME_PK;INCREASED_RISK;DISEASE:HEPATITIS
ANTIINFLAMMATORY AGENTS;HLA-DRB1;*04:03;HLA-DRB1*04:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NON-STEROIDS;HLA-DRB1;*04:03;HLA-DRB1*04:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:ON-TREATMENT_PLATELET_REACTIVITY
ETHAMBUTOL;NAT2;*16/*4;NAT2*4, NAT2*16;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ETHAMBUTOL;NAT2;*16/*4;NAT2*4, NAT2*16;LADME_PK;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*16/*4;NAT2*4, NAT2*16;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*16/*4;NAT2*4, NAT2*16;LADME_PK;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*16/*4;NAT2*4, NAT2*16;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*16/*4;NAT2*4, NAT2*16;LADME_PK;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*16/*4;NAT2*4, NAT2*16;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*16/*4;NAT2*4, NAT2*16;LADME_PK;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
PLATINUM COMPOUNDS;SLC31A1;AC;rs10759637;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
CAPECITABINE;CDA;AC + CC;rs2072671;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY | HAND-FOOT_SYNDROME
ETHAMBUTOL;NAT2;*16/*7 + *6/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATOTOXICITY
ISONIAZID;NAT2;*16/*7 + *6/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATOTOXICITY
PYRAZINAMIDE;NAT2;*16/*7 + *6/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATOTOXICITY
RIFAMPIN;NAT2;*16/*7 + *6/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATOTOXICITY
ISONIAZID;NAT2;*16;NAT2*16;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*16 + *6 + *7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
OLANZAPINE;DRD2;del;rs1799732;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_RESPOND
RISPERIDONE;DRD2;del;rs1799732;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_RESPOND
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;*5/*6 + *5/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*5, NAT2*6, NAT2*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
OPIOIDS;CYP2A7P1;GG;rs3745274;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
OPIOIDS;CYP2B6;GG;rs3745274;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
ETHAMBUTOL;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ANTIINFLAMMATORY AGENTS;HLA-B;*35:03;HLA-B*35:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NON-STEROIDS;HLA-B;*35:03;HLA-B*35:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PLATINUM COMPOUNDS;SLC31A1;AC;rs4979223;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
NO_DRUG_RELATED;CHRNA3;A;rs1051730;OTHER;INCREASED_LIKELIHOOD;OTHER:TOBACCO_USE_DISORDER
RIBAVIRIN;ITPA;CC;rs1127354;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMOLYTIC_ANEMIA
SOFOSBUVIR;ITPA;CC;rs1127354;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMOLYTIC_ANEMIA
PROTON PUMP INHIBITORS;CYP2C19;nan;CYP2C19 rapid and ultrarapid metabolizer genotypes;TOXICITY;DECREASED_RISK;SIDE_EFFECT:INFECTIOUS_DISEASE
ANTINEOPLASTIC AGENTS;TYMS;AG + GG;rs2853539;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CYCLOPHOSPHAMIDE;CYP2B6;AG + GG;rs2279343;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
DACTINOMYCIN;CYP2B6;AG + GG;rs2279343;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
VINCRISTINE;CYP2B6;AG + GG;rs2279343;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
ANTIPSYCHOTICS;CYP2D6;nan;CYP2D6 poor metabolizer genotype;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TARDIVE_DYSKINESIA
OMEPRAZOLE;CYP2C19;nan;CYP2C19 normal metabolizers;LADME_PK;DECREASED;OTHER:GASTRIC_PH
TAMOXIFEN;CYP2D6;nan;CYP2D6 poor metabolizers and intermediate metabolizers;EFFICACY;INCREASED_RISK;SIDE_EFFECT:HOT_FLASHES
TAMOXIFEN;CYP2D6;nan;CYP2D6 poor metabolizers and intermediate metabolizers;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HOT_FLASHES
ANTINEOPLASTIC AGENTS;AKR1C3;G;rs1937840;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ANTIHYPERTENSIVES;ADIPOQ;CG + GG;rs266729;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:HYPERTENSION
MYCOPHENOLIC ACID;IMPDH1;T;rs2278293;EFFICACY;DECREASED_LIKELIHOOD;OTHER:SUBCLINICAL_ACUTE_REJECTION
TACROLIMUS;IMPDH1;T;rs2278293;EFFICACY;DECREASED_LIKELIHOOD;OTHER:SUBCLINICAL_ACUTE_REJECTION
GEMCITABINE;CDA;AA;rs2072671;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ATOMOXETINE;CYP2D6;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*10, CYP2D6*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRY_MOUTH | ERECTILE_DYSFUNCTION | HYPERHIDROSIS | INSOMNIA
CODEINE;CYP2D6;nan;CYP2D6 poor metabolizers;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
NICOTINE;CYP2D6;*2xN;CYP2D6*2xN, CYP2D6*4, CYP2D6*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOBACCO_USE_DISORDER
GEMCITABINE;DCK;TT;rs4694362;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CYCLOPHOSPHAMIDE;RBX1;A;rs141084494;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;RBX1;A;rs141084494;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;RBX1;A;rs141084494;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ETHAMBUTOL;NAT2;T;rs1801280;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;T;rs1801280;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;T;rs1801280;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;T;rs1801280;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PLATINUM COMPOUNDS;SLC31A1;AG + GG;rs4978536;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
OPIOIDS;BDNF-AS;CC + CT;rs11030096;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
IRINOTECAN;NAT2;AA;rs1799930;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PLATINUM COMPOUNDS;NAT2;AA;rs1799930;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PLATINUM COMPOUNDS;SLC31A1;CC + CT;rs10817464;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY | HEMATOLOGIC_DISORDER | LEUKOPENIA | THROMBOCYTOPENIA
VORICONAZOLE;CYP2C19;nan;CYP2C19 poor metabolizer genotype;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
PLATINUM COMPOUNDS;SLC31A1;AC;rs4979223;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
COCAINE;SYT1;G;rs2251214;TOXICITY;INCREASED_RISK;SIDE_EFFECT:COCAINE_DEPENDENCE
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
VALGANCICLOVIR;ABCB1;CT;rs2229109;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOXETINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;LADME_PK;INCREASED_PK;PK:FLUOXETINE_PLASMA_CONCENTRATION
TETRABENAZINE;CYP2D6;nan;CYP2D6 ultrarapid metabolizer phenotype;EFFICACY;nan;OTHER:LONGER_TITRATION_TO_ACHIEVE_OPTIMAL_BENEFIT
MYCOPHENOLATE MOFETIL;UGT1A9;T;rs3832043;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_AREA_UNDER_THE_CONCENTRATION_VERSUS_TIME_CURVE_(AUC6-12)_LEVEL_OF_MYCOPHENOLIC_ACID
OLANZAPINE;CYP2C9;nan;CYP2C9 poor metabolizers;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIZZINESS
"""FOLIC ACID""";MTRR;AA + AG;rs1801394;EFFICACY;DECREASED_SEVERITY;DISEASE:PAIN
"""VITAMIN B-COMPLEX";MTRR;AA + AG;rs1801394;EFFICACY;DECREASED_SEVERITY;DISEASE:PAIN
"PLAIN""";MTRR;AA + AG;rs1801394;EFFICACY;DECREASED_SEVERITY;DISEASE:PAIN
NICOTINE;HTR3B;TT;rs3758987;TOXICITY;INCREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
CAPECITABINE;TYMS;TTAAAGTTA;rs11280056;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA | DRUG_TOXICITY | HAND-FOOT_SYNDROME,
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
ANTIDEPRESSANTS;CYP2D6;*3/*4 + *4/*4 + *4/*5 + *4/*6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATIONS
ENALAPRIL;PCGF3;A;rs1044147;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:COUGH
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*11;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
PAROXETINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;LADME_PK;INCREASED_PK;PK:PAROXETINE_PLASMA_CONCENTRATION
TRAMADOL;COMT;AA + AG;rs4680;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SEDATION
ANTICHOLINERGIC AGENTS;CYP2C19;nan;CYP2C19 poor metabolizers;LADME_PK;INCREASED_PK;PK:SERUM_ANTICHOLINERGIC_ACTIVITY
VENLAFAXINE;CYP2D6;nan;CYP2D6 normal metabolizers;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
ANTINEOPLASTIC AGENTS;ABCG2;CC + CT;rs2231164;EFFICACY;INCREASED_EFFICACY;EFFICACY:SURVIVAL
CITALOPRAM;CYP2D6;nan;CYP2D6 normal metabolizers;EFFICACY;DECREASED_EFFICACY;EFFICACY:NUMBER_OF_FAILED_MEDICATION_TRAILS
CLOMIPRAMINE;CYP2D6;nan;CYP2D6 normal metabolizers;EFFICACY;DECREASED_EFFICACY;EFFICACY:NUMBER_OF_FAILED_MEDICATION_TRAILS
DULOXETINE;CYP2D6;nan;CYP2D6 normal metabolizers;EFFICACY;DECREASED_EFFICACY;EFFICACY:NUMBER_OF_FAILED_MEDICATION_TRAILS
ESCITALOPRAM;CYP2D6;nan;CYP2D6 normal metabolizers;EFFICACY;DECREASED_EFFICACY;EFFICACY:NUMBER_OF_FAILED_MEDICATION_TRAILS
FLUOXETINE;CYP2D6;nan;CYP2D6 normal metabolizers;EFFICACY;DECREASED_EFFICACY;EFFICACY:NUMBER_OF_FAILED_MEDICATION_TRAILS
FLUVOXAMINE;CYP2D6;nan;CYP2D6 normal metabolizers;EFFICACY;DECREASED_EFFICACY;EFFICACY:NUMBER_OF_FAILED_MEDICATION_TRAILS
MIRTAZAPINE;CYP2D6;nan;CYP2D6 normal metabolizers;EFFICACY;DECREASED_EFFICACY;EFFICACY:NUMBER_OF_FAILED_MEDICATION_TRAILS
PAROXETINE;CYP2D6;nan;CYP2D6 normal metabolizers;EFFICACY;DECREASED_EFFICACY;EFFICACY:NUMBER_OF_FAILED_MEDICATION_TRAILS
SERTRALINE;CYP2D6;nan;CYP2D6 normal metabolizers;EFFICACY;DECREASED_EFFICACY;EFFICACY:NUMBER_OF_FAILED_MEDICATION_TRAILS
VENLAFAXINE;CYP2D6;nan;CYP2D6 normal metabolizers;EFFICACY;DECREASED_EFFICACY;EFFICACY:NUMBER_OF_FAILED_MEDICATION_TRAILS
MYCOPHENOLATE MOFETIL;UGT1A9;T;rs3832043;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_AREA_UNDER_THE_CONCENTRATION_VERSUS_TIME_CURVE_(AUC6-12)_LEVEL_OF_MYCOPHENOLIC_ACID-7-O-GLUCURONIDE
MYCOPHENOLATE MOFETIL;ABCC2;AG;rs2273697;LADME_PK;INCREASED_PK;PK:AREA_UNDER_THE_CONCENTRATION_VERSUS_TIME_CURVE_(AUC6-12)_LEVEL_OF_THE_ACYL_GLUCURONIDE_OF_MYCOPHENOLIC_ACID
CAPECITABINE;DPYD;CT;rs2297595;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
OPIOIDS;OPRM1;GG;rs1799971;TOXICITY;DECREASED;SIDE_EFFECT:NAUSEA | VOMITING
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
CLOPIDOGREL;CYP2C19;*1/*17 + *17/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
ATENOLOL;PAH;AA;rs2245360;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:INSULIN_RESISTANCE
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *4/*4 + *4/*5;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *4/*4 + *4/*5 + *4/*7;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*7;EFFICACY;INCREASED_LIKELIHOOD;DISEASE:BREAST_NEOPLASMS
ASPIRIN;PON1;CT + TT;rs662;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
OPIOIDS;DRD2;CC + CT;rs1125394;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
OPIOIDS;OPRM1;G;rs1799971;TOXICITY;DECREASED;SIDE_EFFECT:ADVERSE_EVENTS
SORAFENIB;VEGFA;CC;rs3025040;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
OPIOIDS;DRD2;CT + TT;rs1079596;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
TRAMADOL;COMT;AA + AG;rs4680;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
EFAVIRENZ;CYP2B6;nan;CYP2B6 poor metabolizer and intermediate metabolizer genotypes;OTHER;INCREASED_RISK;SIDE_EFFECT:SUICIDE
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;TT;rs3740066;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:FEBRILE_NEUTROPENIA
AZATHIOPRINE;TPMT;nan;TPMT intermediate metabolizers;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
MERCAPTOPURINE;TPMT;nan;TPMT intermediate metabolizers;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
PURINE ANALOGUES;TPMT;nan;TPMT intermediate metabolizers;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
FLUOROURACIL;TYMS;AG + GG;rs2847153;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SURVIVAL
MORPHINE;ABCC3;T;rs4148412;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPOVENTILATION
SORAFENIB;UGT1A9;AA;rs7574296;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
IRINOTECAN;UGT1A1;*1/*1 + *1/*28;UGT1A1*1, UGT1A1*28;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
SORAFENIB;KDR;AA;rs2071559;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
TACROLIMUS;CYP3A5;nan;CYP3A5 intermediate metabolizer and normal metabolizer;DOSAGE;INCREASED_LIKELIHOOD;OTHER:DRUG_DOSAGE_ALTERED
TRAMADOL;COMT;GG;rs4680;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:POSTOPERATIVE_PAIN
"""FOLIC ACID""";MTHFR;AG + GG;rs1801133;EFFICACY;EFFICACY;EFFICACY:GREATER_REDUCTION_IN_HOMOCYSTEINE
"""VITAMIN B-COMPLEX";MTHFR;AG + GG;rs1801133;EFFICACY;EFFICACY;EFFICACY:GREATER_REDUCTION_IN_HOMOCYSTEINE
"PLAIN""";MTHFR;AG + GG;rs1801133;EFFICACY;EFFICACY;EFFICACY:GREATER_REDUCTION_IN_HOMOCYSTEINE
AMITRIPTYLINE;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;INCREASED_PK;PK:ANTIDEPRESSANT_SERUM_LEVELS
CLOMIPRAMINE;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;INCREASED_PK;PK:ANTIDEPRESSANT_SERUM_LEVELS
DOXEPIN;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;INCREASED_PK;PK:ANTIDEPRESSANT_SERUM_LEVELS
IMIPRAMINE;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;INCREASED_PK;PK:ANTIDEPRESSANT_SERUM_LEVELS
TRIMIPRAMINE;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;INCREASED_PK;PK:ANTIDEPRESSANT_SERUM_LEVELS
SORAFENIB;SLC15A2;CC;rs2257212;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
FLUOROURACIL;CCND1;AA;rs9344;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME-TO-TUMOR_RECURRENCE
AZATHIOPRINE;TPMT;nan;TPMT intermediate metabolizer genotype;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EFFECTS
CAPECITABINE;UMPS;CC + CT;rs2279199;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | VOMITING
METFORMIN;nan;TT;rs578427;LADME_PK;INCREASED_PK;PK:RENAL_CLEARANCE_AND_SECRETION_CLEARANCE_OF_METFORMIN
CAPECITABINE;TYMS;CT + TT;rs2853741;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
CLOPIDOGREL;CYP2C19;nan;CYP2C19 rapid and ultrarapid metabolizer genotypes;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
CAPECITABINE;SLC22A7;AG + GG;rs4149178;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
CISPLATIN;ABCC3;G;rs1051640;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*41;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_PLASMA_LEVELS
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*35;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
CLOPIDOGREL;CYP2C19;nan;CYP2C19 normal metabolizers;OTHER;DECREASED_RISK;OTHER:MAJOR_ADVERSE_CARDIAC_EVENTS
METHOTREXATE;SLC19A1;T;rs1051266;TOXICITY;INCREASED;DISEASE:DRUG-INDUCED_LIVER_INJURY
CLOPIDOGREL;CYP2C19;nan;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
ABT-751;UGT1A4;AC;rs6755571;LADME_PK;DECREASED_PK;PK:PLASMA_PREDOSE_CONCENTRATION_(CTROUGH)
CAPECITABINE;UMPS;CC + CG;rs4678145;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ASTHENIA
ABT-751;UGT1A8;CC + CT;rs6431558;LADME_PK;INCREASED_PK;PK:GLUCURONIDATION_METABOLIC_RATIOS
IMIPRAMINE;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;INCREASED_PK;PK:MEAN_AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_(AUC)_OF_DESIPRAMINE
ANTINEOPLASTIC AGENTS;DPYD;AA + AG;rs1760217;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
AZATHIOPRINE;TPMT;CC + CT;rs1142345;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ANTINEOPLASTIC AGENTS;SERPINA3;AC + CC;rs17091162;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17;CYP2C19*1, CYP2C19*2, CYP2C19*17;LADME_PK;DECREASED_PK;PK:MEAN_PEAK_PLASMA_CONCENTRATION_OF_H4
VALPROIC ACID;CYP2C19;nan;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;TOXICITY;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
ASPIRIN;PTGS1;AG + GG;rs10306114;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
CLOPIDOGREL;PTGS1;AG + GG;rs10306114;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
METFORMIN;SLC47A2;AA;rs12943590;LADME_PK;INCREASED_PK;PK:RENAL_CLEARANCE_AND_SECRETION_CLEARANCE_OF_METFORMIN
TAMOXIFEN;NCOA1;CT;rs1804645;OTHER;INCREASED_SEVERITY;SIDE_EFFECT:CHANGE_IN_LUMBAR_BONE_MINERAL_DENSITY
CLOPIDOGREL;CYP2C19;nan;CYP2C19 intermediate metabolizer genotype;EFFICACY;INCREASED_RISK;OTHER:CARDIOVASCULAR_DEATH,MYOCARDIAL_INFARCTION_OR_STROKE
CITALOPRAM;nan;A;rs352428;EFFICACY;EFFICACY;EFFICACY:POOR_RESPONSE_AT_8_WEEK_OF_TREATMENT
ESCITALOPRAM;nan;A;rs352428;EFFICACY;EFFICACY;EFFICACY:POOR_RESPONSE_AT_8_WEEK_OF_TREATMENT
CLOPIDOGREL;CYP2C19;nan;CYP2C19 intermediate metabolizer genotype;EFFICACY;INCREASED_RISK;DISEASE:THROMBOTIC_DISEASE
CITALOPRAM;nan;A;rs352428;EFFICACY;EFFICACY;EFFICACY:POOR_RESPONSE_AT_6_WEEK_OF_TREATMENT
CLOPIDOGREL;CYP2C19;nan;CYP2C19 poor metabolizer genotype;EFFICACY;INCREASED_RISK;OTHER:CARDIOVASCULAR_DEATH,MYOCARDIAL_INFARCTION_OR_STROKE
MIDAZOLAM;POR;CT;rs1057868;LADME_PK;DECREASED_PK;PK:MIDAZOLAM_METABOLIC_RATIOS_BY_45%
CLOPIDOGREL;CYP2C19;nan;CYP2C19 poor metabolizer genotype;EFFICACY;INCREASED_RISK;DISEASE:THROMBOTIC_DISEASE
LENVATINIB;ABCG2;GG;rs2231142;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRY_MOUTH | MUCOSITIS
NICOTINE;CHRNA3;G;rs578776;LADME_PK;INCREASED_PK;PK:PLASMA_LEVEL
GALANTAMINE;CYP2D6;*3/*4 + *4/*4 + *4/*5;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*41;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_PLASMA_LEVELS
TRAZODONE;CYP2D6;nan;CYP2D6 normal metabolizer genotype;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIZZINESS
CAPECITABINE;DPYD;AG;rs17376848;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:STOMATITIS
RISPERIDONE;CYP2D6;nan;CYP2D6 ultrarapid metabolizer phenotype;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
ASPIRIN;CYP2C19;AA;rs4244285;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
LENVATINIB;CYP3A4;C;rs2242480;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
LENVATINIB;CYP3A5;C;rs776746;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
CAPECITABINE;ENOSF1;TT;rs699517;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | VOMITING
CAPECITABINE;TYMS;TT;rs699517;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | VOMITING
HEROIN;OPRK1;C;rs6473797;TOXICITY;DECREASED_RISK;OTHER:HEROIN_DEPENDENCE
HEROIN;CSNK1E;T;rs1534891;TOXICITY;DECREASED_RISK;OTHER:HEROIN_DEPENDENCE
CAPECITABINE;DPYD;AG;rs12119882;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
ETHANOL;CHRNA5;G;rs16969968;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ALCOHOL_ABUSE
HEROIN;GAL;A;rs694066;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
CLOPIDOGREL;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;OTHER:PLATELET_REACTIVITY
HEROIN;OPRD1;A;rs2236861;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
CAPECITABINE;SLC22A7;TT;rs2270860;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
HEROIN;OPRD1;C;rs3766951;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
METHADONE;CRHBP;G;rs1500;OTHER;DECREASED;OTHER:RECURRENCE
METHAMPHETAMINE;FAAH;A;rs324420;OTHER;INCREASED_LIKELIHOOD;OTHER:DEPENDENCE
ETHANOL;CHRNA3;G;rs1051730;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ALCOHOL_ABUSE
TAMOXIFEN;CYP2D6;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*35;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
HEROIN;OPRD1;C;rs2236857;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
NALOXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED_EFFICACY;EFFICACY:PEAK_CORTISOL_RESPONSE
TAMOXIFEN;CYP2D6;nan;CYP2D6 ultrarapid metabolizer phenotype;TOXICITY;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
CAPECITABINE;ENOSF1;CT + TT;rs699517;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ASTHENIA
CAPECITABINE;TYMS;CT + TT;rs699517;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ASTHENIA
TAMOXIFEN;CYP2D6;*1/*1 + *1/*10;CYP2D6*1, CYP2D6*10;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEIOMYOMA | LIVER_DISORDER | OVARIAN_CYSTS,
HEROIN;HTR3B;C;rs3758987;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
METOPROLOL;CYP2D6;nan;CYP2D6 poor metabolizer genotype;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_DISEASE
OSIMERTINIB;ABCG2;GG;rs2231142;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
TAMOXIFEN;CYP2D6;nan;CYP2D6 normal metabolizers;EFFICACY;INCREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
ESCITALOPRAM;HTR2C;C;rs6318;EFFICACY;DECREASED;DISEASE:PAIN
OXYCODONE;CYP2D6;nan;CYP2D6 poor metabolizer phenotype;LADME_PK;DECREASED_PK;PK:PLASMA_OXYMORPHONE/OXYCODONE_RATIO
OXYCODONE;CYP2D6;nan;CYP2D6 poor metabolizer phenotype;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_PAIN_AUC
MERCAPTOPURINE;GNMT;CT + TT;rs10948059;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION
NICOTINE;CHRNA5;A;rs16969968;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER
OXYCODONE;CYP2D6;nan;CYP2D6 poor metabolizer phenotype;EFFICACY;DECREASED_PK;PK:PLASMA_OXYMORPHONE/OXYCODONE_RATIO
NICOTINE;CHRNA3;A;rs1051730;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER
PAROXETINE;CYP2D6;nan;CYP2D6 normal metabolizers;OTHER;INCREASED;OTHER:METABOLIC_RATIO_DEM/DOR
IRINOTECAN;NAT2;AA;rs1799931;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PLATINUM COMPOUNDS;NAT2;AA;rs1799931;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PAROXETINE;CYP2D6;nan;CYP2D6 poor metabolizers;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEXUAL_DYSFUNCTION
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED;OTHER:PLATELET_REACTIVITY
HEROIN;OPRM1;C;rs3778151;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
ESCITALOPRAM;CYP2D6;nan;CYP2D6 intermediate metabolizers;LADME_PK;INCREASED_PK;PK:MEAN_LOGARITHM_ESCITALOPRAM_CONCENTRATION
PAROXETINE;CYP2D6;nan;CYP2D6 poor metabolizers;LADME_PK;INCREASED_PK;PK:MEDIAN_AUC | PLASMA_HALF-LIFE_AND_STEADY-STATE_PLASMA_CONCENTRATIONS_OF_PAROXETINE
CAPECITABINE;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED_RISK;DISEASE:HAND-FOOT_SYNDROME
PAROXETINE;CYP2D6;nan;CYP2D6 poor metabolizers;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEXUAL_DYSFUNCTION
FLUOXETINE;CYP2D6;*1/*1;CYP2D6*1, CYP2D6*1xN;LADME_PK;INCREASED_PK;PK:FLUOXETINE/(S)-NORFLUOXETINE_RATIO
CAPECITABINE;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
ALKYLATING AGENTS;ESR1;A;rs2207396;TOXICITY;INCREASED_RISK;DISEASE:OLIGOSPERMIA
CISPLATIN;ESR1;A;rs2207396;TOXICITY;INCREASED_RISK;DISEASE:OLIGOSPERMIA
HEROIN;OPRM1;T;rs510769;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
CLOPIDOGREL;CYP2C19;*2/*2 + *3/*3 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_DISEASE
ANTIDEPRESSANTS;CYP2D6;nan;CYP2D6 poor metabolizers;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
CITALOPRAM;CYP2C19;nan;CYP2C19 poor metabolizers;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION_IF_TOLERANT_TO_CITALOPRAM_TREATMENT
TAMOXIFEN;CYP2D6;*1/*1;CYP2D6 normal metabolizers;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL | OVERALL_SURVIVAL
TAMOXIFEN;CYP2D6;nan;CYP2D6 normal metabolizers;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
ANTIPSYCHOTICS;CYP2D6;nan;CYP2D6 poor metabolizers and intermediate metabolizers;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PARKINSONIAN_DISORDER | TARDIVE_DYSKINESIA
OSIMERTINIB;STAT3;GG;rs4796793;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAIL_DISORDER
ESCITALOPRAM;CYP2D6;AA;rs1065852;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESPONSE_AND_REMISSION_RATE
3;CYP2C19;nan;CYP2C19 poor metabolizer genotype;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERTENSION
4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2C19;nan;CYP2C19 poor metabolizer genotype;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERTENSION
DRUGS FOR TREATMENT OF TUBERCULOSIS;SLCO1B1;GG + GT;rs4149014;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
DOCETAXEL;nan;nan;poor metabolizer genotype;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
EPIRUBICIN;nan;nan;poor metabolizer genotype;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
NO_DRUG_RELATED;nan;T;rs6968865;DOSAGE;INCREASED;OTHER:COFFEE_CONSUMPTION
SULFAMETHOXAZOLE;GCLC;AA;rs761142;TOXICITY;DECREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
AZATHIOPRINE;TPMT;nan;TPMT intermediate metabolizer genotype;EFFICACY;INCREASED_PK;PK:6-TG_LEVELS
AZATHIOPRINE;TPMT;nan;TPMT intermediate metabolizer genotype;TOXICITY;INCREASED_PK;PK:6-TG_LEVELS
AZATHIOPRINE;TPMT;nan;TPMT intermediate metabolizer genotype;LADME_PK;INCREASED_PK;PK:6-TG_LEVELS
MERCAPTOPURINE;TPMT;nan;TPMT intermediate metabolizer genotype;EFFICACY;INCREASED_PK;PK:6-TG_LEVELS
MERCAPTOPURINE;TPMT;nan;TPMT intermediate metabolizer genotype;TOXICITY;INCREASED_PK;PK:6-TG_LEVELS
MERCAPTOPURINE;TPMT;nan;TPMT intermediate metabolizer genotype;LADME_PK;INCREASED_PK;PK:6-TG_LEVELS
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DEATH | MYOCARDIAL_INFARCTION | STROKE,
NO_DRUG_RELATED;CYP1A1;T;rs2472297;DOSAGE;INCREASED;OTHER:COFFEE_CONSUMPTION
SULFAMETHOXAZOLE;GCLC;A;rs761142;TOXICITY;DECREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
APIXABAN;CES1;GT + TT;rs2244613;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
DABIGATRAN;CES1;GT + TT;rs2244613;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
EDOXABAN;CES1;GT + TT;rs2244613;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
RIVAROXABAN;CES1;GT + TT;rs2244613;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
TRAMADOL;CYP2D6;nan;CYP2D6 normal metabolizer and ultrarapid metabolizer;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;AG + GG;rs2273697;EFFICACY;INCREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
SORAFENIB;KDR;TT;rs1870377;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
TACROLIMUS;CYP3A4;AG;rs35599367;OTHER;INCREASED_PK;PK:CREATININE_CLEARANCE
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;TT;rs3740066;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOPIDOGREL;PON1;CC;rs662;EFFICACY;DECREASED_EFFICACY;EFFICACY:ON-CLOPIDOGREL_PLATELET_REACTIVITY_(PR)_AT_1_MONTH_AND_AT_6_MONTHS_AFTER_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI)
ANTIPSYCHOTICS;CYP2D6;nan;CYP2D6 ultrarapid metabolizer genotype;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TARDIVE_DYSKINESIA
ISONIAZID;ASTN2;C;rs117491755;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ALECTINIB;PPARA;AA + AG;rs4253728;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
VALPROIC ACID;SCN1A;TT;rs2298771;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
SULFAMETHOXAZOLE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS | DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS,
TRIMETHOPRIM;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS | DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS,
IRINOTECAN;UGT1A1;*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA | DIARRHEA,
ATOMOXETINE;CYP2D6;*10/*10;CYP2D6*10;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
CISPLATIN;GSTT1;nan;GSTT1 non-null, GSTT1 null;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY
CISPLATIN;GSTM1;nan;GSTM1 non-null, GSTM1 null;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY
ARIPIPRAZOLE;CYP2D6;*1/*4 + *4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
OLANZAPINE;CYP2D6;*1/*4 + *4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
RISPERIDONE;CYP2D6;*1/*4 + *4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
CODEINE;ABCB1;AA;rs2032582;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CNS_DEPRESSION_IN_BREAST-FEEDING_INFANTS
CODEINE;ABCB1;AA;rs2032582;LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:CNS_DEPRESSION_IN_BREAST-FEEDING_INFANTS
ETHANOL;CRHBP;TT;rs10055255;TOXICITY;INCREASED_SEVERITY;OTHER:ALCOHOL_ABUSE
SUNITINIB;NR1I2;TT;rs2276707;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ANTIPSYCHOTICS;DRD2;del;rs1799732;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SEXUAL_DYSFUNCTION
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
OXALIPLATIN;HLA-DRB1;*12:01;HLA-DRB1*12:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
TEGAFUR;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
GIMERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
OTERACIL;CYP2A6;*4 + *7 + *9 + *10;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
CEFACLOR;HLA-DRB1;*14:54;HLA-DRB1*14:54;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ETHANOL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED_SEVERITY;OTHER:ALCOHOL_ABUSE
SULFASALAZINE;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS | DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
SULFASALAZINE;HLA-B;*39:01;HLA-B*39:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS | DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
SULFASALAZINE;HLA-B;*56:03;HLA-B*56:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS | DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
METOPROLOL;CYP2D6;*1/*2;CYP2D6*1, CYP2D6*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:HEART_RATE
METHAMPHETAMINE;DAOA;C;rs778293;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER
CEFACLOR;HLA-DRB1;*04:03;HLA-DRB1*04:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANAPHYLAXIS
CEFACLOR;HLA-DRB1;*04:03;HLA-DRB1*04:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*15;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*15;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
SIMVASTATIN;SLCO1B1;*15;SLCO1B1*15;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
SIMVASTATIN;SLCO1B1;*15;SLCO1B1*15;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
ATORVASTATIN;SLCO1B1;*20;SLCO1B1*20;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
SIMVASTATIN;SLCO1B1;*20;SLCO1B1*20;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
ATORVASTATIN;SLCO1B1;*37;SLCO1B1*37;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION | ANGINA_PECTORIS
SIMVASTATIN;SLCO1B1;*37;SLCO1B1*37;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION | ANGINA_PECTORIS
ATORVASTATIN;SLCO1B1;*5;SLCO1B1*5;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:HYPERCHOLESTEROLEMIA
SIMVASTATIN;SLCO1B1;*5;SLCO1B1*5;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:HYPERCHOLESTEROLEMIA
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*15;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:HYPERCHOLESTEROLEMIA
SIMVASTATIN;SLCO1B1;*15;SLCO1B1*15;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:HYPERCHOLESTEROLEMIA
ATORVASTATIN;SLCO1B1;*5;SLCO1B1*5;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
ATORVASTATIN;SLCO1B1;*5;SLCO1B1*5;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
SIMVASTATIN;SLCO1B1;*5;SLCO1B1*5;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
SIMVASTATIN;SLCO1B1;*5;SLCO1B1*5;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
SORAFENIB;KDR;GG;rs2071559;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ATORVASTATIN;SLCO1B1;*15;SLCO1B1*15;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
SIMVASTATIN;SLCO1B1;*15;SLCO1B1*15;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
ATORVASTATIN;SLCO1B1;*14;SLCO1B1*14;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:HYPERCHOLESTEROLEMIA
SIMVASTATIN;SLCO1B1;*14;SLCO1B1*14;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:HYPERCHOLESTEROLEMIA
TACROLIMUS;ABCB1;AG;rs1045642;EFFICACY;INCREASED_RISK;DISEASE:HYPOKALEMIA
RISPERIDONE;ADRB2;G;rs1042713;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEXUAL_ADVERSE_EVENTS
BECLOMETHASONE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:STATUS_ASTHMATICUS
BUDESONIDE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:STATUS_ASTHMATICUS
FLUTICASONE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:STATUS_ASTHMATICUS
FLUTICASONE PROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:STATUS_ASTHMATICUS
MOMETASONE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:STATUS_ASTHMATICUS
NICOTINE;CYP2A6;*1/*1x2;CYP2A6*1, CYP2A6*1x2;TOXICITY;INCREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
CYTARABINE;GLI1;AA;rs2228224;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
CYTARABINE;ARHGAP9;GT + TT;rs2229300;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL | OVERALL_SURVIVAL
CYTARABINE;GLI1;GT + TT;rs2229300;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL | OVERALL_SURVIVAL
CODEINE;ABCB1;A;rs1128503;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CNS_DEPRESSION_IN_BREAST-FEEDING_INFANTS
CODEINE;ABCB1;A;rs1128503;LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:CNS_DEPRESSION_IN_BREAST-FEEDING_INFANTS
CAPECITABINE;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
FLUOROURACIL;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
LEUCOVORIN;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
OXALIPLATIN;TYMS;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;rs45445694;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
SORAFENIB;KDR;TT;rs1870377;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
CODEINE;ABCB1;AA;rs2032582;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CNS_DEPRESSION
CODEINE;ABCB1;AA;rs2032582;LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:CNS_DEPRESSION
CODEINE;ABCB1;A;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CNS_DEPRESSION_IN_BREAST-FEEDING_INFANTS
CODEINE;ABCB1;A;rs1045642;LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:CNS_DEPRESSION_IN_BREAST-FEEDING_INFANTS
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
RESPIRATORY SYSTEM;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
NO_DRUG_RELATED;CELSR2;T;rs602633;LADME_PK;PK;PK:BASELINE_LDL_CHOLESTEROL
NO_DRUG_RELATED;PSRC1;T;rs602633;LADME_PK;PK;PK:BASELINE_LDL_CHOLESTEROL
COCAINE;OPRM1;A;rs524731;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE | COCAINE_DEPENDENCE | OPIOID-RELATED_DISORDERS,
ETHANOL;OPRM1;A;rs524731;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE | COCAINE_DEPENDENCE | OPIOID-RELATED_DISORDERS,
OPIOIDS;OPRM1;A;rs524731;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE | COCAINE_DEPENDENCE | OPIOID-RELATED_DISORDERS,
ATAZANAVIR;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
INDINAVIR;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
ATAZANAVIR;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
RITONAVIR;UGT1A1;*28/*28;UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
PHENPROCOUMON;CYP2C9;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
ATAZANAVIR;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
RITONAVIR;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
METHOTREXATE;SLCO1B1;G;rs4149081;OTHER;INCREASED_PK;PK:CLEARANCE
METHOTREXATE;SLCO1B1;G;rs4149081;LADME_PK;INCREASED_PK;PK:CLEARANCE
BETA BLOCKING AGENTS;GRK5;AA;rs2230345;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:DEATH
VALPROIC ACID;SCN1A;AA;rs10167228;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:GRAFT_VS_HOST_DISEASE
TACROLIMUS;ABCB1;AG;rs1045642;EFFICACY;INCREASED_RISK;DISEASE:TRANSPLANT_REJECTION
CLOPIDOGREL;CYP2C19;*5;CYP2C19*1, CYP2C19*5;TOXICITY;INCREASED_RISK;DISEASE:DEATH
MIRTAZAPINE;CYP2D6;*4/*4 + *4/*6;CYP2D6*1, CYP2D6*4, CYP2D6*6;LADME_PK;INCREASED_PK;PK:DOSE/WEIGHT_ADJUSTED_AUC_FOR_MIRTAZAPINE
TROGLITAZONE;nan;C;rs10811661;EFFICACY;INCREASED_EFFICACY;EFFICACY:BETA_CELL_FUNCTION
PLATINUM COMPOUNDS;ERCC2;CC + CT;rs1799793;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
NEVIRAPINE;CYP2B6;T;rs3745274;LADME_PK;INCREASED;OTHER:PLASMA_LEVEL
CITALOPRAM;CYP2C19;*3;CYP2C19*1, CYP2C19*3;LADME_PK;DECREASED_PK;PK:CITALOPRAM_ORAL_CLEARANCES_OF_CITALOPRAM
METHAMPHETAMINE;PICK1;T;rs713729;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:SUBSTANCE-RELATED_DISORDERS
IMATINIB;ABCG2;T;rs2231142;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:EXANTHEMA
CAFFEINE;DRD2;GG;rs1110976;OTHER;DECREASED;SIDE_EFFECT:ANXIETY
OPIOIDS;nan;AG + GG;rs4530637;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
NEVIRAPINE;ABCB1;A;rs1045642;TOXICITY;DECREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
COCAINE;OPRM1;G;rs3778156;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE | COCAINE_DEPENDENCE | OPIOID-RELATED_DISORDERS,
ETHANOL;OPRM1;G;rs3778156;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE | COCAINE_DEPENDENCE | OPIOID-RELATED_DISORDERS,
OPIOIDS;OPRM1;G;rs3778156;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE | COCAINE_DEPENDENCE | OPIOID-RELATED_DISORDERS,
NO_DRUG_RELATED;nan;C;rs1111875;LADME_PK;DECREASED_PK;PK:INSULIN_SECRETION_AT_BASELINE
CISPLATIN;COMT;T;rs9332377;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
FLUOXETINE;CYP2D6;*4 + *6;CYP2D6*1, CYP2D6*4, CYP2D6*6;LADME_PK;INCREASED_PK;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS_OF_FLUOXETINE
OPIOIDS;TACR3;AG + GG;rs1384401;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
CISPLATIN;COMT;C;rs4646316;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
FOLFIRI;ABCC2;GG;rs2273697;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_PK;PK:CITALOPRAM_AUC_AND_TERMINAL_ELIMINATION_HALF-LIFE
PLATINUM COMPOUNDS;SLC22A2;CT + TT;rs316003;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL | OVERALL_SURVIVAL
METHOTREXATE;ABCC2;T;rs717620;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
TAMOXIFEN;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;EFFICACY;INCREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
METHAMPHETAMINE;PICK1;T;rs713729;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:RECURRENCE
OPIOIDS;CYP2D6;AA;rs1065852;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
FOLFIRI;ABCC2;AA;rs1885301;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NAUSEA
CITALOPRAM;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;LADME_PK;INCREASED_PK;PK:MEDIAN_CONCENTRATION/DOSE_RATIO_AND_MEDIAN_PARENT_DRUG/METABOLITE_RATIO
ESCITALOPRAM;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;LADME_PK;INCREASED_PK;PK:MEDIAN_CONCENTRATION/DOSE_RATIO_AND_MEDIAN_PARENT_DRUG/METABOLITE_RATIO
OPIOIDS;DRD3;CC + CT;rs6280;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
HYDROCHLOROTHIAZIDE;nan;CC + CT;rs17137967;TOXICITY;INCREASED;SIDE_EFFECT:FASTING_GLUCOSE
NO_DRUG_RELATED;CYP2A6;*4/*4 + *4/*7 + *4/*9 + *7/*7 + *7/*9 + *9/*9;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;OTHER;DECREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
OPIOIDS;DRD3;AA + AG;rs324029;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
TAMOXIFEN;CYP2D6;nan;CYP2D6 poor metabolizers and intermediate metabolizers;TOXICITY;DECREASED_SEVERITY;DISEASE:BREAST_TENDERNESS | VAGINAL_DRYNESS | VOMITING,
OPIOIDS;EXOC4;TT;rs718656;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
ETHAMBUTOL;NAT2;A;rs4646244;TOXICITY;INCREASED_RISK;DISEASE:HEPATITIS
ETHAMBUTOL;NAT2;A;rs4646244;LADME_PK;INCREASED_RISK;DISEASE:HEPATITIS
ISONIAZID;NAT2;A;rs4646244;TOXICITY;INCREASED_RISK;DISEASE:HEPATITIS
ISONIAZID;NAT2;A;rs4646244;LADME_PK;INCREASED_RISK;DISEASE:HEPATITIS
PYRAZINAMIDE;NAT2;A;rs4646244;TOXICITY;INCREASED_RISK;DISEASE:HEPATITIS
PYRAZINAMIDE;NAT2;A;rs4646244;LADME_PK;INCREASED_RISK;DISEASE:HEPATITIS
RIFAMPIN;NAT2;A;rs4646244;TOXICITY;INCREASED_RISK;DISEASE:HEPATITIS
RIFAMPIN;NAT2;A;rs4646244;LADME_PK;INCREASED_RISK;DISEASE:HEPATITIS
AMISULPRIDE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
CLOZAPINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
HALOPERIDOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
OLANZAPINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
QUETIAPINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
RISPERIDONE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
ZIPRASIDONE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
ZUCLOPENTHIXOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
NICOTINE;CHRNB2;T;rs2072660;OTHER;INCREASED_SEVERITY;DISEASE:TOBACCO_USE_DISORDER
DIRECT ACTING ANTIVIRALS;IFNL4;GG;rs11322783;EFFICACY;DECREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PLATINUM COMPOUNDS;APLF;CCGG/CCGG + CCGG/del;rs3213239;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
PEGINTERFERON ALFA-2A;IFNL3;GG;rs8099917;EFFICACY;EFFICACY;EFFICACY:LACK_OF_TREATMENT_RESPONSE
RIBAVIRIN;IFNL3;GG;rs8099917;EFFICACY;EFFICACY;EFFICACY:LACK_OF_TREATMENT_RESPONSE
ATAZANAVIR;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
RITONAVIR;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PLATINUM COMPOUNDS;ERCC2;GG;rs50872;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PLATINUM COMPOUNDS;ABCG2;GG;rs1448784;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ETHAMBUTOL;NAT2;A;rs1799930;TOXICITY;INCREASED_RISK;DISEASE:HEPATITIS
ETHAMBUTOL;NAT2;A;rs1799930;LADME_PK;INCREASED_RISK;DISEASE:HEPATITIS
ISONIAZID;NAT2;A;rs1799930;TOXICITY;INCREASED_RISK;DISEASE:HEPATITIS
ISONIAZID;NAT2;A;rs1799930;LADME_PK;INCREASED_RISK;DISEASE:HEPATITIS
PYRAZINAMIDE;NAT2;A;rs1799930;TOXICITY;INCREASED_RISK;DISEASE:HEPATITIS
PYRAZINAMIDE;NAT2;A;rs1799930;LADME_PK;INCREASED_RISK;DISEASE:HEPATITIS
RIFAMPIN;NAT2;A;rs1799930;TOXICITY;INCREASED_RISK;DISEASE:HEPATITIS
RIFAMPIN;NAT2;A;rs1799930;LADME_PK;INCREASED_RISK;DISEASE:HEPATITIS
NICOTINE;CHRNB2;A;rs2072661;OTHER;INCREASED_SEVERITY;DISEASE:TOBACCO_USE_DISORDER
CODEINE;CYP2D6;*3/*3 + *4/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
HYDROCODONE;CYP2D6;*3/*3 + *4/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
OXYCODONE;CYP2D6;*3/*3 + *4/*4;CYP2D6*1, CYP2D6*3, CYP2D6*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
IRINOTECAN;UGT1A1;*1/*1 + *1/*28;UGT1A1*1, UGT1A1*28;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
BOCEPREVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
BOCEPREVIR;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PLATINUM COMPOUNDS;ERCC1;AA + AG;rs11615;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
CARBAMAZEPINE;HLA-B;*15:11;HLA-B*15:11;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
HYDROXYCHLOROQUINE;CYP2C8;GG;rs10882526;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA5;GG;rs660652;TOXICITY;INCREASED;DISEASE:TOBACCO_USE_DISORDER
METHAMPHETAMINE;nan;T;rs1421292;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER
ACE INHIBITORS;ABO;GT + TT;rs495828;TOXICITY;nan;DISEASE:COUGH
PLAIN;ABO;GT + TT;rs495828;TOXICITY;nan;DISEASE:COUGH
AMITRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
CLOMIPRAMINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
DOXEPIN;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
IMIPRAMINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
MAPROTILINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
NORTRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
OPIPRAMOL;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
GLICLAZIDE;KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED_EFFICACY;EFFICACY:EFFICACY_AS_MEASURED_BY_DECREASE_IN_HBA1C
CLOPIDOGREL;CYP2C19;*1 + *17;CYP2C19*1, CYP2C19*2, CYP2C19*17;EFFICACY;DECREASED;OTHER:PLATELET_REACTIVITY
PLATINUM COMPOUNDS;ABCB1;AA;rs1128503;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CLOPIDOGREL;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_DISEASE
OPIOIDS;ZNF804A;CC;rs7597593;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
NORTRIPTYLINE;CYP2D6;*4/*4;CYP2D6*1, CYP2D6*4;LADME_PK;DECREASED_PK;PK:MAXIMUM_PLASMA_CONCENTRATION_OF_10-HYDROXY_NORTRIPTYLINE
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA3;AA;rs1051730;TOXICITY;INCREASED_SEVERITY;DISEASE:SUBSTANCE-RELATED_DISORDERS
HYDROXYCHLOROQUINE;CYP3A5;TT;rs776746;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
PLATINUM COMPOUNDS;IL16;GT + TT;rs7170924;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
INDOMETHACIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
NO_DRUG_RELATED;CHRNA3;AA + AG;rs1051730;OTHER;INCREASED_LIKELIHOOD;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA
NEVIRAPINE;HLA-B;*15:10;HLA-B*15:10;TOXICITY;DECREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ACENOCOUMAROL;CYP2C9;*1/*3 + *3/*3;CYP2C9*1, CYP2C9*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:STROKE | MYOCARDIAL_INFARCTION | DEATH,
ASPIRIN;TBXA2R;A;rs1131882;EFFICACY;INCREASED_RISK;SIDE_EFFECT:DEATH
ASPIRIN;TBXA2R;A;rs1131882;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DEATH
OPIOIDS;CNR1;TT;rs2023239;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
NO_DRUG_RELATED;NQO1;AA;rs1800566;OTHER;nan;OTHER:SIGNIFICANTLY_SHORTER_SURVIVAL
BUSULFAN;CYP2C9;*2 + *3;CYP2C9*1, CYP2C9*2, CYP2C9*3;LADME_PK;INCREASED_PK;PK:METABOLIC_RATIO
PLATINUM COMPOUNDS;ABCB1;AA;rs1128503;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
METFORMIN;SLC29A4;G;rs3889348;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
FOLFIRI;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
NO_DRUG_RELATED;NQO1;A;rs1800566;TOXICITY;INCREASED_RISK;DISEASE:LEUKEMIA
HYDROCHLOROTHIAZIDE;ACE;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;rs1799752;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;nan;GSTM1 null;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTT1;nan;GSTT1 null;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
OPIOIDS;CNR1;CC;rs6928499;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
NEVIRAPINE;CYP2B6;CC + CG;rs58425034;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
FLUOROURACIL;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;DECREASED;DISEASE:EVENT-FREE_SURVIVAL | OVERALL_SURVIVAL
CLOPIDOGREL;CYP2C19;*2/*2;CYP2C19*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT:DEATH | MYOCARDIAL_INFARCTION
DOCETAXEL;CHST3;C;rs4148945;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
THALIDOMIDE;CHST3;C;rs4148945;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
"""FOLIC ACID""";MTHFR;AG + GG;rs1801133;EFFICACY;DECREASED_SEVERITY;DISEASE:PAIN
"""VITAMIN B-COMPLEX";MTHFR;AG + GG;rs1801133;EFFICACY;DECREASED_SEVERITY;DISEASE:PAIN
"PLAIN""";MTHFR;AG + GG;rs1801133;EFFICACY;DECREASED_SEVERITY;DISEASE:PAIN
CARBAMAZEPINE;HLA-B;*51:01;HLA-B*51:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
DOCETAXEL;SLC10A2;A;rs2301159;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
THALIDOMIDE;SLC10A2;A;rs2301159;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
AXITINIB;HIF1A;CT;rs11549465;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SORAFENIB;HIF1A;CT;rs11549465;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
FLUOROURACIL;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DISEASE_PROGRESSION
IRINOTECAN;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DISEASE_PROGRESSION
LEUCOVORIN;TYMS;TTAAAGTTA/TTAAAGTTA;rs11280056;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DISEASE_PROGRESSION
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
EFAVIRENZ;CYP2B6;*6/*6;CYP2B6*1, CYP2B6*6;LADME_PK;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
METHOTREXATE;SLC19A1;CC + CT;rs1051266;EFFICACY;INCREASED_SEVERITY;DISEASE:RHEUMATOID_ARTHRITIS
SORAFENIB;KDR;AA;rs2071559;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_IN_THERAPEUTIC_RANGE
NICOTINE;DBH;AA + AG;rs77905;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
METHOTREXATE;ADORA2A;GG;rs2298383;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
ANTINEOPLASTIC AGENTS;CYP2D6;*5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
TAMOXIFEN;CYP2D6;*5/*10;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
CLOPIDOGREL;CYP2C19;*1/*2;CYP2C19*1, CYP2C19*2;OTHER;INCREASED;OTHER:PLATELET_AGGREGATION_WITH_ADP
RISPERIDONE;CYP2D6;CT + TT;rs3892097;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS | TREMOR | MUSCLE_RIGIDITY,
NO_DRUG_RELATED;CYP2B6;TT;rs3211371;OTHER;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
NO_DRUG_RELATED;CYP2B6;CT;rs3211371;OTHER;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *10 + *41;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
FLUOXETINE;SLC6A4;HTTLPR short form (S allele)/HTTLPR short form (S allele);SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT:PSYCHOMOTOR_AGITATION | INSOMNIA
IRINOTECAN;UGT1A1;G;rs4124874;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
NO_DRUG_RELATED;CYP24A1;C;rs2762939;OTHER;DECREASED_RISK;DISEASE:CORONARY_ARTERY_DISEASE
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA5;A;rs16969968;TOXICITY;INCREASED_SEVERITY;DISEASE:SUBSTANCE-RELATED_DISORDERS
WARFARIN;CYP2C9;*1/*2 + *1/*3 + *2/*3;CYP2C9*1, CYP2C9*2, CYP2C9*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_OUTCOME
MORPHINE;ABCC3;G;rs739923;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPOVENTILATION
CITALOPRAM;PAPLN;T;rs11628713;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
WARFARIN;CYP2C9;*2;CYP2C9*1, CYP2C9*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER_ANTI-COAGULATION
SULFONAMIDES;KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED_EFFICACY;EFFICACY:EFFICACY_AS_MEASURED_BY_DECREASE_IN_HBA1C_AFTER_6-MONTH_TREATMENT
UREA DERIVATIVES;KCNJ11;CT + TT;rs5219;EFFICACY;INCREASED_EFFICACY;EFFICACY:EFFICACY_AS_MEASURED_BY_DECREASE_IN_HBA1C_AFTER_6-MONTH_TREATMENT
FLUOXETINE;CYP2D6;*1/*1xN;CYP2D6*1, CYP2D6*1xN;LADME_PK;DECREASED_PK;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS_OF_FLUOXETINE
IMATINIB;SLC22A1;TT;rs1867351;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIORBITAL_EDEMA
FLUOROURACIL;ERCC2;GG + GT;rs13181;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
LEUCOVORIN;ERCC2;GG + GT;rs13181;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
VERAPAMIL;KCNIP1;CT + TT;rs11739136;EFFICACY;EFFICACY;EFFICACY:EARLIER_ACHIEVEMENT_OF_BLOOD_PRESSURE_CONTROL
VERAPAMIL;KCNMB1;CT + TT;rs11739136;EFFICACY;EFFICACY;EFFICACY:EARLIER_ACHIEVEMENT_OF_BLOOD_PRESSURE_CONTROL
OPIOIDS;DRD3;AG + GG;rs9288993;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
PEGINTERFERON ALFA-2A;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
PEGINTERFERON ALFA-2B;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
RIBAVIRIN;IFNL4;TT/TT;rs11322783;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
OSIMERTINIB;CYP2C9;AC;rs1057910;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
OPIOIDS;DRD3;AG + GG;rs2654754;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
OPIOIDS;ZNF568;G;rs10405238;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NAUSEA | VOMITING
ANTIEPILEPTICS;HLA-B;*53:01;HLA-B*53:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
SULFAMETHOXAZOLE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS | SEVERE_CUTANEOUS_ADVERSE_REACTIONS,
SULFAMETHOXAZOLE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS | SEVERE_CUTANEOUS_ADVERSE_REACTIONS,
TRIMETHOPRIM;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS | SEVERE_CUTANEOUS_ADVERSE_REACTIONS,
PENICILLIN G;HLA-DPB1;*05:01;HLA-DPB1*05:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
SULFAMETHOXAZOLE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
SULFAMETHOXAZOLE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
TRIMETHOPRIM;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
SULFAMETHOXAZOLE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS | SEVERE_CUTANEOUS_ADVERSE_REACTIONS,
SULFAMETHOXAZOLE;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS | SEVERE_CUTANEOUS_ADVERSE_REACTIONS,
TRIMETHOPRIM;HLA-B;*38:02;HLA-B*38:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS | SEVERE_CUTANEOUS_ADVERSE_REACTIONS,
APIXABAN;ABCB1;CC;rs3842;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
DABIGATRAN;ABCB1;CC;rs3842;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
EDOXABAN;ABCB1;CC;rs3842;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
RIVAROXABAN;ABCB1;CC;rs3842;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:CORONARY_RESTENOSIS | THROMBOTIC_DISEASE
METFORMIN;AMHR2;G;rs784892;LADME_PK;DECREASED_PK;PK:METFORMIN_SECRETORY_CLEARANCE
MYCOPHENOLATE MOFETIL;SLCO1B3;GG;rs4149117;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_AREA_UNDER_THE_CURVE_(AUC6-12)_OF_MYCOPHENOLIC_ACID_(MPA)
CLOPIDOGREL;CYP2C19;INTERMEDIATE_METABOLIZER;CYP2C19;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CLOPIDOGREL;CYP2C19;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*9, CYP2C19*13, CYP2C19*17;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE) | DEATH | MYOCARDIAL_INFARCTION | STROKE
ASPIRIN;PON1;CT + TT;rs662;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:THROMBOTIC_DISEASE
CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:THROMBOTIC_DISEASE
OPIOIDS;OPRM1;AA;rs1799971;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
CLOPIDOGREL;CYP2C19;*2 + *4;CYP2C19*1, CYP2C19*2, CYP2C19*4, CYP2C19*17;OTHER;INCREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
CLOPIDOGREL;CYP2C19;*8;CYP2C19*1, CYP2C19*8;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS
CLOPIDOGREL;CYP2C19;*5;CYP2C19*1, CYP2C19*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS
ACENOCOUMAROL;CYP2C9;*2;CYP2C9*1, CYP2C9*2;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:INTERNATIONAL_NORMALIZED_RATIO_VARIABILITY_(INR-VAR)
ATEZOLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:THYROTOXICOSIS | HYPOTHYROIDISM
DURVALUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:THYROTOXICOSIS | HYPOTHYROIDISM
IPILIMUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:THYROTOXICOSIS | HYPOTHYROIDISM
NIVOLUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:THYROTOXICOSIS | HYPOTHYROIDISM
PEMBROLIZUMAB;HLA-A;*26:01;HLA-A*26:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:THYROTOXICOSIS | HYPOTHYROIDISM
CARBOPLATIN;RRM1;GG;rs9937;TOXICITY;RISK;DISEASE:HEMATOLOGIC_DISORDER
GEMCITABINE;RRM1;GG;rs9937;TOXICITY;RISK;DISEASE:HEMATOLOGIC_DISORDER
ETHANOL;OPRM1;AA;rs1799971;TOXICITY;INCREASED_SEVERITY;OTHER:ALCOHOL_ABUSE
METFORMIN;SLC22A1;A;rs628031;TOXICITY;nan;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
METFORMIN;SLC22A1;A;rs628031;LADME_PK;nan;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
OPIOIDS;GABRB3;AA;rs4906902;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
AMITRIPTYLINE;CYP2D6;*4;CYP2D6*1, CYP2D6*4;OTHER;INCREASED_PK;PK:PLASMA_NORTRIPTYLINE
AMITRIPTYLINE;CYP2D6;*4;CYP2D6*1, CYP2D6*4;LADME_PK;INCREASED_PK;PK:PLASMA_NORTRIPTYLINE
AMITRIPTYLINE;CYP2D6;*10;CYP2D6*1, CYP2D6*10;OTHER;INCREASED_PK;PK:PLASMA_NORTRIPTYLINE
AMITRIPTYLINE;CYP2D6;*10;CYP2D6*1, CYP2D6*10;LADME_PK;INCREASED_PK;PK:PLASMA_NORTRIPTYLINE
BECLOMETHASONE DIPROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:STATUS_ASTHMATICUS | EMERGENCIES
FLUTICASONE PROPIONATE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:STATUS_ASTHMATICUS | EMERGENCIES
AMITRIPTYLINE;CYP2C19;*1/*3 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_PK;PK:AMITRIPTYLINE/NORTRIPTYLINE_RATIO_CORRECTED_FOR_DOSE_AND_WEIGHT
MYCOPHENOLATE MOFETIL;SLCO1B3;AA;rs7311358;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_AREA_UNDER_THE_CURVE_(AUC6-12)_OF_MYCOPHENOLIC_ACID_(MPA)
PEGINTERFERON ALFA-2A;IFNL3;TT;rs12979860;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;TT;rs12979860;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;TT;rs12979860;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;TT;rs12979860;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;TT;rs12979860;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;TT;rs12979860;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SOFOSBUVIR;IFNL3;TT;rs12979860;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SOFOSBUVIR;IFNL4;TT;rs12979860;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
ISONIAZID;HLA-DPB1;*05:01;HLA-DPB1*05:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
RIFAMPIN;HLA-DPB1;*05:01;HLA-DPB1*05:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
RIFAMPIN;HLA-A;*11:01;HLA-A*11:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ETHANOL;DRD2;GG;rs1799732;TOXICITY;INCREASED_SEVERITY;OTHER:ALCOHOL_ABUSE
SALBUTAMOL;THRB;A;rs892940;EFFICACY;INCREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(BDR)
OPIOIDS;TACR1;AA;rs735668;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
TAMOXIFEN;CYP2D6;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*41;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
ASPIRIN;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
ASPIRIN;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:THROMBOTIC_DISEASE
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:THROMBOTIC_DISEASE
APIXABAN;APOB;AA + AG;rs13306198;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
DABIGATRAN;APOB;AA + AG;rs13306198;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
EDOXABAN;APOB;AA + AG;rs13306198;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
RIVAROXABAN;APOB;AA + AG;rs13306198;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
ANTINEOPLASTIC AGENTS;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH | RECURRENCE
TAMOXIFEN;CYP2D6;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH | RECURRENCE
ANTINEOPLASTIC AGENTS;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
TAMOXIFEN;CYP2D6;*10/*10;CYP2D6*1, CYP2D6*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
OPIOIDS;OPRM1;CC;rs510769;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
ETHANOL;OPRM1;G;rs1799971;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE
FIRST-GENERATION CEPHALOSPORINS;HLA-B;*55:02;HLA-B*55:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
FOURTH-GENERATION CEPHALOSPORINS;HLA-B;*55:02;HLA-B*55:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
OTHER CEPHALOSPORINS;HLA-B;*55:02;HLA-B*55:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
THIRD-GENERATION CEPHALOSPORINS;HLA-B;*55:02;HLA-B*55:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
AMOXICILLIN;HLA-B;*15:01;HLA-B*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
"""METFORMIN""";SLC22A1;GAT/del;rs72552763;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
"""SULFONAMIDES";SLC22A1;GAT/del;rs72552763;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
"UREA DERIVATIVES""";SLC22A1;GAT/del;rs72552763;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
ETHAMBUTOL;NAT2;*4;NAT2*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEPATOTOXICITY
ISONIAZID;NAT2;*4;NAT2*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEPATOTOXICITY
PYRAZINAMIDE;NAT2;*4;NAT2*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEPATOTOXICITY
RIFAMPIN;NAT2;*4;NAT2*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEPATOTOXICITY
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*6, NAT2*7, NAT2*16;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*6, NAT2*7, NAT2*16;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;NAT2*6, NAT2*7, NAT2*16;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
FIRST-GENERATION CEPHALOSPORINS;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
FOURTH-GENERATION CEPHALOSPORINS;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
OTHER CEPHALOSPORINS;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
THIRD-GENERATION CEPHALOSPORINS;HLA-C;*01:02;HLA-C*01:02;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
FIRST-GENERATION CEPHALOSPORINS;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
FOURTH-GENERATION CEPHALOSPORINS;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
OTHER CEPHALOSPORINS;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
THIRD-GENERATION CEPHALOSPORINS;HLA-DQB1;*06:09;HLA-DQB1*06:09;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
INFLIXIMAB;HLA-DQA1;*05;HLA-DQA1*05;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DISCONTINUATION
NICOTINE;CYP2A13;CT;rs72552266;TOXICITY;INCREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
CLOPIDOGREL;CYP2C19;*1/*1;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
CYCLOPHOSPHAMIDE;CYP3A5;*1/*3 + *1/*6 + *3/*3 + *3/*6;CYP3A5*1, CYP3A5*3, CYP3A5*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:CYSTITIS
NO_DRUG_RELATED;UGT1A1;*28;UGT1A1*28;OTHER;INCREASED_LIKELIHOOD;OTHER:GILBERT_SYNDROME | CRIGLER-NAJJAR_SYNDROME
DOXORUBICIN;GSTT1;nan;GSTT1 non-null, GSTT1 null;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQB1;*03:01;HLA-DQB1*03:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BULLOUS_PEMPHIGOID
IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA | NEUTROPENIA
TACROLIMUS;CYP3A5;*1/*1;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:GRAFT_VS_HOST_DISEASE
IRINOTECAN;UGT1A1;*1/*6 + *6/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
FOLFIRI;UGT1A1;*1/*6 + *6/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION
FOLFIRI;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:ACUTE_CELLULAR_REJECTION
SACITUZUMAB GOVITECAN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION | DRUG_TOXICITY | NEUTROPENIA | DIARRHEA
FOLFIRI;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
FOLFIRI;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA | FEBRILE_NEUTROPENIA | LEUKOPENIA,
IRINOTECAN;UGT1A1;*28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA | FEBRILE_NEUTROPENIA | LEUKOPENIA,
IRINOTECAN;UGT1A1;*1/*28 + *28/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
FOLFIRI;UGT1A1;*28/*28 + *1/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
IRINOTECAN;UGT1A1;*28/*28 + *1/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
FOLFIRI;UGT1A1;*28/*28 + *1/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
IRINOTECAN;UGT1A1;*28/*28 + *1/*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
SUNITINIB;KDR;TT;rs1870377;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IRINOTECAN;UGT1A1;*28 + *6;UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
IRINOTECAN;UGT1A1;*28;UGT1A1*1, UGT1A1*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
IRINOTECAN;UGT1A1;*6/*6;UGT1A1*1, UGT1A1*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
FOLFIRI;UGT1A1;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
IRINOTECAN;UGT1A1;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
MIRABEGRON;CYP2D6;INTERMEDIATE_METABOLIZER;CYP2D6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | HEADACHE | INSOMNIA | DRUG_TOXICITY
MIRABEGRON;SLCO1B1;nan;SLCO1B1 deficiency;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | HEADACHE | INSOMNIA | DRUG_TOXICITY
TRAMADOL;CYP2D6;ULTRARAPID_METABOLIZER;CYP2D6;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:PAIN
METHOTREXATE;MTR;GG;rs3768142;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
CARBAMAZEPINE;HLA-B;*13:01;HLA-B*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
CARBAMAZEPINE;HLA-B;*15:01;HLA-B*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED_PK;PK:LEVELS_OF_ERYTHROCYTE_6-THIOGUANINE_NUCLEOTIDE_METABOLITES
AZATHIOPRINE;TPMT;*1/*3A + *3A/*3C;TPMT*1, TPMT*3A, TPMT*3C;LADME_PK;INCREASED_PK;PK:LEVELS_OF_ERYTHROCYTE_6-THIOGUANINE_NUCLEOTIDE_METABOLITES
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED_PK;PK:LEVELS_OF_ERYTHROCYTE_6-THIOGUANINE_NUCLEOTIDE_METABOLITES
MERCAPTOPURINE;TPMT;*1/*3A + *3A/*3C;TPMT*1, TPMT*3A, TPMT*3C;LADME_PK;INCREASED_PK;PK:LEVELS_OF_ERYTHROCYTE_6-THIOGUANINE_NUCLEOTIDE_METABOLITES
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED_PK;PK:LEVELS_OF_ERYTHROCYTE_6-THIOGUANINE_NUCLEOTIDE_METABOLITES
PURINE ANALOGUES;TPMT;*1/*3A + *3A/*3C;TPMT*1, TPMT*3A, TPMT*3C;LADME_PK;INCREASED_PK;PK:LEVELS_OF_ERYTHROCYTE_6-THIOGUANINE_NUCLEOTIDE_METABOLITES
CISPLATIN;GSTT1;non-null;GSTT1 non-null, GSTT1 null;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEARING_LOSS
SULFAMETHOXAZOLE;NAT2;*4;NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*16;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_REACTIONS
TRIMETHOPRIM;NAT2;*4;NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*16;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_REACTIONS
MERCAPTOPURINE;TPMT;*1/*3A + *1/*3C + *3A/*3A;TPMT*1, TPMT*3A, TPMT*3C;DOSAGE;INCREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION
ASPIRIN;CYP2C19;*2 + *3 + *8;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:TRANSIENT_ISCHEMIC_ATTACK | DEATH | STROKE | MYOCARDIAL_INFARCTION
CLOPIDOGREL;CYP2C19;*2 + *3 + *8;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:TRANSIENT_ISCHEMIC_ATTACK | DEATH | STROKE | MYOCARDIAL_INFARCTION
TACROLIMUS;CYP3A4;AG + GG;rs4646437;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
DIHYDROPYRIDINE DERIVATIVES;RYR3;TT;rs877087;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HEART_FAILURE | MYOCARDIAL_INFARCTION | ANGINA_PECTORIS,
NO_DRUG_RELATED;CYP4A11;AG + GG;rs1126742;LADME_PK;DECREASED_PK;PK:HDL-C_CONCENTRATION
CODEINE;CYP2D6;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;CYP2D6*1, CYP2D6*1x2, CYP2D6*2, CYP2D6*2x2, CYP2D6*2xN, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41, CYP2D6*41x2;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
TICAGRELOR;CYP2C19;*1/*2 + *1/*3 + *2/*17 + *3/*17;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
PEMETREXED;SLC19A1;TT;rs914232;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IRINOTECAN;UGT1A1;*6 + *28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
FLUOROURACIL;UGT1A1;*1/*28 + *28/*28 + *6/*6;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
IRINOTECAN;UGT1A1;*1/*28 + *28/*28 + *6/*6;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;DPYD;c.1627A>G (*5);DPYD c.1627A>G (*5);TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
IRINOTECAN;DPYD;c.1627A>G (*5);DPYD c.1627A>G (*5);TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
CITALOPRAM;CYP2C19;*2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;LADME_PK;INCREASED_PK;PK:AUC_OF_THE_S-ENANTIOMER_OF_CITALOPRAM_(NO_EFFECT_ON_R-CT)
PEMETREXED;SLC19A1;AA + AG;rs1051298;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
RISPERIDONE;CYP2C19;*1/*1 + *1/*2;CYP2C19*1, CYP2C19*2, CYP2C19*4;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEADACHE | MUSCLE_SPASM | SOMNOLENCE | DIZZINESS
CETUXIMAB;FCGR2A;GG;rs1801274;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
AMOXICILLIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
AMPICILLIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
BACAMPICILLIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
METHAMPHETAMINE;DRD3;CC + CT;rs6280;TOXICITY;INCREASED_RISK;SIDE_EFFECT:COGNITIVE_DISORDER
NICOTINE;CYP2A6;nan;CYP2A6 low activity;OTHER;DECREASED_RISK;DISEASE:LUNG_NEOPLASMS
VINCRISTINE;ACTN1;T;rs2268979;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
CAPECITABINE;UPB1;GG;rs2070474;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MUCOSITIS
FLUOROURACIL;UPB1;GG;rs2070474;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MUCOSITIS
PEMETREXED;MTHFR;AA + AG;rs1801133;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CAPECITABINE;DPYD;c.2194G>A (*6);DPYD c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA | DIARRHEA | STOMATITIS | LEUKOPENIA
FLUOROURACIL;DPYD;c.2194G>A (*6);DPYD c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA | DIARRHEA | STOMATITIS | LEUKOPENIA
FOLFIRI;DPYD;c.2194G>A (*6);DPYD c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA | DIARRHEA | STOMATITIS | LEUKOPENIA
FOLFIRINOX;DPYD;c.2194G>A (*6);DPYD c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA | DIARRHEA | STOMATITIS | LEUKOPENIA
FOLFOX;DPYD;c.2194G>A (*6);DPYD c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA | DIARRHEA | STOMATITIS | LEUKOPENIA
VINCRISTINE;PAPPA;A;rs12235805;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
CAPECITABINE;UPB1;GG;rs2070474;TOXICITY;DECREASED_SEVERITY;DISEASE:DIARRHEA
FLUOROURACIL;UPB1;GG;rs2070474;TOXICITY;DECREASED_SEVERITY;DISEASE:DIARRHEA
CAPECITABINE;DPYD;AA + AG;rs1801265;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
FLUOROURACIL;DPYD;AA + AG;rs1801265;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
PEMETREXED;SLC19A1;GG + GT;rs3788189;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
NICOTINE;ANKK1;AA + AG;rs1800497;TOXICITY;DECREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
NICOTINE;DRD2;AA + AG;rs1800497;TOXICITY;DECREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
CAPECITABINE;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD c.1129-5923C>G, c.1236G>A (HapB3), DPYD c.1679T>G (*13), DPYD c.2846A>T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DEATH
FLUOROURACIL;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD c.1129-5923C>G, c.1236G>A (HapB3), DPYD c.1679T>G (*13), DPYD c.2846A>T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DEATH
FOLFOX;DPYD;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);DPYD c.1129-5923C>G, c.1236G>A (HapB3), DPYD c.1679T>G (*13), DPYD c.2846A>T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DEATH
AMITRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ANTIDEPRESSANTS;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
CLOMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
DESIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
FLUOXETINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
IMIPRAMINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
NORTRIPTYLINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PAROXETINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
VENLAFAXINE;CYP2D6;*3 + *4 + *5 + *6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
SIROLIMUS;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;SIDE_EFFECT:TOTAL_CHOLESTEROL
FOLFIRI;UGT1A1;*28/*28 + *1/*28 + *1/*6 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
IRINOTECAN;UGT1A1;*28/*28 + *1/*28 + *1/*6 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
FOLFIRI;UGT1A1;*1/*1;UGT1A1*1, UGT1A1*6, UGT1A1*28;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA | DIARRHEA
ATOMOXETINE;CYP2D6;POOR_METABOLIZER;CYP2D6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
VINCRISTINE;NRG3;T;rs12253008;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
IRINOTECAN;UGT1A1;*28/*28 + *6/*6 + *6/*28;UGT1A1*1, UGT1A1*6, UGT1A1*28;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
AZATHIOPRINE;TPMT;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA | MYELOSUPPRESSION
MERCAPTOPURINE;TPMT;INTERMEDIATE_METABOLIZER;TPMT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
METHOTREXATE;TPMT;INTERMEDIATE_METABOLIZER;TPMT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
VINCRISTINE;LRRTM3;G;rs10997459;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
AZATHIOPRINE;TPMT;*1/*3A + *1/*3C;TPMT*1, TPMT*3A, TPMT*3C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
VINCRISTINE;ARHGAP5;G;rs8006511;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
MERCAPTOPURINE;TPMT;nan;TPMT normal metabolizer;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
METHOTREXATE;TPMT;nan;TPMT normal metabolizer;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
NICOTINE;CYP2A6;CC;rs28399433;TOXICITY;DECREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
VINCRISTINE;METTL8;G;rs79802223;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DEATH | STROKE | HEART_FAILURE | MYOCARDIAL_INFARCTION
NO_DRUG_RELATED;UGT1A1;CT;rs4148325;LADME_PK;DECREASED_LIKELIHOOD;OTHER:NEONATAL_HYPERBILIRUBINEMIA
NO_DRUG_RELATED;UGT1A1;G;rs11888492;LADME_PK;DECREASED_LIKELIHOOD;OTHER:NEONATAL_HYPERBILIRUBINEMIA
NALOXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED_EFFICACY;EFFICACY:CORTISOL_RESPONSE
CISPLATIN;CERS6;T;rs13022792;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY
CISPLATIN;TLR4;C;rs10759932;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY
VINCRISTINE;NFIB;G;rs10961381;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
ANTIARRHYTHMICS;nan;GT + TT;rs10033464;EFFICACY;INCREASED_EFFICACY;EFFICACY:RECURRENCE
CLASS I AND III;nan;GT + TT;rs10033464;EFFICACY;INCREASED_EFFICACY;EFFICACY:RECURRENCE
VINCRISTINE;MCM3AP;T;rs1815857;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
VINCRISTINE;SPDYA;T;rs12474420;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
VINCRISTINE;PDE4D;C;rs12658429;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
VINCRISTINE;FBN2;T;rs12656510;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
VINCRISTINE;VTI1A;T;rs17129858;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
VINCRISTINE;ZFAND3;C;rs200858088;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
ANTIINFLAMMATORY AGENTS;HLA-DRB1;*11:01;HLA-DRB1*11:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANAPHYLAXIS
NON-STEROIDS;HLA-DRB1;*11:01;HLA-DRB1*11:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANAPHYLAXIS
CLOPIDOGREL;CYP2C19;*2;CYP2C19*1, CYP2C19*2;TOXICITY;INCREASED_RISKEFFICACY;EFFICACY:PERIPHERAL_VASCULAR_DISEASES
MYCOPHENOLATE MOFETIL;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:VIRUS_DISEASES
PREDNISONE;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:VIRUS_DISEASES
TACROLIMUS;CYP3A5;*1/*1 + *1/*3;CYP3A5*1, CYP3A5*3;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:VIRUS_DISEASES
SIROLIMUS;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;SIDE_EFFECT:LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL
ACETAMINOPHEN;CYP2D6;POOR_METABOLIZER;CYP2D6;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:CONSTIPATION
CODEINE;CYP2D6;POOR_METABOLIZER;CYP2D6;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:CONSTIPATION
RASBURICASE;G6PD;nan;G6PD deficiency;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMOLYTIC_ANEMIA
NEVIRAPINE;CYP2B6;*1/*6 + *6/*6;CYP2B6*1, CYP2B6*6;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
EFAVIRENZ;CYP2B6;*1/*6 + *6/*6;CYP2B6*1, CYP2B6*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
SIROLIMUS;ABCB1;AA;rs1128503;TOXICITY;INCREASED;SIDE_EFFECT:TRIGLYCERIDES
CLOPIDOGREL;CYP2C19;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ATRIAL_FIBRILLATION
RISPERIDONE;CYP2D6;POOR_METABOLIZER;CYP2D6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
ISONIAZID;NAT2;*5/*7 + *5/*6 + *6/*6;NAT2*5, NAT2*6, NAT2*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TACROLIMUS;CYP3A5;*1/*3;CYP3A5*1, CYP3A5*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DECREASED_GLOMERULAR_FILTRATION_RATE
ADALIMUMAB;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
AMIODARONE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
BEVACIZUMAB;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
BICALUTAMIDE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
CARBOPLATIN;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
CYCLOPHOSPHAMIDE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
DOCETAXEL;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
ERLOTINIB;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
EVEROLIMUS;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
FLUOROURACIL;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
GEFITINIB;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
GEMCITABINE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
IRINOTECAN;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
LEUCOVORIN;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
METHOTREXATE;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
OXALIPLATIN;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
PACLITAXEL;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
PEMBROLIZUMAB;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
SITAGLIPTIN;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
TEGAFUR;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
GIMERACIL;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
OTERACIL;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
TRASTUZUMAB;HLA-DRB1;*04:05;HLA-DRB1*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
TAMSULOSIN;CYP2D6;INTERMEDIATE_METABOLIZER;CYP2D6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
ANASTROZOLE;CCDC148;CT + TT;rs79048288;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN
EXEMESTANE;CCDC148;CT + TT;rs79048288;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN
LETROZOLE;CCDC148;CT + TT;rs79048288;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN
ALLOPURINOL;HLA-B;*58:01;HLA-B*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | ERYTHEMA_MULTIFORME
PEMETREXED;DHFR;AA + AG;rs1650697;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
TACROLIMUS;CYP3A5;*3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;EFFICACY;EFFICACY;EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE
TACROLIMUS;CYP2C8;*1/*1;CYP2C8*1, CYP2C8*3;EFFICACY;EFFICACY;EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE
FLUOROURACIL;DPYD;c.85T>C (*9A)/c.85T>C (*9A);DPYD c.85T>C (*9A);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA | THROMBOCYTOPENIA,
FOLFIRI;DPYD;c.85T>C (*9A)/c.85T>C (*9A);DPYD c.85T>C (*9A);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA | THROMBOCYTOPENIA,
FOLFOX;DPYD;c.85T>C (*9A)/c.85T>C (*9A);DPYD c.85T>C (*9A);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA | THROMBOCYTOPENIA,
LACOSAMIDE;CYP2C19;*2/*2 + *2/*3 + *3/*3;CYP2C19*1, CYP2C19*2, CYP2C19*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE | DIZZINESS | DRUG_TOXICITY,
FLUOROURACIL;DPYD;c.1627A>G (*5)/c.1627A>G (*5);DPYD c.1627A>G (*5);TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA | THROMBOCYTOPENIA,
FOLFIRI;DPYD;c.1627A>G (*5)/c.1627A>G (*5);DPYD c.1627A>G (*5);TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA | THROMBOCYTOPENIA,
FOLFOX;DPYD;c.1627A>G (*5)/c.1627A>G (*5);DPYD c.1627A>G (*5);TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA | THROMBOCYTOPENIA,
CARBAMAZEPINE;HLA-A;*31:01;HLA-A*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ASPIRIN;PTGS2;GG;rs12042763;EFFICACY;DECREASED_RISK;DISEASE:PROSTATIC_NEOPLASMS
METHOTREXATE;SLCO1B1;*37/*37 + *37/*15;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NO_DRUG_RELATED;CYP2A6;G;rs56267346;OTHER;DECREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
NO_DRUG_RELATED;DBH;C;rs6479643;OTHER;DECREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*6, NAT2*7, NAT2*16;LADME_PK;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*6, NAT2*7, NAT2*16;LADME_PK;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*6, NAT2*7, NAT2*16;LADME_PK;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*6, NAT2*7, NAT2*16;LADME_PK;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ETHAMBUTOL;NAT2;*16 + *6 + *7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*16 + *6 + *7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;*16 + *6 + *7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;*16 + *6 + *7;NAT2*4, NAT2*6, NAT2*7, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;*16 + *5 + *6 + *7 + *14;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*14, NAT2*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
FLURBIPROFEN;UGT1A1;*1/*36;UGT1A1*1, UGT1A1*36;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IRINOTECAN;UGT1A1;*1/*36;UGT1A1*1, UGT1A1*36;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ISONIAZID;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*1, NAT2*5, NAT2*6, NAT2*7, NAT2*14;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RIFAMPIN;NAT2;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;NAT2*1, NAT2*5, NAT2*6, NAT2*7, NAT2*14;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TACROLIMUS;CYP3A5;*3/*3;CYP3A5*1, CYP3A5*3;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:GRAFT_VS_HOST_DISEASE
IRINOTECAN;UGT1A1;A;rs4148323;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
NO_DRUG_RELATED;CASP9;T;rs1052576;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:LEUKOCYTOSIS
CAPECITABINE;DPYD;AA + AG;rs1801265;TOXICITY;DECREASED;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;DPYD;AA + AG;rs1801265;TOXICITY;DECREASED;SIDE_EFFECT:DRUG_TOXICITY
IRINOTECAN;UGT1A1;A;rs4148323;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
CYCLOSPORINE;SLC19A1;CC;rs1051266;EFFICACY;DECREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
METHOTREXATE;SLC19A1;CC;rs1051266;EFFICACY;DECREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
CYCLOSPORINE;ATIC;CC;rs17514110;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
METHOTREXATE;ATIC;CC;rs17514110;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
CYCLOSPORINE;NFATC2;TT;rs3787186;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
METHOTREXATE;NFATC2;TT;rs3787186;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
CYCLOSPORINE;ABCC2;AA;rs3740065;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
METHOTREXATE;ABCC2;AA;rs3740065;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
CETUXIMAB;FCGR3A;CC;rs396991;EFFICACY;INCREASED_EFFICACY;EFFICACY:ANTIBODY-DEPENDENT_CELLULAR_CYTOTOXICITY
CYCLOSPORINE;ABCC1;AA;rs8058040;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
METHOTREXATE;ABCC1;AA;rs8058040;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
CARBAMAZEPINE;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
LAMOTRIGINE;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
PHENYTOIN;HLA-A;*24:02;HLA-A*24:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS
LAMOTRIGINE;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS
PHENYTOIN;HLA-B;*15:02;HLA-B*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS
ATAZANAVIR;TPH2;GG;rs7305115;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DEPRESSION
EFAVIRENZ;TPH2;GG;rs7305115;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DEPRESSION
CARBAMAZEPINE;HLA-A;*01:02;HLA-A*01:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS
LAMOTRIGINE;HLA-A;*01:02;HLA-A*01:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS
PHENYTOIN;HLA-A;*01:02;HLA-A*01:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS
CARBAMAZEPINE;HLA-B;*52:01;HLA-B*52:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS
LAMOTRIGINE;HLA-B;*52:01;HLA-B*52:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS
PHENYTOIN;HLA-B;*52:01;HLA-B*52:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS
CARBAMAZEPINE;HLA-DRB1;*03:01;HLA-DRB1*03:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS
LAMOTRIGINE;HLA-DRB1;*03:01;HLA-DRB1*03:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS
PHENYTOIN;HLA-DRB1;*03:01;HLA-DRB1*03:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS
ATAZANAVIR;TPH2;GG;rs1386493;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DEPRESSION
EFAVIRENZ;TPH2;GG;rs1386493;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DEPRESSION
CARBAMAZEPINE;HLA-DRB1;*13:01;HLA-DRB1*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
LAMOTRIGINE;HLA-DRB1;*13:01;HLA-DRB1*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
PHENYTOIN;HLA-DRB1;*13:01;HLA-DRB1*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
CAPECITABINE;ENOSF1;TT;rs2612091;EFFICACY;INCREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
CARBAMAZEPINE;HLA-A;*02:01;HLA-A*02:01;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
LAMOTRIGINE;HLA-A;*02:01;HLA-A*02:01;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
PHENYTOIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;HLA-B;*40:02;HLA-B*40:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
LAMOTRIGINE;HLA-B;*40:02;HLA-B*40:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
PHENYTOIN;HLA-B;*40:02;HLA-B*40:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
CARBAMAZEPINE;HLA-A;*31:03;HLA-A*31:03;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
LAMOTRIGINE;HLA-A;*31:03;HLA-A*31:03;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
PHENYTOIN;HLA-A;*31:03;HLA-A*31:03;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
CARBOPLATIN;OPRM1;GG + GT;rs544093;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PACLITAXEL;OPRM1;GG + GT;rs544093;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
MYCOPHENOLATE MOFETIL;IMPDH1;T;rs2228075;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GI_INTOLERANCE
MYCOPHENOLATE MOFETIL;IMPDH1;T;rs2228075;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GI_INTOLERANCE
CAPECITABINE;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY | NEUTROPENIA
FLUOROURACIL;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY | NEUTROPENIA
ISONIAZID;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ERLOTINIB;USP36;CC;rs3744797;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
GEFITINIB;USP36;CC;rs3744797;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
OSIMERTINIB;HLA-B;*51:02;HLA-B*51:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME | TOXIC_EPIDERMAL_NECROLYSIS
DEXMEDETOMIDINE;CACNB2;CT;rs10764319;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA | HYPOTENSIVE_DISORDER
DEXMEDETOMIDINE;CACNA2D2;AA;rs2236957;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA | HYPOTENSIVE_DISORDER
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;slow_acetylator;NAT2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
DEXMEDETOMIDINE;UGT2B10;AA;rs1841042;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA | HYPOTENSIVE_DISORDER
DEXMEDETOMIDINE;ADRA2B;AA + CC;rs3813662;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA | HYPOTENSIVE_DISORDER
METHYLPHENIDATE;CES1;T;rs2307227;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
PURINE ANALOGUES;NUDT15;*1/*3;NUDT15*1, NUDT15*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MYELOSUPPRESSION
CLOPIDOGREL;THSD7A;G;rs7807369;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
CLOPIDOGREL;nan;C;rs1149515;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY | MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
ONDANSETRON;CYP2D6;nan;CYP2D6 normal metabolizer;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:POSTOPERATIVE_NAUSEA_AND_VOMITING
NO_DRUG_RELATED;ERAP2;TT;rs17524572;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
MYCOPHENOLATE MOFETIL;UGT1A8;CC;rs1042597;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
PEMBROLIZUMAB;HLA-DRB1;*13:01;HLA-DRB1*13:01;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PEMBROLIZUMAB;HLA-DPB1;*02:02;HLA-DPB1*02:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS
CAPECITABINE;DPYD;CT;rs1801158;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;DPYD;CT;rs1801158;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
MORPHINE;SLC22A1;del/del;rs72552763;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPOVENTILATION
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;nan;GSTM1 non-null, GSTM1 null;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NO_DRUG_RELATED;CASP9;C;rs4661636;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:LEUKOCYTOSIS
NO_DRUG_RELATED;CASP8;G;rs6736233;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
CLOZAPINE;LEPR;AG + GG;rs6657868;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PNEUMONIA
CLOZAPINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED_RISK;DISEASE:SEIZURES
CISPLATIN;GGT1;CC;rs2017869;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA
PACLITAXEL;GGT1;CC;rs2017869;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA
CISPLATIN;TPMT;T;rs12201199;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
NO_DRUG_RELATED;UGT1A1;A;rs4148323;OTHER;INCREASED_LIKELIHOOD;OTHER:GILBERT_SYNDROME | CRIGLER-NAJJAR_SYNDROME
CLOZAPINE;LEPR;AA;rs1137101;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PNEUMONIA
CLOZAPINE;LEPROT;AA;rs1137101;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PNEUMONIA
DOLUTEGRAVIR;NR1I2;CT + TT;rs2472677;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION | ADVERSE_EVENTS
CISPLATIN;TPMT;T;rs1800460;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
CLOZAPINE;LEPR;GG;rs1805096;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PNEUMONIA
CLOZAPINE;LEPR;AC + CC;rs9436746;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PNEUMONIA
RISPERIDONE;DRD2;AA + AG;rs1800497;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
NO_DRUG_RELATED;UGT1A1;A;rs35350960;OTHER;INCREASED_LIKELIHOOD;OTHER:GILBERT_SYNDROME | CRIGLER-NAJJAR_SYNDROME
CISPLATIN;TPMT;C;rs1142345;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
WARFARIN;ASPH;T;rs4379440;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_IN_THERAPEUTIC_RANGE
CARBOPLATIN;SLCO1B3;AA;rs7311358;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
PACLITAXEL;SLCO1B3;AA;rs7311358;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ASPIRIN;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
CLOPIDOGREL;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
TICAGRELOR;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED;SIDE_EFFECT:DRUG_TOXICITY
METHOTREXATE;MTHFR;G;rs1801131;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY
PEGINTERFERON ALFA-2A;ITPA;AC;rs1127354;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_DISTURBANCES_IN_HCV-HIV_COINFECTED_PATIENTS
PEGINTERFERON ALFA-2B;ITPA;AC;rs1127354;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_DISTURBANCES_IN_HCV-HIV_COINFECTED_PATIENTS
RIBAVIRIN;ITPA;AC;rs1127354;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_DISTURBANCES_IN_HCV-HIV_COINFECTED_PATIENTS
HMG COA REDUCTASE INHIBITORS;CETP;A;rs3764261;EFFICACY;INCREASED;OTHER:HDL_CHOLESTEROL
HMG COA REDUCTASE INHIBITORS;CETP;A;rs3764261;LADME_PK;INCREASED;OTHER:HDL_CHOLESTEROL
PYRIMIDINE ANALOGUES;MTHFR;AA + AC;rs1801133;nan;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
METHOTREXATE;ITPA;A;rs1127354;TOXICITY;nan;SIDE_EFFECT:GASTROINTESTINAL_TOXICITIES
GEFITINIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA
PEGINTERFERON ALFA-2A;CTLA4;A;rs231775;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)_IN_HCV-HIV_COINFECTED_PATIENTS
PEGINTERFERON ALFA-2B;CTLA4;A;rs231775;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)_IN_HCV-HIV_COINFECTED_PATIENTS
RIBAVIRIN;CTLA4;A;rs231775;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)_IN_HCV-HIV_COINFECTED_PATIENTS
CAFFEINE;nan;T;rs4410790;OTHER;nan;OTHER:HABITUAL_CONSUMPTION
LIRAGLUTIDE;GLP1R;AA + AG;rs6923761;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:WEIGHT_LOSS
METHAMPHETAMINE;ESR1;CC;rs2234693;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER
NO_DRUG_RELATED;ABCG8;CG;rs11887534;OTHER;INCREASED_RISK;DISEASE:CORONARY_ARTERY_DISEASE
PLATINUM;ERCC5;GG;rs17655;EFFICACY;INCREASED_EFFICACY;EFFICACY:SURVIVAL
PLATINUM;ERCC5;GG;rs17655;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
RISPERIDONE;HTR2C;T;rs3813929;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
PACLITAXEL;FGD4;A;rs10771973;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SENSORY_PERIPHERAL_NEUROPATHY
CAFFEINE;CYP1A1;T;rs2470893;OTHER;nan;OTHER:HABITUAL_CONSUMPTION
CITALOPRAM;SLC6A4;C;rs25531;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SIDE_EFFECTS
PEGINTERFERON ALFA-2A;SOCS3;AG;rs4969170;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA_IN_HCV-HIV_COINFECTED_PATIENTS
PEGINTERFERON ALFA-2B;SOCS3;AG;rs4969170;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA_IN_HCV-HIV_COINFECTED_PATIENTS
RIBAVIRIN;SOCS3;AG;rs4969170;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA_IN_HCV-HIV_COINFECTED_PATIENTS
MIDAZOLAM;POR;TT;rs1057868;OTHER;INCREASED_PK;PK:METABOLIC_RATIO_OF_MIDAZOLAM
MIDAZOLAM;POR;TT;rs1057868;LADME_PK;INCREASED_PK;PK:METABOLIC_RATIO_OF_MIDAZOLAM
ENALAPRIL;PNPT1;G;rs13009649;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:COUGH
METHOTREXATE;ITPA;A;rs1127354;EFFICACY;EFFICACY;EFFICACY:RESPONSE_TO_METHOTREXATE
NICOTINE;HTR3B;CT + TT;rs11606194;TOXICITY;INCREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
ASPIRIN;SLC6A12;A;rs499368;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ASTHMA
GEFITINIB;ABCB1;AA;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
WARFARIN;CYP4F2;GG;rs2189784;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
ASPIRIN;SLC6A12;G;rs557881;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ASTHMA
PLATINUM COMPOUNDS;WIF1;GG + GT;rs10878232;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ANTIEPILEPTICS;ABCB1;G;rs1045642;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:NON-RESPONSE
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;AG;rs1056892;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
PLATINUM COMPOUNDS;WNT5B;AG + GG;rs12819505;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PLATINUM COMPOUNDS;AXIN2;AA + AC;rs4541111;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
MERCAPTOPURINE;PACSIN2;T;rs2413739;TOXICITY;INCREASED;SIDE_EFFECT:GI_TOXICITY
METHOTREXATE;PACSIN2;T;rs2413739;TOXICITY;INCREASED;SIDE_EFFECT:GI_TOXICITY
MERCAPTOPURINE;SLCO1B1;T;rs11045879;TOXICITY;INCREASED;SIDE_EFFECT:GI_TOXICITY
MERCAPTOPURINE;ITPA;CC;rs1127354;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
METHOTREXATE;ITPA;CC;rs1127354;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
PLATINUM COMPOUNDS;CXXC4;AA + AG;rs4413407;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ENALAPRIL;PNPT1;C;rs13015243;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:COUGH
AZATHIOPRINE;nan;T;rs11969064;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MYELOSUPPRESSION
MERCAPTOPURINE;nan;T;rs11969064;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MYELOSUPPRESSION
THIOGUANINE;nan;T;rs11969064;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MYELOSUPPRESSION
PEGINTERFERON ALFA-2A;IFNL3;T;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(SVR_AND_RVR)_IN_HCV-HIV_COINFECTED_PATIENTS
PEGINTERFERON ALFA-2B;IFNL3;T;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(SVR_AND_RVR)_IN_HCV-HIV_COINFECTED_PATIENTS
RIBAVIRIN;IFNL3;T;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(SVR_AND_RVR)_IN_HCV-HIV_COINFECTED_PATIENTS
PLATINUM COMPOUNDS;ERCC2;GG;rs13181;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PNEUMONITIS
PLATINUM COMPOUNDS;ERCC2;CT + TT;rs1799793;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PNEUMONITIS
DOXORUBICIN;NCF4;AA + AG;rs1883112;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
AMPHETAMINE;DRD2;AA;rs12364283;EFFICACY;DECREASED;OTHER:STOP_REACTION_TIME
ANTIEPILEPTICS;ABCB1;AA;rs1045642;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DRUG-RESISTANCE
ANTIEPILEPTICS;ABCB1;GG;rs1045642;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DRUG-RESISTANCE
PAROXETINE;HTR2A;GG;rs6313;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DISCONTINUATIONS_DUE_TO_ADVERSE_EVENTS_AND_GREATER_SEVERITY_OF_SIDE_EFFECTS
CLOPIDOGREL;CD80;AA;rs34394661;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
MYCOPHENOLATE MOFETIL;UGT1A9;A;rs6714486;LADME_PK;PK;PK:CHANGES_IN_MYCOPHENOLIC_ACID_EXPOSURE-RELATED_PARAMETERS_ON_DAY_7_AFTER_TRANSPLANTATION_(TREATMENT_WITH_2G_PER_DAY)
CARBAMAZEPINE;nan;TT;rs1633021;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
PLATINUM COMPOUNDS;AXIN2;CC + CG;rs11868547;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
MYCOPHENOLATE MOFETIL;UGT1A9;T;rs17868320;LADME_PK;PK;PK:CHANGES_IN_MYCOPHENOLIC_ACID_EXPOSURE-RELATED_PARAMETERS_ON_DAY_7_AFTER_TRANSPLANTATION_(TREATMENT_WITH_2G_PER_DAY)
MORPHINE;ABCB1;GG;rs1045642;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | VOMITING
CYCLOSPORINE;UGT1A8;CC;rs1042597;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
MYCOPHENOLATE MOFETIL;UGT1A8;CC;rs1042597;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
TACROLIMUS;IL10;AA;rs1800871;LADME_PK;INCREASED_LIKELIHOODPK;PK:ACHIEVING_TARGET_CONCENTRATIONS
METHOTREXATE;ARID5B;CC + CT;rs4948496;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
NO_DRUG_RELATED;CYP2B6;AA;rs3760657;OTHER;DECREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
FOLLITROPIN BETA;FSHR;T;rs6166;EFFICACY;EFFICACY;EFFICACY:GOOD_RESPONSE_TO_CONTROLLED_OVARIAN_HYPERSTIMULATION
FOLLITROPIN BETA;FSHR;T;rs6166;LADME_PK;EFFICACY;EFFICACY:GOOD_RESPONSE_TO_CONTROLLED_OVARIAN_HYPERSTIMULATION
THYROTROPIN ALFA;FSHR;T;rs6166;EFFICACY;EFFICACY;EFFICACY:GOOD_RESPONSE_TO_CONTROLLED_OVARIAN_HYPERSTIMULATION
THYROTROPIN ALFA;FSHR;T;rs6166;LADME_PK;EFFICACY;EFFICACY:GOOD_RESPONSE_TO_CONTROLLED_OVARIAN_HYPERSTIMULATION
UROFOLLITROPIN;FSHR;T;rs6166;EFFICACY;EFFICACY;EFFICACY:GOOD_RESPONSE_TO_CONTROLLED_OVARIAN_HYPERSTIMULATION
UROFOLLITROPIN;FSHR;T;rs6166;LADME_PK;EFFICACY;EFFICACY:GOOD_RESPONSE_TO_CONTROLLED_OVARIAN_HYPERSTIMULATION
ASPIRIN;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_RISK;DISEASE:THROMBOTIC_DISEASE
ASPIRIN;CYP2C19;AA + AG;rs4244285;OTHER;INCREASED_RISK;DISEASE:THROMBOTIC_DISEASE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_RISK;DISEASE:THROMBOTIC_DISEASE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;OTHER;INCREASED_RISK;DISEASE:THROMBOTIC_DISEASE
NO_DRUG_RELATED;UGT2B10;CC;rs11726322;OTHER;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;T;rs6025;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOEMBOLISM
ASPIRIN;CYP2C19;CT + TT;rs12248560;EFFICACY;DECREASED_RISK;DISEASE:THROMBOTIC_DISEASE
ASPIRIN;CYP2C19;CT + TT;rs12248560;OTHER;DECREASED_RISK;DISEASE:THROMBOTIC_DISEASE
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;EFFICACY;DECREASED_RISK;DISEASE:THROMBOTIC_DISEASE
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;OTHER;DECREASED_RISK;DISEASE:THROMBOTIC_DISEASE
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;A;rs1799963;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOEMBOLISM
CLOPIDOGREL;ABCB1;AG;rs1045642;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
CAPECITABINE;TYMP;AA + AG;rs11479;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
FLUOROURACIL;TYMP;AA + AG;rs11479;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
WARFARIN;CYP4F2;CT + TT;rs2108622;LADME_PK;INCREASED_PK;PK:PLASMA_MK-4_CONCENTRATION
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CAPECITABINE;DPYD;CT;rs3918290;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CAPECITABINE;DPYD;CG;rs75017182;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
FLUOROURACIL;DPYD;CG;rs75017182;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
ALENDRONATE;VDR;CC;rs1544410;EFFICACY;INCREASED_EFFICACY;EFFICACY:BONE_MINERAL_DENSITY
FENOFIBRATE;PPARA;TT;rs135543;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_FASTING_LDL-C
FENOFIBRATE;PPARA;CC + CT;rs9626730;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_FASTING_IL-2
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;DECREASED;OTHER:WARFARIN_SENSITIVITY_INDEX_(INR/CPSS)
NO_DRUG_RELATED;VDR;CC;rs1544410;nan;DECREASED_EFFICACY;EFFICACY:BONE_MINERAL_DENSITY
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_RISK;OTHER:MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_RISK;DISEASE:DEATH
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_RISK;DISEASE:THROMBOTIC_DISEASE
FENOFIBRATE;PPARA;TT;rs135550;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_FASTING_LDL-C
ALENDRONATE;VDR;CC;rs1544410;EFFICACY;DECREASED_EFFICACY;EFFICACY:URINARY_DPD/CR_LEVELS
EXEMESTANE;CYP19A1;TT;rs7176005;TOXICITY;nan;SIDE_EFFECT:A_SIGNIFICANTLY_HIGHER_ODDS_OF_VASOMOTOR_SYMPTOMS_IN_POSTMENOPAUSAL_HORMONE_RECEPTOR_(HR)-POSITIVE_BREAST_CANCER_PATIENTS
TACROLIMUS;PPARA;GG;rs4253728;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ACUTE_CELLULAR_REJECTION
VINCRISTINE;SLC5A7;AG + GG;rs1013940;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ETHANOL;ADH1B;T;rs1229984;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERURICEMIA
VINCRISTINE;NKAIN3;A;rs10504361;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
SIMVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULAR_DISEASES
ATENOLOL;PROX1;C;rs340874;TOXICITY;INCREASED;SIDE_EFFECT:GLUCOSE_ELEVATION
TACROLIMUS;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEPSIS | SEIZURES | NEPHROTOXICITY,
ABEMACICLIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
PALBOCICLIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
RIBOCICLIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
SIMVASTATIN;ABCG2;GT;rs2231142;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
VINCRISTINE;ABCC1;T;rs3784867;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CLOPIDOGREL;CYP2C19;AG;rs4244285;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:SIGNIFICANTLY_HIGHER_ON-TREATMENT_PLATELET_REACTIVITY_WITH_A_MAINTENANCE_DOSE_OF_75_MG_DAILY
OPIOIDS;COMT;AA + AG;rs4680;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE | NAUSEA | ADVERSE_EVENTS,
OPIOIDS;IL6;CG + GG;rs1800795;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE | NAUSEA | ADVERSE_EVENTS,
FLUOROURACIL;DPYD;A;rs67376798;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
SUNITINIB;CYP3A5;CT + TT;rs776746;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ABEMACICLIB;CYP3A4;AG;rs35599367;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY | TREATMENT_INTERRUPTION
PALBOCICLIB;CYP3A4;AG;rs35599367;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY | TREATMENT_INTERRUPTION
RIBOCICLIB;CYP3A4;AG;rs35599367;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY | TREATMENT_INTERRUPTION
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
METOPROLOL;CYP2D6;GG;rs1065852;EFFICACY;DECREASED_EFFICACY;EFFICACY:HEART_RATE
CONJUGATED ESTROGENS;VDR;TT;rs1544410;EFFICACY;INCREASED;OTHER:SPINE_BONE_MINERAL_DENSITY
MEDROXYPROGESTERONE;VDR;TT;rs1544410;EFFICACY;INCREASED;OTHER:SPINE_BONE_MINERAL_DENSITY
VERAPAMIL;CACNB2;GG;rs2357928;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:ADVERSE_OUTCOME
VERAPAMIL;CACNB2;GG;rs2357928;TOXICITY;INCREASED_RISKEFFICACY;EFFICACY:ADVERSE_OUTCOME
METFORMIN;SLC47A1;CC;rs2252281;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_TO_METFORMIN
TACROLIMUS;CYP3A5;A;rs4646450;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
METFORMIN;SLC47A1;CC;rs2252281;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_TO_METFORMIN
TRAZODONE;ABCB1;AA;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PROLONGED_QTC_INTERVAL
INTERFERONS;BCL2;T;rs1800477;EFFICACY;INCREASED_EFFICACY;EFFICACY:FREQUENCY_(ABOUT_DOUBLE)_IN_NON-RESPONDER_PATIENTS_COMPARED_WITH_RESPONDER_PATIENTS_(HCV_GENOTYPE_4)
RIBAVIRIN;BCL2;T;rs1800477;EFFICACY;INCREASED_EFFICACY;EFFICACY:FREQUENCY_(ABOUT_DOUBLE)_IN_NON-RESPONDER_PATIENTS_COMPARED_WITH_RESPONDER_PATIENTS_(HCV_GENOTYPE_4)
CETUXIMAB;KRAS;T;rs112445441;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
FLUOROURACIL;KRAS;T;rs112445441;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
IRINOTECAN;KRAS;T;rs112445441;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
OXALIPLATIN;KRAS;T;rs112445441;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
FLUOROURACIL;MSH6;GG;rs3136228;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
LEUCOVORIN;MSH6;GG;rs3136228;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
OXALIPLATIN;MSH6;GG;rs3136228;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
FLUOROURACIL;XRCC3;CC;rs1799794;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
LEUCOVORIN;XRCC3;CC;rs1799794;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
OXALIPLATIN;XRCC3;CC;rs1799794;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
NO_DRUG_RELATED;NR1I2;GG;rs7643645;OTHER;INCREASED_RISK;OTHER:DEATH
PLATINUM COMPOUNDS;CCND1;AA;rs9344;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NAUSEA | VOMITING
VERAPAMIL;CACNB2;AT + TT;rs11014166;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:ADVERSE_OUTCOME
VERAPAMIL;CACNB2;AT + TT;rs11014166;TOXICITY;INCREASED_RISKEFFICACY;EFFICACY:ADVERSE_OUTCOME
FLUOROURACIL;ABCC1;C;rs2074087;TOXICITY;DECREASED_SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES
LEUCOVORIN;ABCC1;C;rs2074087;TOXICITY;DECREASED_SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES
OXALIPLATIN;ABCC1;C;rs2074087;TOXICITY;DECREASED_SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES
FLUOROURACIL;nan;AA;rs2960436;EFFICACY;nan;OTHER:BETTER_SURVIVAL_OUTCOME
FLUOROURACIL;ABCC2;AA;rs1885301;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES
LEUCOVORIN;ABCC2;AA;rs1885301;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES
OXALIPLATIN;ABCC2;AA;rs1885301;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES
FLUOROURACIL;IGFBP3;TT;rs2854744;EFFICACY;nan;OTHER:BETTER_SURVIVAL_OUTCOME
FLUOROURACIL;ABCC2;TT;rs717620;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES
LEUCOVORIN;ABCC2;TT;rs717620;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES
OXALIPLATIN;ABCC2;TT;rs717620;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES
FLUOROURACIL;ABCC2;TT;rs3740066;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES
LEUCOVORIN;ABCC2;TT;rs3740066;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES
OXALIPLATIN;ABCC2;TT;rs3740066;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES
COCAINE;DRD2;C;rs1125394;TOXICITY;INCREASED_RISK;DISEASE:COCAINE_DEPENDENCE
COCAINE;DRD2;A;rs1076560;TOXICITY;INCREASED_RISK;DISEASE:COCAINE_DEPENDENCE
COCAINE;DRD2;A;rs2283265;TOXICITY;INCREASED_RISK;DISEASE:COCAINE_DEPENDENCE
MYCOPHENOLATE MOFETIL;SLCO1B1;A;rs4149015;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_DRUG_REACTIONS
TACROLIMUS;CYP3A5;CC;rs4646453;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
TACROLIMUS;CYP3A5;CC;rs776746;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TRANSPLANT_REJECTION
MYCOPHENOLATE MOFETIL;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_DRUG_REACTION
MYCOPHENOLATE MOFETIL;SLCO1B1;TT;rs4149056;LADME_PK;INCREASED_RISK;SIDE_EFFECT:ADVERSE_DRUG_REACTION
OPIOIDS;COMT;CC;rs4633;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER
MYCOPHENOLATE MOFETIL;SLCO1B1;C;rs4149056;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_DRUG_REACTIONS
MYCOPHENOLATE MOFETIL;SLCO1B1;C;rs4149056;LADME_PK;DECREASED_RISK;SIDE_EFFECT:ADVERSE_DRUG_REACTIONS
ACETAMINOPHEN;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CONSTIPATION
TRAMADOL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CONSTIPATION
NO_DRUG_RELATED;VDR;AA + AG;rs2228570;nan;DECREASED_EFFICACY;EFFICACY:BONE_MINERAL_DENSITY
OPIOIDS;COMT;CT;rs4633;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIZZINESS
CAPECITABINE;ABCB1;AA;rs1128503;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME | NEUTROPENIA
OPIOIDS;OPRM1;G;rs1799971;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:OPIOID-RELATED_DISORDERS
CAPECITABINE;ABCB1;CC;rs2032582;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
OPIOIDS;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ERECTILE_DYSFUNCTION | INSOMNIA | SEDATION | PHYSIOLOGICAL_SEXUAL_DISORDER
FLUOROURACIL;ABCB1;GG;rs1045642;TOXICITY;DECREASED_RISK;DISEASE:DIARRHEA
CAPECITABINE;ABCB1;GG;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
WARFARIN;CYP2C9;A;rs7900194;DOSAGE;nan;OTHER:WARFARIN_VARIABILITY
WARFARIN;CYP2C9;A;rs7900194;LADME_PK;nan;OTHER:WARFARIN_VARIABILITY
SUNITINIB;NR1I2;TT;rs3814055;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
AMPHETAMINE;OPRM1;TT;rs510769;OTHER;DECREASED;OTHER:STIMULATION_AND_EUPHORIA_SCORES_AFTER_AMPHETAMINE
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_RISK;DISEASE:MUSCULAR_DISEASES
SUNITINIB;ABCG2;CT;rs2231137;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
NO_DRUG_RELATED;LRP5;T;rs3736228;nan;DECREASED;OTHER:BONE_MINERAL_DENSITY
CISPLATIN;NHLH1;CT + TT;rs11265375;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
NO_DRUG_RELATED;nan;A;rs4355801;nan;DECREASED;OTHER:LUMBAR_SPINE_BONE_MINERAL_DENSITY
NO_DRUG_RELATED;nan;A;rs4355801;nan;INCREASED_RISK;DISEASE:OSTEOPOROSIS
NO_DRUG_RELATED;LRP5;T;rs3736228;nan;INCREASED_RISK;DISEASE:OSTEOPOROSIS
BORTEZOMIB;CBS;TT;rs915854;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES | PAIN | NEUROPATHIC_PAIN,
NO_DRUG_RELATED;UGT2B15;AA;rs3100;OTHER;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
AMPHETAMINE;OPRM1;CC;rs2281617;OTHER;INCREASED;OTHER:EUPHORIC_AND_ENERGETIC_AFTER_AMPHETAMINE_(10_MG)
WARFARIN;HNF4A;CC;rs6130615;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
CISPLATIN;SEMA6A;A;rs3806915;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ASPIRIN;ABCB1;AA;rs1045642;EFFICACY;INCREASED_RISK;DISEASE:THROMBOTIC_DISEASE
ASPIRIN;ABCB1;AA;rs1045642;OTHER;INCREASED_RISK;DISEASE:THROMBOTIC_DISEASE
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED_RISK;DISEASE:THROMBOTIC_DISEASE
CLOPIDOGREL;ABCB1;AA;rs1045642;OTHER;INCREASED_RISK;DISEASE:THROMBOTIC_DISEASE
WARFARIN;HNF4A;GG;rs1884613;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
ASPIRIN;ITGB3;CC + CT;rs5918;EFFICACY;DECREASED_RISK;DISEASE:THROMBOTIC_DISEASE
ASPIRIN;ITGB3;CC + CT;rs5918;OTHER;DECREASED_RISK;DISEASE:THROMBOTIC_DISEASE
CLOPIDOGREL;ITGB3;CC + CT;rs5918;EFFICACY;DECREASED_RISK;DISEASE:THROMBOTIC_DISEASE
CLOPIDOGREL;ITGB3;CC + CT;rs5918;OTHER;DECREASED_RISK;DISEASE:THROMBOTIC_DISEASE
WARFARIN;HNF4A;TT;rs3212191;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
ONDANSETRON;SLC6A4;AA;rs1042173;EFFICACY;INCREASED_EFFICACY;EFFICACY:TREATMENT_RESPONSE_AMONG_PATIENTS_CARRYING_THE_SLC6A4_PROMOTER_LENGTH_POLYMORPHISM_LONG/LONG_GENOTYPE
WARFARIN;nan;G;rs61162043;OTHER;INCREASED_LIKELIHOOD;OTHER:HAVING_WARFARIN_DOSE_GREATER_THAN_7.5_MG/DAY
RISPERIDONE;HTR2A;GG;rs6313;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
HEROIN;OPRM1;G;rs2075572;TOXICITY;INCREASED_RISK;DISEASE:HEROIN_DEPENDENCE
RISPERIDONE;nan;TT;rs1805054;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
ANTIHYPERTENSIVES;NEDD4L;AA;rs4149601;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESISTANT_HYPERTENSION
ANTIHYPERTENSIVES;ADRB1;GG;rs1801252;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESISTANT_HYPERTENSION
FLUOROURACIL;MTHFR;AA + AG;rs1801133;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
RISPERIDONE;HTR2C;CT + TT;rs3813929;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
HEROIN;OPRM1;G;rs1799971;TOXICITY;INCREASED_RISK;DISEASE:HEROIN_DEPENDENCE
BLEOMYCIN;ABCB1;CT;rs2229109;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA | VOMITING
CYCLOPHOSPHAMIDE;ABCB1;CT;rs2229109;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA | VOMITING
DOXORUBICIN;ABCB1;CT;rs2229109;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA | VOMITING
PREDNISONE;ABCB1;CT;rs2229109;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA | VOMITING
RITUXIMAB;ABCB1;CT;rs2229109;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA | VOMITING
VINCRISTINE;ABCB1;CT;rs2229109;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA | VOMITING
VINDESINE;ABCB1;CT;rs2229109;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA | VOMITING
CYCLOPHOSPHAMIDE;CYP2B6;C;rs4802101;TOXICITY;DECREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY | LEUKOPENIA
ANTIHYPERTENSIVES;CYP3A5;CC;rs776746;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:RESISTANT_HYPERTENSION
ANTIHYPERTENSIVES;ZSCAN25;CC;rs776746;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:RESISTANT_HYPERTENSION
CISPLATIN;XPC;GG + GT;rs2228001;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
METHADONE;OPRM1;G;rs1799971;OTHER;DECREASED_LIKELIHOOD;DISEASE:RECURRENCE
NO_DRUG_RELATED;CYP2C9;C;rs1057910;nan;DECREASED_RISK;DISEASE:CORONARY_ARTERY_DISEASE
NO_DRUG_RELATED;CYP2C9;C;rs1057910;nan;INCREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
SUFENTANIL;CYP3A4;TT;rs2242480;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPOVENTILATION
NO_DRUG_RELATED;ADRA2A;A;rs3750625;OTHER;INCREASED_LIKELIHOOD;DISEASE:DIABETES | GESTATIONAL
NO_DRUG_RELATED;ADRA2A;G;rs11195418;OTHER;DECREASED_LIKELIHOOD;DISEASE:DIABETES | GESTATIONAL
MURAGLITAZAR;REN;TT;rs2368564;TOXICITY;DECREASED_RISK;DISEASE:EDEMA
CHLOROQUINE;SLCO2B1;GG;rs12422149;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PARASITEMIA
PRIMAQUINE;SLCO2B1;GG;rs12422149;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PARASITEMIA
ASPIRIN;IL4;TT;rs2243250;OTHER;DECREASED;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ANTIPSYCHOTICS;CNR1;CC;rs806374;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TARDIVE_DYSKINESIA
WARFARIN;CYP2C9;AC + CC;rs1057910;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
METHOTREXATE;SLC16A7;A;rs3763980;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_TO_METHOTREXATE
METFORMIN;AMHR2;G;rs784892;EFFICACY;DECREASED_EFFICACY;EFFICACY:POST-HBA1C_LEVELS
ACETAMINOPHEN;PLA2G4A;G;rs12746200;TOXICITY;INCREASED_RISK;SIDE_EFFECT:URTICARIA
ASPIRIN;PLA2G4A;G;rs12746200;TOXICITY;INCREASED_RISK;SIDE_EFFECT:URTICARIA
DICLOFENAC;PLA2G4A;G;rs12746200;TOXICITY;INCREASED_RISK;SIDE_EFFECT:URTICARIA
PROPIONIC ACID DERIVATIVES;PLA2G4A;G;rs12746200;TOXICITY;INCREASED_RISK;SIDE_EFFECT:URTICARIA
PYRAZOLONES;PLA2G4A;G;rs12746200;TOXICITY;INCREASED_RISK;SIDE_EFFECT:URTICARIA
ANTIPSYCHOTICS;CNR1;CC;rs806374;TOXICITY;INCREASED_SEVERITY;DISEASE:TARDIVE_DYSKINESIA
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;EFFICACY;EFFICACY:SHORTER_TIME_TO_FIRST_THERAPEUTIC_INR_AND_TIME_TO_FIRST_INR>4
FLUOROURACIL;DPYD;C;rs75017182;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
ETHANOL;OPRM1;AA;rs1799971;TOXICITY;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
NEVIRAPINE;CYCSP5;A;rs3099844;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
NEVIRAPINE;CYCSP5;A;rs3099844;OTHER;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
ACETAMINOPHEN;PLCG1;G;rs2228246;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
ASPIRIN;PLCG1;G;rs2228246;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
DICLOFENAC;PLCG1;G;rs2228246;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
PROPIONIC ACID DERIVATIVES;PLCG1;G;rs2228246;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
PYRAZOLONES;PLCG1;G;rs2228246;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
ACETAMINOPHEN;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA | URTICARIA
ASPIRIN;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA | URTICARIA
DICLOFENAC;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA | URTICARIA
PROPIONIC ACID DERIVATIVES;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA | URTICARIA
PYRAZOLONES;TNFRSF11A;C;rs1805034;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA | URTICARIA
ANTIHYPERTENSIVES;NOS3;G;rs1799983;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE
ANTIHYPERTENSIVES;NOS3;C;rs2070744;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE
METHOTREXATE;ABCB1;AG;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
NO_DRUG_RELATED;ADRA2A;A;rs1800038;OTHER;INCREASED_LIKELIHOOD;DISEASE:DIABETES | GESTATIONAL
TACROLIMUS;CYP3A5;T;rs776746;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
CISPLATIN;SLC22A1;CG + GG;rs683369;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
NICOTINE;nan;G;rs4887074;TOXICITY;DECREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
FLUOROURACIL;ABCC5;T;rs10937158;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DIARRHEA
IRINOTECAN;ABCC5;T;rs10937158;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DIARRHEA
LEUCOVORIN;ABCC5;T;rs10937158;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DIARRHEA
FLUOROURACIL;ABCC5;A;rs3749438;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
IRINOTECAN;ABCC5;A;rs3749438;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
LEUCOVORIN;ABCC5;A;rs3749438;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
FLUOROURACIL;ABCG1;T;rs225440;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
IRINOTECAN;ABCG1;T;rs225440;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
LEUCOVORIN;ABCG1;T;rs225440;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CLOPIDOGREL;PON1;CC;rs854552;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
FLUOROURACIL;nan;A;rs2292997;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
IRINOTECAN;nan;A;rs2292997;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
LEUCOVORIN;nan;A;rs2292997;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CISPLATIN;PPARD;AG + GG;rs2038067;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
TACROLIMUS;CYP3A5;C;rs6977165;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
CYCLOPHOSPHAMIDE;CYP2C19;A;rs4244285;TOXICITY;DECREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY | LEUKOPENIA
WARFARIN;VKORC1;CT;rs9923231;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
WARFARIN;VKORC1;T;rs9923231;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROPERTION_OF_THE_FIRST_6_MONTHS'_TREATMENT_TIME_SPENT_WITHIN_THE_TARGET_INR_RANGE_(PTIR)
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED_SEVERITY;DISEASE:MYELOSUPPRESSION
NO_DRUG_RELATED;OPRM1;AA;rs1799971;TOXICITY;INCREASED_SEVERITY;DISEASE:SUBSTANCE-RELATED_DISORDERS
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED_SEVERITY;DISEASE:HAND-FOOT_SYNDROME
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED_SEVERITY;DISEASE:DIARRHEA
FLUOROURACIL;DPYD;G;rs17376848;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
OPIOIDS;CYP3A5;CC + CT;rs776746;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
ACETAMINOPHEN;MIR107;AA + AG;rs2296616;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA
TRAMADOL;MIR107;AA + AG;rs2296616;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA
LITHIUM;GSK3B;AA;rs334558;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESPONSE
CYCLOPHOSPHAMIDE;NQO1;AA;rs1800566;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ANEMIA | DRUG_TOXICITY
DOXORUBICIN;NQO1;AA;rs1800566;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ANEMIA | DRUG_TOXICITY
EPIRUBICIN;NQO1;AA;rs1800566;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ANEMIA | DRUG_TOXICITY
FLUOROURACIL;NQO1;AA;rs1800566;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ANEMIA | DRUG_TOXICITY
METHOTREXATE;NQO1;AA;rs1800566;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ANEMIA | DRUG_TOXICITY
ACETAMINOPHEN;MIR23B;GG;rs1011784;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA
TRAMADOL;MIR23B;GG;rs1011784;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA
ACETAMINOPHEN;MIR23B;CG + GG;rs1011784;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:NEUROPATHIC_PAIN
TRAMADOL;MIR23B;CG + GG;rs1011784;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:NEUROPATHIC_PAIN
OPIOIDS;CYP1A2;AA + AG;rs2069514;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
OPIOIDS;DRD3;AA + AG;rs2654754;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
SIMVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
OPIOIDS;DRD3;AG + GG;rs324029;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
METHAMPHETAMINE;FAAH;A;rs324420;TOXICITY;INCREASED_RISK;SIDE_EFFECT:METHAMPHETAMINE_DEPENDENCE
OPIOIDS;CYP3A4;CC + CT;rs2740574;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
RISPERIDONE;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
ASPIRIN;UGT1A6;AC + CC;rs1105879;EFFICACY;INCREASED_RISK;DISEASE:COLONIC_NEOPLASMS
ACETAMINOPHEN;OPRM1;CT + TT;rs677830;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CONSTIPATION
TRAMADOL;OPRM1;CT + TT;rs677830;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CONSTIPATION
OPIOIDS;CYP3A5;AA + AG;rs15524;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
REGORAFENIB;KDR;A;rs4864950;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
EFAVIRENZ;NR1I2;TT;rs2472677;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DEATH
ETHAMBUTOL;NR1I2;TT;rs2472677;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DEATH
ISONIAZID;NR1I2;TT;rs2472677;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DEATH
RIFAMPIN;NR1I2;TT;rs2472677;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DEATH
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE
EFAVIRENZ;NR1I2;TT;rs2472677;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ETHAMBUTOL;NR1I2;TT;rs2472677;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ISONIAZID;NR1I2;TT;rs2472677;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
RIFAMPIN;NR1I2;TT;rs2472677;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CYCLOPHOSPHAMIDE;ABCB1;AA + TT;rs2032582;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
DOXORUBICIN;ABCB1;AA + TT;rs2032582;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
TAXANES;NR1I3;CC;rs11584174;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ATAZANAVIR;UGT1A1;G;rs8330;OTHER;INCREASED_RISK;SIDE_EFFECT:NEPHROLITHIASIS
RITONAVIR;UGT1A1;G;rs8330;OTHER;INCREASED_RISK;SIDE_EFFECT:NEPHROLITHIASIS
CYCLOPHOSPHAMIDE;ABCB1;AC + CT;rs2032582;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
DOXORUBICIN;ABCB1;AC + CT;rs2032582;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EFAVIRENZ;CYP2B6;TT;rs28399499;TOXICITY;INCREASED_RISK;DISEASE:CENTRAL_NERVOUS_SYSTEM_DISORDER
NEVIRAPINE;ABCB1;TT;rs10276036;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
TAXANES;UGT2B7;AA;rs7438284;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ATAZANAVIR;UGT1A1;T;rs10929303;OTHER;INCREASED_RISK;SIDE_EFFECT:NEPHROLITHIASIS
RITONAVIR;UGT1A1;T;rs10929303;OTHER;INCREASED_RISK;SIDE_EFFECT:NEPHROLITHIASIS
TAXANES;UGT2B7;TT;rs7439366;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ATAZANAVIR;UGT1A1;G;rs1042640;OTHER;INCREASED_RISK;SIDE_EFFECT:NEPHROLITHIASIS
RITONAVIR;UGT1A1;G;rs1042640;OTHER;INCREASED_RISK;SIDE_EFFECT:NEPHROLITHIASIS
TAXANES;UGT2B7;AA;rs7662029;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
TAXANES;UGT2B7;TT;rs7668258;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;INCREASED_RISK;DISEASE:CENTRAL_NERVOUS_SYSTEM_DISORDER
ANTIPSYCHOTICS;GRM3;TT;rs1468412;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MEMORY_IMPAIRMENT
ASPIRIN;PON1;CT + TT;rs662;EFFICACY;INCREASED_EFFICACY;EFFICACY:NON-RESPONSIVENESS
CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;INCREASED_EFFICACY;EFFICACY:NON-RESPONSIVENESS
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
RISPERIDONE;BDNF;TT;rs6265;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
CORTICOSTEROIDS;FCER2;G;rs28364072;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ASTHMA-RELATED_ER_VISIT_OR_HOSPITALIZATION
FLUOROURACIL;CXCL8;AA;rs4073;EFFICACY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
RADIOTHERAPY;CXCL8;AA;rs4073;EFFICACY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
METHOTREXATE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
FLUOROURACIL;KDR;AA;rs1870377;TOXICITY;RISK;SIDE_EFFECT:MUCOSITIS
RADIOTHERAPY;KDR;AA;rs1870377;TOXICITY;RISK;SIDE_EFFECT:MUCOSITIS
PEGINTERFERON ALFA-2B;IL6;CC;rs1800795;TOXICITY;DECREASED_RISK;DISEASE:DEPRESSION
RIBAVIRIN;IL6;CC;rs1800795;TOXICITY;DECREASED_RISK;DISEASE:DEPRESSION
ATORVASTATIN;CYP7A1;TT;rs3808607;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEAN_PERCENTAGE_REDUCTION_OF_TRIGLYCERIDES_LEVEL
CANGRELOR;P2RY12;G;rs6787801;OTHER;nan;OTHER:5%_LOWER_ADP-INDUCED_PEAK_PLATELET_AGGREGATION_IN-VITRO
NO_DRUG_RELATED;APOC1;A;rs445925;LADME_PK;PK;PK:BASELINE_LDL_CHOLESTEROL
NO_DRUG_RELATED;APOE;A;rs445925;LADME_PK;PK;PK:BASELINE_LDL_CHOLESTEROL
SUNITINIB;FGFR2;AA;rs2981582;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SULFAMETHOXAZOLE;NAT2;A;rs1799931;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_REACTIONS
TRIMETHOPRIM;NAT2;A;rs1799931;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_REACTIONS
SUNITINIB;FLT4;CC + CT;rs307826;EFFICACY;DECREASED;DISEASE:OVERALL_SURVIVAL
HEROIN;OPRM1;AG + GG;rs1799971;TOXICITY;DECREASED_RISK;DISEASE:HEROIN_DEPENDENCE
SUNITINIB;NR1I3;AA + AG;rs2307424;EFFICACY;DECREASED;DISEASE:OVERALL_SURVIVAL
NO_DRUG_RELATED;FADS1;T;rs174541;LADME_PK;PK;PK:BASELINE_LDL_CHOLESTEROL
NO_DRUG_RELATED;FEN1;T;rs174541;LADME_PK;PK;PK:BASELINE_LDL_CHOLESTEROL
NO_DRUG_RELATED;MIR611;T;rs174541;LADME_PK;PK;PK:BASELINE_LDL_CHOLESTEROL
NO_DRUG_RELATED;TMEM258;T;rs174541;LADME_PK;PK;PK:BASELINE_LDL_CHOLESTEROL
NO_DRUG_RELATED;nan;C;rs258494;LADME_PK;PK;PK:BASELINE_LDL_CHOLESTEROL
NO_DRUG_RELATED;LDLR;T;rs6511720;OTHER;PK;PK:BASELINE_LDL_CHOLESTEROL
NO_DRUG_RELATED;PNMT;T;rs2934965;OTHER;DECREASED_RISK;OTHER:SICKLE_CELL_PAIN_CRISIS
FLUOROURACIL;GSTP1;GG;rs1695;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
LEUCOVORIN;GSTP1;GG;rs1695;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
LEVAMISOLE;GSTP1;GG;rs1695;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
RADIOTHERAPY;GSTP1;GG;rs1695;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DEXAMETHASONE;ABCB1;CT;rs2229109;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
LENALIDOMIDE;ABCB1;CT;rs2229109;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
AZATHIOPRINE;DDRGK1;AC;rs1127354;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:NON-RESPONSE
AZATHIOPRINE;ITPA;AC;rs1127354;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:NON-RESPONSE
NO_DRUG_RELATED;PNMT;GG;rs2941523;OTHER;DECREASED_RISK;OTHER:SICKLE_CELL_PAIN_CRISIS
MYCOPHENOLIC ACID;SLCO1B3;GT + TT;rs4149117;EFFICACY;INCREASED_RISK;OTHER:CHRONIC_LUNG_ALLOGRAFT_DYSFUNCTION
NO_DRUG_RELATED;PNMT;AA + AG;rs876493;OTHER;DECREASED_RISK;OTHER:SICKLE_CELL_PAIN_CRISIS
ATENOLOL;ACY3;C;rs2514036;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE | ELEVATED_SYSTOLIC_BLOOD_PRESSURE
BISOPROLOL;ACY3;C;rs2514036;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE | ELEVATED_SYSTOLIC_BLOOD_PRESSURE
LOSARTAN;KIRREL2;T;rs3814995;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE
LOSARTAN;NPHS1;T;rs3814995;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE
ASPIRIN;ADORA1;TT;rs16851030;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA
ANTINEOPLASTIC AGENTS;FPGS;TT;rs1544105;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
SUNITINIB;NR1I3;AA;rs4073054;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SUNITINIB;FLT4;AA + AC;rs307821;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ALPRAZOLAM;CYP3A4;AG;rs35599367;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
MYCOPHENOLIC ACID;SLCO1B3;AG + GG;rs7311358;EFFICACY;INCREASED_RISK;OTHER:TRANSPLANT_REJECTION
MYCOPHENOLIC ACID;SLCO1B3;AG + GG;rs7311358;EFFICACY;DECREASED_LIKELIHOOD;OTHER:OVERALL_SURVIVAL
SUNITINIB;ABCB1;AG + GG;rs1128503;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
OLANZAPINE;CYP1A1;T;rs2472297;LADME_PK;PK;PK:25%_HIGHER_MEAN_4'-DESMETHYL_OLA/OLANZAPINE_(OLA)_RATIO
MYCOPHENOLIC ACID;SLCO1B3;GT + TT;rs4149117;EFFICACY;INCREASED_RISK;OTHER:TRANSPLANT_REJECTION
BEVACIZUMAB;MGAT4A;G;rs885036;EFFICACY;INCREASED;DISEASE:PROGRESSION-FREE_SURVIVAL
CAPECITABINE;MGAT4A;G;rs885036;EFFICACY;INCREASED;DISEASE:PROGRESSION-FREE_SURVIVAL
CETUXIMAB;MGAT4A;G;rs885036;EFFICACY;INCREASED;DISEASE:PROGRESSION-FREE_SURVIVAL
OXALIPLATIN;MGAT4A;G;rs885036;EFFICACY;INCREASED;DISEASE:PROGRESSION-FREE_SURVIVAL
OPIOIDS;ADGRV1;C;rs2366929;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
BEVACIZUMAB;MGAT4A;G;rs885036;EFFICACY;DECREASED;DISEASE:PROGRESSION-FREE_SURVIVAL
CAPECITABINE;MGAT4A;G;rs885036;EFFICACY;DECREASED;DISEASE:PROGRESSION-FREE_SURVIVAL
OXALIPLATIN;MGAT4A;G;rs885036;EFFICACY;DECREASED;DISEASE:PROGRESSION-FREE_SURVIVAL
CLOPIDOGREL;FMO3;AA;rs1736557;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
MYCOPHENOLIC ACID;SLCO1B3;GT + TT;rs4149117;EFFICACY;DECREASED_LIKELIHOOD;OTHER:OVERALL_SURVIVAL
IRINOTECAN;UGT1A1;AA;rs10929302;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
ASPIRIN;PEAR1;G;rs2644592;EFFICACY;EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
CLOPIDOGREL;PEAR1;G;rs2644592;EFFICACY;EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
ASPIRIN;PEAR1;C;rs11264580;EFFICACY;EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
CLOPIDOGREL;PEAR1;C;rs11264580;EFFICACY;EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
BUPROPION;APOE;CC + CT;rs429358;OTHER;INCREASED_LIKELIHOOD;DISEASE:RECURRENCE
NICOTINE;APOE;CC + CT;rs429358;OTHER;INCREASED_LIKELIHOOD;DISEASE:RECURRENCE
ASPIRIN;PEAR1;TT;rs57731889;EFFICACY;EFFICACY;EFFICACY:LOW_ON-TREATMENT_PLATELET_REACTIVITY
CLOPIDOGREL;PEAR1;TT;rs57731889;EFFICACY;EFFICACY;EFFICACY:LOW_ON-TREATMENT_PLATELET_REACTIVITY
ALENDRONATE;SIRT1;A;rs932658;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS_OF_THE_JAW
IBANDRONATE;SIRT1;A;rs932658;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS_OF_THE_JAW
RISEDRONATE;SIRT1;A;rs932658;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS_OF_THE_JAW
ZOLEDRONATE;SIRT1;A;rs932658;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS_OF_THE_JAW
VALPROIC ACID;LEPR;AG + GG;rs1137101;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
ANTINEOPLASTIC AGENTS;GSTM5;C;rs3754446;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
ATORVASTATIN;APOE;AT + TT;rs449647;EFFICACY;INCREASED_EFFICACY;EFFICACY:LIPID-LOWERING_EFFECT
BEZAFIBRATE;APOE;AT + TT;rs449647;EFFICACY;INCREASED_EFFICACY;EFFICACY:LIPID-LOWERING_EFFECT
HALOPERIDOL;SLC6A5;AA;rs2298826;TOXICITY;nan;SIDE_EFFECT:MOTOR_SIDE_EFFECTS
OLANZAPINE;AHR;T;rs4410790;LADME_PK;PK;PK:29%_LOWER_MEAN_4'-DESMETHYL_OLA/OLANZAPINE_(OLA)_RATIO
CLOPIDOGREL;P2RY12;AA + AG;rs6785930;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
ASPIRIN;PEAR1;T;rs3737224;EFFICACY;EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
CLOPIDOGREL;PEAR1;T;rs3737224;EFFICACY;EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
ASPIRIN;CYP4F2;T;rs3093135;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EPISTAXIS | GASTROINTESTINAL_HEMORRHAGE | HEMATOMA | HEMATURIA
CLOPIDOGREL;CYP4F2;T;rs3093135;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EPISTAXIS | GASTROINTESTINAL_HEMORRHAGE | HEMATOMA | HEMATURIA
ETHANOL;OPRM1;G;rs1799971;TOXICITY;INCREASED_SEVERITY;DISEASE:ALCOHOL_ABUSE
VENLAFAXINE;CYP2D6;del;rs5030655;LADME_PK;PK;PK:IMPAIRED_METABOLIC_ACTIVITY
ASPIRIN;CYP4F2;T;rs3093135;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EPISTAXIS | GASTROINTESTINAL_HEMORRHAGE | HEMATOMA | HEMATURIA
TICAGRELOR;CYP4F2;T;rs3093135;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EPISTAXIS | GASTROINTESTINAL_HEMORRHAGE | HEMATOMA | HEMATURIA
CLOPIDOGREL;P2RY12;AA + AC;rs6809699;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
CISPLATIN;CASP3;C;rs2720376;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
DOXORUBICIN;CASP3;C;rs2720376;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ACE INHIBITORS;XPNPEP2;A;rs3788853;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA
PLAIN;XPNPEP2;A;rs3788853;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA
HMG COA REDUCTASE INHIBITORS;SLCO1B1;C;rs59502379;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
CAPECITABINE;CES1;GG + GT;rs2244613;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
NEVIRAPINE;CCHCR1;C;rs1265112;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEVIRAPINE-INDUCED_RASH
CISPLATIN;CYP3A4;A;rs4646437;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
DOXORUBICIN;CYP3A4;A;rs4646437;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
NO_DRUG_RELATED;GLI1;CC;rs2228226;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
NICOTINE;ANKK1;AA + AG;rs1800497;TOXICITY;INCREASED_SEVERITY;DISEASE:TOBACCO_USE_DISORDER
NICOTINE;DRD2;AA + AG;rs1800497;TOXICITY;INCREASED_SEVERITY;DISEASE:TOBACCO_USE_DISORDER
VALPROIC ACID;UGT1A6;AG + GG;rs2070959;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TREMOR
ESCITALOPRAM;CYP1A2;T;rs4646425;TOXICITY;INCREASED;DISEASE:FATIGUE
CLOZAPINE;ACKR1;CC;rs2814778;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
ESCITALOPRAM;nan;A;rs2069521;TOXICITY;INCREASED;DISEASE:FATIGUE
ASPIRIN;PEAR1;T;rs41273215;EFFICACY;EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
CLOPIDOGREL;PEAR1;T;rs41273215;EFFICACY;EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
ESCITALOPRAM;CYP1A2;C;rs4646427;TOXICITY;INCREASED;DISEASE:FATIGUE
ESCITALOPRAM;nan;A;rs2069521;TOXICITY;INCREASED;SIDE_EFFECT:NAUSEA/VOMITING
ESCITALOPRAM;CYP1A2;T;rs4646425;TOXICITY;INCREASED;SIDE_EFFECT:NAUSEA/VOMITING
ESCITALOPRAM;CYP1A2;C;rs4646427;TOXICITY;INCREASED;SIDE_EFFECT:NAUSEA/VOMITING
ALLOPURINOL;CYCSP5;AA + AC;rs3099844;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS | STEVENS-JOHNSON_SYNDROME
CLOPIDOGREL;CYP1A2;AA + AC;rs762551;EFFICACY;DECREASED_EFFICACY;EFFICACY:ON-TREATMENT_PLATELET_REACTIVITY
CLOPIDOGREL;CYP1A2;AA + AC;rs762551;LADME_PK;DECREASED_EFFICACY;EFFICACY:ON-TREATMENT_PLATELET_REACTIVITY
ETHANOL;OPRK1;CC + CT;rs6473797;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ALCOHOL_ABUSE
CYCLOPHOSPHAMIDE;NQO1;A;rs1800566;EFFICACY;EFFICACY;EFFICACY:WORSE_OUTCOME_(OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL)
DOXORUBICIN;NQO1;A;rs1800566;EFFICACY;EFFICACY;EFFICACY:WORSE_OUTCOME_(OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL)
HEROIN;GRM3;T;rs274618;OTHER;INCREASED_RISK;DISEASE:HEROIN_DEPENDENCE
THIAZOLIDINEDIONES;AQP2;T;rs296766;TOXICITY;INCREASED_RISK;DISEASE:EDEMA
ETHANOL;CHRNA3;G;rs578776;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:ALCOHOL_ABUSE
ETHANOL;CHRNA3;G;rs578776;OTHER;DECREASED_LIKELIHOOD;DISEASE:ALCOHOL_ABUSE
CISPLATIN;ABCC5;G;rs939338;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
DOXORUBICIN;ABCC5;G;rs939338;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CISPLATIN;FASLG;T;rs763110;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
DOXORUBICIN;FASLG;T;rs763110;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CISPLATIN;MSH2;C;rs4638843;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
DOXORUBICIN;MSH2;C;rs4638843;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;SLC1A1;C;rs3087879;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PHARMACOLOGICAL_RESISTANCE
COCAINE;CHRNA5;G;rs684513;OTHER;INCREASED_LIKELIHOOD;DISEASE:COCAINE_DEPENDENCE
ACE INHIBITORS;XPNPEP2;A;rs3788853;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA
PLAIN;XPNPEP2;A;rs3788853;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA
ALLOPURINOL;nan;AG + GG;rs2734583;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS | STEVENS-JOHNSON_SYNDROME
METHOTREXATE;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
ALLOPURINOL;PSORS1C1;AA + AG;rs9263726;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS | STEVENS-JOHNSON_SYNDROME
FEXOFENADINE;SLCO2B1;T;rs2306168;LADME_PK;DECREASED_PK;PK:AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE
ANTINEOPLASTIC AGENTS;SLC28A3;AA;rs17343066;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION_(P<0.001)
CLOZAPINE;TRAT1;C;rs116982346;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
MERCAPTOPURINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA | NEUTROPENIA | PANCYTOPENIA | THROMBOCYTOPENIA
EFAVIRENZ;CYP2A6;AC + CC;rs8192726;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION_(P=0.028)
CYCLOPHOSPHAMIDE;CYP3A4;CC;rs2740574;EFFICACY;DECREASED_EFFICACY;EFFICACY:DISEASE_FREE_SURVIVAL
DOXORUBICIN;CYP3A4;CC;rs2740574;EFFICACY;DECREASED_EFFICACY;EFFICACY:DISEASE_FREE_SURVIVAL
FLUOROURACIL;CYP3A4;CC;rs2740574;EFFICACY;DECREASED_EFFICACY;EFFICACY:DISEASE_FREE_SURVIVAL
CYCLOPHOSPHAMIDE;CYP3A4;CT;rs2740574;EFFICACY;DECREASED_EFFICACY;EFFICACY:DISEASE_FREE_SURVIVAL
DOXORUBICIN;CYP3A4;CT;rs2740574;EFFICACY;DECREASED_EFFICACY;EFFICACY:DISEASE_FREE_SURVIVAL
FLUOROURACIL;CYP3A4;CT;rs2740574;EFFICACY;DECREASED_EFFICACY;EFFICACY:DISEASE_FREE_SURVIVAL
NO_DRUG_RELATED;ADH1B;A;rs1789891;OTHER;INCREASED;DISEASE:ALCOHOL_ABUSE
ANTINEOPLASTIC AGENTS;DCTD;AA;rs12067645;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
EFAVIRENZ;UGT2B7;CC + CT;rs7439366;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
MERCAPTOPURINE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA | NEUTROPENIA | PANCYTOPENIA | THROMBOCYTOPENIA
FLUOROURACIL;ERCC2;G;rs13181;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
LEUCOVORIN;ERCC2;G;rs13181;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
OXALIPLATIN;ERCC2;G;rs13181;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CLOZAPINE;TRAC;A;rs377360;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
NEVIRAPINE;CCHCR1;G;rs746647;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
NO_DRUG_RELATED;FGFBP1;CC;rs2245964;OTHER;INCREASED;OTHER:BONE_MINERAL_DENSITY
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;EFFICACY;INCREASED_RISK;SIDE_EFFECT:DEATH | GASTROINTESTINAL_HEMORRHAGE
NO_DRUG_RELATED;FGFBP1;TT;rs16892645;OTHER;INCREASED;OTHER:BONE_MINERAL_DENSITY
ATORVASTATIN;SLCO1B1;GG;rs2306283;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_LDL
NO_DRUG_RELATED;nan;G;rs2824292;OTHER;INCREASED_RISK;DISEASE:VENTRICULAR_FIBRILLATION
NEVIRAPINE;nan;G;rs6545803;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEVIRAPINE-INDUCED_RASH
NICOTINE;FMO1;C;rs10912675;OTHER;INCREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
NEVIRAPINE;POLR3G;T;rs2562519;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
NICOTINE;FMO1;T;rs7877;OTHER;INCREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
ASPARAGINASE;GRIA1;T;rs4958381;TOXICITY;INCREASED_RISK;nan
PACLITAXEL;CYP17A1;AG + GG;rs743572;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ACENOCOUMAROL;CYP2C9;C;rs1057910;EFFICACY;INCREASED_RISK;SIDE_EFFECT:DEATH | GASTROINTESTINAL_HEMORRHAGE
CISPLATIN;ERCC1;AA + AC;rs3212986;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FLUOROURACIL;ERCC1;AA + AC;rs3212986;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NAUSEA | VOMITING
ANASTROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:METABOLIC_BONE_DISORDER | OSTEOPOROSIS
LETROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:METABOLIC_BONE_DISORDER | OSTEOPOROSIS
CARBOPLATIN;SOX10;CG;rs139887;TOXICITY;INCREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES
DOCETAXEL;SOX10;CG;rs139887;TOXICITY;INCREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES
PACLITAXEL;SOX10;CG;rs139887;TOXICITY;INCREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES
ANASTROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN | ARTHRITIS | PAIN,
LETROZOLE;TNFRSF11B;CC;rs2073618;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN | ARTHRITIS | PAIN,
ANASTROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:METABOLIC_BONE_DISORDER | OSTEOPOROSIS
LETROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:METABOLIC_BONE_DISORDER | OSTEOPOROSIS
ANTINEOPLASTIC AGENTS;CTPS1;A;rs12067645;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ANTINEOPLASTIC AGENTS;CTPS1;A;rs12067645;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
CAPECITABINE;CES2;CG + GG;rs11075646;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
WARFARIN;VKORC1;T;rs9923231;EFFICACY;EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
ANASTROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN | ARTHRITIS | PAIN,
LETROZOLE;TNFSF11;CC;rs7984870;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN | ARTHRITIS | PAIN,
DRUGS FOR TREATMENT OF TUBERCULOSIS;SOD2;AG + GG;rs4880;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
"""ANALGESICS AND ANESTHETICS""";SOD2;AG + GG;rs4880;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
"""ANTIBIOTICS""";SOD2;AG + GG;rs4880;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
"""ANTIEPILEPTICS""";SOD2;AG + GG;rs4880;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
"""ANTIFUNGALS FOR SYSTEMIC USE""";SOD2;AG + GG;rs4880;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
"""ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS";SOD2;AG + GG;rs4880;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
"NON-STEROIDS""";SOD2;AG + GG;rs4880;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
"""ANTIMYCOBACTERIALS""";SOD2;AG + GG;rs4880;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
"""ANTITHYROID PREPARATIONS""";SOD2;AG + GG;rs4880;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ANEMIA | THROMBOCYTOPENIA | NEUTROPENIA,
METFORMIN;PPARG;G;rs1801282;OTHER;INCREASED_LIKELIHOOD;OTHER:SHORT_AND_LONG-TERM_WEIGHT_LOSS
MITOTANE;CYP2B6;GT + TT;rs3745274;LADME_PK;PK;PK:BEING_A_PREDICTOR_OF_MITOTANE_PLASMA_CONCENTRATIONS_OF_AT_LEAST_14_ÃÂ¿Â½G/ML_AFTER_3_MONTHS_OF_TREATMENT
BORTEZOMIB;CTLA4;GG;rs4553808;TOXICITY;nan;SIDE_EFFECT:EARLIER_ONSET_OF_BORTEZOMIB-INDUCED_PERIPHERAL_NEUROPATHY
MELPHALAN;CTLA4;GG;rs4553808;TOXICITY;nan;SIDE_EFFECT:EARLIER_ONSET_OF_BORTEZOMIB-INDUCED_PERIPHERAL_NEUROPATHY
PREDNISONE;CTLA4;GG;rs4553808;TOXICITY;nan;SIDE_EFFECT:EARLIER_ONSET_OF_BORTEZOMIB-INDUCED_PERIPHERAL_NEUROPATHY
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_PK;PK:PBMC-ASSOCIATED_DRUG_CONCENTRATIONS
NO_DRUG_RELATED;CRHR1;TT;rs1876828;LADME_PK;DECREASED_PK;PK:BASELINE_CORTISOL_LEVELS
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;INCREASED_PK;PK:INTRACELLULAR_PBMC_EXPOSURE
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_PK;PK:INTRACELLULAR_PBMC_EXPOSURE
VALPROIC ACID;SOD2;AG + GG;rs4880;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ALOPECIA
NO_DRUG_RELATED;ABCB1;AA;rs1045642;OTHER;INCREASED_LIKELIHOOD;OTHER:HELICOBACTER_PYLORI_INFECTION
VALPROIC ACID;LEPR;AG + GG;rs1137101;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ALOPECIA
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED;OTHER:ADP-STIMULATED_PLATELET_AGGREGATION
CAPECITABINE;CDA;AG + GG;rs10916825;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HAND-FOOT_SYNDROME
ANTINEOPLASTIC AGENTS;ABCB1;CC + CT;rs4148737;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
HMG COA REDUCTASE INHIBITORS;SLCO1B1;C;rs4149056;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
CLOPIDOGREL;CYP4F2;TT;rs3093135;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION | RECURRENCE
TICAGRELOR;CYP4F2;TT;rs3093135;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION | RECURRENCE
EFAVIRENZ;CYP2B6;CT;rs28399499;LADME_PK;INCREASED_PK;PK:MINIMUM_PLASMA_CONCENTRATIONS
DEFERASIROX;UGT1A3;CC;rs3806596;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:IRON_OVERLOAD
CAPECITABINE;ERCC2;GG;rs13181;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN;ERCC2;GG;rs13181;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DOCETAXEL;ERCC2;GG;rs13181;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
EPIRUBICIN;ERCC2;GG;rs13181;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
GEMCITABINE;ERCC2;GG;rs13181;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DEFERASIROX;UGT1A1;TT;rs887829;EFFICACY;DECREASED_RISK;DISEASE:IRON_OVERLOAD
METFORMIN;SLC47A2;AA + AG;rs12943590;LADME_PK;INCREASED_PK;PK:RENAL_AND_SECRETORY_CLEARANCE_OF_METFORMIN
METFORMIN;SLC47A2;AA;rs12943590;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESPONSE_TO_METFORMIN
CAPECITABINE;CES1;GG + GT;rs2244613;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HAND-FOOT_SYNDROME
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;LADME_PK;DECREASED_PK;PK:ORAL_CLEARANCE_OF_ATORVASTATIN
CAPECITABINE;CES1;GG + GT;rs2244613;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
DEFERASIROX;CYP1A2;AA;rs762551;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:IRON_OVERLOAD
ANTINEOPLASTIC AGENTS;CYP3A5;T;rs776746;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
CAPECITABINE;ERCC2;GG;rs13181;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CISPLATIN;ERCC2;GG;rs13181;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
DOCETAXEL;ERCC2;GG;rs13181;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
EPIRUBICIN;ERCC2;GG;rs13181;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
GEMCITABINE;ERCC2;GG;rs13181;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
DEFERASIROX;CYP1A1;CC;rs2606345;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:IRON_OVERLOAD
HEROIN;GRM3;C;rs274622;OTHER;INCREASED_RISK;DISEASE:HEROIN_DEPENDENCE
EFAVIRENZ;ABCB1;CC + CT;rs3842;LADME_PK;INCREASED_PK;PK:ACCUMULATION_OF_DRUG_IN_PBMCS
ETHANOL;CHRNA4;G;rs1044394;TOXICITY;DECREASED_RISK;OTHER:ALCOHOL_ABUSE
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;AG;rs1799963;TOXICITY;INCREASED_RISK;DISEASE:VENOUS_THROMBOSIS
OPIOIDS;ENPP2;AA;rs2249015;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;CT;rs6025;TOXICITY;INCREASED_RISK;DISEASE:VENOUS_THROMBOSIS
CAPECITABINE;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DOCETAXEL;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
EPIRUBICIN;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
GEMCITABINE;XRCC1;CT + TT;rs25487;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ASPIRIN;ADORA1;GG + GT;rs2228079;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA
LOVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
METHOTREXATE;MTHFR;GG + GT;rs1801131;TOXICITY;DECREASED_RISK;SIDE_EFFECT:SKIN_DISORDER
METHOTREXATE;FASTKD3;AG + GG;rs1801394;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
METHOTREXATE;MTRR;AG + GG;rs1801394;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
FLUOROURACIL;DPYD;T;rs56038477;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:THROMBOCYTOPENIA
PROPRANOLOL;CYP2D6;AA;rs1065852;LADME_PK;INCREASED_PK;PK:AREA_UNDER_PLASMA_CONCENTRATION_OF_PROPRANOLOL
CAPECITABINE;DPYD;T;rs6668296;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
FLUOROURACIL;DPYD;T;rs6668296;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
CLOZAPINE;HLA-DQB1;G;rs113332494;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:AGRANULOCYTOSIS
CAPECITABINE;ERCC2;CC;rs1799793;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN;ERCC2;CC;rs1799793;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DOCETAXEL;ERCC2;CC;rs1799793;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
EPIRUBICIN;ERCC2;CC;rs1799793;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
GEMCITABINE;ERCC2;CC;rs1799793;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
NO_DRUG_RELATED;APOE;CT + TT;rs7412;OTHER;INCREASED;OTHER:HYPERURICEMIA
CAPECITABINE;DPYD;C;rs115349832;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
FLUOROURACIL;DPYD;C;rs115349832;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
METFORMIN;PPARG;G;rs1801282;OTHER;INCREASED_LIKELIHOOD;OTHER:WEIGHT_REGAIN_AFTER_INTENTIONAL_WEIGHT_LOSS
NO_DRUG_RELATED;APOE;CC + CT;rs429358;OTHER;INCREASED;OTHER:HYPERTRIGLYCERIDEMIA
CLOZAPINE;HLA-DQB1;G;rs113332494;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
SIMVASTATIN;APOE;C;rs429358;EFFICACY;INCREASED_RISK;OTHER:MORTALITY_AFTER_MYOCARDIAL_INFARCTION | HOWEVER_THIS_CAN_BE_ELIMINATED
CLOZAPINE;HTR2C;G;rs518147;OTHER;INCREASED_LIKELIHOOD;DISEASE:WEIGHT_GAIN
HALOPERIDOL;HTR2C;G;rs518147;OTHER;INCREASED_LIKELIHOOD;DISEASE:WEIGHT_GAIN
OLANZAPINE;HTR2C;G;rs518147;OTHER;INCREASED_LIKELIHOOD;DISEASE:WEIGHT_GAIN
RISPERIDONE;HTR2C;G;rs518147;OTHER;INCREASED_LIKELIHOOD;DISEASE:WEIGHT_GAIN
AMISULPRIDE;HTR2C;C;rs3813929;OTHER;INCREASED_RISK;DISEASE:WEIGHT_GAIN
CLOZAPINE;HTR2C;C;rs3813929;OTHER;INCREASED_RISK;DISEASE:WEIGHT_GAIN
HALOPERIDOL;HTR2C;C;rs3813929;OTHER;INCREASED_RISK;DISEASE:WEIGHT_GAIN
ILOPERIDONE;HTR2C;C;rs3813929;OTHER;INCREASED_RISK;DISEASE:WEIGHT_GAIN
OLANZAPINE;HTR2C;C;rs3813929;OTHER;INCREASED_RISK;DISEASE:WEIGHT_GAIN
QUETIAPINE;HTR2C;C;rs3813929;OTHER;INCREASED_RISK;DISEASE:WEIGHT_GAIN
RISPERIDONE;HTR2C;C;rs3813929;OTHER;INCREASED_RISK;DISEASE:WEIGHT_GAIN
ZIPRASIDONE;HTR2C;C;rs3813929;OTHER;INCREASED_RISK;DISEASE:WEIGHT_GAIN
HEROIN;SOD2;TT;rs5746136;TOXICITY;INCREASED_RISK;DISEASE:HEROIN_DEPENDENCE
OPIOIDS;ENPP2;A;rs7832704;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN
CARBOPLATIN;BCL2;TT;rs2849380;TOXICITY;INCREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES
DOCETAXEL;BCL2;TT;rs2849380;TOXICITY;INCREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES
PACLITAXEL;BCL2;TT;rs2849380;TOXICITY;INCREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES
CARBOPLATIN;OPRM1;TT;rs544093;TOXICITY;INCREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES
DOCETAXEL;OPRM1;TT;rs544093;TOXICITY;INCREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES
PACLITAXEL;OPRM1;TT;rs544093;TOXICITY;INCREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES
CARBOPLATIN;nan;AG;rs879207;TOXICITY;INCREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES
DOCETAXEL;nan;AG;rs879207;TOXICITY;INCREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES
PACLITAXEL;nan;AG;rs879207;TOXICITY;INCREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES
TOLCAPONE;nan;GG;rs4680;EFFICACY;INCREASED_EFFICACY;EFFICACY:REACTION_TIME
DOLASETRON;NOS1AP;GT + TT;rs10494366;TOXICITY;INCREASED_RISK;SIDE_EFFECT:QTC_PROLONGATION
GRANISETRON;NOS1AP;GT + TT;rs10494366;TOXICITY;INCREASED_RISK;SIDE_EFFECT:QTC_PROLONGATION
SUNITINIB;ABCB1;A;rs2032582;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CAPECITABINE;DPYD;T;rs56276561;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
FLUOROURACIL;DPYD;T;rs56276561;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
CLOZAPINE;ELAVL2;A;rs73482673;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_PK;PK:MID-DOSE_PLASMA_CONCENTRATIONS
FLUOROURACIL;DPYD;CC + CT;rs2297595;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
DOCETAXEL;SLCO1B3;G;rs4149118;OTHER;INCREASED_PK;PK:AUC
DOCETAXEL;SLCO1B3;G;rs4149118;LADME_PK;INCREASED_PK;PK:AUC
NEVIRAPINE;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_PK;PK:PLASMA_EXPOSURE
TOLCAPONE;COMT;AG;rs4680;EFFICACY;DECREASED_EFFICACY;EFFICACY:REACTION_TIME
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_PK;PK:PLASMA_EXPOSURE
HEROIN;SOD2;AC + CC;rs2758339;TOXICITY;DECREASED_RISK;DISEASE:HEROIN_DEPENDENCE
DOCETAXEL;SLCO1B3;G;rs11045585;OTHER;INCREASED_PK;PK:AUC
DOCETAXEL;SLCO1B3;G;rs11045585;LADME_PK;INCREASED_PK;PK:AUC
DOCETAXEL;SLCO1B3;A;rs7311358;OTHER;INCREASED_PK;PK:AUC
DOCETAXEL;SLCO1B3;A;rs7311358;LADME_PK;INCREASED_PK;PK:AUC
IRINOTECAN;TOP1;GG;rs6072262;TOXICITY;DECREASED_SEVERITY;DISEASE:NEUTROPENIA
WARFARIN;APOB;G;rs679899;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
ERLOTINIB;EGFR;GG;rs712829;TOXICITY;INCREASED_SEVERITY;DISEASE:DIARRHEA
ERLOTINIB;ABCG2;CC;rs2622604;OTHER;DECREASED_PK;PK:MEAN_AUC
ERLOTINIB;ABCG2;CC;rs2622604;LADME_PK;DECREASED_PK;PK:MEAN_AUC
WARFARIN;APOB;G;rs1367117;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
CAPECITABINE;DPYD;T;rs56038477;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;DPYD;T;rs56038477;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
MORPHINE;OPRM1;AA;rs1799971;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_PAIN
MORPHINE;ABCB1;AA;rs1045642;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_PAIN
PHENYTOIN;ABCB1;G;rs1045642;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DRUG_RESISTANCE
ATORVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;nan;SIDE_EFFECT:ALL_STATIN-INDUCED_MYOPATHY_AND_SEVERE_MYOPATHY
FLUVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;nan;SIDE_EFFECT:ALL_STATIN-INDUCED_MYOPATHY_AND_SEVERE_MYOPATHY
HMG COA REDUCTASE INHIBITORS;SLCO1B1;C;rs4149056;TOXICITY;nan;SIDE_EFFECT:ALL_STATIN-INDUCED_MYOPATHY_AND_SEVERE_MYOPATHY
PRAVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;nan;SIDE_EFFECT:ALL_STATIN-INDUCED_MYOPATHY_AND_SEVERE_MYOPATHY
ROSUVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;nan;SIDE_EFFECT:ALL_STATIN-INDUCED_MYOPATHY_AND_SEVERE_MYOPATHY
SIMVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;nan;SIDE_EFFECT:ALL_STATIN-INDUCED_MYOPATHY_AND_SEVERE_MYOPATHY
ASPIRIN;B4GALT2;CT + TT;rs1061781;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
CLOPIDOGREL;B4GALT2;CT + TT;rs1061781;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
LEFLUNOMIDE;CYB5A;AA + AG;rs1790834;EFFICACY;DECREASED_EFFICACY;EFFICACY:DISEASE_ACTIVITY_SCORE_28_IN_RHEUMATOID_ARTHRITIS
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;CT;rs6025;TOXICITY;INCREASED_RISK;DISEASE:STROKE
NEVIRAPINE;CYP2B6;CT;rs28399499;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
NEVIRAPINE;CYP2B6;T;rs3745274;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
CETUXIMAB;KRAS;C;rs61764370;EFFICACY;EFFICACY;EFFICACY:NONRESPONSE_TO_ANTI-EGFR-BASED_TREATMENT
PANITUMUMAB;KRAS;C;rs61764370;EFFICACY;EFFICACY;EFFICACY:NONRESPONSE_TO_ANTI-EGFR-BASED_TREATMENT
EDOXABAN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
CYCLOSPORINE;ABCB1;GG;rs1045642;EFFICACY;DECREASED_PK;PK:INTRACELLULAR_AND_BLOOD_CONCENTRATION
CYCLOSPORINE;ABCB1;GG;rs1045642;LADME_PK;DECREASED_PK;PK:INTRACELLULAR_AND_BLOOD_CONCENTRATION
BLEOMYCIN;BLMH;CC;rs1050565;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
CISPLATIN;GSTP1;AA + AG;rs1695;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_HEARING_IMPAIRMENT
CITALOPRAM;FKBP5;A;rs4713916;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
OPIOIDS;TH;AA + AG;rs10770141;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
DISULFIRAM;DBH;CC;rs1611115;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:COCAINE_DEPENDENCE
OPIOIDS;COMT;AA;rs4680;TOXICITY;DECREASED_RISK;OTHER:DEATH
NO_DRUG_RELATED;VEGFA;CC + CG;rs2010963;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
SOFOSBUVIR;IFNL3;CT + TT;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
SOFOSBUVIR;IFNL4;CT + TT;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
VELPATASVIR;IFNL3;CT + TT;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
VELPATASVIR;IFNL4;CT + TT;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
VOXILAPREVIR;IFNL3;CT + TT;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
VOXILAPREVIR;IFNL4;CT + TT;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
OPIOIDS;TH;CT + TT;rs10770140;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
PHENYTOIN;ABCB1;A;rs1128503;OTHER;INCREASED_PK;PK:PLASMA_DRUG_LEVELS
PHENYTOIN;ABCB1;A;rs1128503;LADME_PK;INCREASED_PK;PK:PLASMA_DRUG_LEVELS
PHENYTOIN;ABCB1;A;rs1045642;OTHER;INCREASED_PK;PK:PLASMA_DRUG_LEVELS
PHENYTOIN;ABCB1;A;rs1045642;LADME_PK;INCREASED_PK;PK:PLASMA_DRUG_LEVELS
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;GG;rs1056892;TOXICITY;INCREASED_RISK;DISEASE:CARDIOMYOPATHIES
DEXMEDETOMIDINE;PRKCB;T;rs9922316;OTHER;INCREASED;OTHER:DEXMEDETOMIDINE_ED50_VALUES_FOR_DRUG-INDUCED_DORSAL_HAND_VEIN_(DHV)_CONSTRICTION
PRASUGREL;CYP2C19;T;rs12248560;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY_INDEX_(PRI)_VASODILATOR-STIMULATED_PHOSPHOPROTEIN_(VASP)_AT_1_MONTH_OF_TREATMENT
CYCLOSPORINE;ABCB1;CC;rs2229109;EFFICACY;INCREASED_PK;PK:INTRACELLULAR_AND_BLOOD_CONCENTRATION
CYCLOSPORINE;ABCB1;CC;rs2229109;LADME_PK;INCREASED_PK;PK:INTRACELLULAR_AND_BLOOD_CONCENTRATION
PRASUGREL;CYP2C19;T;rs12248560;EFFICACY;DECREASED_EFFICACY;EFFICACY:RATE_OF_HIGH_ON-TREATMENT_PLATELET_REACTIVITY_(HTPR)_AT_1_MONTH_OF_TREATMENT
HMG COA REDUCTASE INHIBITORS;LPA;G;rs10455872;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CORONARY_DISEASE
EFAVIRENZ;CYP2B6;C;rs28399499;TOXICITY;INCREASED_PK;PK:PLASMA_CONCENTRATION
EFAVIRENZ;CYP2B6;C;rs28399499;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
PRASUGREL;CYP2C19;T;rs12248560;TOXICITY;INCREASED_RISK;SIDE_EFFECT:BLEEDING_COMPLICATIONS
NICOTINE;DRD1;A;rs686;EFFICACY;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
NICOTINE;DRD1;A;rs686;TOXICITY;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
NICOTINE;DRD1;A;rs686;OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
PRASUGREL;CYP2C19;T;rs12248560;EFFICACY;INCREASED_EFFICACY;EFFICACY:RATE_OF_HYPER-RESPONSE_AT_1_MONTH_OF_TREATMENT
ANTIPSYCHOTICS;DRD2;del;rs1799732;TOXICITY;INCREASED_RISK;DISEASE:WEIGHT_GAIN
MITOTANE;CYP2B6;GT + TT;rs3745274;LADME_PK;INCREASED_PK;PK:MITOTANE_PLASMA_CONCENTRATIONS
NICOTINE;DRD1;T;rs4532;EFFICACY;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
NICOTINE;DRD1;T;rs4532;TOXICITY;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
NICOTINE;DRD1;T;rs4532;OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
REPAGLINIDE;SLC30A8;AG;rs16889462;EFFICACY;INCREASED_EFFICACY;EFFICACY:EFFICACY
ATAZANAVIR;UGT1A7;AA;rs17863778;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
ATAZANAVIR;UGT1A7;AA;rs17863778;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
RITONAVIR;UGT1A7;AA;rs17863778;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
RITONAVIR;UGT1A7;AA;rs17863778;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
BEVACIZUMAB;EDN1;TT;rs5370;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
NO_DRUG_RELATED;G6PD;A;rs5030868;nan;nan;OTHER:PROTECTION_FROM_PLASMODIUM_VIVAX_MALARIA_INFECTION
NO_DRUG_RELATED;IKBKG;A;rs5030868;nan;nan;OTHER:PROTECTION_FROM_PLASMODIUM_VIVAX_MALARIA_INFECTION
MYCOPHENOLATE MOFETIL;IMPDH1;T;rs2278294;EFFICACY;DECREASED_RISK;DISEASE:TRANSPLANT_REJECTION
ATAZANAVIR;UGT1A3;CC;rs3806596;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
ATAZANAVIR;UGT1A3;CC;rs3806596;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
RITONAVIR;UGT1A3;CC;rs3806596;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
RITONAVIR;UGT1A3;CC;rs3806596;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
GEFITINIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA | EXANTHEMA
MYCOPHENOLATE MOFETIL;IMPDH1;T;rs2278294;TOXICITY;INCREASED_RISK;DISEASE:LEUKOPENIA
ATAZANAVIR;UGT1A7;GG;rs7586110;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
ATAZANAVIR;UGT1A7;GG;rs7586110;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
RITONAVIR;UGT1A7;GG;rs7586110;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
RITONAVIR;UGT1A7;GG;rs7586110;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
OXALIPLATIN;ERCC2;GG + GT;rs13181;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
OXALIPLATIN;KLC3;GG + GT;rs13181;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
APREPITANT;HTR3C;CC;rs6766410;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:NAUSEA | VOMITING
OLANZAPINE;HTR3C;CC;rs6766410;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:NAUSEA | VOMITING
ATAZANAVIR;UGT1A7;GG;rs17868323;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
ATAZANAVIR;UGT1A7;GG;rs17868323;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
RITONAVIR;UGT1A7;GG;rs17868323;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
RITONAVIR;UGT1A7;GG;rs17868323;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
BEVACIZUMAB;VEGFA;TT;rs3025039;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
APREPITANT;MTHFR;TT;rs1801131;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:NAUSEA | VOMITING
OLANZAPINE;MTHFR;TT;rs1801131;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:NAUSEA | VOMITING
APREPITANT;HTR3B;GG;rs7943062;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:NAUSEA | VOMITING
OLANZAPINE;HTR3B;GG;rs7943062;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:NAUSEA | VOMITING
TAFENOQUINE;nan;A;rs62103056;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
METHOTREXATE;GGH;CC;rs719235;EFFICACY;INCREASED_RISK;SIDE_EFFECT:BONE_MARROW_TOXICITY
METHOTREXATE;GGH;CC;rs719235;TOXICITY;INCREASED_RISK;SIDE_EFFECT:BONE_MARROW_TOXICITY
TIMOLOL;ADRB1;AA;rs1801252;OTHER;INCREASED;OTHER:SYSTOLIC_(SAP)_AND_DIASTOLIC_(DAP)_ARTERIAL_PRESSURE_RESPONSES_TO_TIMOLOL
CISPLATIN;LRP2;G;rs2228171;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
DISULFIRAM;DBH;CT + TT;rs1611115;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
FENTANYL;ADRB2;AA;rs1042718;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPOTENSIVE_DISORDER
PROPOFOL;ADRB2;AA;rs1042718;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPOTENSIVE_DISORDER
REMIFENTANIL;ADRB2;AA;rs1042718;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPOTENSIVE_DISORDER
SEVOFLURANE;ADRB2;AA;rs1042718;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPOTENSIVE_DISORDER
ROSUVASTATIN;ABCG2;T;rs2231142;EFFICACY;SEVERITY_EFFICACY;EFFICACY:HYPERCHOLESTEROLEMIA
NO_DRUG_RELATED;SLC30A8;C;rs13266634;OTHER;INCREASED_RISK;DISEASE:DIABETES_MELLITUS_TYPE2
THIAZIDES;SLCO2A1;T;rs34550074;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPONATREMIA
PLAIN;SLCO2A1;T;rs34550074;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPONATREMIA
ROSUVASTATIN;FMO3;A;rs1736557;EFFICACY;SEVERITY_EFFICACY;EFFICACY:HYPERCHOLESTEROLEMIA
WARFARIN;GGCX;C;rs699664;EFFICACY;INCREASED_EFFICACY;EFFICACY:INTERNATIONAL_NORMALIZED_RATIO_VARIABILITY_(INR-VAR)
CISPLATIN;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
WARFARIN;GGCX;G;rs11676382;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_IN_THERAPEUTIC_RANGE
METHYLPHENIDATE;COMT;A;rs4680;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
ANTIEPILEPTICS;SCN2A;A;rs2304016;EFFICACY;EFFICACY;EFFICACY:DRUG_RESISTANCE
WARFARIN;GGCX;G;rs11676382;EFFICACY;INCREASED_EFFICACY;EFFICACY:INTERNATIONAL_NORMALIZED_RATIO_VARIABILITY_(INR-VAR)
WARFARIN;NQO1;AA + AG;rs1800566;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
NO_DRUG_RELATED;G6PD;T;rs1050828;nan;INCREASED;OTHER:PROTECTION_AGAINST_SEVERE_(P=0.006)_AND_MILD_MALARIA_(P=0.027)
ANTITHYROID PREPARATIONS;KLRC4;C;rs2734565;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:AGRANULOCYTOSIS
METHIMAZOLE;KLRC4;C;rs2734565;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:AGRANULOCYTOSIS
PROPYLTHIOURACIL;KLRC4;C;rs2734565;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:AGRANULOCYTOSIS
OXALIPLATIN;ERCC1;AA;rs11615;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
FLUOROURACIL;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA | MUCOSITIS | NEUTROPENIA,
ACE INHIBITORS;nan;CC + CT;rs4267385;OTHER;nan;OTHER:SAME_PROTECTIVE_PROPERTIES_AGAINST_ANGIOTENSIN-CONVERTING_ENZYME_INHIBITORS-INDUCED_COUGH
PLAIN;nan;CC + CT;rs4267385;OTHER;nan;OTHER:SAME_PROTECTIVE_PROPERTIES_AGAINST_ANGIOTENSIN-CONVERTING_ENZYME_INHIBITORS-INDUCED_COUGH
ACE INHIBITORS;nan;AA + AT;rs4459610;OTHER;nan;OTHER:SAME_PROTECTIVE_PROPERTIES_AGAINST_ANGIOTENSIN-CONVERTING_ENZYME_INHIBITORS-INDUCED_COUGH
PLAIN;nan;AA + AT;rs4459610;OTHER;nan;OTHER:SAME_PROTECTIVE_PROPERTIES_AGAINST_ANGIOTENSIN-CONVERTING_ENZYME_INHIBITORS-INDUCED_COUGH
NO_DRUG_RELATED;G6PD;T;rs1050828;nan;INCREASED;OTHER:PROTECTION_AGAINST_DEVELOPING_SEVERE_MALARIA
METHOTREXATE;MTHFR;AG;rs1801133;TOXICITY;INCREASED_RISK;DISEASE:ALOPECIA
ACE INHIBITORS;BDKRB2;AG;rs8016905;TOXICITY;nan;DISEASE:COUGH
PLAIN;BDKRB2;AG;rs8016905;TOXICITY;nan;DISEASE:COUGH
NO_DRUG_RELATED;F5;C;rs6025;OTHER;INCREASED_LIKELIHOOD;OTHER:RECURRENT_PREGNANCY_LOSS
CARBOPLATIN;TRIM5;C;rs7950311;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PACLITAXEL;TRIM5;C;rs7950311;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
NO_DRUG_RELATED;MTHFR;G;rs1801131;OTHER;INCREASED_LIKELIHOOD;OTHER:RECURRENT_PREGNANCY_LOSS
ANTINEOPLASTIC AGENTS;nan;G;rs6674079;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
NO_DRUG_RELATED;MTHFR;G;rs1801133;OTHER;INCREASED_LIKELIHOOD;OTHER:RECURRENT_PREGNANCY_LOSS
CARBOPLATIN;nan;C;rs2549714;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PACLITAXEL;nan;C;rs2549714;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
NO_DRUG_RELATED;SERPINE1;A;rs2227631;OTHER;INCREASED_LIKELIHOOD;OTHER:RECURRENT_PREGNANCY_LOSS
ANTINEOPLASTIC AGENTS;nan;G;rs4910232;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
WARFARIN;CYP4F2;CT + TT;rs2108622;EFFICACY;DECREASED_EFFICACY;EFFICACY:INTERNATIONAL_NORMALIZED_RATIO_VARIABILITY_(INR-VAR)
ASPIRIN;PPARG;TT;rs3856806;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN_HYPERSENSITIVITY
CYCLOSPORINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
ANTINEOPLASTIC AGENTS;ZNF100;C;rs3795247;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
WARFARIN;VKORC1;T;rs9923231;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEAN_INR_DURING_3-MONTH_DAILY_OBSERVATION_PERIOD_IN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT
ASPIRIN;PTGIR;AG + GG;rs1126510;OTHER;DECREASED_RISK;OTHER:ASPIRIN-INTOLERANT_ASTHMA
WARFARIN;VKORC1;CT + TT;rs9923231;EFFICACY;INCREASED_EFFICACY;EFFICACY:NUMBER_OF_EXAMINATIONS_ABOVE_THE_THERAPEUTIC_RANGE_DURING_3-MONTH_DAILY_OBSERVATION_PERIOD_IN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT
ASPIRIN;TBXA2R;GG;rs1131882;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA
ASPIRIN;PTGER3;A;rs7551789;OTHER;INCREASED_RISK;OTHER:ASPIRIN-INTOLERANT_ASTHMA
WARFARIN;VKORC1;CT + TT;rs9923231;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR>=2
ASPIRIN;PTGER2;GG;rs1353411;OTHER;INCREASED_RISK;OTHER:ASPIRIN-INTOLERANT_ASTHMA
ASPIRIN;PTGER2;G;rs2075797;OTHER;DECREASED_RISK;OTHER:ASPIRIN-INTOLERANT_ASTHMA
DOCETAXEL;CYP3A4;CC;rs2740574;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
PACLITAXEL;CYP3A4;CC;rs2740574;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
DOXORUBICIN;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NAUSEA | VOMITING
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;OTHER:STABLE_WARFARIN_DOSE
CLOPIDOGREL;CYP2C19;AG + GG;rs4244285;EFFICACY;INCREASED_EFFICACY;EFFICACY:VASP_INDEX
ASPIRIN;PPARG;TT;rs3856806;TOXICITY;INCREASED;SIDE_EFFECT:DECLINE_IN_FEV_1_AFTER_ASPIRIN_PROVOCATION
CLOPIDOGREL;CYP2C19;AG + GG;rs4986893;EFFICACY;EFFICACY;EFFICACY:HIGH_POST-CLOPIDOGREL_PLATELET_REACTIVITY
ASPIRIN;NECAB1;G;rs74569896;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CLOPIDOGREL;NECAB1;G;rs74569896;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CLOPIDOGREL;CYP2C19;AG + GG;rs4244285;EFFICACY;EFFICACY;EFFICACY:HIGH_POST-CLOPIDOGREL_PLATELET_REACTIVITY
WARFARIN;VKORC1;T;rs9923231;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ATHEROTHROMBOTIC_EVENTS_DURING_THE_6-YEAR_FOLLOW_UP_IN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT
WARFARIN;CYP2C9;T;rs1799853;EFFICACY;INCREASED;SIDE_EFFECT:BLOOD_COAGULATION_DISORDERS
WARFARIN;CYP2C9;T;rs1799853;TOXICITY;INCREASED;SIDE_EFFECT:BLOOD_COAGULATION_DISORDERS
ASPIRIN;EFR3A;G;rs4736529;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CLOPIDOGREL;EFR3A;G;rs4736529;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
DOCETAXEL;ABCB1;AA;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
PACLITAXEL;ABCB1;AA;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
GEMCITABINE;SLC28A1;GG;rs2242046;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEMATOLOGIC_TOXICITY
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE_DURING_3-MONTH_DAILY_OBSERVATION_PERIOD_IN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT
WARFARIN;CYP2C9;C;rs1057910;EFFICACY;INCREASED;SIDE_EFFECT:BLOOD_COAGULATION_DISORDERS
WARFARIN;CYP2C9;C;rs1057910;TOXICITY;INCREASED;SIDE_EFFECT:BLOOD_COAGULATION_DISORDERS
GEMCITABINE;CDA;CC + CT;rs1048977;OTHER;INCREASED_PK;PK:ELIMINATION_CLEARANCE_OF_DFDU_AND_FORMATION_CLEARANCE_OF_DFDCTP
GEMCITABINE;CDA;CC + CT;rs1048977;LADME_PK;INCREASED_PK;PK:ELIMINATION_CLEARANCE_OF_DFDU_AND_FORMATION_CLEARANCE_OF_DFDCTP
PACLITAXEL;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
HMG COA REDUCTASE INHIBITORS;LPA;AG + GG;rs10455872;TOXICITY;INCREASED_RISK;DISEASE:CORONARY_ARTERY_DISEASE
HMG COA REDUCTASE INHIBITORS;LPA;AG + GG;rs10455872;TOXICITY;INCREASED_RISK;DISEASE:CORONARY_ARTERY_DISEASE
CYTARABINE;ABCB1;GG;rs1128503;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
HMG COA REDUCTASE INHIBITORS;LPA;AG + GG;rs10455872;EFFICACY;EFFICACY;EFFICACY:POORER_REDUCTION_IN_LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_(LDLC)
ETHAMBUTOL;NAT2;AA;rs1799930;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ISONIAZID;NAT2;AA;rs1799930;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PYRAZINAMIDE;NAT2;AA;rs1799930;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RIFAMPIN;NAT2;AA;rs1799930;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
HMG COA REDUCTASE INHIBITORS;LPA;AG + GG;rs10455872;EFFICACY;EFFICACY;EFFICACY:POORER_REDUCTION_IN_LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_(LDLC)
PRAVASTATIN;ABCB1;CC;rs2032582;EFFICACY;INCREASED_EFFICACY;EFFICACY:PERCENT_REDUCTION_IN_LDL-CHOLESTEROL
GEMCITABINE;CMPK1;CC;rs1044457;OTHER;DECREASED_PK;PK:FORMATION_CLEARANCE_OF_DFDCTP
GEMCITABINE;CMPK1;CC;rs1044457;LADME_PK;DECREASED_PK;PK:FORMATION_CLEARANCE_OF_DFDCTP
ASPIRIN;WDR24;G;rs11640115;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CLOPIDOGREL;WDR24;G;rs11640115;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
GEMCITABINE;CDA;CC;rs4655226;OTHER;INCREASED_PK;PK:ELIMINATION_CLEARANCE_OF_DFDU
GEMCITABINE;CDA;CC;rs4655226;LADME_PK;INCREASED_PK;PK:ELIMINATION_CLEARANCE_OF_DFDU
CARBOPLATIN;MAD1L1;CT + TT;rs1801368;OTHER;DECREASED;OTHER:BIOCHEMICAL_RESPONSE | OPTIMAL_CYTOREDUCTION | AND_SENSITIVITY_TO_THE_INDUCTION_CHEMOTHERAPY_TREATMENT
PACLITAXEL;MAD1L1;CT + TT;rs1801368;OTHER;DECREASED;OTHER:BIOCHEMICAL_RESPONSE | OPTIMAL_CYTOREDUCTION | AND_SENSITIVITY_TO_THE_INDUCTION_CHEMOTHERAPY_TREATMENT
VARENICLINE;ICAM5;T;rs901886;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SLEEP_DISORDERS
METHOTREXATE;ABCC1;AG;rs2238476;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
MITOXANTRONE;ABCB1;AA;rs1128503;OTHER;INCREASED;OTHER:SENSITIVITY_IN_VITRO
MERCAPTOPURINE;FOLH1;A;rs61886492;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
METHOTREXATE;FOLH1;A;rs61886492;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CYTARABINE;ABCB1;CC;rs2032582;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
ETHAMBUTOL;NAT2;TT;rs1041983;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ISONIAZID;NAT2;TT;rs1041983;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PYRAZINAMIDE;NAT2;TT;rs1041983;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RIFAMPIN;NAT2;TT;rs1041983;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NEVIRAPINE;CYP2B6;C;rs28399499;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME/EPIDERMAL_NECROLYSIS | TOXIC
NO_DRUG_RELATED;PPARA;AA + AG;rs135561;OTHER;DECREASED_RISK;OTHER:ALL-CAUSE_MORTALITY
CLOZAPINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS | NEUTROPENIA
DRUGS FOR TREATMENT OF TUBERCULOSIS;nan;AA;rs1495741;TOXICITY;DECREASED;SIDE_EFFECT:MEAN_CUMULATIVE_DOSES_OF_ISONIAZID_BEFORE_THE_DEVELOPMENT_OF_ABNORMAL_LIVER-FUNCTION_TESTS_(ALFTS)
ISONIAZID;nan;AA;rs1495741;TOXICITY;DECREASED;SIDE_EFFECT:MEAN_CUMULATIVE_DOSES_OF_ISONIAZID_BEFORE_THE_DEVELOPMENT_OF_ABNORMAL_LIVER-FUNCTION_TESTS_(ALFTS)
METHOTREXATE;ATIC;C;rs4673993;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:DISEASE_ACTIVITY
DRUGS FOR TREATMENT OF TUBERCULOSIS;nan;AA;rs1495741;TOXICITY;DECREASED;SIDE_EFFECT:MEAN_CUMULATIVE_DOSES_OF_ISONIAZID_BEFORE_THE_DEVELOPMENT_OF_ANTITUBERCULOSIS_DRUG-INDUCED_HEPATOTOXICITY_(ATDIH)
ISONIAZID;nan;AA;rs1495741;TOXICITY;DECREASED;SIDE_EFFECT:MEAN_CUMULATIVE_DOSES_OF_ISONIAZID_BEFORE_THE_DEVELOPMENT_OF_ANTITUBERCULOSIS_DRUG-INDUCED_HEPATOTOXICITY_(ATDIH)
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS;APOC3;CG + GG;rs5128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERLIPIDEMIAS
COMBINATIONS;APOC3;CG + GG;rs5128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERLIPIDEMIAS
FLUTICASONE PROPIONATE;CYP3A4;AA + AG;rs35599367;EFFICACY;EFFICACY;EFFICACY:IMPROVED_ASTHMA_CONTROL_(AS_MEASURED_BY_DECREASE_IN_AVERAGE_ASTHMA_CONTROL_SCORE)
ALLOPURINOL;CCHCR1;A;rs9263745;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
LETROZOLE;nan;C;rs74418677;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN | ARTHRITIS | DISCONTINUATION,
ACE INHIBITORS;AGTR1;C;rs5186;TOXICITY;INCREASED;SIDE_EFFECT:MAJOR_CARDIOVASCULAR_EVENTS_(MACE)_RATE
PLAIN;AGTR1;C;rs5186;TOXICITY;INCREASED;SIDE_EFFECT:MAJOR_CARDIOVASCULAR_EVENTS_(MACE)_RATE
CYTARABINE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL | OVERALL_SURVIVAL
DAUNORUBICIN;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL | OVERALL_SURVIVAL
ETOPOSIDE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL | OVERALL_SURVIVAL
MITOXANTRONE;SLCO1B1;CT + TT;rs2291075;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL | OVERALL_SURVIVAL
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_PK;PK:TROUGH_BLOOD_CONCENTRATION_NORMALIZED_FOR_THE_DAILY_DOSE_(C)_PER_KILOGRAM_BODY_WEIGHT_(D)_(C/D | NG/ML/MG/KG/DAY)_RATIO_DURING_THE_FIRST_MONTH_AFTER_TRANSPLANTATION
CYCLOSPORINE;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DELAYED_GRAFT_FUNCTION
ALLOPURINOL;CYCSP5;A;rs3099844;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
METHOTREXATE;FOXP3;GT;rs3761548;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
NO_DRUG_RELATED;CHAT;G;rs1880676;OTHER;INCREASED_RISK;DISEASE:SCHIZOPHRENIA
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS;SIK3;AA + AG;rs139961185;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERLIPIDEMIAS
COMBINATIONS;SIK3;AA + AG;rs139961185;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERLIPIDEMIAS
OXALIPLATIN;XRCC1;TT;rs25487;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CYCLOSPORINE;CYP3A4;AA + AG;rs35599367;TOXICITY;DECREASED;SIDE_EFFECT:RENAL_FUNCTION_(LOWER_CREATININE_CLEARANCE)_AT_3_MONTHS_OF_FOLLOW-UP
METFORMIN;SLC22A1;AA;rs622342;LADME_PK;DECREASED_PK;PK:CL_RENAL_REFERENCE_AND_LOWER_AND_CL_SEC_REFERENCE
ALLOPURINOL;PSORS1C2;T;rs9263733;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CYCLOSPORINE;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DELAYED_GRAFT_FUNCTION
METHOTREXATE;ABCG2;CT + TT;rs13120400;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
ALLOPURINOL;PSORS1C1;A;rs9263726;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ALLOPURINOL;PSORS1C2;A;rs9263726;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
DRUGS FOR TREATMENT OF TUBERCULOSIS;nan;AA;rs1495741;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
EXEMESTANE;nan;G;rs912571;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN | ARTHRITIS | DISCONTINUATION,
LETROZOLE;nan;G;rs912571;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN | ARTHRITIS | DISCONTINUATION,
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS;APOA5;CG + GG;rs964184;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERLIPIDEMIAS
COMBINATIONS;APOA5;CG + GG;rs964184;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERLIPIDEMIAS
VALPROIC ACID;POLG;C;rs2307441;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CISPLATIN;ADH1C;CT;rs698;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:COMPLETE_RESPONSE
CYCLOPHOSPHAMIDE;ADH1C;CT;rs698;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:COMPLETE_RESPONSE
EXEMESTANE;CCDC148;T;rs79048288;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN | ARTHRITIS | DISCONTINUATION,
LETROZOLE;CCDC148;T;rs79048288;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN | ARTHRITIS | DISCONTINUATION,
OXALIPLATIN;GSTP1;GG;rs1695;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
NO_DRUG_RELATED;DRD2;G;rs6277;nan;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
ATORVASTATIN;CYP3A4;AA + AG;rs35599367;DOSAGE;DECREASED;OTHER:STATIN_DOSES_FOR_OPTIMAL_LIPID_CONTROL
ATORVASTATIN;CYP3A4;AA + AG;rs35599367;LADME_PK;DECREASED;OTHER:STATIN_DOSES_FOR_OPTIMAL_LIPID_CONTROL
LOVASTATIN;CYP3A4;AA + AG;rs35599367;DOSAGE;DECREASED;OTHER:STATIN_DOSES_FOR_OPTIMAL_LIPID_CONTROL
LOVASTATIN;CYP3A4;AA + AG;rs35599367;LADME_PK;DECREASED;OTHER:STATIN_DOSES_FOR_OPTIMAL_LIPID_CONTROL
SIMVASTATIN;CYP3A4;AA + AG;rs35599367;DOSAGE;DECREASED;OTHER:STATIN_DOSES_FOR_OPTIMAL_LIPID_CONTROL
SIMVASTATIN;CYP3A4;AA + AG;rs35599367;LADME_PK;DECREASED;OTHER:STATIN_DOSES_FOR_OPTIMAL_LIPID_CONTROL
NO_DRUG_RELATED;DRD2;G;rs1799732;nan;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
VALPROIC ACID;POLG;A;rs3087374;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
EDOXABAN;SLCO1B1;GG;rs2306283;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
EDOXABAN;ABCB1;CC;rs3842;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
HYDROCHLOROTHIAZIDE;ADD1;TT;rs4961;OTHER;INCREASED;OTHER:HYDROCHLOROTHIAZIDE_INDUCED_CALCIUM_RETENTION
EDOXABAN;SLCO1B1;AA + AC;rs999278;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
LEVODOPA;DRD3;TT;rs6280;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
LEVODOPA;DRD2;GG;rs1799732;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
BUSULFAN;CTH;TT;rs1021737;TOXICITY;INCREASED_RISK;DISEASE:HEPATIC_VENO-OCCLUSIVE_DISEASE
CYCLOPHOSPHAMIDE;CTH;TT;rs1021737;TOXICITY;INCREASED_RISK;DISEASE:HEPATIC_VENO-OCCLUSIVE_DISEASE
FUROSEMIDE;CYP11B2;AA + AG;rs1799998;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DIURETIC_UNRESPONSIVENESS
SPIRONOLACTONE;CYP11B2;AA + AG;rs1799998;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DIURETIC_UNRESPONSIVENESS
EDOXABAN;SLCO1B1;CC + CT;rs4149057;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
SIMVASTATIN;ABCB1;AA;rs2032582;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL
SIMVASTATIN;ABCB1;AC;rs2032582;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL
FUROSEMIDE;ACE;CG + GG;rs4341;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DIURETIC_UNRESPONSIVENESS
SPIRONOLACTONE;ACE;CG + GG;rs4341;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DIURETIC_UNRESPONSIVENESS
SIMVASTATIN;ABCB1;AA;rs1045642;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL
ATORVASTATIN;NOS3;CC;rs2070744;EFFICACY;INCREASED_EFFICACY;EFFICACY:ANTI-INFLAMMATORY_EFFECTS
ATORVASTATIN;NOS3;CC;rs2070744;OTHER;INCREASED;OTHER:WHOLE_BLOOD_NITRITE
PAROXETINE;CYP1A2;A;rs2472304;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
FUROSEMIDE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DIURETIC_UNRESPONSIVENESS
SPIRONOLACTONE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DIURETIC_UNRESPONSIVENESS
PAROXETINE;CYP1A2;T;rs4646425;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
ATORVASTATIN;ABCB1;AA;rs2032582;OTHER;INCREASED_PK;PK:AUC
ATORVASTATIN;ABCB1;AA;rs2032582;LADME_PK;INCREASED_PK;PK:AUC
CISPLATIN;ERCC1;AA;rs11615;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MUCOSITIS
DOXORUBICIN;ERCC1;AA;rs11615;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MUCOSITIS
METHAMPHETAMINE;ARRB2;C;rs4790694;OTHER;INCREASED_LIKELIHOOD;DISEASE:SUBSTANCE-RELATED_DISORDERS
METHOTREXATE;ABCG2;GT;rs2231142;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PAROXETINE;CYP1A2;T;rs2470890;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
PEGINTERFERON ALFA-2A;SCARB1;GG;rs10846744;EFFICACY;DECREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;SCARB1;GG;rs10846744;EFFICACY;DECREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PLATINUM COMPOUNDS;nan;AA;rs1829346;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DERMATITIS
RADIOTHERAPY;nan;AA;rs1829346;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DERMATITIS
CISPLATIN;CYBA;AA + AG;rs4673;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ANEMIA | MUCOSITIS
DOXORUBICIN;CYBA;AA + AG;rs4673;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ANEMIA | MUCOSITIS
ATORVASTATIN;ABCB1;AA;rs1128503;OTHER;INCREASED_PK;PK:AUC
ATORVASTATIN;ABCB1;AA;rs1128503;LADME_PK;INCREASED_PK;PK:AUC
CLOZAPINE;CYP2C19;AA;rs4244285;OTHER;INCREASED_PK;PK:PLASMA_CONCENTRATIONS
CLOZAPINE;CYP2C19;AA;rs4244285;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATIONS
ATORVASTATIN;ABCB1;AA;rs1045642;OTHER;INCREASED_PK;PK:AUC
ATORVASTATIN;ABCB1;AA;rs1045642;LADME_PK;INCREASED_PK;PK:AUC
PRASUGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
IRINOTECAN;SLCO1B1;GG;rs2306283;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
PLATINUM COMPOUNDS;nan;AG + GG;rs2027701;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
RADIOTHERAPY;nan;AG + GG;rs2027701;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
SIMVASTATIN;ABCB1;AA;rs1128503;OTHER;INCREASED_PK;PK:AUC_SIMVASTATIN_ACID
SIMVASTATIN;ABCB1;AA;rs1128503;LADME_PK;INCREASED_PK;PK:AUC_SIMVASTATIN_ACID
PRASUGREL;CYP2C19;A;rs4244285;EFFICACY;EFFICACY;EFFICACY:HIGHER_PLATELET_REACTIVITY_INDEX_(PRI)_VASODILATOR-STIMULATED_PHOSPHOPROTEIN_(VASP)_AT_1_MONTH_OF_TREATMENT
ANTIPSYCHOTICS;SLC18A2;TT;rs363341;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PLATINUM COMPOUNDS;nan;CC;rs1059698;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MYELOSUPPRESSION
RADIOTHERAPY;nan;CC;rs1059698;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MYELOSUPPRESSION
ANTIPSYCHOTICS;GRIK3;CT;rs1334802;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PLATINUM COMPOUNDS;nan;AA + AG;rs73594404;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA | NEUTROPENIA
RADIOTHERAPY;nan;AA + AG;rs73594404;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA | NEUTROPENIA
PAROXETINE;CYP1A2;TT;rs4646427;EFFICACY;EFFICACY;EFFICACY:SLOWER_RESPONSE_TIME
METHOTREXATE;SHMT1;AG + GG;rs1979277;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ABDOMINAL_PAIN
PAROXETINE;CYP1A2;A;rs762551;TOXICITY;INCREASED_RISK;DISEASE:FATIGUE
ANTIPSYCHOTICS;HTR2A;AG + GG;rs9567733;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PLATINUM COMPOUNDS;nan;CC;rs36080650;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DERMATITIS
RADIOTHERAPY;nan;CC;rs36080650;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DERMATITIS
METHOTREXATE;ABCB1;AG + GG;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
ANTIPSYCHOTICS;DRD2;AA + AG;rs1124491;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PLATINUM COMPOUNDS;MEG3;CC;rs10132552;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
RADIOTHERAPY;MEG3;CC;rs10132552;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
WARFARIN;CYP4F2;CT + TT;rs2108622;LADME_PK;INCREASED_PK;PK:SERUM_R_-WARFARIN_CONCENTRATION
MYCOPHENOLATE MOFETIL;UGT1A9;C;rs72551330;TOXICITY;nan;SIDE_EFFECT:DIMINISHED_ESTIMATED_GLOMERULAR_FILTRATION_RATE_(EGFR)_DURING_THE_FIRST_YEAR_AFTER_ENGRAFTMENT
METHOTREXATE;ABCC2;AT + TT;rs17222723;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
METHAMPHETAMINE;SLC6A9;T;rs2486001;TOXICITY;INCREASED_RISK;DISEASE:SUBSTANCE-RELATED_DISORDERS
METHAMPHETAMINE;SLC6A9;T;rs2486001;OTHER;INCREASED_RISK;DISEASE:SUBSTANCE-RELATED_DISORDERS
MYCOPHENOLATE MOFETIL;UGT1A9;C;rs72551330;TOXICITY;INCREASED_RISK;DISEASE:PROTEINURIA
ANTIPSYCHOTICS;HTR2C;C;rs1414334;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
CLOZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
OLANZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
NO_DRUG_RELATED;KCNH2;T;rs1805123;OTHER;INCREASED_LIKELIHOOD;DISEASE:ATRIAL_FIBRILLATION
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
METHAMPHETAMINE;ARRB2;A;rs2036657;OTHER;INCREASED_LIKELIHOOD;DISEASE:SUBSTANCE-RELATED_DISORDERS
METHOTREXATE;MTHFR;AA + AG;rs1801133;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
ASPIRIN;P2RY1;CT;rs1065776;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:ASPIRIN-RESISTANT_PHENOTYPE
ROSUVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
NO_DRUG_RELATED;CRHR1;AA;rs110402;OTHER;INCREASED_RISK;DISEASE:MAJOR_DEPRESSIVE_DISORDER
NICOTINE;ARRB2;A;rs4790694;OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
WARFARIN;CYP2C9;A;rs7900194;DOSAGE;DECREASED_EFFICACY;EFFICACY:MEDIAN_WEEKLY_WARFARIN_DOSE_REQUIREMENTS
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMATOLOGICAL_TOXICITY
ATORVASTATIN;ABCB1;A;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYALGIA
CAPECITABINE;MTHFR;GG;rs1801133;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTION
CARVEDILOL;ADRB2;C;rs1042714;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_RESTING_BLOOD_PRESSURE
CLOPIDOGREL;PON1;CC + CT;rs662;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
ANTIDEPRESSANTS;NTRK2;G;rs1439050;TOXICITY;INCREASED_RISK;DISEASE:SUICIDE
IRINOTECAN;UGT1A1;AA;rs10929302;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
BEVACIZUMAB;nan;CT + TT;rs1478947;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
ASPIRIN;TBXA2R;AA;rs4523;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN_RESISTANCE
METHAMPHETAMINE;ARRB2;T;rs1045280;OTHER;INCREASED_LIKELIHOOD;DISEASE:SUBSTANCE-RELATED_DISORDERS
ASPIRIN;GP1BA;CC;rs6065;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN_RESISTANCE
OLANZAPINE;PMCH;G;rs7973796;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:OBESITY
IRINOTECAN;UGT1A1;AA;rs10929302;TOXICITY;INCREASED;DISEASE:NEUTROPENIA
WARFARIN;VKORC1;AA;rs9934438;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
ASPIRIN;TGFB1;AA + AG;rs1800469;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_CHRONIC_URTICARIA
WARFARIN;F7;AA;rs6046;EFFICACY;INCREASED_EFFICACY;EFFICACY:SEN_SITIVITY_TO_WARFARIN_DURING_INDUCTION
WARFARIN;F7;AA;rs6046;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
CARBOPLATIN;MTHFR;AA;rs1801133;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE_TO_CHEMOTHERAPY
CISPLATIN;MTHFR;AA;rs1801133;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE_TO_CHEMOTHERAPY
DOCETAXEL;MTHFR;AA;rs1801133;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE_TO_CHEMOTHERAPY
GEMCITABINE;MTHFR;AA;rs1801133;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE_TO_CHEMOTHERAPY
PACLITAXEL;MTHFR;AA;rs1801133;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE_TO_CHEMOTHERAPY
VINORELBINE;MTHFR;AA;rs1801133;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE_TO_CHEMOTHERAPY
ASPIRIN;KRTAP10-4;A;rs201441480;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
ASPIRIN;TSPEAR;A;rs201441480;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CLOPIDOGREL;KRTAP10-4;A;rs201441480;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CLOPIDOGREL;TSPEAR;A;rs201441480;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CAPECITABINE;DPYD;CT;rs3918290;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY | TREATMENT_MODIFICATION
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY | TREATMENT_MODIFICATION
METHOTREXATE;MTHFD1;AA + AG;rs2236225;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
PACLITAXEL;ABCB1;AA;rs1128503;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
METHOTREXATE;MTHFR;GT + TT;rs1801131;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA | DRUG_TOXICITY
ATORVASTATIN;NOS3;CC;rs2070744;OTHER;DECREASED;OTHER:ERYTHROCYTE_PLASMA_MEMBRANE_FLUIDITY
WARFARIN;CYP2C9;A;rs7900194;LADME_PK;DECREASED_PK;PK:S-WARFARIN_CLEARANCE
ASPIRIN;ECHS1;T;rs140410716;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CLOPIDOGREL;ECHS1;T;rs140410716;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CYCLOPHOSPHAMIDE;PIGB;G;rs12050587;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
EPIRUBICIN;PIGB;G;rs12050587;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
FLUOROURACIL;PIGB;G;rs12050587;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
ATORVASTATIN;SLCO1B1;CT + TT;rs4149035;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
FLUVASTATIN;SLCO1B1;CT + TT;rs4149035;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
LOVASTATIN;SLCO1B1;CT + TT;rs4149035;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PITAVASTATIN;SLCO1B1;CT + TT;rs4149035;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
SIMVASTATIN;SLCO1B1;CT + TT;rs4149035;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ASPIRIN;AGAP3;A;rs75750968;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CLOPIDOGREL;AGAP3;A;rs75750968;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
ATORVASTATIN;SLCO1B1;AA + AG;rs11045818;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
FLUVASTATIN;SLCO1B1;AA + AG;rs11045818;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
LOVASTATIN;SLCO1B1;AA + AG;rs11045818;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PITAVASTATIN;SLCO1B1;AA + AG;rs11045818;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
SIMVASTATIN;SLCO1B1;AA + AG;rs11045818;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
GEMCITABINE;SLC28A2;CC;rs11854484;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEMATOLOGIC_TOXICITY
SIMVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DISCONTINUATION
ACETAMINOPHEN;TLR4;AA + AG;rs1927911;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ASTHMA
TIMOLOL;nan;AA + AG;rs16947;TOXICITY;INCREASED_RISK;DISEASE:BRADYCARDIA
CYCLOPHOSPHAMIDE;nan;C;rs11636687;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
EPIRUBICIN;nan;C;rs11636687;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
FLUOROURACIL;nan;C;rs11636687;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
GEMCITABINE;SLC28A2;CC;rs1060896;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEMATOLOGIC_TOXICITY
ATORVASTATIN;ABCG2;TT;rs2622629;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
FLUVASTATIN;ABCG2;TT;rs2622629;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
LOVASTATIN;ABCG2;TT;rs2622629;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PITAVASTATIN;ABCG2;TT;rs2622629;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
SIMVASTATIN;ABCG2;TT;rs2622629;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PRAVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DISCONTINUATION
ASPIRIN;ZDHHC3;A;rs3749187;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CLOPIDOGREL;ZDHHC3;A;rs3749187;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
VENLAFAXINE;CYP2D6;CT + TT;rs3892097;LADME_PK;INCREASED_PK;PK:VENLAFAXINE_CONCENTRATION_PER_UNIT_DOSE
NO_DRUG_RELATED;ADORA2A;AC + CC;rs5996696;OTHER;DECREASED_RISK;DISEASE:PARKINSON_DISEASE
NO_DRUG_RELATED;ADORA2A;CT;rs71651683;OTHER;DECREASED_RISK;DISEASE:PARKINSON_DISEASE
NO_DRUG_RELATED;IFITM3;GG;rs12252;OTHER;INCREASED_SEVERITY;OTHER:COVID-19
METHOTREXATE;ABCB1;AG + GG;rs1128503;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CAFFEINE;CYP1A2;CC;rs762551;OTHER;DECREASED_RISK;DISEASE:PARKINSON_DISEASE
CAFFEINE;CYP1A2;CC;rs2470890;OTHER;DECREASED_RISK;DISEASE:PARKINSON_DISEASE
CLOZAPINE;ABCB1;AA;rs1045642;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATIONS
HMG COA REDUCTASE INHIBITORS;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
WARFARIN;VKORC1;AA;rs9934438;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEAN_AUC_(AREA_UNDER_CURVE)_PROTHROMBIN_TIME
PEGINTERFERON ALFA-2A;ITPA;CC;rs1127354;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA
PEGINTERFERON ALFA-2B;ITPA;CC;rs1127354;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA
RIBAVIRIN;ITPA;CC;rs1127354;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA
NO_DRUG_RELATED;KCNJ11;TT;rs5219;nan;INCREASED_LIKELIHOOD;DISEASE:DIABETES_MELLITUS_TYPE2
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
ATORVASTATIN;SLCO1B1;A;rs374113543;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:HYPERCHOLESTEROLEMIA
SIMVASTATIN;SLCO1B1;A;rs374113543;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:HYPERCHOLESTEROLEMIA
ATORVASTATIN;SLCO1B1;A;rs373327528;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:HYPERCHOLESTEROLEMIA
SIMVASTATIN;SLCO1B1;A;rs373327528;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:HYPERCHOLESTEROLEMIA
PEGINTERFERON ALFA-2A;DNAAF9;AA;rs6051702;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
PEGINTERFERON ALFA-2B;DNAAF9;AA;rs6051702;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
RIBAVIRIN;DNAAF9;AA;rs6051702;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
DEXAMETHASONE;SERPINE1;AA + AG;rs6092;TOXICITY;INCREASED_RISK;DISEASE:OSTEONECROSIS
GEMCITABINE;CDA;AA + AC;rs2072671;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
NICOTINE;CHRNB2;GG;rs2072661;EFFICACY;INCREASED;OTHER:ABSTINENCE
NICOTINE;CHRNB2;GG;rs2072661;TOXICITY;INCREASED;OTHER:ABSTINENCE
NICOTINE;CHRNB2;GG;rs2072661;OTHER;INCREASED;OTHER:ABSTINENCE
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;A;rs7853758;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SIMEPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SIMEPREVIR;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
CLOZAPINE;CYP1A2;A;rs2069514;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_INSULIN_LEVELS
CISPLATIN;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
DOXORUBICIN;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
CISPLATIN;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
DOXORUBICIN;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
METHOTREXATE;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
EVEROLIMUS;MTOR;C;rs2024627;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CAPECITABINE;DPYD;CT;rs3918290;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
CISPLATIN;ERCC2;GG + GT;rs13181;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
DOXORUBICIN;ERCC2;GG + GT;rs13181;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
METHOTREXATE;ERCC2;GG + GT;rs13181;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
NICOTINE;CHRM2;T;rs324650;TOXICITY;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
NICOTINE;CHRM2;T;rs324650;OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
CETUXIMAB;EGFR;GT + TT;rs712829;EFFICACY;INCREASED_EFFICACY;EFFICACY:SURVIVAL
PANITUMUMAB;EGFR;GT + TT;rs712829;EFFICACY;INCREASED_EFFICACY;EFFICACY:SURVIVAL
NO_DRUG_RELATED;VDR;C;rs1544410;nan;INCREASED_RISK;DISEASE:ASTHMA
CLOZAPINE;CYP1A2;del;rs35694136;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_INSULIN_LEVELS
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
CETUXIMAB;AREG;AA + AG;rs9996584;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PANITUMUMAB;AREG;AA + AG;rs9996584;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
BEVACIZUMAB;VEGFA;GG;rs1570360;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IRINOTECAN;VEGFA;GG;rs1570360;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOPIDOGREL;PON1;CT + TT;rs662;OTHER;INCREASED;OTHER:SMALL-DENSE_LDL_LEVELS
PROTON PUMP INHIBITORS;TRPM6;T;rs3750425;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPOMAGNESEMIA_PRIMARY
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
NO_DRUG_RELATED;FKBP5;CC + CT;rs1360780;EFFICACY;INCREASED_LIKELIHOOD;nan
CLOZAPINE;HTR2C;GG;rs12836771;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
CLOZAPINE;MIR1264;GG;rs12836771;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
CLOZAPINE;MIR1912;GG;rs12836771;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
OLANZAPINE;HTR2C;GG;rs12836771;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
OLANZAPINE;MIR1264;GG;rs12836771;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
OLANZAPINE;MIR1912;GG;rs12836771;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
QUETIAPINE;HTR2C;GG;rs12836771;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
QUETIAPINE;MIR1264;GG;rs12836771;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
QUETIAPINE;MIR1912;GG;rs12836771;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
RISPERIDONE;HTR2C;GG;rs12836771;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
RISPERIDONE;MIR1264;GG;rs12836771;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
RISPERIDONE;MIR1912;GG;rs12836771;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
METHOTREXATE;GGH;AA;rs3758149;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
HALOTHANE;RYR1;T;rs193922803;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
SUCCINYLCHOLINE;RYR1;T;rs193922803;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
CETUXIMAB;AREG;AA;rs11942466;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
PANITUMUMAB;AREG;AA;rs11942466;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
SIMVASTATIN;ABCB1;AA;rs1045642;OTHER;INCREASED_PK;PK:AUC_SIMVASTATIN_ACID
SIMVASTATIN;ABCB1;AA;rs1045642;LADME_PK;INCREASED_PK;PK:AUC_SIMVASTATIN_ACID
PROTON PUMP INHIBITORS;TRPM6;C;rs2274924;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPOMAGNESEMIA_PRIMARY
DOXORUBICIN;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
DOXORUBICIN;ERCC1;AA + AC;rs3212986;TOXICITY;DECREASED_RISK;SIDE_EFFECT:INFECTIOUS_DISEASE | LEUKOPENIA
CLOZAPINE;HTR2C;CC;rs518147;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
OLANZAPINE;HTR2C;CC;rs518147;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
QUETIAPINE;HTR2C;CC;rs518147;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
RISPERIDONE;HTR2C;CC;rs518147;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
SIMVASTATIN;ABCB1;AA;rs2032582;OTHER;INCREASED_PK;PK:AUC_SIMVASTATIN_ACID
SIMVASTATIN;ABCB1;AA;rs2032582;LADME_PK;INCREASED_PK;PK:AUC_SIMVASTATIN_ACID
DESFLURANE;RYR1;T;rs118192172;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
ENFLURANE;RYR1;T;rs118192172;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
HALOTHANE;RYR1;T;rs118192172;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
ISOFLURANE;RYR1;T;rs118192172;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
SEVOFLURANE;RYR1;T;rs118192172;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
SUCCINYLCHOLINE;RYR1;T;rs118192172;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
NEVIRAPINE;CYP2B6;C;rs2054675;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ASUNAPREVIR;IFNL3;GG + GT;rs8099917;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERCHOLESTEROLEMIA
ASUNAPREVIR;IFNL4;GG + GT;rs8099917;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERCHOLESTEROLEMIA
DACLATASVIR;IFNL3;GG + GT;rs8099917;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERCHOLESTEROLEMIA
DACLATASVIR;IFNL4;GG + GT;rs8099917;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERCHOLESTEROLEMIA
DIRECT ACTING ANTIVIRALS;IFNL3;GG + GT;rs8099917;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERCHOLESTEROLEMIA
DIRECT ACTING ANTIVIRALS;IFNL4;GG + GT;rs8099917;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERCHOLESTEROLEMIA
LEDIPASVIR;IFNL3;GG + GT;rs8099917;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERCHOLESTEROLEMIA
LEDIPASVIR;IFNL4;GG + GT;rs8099917;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERCHOLESTEROLEMIA
SOFOSBUVIR;IFNL3;GG + GT;rs8099917;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERCHOLESTEROLEMIA
SOFOSBUVIR;IFNL4;GG + GT;rs8099917;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERCHOLESTEROLEMIA
OMBITASVIR;IFNL3;GG + GT;rs8099917;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERCHOLESTEROLEMIA
OMBITASVIR;IFNL4;GG + GT;rs8099917;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERCHOLESTEROLEMIA
PARITAPREVIR;IFNL3;GG + GT;rs8099917;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERCHOLESTEROLEMIA
PARITAPREVIR;IFNL4;GG + GT;rs8099917;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERCHOLESTEROLEMIA
RITONAVIR;IFNL3;GG + GT;rs8099917;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERCHOLESTEROLEMIA
RITONAVIR;IFNL4;GG + GT;rs8099917;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERCHOLESTEROLEMIA
DESFLURANE;RYR1;A;rs118192176;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
ENFLURANE;RYR1;A;rs118192176;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
HALOTHANE;RYR1;A;rs118192176;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
ISOFLURANE;RYR1;A;rs118192176;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
SEVOFLURANE;RYR1;A;rs118192176;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
SUCCINYLCHOLINE;RYR1;A;rs118192176;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
DESFLURANE;RYR1;T;rs118192177;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
ENFLURANE;RYR1;T;rs118192177;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
HALOTHANE;RYR1;T;rs118192177;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
ISOFLURANE;RYR1;T;rs118192177;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
SEVOFLURANE;RYR1;T;rs118192177;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
SUCCINYLCHOLINE;RYR1;T;rs118192177;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
DESFLURANE;RYR1;A;rs121918593;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
ENFLURANE;RYR1;A;rs121918593;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
HALOTHANE;RYR1;A;rs121918593;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
ISOFLURANE;RYR1;A;rs121918593;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
SEVOFLURANE;RYR1;A;rs121918593;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
SUCCINYLCHOLINE;RYR1;A;rs121918593;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
NEVIRAPINE;CYP2B6;C;rs3786547;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
CAPECITABINE;DPYD;CC + CT;rs1801160;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTION
DESFLURANE;RYR1;A;rs121918592;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
ENFLURANE;RYR1;A;rs121918592;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
HALOTHANE;RYR1;A;rs121918592;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
ISOFLURANE;RYR1;A;rs121918592;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
SEVOFLURANE;RYR1;A;rs121918592;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
SUCCINYLCHOLINE;RYR1;A;rs121918592;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
CAPECITABINE;DPYD;C;rs1801159;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
METHYLPHENIDATE;DRD3;CT + TT;rs6280;TOXICITY;INCREASED;SIDE_EFFECT:INTOLERABILITY
CISPLATIN;ACYP2;AA + AG;rs1872328;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OTOTOXICITY
CLOPIDOGREL;PON1;CT + TT;rs662;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS_(COMPOSITE_OF_CARDIAC_DEATH | MI | STENT_THROMBOSIS)_IN_KOREAN_PATIENTS_AFTER_PCI
DOXORUBICIN;XPC;GG + GT;rs2228001;TOXICITY;DECREASED_RISK;SIDE_EFFECT:INFECTIOUS_DISEASE
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
TELAPREVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
TELAPREVIR;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
HEROIN;OPRM1;GG;rs9479757;TOXICITY;INCREASED_SEVERITY;OTHER:HEROIN_DEPENDENCE
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
NALTREXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED_EFFICACY;EFFICACY:BLUNTING_OF_ALCOHOL_CRAVING
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;EFFICACY;EFFICACY:HIGHER_RATE_OF_SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;EFFICACY;EFFICACY:HIGHER_RATE_OF_SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;EFFICACY;EFFICACY:HIGHER_RATE_OF_SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PD-1;FTO;CC;rs1125338;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1;FTO;CC;rs1125338;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
DEATH LIGAND 1) INHIBITORS;FTO;CC;rs1125338;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
BETA-LACTAM ANTIBACTERIALS;nan;T;rs71542416;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
PENICILLINS;nan;T;rs71542416;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
IRINOTECAN;ABCG1;GG;rs425215;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
XELOX;ABCA2;AA;rs2271862;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
IRINOTECAN;ABCC5;CC;rs562;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
OPIOIDS;TACR1;AG + GG;rs6715729;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:OVERDOSE
OPIOIDS;DRD2;CT + TT;rs4436578;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVERDOSE
OPIOIDS;CYP3A5;CC + CT;rs776746;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVERDOSE
IRINOTECAN;SLCO1B1;AG;rs2306283;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
TRAMADOL;ABCB1;AA;rs1045642;TOXICITY;DECREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
NO_DRUG_RELATED;ABCB1;CC + TT;rs2032582;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CARBOPLATIN;SLCO1B3;AA;rs7311358;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
PACLITAXEL;SLCO1B3;AA;rs7311358;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
METHOTREXATE;FPGS;CC + CT;rs10106;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ALOPECIA | LEUKOPENIA
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ALOPECIA | LEUKOPENIA
NO_DRUG_RELATED;HIF1A;AG;rs11549467;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PD-1;FTO;GG;rs12596638;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL | OVERALL_SURVIVAL
PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1;FTO;GG;rs12596638;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL | OVERALL_SURVIVAL
DEATH LIGAND 1) INHIBITORS;FTO;GG;rs12596638;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL | OVERALL_SURVIVAL
COUMARIN;CYP2A6;C;rs28399433;OTHER;DECREASED;OTHER:EXPRESSION_OF_ENZYME_CONTRIBUTING_TO_THE_METABOLISM
COUMARIN;CYP2A6;C;rs28399433;LADME_PK;DECREASED;OTHER:EXPRESSION_OF_ENZYME_CONTRIBUTING_TO_THE_METABOLISM
NICOTINE;CYP2A6;C;rs28399433;OTHER;DECREASED;OTHER:EXPRESSION_OF_ENZYME_CONTRIBUTING_TO_THE_METABOLISM
NICOTINE;CYP2A6;C;rs28399433;LADME_PK;DECREASED;OTHER:EXPRESSION_OF_ENZYME_CONTRIBUTING_TO_THE_METABOLISM
SUNITINIB;ABCG2;TT;rs2231142;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
NO_DRUG_RELATED;PEMT;T;rs7946;nan;INCREASED_RISK;DISEASE:FATTY_LIVER_DISEASE
ANTIBIOTICS;LGALS3;AT + TT;rs11125;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
SUNITINIB;ABCG2;TT;rs2231142;TOXICITY;INCREASED_RISK;DISEASE:THROMBOCYTOPENIA
PD-1;nan;CG + GG;rs12600192;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1;nan;CG + GG;rs12600192;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
DEATH LIGAND 1) INHIBITORS;nan;CG + GG;rs12600192;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
SUNITINIB;ABCG2;TT;rs2231142;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
NO_DRUG_RELATED;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
SUNITINIB;ABCG2;TT;rs2231142;TOXICITY;INCREASED_RISK;DISEASE:HAND-FOOT_SYNDROME
METHOTREXATE;DHFR;T;rs1650723;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MUCOSITIS
PD-1;nan;CC;rs12600192;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL | OVERALL_SURVIVAL
PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1;nan;CC;rs12600192;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL | OVERALL_SURVIVAL
DEATH LIGAND 1) INHIBITORS;nan;CC;rs12600192;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL | OVERALL_SURVIVAL
METHOTREXATE;ABCG2;AG;rs2231135;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
NICOTINE;HINT1;CC;rs3852209;OTHER;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:METASTATIC_NEOPLASM
NO_DRUG_RELATED;VDR;CC;rs1544410;OTHER;DECREASED_LIKELIHOOD;OTHER:PRE-ECLAMPSIA
ETHAMBUTOL;ALAS1;AA + AG;rs352139;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ISONIAZID;ALAS1;AA + AG;rs352139;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PYRAZINAMIDE;ALAS1;AA + AG;rs352139;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RIFAMPIN;ALAS1;AA + AG;rs352139;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RISPERIDONE;SLC6A4;AA;rs3813034;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
ISONIAZID;GSTP1;AA;rs1695;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RIFAMPIN;GSTP1;AA;rs1695;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CYCLOPHOSPHAMIDE;ALDH1A1;A;rs3764435;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
DOXORUBICIN;ALDH1A1;A;rs3764435;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CYCLOPHOSPHAMIDE;ALDH1A1;A;rs168351;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
DOXORUBICIN;ALDH1A1;A;rs168351;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
METHOTREXATE;MTHFR;A;rs1801133;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CARBOPLATIN;SLCO1B3;GG;rs4149117;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
PACLITAXEL;SLCO1B3;GG;rs4149117;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
PEGINTERFERON ALFA-2A;IFNL3;AA + AG;rs117648444;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;AA + AG;rs117648444;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;AA + AG;rs117648444;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;AA + AG;rs117648444;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;AA + AG;rs117648444;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;AA + AG;rs117648444;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
ETHANOL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:INTOXICATION
NALTREXONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:INTOXICATION
ISONIAZID;NAT2;TT;rs1799929;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;TT;rs1799929;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;TT;rs1799929;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;TT;rs1799929;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
OPIOIDS;COMT;AG;rs4680;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERALGESIA
ISONIAZID;NAT2;AA;rs1799930;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;AA;rs1799930;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;AA;rs1799930;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;AA;rs1799930;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
METHOTREXATE;SLC19A1;CC;rs1051266;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
METHOTREXATE;DHFR;CC;rs1053129;TOXICITY;INCREASED_RISKEFFICACY;EFFICACY:METASTATIC_NEOPLASM
METHOTREXATE;MTHFR;GG;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
TAMOXIFEN;HS6ST3;A;rs118042719;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
PHENYTOIN;ABCB1;A;rs2229107;OTHER;INCREASED_PK;PK:PLASMA_DRUG_LEVELS
PHENYTOIN;ABCB1;A;rs2229107;LADME_PK;INCREASED_PK;PK:PLASMA_DRUG_LEVELS
"""3";OPRM1;AG;rs1799971;TOXICITY;INCREASED_RISK;OTHER:SUBSTANCE-RELATED_DISORDERS
"4-METHYLENEDIOXYMETHAMPHETAMINE""";OPRM1;AG;rs1799971;TOXICITY;INCREASED_RISK;OTHER:SUBSTANCE-RELATED_DISORDERS
"""COCAINE""";OPRM1;AG;rs1799971;TOXICITY;INCREASED_RISK;OTHER:SUBSTANCE-RELATED_DISORDERS
"""ETHANOL""";OPRM1;AG;rs1799971;TOXICITY;INCREASED_RISK;OTHER:SUBSTANCE-RELATED_DISORDERS
"""OPIOIDS""";OPRM1;AG;rs1799971;TOXICITY;INCREASED_RISK;OTHER:SUBSTANCE-RELATED_DISORDERS
TRASTUZUMAB;FCGR3A;CC;rs396991;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
MYCOPHENOLIC ACID;ABCC2;C;rs717620;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PRIMARY_GRAFT_FAILURE | KIDNEY_TUBULAR_NECROSIS | ACUTE
TACROLIMUS;ABCC2;C;rs717620;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PRIMARY_GRAFT_FAILURE | KIDNEY_TUBULAR_NECROSIS | ACUTE
METHADONE;CYP2B6;TT;rs1038376;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
TRASTUZUMAB;FCGR2A;AA;rs1801274;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
METHOTREXATE;SLC19A1;CC + CT;rs1051266;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
SUCCINYLCHOLINE;BCHE;C;rs1799807;LADME_PK;nan;SIDE_EFFECT:BUTYRYLCHOLINESTERASE_DEFICIENCY
SUCCINYLCHOLINE;BCHE;T;rs1803274;LADME_PK;nan;SIDE_EFFECT:BUTYRYLCHOLINESTERASE_DEFICIENCY
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:THROMBOCYTOPENIA
CLOPIDOGREL;CYP2C18;A;rs1042192;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
CLOZAPINE;HNMT;GG;rs2737385;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:SEDATION
FLUOROURACIL;DPYD;CT;rs1801160;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
METHADONE;CYP2B6;AG + GG;rs2279343;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
CLOPIDOGREL;NOC3L;A;rs12572897;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
TAMOXIFEN;LPP;A;rs6790761;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
ETHAMBUTOL;NAT2;T;rs1799929;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
ISONIAZID;NAT2;T;rs1799929;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
PYRAZINAMIDE;NAT2;T;rs1799929;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
RIFAMPIN;NAT2;T;rs1799929;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
SUNITINIB;ABCB1;AA + AG;rs1128503;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
NICOTINE;CHRNA5;A;rs16969968;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER
NICOTINE;CHRNA5;A;rs16969968;OTHER;INCREASED_LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER
CLOPIDOGREL;CYP2C8;A;rs1058932;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
SUNITINIB;ABCB1;AA + AC;rs2032582;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
NICOTINE;CHRNA3;A;rs578776;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER
NICOTINE;CHRNA3;A;rs578776;OTHER;DECREASED_LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER
TAMOXIFEN;LPP;A;rs77693286;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
ANTHRACYCLINES AND RELATED SUBSTANCES;UGT1A6;T;rs17863783;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;INCREASED_RISK;DISEASE:TRANSPLANT_REJECTION
RIFAMPIN;RIPOR2;C;rs10946739;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;A;rs2229774;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
NO_DRUG_RELATED;EGFR;AA;rs763317;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
NO_DRUG_RELATED;GAL;C;rs948854;OTHER;INCREASED_SEVERITY;DISEASE:ANXIETY_DISORDERS
HMG COA REDUCTASE INHIBITORS;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
CARBAMAZEPINE;ZNRD1-AS1;AG + GG;rs3869066;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
ATAZANAVIR;ABCB1;AA;rs2032582;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
HMG COA REDUCTASE INHIBITORS;EYS;G;rs1337512;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:RHABDOMYOLYSIS
RIFAMPIN;AGBL4;A;rs393994;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ATAZANAVIR;ABCB1;AA;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
PHENYTOIN;CYP2C9;T;rs1799853;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
HMG COA REDUCTASE INHIBITORS;EYS;A;rs9342288;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:RHABDOMYOLYSIS
OTHER COMBINATIONS;EYS;A;rs9342288;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:RHABDOMYOLYSIS
ASPIRIN;SLC30A9;A;rs1047626;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ASPIRIN;SLC30A9;A;rs1047626;OTHER;DECREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ESCITALOPRAM;BDNF;C;rs962369;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SUICIDAL_IDEATION
ESCITALOPRAM;BDNF;C;rs962369;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SUICIDAL_IDEATION
NORTRIPTYLINE;BDNF;C;rs962369;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SUICIDAL_IDEATION
NORTRIPTYLINE;BDNF;C;rs962369;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SUICIDAL_IDEATION
ACE INHIBITORS;KCNMA1;G;rs2253201;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
PLAIN;KCNMA1;G;rs2253201;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
HMG COA REDUCTASE INHIBITORS;EYS;A;rs3857532;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:RHABDOMYOLYSIS
OTHER COMBINATIONS;EYS;A;rs3857532;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:RHABDOMYOLYSIS
ASPIRIN;TSC1;C;rs7862221;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ASPIRIN;TSC1;C;rs7862221;OTHER;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
RIFAMPIN;AGBL4;G;rs320003;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ASPIRIN;THRA;G;rs11819745;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ASPIRIN;THRA;G;rs11819745;OTHER;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
RIFAMPIN;CUX2;G;rs7958375;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;A;rs7853758;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
HMG COA REDUCTASE INHIBITORS;GATM;A;rs9806699;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
HMG COA REDUCTASE INHIBITORS;SLCO1B1;CC + CT;rs4363657;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
ASPIRIN;CHIA;A;rs3818822;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ASPIRIN;CHIA;A;rs3818822;OTHER;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ATAZANAVIR;ABCB1;AA;rs1128503;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
ASPIRIN;nan;C;rs1074373;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ASPIRIN;nan;C;rs1074373;OTHER;DECREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
PHENYTOIN;CYP2C9;T;rs1799853;TOXICITY;INCREASED_PK;PK:PLASMA_FREE_PHENYTOIN_CONCENTRATION
PHENYTOIN;CYP2C9;T;rs1799853;LADME_PK;INCREASED_PK;PK:PLASMA_FREE_PHENYTOIN_CONCENTRATION
PHENYTOIN;CYP2C9;C;rs1057910;TOXICITY;INCREASED_PK;PK:PLASMA_FREE_PHENYTOIN_CONCENTRATION
PHENYTOIN;CYP2C9;C;rs1057910;LADME_PK;INCREASED_PK;PK:PLASMA_FREE_PHENYTOIN_CONCENTRATION
HEROIN;GRM3;A;rs1990040;OTHER;INCREASED_RISK;DISEASE:HEROIN_DEPENDENCE
ASPIRIN;ZBTB22;C;rs3130100;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ASPIRIN;ZBTB22;C;rs3130100;OTHER;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
CYCLOSPORINE;TCF7L2;T;rs7903146;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DIABETES_MELLITUS
SIROLIMUS;TCF7L2;T;rs7903146;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DIABETES_MELLITUS
TACROLIMUS;TCF7L2;T;rs7903146;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DIABETES_MELLITUS
HMG COA REDUCTASE INHIBITORS;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:RHABDOMYOLYSIS
PHENYTOIN;CYP2C9;C;rs1057910;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
ASPIRIN;HLA-DPB1;C;rs3097671;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ASPIRIN;HLA-DPB1;C;rs3097671;OTHER;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ASPIRIN;HLA-DPB2;C;rs3129294;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ASPIRIN;HLA-DPB2;C;rs3129294;OTHER;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ASPIRIN;HLA-DPB1;G;rs1042151;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ASPIRIN;HLA-DPB1;G;rs1042151;OTHER;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ASPIRIN;HLA-DPB1;C;rs1042136;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ASPIRIN;HLA-DPB1;C;rs1042136;OTHER;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
RIFAMPIN;RIPOR2;A;rs10946737;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PREDNISOLONE;GATA3;AA;rs3824662;PD;INCREASED_RISK;SIDE_EFFECT:SEPSIS
RIFAMPIN;AGBL4;A;rs319952;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NICOTINE;OPRM1;AA;rs10485057;TOXICITY;INCREASED_RISK;OTHER:TOBACCO_USE_DISORDER
ETHANOL;DPP6;C;rs2533200;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
CISPLATIN;EPHX1;CT;rs1051740;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY_GRADES_1-4
CYCLOPHOSPHAMIDE;EPHX1;CT;rs1051740;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY_GRADES_1-4
CARBAMAZEPINE;nan;G;rs192543598;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ETHANOL;nan;T;rs7900002;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;nan;T;rs2582405;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
CISPLATIN;NAT2;CT;rs1801280;TOXICITY;INCREASED_RISK;DISEASE:ANEMIA
CYCLOPHOSPHAMIDE;NAT2;CT;rs1801280;TOXICITY;INCREASED_RISK;DISEASE:ANEMIA
ETHANOL;nan;T;rs56722963;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
CISPLATIN;MUTYH;CT;rs3219484;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA_GRADE_3-4
CYCLOPHOSPHAMIDE;MUTYH;CT;rs3219484;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA_GRADE_3-4
CARBAMAZEPINE;ALK;G;rs187926838;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ETHANOL;MED19;A;rs576859;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;TMX2;A;rs576859;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
METHOTREXATE;ATIC;CC;rs7563206;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ENZYMES;A2M;TT;rs669;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGIC_TRANSFORMATION
METHOTREXATE;ATIC;GT + TT;rs3821353;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CHOP;NCF4;AA;rs1883112;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL | OVERALL_SURVIVAL
RITUXIMAB;NCF4;AA;rs1883112;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL | OVERALL_SURVIVAL
ENZYMES;F12;GG;rs1801020;TOXICITY;INCREASED_RISK;DISEASE:DEATH
SUNITINIB;ABCB1;A;rs1128503;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
METHOTREXATE;ATIC;CG + GG;rs2372536;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ETHANOL;nan;T;rs6589386;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE
ETHANOL;ADH1C;A;rs13125415;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
METHOTREXATE;ATIC;CC;rs12995526;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CISPLATIN;RAD52;AG;rs11226;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA_GRADE_3-4
CYCLOPHOSPHAMIDE;RAD52;AG;rs11226;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA_GRADE_3-4
ETHANOL;SLC39A8;A;rs13135092;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
CISPLATIN;LIG3;CC;rs1052536;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA_GRADE_3-4
CYCLOPHOSPHAMIDE;LIG3;CC;rs1052536;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA_GRADE_3-4
ABIRATERONE;TSPYL1;AA;rs3828743;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PREDNISOLONE;TSPYL1;AA;rs3828743;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
OPIOIDS;COMT;AA + AG;rs4680;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | FATIGUE | DEPRESSION,
CISPLATIN;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
FLUOROURACIL;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
RADIOTHERAPY;XRCC1;AA + AG;rs1799782;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
INDINAVIR;UGT1A1;AG;rs4148323;TOXICITY;INCREASED_RISK;DISEASE:HYPERBILIRUBINEMIA
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
ETHANOL;ADH1B;T;rs1229984;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
METHOTREXATE;FPGS;AA;rs10760502;EFFICACY;DECREASED_LIKELIHOOD;OTHER:DISCONTINUATION
METHOTREXATE;FPGS;AA;rs10760502;TOXICITY;DECREASED_LIKELIHOOD;OTHER:DISCONTINUATION
METHOTREXATE;FPGS;AA;rs10760502;OTHER;DECREASED_LIKELIHOOD;OTHER:DISCONTINUATION
METHOTREXATE;FPGS;TT;rs10106;EFFICACY;DECREASED_LIKELIHOOD;OTHER:DISCONTINUATION
METHOTREXATE;FPGS;TT;rs10106;TOXICITY;DECREASED_LIKELIHOOD;OTHER:DISCONTINUATION
METHOTREXATE;FPGS;TT;rs10106;OTHER;DECREASED_LIKELIHOOD;OTHER:DISCONTINUATION
CAPECITABINE;DPYD;AC + CC;rs55886062;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;DPYD;AC + CC;rs55886062;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
TEGAFUR;DPYD;AC + CC;rs55886062;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
METHOTREXATE;FPGS;TT;rs10106;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ETHANOL;nan;T;rs9679319;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;nan;A;rs1402398;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;THSD7B;A;rs13382553;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
PEGINTERFERON ALFA-2A;nan;GG;rs4273729;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;nan;GG;rs4273729;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
METHOTREXATE;ABCB1;TT;rs868755;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ETHANOL;nan;A;rs2673136;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;nan;A;rs13129401;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
METHOTREXATE;ABCB1;TT;rs10280623;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ETHANOL;CADM2;A;rs62250713;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;ADH1B;T;rs75967634;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
CARBOPLATIN;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:FEVER | MUCOSITIS
CYCLOPHOSPHAMIDE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:FEVER | MUCOSITIS
ETOPOSIDE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:FEVER | MUCOSITIS
LOMUSTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:FEVER | MUCOSITIS
METHOTREXATE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:FEVER | MUCOSITIS
VINCRISTINE;METTL3;AA + AG;rs1139130;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:FEVER | MUCOSITIS
HEROIN;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED_SEVERITY;OTHER:HEROIN_DEPENDENCE
PEGINTERFERON ALFA-2A;nan;GG;rs4273729;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;nan;GG;rs4273729;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;nan;GG;rs4273729;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
NO_DRUG_RELATED;CYP2A6;T;rs56113850;OTHER;DECREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
ETHANOL;PDE4B;A;rs6421482;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;nan;A;rs61767420;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;GCKR;T;rs1260326;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;nan;T;rs494904;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
NO_DRUG_RELATED;CHRNA5;AA + AT;rs503464;OTHER;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
METHOTREXATE;SPATA9;A;rs72783407;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
METHOTREXATE;BIRC5;GG;rs9904341;EFFICACY;INCREASED_EFFICACY;EFFICACY:DISEASE_ACTIVITY_SCORE_28_IN_RHEUMATOID_ARTHRITIS
PROTEIN KINASE INHIBITORS;STAT6;TT;rs324011;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ADVERSE_EVENTS
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CAPECITABINE;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
TEGAFUR;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
OPIOIDS;ANKK1;AA + AG;rs1800497;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
OPIOIDS;DRD2;AA + AG;rs1800497;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
TAMOXIFEN;C1QTNF6;C;rs114557570;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
NO_DRUG_RELATED;CHRNA5;AA + AT;rs637137;OTHER;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
DOCETAXEL;VEGFA;CC;rs833061;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DOCETAXEL;VEGFA;GG;rs13207351;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
DOCETAXEL;VEGFA;GG;rs35864111;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ASPARAGINASE;GATA3;A;rs3824662;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RELAPSE
CYCLOPHOSPHAMIDE;GATA3;A;rs3824662;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RELAPSE
CYTARABINE;GATA3;A;rs3824662;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RELAPSE
DAUNORUBICIN;GATA3;A;rs3824662;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RELAPSE
DEXAMETHASONE;GATA3;A;rs3824662;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RELAPSE
DOXORUBICIN;GATA3;A;rs3824662;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RELAPSE
LEUCOVORIN;GATA3;A;rs3824662;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RELAPSE
MERCAPTOPURINE;GATA3;A;rs3824662;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RELAPSE
METHOTREXATE;GATA3;A;rs3824662;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RELAPSE
PEGASPARGASE;GATA3;A;rs3824662;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RELAPSE
PREDNISONE;GATA3;A;rs3824662;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RELAPSE
THIOGUANINE;GATA3;A;rs3824662;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RELAPSE
VINCRISTINE;GATA3;A;rs3824662;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RELAPSE
ASPARAGINASE;GATA3;A;rs3824662;EFFICACY;INCREASED_EFFICACY;EFFICACY:MINIMAL_RESIDUAL_DISEASE
CYCLOPHOSPHAMIDE;GATA3;A;rs3824662;EFFICACY;INCREASED_EFFICACY;EFFICACY:MINIMAL_RESIDUAL_DISEASE
CYTARABINE;GATA3;A;rs3824662;EFFICACY;INCREASED_EFFICACY;EFFICACY:MINIMAL_RESIDUAL_DISEASE
DAUNORUBICIN;GATA3;A;rs3824662;EFFICACY;INCREASED_EFFICACY;EFFICACY:MINIMAL_RESIDUAL_DISEASE
DEXAMETHASONE;GATA3;A;rs3824662;EFFICACY;INCREASED_EFFICACY;EFFICACY:MINIMAL_RESIDUAL_DISEASE
DOXORUBICIN;GATA3;A;rs3824662;EFFICACY;INCREASED_EFFICACY;EFFICACY:MINIMAL_RESIDUAL_DISEASE
LEUCOVORIN;GATA3;A;rs3824662;EFFICACY;INCREASED_EFFICACY;EFFICACY:MINIMAL_RESIDUAL_DISEASE
MERCAPTOPURINE;GATA3;A;rs3824662;EFFICACY;INCREASED_EFFICACY;EFFICACY:MINIMAL_RESIDUAL_DISEASE
METHOTREXATE;GATA3;A;rs3824662;EFFICACY;INCREASED_EFFICACY;EFFICACY:MINIMAL_RESIDUAL_DISEASE
PEGASPARGASE;GATA3;A;rs3824662;EFFICACY;INCREASED_EFFICACY;EFFICACY:MINIMAL_RESIDUAL_DISEASE
PREDNISONE;GATA3;A;rs3824662;EFFICACY;INCREASED_EFFICACY;EFFICACY:MINIMAL_RESIDUAL_DISEASE
THIOGUANINE;GATA3;A;rs3824662;EFFICACY;INCREASED_EFFICACY;EFFICACY:MINIMAL_RESIDUAL_DISEASE
VINCRISTINE;GATA3;A;rs3824662;EFFICACY;INCREASED_EFFICACY;EFFICACY:MINIMAL_RESIDUAL_DISEASE
DOCETAXEL;VEGFA;AA;rs699947;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
EXEMESTANE;nan;C;rs62293499;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:RECURRENCE
ASPIRIN;CYP4F2;CT;rs2108622;OTHER;INCREASED;OTHER:PLATELET_AGGREGATION_WITH_EPINEPHRINE
CLOPIDOGREL;CYP4F2;CT;rs2108622;OTHER;INCREASED;OTHER:PLATELET_AGGREGATION_WITH_EPINEPHRINE
FLUOROURACIL;DPYD;AT + TT;rs4294451;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
CITALOPRAM;COL26A1;T;rs17135437;TOXICITY;INCREASED;SIDE_EFFECT:HEARING_AND_VISION-RELATED_SIDE-EFFECTS
CITALOPRAM;nan;A;rs16965962;TOXICITY;INCREASED;SIDE_EFFECT:GENERAL_SIDE-EFFECT_BURDEN
ALLOPURINOL;PSORS1C1;A;rs9263726;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ALLOPURINOL;PSORS1C2;A;rs9263726;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ASPIRIN;ACE;CC + CT;rs4292;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN_INTOLERANCE
CLOPIDOGREL;P2RY12;AA;rs6809699;EFFICACY;EFFICACY;EFFICACY:STRONGER_AGGREAGTION
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC22A17;T;rs4982753;TOXICITY;DECREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
TACROLIMUS;CYP3A5;T;rs776746;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIABETES_MELLITUS
FLUOROURACIL;DPYD;AT + TT;rs4294451;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
NO_DRUG_RELATED;ACE2;T;rs2074192;OTHER;INCREASED_SEVERITY;OTHER:COVID-19
CLOPIDOGREL;P2RY12;AA;rs6809699;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CLOPIDOGREL_RESISTANCE
ASPIRIN;F2R;T;rs168753;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
CLOPIDOGREL;F2R;T;rs168753;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
CLOPIDOGREL;P2RY12;AA;rs6809699;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
ASPIRIN;P2RY1;CT;rs1065776;EFFICACY;INCREASED_EFFICACY;EFFICACY:NET_DECREASE_IN_AA-INDUCED_PLATELET_AGGREGATION_AFTER_ASPIRIN_TREATMENT
MERCAPTOPURINE;ITPA;AC;rs1127354;LADME_PK;INCREASED_PK;PK:6-MMPN_LEVELS
NO_DRUG_RELATED;FGFR2;G;rs1219648;TOXICITY;INCREASED_RISK;DISEASE:BREAST_NEOPLASMS
NO_DRUG_RELATED;FGFR2;G;rs1219648;OTHER;INCREASED_RISK;DISEASE:BREAST_NEOPLASMS
ANASTROZOLE;nan;T;rs6735923;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
ACENOCOUMAROL;CYP2C9;CT + TT;rs1799853;TOXICITY;INCREASED_RISK;DISEASE:GASTROINTESTINAL_HEMORRHAGE
ASPIRIN;CYP2C19;A;rs4244285;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC10A2;A;rs7319981;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
NO_DRUG_RELATED;AGT;AG;rs699;OTHER;INCREASED_LIKELIHOOD;OTHER:COVID-19
ANASTROZOLE;nan;C;rs1877193;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
CAPECITABINE;DPYD;A;rs2786783;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
NO_DRUG_RELATED;COMT;CC + CG;rs4818;OTHER;INCREASED_SEVERITY;OTHER:PAIN
DRUGS FOR TREATMENT OF TUBERCULOSIS;UGT2B7;G;rs7662029;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
DRUGS FOR TREATMENT OF TUBERCULOSIS;UGT2B7;C;rs7439366;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CEFACLOR;LIMD1;C;rs62242178;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
CEFACLOR;LIMD1;G;rs62242177;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
REPAGLINIDE;SLCO1B1;CC;rs4149056;OTHER;INCREASED_PK;PK:MEAN_PLASMA_AUC
REPAGLINIDE;SLCO1B1;CC;rs4149056;LADME_PK;INCREASED_PK;PK:MEAN_PLASMA_AUC
DIHYDROPYRIDINE DERIVATIVES;ADRA1A;AG + GG;rs1048101;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:KIDNEY_DISORDER
THALIDOMIDE;XRCC5;AG;rs1051685;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
THALIDOMIDE;ERCC1;AC + CC;rs735482;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOZAPINE;GCG;C;rs13429709;OTHER;INCREASED;DISEASE:WEIGHT_GAIN
OLANZAPINE;GCG;C;rs13429709;OTHER;INCREASED;DISEASE:WEIGHT_GAIN
CLOZAPINE;GLP1R;T;rs2268639;OTHER;INCREASED;DISEASE:WEIGHT_GAIN
OLANZAPINE;GLP1R;T;rs2268639;OTHER;INCREASED;DISEASE:WEIGHT_GAIN
NICOTINE;OPRM1;AA + AG;rs1799971;DOSAGE;INCREASED;OTHER:SMOKING
NICOTINE;OPRM1;AG + GG;rs1799971;DOSAGE;INCREASED;OTHER:SMOKING
TOLCAPONE;COMT;AA;rs4680;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:ALCOHOL_ABUSE
NICOTINE;UGT2B10;AG + GG;rs112561475;LADME_PK;INCREASED_PK;PK:GLUCURONIDATION_OF_NICOTINE
NICOTINE;UGT2B10;T;rs61750900;LADME_PK;DECREASED_PK;PK:NICOTINE_GLUCURONIDATION
CLOZAPINE;GCG;CC;rs13429709;OTHER;INCREASED;DISEASE:WEIGHT_GAIN
OLANZAPINE;GCG;CC;rs13429709;OTHER;INCREASED;DISEASE:WEIGHT_GAIN
DIHYDROPYRIDINE DERIVATIVES;CYP3A5;TT;rs776746;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:KIDNEY_DISORDER
METHAMPHETAMINE;HTR1A;A;rs878567;TOXICITY;nan;DISEASE:PSYCHOTIC_DISORDER
METHAMPHETAMINE;HTR1A;A;rs878567;OTHER;nan;DISEASE:PSYCHOTIC_DISORDER
METHOTREXATE;MTHFR;A;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
CISPLATIN;GALNT14;TT;rs9679162;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
FLUOROURACIL;GALNT14;TT;rs9679162;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
MITOXANTRONE;GALNT14;TT;rs9679162;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
CAPTOPRIL;ACE;AA;rs4291;EFFICACY;DECREASED_SEVERITY;DISEASE:KIDNEY_FAILURE
ANTIEPILEPTICS;nan;T;rs4471527;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
ANTIPSYCHOTICS;LEPR;G;rs1137101;OTHER;INCREASED_LIKELIHOOD;DISEASE:OBESITY
ANTHRACYCLINES AND RELATED SUBSTANCES;HAS3;A;rs2232228;TOXICITY;DECREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
ETHANOL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE
ANTIEPILEPTICS;nan;T;rs77542827;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
STAVUDINE;SAMHD1;A;rs8124728;TOXICITY;DECREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CARVEDILOL;ADRB1;CC;rs1801253;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESPONSE_(HEART-RATE_LOWERING)
IRINOTECAN;TGFB1;AG + GG;rs1800469;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;A;rs2229774;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
CYTARABINE;DCK;CT;rs4643786;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DAUNORUBICIN;DCK;CT;rs4643786;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
MITOXANTRONE;DCK;CT;rs4643786;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ANTIEPILEPTICS;NIPAL2;A;rs199755581;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
OXALIPLATIN;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
PACLITAXEL;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
AMLODIPINE;ACE;AA + AT;rs4291;OTHER;DECREASED;SIDE_EFFECT:FASTING_GLUCOSE
CHLORTHALIDONE;ACE;AA + AT;rs4291;OTHER;DECREASED;SIDE_EFFECT:FASTING_GLUCOSE
LISINOPRIL;ACE;AA + AT;rs4291;OTHER;DECREASED;SIDE_EFFECT:FASTING_GLUCOSE
SORAFENIB;KDR;T;rs1870377;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
IRINOTECAN;TGFBR2;GG;rs3087465;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
SORAFENIB;KDR;T;rs1870377;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERTENSION
SUNITINIB;FLT4;CT;rs307826;EFFICACY;EFFICACY;EFFICACY:REDUCED_PROGRESSION-FREE_SURVIVAL
SUNITINIB;CYP3A5;TT;rs776746;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DOSE_REDUCTIONS_DUE_TO_TOXICITY
RITODRINE;PDE4B;AA;rs17128809;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
CYCLOPHOSPHAMIDE;ABCC1;CC;rs246221;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
DOCETAXEL;ABCC1;CC;rs246221;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
EPIRUBICIN;ABCC1;CC;rs246221;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
SUNITINIB;FLT4;AC;rs307821;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
BETA BLOCKING AGENTS;ADRB2;AG + GG;rs1042713;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HEART_TRANSPLANTATION | DEATH
SALBUTAMOL;nan;C;rs9552679;EFFICACY;DECREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
SALBUTAMOL;COL22A1;T;rs6988229;EFFICACY;INCREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
SALBUTAMOL;nan;T;rs17495520;EFFICACY;INCREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
ASPIRIN;CDH15;C;rs72819363;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:CORONARY_RESTENOSIS | DISEASE_PROGRESSION
CLOPIDOGREL;CDH15;C;rs72819363;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:CORONARY_RESTENOSIS | DISEASE_PROGRESSION
ANTIEPILEPTICS;DDX12P;C;rs77491650;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
SALBUTAMOL;nan;T;rs1663332;EFFICACY;INCREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
SALBUTAMOL;nan;G;rs1663330;EFFICACY;INCREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
SALBUTAMOL;nan;A;rs17701271;EFFICACY;INCREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
SALBUTAMOL;nan;T;rs518350;EFFICACY;INCREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
SALBUTAMOL;nan;G;rs10511905;EFFICACY;DECREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
SORAFENIB;ABCC2;CC;rs717620;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
SALBUTAMOL;CLOCK;A;rs1522113;EFFICACY;INCREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
SALBUTAMOL;nan;A;rs1423515;EFFICACY;INCREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
SALBUTAMOL;nan;T;rs1419555;EFFICACY;INCREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
SALBUTAMOL;nan;C;rs6002674;EFFICACY;DECREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
NO_DRUG_RELATED;ACE2;A;rs2106809;OTHER;INCREASED_LIKELIHOOD;OTHER:COVID-19
DOXORUBICIN;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
METHOTREXATE;ABCB1;A;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
ASPIRIN;CDH13;AA + AG;rs11859453;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:CORONARY_RESTENOSIS | DISEASE_PROGRESSION
CLOPIDOGREL;CDH13;AA + AG;rs11859453;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:CORONARY_RESTENOSIS | DISEASE_PROGRESSION
ALLOPURINOL;CYCSP5;A;rs3099844;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ALLOPURINOL;nan;T;rs1634776;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
PACLITAXEL;ABCB1;AA + AG;rs1128503;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
SALBUTAMOL;nan;A;rs11252394;EFFICACY;INCREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
SORAFENIB;SLCO1B1;CT + TT;rs4149056;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
COCAINE;GABRA2;G;rs11503014;TOXICITY;INCREASED_SEVERITY;OTHER:COCAINE_DEPENDENCE
COCAINE;OPRM1;C;rs2236256;TOXICITY;DECREASED_SEVERITY;OTHER:COCAINE_DEPENDENCE
SORAFENIB;SLCO1B1;AG + GG;rs2306283;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
SORAFENIB;SLCO1B1;AG + GG;rs2306283;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
METHOTREXATE;ABCB1;A;rs1128503;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
NO_DRUG_RELATED;AGT;A;rs699;OTHER;DECREASED_SEVERITY;OTHER:COVID-19
CANGRELOR;P2RY12;TT;rs9859552;OTHER;nan;OTHER:20%_AND_17%_LESS_INHIBITION_OF_PLATELET_AGGREGATION_WITH_CRANGRELOR_(0.05_AND_0.25_MICROM)_IN-VITRO
SORAFENIB;NOS3;TT;rs2070744;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
RADIOTHERAPY;TANC1;C;rs10497203;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED_RISK;DISEASE:LEUKOPENIA
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED_RISK;DISEASE:LEUKOPENIA
SORAFENIB;NOS3;GG;rs1799983;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SORAFENIB;NOS3;GG;rs1799983;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
GLUCOCORTICOIDS;GLCCI1;GG;rs37973;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:POOR_RESPONSE
FLUOROURACIL;ABCG2;A;rs7699188;EFFICACY;INCREASED_EFFICACY;EFFICACY:TUMOR_RESPONSE_RATE
IRINOTECAN;ABCG2;A;rs7699188;EFFICACY;INCREASED_EFFICACY;EFFICACY:TUMOR_RESPONSE_RATE
LEUCOVORIN;ABCG2;A;rs7699188;EFFICACY;INCREASED_EFFICACY;EFFICACY:TUMOR_RESPONSE_RATE
SORAFENIB;NOS3;TT;rs2070744;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;DECREASED;SIDE_EFFECT:INTERVAL_OF_THERAPY_TO_LEUKOPENIA_ONSET
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CTLA4;AG + GG;rs3087243;TOXICITY;DECREASED_RISK;SIDE_EFFECT:PSORIASIS
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED_RISK;DISEASE:LEUKOPENIA
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED_RISK;DISEASE:LEUKOPENIA
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FBXL19;GG;rs10782001;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PSORIASIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL23R;AG;rs11209026;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PSORIASIS
AZATHIOPRINE;NUDT15;TT;rs116855232;TOXICITY;INCREASED_SEVERITY;DISEASE:LEUKOPENIA
METHOTREXATE;MTHFR;A;rs1801133;LADME_PK;INCREASED_RISKPK;PK:PROLONGED_HIGH_CONCENTRATIONS
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
ETHANOL;OPRM1;G;rs1799971;TOXICITY;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
MORPHINE;ABCB1;CC;rs2032582;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | VOMITING
COLISTIMETHATE;SLC15A2;T;rs2257212;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY
HEROIN;OPRM1;G;rs1799971;TOXICITY;INCREASED_RISK;DISEASE:HEROIN_DEPENDENCE
ASPARAGINASE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:FOLIC_ACID_DEFICIENCY_ANEMIA
DAUNORUBICIN;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:FOLIC_ACID_DEFICIENCY_ANEMIA
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:FOLIC_ACID_DEFICIENCY_ANEMIA
PREDNISOLONE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:FOLIC_ACID_DEFICIENCY_ANEMIA
VINCRISTINE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:FOLIC_ACID_DEFICIENCY_ANEMIA
ASPARAGINASE;MTHFR;GT + TT;rs1801131;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
DAUNORUBICIN;MTHFR;GT + TT;rs1801131;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
METHOTREXATE;MTHFR;GT + TT;rs1801131;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
PREDNISOLONE;MTHFR;GT + TT;rs1801131;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
VINCRISTINE;MTHFR;GT + TT;rs1801131;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
WARFARIN;GGCX;CT + TT;rs699664;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
CETUXIMAB;FCGR3A;A;rs396991;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL
WARFARIN;CYP2C9;CT;rs28371685;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
CETUXIMAB;CCND1;G;rs9344;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL
WARFARIN;F7;GT + TT;rs510335;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
TACROLIMUS;IL10;AA;rs1800871;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TRANSPLANT_REJECTION
ESCITALOPRAM;HTR1B;AC + CC;rs11568817;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_COGNITIVE_EFFECTS
CETUXIMAB;CCND1;AA;rs9344;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
FLUVOXAMINE;MDGA2;A;rs1160351;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEXSUAL_DYSFUNCTION
MILNACIPRAN;MDGA2;A;rs1160351;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEXSUAL_DYSFUNCTION
PAROXETINE;MDGA2;A;rs1160351;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEXSUAL_DYSFUNCTION
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";APOC1;CC + CT;rs429358;TOXICITY;INCREASED;SIDE_EFFECT:NON-HDL_CHOLESTEROL
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";APOE;CC + CT;rs429358;TOXICITY;INCREASED;SIDE_EFFECT:NON-HDL_CHOLESTEROL
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";TOMM40;CC + CT;rs429358;TOXICITY;INCREASED;SIDE_EFFECT:NON-HDL_CHOLESTEROL
"COMBINATIONS""";APOC1;CC + CT;rs429358;TOXICITY;INCREASED;SIDE_EFFECT:NON-HDL_CHOLESTEROL
"COMBINATIONS""";APOE;CC + CT;rs429358;TOXICITY;INCREASED;SIDE_EFFECT:NON-HDL_CHOLESTEROL
"COMBINATIONS""";TOMM40;CC + CT;rs429358;TOXICITY;INCREASED;SIDE_EFFECT:NON-HDL_CHOLESTEROL
"""RITONAVIR""";APOC1;CC + CT;rs429358;TOXICITY;INCREASED;SIDE_EFFECT:NON-HDL_CHOLESTEROL
"""RITONAVIR""";APOE;CC + CT;rs429358;TOXICITY;INCREASED;SIDE_EFFECT:NON-HDL_CHOLESTEROL
"""RITONAVIR""";TOMM40;CC + CT;rs429358;TOXICITY;INCREASED;SIDE_EFFECT:NON-HDL_CHOLESTEROL
ESCITALOPRAM;HTR2A;CT + TT;rs6311;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_COGNITIVE_EFFECTS
TACROLIMUS;IL10;TT;rs1800872;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TRANSPLANT_REJECTION
NO_DRUG_RELATED;nan;G;rs17234657;nan;INCREASED_RISK;DISEASE:CROHN_DISEASE
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;OTHER:WARFARIN_DOSE
LEVODOPA;HOMER1;AG + GG;rs4704559;TOXICITY;DECREASED_RISK;DISEASE:DYSKINESIAS
CYCLOPHOSPHAMIDE;SOD2;AG + GG;rs4880;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
DOCETAXEL;SOD2;AG + GG;rs4880;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
EPIRUBICIN;SOD2;AG + GG;rs4880;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
LEVODOPA;HOMER1;AG + GG;rs4704559;TOXICITY;DECREASED_RISK;DISEASE:HALLUCINATIONS
NO_DRUG_RELATED;nan;T;rs2200733;nan;INCREASED_RISK;DISEASE:ATRIAL_FIBRILLATION
ESTRADIOL;NFE2L2;T;rs6721961;TOXICITY;INCREASED_RISK;DISEASE:VENOUS_THROMBOEMBOLISM
HYDROCHLOROTHIAZIDE;YEATS4;CC;rs7297610;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
CAPECITABINE;DPYD;CT;rs3918290;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
WARFARIN;F2;CT + TT;rs5896;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
NO_DRUG_RELATED;HLA-DRA;A;rs3135388;nan;INCREASED_RISK;DISEASE:MULTIPLE_SCLEROSIS
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
NO_DRUG_RELATED;NOD2;G;rs17221417;nan;INCREASED_RISK;DISEASE:CROHN_DISEASE
CISPLATIN;TP53;CG + GG;rs1042522;EFFICACY;DECREASED_EFFICACY;EFFICACY:ONE_YEAR_PROGRESSION_FREE_SURVIVAL
PACLITAXEL;TP53;CG + GG;rs1042522;EFFICACY;DECREASED_EFFICACY;EFFICACY:ONE_YEAR_PROGRESSION_FREE_SURVIVAL
AZATHIOPRINE;ITPA;AC;rs1127354;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:FLU-LIKE_SYMPTOMS
CLOPIDOGREL;CES1;CT;rs71647871;PD;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PLATELET_REACTIVITY
NO_DRUG_RELATED;TCF7L2;T;rs12255372;nan;INCREASED_RISK;DISEASE:DIABETES_MELLITUS_TYPE2
NO_DRUG_RELATED;IL6;AG + GG;rs1800797;OTHER;INCREASED_SEVERITY;OTHER:PAIN
NO_DRUG_RELATED;TCF7L2;C;rs12243326;nan;INCREASED_RISK;DISEASE:DIABETES_MELLITUS_TYPE2
NO_DRUG_RELATED;TCF7L2;T;rs4506565;nan;INCREASED_RISK;DISEASE:DIABETES_MELLITUS_TYPE2
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
ETHANOL;ADH1B;T;rs1229984;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
WARFARIN;VKORC1;AG;rs9934438;DOSAGE;INCREASED;OTHER:WARFARIN_DOSE
NO_DRUG_RELATED;CDKN2B-AS1;G;rs10965219;OTHER;INCREASED;OTHER:PLATELET_REACTIVITY
MORPHINE;COMT;AA;rs4680;EFFICACY;INCREASED_EFFICACY;EFFICACY:NUMERICAL_RATING_SCALE_(NRS)_SCORE_FOR_PAIN_DURING_PAINFUL_PROCEDURE
ETHANOL;RABGAP1L;G;rs61826952;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
MORPHINE;COMT;AA;rs4680;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_MEAN_NUMERICAL_RATING_SCALE_(NRS)_SCORE_FOR_PAIN
NO_DRUG_RELATED;CDKN2B-AS1;G;rs10965219;OTHER;INCREASED_RISK;DISEASE:CORONARY_ARTERY_DISEASE
TRAMADOL;CYP2D6;CC;rs1058172;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVERDOSE
CLOZAPINE;CYP2D6;GG;rs16947;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:LEUKOPENIA
TRAMADOL;CYP2B6;CC;rs4803419;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVERDOSE
NO_DRUG_RELATED;ACE2;CC;rs4240157;OTHER;INCREASED_RISK;OTHER:DEATH
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;DECREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
NO_DRUG_RELATED;ACE2;C;rs4240157;OTHER;INCREASED_LIKELIHOOD;OTHER:COVID-19
CLOZAPINE;CYP2D6;AA;rs1065852;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION | ELEVATED_LIVER_ENZYMES
CLOZAPINE;CYP2D6;AA;rs1065852;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:LEUKOPENIA
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_PK;PK:CONCENTRATION-TO-ADJUSTED_DOSE_RATIO
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS | NEUTROPENIA | PANCREATITIS | VOMITING
CLOZAPINE;CYP2D6;GG;rs16947;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION | ELEVATED_LIVER_ENZYMES
HMG COA REDUCTASE INHIBITORS;COQ5;AA + AG;rs10849757;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
AZATHIOPRINE;ITPA;AC;rs1127354;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
ZOLEDRONATE;FDPS;TT;rs2297480;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS
HMG COA REDUCTASE INHIBITORS;COQ3;TT;rs11548336;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
IMATINIB;CYP2B6;GG;rs3745274;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
HMG COA REDUCTASE INHIBITORS;COQ2;CG + GG;rs4693075;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
CYCLOPHOSPHAMIDE;ABCB1;CT + TT;rs2032582;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
DOXORUBICIN;ABCB1;CT + TT;rs2032582;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
CYCLOPHOSPHAMIDE;CYP2B6;T;rs3211371;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY
DOXORUBICIN;CYP2B6;T;rs3211371;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY
ATORVASTATIN;CLMN;A;rs8014194;EFFICACY;EFFICACY;EFFICACY:CHANGE_IN_TOTAL_CHOLESTEROL
PRAVASTATIN;CLMN;A;rs8014194;EFFICACY;EFFICACY;EFFICACY:CHANGE_IN_TOTAL_CHOLESTEROL
SIMVASTATIN;CLMN;A;rs8014194;EFFICACY;EFFICACY;EFFICACY:CHANGE_IN_TOTAL_CHOLESTEROL
CYCLOPHOSPHAMIDE;CYP2B6;AG;rs12721655;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
DOXORUBICIN;CYP2B6;AG;rs12721655;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
NINTEDANIB;DSP;TT;rs2076295;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
CYCLOPHOSPHAMIDE;CYP2B6;CT;rs8192709;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_PROGRESSION
DOXORUBICIN;CYP2B6;CT;rs8192709;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_PROGRESSION
FLUOROURACIL;MTHFR;GG;rs1801133;TOXICITY;DECREASED_SEVERITY;DISEASE:DRUG_TOXICITY
LEUCOVORIN;MTHFR;GG;rs1801133;TOXICITY;DECREASED_SEVERITY;DISEASE:DRUG_TOXICITY
WARFARIN;F2;CT + TT;rs5896;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
BUSULFAN;CYP2C19;CC;rs12248560;LADME_PK;INCREASED_PK;PK:METABOLIC_RATIO
CAPECITABINE;MTHFR;TT;rs1801131;TOXICITY;DECREASED;DISEASE:DRUG_TOXICITY
WARFARIN;F7;GG;rs510317;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TAP1;CT;rs1135216;TOXICITY;DECREASED_RISK;SIDE_EFFECT:PSORIASIS
OLANZAPINE;ANKK1;AA;rs1800497;TOXICITY;INCREASED_RISK;DISEASE:HEADACHE
QUETIAPINE;ANKK1;AA;rs1800497;TOXICITY;INCREASED_RISK;DISEASE:HEADACHE
RISPERIDONE;ANKK1;AA;rs1800497;TOXICITY;INCREASED_RISK;DISEASE:HEADACHE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLC12A8;AA;rs651630;TOXICITY;DECREASED_RISK;SIDE_EFFECT:PSORIASIS
RADIOTHERAPY;TANC1;A;rs264588;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;INCREASED_PK;PK:PLASMA_CONCENTRATION
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
RADIOTHERAPY;TANC1;G;rs264631;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
BUSULFAN;CYP2C9;CT + TT;rs1799853;LADME_PK;INCREASED_PK;PK:METABOLIC_RATIO
CYCLOPHOSPHAMIDE;SLC22A16;C;rs714368;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY
DOXORUBICIN;SLC22A16;C;rs714368;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY
RADIOTHERAPY;TANC1;T;rs7582141;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
FLUOROURACIL;ABCG2;A;rs7699188;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GRADE_3-4_NONHEMATOLOGICAL_TOXICITY
IRINOTECAN;ABCG2;A;rs7699188;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GRADE_3-4_NONHEMATOLOGICAL_TOXICITY
LEUCOVORIN;ABCG2;A;rs7699188;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GRADE_3-4_NONHEMATOLOGICAL_TOXICITY
RADIOTHERAPY;TANC1;T;rs6432512;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
RADIOTHERAPY;TANC1;T;rs264663;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
FLUOROURACIL;ABCB1;CC;rs2032582;EFFICACY;EFFICACY;EFFICACY:OVERALL_SURVIVAL
IRINOTECAN;ABCB1;CC;rs2032582;EFFICACY;EFFICACY;EFFICACY:OVERALL_SURVIVAL
LEUCOVORIN;ABCB1;CC;rs2032582;EFFICACY;EFFICACY;EFFICACY:OVERALL_SURVIVAL
RADIOTHERAPY;TANC1;G;rs264651;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
CYCLOPHOSPHAMIDE;CYP2B6;T;rs3745274;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION
DOXORUBICIN;CYP2B6;T;rs3745274;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION
CYCLOPHOSPHAMIDE;CYP2B6;T;rs8192709;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY
DOXORUBICIN;CYP2B6;T;rs8192709;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY
PLATINUM COMPOUNDS;XPC;AA + AG;rs2228000;TOXICITY;DECREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY | HEMATOLOGIC_DISORDER | LEUKOPENIA,
SECUKINUMAB;ERAP2;GG;rs2248374;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
CYCLOPHOSPHAMIDE;SLC22A16;G;rs12210538;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
DOXORUBICIN;SLC22A16;G;rs12210538;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
CYCLOPHOSPHAMIDE;SLC22A16;G;rs723685;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY
DOXORUBICIN;SLC22A16;G;rs723685;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY
CYCLOPHOSPHAMIDE;SLC22A16;G;rs6907567;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY
DOXORUBICIN;SLC22A16;G;rs6907567;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY
ASPIRIN;LTC4S;C;rs730012;TOXICITY;INCREASED_RISK;SIDE_EFFECT:URTICARIA
ATORVASTATIN;COQ2;G;rs4693075;TOXICITY;INCREASED_RISK;DISEASE:MUSCULAR_DISEASES
ROSUVASTATIN;COQ2;G;rs4693075;TOXICITY;INCREASED_RISK;DISEASE:MUSCULAR_DISEASES
ATEZOLIZUMAB;SEMA5A;A;rs35719165;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
AVELUMAB;SEMA5A;A;rs35719165;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
DURVALUMAB;SEMA5A;A;rs35719165;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
IPILIMUMAB;SEMA5A;A;rs35719165;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NIVOLUMAB;SEMA5A;A;rs35719165;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PEMBROLIZUMAB;SEMA5A;A;rs35719165;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
METHOTREXATE;MTHFD1;AA + AG;rs2236225;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
WARFARIN;VKORC1;CC;rs2884737;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
EFAVIRENZ;ABCB1;AA;rs1045642;EFFICACY;INCREASED_EFFICACY;EFFICACY:RISE_IN_CD4-CELL_COUNT
EFAVIRENZ;ABCB1;AA;rs1045642;OTHER;INCREASED_EFFICACY;EFFICACY:RISE_IN_CD4-CELL_COUNT
NELFINAVIR;ABCB1;AA;rs1045642;EFFICACY;INCREASED_EFFICACY;EFFICACY:RISE_IN_CD4-CELL_COUNT
NELFINAVIR;ABCB1;AA;rs1045642;OTHER;INCREASED_EFFICACY;EFFICACY:RISE_IN_CD4-CELL_COUNT
EFAVIRENZ;ABCB1;AA;rs1045642;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:FAVORABLE_VIROLOGIC_RESPONSES
ATEZOLIZUMAB;EDIL3;T;rs1862167;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
AVELUMAB;EDIL3;T;rs1862167;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
DURVALUMAB;EDIL3;T;rs1862167;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
IPILIMUMAB;EDIL3;T;rs1862167;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NIVOLUMAB;EDIL3;T;rs1862167;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PEMBROLIZUMAB;EDIL3;T;rs1862167;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_PK;PK:TROUGH_CONCENTRATION
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_PK;PK:TROUGH_CONCENTRATIONS
DOXORUBICIN;ABCC2;A;rs17222723;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
DOXORUBICIN;ABCC2;A;rs17222723;LADME_PK;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
AMITRIPTYLINE;ABCB1;AG + GG;rs2032583;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
CITALOPRAM;ABCB1;AG + GG;rs2032583;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
PAROXETINE;ABCB1;AG + GG;rs2032583;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
VENLAFAXINE;ABCB1;AG + GG;rs2032583;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
AZATHIOPRINE;XDH;AA + AG;rs2295475;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
NO_DRUG_RELATED;ATP8B3;G;rs10421558;TOXICITY;DECREASED_LIKELIHOOD;OTHER:ASPIRIN-INDUCED_ASTHMA
NO_DRUG_RELATED;ABCB1;AA;rs1045642;OTHER;INCREASED_LIKELIHOOD;DISEASE:BREAST_NEOPLASMS
ISONIAZID;NAT2;T;rs1799929;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;T;rs1799929;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;T;rs1799929;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;T;rs1799929;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;T;rs1799929;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;T;rs1799929;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;A;rs1799930;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;A;rs1799930;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;A;rs1799930;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;A;rs1799930;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;A;rs1799930;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;A;rs1799930;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCB1;GG;rs1045642;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_PROGRESSION
DOXORUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_PROGRESSION
EPIRUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_PROGRESSION
RITONAVIR;APOC3;T;rs2854117;TOXICITY;INCREASED_RISK;DISEASE:HYPERTRIGLYCERIDEMIA
NO_DRUG_RELATED;AGTR1;CC;rs5186;OTHER;INCREASED_RISK;DISEASE:ISCHEMIA
IMATINIB;ARID5B;TT;rs10821936;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
ISONIAZID;NAT2;T;rs1041983;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;T;rs1041983;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;T;rs1041983;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;T;rs1041983;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;T;rs1041983;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;T;rs1041983;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;C;rs1801280;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;C;rs1801280;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;C;rs1801280;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;C;rs1801280;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;C;rs1801280;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;C;rs1801280;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
FEXOFENADINE;ABCB1;AA;rs1045642;DOSAGE;DECREASED_PK;PK:PLASMA_CONCENTRATION
FEXOFENADINE;ABCB1;AA;rs1045642;LADME_PK;DECREASED_PK;PK:PLASMA_CONCENTRATION
EFAVIRENZ;CYP2B6;C;rs28399499;LADME_PK;INCREASED_PK;PK:PLASMA_CMIN_VALUES
EFAVIRENZ;CYP2B6;T;rs4803419;LADME_PK;INCREASED_PK;PK:PLASMA_CMIN_VALUES
IMATINIB;ATIC;G;rs2372536;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
ATORVASTATIN;CYP3A4;CC + CT;rs2740574;OTHER;DECREASED_RISK;OTHER:DOSE_DECREASE_OR_DRUG_SWITCHING
SIMVASTATIN;CYP3A4;CC + CT;rs2740574;OTHER;DECREASED_RISK;OTHER:DOSE_DECREASE_OR_DRUG_SWITCHING
FEXOFENADINE;ABCB1;AA;rs2032582;DOSAGE;DECREASED_PK;PK:PLASMA_CONCENTRATION
FEXOFENADINE;ABCB1;AA;rs2032582;LADME_PK;DECREASED_PK;PK:PLASMA_CONCENTRATION
RITODRINE;KCNMB2;GG;rs7625907;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
EFAVIRENZ;CYP2B6;T;rs3745274;LADME_PK;INCREASED_PK;PK:PLASMA_CMIN_VALUES
DOXORUBICIN;ABCC1;T;rs45511401;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
DOXORUBICIN;ABCC1;T;rs45511401;LADME_PK;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
DOXORUBICIN;ABCC2;A;rs8187710;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
DOXORUBICIN;ABCC2;A;rs8187710;LADME_PK;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
CAPECITABINE;SMAD7;CC;rs4939827;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FOLFOX;SMAD7;CC;rs4939827;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
TEGAFUR;SMAD7;CC;rs4939827;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DOXORUBICIN;NCF4;AA;rs1883112;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
NO_DRUG_RELATED;ATP8B3;A;rs10403288;TOXICITY;DECREASED_LIKELIHOOD;OTHER:ASPIRIN-INDUCED_ASTHMA
SIMVASTATIN;ABCB1;A;rs1128503;EFFICACY;DECREASED_RISK;SIDE_EFFECT:MYALGIA
NO_DRUG_RELATED;ACE2;T;rs2074192;OTHER;INCREASED_SEVERITY;OTHER:COVID-19
DOXORUBICIN;CYBA;A;rs4673;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
SIMVASTATIN;ABCB1;A;rs1045642;EFFICACY;DECREASED_RISK;SIDE_EFFECT:MYALGIA
DOXORUBICIN;RAC2;T;rs13058338;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
SIMVASTATIN;ABCB1;C;rs2032582;EFFICACY;INCREASED_RISK;SIDE_EFFECT:MYALGIA
NO_DRUG_RELATED;ABO;T;rs8176746;nan;INCREASED;OTHER:ACE_ACTIVITY
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;DECREASED_PK;PK:CONCENTRATION-TO-ADJUSTED_DOSE_RATIO
ATORVASTATIN;PON1;AA + AG;rs705379;EFFICACY;EFFICACY;EFFICACY:CHANGE_IN_HDL-CHOLESTEROL
SIMVASTATIN;PON1;AA + AG;rs705379;EFFICACY;EFFICACY;EFFICACY:CHANGE_IN_HDL-CHOLESTEROL
ATORVASTATIN;PON1;CC + CT;rs662;EFFICACY;EFFICACY;EFFICACY:CHANGE_IN_HDL-CHOLESTEROL
SIMVASTATIN;PON1;CC + CT;rs662;EFFICACY;EFFICACY;EFFICACY:CHANGE_IN_HDL-CHOLESTEROL
ATORVASTATIN;PON1;GG;rs705379;OTHER;DECREASED;OTHER:OXIDATIVE_STRESS
CLOZAPINE;TACR1;C;rs58933792;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRY_MOUTH
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;DECREASED_PK;PK:CONCENTRATION/DOSE_RATIO
FLUCONAZOLE;CYP3A5;CC;rs776746;DOSAGE;DECREASED_PK;PK:TIME_TO_REACH_STABLE_DOSE_OF_TACROLIMUS
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED_PK;PK:TIME_TO_REACH_STABLE_DOSE_OF_TACROLIMUS
FLUCONAZOLE;CYP3A5;CC;rs776746;DOSAGE;DECREASED_PK;PK:DOSE_OF_TACROLIMUS
TACROLIMUS;CYP3A5;CC;rs776746;DOSAGE;DECREASED_PK;PK:DOSE_OF_TACROLIMUS
TACROLIMUS;CYP3A5;CT + TT;rs776746;DOSAGE;INCREASED_PK;PK:TIME_TO_REACH_STABLE_DOSE
TAMOXIFEN;SLCO1A2;AG + GG;rs10841795;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:DIZZINESS
CLOZAPINE;ERBB4;C;rs3942465;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRY_MOUTH
DIAZEPAM;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ADVERSE_EVENTS
"""ACE INHIBITORS";ADRB2;GG;rs1042713;OTHER;INCREASED_RISK;OTHER:EMERGENCY_DEPARTMENT_AND_HOSPITAL_UTLIIZATION
"PLAIN""";ADRB2;GG;rs1042713;OTHER;INCREASED_RISK;OTHER:EMERGENCY_DEPARTMENT_AND_HOSPITAL_UTLIIZATION
"""ANGIOTENSIN II ANTAGONISTS""";ADRB2;GG;rs1042713;OTHER;INCREASED_RISK;OTHER:EMERGENCY_DEPARTMENT_AND_HOSPITAL_UTLIIZATION
"""BETA BLOCKING AGENTS""";ADRB2;GG;rs1042713;OTHER;INCREASED_RISK;OTHER:EMERGENCY_DEPARTMENT_AND_HOSPITAL_UTLIIZATION
"""DIGOXIN""";ADRB2;GG;rs1042713;OTHER;INCREASED_RISK;OTHER:EMERGENCY_DEPARTMENT_AND_HOSPITAL_UTLIIZATION
"""DIURETICS""";ADRB2;GG;rs1042713;OTHER;INCREASED_RISK;OTHER:EMERGENCY_DEPARTMENT_AND_HOSPITAL_UTLIIZATION
"""SPIRONOLACTONE""";ADRB2;GG;rs1042713;OTHER;INCREASED_RISK;OTHER:EMERGENCY_DEPARTMENT_AND_HOSPITAL_UTLIIZATION
PEGINTERFERON ALFA-2B;ITPA;AA + AC;rs1127354;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;ITPA;AA + AC;rs1127354;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
L-ASPARAGINE;ASNS;AT;rs1049674;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CUSHING_SYNDROME
PREDNISONE;ASNS;AT;rs1049674;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CUSHING_SYNDROME
VINCRISTINE;ASNS;AT;rs1049674;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CUSHING_SYNDROME
"""ACE INHIBITORS";NOS3;TT;rs1799983;OTHER;INCREASED_RISK;OTHER:EMERGENCY_DEPARTMENT_UTLIIZATION
"PLAIN""";NOS3;TT;rs1799983;OTHER;INCREASED_RISK;OTHER:EMERGENCY_DEPARTMENT_UTLIIZATION
"""ANGIOTENSIN II ANTAGONISTS""";NOS3;TT;rs1799983;OTHER;INCREASED_RISK;OTHER:EMERGENCY_DEPARTMENT_UTLIIZATION
"""BETA BLOCKING AGENTS""";NOS3;TT;rs1799983;OTHER;INCREASED_RISK;OTHER:EMERGENCY_DEPARTMENT_UTLIIZATION
"""DIGOXIN""";NOS3;TT;rs1799983;OTHER;INCREASED_RISK;OTHER:EMERGENCY_DEPARTMENT_UTLIIZATION
"""DIURETICS""";NOS3;TT;rs1799983;OTHER;INCREASED_RISK;OTHER:EMERGENCY_DEPARTMENT_UTLIIZATION
"""SPIRONOLACTONE""";NOS3;TT;rs1799983;OTHER;INCREASED_RISK;OTHER:EMERGENCY_DEPARTMENT_UTLIIZATION
EFAVIRENZ;nan;G;rs2853826;TOXICITY;INCREASED;SIDE_EFFECT:BASELINE_ADIPONECTIN_AND_WITH_GREATER_ADIPONECTIN_DECLINE
LOPINAVIR;nan;G;rs2853826;TOXICITY;INCREASED;SIDE_EFFECT:BASELINE_ADIPONECTIN_AND_WITH_GREATER_ADIPONECTIN_DECLINE
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS;nan;G;rs2853826;TOXICITY;INCREASED;SIDE_EFFECT:BASELINE_ADIPONECTIN_AND_WITH_GREATER_ADIPONECTIN_DECLINE
RITONAVIR;nan;G;rs2853826;TOXICITY;INCREASED;SIDE_EFFECT:BASELINE_ADIPONECTIN_AND_WITH_GREATER_ADIPONECTIN_DECLINE
DIAZEPAM;CYP2C19;CT + TT;rs12248560;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ADVERSE_EVENTS
"""ACE INHIBITORS";ADRB1;GG;rs1801253;OTHER;DECREASED_RISK;OTHER:EMERGENCIES
"PLAIN""";ADRB1;GG;rs1801253;OTHER;DECREASED_RISK;OTHER:EMERGENCIES
"""ANGIOTENSIN II ANTAGONISTS""";ADRB1;GG;rs1801253;OTHER;DECREASED_RISK;OTHER:EMERGENCIES
"""BETA BLOCKING AGENTS""";ADRB1;GG;rs1801253;OTHER;DECREASED_RISK;OTHER:EMERGENCIES
"""DIGOXIN""";ADRB1;GG;rs1801253;OTHER;DECREASED_RISK;OTHER:EMERGENCIES
"""DIURETICS""";ADRB1;GG;rs1801253;OTHER;DECREASED_RISK;OTHER:EMERGENCIES
"""SPIRONOLACTONE""";ADRB1;GG;rs1801253;OTHER;DECREASED_RISK;OTHER:EMERGENCIES
L-ASPARAGINE;ABCB1;CT;rs9282564;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
PREDNISONE;ABCB1;CT;rs9282564;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
VINCRISTINE;ABCB1;CT;rs9282564;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
OLANZAPINE;UGT1A4;GG + GT;rs2011425;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:AUTONOMIC_NERVOUS_SYSTEM_DISORDER
OLANZAPINE;CYP3A4;CC + CT;rs2740574;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRY_MOUTH
CABAZITAXEL;ABCB1;T;rs17327624;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
SIMVASTATIN;ABCB1;AA;rs1128503;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL
OLANZAPINE;UGT1A4;GG + GT;rs2011425;LADME_PK;INCREASED_PK;PK:GLUCURONIDATED_METABOLITES_OF_OLANZAPINE
NO_DRUG_RELATED;COL1A1;AA + AC;rs1800012;nan;INCREASED_RISK;DISEASE:FRACTURES | BONE
CYCLOSPORINE;ABCB1;AG;rs1045642;TOXICITY;INCREASED_SEVERITY;DISEASE:GINGIVAL_HYPERPLASIA
TACROLIMUS;CYP3A5;CT;rs776746;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:ACUTE_REJECTION
CLOPIDOGREL;P2RY12;AA + AG;rs6785930;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DRUG_RESISTANCE
CABAZITAXEL;ABCB1;T;rs2235040;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ASTHENIA
TACROLIMUS;NOD2;CC;rs2066844;OTHER;INCREASED;OTHER:HOSPITAL_STAY
TACROLIMUS;CYP3A5;TT;rs776746;EFFICACY;INCREASED_RISK;OTHER:ACUTE_REJECTION
TACROLIMUS;CYP3A5;CT;rs776746;EFFICACY;INCREASED_RISK;OTHER:ACUTE_REJECTION
CYCLOSPORINE;CYP3A4;CT;rs2740574;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TRANSPLANT_REJECTION
TACROLIMUS;CYP3A4;CT;rs2740574;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TRANSPLANT_REJECTION
WARFARIN;VKORC1;AA + AG;rs2359612;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THE_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE
AZATHIOPRINE;FTO;CC;rs16952570;TOXICITY;DECREASED_RISK;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
MERCAPTOPURINE;FTO;CC;rs16952570;TOXICITY;DECREASED_RISK;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
OSELTAMIVIR;CES1;CT + TT;rs121912777;LADME_PK;PK;PK:SIGNIFICANTLY_LARGER_MEAN_AUC_OF_OSELTAMIVIR | LOWER_CMAX_OF_OSELTAMIVIR_CARBOXYLATE | AND_A_SMALLER_OSELTAMIVIR_CARBOXYLATE-TO-OSELTAMIVIR_AUC_RATIO
AZATHIOPRINE;FTO;CT;rs16952570;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
MERCAPTOPURINE;FTO;CT;rs16952570;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_PK;PK:PBMC_CONCENTRATIONS
CABAZITAXEL;CYP2C8;T;rs11572093;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ASTHENIA
WARFARIN;VKORC1;CT + TT;rs9923231;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THE_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE
CITALOPRAM;CYP2C19;A;rs4244285;TOXICITY;INCREASED;SIDE_EFFECT:INTOLERANCE
WARFARIN;VKORC1;AA + AG;rs9934438;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THE_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE
NORTRIPTYLINE;GNB3;TT;rs5443;TOXICITY;nan;DISEASE:WEIGHT_GAIN
WARFARIN;VKORC1;CG + GG;rs8050894;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THE_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE
NORTRIPTYLINE;GNB3;TT;rs5443;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SLEEP_INITIATION_AND_MAINTENANCE_DISORDERS
WARFARIN;VKORC1;AC + CC;rs2884737;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THE_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE
NORTRIPTYLINE;GNB3;TT;rs5443;EFFICACY;EFFICACY;EFFICACY:IMPROVEMENTS_IN_NEUROVEGETATIVE_SYMPTOMS
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_PK;PK:TROUGH_CONCENTRATION
WARFARIN;VKORC1;A;rs9934438;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
TACROLIMUS;CYP3A5;CC;rs776746;LADME_PK;INCREASED_PK;PK:TROUGH_CONCENTRATION
NO_DRUG_RELATED;SLC19A1;C;rs1051266;OTHER;INCREASED_LIKELIHOOD;OTHER:DOWN_SYNDROME
DIGOXIN;ABCB1;AA;rs1045642;LADME_PK;DECREASED_PK;PK:DUODENAL_ABSORPTION_OF_DIGOXIN_AFTER_DIRECT_DELIVERY_TO_THE_SURFACE_OF_THE_DUODENUM_BY_ENDOSCOPE
OLANZAPINE;HTR2A;AA;rs7997012;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
CAPECITABINE;DPYD;T;rs3918290;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
FLUOROURACIL;DPYD;T;rs3918290;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
TEGAFUR;DPYD;T;rs3918290;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CAPECITABINE;DPYD;A;rs67376798;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
FLUOROURACIL;DPYD;A;rs67376798;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
TEGAFUR;DPYD;A;rs67376798;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
OLANZAPINE;ABCB1;A;rs1045642;EFFICACY;EFFICACY;EFFICACY:POSITIVE_RELATIONSHIP_BETWEEN_OLANZAPINE_PLASMA_LEVELS_AND_POSITIVE_SYMPTOM_REDUCTION_COMPARED_TO_SUBJECTS_WITH_THE_GG_GENOTYPE
OLANZAPINE;CYP1A2;AA;rs762551;LADME_PK;DECREASED_PK;PK:PLASMA_CONCENTRATIONS
NICOTINE;OPRM1;AA;rs1799971;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
OLANZAPINE;DRD2;A;rs6275;OTHER;INCREASED;OTHER:PROLACTIN
OLANZAPINE;DRD2;A;rs6275;LADME_PK;INCREASED;OTHER:PROLACTIN
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR1;GG;rs9024;TOXICITY;INCREASED_RISK;DISEASE:CARDIOMYOPATHIES
OLANZAPINE;DRD2;G;rs6279;OTHER;INCREASED;OTHER:PROLACTIN
OLANZAPINE;DRD2;G;rs6279;LADME_PK;INCREASED;OTHER:PROLACTIN
CEPHALEXIN;nan;T;rs34545984;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
OLANZAPINE;DRD2;T;rs1124493;OTHER;INCREASED;OTHER:PROLACTIN
OLANZAPINE;DRD2;T;rs1124493;LADME_PK;INCREASED;OTHER:PROLACTIN
OLANZAPINE;DRD2;A;rs2734841;OTHER;INCREASED;OTHER:PROLACTIN
OLANZAPINE;DRD2;A;rs2734841;LADME_PK;INCREASED;OTHER:PROLACTIN
ASPIRIN;nan;A;rs115346678;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
METHOTREXATE;MTHFD1;A;rs2236225;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
SIMVASTATIN;PPARA;AA;rs4253728;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL_AND_LDL-CHOLESTEROL
METHOTREXATE;MTHFR;A;rs1801133;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
CODEINE;WBP2NL;G;rs9620007;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE_IN_KOREAN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT_SINCE_DAY_7_OF_WARFARIN_THERAPY
CODEINE;OPRM1;T;rs62436463;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
HYDROCODONE;OPRM1;T;rs62436463;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
OXYCODONE;OPRM1;T;rs62436463;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
TRAMADOL;OPRM1;T;rs62436463;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
METFORMIN;SLC22A2;CC;rs316009;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
METFORMIN;SLC22A2;CC;rs316019;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
SIMVASTATIN;PPARA;GG;rs4823613;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL_AND_LDL-CHOLESTEROL
NO_DRUG_RELATED;ANKK1;GG;rs1800497;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
NICOTINE;COMT;GG;rs4680;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RELAPSE
ESCITALOPRAM;HTR2A;CT + TT;rs6311;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SUICIDAL_IDEATION | ADVERSE_EVENTS | DELIBERATE_SELF-HARM,
NICOTINE;ANKK1;AA + AG;rs1800497;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
AMIODARONE;KCNE1;T;rs1805128;TOXICITY;INCREASED_RISK;DISEASE:TORSADES_DE_POINTES
ANTIBIOTICS;KCNE1;T;rs1805128;TOXICITY;INCREASED_RISK;DISEASE:TORSADES_DE_POINTES
ANTIPSYCHOTICS;KCNE1;T;rs1805128;TOXICITY;INCREASED_RISK;DISEASE:TORSADES_DE_POINTES
DIURETICS;KCNE1;T;rs1805128;TOXICITY;INCREASED_RISK;DISEASE:TORSADES_DE_POINTES
QUINIDINE;KCNE1;T;rs1805128;TOXICITY;INCREASED_RISK;DISEASE:TORSADES_DE_POINTES
SOTALOL;KCNE1;T;rs1805128;TOXICITY;INCREASED_RISK;DISEASE:TORSADES_DE_POINTES
NICOTINE;OPRM1;GG;rs1799971;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
NICOTINE;OPRM1;AG;rs1799971;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
BUPROPION;ANKK1;GG;rs1800497;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
OLANZAPINE;DRD2;G;rs2734842;OTHER;INCREASED;OTHER:PROLACTIN
OLANZAPINE;DRD2;G;rs2734842;LADME_PK;INCREASED;OTHER:PROLACTIN
METHOTREXATE;MTHFR;A;rs1801133;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
PYRIMIDINE ANALOGUES;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ROSUVASTATIN;ABCG2;GG;rs2231142;EFFICACY;DECREASED_EFFICACY;EFFICACY:PERCENTAGE_CHANGE_IN_LDL-CHOLESTEROL_LEVELS
AMITRIPTYLINE;CYP2C19;AA;rs4244285;OTHER;INCREASED_PK;PK:LOG_METABOLIC_RATIO_OF_AMITRIPTYLINE/NORTRIPTYLINE
AMITRIPTYLINE;CYP2C19;AA;rs4244285;LADME_PK;INCREASED_PK;PK:LOG_METABOLIC_RATIO_OF_AMITRIPTYLINE/NORTRIPTYLINE
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CARDIOVASCULAR_DEATH | MYOCARDIAL_INFARCTION | OR_STROKE
ROSUVASTATIN;SLCO1B1;TT;rs4149056;LADME_PK;DECREASED_PK;PK:PLASMA_CONCENTRATIONS_OF_ROSUVASTATIN
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CARDIOVASCULAR_DEATH | MYOCARDIAL_INFARCTION | OR_STROKE
ROSUVASTATIN;ABCG2;TT;rs2231142;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATIONS_OF_ROSUVASTATIN
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CARDIOVASCULAR_DEATH | MYOCARDIAL_INFARCTION | OR_STROKE
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:CORONARY_RESTENOSIS
CISPLATIN;CCL2;GG;rs1024611;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ANEMIA
DOCETAXEL;CCL2;GG;rs1024611;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ANEMIA
FLUOROURACIL;CCL2;GG;rs1024611;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ANEMIA
NO_DRUG_RELATED;SERPINE1;T;rs7242;OTHER;INCREASED_LIKELIHOOD;DISEASE:MAJOR_DEPRESSIVE_DISORDER
NO_DRUG_RELATED;SERPINE1;G;rs2227684;OTHER;INCREASED_LIKELIHOOD;DISEASE:MAJOR_DEPRESSIVE_DISORDER
METHOTREXATE;MTHFR;G;rs1801131;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:CLINICAL_RESPONSE
GEMCITABINE;CDA;A;rs60369023;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
GEMCITABINE;CDA;A;rs60369023;LADME_PK;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
METHOTREXATE;GGH;AA;rs3758149;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA
BISPHOSPHONATES;IL1B;GG;rs16944;EFFICACY;INCREASED_LIKELIHOODPK;PK:RESISTANCE
CLODRONATE;VDR;C;rs1544410;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESISTANCE
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER_ANTI-COAGULATION
CLODRONATE;VDR;A;rs731236;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESISTANCE
CYTARABINE;NT5C3A;GG;rs3750117;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:INDUCTION_FAILURE
IDARUBICIN;NT5C3A;GG;rs3750117;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:INDUCTION_FAILURE
ATORVASTATIN;APOA5;AG + GG;rs662799;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_LDLC
LOVASTATIN;APOA5;AG + GG;rs662799;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_LDLC
SIMVASTATIN;APOA5;AG + GG;rs662799;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_LDLC
CITALOPRAM;HTR2A;T;rs6311;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER
SERTRALINE;HTR2A;T;rs6311;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER
CISPLATIN;IL6;CC;rs1800796;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
DOCETAXEL;IL6;CC;rs1800796;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
FLUOROURACIL;IL6;CC;rs1800796;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
CITALOPRAM;HTR2A;AA;rs6313;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA | THROMBOCYTOPENIA | ANEMIA,
BUPRENORPHINE;OPRM1;AG + GG;rs648893;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:DEPRESSION
NALOXONE;OPRM1;AG + GG;rs648893;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:DEPRESSION
METHOTREXATE;ADORA2A;T;rs2267076;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
METHOTREXATE;ADORA2A;T;rs2236624;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
METHOTREXATE;ADORA2A;T;rs2298383;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
TACROLIMUS;CYP3A5;CT + TT;rs776746;OTHER;INCREASED_PK;PK:BLOOD_PRESSURE
METHOTREXATE;ADORA2A;T;rs3761422;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
CISPLATIN;TNF;CC + CT;rs1799964;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
DOCETAXEL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
FLUOROURACIL;TNF;CC + CT;rs1799964;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DRUG_RESISTANCE
ASPIRIN;PEAR1;AA + AG;rs12041331;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
CLOPIDOGREL;PEAR1;AA + AG;rs12041331;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
CISPLATIN;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
DOCETAXEL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
HYDROCHLOROTHIAZIDE;NELL1;C;rs12279250;LADME_PK;INCREASED;SIDE_EFFECT:PLASMA_TRIGLYCERIDES
BUPRENORPHINE;OPRD1;TT;rs678849;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ANXIETY_DISORDERS
NALOXONE;OPRD1;TT;rs678849;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ANXIETY_DISORDERS
ARIPIPRAZOLE;DAOA;A;rs2391191;EFFICACY;DECREASED_EFFICACY;EFFICACY:BRIEF_PSYCHIATRIC_RATING_SCALE_SCORES
BUPRENORPHINE;OPRD1;A;rs569356;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:CRAVING
NALOXONE;OPRD1;A;rs569356;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:CRAVING
OLANZAPINE;HTR2C;C;rs6318;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
TACROLIMUS;CYP3A5;T;rs776746;TOXICITY;INCREASED_RISK;OTHER:TACROLIMUS_NEPHROTOXICITY
TACROLIMUS;CYP3A5;CC;rs776746;EFFICACY;INCREASED_RISK;OTHER:SUBCLINICAL_ALLOGRAFT_NEPHROPATHY
TACROLIMUS;CYP3A5;CC;rs776746;TOXICITY;INCREASED_RISK;OTHER:SUBCLINICAL_ALLOGRAFT_NEPHROPATHY
SIMVASTATIN;CYBA;AA + AG;rs4673;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_DNA_DAMAGE
BUPROPION;CYP2B6;CT;rs3211371;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
ASPIRIN;ABCB1;AG + GG;rs1045642;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DRUG_RESISTANCE
OLANZAPINE;DRD3;CC;rs6280;EFFICACY;EFFICACY;EFFICACY:GREATER_POSITIVE_SYMPTOM_IMPROVEMENT_AND_POSITIVE_SYMPTOM_REMISSION
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
OLANZAPINE;RGS4;CT;rs951439;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE
CABAZITAXEL;TUBB1;G;rs151352;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
RISPERIDONE;RGS4;TT;rs951439;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE
OLANZAPINE;RGS4;CC;rs951439;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:POSITIVE_RESPONSE
PERPHENAZINE;RGS4;CC;rs951439;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:POSITIVE_RESPONSE
CABAZITAXEL;CYP2C8;C;rs1341164;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
OLANZAPINE;LEP;GG;rs4731426;TOXICITY;INCREASED_RISK;DISEASE:WEIGHT_GAIN
HEROIN;GRM3;T;rs13242038;OTHER;INCREASED_RISK;DISEASE:HEROIN_DEPENDENCE
AMITRIPTYLINE;ABCB1;A;rs2235015;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
CITALOPRAM;ABCB1;A;rs2235015;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
PAROXETINE;ABCB1;A;rs2235015;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
VENLAFAXINE;ABCB1;A;rs2235015;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
NO_DRUG_RELATED;ACE;G;rs4343;LADME_PK;INCREASED;OTHER:ACE_ACTIVITY
ANTIDEPRESSANTS;HTR1A;GG;rs6295;EFFICACY;DECREASED_EFFICACY;EFFICACY:TREATMENT_RESPONSE
OPIOIDS;ABCB1;CC + CT;rs9282564;TOXICITY;DECREASED_RISK;OTHER:DEATH
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCB1;AA;rs1045642;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:COMPLETE_RESPONSE
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCB1;AA;rs1045642;LADME_PK;INCREASED_LIKELIHOODEFFICACY;EFFICACY:COMPLETE_RESPONSE
TAXANES;ABCB1;AA;rs1045642;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:COMPLETE_RESPONSE
TAXANES;ABCB1;AA;rs1045642;LADME_PK;INCREASED_LIKELIHOODEFFICACY;EFFICACY:COMPLETE_RESPONSE
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PAROXETINE;HTR1A;CC;rs6295;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:NON-RESPONSE
SERTRALINE;HTR1A;CC;rs6295;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:NON-RESPONSE
OPIOIDS;KCNJ6;TT;rs2070995;EFFICACY;INCREASED_EFFICACY;EFFICACY:FREQUENCY_OF_RESCUE_ANALGESIC_ADMINISTRATION
WARFARIN;VKORC1;G;rs8050894;DOSAGE;EFFICACY;EFFICACY:DECREASED_WARFARIN_DOSE_AND_INCREASED_RISK_OF_OVER-ANTICOAGULATION
WARFARIN;VKORC1;G;rs8050894;EFFICACY;EFFICACY;EFFICACY:DECREASED_WARFARIN_DOSE_AND_INCREASED_RISK_OF_OVER-ANTICOAGULATION
WARFARIN;VKORC1;T;rs9923231;DOSAGE;EFFICACY;EFFICACY:DECREASED_WARFARIN_DOSE_AND_INCREASED_RISK_OF_OVER-ANTICOAGULATION
WARFARIN;VKORC1;T;rs9923231;EFFICACY;EFFICACY;EFFICACY:DECREASED_WARFARIN_DOSE_AND_INCREASED_RISK_OF_OVER-ANTICOAGULATION
NEVIRAPINE;CYP2B6;CT;rs28399499;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
NEVIRAPINE;CYP3A5;CC + CT;rs776746;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;C9orf72;T;rs3849942;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
METHAMPHETAMINE;DTNBP1;C;rs3213207;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PSYCHOTIC_DISORDER
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;T;rs2814707;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
METHAMPHETAMINE;PICK1;T;rs2076369;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:RELAPSE_OF_PSYCHOSIS
NEVIRAPINE;CYP2B6;CT + TT;rs12721646;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;GBP6;A;rs928655;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
FLUOROURACIL;DPYD;AG + GG;rs1801265;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:OVERALL_GASTROINTESTINAL_TOXICITY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;C9orf72;C;rs774359;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CSRP3;T;rs983332;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;A;rs868856;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
METHOTREXATE;MTHFR;G;rs1801131;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
METHOTREXATE;MTHFR;TT;rs1801131;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_BASE_ON_DISEASE_ACTIVITY_SCORE_IN_44_JOINTS_IMPROVEMENT_AT_6_MONTHS_OF_TREATMENT
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;DECREASED_EFFICACY;EFFICACY:DISEASE_ACTIVITY_AS_ASSESSED_BY_THE_PHYSICIAN | LESS_PATIENT-ASSESSED_DIFFICULTY_WITH_PHYSICAL_TASKS | AND_FEWER_SWOLLEN_JOINTS
GEFITINIB;EGFR;GT + TT;rs712829;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
ANTIANDROGENS;AKR1C3;CC;rs12529;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:PROSTATE_CANCER-SPECIFIC_MORTALITY
WARFARIN;VKORC1;AA + AG;rs9934438;DOSAGE;DECREASED;OTHER:MAINTENANCE_DOSE_OF_WARFARIN
CISPLATIN;ERCC1;AG;rs11615;TOXICITY;INCREASED_RISK;DISEASE:NEPHROTOXICITY
CYCLOPHOSPHAMIDE;ERCC1;AG;rs11615;TOXICITY;INCREASED_RISK;DISEASE:NEPHROTOXICITY
CISPLATIN;TP53;GG;rs1042522;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
CYCLOPHOSPHAMIDE;TP53;GG;rs1042522;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
PACLITAXEL;CYP2C8;TT;rs11572080;TOXICITY;INCREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES
METHOTREXATE;ABCC1;GG;rs2238476;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAFB;T;rs6028945;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
OLANZAPINE;HTR2C;T;rs3813929;TOXICITY;DECREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAFB;C;rs6071980;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
OLANZAPINE;HTR2C;T;rs3813929;TOXICITY;DECREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CST5;T;rs6138150;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
OLANZAPINE;HTR2C;T;rs3813929;TOXICITY;DECREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
CISPLATIN;GSTP1;AA;rs1695;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
CISPLATIN;GSTP1;AA;rs1695;LADME_PK;INCREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
CYCLOPHOSPHAMIDE;GSTP1;AA;rs1695;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
CYCLOPHOSPHAMIDE;GSTP1;AA;rs1695;LADME_PK;INCREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
ANTIPSYCHOTICS;CLCN6;A;rs1801133;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:METABOLIC_SYNDROME
ANTIPSYCHOTICS;MTHFR;A;rs1801133;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:METABOLIC_SYNDROME
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PON1;A;rs854548;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PON1;A;rs854555;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;A;rs7046653;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
BUPRENORPHINE;CYP3A4;CC + CT;rs2740574;EFFICACY;INCREASED_RISK;OTHER:SUBSTANCE_WITHDRAWAL_SYNDROME
WARFARIN;VKORC1;AG;rs9934438;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_IN_THERAPEUTIC_RANGE_OF_INR_(TTR)
DOCETAXEL;nan;CT;rs11185648;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE_IN_JAPANESE_PATIENTS
DOCETAXEL;RXRA;AG;rs11185647;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA | NEUTROPENIA
CISPLATIN;TPMT;T;rs12201199;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
DOCETAXEL;RXRA;AG;rs2234753;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
DOCETAXEL;RXRA;GT;rs6413517;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
DOCETAXEL;RXRA;GG;rs62576288;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
NO_DRUG_RELATED;DRD2;GG;rs1799732;nan;INCREASED_LIKELIHOOD;DISEASE:SCHIZOPHRENIA
NO_DRUG_RELATED;SCN1A;CT;rs2298771;OTHER;INCREASED_LIKELIHOOD;DISEASE:EPILEPSY
METHOTREXATE;nan;G;rs9345389;TOXICITY;nan;SIDE_EFFECT:END-OF-INDUCTION_MINIMAL_RISIDUAL_DISEASE_(MRD)_IN_CHILDHOOD_ACUTE_LYMPHOBLASTIC_LEUKEMIA_(ALL)_AND_IS_ALSO_ASSOCIATED_WITH_GREATER_METHOTREXATE_CLEARANCE.
DOCETAXEL;HNF4A;TT;rs6130615;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
ANTIPSYCHOTICS;HTR2A;GG;rs7997012;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DRUG_RESISTANCE
SIMVASTATIN;nan;A;rs76103438;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
DIAZEPAM;CYP3A4;GG;rs35599367;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ADVERSE_EVENTS
ANTIPSYCHOTICS;HTR2A;AG;rs6314;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DRUG_RESISTANCE
DOCETAXEL;HNF4A;CT;rs2273618;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
DOCETAXEL;HNF4A;CT;rs3746574;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
WARFARIN;VKORC1;A;rs9934438;DOSAGE;nan;OTHER:A_MORE_RAPID_ATTAINMENT_OF_TARGET_INR_AND_HIGHER_FREQUENCY_OF_DOSE_ADJUSTMENTS
WARFARIN;VKORC1;A;rs9934438;EFFICACY;nan;OTHER:A_MORE_RAPID_ATTAINMENT_OF_TARGET_INR_AND_HIGHER_FREQUENCY_OF_DOSE_ADJUSTMENTS
DOCETAXEL;NR1I2;TT;rs3732360;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
NO_DRUG_RELATED;NRXN1;C;rs985919;OTHER;INCREASED_LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER
"""BETA BLOCKING AGENTS";NEDD4L;AG + GG;rs4149601;EFFICACY;DECREASED_RISK;OTHER:CARDIOVASCULAR_EVENTS
"SELECTIVE""";NEDD4L;AG + GG;rs4149601;EFFICACY;DECREASED_RISK;OTHER:CARDIOVASCULAR_EVENTS
"""DIURETICS""";NEDD4L;AG + GG;rs4149601;EFFICACY;DECREASED_RISK;OTHER:CARDIOVASCULAR_EVENTS
MEPERIDINE;SERINC5;C;rs185462714;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
CISPLATIN;GSTA1;AA;rs3957357;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CYCLOPHOSPHAMIDE;GSTA1;AA;rs3957357;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DOCETAXEL;NR1I2;AA;rs3732359;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
NO_DRUG_RELATED;CHRNA5;C;rs17408276;OTHER;INCREASED_LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER
BETA BLOCKING AGENTS;nan;T;rs139945292;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_EVENTS
NICOTINE;COMT;AA;rs4680;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_RISK;DISEASE:MUSCULAR_DISEASES
PENICILLIN G;nan;A;rs115200108;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
PENICILLIN V;nan;A;rs115200108;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
NICOTINE;COMT;AG;rs4680;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RELAPSE
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
DOCETAXEL;NR1I2;CC + TT;rs3814058;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
NO_DRUG_RELATED;CHRNA5;A;rs16969968;OTHER;INCREASED_LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER
NO_DRUG_RELATED;NRXN1;C;rs1882296;OTHER;INCREASED_LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER
DOCETAXEL;NR1I3;TT;rs10538494;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
CODEINE;SEPTIN3;A;rs739296;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
CODEINE;WBP2NL;A;rs739296;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
HYDROCODONE;SEPTIN3;A;rs739296;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
HYDROCODONE;WBP2NL;A;rs739296;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
OXYCODONE;SEPTIN3;A;rs739296;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
OXYCODONE;WBP2NL;A;rs739296;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
TRAMADOL;SEPTIN3;A;rs739296;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
TRAMADOL;WBP2NL;A;rs739296;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
MEPERIDINE;FIP1L1;G;rs113100019;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
DOCETAXEL;NR1I3;AG;rs75114882;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
NO_DRUG_RELATED;NRXN1;C;rs10865246;OTHER;INCREASED_SEVERITY;DISEASE:TOBACCO_USE_DISORDER
CISPLATIN;COMT;T;rs9332377;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
DOCETAXEL;NR1I3;CC;rs2501873;TOXICITY;DECREASED_SEVERITY;DISEASE:ANEMIA
CISPLATIN;ERCC2;CT;rs1799793;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
CYCLOPHOSPHAMIDE;ERCC2;CT;rs1799793;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
CISPLATIN;ERCC1;AC;rs3212986;TOXICITY;INCREASED_RISK;DISEASE:NEPHROTOXICITY
CYCLOPHOSPHAMIDE;ERCC1;AC;rs3212986;TOXICITY;INCREASED_RISK;DISEASE:NEPHROTOXICITY
CISPLATIN;XRCC1;CC;rs25487;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
CYCLOPHOSPHAMIDE;XRCC1;CC;rs25487;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
MEPERIDINE;nan;A;rs11049274;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
DOCETAXEL;RXRA;AG;rs1536475;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
CISPLATIN;XPC;G;rs2228001;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
DOCETAXEL;NR1I3;GG;rs2502815;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
DOCETAXEL;NR1I3;AA;rs9725457;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
CISPLATIN;ERCC2;G;rs13181;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
CISPLATIN;KLC3;G;rs13181;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
ETHANOL;ACSS2;T;rs6088638;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE
CAPECITABINE;DPYD;AG;rs17376848;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
FLUOROURACIL;DPYD;AG;rs17376848;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
ETHANOL;OPRM1;G;rs1799971;TOXICITY;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
ANGIOTENSIN II ANTAGONISTS;CYP2D6;C;rs1058164;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE
CISPLATIN;ERCC1;G;rs11615;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL
NO_DRUG_RELATED;APOE;CC;rs429358;OTHER;INCREASED_SEVERITY;OTHER:COVID-19
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
CLOPIDOGREL;CYP2C19;A;rs4986893;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
ANGIOTENSIN II ANTAGONISTS;CYP2D6;T;rs1985842;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE
NO_DRUG_RELATED;NAT2;T;rs1801280;OTHER;INCREASED_SEVERITY;DISEASE:INSULIN_RESISTANCE
ANGIOTENSIN II ANTAGONISTS;CYP2D6;G;rs1135840;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE
CLOPIDOGREL;CYP2C19;G;rs28399504;EFFICACY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
CLOPIDOGREL;CYP2C19;G;rs28399504;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
ANGIOTENSIN II ANTAGONISTS;CYP2D6;G;rs28371713;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE
NO_DRUG_RELATED;NAT2;A;rs1208;OTHER;INCREASED_SEVERITY;DISEASE:INSULIN_RESISTANCE
AMOXICILLIN;nan;C;rs72631546;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLAVULANATE;nan;C;rs72631546;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
FLUCLOXACILLIN;nan;C;rs72631546;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
GEFITINIB;ABCG2;GT;rs2231142;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
ANGIOTENSIN II ANTAGONISTS;CYP2D6;G;rs112568578;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE
CAPECITABINE;MIR23A;C;rs895819;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
CAPECITABINE;MIR24-2;C;rs895819;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
CAPECITABINE;MIR27A;C;rs895819;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;MIR23A;C;rs895819;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;MIR24-2;C;rs895819;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;MIR27A;C;rs895819;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;nan;DISEASE:NEUTROPENIA
AMOXICILLIN;PTPN22;A;rs2476601;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLAVULANATE;PTPN22;A;rs2476601;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SLEEP_APNEA_SYNDROMES
COCAINE;CNR1;GT + TT;rs6454674;OTHER;INCREASED_RISK;DISEASE:COCAINE_DEPENDENCE
NO_DRUG_RELATED;PTGS2;G;rs20417;nan;INCREASED_RISK;DISEASE:STROKE
ATENOLOL;PPARA;GG;rs4253778;EFFICACY;DECREASED;OTHER:CARDIAC_REHOSPITALIZATION
BETA BLOCKING AGENTS;PPARA;GG;rs4253778;EFFICACY;DECREASED;OTHER:CARDIAC_REHOSPITALIZATION
CARVEDILOL;PPARA;GG;rs4253778;EFFICACY;DECREASED;OTHER:CARDIAC_REHOSPITALIZATION
METOPROLOL;PPARA;GG;rs4253778;EFFICACY;DECREASED;OTHER:CARDIAC_REHOSPITALIZATION
DOXORUBICIN;RARG;AG;rs2229774;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
FLUVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
ASPIRIN;TMEM196;T;rs9886152;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
PAZOPANIB;HIF1A;AG;rs11549467;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
NO_DRUG_RELATED;CLOCK;AA + AG;rs1801260;OTHER;INCREASED_LIKELIHOOD;OTHER:ADHD
MERCAPTOPURINE;ITPA;CC;rs7270101;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
METHOTREXATE;ITPA;CC;rs7270101;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
COCAINE;CNR1;GT + TT;rs6454674;OTHER;INCREASED_RISK;DISEASE:COCAINE_DEPENDENCE
RITUXIMAB;FCGR3A;C;rs396991;EFFICACY;INCREASED_EFFICACY;EFFICACY:COMPLETE_RESPONSE_RATE
MERCAPTOPURINE;IMPDH1;CT;rs2278293;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
METHOTREXATE;IMPDH1;CT;rs2278293;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
RITUXIMAB;FCGR3A;AA;rs396991;nan;DECREASED;OTHER:LEVELS_OF_IGG
COCAINE;CNR1;C;rs806368;OTHER;DECREASED_RISK;DISEASE:COCAINE_DEPENDENCE
MERCAPTOPURINE;ITPA;CC;rs1127354;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
METHOTREXATE;ITPA;CC;rs1127354;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
ALENDRONATE;VDR;CC;rs1544410;EFFICACY;INCREASED_EFFICACY;EFFICACY:IMPROVEMENT_IN_BONE_MINERAL_DENSITY
RALOXIFENE;VDR;CC;rs1544410;EFFICACY;INCREASED_EFFICACY;EFFICACY:IMPROVEMENT_IN_BONE_MINERAL_DENSITY
ASPARAGINASE;PYGL;CC + CT;rs7142143;DOSAGE;INCREASED_RISKEFFICACY;EFFICACY:RELAPSE
DEXAMETHASONE;PYGL;CC + CT;rs7142143;DOSAGE;INCREASED_RISKEFFICACY;EFFICACY:RELAPSE
METHOTREXATE;PYGL;CC + CT;rs7142143;DOSAGE;INCREASED_RISKEFFICACY;EFFICACY:RELAPSE
INTERFERONS;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
INTERFERONS;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PAZOPANIB;CXCL8;AA;rs4073;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ERLOTINIB;EGFR;T;rs121434569;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
ERLOTINIB;EGFR;T;rs121434569;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
GEFITINIB;EGFR;T;rs121434569;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
INTERFERONS;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(SVR)_TO_INTERFERON_MONOTHERAPY_IN_HCV_GENOTYPE_1_PATIENTS
CAPECITABINE;DPYD;AG;rs17376848;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
IRINOTECAN;DPYD;AG;rs17376848;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
OXALIPLATIN;DPYD;AG;rs17376848;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
METHOTREXATE;nan;G;rs4888024;TOXICITY;nan;SIDE_EFFECT:END-OF-INDUCTION_MINIMAL_RISIDUAL_DISEASE_(MRD)_IN_CHILDHOOD_ACUTE_LYMPHOBLASTIC_LEUKEMIA_(ALL)_AND_IS_ALSO_ASSOCIATED_WITH_GREATER_METHOTREXATE_CLEARANCE
TACROLIMUS;ABCB1;AG;rs1128503;LADME_PK;INCREASED_PK;PK:TROUGH_CONCENTRATIONS
TACROLIMUS;ABCB1;AC + CT;rs2032582;LADME_PK;INCREASED_PK;PK:TROUGH_CONCENTRATIONS
METHOTREXATE;ABCC1;AA;rs3784862;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXICITY
ETHANOL;OPRM1;A;rs1799971;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
CAPECITABINE;DPYD;CT;rs2297595;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
CLOPIDOGREL;ABCB1;A;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;CTBP2;A;rs945665113;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(SVR)_IN_HCV_GENOTYPE_1_PATIENTS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(SVR)_IN_HCV_GENOTYPE_1_PATIENTS
CAPECITABINE;MTHFR;AG;rs1801133;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
FLUOROURACIL;MTHFR;AG;rs1801133;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
LEUCOVORIN;MTHFR;AG;rs1801133;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
OXALIPLATIN;MTHFR;AG;rs1801133;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
ANTIDEPRESSANTS;HTR2A;AA + AG;rs6313;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SUNITINIB;SLC22A5;C;rs2631367;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME
CLOPIDOGREL;CYP2C19;AA;rs4244285;EFFICACY;INCREASED_RISK;SIDE_EFFECT:PRIMARY_CLINICAL_ENDPOINT_OF_DEATH_DUE_TO_CARDIOVASCULAR_CAUSES | NON-FATAL_MI_OR_STENT_THROMBOSIS
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PRIMARY_CLINICAL_ENDPOINT_OF_DEATH_DUE_TO_CARDIOVASCULAR_CAUSES | NON-FATAL_MI_OR_STENT_THROMBOSIS
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
SUNITINIB;SLC22A5;C;rs2631370;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
NO_DRUG_RELATED;PTGS2;CG + GG;rs20417;nan;DECREASED_RISK;DISEASE:STROKE
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;CTBP2;G;rs376695472;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ANTIDEPRESSANTS;HTR2A;CC;rs6311;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
BETA BLOCKING AGENTS;ADRB2;GG;rs1042713;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:DEATH
HMG COA REDUCTASE INHIBITORS;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
FLUOROURACIL;DPYS;G;rs2959023;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
SUNITINIB;IL4R;C;rs1805015;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
OMEGA-3 POLYUNSATURATED FATTY ACIDS;PTGS2;CG + GG;rs20417;OTHER;INCREASED_RISK;DISEASE:COLONIC_NEOPLASMS
NO_DRUG_RELATED;PTGS2;CG + GG;rs20417;OTHER;DECREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
FLUOROURACIL;DPYS;G;rs2669429;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
METHOTREXATE;CLCN6;AG;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MYELOSUPPRESSION
METHOTREXATE;MTHFR;AG;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MYELOSUPPRESSION
CAPECITABINE;DPYD;CT;rs3918290;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
SUNITINIB;SLC22A5;C;rs2631372;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CAPECITABINE;MTHFR;GG;rs1801131;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
FLUOROURACIL;MTHFR;GG;rs1801131;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
LEUCOVORIN;MTHFR;GG;rs1801131;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
OXALIPLATIN;MTHFR;GG;rs1801131;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
SUNITINIB;IL4R;G;rs1801275;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
HEROIN;BDNF;TT;rs16917234;TOXICITY;DECREASED_AGE AT ONSET;SIDE_EFFECT:HEROIN_DEPENDENCE
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;T;rs267606619;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OTOTOXICITY
TENOFOVIR;ABCC4;CC + CT;rs1751034;LADME_PK;INCREASED_PK;PK:INTRACELLULAR_TENOFOVIR_DIPHOSPHATE_(TFV-DP)_CONCENTRATIONS
AZITHROMYCIN;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PAIN | DIARRHEA
ERYTHROMYCIN;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PAIN | DIARRHEA
CORTICOSTEROIDS;DTNBP1;T;rs35514893;EFFICACY;DECREASED_SEVERITY;DISEASE:ASTHMA
NO_DRUG_RELATED;CYP1B1;CC + CG;rs1056836;OTHER;INCREASED_RISK;DISEASE:BREAST_NEOPLASMS
THIOTEPA;GSTP1;T;rs1138272;OTHER;INCREASED_PK;PK:NON-INDUCIBLE_THIOTEPA_CLEARANCE_AND_DECREASED_TEPA_CLEARANCE
TENOFOVIR;ABCC4;TT;rs1751034;OTHER;INCREASED_PK;PK:TENOFOVIR_RENAL_CLEARANCE | AND_LOWER_AUC
FLUOROURACIL;DPYD;A;rs2786783;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
NO_DRUG_RELATED;G6PD;T;rs72554664;OTHER;INCREASED_LIKELIHOOD;OTHER:DIABETES_MELLITUS_TYPE2
OPIOIDS;nan;T;rs12442183;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:OPIOID-RELATED_DISORDERS
CORTICOSTEROIDS;KL;G;rs450789;EFFICACY;DECREASED_SEVERITY;DISEASE:ASTHMA
INTERFERON BETA-1A;IRF6;G;rs2205986;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
INTERFERON BETA-1B;IRF6;G;rs2205986;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
METHOTREXATE;NR1I2;C;rs3814058;TOXICITY;DECREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
METHOTREXATE;ABCC2;A;rs2273697;TOXICITY;INCREASED_RISK;SIDE_EFFECT:BONE_MARROW_DISORDER
FLUOROURACIL;WNT5B;CC;rs2010851;EFFICACY;DECREASED;OTHER:TIME_TO_TUMOR_RECURRENCE_(TTR)
CORTICOSTEROIDS;ME3;A;rs2125362;EFFICACY;INCREASED_SEVERITY;DISEASE:ASTHMA
HEROIN;OPRD1;GG;rs508448;TOXICITY;DECREASED_AGE AT ONSET;SIDE_EFFECT:HEROIN_DEPENDENCE
METHOTREXATE;NR1I2;G;rs6785049;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CORTICOSTEROIDS;LHX2;A;rs7851998;EFFICACY;DECREASED_SEVERITY;DISEASE:ASTHMA
FLUOROURACIL;DPYD;C;rs2811178;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CORTICOSTEROIDS;LHFPL3;G;rs61585310;EFFICACY;DECREASED_SEVERITY;DISEASE:ASTHMA
ASPARAGINASE;IL10;CC;rs1800896;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CORTICOSTEROIDS;IL10;CC;rs1800896;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CYCLOPHOSPHAMIDE;IL10;CC;rs1800896;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CYTARABINE;IL10;CC;rs1800896;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
MERCAPTOPURINE;IL10;CC;rs1800896;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
METHOTREXATE;IL10;CC;rs1800896;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
VINCRISTINE;IL10;CC;rs1800896;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
METHOTREXATE;GSK3B;A;rs3732361;LADME_PK;DECREASED_RISK;SIDE_EFFECT:BONE_MARROW_DISORDER | TOXIC_LIVER_DISEASE
HEROIN;BDNF;TT;rs6265;TOXICITY;DECREASED_AGE AT ONSET;SIDE_EFFECT:HEROIN_DEPENDENCE
MORPHINE;SLC22A1;T;rs12208357;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
CORTICOSTEROIDS;TRDN;T;rs4897302;EFFICACY;INCREASED_SEVERITY;DISEASE:ASTHMA
NICOTINE;CHRNA5;G;rs55781567;TOXICITY;INCREASED;DISEASE:TOBACCO_USE_DISORDER
HEROIN;OPRD1;AA;rs4654327;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEROIN_DEPENDENCE
OLANZAPINE;GIPR;AA + AT;rs10423928;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
NICOTINE;CHRNA5;A;rs16969968;TOXICITY;INCREASED;DISEASE:TOBACCO_USE_DISORDER
NICOTINE;CHRNA5;A;rs503464;TOXICITY;INCREASED;DISEASE:TOBACCO_USE_DISORDER
ALLOPURINOL;CYCSP5;C;rs9469003;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
FLUOROURACIL;DPYD;G;rs1801265;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
DAUNORUBICIN;SLC22A17;T;rs4982753;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DOXORUBICIN;SLC22A17;T;rs4982753;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_IN_THERAPEUTIC_RANGE
ALLOPURINOL;CYCSP5;C;rs9469003;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;CYCSP5;C;rs9469003;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
PHENYTOIN;CYCSP5;C;rs9469003;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
NICOTINE;CHRNA5;G;rs55853698;TOXICITY;INCREASED;DISEASE:TOBACCO_USE_DISORDER
AMANTADINE;SLC22A1;C;rs622342;DOSAGE;INCREASED_RISK;DISEASE:DEATH
AMANTADINE;SLC22A1;C;rs622342;EFFICACY;INCREASED_RISK;DISEASE:DEATH
AMANTADINE;SLC22A1;C;rs622342;TOXICITY;INCREASED_RISK;DISEASE:DEATH
ANTICHOLINERGICS;SLC22A1;C;rs622342;DOSAGE;INCREASED_RISK;DISEASE:DEATH
ANTICHOLINERGICS;SLC22A1;C;rs622342;EFFICACY;INCREASED_RISK;DISEASE:DEATH
ANTICHOLINERGICS;SLC22A1;C;rs622342;TOXICITY;INCREASED_RISK;DISEASE:DEATH
DOPAMINE AGONISTS;SLC22A1;C;rs622342;DOSAGE;INCREASED_RISK;DISEASE:DEATH
DOPAMINE AGONISTS;SLC22A1;C;rs622342;EFFICACY;INCREASED_RISK;DISEASE:DEATH
DOPAMINE AGONISTS;SLC22A1;C;rs622342;TOXICITY;INCREASED_RISK;DISEASE:DEATH
LEVODOPA;SLC22A1;C;rs622342;DOSAGE;INCREASED_RISK;DISEASE:DEATH
LEVODOPA;SLC22A1;C;rs622342;EFFICACY;INCREASED_RISK;DISEASE:DEATH
LEVODOPA;SLC22A1;C;rs622342;TOXICITY;INCREASED_RISK;DISEASE:DEATH
SELEGILINE;SLC22A1;C;rs622342;DOSAGE;INCREASED_RISK;DISEASE:DEATH
SELEGILINE;SLC22A1;C;rs622342;EFFICACY;INCREASED_RISK;DISEASE:DEATH
SELEGILINE;SLC22A1;C;rs622342;TOXICITY;INCREASED_RISK;DISEASE:DEATH
MELPHALAN;POLR1G;A;rs967591;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_AND_TIME-TO-TREAT_FAILURE
MELPHALAN;POLR1G;A;rs967591;TOXICITY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_AND_TIME-TO-TREAT_FAILURE
CORTICOSTEROIDS;ACOT7;G;rs11121611;EFFICACY;DECREASED_SEVERITY;DISEASE:ASTHMA
PEGINTERFERON ALFA-2B;ITPA;CC;rs1127354;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
RIBAVIRIN;ITPA;CC;rs1127354;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
TELAPREVIR;ITPA;CC;rs1127354;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
MORPHINE;TLR2;CC + CT;rs3804100;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | FATIGUE | COGNITIVE_DISORDER | CONSTIPATION
DAUNORUBICIN;SLC22A7;G;rs4149178;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DOXORUBICIN;SLC22A7;G;rs4149178;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
ROSUVASTATIN;SCAP;CC + CT;rs12487736;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:HYPERLIPIDEMIAS
ALLOPURINOL;PSORS1C3;A;rs3094188;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
CORTICOSTEROIDS;APOBEC3B;A;rs5995653;EFFICACY;DECREASED_SEVERITY;DISEASE:ASTHMA
ALLOPURINOL;PSORS1C3;A;rs3094188;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;PSORS1C3;A;rs3094188;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
PHENYTOIN;PSORS1C3;A;rs3094188;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
MORPHINE;COMT;AA + AG;rs4680;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | FATIGUE | DEPRESSION,
GEMCITABINE;CDA;CC;rs2072671;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
PACLITAXEL;CDA;CC;rs2072671;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
MONTELUKAST;ABCC1;CT;rs119774;EFFICACY;INCREASED_EFFICACY;EFFICACY:CHANGES_IN_FEV1
TRIAMCINOLONE;HCG22;T;rs2523864;TOXICITY;INCREASED;SIDE_EFFECT:OCULAR_HYPERTENSION
ANTIDEPRESSANTS;CREB1;GG;rs7569963;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
ANTIDEPRESSANTS;METTL21A;GG;rs7569963;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
MORPHINE;IL6;CC;rs10499563;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | FATIGUE | DEPRESSION,
ALLOPURINOL;POU5F1;G;rs3130501;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
ALLOPURINOL;POU5F1;G;rs3130501;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;POU5F1;G;rs3130501;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
PHENYTOIN;POU5F1;G;rs3130501;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;A;rs184278615;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CITALOPRAM;nan;T;rs4675690;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TREATMENT-EMERGENT_SUICIDALITY
CITALOPRAM;CREB1;A;rs7569963;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:TREATMENT-EMERGENT_SUICIDALITY
CITALOPRAM;METTL21A;A;rs7569963;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:TREATMENT-EMERGENT_SUICIDALITY
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;T;rs201469165;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";APOE;T;rs7412;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERTRIGLYCERIDEMIA
"COMBINATIONS""";APOE;T;rs7412;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERTRIGLYCERIDEMIA
"""RITONAVIR""";APOE;T;rs7412;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERTRIGLYCERIDEMIA
ALLOPURINOL;POU5F1;C;rs3130931;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
TRIAMCINOLONE;HCG22;G;rs3873352;TOXICITY;INCREASED;SIDE_EFFECT:OCULAR_HYPERTENSION
ALLOPURINOL;PSORS1C1;A;rs3815087;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;PSORS1C1;A;rs3815087;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
PHENYTOIN;PSORS1C1;A;rs3815087;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
MORPHINE;IL6R;AC + CC;rs2228145;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | FATIGUE | DEPRESSION,
ALLOPURINOL;POU5F1;C;rs3130931;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;POU5F1;C;rs3130931;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
PHENYTOIN;POU5F1;C;rs3130931;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
MORPHINE;BDNF;TT;rs6265;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | FATIGUE | DEPRESSION,
ALLOPURINOL;PSORS1C1;A;rs3815087;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
MORPHINE;IL2;AC + CC;rs2069762;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | FATIGUE | DEPRESSION,
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;C;rs1071748;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ASPIRIN;B4GALT2;CT + TT;rs1061781;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
CLOPIDOGREL;B4GALT2;CT + TT;rs1061781;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
METHOTREXATE;ABCB1;AA + AG;rs1128503;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
ALLOPURINOL;nan;C;rs2844665;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
MERCAPTOPURINE;SLC28A2;AA;rs2413775;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
METHOTREXATE;SLC28A2;AA;rs2413775;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
CHLORTHALIDONE;NPPA;G;rs5065;EFFICACY;DECREASED_EFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
METHOTREXATE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
MERCAPTOPURINE;SLC28A2;AT;rs2413775;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
METHOTREXATE;SLC28A2;AT;rs2413775;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CYCLOPHOSPHAMIDE;SOD2;G;rs4880;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
CYCLOPHOSPHAMIDE;CYP3A4;C;rs2740574;TOXICITY;DECREASED_RISK;SIDE_EFFECT:PRIMARY_OVARIAN_FAILURE
DOXORUBICIN;SLC22A16;CC;rs714368;TOXICITY;INCREASED_PK;PK:DOXORUBICINOL_AUC
DOXORUBICIN;SLC22A16;CC;rs714368;LADME_PK;INCREASED_PK;PK:DOXORUBICINOL_AUC
MERCAPTOPURINE;SLC29A1;CC;rs747199;TOXICITY;DECREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS | LEUKOPENIA
METHOTREXATE;SLC29A1;CC;rs747199;TOXICITY;DECREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS | LEUKOPENIA
ALLOPURINOL;nan;C;rs2844665;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;nan;C;rs2844665;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
PHENYTOIN;nan;C;rs2844665;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
CYCLOPHOSPHAMIDE;CYP2B6;AG + GG;rs2279343;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ORAL_MUCOSITIS
CYCLOPHOSPHAMIDE;CYP2B6;AG + GG;rs2279343;LADME_PK;INCREASED_RISK;SIDE_EFFECT:ORAL_MUCOSITIS
CYCLOPHOSPHAMIDE;CYP2B6;CT + TT;rs8192709;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGIC_CYSTITIS
CYCLOPHOSPHAMIDE;CYP2B6;CT + TT;rs8192709;LADME_PK;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGIC_CYSTITIS
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;KIR3DL2;G;rs973541788;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
AMOXICILLIN;HLA-DRA;T;rs3129880;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLAVULANATE;HLA-DRA;T;rs3129880;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
FLUCLOXACILLIN;HLA-DRA;T;rs3129880;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CYCLOPHOSPHAMIDE;CYP2B6;GT + TT;rs3745274;TOXICITY;DECREASED_RISK;SIDE_EFFECT:VENOOCCLUSIVE_DISEASE_OF_THE_LIVER
CYCLOPHOSPHAMIDE;CYP2B6;GT + TT;rs3745274;LADME_PK;DECREASED_RISK;SIDE_EFFECT:VENOOCCLUSIVE_DISEASE_OF_THE_LIVER
ANGIOTENSIN II ANTAGONISTS;CYP2D6;C;rs28371725;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE
OPIOIDS;OPRM1;GG;rs1799971;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SLEEP_DISORDERS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
CYCLOSPORINE;MTHFR;A;rs1801133;OTHER;nan;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
METHOTREXATE;MTHFR;A;rs1801133;OTHER;nan;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
CARBOPLATIN;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
CISPLATIN;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
GEMCITABINE;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
ANGIOTENSIN II ANTAGONISTS;CYP2D6;T;rs2004511;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE
MERCAPTOPURINE;ABCC4;CC;rs2274407;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
METHOTREXATE;ABCC4;CC;rs2274407;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
DOXORUBICIN;CBR3;G;rs8133052;EFFICACY;DECREASED_EFFICACY;EFFICACY:TUMOR_RESPONSE
DOXORUBICIN;CBR3;G;rs8133052;TOXICITY;DECREASED_SEVERITY;DISEASE:NEUTROPENIA
DOXORUBICIN;CBR3;G;rs8133052;LADME_PK;DECREASED_SEVERITY;DISEASE:NEUTROPENIA
DOXORUBICIN;CBR3;A;rs1056892;DOSAGE;INCREASED_PK;PK:DOXORUBICINOL_AUC
DOXORUBICIN;CBR3;A;rs1056892;LADME_PK;INCREASED_PK;PK:DOXORUBICINOL_AUC
ANTIHYPERTENSIVES;ATP2B1;AA + AG;rs1401982;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESISTANT_HYPERTENSION
ANGIOTENSIN II ANTAGONISTS;CYP2D6;A;rs28371702;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PRURITUS
MERCAPTOPURINE;SLC28A3;CC + CT;rs10868138;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
METHOTREXATE;SLC28A3;CC + CT;rs10868138;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
HEROIN;GRM3;A;rs724226;OTHER;INCREASED_RISK;DISEASE:HEROIN_DEPENDENCE
ACENOCOUMAROL;VKORC1;T;rs7294;OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESIDUAL_PLATELET_REACTIVITY
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
CORTICOSTEROIDS;CRHR1;AA;rs242941;EFFICACY;INCREASED_EFFICACY;EFFICACY:PERCENT_CHANGE_IN_FEV
METHOTREXATE;CLCN6;AA;rs1801133;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
CORTICOSTEROIDS;FKBP5;AA + AG;rs4713916;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:GLUCOCORTICOID_RESPONSIVENESS
BUDESONIDE;CRHR1;AA;rs242941;EFFICACY;PK;PK:DELAYED_CORTISOL_RESPONSE_TO_STRESS
FLUTICASONE PROPIONATE;CRHR1;AA;rs242941;EFFICACY;PK;PK:DELAYED_CORTISOL_RESPONSE_TO_STRESS
OPIOIDS;ABCB1;G;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA
CORTICOSTEROIDS;CRHR1;TT;rs1876828;EFFICACY;INCREASED_EFFICACY;EFFICACY:PERCENT_CHANGE_IN_FEV
GEMCITABINE;nan;C;rs1155463;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CENTRAL_NERVOUS_SYSTEM_DISORDER
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;AA + AT;rs212090;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA | THROMBOCYTOPENIA | ANEMIA
BUDESONIDE;CRHR1;TT;rs1876828;EFFICACY;PK;PK:DELAYED_CORTISOL_RESPONSE_TO_STRESS
FLUTICASONE PROPIONATE;CRHR1;TT;rs1876828;EFFICACY;PK;PK:DELAYED_CORTISOL_RESPONSE_TO_STRESS
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;CC + CT;rs4149171;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA | THROMBOCYTOPENIA | ANEMIA
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;nan;AA + AG;rs955434;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA | THROMBOCYTOPENIA | ANEMIA
CHLOROTHIAZIDE;nan;A;rs61824877;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERGLYCEMIA
CHLOROTHIAZIDE;nan;A;rs61824877;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERGLYCEMIA
HYDROCHLOROTHIAZIDE;nan;A;rs61824877;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERGLYCEMIA
HYDROCHLOROTHIAZIDE;nan;A;rs61824877;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERGLYCEMIA
WARFARIN;VKORC1;CT + TT;rs9923231;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;CT + TT;rs4149170;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA | THROMBOCYTOPENIA | ANEMIA
TRAMADOL;OPRM1;GG;rs1799971;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:NAUSEA
CHLOROTHIAZIDE;HMGCS2;G;rs9943291;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERGLYCEMIA
CHLOROTHIAZIDE;HMGCS2;G;rs9943291;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERGLYCEMIA
HYDROCHLOROTHIAZIDE;HMGCS2;G;rs9943291;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERGLYCEMIA
HYDROCHLOROTHIAZIDE;HMGCS2;G;rs9943291;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERGLYCEMIA
METHOTREXATE;CLCN6;AG;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
METHOTREXATE;MTHFR;AG;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
METHADONE;DAO;TT;rs55944529;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:SUBSTANCE_WITHDRAWAL_SYNDROME
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;CC;rs4148579;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA | THROMBOCYTOPENIA | ANEMIA
NO_DRUG_RELATED;KCNIP1;CT + TT;rs11739136;OTHER;DECREASED_RISK;DISEASE:HYPERTENSION
NO_DRUG_RELATED;KCNMB1;CT + TT;rs11739136;OTHER;DECREASED_RISK;DISEASE:HYPERTENSION
INFLIXIMAB;IL1B;GG;rs1143634;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
IRINOTECAN;UGT1A1;AA;rs10929302;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA | VOMITING
ATAZANAVIR;ABCB1;AT;rs2032582;TOXICITY;INCREASED_RISK;DISEASE:HYPERBILIRUBINEMIA
DABIGATRAN;ABCB1;CC + CT;rs4148738;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
NICOTINE;CHRNA5;A;rs16969968;OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;AA + AG;rs212087;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA | THROMBOCYTOPENIA | ANEMIA
INFLIXIMAB;IL23R;TT;rs10489629;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
IRINOTECAN;UGT1A1;AA;rs10929302;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;CC;rs4148580;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA | THROMBOCYTOPENIA | ANEMIA
INFLIXIMAB;SLCO1C1;GG;rs3794271;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
NICOTINE;CHRNA3;A;rs578776;OTHER;DECREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
CARVEDILOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED_EFFICACY;EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR_FUNCTION_(LVEF)
PEGINTERFERON ALFA-2A;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:CRYOGLOBULINEMIA
PD-1;IL7;A;rs16906115;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1;IL7;A;rs16906115;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
DEATH LIGAND 1) INHIBITORS;IL7;A;rs16906115;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
IRINOTECAN;ABCC1;CT + TT;rs3743527;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
NICOTINE;CHRNA3;A;rs1051730;OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
IRINOTECAN;ABCB1;AC + CC;rs12720066;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
NICOTINE;CHRNA3;C;rs3743078;OTHER;DECREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;GG;rs4148575;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA | THROMBOCYTOPENIA | ANEMIA
NICOTINE;CHRNB4;G;rs3813567;OTHER;DECREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
IRINOTECAN;ABCC1;AG + GG;rs17501331;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
CARVEDILOL;ADRB1;CC;rs1801253;EFFICACY;EFFICACY;EFFICACY:SIGNIFICANTLY_GREATER_IMPROVEMENT_IN_LEFT_VENTRICULAR_EJECTION_FRACTION_(LVEF)
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:CRYOGLOBULINEMIA
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:CRYOGLOBULINEMIA
PEGINTERFERON ALFA-2A;IFNL4;TT;rs8099917;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:CRYOGLOBULINEMIA
NO_DRUG_RELATED;UGT1A1;AA;rs4148323;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS | CEREBRAL_PALSY | HEARING_LOSS,
PEGINTERFERON ALFA-2A;NT5C2;CT;rs10883841;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:CRYOGLOBULINEMIA
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
INFLIXIMAB;ADAM17;TT;rs10929587;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
CLOPIDOGREL;MED12L;AG;rs10935838;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
CLOPIDOGREL;P2RY12;AG;rs10935838;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
NO_DRUG_RELATED;ago-02;AA + AC;rs4961280;OTHER;DECREASED;OTHER:PROGRESSION-FREE_SURVIVAL
STAVUDINE;TNF;C;rs1799964;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUROPATHY
CLOPIDOGREL;MED12L;AG;rs2046934;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
CLOPIDOGREL;P2RY12;AG;rs2046934;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
CLOPIDOGREL;MED12L;AC;rs6809699;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
CLOPIDOGREL;P2RY12;AC;rs6809699;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;AA;rs3749442;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA | THROMBOCYTOPENIA | ANEMIA
NICOTINE;CHRNA5;G;rs684513;OTHER;DECREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;C;rs267606618;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OTOTOXICITY
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;GG;rs1132776;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA | THROMBOCYTOPENIA | ANEMIA
NICOTINE;CHRNA5;A;rs637137;OTHER;DECREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
NO_DRUG_RELATED;IL1A;A;rs1800587;OTHER;INCREASED_SEVERITY;DISEASE:PAIN
FLUTICASONE;CRHR1;CC;rs242941;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEAN_CHANGE_IN_FEV
SALMETEROL;CRHR1;CC;rs242941;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEAN_CHANGE_IN_FEV
PROPRANOLOL;COMT;G;rs4680;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;AA;rs939338;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA | THROMBOCYTOPENIA | ANEMIA
PEGINTERFERON ALFA-2A;CYP27B1;GT + TT;rs10877012;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;METTL1;GT + TT;rs10877012;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PROPRANOLOL;COMT;G;rs4818;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN
CORTICOSTEROIDS;APOBEC3B;T;rs6001366;EFFICACY;DECREASED_SEVERITY;DISEASE:ASTHMA
PEGINTERFERON ALFA-2A;IFNL3;TT;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
CORTICOSTEROIDS;KCNN1;C;rs2278992;EFFICACY;DECREASED_SEVERITY;DISEASE:ASTHMA
PEGINTERFERON ALFA-2A;VDR;AA;rs7975232;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
CORTICOSTEROIDS;ANKRD30B;A;rs12959468;EFFICACY;DECREASED_SEVERITY;DISEASE:ASTHMA
ROSUVASTATIN;CRP;CT + TT;rs1205;EFFICACY;DECREASED;OTHER:PLASMA_LEVEL_OF_HIGH-SENSITIVITY_C-REACTIVE_PROTEIN
ROSUVASTATIN;CRP;CT + TT;rs1205;OTHER;DECREASED;OTHER:PLASMA_LEVEL_OF_HIGH-SENSITIVITY_C-REACTIVE_PROTEIN
ROSUVASTATIN;CRP;CT + TT;rs1205;LADME_PK;DECREASED;OTHER:PLASMA_LEVEL_OF_HIGH-SENSITIVITY_C-REACTIVE_PROTEIN
PROPRANOLOL;COMT;G;rs6269;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;CC + CG;rs129081;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA | LEUKOPENIA | THROMBOCYTOPENIA | ANEMIA
RISPERIDONE;HTR2A;TT;rs6311;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
HEROIN;GRM3;T;rs2189814;OTHER;INCREASED_RISK;DISEASE:HEROIN_DEPENDENCE
ROSUVASTATIN;nan;CC + CT;rs2808630;EFFICACY;DECREASED;OTHER:PLASMA_LEVEL_OF_HIGH-SENSITIVITY_C-REACTIVE_PROTEIN
ROSUVASTATIN;nan;CC + CT;rs2808630;OTHER;DECREASED;OTHER:PLASMA_LEVEL_OF_HIGH-SENSITIVITY_C-REACTIVE_PROTEIN
ROSUVASTATIN;nan;CC + CT;rs2808630;LADME_PK;DECREASED;OTHER:PLASMA_LEVEL_OF_HIGH-SENSITIVITY_C-REACTIVE_PROTEIN
METHADONE;OPRD1;AT + TT;rs204076;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ROSUVASTATIN;HNF1A;AC + CC;rs1169288;EFFICACY;DECREASED;OTHER:PLASMA_LEVEL_OF_HIGH-SENSITIVITY_C-REACTIVE_PROTEIN
ROSUVASTATIN;HNF1A;AC + CC;rs1169288;OTHER;DECREASED;OTHER:PLASMA_LEVEL_OF_HIGH-SENSITIVITY_C-REACTIVE_PROTEIN
ROSUVASTATIN;HNF1A;AC + CC;rs1169288;LADME_PK;DECREASED;OTHER:PLASMA_LEVEL_OF_HIGH-SENSITIVITY_C-REACTIVE_PROTEIN
METOPROLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED_EFFICACY;EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR(LV)_REMODELING_AND_GREATER_INCREASE_IN_LVEF_(LEFT_VENTRICULAR_EJECTION_FRACTION)
PROPRANOLOL;COMT;C;rs4633;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN
BUCINDOLOL;ADRB1;CC;rs1801253;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE
ERYTHROMYCIN;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
ASPIRIN;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
NO_DRUG_RELATED;KCNIP1;CT + TT;rs11739136;OTHER;DECREASED;OTHER:BLOOD_PRESSURE
NO_DRUG_RELATED;KCNMB1;CT + TT;rs11739136;OTHER;DECREASED;OTHER:BLOOD_PRESSURE
TACROLIMUS;ABCB1;A;rs2032582;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TRANSPLANT_REJECTION
CAFFEINE;RYR1;AC;rs118192162;TOXICITY;nan;DISEASE:MALIGNANT_HYPERTHERMIA
ISOFLURANE;RYR1;AC;rs118192162;TOXICITY;nan;DISEASE:MALIGNANT_HYPERTHERMIA
RISPERIDONE;NR1I2;GG;rs7643645;LADME_PK;DECREASED_PK;PK:9-HYDROXY-RISPERIDONE_LEVELS
REPAGLINIDE;SLCO1B1;GG;rs2306283;OTHER;DECREASED_PK;PK:REPAGLINIDE_PLASMA_CONCENTRATION_(AUC)_AND_CMAX
REPAGLINIDE;SLCO1B1;GG;rs2306283;LADME_PK;DECREASED_PK;PK:REPAGLINIDE_PLASMA_CONCENTRATION_(AUC)_AND_CMAX
HALOTHANE;RYR1;CT;rs118192161;TOXICITY;nan;DISEASE:MALIGNANT_HYPERTHERMIA
RISPERIDONE;NR1I2;GG;rs7643645;LADME_PK;DECREASED_PK;PK:ACTIVE_MOIETY_LEVELS
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
TACROLIMUS;ABCB1;G;rs1045642;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TRANSPLANT_REJECTION
GEFITINIB;CYP2D6;AA + AG;rs1065852;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
DALCETRAPIB;ADCY9;AA;rs1967309;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
EGFR INHIBITORS;PIK3CA;C;rs6443624;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:EXANTHEMA
EGFR INHIBITORS;PIK3CA;T;rs2677760;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:EXANTHEMA
MISOPROSTOL;SLCO1B1;GG;rs4149087;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:FEVER
MISOPROSTOL;ABCC4;AA;rs11568658;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:FEVER
ASPIRIN;PEAR1;A;rs12041331;EFFICACY;DECREASED_EFFICACY;EFFICACY:COLLAGEN_INDUCED_PLATELET_AGGREGATION_AFTER_ASPIRIN_OR_DUAL_ANTIPLATELET_THERAPY_(DAPT)_ADMINISTRATION
CLOPIDOGREL;PEAR1;A;rs12041331;EFFICACY;DECREASED_EFFICACY;EFFICACY:COLLAGEN_INDUCED_PLATELET_AGGREGATION_AFTER_ASPIRIN_OR_DUAL_ANTIPLATELET_THERAPY_(DAPT)_ADMINISTRATION
ETHAMBUTOL;CYP2E1;TT;rs2031920;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID;CYP2E1;TT;rs2031920;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;CYP2E1;TT;rs2031920;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
RIFAMPIN;CYP2E1;TT;rs2031920;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CARBOPLATIN;RAF1;AG;rs11710163;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN;RAF1;AG;rs11710163;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DOCETAXEL;RAF1;AG;rs11710163;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
GEMCITABINE;RAF1;AG;rs11710163;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PACLITAXEL;RAF1;AG;rs11710163;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOPIDOGREL;CYP2C19;T;rs12248560;TOXICITY;DECREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
ASPIRIN;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;SIDE_EFFECT:CARDIOVASCULAR_EVENTS_IN_PATIENTS_UNDERGOING_PCI
CLOPIDOGREL;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;SIDE_EFFECT:CARDIOVASCULAR_EVENTS_IN_PATIENTS_UNDERGOING_PCI
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
OLANZAPINE;GSTP1;AG + GG;rs1695;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
ASPIRIN;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;SIDE_EFFECT:CARDIOVASCULAR_EVENTS_IN_PATIENTS_UNDERGOING_PCI
CLOPIDOGREL;PEAR1;AA + AG;rs12041331;TOXICITY;INCREASED;SIDE_EFFECT:CARDIOVASCULAR_EVENTS_IN_PATIENTS_UNDERGOING_PCI
ANTIINFLAMMATORY AGENTS;ALOX15;C;rs3892408;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
NON-STEROIDS;ALOX15;C;rs3892408;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
METHADONE;CCL11;A;rs1129844;TOXICITY;INCREASED;SIDE_EFFECT:INSOMNIA
EGFR INHIBITORS;PIK3CA;C;rs2699905;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:EXANTHEMA
FLUOXETINE;nan;GG;rs2433320;EFFICACY;DECREASED_EFFICACY;EFFICACY:HAMD_SCORES
ANTIPSYCHOTICS;MTHFR;G;rs1801133;TOXICITY;INCREASED;SIDE_EFFECT:WEIGHT_GAIN
ASPARAGINASE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CYCLOPHOSPHAMIDE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CYTARABINE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
DAUNORUBICIN;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
MERCAPTOPURINE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PREDNISOLONE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
VINCRISTINE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ANTIINFLAMMATORY AGENTS;PTGS1;C;rs5789;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
NON-STEROIDS;PTGS1;C;rs5789;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
CLOZAPINE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;SIDE_EFFECT:WEIGHT_GAIN
OLANZAPINE;MTHFR;GG;rs1801131;TOXICITY;INCREASED;SIDE_EFFECT:WEIGHT_GAIN
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;CT;rs1799929;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CYCLOPHOSPHAMIDE;PNPLA3;G;rs738409;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
CYTARABINE;PNPLA3;G;rs738409;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
DAUNORUBICIN;PNPLA3;G;rs738409;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
DOXORUBICIN;PNPLA3;G;rs738409;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
MERCAPTOPURINE;PNPLA3;G;rs738409;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
METHOTREXATE;PNPLA3;G;rs738409;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
PEGASPARGASE;PNPLA3;G;rs738409;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
THIOGUANINE;PNPLA3;G;rs738409;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
VINCRISTINE;PNPLA3;G;rs738409;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
LEUCOVORIN;UMPS;CC;rs1801019;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA | DRUG_TOXICITY
TEGAFUR;UMPS;CC;rs1801019;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA | DRUG_TOXICITY
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
GEFITINIB;EGFR;T;rs121434568;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
CARBOPLATIN;MAP3K1;AA + AG;rs726501;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN;MAP3K1;AA + AG;rs726501;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DOCETAXEL;MAP3K1;AA + AG;rs726501;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PACLITAXEL;MAP3K1;AA + AG;rs726501;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ETHAMBUTOL;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:MACULOPAPULAR_EXANTHEMA
ISONIAZID;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:MACULOPAPULAR_EXANTHEMA
PYRAZINAMIDE;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:MACULOPAPULAR_EXANTHEMA
RIFAMPIN;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:MACULOPAPULAR_EXANTHEMA
ANTHRACYCLINES AND RELATED SUBSTANCES;CYP4X1;AA;rs17102977;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CYCLOPHOSPHAMIDE;CYP4X1;AA;rs17102977;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
FLUOROURACIL;CYP4X1;AA;rs17102977;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
TAXANES;CYP4X1;AA;rs17102977;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CYCLOPHOSPHAMIDE;TPMT;C;rs1142345;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
CYTARABINE;TPMT;C;rs1142345;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
DAUNORUBICIN;TPMT;C;rs1142345;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
DOXORUBICIN;TPMT;C;rs1142345;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
MERCAPTOPURINE;TPMT;C;rs1142345;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
METHOTREXATE;TPMT;C;rs1142345;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
PEGASPARGASE;TPMT;C;rs1142345;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
THIOGUANINE;TPMT;C;rs1142345;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
VINCRISTINE;TPMT;C;rs1142345;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
ETHAMBUTOL;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:MACULOPAPULAR_EXANTHEMA
ISONIAZID;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:MACULOPAPULAR_EXANTHEMA
PYRAZINAMIDE;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:MACULOPAPULAR_EXANTHEMA
RIFAMPIN;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:MACULOPAPULAR_EXANTHEMA
SIMVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DOSE_DECREASE_OR_SWITCH_TO_ANOTHER_CHOLESTEROL-LOWERING_DRUG
ANTIINFLAMMATORY AGENTS;PTGS1;A;rs10306135;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
NON-STEROIDS;PTGS1;A;rs10306135;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
IMATINIB;SLC22A1;CG + GG;rs683369;EFFICACY;DECREASED;DISEASE:EVENT-FREE_SURVIVAL
ANTIPSYCHOTICS;GABRG3;A;rs2061051;TOXICITY;INCREASED_SEVERITY;DISEASE:TARDIVE_DYSKINESIA
GEMCITABINE;nan;CT + TT;rs642990;TOXICITY;DECREASED_RISK;DISEASE:NEUTROPENIA
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:LONGER_MEDIAN_PROGRESSION-FREE_SURVIVAL_TIME
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
CARBOPLATIN;MAP3K1;CC + CT;rs16886403;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN;MAP3K1;CC + CT;rs16886403;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DOCETAXEL;MAP3K1;CC + CT;rs16886403;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PACLITAXEL;MAP3K1;CC + CT;rs16886403;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
GEMCITABINE;RRM1;A;rs1042858;DOSAGE;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CARBOPLATIN;nan;AG + GG;rs17661089;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN;nan;AG + GG;rs17661089;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DOCETAXEL;nan;AG + GG;rs17661089;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PACLITAXEL;nan;AG + GG;rs17661089;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CARBOPLATIN;ACSS2;AT;rs17309872;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN;ACSS2;AT;rs17309872;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DOCETAXEL;ACSS2;AT;rs17309872;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
GEMCITABINE;ACSS2;AT;rs17309872;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PACLITAXEL;ACSS2;AT;rs17309872;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
METHOTREXATE;ABCC1;AG + GG;rs246240;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ONSET_OF_TOXICITY
BUPROPION;EPB41;AA;rs6702335;EFFICACY;INCREASED_EFFICACY;EFFICACY:ABSTINENCE
NICOTINE;EPB41;AA;rs6702335;EFFICACY;INCREASED_EFFICACY;EFFICACY:ABSTINENCE
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL14;G;rs62328061;TOXICITY;DECREASED_RISK;SIDE_EFFECT:LEUKOPENIA
NO_DRUG_RELATED;IL17F;CC;rs763780;OTHER;INCREASED_LIKELIHOOD;OTHER:RECURRENT_PREGNANCY_LOSS
DAUNORUBICIN;NOS3;GG;rs1799983;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
NO_DRUG_RELATED;IL17A;AA;rs2275913;OTHER;INCREASED_LIKELIHOOD;OTHER:RECURRENT_PREGNANCY_LOSS
ACE INHIBITORS;KCNIP4;A;rs145489027;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:COUGH
PLAIN;KCNIP4;A;rs145489027;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:COUGH
PEMETREXED;ATIC;C;rs12995526;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
OPIOIDS;PDYN;A;rs910080;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
ACE INHIBITORS;KCNIP4;C;rs1495509;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:COUGH
PLAIN;KCNIP4;C;rs1495509;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:COUGH
FOLFIRI;MTHFR;GG;rs1801131;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FOLFOX;MTHFR;GG;rs1801131;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
XELOX;MTHFR;GG;rs1801131;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
GEMCITABINE;ALG10;AA + AG;rs1705772;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXICITY
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MYELOSUPPRESSION
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
CYCLOPHOSPHAMIDE;UGT1A1;T;rs887829;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
CYTARABINE;UGT1A1;T;rs887829;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
DAUNORUBICIN;UGT1A1;T;rs887829;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
DOXORUBICIN;UGT1A1;T;rs887829;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
MERCAPTOPURINE;UGT1A1;T;rs887829;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
METHOTREXATE;UGT1A1;T;rs887829;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
PEGASPARGASE;UGT1A1;T;rs887829;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
THIOGUANINE;UGT1A1;T;rs887829;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
VINCRISTINE;UGT1A1;T;rs887829;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
RITONAVIR;APOC3;C;rs2854116;OTHER;INCREASED_RISK;DISEASE:HYPERTRIGLYCERIDEMIA
PEMETREXED;GGH;CT + TT;rs16930092;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ANASTROZOLE;UGT1A4;GG;rs3732218;LADME_PK;INCREASED_PK;PK:GLUCURONIDATION
HALOPERIDOL;CYP2D6;CT;rs3892097;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
FOLFIRI;ABCB1;GG;rs1045642;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FOLFOX;ABCB1;GG;rs1045642;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
XELOX;ABCB1;GG;rs1045642;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ACE INHIBITORS;KCNIP4;A;rs7675300;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:COUGH
PLAIN;KCNIP4;A;rs7675300;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:COUGH
CYCLOPHOSPHAMIDE;VEGFA;CC;rs2010963;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
NICOTINE;CHRNA3;A;rs1051730;OTHER;INCREASED_LIKELIHOOD;OTHER:SMOKING
NEVIRAPINE;TRAF3IP2;C;rs76228616;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
GEMCITABINE;ALOX5AP;AG + GG;rs4769060;LADME_PK;DECREASED_PK;PK:CMAX_AND_A_LOWER_MEAN_AUC
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
SUFENTANIL;OPRM1;AG;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
IPILIMUMAB;IL7;AA + AG;rs16906115;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
NIVOLUMAB;IL7;AA + AG;rs16906115;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
PEMBROLIZUMAB;IL7;AA + AG;rs16906115;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
GEMTUZUMAB OZOGAMICIN;CD33;CC + CG;rs1803254;TOXICITY;INCREASED;SIDE_EFFECT:DEATH
FOLFIRI;BRAF;T;rs113488022;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FOLFOX;BRAF;T;rs113488022;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
XELOX;BRAF;T;rs113488022;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
METHOTREXATE;CLCN6;AG + GG;rs1801133;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:LEUKOPENIA
METHOTREXATE;MTHFR;AG + GG;rs1801133;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:LEUKOPENIA
OPIOIDS;TH;G;rs2070762;TOXICITY;INCREASED_RISK;DISEASE:OPIOID-RELATED_DISORDERS
GEMTUZUMAB OZOGAMICIN;CD33;GG;rs35112940;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ISONIAZID;CYP2E1;AT;rs6413432;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID;DUX1;AT;rs6413432;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
RIFAMPIN;CYP2E1;AT;rs6413432;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
RIFAMPIN;DUX1;AT;rs6413432;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CISPLATIN;SLC22A2;A;rs316019;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OTOTOXICITY
ANTINEOPLASTIC AGENTS;SPARC;AG + GG;rs1059829;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_TUMOR_RECURRENCE
FLUOROURACIL;SPARC;AG + GG;rs1059829;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_TUMOR_RECURRENCE
LEUCOVORIN;SPARC;AG + GG;rs1059829;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_TUMOR_RECURRENCE
OPIOIDS;DBH;G;rs1611131;TOXICITY;DECREASED_RISK;DISEASE:OPIOID-RELATED_DISORDERS
ANTIPSYCHOTICS;HSPG2;C;rs2445142;TOXICITY;INCREASED_SEVERITY;DISEASE:TARDIVE_DYSKINESIA
FOLFIRI;DPYD;AG + GG;rs1801265;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FOLFOX;DPYD;AG + GG;rs1801265;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
XELOX;DPYD;AG + GG;rs1801265;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ANTIPSYCHOTICS;HSPG2;T;rs878949;TOXICITY;INCREASED_RISK;DISEASE:TARDIVE_DYSKINESIA
QUETIAPINE;RIMS1;CC + CT;rs502046;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:DISCONTINUATION
QUETIAPINE;RIMS1;CC + CT;rs502046;TOXICITY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:DISCONTINUATION
ETHANOL;TAS2R16;C;rs846664;OTHER;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL3;G;rs1139130;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
METHOTREXATE;C1orf167;GG + GT;rs1801131;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
METHOTREXATE;CLCN6;GG + GT;rs1801131;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
METHOTREXATE;MTHFR;GG + GT;rs1801131;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;T;rs6025;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOSIS
SORAFENIB;KDR;CT + TT;rs2239702;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
FLUOROURACIL;SCN1A;CC;rs3812718;OTHER;DECREASED;OTHER:TIME_TO_TUMOR_RECURRENCE_(TTR)
EFAVIRENZ;CYP2B6;GT + TT;rs3745274;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DISCONTINUATION
"""ACETAMINOPHEN""";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:PAIN
"""ANTIEPILEPTICS""";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:PAIN
"""ANTIINFLAMMATORY AGENTS";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:PAIN
"NON-STEROIDS""";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:PAIN
"""OPIOIDS""";OPRM1;CT + TT;rs510769;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:PAIN
WARFARIN;VKORC1;A;rs9934438;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_IN_THERAPEUTIC_RANGE
OPIOIDS;DRD2;A;rs1076560;TOXICITY;INCREASED_RISK;DISEASE:OPIOID-RELATED_DISORDERS
EFAVIRENZ;NR1I2;TT;rs2472677;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:DISCONTINUATION
EFAVIRENZ;CYP2B6;TT;rs3745274;EFFICACY;INCREASED_EFFICACY;EFFICACY:VIROLOGICAL_RESPONSE
CETUXIMAB;KRAS;T;rs112445441;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN;MTHFR;AA;rs1801133;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
CYCLOPHOSPHAMIDE;MTHFR;AA;rs1801133;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
DACTINOMYCIN;MTHFR;AA;rs1801133;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
DOXORUBICIN;MTHFR;AA;rs1801133;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
VINCRISTINE;MTHFR;AA;rs1801133;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
SORAFENIB;VEGFA;CG + GG;rs2010963;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
CISPLATIN;MTR;GG;rs1805087;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
CYCLOPHOSPHAMIDE;MTR;GG;rs1805087;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
DACTINOMYCIN;MTR;GG;rs1805087;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
DOXORUBICIN;MTR;GG;rs1805087;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
METHOTREXATE;MTR;GG;rs1805087;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
VINCRISTINE;MTR;GG;rs1805087;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
SORAFENIB;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERTENSION
SORAFENIB;VEGFA;AA + AG;rs1570360;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ATORVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY | MUSCULAR_DISEASES | RHABDOMYOLYSIS | TOXIC_LIVER_DISEASE
COCAINE;OPRM1;T;rs62638690;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:COCAINE_DEPENDENCE | HEROIN_DEPENDENCE
HEROIN;OPRM1;T;rs62638690;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:COCAINE_DEPENDENCE | HEROIN_DEPENDENCE
SORAFENIB;KDR;CT + TT;rs2239702;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
EFAVIRENZ;ABCB1;AA;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CENTRAL_NERVOUS_SYSTEM_DISORDER
CETUXIMAB;KRAS;A;rs112445441;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PANITUMUMAB;KRAS;A;rs112445441;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;CYP2C9;T;rs1799853;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOSIS
NO_DRUG_RELATED;MTR;GG;rs1805087;OTHER;INCREASED_LIKELIHOOD;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;MTR;GG;rs1805087;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METHOTREXATE-INDUCED_NODULOSIS
"""ACETAMINOPHEN""";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
"""ANTIEPILEPTICS""";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
"""ANTIINFLAMMATORY AGENTS";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
"NON-STEROIDS""";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
"""OPIOIDS""";OPRD1;AG + GG;rs2236861;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
PRAVASTATIN;SLCO1B1;CT;rs4149056;LADME_PK;INCREASED_PK;PK:AUC0-12
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;A;rs1799963;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOSIS
EFAVIRENZ;CYP2B6;TT;rs3745274;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DISCONTINUATION
FLUOROURACIL;SCN1A;TT;rs3812718;OTHER;DECREASED;OTHER:TIME_TO_TUMOR_RECURRENCE_(TTR)
ATAZANAVIR;UGT1A1;T;rs887829;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
SIMVASTATIN;SLCO1B1;CC;rs4363657;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULAR_DISEASES
EFAVIRENZ;CYP2B6;CC + CT;rs28399499;TOXICITY;DECREASED_RISK;SIDE_EFFECT:CENTRAL_NERVOUS_SYSTEM_DISORDER
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
TACROLIMUS;CYP3A5;CT;rs776746;TOXICITY;INCREASED_RISK;DISEASE:NEPHROTOXICITY
SIMVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:MUSCULAR_DISEASES
EFAVIRENZ;CYP2B6;CT + TT;rs4803419;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CENTRAL_NERVOUS_SYSTEM_DISORDER
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
FLUOROURACIL;DPYD;CT;rs1801160;LADME_PK;DECREASED_PK;PK:DPD_ACTIVITY
ALLOPURINOL;PSORS1C1;AG + GG;rs3131003;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
FLUOROURACIL;MTHFR;GG;rs1801133;EFFICACY;INCREASED;DISEASE:EVENT-FREE_SURVIVAL | OVERALL_SURVIVAL
OPIOIDS;PDYN;CT + TT;rs1997794;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:OPIOID-RELATED_DISORDERS
ONDANSETRON;ABCB1;GG;rs1045642;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
DEXMEDETOMIDINE;CYP2A6;GG;rs8192733;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA | HYPOTENSIVE_DISORDER
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
"""ACETAMINOPHEN""";OPRM1;AA;rs1799971;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PAIN
"""ANTIEPILEPTICS""";OPRM1;AA;rs1799971;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PAIN
"""ANTIINFLAMMATORY AGENTS";OPRM1;AA;rs1799971;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PAIN
"NON-STEROIDS""";OPRM1;AA;rs1799971;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PAIN
"""OPIOIDS""";OPRM1;AA;rs1799971;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PAIN
OPIOIDS;PDYN;CC;rs1022563;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:OPIOID-RELATED_DISORDERS
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RISPERIDONE;LEP;GG;rs7799039;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OBESITY
PERINDOPRIL;AGTR1;TT;rs5182;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:CARDIAC_EVENTS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)_AND_CHANGES_IN_VIRAL_LOAD_AFTER_4_WEEKS_OF_TREATMENT
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)_AND_CHANGES_IN_VIRAL_LOAD_AFTER_4_WEEKS_OF_TREATMENT
GEMCITABINE;CDA;AC + CC;rs2072671;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_NEUTROPENIA
CYTARABINE;CDA;GG;rs602950;EFFICACY;INCREASED_EFFICACY;EFFICACY:CYTOTOXICITY
CYTARABINE;CDA;GG;rs602950;LADME_PK;INCREASED_EFFICACY;EFFICACY:CYTOTOXICITY
HALOPERIDOL;CYP2D6;CC;rs3892097;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
CYTARABINE;CDA;TT;rs532545;EFFICACY;INCREASED_EFFICACY;EFFICACY:CYTOTOXICITY
CYTARABINE;CDA;TT;rs532545;LADME_PK;INCREASED_EFFICACY;EFFICACY:CYTOTOXICITY
ALLOPURINOL;CYCSP5;AA + AC;rs3099844;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
BISPHOSPHONATES;RBMS3;A;rs17024608;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:OSTEONECROSIS
NO_DRUG_RELATED;NEDD4L;AG;rs4149601;OTHER;INCREASED_RISK;DISEASE:CARDIOVASCULAR_DISEASE
FLUOROURACIL;DPYD;AC;rs55886062;LADME_PK;DECREASED_PK;PK:DPD_ACTIVITY
ANTIPSYCHOTICS;INSIG2;C;rs17587100;OTHER;INCREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
ONDANSETRON;ABCB1;CC;rs2032582;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
NO_DRUG_RELATED;CTLA4;A;rs3087243;OTHER;DECREASED_RISK;DISEASE:RHEUMATOID_ARTHRITIS
EPIRUBICIN;GCKR;CC + CT;rs780094;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FLUOROURACIL;GCKR;CC + CT;rs780094;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
OXALIPLATIN;GCKR;CC + CT;rs780094;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FLUOROURACIL;DPYD;CT;rs115232898;LADME_PK;DECREASED_PK;PK:DPD_ACTIVITY
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SOFOSBUVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SOFOSBUVIR;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
TENOFOVIR;ABCC4;G;rs1059751;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:KIDNEY_DISORDER
EPIRUBICIN;IGF2BP2;C;rs6769511;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DISEASE_PROGRESSION
FLUOROURACIL;IGF2BP2;C;rs6769511;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DISEASE_PROGRESSION
OXALIPLATIN;IGF2BP2;C;rs6769511;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DISEASE_PROGRESSION
WARFARIN;VKORC1;A;rs9934438;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
CYTARABINE;CDA;CC;rs2072671;EFFICACY;INCREASED_EFFICACY;EFFICACY:CYTOTOXICITY
CYTARABINE;CDA;CC;rs2072671;LADME_PK;INCREASED_EFFICACY;EFFICACY:CYTOTOXICITY
WARFARIN;VKORC1;A;rs9934438;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
ALLOPURINOL;NOTCH4;AA + AG;rs367398;TOXICITY;DECREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
EPIRUBICIN;KCNQ1;CC + GG;rs163182;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:DISEASE_PROGRESSION
FLUOROURACIL;KCNQ1;CC + GG;rs163182;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:DISEASE_PROGRESSION
OXALIPLATIN;KCNQ1;CC + GG;rs163182;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:DISEASE_PROGRESSION
NO_DRUG_RELATED;NQO1;AA;rs1800566;OTHER;DECREASED_LIKELIHOOD;OTHER:SURVIVAL
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;EFFICACY;EFFICACY:RAPID_VIRAL_RESPONSE_(RVR)_TO_PEG-IFN/RIBAVIRIN_THERAPY_AT_4_WEEKS_IN_HCV_GENOTYPE_3_PATIENTS
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;EFFICACY;EFFICACY:RAPID_VIRAL_RESPONSE_(RVR)_TO_PEG-IFN/RIBAVIRIN_THERAPY_AT_4_WEEKS_IN_HCV_GENOTYPE_3_PATIENTS
EPIRUBICIN;IGF2BP2;G;rs4402960;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:DISEASE_PROGRESSION
FLUOROURACIL;IGF2BP2;G;rs4402960;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:DISEASE_PROGRESSION
OXALIPLATIN;IGF2BP2;G;rs4402960;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:DISEASE_PROGRESSION
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
EFAVIRENZ;CYP2B6;GG;rs3745274;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:IMMUNOLOGICAL_FAILURE
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
CYCLOPHOSPHAMIDE;NQO1;AA;rs1800566;TOXICITY;DECREASED_LIKELIHOOD;OTHER:SURVIVAL
EPIRUBICIN;NQO1;AA;rs1800566;TOXICITY;DECREASED_LIKELIHOOD;OTHER:SURVIVAL
FLUOROURACIL;NQO1;AA;rs1800566;TOXICITY;DECREASED_LIKELIHOOD;OTHER:SURVIVAL
METHOTREXATE;SLCO1B1;AG + GG;rs2306283;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY | GASTROINTESTINAL_TOXICITY | TOXIC_LIVER_DISEASE,
EFAVIRENZ;CYP2B6;GT;rs3745274;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:SLEEP_DISORDERS
SUNITINIB;ABCB1;AA;rs1045642;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
VERAPAMIL;CACNA1C;AA;rs1051375;EFFICACY;DECREASED_RISK;OTHER:PRIMARY_OUTCOME
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEDIAN_SURVIVAL_TIME_(MST)
CISPLATIN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED_SEVERITY;DISEASE:THROMBOCYTOPENIA
IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED_SEVERITY;DISEASE:THROMBOCYTOPENIA
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME
SUNITINIB;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DIARRHEA
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
EFAVIRENZ;CYP2B6;GT;rs3745274;LADME_PK;INCREASED_PK;PK:PLASMA_LEVEL
CISPLATIN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED_SEVERITY;DISEASE:DIARRHEA
IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED_SEVERITY;DISEASE:DIARRHEA
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME
EFAVIRENZ;CYP2A6;AC + CC;rs28399433;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
NO_DRUG_RELATED;DRD2;AA + AG;rs1800497;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DEATH
EFAVIRENZ;CYP2B6;CC + CT;rs28399499;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
VERAPAMIL;CACNA1C;GG;rs1051375;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:PRIMARY_OUTCOME
EPIRUBICIN;GCKR;CC + CT;rs780093;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FLUOROURACIL;GCKR;CC + CT;rs780093;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
OXALIPLATIN;GCKR;CC + CT;rs780093;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
SIMVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DOSE_DECREASE_OR_SWITCH_TO_ANOTHER_CHOLESTEROL-LOWERING_DRUG
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DOSE_DECREASE_OR_SWITCH_TO_ANOTHER_CHOLESTEROL-LOWERING_DRUG_IN_USERS_WITH_A_STARTING_DOSE_OF_MORE_THAN_20_MG
CARBOPLATIN;nan;AG;rs12118636;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN;nan;AG;rs12118636;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
GEMCITABINE;nan;AG;rs12118636;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
CISPLATIN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
IRINOTECAN;UGT1A1;AA + AG;rs4148323;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
AZATHIOPRINE;NUDT15;TT;rs116855232;TOXICITY;nan;SIDE_EFFECT:ALOPECIA
MERCAPTOPURINE;NUDT15;TT;rs116855232;TOXICITY;nan;SIDE_EFFECT:ALOPECIA
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
ANTINEOPLASTIC AGENTS;ABCB1;AG;rs1045642;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NAUSEA
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEDIAN_SURVIAL_TIME
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
CARBOPLATIN;NRAS;CT;rs1065634;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN;NRAS;CT;rs1065634;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
GEMCITABINE;NRAS;CT;rs1065634;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
CARBOPLATIN;GPX5;AG + GG;rs451774;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN;GPX5;AG + GG;rs451774;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
GEMCITABINE;GPX5;AG + GG;rs451774;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
VINCRISTINE;ACTG1;A;rs1135989;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
ACENOCOUMAROL;VKORC1;T;rs9923231;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
WARFARIN;VKORC1;T;rs9923231;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
METHADONE;CYP2B6;GG;rs3745274;TOXICITY;INCREASED_SEVERITY;OTHER:NEONATAL_ABSTINENCE_SYNDROME
CARBOPLATIN;ATP7B;AA;rs1801249;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
TAXANES;ATP7B;AA;rs1801249;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
VINCRISTINE;CAPG;T;rs3770102;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
VALPROIC ACID;COL1A1;AA + AC;rs1800012;TOXICITY;DECREASED;SIDE_EFFECT:BONE_DENSITY
VINCRISTINE;ABCB1;A;rs4728709;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
DOXORUBICIN;AKR1C3;GG;rs1937840;OTHER;DECREASED;OTHER:ABSOLUTE_LEUCOCYTE_AND_NEUTROPHIL_COUNTS_ON_DAY_15
METHADONE;CYP2B6;AA;rs2279343;TOXICITY;INCREASED_SEVERITY;OTHER:NEONATAL_ABSTINENCE_SYNDROME
KETOPROFEN;CYP2C9;CC;rs1799853;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:DYSPEPSIA
ACENOCOUMAROL;VKORC1;T;rs9923231;EFFICACY;INCREASED;OTHER:TIME_TO_THERAPEUTIC_INR
WARFARIN;VKORC1;T;rs9923231;EFFICACY;INCREASED;OTHER:TIME_TO_THERAPEUTIC_INR
MYCOPHENOLATE MOFETIL;SLCO1B3;GG;rs4149117;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
REMIFENTANIL;OPRM1;GG;rs1799971;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
WARFARIN;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
MERCAPTOPURINE;ITPA;AA + AC;rs1127354;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION
CARBOPLATIN;GSR;CC;rs3594;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
TAXANES;GSR;CC;rs3594;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
ACENOCOUMAROL;APOE;C;rs429358;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
WARFARIN;APOE;C;rs429358;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
ETHANOL;SLC6A4;T;rs4251417;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
CARBOPLATIN;VEGFA;TT;rs6900017;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
TAXANES;VEGFA;TT;rs6900017;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
ACENOCOUMAROL;CYP2C9;C;rs1057910;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
WARFARIN;CYP2C9;C;rs1057910;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
METHYLPHENIDATE;COMT;AA + AG;rs4680;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
NALOXONE;OPRM1;G;rs1799971;EFFICACY;INCREASED_EFFICACY;EFFICACY:CORTISOL_RESPONSE
ETHANOL;SLC6A4;C;rs25531;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
INTERFERONS;VDR;AG + GG;rs2228570;TOXICITY;DECREASED_RISK;SIDE_EFFECT:CRYOGLOBULINEMIA
RIBAVIRIN;VDR;AG + GG;rs2228570;TOXICITY;DECREASED_RISK;SIDE_EFFECT:CRYOGLOBULINEMIA
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
EGFR INHIBITORS;PIK3CA;C;rs2677760;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DIARRHEA
CETUXIMAB;EGFR;AA + AG;rs2227983;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
EGFR INHIBITORS;PIK3CA;T;rs2459693;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DIARRHEA
IRINOTECAN;CES1;CC;rs7187684;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
METHOTREXATE;ATIC;GG;rs2372536;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ETHANOL;SLC6A4;A;rs2066713;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
CORTICOSTEROIDS;ADRB2;AA;rs1042713;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:EXACERBATIONS
SALMETEROL;ADRB2;AA;rs1042713;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:EXACERBATIONS
ANTIPSYCHOTICS;IL1B;AA + AG;rs4849127;TOXICITY;INCREASED;SIDE_EFFECT:WEIGHT_GAIN
BETA BLOCKING AGENTS;CYP2D6;GG;rs1065852;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA
FLUOROURACIL;DPYD;GG;rs1801265;LADME_PK;INCREASED_PK;PK:DPD_ACTIVITY
EGFR INHIBITORS;PIK3CA;C;rs6443624;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ANTIPSYCHOTICS;IL1B;AG;rs16944;TOXICITY;INCREASED;SIDE_EFFECT:WEIGHT_GAIN
DAUNORUBICIN;SLC28A3;A;rs885004;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:CARDIOTOXICITY
DOXORUBICIN;SLC28A3;A;rs885004;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:CARDIOTOXICITY
CYCLOSPORINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GINGIVAL_OVERGROWTH
EGFR INHIBITORS;PIK3CA;T;rs2677760;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CORTICOSTEROIDS;ADRB2;AA;rs1042713;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:UNCONTROLLED_ASTHMA
IRINOTECAN;CES1;AA + AG;rs2244614;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
EXEMESTANE;CYP19A1;AA;rs6493497;TOXICITY;DECREASED;SIDE_EFFECT:BONE_DENSITY
LETROZOLE;CYP19A1;AA;rs6493497;TOXICITY;DECREASED;SIDE_EFFECT:BONE_DENSITY
ANTIPSYCHOTICS;IL1B;AA;rs1143634;TOXICITY;DECREASED;SIDE_EFFECT:WEIGHT_GAIN
ANTIPSYCHOTICS;BDNF;CT + TT;rs6265;TOXICITY;DECREASED;SIDE_EFFECT:WEIGHT_GAIN
METHYLPHENIDATE;ADGRL3;CG + GG;rs2345039;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
DAUNORUBICIN;SLC28A3;A;rs7853758;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:CARDIOTOXICITY
DOXORUBICIN;SLC28A3;A;rs7853758;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:CARDIOTOXICITY
MERCAPTOPURINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION
WARFARIN;CYP2C9;T;rs1799853;EFFICACY;EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
CARBOPLATIN;ATP7B;TT;rs1061472;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
TAXANES;ATP7B;TT;rs1061472;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
IRINOTECAN;UGT1A1;AG;rs4148323;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
HMG COA REDUCTASE INHIBITORS;SLCO1B1;C;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;SUGCT;T;rs4379368;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOSIS
NO_DRUG_RELATED;FMO3;AG + GG;rs2266780;OTHER;DECREASED_SEVERITY;DISEASE:TOBACCO_USE_DISORDER
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;KNG1;C;rs710446;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOSIS
FLUOROURACIL;DPYD;AA;rs1801265;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
IRINOTECAN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ASPIRIN;LPA;CT;rs3798220;EFFICACY;DECREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
BOCEPREVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
BOCEPREVIR;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
TELAPREVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
TELAPREVIR;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
WARFARIN;CYP2C19;T;rs3814637;TOXICITY;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
FLUOROURACIL;DPYD;CT;rs72728438;LADME_PK;DECREASED_PK;PK:DPD_ACTIVITY
FLUOROURACIL;ABCC11;GG + GT;rs7194667;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
EGFR INHIBITORS;PIK3CA;C;rs2699905;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FLUOROURACIL;DPYD;CT;rs115632870;LADME_PK;DECREASED_PK;PK:DPD_ACTIVITY
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;ABO;del;rs56392308;TOXICITY;DECREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOSIS
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
ETHANOL;SLC6A3;AG;rs6350;TOXICITY;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;ABO;C;rs8176719;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOSIS
METHOTREXATE;SLCO1B1;TT;rs4149056;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;PROCR;G;rs9574;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOSIS
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F11;T;rs2289252;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOSIS
METHOTREXATE;SLCO1B1;AG + GG;rs2306283;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED;SIDE_EFFECT:INFECTIOUS_DISEASE | TOXIC_LIVER_DISEASE
DEXMEDETOMIDINE;NR1I2;CC;rs3814057;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA | HYPOTENSIVE_DISORDER
NO_DRUG_RELATED;MAOA;TT;rs1137070;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOBACCO_USE_DISORDER
NO_DRUG_RELATED;MAOB;CC;rs1799836;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOBACCO_USE_DISORDER
CAPECITABINE;nan;C;rs9936750;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
FLUOROURACIL;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED;SIDE_EFFECT:INFECTIOUS_DISEASE | NEPHROTOXICITY | TOXIC_LIVER_DISEASE,
DOXORUBICIN;ABCB1;A;rs1045642;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DOXORUBICIN;CBR3;A;rs1056892;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
CAPECITABINE;DPYD;T;rs3918290;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
FOLFIRI;UGT1A1;GG;rs4124874;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION
CAPECITABINE;DPYD;A;rs67376798;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
CETUXIMAB;EGF;GG;rs4444903;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:COMPLETE_PATHOLOGIC_RESPONSE
AFATINIB;UHRF1;TT;rs2261988;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
ERLOTINIB;UHRF1;TT;rs2261988;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
GEFITINIB;UHRF1;TT;rs2261988;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
NO_DRUG_RELATED;HAVCR2;AA + AC;rs10515746;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
NO_DRUG_RELATED;HAVCR2;AC + CC;rs1036199;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
AFATINIB;DVL2;AA;rs2074216;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
ERLOTINIB;DVL2;AA;rs2074216;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
GEFITINIB;DVL2;AA;rs2074216;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
GLATIRAMER ACETATE;nan;T;rs12459996;TOXICITY;INCREASED_RISK;DISEASE:CORONARY_ARTERY_DISEASE
WARFARIN;VKORC1;T;rs9923231;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
WARFARIN;VKORC1;T;rs9923231;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
FLUOROURACIL;OR10AE3P;A;rs10876844;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DIARRHEA
FLUOROURACIL;PSMB3P;A;rs10876844;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DIARRHEA
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
HEROIN;BDNF;TT;rs6265;OTHER;INCREASED_RISK;OTHER:ADDICTION
METHAMPHETAMINE;BDNF;T;rs6265;OTHER;INCREASED_RISK;OTHER:ADDICTION
DOXORUBICIN;ABCB1;C;rs2235047;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
PACLITAXEL;ABCB1;C;rs2235047;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
TRASTUZUMAB;ABCB1;C;rs2235047;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
DOXORUBICIN;CBR3;A;rs1056892;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
PACLITAXEL;CBR3;A;rs1056892;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
TRASTUZUMAB;CBR3;A;rs1056892;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
FENTANYL;OPRM1;T;rs540825;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
ASPIRIN;CYP4F2;AA;rs3093135;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
TICAGRELOR;CYP4F2;AA;rs3093135;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
CLOPIDOGREL;ABCB1;T;rs2032582;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
AFATINIB;NUP62;CC;rs9523;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
ERLOTINIB;NUP62;CC;rs9523;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
GEFITINIB;NUP62;CC;rs9523;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
NO_DRUG_RELATED;nan;GG;rs2207418;OTHER;INCREASED_RISK;DISEASE:DEATH
ALFENTANIL;OPRM1;GG;rs1799971;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:RESPIRATORY_INSUFFICIENCY
WARFARIN;CYP2C9;C;rs9332197;EFFICACY;EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
WARFARIN;CYP2C9;C;rs1057910;TOXICITY;RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
WARFARIN;CYP2C18;AG + GG;rs2901783;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
WARFARIN;F5;G;rs6018;TOXICITY;RISK;SIDE_EFFECT:HEMORRHAGE
WARFARIN;PROS1;AA;rs8178607;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
NO_DRUG_RELATED;CHRM3;GG;rs2165870;TOXICITY;INCREASED_RISK;DISEASE:POSTOPERATIVE_NAUSEA_AND_VOMITING
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
CISPLATIN;CDA;AA;rs2072671;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
GEMCITABINE;CDA;AA;rs2072671;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
CAPECITABINE;DPYD;G;rs1801265;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
DOXORUBICIN;GSTP1;GG;rs1695;TOXICITY;INCREASED;SIDE_EFFECT:MICRONUCLEATED_BINUCLEATED_CELLS
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
METHOTREXATE;MTHFR;TT;rs1801131;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
METHOTREXATE;MTHFR;GG;rs1801133;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;AG;rs1801274;EFFICACY;DECREASED_EFFICACY;EFFICACY:DISEASE_ACTIVITY_SCORE_28_IN_RHEUMATOID_ARTHRITIS
NO_DRUG_RELATED;SCN5A;GT + TT;rs7626962;OTHER;INCREASED_LIKELIHOOD;DISEASE:CARDIAC_RHYTHM_DISEASE
CARBOPLATIN;VEGFA;GG;rs879825;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
TAXANES;VEGFA;GG;rs879825;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
EXEMESTANE;ESR1;CT + TT;rs4870061;TOXICITY;DECREASED;SIDE_EFFECT:BONE_DENSITY
LETROZOLE;ESR1;CT + TT;rs4870061;TOXICITY;DECREASED;SIDE_EFFECT:BONE_DENSITY
METHOTREXATE;MTRR;AG + GG;rs1801394;LADME_PK;DECREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CARBOPLATIN;SCN10A;TT;rs9825762;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
TAXANES;SCN10A;TT;rs9825762;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
CARBOPLATIN;VEGFA;CC;rs9369421;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
TAXANES;VEGFA;CC;rs9369421;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
LETROZOLE;ESR1;TT;rs4870061;TOXICITY;DECREASED;SIDE_EFFECT:BONE_DENSITY
WARFARIN;CYP2C9;CC;rs1057910;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
METHOTREXATE;ABCC2;AA + AG;rs2273697;LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
EXEMESTANE;ESR1;TT;rs9322335;TOXICITY;DECREASED;SIDE_EFFECT:BONE_DENSITY
LETROZOLE;ESR1;TT;rs9322335;TOXICITY;DECREASED;SIDE_EFFECT:BONE_DENSITY
LETROZOLE;ESR1;TT;rs9322335;TOXICITY;DECREASED;SIDE_EFFECT:BONE_DENSITY
CISPLATIN;NQO1;AA;rs1800566;OTHER;DECREASED;OTHER:OVERALL_SURVIVAL
ETOPOSIDE;NQO1;AA;rs1800566;OTHER;DECREASED;OTHER:OVERALL_SURVIVAL
CISPLATIN;SLC22A2;AC;rs316019;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEPHROTOXICITY
LETROZOLE;ESR2;CC;rs10140457;TOXICITY;DECREASED;SIDE_EFFECT:BONE_DENSITY
EXEMESTANE;ESR1;AA;rs2813543;TOXICITY;DECREASED;SIDE_EFFECT:BONE_DENSITY
EXEMESTANE;CYP19A1;AA;rs6493497;TOXICITY;DECREASED;SIDE_EFFECT:BONE_DENSITY
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
BISPHOSPHONATES;nan;C;rs2736308;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS_OF_THE_JAW
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
BISPHOSPHONATES;nan;C;rs2736308;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS_OF_THE_JAW
ANTIINFLAMMATORY AGENTS;PTGS1;TT;rs10306135;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
NON-STEROIDS;PTGS1;TT;rs10306135;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
BEVACIZUMAB;DPYD;AT;rs67376798;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
CISPLATIN;DPYD;AT;rs67376798;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
DOCETAXEL;DPYD;AT;rs67376798;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
EPIRUBICIN;DPYD;AT;rs67376798;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
OXALIPLATIN;DPYD;AT;rs67376798;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
TRASTUZUMAB;DPYD;AT;rs67376798;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
CARBOPLATIN;TNF;A;rs1800629;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;TNF;A;rs1800629;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
SORAFENIB;KDR;CC;rs2305948;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
NO_DRUG_RELATED;COMT;AG + GG;rs4680;OTHER;DECREASED;OTHER:LENGTH_OF_HOSPITAL_STAY
CARBOPLATIN;PRRC2A;G;rs11229;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;PRRC2A;G;rs11229;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
CARBOPLATIN;PRRC2A;T;rs10885;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;PRRC2A;T;rs10885;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
METHADONE;COMT;AG + GG;rs4680;OTHER;DECREASED_LIKELIHOOD;OTHER:TREATMENT
MORPHINE;COMT;AG + GG;rs4680;OTHER;DECREASED_LIKELIHOOD;OTHER:TREATMENT
SORAFENIB;FLT1;TT;rs664393;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
SORAFENIB;KDR;AA;rs2071559;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
CARBOPLATIN;MSH5;T;rs3115672;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;MSH5;T;rs3115672;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
CYCLOPHOSPHAMIDE;ALDH1A1;AA + AG;rs13959;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA
DOXORUBICIN;ALDH1A1;AA + AG;rs13959;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA
FEC100;ALDH1A1;AA + AG;rs13959;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA
FLUOROURACIL;ALDH1A1;AA + AG;rs13959;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA
HMG COA REDUCTASE INHIBITORS;ATP2B1;T;rs17381194;TOXICITY;INCREASED_RISK;DISEASE:MYALGIA
CARBOPLATIN;DOCK8;A;rs10491684;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;DOCK8;A;rs10491684;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
HMG COA REDUCTASE INHIBITORS;nan;C;rs4693570;TOXICITY;INCREASED_RISK;DISEASE:MYALGIA
NO_DRUG_RELATED;EPO;A;rs1617640;OTHER;INCREASED;OTHER:ENDOGENOUS_LEVELS_OF_EPO
HMG COA REDUCTASE INHIBITORS;DMPK;G;rs672348;TOXICITY;INCREASED_RISK;DISEASE:MYALGIA
ASPIRIN;EYA1;T;rs12678747;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PEPTIC_ULCER_DISEASE
CARBOPLATIN;CYP2C8;A;rs1058932;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;CYP2C8;A;rs1058932;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
CARBOPLATIN;CYP2C8;A;rs11572078;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;CYP2C8;A;rs11572078;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
AZITHROMYCIN;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
CHLORPROMAZINE;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
CILOSTAZOL;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
CIPROFLOXACIN;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
CITALOPRAM;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
CLARITHROMYCIN;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
DOFETILIDE;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
DONEPEZIL;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
DRONEDARONE;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
ERYTHROMYCIN;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
ESCITALOPRAM;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
FLECAINIDE;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
FLUCONAZOLE;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
HALOPERIDOL;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
HYDROXYCHLOROQUINE;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
LEVOFLOXACIN;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
METHADONE;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
MOXIFLOXACIN;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
ONDANSETRON;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
OXALIPLATIN;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
PAPAVERINE;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
PENTAMIDINE;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
PROCAINAMIDE;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
PROPOFOL;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
QUINIDINE;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
SOTALOL;KCNE1;T;rs1805128;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
CARBOPLATIN;C6orf15;A;rs2233980;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;C6orf15;A;rs2233980;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
CARBOPLATIN;CDSN;T;rs3130985;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;CDSN;T;rs3130985;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
ETOPOSIDE;DYNC2H1;AG + GG;rs716274;EFFICACY;INCREASED_RISK;DISEASE:DEATH
PLATINUM COMPOUNDS;DYNC2H1;AG + GG;rs716274;EFFICACY;INCREASED_RISK;DISEASE:DEATH
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
METHADONE;OPRM1;AG + GG;rs1799971;OTHER;DECREASED_LIKELIHOOD;OTHER:TREATMENT
MORPHINE;OPRM1;AG + GG;rs1799971;OTHER;DECREASED_LIKELIHOOD;OTHER:TREATMENT
CYCLOPHOSPHAMIDE;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA | NEUTROPENIA | GASTROINTESTINAL_TOXICITY,
DOXORUBICIN;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA | NEUTROPENIA | GASTROINTESTINAL_TOXICITY,
FEC100;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA | NEUTROPENIA | GASTROINTESTINAL_TOXICITY,
FLUOROURACIL;NQO1;AA + AG;rs1800566;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA | NEUTROPENIA | GASTROINTESTINAL_TOXICITY,
ETOPOSIDE;YAP1;GT + TT;rs10895256;EFFICACY;INCREASED_RISK;DISEASE:DEATH
PLATINUM COMPOUNDS;YAP1;GT + TT;rs10895256;EFFICACY;INCREASED_RISK;DISEASE:DEATH
HMG COA REDUCTASE INHIBITORS;COQ2;A;rs6535454;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN_INTOLERANCE | DEFINED_PRIMARILY_THROUGH_MUSCLE_SYMPTOMATOLOGY
HMG COA REDUCTASE INHIBITORS;COQ2;G;rs4693075;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN_INTOLERANCE | DEFINED_PRIMARILY_THROUGH_MUSCLE_SYMPTOMATOLOGY
CARBOPLATIN;HLA-C;C;rs1049709;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;HLA-C;C;rs1049709;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
CARBOPLATIN;HCP5;G;rs3130907;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;HCP5;G;rs3130907;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
LENALIDOMIDE;CTNNB1;AA;rs4135385;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CARBOPLATIN;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
PACLITAXEL;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
CARBOPLATIN;SERPINC1;C;rs5877;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;SERPINC1;C;rs5877;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
IBRUTINIB;KCNQ1;AA;rs2237895;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIAC_RHYTHM_DISEASE | CARDIOTOXICITY
TAMOXIFEN;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
METHOTREXATE;SLC19A1;CC;rs1051266;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MUCOSITIS
NO_DRUG_RELATED;SCN5A;GG;rs7626962;OTHER;INCREASED_LIKELIHOOD;DISEASE:SUDDEN_INFANT_DEATH
LENALIDOMIDE;CTNNB1;AA;rs4533622;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CARBOPLATIN;nan;C;rs886423;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;nan;C;rs886423;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
CARBOPLATIN;nan;T;rs886424;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;nan;T;rs886424;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
BETA BLOCKING AGENTS;ADRB1;AG + GG;rs1801252;EFFICACY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CARBOPLATIN;ATAT1;C;rs9262132;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;ATAT1;C;rs9262132;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
SORAFENIB;VEGFA;GG;rs2010963;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SORAFENIB;VEGFA;GG;rs2010963;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
NO_DRUG_RELATED;ABO;GG;rs495828;LADME_PK;INCREASED;OTHER:ACE_ACTIVITY
CARBOPLATIN;PPP1R18;T;rs9262143;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;PPP1R18;T;rs9262143;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
NO_DRUG_RELATED;OPRM1;AG + GG;rs1799971;OTHER;DECREASED;OTHER:LENGTH_OF_HOSPITAL_STAY
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
SORAFENIB;nan;CC;rs4604006;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
IBRUTINIB;KCNQ1;GG;rs163182;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIAC_RHYTHM_DISEASE | CARDIOTOXICITY
CARBOPLATIN;MUCL3;A;rs3094086;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;MUCL3;A;rs3094086;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
OLANZAPINE;GIPR;AA;rs10423928;TOXICITY;INCREASED;SIDE_EFFECT:PLASMA_INSULIN_LEVELS
SORAFENIB;nan;CC;rs4604006;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
SORAFENIB;VEGFA;CC;rs25648;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ANTHRACYCLINES AND RELATED SUBSTANCES;nan;A;rs28714259;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
CYCLOSPORINE;CTLA4;A;rs231775;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GINGIVAL_OVERGROWTH
SORAFENIB;VEGFA;CC;rs833061;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
SORAFENIB;VEGFA;CC;rs699947;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
SORAFENIB;VEGFA;CC;rs25648;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FENTANYL;OPRM1;AG;rs9397685;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NAUSEA | VOMITING
SORAFENIB;VEGFA;CC;rs833061;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;EFFICACY;EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE
NO_DRUG_RELATED;ABCC4;AA + AC;rs2274407;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:PHYSICAL_AND_LIFE_WELL-BEING_QUALITY_OF_LIFE_(QOL)_SCALES
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME
WARFARIN;VKORC1;TT;rs9923231;DOSAGE;INCREASED_RISKEFFICACY;EFFICACY:OVER-ANTICOAGULATION
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:OVER-ANTICOAGULATION
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED_RISKEFFICACY;EFFICACY:OVER-ANTICOAGULATION
PAZOPANIB;HFE;TT;rs2858996;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PACLITAXEL;ABCB1;AA;rs1128503;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
NO_DRUG_RELATED;nan;GG;rs2207418;OTHER;INCREASED_RISK;DISEASE:HEART_FAILURE
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;DECREASED_PK;PK:TROUGH_CONCENTRATIONS
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;DECREASED_PK;PK:TROUGH_CONCENTRATIONS
GLATIRAMER ACETATE;nan;A;rs75041078;TOXICITY;INCREASED_RISK;DISEASE:CORONARY_ARTERY_DISEASE
GLATIRAMER ACETATE;nan;A;rs1056854;TOXICITY;INCREASED_RISK;DISEASE:CORONARY_ARTERY_DISEASE
METHAMPHETAMINE;GAD2;AG + GG;rs2236418;OTHER;INCREASED_LIKELIHOOD;DISEASE:METHAMPHETAMINE_DEPENDENCE | PSYCHOTIC_DISORDER | SUBSTANCE-RELATED_DISORDERS,
GLICLAZIDE;ABCC8;CC;rs757110;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
GLICLAZIDE;KCNJ11;CC;rs757110;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
GLYBURIDE;ABCC8;CC;rs757110;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
GLYBURIDE;KCNJ11;CC;rs757110;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
PEGINTERFERON ALFA-2A;IFNL3;AA + AC;rs4803217;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
PEGINTERFERON ALFA-2B;IFNL3;AA + AC;rs4803217;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
RIBAVIRIN;IFNL3;AA + AC;rs4803217;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
TACROLIMUS;ABCB1;CT + TT;rs2229109;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RENAL_TRANSPLANT_FAILURE
PEGINTERFERON ALFA-2A;IFNL3;CC;rs4803217;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;CC;rs4803217;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CC;rs4803217;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TRANSPLANT_REJECTION
FENTANYL;ABCB1;AA;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPOVENTILATION
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;DECREASED_PK;PK:TROUGH_LEVELS
TACROLIMUS;CYP3A5;CT + TT;rs776746;LADME_PK;DECREASED_PK;PK:TROUGH_LEVELS
AFATINIB;ARF1;GT + TT;rs11541557;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
ERLOTINIB;ARF1;GT + TT;rs11541557;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
GEFITINIB;ARF1;GT + TT;rs11541557;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;CT + TT;rs2031920;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
OSELTAMIVIR;ABCB1;AG + GG;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DEPRESSION | GASTRITIS | HYPERSENSITIVITY,
METHOTREXATE;ABCC3;AA + AT;rs9895420;TOXICITY;INCREASED;SIDE_EFFECT:PLASMA_LEVELS
METHOTREXATE;ABCC3;AA + AT;rs9895420;LADME_PK;INCREASED;SIDE_EFFECT:PLASMA_LEVELS
METHOTREXATE;ABCC3;AA + AT;rs9895420;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
COCAINE;OPRD1;T;rs678849;TOXICITY;DECREASED_RISK;OTHER:COCAINE_DEPENDENCE
CERIVASTATIN;RYR2;AA;rs2819742;TOXICITY;DECREASED_RISK;DISEASE:RHABDOMYOLYSIS
CYCLOPHOSPHAMIDE;nan;A;rs1891059;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
CYTARABINE;nan;A;rs1891059;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
DAUNORUBICIN;nan;A;rs1891059;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
DEXAMETHASONE;nan;A;rs1891059;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
DOXORUBICIN;nan;A;rs1891059;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
METHOTREXATE;nan;A;rs1891059;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
PEGASPARGASE;nan;A;rs1891059;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
PREDNISONE;nan;A;rs1891059;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
THIOGUANINE;nan;A;rs1891059;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
VINCRISTINE;nan;A;rs1891059;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
ANTIEPILEPTICS;ABCC2;A;rs2273697;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROBABILITY_OF_ANTIEPILEPTIC_DRUG_RESPONSE
METHOTREXATE;ABCC3;AA + AT;rs9895420;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RELAPSE_IN_THE_CENTRAL_NERVOUS_SYSTEM
NO_DRUG_RELATED;CYP1A2;T;rs35694136;OTHER;INCREASED_LIKELIHOOD;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE
ANTITHYMOCYTE GLOBULIN;FCGR3A;AC + CC;rs396991;OTHER;INCREASED;OTHER:SENSITIVE_TO_ANTILYMPHOCYTE_SERUM
CYCLOPHOSPHAMIDE;LINC00251;G;rs141059755;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
CYTARABINE;LINC00251;G;rs141059755;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
DAUNORUBICIN;LINC00251;G;rs141059755;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
DEXAMETHASONE;LINC00251;G;rs141059755;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
DOXORUBICIN;LINC00251;G;rs141059755;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
METHOTREXATE;LINC00251;G;rs141059755;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
PEGASPARGASE;LINC00251;G;rs141059755;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
PREDNISONE;LINC00251;G;rs141059755;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
THIOGUANINE;LINC00251;G;rs141059755;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
VINCRISTINE;LINC00251;G;rs141059755;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
CYCLOPHOSPHAMIDE;nan;C;rs17021408;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
CYTARABINE;nan;C;rs17021408;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
DAUNORUBICIN;nan;C;rs17021408;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
DEXAMETHASONE;nan;C;rs17021408;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
DOXORUBICIN;nan;C;rs17021408;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
METHOTREXATE;nan;C;rs17021408;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
PEGASPARGASE;nan;C;rs17021408;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
PREDNISONE;nan;C;rs17021408;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
THIOGUANINE;nan;C;rs17021408;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
VINCRISTINE;nan;C;rs17021408;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
PEGASPARGASE;ARHGAP28;T;rs9958628;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
CYCLOPHOSPHAMIDE;DOK5;A;rs117532069;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
CYTARABINE;DOK5;A;rs117532069;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
DAUNORUBICIN;DOK5;A;rs117532069;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
DEXAMETHASONE;DOK5;A;rs117532069;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
DOXORUBICIN;DOK5;A;rs117532069;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
METHOTREXATE;DOK5;A;rs117532069;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
PEGASPARGASE;DOK5;A;rs117532069;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
PREDNISONE;DOK5;A;rs117532069;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
THIOGUANINE;DOK5;A;rs117532069;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
VINCRISTINE;DOK5;A;rs117532069;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
CYCLOPHOSPHAMIDE;nan;G;rs80223967;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
CYTARABINE;nan;G;rs80223967;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
DAUNORUBICIN;nan;G;rs80223967;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
DEXAMETHASONE;nan;G;rs80223967;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
DOXORUBICIN;nan;G;rs80223967;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
METHOTREXATE;nan;G;rs80223967;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
PEGASPARGASE;nan;G;rs80223967;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
PREDNISONE;nan;G;rs80223967;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
THIOGUANINE;nan;G;rs80223967;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
VINCRISTINE;nan;G;rs80223967;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
CARBOPLATIN;ABCG2;CT + TT;rs3114020;EFFICACY;INCREASED_RISK;SIDE_EFFECT:DEATH
ETOPOSIDE;ABCG2;CT + TT;rs3114020;EFFICACY;INCREASED_RISK;SIDE_EFFECT:DEATH
IFOSFAMIDE;ABCG2;CT + TT;rs3114020;EFFICACY;INCREASED_RISK;SIDE_EFFECT:DEATH
THEOPHYLLINE;CYP1A2;T/del + TT;rs35694136;EFFICACY;INCREASED_SEVERITY;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE
THEOPHYLLINE;CYP1A2;T;rs35694136;EFFICACY;DECREASED_PK;PK:PLASMA_DRUG_LEVELS
THEOPHYLLINE;CYP1A2;T;rs35694136;LADME_PK;DECREASED_PK;PK:PLASMA_DRUG_LEVELS
NO_DRUG_RELATED;CYP1A2;C;rs762551;OTHER;INCREASED_LIKELIHOOD;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE
ETHAMBUTOL;ATP7B;CC;rs1061472;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ISONIAZID;ATP7B;CC;rs1061472;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PYRAZINAMIDE;ATP7B;CC;rs1061472;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RIFAMPIN;ATP7B;CC;rs1061472;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
VERAPAMIL;NR1H3;T;rs2279238;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION | STROKE
VERAPAMIL;NR1H3;A;rs12221497;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION | STROKE
NO_DRUG_RELATED;DDC;T;rs921451;nan;SEVERITY;DISEASE:TOBACCO_USE_DISORDER
ATENOLOL;NR1H3;G;rs11039149;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION | STROKE
VERAPAMIL;NR1H3;G;rs11039149;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION | STROKE
NO_DRUG_RELATED;DDC;C;rs3735273;nan;SEVERITY;DISEASE:TOBACCO_USE_DISORDER
SEVOFLURANE;KCNK2;CC + CG;rs6686529;EFFICACY;INCREASED_EFFICACY;EFFICACY:SEDATION
NO_DRUG_RELATED;DDC;T;rs1451371;nan;SEVERITY;DISEASE:TOBACCO_USE_DISORDER
CHOP;SLC35F4;CC;rs74832512;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
RITUXIMAB;SLC35F4;CC;rs74832512;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PROTEASE INHIBITORS;APOC3;CC + CT;rs2854116;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT:HYPERTRIGLYCERIDEMIA
VARENICLINE;CHRNB1;C;rs2302764;TOXICITY;INCREASED_SEVERITY;DISEASE:NAUSEA
VARENICLINE;ZBTB4;C;rs2302764;TOXICITY;INCREASED_SEVERITY;DISEASE:NAUSEA
PROTEASE INHIBITORS;APOC3;CT + TT;rs2854117;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:HYPERTRIGLYCERIDEMIA
VARENICLINE;CHRNB2;A;rs2072661;TOXICITY;INCREASED_SEVERITY;DISEASE:NAUSEA
CYCLOPHOSPHAMIDE;BMP7;T;rs79085477;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
CYTARABINE;BMP7;T;rs79085477;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
DAUNORUBICIN;BMP7;T;rs79085477;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
DEXAMETHASONE;BMP7;T;rs79085477;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
DOXORUBICIN;BMP7;T;rs79085477;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
METHOTREXATE;BMP7;T;rs79085477;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
PEGASPARGASE;BMP7;T;rs79085477;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
PREDNISONE;BMP7;T;rs79085477;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
THIOGUANINE;BMP7;T;rs79085477;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
VINCRISTINE;BMP7;T;rs79085477;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
VARENICLINE;CHRNB2;T;rs4292956;TOXICITY;INCREASED_SEVERITY;DISEASE:NAUSEA
VARENICLINE;CHRNB2;C;rs2072660;TOXICITY;INCREASED_SEVERITY;DISEASE:NAUSEA
CARBOPLATIN;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED_RISK;SIDE_EFFECT:DEATH
ETOPOSIDE;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED_RISK;SIDE_EFFECT:DEATH
IFOSFAMIDE;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED_RISK;SIDE_EFFECT:DEATH
AZATHIOPRINE;DDRGK1;A;rs1127354;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
AZATHIOPRINE;ITPA;A;rs1127354;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
MORPHINE;FAAH;AA;rs324420;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:RESPIRATORY_INSUFFICIENCY
CHOP;OXNAD1;TT;rs11721010;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
RITUXIMAB;OXNAD1;TT;rs11721010;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
MORPHINE;FAAH;TT;rs11576941;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
PROTEASE INHIBITORS;APOC3;CG + GG;rs5128;TOXICITY;DECREASED;SIDE_EFFECT:HYPERTRIGLYCERIDEMIA
SUNITINIB;ABCB1;AC;rs2032582;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
DOCETAXEL;SLCO1B3;G;rs11045585;TOXICITY;INCREASED_RISK;DISEASE:LEUKOPENIA
APIXABAN;ABCB1;CT + TT;rs4148738;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEMORRHAGE
DOCETAXEL;ABCC2;G;rs12762549;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
NO_DRUG_RELATED;DTNBP1;T;rs3213207;nan;DECREASED_RISK;DISEASE:BIPOLAR_DISORDER
ASPIRIN;ITGB3;CT;rs5918;OTHER;INCREASED;OTHER:SENSITIVITY_TO_ASPIRIN
CHOP;CIDEA;TT;rs75614943;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
RITUXIMAB;CIDEA;TT;rs75614943;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CYTARABINE;CDA;C/del + del/del;rs3215400;TOXICITY;INCREASED;DISEASE:DRUG_TOXICITY
METHAMPHETAMINE;BDNF;CC;rs6265;OTHER;INCREASED_LIKELIHOOD;DISEASE:SUBSTANCE-RELATED_DISORDERS
CHOP;NOS1;GG;rs77241831;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
RITUXIMAB;NOS1;GG;rs77241831;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
METHAMPHETAMINE;BDNF;CC;rs6265;OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT:PSYCHOTIC_DISORDER
CYTARABINE;CDA;AC + CC;rs2072671;TOXICITY;INCREASED;DISEASE:DRUG_TOXICITY
ANTIPSYCHOTICS;nan;GG + GT;rs9346455;TOXICITY;INCREASED;SIDE_EFFECT:WEIGHT_GAIN
NO_DRUG_RELATED;DTNBP1;T;rs3213207;nan;DECREASED_SEVERITY;OTHER:MANIC_SYMPTOMS_IN_PSYCHOSIS
SUFENTANIL;ABCB1;GG;rs1045642;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:POSTOPERATIVE_PAIN
NO_DRUG_RELATED;DTNBP1;C;rs2619539;nan;DECREASED_SEVERITY;OTHER:MANIC_SYMPTOMS_IN_PSYCHOSIS
CYTARABINE;CDA;AG + GG;rs602950;TOXICITY;INCREASED;DISEASE:DRUG_TOXICITY
HEROIN;OPRD1;C;rs2236857;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
CYTARABINE;CDA;CT + TT;rs532545;TOXICITY;INCREASED;DISEASE:DRUG_TOXICITY
HEROIN;OPRD1;A;rs2236855;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
SUNITINIB;ABCB1;AG;rs1128503;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
RIVAROXABAN;ABCB1;AA + AG;rs1045642;TOXICITY;DECREASED_RISK;SIDE_EFFECT:THROMBOEMBOLISM
HEROIN;OPRD1;C;rs3766951;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
NICOTINE;NRXN1;C;rs2193225;OTHER;nan;OTHER:SMOKING_QUANTITY
HEROIN;OPRD1;C;rs2298897;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
NICOTINE;NRXN1;C;rs2193225;OTHER;nan;OTHER:SMOKING_QUANTITY | HEAVINESS_OF_SMOKING_INDEX_AND_FAGERSTROM_TEST_FOR_NICOTINE_DEPENDENCE
NICOTINE;NRXN1;A;rs6721498;OTHER;nan;OTHER:SMOKING_QUANTITY | HEAVINESS_OF_SMOKING_INDEX_AND_FAGERSTROM_TEST_FOR_NICOTINE_DEPENDENCE
SUNITINIB;ABCB1;AG;rs1045642;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CHOP;nan;CC;rs1607795;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
RITUXIMAB;nan;CC;rs1607795;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SUFENTANIL;COMT;AA;rs4680;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:POSTOPERATIVE_PAIN
NO_DRUG_RELATED;DTNBP1;T;rs2619538;nan;DECREASED_SEVERITY;OTHER:MANIC_SYMPTOMS_IN_PSYCHOSIS
ETHANOL;FUT2;A;rs492602;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;FTO;A;rs9937709;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
PLATINUM;RICTOR;GG;rs6878291;TOXICITY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ANTIDEPRESSANTS;NR3C1;G;rs852977;EFFICACY;INCREASED_PK;PK:ANTIDEPRESSANT_RESPONSE
CERIVASTATIN;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED_RISK;DISEASE:RHABDOMYOLYSIS
PAROXETINE;HTR3B;AA;rs1176744;TOXICITY;INCREASED_RISK;DISEASE:NAUSEA
ETHANOL;nan;A;rs1783835;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
CHOP;TNIP3;CC;rs116665727;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
RITUXIMAB;TNIP3;CC;rs116665727;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CISPLATIN;APEX1;GG;rs1760944;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
FLUOROURACIL;APEX1;GG;rs1760944;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
RADIOTHERAPY;APEX1;GG;rs1760944;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
CHOP;IL10;AG + GG;rs1800871;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL | OVERALL_SURVIVAL
RITUXIMAB;IL10;AG + GG;rs1800871;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL | OVERALL_SURVIVAL
SUNITINIB;ABCB1;A;rs2032582;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CISPLATIN;MUTYH;CG + GG;rs3219489;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
FLUOROURACIL;MUTYH;CG + GG;rs3219489;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
RADIOTHERAPY;MUTYH;CG + GG;rs3219489;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ETHANOL;SLC4A8;C;rs12296477;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ASPIRIN;ITGB3;CC + CT;rs5918;OTHER;nan;OTHER:SHORTER_BLEEDING_TIME
NO_DRUG_RELATED;NR3C1;G;rs10482633;nan;INCREASED_EFFICACY;EFFICACY:ANTIDEPRESSANT_RESPONSE
ESCITALOPRAM;HTR2A;C;rs9316233;EFFICACY;INCREASED_EFFICACY;EFFICACY:ANTIDEPRESSANT_RESPONSE
ETHANOL;ARID4A;T;rs61974485;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;nan;T;rs8008020;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
NICOTINE;OPRM1;AG;rs1799971;TOXICITY;INCREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
ETHANOL;TNRC6A;A;rs72768626;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
GLIMEPIRIDE;NOS1AP;T;rs10494366;TOXICITY;INCREASED_RISK;OTHER:HYPOGLYCEMIA
GLIPIZIDE;NOS1AP;T;rs10494366;TOXICITY;INCREASED_RISK;OTHER:HYPOGLYCEMIA
GLYBURIDE;NOS1AP;T;rs10494366;TOXICITY;INCREASED_RISK;OTHER:HYPOGLYCEMIA
KETOROLAC;nan;CC;rs2562456;EFFICACY;EFFICACY;EFFICACY:SLOWER_ANALGESIC_ONSET_IN_EUROPEAN_AMERICANS_UNDERGOING_ORAL_SURGERY
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;DECREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
AZATHIOPRINE;ABCC1;CC + CG;rs2074087;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LYMPHOPENIA
FLUVASTATIN;SREBF1;CC;rs60282872;EFFICACY;INCREASED_EFFICACY;EFFICACY:APOLIPOPROTEIN_A1_AND_C3
BEVACIZUMAB;SLC19A1;G;rs1051298;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PEMETREXED;SLC19A1;G;rs1051298;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CISPLATIN;TP53;CG;rs1042522;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
RADIOTHERAPY;TP53;CG;rs1042522;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
NO_DRUG_RELATED;SLC30A8;C;rs13266634;OTHER;INCREASED;OTHER:BASELINE_PROINSULIN_LEVELS_AFTER_ADJUSTING_FOR_INSULIN_LEVELS
NO_DRUG_RELATED;SLC30A8;C;rs13266634;LADME_PK;INCREASED;OTHER:BASELINE_PROINSULIN_LEVELS_AFTER_ADJUSTING_FOR_INSULIN_LEVELS
OPIOIDS;OPRM1;AG + GG;rs1799971;DOSAGE;DECREASED_LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
ANTIINFLAMMATORY AGENTS;AGT;GG;rs943580;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
NON-STEROIDS;AGT;GG;rs943580;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
ANTIINFLAMMATORY AGENTS;MMP1;AG + GG;rs2071230;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
ANTIINFLAMMATORY AGENTS;MMP10;AG + GG;rs2071230;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
NON-STEROIDS;MMP1;AG + GG;rs2071230;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
NON-STEROIDS;MMP10;AG + GG;rs2071230;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
LEVONORGESTREL;ADAMTS10;CG;rs7255721;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
ANTIINFLAMMATORY AGENTS;MMP1;CT + TT;rs7945189;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
ANTIINFLAMMATORY AGENTS;MMP10;CT + TT;rs7945189;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
NON-STEROIDS;MMP1;CT + TT;rs7945189;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
NON-STEROIDS;MMP10;CT + TT;rs7945189;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
CITALOPRAM;HTR2A;AA;rs6313;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEART_PALPITATIONS
ANTIINFLAMMATORY AGENTS;PTGS1;TT;rs12353214;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
NON-STEROIDS;PTGS1;TT;rs12353214;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
ANTIINFLAMMATORY AGENTS;KL;CG + GG;rs211247;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
NON-STEROIDS;KL;CG + GG;rs211247;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
ANTIINFLAMMATORY AGENTS;CRP;CT + TT;rs1205;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
NON-STEROIDS;CRP;CT + TT;rs1205;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
NICOTINE;CHRNA4;AG;rs1044396;OTHER;INCREASED_LIKELIHOOD;OTHER:SMOKING_INITIATION
ANTIINFLAMMATORY AGENTS;CDKN2B-AS1;AA + AG;rs10757274;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
NON-STEROIDS;CDKN2B-AS1;AA + AG;rs10757274;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
NICOTINE;CHRNA4;GG;rs1044396;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER
ANTIINFLAMMATORY AGENTS;AGT;GG;rs699;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
NON-STEROIDS;AGT;GG;rs699;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
NICOTINE;CHRNA4;CC;rs1044397;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER
COXIBS;PTGS2;CG + GG;rs20417;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
COXIBS;PTGS2;AG + GG;rs4648276;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
SEVOFLURANE;FASTKD3;CC + CT;rs3733784;EFFICACY;INCREASED_EFFICACY;EFFICACY:VOL%_END-TIDAL_SEVOFLURANE_CONCENTRATION
SEVOFLURANE;MTRR;CC + CT;rs3733784;EFFICACY;INCREASED_EFFICACY;EFFICACY:VOL%_END-TIDAL_SEVOFLURANE_CONCENTRATION
HEROIN;OPRM1;A;rs524731;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
HEROIN;OPRM1;T;rs511435;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
HEROIN;OPRM1;G;rs495491;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
AZATHIOPRINE;ADK;TT;rs10824095;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
HEROIN;OPRM1;T;rs510769;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
CISPLATIN;ACYP2;A;rs1872328;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OTOTOXICITY
AZATHIOPRINE;SLC29A1;CG + GG;rs747199;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_EFFICACY;EFFICACY:ON-TREATMENT_PLATELET_AGGREGATION
AZATHIOPRINE;IMPDH2;AG + GG;rs11706052;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LYMPHOPENIA
HEROIN;OPRM1;C;rs3778151;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
AZATHIOPRINE;IMPDH1;CT + TT;rs2278294;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:LYMPHOPENIA
CLOZAPINE;SLC1A1;A;rs2228622;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OBSESSIVE-COMPULSIVE_SYMPTOMS
OLANZAPINE;SLC1A1;A;rs2228622;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OBSESSIVE-COMPULSIVE_SYMPTOMS
RISPERIDONE;SLC1A1;A;rs2228622;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OBSESSIVE-COMPULSIVE_SYMPTOMS
HEROIN;OPRM1;A;rs3823010;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
CLOZAPINE;SLC1A1;G;rs3780413;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OBSESSIVE-COMPULSIVE_SYMPTOMS
OLANZAPINE;SLC1A1;G;rs3780413;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OBSESSIVE-COMPULSIVE_SYMPTOMS
RISPERIDONE;SLC1A1;G;rs3780413;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OBSESSIVE-COMPULSIVE_SYMPTOMS
CLOZAPINE;SLC1A1;C;rs3780412;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OBSESSIVE-COMPULSIVE_SYMPTOMS
OLANZAPINE;SLC1A1;C;rs3780412;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OBSESSIVE-COMPULSIVE_SYMPTOMS
RISPERIDONE;SLC1A1;C;rs3780412;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OBSESSIVE-COMPULSIVE_SYMPTOMS
HEROIN;nan;A;rs9478495;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
NO_DRUG_RELATED;nan;G;rs9424490;nan;INCREASED_RISK;OTHER:CURRENT_SMOKING
NO_DRUG_RELATED;USH2A;C;rs12126638;nan;INCREASED_RISK;OTHER:CURRENT_SMOKING
NO_DRUG_RELATED;AK4;C;rs1109374;nan;INCREASED_RISK;OTHER:CURRENT_SMOKING
ASPIRIN;ITGA2;AA + AG;rs1062535;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RESIDUAL_PLATELET_REACTIVITY
CLOPIDOGREL;ITGA2;AA + AG;rs1062535;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RESIDUAL_PLATELET_REACTIVITY
NO_DRUG_RELATED;ITGB1;AA;rs1187075;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
HEROIN;OPRM1;C;rs562859;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
FLUOROURACIL;DPYD;T;rs3918290;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
LETROZOLE;nan;A;rs1324052;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN | ARTHRITIS | DISCONTINUATION,
PLATINUM;STMN1;AA;rs182455;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
VINORELBINE;STMN1;AA;rs182455;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
TEGAFUR;DPYD;TT;rs1801159;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
NO_DRUG_RELATED;ITGB1;GG;rs2230395;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
HEROIN;OPRM1;C;rs3778150;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
BEVACIZUMAB;GGH;G;rs3780126;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PEMETREXED;GGH;G;rs3780126;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
NO_DRUG_RELATED;TPH2;TT;rs1843809;OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT:AGGRESSION | DEPRESSION
ASPIRIN;ITGA2;CT + TT;rs1126643;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RESIDUAL_PLATELET_REACTIVITY
CLOPIDOGREL;ITGA2;CT + TT;rs1126643;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RESIDUAL_PLATELET_REACTIVITY
HEROIN;nan;C;rs9384169;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
ANTIPSYCHOTICS;CYP1A2;AC + CC;rs762551;TOXICITY;INCREASED;SIDE_EFFECT:QT_INTERVAL
PLATINUM COMPOUNDS;SLC22A2;AA + AC;rs316019;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
PLATINUM COMPOUNDS;SLC22A2;AA + AC;rs316019;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ANTIDEPRESSANTS;OPRM1;G;rs1799971;TOXICITY;INCREASED_RISK;OTHER:CARDIAC_ARREST | RESPIRATORY_INSUFFICIENCY
ANTIPSYCHOTICS;OPRM1;G;rs1799971;TOXICITY;INCREASED_RISK;OTHER:CARDIAC_ARREST | RESPIRATORY_INSUFFICIENCY
BENZODIAZEPINE DERIVATIVES;OPRM1;G;rs1799971;TOXICITY;INCREASED_RISK;OTHER:CARDIAC_ARREST | RESPIRATORY_INSUFFICIENCY
OPIOIDS;OPRM1;G;rs1799971;TOXICITY;INCREASED_RISK;OTHER:CARDIAC_ARREST | RESPIRATORY_INSUFFICIENCY
SYMPATHOMIMETICS;OPRM1;G;rs1799971;TOXICITY;INCREASED_RISK;OTHER:CARDIAC_ARREST | RESPIRATORY_INSUFFICIENCY
BEVACIZUMAB;GGH;CT;rs11545077;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PEMETREXED;GGH;CT;rs11545077;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DIGOXIN;NOS1AP;GG;rs10494366;TOXICITY;INCREASED;SIDE_EFFECT:SHORTENED_QT_INTERVAL
SUNITINIB;ABCB1;CC;rs2032582;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS | HAND-FOOT_SYNDROME | HYPERTENSION,
ASPIRIN;ITGA2;CT + TT;rs1126643;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION_AFTER_STIMULI_WITH_ADENOSINE_DIPHOSPHATE | COLLAGEN | AND_EPINEPHRINE
CLOPIDOGREL;ITGA2;CT + TT;rs1126643;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION_AFTER_STIMULI_WITH_ADENOSINE_DIPHOSPHATE | COLLAGEN | AND_EPINEPHRINE
FENTANYL;OPRM1;GG;rs1799971;DOSAGE;EFFICACY;EFFICACY:HIGHER_FENTANYL_DOSE_REQUIREMENT_TO_ACHIEVE_ADEQUATE_PAIN_RELIEF_IN_CHINESE_WOMEN_UNDERGOING_GYNECOLOGIC_SURGERY
CANNABINOIDS;OPRM1;G;rs1799971;TOXICITY;DECREASED_RISK;OTHER:SUBSTANCE-RELATED_DISORDERS
COCAINE;OPRM1;G;rs1799971;TOXICITY;DECREASED_RISK;OTHER:SUBSTANCE-RELATED_DISORDERS
ETHANOL;OPRM1;G;rs1799971;TOXICITY;DECREASED_RISK;OTHER:SUBSTANCE-RELATED_DISORDERS
NICOTINE;OPRM1;G;rs1799971;TOXICITY;DECREASED_RISK;OTHER:SUBSTANCE-RELATED_DISORDERS
OPIOIDS;OPRM1;G;rs1799971;TOXICITY;DECREASED_RISK;OTHER:SUBSTANCE-RELATED_DISORDERS
CAPECITABINE;MIR27A;CT;rs895819;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;MIR27A;CT;rs895819;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
SUNITINIB;FLT1;GG;rs7993418;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN;NFE2L2;GG + GT;rs6721961;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY
SUNITINIB;FLT1;CC;rs9582036;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
FENTANYL;OPRM1;AG + GG;rs1799971;DOSAGE;EFFICACY;EFFICACY:HIGHER_RESPONSIVENESS_TO_OPIOIDS_AND_REQUIRED_LESS_ANALGESIC_DRUGS_IN_LABORING_WOMEN
FENTANYL;OPRM1;AG + GG;rs1799971;EFFICACY;EFFICACY;EFFICACY:HIGHER_RESPONSIVENESS_TO_OPIOIDS_AND_REQUIRED_LESS_ANALGESIC_DRUGS_IN_LABORING_WOMEN
FLUVOXAMINE;HTR2A;CC + CT;rs6311;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_SIDE_EFFECTS
FENTANYL;OPRM1;AG + GG;rs1799971;EFFICACY;EFFICACY;EFFICACY:LESS_PAIN_CONTROL_IN_JAPANESE_PATIENTS_UNDERGOING_PAINFUL_OROFACIAL_COSMETIC_SURGERY
OLANZAPINE;FMO3;GG;rs2266780;LADME_PK;DECREASED_PK;PK:DOSE-ADJUSTED_SERUM_OLANZAPINE_N-OXIDE_CONCENTRATIONS
METOPROLOL;CYP2D6;T;rs3892097;EFFICACY;INCREASED_PK;PK:PLASMA_CONCENTRATIONS_OF_METOPROLOL_AND_GREATER_REDUCTIONS_IN_HEART_RATE | DIASTOLIC_BLOOD_PRESSURE | AND_MEAN_ARTERIAL_PRESSURE_IN_PMS_THAN_IN_NON-PMS.
METOPROLOL;CYP2D6;T;rs3892097;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATIONS_OF_METOPROLOL_AND_GREATER_REDUCTIONS_IN_HEART_RATE | DIASTOLIC_BLOOD_PRESSURE | AND_MEAN_ARTERIAL_PRESSURE_IN_PMS_THAN_IN_NON-PMS.
SUNITINIB;FLT1;AA;rs9554320;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESIDUAL_PLATELET_REACTIVITY
PLATINUM COMPOUNDS;CCN4;AA + AC;rs10956697;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
ASPIRIN;ITGB3;CC + CT;rs5918;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:THE_LACK_OF_ASPIRIN_EFFECT
SUNITINIB;FLT1;AA;rs9554320;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
OLANZAPINE;FMO1;AA + AC;rs12720462;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_SERUM_OLANZAPINE_CONCENTRATIONS
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
PLATINUM COMPOUNDS;ERCC1;CC;rs3212986;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ARIPIPRAZOLE;DRD2;CC;rs2514218;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PSYCHOMOTOR_AGITATION
PLATINUM COMPOUNDS;GSTP1;AA;rs1695;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMATOLOGICAL_TOXICITY
PLATINUM COMPOUNDS;GSTP1;AA;rs1695;LADME_PK;INCREASED_RISK;SIDE_EFFECT:HEMATOLOGICAL_TOXICITY
TAXANES;GSTP1;AA;rs1695;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMATOLOGICAL_TOXICITY
TAXANES;GSTP1;AA;rs1695;LADME_PK;INCREASED_RISK;SIDE_EFFECT:HEMATOLOGICAL_TOXICITY
PLATINUM;ABCB1;CC;rs2032582;TOXICITY;DECREASED_RISK;SIDE_EFFECT:GRADE_3_OR_4_GASTROINTESTINAL_TOXICITY
PLATINUM;ABCB1;CC;rs2032582;LADME_PK;DECREASED_RISK;SIDE_EFFECT:GRADE_3_OR_4_GASTROINTESTINAL_TOXICITY
TAXANES;ABCB1;CC;rs2032582;TOXICITY;DECREASED_RISK;SIDE_EFFECT:GRADE_3_OR_4_GASTROINTESTINAL_TOXICITY
TAXANES;ABCB1;CC;rs2032582;LADME_PK;DECREASED_RISK;SIDE_EFFECT:GRADE_3_OR_4_GASTROINTESTINAL_TOXICITY
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
CLOPIDOGREL;CYP2C19;A;rs4986893;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
SUNITINIB;FLT1;CC;rs9582036;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
OLANZAPINE;FMO1;CT + TT;rs7877;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_SERUM_OLANZAPINE_CONCENTRATIONS
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESIDUAL_PLATELET_REACTIVITY
BUMETANIDE;SLC12A3;C;rs1529927;EFFICACY;INCREASED_EFFICACY;EFFICACY:24-H_EXCRETION_OF_CHLORIDE_AND_POTASSIUM
FUROSEMIDE;SLC12A3;C;rs1529927;EFFICACY;INCREASED_EFFICACY;EFFICACY:24-H_EXCRETION_OF_CHLORIDE_AND_POTASSIUM
TORASEMIDE;SLC12A3;C;rs1529927;EFFICACY;INCREASED_EFFICACY;EFFICACY:24-H_EXCRETION_OF_CHLORIDE_AND_POTASSIUM
AMPHETAMINE;KAT2B;C;rs9829896;TOXICITY;DECREASED_RISK;OTHER:SUBSTANCE-RELATED_DISORDERS
CANNABINOIDS;KAT2B;C;rs9829896;TOXICITY;DECREASED_RISK;OTHER:SUBSTANCE-RELATED_DISORDERS
COCAINE;KAT2B;C;rs9829896;TOXICITY;DECREASED_RISK;OTHER:SUBSTANCE-RELATED_DISORDERS
OPIOIDS;KAT2B;C;rs9829896;TOXICITY;DECREASED_RISK;OTHER:SUBSTANCE-RELATED_DISORDERS
PACLITAXEL;EPHA5;TT;rs7349683;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
IMATINIB;ABCG2;TT;rs2231142;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ASPIRIN;NAT2;C;rs4271002;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTOLERANCE
OPIOIDS;OPRM1;AG + GG;rs1799971;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA
METHADONE;ARRB2;AA;rs3786047;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NONRESPONSE_TO_METHADONE_MAINTENANCE_TREATMENT
BUMETANIDE;SCNN1G;G;rs5723;EFFICACY;DECREASED_EFFICACY;EFFICACY:24-H_EXCRETION_OF_CALCIUM_AND_DECREASED_URINARY_VOLUME
FUROSEMIDE;SCNN1G;G;rs5723;EFFICACY;DECREASED_EFFICACY;EFFICACY:24-H_EXCRETION_OF_CALCIUM_AND_DECREASED_URINARY_VOLUME
TORASEMIDE;SCNN1G;G;rs5723;EFFICACY;DECREASED_EFFICACY;EFFICACY:24-H_EXCRETION_OF_CALCIUM_AND_DECREASED_URINARY_VOLUME
PLATINUM COMPOUNDS;CCN4;GG + GT;rs2929973;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ENALAPRIL;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:COUGH
ANTIPSYCHOTICS;HTR2A;TT;rs6311;TOXICITY;INCREASED_RISK;DISEASE:TARDIVE_DYSKINESIA
METHADONE;ARRB2;CC;rs1045280;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NONRESPONSE_TO_METHADONE_MAINTENANCE_TREATMENT
METHADONE;MYOCD;AA + AG;rs1714984;EFFICACY;EFFICACY;EFFICACY:INCREASED_RISK_OF_BEING_NONRESPONDERS
METHADONE;ARRB2;GG;rs2036657;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NONRESPONSE_TO_METHADONE_MAINTENANCE_TREATMENT
BUMETANIDE;SCNN1G;A;rs5729;EFFICACY;DECREASED_EFFICACY;EFFICACY:24-H_EXCRETION_OF_CALCIUM_AND_DECREASED_URINARY_VOLUME
FUROSEMIDE;SCNN1G;A;rs5729;EFFICACY;DECREASED_EFFICACY;EFFICACY:24-H_EXCRETION_OF_CALCIUM_AND_DECREASED_URINARY_VOLUME
TORASEMIDE;SCNN1G;A;rs5729;EFFICACY;DECREASED_EFFICACY;EFFICACY:24-H_EXCRETION_OF_CALCIUM_AND_DECREASED_URINARY_VOLUME
ANTIPSYCHOTICS;CYP1A2;CC;rs762551;TOXICITY;INCREASED_RISK;DISEASE:TARDIVE_DYSKINESIA
ANTIPSYCHOTICS;CYP2D6;A;rs1065852;TOXICITY;INCREASED_RISK;DISEASE:TARDIVE_DYSKINESIA
OLANZAPINE;HTR2C;C;rs518147;TOXICITY;DECREASED_RISK;DISEASE:WEIGHT_GAIN
PRAVASTATIN;CETP;AG;rs708272;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:CORONARY_ARTERY_DISEASE
ATORVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;INCREASED_EFFICACY;EFFICACY:BENEFIT
ASPIRIN;ITGB3;TT;rs5918;EFFICACY;EFFICACY;EFFICACY:ASPIRIN-DEPRESSED_THROMBIN_GENERATION_AND_PROLONGED_BLEEDING_TIME_AFTER_ASPIRIN
ASPIRIN;F13A1;AA + AC;rs5985;EFFICACY;INCREASED_EFFICACY;EFFICACY:INHIBITION_OF_FXIII_ACTIVATION_BY_ASPIRIN
VERAPAMIL;ADRB1;CC + CG;rs1801253;EFFICACY;INCREASED_RISK;DISEASE:DEATH
AZATHIOPRINE;ITPA;C;rs1127354;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:TRANSPLANT_REJECTION
CHOP;NCF4;GG;rs1883112;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
RITUXIMAB;NCF4;GG;rs1883112;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
IVACAFTOR;CFTR;AA + AG;rs75527207;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT:BONE_DENSITY
CHOP;ABCG2;CC;rs2231137;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
RITUXIMAB;ABCG2;CC;rs2231137;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PRAVASTATIN;CETP;GG;rs708272;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_LUMINAL_DIAMETER
AMIODARONE;NOS1AP;T;rs10800397;TOXICITY;nan;SIDE_EFFECT:DRUG-INDUCED_VENTRICULAR_ARRHYTHMIA_AND_QT_PROLONGATION
DIURETICS;NOS1AP;T;rs10800397;TOXICITY;nan;SIDE_EFFECT:DRUG-INDUCED_VENTRICULAR_ARRHYTHMIA_AND_QT_PROLONGATION
SOTALOL;NOS1AP;T;rs10800397;TOXICITY;nan;SIDE_EFFECT:DRUG-INDUCED_VENTRICULAR_ARRHYTHMIA_AND_QT_PROLONGATION
ANTIPSYCHOTICS;nan;CT + TT;rs6977820;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TARDIVE_DYSKINESIA
AMIODARONE;NOS1AP;T;rs10800397;TOXICITY;nan;SIDE_EFFECT:AMIODARONE-INDUCED_VENTRICULAR_ARRHYTHMIA_AND_QT_PROLONGATION
WARFARIN;VKORC1;T;rs17880887;DOSAGE;EFFICACY;EFFICACY:LOWER_LEVELS_OF_TRANSTHYRETIN_PRECUROR
AMIODARONE;NOS1AP;T;rs10919035;TOXICITY;nan;SIDE_EFFECT:AMIODARONE-INDUCED_VENTRICULAR_ARRHYTHMIA_AND_QT_PROLONGATION
ASPIRIN;HNMT;G;rs1050891;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ACETYLSALICYLIC_ACID-INTOLERANT_CHRONIC_URTICARIA
AMIODARONE;NOS1AP;T;rs10919035;TOXICITY;nan;SIDE_EFFECT:AMIODARONE-INDUCED_VENTRICULAR_ARRHYTHMIA_AND_QT_PROLONGATION
ASPIRIN;LTC4S;AC + CC;rs730012;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SENSITIVITY_TO_ASPIRIN
ANTIPSYCHOTICS;SMYD3;T;rs2485914;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TARDIVE_DYSKINESIA
ETHAMBUTOL;NAT2;TT;rs1799929;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATOTOXICTY
ISONIAZID;NAT2;TT;rs1799929;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATOTOXICTY
PYRAZINAMIDE;NAT2;TT;rs1799929;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATOTOXICTY
RIFAMPIN;NAT2;TT;rs1799929;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATOTOXICTY
ETHAMBUTOL;NAT2;CC;rs1799929;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEPATOTOXICTY
ISONIAZID;NAT2;CC;rs1799929;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEPATOTOXICTY
PYRAZINAMIDE;NAT2;CC;rs1799929;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEPATOTOXICTY
RIFAMPIN;NAT2;CC;rs1799929;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEPATOTOXICTY
CYTARABINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:COMPLETE_REMISSION
IDARUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:COMPLETE_REMISSION
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE_REQUIREMENTS_ON_DAY_14
LEVONORGESTREL;TP53;CG;rs1042522;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
ASPIRIN;GP6;AG;rs1613662;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_TO_ASPIRIN
CISPLATIN;ERCC2;CT + TT;rs1799793;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
DOXORUBICIN;ERCC2;CT + TT;rs1799793;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
IFOSFAMIDE;ERCC2;CT + TT;rs1799793;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
METHOTREXATE;ERCC2;CT + TT;rs1799793;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
CYTARABINE;ABCB1;GG;rs1045642;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:3-YEAR_EVENT_FREE_SURVIVAL
IDARUBICIN;ABCB1;GG;rs1045642;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:3-YEAR_EVENT_FREE_SURVIVAL
CISPLATIN;ERCC2;GG;rs13181;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
CISPLATIN;KLC3;GG;rs13181;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
DOXORUBICIN;ERCC2;GG;rs13181;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
DOXORUBICIN;KLC3;GG;rs13181;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
IFOSFAMIDE;ERCC2;GG;rs13181;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
IFOSFAMIDE;KLC3;GG;rs13181;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
METHOTREXATE;ERCC2;GG;rs13181;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
METHOTREXATE;KLC3;GG;rs13181;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;DOSAGE;EFFICACY;EFFICACY:8.3%_HIGHER_MEAN_DAILY_COUMARIN_DOSE_TO_REACH_A_STABLE_INTERNATIONAL_NORMALIZED_RATIO_(INR)
PHENPROCOUMON;CYP4F2;CT + TT;rs2108622;DOSAGE;EFFICACY;EFFICACY:8.3%_HIGHER_MEAN_DAILY_COUMARIN_DOSE_TO_REACH_A_STABLE_INTERNATIONAL_NORMALIZED_RATIO_(INR)
WARFARIN;CYP4F2;CT + TT;rs2108622;DOSAGE;EFFICACY;EFFICACY:8.3%_HIGHER_MEAN_DAILY_COUMARIN_DOSE_TO_REACH_A_STABLE_INTERNATIONAL_NORMALIZED_RATIO_(INR)
ASPIRIN;ITGB3;CT;rs5918;TOXICITY;INCREASED;SIDE_EFFECT:BLOOD_LOSS
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA | THROMBOCYTOPENIA
SUNITINIB;KDR;C;rs2305948;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
CAPECITABINE;GSTP1;GG;rs1695;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
EPIRUBICIN;GSTP1;GG;rs1695;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PLATINUM;GSTP1;GG;rs1695;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;INCREASED_EFFICACY;EFFICACY:ON-CLOPIDOGREL_PLATELET_REACTIVITY_(HPR)
NO_DRUG_RELATED;ITGB3;CC + CT;rs5918;OTHER;nan;OTHER:SHORTER_BLEEDING_TIME
BETA BLOCKING AGENTS;GRK5;AA;rs2230345;OTHER;INCREASED_RISK;OTHER:DEATH
FENTANYL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PAIN
HYDROMORPHONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PAIN
OXYCODONE;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PAIN
CLOPIDOGREL;PON1;CT + TT;rs662;EFFICACY;INCREASED_EFFICACY;EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION
BEVACIZUMAB;CXCR4;AA + AG;rs2228014;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
BETA BLOCKING AGENTS;ADRB1;CC;rs1801253;OTHER;DECREASED_RISK;OTHER:DEATH
DOCETAXEL;PPCDC;G;rs147451859;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:AMENORRHEA
FEC100;PPCDC;G;rs147451859;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:AMENORRHEA
GEMCITABINE;PPCDC;G;rs147451859;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:AMENORRHEA
TRASTUZUMAB;PPCDC;G;rs147451859;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:AMENORRHEA
ZOLEDRONATE;PPCDC;G;rs147451859;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:AMENORRHEA
SUNITINIB;FLT4;GG;rs6877011;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:DISEASE_PROGRESSION
HALOPERIDOL;ABCB5;CT;rs17143212;TOXICITY;INCREASED;SIDE_EFFECT:DRUG_TOXICITY
DOCETAXEL;nan;G;rs17587029;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:AMENORRHEA
FEC100;nan;G;rs17587029;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:AMENORRHEA
GEMCITABINE;nan;G;rs17587029;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:AMENORRHEA
TRASTUZUMAB;nan;G;rs17587029;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:AMENORRHEA
ZOLEDRONATE;nan;G;rs17587029;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:AMENORRHEA
SUNITINIB;ABCG2;T;rs2231142;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
OPIOIDS;CNIH3;A;rs10799590;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
AZATHIOPRINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
MERCAPTOPURINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
SUNITINIB;VEGFA;CT + TT;rs3025039;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
ANTIPSYCHOTICS;CYP1A2;CC;rs762551;TOXICITY;INCREASED_SEVERITY;DISEASE:TARDIVE_DYSKINESIA
METHOTREXATE;MTHFR;A;rs1801133;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CISPLATIN;SLC22A2;A;rs316019;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OTOTOXICITY
SUNITINIB;CYP3A4;AA + AG;rs4646437;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERTENSION
ATORVASTATIN;ABCB1;C;rs2032582;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
"""ACE INHIBITORS";F5;CT + TT;rs6025;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
"PLAIN""";F5;CT + TT;rs6025;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
"""ANGIOTENSIN II ANTAGONISTS""";F5;CT + TT;rs6025;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
CISPLATIN;NFE2L2;T;rs6721961;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OTOTOXICITY
CARVEDILOL;ADRB2;CC;rs1042714;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:IMPROVED_LEFT_VENTRICULAR_EJECTION_FRACTION
TACROLIMUS;FOXP3;GT + TT;rs3761548;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
TACROLIMUS;CYP3A4;CC + CT;rs2740574;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DIABETES_MELLITUS
METHOTREXATE;RAVER2;A;rs72675408;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
PHENYTOIN;CYP2C9;C;rs1057910;EFFICACY;INCREASED_RISK;SIDE_EFFECT:ATAXIA | DIPLOPIA | DIZZINESS | DYSARTHRIA
PHENYTOIN;CYP2C9;T;rs1799853;EFFICACY;INCREASED_RISK;SIDE_EFFECT:ATAXIA | DIPLOPIA | DIZZINESS | DYSARTHRIA
CAPECITABINE;PPARD;T;rs2016520;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;PPARD;T;rs2016520;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
EFAVIRENZ;CYP2B6;CT + TT;rs8192719;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
NO_DRUG_RELATED;SULT1A1;CC + CT;rs1801030;OTHER;INCREASED_LIKELIHOOD;DISEASE:HOT_FLASHES
NO_DRUG_RELATED;SULT1A2;CC + CT;rs1801030;OTHER;INCREASED_LIKELIHOOD;DISEASE:HOT_FLASHES
OPIOIDS;MCOLN1;A;rs116181528;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:OVERDOSE
CERIVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
HMG COA REDUCTASE INHIBITORS;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
NO_DRUG_RELATED;AKT1;CC;rs2494732;OTHER;INCREASED_LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER
CAPECITABINE;MTHFR;GG;rs1801131;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE_REQUIREMENTS_ON_DAY_14
BEVACIZUMAB;KCNAB1;G;rs6770663;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERTENSION
WARFARIN;VKORC1;A;rs9934438;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE_REQUIREMENTS_ON_DAY_14
CYCLOPHOSPHAMIDE;GSTP1;AA + AG;rs1695;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:TOXICITY
EPIRUBICIN;GSTP1;AA + AG;rs1695;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:TOXICITY
ASPIRIN;CEP68;AA;rs7572857;TOXICITY;INCREASED;SIDE_EFFECT:DECLINE_OF_FORCED_EXPIRATORY_VOLUME_IN_1S_(FEV(1))_BY_ASPIRIN_PROVOCATION
OPIOIDS;MCOLN1;T;rs114077267;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:OVERDOSE
ACENOCOUMAROL;VKORC1;TT;rs9923231;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
PLATINUM COMPOUNDS;MDM2;GT + TT;rs2279744;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
SUNITINIB;FLT3;AG + GG;rs1933437;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
ASPIRIN;ITGB3;CT;rs5918;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_INHIBITION_BY_ASPIRIN
NO_DRUG_RELATED;SLC2A9;AG;rs62293298;OTHER;DECREASED_LIKELIHOOD;OTHER:HYPERURICEMIA
EFAVIRENZ;CYP2B6;GG;rs2279343;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
ASPIRIN;TLR3;CT + TT;rs3775291;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-EXACERBATED_RESPIRATORY_DISEASE
EFAVIRENZ;CYP2B6;CC + CT;rs2279345;LADME_PK;DECREASED_PK;PK:PLASMA_CONCENTRATION
OPIOIDS;MCOLN1;G;rs115208233;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:OVERDOSE
TACROLIMUS;CYP3A4;CC + CT;rs2740574;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:ACUTE_CELLULAR_REJECTION
NICOTINE;DRD2;AA + AG;rs1800497;TOXICITY;INCREASED;SIDE_EFFECT:CRAVING
NICOTINE;DRD2;GG;rs1800497;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:CRAVING
WARFARIN;VKORC1;CC;rs2884737;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE_REQUIREMENTS_ON_DAY_14
PEGINTERFERON ALFA-2A;IL6;CC;rs1800795;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IL6;CC;rs1800795;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IL6;CC;rs1800795;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
NO_DRUG_RELATED;ABCG2;GT + TT;rs2231142;OTHER;INCREASED_LIKELIHOOD;OTHER:HYPERURICEMIA
ACENOCOUMAROL;CYP2C9;AG;rs72558189;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
WARFARIN;CYP2C9;AG;rs72558189;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
TELBIVUDINE;TK2;CC + CT;rs3826160;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION
SUNITINIB;FLT1;CC;rs9582036;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE_REQUIREMENTS_ON_DAY_14
NO_DRUG_RELATED;SLC22A12;CT;rs3825017;OTHER;INCREASED_LIKELIHOOD;OTHER:HYPERURICEMIA
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
WARFARIN;CYP4F2;CT + TT;rs2108622;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
SUNITINIB;CYP1A1;C;rs1048943;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA | MUCOSITIS
OLANZAPINE;DRD2;T;rs2440390;TOXICITY;INCREASED;DISEASE:WEIGHT_GAIN
PRAVASTATIN;ADAMTS1;GG;rs428785;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:FATAL_CORONARY_DISEASE_OR_NONFATAL_MYOCARDIAL_INFARCTION
OLANZAPINE;HTR2C;G;rs6318;TOXICITY;INCREASED;DISEASE:WEIGHT_GAIN
CAFFEINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:NEURAL_TUBE_DEFECTS
OLANZAPINE;HTR2C;C;rs2497538;TOXICITY;INCREASED;DISEASE:WEIGHT_GAIN
OLANZAPINE;HTR2C;G;rs1414334;TOXICITY;INCREASED;DISEASE:WEIGHT_GAIN
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
PIOGLITAZONE;LPL;CG + GG;rs328;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESPONSE_RATE_AFTER_10_WEEKS_OF_PIOGLITAZONE_TREATMENT
PACLITAXEL;EPHA5;CT + TT;rs7349683;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
NO_DRUG_RELATED;SCN1A;T;rs3812718;OTHER;INCREASED_RISK;DISEASE:SEIZURES | FEBRILE
NO_DRUG_RELATED;UGT1A1;AA + AG;rs4148323;OTHER;INCREASED_SEVERITY;OTHER:NEONATAL_HYPERBILIRUBINEMIA | HYPERBILIRUBINEMIA
NO_DRUG_RELATED;CHRNA5;A;rs16969968;OTHER;INCREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
PACLITAXEL;ABCB1;AG + GG;rs3213619;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
VERAPAMIL;NOS1AP;GG;rs10494366;TOXICITY;INCREASED_RISK;SIDE_EFFECT:QTC_PROLONGATION
MERCAPTOPURINE;PACSIN2;TT;rs2413739;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
NO_DRUG_RELATED;nan;A;rs1051730;OTHER;INCREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
NO_DRUG_RELATED;CYP2R1;A;rs12794714;OTHER;INCREASED_LIKELIHOOD;OTHER:VITAMIN_D_DEFICIENCY
OLANZAPINE;ABCB1;AA;rs1045642;EFFICACY;INCREASED_EFFICACY;EFFICACY:SOCIAL_AND_CLINICAL_NEEDS
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SIMEPREVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SIMEPREVIR;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
ETHAMBUTOL;NAT2;A;rs1799930;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;A;rs1799930;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;A;rs1799930;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;A;rs1799930;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
NO_DRUG_RELATED;CYP2R1;A;rs10741657;OTHER;DECREASED_LIKELIHOOD;OTHER:VITAMIN_D_DEFICIENCY
ETHAMBUTOL;NAT2;T;rs1799929;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;T;rs1799929;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;T;rs1799929;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;T;rs1799929;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
PAROXETINE;HTR1A;GG;rs6295;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_AT_4_WEEKS_AFTER_THE_INITIATION_OF_TREATMENT
TAMOXIFEN;E2F7;CC;rs310786;TOXICITY;INCREASED;SIDE_EFFECT:LUMBAR_BONE_LOSS
ALENDRONATE;DKK1;AA;rs2241529;EFFICACY;DECREASED_EFFICACY;EFFICACY:BONE_DENSITY
CLOPIDOGREL;CES1;G;rs8192950;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:TRANSIENT_ISCHEMIC_ATTACK | STROKE
ANTIPSYCHOTICS;DRD2;GG;rs1799732;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SIDE_EFFECTS
SUNITINIB;KDR;CC;rs2305948;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
WARFARIN;CYP2C9;C;rs4918758;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE_REQUIREMENT_IN_MECHANICAL_HEART_VALVE_REPLACEMENT_PATIENTS
SUNITINIB;VEGFA;CC;rs3025039;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
OLANZAPINE;ANKK1;GG;rs1800497;OTHER;DECREASED_PK;PK:AREA_UNDER_THE_CURVE_FROM_BASELINE_TO_THE_LAST_MEASURED_CONCENTRATION
EXEMESTANE;ESR1;CC;rs9322336;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_TOXICITY
WARFARIN;CYP2C9;T;rs9332096;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE_REQUIREMENT_IN_MECHANICAL_HEART_VALVE_REPLACEMENT_PATIENTS
OLANZAPINE;ANKK1;GG;rs1800497;OTHER;DECREASED;OTHER:PEAK_PLASMA_CONCENTRATION_OF_INCREASED_PROLACTIN
SUNITINIB;VEGFA;G;rs2010963;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERTENSION
SUNITINIB;FLT4;C;rs6877011;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
OLANZAPINE;GSTP1;AA;rs1695;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:SYNCOPE
SUNITINIB;NR1I2;TT;rs2276707;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;OTHER:WARFARIN_DOSE
ANTHRACYCLINES AND RELATED SUBSTANCES;HAS3;AA;rs2232228;TOXICITY;INCREASED_RISK;DISEASE:CARDIOMYOPATHIES
WARFARIN;VKORC1;T;rs9923231;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
SUNITINIB;FLT3;AG + GG;rs1933437;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
NORTRIPTYLINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ORTHOSTATIC_HYPOTENSION
WARFARIN;VKORC1;A;rs2359612;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
MORPHINE;OPRM1;GG;rs1799971;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE
OXYCODONE;OPRM1;GG;rs1799971;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE
MORPHINE;COMT;GG;rs4680;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE
OXYCODONE;COMT;GG;rs4680;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE
CARBAMAZEPINE;HNF4A;GG;rs2071197;EFFICACY;INCREASED_PK;PK:CONCENTRATION-TO-DOSE_RATIOS
WARFARIN;VKORC1;G;rs8050894;DOSAGE;DECREASED;OTHER:WARFARIN_DOSE
PRAVASTATIN;MTHFR;GG;rs1801133;EFFICACY;DECREASED_LIKELIHOOD;DISEASE:CORONARY_ARTERY_DISEASE | MYOCARDIAL_INFARCTION
SUNITINIB;ABCB1;AA;rs1128503;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
SUNITINIB;VEGFA;CC + CT;rs833061;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
CYCLOSPORINE;IMPDH2;AG + GG;rs11706052;EFFICACY;INCREASED_RISK;DISEASE:TRANSPLANT_REJECTION
MYCOPHENOLATE MOFETIL;IMPDH2;AG + GG;rs11706052;EFFICACY;INCREASED_RISK;DISEASE:TRANSPLANT_REJECTION
CYCLOSPORINE;TNF;AA + AG;rs1800629;EFFICACY;INCREASED_RISK;DISEASE:TRANSPLANT_REJECTION
MYCOPHENOLATE MOFETIL;TNF;AA + AG;rs1800629;EFFICACY;INCREASED_RISK;DISEASE:TRANSPLANT_REJECTION
METHOTREXATE;MTHFR;GG;rs1801131;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
CYCLOSPORINE;IL10;TT;rs1800872;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TRANSPLANT_REJECTION
MYCOPHENOLATE MOFETIL;IL10;TT;rs1800872;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TRANSPLANT_REJECTION
SUNITINIB;ABCB1;AA + AT;rs2032582;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TRANSIENT_ISCHEMIC_ATTACK | STROKE
SUNITINIB;VEGFA;G;rs2010963;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
NICOTINE;CHRNA5;A;rs16969968;OTHER;INCREASED_SEVERITY;OTHER:SMOKING
NICOTINE;CHRNA5;A;rs16969968;OTHER;INCREASED_SEVERITY;OTHER:SMOKING
NO_DRUG_RELATED;CHRNA5;A;rs16969968;OTHER;INCREASED_LIKELIHOOD;DISEASE:SCHIZOPHRENIA
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
CLOPIDOGREL;N6AMT1;GG;rs2254638;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:THROMBOCYTOPENIA | TOXIC_LIVER_DISEASE
NICOTINE;GALR1;CT + TT;rs2717162;OTHER;INCREASED_SEVERITY;OTHER:CRAVING
CAPECITABINE;DPYD;A;rs67376798;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
FLUOROURACIL;DPYD;A;rs67376798;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
CAPECITABINE;DPYD;T;rs3918290;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
FLUOROURACIL;DPYD;T;rs3918290;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
ERYTHROMYCIN;SLCO1B1;C;rs4149056;LADME_PK;DECREASED_PK;PK:ERYTHROMYCIN_METABOLISM
PAZOPANIB;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
SIMVASTATIN;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
GENTAMICIN;MT-RNR1;G;rs267606617;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OTOTOXICITY
CYCLOSPORINE;LEP;A;rs2167270;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DIABETES_MELLITUS
TACROLIMUS;LEP;A;rs2167270;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DIABETES_MELLITUS
ERLOTINIB;ABCB1;AA;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ERLOTINIB;ABCB1;AA;rs1045642;LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
MERCAPTOPURINE;NUDT15;GT;rs73189762;DOSAGE;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
ETHANOL;HTR3B;C;rs1176744;OTHER;INCREASED_LIKELIHOOD;DISEASE:ALCOHOL_ABUSE
CLOPIDOGREL;CYP2C19;T;rs12248560;TOXICITY;DECREASED;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MUCOSITIS
METHOTREXATE;ADORA2A;G;rs5760410;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
METHOTREXATE;SPECC1L;G;rs5760410;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
CALCIUM CHANNEL BLOCKERS;KCNH2;AA + AG;rs1137617;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
NITRENDIPINE;KCNH2;AA + AG;rs1137617;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
CLOPIDOGREL;KDR;CC;rs7667298;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ANGINA_PECTORIS
METHOTREXATE;MTHFR;G;rs1801131;EFFICACY;INCREASED_RISK;DISEASE:GRAFT_VS_HOST_DISEASE
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;DECREASED_RISK;DISEASE:GRAFT_VS_HOST_DISEASE
NICOTINE;GALR1;CT + TT;rs2717162;OTHER;INCREASED_SEVERITY;OTHER:CRAVING
ANTINEOPLASTIC AGENTS;CLCN6;GG;rs1801133;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
ANTINEOPLASTIC AGENTS;MTHFR;GG;rs1801133;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
IRINOTECAN;UGT1A1;AG;rs4148323;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
NO_DRUG_RELATED;MTHFR;G;rs1801131;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
BUSULFAN;MTHFR;AA;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
CYCLOPHOSPHAMIDE;MTHFR;AA;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
ERLOTINIB;ABCB1;AA;rs1128503;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ERLOTINIB;ABCB1;AA;rs1128503;LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
METHOTREXATE;MTHFR;GG;rs1801131;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:RELAPSE
CLOPIDOGREL;KDR;TT;rs2305948;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGINA_PECTORIS | MYOCARDIAL_INFARCTION
METHOTREXATE;ABCB1;GG;rs1128503;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MUCOSITIS
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
METHOTREXATE;MTHFR;GG;rs1801131;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ORAL_MUCOSITIS
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
ERLOTINIB;ABCB1;AA;rs2032582;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ERLOTINIB;ABCB1;AA;rs2032582;LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
PACLITAXEL;ARHGEF10;C;rs9657362;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
NO_DRUG_RELATED;FKBP5;CC + CT;rs1360780;nan;INCREASED_RISK;OTHER:POST-TRAUMATIC_STRESS_DISORDER_(PTSD)
NO_DRUG_RELATED;FKBP5;AA + AC;rs3800373;OTHER;INCREASED_RISK;DISEASE:ADHD
PACLITAXEL;ARHGEF10;C;rs9657362;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
NO_DRUG_RELATED;TBX21;A;rs17244587;nan;INCREASED_RISK;DISEASE:MAJOR_DEPRESSIVE_DISORDER
NO_DRUG_RELATED;PSMB4;T;rs2296840;OTHER;INCREASED_RISK;DISEASE:MAJOR_DEPRESSIVE_DISORDER
METFORMIN;SLC22A1;A;rs34059508;DOSAGE;INCREASED_PK;PK:BIOAVAILABILITY
METFORMIN;SLC22A1;A;rs34059508;LADME_PK;INCREASED_PK;PK:BIOAVAILABILITY
METFORMIN;SLC22A1;C;rs12208357;DOSAGE;INCREASED_PK;PK:BIOAVAILABILITY_(AUC | CL_&_AUC/CL_RATIO)
METFORMIN;SLC22A1;C;rs12208357;LADME_PK;INCREASED_PK;PK:BIOAVAILABILITY_(AUC | CL_&_AUC/CL_RATIO)
CLOPIDOGREL;CYP2C19;T;rs12248560;TOXICITY;INCREASED_RISK;SIDE_EFFECT:BLEEDING_EVENTS
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DEATH
NO_DRUG_RELATED;CHRNA5;C;rs680244;OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
METHOTREXATE;PTPN22;AA;rs2476601;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
NO_DRUG_RELATED;CHRNA3;G;rs1051730;nan;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
METHOTREXATE;TNFAIP3;A;rs6920220;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
NO_DRUG_RELATED;CHRNA3;G;rs578776;nan;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
NO_DRUG_RELATED;CHRNA5;G;rs578776;nan;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
SUNITINIB;ABCG2;TT;rs2231142;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
NO_DRUG_RELATED;CHRNA5;A;rs16969968;nan;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
RISPERIDONE;ABCB1;AA;rs1045642;LADME_PK;INCREASED_SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA
NO_DRUG_RELATED;CHRNA5;C;rs569207;nan;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
CARBAMAZEPINE;CYP1A1;A;rs2606345;EFFICACY;INCREASED_RISK;DISEASE:SEIZURES
CARBAMAZEPINE;CYP1A1;A;rs2606345;LADME_PK;INCREASED_RISK;DISEASE:SEIZURES
PHENOBARBITAL;CYP1A1;A;rs2606345;EFFICACY;INCREASED_RISK;DISEASE:SEIZURES
PHENOBARBITAL;CYP1A1;A;rs2606345;LADME_PK;INCREASED_RISK;DISEASE:SEIZURES
PHENYTOIN;CYP1A1;A;rs2606345;EFFICACY;INCREASED_RISK;DISEASE:SEIZURES
PHENYTOIN;CYP1A1;A;rs2606345;LADME_PK;INCREASED_RISK;DISEASE:SEIZURES
VALPROIC ACID;CYP1A1;A;rs2606345;EFFICACY;INCREASED_RISK;DISEASE:SEIZURES
VALPROIC ACID;CYP1A1;A;rs2606345;LADME_PK;INCREASED_RISK;DISEASE:SEIZURES
NO_DRUG_RELATED;SLCO1B3;C;rs2417940;OTHER;INCREASED_SEVERITY;OTHER:NEONATAL_HYPERBILIRUBINEMIA | HYPERBILIRUBINEMIA
SERTRALINE;nan;G;rs13432159;TOXICITY;INCREASED;SIDE_EFFECT:GENERAL_SIDE-EFFECTS
HMG COA REDUCTASE INHIBITORS;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
TAMOXIFEN;CYP2D6;TT;rs3892097;EFFICACY;INCREASED_EFFICACY;EFFICACY:DISEASE_FREE_SURVIVAL
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
TAMOXIFEN;CYP2D6;TT;rs3892097;EFFICACY;DECREASED_EFFICACY;EFFICACY:DISEASE_FREE_SURVIVAL
TAMOXIFEN;CYP2D6;TT;rs3892097;EFFICACY;DECREASED_EFFICACY;EFFICACY:RELAPSE_FREE_TIME
NO_DRUG_RELATED;KIF6;AG + GG;rs20455;OTHER;INCREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
PEGINTERFERON ALFA-2B;ITPA;A;rs1127354;TOXICITY;DECREASED;SIDE_EFFECT:ANEMIA
RIBAVIRIN;ITPA;A;rs1127354;TOXICITY;DECREASED;SIDE_EFFECT:ANEMIA
ROSUVASTATIN;GATM;AA + AG;rs9806699;TOXICITY;DECREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
TAMOXIFEN;CYP2D6;T;rs3892097;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
HMG COA REDUCTASE INHIBITORS;SLCO1B1;CC + CT;rs4363657;TOXICITY;DECREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
PEGINTERFERON ALFA-2B;ITPA;C;rs7270101;TOXICITY;DECREASED;SIDE_EFFECT:ANEMIA
RIBAVIRIN;ITPA;C;rs7270101;TOXICITY;DECREASED;SIDE_EFFECT:ANEMIA
IRINOTECAN;UGT1A1;AA;rs4148323;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
FLUOROURACIL;GSTP1;AA;rs1695;TOXICITY;INCREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES | NEUTROPENIA
IRINOTECAN;GSTP1;AA;rs1695;TOXICITY;INCREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES | NEUTROPENIA
OXALIPLATIN;GSTP1;AA;rs1695;TOXICITY;INCREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES | NEUTROPENIA
PRAVASTATIN;IL1B;GG;rs16944;OTHER;INCREASED;OTHER:CORONARY_FLOW_RESERVE
HMG COA REDUCTASE INHIBITORS;nan;G;rs116561224;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NO_DRUG_RELATED;KCNH2;T;rs3815459;OTHER;INCREASED;OTHER:QT_INTERVAL
FENOFIBRATE;nan;C;rs114577328;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
SERTRALINE;nan;C;rs114577328;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TERBINAFINE;nan;C;rs114577328;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TICLOPIDINE;nan;C;rs114577328;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ANTIDEPRESSANTS;HTR2A;CC;rs17288723;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
NO_DRUG_RELATED;KCNH2;CT + TT;rs3807375;OTHER;INCREASED;OTHER:QT_INTERVAL
CITALOPRAM;GRIK4;C;rs1954787;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:NON-RESPONSE
NO_DRUG_RELATED;KCNH2;GT + TT;rs1805123;OTHER;INCREASED;OTHER:QT_INTERVAL
CYCLOSPORINE;NR1I2;C;rs2276707;DOSAGE;DECREASED_PK;PK:BIOAVAILABILITY
CYCLOSPORINE;NR1I2;C;rs2276707;LADME_PK;DECREASED_PK;PK:BIOAVAILABILITY
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;CT + TT;rs1799929;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;AA + AG;rs1799930;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PLATINUM COMPOUNDS;GSTP1;G;rs1695;TOXICITY;DECREASED_RISK;DISEASE:NEUTROPENIA
PLATINUM COMPOUNDS;GSTP1;G;rs1695;LADME_PK;DECREASED_RISK;DISEASE:NEUTROPENIA
CLOZAPINE;nan;T;rs149104283;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;AA + AG;rs1799931;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NO_DRUG_RELATED;KCNH2;G;rs1805123;OTHER;DECREASED;OTHER:QT_INTERVAL
ASPARAGINASE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CYCLOPHOSPHAMIDE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
DAUNORUBICIN;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PREDNISOLONE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
VINCRISTINE;PNPLA3;CG + GG;rs738409;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
NO_DRUG_RELATED;KCNH2;T;rs3807375;OTHER;INCREASED;OTHER:QT_INTERVAL
OXALIPLATIN;GSTP1;GG;rs1695;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES
NO_DRUG_RELATED;KCNQ1;G;rs757092;OTHER;INCREASED;OTHER:QT_INTERVAL
NO_DRUG_RELATED;KCNH2;T;rs3815459;OTHER;INCREASED;OTHER:QT_INTERVAL
PRAVASTATIN;IL1B;GG;rs16944;OTHER;INCREASED;OTHER:ADENOSINE-STIMULATED_MYOCARDIAL_FLOW
NO_DRUG_RELATED;VEGFA;CG + GG;rs2010963;OTHER;INCREASED_RISK;OTHER:PREMATURE_BIRTH
NO_DRUG_RELATED;KCNH2;GG;rs1805123;OTHER;DECREASED;OTHER:QT_INTERVAL
NO_DRUG_RELATED;KCNQ1;G;rs757092;OTHER;INCREASED;OTHER:QT_INTERVAL
OXALIPLATIN;GSTP1;AA;rs1695;TOXICITY;INCREASED_SEVERITY;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
OXALIPLATIN;GSTP1;AA;rs1695;LADME_PK;INCREASED_SEVERITY;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
METHOTREXATE;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:INFECTIOUS_DISEASE
CYCLOSPORINE;NR1I2;T;rs2276707;DOSAGE;INCREASED_PK;PK:BIOAVAILABILITY
CYCLOSPORINE;NR1I2;T;rs2276707;LADME_PK;INCREASED_PK;PK:BIOAVAILABILITY
RIFAMPIN;NR1I2;TT;rs3814055;OTHER;INCREASED_PK;PK:ERYTHROMYCIN_BREATH_TEST
PLATINUM COMPOUNDS;CCN4;CC + CT;rs2977549;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CITALOPRAM;HTR2A;AA;rs7997012;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE
TACROLIMUS;CYP3A4;CC + TT;rs2740574;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
TACROLIMUS;CYP3A4;CC + TT;rs2740574;LADME_PK;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
CITALOPRAM;HTR2A;A;rs7997012;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE
TACROLIMUS;CYP3A5;T;rs776746;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
TACROLIMUS;CYP3A5;T;rs776746;LADME_PK;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
CYCLOSPORINE;NR1I2;C;rs3814055;DOSAGE;DECREASED_PK;PK:BIOAVAILABILTY
CYCLOSPORINE;NR1I2;C;rs3814055;LADME_PK;DECREASED_PK;PK:BIOAVAILABILTY
ASPIRIN;MYOM2;CC + CT;rs17064642;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CLOPIDOGREL;MYOM2;CC + CT;rs17064642;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
ANTIDEPRESSANTS;HTR2A;G;rs7997012;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
CITALOPRAM;HTR2A;A;rs7997012;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE
SUFENTANIL;COMT;AA + AG;rs4680;DOSAGE;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN
ANTIDEPRESSANTS;GRIK4;CC;rs1954787;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
SUFENTANIL;OPRM1;AG + GG;rs1799971;DOSAGE;DECREASED_SEVERITYEFFICACY;EFFICACY:PAIN
ANTIDEPRESSANTS;GRIK4;GG;rs12800734;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
PRAVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;DECREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
NO_DRUG_RELATED;KIF6;AG + GG;rs20455;OTHER;INCREASED_RISK;DISEASE:CORONARY_DISEASE
PRAVASTATIN;SLCO1B1;G;rs2306283;LADME_PK;DECREASED_PK;PK:PLASMA_AUC
PRAVASTATIN;SLCO1B1;AG;rs4149015;OTHER;INCREASED_PK;PK:AUC0-12
PRAVASTATIN;SLCO1B1;AG;rs4149015;LADME_PK;INCREASED_PK;PK:AUC0-12
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
PLATINUM COMPOUNDS;CCN4;CC + CT;rs2977551;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
FLUOROURACIL;TP53;GG;rs1042522;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PEGINTERFERON ALFA-2A;ITPA;AC + CC;rs6051702;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ANEMIA
RIBAVIRIN;ITPA;AC + CC;rs6051702;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ANEMIA
NICOTINE;CHRNA3;GG;rs578776;TOXICITY;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
NICOTINE;CHRNA5;GG;rs578776;TOXICITY;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
NICOTINE;CHRNA4;AA;rs1044396;TOXICITY;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
NICOTINE;CHRNA4;CC;rs2229959;TOXICITY;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;COMT;T;rs13306278;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;TXNRD2;T;rs13306278;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
PRAVASTATIN;TLR4;AG + GG;rs4986790;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:CARDIOVASCULAR_EVENTS
PHENPROCOUMON;VKORC1;TT;rs9923231;EFFICACY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;G;rs267606617;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OTOTOXICITY
PEGINTERFERON ALFA-2A;VDR;TT;rs1544410;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
RIBAVIRIN;VDR;TT;rs1544410;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
PHENPROCOUMON;VKORC1;TT;rs9923231;TOXICITY;INCREASED;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE
FLUOROURACIL;IGFBP3;CC;rs2854746;EFFICACY;nan;OTHER:BETTER_SURVIVAL_OUTCOME
PHENPROCOUMON;VKORC1;TT;rs9923231;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
PLATINUM COMPOUNDS;GSTP1;AA;rs1695;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DYING
PLATINUM COMPOUNDS;ERCC2;GG;rs13181;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DYING
PLATINUM COMPOUNDS;KLC3;GG;rs13181;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DYING
PHENPROCOUMON;EPHX1;CC;rs1051740;TOXICITY;INCREASED;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE
PLATINUM COMPOUNDS;ERCC1;AA;rs11615;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DYING
CLOPIDOGREL;ABCB1;AA;rs2032582;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
PLATINUM COMPOUNDS;GSTP1;AA;rs1695;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DISEASE_PROGRESSION
CARBOPLATIN;NR1I2;TT;rs1523130;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
PACLITAXEL;NR1I2;TT;rs1523130;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
CETUXIMAB;EGF;AA;rs4444903;EFFICACY;INCREASED_EFFICACY;EFFICACY:SURVIVAL
CARBOPLATIN;NR1I2;CC;rs1523127;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
PACLITAXEL;NR1I2;CC;rs1523127;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
IRINOTECAN;UGT1A1;AA + AG;rs10929302;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
CARBOPLATIN;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
PACLITAXEL;SLCO1B3;GT + TT;rs4149117;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
NICOTINE;CHRNA4;G;rs1044396;OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
CISPLATIN;LRP2;T;rs2075252;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
CETUXIMAB;EGF;AA;rs4444903;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CAPECITABINE;CDA;C/del + CC;rs3215400;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CLOPIDOGREL;POR;GG;rs2286823;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
SUNITINIB;POR;TT;rs1057868;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SUNITINIB;SLCO1B3;GG;rs4149117;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
METHOTREXATE;SLC19A1;CC + CT;rs1051266;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
PHENPROCOUMON;VKORC1;TT;rs9923231;TOXICITY;INCREASED;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE
CAPECITABINE;CDA;T;rs532545;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:HAND-FOOT_SYNDROME
CLOPIDOGREL;CES1P1;AC + CC;rs3785161;EFFICACY;INCREASED_EFFICACY;EFFICACY:ON-TREATMENT_PLATELET_ACTIVITY
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
METHOTREXATE;ATIC;G;rs2372536;nan;SEVERITY;DISEASE:RHEUMATOID_ARTHRITIS
LEUCOVORIN;FASTKD3;GG;rs1801394;TOXICITY;INCREASED_SEVERITY;DISEASE:STOMATITIS
LEUCOVORIN;MTRR;GG;rs1801394;TOXICITY;INCREASED_SEVERITY;DISEASE:STOMATITIS
TEGAFUR;FASTKD3;GG;rs1801394;TOXICITY;INCREASED_SEVERITY;DISEASE:STOMATITIS
TEGAFUR;MTRR;GG;rs1801394;TOXICITY;INCREASED_SEVERITY;DISEASE:STOMATITIS
CAPECITABINE;DPYD;A;rs67376798;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
LEUCOVORIN;UMPS;CC;rs1801019;TOXICITY;INCREASED_SEVERITY;DISEASE:DIARRHEA
TEGAFUR;UMPS;CC;rs1801019;TOXICITY;INCREASED_SEVERITY;DISEASE:DIARRHEA
LEUCOVORIN;UMPS;CC;rs1801019;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANY_GRADE_3_ADVERSE_EVENT
TEGAFUR;UMPS;CC;rs1801019;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANY_GRADE_3_ADVERSE_EVENT
ASPIRIN;F13A1;AA + AC;rs5985;EFFICACY;INCREASED_RISK;DISEASE:DEATH
CLOPIDOGREL;F13A1;AA + AC;rs5985;EFFICACY;INCREASED_RISK;DISEASE:DEATH
PAZOPANIB;CXCL8;TT;rs1126647;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
NICOTINE;CHRNA4;G;rs2236196;OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
ANGIOTENSIN II ANTAGONISTS;CYP2D6;CT;rs111564371;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE | ELEVATED_SYSTOLIC_BLOOD_PRESSURE
METHOTREXATE;SLC19A1;CT + TT;rs1051266;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MUCOSITIS
NICOTINE;CHRNA3;AA + AG;rs1051730;TOXICITY;DECREASED;SIDE_EFFECT:LUNG_FUNCTION
CYCLOPHOSPHAMIDE;MTHFR;A;rs1801133;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
FLUOROURACIL;MTHFR;A;rs1801133;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
LEDIPASVIR;IFNL3;TT;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
LEDIPASVIR;IFNL4;TT;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
SOFOSBUVIR;IFNL3;TT;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
SOFOSBUVIR;IFNL4;TT;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
CARBAMAZEPINE;HSPA1A;T;rs1043620;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:HYPERSENSITIVITY
ASPIRIN;F13A1;AA + AC;rs5985;EFFICACY;INCREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
CLOPIDOGREL;F13A1;AA + AC;rs5985;EFFICACY;INCREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
LEDIPASVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
LEDIPASVIR;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SOFOSBUVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SOFOSBUVIR;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
CARBAMAZEPINE;HSPA1A;G;rs506770;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:HYPERSENSITIVITY
ASPIRIN;F13A1;AA;rs5985;EFFICACY;DECREASED_EFFICACY;EFFICACY:FIBRIN_CLOT_FORMATION_TIME
CLOPIDOGREL;F13A1;AA;rs5985;EFFICACY;DECREASED_EFFICACY;EFFICACY:FIBRIN_CLOT_FORMATION_TIME
CYCLOPHOSPHAMIDE;TP53;G;rs1042522;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
FLUOROURACIL;TP53;G;rs1042522;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
CARBAMAZEPINE;HSPA1L;G;rs2227956;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:HYPERSENSITIVITY
CLOPIDOGREL;P2RY12;AG + GG;rs6787801;EFFICACY;EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY_IN_CYP2C19*1/*1_CARRIERS
CLOZAPINE;ABCB1;AG + GG;rs1045642;TOXICITY;INCREASED;SIDE_EFFECT:HYPERTENSION
RIBAVIRIN;ITPA;CC;rs1127354;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION | TREATMENT_INTERRUPTION
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_PK;PK:EXPOSURE
CLOZAPINE;ABCC1;AT + TT;rs212090;TOXICITY;INCREASED;SIDE_EFFECT:HYPERTENSION
CARBAMAZEPINE;MLN;A;rs2894342;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY_SYNDROME
EFAVIRENZ;CYP2B6;CC + CT;rs28399499;LADME_PK;INCREASED_PK;PK:EXPOSURE
CLOZAPINE;ABCB1;AG + GG;rs1045642;TOXICITY;INCREASED;SIDE_EFFECT:WEIGHT_GAIN
CLOZAPINE;ABCC1;AT + TT;rs212090;TOXICITY;INCREASED;SIDE_EFFECT:WEIGHT_GAIN
CAFFEINE;ADORA2A;TT;rs5751876;TOXICITY;INCREASED;SIDE_EFFECT:ANXIETY
CAFFEINE;ADORA2A;CC;rs2298383;TOXICITY;INCREASED;SIDE_EFFECT:ANXIETY
CAFFEINE;nan;CC;rs4822492;TOXICITY;INCREASED;SIDE_EFFECT:ANXIETY
NO_DRUG_RELATED;MT-RNR1;G;rs267606617;OTHER;INCREASED_LIKELIHOOD;OTHER:HEARING_LOSS | SENSORINEURAL
CARBAMAZEPINE;nan;T;rs3130690;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
CAFFEINE;ADORA2A;CC;rs5751876;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:BEING_SENSITIVE_TO_CAFFEINE
CAFFEINE;ADORA2A;CC;rs5751876;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:INSOMNIA
ETHANOL;ANKS1B;T;rs2133896;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE | HEROIN_DEPENDENCE | METHAMPHETAMINE_DEPENDENCE,
HEROIN;ANKS1B;T;rs2133896;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE | HEROIN_DEPENDENCE | METHAMPHETAMINE_DEPENDENCE,
METHAMPHETAMINE;ANKS1B;T;rs2133896;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE | HEROIN_DEPENDENCE | METHAMPHETAMINE_DEPENDENCE,
CARBAMAZEPINE;MICA;C;rs2848716;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
"""ANTIINFLAMMATORY AGENTS";nan;TT;rs2965667;OTHER;DECREASED_RISK;DISEASE:COLORECTAL_NEOPLASMS
"NON-STEROIDS""";nan;TT;rs2965667;OTHER;DECREASED_RISK;DISEASE:COLORECTAL_NEOPLASMS
"""ASPIRIN""";nan;TT;rs2965667;OTHER;DECREASED_RISK;DISEASE:COLORECTAL_NEOPLASMS
CAFFEINE;ADORA2A;TT;rs5751876;DOSAGE;DECREASED;OTHER:HABITUAL_CONSUMPTION
CARBAMAZEPINE;BAG6;C;rs750332;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;PRRC2A;C;rs750332;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
"""ANTIINFLAMMATORY AGENTS";nan;AA;rs16973225;OTHER;DECREASED_LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS
"NON-STEROIDS""";nan;AA;rs16973225;OTHER;DECREASED_LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS
"""ASPIRIN""";nan;AA;rs16973225;OTHER;DECREASED_LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS
NO_DRUG_RELATED;CHRNA5;T;rs588765;EFFICACY;EFFICACY;EFFICACY:DECREASED_CHANCE_OF_ACHIEVING_6_MONTH_ABSTINENCE_IN_THE_PLACEBO_GROUP
WARFARIN;VKORC1;AG + GG;rs9934438;DOSAGE;INCREASED;OTHER:WARFARIN_DOSE
RIBAVIRIN;ITPA;AA;rs7270101;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMOLYTIC_ANEMIA
SIMVASTATIN;LEPR;GG;rs1137101;EFFICACY;INCREASED_EFFICACY;EFFICACY:PERCENTAGE_CHANGE_IN_HDL-C_LEVELS
ALENDRONATE;SOST;CC;rs1234612;EFFICACY;INCREASED_EFFICACY;EFFICACY:BONE_DENSITY
CYTARABINE;ABCB1;GG;rs1128503;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DAUNORUBICIN;ABCB1;GG;rs1128503;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
CYTARABINE;CDA;CC;rs532545;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:COLITIS
DAUNORUBICIN;CDA;CC;rs532545;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:COLITIS
CYTARABINE;ABCB1;GG;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
DAUNORUBICIN;ABCB1;GG;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
ALENDRONATE;SOST;GG;rs865429;EFFICACY;DECREASED_EFFICACY;EFFICACY:BONE_DENSITY
RIBAVIRIN;ITPA;CC;rs1127354;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMOLYTIC_ANEMIA
CYTARABINE;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOPIDOGREL;MED12L;T;rs6801273;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESIDUAL_ON-CLOPIDOGREL_PLATELET_REACTIVITY
CLOPIDOGREL;P2RY12;T;rs6801273;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESIDUAL_ON-CLOPIDOGREL_PLATELET_REACTIVITY
CYTARABINE;ABCB1;AA + AC;rs2032582;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOPIDOGREL;MED12L;G;rs6798347;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESIDUAL_ON-CLOPIDOGREL_PLATELET_REACTIVITY
ERLOTINIB;EGFR;T;rs121434569;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL_(PFS)_TIME
GEFITINIB;EGFR;T;rs121434569;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL_(PFS)_TIME
CYTARABINE;ABCB1;AA + AG;rs1045642;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
SEVOFLURANE;ABCB1;GG;rs1128503;OTHER;DECREASED_LIKELIHOOD;OTHER:ADVERSE_EVENTS
TACROLIMUS;KCNJ11;CT + TT;rs5219;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIABETES_MELLITUS_TYPE2
ACE INHIBITORS;ETV6;GG;rs2724635;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA
PLAIN;ETV6;GG;rs2724635;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA
ERLOTINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
SUNITINIB;ABCB1;AA;rs1128503;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ASPIRIN;TAPBP;CC + CG;rs2071888;TOXICITY;INCREASED;SIDE_EFFECT:FEV1_DECREASE_AFTER_ASPIRIN_CHALLENGE
DRUGS FOR TREATMENT OF TUBERCULOSIS;ABCC2;AG + GG;rs3740065;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ESCITALOPRAM;HTR2A;CT + TT;rs6311;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED_RISK;SIDE_EFFECT:COMPOSITE_OUTCOME_OF_NON-FATAL_MI | ALL_CAUSE_DEATH_AND_STENT_THROMBOSIS
HYDROCHLOROTHIAZIDE;KCNJ1;C;rs12795437;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DIABETES_MELLITUS
PHENPROCOUMON;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
VALPROIC ACID;LEPR;AA + AG;rs1137101;TOXICITY;INCREASED;SIDE_EFFECT:WEIGHT_GAIN
PHENYTOIN;CFHR4;G;rs78239784;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
HYDROCHLOROTHIAZIDE;KCNJ1;A;rs11600347;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DIABETES_MELLITUS
CABAZITAXEL;ABCB1;A;rs2032582;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
VALPROIC ACID;ANKK1;AG + GG;rs1800497;TOXICITY;INCREASED;SIDE_EFFECT:WEIGHT_GAIN
HYDROCHLOROTHIAZIDE;KCNJ1;A;rs658903;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:DIABETES_MELLITUS
CABAZITAXEL;ABCB1;A;rs1045642;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
CLOPIDOGREL;P2RY12;G;rs6787801;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESIDUAL_ON-CLOPIDOGREL_PLATELET_REACTIVITY
CABAZITAXEL;CYP3A5;T;rs776746;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
ACE INHIBITORS;PRKCQ;CT + TT;rs500766;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA
PLAIN;PRKCQ;CT + TT;rs500766;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA
HYDROCHLOROTHIAZIDE;KCNJ1;A;rs675388;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DIABETES_MELLITUS
DOXORUBICIN;GSTP1;GG;rs1695;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:CHEMORESISTANCE
CABAZITAXEL;ABCB1;A;rs1128503;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
PROPOFOL;DRD2;AA + AC;rs2283265;OTHER;DECREASED;OTHER:HEART_RATE
NICOTINE;CHRNA4;A;rs2236196;OTHER;INCREASED_LIKELIHOOD;OTHER:NICOTINE_DEPENDENCE
ACETAMINOPHEN;UGT1A;CG + GG;rs1042640;TOXICITY;DECREASED_RISK;DISEASE:LIVER_FAILURE | ACUTE
CLOPIDOGREL;ABCB1;AA;rs1045642;TOXICITY;DECREASED;SIDE_EFFECT:BLEEDING_EVENTS
ACETAMINOPHEN;UGT1A;CG + GG;rs8330;TOXICITY;DECREASED_RISK;DISEASE:LIVER_FAILURE | ACUTE
GEFITINIB;EGFR;T;rs121434569;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESPONSE_RATE_(RR)
HYDROCHLOROTHIAZIDE;KCNJ1;AG;rs59172778;TOXICITY;INCREASED;SIDE_EFFECT:SERUM_POTASSIUM
ETHANOL;CACNA1C;TT;rs1034936;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
DOXORUBICIN;ABCB1;AA;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA | THROMBOCYTOPENIA
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA | THROMBOCYTOPENIA
PREDNISOLONE;ABCB1;AA;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA | THROMBOCYTOPENIA
VINCRISTINE;ABCB1;AA;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA | THROMBOCYTOPENIA
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
WARFARIN;EPHA7;A;rs114504854;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
ACETAMINOPHEN;UGT1A;CT + TT;rs10929303;TOXICITY;DECREASED_RISK;DISEASE:LIVER_FAILURE | ACUTE
ACE INHIBITORS;XPNPEP2;T;rs2050011;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA
PLAIN;XPNPEP2;T;rs2050011;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA
ETHAMBUTOL;TNF;AA + AG;rs1800629;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;TNF;AA + AG;rs1800629;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;TNF;AA + AG;rs1800629;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;TNF;AA + AG;rs1800629;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
NICOTINE;ADGRL3;AG;rs2271339;TOXICITY;INCREASED_RISK;OTHER:TOBACCO_USE_DISORDER
NICOTINE;ADGRL3;AT;rs1456862;TOXICITY;INCREASED_RISK;OTHER:TOBACCO_USE_DISORDER
GEFITINIB;EGFR;CC;rs2293347;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE_(RR)
GEFITINIB;EGFR;CC;rs2293347;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
ETHANOL;MAP2K4;CT;rs2159140;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE
SUNITINIB;ABCB1;GG;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA | MUCOSITIS
SORAFENIB;UGT1A9;T;rs17868320;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME
GEFITINIB;EGFR;GT + TT;rs712829;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE_(RR)
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPOVENTILATION
ACE INHIBITORS;XPNPEP2;A;rs3788853;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA
PLAIN;XPNPEP2;A;rs3788853;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS_(MACE)_(MORE_THAN_ONE_YEAR)_WHEN_RECEIVING_A_LOADING_DOSE_OF_300_MG
DOCETAXEL;ABCC10;CT;rs2125739;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
NO_DRUG_RELATED;ARNT;CG + GG;rs2228099;OTHER;DECREASED_LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS
ETHAMBUTOL;CYP2E1;GG;rs3813867;TOXICITY;INCREASED_SEVERITY;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;CYP2E1;GG;rs3813867;TOXICITY;INCREASED_SEVERITY;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;CYP2E1;GG;rs3813867;TOXICITY;INCREASED_SEVERITY;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;CYP2E1;GG;rs3813867;TOXICITY;INCREASED_SEVERITY;DISEASE:TOXIC_LIVER_DISEASE
CLOPIDOGREL;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EARLY_MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS_(MACE)
NO_DRUG_RELATED;DEPTOR;AA + AG;rs4871827;OTHER;INCREASED;OTHER:HDL_CHOLESTEROL
CISPLATIN;SYNE3;CC;rs8020368;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IRINOTECAN;SYNE3;CC;rs8020368;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
NO_DRUG_RELATED;DEPTOR;AG;rs4871827;OTHER;DECREASED_LIKELIHOOD;OTHER:BRAIN_ISCHEMIA | MYOCARDIAL_INFARCTION | PERIPHERAL_VASCULAR_DISEASES,
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";CYP2B6;TT;rs3745274;TOXICITY;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
"COMBINATIONS""";CYP2B6;TT;rs3745274;TOXICITY;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";CYP2B6;TT;rs3745274;TOXICITY;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
NO_DRUG_RELATED;DEPTOR;AG;rs4871827;OTHER;DECREASED_LIKELIHOOD;OTHER:DIABETIC_RETINOPATHY | CHRONIC_KIDNEY_FAILURE
LOSARTAN;STK39;GG + GT;rs6749447;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_AMBULATORY_BLOOD_PRESSURE
CLOPIDOGREL;ABCB1;AA;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EARLY_MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS_(MACE)
NO_DRUG_RELATED;AHR;AA + AG;rs2066853;OTHER;INCREASED_RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS
RISPERIDONE;HTR6;CC + CT;rs9659997;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA
CISPLATIN;DCBLD1;AG;rs17574269;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IRINOTECAN;DCBLD1;AG;rs17574269;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN;nan;AG + GG;rs7186128;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IRINOTECAN;nan;AG + GG;rs7186128;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
RISPERIDONE;TYMS;A;rs3786362;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERPROLACTINEMIA
NO_DRUG_RELATED;TNF;C;rs1800630;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:LEUKOCYTOSIS
CISPLATIN;nan;TT;rs2166219;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IRINOTECAN;nan;TT;rs2166219;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
RISPERIDONE;HTR2A;CC;rs6311;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA
CISPLATIN;nan;CC;rs4655567;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IRINOTECAN;nan;CC;rs4655567;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ANTINEOPLASTIC AGENTS;ITPA;AA + AC;rs1127354;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY | NEUROTOXICITY_SYNDROMES
CORTICOSTEROIDS;ITPA;AA + AC;rs1127354;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY | NEUROTOXICITY_SYNDROMES
CISPLATIN;nan;TT;rs2018683;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IRINOTECAN;nan;TT;rs2018683;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
RISPERIDONE;BDNF;CT + TT;rs6265;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA
ANTINEOPLASTIC AGENTS;ADORA2A;CC;rs2236624;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
CORTICOSTEROIDS;ADORA2A;CC;rs2236624;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
LEUCOVORIN;ABCC2;CT + TT;rs717620;LADME_PK;INCREASED_PK;PK:DISTRIBUTION_VOLUME
METHOTREXATE;ABCC2;CT + TT;rs717620;LADME_PK;INCREASED_PK;PK:DISTRIBUTION_VOLUME
CISPLATIN;nan;TT;rs2018683;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RESISTANT_RELAPSE
IRINOTECAN;nan;TT;rs2018683;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RESISTANT_RELAPSE
NO_DRUG_RELATED;OPRM1;G;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:HEROIN_DEPENDENCE
CISPLATIN;SYNE3;CC;rs8020368;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RESISTANT_RELAPSE
IRINOTECAN;SYNE3;CC;rs8020368;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RESISTANT_RELAPSE
CISPLATIN;nan;CC;rs4655567;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RESISTANT_RELAPSE
IRINOTECAN;nan;CC;rs4655567;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RESISTANT_RELAPSE
METHOTREXATE;ABCC4;AA;rs7317112;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
RISPERIDONE;UGT1A1;AG;rs1976391;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERPROLACTINEMIA
RISPERIDONE;HTR2C;C;rs6318;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA
CYCLOSPORINE;nan;GG;rs2275913;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TRANSPLANT_REJECTION
LENALIDOMIDE;ABCB1;AA;rs2032582;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
HEROIN;DBH;TT;rs1611114;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MEMORY_IMPAIRMENT
DILTIAZEM;PLCD3;T;rs12946454;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
CAPECITABINE;MTHFR;GG;rs1801131;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL | OVERALL_SURVIVAL
FLUOROURACIL;MTHFR;GG;rs1801131;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL | OVERALL_SURVIVAL
OXALIPLATIN;MTHFR;GG;rs1801131;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL | OVERALL_SURVIVAL
PEGINTERFERON ALFA-2B;ITPA;AC;rs1127354;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ANEMIA
RIBAVIRIN;ITPA;AC;rs1127354;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ANEMIA
DOCETAXEL;ABCB1;AA;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
"""BETA BLOCKING AGENTS""";nan;C;rs11191548;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_DIASTOLIC_BLOOD_PRESSURE
"""THIAZIDES";nan;C;rs11191548;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_DIASTOLIC_BLOOD_PRESSURE
"PLAIN""";nan;C;rs11191548;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_DIASTOLIC_BLOOD_PRESSURE
NICOTINE;COMT;GG;rs4680;OTHER;INCREASED_SEVERITY;SIDE_EFFECT:WITHDRAWAL
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_PK;PK:MINIMUM_PLASMA_CONCENTRATIONS
MORPHINE;ABCB1;CC + CT;rs9282564;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPOVENTILATION
ANTINEOPLASTIC AGENTS;ABCC1;GG;rs246240;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
CORTICOSTEROIDS;ABCC1;GG;rs246240;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
LENALIDOMIDE;NCF4;AA + AG;rs1883112;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
NICOTINE;COMT;GG;rs4680;OTHER;INCREASED;OTHER:BLOOD_PRESSURE
LENALIDOMIDE;GSTP1;GG;rs1695;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
CISPLATIN;ABCC4;CT;rs16950650;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IRINOTECAN;ABCC4;CT;rs16950650;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ASPIRIN;ITGA2;CT + TT;rs1126643;OTHER;INCREASED;OTHER:COLLAGEN-INDUCED_PLATELET_AGGREGATION
CLOPIDOGREL;ITGA2;CT + TT;rs1126643;OTHER;INCREASED;OTHER:COLLAGEN-INDUCED_PLATELET_AGGREGATION
MYCOPHENOLATE MOFETIL;SLCO1B3;TT;rs4149117;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
EFAVIRENZ;ABCB1;GG;rs1045642;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA
LAMIVUDINE;ABCB1;GG;rs1045642;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA
TENOFOVIR;ABCB1;GG;rs1045642;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA
GEMCITABINE;SLC29A3;CT + TT;rs780668;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PEGINTERFERON ALFA-2B;ITPA;A;rs1127354;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ANEMIA
RIBAVIRIN;ITPA;A;rs1127354;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ANEMIA
MYCOPHENOLATE MOFETIL;SLCO1B3;TT;rs4149117;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
ATORVASTATIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
PEGINTERFERON ALFA-2B;ITPA;C;rs7270101;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ANEMIA
RIBAVIRIN;ITPA;C;rs7270101;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ANEMIA
CAFFEINE;CYP1A2;AC + CC;rs762551;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ALBUMINURIA | HYPERTENSION
GEMCITABINE;ABCG2;GT + TT;rs2231142;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
PLATINUM COMPOUNDS;ERCC1;AA;rs11615;EFFICACY;INCREASED_RISK;DISEASE:DEATH
CAPECITABINE;CDA;CT + TT;rs1048977;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
CLOPIDOGREL;CYP2C9;CT + TT;rs1799853;LADME_PK;DECREASED_PK;PK:EXPOSURE_TO_CLOPIDOGREL_ACTIVE_METABOLITE
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY | MUSCULAR_DISEASES | RHABDOMYOLYSIS | TOXIC_LIVER_DISEASE
ALLOPURINOL;CFLAR;A;rs1594;TOXICITY;nan;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
OXYCODONE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
CAPECITABINE;CES2;CG + GG;rs11075646;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_PROGRESSION
PLATINUM COMPOUNDS;ERCC1;AA;rs11615;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE_OF_DISEASE
CLOPIDOGREL;CYP2C9;CT + TT;rs1799853;EFFICACY;DECREASED_EFFICACY;EFFICACY:INHIBITION_OF_PLATELET_AGGREGATION_AND_POOR-RESPONDER_STATUS
PLATINUM COMPOUNDS;HSPA5;TT;rs430397;EFFICACY;DECREASED;OTHER:PROGRESSION-FREE_SURVIVAL
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED_EFFICACY;EFFICACY:INHIBITION_OF_PLATELET_AGGREGATION_AND_POOR-RESPONDER_STATUS
ASPIRIN;AGT;GG;rs5050;TOXICITY;INCREASED_RISK;DISEASE:PEPTIC_ULCER_HEMORRHAGE
SUNITINIB;NR1I2;A;rs6785049;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERTENSION
BUPROPION;SACM1L;C;rs2251954;TOXICITY;DECREASED;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS
ROSUVASTATIN;GATM;AA;rs9806699;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
CLOPIDOGREL;CYP2C19;A;rs4244285;LADME_PK;DECREASED_PK;PK:EXPOSURE_TO_CLOPIDOGREL_ACTIVE_METABOLITE
BUPROPION;SACM1L;G;rs2742421;TOXICITY;DECREASED;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS
ETHAMBUTOL;CYP3A4;AG;rs28371759;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ISONIAZID;CYP3A4;AG;rs28371759;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PYRAZINAMIDE;CYP3A4;AG;rs28371759;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RIFAMPIN;CYP3A4;AG;rs28371759;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ROSUVASTATIN;SLCO1B1;AG;rs4149081;EFFICACY;INCREASED_EFFICACY;EFFICACY:LDL-C_REDUCTION
BUPROPION;SACM1L;G;rs2742423;TOXICITY;DECREASED;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;nan;SIDE_EFFECT:EARLY_(<_3_MONTHS)_TERMINATION_OF_EFAVIRENZ_THERAPY
CLOPIDOGREL;CYP2C9;AC + CC;rs1057910;LADME_PK;DECREASED_PK;PK:EXPOSURE_TO_CLOPIDOGREL_ACTIVE_METABOLITE
BUPROPION;SACM1L;T;rs1969624;TOXICITY;DECREASED;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS
EFAVIRENZ;NR1I3;GG;rs2307424;TOXICITY;nan;SIDE_EFFECT:EARLY_(<_3_MONTHS)_TERMINATION_OF_EFAVIRENZ_THERAPY
BUPROPION;SACM1L;C;rs2245705;TOXICITY;DECREASED;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS
BUPROPION;SACM1L;G;rs2742435;TOXICITY;DECREASED;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS
CLOPIDOGREL;CYP2C9;AC + CC;rs1057910;EFFICACY;DECREASED_EFFICACY;EFFICACY:INHIBITION_OF_PLATELET_AGGREGATION_AND_POOR-RESPONDER_STATUS
BUPROPION;SACM1L;A;rs2742390;TOXICITY;DECREASED;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS
SIMVASTATIN;SLCO1B1;AG;rs4149081;EFFICACY;INCREASED_EFFICACY;EFFICACY:LDL-C_REDUCTION
PLATINUM COMPOUNDS;HSPA5;TT;rs430397;EFFICACY;INCREASED_LIKELIHOOD;OTHER:EARLY_RELAPSE
SIMVASTATIN;SLCO1B1;AA;rs4149081;EFFICACY;INCREASED_EFFICACY;EFFICACY:LDL-C_REDUCTION
PEMETREXED;DHFR;GG;rs442767;TOXICITY;INCREASED_RISK;DISEASE:FATIGUE
FLUOROURACIL;MTHFR;GG;rs1801131;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
BUPROPION;SACM1L;T;rs2742417;TOXICITY;DECREASED;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS
TEMSIROLIMUS;NR1I2;T;rs3814055;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
PHENPROCOUMON;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
SUNITINIB;FLT3;AA;rs1933437;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
CAPECITABINE;CES1;CT + TT;rs71647871;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HAND-FOOT_SYNDROME | DRUG_TOXICITY
ROSUVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
GEMCITABINE;ABCG2;GT + TT;rs2231142;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PLATINUM COMPOUNDS;HSPA5;TT;rs430397;EFFICACY;INCREASED_RISK;DISEASE:DEATH
ROSUVASTATIN;SLCO1B1;AA;rs4149081;EFFICACY;INCREASED_EFFICACY;EFFICACY:LDL-C_REDUCTION
NALTREXONE;OPRD1;A;rs4654327;EFFICACY;INCREASED_EFFICACY;EFFICACY:NALTREXONE-INDUCED_BLUNTING_OF_ALCOHOL_STIMULATION_AND_ALCOHOL_CRAVING
IRINOTECAN;UGT1A;AG + GG;rs11563250;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ATORVASTATIN;RYR2;A;rs2819742;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:MUSCULAR_DISEASES | MYALGIA
SIMVASTATIN;RYR2;A;rs2819742;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:MUSCULAR_DISEASES | MYALGIA
CAPECITABINE;SPARC;GG;rs2347128;EFFICACY;INCREASED;OTHER:PROGRESSION-FREE_SURVIVAL
FLUOROURACIL;SPARC;GG;rs2347128;EFFICACY;INCREASED;OTHER:PROGRESSION-FREE_SURVIVAL
GEMCITABINE;SPARC;GG;rs2347128;EFFICACY;INCREASED;OTHER:PROGRESSION-FREE_SURVIVAL
NO_DRUG_RELATED;MET;AG + GG;rs40239;OTHER;INCREASED;OTHER:OVERALL_SURVIVAL
AZATHIOPRINE;ITPA;AC + CC;rs7270101;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION | DRUG_TOXICITY | ADVERSE_EVENTS,
CAPECITABINE;SPARC;TT;rs17718347;EFFICACY;INCREASED;OTHER:PROGRESSION-FREE_SURVIVAL
FLUOROURACIL;SPARC;TT;rs17718347;EFFICACY;INCREASED;OTHER:PROGRESSION-FREE_SURVIVAL
GEMCITABINE;SPARC;TT;rs17718347;EFFICACY;INCREASED;OTHER:PROGRESSION-FREE_SURVIVAL
NO_DRUG_RELATED;MET;AG + GG;rs40239;OTHER;INCREASED;OTHER:OVERALL_SURVIVAL
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";ABCB1;AA;rs1045642;TOXICITY;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS";ABCB1;AA;rs1045642;LADME_PK;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
"COMBINATIONS""";ABCB1;AA;rs1045642;TOXICITY;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
"COMBINATIONS""";ABCB1;AA;rs1045642;LADME_PK;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";ABCB1;AA;rs1045642;TOXICITY;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
"""DRUGS FOR TREATMENT OF TUBERCULOSIS""";ABCB1;AA;rs1045642;LADME_PK;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
EFAVIRENZ;CYP2B6;T;rs3745274;OTHER;INCREASED_PK;PK:PLASMA_EFAVIRENZ_EXPOSURE_(AUC)_DURING_THE_FIRST_24_WEEKS_OF_ANTIRETROVIRAL_THERAPY
EFAVIRENZ;CYP2B6;T;rs3745274;LADME_PK;INCREASED_PK;PK:PLASMA_EFAVIRENZ_EXPOSURE_(AUC)_DURING_THE_FIRST_24_WEEKS_OF_ANTIRETROVIRAL_THERAPY
EFAVIRENZ;CYP2B6;T;rs3745274;TOXICITY;INCREASED_RISK;DISEASE:CENTRAL_NERVOUS_SYSTEM_DISORDER
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
DESFLURANE;RYR1;A;rs112563513;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
ENFLURANE;RYR1;A;rs112563513;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
HALOTHANE;RYR1;A;rs112563513;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
ISOFLURANE;RYR1;A;rs112563513;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
SEVOFLURANE;RYR1;A;rs112563513;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
SUCCINYLCHOLINE;RYR1;A;rs112563513;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
EFAVIRENZ;CYP3A4;C;rs2740574;OTHER;INCREASED_PK;PK:PLASMA_EFAVIRENZ_EXPOSURE
EFAVIRENZ;CYP3A4;C;rs2740574;LADME_PK;INCREASED_PK;PK:PLASMA_EFAVIRENZ_EXPOSURE
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DISCONTINUATION
EFAVIRENZ;CYP3A5;C;rs776746;LADME_PK;DECREASED_PK;PK:PLASMA_EFAVIRENZ_EXPOSURE
CLOPIDOGREL;ABCB1;GG;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS
CLOPIDOGREL;CYP2C19;AA;rs4244285;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
CLOPIDOGREL;CYP2C19;A;rs4986893;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS
ACE INHIBITORS;MME;CT + TT;rs989692;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA
PLAIN;MME;CT + TT;rs989692;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA
HMG COA REDUCTASE INHIBITORS;LILRB5;TT;rs12975366;DOSAGE;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
HMG COA REDUCTASE INHIBITORS;LILRB5;TT;rs12975366;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
ESCITALOPRAM;HTR2A;TT;rs6311;TOXICITY;INCREASED_LIKELIHOOD;OTHER:PHYSIOLOGICAL_SEXUAL_DISORDER
FLUOXETINE;HTR2A;TT;rs6311;TOXICITY;INCREASED_LIKELIHOOD;OTHER:PHYSIOLOGICAL_SEXUAL_DISORDER
PAROXETINE;HTR2A;TT;rs6311;TOXICITY;INCREASED_LIKELIHOOD;OTHER:PHYSIOLOGICAL_SEXUAL_DISORDER
SERTRALINE;HTR2A;TT;rs6311;TOXICITY;INCREASED_LIKELIHOOD;OTHER:PHYSIOLOGICAL_SEXUAL_DISORDER
VENLAFAXINE;HTR2A;TT;rs6311;TOXICITY;INCREASED_LIKELIHOOD;OTHER:PHYSIOLOGICAL_SEXUAL_DISORDER
CABAZITAXEL;CYP3A5;CT;rs776746;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CLOPIDOGREL;CYP2C19;AA;rs4986893;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
CITALOPRAM;HTR2A;CC;rs6311;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER
ESCITALOPRAM;HTR2A;CC;rs6311;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER
FLUOXETINE;HTR2A;CC;rs6311;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER
PAROXETINE;HTR2A;CC;rs6311;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER
SERTRALINE;HTR2A;CC;rs6311;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER
CABAZITAXEL;TUBB1;AC;rs463312;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CLOPIDOGREL;CYP2C19;G;rs28399504;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CLOPIDOGREL;CYP2C19;AA;rs4986893;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
NEVIRAPINE;CYP2B6;C;rs28399499;LADME_PK;INCREASED;OTHER:PLASMA_LEVEL
NO_DRUG_RELATED;SLC2A9;T;rs16890979;LADME_PK;DECREASED_PK;PK:SERUM_URIC_ACID
CYCLOPHOSPHAMIDE;IKZF3;CC;rs9908694;EFFICACY;INCREASED;DISEASE:EVENT-FREE_SURVIVAL
METHOTREXATE;ABCB1;AG;rs1045642;TOXICITY;DECREASED_RISK;DISEASE:DRUG_TOXICITY
DESFLURANE;RYR1;A;rs118192122;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
ENFLURANE;RYR1;A;rs118192122;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
HALOTHANE;RYR1;A;rs118192122;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
ISOFLURANE;RYR1;A;rs118192122;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
SEVOFLURANE;RYR1;A;rs118192122;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
SUCCINYLCHOLINE;RYR1;A;rs118192122;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
DESFLURANE;RYR1;T;rs193922816;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
ENFLURANE;RYR1;T;rs193922816;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
HALOTHANE;RYR1;T;rs193922816;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
ISOFLURANE;RYR1;T;rs193922816;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
SEVOFLURANE;RYR1;T;rs193922816;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
SUCCINYLCHOLINE;RYR1;T;rs193922816;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
METHAMPHETAMINE;DRD4;CC + CT;rs1800955;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_PSYCHOSIS
BEVACIZUMAB;GC;TT;rs4588;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CETUXIMAB;GC;TT;rs4588;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DESFLURANE;RYR1;T;rs28933397;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
ENFLURANE;RYR1;T;rs28933397;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
HALOTHANE;RYR1;T;rs28933397;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
ISOFLURANE;RYR1;T;rs28933397;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
SEVOFLURANE;RYR1;T;rs28933397;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
SUCCINYLCHOLINE;RYR1;T;rs28933397;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
ASPIRIN;TAPBP;AG + GG;rs1059288;TOXICITY;INCREASED;SIDE_EFFECT:FEV1_DECREASE_AFTER_ASPIRIN_CHALLENGE
"""ACE INHIBITORS";F5;CT;rs140530655;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
"PLAIN""";F5;CT;rs140530655;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
"""ANGIOTENSIN II ANTAGONISTS""";F5;CT;rs140530655;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
CLOPIDOGREL;CYP2C19;AG;rs4244285;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
GEFITINIB;IKBKB;CC;rs2272733;TOXICITY;DECREASED_RISK;SIDE_EFFECT:EXANTHEMA
"""METFORMIN""";SLC22A1;AA + AG;rs628031;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
"""SULFONAMIDES";SLC22A1;AA + AG;rs628031;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
"UREA DERIVATIVES""";SLC22A1;AA + AG;rs628031;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
CLOPIDOGREL;CYP2C19;AA;rs4244285;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
DESFLURANE;RYR1;T;rs193922772;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
ENFLURANE;RYR1;T;rs193922772;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
HALOTHANE;RYR1;T;rs193922772;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
ISOFLURANE;RYR1;T;rs193922772;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
SEVOFLURANE;RYR1;T;rs193922772;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
SUCCINYLCHOLINE;RYR1;T;rs193922772;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
CLOPIDOGREL;CYP2C19;AG;rs4986893;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
FENOTEROL;SLC22A1;T;rs12208357;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
FENOTEROL;SLC22A1;A;rs34130495;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
ACE INHIBITORS;AGT;GG;rs699;EFFICACY;DECREASED_RISK;DISEASE:STROKE
PLAIN;AGT;GG;rs699;EFFICACY;DECREASED_RISK;DISEASE:STROKE
NO_DRUG_RELATED;P2RY12;G;rs2046934;OTHER;INCREASED_RISK;DISEASE:PERIPHERAL_VASCULAR_DISEASES
GEFITINIB;RELA;CC;rs11227247;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
FENOTEROL;SLC22A1;C;rs55918055;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
IRINOTECAN;KCNQ5;C;rs9351963;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
FENOTEROL;SLC22A1;A;rs34059508;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
NO_DRUG_RELATED;P2RY12;G;rs2046934;OTHER;INCREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
GEFITINIB;IKBKE;AG + GG;rs2151222;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DIARRHEA
ISONIAZID;NAT2;C;rs1801280;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PHENYTOIN;NAT2;C;rs1801280;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ISONIAZID;NAT2;A;rs1799931;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PHENYTOIN;NAT2;A;rs1799931;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
TAMOXIFEN;CYP2D6;T;rs28371725;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
TAMOXIFEN;CYP2D6;C;rs3892097;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
TAMOXIFEN;CYP2D6;A;rs1065852;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
PAROXETINE;HTR2A;AG;rs6314;EFFICACY;EFFICACY;EFFICACY:IMPROVED_RESPONSE
GABAPENTIN;SLC7A5;AG;rs4240803;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
PREGABALIN;SLC7A5;AG;rs4240803;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
BEVACIZUMAB;CXCR2;TT;rs2230054;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
CYCLOPHOSPHAMIDE;CXCR2;TT;rs2230054;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
PAROXETINE;HTR2A;AG;rs6314;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
TAMOXIFEN;CYP2C19;T;rs12248560;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:RECURRENCE
GEMCITABINE;SLCO1B1;AG + GG;rs4149086;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PAROXETINE;HTR2A;GG;rs6313;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_DRUG_REACTION
HYDROCHLOROTHIAZIDE;CDCA3;TT;rs5443;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
HYDROCHLOROTHIAZIDE;GNB3;TT;rs5443;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
HYDROCHLOROTHIAZIDE;USP5;TT;rs5443;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
BETA BLOCKING AGENTS;GRK5;AT + TT;rs2230345;OTHER;DECREASED_RISK;DISEASE:DEATH
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
NO_DRUG_RELATED;CHRNA3;A;rs1051730;OTHER;INCREASED_RISK;DISEASE:LUNG_NEOPLASMS
CITALOPRAM;GRIK2;CC;rs2518224;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TREATMENT-EMERGENT_SUICIDAL_IDEATION
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
WARFARIN;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
IRINOTECAN;UGT1A9;G;rs7586110;TOXICITY;INCREASED_RISK;DISEASE:ANEMIA
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
WARFARIN;CYP4F2;CT + TT;rs2108622;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
NO_DRUG_RELATED;HYKK;C;rs8034191;OTHER;INCREASED_RISK;DISEASE:LUNG_NEOPLASMS
ISONIAZID;NAT2;T;rs1041983;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PHENYTOIN;NAT2;T;rs1041983;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
TACROLIMUS;TCF7L2;CC + CT;rs290487;TOXICITY;INCREASED_RISK;DISEASE:DIABETES_MELLITUS
ACE INHIBITORS;AGT;GG;rs699;EFFICACY;DECREASED_RISK;DISEASE:STROKE
PLAIN;AGT;GG;rs699;EFFICACY;DECREASED_RISK;DISEASE:STROKE
GEMCITABINE;POLR2A;CC;rs2228130;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
VALPROIC ACID;CYP2C9;AC;rs1057910;OTHER;INCREASED_PK;PK:MEAN_PLASMA_DRUG_CONCENTRATIONS
VALPROIC ACID;CYP2C9;AC;rs1057910;LADME_PK;INCREASED_PK;PK:MEAN_PLASMA_DRUG_CONCENTRATIONS
CITALOPRAM;GRIA3;G;rs4825476;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TREATMENT-EMERGENT_SUICIDAL_IDEATION
IMATINIB;SLC22A5;AA + AG;rs274558;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY | EYE_DISEASES
ISONIAZID;NAT2;G;rs1208;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PHENYTOIN;NAT2;G;rs1208;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ANTIPSYCHOTICS;COMT;CC + CG;rs4818;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:TARDIVE_DYSKINESIA
NO_DRUG_RELATED;CHRNA3;A;rs1051730;OTHER;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_VASCULAR_DISEASES
NO_DRUG_RELATED;CHRNA3;A;rs1051730;OTHER;INCREASED_LIKELIHOOD;DISEASE:LUNG_NEOPLASMS
DACARBAZINE;EPM2AIP1;AA + AG;rs1800734;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:BREAST_NEOPLASMS
PROCARBAZINE;EPM2AIP1;AA + AG;rs1800734;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:BREAST_NEOPLASMS
ISONIAZID;NAT2;A;rs1799930;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PHENYTOIN;NAT2;A;rs1799930;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
NO_DRUG_RELATED;CHRNA3;A;rs1051730;OTHER;INCREASED;OTHER:NUMBER_OF_CIGARETTES_SMOKED_PER_DAY
ISONIAZID;NAT2;T;rs1799929;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PHENYTOIN;NAT2;T;rs1799929;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
IMATINIB;ABCB1;CT;rs2235040;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY | EYE_DISEASES
DEXAMETHASONE;ABCB1;AA + AC;rs2032582;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DOXORUBICIN;ABCB1;AA + AC;rs2032582;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
VINCRISTINE;ABCB1;AA + AC;rs2032582;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DACARBAZINE;EPM2AIP1;AA + AG;rs1800734;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:THERAPY-RELATED_ACUTE_MYELOID_LEUKEMIA_(T-AML)
PROCARBAZINE;EPM2AIP1;AA + AG;rs1800734;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:THERAPY-RELATED_ACUTE_MYELOID_LEUKEMIA_(T-AML)
IMATINIB;EGFR;CT + TT;rs10258429;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY | EYE_DISEASES
ANTIPSYCHOTICS;COMT;AG;rs165599;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:TARDIVE_DYSKINESIA
IMATINIB;SLC22A1;CG + GG;rs683369;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY | EYE_DISEASES
RISPERIDONE;CYP2D6;AA;rs1065852;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OBESITY
DACLATASVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
DACLATASVIR;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SOFOSBUVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SOFOSBUVIR;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
"""ANALGESICS""";HTR2A;A;rs6305;OTHER;INCREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""ANTIINFLAMMATORY AGENTS";HTR2A;A;rs6305;OTHER;INCREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"NON-STEROIDS""";HTR2A;A;rs6305;OTHER;INCREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""ERGOT ALKALOIDS""";HTR2A;A;rs6305;OTHER;INCREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""OPIOIDS""";HTR2A;A;rs6305;OTHER;INCREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""SUMATRIPTAN""";HTR2A;A;rs6305;OTHER;INCREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
ASPIRIN;TBXA2R;AA;rs4523;EFFICACY;INCREASED_RISK;OTHER:HIGH_ON-ASPIRIN_RESIDUAL_PLATELET_REACTIVITY
"""ANALGESICS""";DBH;T;rs1611115;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""ANTIINFLAMMATORY AGENTS";DBH;T;rs1611115;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"NON-STEROIDS""";DBH;T;rs1611115;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""ERGOT ALKALOIDS""";DBH;T;rs1611115;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""OPIOIDS""";DBH;T;rs1611115;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""SUMATRIPTAN""";DBH;T;rs1611115;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
RISPERIDONE;DRD2;CT;rs1799978;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:INSULIN_RESISTANCE
PACLITAXEL;ABCB1;AA;rs2032582;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
PACLITAXEL;ABCB1;AA;rs1045642;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
"""ANALGESICS""";OPRM1;G;rs1799971;OTHER;INCREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""ANTIINFLAMMATORY AGENTS";OPRM1;G;rs1799971;OTHER;INCREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"NON-STEROIDS""";OPRM1;G;rs1799971;OTHER;INCREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""ERGOT ALKALOIDS""";OPRM1;G;rs1799971;OTHER;INCREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""OPIOIDS""";OPRM1;G;rs1799971;OTHER;INCREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""SUMATRIPTAN""";OPRM1;G;rs1799971;OTHER;INCREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
"""ANALGESICS""";BDNF;T;rs6265;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""ANTIINFLAMMATORY AGENTS";BDNF;T;rs6265;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"NON-STEROIDS""";BDNF;T;rs6265;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""ERGOT ALKALOIDS""";BDNF;T;rs6265;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""OPIOIDS""";BDNF;T;rs6265;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""SUMATRIPTAN""";BDNF;T;rs6265;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
ANTIPSYCHOTICS;COMT;AA;rs4680;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:TARDIVE_DYSKINESIA
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
"""ANALGESICS""";COMT;AA;rs4680;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""ANTIINFLAMMATORY AGENTS";COMT;AA;rs4680;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"NON-STEROIDS""";COMT;AA;rs4680;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""ERGOT ALKALOIDS""";COMT;AA;rs4680;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""OPIOIDS""";COMT;AA;rs4680;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""SUMATRIPTAN""";COMT;AA;rs4680;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
RISPERIDONE;CYP2D6;AA;rs1065852;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERTENSION
TACROLIMUS;CAPN10;CT;rs5030952;TOXICITY;INCREASED_RISK;DISEASE:DIABETES_MELLITUS
WARFARIN;CYP2C18;G;rs2901783;DOSAGE;nan;OTHER:OUTCOME_TIME_TO_STABLE_DOSE
IDARUBICIN;RAC2;AA;rs13058338;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
"""ANALGESICS""";DRD2;AA;rs6275;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""ANTIINFLAMMATORY AGENTS";DRD2;AA;rs6275;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"NON-STEROIDS""";DRD2;AA;rs6275;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""ERGOT ALKALOIDS""";DRD2;AA;rs6275;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""OPIOIDS""";DRD2;AA;rs6275;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
"""SUMATRIPTAN""";DRD2;AA;rs6275;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS | SUBSTANCE_WITHDRAWAL_SYNDROME
IDARUBICIN;NCF4;AA;rs1883112;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
OPIOIDS;OPRM1;AG;rs9479757;OTHER;DECREASED_RISK;DISEASE:OPIOID-RELATED_DISORDERS
TACROLIMUS;CYP3A5;CC;rs776746;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
PEGINTERFERON ALFA-2B;ITPA;AA + AC;rs1127354;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ANEMIA
PROTEASE INHIBITORS;ITPA;AA + AC;rs1127354;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ANEMIA
RIBAVIRIN;ITPA;AA + AC;rs1127354;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ANEMIA
OPIOIDS;GAL;CC;rs948854;OTHER;INCREASED_RISK;DISEASE:OPIOID-RELATED_DISORDERS
OPIOIDS;ABCB1;GG;rs1045642;OTHER;DECREASED_RISK;DISEASE:OPIOID-RELATED_DISORDERS
OPIOIDS;OPRD1;A;rs2236861;OTHER;DECREASED_RISK;DISEASE:OPIOID-RELATED_DISORDERS
IDARUBICIN;CYBA;AG + GG;rs4673;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
HYDROCHLOROTHIAZIDE;NOS3;GG;rs1799983;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_DIASTOLIC_BLOOD_PRESSURE
IDARUBICIN;CYBA;AA + AG;rs4673;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PRAVASTATIN;CETP;A;rs708272;EFFICACY;INCREASED_RISK;DISEASE:DEATH
PEGINTERFERON ALFA-2B;SLC28A2;TT;rs11854484;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
PROTEASE INHIBITORS;SLC28A2;TT;rs11854484;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
RIBAVIRIN;SLC28A2;TT;rs11854484;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
DACLATASVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
DACLATASVIR;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SOFOSBUVIR;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SOFOSBUVIR;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
DIURETICS;PDE4D;TT;rs702553;EFFICACY;DECREASED_EFFICACY;EFFICACY:BASELINE_MEAN_ARTERIAL_BLOOD_PRESSURE
CITALOPRAM;ABCB1;T;rs2235040;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EFFECTS
FLUVOXAMINE;ABCB1;T;rs2235040;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EFFECTS
PAROXETINE;ABCB1;T;rs2235040;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EFFECTS
SERTRALINE;ABCB1;T;rs2235040;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EFFECTS
VENLAFAXINE;ABCB1;T;rs2235040;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EFFECTS
ESCITALOPRAM;KCNE1;C;rs1805127;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_INHIBITION
ESCITALOPRAM;KCNE1;TT;rs4817668;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED_RISK;OTHER:HIGH_PLATELET_REACTIVITY
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;T;rs588765;EFFICACY;EFFICACY;EFFICACY:INCREASED_CHANCE_OF_ACHIEVING_6_MONTH_ABSTINENCE_IF_PRESCRIBED_NRT_(NICOTIENE_REPLACEMENT_THERAPY)
NO_DRUG_RELATED;CHRNA3;A;rs1051730;EFFICACY;EFFICACY;EFFICACY:DECREASED_CHANCE_OF_ACHIEVING_6_MONTH_ABSTINENCE_IN_THE_PLACEBO_GROUP
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PANCYTOPENIA | THROMBOCYTOPENIA
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PANCYTOPENIA | THROMBOCYTOPENIA
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3;A;rs1051730;EFFICACY;EFFICACY;EFFICACY:INCREASED_CHANCE_OF_ACHIEVING_6_MONTH_ABSTINENCE_IF_PRESCRIBED_NRT_(NICOTIENE_REPLACEMENT_THERAPY)
CITALOPRAM;ABCB1;G;rs2032583;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EFFECTS
FLUVOXAMINE;ABCB1;G;rs2032583;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EFFECTS
PAROXETINE;ABCB1;G;rs2032583;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EFFECTS
SERTRALINE;ABCB1;G;rs2032583;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EFFECTS
VENLAFAXINE;ABCB1;G;rs2032583;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EFFECTS
FLUOROURACIL;DPYD;CC;rs1801159;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
FLUOROURACIL;DPYD;CC;rs1801159;LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
FLUOROURACIL;DPYD;CC;rs1801159;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | VOMITING
FLUOROURACIL;DPYD;CC;rs1801159;LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | VOMITING
CISPLATIN;ABCB1;C;rs4148737;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
CYCLOPHOSPHAMIDE;ABCB1;C;rs4148737;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
DOXORUBICIN;ABCB1;C;rs4148737;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
METHOTREXATE;ABCB1;C;rs4148737;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
VINCRISTINE;ABCB1;C;rs4148737;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
CISPLATIN;ABCC3;T;rs4148416;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
CYCLOPHOSPHAMIDE;ABCC3;T;rs4148416;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
DOXORUBICIN;ABCC3;T;rs4148416;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
METHOTREXATE;ABCC3;T;rs4148416;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
VINCRISTINE;ABCC3;T;rs4148416;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
NO_DRUG_RELATED;FOXO3;TT;rs4946936;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
NEVIRAPINE;ABCB1;A;rs1045642;TOXICITY;DECREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
NO_DRUG_RELATED;FOXO3;GG;rs17069665;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
NO_DRUG_RELATED;ARNT;T/del + del/del;rs3215133;OTHER;DECREASED_LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS
METHADONE;ARRB2;GG;rs2036657;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN
CYCLOPHOSPHAMIDE;ABCB1;A;rs2032582;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
EPIRUBICIN;ABCB1;A;rs2032582;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
PACLITAXEL;ABCB1;A;rs2032582;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ETHANOL;GHSR;AG;rs2232165;OTHER;nan;OTHER:HEAVY_CONSUMPTION
CYCLOPHOSPHAMIDE;ABCB1;G;rs1045642;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
EPIRUBICIN;ABCB1;G;rs1045642;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
PACLITAXEL;ABCB1;G;rs1045642;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CISPLATIN;ABCB1;C;rs10276036;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:OVERALL_SURVIVAL
CYCLOPHOSPHAMIDE;ABCB1;C;rs10276036;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:OVERALL_SURVIVAL
DOXORUBICIN;ABCB1;C;rs10276036;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:OVERALL_SURVIVAL
METHOTREXATE;ABCB1;C;rs10276036;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:OVERALL_SURVIVAL
VINCRISTINE;ABCB1;C;rs10276036;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:OVERALL_SURVIVAL
ANTIPSYCHOTICS;NEFM;G;rs1379357;EFFICACY;EFFICACY;EFFICACY:RESPONSE_TIME
CISPLATIN;ABCB1;G;rs1128503;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
CYCLOPHOSPHAMIDE;ABCB1;G;rs1128503;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
DOXORUBICIN;ABCB1;G;rs1128503;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
METHOTREXATE;ABCB1;G;rs1128503;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
VINCRISTINE;ABCB1;G;rs1128503;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
ANTIPSYCHOTICS;NEFM;G;rs1457266;EFFICACY;EFFICACY;EFFICACY:RESPONSE_TIME
NO_DRUG_RELATED;ARNT;AA + AG;rs12410394;OTHER;DECREASED_LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS
CELECOXIB;IL23R;A;rs7518660;TOXICITY;INCREASED_RISK;DISEASE:ADENOMA
CELECOXIB;ALOX12;A;rs11078659;TOXICITY;INCREASED_RISK;DISEASE:ADENOMA
NO_DRUG_RELATED;CYP1A2;CT + TT;rs2470890;OTHER;DECREASED_LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS
NO_DRUG_RELATED;nan;CT + TT;rs11072508;OTHER;DECREASED_LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS
CELECOXIB;PTGES;C;rs2302821;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_TOXICITY_AND_SYMPTOMS
NO_DRUG_RELATED;CSK;CG + GG;rs4886410;OTHER;DECREASED_LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS
CELECOXIB;PTGER4;T;rs4133101;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITIES
CARBOPLATIN;ALDH3A1;CC + CG;rs2228100;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:CYSTITIS
CYCLOPHOSPHAMIDE;ALDH3A1;CC + CG;rs2228100;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:CYSTITIS
THIOTEPA;ALDH3A1;CC + CG;rs2228100;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:CYSTITIS
TAMOXIFEN;ABCC2;AA;rs3740065;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE_OF_BREAST_CANCER
TAMOXIFEN;ABCC2;AA;rs3740065;LADME_PK;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE_OF_BREAST_CANCER
CAFFEINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:INSOMNIA
DEXAMETHASONE;ABCB1;GG;rs1045642;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
DOXORUBICIN;ABCB1;GG;rs1045642;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
VINCRISTINE;ABCB1;GG;rs1045642;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
FARGLITAZAR;SCNN1B;A;rs34241435;TOXICITY;nan;SIDE_EFFECT:OEDEMA
INSULINS AND ANALOGUES;SCNN1B;A;rs34241435;TOXICITY;nan;SIDE_EFFECT:OEDEMA
HYDROCHLOROTHIAZIDE;SCNN1G;CC;rs5723;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_OFFICE_DIASTOLIC_BLOOD_PRESSURE
FARGLITAZAR;SCNN1B;A;rs889299;TOXICITY;nan;SIDE_EFFECT:OEDEMA
GLYBURIDE;SCNN1B;A;rs889299;TOXICITY;nan;SIDE_EFFECT:OEDEMA
HYDROCHLOROTHIAZIDE;SCNN1G;TT;rs5729;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_OFFICE_DIASTOLIC_BLOOD_PRESSURE
GEFITINIB;IKBKE;CC;rs12142086;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
NICOTINE;CHRNA5;C;rs680244;OTHER;DECREASED_LIKELIHOOD;OTHER:ABSTINENCE
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS | ORAL_ULCER
METHADONE;ARRB2;CC;rs1045280;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN
TACROLIMUS;CYP3A5;CT;rs776746;EFFICACY;DECREASED_EFFICACY;EFFICACY:DOSE-ADJUSTED_TACROLIMUS_BLOOD_CONCENTRATION
LORAZEPAM;UGT2B15;AA;rs1902023;LADME_PK;INCREASED_PK;PK:AREA_UNDER_THE_VISUAL_ANALOG_SCALE-TIME_CURVE_DURING_THE_INDUCED_STATE
CYCLOPHOSPHAMIDE;ABCB1;G;rs3213619;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
EPIRUBICIN;ABCB1;G;rs3213619;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
PACLITAXEL;ABCB1;G;rs3213619;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CYCLOPHOSPHAMIDE;TUBB2A;C;rs9501929;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
EPIRUBICIN;TUBB2A;C;rs9501929;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
PACLITAXEL;TUBB2A;C;rs9501929;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
NALOXONE;COMT;GG;rs4680;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ERYTHEMA
OXYCODONE;COMT;GG;rs4680;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ERYTHEMA
TACROLIMUS;CYP3A4;CT;rs2740574;LADME_PK;DECREASED_PK;PK:DOSE-ADJUSTED_TACROLIMUS_BLOOD_CONCENTRATIONS
NICOTINE;CHRNA5;A;rs16969968;OTHER;DECREASED_LIKELIHOOD;OTHER:ABSTINENCE
METHADONE;ARRB2;AA;rs3786047;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
BISOPROLOL;CYP3A5;TT;rs776746;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_SYSTOLIC_BLOOD_PRESSURE | ELEVATED_DIASTOLIC_BLOOD_PRESSURE
NALOXONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ERYTHEMA
OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ERYTHEMA
PAZOPANIB;VEGFA;CC;rs2010963;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
HYDROCHLOROTHIAZIDE;WNK1;GG;rs1159744;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_WHOLE_DAY_AMBULATORY_BLOOD_PRESSURE
TAMOXIFEN;CYP2C19;T;rs12248560;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CYCLOPHOSPHAMIDE;CYP2B6;TT;rs3745274;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
NO_DRUG_RELATED;SLC22A3;TT;rs2504938;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
NALOXONE;COMT;AA;rs4680;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
OXYCODONE;COMT;AA;rs4680;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
CYCLOPHOSPHAMIDE;CYP2B6;GT;rs3745274;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
FLUOROURACIL;UMPS;CC + CG;rs1801019;TOXICITY;nan;DISEASE:DIARRHEA
FLUOROURACIL;UMPS;CC + CG;rs1801019;LADME_PK;nan;DISEASE:DIARRHEA
LEUCOVORIN;UMPS;CC + CG;rs1801019;TOXICITY;nan;DISEASE:DIARRHEA
LEUCOVORIN;UMPS;CC + CG;rs1801019;LADME_PK;nan;DISEASE:DIARRHEA
FLUOROURACIL;UMPS;CC;rs1801019;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
FLUOROURACIL;UMPS;CC;rs1801019;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
LEUCOVORIN;UMPS;CC;rs1801019;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
LEUCOVORIN;UMPS;CC;rs1801019;LADME_PK;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
BUPRENORPHINE;COMT;AG + GG;rs4680;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:PAIN
METHADONE;COMT;AG + GG;rs4680;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:PAIN
CAPECITABINE;DPYD;T;rs56038477;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
FLUOROURACIL;DPYD;T;rs56038477;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
NO_DRUG_RELATED;SLC22A3;AA;rs512077;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
BUPRENORPHINE;OPRM1;AG + GG;rs1799971;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:PAIN
METHADONE;OPRM1;AG + GG;rs1799971;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:PAIN
CAPECITABINE;DPYD;CC + CT;rs2297595;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;DPYD;CC + CT;rs2297595;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
GLUCARPIDASE;ABCC4;AG + GG;rs7317112;TOXICITY;INCREASED_RISK;OTHER:NEPHROTOXICITY
HYDROCHLOROTHIAZIDE;ADRB2;AA + AG;rs2400707;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_WHOLE_DAY_AMBULATORY_BLOOD_PRESSURE
CYCLOPHOSPHAMIDE;CYP2B6;TT;rs3745274;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
NICOTINE;CHRNA5;GG;rs16969968;OTHER;INCREASED;OTHER:FUNCTIONAL_MRI_REACTIVITY_TO_SMOKING_IMAGES
HYDROCHLOROTHIAZIDE;WNK1;CC;rs1159744;OTHER;INCREASED;SIDE_EFFECT:URINARY_POTASSIUM_EXCRETION
HEROIN;DRD2;A;rs1076560;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:HEROIN_DEPENDENCE
SUFENTANIL;ABCB1;GG;rs1128503;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:POSTOPERATIVE_PAIN
HYDROCHLOROTHIAZIDE;WNK1;CC + CT;rs2107614;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_WHOLE_DAY_AMBULATORY_BLOOD_PRESSURE
HYDROCHLOROTHIAZIDE;RAD52;CC;rs2277869;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_WHOLE_DAY_AMBULATORY_BLOOD_PRESSURE
HYDROCHLOROTHIAZIDE;WNK1;CC;rs2277869;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_WHOLE_DAY_AMBULATORY_BLOOD_PRESSURE
ASPARAGINASE;XRCC1;AA + AG;rs1799782;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
CYCLOPHOSPHAMIDE;XRCC1;AA + AG;rs1799782;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
CYTARABINE;XRCC1;AA + AG;rs1799782;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
DOXORUBICIN;XRCC1;AA + AG;rs1799782;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
MERCAPTOPURINE;XRCC1;AA + AG;rs1799782;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
PREDNISONE;XRCC1;AA + AG;rs1799782;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
VINCRISTINE;XRCC1;AA + AG;rs1799782;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
METFORMIN;SLC47A2;T;rs34399035;LADME_PK;DECREASED_PK;PK:METFORMIN_UPTAKE_IN_HEK-293_CELLS_AND_REDUCTION_IN_PROTEIN_EXPRESSION_LEVELS
OXALIPLATIN;ABCB1;AA;rs1128503;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ANLOTINIB;KDR;A;rs1870377;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERTENSION | HAND-FOOT_SYNDROME
APATINIB;KDR;A;rs1870377;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERTENSION | HAND-FOOT_SYNDROME
AXITINIB;KDR;A;rs1870377;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERTENSION | HAND-FOOT_SYNDROME
BEVACIZUMAB;KDR;A;rs1870377;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERTENSION | HAND-FOOT_SYNDROME
SORAFENIB;KDR;A;rs1870377;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERTENSION | HAND-FOOT_SYNDROME
SUNITINIB;KDR;A;rs1870377;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERTENSION | HAND-FOOT_SYNDROME
CYTARABINE;CBR3;GG;rs8133052;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
IDARUBICIN;CBR3;GG;rs8133052;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
WARFARIN;nan;T;rs16871327;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
WARFARIN;EPHA7;C;rs78132896;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
FENOFIBRATE;FABP1;CC + CT;rs2241883;TOXICITY;INCREASED_RISK;DISEASE:HYPERTRIGLYCERIDEMIA
ANTIPSYCHOTICS;SNAP25;TT;rs1051312;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
GEFITINIB;TAB2;CT + TT;rs577001;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DIARRHEA
PEGINTERFERON ALFA-2B;IFIT1;TT;rs304478;EFFICACY;INCREASED_EFFICACY;EFFICACY:SVR_(SUSTAINED_VIROLOGICAL_RESPONSE)
RIBAVIRIN;IFIT1;TT;rs304478;EFFICACY;INCREASED_EFFICACY;EFFICACY:SVR_(SUSTAINED_VIROLOGICAL_RESPONSE)
PEGINTERFERON ALFA-2B;OASL;T;rs12819210;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;OASL;T;rs12819210;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
OXALIPLATIN;ABCB1;AG;rs1045642;EFFICACY;INCREASED_EFFICACY;EFFICACY:RECURRENCE-FREE_SURVIVAL
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PAZOPANIB;VEGFA;TT;rs833061;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
COCAINE;SLC6A3;TT;rs6347;TOXICITY;INCREASED_RISK;DISEASE:DEATH
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE_(RR)
ATORVASTATIN;ABCB1;AA;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
CYCLOPHOSPHAMIDE;ABCC2;A;rs8187710;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
EPIRUBICIN;ABCC2;A;rs8187710;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
PACLITAXEL;ABCC2;A;rs8187710;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
COCAINE;DRD2;A;rs1076560;TOXICITY;INCREASED_RISK;DISEASE:DEATH
ANTIINFLAMMATORY AGENTS;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_HEMORRHAGE
NON-STEROIDS;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_HEMORRHAGE
CYCLOPHOSPHAMIDE;ABCC2;A;rs17222723;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
EPIRUBICIN;ABCC2;A;rs17222723;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
PACLITAXEL;ABCC2;A;rs17222723;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CYCLOPHOSPHAMIDE;CYP1B1;C;rs1056836;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
EPIRUBICIN;CYP1B1;C;rs1056836;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
PACLITAXEL;CYP1B1;C;rs1056836;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ANLOTINIB;KDR;A;rs1870377;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
APATINIB;KDR;A;rs1870377;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
AXITINIB;KDR;A;rs1870377;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
BEVACIZUMAB;KDR;A;rs1870377;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SORAFENIB;KDR;A;rs1870377;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SUNITINIB;KDR;A;rs1870377;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
GEFITINIB;EGFR;G;rs121434568;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE_(RR)
GEFITINIB;NFKBIA;AA + AT;rs2233407;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CYCLOPHOSPHAMIDE;SPIDR;G;rs6473187;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
EPIRUBICIN;SPIDR;G;rs6473187;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
PACLITAXEL;SPIDR;G;rs6473187;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
GEFITINIB;NR1H2;CT + TT;rs2695121;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DIARRHEA
CYCLOPHOSPHAMIDE;SLCO1B1;T;rs3829306;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
EPIRUBICIN;SLCO1B1;T;rs3829306;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
PACLITAXEL;SLCO1B1;T;rs3829306;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
SUNITINIB;VEGFA;CG + GG;rs2010963;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CYCLOPHOSPHAMIDE;EPHA6;G;rs301927;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
EPIRUBICIN;EPHA6;G;rs301927;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
PACLITAXEL;EPHA6;G;rs301927;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
WARFARIN;nan;G;rs115112393;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
ANTIPSYCHOTICS;HTR2C;GG;rs6318;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
ANTIPSYCHOTICS;HTR2C;CC;rs3813929;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
ANTIPSYCHOTICS;HTR2C;GG;rs518147;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
ATORVASTATIN;ABCB1;AA;rs2032582;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
COCAINE;DRD2;A;rs2283265;TOXICITY;INCREASED_RISK;DISEASE:DEATH
ANLOTINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
APATINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
AXITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
BEVACIZUMAB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
SORAFENIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
SUNITINIB;KDR;CT + TT;rs2305948;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
ANTIPSYCHOTICS;DRD2;A;rs6275;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
ANTIPSYCHOTICS;DRD2;CC;rs7131056;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
ANTIPSYCHOTICS;INSIG2;C;rs17047764;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
ANTIPSYCHOTICS;GNB3;TT;rs5443;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
ANTIPSYCHOTICS;MC4R;AA;rs489693;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
TIANEPTINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED_RISK;OTHER:SUICIDAL_IDEATION
ATORVASTATIN;ABCB1;A;rs1128503;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
ANTIPSYCHOTICS;BDNF;CC;rs6265;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
ANTIPSYCHOTICS;BDNF-AS;CC;rs6265;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
ANTIPSYCHOTICS;ADRA2A;G;rs1800544;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
ANLOTINIB;KDR;G;rs2071559;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
APATINIB;KDR;G;rs2071559;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
AXITINIB;KDR;G;rs2071559;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
BEVACIZUMAB;KDR;G;rs2071559;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SORAFENIB;KDR;G;rs2071559;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SUNITINIB;KDR;G;rs2071559;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
THEOPHYLLINE;CYP1A2;GG;rs2069514;LADME_PK;INCREASED_PK;PK:RATIO_OF_1,3_DMU/THEOPHYLLINE
ANTIPSYCHOTICS;DRD2;del;rs1799732;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
GEFITINIB;NFKBIA;AG + GG;rs2233409;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DIARRHEA
GEFITINIB;NFKBIA;AG + GG;rs8904;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CLOPIDOGREL_RESISTANCE
GEFITINIB;NFKBIB;CC;rs2053071;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
LEVODOPA;DRD3;CT + TT;rs6280;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HALLUCINATIONS
GEFITINIB;NFKBIA;AG + GG;rs2233406;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DIARRHEA
CLOPIDOGREL;ITGB3;C;rs5918;EFFICACY;EFFICACY;EFFICACY:LESS_DECREASE_IN_THE_PLATELET_REACTIVITY_AFTER_600_MG_OF_CLOPIDOGREL
CLOPIDOGREL;ITGB3;CT;rs5918;EFFICACY;DECREASED_EFFICACY;EFFICACY:ANTIPLATELET_EFFECT_TO_A_300_MG_CLOPIDOGREL_LOADING-DOSE_UP_TO_24_H_FOLLOWING_INTERVENTION
CYTARABINE;CYP2E1;A;rs2070673;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
FLUDARABINE;CYP2E1;A;rs2070673;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
GEMTUZUMAB OZOGAMICIN;CYP2E1;A;rs2070673;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
IDARUBICIN;CYP2E1;A;rs2070673;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
CYTARABINE;CYP2E1;T;rs2515641;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
FLUDARABINE;CYP2E1;T;rs2515641;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
GEMTUZUMAB OZOGAMICIN;CYP2E1;T;rs2515641;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
IDARUBICIN;CYP2E1;T;rs2515641;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
CYTARABINE;SLCO1B1;C;rs4149056;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
FLUDARABINE;SLCO1B1;C;rs4149056;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
GEMTUZUMAB OZOGAMICIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
IDARUBICIN;SLCO1B1;C;rs4149056;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
PERINDOPRIL;AGTR1;TT;rs275651;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:CARDIAC_EVENTS
CYTARABINE;SULT2B1;T;rs2302948;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:FEVER
FLUDARABINE;SULT2B1;T;rs2302948;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:FEVER
GEMTUZUMAB OZOGAMICIN;SULT2B1;T;rs2302948;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:FEVER
IDARUBICIN;SULT2B1;T;rs2302948;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:FEVER
ESCITALOPRAM;KCNH2;AA;rs3807372;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
HEROIN;OPRM1;AA + AG;rs1799971;OTHER;DECREASED_LIKELIHOOD;OTHER:ADDICTION
GEFITINIB;IKBKB;AA;rs9694958;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
CYTARABINE;SLC22A12;TT;rs11231825;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:FEVER
FLUDARABINE;SLC22A12;TT;rs11231825;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:FEVER
GEMTUZUMAB OZOGAMICIN;SLC22A12;TT;rs11231825;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:FEVER
IDARUBICIN;SLC22A12;TT;rs11231825;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:FEVER
GEFITINIB;IKBKE;CC + CT;rs3748022;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
ASPIRIN;FSIP1;G;rs7179742;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA
ASPIRIN;PTGS1;G;rs10306114;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_TO_ASPIRIN
DRUGS FOR TREATMENT OF TUBERCULOSIS;XPO1;AA;rs4430924;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ASPIRIN;CEP68;AA + AG;rs7572857;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA
CYCLOSPORINE;ABCB1;A;rs2032582;EFFICACY;INCREASED_RISK;DISEASE:TRANSPLANT_REJECTION
MYCOPHENOLATE MOFETIL;ABCB1;A;rs2032582;EFFICACY;INCREASED_RISK;DISEASE:TRANSPLANT_REJECTION
PAROXETINE;HTR2A;CC;rs6311;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NAUSEA
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;nan;G;rs10945919;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
AMISULPRIDE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
CLOZAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
HALOPERIDOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
OLANZAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
QUETIAPINE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
RISPERIDONE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
ZIPRASIDONE;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
ZUCLOPENTHIXOL;CYP2D6;A/DELA;rs5030655;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
DAUNORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEFT_VENTRICULAR_DYSFUNCTION
DOXORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEFT_VENTRICULAR_DYSFUNCTION
EPIRUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEFT_VENTRICULAR_DYSFUNCTION
ETHAMBUTOL;NAT2;AA;rs1799930;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;AA;rs1799930;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;AA;rs1799930;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;AA;rs1799930;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ETHAMBUTOL;NAT2;AG;rs1799931;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;AG;rs1799931;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;AG;rs1799931;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;AG;rs1799931;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
CETUXIMAB;KRAS;AC + CC;rs61764370;EFFICACY;INCREASED;DISEASE:PROGRESSION-FREE_SURVIVAL
PANITUMUMAB;KRAS;AC + CC;rs61764370;EFFICACY;INCREASED;DISEASE:PROGRESSION-FREE_SURVIVAL
ETHAMBUTOL;NAT2;TT;rs1041983;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;TT;rs1041983;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;TT;rs1041983;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;TT;rs1041983;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
CYCLOPHOSPHAMIDE;FGFR4;GG;rs351855;EFFICACY;INCREASED_LIKELIHOOD;OTHER:DISEASE_FREE_SURVIVAL
FLUOROURACIL;FGFR4;GG;rs351855;EFFICACY;INCREASED_LIKELIHOOD;OTHER:DISEASE_FREE_SURVIVAL
METHOTREXATE;FGFR4;GG;rs351855;EFFICACY;INCREASED_LIKELIHOOD;OTHER:DISEASE_FREE_SURVIVAL
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CERS6;A;rs13393173;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
CLOPIDOGREL;CES1;CT;rs71647871;LADME_PK;INCREASED_PK;PK:LEVELS_OF_CLOPIDOGREL_ACTIVE_METABOLITE
CLOPIDOGREL;CES1;CT;rs71647871;EFFICACY;DECREASED_EFFICACY;EFFICACY:ON-TREATMENT_ADP-INDUCED_PLATELET_AGGREGATION
CLOPIDOGREL;CES1;CT;rs71647871;EFFICACY;DECREASED_EFFICACY;EFFICACY:ON-TREATMENT_ADP-INDUCED_PLATELET_AGGREGATION
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;DECREASED_PK;PK:CMAX_OF_THE_ACTIVE_METABOLITE
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED_PK;PK:CMAX_OF_THE_ACTIVE_METABOLITE
CARBOPLATIN;MTHFR;AA;rs1801133;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PEMETREXED;MTHFR;AA;rs1801133;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
VEMURAFENIB;ABCB1;AA;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
VEMURAFENIB;CYP3A4;AA + AG;rs35599367;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARCINOMA | SQUAMOUS_CELL | HYPERBILIRUBINEMIA | NAUSEA,
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY_INDEX_(PRI)_AT_4_H_AFTER_THE_DOSING
CITALOPRAM;HTR2A;AA;rs7997012;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ESCITALOPRAM;HTR2A;AA;rs7997012;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
FLUOXETINE;HTR2A;AA;rs7997012;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
PAROXETINE;HTR2A;AA;rs7997012;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
SERTRALINE;HTR2A;AA;rs7997012;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY_INDEX_(PRI)_AT_4_H_AFTER_THE_DOSING
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
FLUOROURACIL;KLC1;GG;rs861539;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
FLUOROURACIL;XRCC3;GG;rs861539;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
IRINOTECAN;KLC1;GG;rs861539;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
IRINOTECAN;XRCC3;GG;rs861539;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
LEUCOVORIN;KLC1;GG;rs861539;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
LEUCOVORIN;XRCC3;GG;rs861539;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
TACROLIMUS;CYP3A5;TT;rs776746;DOSAGE;PK;PK:RISK_OF_BEING_UNDERDOSED
TACROLIMUS;CYP3A5;TT;rs776746;LADME_PK;PK;PK:RISK_OF_BEING_UNDERDOSED
OPIOIDS;SLC18A2;A;rs363332;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
OPIOIDS;SLC18A2;G;rs363334;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
OPIOIDS;SLC18A2;C;rs363338;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
CYCLOPHOSPHAMIDE;MISP;G;rs8110536;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
EPIRUBICIN;MISP;G;rs8110536;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
PACLITAXEL;MISP;G;rs8110536;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CLOPIDOGREL;CYP2C19;AA + AG;rs4986893;EFFICACY;EFFICACY;EFFICACY:HIGHER_P2Y12_REACTION_UNITS_(PRU)_AND_LOWER_PERCENT_INHIBITION
PACLITAXEL;EPHA5;TT;rs7349683;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_TO_CLOPIDOGREL
SUNITINIB;VEGFA;AA + AC;rs699947;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PAZOPANIB;VEGFA;CC;rs699947;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CYTARABINE;NQO2;CC;rs1143684;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
IDARUBICIN;NQO2;CC;rs1143684;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
PACLITAXEL;EPHA6;G;rs301927;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
TACROLIMUS;CYP3A5;CC;rs776746;TOXICITY;INCREASED_RISK;DISEASE:HYPERLIPIDEMIAS
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_TO_CLOPIDOGREL
WARFARIN;VEGFA;CC;rs35410204;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
PACLITAXEL;EPHA8;G;rs209709;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
URSODEOXYCHOLIC ACID;MGAT5;TT;rs661899;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
GLUCOCORTICOIDS;CDH2;AT + TT;rs1944294;TOXICITY;DECREASED;SIDE_EFFECT:BONE_DENSITY
METHOTREXATE;CDH2;AT + TT;rs1944294;TOXICITY;DECREASED;SIDE_EFFECT:BONE_DENSITY
RADIOTHERAPY;CDH2;AT + TT;rs1944294;TOXICITY;DECREASED;SIDE_EFFECT:BONE_DENSITY
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
MYCOPHENOLATE MOFETIL;IMPDH2;AG;rs11706052;TOXICITY;DECREASED_RISK;DISEASE:LYMPHOPENIA
PACLITAXEL;EPHA5;TT;rs7349683;TOXICITY;DECREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;EFFICACY;EFFICACY:HIGHER_P2Y12_REACTION_UNITS_(PRU)_AND_LOWER_PERCENT_INHIBITION
CYTARABINE;NQO1;AA;rs1800566;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
IDARUBICIN;NQO1;AA;rs1800566;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
WARFARIN;VEGFA;AA;rs866236;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
PACLITAXEL;ABCG1;AA;rs492338;TOXICITY;INCREASED_RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CISPLATIN;AQP1;CC + CG;rs1049305;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
OXALIPLATIN;ABCB1;AG;rs1128503;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PACLITAXEL;EPHA6;AA;rs301927;TOXICITY;DECREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
NO_DRUG_RELATED;SULT1A1;T;rs1042028;OTHER;INCREASED_LIKELIHOOD;DISEASE:BREAST_NEOPLASMS
NO_DRUG_RELATED;SULT1A1;T;rs1042028;OTHER;INCREASED_LIKELIHOOD;DISEASE:LUNG_NEOPLASMS
NO_DRUG_RELATED;SULT1A1;T;rs1042028;OTHER;INCREASED_LIKELIHOOD;OTHER:LYMPH_NODE_METASTASIS
CLOPIDOGREL;CYP2C19;AG;rs4244285;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_RESPONSIVENESS_TO_CLOPIDOGREL
AMITRIPTYLINE;CYP2D6;TT;rs3892097;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
CLOMIPRAMINE;CYP2D6;TT;rs3892097;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
DOXEPIN;CYP2D6;TT;rs3892097;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
IMIPRAMINE;CYP2D6;TT;rs3892097;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
MAPROTILINE;CYP2D6;TT;rs3892097;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
NORTRIPTYLINE;CYP2D6;TT;rs3892097;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
OPIPRAMOL;CYP2D6;TT;rs3892097;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
CALCIUM;VDR;G;rs731236;EFFICACY;INCREASED_RISK;DISEASE:FRACTURES | BONE
NO_DRUG_RELATED;SULT1A1;T;rs1042028;OTHER;DECREASED_LIKELIHOOD;DISEASE:UROLOGIC_NEOPLASMS
CLOPIDOGREL;CYP2C19;AG;rs4244285;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_RESPONSIVENESS_TO_CLOPIDOGREL
NO_DRUG_RELATED;SULT1A1;T;rs1042028;OTHER;INCREASED_LIKELIHOOD;DISEASE:BREAST_NEOPLASMS
AMITRIPTYLINE;ABCB1;T;rs2235040;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
CITALOPRAM;ABCB1;T;rs2235040;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
PAROXETINE;ABCB1;T;rs2235040;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
VENLAFAXINE;ABCB1;T;rs2235040;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
AMITRIPTYLINE;ABCB1;T;rs12720067;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
CITALOPRAM;ABCB1;T;rs12720067;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
PAROXETINE;ABCB1;T;rs12720067;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
VENLAFAXINE;ABCB1;T;rs12720067;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
ASPIRIN;IRS1;AG + GG;rs13431554;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
CLOPIDOGREL;IRS1;AG + GG;rs13431554;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
DOCETAXEL;VAC14;T;rs875858;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CLOPIDOGREL;CYP3A4;CT + TT;rs2242480;EFFICACY;EFFICACY;EFFICACY:REDUCED_GP_IIB/IIIA_ACTIVATION_AND_LOWER_PLATELET_ACTIVATION
AMITRIPTYLINE;ABCB1;C;rs10280101;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
CITALOPRAM;ABCB1;C;rs10280101;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
PAROXETINE;ABCB1;C;rs10280101;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
VENLAFAXINE;ABCB1;C;rs10280101;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
DIRECT FACTOR XA INHIBITORS;FGG;CC;rs1800792;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
DIRECT THROMBIN INHIBITORS;FGG;CC;rs1800792;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
AMITRIPTYLINE;ABCB1;A;rs7787082;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
CITALOPRAM;ABCB1;A;rs7787082;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
PAROXETINE;ABCB1;A;rs7787082;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
VENLAFAXINE;ABCB1;A;rs7787082;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
OPIOIDS;COMT;AG + GG;rs6269;OTHER;INCREASED_LIKELIHOOD;OTHER:REQUIRING_POSTOPERATIVE_INTERVENTION
FLUINDIONE;VKORC1;AA;rs9934438;EFFICACY;DECREASED_EFFICACY;EFFICACY:THE_TIME_TO_ACHIEVE_A_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE
FLUINDIONE;VKORC1;AA;rs9934438;EFFICACY;DECREASED_EFFICACY;EFFICACY:THE_TIME_TO_ACHIEVE_A_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE
OSIMERTINIB;EGFR;T;rs121434569;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL | OVERALL_SURVIVAL
AMITRIPTYLINE;ABCB1;C;rs4148739;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
CITALOPRAM;ABCB1;C;rs4148739;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
PAROXETINE;ABCB1;C;rs4148739;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
VENLAFAXINE;ABCB1;C;rs4148739;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
FLUINDIONE;VKORC1;AA;rs9934438;EFFICACY;EFFICACY;EFFICACY:SHORTER_TIME_TO_HAVE_OVER-ANTICOAGULATION_(INR_>4)_RISK
OPIOIDS;COMT;AG + GG;rs4680;OTHER;INCREASED_LIKELIHOOD;OTHER:REQUIRING_POSTOPERATIVE_INTERVENTION
ETHANOL;ADH1B;TT;rs1229984;LADME_PK;INCREASED_PK;PK:VMAX
AMITRIPTYLINE;ABCB1;C;rs11983225;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
CITALOPRAM;ABCB1;C;rs11983225;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
PAROXETINE;ABCB1;C;rs11983225;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
VENLAFAXINE;ABCB1;C;rs11983225;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
FLUINDIONE;VKORC1;AA;rs9934438;EFFICACY;EFFICACY;EFFICACY:SHORTER_TIME_TO_HAVE_OVER-ANTICOAGULATION_(INR_>4)_RISK
OPIOIDS;COMT;CG + GG;rs4818;OTHER;INCREASED_LIKELIHOOD;OTHER:REQUIRING_POSTOPERATIVE_INTERVENTION
FLUINDIONE;VKORC1;AA;rs9934438;EFFICACY;DECREASED_EFFICACY;EFFICACY:AVERAGE_DAILY_DOSE_DURING_THE_FIRST_PERIOD_OF_STABILITY
OPIOIDS;COMT;CC + CT;rs4633;OTHER;INCREASED_LIKELIHOOD;OTHER:REQUIRING_POSTOPERATIVE_INTERVENTION
AMITRIPTYLINE;ABCB1;G;rs10248420;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
CITALOPRAM;ABCB1;G;rs10248420;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
PAROXETINE;ABCB1;G;rs10248420;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
VENLAFAXINE;ABCB1;G;rs10248420;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
ETHAMBUTOL;NAT2;A;rs1799931;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ETHAMBUTOL;NAT2;A;rs1799931;LADME_PK;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;A;rs1799931;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;A;rs1799931;LADME_PK;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;A;rs1799931;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;NAT2;A;rs1799931;LADME_PK;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;A;rs1799931;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
RIFAMPIN;NAT2;A;rs1799931;LADME_PK;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ANTINEOPLASTIC AGENTS;UGT1A;TT;rs6744284;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
DIRECT FACTOR XA INHIBITORS;F2;TT;rs5896;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
DIRECT THROMBIN INHIBITORS;F2;TT;rs5896;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
BORTEZOMIB;PKNOX1;A;rs2839629;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ANTINEOPLASTIC AGENTS;UGT1A;T;rs6744284;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
SUNITINIB;VEGFA;A;rs699947;TOXICITY;INCREASED;SIDE_EFFECT:SYSTOLIC_BLOOD_PRESSURE_AND_INCREASED_RISK_OF_DEVELOPING_GRADE_3_HYPERTENSION
AMITRIPTYLINE;ABCB1;T;rs2235067;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
CITALOPRAM;ABCB1;T;rs2235067;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
PAROXETINE;ABCB1;T;rs2235067;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
VENLAFAXINE;ABCB1;T;rs2235067;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
ATENOLOL;FTO;G;rs9940629;OTHER;nan;DISEASE:HYPERCHOLESTEROLEMIA
SUNITINIB;VEGFA;C;rs833061;TOXICITY;INCREASED;SIDE_EFFECT:SYSTOLIC_BLOOD_PRESSURE_AND_INCREASED_RISK_OF_DEVELOPING_GRADE_3_HYPERTENSION
ALFENTANIL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:POSTOPERATIVE_PAIN
FENTANYL;OPRM1;AG + GG;rs1799971;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:POSTOPERATIVE_PAIN
SUNITINIB;VEGFA;G;rs2010963;TOXICITY;INCREASED;SIDE_EFFECT:SYSTOLIC_BLOOD_PRESSURE_AND_INCREASED_RISK_OF_DEVELOPING_GRADE_3_HYPERTENSION
AMITRIPTYLINE;ABCB1;G;rs4148740;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
CITALOPRAM;ABCB1;G;rs4148740;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
PAROXETINE;ABCB1;G;rs4148740;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
VENLAFAXINE;ABCB1;G;rs4148740;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
ATENOLOL;ABCB1;G;rs10267099;OTHER;INCREASED_RISK;DISEASE:HYPERCHOLESTEROLEMIA
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;OTHER;DECREASED;OTHER:PLATELET_FUNCTION
ATENOLOL;ABCB1;G;rs3213619;OTHER;INCREASED_RISK;DISEASE:HYPERCHOLESTEROLEMIA
CORTICOSTEROIDS;DCAF4;CC;rs7160796;EFFICACY;INCREASED_EFFICACY;EFFICACY:CHANGE_IN_FORCED_EXPIRATORY_VOLUME_IN_1_S_(FEV1)
SUNITINIB;NOS3;CC + CT;rs2070744;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GRADE_3_HYPERTENSION
ATENOLOL;PRKCB;GT + TT;rs11649514;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERGLYCEMIA
ATENOLOL;PRKCB;GT + TT;rs11649514;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERGLYCEMIA
ATENOLOL;FTO;AA;rs12595985;OTHER;INCREASED_RISK;DISEASE:HYPERCHOLESTEROLEMIA
CYCLOPHOSPHAMIDE;ALDH1A1;CT + TT;rs8187996;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY | TREATMENT_MODIFICATION
CLOPIDOGREL;P2RY12;AG + GG;rs2046934;OTHER;DECREASED;OTHER:PLATELET_FUNCTION
ATENOLOL;GALNT2;T;rs2144297;OTHER;nan;DISEASE:HYPERCHOLESTEROLEMIA
ATENOLOL;GALNT2;C;rs2144300;OTHER;nan;DISEASE:HYPERCHOLESTEROLEMIA
ETHANOL;ANKK1;A;rs1800497;TOXICITY;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
ETHANOL;DRD2;A;rs1800497;TOXICITY;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
WARFARIN;CYP2C9;AC;rs1057910;DOSAGE;DECREASED_PK;PK:IN_VIVO_METABOLISM_OF_(S)-WARFARIN_BUT_NOT_(R)-WARFARIN
WARFARIN;CYP2C9;AC;rs1057910;LADME_PK;DECREASED_PK;PK:IN_VIVO_METABOLISM_OF_(S)-WARFARIN_BUT_NOT_(R)-WARFARIN
ATENOLOL;PLA2G4A;C;rs10157410;OTHER;INCREASED_RISK;DISEASE:HYPERCHOLESTEROLEMIA
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION_VALUES
ATENOLOL;PTGS2;G;rs4648287;OTHER;INCREASED_LIKELIHOOD;DISEASE:HYPERCHOLESTEROLEMIA
ISONIAZID;NOS2;CC;rs11080344;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;NOS2;CC;rs11080344;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ENALAPRIL;SLCO1B1;AA;rs2306283;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:COUGH
ISONIAZID;BACH1;GG;rs2070401;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;BACH1;GG;rs2070401;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
CLOPIDOGREL;CYP2C19;CT + TT;rs12248560;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION_VALUES
ISONIAZID;MAFK;AA + AG;rs4720833;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;MAFK;AA + AG;rs4720833;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID;XPO1;AC + CC;rs11125883;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;XPO1;AC + CC;rs11125883;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
CLOPIDOGREL;CYP2C19;CC;rs12248560;EFFICACY;EFFICACY;EFFICACY:GREATER_PLATELET_INHIBITION_2_H_AFTER_A_600-MG_DOSE
ISONIAZID;NAT2;T;rs1041983;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ISONIAZID;NAT2;G;rs1495741;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLOPIDOGREL;CYP2C9;C;rs1057910;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_INHIBITION_7H_AFTER_A_CLOPIDOGREL_600-MG_LOADING_DOSE
CAPECITABINE;DPYD;CT + TT;rs1801158;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;DPYD;CT + TT;rs1801158;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PLATELET_AGGREGATION_INHIBITION
PEGINTERFERON ALFA-2A;ITPA;AA;rs7270101;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
PEGINTERFERON ALFA-2B;ITPA;AA;rs7270101;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
RIBAVIRIN;ITPA;AA;rs7270101;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
ANASTROZOLE;ESR1;A;rs9340799;OTHER;INCREASED_RISK;DISEASE:MUSCULOSKELETAL_PAIN
LETROZOLE;ESR1;A;rs9340799;OTHER;INCREASED_RISK;DISEASE:MUSCULOSKELETAL_PAIN
CLOPIDOGREL;CYP3A5;CT + TT;rs776746;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PLATELET_AGGREGATION_INHIBITION
ANASTROZOLE;ESR1;C;rs2234693;OTHER;INCREASED_RISK;DISEASE:MUSCULOSKELETAL_PAIN
LETROZOLE;ESR1;C;rs2234693;OTHER;INCREASED_RISK;DISEASE:MUSCULOSKELETAL_PAIN
CLOPIDOGREL;P2RY12;AG + GG;rs2046934;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PLATELET_AGGREGATION_INHIBITION
NO_DRUG_RELATED;CYP3A4;CC;rs2740574;OTHER;INCREASED_LIKELIHOOD;OTHER:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION
OPIOIDS;OPRM1;AA + AG;rs1799971;OTHER;DECREASED_LIKELIHOOD;OTHER:ADDICTION
CAPECITABINE;DPYD;C;rs75017182;DOSAGE;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
CAPECITABINE;DPYD;C;rs75017182;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;DPYD;C;rs75017182;DOSAGE;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;DPYD;C;rs75017182;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
REPAGLINIDE;NEUROD1;CT + TT;rs1801262;EFFICACY;DECREASED_EFFICACY;EFFICACY:DIFFERENCE_IN_POSTPRANDIAL_PLASMA_GLUCOSE_(BEFORE_AND_AFTER_DRUG_TREATMENT)
REPAGLINIDE;PAX4;AA + AG;rs114202595;EFFICACY;DECREASED_EFFICACY;EFFICACY:DIFFERENCE_IN_POSTPRANDIAL_PLASMA_GLUCOSE_(BEFORE_AND_AFTER_DRUG_TREATMENT)
NO_DRUG_RELATED;CYP3A4;CT;rs2740574;OTHER;INCREASED_RISK;DISEASE:ENDOMETRIAL_NEOPLASMS
VINCRISTINE;COCH;CG + GG;rs1045644;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CETUXIMAB;EGFR;CC;rs712830;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
IRINOTECAN;EGFR;CC;rs712830;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
LEUCOVORIN;EGFR;CC;rs712830;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
TEGAFUR;EGFR;CC;rs712830;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
TAMOXIFEN;CYP3A4;CT;rs2740574;OTHER;INCREASED_RISK;DISEASE:ENDOMETRIAL_NEOPLASMS
VINCRISTINE;nan;C;rs7963521;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
REPAGLINIDE;NEUROD1;CT + TT;rs1801262;EFFICACY;DECREASED_EFFICACY;EFFICACY:DIFFERENCE_IN_FASTING_PLASMA_GLUCOSE_(BEFORE_AND_AFTER_DRUG_TREATMENT)
NO_DRUG_RELATED;VDR;G;rs3782905;OTHER;INCREASED_RISK;DISEASE:ASTHMA
OPIOIDS;OPRL1;C;rs6090043;TOXICITY;INCREASED_RISK;DISEASE:OPIOID-RELATED_DISORDERS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH-ON_CLOPIDOGREL_PLATELET_REACTIVITY
CLOPIDOGREL;P2RY12;A;rs6785930;EFFICACY;INCREASED_RISK;SIDE_EFFECT:NEUROLOGICAL_EVENTS
OPIOIDS;COMT;AA + AG;rs165599;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE
DOCETAXEL;ABCB1;A;rs2032582;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
PACLITAXEL;ABCB1;A;rs2032582;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
NO_DRUG_RELATED;VDR;G;rs2239185;nan;INCREASED_RISK;DISEASE:ASTHMA
NO_DRUG_RELATED;VDR;T;rs1540339;nan;INCREASED_RISK;DISEASE:ASTHMA
CISPLATIN;AQP1;CC + CG;rs1049305;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALOPECIA
CLOPIDOGREL;CYP2C19;AA + AG;rs4986893;EFFICACY;DECREASED_EFFICACY;EFFICACY:ANTIPLATELET_EFFECT
CALCITRIOL;VDR;A;rs2228570;EFFICACY;INCREASED_RISK;DISEASE:FRACTURES | BONE
CISPLATIN;AQP1;CC + CG;rs1049305;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ANEMIA
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_POST-TREATMENT_PLATELET_REACTIVITY
PERINDOPRIL;BDKRB1;AA;rs12050217;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:CARDIAC_EVENTS
CISPLATIN;AQP1;CC;rs1049305;TOXICITY;INCREASED_RISK;SIDE_EFFECT:THROMBOCYTOPENIA
ATENOLOL;GRK4;TT;rs1801058;EFFICACY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_OUTCOMES
ATENOLOL;GRK4;TT;rs1801058;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_OUTCOMES
ATENOLOL;GRK4;TT;rs1801058;OTHER;INCREASED_RISK;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_OUTCOMES
VERAPAMIL;GRK4;TT;rs1801058;EFFICACY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_OUTCOMES
VERAPAMIL;GRK4;TT;rs1801058;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_OUTCOMES
VERAPAMIL;GRK4;TT;rs1801058;OTHER;INCREASED_RISK;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_OUTCOMES
CLOZAPINE;CYP1A2;AA;rs762551;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
MYCOPHENOLATE MOFETIL;IMPDH1;CT + TT;rs2278294;TOXICITY;DECREASED_RISK;SIDE_EFFECT:BIOPSY-PROVEN_ACUTE_REJECTION
PLATINUM COMPOUNDS;HLA-DOB;CT + TT;rs2071554;EFFICACY;INCREASED_RISK;DISEASE:DEATH
PLATINUM COMPOUNDS;nan;AA + AG;rs2900420;EFFICACY;DECREASED_RISK;DISEASE:DEATH
CLOZAPINE;CYP1A2;AA;rs762551;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
CYCLOPHOSPHAMIDE;DROSHA;T;rs639174;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CYTARABINE;DROSHA;T;rs639174;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
DAUNORUBICIN;DROSHA;T;rs639174;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
MERCAPTOPURINE;DROSHA;T;rs639174;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
METHOTREXATE;DROSHA;T;rs639174;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
PREDNISONE;DROSHA;T;rs639174;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
VINCRISTINE;DROSHA;T;rs639174;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
OPIOIDS;DRD2;AG + GG;rs6275;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE
CISPLATIN;TPMT;T;rs12201199;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
ISONIAZID;CYP2E1;A;rs6413432;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;CYP2E1;A;rs6413432;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
RIFAMPIN;CYP2E1;A;rs6413432;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
CISPLATIN;nan;AG + GG;rs3746444;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ACENOCOUMAROL;CYP2C9;CC;rs1057910;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE | ADVERSE_EVENTS
WARFARIN;CYP2C9;CC;rs1057910;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE | ADVERSE_EVENTS
ASPIRIN;PTGS2;G;rs20417;OTHER;DECREASED_RISK;DISEASE:CORONARY_DISEASE
CISPLATIN;AQP1;AG;rs28362731;TOXICITY;INCREASED_RISK;SIDE_EFFECT:THROMBOCYTOPENIA
ETHAMBUTOL;CYP2E1;CC;rs2031920;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID;CYP2E1;CC;rs2031920;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;CYP2E1;CC;rs2031920;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
RIFAMPIN;CYP2E1;CC;rs2031920;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ASPIRIN;PTGS2;G;rs20417;OTHER;INCREASED_RISK;DISEASE:CORONARY_DISEASE
CLOPIDOGREL;CYP2C19;A;rs4986893;EFFICACY;DECREASED_EFFICACY;EFFICACY:CLOPIDOGREL_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION
FOLFIRI;ABCC1;AA + AG;rs17501011;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
OPIOIDS;OPRL1;G;rs6090041;TOXICITY;INCREASED_RISK;DISEASE:OPIOID-RELATED_DISORDERS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;DECREASED_EFFICACY;EFFICACY:ANTIPLATELET_EFFECT
ANTIDEPRESSANTS;CUX1;G;rs365836;EFFICACY;LIKELIHOOD_EFFICACY;EFFICACY:NON-RESPONSE
NO_DRUG_RELATED;SULT1A1;CC + CT;rs1042028;nan;INCREASED_RISK;DISEASE:PROSTATIC_NEOPLASMS
NO_DRUG_RELATED;SULT1A1;CT + TT;rs1042028;OTHER;INCREASED_RISK;DISEASE:BREAST_NEOPLASMS
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED_EFFICACY;EFFICACY:CLOPIDOGREL_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION
NO_DRUG_RELATED;SULT1A1;CT + TT;rs1042028;OTHER;DECREASED_LIKELIHOOD;DISEASE:BREAST_NEOPLASMS
CLOZAPINE;LEPR;AG + GG;rs1137101;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
ACENOCOUMAROL;VKORC1;TT;rs9923231;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE | ADVERSE_EVENTS
WARFARIN;VKORC1;TT;rs9923231;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE | ADVERSE_EVENTS
ANTIDEPRESSANTS;CUX1;A;rs201522;EFFICACY;LIKELIHOOD_EFFICACY;EFFICACY:NON-RESPONSE
BORTEZOMIB;PKNOX1;AA;rs2839629;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES | PAIN | NEUROPATHIC_PAIN,
CISPLATIN;COMT;T;rs9332377;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
WARFARIN;VKORC1;CT + TT;rs9923231;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
CISPLATIN;COMT;C;rs4646316;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
CAPECITABINE;ENOSF1;T;rs2741171;TOXICITY;INCREASED_RISK;DISEASE:HAND-FOOT_SYNDROME
CAPECITABINE;ENOSF1;C;rs2612091;TOXICITY;INCREASED_RISK;DISEASE:HAND-FOOT_SYNDROME
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED;DISEASE:DRUG_TOXICITY
CISPLATIN;ABCC3;G;rs1051640;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
CAPECITABINE;DPYD;T;rs12022243;TOXICITY;INCREASED_SEVERITY;DISEASE:DIARRHEA
FOLFIRI;CES1;CC;rs9921399;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DEXTROAMPHETAMINE;DRD1;CC;rs4532;TOXICITY;INCREASED_SEVERITY;OTHER:SOCIAL_WITHDRAWAL
METHYLPHENIDATE;DRD1;CC;rs4532;TOXICITY;INCREASED_SEVERITY;OTHER:SOCIAL_WITHDRAWAL
CISPLATIN;TPMT;C;rs1142345;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
METHAMPHETAMINE;GRIN1;GG;rs1126442;TOXICITY;INCREASED_RISK;DISEASE:PSYCHOTIC_DISORDER
FOLFIRI;UGT1A10;AA;rs1113193;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FOLFIRI;UGT1A8;AA;rs1113193;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN;TPMT;T;rs1800460;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
CAPECITABINE;ENOSF1;T;rs2741171;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CAPECITABINE;ENOSF1;C;rs2612091;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CAPECITABINE;DPYD;T;rs12022243;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE_TO_PEGIFN-ALPHA/RBV_TREATMENT_AT_WEEK_20/24
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE_TO_PEGIFN-ALPHA/RBV_TREATMENT_AT_WEEK_20/24
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE_TO_PEGIFN-ALPHA/RBV_TREATMENT_AT_WEEK_20/24
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE_TO_PEGIFN-ALPHA/RBV_TREATMENT_AT_WEEK_20/24
IODINE (131I) COMPOUNDS;TGFB1;AA;rs1800469;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SIALOADENITIS
RADIOTHERAPY;TGFB1;AA;rs1800469;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SIALOADENITIS
NICOTINE;CHRNA5;CT + TT;rs588765;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
PEGINTERFERON ALFA-2B;IFNL3;GG + GT;rs8099917;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_FAILURE
RIBAVIRIN;IFNL3;GG + GT;rs8099917;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_FAILURE
CAPECITABINE;DPYD;A;rs76387818;TOXICITY;INCREASED_SEVERITY;DISEASE:HAND-FOOT_SYNDROME
CAPECITABINE;DPYD;A;rs12132152;TOXICITY;INCREASED_SEVERITY;DISEASE:HAND-FOOT_SYNDROME
CAPECITABINE;DPYD;A;rs76387818;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
ATENOLOL;DPYS;AG + GG;rs2669429;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERGLYCEMIA
LENALIDOMIDE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ADVERSE_EVENTS
CAPECITABINE;DPYD;A;rs12132152;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
NO_DRUG_RELATED;IFNL3;CC;rs12979860;OTHER;INCREASED;OTHER:SPONTANEOUS_HCV_CLEARANCE
NO_DRUG_RELATED;IFNL4;CC;rs12979860;OTHER;INCREASED;OTHER:SPONTANEOUS_HCV_CLEARANCE
RISPERIDONE;LEP;G;rs7799039;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
WARFARIN;VKORC1;T;rs9923231;EFFICACY;INCREASED;SIDE_EFFECT:BLOOD_COAGULATION_DISORDERS
WARFARIN;VKORC1;T;rs9923231;TOXICITY;INCREASED;SIDE_EFFECT:BLOOD_COAGULATION_DISORDERS
IODINE (131I) COMPOUNDS;ATG10;CC;rs10514231;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:FATIGUE
RADIOTHERAPY;ATG10;CC;rs10514231;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:FATIGUE
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CARBOPLATIN;EIF4E2;CC;rs1656402;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
CARBOPLATIN;TIGD1;CC;rs1656402;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
PACLITAXEL;EIF4E2;CC;rs1656402;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
PACLITAXEL;TIGD1;CC;rs1656402;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
IODINE (131I) COMPOUNDS;ATM;AG;rs11212570;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:FATIGUE
RADIOTHERAPY;ATM;AG;rs11212570;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:FATIGUE
NICOTINE;nan;CT + TT;rs2056527;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
NICOTINE;nan;CT + TT;rs2056527;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
CAPECITABINE;DPYD;AA + AT;rs67376798;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
FLUOROURACIL;DPYD;AA + AT;rs67376798;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
PIRFENIDONE;TOLLIP;CC + CT;rs5743890;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CAPECITABINE;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
WARFARIN;VKORC1;T;rs9923231;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
IMATINIB;ABCB1;GG;rs1045642;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
PLATINUM COMPOUNDS;XBP1;GG;rs2269577;TOXICITY;INCREASED_RISK;DISEASE:NAUSEA
IMATINIB;SLC22A1;CC;rs683369;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
CARBOPLATIN;DSCAM;TT;rs9981861;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
PACLITAXEL;DSCAM;TT;rs9981861;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
CARBOPLATIN;ETS2;CT + TT;rs1209950;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
PACLITAXEL;ETS2;CT + TT;rs1209950;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
IODINE (131I) COMPOUNDS;ATG10;CC;rs10514231;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIZZINESS | HEADACHE
RADIOTHERAPY;ATG10;CC;rs10514231;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIZZINESS | HEADACHE
IODINE (131I) COMPOUNDS;TGFB1;AA;rs1800469;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIZZINESS | HEADACHE
RADIOTHERAPY;TGFB1;AA;rs1800469;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIZZINESS | HEADACHE
WARFARIN;VKORC1;T;rs9923231;EFFICACY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
IODINE (131I) COMPOUNDS;ATG10;TT;rs1864183;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
RADIOTHERAPY;ATG10;TT;rs1864183;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
MERCAPTOPURINE;NUDT15;A;rs186364861;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
AMISULPRIDE;MC4R;CC;rs17782313;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
CLOZAPINE;MC4R;CC;rs17782313;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
OLANZAPINE;MC4R;CC;rs17782313;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
PALIPERIDONE;MC4R;CC;rs17782313;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
QUETIAPINE;MC4R;CC;rs17782313;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
RISPERIDONE;MC4R;CC;rs17782313;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
AMISULPRIDE;MC4R;A;rs489693;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
ARIPIPRAZOLE;MC4R;A;rs489693;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
CLOZAPINE;MC4R;A;rs489693;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
HALOPERIDOL;MC4R;A;rs489693;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
QUETIAPINE;MC4R;A;rs489693;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
RISPERIDONE;MC4R;A;rs489693;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
ZIPRASIDONE;MC4R;A;rs489693;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
AMISULPRIDE;MC4R;AA;rs489693;OTHER;INCREASED_LIKELIHOOD;DISEASE:HYPERTRIGLYCERIDEMIA | WEIGHT_GAIN
ARIPIPRAZOLE;MC4R;AA;rs489693;OTHER;INCREASED_LIKELIHOOD;DISEASE:HYPERTRIGLYCERIDEMIA | WEIGHT_GAIN
CLOZAPINE;MC4R;AA;rs489693;OTHER;INCREASED_LIKELIHOOD;DISEASE:HYPERTRIGLYCERIDEMIA | WEIGHT_GAIN
HALOPERIDOL;MC4R;AA;rs489693;OTHER;INCREASED_LIKELIHOOD;DISEASE:HYPERTRIGLYCERIDEMIA | WEIGHT_GAIN
QUETIAPINE;MC4R;AA;rs489693;OTHER;INCREASED_LIKELIHOOD;DISEASE:HYPERTRIGLYCERIDEMIA | WEIGHT_GAIN
RISPERIDONE;MC4R;AA;rs489693;OTHER;INCREASED_LIKELIHOOD;DISEASE:HYPERTRIGLYCERIDEMIA | WEIGHT_GAIN
ZIPRASIDONE;MC4R;AA;rs489693;OTHER;INCREASED_LIKELIHOOD;DISEASE:HYPERTRIGLYCERIDEMIA | WEIGHT_GAIN
ATENOLOL;PLEKHH2;G;rs11124945;TOXICITY;DECREASED_RISK;DISEASE:DIABETES_MELLITUS
VERAPAMIL;PLEKHH2;G;rs11124945;TOXICITY;DECREASED_RISK;DISEASE:DIABETES_MELLITUS
CLOPIDOGREL;CYP2C19;AG;rs4244285;EFFICACY;INCREASED;DISEASE:PLATELET_AGGREGATION
REGADENOSON;AMPD1;AA + AG;rs17602729;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT:ELEVATED_SYSTOLIC_BLOOD_PRESSURE
EFAVIRENZ;CYP2B6;T;rs3745274;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SOMNOLENCE
CLOPIDOGREL;CYP2C19;AA;rs4244285;EFFICACY;INCREASED;OTHER:PLATELET_REACTIVITY
CAPECITABINE;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
NO_DRUG_RELATED;nan;CC;rs2952768;EFFICACY;DECREASED_SEVERITY;OTHER:SUBSTANCE-RELATED_DISORDERS
CISPLATIN;ERCC2;CT;rs1799793;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
CYCLOPHOSPHAMIDE;ERCC2;CT;rs1799793;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE | STROKE
WARFARIN;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE | STROKE
NICOTINE;DBH;CC;rs1541333;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:END_OF_TREATMENT_ABSTINENCE
REGADENOSON;AMPD1;AA + AG;rs17602729;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
RISPERIDONE;CNR1;T;rs806378;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
RISPERIDONE;CNR1;C;rs1049353;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
MERCAPTOPURINE;ABCC4;T;rs3765534;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
ASPARAGINASE;NFATC2;T;rs6021191;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
ASPARAGINASE;HLA-DRB1;T;rs17885382;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
CYCLOPHOSPHAMIDE;GSTP1;AA;rs1695;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EPIRUBICIN;GSTP1;AA;rs1695;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
IVACAFTOR;CFTR;A;rs75527207;EFFICACY;DECREASED_LIKELIHOOD;DISEASE:CYSTIC_FIBROSIS_PULMONARY_EXACERBATION
VANCOMYCIN;nan;A;rs2789047;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION
LISINOPRIL;MMP3;AA;rs35068180;EFFICACY;INCREASED_RISK;SIDE_EFFECT:STROKE
CARBOPLATIN;SERPINA5;C;rs6113;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;SERPINA5;C;rs6113;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;EFFICACY;EFFICACY:SUBOPTIMAL_REPERFUSION_(POST-PCI_TIMI_FLOW_<3)
CARBOPLATIN;SERPINA5;T;rs6118;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;SERPINA5;T;rs6118;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
CARBOPLATIN;XYLT2;G;rs6504649;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;XYLT2;G;rs6504649;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
CARBOPLATIN;SERPINA5;G;rs6119;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;SERPINA5;G;rs6119;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
ETHANOL;CAT;T;rs1001179;OTHER;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
CARBOPLATIN;ETS2;A;rs73450548;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;ETS2;A;rs73450548;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
BEVACIZUMAB;VEGFA;CC;rs2010963;EFFICACY;INCREASED_EFFICACY;EFFICACY:ANTI-VEGF_INJECTIONS
PEGAPTANIB;VEGFA;CC;rs2010963;EFFICACY;INCREASED_EFFICACY;EFFICACY:ANTI-VEGF_INJECTIONS
RANIBIZUMAB;VEGFA;CC;rs2010963;EFFICACY;INCREASED_EFFICACY;EFFICACY:ANTI-VEGF_INJECTIONS
CLOPIDOGREL;ABCB1;AA;rs1045642;EFFICACY;INCREASED;OTHER:PLATELET_REACTIVITY
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;INCREASED_LIKELIHOOD;DISEASE:RECURRENCE
DOXORUBICIN;GSTA1;AA;rs3957357;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
AMISULPRIDE;MC4R;AA;rs489693;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
CLOZAPINE;MC4R;AA;rs489693;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
OLANZAPINE;MC4R;AA;rs489693;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
PALIPERIDONE;MC4R;AA;rs489693;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
QUETIAPINE;MC4R;AA;rs489693;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
RISPERIDONE;MC4R;AA;rs489693;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
ETHANOL;CAT;T;rs1001179;OTHER;INCREASED_SEVERITY;DISEASE:ALCOHOL_ABUSE
NO_DRUG_RELATED;ERCC1;AC;rs3212986;OTHER;DECREASED;OTHER:DISEASE-FREE_SURVIVAL_AND_OVERALL_SURVIVAL
DEXMEDETOMIDINE;GABRA2;GG;rs279847;TOXICITY;DECREASED;SIDE_EFFECT:HEART_RATE
TAMOXIFEN;ESR1;AG + GG;rs9340799;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOEMBOLISM
"""ACE INHIBITORS";F5;AG;rs149389480;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
"PLAIN""";F5;AG;rs149389480;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
"""ANGIOTENSIN II ANTAGONISTS""";F5;AG;rs149389480;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
MORPHINE;FAAH;AA + AG;rs3766246;TOXICITY;INCREASED_RISK;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
CLOZAPINE;TBC1D1;CC;rs9852;TOXICITY;INCREASED;DISEASE:WEIGHT_GAIN
OLANZAPINE;TBC1D1;CC;rs9852;TOXICITY;INCREASED;DISEASE:WEIGHT_GAIN
FLUOROURACIL;DPYD;AT;rs67376798;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
MORPHINE;FAAH;CT + TT;rs4141964;TOXICITY;INCREASED_RISK;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
NO_DRUG_RELATED;ABCB11;GG;rs2287622;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATOCELLULAR_INJURY
HYDROCODONE;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPOVENTILATION
HYDROCODONE;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
NO_DRUG_RELATED;DRD2;AA + AG;rs1800497;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ALCOHOL_ABUSE | SUBSTANCE-RELATED_DISORDERS
OPIOIDS;GNB3;CT + TT;rs5443;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:INCREASED_PULSE_RATE
OPIOIDS;GNB3;CT + TT;rs5443;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:INCREASED_PULSE_RATE
ARIPIPRAZOLE;FAAH;A;rs324420;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:WEIGHT_GAIN
CLOZAPINE;FAAH;A;rs324420;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:WEIGHT_GAIN
HALOPERIDOL;FAAH;A;rs324420;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:WEIGHT_GAIN
OLANZAPINE;FAAH;A;rs324420;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:WEIGHT_GAIN
QUETIAPINE;FAAH;A;rs324420;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:WEIGHT_GAIN
RISPERIDONE;FAAH;A;rs324420;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:WEIGHT_GAIN
MORPHINE;FAAH;GT + TT;rs2295632;TOXICITY;INCREASED_RISK;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
CAFFEINE;CYP1A2;AC + CC;rs762551;OTHER;DECREASED_RISK;DISEASE:BREAST_NEOPLASMS
MORPHINE;FAAH;AA + AC;rs324420;TOXICITY;INCREASED_RISK;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
PEGINTERFERON ALFA-2B;VDR;AA + AG;rs2228570;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;VDR;AA + AG;rs2228570;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
NO_DRUG_RELATED;ABCB11;GG;rs2287622;TOXICITY;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
PEGINTERFERON ALFA-2B;ITPA;CC;rs1127354;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
RIBAVIRIN;ITPA;CC;rs1127354;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
SIMEPREVIR;ITPA;CC;rs1127354;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
DOCETAXEL;NR1I3;AA;rs3003593;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
ANTITHYROID PREPARATIONS;EHMT2;G;rs652888;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:AGRANULOCYTOSIS
IODINE (131I) COMPOUNDS;TNF;AG;rs1800629;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PAIN
RADIOTHERAPY;TNF;AG;rs1800629;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PAIN
HYDROCODONE;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED_RISK;DISEASE:CONSTIPATION
HMG COA REDUCTASE INHIBITORS;HLA-G;G;rs1063320;OTHER;DECREASED_LIKELIHOOD;DISEASE:ASTHMA
HYDROCODONE;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED_RISK;DISEASE:DRY_MOUTH
DEXMEDETOMIDINE;CYP2A6;C;rs28399433;EFFICACY;INCREASED_EFFICACY;EFFICACY:SEDATION
DEFERIPRONE;UGT1A6;GG;rs6759892;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
DEFERIPRONE;UGT1A6;GG;rs6759892;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
ANTITHYROID PREPARATIONS;nan;del;rs111618861;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:AGRANULOCYTOSIS
ANTITHYROID PREPARATIONS;HLA-B;C;rs1071816;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:AGRANULOCYTOSIS
IODINE (131I) COMPOUNDS;ATM;AA + AG;rs11212570;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PAIN
RADIOTHERAPY;ATM;AA + AG;rs11212570;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PAIN
EFAVIRENZ;IL10;TT;rs1800896;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ETHANOL;ANKK1;A;rs1800497;OTHER;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
ETHANOL;DRD2;A;rs1800497;OTHER;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
IODINE (131I) COMPOUNDS;NFKB1;AT;rs230493;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PAIN
RADIOTHERAPY;NFKB1;AT;rs230493;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PAIN
OPIOIDS;OPRM1;G;rs1799971;TOXICITY;DECREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
ETHANOL;DRD2;A;rs1800497;OTHER;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
IODINE (131I) COMPOUNDS;TGFB1;TT;rs2241716;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PAIN
RADIOTHERAPY;TGFB1;TT;rs2241716;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PAIN
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
IODINE (131I) COMPOUNDS;TGFB1;GG;rs1800469;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PAIN
RADIOTHERAPY;TGFB1;GG;rs1800469;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PAIN
ANTITHYROID PREPARATIONS;FOXF2;del;rs199564443;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:AGRANULOCYTOSIS
CAPECITABINE;CES1P1;T;rs7187684;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ASPARAGINASE;nan;GG;rs6977967;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
CYCLOPHOSPHAMIDE;nan;GG;rs6977967;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
CYTARABINE;nan;GG;rs6977967;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
DAUNORUBICIN;nan;GG;rs6977967;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
HYDROCORTISONE;nan;GG;rs6977967;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
METHOTREXATE;nan;GG;rs6977967;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
PREDNISONE;nan;GG;rs6977967;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
VINCRISTINE;nan;GG;rs6977967;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
CAPECITABINE;CES1P1;G;rs11861118;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PLATINUM;XRCC1;TT;rs25487;EFFICACY;nan;OTHER:WORSE_OVERALL_SURVIVAL_OUTCOME
PLATINUM;ERCC1;AG + GG;rs11615;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE
CAPECITABINE;CES1;G;rs2244613;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PLATINUM;ERCC1;AA + AC;rs3212986;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOZAPINE;CYP1A2;GG;rs2069514;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
ETHANOL;CYP1A2;GG;rs2069514;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
MERCAPTOPURINE;PACSIN2;CT + TT;rs2413739;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
METHOTREXATE;PACSIN2;CT + TT;rs2413739;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
ASPARAGINASE;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
CYCLOPHOSPHAMIDE;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
CYTARABINE;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
DAUNORUBICIN;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
HYDROCORTISONE;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
METHOTREXATE;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
PREDNISONE;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
VINCRISTINE;MIR4268;CC + CT;rs4674470;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
CAPECITABINE;CES1;G;rs2244614;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PEGINTERFERON ALFA-2B;IFNL3;CT + TT;rs12979860;EFFICACY;DECREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;CT + TT;rs12979860;EFFICACY;DECREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CT + TT;rs12979860;EFFICACY;DECREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CT + TT;rs12979860;EFFICACY;DECREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
CITALOPRAM;CYP2C19;AG;rs4244285;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
IODINE (131I) COMPOUNDS;ATM;TT;rs620815;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
RADIOTHERAPY;ATM;TT;rs620815;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
PEGINTERFERON ALFA-2A;IFNL3;TT;rs12979860;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_FAILURE_TO_PEGYLATED_INTERFERON-ALPHA/RIBAVIRIN_THERAPY_IN_HCV/HIV-1_COINFECTED_PATIENTS
PEGINTERFERON ALFA-2A;IFNL4;TT;rs12979860;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_FAILURE_TO_PEGYLATED_INTERFERON-ALPHA/RIBAVIRIN_THERAPY_IN_HCV/HIV-1_COINFECTED_PATIENTS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs12979860;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_FAILURE_TO_PEGYLATED_INTERFERON-ALPHA/RIBAVIRIN_THERAPY_IN_HCV/HIV-1_COINFECTED_PATIENTS
PEGINTERFERON ALFA-2B;IFNL4;TT;rs12979860;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_FAILURE_TO_PEGYLATED_INTERFERON-ALPHA/RIBAVIRIN_THERAPY_IN_HCV/HIV-1_COINFECTED_PATIENTS
RIBAVIRIN;IFNL3;TT;rs12979860;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_FAILURE_TO_PEGYLATED_INTERFERON-ALPHA/RIBAVIRIN_THERAPY_IN_HCV/HIV-1_COINFECTED_PATIENTS
RIBAVIRIN;IFNL4;TT;rs12979860;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_FAILURE_TO_PEGYLATED_INTERFERON-ALPHA/RIBAVIRIN_THERAPY_IN_HCV/HIV-1_COINFECTED_PATIENTS
TENOFOVIR;ABCC2;A;rs17222723;TOXICITY;DECREASED_RISK;SIDE_EFFECT:RENAL_PROXIMAL_TUBULOPATHY
TENOFOVIR;ABCC2;A;rs2273697;TOXICITY;INCREASED_RISK;SIDE_EFFECT:RENAL_PROXIMAL_TUBULOPATHY
FLUOROURACIL;DPYD;CT;rs1801160;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CYTARABINE;nan;AA + AG;rs12036333;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
IDARUBICIN;nan;AA + AG;rs12036333;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
ASPARAGINASE;ATF5;AA + AG;rs8667;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
CYCLOPHOSPHAMIDE;ATF5;AA + AG;rs8667;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
CYTARABINE;ATF5;AA + AG;rs8667;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
DAUNORUBICIN;ATF5;AA + AG;rs8667;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
HYDROCORTISONE;ATF5;AA + AG;rs8667;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
METHOTREXATE;ATF5;AA + AG;rs8667;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
PREDNISONE;ATF5;AA + AG;rs8667;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
VINCRISTINE;ATF5;AA + AG;rs8667;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
NEVIRAPINE;CYP2B6;CC + CT;rs28399499;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
PEGINTERFERON ALFA-2B;CYP2R1;AA + AG;rs10741657;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;CYP2R1;AA + AG;rs10741657;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
ASPARAGINASE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
CYCLOPHOSPHAMIDE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
CYTARABINE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
DAUNORUBICIN;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
HYDROCORTISONE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
METHOTREXATE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
PREDNISONE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
VINCRISTINE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
NEVIRAPINE;CYP2B6;T;rs3745274;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
TENOFOVIR DISOPROXIL FUMARATE;CYP24A1;TT;rs2248359;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEPHROTOXICITY
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
CYCLOPHOSPHAMIDE;CYP2C19;GG;rs4244285;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
TENOFOVIR DISOPROXIL FUMARATE;CYP27B1;GG;rs4646536;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEPHROTOXICITY
NICOTINE;DDC;C;rs2060761;OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
DRUGS FOR TREATMENT OF TUBERCULOSIS;RIPOR2;AA + AG;rs10946737;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NICOTINE;DDC;A;rs12718541;OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(RAPID_AND_SUSTAINED_VIROLOGICAL_RESPONSE)_FOR_PATIENTS_WITH_HEPATITIS_C_VIRUS_GENOTYPE_1
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(RAPID_AND_SUSTAINED_VIROLOGICAL_RESPONSE)_FOR_PATIENTS_WITH_HEPATITIS_C_VIRUS_GENOTYPE_1
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(RAPID_AND_SUSTAINED_VIROLOGICAL_RESPONSE)_FOR_PATIENTS_WITH_HEPATITIS_C_VIRUS_GENOTYPE_1
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(RAPID_AND_SUSTAINED_VIROLOGICAL_RESPONSE)_FOR_PATIENTS_WITH_HEPATITIS_C_VIRUS_GENOTYPE_1
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(RAPID_AND_SUSTAINED_VIROLOGICAL_RESPONSE)_FOR_PATIENTS_WITH_HEPATITIS_C_VIRUS_GENOTYPE_1
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(RAPID_AND_SUSTAINED_VIROLOGICAL_RESPONSE)_FOR_PATIENTS_WITH_HEPATITIS_C_VIRUS_GENOTYPE_1
IMIPRAMINE;CYP2C19;CT + TT;rs12248560;LADME_PK;DECREASED_PK;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS
IMIPRAMINE;CYP2C19;CT + TT;rs11188072;LADME_PK;DECREASED_PK;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;AA;rs12980275;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
NO_DRUG_RELATED;CXCL5;GG;rs352046;OTHER;INCREASED_RISK;DISEASE:DEATH
NEVIRAPINE;CYP2B6;C;rs28399499;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
WARFARIN;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
CAPECITABINE;CDA;G;rs602950;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
CAPECITABINE;CDA;T;rs532545;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
TENOFOVIR DISOPROXIL FUMARATE;ABCC2;TT;rs717620;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEPHROTOXICITY
CAPECITABINE;CDA;A;rs6690069;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
TENOFOVIR;ABCC2;CC;rs717620;TOXICITY;INCREASED_RISK;SIDE_EFFECT:KIDNEY_TUBULAR_DYSFUNCTION
METHYLPHENIDATE;DRD1;CC;rs4532;TOXICITY;INCREASED_SEVERITY;OTHER:SOCIAL_WITHDRAWAL
CAPECITABINE;DPYD;AA + AT;rs67376798;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;DPYD;AA + AT;rs67376798;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:SUBCLINICAL_INTRA-STENT_THROMBUS
CAPECITABINE;CES1;G;rs3217164;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
CAPECITABINE;CDA;A;rs10916825;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
CAPECITABINE;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
TENOFOVIR DISOPROXIL FUMARATE;SLC28A2;CT + TT;rs11854484;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEPHROTOXICITY
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;CC;rs6311;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DIZZINESS
CAPECITABINE;NSUN3;C;rs144470777;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CAPECITABINE;PHC1;C;rs187805828;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
ALENDRONATE;VDR;CC;rs1544410;EFFICACY;DECREASED_EFFICACY;EFFICACY:SERUM_OSTEOCALCIN
ASPIRIN;ITGB3;TT;rs5918;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:INADEQUATE_INHIBITION_OF_PLATELET_ACTIVITY
CAPECITABINE;FAT1;T;rs116134453;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CISPLATIN;XPC;GG + GT;rs2228001;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CAPECITABINE;TENM4;C;rs141531882;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
TICAGRELOR;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DYSPNEA
WARFARIN;CYP4F2;T;rs2108622;DOSAGE;EFFICACY;EFFICACY:A_22%_INCREASE_IN_THERAPEUTIC_WARFARIN_DOSE_REQUIREMENT_AFTER_ADJUSTMENT_FOR_CLINICAL_AND_GENETIC_COVARIATES_IN_HISPANIC-AMERICANS
AMOXICILLIN;HLA-DQB1;A;rs9274407;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_INDUCED_LIVER_INJURY
CLAVULANATE;HLA-DQB1;A;rs9274407;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_INDUCED_LIVER_INJURY
CAPECITABINE;CD96;C;rs77475703;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CYCLOPHOSPHAMIDE;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AMENORRHEA
DOCETAXEL;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AMENORRHEA
DOXORUBICIN;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AMENORRHEA
EPIRUBICIN;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AMENORRHEA
FLUOROURACIL;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AMENORRHEA
GOSERELIN;SLCO1B1;TT;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AMENORRHEA
WARFARIN;NQO1;A;rs1800566;DOSAGE;EFFICACY;EFFICACY:A_34%_INCREASE_IN_THERAPEUTIC_WARFARIN_DOSE_REQUIREMENT_WHILE_HOLDING_CLINICAL_AND_GENETIC_PREDICTORS_CONSTANT_IN_HISPANIC-AMERICANS
CAPECITABINE;ZMIZ1;C;rs117484357;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CAPECITABINE;VPS13D;G;rs138385713;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CETUXIMAB;RASSF1;CC;rs2236947;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PAROXETINE;CYP1A2;CC;rs4646425;EFFICACY;INCREASED_EFFICACY;EFFICACY:SLOWER_RESPONSE_TIME
CAPECITABINE;CCDC77;G;rs141213385;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
ANTIPSYCHOTICS;RGS2;C;rs4606;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS | PARKINSONIAN_DISORDER
PRAVASTATIN;SLCO1B1;C;rs4149056;LADME_PK;INCREASED_PK;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)
DEXMEDETOMIDINE;WBP2NL;AA;rs5758550;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:SEDATION
CAPECITABINE;ADGRG7;T;rs117308378;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CARBOPLATIN;AKT1;AA + AC;rs1130214;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:DISEASE_PROGRESSION
CISPLATIN;AKT1;AA + AC;rs1130214;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:DISEASE_PROGRESSION
CYCLOSPORINE;NFATC1;CC;rs2280055;EFFICACY;EFFICACY;EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE
MYCOPHENOLIC ACID;NFATC1;CC;rs2280055;EFFICACY;EFFICACY;EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE
PREDNISONE;NFATC1;CC;rs2280055;EFFICACY;EFFICACY;EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE
ASPIRIN;PEAR1;T;rs41273215;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION | STROKE | DEATH,
CLOPIDOGREL;PEAR1;T;rs41273215;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION | STROKE | DEATH,
CARBOPLATIN;nan;AA + AC;rs2498804;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:DISEASE_PROGRESSION
CISPLATIN;nan;AA + AC;rs2498804;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:DISEASE_PROGRESSION
CLOZAPINE;DRD2;CC;rs4436578;TOXICITY;INCREASED_RISK;SIDE_EFFECT:BODY_WEIGHT_GAIN
OLANZAPINE;DRD2;CC;rs4436578;TOXICITY;INCREASED_RISK;SIDE_EFFECT:BODY_WEIGHT_GAIN
RISPERIDONE;DRD2;CC;rs4436578;TOXICITY;INCREASED_RISK;SIDE_EFFECT:BODY_WEIGHT_GAIN
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
TELAPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
TELAPREVIR;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
VINCRISTINE;ABCC2;T;rs12826;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
EFAVIRENZ;CYP2B6;TT;rs3745274;LADME_PK;INCREASED_PK;PK:PLASMA_EXPOSURE
NICOTINE;GRIN3A;C;rs10121600;OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
ASPIRIN;CYP1A2;C;rs762551;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION | STROKE | DEATH,
CLOPIDOGREL;CYP1A2;C;rs762551;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION | STROKE | DEATH,
WARFARIN;VKORC1;TT;rs9923231;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEAN_PEAK_INR_DURING_WEEK_1_OF_WARFARIN_THERAPY
ASPIRIN;CYP2C19;A;rs4244285;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION | STROKE | DEATH,
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION | STROKE | DEATH,
CITALOPRAM;HTR1B;CC;rs6296;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGITATION
PRAVASTATIN;ABCA1;TT;rs2230806;EFFICACY;INCREASED_EFFICACY;EFFICACY:HDL-CHOLESTEROL
ASPIRIN;PON1;T;rs662;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION | STROKE | DEATH,
CLOPIDOGREL;PON1;T;rs662;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION | STROKE | DEATH,
DEXMEDETOMIDINE;ABCG2;GG;rs2231142;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:SEDATION
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SIMEPREVIR;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SIMEPREVIR;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
"""ANTIINFLAMMATORY AGENTS";CYP2C9;C;rs1057910;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_BLEEDING
"NON-STEROIDS""";CYP2C9;C;rs1057910;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_BLEEDING
"""CELECOXIB""";CYP2C9;C;rs1057910;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_BLEEDING
"""DICLOFENAC""";CYP2C9;C;rs1057910;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_BLEEDING
"""IBUPROFEN""";CYP2C9;C;rs1057910;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_BLEEDING
"""NAPROXEN""";CYP2C9;C;rs1057910;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_BLEEDING
"""PIROXICAM""";CYP2C9;C;rs1057910;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_BLEEDING
CAPECITABINE;DPYD;A;rs75267292;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
NICOTINE;GRIN3A;G;rs11788456;OTHER;RISK;DISEASE:TOBACCO_USE_DISORDER
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:FATIGUE
"""ANTIINFLAMMATORY AGENTS";CYP2C9;C;rs1057910;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ACUTE_GASTROINTESTINAL_BLEEDING
"NON-STEROIDS""";CYP2C9;C;rs1057910;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ACUTE_GASTROINTESTINAL_BLEEDING
"""CELECOXIB""";CYP2C9;C;rs1057910;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ACUTE_GASTROINTESTINAL_BLEEDING
"""DICLOFENAC""";CYP2C9;C;rs1057910;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ACUTE_GASTROINTESTINAL_BLEEDING
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:SLEEP_DISORDERS
PRAVASTATIN;KIF6;AG + GG;rs20455;EFFICACY;DECREASED_RISK;DISEASE:CORONARY_DISEASE
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
"""ACE INHIBITORS";F5;AG;rs368967198;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
"PLAIN""";F5;AG;rs368967198;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
"""ANGIOTENSIN II ANTAGONISTS""";F5;AG;rs368967198;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
CAPECITABINE;SSU72;C;rs146898897;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
ASPIRIN;F2R;T;rs168753;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION | STROKE | DEATH,
CLOPIDOGREL;F2R;T;rs168753;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION | STROKE | DEATH,
BETA BLOCKING AGENTS;GNB3;CT + TT;rs5443;OTHER;DECREASED;OTHER:HEART_RATE
CARBOPLATIN;PIK3CA;CC;rs2699887;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CISPLATIN;PIK3CA;CC;rs2699887;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
BETA BLOCKING AGENTS;GNB3;CT + TT;rs5443;OTHER;DECREASED;OTHER:HEART_RATE
CARBOPLATIN;PTEN;AC + CC;rs2299939;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CISPLATIN;PTEN;AC + CC;rs2299939;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CAPECITABINE;MAN1A1;A;rs185346775;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CARBOPLATIN;AKT1;C;rs3803304;EFFICACY;RISK_EFFICACY;EFFICACY:DISEASE_PROGRESSION
CISPLATIN;AKT1;C;rs3803304;EFFICACY;RISK_EFFICACY;EFFICACY:DISEASE_PROGRESSION
COCAINE;BCHE;TT;rs1803274;OTHER;nan;DISEASE:COCAINE_DEPENDENCE
PRAVASTATIN;SLCO1B1;CC;rs4149056;LADME_PK;INCREASED_PK;PK:MEAN_PEAK_CONCENTRATION_IN_PLASMA_AND_AREA_UNDER_THE_PLASMA_CONCENTRATION
PEGINTERFERON ALFA-2A;EGFR;AA;rs11506105;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;EGFR;AA;rs11506105;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;EGFR;AA;rs11506105;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
CISPLATIN;ABCB1;GG;rs1045642;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL_RATE
FLUOROURACIL;ABCB1;GG;rs1045642;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL_RATE
ASPIRIN;P2RY12;AG + GG;rs2046934;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
CLOPIDOGREL;P2RY12;AG + GG;rs2046934;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
HMG COA REDUCTASE INHIBITORS;STAT4;T;rs7574865;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CISPLATIN;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:LYMPH_NODE_METASTASES
FLUOROURACIL;ABCB1;AA + AG;rs1045642;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:LYMPH_NODE_METASTASES
MERCAPTOPURINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
HEROIN;ALDH2;AA + AG;rs671;OTHER;INCREASED;DISEASE:HEROIN_DEPENDENCE
FENTANYL;CALCA;GG;rs145837941;DOSAGE;DECREASED_SEVERITY;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
"""METFORMIN""";KCNJ11;T;rs5219;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
"""SULFONAMIDES";KCNJ11;T;rs5219;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
"UREA DERIVATIVES""";KCNJ11;T;rs5219;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
ANTIHYPERTENSIVES;ADRB1;CC;rs1801253;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:STROKE
BETA BLOCKING AGENTS;ADRB1;CC;rs1801253;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:STROKE
DIURETICS;ADRB1;CC;rs1801253;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:STROKE
NICOTINE;GRIN3A;T;rs17189632;OTHER;RISK;DISEASE:TOBACCO_USE_DISORDER
FLUOROURACIL;DPYD;CT + TT;rs3918290;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
HMG COA REDUCTASE INHIBITORS;SLCO1A2;T;rs4149000;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:POOR-RESPONSE_TO_CLOPIDOGREL
TRAMADOL;SLC22A1;del;rs35167514;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATIONS_OF_O-DESMETHYLTRAMADOL
EFAVIRENZ;CYP2B6;TT;rs3745274;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
SEVOFLURANE;FASTKD3;AA + AG;rs2307116;EFFICACY;INCREASED_EFFICACY;EFFICACY:VOL%_END-TIDAL_SEVOFLURANE_CONCENTRATION
SEVOFLURANE;MTRR;AA + AG;rs2307116;EFFICACY;INCREASED_EFFICACY;EFFICACY:VOL%_END-TIDAL_SEVOFLURANE_CONCENTRATION
ASPIRIN;P2RY12;AG + GG;rs2046934;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CLOPIDOGREL;P2RY12;AG + GG;rs2046934;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
METHOTREXATE;ABCB1;AA;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA | MUCOSITIS,
TRAMADOL;SLC22A1;A;rs34130495;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATIONS_OF_O-DESMETHYLTRAMADOL
TRAMADOL;SLC22A1;T;rs12208357;LADME_PK;PK;PK:HIGHER_PLASMA_CONCENTRATIONS_OF_O-DESMETHYLTRAMADOL
METHADONE;KCNJ6;TT;rs2070995;TOXICITY;DECREASED_RISK;SIDE_EFFECT:WITHDRAWAL_EFFECTS
IMATINIB;SLCO1A2;CC;rs3764043;LADME_PK;DECREASED_PK;PK:IMATINIB_CLEARANCE
IMATINIB;SLCO1A2;CC;rs4148978;LADME_PK;INCREASED_PK;PK:IMATINIB_CLEARANCE
VINCRISTINE;ABCC2;T;rs3740066;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
IMATINIB;SLCO1A2;CC;rs4148977;LADME_PK;INCREASED_PK;PK:IMATINIB_CLEARANCE
FLUOROURACIL;DPYD;AC;rs55886062;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
FLUCLOXACILLIN;NR1I2;CC;rs3814055;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
CYCLOSPORINE;NFATC1;CC;rs3894049;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:TRANSPLANT_REJECTION
MYCOPHENOLIC ACID;NFATC1;CC;rs3894049;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:TRANSPLANT_REJECTION
PREDNISONE;NFATC1;CC;rs3894049;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:TRANSPLANT_REJECTION
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
SEVOFLURANE;FASTKD3;AG + GG;rs1801394;EFFICACY;INCREASED_EFFICACY;EFFICACY:VOL%_END-TIDAL_SEVOFLURANE_CONCENTRATION
SEVOFLURANE;MTRR;AG + GG;rs1801394;EFFICACY;INCREASED_EFFICACY;EFFICACY:VOL%_END-TIDAL_SEVOFLURANE_CONCENTRATION
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
EFAVIRENZ;CYP2B6;CC;rs28399499;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
"""ACE INHIBITORS";F5;GT;rs143509841;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
"PLAIN""";F5;GT;rs143509841;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
"""ANGIOTENSIN II ANTAGONISTS""";F5;GT;rs143509841;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
PEGINTERFERON ALFA-2A;IFNL3;G;rs8099917;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;G;rs8099917;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;G;rs8099917;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;G;rs8099917;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;G;rs8099917;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;G;rs8099917;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
"""ACE INHIBITORS";F5;AG;rs200157005;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
"PLAIN""";F5;AG;rs200157005;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
"""ANGIOTENSIN II ANTAGONISTS""";F5;AG;rs200157005;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
PAROXETINE;CYP1A2;TT;rs4646427;EFFICACY;EFFICACY;EFFICACY:SLOWER_RESPONSE_TIME
CARBAMAZEPINE;SCN1A;CC;rs3812718;OTHER;INCREASED;OTHER:CORTICAL_SILENT_PERIOD_DURATION
METHOTREXATE;MIR1206;GG;rs2114358;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
PAROXETINE;CYP1A2;CC;rs4646425;EFFICACY;INCREASED_EFFICACY;EFFICACY:SLOWER_RESPONSE_TIME
ATORVASTATIN;SLCO1B1;G;rs2306283;LADME_PK;DECREASED_PK;PK:PLASMA_CONCENTRATIONS
ATORVASTATIN;SLCO1B1;C;rs4149056;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATIONS
FOLIC ACID;ABCB1;A;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_DRUG_EVENT
METHOTREXATE;ABCB1;A;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_DRUG_EVENT
CYTARABINE;BRD10;AA + AG;rs10758713;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
IDARUBICIN;BRD10;AA + AG;rs10758713;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
HMG COA REDUCTASE INHIBITORS;SLCO1B1;C;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
SORAFENIB;KDR;A;rs4864950;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PEGINTERFERON ALFA-2A;IFNL3;T;rs12979860;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;T;rs12979860;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;T;rs12979860;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;T;rs12979860;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;T;rs12979860;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;T;rs12979860;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SORAFENIB;PIK3R5;T;rs444904;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERTENSION
IRINOTECAN;UGT1A10;G;rs17868323;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA_WITHIN_24_HOURS_AND_THROMBOCYTOPENIA
IRINOTECAN;UGT1A6;G;rs17868323;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA_WITHIN_24_HOURS_AND_THROMBOCYTOPENIA
IRINOTECAN;UGT1A7;G;rs17868323;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA_WITHIN_24_HOURS_AND_THROMBOCYTOPENIA
IRINOTECAN;UGT1A8;G;rs17868323;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA_WITHIN_24_HOURS_AND_THROMBOCYTOPENIA
IRINOTECAN;UGT1A9;G;rs17868323;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA_WITHIN_24_HOURS_AND_THROMBOCYTOPENIA
CYTARABINE;nan;AG;rs2897047;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IDARUBICIN;nan;AG;rs2897047;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
METHOTREXATE;ABCC2;AA;rs2273697;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CYTARABINE;nan;GG;rs6550826;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
IDARUBICIN;nan;GG;rs6550826;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
METHOTREXATE;ABCB1;AG;rs1128503;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
AZATHIOPRINE;ABCC4;CT + TT;rs3765534;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:LEUKOPENIA
MERCAPTOPURINE;ABCC4;CT + TT;rs3765534;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:LEUKOPENIA
METHOTREXATE;ABCC2;CC + CT;rs4148396;TOXICITY;INCREASED;SIDE_EFFECT:TIME_TO_DISCONTINUATION_OR_DOSE_REDUCTION
METHOTREXATE;ABCC2;CC;rs4148396;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ALOPECIA
CYTARABINE;nan;CC;rs9883101;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
IDARUBICIN;nan;CC;rs9883101;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
FOLIC ACID;TLR4;G;rs4986790;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_DRUG_EVENTS
METHOTREXATE;TLR4;G;rs4986790;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_DRUG_EVENTS
ROSUVASTATIN;ABCG2;T;rs2231142;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATIONS
ROSUVASTATIN;SLCO1B1;C;rs4149056;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATIONS
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
LEUCOVORIN;DPYD;AT;rs67376798;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
PRAVASTATIN;SLCO1B1;C;rs4149056;LADME_PK;INCREASED_PK;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;AA;rs12980275;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR) | SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
HYDROCHLOROTHIAZIDE;nan;G;rs10792367;EFFICACY;DECREASED_EFFICACY;EFFICACY:BLOOD_PRESSURE_(BP)_REDUCTION
IRINOTECAN;UGT1A10;G;rs17868323;DOSAGE;INCREASED_LIKELIHOOD;SIDE_EFFECT:NECESSITY_TO_REDUCE_IRINOTECAN_DOSAGE
IRINOTECAN;UGT1A6;G;rs17868323;DOSAGE;INCREASED_LIKELIHOOD;SIDE_EFFECT:NECESSITY_TO_REDUCE_IRINOTECAN_DOSAGE
IRINOTECAN;UGT1A7;G;rs17868323;DOSAGE;INCREASED_LIKELIHOOD;SIDE_EFFECT:NECESSITY_TO_REDUCE_IRINOTECAN_DOSAGE
IRINOTECAN;UGT1A8;G;rs17868323;DOSAGE;INCREASED_LIKELIHOOD;SIDE_EFFECT:NECESSITY_TO_REDUCE_IRINOTECAN_DOSAGE
IRINOTECAN;UGT1A9;G;rs17868323;DOSAGE;INCREASED_LIKELIHOOD;SIDE_EFFECT:NECESSITY_TO_REDUCE_IRINOTECAN_DOSAGE
NO_DRUG_RELATED;HMGCR;AT + TT;rs12654264;OTHER;INCREASED;OTHER:SERUM_TOTAL_CHOLESTEROL
DOXORUBICIN;SLC28A3;AA + AG;rs7853758;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
HMG COA REDUCTASE INHIBITORS;ABCB1;AA;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION
NICOTINE;CHRNA3;T;rs3743075;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:TOBACCO_USE_DISORDER
NICOTINE;CHRNB4;G;rs7178270;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:TOBACCO_USE_DISORDER
VINCRISTINE;NDRG1;G;rs2272653;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
NICOTINE;CHRNB4;A;rs1948;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:TOBACCO_USE_DISORDER
PLATINUM COMPOUNDS;ERCC2;AA + AG;rs1052555;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
HMG COA REDUCTASE INHIBITORS;nan;T;rs1719247;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:MUSCULAR_DISEASES
SIMVASTATIN;nan;T;rs1719247;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:MUSCULAR_DISEASES
HMG COA REDUCTASE INHIBITORS;SLCO1B1;AA;rs2306283;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION
HMG COA REDUCTASE INHIBITORS;SLCO1B1;CC;rs4149056;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION
HMG COA REDUCTASE INHIBITORS;nan;C;rs1346268;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:MUSCULAR_DISEASES
SIMVASTATIN;nan;C;rs1346268;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:MUSCULAR_DISEASES
PRAVASTATIN;SLCO1B1;CT;rs4149056;LADME_PK;INCREASED_PK;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX
CYCLOPHOSPHAMIDE;ABCC2;CT + TT;rs3740066;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
DOXORUBICIN;ABCC2;CT + TT;rs3740066;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
FLUOROURACIL;ABCC2;CT + TT;rs3740066;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
IMATINIB;UGT2A1;CC;rs11249454;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ANTHRACYCLINES AND RELATED SUBSTANCES;ECT2L;A;rs11155012;EFFICACY;INCREASED_RISK;DISEASE:DEATH
HMG COA REDUCTASE INHIBITORS;ABCB1;AA;rs1128503;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION
CYCLOPHOSPHAMIDE;ATM;AA;rs1801516;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VOMITING
DOXORUBICIN;ATM;AA;rs1801516;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VOMITING
FLUOROURACIL;ATM;AA;rs1801516;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VOMITING
GEMCITABINE;SLC28A1;AA;rs3825876;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ATORVASTATIN;SLCO1B1;CC;rs4149056;LADME_PK;INCREASED_PK;PK:AUC
GEMCITABINE;CDA;AC + CC;rs2072671;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
RISPERIDONE;ABCB1;AA + AG;rs1045642;TOXICITY;INCREASED;SIDE_EFFECT:PROLONGED_QTC_INTERVAL
PITAVASTATIN;SLCO1B1;AG + GG;rs2306283;LADME_PK;INCREASED_PK;PK:PITAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX
SORAFENIB;EGFR;C;rs2330951;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERTENSION
ROSUVASTATIN;SLCO1B1;CC;rs4149056;LADME_PK;INCREASED_PK;PK:AUC_(P=0.002)_AND_CMAX_(P=0.003)
HMG COA REDUCTASE INHIBITORS;GATM;A;rs9806699;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:MUSCULAR_DISEASES
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED_RISK;OTHER:MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS
EVEROLIMUS;ABCB1;A;rs2032582;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LYMPHOPENIA
EVEROLIMUS;ABCB1;A;rs2032582;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:LYMPHOPENIA
CYCLOPHOSPHAMIDE;CYP1B1;CC;rs1056836;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
DOXORUBICIN;CYP1B1;CC;rs1056836;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
FLUOROURACIL;CYP1B1;CC;rs1056836;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
AZATHIOPRINE;nan;C;rs2647087;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PANCREATITIS
MERCAPTOPURINE;nan;C;rs2647087;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PANCREATITIS
EVEROLIMUS;RPTOR;T;rs9906827;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS
EVEROLIMUS;RPTOR;T;rs9906827;OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS
RADIOTHERAPY;XPC;G;rs2228001;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA
EVEROLIMUS;ABCB1;A;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
EVEROLIMUS;ABCB1;A;rs1045642;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
CYCLOPHOSPHAMIDE;ATM;AA + AG;rs1801516;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
DOXORUBICIN;ATM;AA + AG;rs1801516;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
FLUOROURACIL;ATM;AA + AG;rs1801516;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
AZATHIOPRINE;NUDT15;C;rs116855232;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
MERCAPTOPURINE;NUDT15;C;rs116855232;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;AA + AG;rs12041331;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION | MYOCARDIAL_ISCHEMIA | STROKE,
SUNITINIB;VEGFA;CC + CT;rs833061;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
AZACITIDINE;MTHFR;AA;rs1801133;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOPIDOGREL;CYP2C19;AA + AG;rs4986893;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_POST-TREATMENT_PLATELET_REACTIVITY
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;AA;rs2768759;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION | MYOCARDIAL_ISCHEMIA | STROKE,
CYCLOPHOSPHAMIDE;ERCC1;AA;rs3212986;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
DOXORUBICIN;ERCC1;AA;rs3212986;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;ERCC1;AA;rs3212986;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
IMATINIB;SLC22A1;GG;rs628031;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ACETAMINOPHEN;nan;CT + TT;rs6500265;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
IBUPROFEN;nan;CT + TT;rs6500265;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
LOXOPROFEN;nan;CT + TT;rs6500265;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
SALICYLAMIDE;nan;CT + TT;rs6500265;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
IMATINIB;SLC19A1;TT;rs1051266;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GRIA1;CC;rs1994862;OTHER;DECREASED_RISK;SIDE_EFFECT:AROUSAL_DYSFUNCTION
EVEROLIMUS;RPTOR;CT + TT;rs9906827;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
IMATINIB;CHST1;AA + AG;rs9787901;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
IMATINIB;CYP2F1;AA;rs305968;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ACETAMINOPHEN;nan;GT + TT;rs9933632;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
IBUPROFEN;nan;GT + TT;rs9933632;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
LOXOPROFEN;nan;GT + TT;rs9933632;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
SALICYLAMIDE;nan;GT + TT;rs9933632;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS | STEVENS-JOHNSON_SYNDROME
CYCLOPHOSPHAMIDE;CBR1;TT;rs20572;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VOMITING
DOXORUBICIN;CBR1;TT;rs20572;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VOMITING
FLUOROURACIL;CBR1;TT;rs20572;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VOMITING
CYCLOPHOSPHAMIDE;TP53;GG;rs1042522;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VOMITING
DOXORUBICIN;TP53;GG;rs1042522;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VOMITING
FLUOROURACIL;TP53;GG;rs1042522;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VOMITING
SORAFENIB;PRKCE;G;rs11125039;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERTENSION
CYCLOPHOSPHAMIDE;SLC22A16;CC + CT;rs714368;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
DOXORUBICIN;SLC22A16;CC + CT;rs714368;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
FLUOROURACIL;SLC22A16;CC + CT;rs714368;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
ANTIINFLAMMATORY AGENTS;IL10;C;rs1800896;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
NON-STEROIDS;IL10;C;rs1800896;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
CYCLOPHOSPHAMIDE;XRCC1;CT + TT;rs25487;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
DOXORUBICIN;XRCC1;CT + TT;rs25487;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
FLUOROURACIL;XRCC1;CT + TT;rs25487;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
ANTIINFLAMMATORY AGENTS;CTLA4;G;rs231775;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
NON-STEROIDS;CTLA4;G;rs231775;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
NO_DRUG_RELATED;ADH7;CT + TT;rs971074;OTHER;INCREASED_SEVERITY;OTHER:PAIN
SORAFENIB;ADAMTS18;A;rs1346563;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERTENSION
PLATINUM COMPOUNDS;XRCC1;CT + TT;rs25487;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CYCLOPHOSPHAMIDE;GSTP1;AA + AG;rs1695;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
DOXORUBICIN;GSTP1;AA + AG;rs1695;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
FLUOROURACIL;GSTP1;AA + AG;rs1695;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
CISPLATIN;SLC31A1;GG + GT;rs10981694;TOXICITY;INCREASED_SEVERITY;DISEASE:OTOTOXICITY
CYCLOPHOSPHAMIDE;CYP2C19;CC;rs12248560;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
DOXORUBICIN;CYP2C19;CC;rs12248560;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
FLUOROURACIL;CYP2C19;CC;rs12248560;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
CYCLOPHOSPHAMIDE;ABCC2;TT;rs3740066;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
DOXORUBICIN;ABCC2;TT;rs3740066;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;ABCC2;TT;rs3740066;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
DEXMEDETOMIDINE;ABCC9;AA;rs11046209;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:SEDATION
CYCLOPHOSPHAMIDE;ABCB1;GG;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
DOXORUBICIN;ABCB1;GG;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
FLUOROURACIL;ABCB1;GG;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
VINCRISTINE;CEP72;A;rs12522955;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CAPECITABINE;nan;T;rs72765700;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CYCLOPHOSPHAMIDE;ABCG2;GT;rs2231142;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
DOXORUBICIN;ABCG2;GT;rs2231142;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
FLUOROURACIL;ABCG2;GT;rs2231142;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
ANTINEOPLASTIC AGENTS;ABCC4;AC;rs2274407;TOXICITY;INCREASED_SEVERITY;DISEASE:THROMBOCYTOPENIA
MERCAPTOPURINE;ABCC4;AC;rs2274407;TOXICITY;INCREASED_SEVERITY;DISEASE:THROMBOCYTOPENIA
METHOTREXATE;ABCC4;AC;rs2274407;TOXICITY;INCREASED_SEVERITY;DISEASE:THROMBOCYTOPENIA
AZATHIOPRINE;FTO;A;rs79206939;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
MERCAPTOPURINE;FTO;A;rs79206939;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
CYCLOPHOSPHAMIDE;ALDH3A1;CG + GG;rs2228100;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA | LEUKOPENIA
DOXORUBICIN;ALDH3A1;CG + GG;rs2228100;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA | LEUKOPENIA
FLUOROURACIL;ALDH3A1;CG + GG;rs2228100;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA | LEUKOPENIA
ANTINEOPLASTIC AGENTS;ABCC4;AC;rs2274407;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
MERCAPTOPURINE;ABCC4;AC;rs2274407;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
METHOTREXATE;ABCC4;AC;rs2274407;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
PRAVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_POST-TREATMENT_PLATELET_REACTIVITY
CYCLOPHOSPHAMIDE;ABCC2;GG;rs2273697;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
DOXORUBICIN;ABCC2;GG;rs2273697;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
FLUOROURACIL;ABCC2;GG;rs2273697;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
CYCLOPHOSPHAMIDE;SLC22A16;AA;rs6907567;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
DOXORUBICIN;SLC22A16;AA;rs6907567;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;SLC22A16;AA;rs6907567;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EVEROLIMUS;FGFR4;A;rs351855;TOXICITY;DECREASED_LIKELIHOOD;OTHER:DISCONTINUATION
EVEROLIMUS;FGFR4;A;rs351855;OTHER;DECREASED_LIKELIHOOD;OTHER:DISCONTINUATION
VINCRISTINE;CEP72;TT;rs924607;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
AZATHIOPRINE;nan;T;rs2834826;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
MERCAPTOPURINE;nan;T;rs2834826;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
CYCLOPHOSPHAMIDE;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
DOXORUBICIN;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
IMATINIB;SLC19A1;AG + GG;rs12659;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
AZATHIOPRINE;FTO;C;rs16952570;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
MERCAPTOPURINE;FTO;C;rs16952570;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
AZACITIDINE;XRCC1;CC;rs25487;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IMATINIB;NQO1;GG;rs10517;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
EVEROLIMUS;PIK3R1;G;rs10515074;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:HYPERGLYCEMIA
EVEROLIMUS;PIK3R1;G;rs10515074;OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT:HYPERGLYCEMIA
DESLORATADINE;HRH1;CC;rs901865;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SEDATION
IMATINIB;ABCC2;GG;rs2273697;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CYTARABINE;NOS3;TT;rs1799983;TOXICITY;DECREASED;SIDE_EFFECT:IQ
DOXORUBICIN;NOS3;TT;rs1799983;TOXICITY;DECREASED;SIDE_EFFECT:IQ
LEUCOVORIN;NOS3;TT;rs1799983;TOXICITY;DECREASED;SIDE_EFFECT:IQ
METHOTREXATE;NOS3;TT;rs1799983;TOXICITY;DECREASED;SIDE_EFFECT:IQ
PREDNISONE;NOS3;TT;rs1799983;TOXICITY;DECREASED;SIDE_EFFECT:IQ
VINCRISTINE;NOS3;TT;rs1799983;TOXICITY;DECREASED;SIDE_EFFECT:IQ
IMATINIB;ABCB4;AA + AG;rs1202283;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
EVEROLIMUS;PIK3R1;G;rs10515074;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
EVEROLIMUS;PIK3R1;G;rs10515074;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
CAPECITABINE;MIR2054;A;rs10024471;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
AZATHIOPRINE;NUDT15;CT + TT;rs116855232;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
METHOTREXATE;DHFR;CT + TT;rs1105525;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
ANTIPSYCHOTICS;PRKAB2;TT;rs3766522;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
CLOZAPINE;PRKAB2;TT;rs3766522;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
OLANZAPINE;PRKAB2;TT;rs3766522;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
METHADONE;NECTIN4;AA;rs11265549;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PRURITUS
CAPECITABINE;SPRY2;A;rs117876855;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
CAPECITABINE;SPRY2;A;rs139544515;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
HMG COA REDUCTASE INHIBITORS;HMGCR;AA;rs12654264;EFFICACY;DECREASED_RISK;DISEASE:COLONIC_NEOPLASMS
RIVAROXABAN;CYP3A4;AA;rs2246709;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
METHOTREXATE;GGH;A;rs11545078;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:THROMBOCYTOPENIA
CAPECITABINE;NCOA7;T;rs185217050;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CAPECITABINE;CCDC70;A;rs139368788;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
NO_DRUG_RELATED;HMGCR;AT + TT;rs12654264;OTHER;INCREASED;OTHER:SERUM_LDL
CYCLOPHOSPHAMIDE;ERCC1;AG + GG;rs11615;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA | NEPHROTOXICITY
DOXORUBICIN;ERCC1;AG + GG;rs11615;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA | NEPHROTOXICITY
FLUOROURACIL;ERCC1;AG + GG;rs11615;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA | NEPHROTOXICITY
CAPECITABINE;TMEM131L;G;rs117412990;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
PRAVASTATIN;HMGCR;AT;rs17244841;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL
HMG COA REDUCTASE INHIBITORS;HMGCR;TT;rs12654264;EFFICACY;DECREASED_RISK;DISEASE:COLONIC_NEOPLASMS
CAPECITABINE;SIRPA;G;rs191934521;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
ANTIPSYCHOTICS;PRKAA2;AA;rs10789038;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
CLOZAPINE;PRKAA2;AA;rs10789038;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
OLANZAPINE;PRKAA2;AA;rs10789038;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
RIVAROXABAN;CYP3A4;TT;rs3735451;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
CAPECITABINE;LMNTD1;T;rs146644707;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
METHOTREXATE;MTHFR;GG;rs1801133;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ANTINEOPLASTIC AGENTS;RBFOX1;G;rs6500843;EFFICACY;INCREASED_RISK;DISEASE:DEATH
HMG COA REDUCTASE INHIBITORS;HMGCR;AA;rs12654264;EFFICACY;DECREASED_RISK;DISEASE:COLONIC_NEOPLASMS
PLATINUM;XRCC5;G;rs1051685;TOXICITY;DECREASED_SEVERITY;DISEASE:ANEMIA | LEUKOPENIA | NEUTROPENIA | THROMBOCYTOPENIA
CLOZAPINE;LEP;AG + GG;rs7799039;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
OLANZAPINE;LEP;AG + GG;rs7799039;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
RISPERIDONE;LEP;AG + GG;rs7799039;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
IRINOTECAN;ABCC1;A;rs17287570;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION
SORAFENIB;EPAS1;C;rs1868089;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DERMATOLOGIC_TOXICITY
PLATINUM;XRCC5;A;rs6941;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA | LEUKOPENIA | NEUTROPENIA | THROMBOCYTOPENIA
CYCLOPHOSPHAMIDE;CYP2A6;A;rs143731390;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DEATH
IRINOTECAN;ABCG2;T;rs2622604;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION
FOLIC ACID;MTHFD1;AA;rs2236225;OTHER;DECREASED_LIKELIHOOD;OTHER:DIABETES | GESTATIONAL
METHOTREXATE;DHFR;GG;rs442767;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
IRINOTECAN;UGT1A10;CT + TT;rs11692021;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION
IRINOTECAN;UGT1A6;CT + TT;rs11692021;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION
IRINOTECAN;UGT1A7;CT + TT;rs11692021;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION
IRINOTECAN;UGT1A8;CT + TT;rs11692021;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION
IRINOTECAN;UGT1A9;CT + TT;rs11692021;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION
PLATINUM;AQP2;T;rs10875989;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA | LEUKOPENIA | NEUTROPENIA | THROMBOCYTOPENIA
APIXABAN;ABCG2;AA + AC;rs3114018;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
RIVAROXABAN;ABCG2;AA + AC;rs3114018;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
IRINOTECAN;SLCO1B3;G;rs7977213;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION
METHOTREXATE;DHFR;TT;rs408626;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CYCLOPHOSPHAMIDE;CYP2B6;T;rs3745274;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
PLATINUM;AQP2;AA + AC;rs3759125;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA | LEUKOPENIA | NEUTROPENIA | THROMBOCYTOPENIA
IRINOTECAN;SLCO1B3;T;rs10841661;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION
METHOTREXATE;DHFR;AA;rs1650697;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
APIXABAN;ABCG2;CT + TT;rs2622604;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
RIVAROXABAN;ABCG2;CT + TT;rs2622604;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
PLATINUM;AQP2;A;rs461872;TOXICITY;DECREASED_SEVERITY;DISEASE:DIARRHEA | NAUSEA | VOMITING,
PLATINUM;AQP2;CC + CT;rs7305534;TOXICITY;INCREASED_SEVERITY;DISEASE:DIARRHEA | NAUSEA | VOMITING,
MEPHENYTOIN;CYP2C19;C;rs41291556;LADME_PK;PK;PK:DRAMATIC_(APPROXIMATELY_90%_AND_70%)_REDUCTION_IN_THE_METABOLISM_OF_S-MEPHENYTOIN_AND_TOLBUTAMIDE
TOLBUTAMIDE;CYP2C19;C;rs41291556;LADME_PK;PK;PK:DRAMATIC_(APPROXIMATELY_90%_AND_70%)_REDUCTION_IN_THE_METABOLISM_OF_S-MEPHENYTOIN_AND_TOLBUTAMIDE
PLATINUM;CD74;A;rs2748249;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
ASPIRIN;TBXAS1;AA;rs6962291;OTHER;DECREASED_RISK;SIDE_EFFECT:INTOLERANCE
PLATINUM;CD74;C;rs1560661;TOXICITY;DECREASED_SEVERITY;DISEASE:DRUG_TOXICITY
CYTARABINE;CDA;AA;rs2072671;TOXICITY;DECREASED_RISK;SIDE_EFFECT:GRADE_III/IV_LIVER_TOXICITY
CYTARABINE;CDA;AA;rs2072671;LADME_PK;DECREASED_RISK;SIDE_EFFECT:GRADE_III/IV_LIVER_TOXICITY
WARFARIN;nan;A;rs12777823;DOSAGE;EFFICACY;EFFICACY:REDUCED_WARFARIN_DOSE_IN_AFRICAN_AMERICANS | INDEPENDENT_OF_CYP2C9*2_AND_CYP2C9*3.
WARFARIN;nan;A;rs12777823;DOSAGE;EFFICACY;EFFICACY:REDUCED_WARFARIN_DOSE_IN_AFRICAN_AMERICANS | INDEPENDENT_OF_CYP2C9*2_AND_CYP2C9*3.
NO_DRUG_RELATED;ALDH1A2;A;rs12915901;OTHER;INCREASED_LIKELIHOOD;OTHER:OSTEOARTHRITIS
RALOXIFENE;nan;G;rs10030044;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:OCCURRENCE_OF_BREAST_CANCER_DURING_SERM_(SELECTIVE_ESTROGEN_RECEPTOR_MODULATORS)_THERAPY
TAMOXIFEN;nan;G;rs10030044;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:OCCURRENCE_OF_BREAST_CANCER_DURING_SERM_(SELECTIVE_ESTROGEN_RECEPTOR_MODULATORS)_THERAPY
CAPECITABINE;DPYD;CT + TT;rs2297595;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME | MUCOSITIS | PERIPHERAL_NERVOUS_SYSTEM_DISEASES,
FLUOROURACIL;DPYD;CT + TT;rs2297595;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME | MUCOSITIS | PERIPHERAL_NERVOUS_SYSTEM_DISEASES,
NO_DRUG_RELATED;SLC2A1;CG + GG;rs841844;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
CAPECITABINE;DPYD;TT;rs2297595;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
FLUOROURACIL;DPYD;TT;rs2297595;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:INSUFFICIENT_ANTIPLATELET_RESPONSE_TO_CLOPIDOGREL
DASATINIB;ABL1;CT;rs121913459;OTHER;DECREASED_PK;PK:AUC_0-4_HOURS
DASATINIB;ABL1;CT;rs121913459;LADME_PK;DECREASED_PK;PK:AUC_0-4_HOURS
PEGINTERFERON ALFA-2B;IFNL3;TT;rs8099917;EFFICACY;DECREASED_SEVERITY;DISEASE:HEPATITIS_C
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;DECREASED_SEVERITY;DISEASE:HEPATITIS_C
HYDROCHLOROTHIAZIDE;AGT;T;rs5051;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
HYDROCHLOROTHIAZIDE;AGTR1;A;rs5186;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
TAMOXIFEN;ESR2;CC;rs4986938;OTHER;INCREASED;SIDE_EFFECT:TRIGLYCERIDES_IN_POSTMENOPAUSAL_WOMAN
AZATHIOPRINE;NUDT15;T;rs116855232;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
MERCAPTOPURINE;NUDT15;T;rs116855232;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:LEUKOPENIA | NEUTROPENIA
ONDANSETRON;ABCB1;AA;rs1045642;EFFICACY;DECREASED_LIKELIHOOD;DISEASE:POSTOPERATIVE_NAUSEA_AND_VOMITING
TAMOXIFEN;ESR1;GG;rs9340799;OTHER;DECREASED;SIDE_EFFECT:IN_TOTAL_CHOLESTEROL_IN_POSTMENOPAUSAL_WOMAN_AND_INCREASE_IN_TRIGLYCERIDES_AND_DECREASE_IN_HIGH_DENSITY_LIPOPROTEIN_IN_PREMENOPAUSAL_WOMEN
TALINOLOL;ABCC2;A;rs2273697;OTHER;INCREASED_PK;PK:RESIDUAL_CLEARANCE_OF_INTRAVENOUS_TALINOLOL_AND_LOWER_BIOAVAILABLILTY_OF_ORALLY_ADMINISTERED_TALINOLOL
CLOZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
OLANZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
DOXORUBICIN;CBR3;G;rs8133052;TOXICITY;INCREASED_PK;PK:DOXORUBICINOL_AUC
DOXORUBICIN;CBR3;G;rs8133052;LADME_PK;INCREASED_PK;PK:DOXORUBICINOL_AUC
ONDANSETRON;ABCB1;AA;rs2032582;EFFICACY;DECREASED_LIKELIHOOD;DISEASE:POSTOPERATIVE_NAUSEA_AND_VOMITING
CLOZAPINE;HTR2C;C;rs518147;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
OLANZAPINE;HTR2C;C;rs518147;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
RISPERIDONE;HTR2C;C;rs518147;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
BEVACIZUMAB;MTHFR;GG + GT;rs1801131;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CYANOCOBALAMIN;MTHFR;GG + GT;rs1801131;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FOLIC ACID;MTHFR;GG + GT;rs1801131;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PEMETREXED;MTHFR;GG + GT;rs1801131;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ARTESUNATE;G6PD;CT;rs1050828;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MODERATE_ANEMIA
ARTESUNATE;IKBKG;CT;rs1050828;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MODERATE_ANEMIA
PRIMAQUINE;G6PD;CT;rs1050828;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MODERATE_ANEMIA
PRIMAQUINE;IKBKG;CT;rs1050828;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MODERATE_ANEMIA
PYRIMETHAMINE;G6PD;CT;rs1050828;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MODERATE_ANEMIA
PYRIMETHAMINE;IKBKG;CT;rs1050828;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MODERATE_ANEMIA
SULFADOXINE;G6PD;CT;rs1050828;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MODERATE_ANEMIA
SULFADOXINE;IKBKG;CT;rs1050828;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MODERATE_ANEMIA
RALOXIFENE;ZNF423;A;rs8060157;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:OCCURRENCE_OF_BREAST_CANCER_DURING_SERM_(SELECTIVE_ESTROGEN_RECEPTOR_MODULATORS)_THERAPY
TAMOXIFEN;ZNF423;A;rs8060157;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:OCCURRENCE_OF_BREAST_CANCER_DURING_SERM_(SELECTIVE_ESTROGEN_RECEPTOR_MODULATORS)_THERAPY
TACROLIMUS;ABCB1;AA + AG;rs1045642;EFFICACY;EFFICACY;EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE
CARBAMAZEPINE;ABCC2;AA + AG;rs2273697;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUROLOGICAL_ADR
CARBAMAZEPINE;ABCC2;AA + AG;rs2273697;LADME_PK;INCREASED_RISK;SIDE_EFFECT:NEUROLOGICAL_ADR
ARTESUNATE;G6PD;TT;rs1050828;OTHER;INCREASED_RISK;SIDE_EFFECT:MODERATE_ANEMIA
ARTESUNATE;IKBKG;TT;rs1050828;OTHER;INCREASED_RISK;SIDE_EFFECT:MODERATE_ANEMIA
PRIMAQUINE;G6PD;TT;rs1050828;OTHER;INCREASED_RISK;SIDE_EFFECT:MODERATE_ANEMIA
PRIMAQUINE;IKBKG;TT;rs1050828;OTHER;INCREASED_RISK;SIDE_EFFECT:MODERATE_ANEMIA
PYRIMETHAMINE;G6PD;TT;rs1050828;OTHER;INCREASED_RISK;SIDE_EFFECT:MODERATE_ANEMIA
PYRIMETHAMINE;IKBKG;TT;rs1050828;OTHER;INCREASED_RISK;SIDE_EFFECT:MODERATE_ANEMIA
SULFADOXINE;G6PD;TT;rs1050828;OTHER;INCREASED_RISK;SIDE_EFFECT:MODERATE_ANEMIA
SULFADOXINE;IKBKG;TT;rs1050828;OTHER;INCREASED_RISK;SIDE_EFFECT:MODERATE_ANEMIA
SORAFENIB;VEGFB;T;rs12366035;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DERMATOLOGIC_TOXICITY
CYTARABINE;CDA;TT;rs532545;EFFICACY;DECREASED_EFFICACY;EFFICACY:5_YEAR_SURVIVAL
CYTARABINE;CDA;TT;rs532545;EFFICACY;INCREASED_RISK;DISEASE:DEATH
VINCRISTINE;CEP72;C;rs71585289;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CYCLOSPORINE;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED_RISK;DISEASE:INFECTIOUS_DISEASE
TACROLIMUS;ABCB1;AA + AG;rs1128503;EFFICACY;INCREASED_RISK;DISEASE:INFECTIOUS_DISEASE
CLOPIDOGREL;P2RY12;GG;rs2046934;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACUTE_CORONARY_SYNDROME
VINCRISTINE;MIR6076;CC + CG;rs35650931;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
SORAFENIB;WWOX;A;rs9927200;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
DOXEPIN;CYP2C19;AA;rs4244285;LADME_PK;DECREASED_PK;PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;A;rs2229774;TOXICITY;INCREASED_RISK;DISEASE:CARDIOTOXICITY
VINCRISTINE;MIR4481;G;rs7896283;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
CLOMIPRAMINE;CYP2C19;AG;rs4244285;LADME_PK;INCREASED_PK;PK:MEAN_CLOMIPRAMINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT_AND_HIGHER_METABOLIC_RATIO_OF_CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE
CAPECITABINE;DPYD;CC;rs2297595;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
FLUOROURACIL;DPYD;CC;rs2297595;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
METHOTREXATE;SLC19A1;CT;rs1051266;EFFICACY;INCREASED_RISK;OTHER:TOXIC_LIVER_DISEASE
CORTICOSTEROIDS;ACP1;TT;rs11553746;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS
SORAFENIB;MAP2K6;C;rs11651488;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
METHOTREXATE;MTHFR;GT;rs1801131;EFFICACY;DECREASED_RISK;OTHER:TOXIC_LIVER_DISEASE
SORAFENIB;CDH13;C;rs17682789;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DIARRHEA
TACROLIMUS;CYP3A5;CC;rs776746;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
CLOMIPRAMINE;CYP2C19;AA;rs4244285;LADME_PK;INCREASED_PK;PK:MEAN_CLOMIPRAMINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT_AND_HIGHER_METABOLIC_RATIO_OF_CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE
PAROXETINE;FKBP5;T;rs1360780;OTHER;INCREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
CLOMIPRAMINE;FKBP5;T;rs1360780;OTHER;INCREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
LIOTHYRONINE;FKBP5;T;rs1360780;OTHER;INCREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
LITHIUM;FKBP5;T;rs1360780;OTHER;INCREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
NEFAZODONE;FKBP5;T;rs1360780;OTHER;INCREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
PAROXETINE;FKBP5;T;rs1360780;OTHER;INCREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
VENLAFAXINE;FKBP5;T;rs1360780;OTHER;INCREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
ILOPERIDONE;CYP2D6;GG;rs1065852;OTHER;INCREASED;SIDE_EFFECT:QTC_INTERVAL
GEMCITABINE;SLC28A1;A;rs12148896;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
METHOTREXATE;MTHFR;AA;rs1801133;EFFICACY;INCREASED_RISK;SIDE_EFFECT:MYELOSUPPRESSION
CLOMIPRAMINE;HTR1B;A;rs130058;EFFICACY;DECREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
LIOTHYRONINE;HTR1B;A;rs130058;EFFICACY;DECREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
LITHIUM;HTR1B;A;rs130058;EFFICACY;DECREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
NEFAZODONE;HTR1B;A;rs130058;EFFICACY;DECREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
VENLAFAXINE;HTR1B;A;rs130058;EFFICACY;DECREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
PAROXETINE;HTR1B;A;rs130058;OTHER;INCREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
GEMCITABINE;CDA;A;rs471760;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CANNABIDIOL;ABCC5;AA + AG;rs3749442;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEDATION
CISPLATIN;ACYP2;AG;rs1872328;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OTOTOXICITY
CLOMIPRAMINE;ABCB1;A;rs2032582;OTHER;INCREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
LIOTHYRONINE;ABCB1;A;rs2032582;OTHER;INCREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
LITHIUM;ABCB1;A;rs2032582;OTHER;INCREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
NEFAZODONE;ABCB1;A;rs2032582;OTHER;INCREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
PAROXETINE;ABCB1;A;rs2032582;OTHER;INCREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
VENLAFAXINE;ABCB1;A;rs2032582;OTHER;INCREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
MELPHALAN;SLC7A5;AA + AG;rs4240803;TOXICITY;DECREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
ANTIPSYCHOTICS;MC4R;CC + CT;rs17782313;OTHER;INCREASED_RISK;DISEASE:WEIGHT_GAIN
PLATINUM;SLC2A1;T;rs3738514;TOXICITY;DECREASED_SEVERITY;DISEASE:DRUG_TOXICITY
DOXORUBICIN;RARG;AA;rs2229774;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
VINCRISTINE;GARS1;G;rs1049402;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
SORAFENIB;EGFR;A;rs917881;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
VINCRISTINE;FGD4;A;rs12823621;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CARBOPLATIN;SLC31A1;AA;rs7851395;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN;SLC31A1;AA;rs7851395;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
VINCRISTINE;MIR3117;AA + AG;rs12402181;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
FLUOROURACIL;ERCC2;GT;rs13181;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
FLUOROURACIL;KLC3;GT;rs13181;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
OXALIPLATIN;ERCC2;GT;rs13181;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
OXALIPLATIN;KLC3;GT;rs13181;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PLATINUM;SLC2A1;CC;rs4658;TOXICITY;DECREASED_SEVERITY;DISEASE:DRUG_TOXICITY
PEGINTERFERON ALFA-2B;ITPA;CC;rs1127354;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ANEMIA
RIBAVIRIN;ITPA;CC;rs1127354;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ANEMIA
TELAPREVIR;ITPA;CC;rs1127354;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ANEMIA
FLUOROURACIL;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
OXALIPLATIN;GSTP1;AG + GG;rs1695;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
NO_DRUG_RELATED;ADD1;GT + TT;rs4961;OTHER;INCREASED;OTHER:AMBULATORY_BLOOD_PRESSURE
BLEOMYCIN;ERCC2;GT + TT;rs238406;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
CISPLATIN;ERCC2;GT + TT;rs238406;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
ETOPOSIDE;ERCC2;GT + TT;rs238406;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
ATORVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
CLOPIDOGREL;CYP3A5;CC + CT;rs776746;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
HMG COA REDUCTASE INHIBITORS;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
NO_DRUG_RELATED;RAD52;CC;rs2277869;OTHER;INCREASED;OTHER:AMBULATORY_BLOOD_PRESSURE
NO_DRUG_RELATED;WNK1;CC;rs2277869;OTHER;INCREASED;OTHER:AMBULATORY_BLOOD_PRESSURE
FENTANYL;nan;C;rs13422094;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
MORPHINE;nan;C;rs13422094;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
OPIOIDS;nan;C;rs13422094;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
OXYCODONE;nan;C;rs13422094;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
SUNITINIB;IL13;TT;rs1800925;OTHER;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
FENTANYL;nan;G;rs12211463;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
MORPHINE;nan;G;rs12211463;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
OPIOIDS;nan;G;rs12211463;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
OXYCODONE;nan;G;rs12211463;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
FENTANYL;nan;A;rs7757130;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
MORPHINE;nan;A;rs7757130;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
OPIOIDS;nan;A;rs7757130;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
OXYCODONE;nan;A;rs7757130;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
FENTANYL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE
FENTANYL;nan;G;rs2473967;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
MORPHINE;nan;G;rs2473967;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
OPIOIDS;nan;G;rs2473967;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
OXYCODONE;nan;G;rs2473967;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
THIAZIDES;ADD1;GG;rs4961;EFFICACY;DECREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
PLAIN;ADD1;GG;rs4961;EFFICACY;DECREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
BLEOMYCIN;ERCC2;TT;rs1799793;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
CISPLATIN;ERCC2;TT;rs1799793;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
ETOPOSIDE;ERCC2;TT;rs1799793;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
SUNITINIB;IL13;TT;rs1800925;OTHER;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
FENTANYL;COMT;AG;rs4680;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE
SIMVASTATIN;SLCO1B1;CC + CT;rs4149056;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
FENTANYL;RHBDF2;AA + AG;rs12948783;EFFICACY;DECREASED_EFFICACY;EFFICACY:EFFICACT_AS_MEASURED_BY_LOWER_PAIN_RELIEF_TO_OPIOIDS
MORPHINE;RHBDF2;AA + AG;rs12948783;EFFICACY;DECREASED_EFFICACY;EFFICACY:EFFICACT_AS_MEASURED_BY_LOWER_PAIN_RELIEF_TO_OPIOIDS
OPIOIDS;RHBDF2;AA + AG;rs12948783;EFFICACY;DECREASED_EFFICACY;EFFICACY:EFFICACT_AS_MEASURED_BY_LOWER_PAIN_RELIEF_TO_OPIOIDS
OXYCODONE;RHBDF2;AA + AG;rs12948783;EFFICACY;DECREASED_EFFICACY;EFFICACY:EFFICACT_AS_MEASURED_BY_LOWER_PAIN_RELIEF_TO_OPIOIDS
ACE INHIBITORS;SH2B1;T;rs192613545;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
PLAIN;SH2B1;T;rs192613545;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
RADIOTHERAPY;OSMR;T;rs1239344;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ESOPHAGITIS
BLEOMYCIN;BLMH;CC;rs1050565;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PAIN
CISPLATIN;BLMH;CC;rs1050565;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PAIN
ETOPOSIDE;BLMH;CC;rs1050565;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PAIN
RADIOTHERAPY;CDK1;G;rs10711;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PNEUMONITIS
BLEOMYCIN;BLMH;CC;rs1050565;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALOPECIA
CISPLATIN;BLMH;CC;rs1050565;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALOPECIA
ETOPOSIDE;BLMH;CC;rs1050565;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALOPECIA
CELECOXIB;CYP2C9;CT;rs1799853;LADME_PK;PK;PK:HIGHER_PLASMA_CONCENTRATIONS_OF_CELECOXIB
HYDROCHLOROTHIAZIDE;REN;GG;rs11240688;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_SBP
HYDROCHLOROTHIAZIDE;YEATS4;C;rs7297610;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
ACE INHIBITORS;RBFOX3;C;rs62063838;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
PLAIN;RBFOX3;C;rs62063838;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
HYDROCHLOROTHIAZIDE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
RADIOTHERAPY;PRKCE;G;rs940052;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ESOPHAGITIS
ACE INHIBITORS;MBOAT1;T;rs10946364;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
PLAIN;MBOAT1;T;rs10946364;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
RADIOTHERAPY;PRKCE;T;rs11125035;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ESOPHAGITIS
ROFECOXIB;PTGS1;T;rs3842787;EFFICACY;EFFICACY;EFFICACY:REDUCTION_IN_COX-1_INHIBITION_AND_DEPRESSION_OF_THE_URINARY_THROMBOXANE_METABOLITE
BLEOMYCIN;ERCC1;AA;rs11615;TOXICITY;INCREASED_RISK;SIDE_EFFECT:FEBRILE_NEUTROPENIA
CISPLATIN;ERCC1;AA;rs11615;TOXICITY;INCREASED_RISK;SIDE_EFFECT:FEBRILE_NEUTROPENIA
ETOPOSIDE;ERCC1;AA;rs11615;TOXICITY;INCREASED_RISK;SIDE_EFFECT:FEBRILE_NEUTROPENIA
RADIOTHERAPY;RIGI;C;rs11795343;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PNEUMONITIS
CISPLATIN;TPMT;T;rs12201199;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OTOTOXICITY
DRUGS FOR TREATMENT OF TUBERCULOSIS;nan;AA;rs1495741;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ACE INHIBITORS;RBFOX3;G;rs56044629;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
PLAIN;RBFOX3;G;rs56044629;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
HYDROCHLOROTHIAZIDE;WNK1;TT;rs880054;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_SBP
RADIOTHERAPY;nan;C;rs7259857;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ESOPHAGITIS
CELECOXIB;PTGS1;T;rs3842787;EFFICACY;EFFICACY;EFFICACY:REDUCTION_IN_COX-1_INHIBITION
NO_DRUG_RELATED;COL1A1;AA + AC;rs1800012;nan;INCREASED_RISK;DISEASE:FRACTURES | BONE
HYDROCHLOROTHIAZIDE;ADD1;T;rs4961;EFFICACY;DECREASED_EFFICACY;EFFICACY:ABSOLUTE_MEAN_BLOOD_PRESSURE
ACE INHIBITORS;GABRG2;G;rs77370934;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
PLAIN;GABRG2;G;rs77370934;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
NO_DRUG_RELATED;COL1A1;AA + AC;rs1800012;nan;DECREASED;OTHER:BONE_MINERAL_DENSITY_(BMD)
VINCRISTINE;BAHD1;AA + AC;rs3803357;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ACE INHIBITORS;RBFOX3;G;rs56209714;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
PLAIN;RBFOX3;G;rs56209714;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
CAPECITABINE;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;DPYD;CT + TT;rs1801160;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
METHYLPREDNISOLONE;ABCB1;AA;rs1045642;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
PREDNISOLONE;ABCB1;AA;rs1045642;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
BLEOMYCIN;GSTP1;GG;rs1695;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INFECTIOUS_DISEASE
CISPLATIN;GSTP1;GG;rs1695;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INFECTIOUS_DISEASE
ETOPOSIDE;GSTP1;GG;rs1695;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INFECTIOUS_DISEASE
ANASTROZOLE;ZNF613;C;rs8113308;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
LETROZOLE;ZNF613;C;rs8113308;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
TAMOXIFEN;ZNF613;C;rs8113308;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PIRFENIDONE;CYP1A2;AA;rs762551;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
BLEOMYCIN;ERCC2;GG + GT;rs13181;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALOPECIA
CISPLATIN;ERCC2;GG + GT;rs13181;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALOPECIA
ETOPOSIDE;ERCC2;GG + GT;rs13181;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALOPECIA
CISPLATIN;OTOS;CC + CT;rs2291767;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OTOTOXICITY
ACE INHIBITORS;RBFOX3;G;rs2061538;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
PLAIN;RBFOX3;G;rs2061538;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;CC;rs6311;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIMINISHED_ABILITY_TO_CONCENTRATE
CITALOPRAM;HTR2A;CC;rs6311;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA | VOMITING
TACROLIMUS;CYP3A5;CT + TT;rs776746;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
MERCAPTOPURINE;MTHFR;GG;rs1801131;TOXICITY;DECREASED_RISK;DISEASE:MYELOSUPPRESSION
METHOTREXATE;MTHFR;GG;rs1801131;TOXICITY;DECREASED_RISK;DISEASE:MYELOSUPPRESSION
SUNITINIB;CXCL8;TT;rs1126647;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERTENSION
BEVACIZUMAB;PDGFRB;AA + AG;rs2302273;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
FLUOROURACIL;PDGFRB;AA + AG;rs2302273;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
IRINOTECAN;PDGFRB;AA + AG;rs2302273;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
LEUCOVORIN;PDGFRB;AA + AG;rs2302273;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ETHANOL;PNPLA3;GG;rs738409;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE
BEVACIZUMAB;RGS5;CC + CG;rs2661280;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FLUOROURACIL;RGS5;CC + CG;rs2661280;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IRINOTECAN;RGS5;CC + CG;rs2661280;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
LEUCOVORIN;RGS5;CC + CG;rs2661280;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
SORAFENIB;EPAS1;T;rs9973653;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
NO_DRUG_RELATED;WT1;CC + CT;rs16754;OTHER;INCREASED_LIKELIHOOD;DISEASE:EVENT-FREE_SURVIVAL
TACROLIMUS;CYP3A5;CT + TT;rs776746;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TRANSPLANT_REJECTION
MERCAPTOPURINE;ITPA;A;rs1127354;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
CANNABINOIDS;FAAH;AA;rs324420;TOXICITY;DECREASED_RISK;DISEASE:SUBSTANCE-RELATED_DISORDERS
SORAFENIB;nan;C;rs315498;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
CYCLOPHOSPHAMIDE;GSTA1;A;rs3957357;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DEATH
VINCRISTINE;MRPL47;CT + TT;rs10513762;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
FLUOROURACIL;DPYD;AT;rs67376798;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
VINCRISTINE;SYNE2;A;rs2781377;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
SORAFENIB;EPAS1;A;rs4035887;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ANTIPSYCHOTICS;COMT;AA + AG;rs4680;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_DIASTOLIC_BLOOD_PRESSURE | ELEVATED_SYSTOLIC_BLOOD_PRESSURE
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED_EFFICACY;EFFICACY:ON-TREATMENT_PLATELET_REACTIVITY
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
METHOTREXATE;DHFR;CC;rs408626;EFFICACY;DECREASED;OTHER:EVENT-FREE_SURVIVAL | OVERALL_SURVIVAL
METHOTREXATE;MTHFR;G;rs1801131;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_TRANSAMINASES
CYCLOPHOSPHAMIDE;GSTA1;C;rs1051775;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DEATH
EFAVIRENZ;ABCB1;A;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXICITY-RELATED_TREATMENT_FAILURE
DOXORUBICIN;GALNT14;TT;rs9679162;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ASPIRIN;CYP2D6;CC;rs28360521;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_HEMORRHAGE
ASPIRIN;CYP2D6;CC;rs28360521;OTHER;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_HEMORRHAGE
DESFLURANE;ATP8B3;CT + TT;rs45574836;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING | VOMITING
PROPOFOL;ATP8B3;CT + TT;rs45574836;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING | VOMITING
LOSARTAN;CAMK1D;AG + GG;rs10752271;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_SYSTOLIC_BLOOD_PRESSURE
METHOTREXATE;MTHFR;AA;rs1801133;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
METHOTREXATE;DHFR;TT;rs408626;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
LOSARTAN;CAMK1D;AG + GG;rs10737062;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_SYSTOLIC_BLOOD_PRESSURE
CYCLOPHOSPHAMIDE;GSTA1;C;rs1051775;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
METHOTREXATE;MTHFR;T;rs1801131;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
METHOTREXATE;DHFR;GT;rs442767;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
CELECOXIB;CYP2C9;C;rs1057910;EFFICACY;DECREASED_RISK;DISEASE:ADENOMA
MERCAPTOPURINE;SLC19A1;CT + TT;rs1051266;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTIONS
BLEOMYCIN;CYP3A4;CT;rs2740574;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALOPECIA
CISPLATIN;CYP3A4;CT;rs2740574;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALOPECIA
ETOPOSIDE;CYP3A4;CT;rs2740574;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALOPECIA
MERCAPTOPURINE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTION
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTION
EFAVIRENZ;ABCB1;A;rs1045642;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:EMERGING_VIRAL_DRUG_RESISTANCE
BEVACIZUMAB;CSPG4;AG;rs1127648;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
FLUOROURACIL;CSPG4;AG;rs1127648;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
IRINOTECAN;CSPG4;AG;rs1127648;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
LEUCOVORIN;CSPG4;AG;rs1127648;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SORAFENIB;nan;G;rs10958704;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DERMATOLOGIC_TOXICITY
METHOTREXATE;SHMT1;AG;rs1979277;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
METHOTREXATE;FASTKD3;AG;rs1801394;TOXICITY;INCREASED;SIDE_EFFECT:SPEED_OF_PLATELET_RECOVERY
METHOTREXATE;MTRR;AG;rs1801394;TOXICITY;INCREASED;SIDE_EFFECT:SPEED_OF_PLATELET_RECOVERY
SORAFENIB;EPAS1;G;rs7557402;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DERMATOLOGIC_TOXICITY
METHOTREXATE;MTHFR;TT;rs1801131;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:RED_BLOOD_CELL_TRANSFUSIONS
CYCLOPHOSPHAMIDE;CYP2B6;T;rs3211371;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
APIXABAN;ABCB1;AA;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
RIVAROXABAN;ABCB1;AA;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
EFAVIRENZ;ABCB1;A;rs2032582;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:EMERGING_VIRAL_DRUG_RESISTANCE
CYCLOPHOSPHAMIDE;VEGFA;AA;rs1570360;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
DOCETAXEL;VEGFA;AA;rs1570360;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CARBOPLATIN;OR4D6;CC;rs1453542;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
GEMCITABINE;OR4D6;CC;rs1453542;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
SORAFENIB;MAP2K6;G;rs12948059;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DERMATOLOGIC_TOXICITY
CARBOPLATIN;DDX53;T;rs5925720;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
GEMCITABINE;DDX53;T;rs5925720;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
METHOTREXATE;MTHFD1;AA;rs2236225;OTHER;INCREASED_PK;PK:RED_BLOOD_CELL_FOLATE
METHOTREXATE;FASTKD3;AA;rs1801394;OTHER;INCREASED_PK;PK:RED_BLOOD_CELL_FOLATE
METHOTREXATE;MTRR;AA;rs1801394;OTHER;INCREASED_PK;PK:RED_BLOOD_CELL_FOLATE
IRINOTECAN;SEMA3C;T;rs11979430;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
ANTIPSYCHOTICS;DRD2;A;rs1800497;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
ANTIPSYCHOTICS;COMT;AA + AG;rs4680;TOXICITY;DECREASED_RISK;DISEASE:TARDIVE_DYSKINESIA
IRINOTECAN;SEMA3C;C;rs7779029;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
ANTIEPILEPTICS;ABCB1;C;rs2032582;EFFICACY;EFFICACY;EFFICACY:PROTECTION_FROM_DRUG_RESISTANCE
ANTIPSYCHOTICS;DRD2;G;rs1800497;TOXICITY;INCREASED_RISK;DISEASE:TARDIVE_DYSKINESIA
ANTIEPILEPTICS;ABCB1;C;rs2032582;EFFICACY;EFFICACY;EFFICACY:PROTECTION_FROM_DRUG_RESISTANCE
ANTIPSYCHOTICS;DRD2;G;rs1800497;TOXICITY;INCREASED_RISK;DISEASE:TARDIVE_DYSKINESIA
IRINOTECAN;nan;G;rs1661167;TOXICITY;INCREASED_SEVERITY;DISEASE:DIARRHEA
ANTIEPILEPTICS;ABCB1;C;rs2032582;EFFICACY;EFFICACY;EFFICACY:PROTECTION_FROM_DRUG_RESISTANCE
AMISULPRIDE;HTR2C;AA;rs498207;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
CLOZAPINE;HTR2C;AA;rs498207;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
OLANZAPINE;HTR2C;AA;rs498207;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
QUETIAPINE;HTR2C;AA;rs498207;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
RISPERIDONE;HTR2C;AA;rs498207;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
CISPLATIN;CYP2E1;TT;rs6413432;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CYCLOPHOSPHAMIDE;CYP2E1;TT;rs6413432;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
BUDESONIDE;FCER2;G;rs28364072;OTHER;nan;OTHER:SEVERE_EXACERBATIONS_WITH_ASTHMA
CYCLOPHOSPHAMIDE;NOS3;TT;rs1799983;EFFICACY;INCREASED_EFFICACY;EFFICACY:DISEASE_FREE_SURVIVAL
AMISULPRIDE;HTR2C;GG;rs3813928;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
CLOZAPINE;HTR2C;GG;rs3813928;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
OLANZAPINE;HTR2C;GG;rs3813928;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
QUETIAPINE;HTR2C;GG;rs3813928;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
RISPERIDONE;HTR2C;GG;rs3813928;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
MYCOPHENOLATE MOFETIL;IL12A;A;rs568408;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TIME_TO_ANEMIA_IN_PATIENTS_UNDERGOING_LIVING_OR_DECEASED_DONOR_KIDNEY_TRANSPLANT
IRINOTECAN;PLCB1;C;rs2745761;TOXICITY;INCREASED_SEVERITY;DISEASE:DIARRHEA
CYCLOPHOSPHAMIDE;NOS3;CC;rs2070744;EFFICACY;INCREASED_EFFICACY;EFFICACY:DISEASE_FREE_SURVIVAL
AMISULPRIDE;HTR2C;CC;rs3813929;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
CLOZAPINE;HTR2C;CC;rs3813929;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
OLANZAPINE;HTR2C;CC;rs3813929;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
QUETIAPINE;HTR2C;CC;rs3813929;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
RISPERIDONE;HTR2C;CC;rs3813929;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
CYCLOPHOSPHAMIDE;NOS3;GG + GT;rs1799983;EFFICACY;INCREASED_EFFICACY;EFFICACY:DISEASE_FREE_SURVIVAL
DOXORUBICIN;NOS3;GG + GT;rs1799983;EFFICACY;INCREASED_EFFICACY;EFFICACY:DISEASE_FREE_SURVIVAL
FLUOROURACIL;NOS3;GG + GT;rs1799983;EFFICACY;INCREASED_EFFICACY;EFFICACY:DISEASE_FREE_SURVIVAL
METHOTREXATE;NOS3;GG + GT;rs1799983;EFFICACY;INCREASED_EFFICACY;EFFICACY:DISEASE_FREE_SURVIVAL
IRINOTECAN;PDZRN3;C;rs11128347;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
METHADONE;UGT2B7;TT;rs4554144;EFFICACY;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
METHADONE;UGT2B7;TT;rs4554144;LADME_PK;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
DAPSONE;HLA-DRB1;A;rs201929247;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
OLANZAPINE;PPARG;CG;rs1801282;OTHER;INCREASED;DISEASE:WEIGHT_GAIN
METHADONE;UGT2B7;CC;rs11940316;EFFICACY;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
METHADONE;UGT2B7;CC;rs11940316;LADME_PK;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
CORTICOSTEROIDS;BCL2L11;AA;rs2241843;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
METHADONE;UGT2B7;AA;rs7438135;EFFICACY;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
METHADONE;UGT2B7;AA;rs7438135;LADME_PK;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
METHADONE;UGT2B7;GG;rs7662029;EFFICACY;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
METHADONE;UGT2B7;GG;rs7662029;LADME_PK;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
CISPLATIN;GSTA1;AA + AG;rs3957357;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ANEMIA
CYCLOPHOSPHAMIDE;GSTA1;AA + AG;rs3957357;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ANEMIA
OXALIPLATIN;PIN1;CC + CG;rs2233678;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL | PROGRESSION-FREE_SURVIVAL
METHADONE;UGT2B7;CC;rs7668258;EFFICACY;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
METHADONE;UGT2B7;CC;rs7668258;LADME_PK;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
ETHAMBUTOL;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
ISONIAZID;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
PYRAZINAMIDE;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
RIFAMPIN;CYP2C9;CT + TT;rs9332096;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
METHOTREXATE;ABCG2;TT;rs2231142;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
METHOTREXATE;AMPD1;AG;rs17602729;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CNS_ADVERSE_EVENTS
ANTIEPILEPTICS;ABCB1;A;rs1045642;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DRUG_RESISTANCE
METHADONE;UGT2B7;CC;rs7439366;EFFICACY;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
METHADONE;UGT2B7;CC;rs7439366;LADME_PK;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
ANTIEPILEPTICS;ABCB1;A;rs1128503;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DRUG_RESISTANCE
ANTIEPILEPTICS;ABCB1;G;rs3789243;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DRUG_RESISTANCE
METHADONE;UGT2B7;GG;rs4292394;EFFICACY;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
METHADONE;UGT2B7;GG;rs4292394;LADME_PK;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
ETHAMBUTOL;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
ISONIAZID;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
PYRAZINAMIDE;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
RIFAMPIN;CYP2C19;AA + AG;rs4986893;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
CISPLATIN;CYP2E1;CG;rs2070676;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_EMESIS
CYCLOPHOSPHAMIDE;CYP2E1;CG;rs2070676;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_EMESIS
ANTIEPILEPTICS;ABCB1;G;rs3789243;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DRUG_RESISTANCE
FLUOROURACIL;DPYD;CT;rs3918290;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY | LEUKOPENIA | MUCOSITIS,
THIAZIDES;GNB3;CC;rs5443;TOXICITY;INCREASED_RISK;DISEASE:DIABETES_MELLITUS
PLAIN;GNB3;CC;rs5443;TOXICITY;INCREASED_RISK;DISEASE:DIABETES_MELLITUS
AMLODIPINE;RYR3;TT;rs877087;EFFICACY;INCREASED_RISK;DISEASE:HEART_FAILURE
FLUOROURACIL;GSTP1;GG;rs1695;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HAEMATOLOGICAL_TOXICITY
NO_DRUG_RELATED;COL1A1;AA;rs1800012;nan;DECREASED;OTHER:BONE_MINERAL_DENSITY_AT_FEMORAL_NECK_AND_LUMBAR_SPINE
METHADONE;UGT2B7;GG;rs6600879;EFFICACY;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
METHADONE;UGT2B7;GG;rs6600879;LADME_PK;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
NO_DRUG_RELATED;COL1A1;AA + AC;rs1800012;nan;DECREASED;OTHER:BMD_VALUES_AT_THE_LUMBAR_SPINE_AND_FEMORAL_NECK
METHADONE;UGT2B7;AA;rs6600880;EFFICACY;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
METHADONE;UGT2B7;AA;rs6600880;LADME_PK;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
PLATINUM COMPOUNDS;EIF3A;A;rs10510050;TOXICITY;INCREASED_RISK;SIDE_EFFECT:THROMBOCYTOPENIA | TOXIC_LIVER_DISEASE | VOMITING,
CAPECITABINE;DPYD;AT;rs67376798;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
THIAZIDES;AGTR1;AA + AC;rs5186;TOXICITY;INCREASED_RISK;DISEASE:DIABETES_MELLITUS
PLAIN;AGTR1;AA + AC;rs5186;TOXICITY;INCREASED_RISK;DISEASE:DIABETES_MELLITUS
THIAZIDES;ACE;GG;rs4341;TOXICITY;INCREASED_RISK;DISEASE:DIABETES_MELLITUS
PLAIN;ACE;GG;rs4341;TOXICITY;INCREASED_RISK;DISEASE:DIABETES_MELLITUS
ATORVASTATIN;SLCO1B1;TT;rs4149056;LADME_PK;PK;PK:A_NEARLY_TRIPLED_INCREASED_PERCENTAGE_OF_ATORVASTATIN_AUC(0_-_48)_VALUES_AFTER_A_SINGLE_ORAL_DOSE_OF_RIFAMPICIN
RIFAMPIN;SLCO1B1;TT;rs4149056;LADME_PK;PK;PK:A_NEARLY_TRIPLED_INCREASED_PERCENTAGE_OF_ATORVASTATIN_AUC(0_-_48)_VALUES_AFTER_A_SINGLE_ORAL_DOSE_OF_RIFAMPICIN
CAPECITABINE;MIR27A;C;rs895819;TOXICITY;RISK;SIDE_EFFECT:DRUG_TOXICITY
FLUOROURACIL;MIR27A;C;rs895819;TOXICITY;RISK;SIDE_EFFECT:DRUG_TOXICITY
ATORVASTATIN;FDPS;TT;rs2297480;TOXICITY;INCREASED;SIDE_EFFECT:BONE_DENSITY
ETHANOL;OPRM1;G;rs1799971;nan;INCREASED;OTHER:SUBJECTIVE_FEELINGS_OF_INTOXICATION | STIMULATION | SEDATION | AND_HAPPINESS
NO_DRUG_RELATED;ABCC2;C;rs3740066;LADME_PK;nan;OTHER:ALLELIC_IMBALENCE
CISPLATIN;GSTM4;CC;rs560018;EFFICACY;INCREASED_EFFICACY;EFFICACY:IC-50
CISPLATIN;GSTM4;CC;rs560018;TOXICITY;INCREASED_EFFICACY;EFFICACY:IC-50
ATORVASTATIN;FDPS;AA;rs11264359;TOXICITY;INCREASED;SIDE_EFFECT:BONE_DENSITY
IRINOTECAN;C8orf34;C;rs1517114;TOXICITY;INCREASED_SEVERITY;DISEASE:DIARRHEA
DICLOXACILLIN;ABCB1;GG;rs1045642;OTHER;INCREASED_PK;PK:CLEARANCE_OF_DICLOXACILLIN
DICLOXACILLIN;ABCB1;GG;rs1045642;LADME_PK;INCREASED_PK;PK:CLEARANCE_OF_DICLOXACILLIN
PROBENECID;ABCB1;GG;rs1045642;OTHER;INCREASED_PK;PK:CLEARANCE_OF_DICLOXACILLIN
PROBENECID;ABCB1;GG;rs1045642;LADME_PK;INCREASED_PK;PK:CLEARANCE_OF_DICLOXACILLIN
ANTIPSYCHOTICS;HTR2C;C;rs1414334;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OBESITY
CLOZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OBESITY
OLANZAPINE;HTR2C;C;rs1414334;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OBESITY
RISPERIDONE;HTR2C;C;rs1414334;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OBESITY
ETHANOL;OPRM1;G;rs1799971;OTHER;RISK;DISEASE:ALCOHOL_ABUSE
CYCLOSPORINE;ABCB1;CC;rs2032582;OTHER;INCREASED_PK;PK:CLEARANCE_OF_DICLOXACILLIN
CYCLOSPORINE;ABCB1;CC;rs2032582;LADME_PK;INCREASED_PK;PK:CLEARANCE_OF_DICLOXACILLIN
DICLOXACILLIN;ABCB1;CC;rs2032582;OTHER;INCREASED_PK;PK:CLEARANCE_OF_DICLOXACILLIN
DICLOXACILLIN;ABCB1;CC;rs2032582;LADME_PK;INCREASED_PK;PK:CLEARANCE_OF_DICLOXACILLIN
ETHAMBUTOL;CYP2E1;CT + TT;rs2031920;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID;CYP2E1;CT + TT;rs2031920;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PYRAZINAMIDE;CYP2E1;CT + TT;rs2031920;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
RIFAMPIN;CYP2E1;CT + TT;rs2031920;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ATORVASTATIN;SLCO1B1;CC;rs4149056;nan;INCREASED;OTHER:CHOLESTEROL_SYNTHESIS_RATE
FLUVASTATIN;SLCO1B1;CC;rs4149056;nan;INCREASED;OTHER:CHOLESTEROL_SYNTHESIS_RATE
PRAVASTATIN;SLCO1B1;CC;rs4149056;nan;INCREASED;OTHER:CHOLESTEROL_SYNTHESIS_RATE
ROSUVASTATIN;SLCO1B1;CC;rs4149056;nan;INCREASED;OTHER:CHOLESTEROL_SYNTHESIS_RATE
SIMVASTATIN;SLCO1B1;CC;rs4149056;nan;INCREASED;OTHER:CHOLESTEROL_SYNTHESIS_RATE
PLATINUM COMPOUNDS;MDM2;CC;rs1690924;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
METHOTREXATE;SLC19A1;TT;rs1051266;LADME_PK;INCREASED_PK;PK:PLASMA_DRUG_LEVELS
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_INHIBITION_AFTER_A_CLOPIDOGREL_600-MG_LOADING_DOSE
SEVOFLURANE;GRIN2B;AA + AG;rs1806201;OTHER;INCREASED;OTHER:MEAN_ARTERIAL_PRESSURE
CLOPIDOGREL;CYP2C19;G;rs28399504;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_INHIBITION_AFTER_A_CLOPIDOGREL_600-MG_LOADING_DOSE
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;ADRB2;GG;rs1042714;EFFICACY;INCREASED;OTHER:STATUS_ASTHMATICUS
METHOTREXATE;CCND1;AA;rs9344;TOXICITY;DECREASED_SEVERITY;DISEASE:DRUG_TOXICITY
RISPERIDONE;ABCB1;A;rs1045642;TOXICITY;INCREASED;SIDE_EFFECT:WEIGHT_GAIN
METHOTREXATE;MTHFR;AA + AG;rs1801133;TOXICITY;DECREASED_SEVERITY;DISEASE:LEUKOPENIA
PACLITAXEL;SOD2;AA;rs4880;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
MERCAPTOPURINE;SLC19A1;CT + TT;rs1051266;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
METHOTREXATE;SLC19A1;CT + TT;rs1051266;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
METHYLPHENIDATE;ABCB1;AA;rs2032582;TOXICITY;INCREASED;SIDE_EFFECT:ADVERSE_EVENTS
DOCETAXEL;ERCC2;TT;rs13181;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CYCLOSPORINE;CRTC2;AA;rs8450;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERLIPIDEMIAS
TACROLIMUS;CRTC2;AA;rs8450;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERLIPIDEMIAS
DOCETAXEL;ERCC1;AA;rs11615;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
CLOPIDOGREL;CYP2C19;T;rs12248560;EFFICACY;DECREASED_EFFICACY;EFFICACY:RATES_OF_TARGET_LESION_REVASCULARIZATION_AND_MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS
METFORMIN;SP1;C;rs2683511;LADME_PK;DECREASED_PK;PK:METFORMIN_SECRETORY_CLEARANCE
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
NICOTINE;CHRNA3;A;rs16969968;TOXICITY;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
NICOTINE;CHRNA5;A;rs16969968;TOXICITY;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
METFORMIN;nan;G;rs10747673;EFFICACY;DECREASED_EFFICACY;EFFICACY:POST-HBA1C_LEVELS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TO_BE_CLASSIFIED_AS_CLOPIDOGREL_POOR_RESPONDERS
METFORMIN;nan;G;rs10747673;LADME_PK;DECREASED_PK;PK:METFORMIN_SECRETORY_CLEARANCE
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
CLOPIDOGREL;ATP10A;AA + AG;rs12913988;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
PLATINUM COMPOUNDS;EIF3A;A;rs4752220;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA | LEUKOPENIA | THROMBOCYTOPENIA | TOXIC_LIVER_DISEASE
CHOP;NCF4;AG + GG;rs1883112;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXICITY
RITUXIMAB;NCF4;AG + GG;rs1883112;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXICITY
CLOPIDOGREL;CYP2C9;AC + CC;rs1057910;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CLOPIDOGREL_POOR_RESPONSE
PLATINUM COMPOUNDS;EIF3A;A;rs1409314;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA | LEUKOPENIA | THROMBOCYTOPENIA | TOXIC_LIVER_DISEASE
PLATINUM COMPOUNDS;EIF3A;C;rs4752219;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA | LEUKOPENIA | THROMBOCYTOPENIA | TOXIC_LIVER_DISEASE
CLOPIDOGREL;CYP2C9;AC + CC;rs1057910;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
MERCAPTOPURINE;GSTP1;GG;rs1695;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
METHOTREXATE;GSTP1;GG;rs1695;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
CLOZAPINE;HTR2C;T;rs3813929;TOXICITY;DECREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
ACENOCOUMAROL;ABCB1;GG + GT;rs1045642;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
RISPERIDONE;ABCB1;A;rs2032582;TOXICITY;INCREASED;SIDE_EFFECT:WEIGHT_GAIN
METHOTREXATE;SLC19A1;TT;rs1051266;LADME_PK;INCREASED_PK;PK:PLASMA_DRUG_LEVELS
SEVOFLURANE;KCNK3;CT + TT;rs1275988;OTHER;INCREASED;OTHER:MEAN_ARTERIAL_PRESSURE
LEUCOVORIN;SLC19A1;CC;rs1051266;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
MERCAPTOPURINE;SLC19A1;CC;rs1051266;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
METHOTREXATE;SLC19A1;CC;rs1051266;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
LEUCOVORIN;SLC19A1;TT;rs1051266;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:MYELOSUPPRESSION
MERCAPTOPURINE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:MYELOSUPPRESSION
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:MYELOSUPPRESSION
DOCETAXEL;CYP3A4;CC + CT;rs2740574;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INFUSION_RELATED_REACTION
METFORMIN;SP1;G;rs784888;EFFICACY;DECREASED_SEVERITY;DISEASE:HYPERGLYCEMIA
PLATINUM COMPOUNDS;MTR;AA + AG;rs1805087;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SEVOFLURANE;GABRA2;CC + CT;rs279858;OTHER;DECREASED;OTHER:MEAN_ARTERIAL_PRESSURE
LEUCOVORIN;SLC19A1;TT;rs1051266;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:STAYING_IN_REMISSION
MERCAPTOPURINE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:STAYING_IN_REMISSION
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:STAYING_IN_REMISSION
ACENOCOUMAROL;VKORC1;CT + TT;rs9923231;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
PLATINUM COMPOUNDS;EIF3A;T;rs7091672;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA | LEUKOPENIA | THROMBOCYTOPENIA | TOXIC_LIVER_DISEASE
PACLITAXEL;CYP2C8;CG + GG;rs1113129;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
METFORMIN;PPARA;T;rs149711321;EFFICACY;DECREASED_EFFICACY;EFFICACY:POST-HBA1C_LEVELS
NO_DRUG_RELATED;COL1A1;AA;rs1800012;nan;INCREASED_RISK;DISEASE:FRACTURES | BONE
ACENOCOUMAROL;CYP4F2;CT + TT;rs2108622;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
PLATINUM COMPOUNDS;SLC19A1;TT;rs1051266;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PACLITAXEL;CYP2C8;CT + TT;rs1934951;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
LENALIDOMIDE;VEGFA;AA;rs699947;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
METFORMIN;SP1;C;rs2683511;EFFICACY;DECREASED_EFFICACY;EFFICACY:POST-HBA1C_LEVELS
SEVOFLURANE;FASTKD3;AG + GG;rs1801394;OTHER;DECREASED;OTHER:MEAN_ARTERIAL_PRESSURE
SEVOFLURANE;MTRR;AG + GG;rs1801394;OTHER;DECREASED;OTHER:MEAN_ARTERIAL_PRESSURE
CLOPIDOGREL;CYP2C19;G;rs28399504;TOXICITY;INCREASED_RISK;DISEASE:DEATH
BUPROPION;DRD1;A;rs2168631;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_ABSTINENCE_WITHIN_SLOW_NICOTINE_METABOLIZERS
NICOTINE;DRD1;A;rs2168631;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_ABSTINENCE_WITHIN_SLOW_NICOTINE_METABOLIZERS
SIMVASTATIN;HMGCR;TT;rs17238540;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_OF_LDL_CHOLESTEROL
NO_DRUG_RELATED;NR3C1;C;rs9324918;OTHER;INCREASED;DISEASE:SICKLE_CELL_PAIN_CRISIS
CLOPIDOGREL;CYP2C19;A;rs4986893;TOXICITY;INCREASED_RISK;DISEASE:DEATH
SEVOFLURANE;FASTKD3;AA + AG;rs2307116;OTHER;DECREASED;OTHER:MEAN_ARTERIAL_PRESSURE
SEVOFLURANE;MTRR;AA + AG;rs2307116;OTHER;DECREASED;OTHER:MEAN_ARTERIAL_PRESSURE
PACLITAXEL;ERCC1;AA + AC;rs3212986;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
MORPHINE;ABCC3;C;rs1978153;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPOVENTILATION
NO_DRUG_RELATED;P2RY12;G;rs2046934;nan;INCREASED_RISK;SIDE_EFFECT:CORONARY_ARTERY_DISEASE
CLOPIDOGREL;CYP2C19;T;rs12248560;TOXICITY;INCREASED_RISK;SIDE_EFFECT:BLEEDING
BUPROPION;DRD1;T;rs11749035;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_ABSTINENCE_WITHIN_SLOW_NICOTINE_METABOLIZERS
NICOTINE;DRD1;T;rs11749035;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_ABSTINENCE_WITHIN_SLOW_NICOTINE_METABOLIZERS
CLOPIDOGREL;CYP2C19;T;rs12248560;EFFICACY;DECREASED_EFFICACY;EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION
PAZOPANIB;CXCL8;T;rs1126647;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
SUNITINIB;CXCL8;T;rs1126647;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
NO_DRUG_RELATED;NR3C1;G;rs2963155;OTHER;INCREASED;DISEASE:SICKLE_CELL_PAIN_CRISIS
MORPHINE;ABCC3;G;rs733392;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPOVENTILATION
METHADONE;UGT2B7;CC;rs6600893;EFFICACY;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
METHADONE;UGT2B7;CC;rs6600893;LADME_PK;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
FENTANYL;MYD88;G;rs6853;TOXICITY;DECREASED_RISK;SIDE_EFFECT:COGNITIVE_DISORDER
METHOTREXATE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
PREDNISONE;SLC19A1;TT;rs1051266;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
BUPROPION;DRD1;G;rs11746641;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_ABSTINENCE_WITHIN_SLOW_NICOTINE_METABOLIZERS
NICOTINE;DRD1;G;rs11746641;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_ABSTINENCE_WITHIN_SLOW_NICOTINE_METABOLIZERS
NO_DRUG_RELATED;NR3C1;T;rs33389;OTHER;INCREASED;DISEASE:SICKLE_CELL_PAIN_CRISIS
SPIRONOLACTONE;ACE;AA + AG;rs4343;EFFICACY;EFFICACY;EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR_EJECTION_FRACTION | END-SYSTOLIC_AND_END-DIASTOLIC_VOLUME
SIMVASTATIN;HMGCR;AA;rs17244841;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_OF_LDL_CHOLESTEROL
DOCETAXEL;ERCC1;CC;rs3212986;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
SEVOFLURANE;CYP2E1;CC + CG;rs3813867;OTHER;DECREASED;OTHER:MEAN_ARTERIAL_PRESSURE
CYCLOPHOSPHAMIDE;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
DOXORUBICIN;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
PREDNISONE;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
RITUXIMAB;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
VINCRISTINE;GSTA1;AA + AG;rs3957357;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
SEVOFLURANE;CYP2E1;CT + TT;rs2031920;OTHER;DECREASED;OTHER:MEAN_ARTERIAL_PRESSURE
SEVOFLURANE;DUX1;CT + TT;rs2031920;OTHER;DECREASED;OTHER:MEAN_ARTERIAL_PRESSURE
ANTIHYPERTENSIVES;NOS3;CC;rs2070744;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RESISTANT_HYPERTENSION
DIURETICS;NOS3;CC;rs2070744;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RESISTANT_HYPERTENSION
CYCLOPHOSPHAMIDE;CYBA;AA;rs4673;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
DOXORUBICIN;CYBA;AA;rs4673;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
PREDNISONE;CYBA;AA;rs4673;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
RITUXIMAB;CYBA;AA;rs4673;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
VINCRISTINE;CYBA;AA;rs4673;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
IBUPROFEN;PTGS2;CG + GG;rs20417;EFFICACY;INCREASED_EFFICACY;EFFICACY:PAIN_RELIEF
DIFLOMOTECAN;ABCG2;T;rs2231142;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATIONS_OF_DIFLOMOTECAN
CYCLOSPORINE;ABCB1;AA;rs2032582;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RESISTANCE
CYCLOSPORINE;CRTC2;AA;rs8450;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIABETES_MELLITUS
TACROLIMUS;CRTC2;AA;rs8450;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIABETES_MELLITUS
ROFECOXIB;PTGS2;CC;rs20417;EFFICACY;INCREASED_EFFICACY;EFFICACY:PAIN_RELIEF
FENTANYL;nan;G;rs2884129;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
MORPHINE;nan;G;rs2884129;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
OPIOIDS;nan;G;rs2884129;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
OXYCODONE;nan;G;rs2884129;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
HMG COA REDUCTASE INHIBITORS;nan;C;rs13210472;TOXICITY;INCREASED_RISK;OTHER:NEOPLASMS
FENTANYL;nan;T;rs7104613;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
MORPHINE;nan;T;rs7104613;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
OPIOIDS;nan;T;rs7104613;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
OXYCODONE;nan;T;rs7104613;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
PAZOPANIB;CXCL8;A;rs4073;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
SUNITINIB;CXCL8;A;rs4073;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
BLEOMYCIN;GSTP1;GG;rs1695;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
CISPLATIN;GSTP1;GG;rs1695;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
ETOPOSIDE;GSTP1;GG;rs1695;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
FENTANYL;nan;T;rs10413396;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
MORPHINE;nan;T;rs10413396;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
OPIOIDS;nan;T;rs10413396;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
OXYCODONE;nan;T;rs10413396;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;DECREASED_EFFICACY;EFFICACY:PHARMACODYNAMIC_RESPONSE
METHOTREXATE;CCND1;AA;rs9344;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
BLEOMYCIN;ERCC1;AC + CC;rs3212986;TOXICITY;DECREASED_RISK;SIDE_EFFECT:VOMITING
CISPLATIN;ERCC1;AC + CC;rs3212986;TOXICITY;DECREASED_RISK;SIDE_EFFECT:VOMITING
ETOPOSIDE;ERCC1;AC + CC;rs3212986;TOXICITY;DECREASED_RISK;SIDE_EFFECT:VOMITING
ASPIRIN;PTGS1;AA + AG;rs10306114;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
FLUOROURACIL;DPYD;A;rs67376798;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCB1;CC;rs2032582;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RESISTANCE
CYCLOSPORINE;CRTC2;AA + AG;rs8450;TOXICITY;INCREASED;SIDE_EFFECT:WEIGHT_GAIN
TACROLIMUS;CRTC2;AA + AG;rs8450;TOXICITY;INCREASED;SIDE_EFFECT:WEIGHT_GAIN
CLOPIDOGREL;CYP2C19;A;rs4244285;LADME_PK;DECREASED_PK;PK:PLASMA_EXPOSURE_TO_THE_ACTIVE_METABOLITE_OF_CLOPIDOGREL
ACENOCOUMAROL;VKORC1;TT;rs9923231;DOSAGE;DECREASED_EFFICACY;EFFICACY:ACENOCOUMAROL_DOSE
FLUOROURACIL;DPYD;T;rs1801160;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
MORPHINE;ABCC3;G;rs886493;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPOVENTILATION
BLEOMYCIN;ABCB1;AA;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VOMITING
CISPLATIN;ABCB1;AA;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VOMITING
ETOPOSIDE;ABCB1;AA;rs1045642;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VOMITING
MORPHINE;ABCC3;T;rs7216383;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPOVENTILATION
METHOTREXATE;ABCB1;A;rs1045642;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
ETHANOL;nan;A;rs10516440;TOXICITY;DECREASED_RISK;OTHER:ALCOHOL_ABUSE
TRAMADOL;ABCB1;A;rs1045642;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:A_DECREASE_IN_VISUAL_ANALOG_SCALE_>30MM_WITHIN_6_HOURS
CITALOPRAM;CYP2C19;TT;rs12248560;LADME_PK;DECREASED_PK;PK:METABOLIC_RATIO_CIT/DCIT_VALUES
TRAMADOL;ABCB1;A;rs2032582;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:A_DECREASE_IN_VISUAL_ANALOG_SCALE_>30MM_WITHIN_6_HOURS
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL3;CC;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;IFNL4;CC;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B;ITPA;A;rs1127354;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ANEMIA
RIBAVIRIN;ITPA;A;rs1127354;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ANEMIA
CLOPIDOGREL;CYP2C19;A;rs4244285;EFFICACY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
CLOPIDOGREL;CYP2C19;A;rs4244285;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
METHOTREXATE;ABCC2;A;rs17222723;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
RISPERIDONE;UGT1A1;CT;rs887829;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERPROLACTINEMIA
FLUOXETINE;CRHR1;CC;rs242941;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE
RISPERIDONE;UGT1A1;AG;rs10929302;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERPROLACTINEMIA
SARILUMAB;IL6R;CC;rs11265618;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CISPLATIN;ERCC2;CT + TT;rs1799793;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CISPLATIN;GSTP1;CT + TT;rs1138272;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL | OVERALL_SURVIVAL
SARILUMAB;IL6R;TT;rs4845625;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
VITAMIN K ANTAGONISTS;CYP4F2;TT;rs2108622;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:STROKE
RISPERIDONE;HTR2C;GG;rs6318;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
WARFARIN;CRP;CT + TT;rs1205;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
HYDROCHLOROTHIAZIDE;TCF7L2;A;rs4132670;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIABETES
HYDROCHLOROTHIAZIDE;TCF7L2;T;rs7917983;TOXICITY;INCREASED_RISK;DISEASE:DIABETES_MELLITUS
ATORVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:REACHING_TARGET_CHOLESTEROL_LEVELS
CERIVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:REACHING_TARGET_CHOLESTEROL_LEVELS
FLUVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:REACHING_TARGET_CHOLESTEROL_LEVELS
PRAVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:REACHING_TARGET_CHOLESTEROL_LEVELS
ROSUVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:REACHING_TARGET_CHOLESTEROL_LEVELS
SIMVASTATIN;HMGCR;GT;rs17238540;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:REACHING_TARGET_CHOLESTEROL_LEVELS
HYDROCHLOROTHIAZIDE;TCF7L2;T;rs4506565;TOXICITY;INCREASED_RISK;DISEASE:DIABETES_MELLITUS
CLOPIDOGREL;CYP2C19;AA + AG;rs4244285;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
CITALOPRAM;CYP2C19;AA;rs4244285;LADME_PK;INCREASED_PK;PK:METABOLIC_RATIO_CIT/DCIT_VALUES_AND_MEAN_CITALOPRAM_DOSE
LENALIDOMIDE;ABCB1;CC;rs2032582;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FLUOROURACIL;XRCC1;CC;rs25487;OTHER;nan;OTHER:LATER_ONSET_OF_SENSORY_NEUROPATHY
LEUCOVORIN;XRCC1;CC;rs25487;OTHER;nan;OTHER:LATER_ONSET_OF_SENSORY_NEUROPATHY
OXALIPLATIN;XRCC1;CC;rs25487;OTHER;nan;OTHER:LATER_ONSET_OF_SENSORY_NEUROPATHY
DOCETAXEL;CHST3;A;rs4148950;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
THALIDOMIDE;CHST3;A;rs4148950;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
IRINOTECAN;UGT1A9;T/del + del/del;rs3832043;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
BUPRENORPHINE;COMT;AA;rs4680;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
FENTANYL;COMT;AA;rs4680;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
TRAMADOL;COMT;AA;rs4680;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
SARILUMAB;IL6R;CC;rs4537545;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DYSLIPIDAEMIA
CALCIUM;VDR;TT;rs1544410;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEAN_SPINAL_BONE_MINERAL_DENSITY_CHANGES
ETIDRONIC ACID;VDR;TT;rs1544410;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEAN_SPINAL_BONE_MINERAL_DENSITY_CHANGES
SARILUMAB;IL6R;AA;rs2228145;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DYSLIPIDAEMIA
BUPRENORPHINE;OPRD1;CT;rs2234918;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER
FENTANYL;OPRD1;CT;rs2234918;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER
TRAMADOL;OPRD1;CT;rs2234918;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER
VALPROIC ACID;SOD2;AA + AG;rs4880;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
SARILUMAB;IL6R;TT;rs4329505;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE
BUPRENORPHINE;ARRB2;TT;rs1045280;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
FENTANYL;ARRB2;TT;rs1045280;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
TRAMADOL;ARRB2;TT;rs1045280;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
PEGINTERFERON ALFA-2A;nan;GG;rs4273729;EFFICACY;INCREASED_EFFICACY;EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE
RIBAVIRIN;nan;GG;rs4273729;EFFICACY;INCREASED_EFFICACY;EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE
BISPHOSPHONATES;CYP2C8;TT;rs1934951;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS_OF_THE_JAW
BUPRENORPHINE;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA
FENTANYL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA
TRAMADOL;OPRM1;AG + GG;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA
BUPRENORPHINE;COMT;AG;rs4680;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA
FENTANYL;COMT;AG;rs4680;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA
TRAMADOL;COMT;AG;rs4680;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
BUPRENORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
FENTANYL;OPRM1;AA;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
TRAMADOL;OPRM1;AA;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
BUPRENORPHINE;COMT;AA + GG;rs4680;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS | PHYSIOLOGICAL_SEXUAL_DISORDER
FENTANYL;COMT;AA + GG;rs4680;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS | PHYSIOLOGICAL_SEXUAL_DISORDER
TRAMADOL;COMT;AA + GG;rs4680;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS | PHYSIOLOGICAL_SEXUAL_DISORDER
NO_DRUG_RELATED;IFNL3;CC;rs12979860;OTHER;INCREASED_LIKELIHOOD;DISEASE:JAUNDICE
NO_DRUG_RELATED;IFNL4;CC;rs12979860;OTHER;INCREASED_LIKELIHOOD;DISEASE:JAUNDICE
BUPRENORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA
FENTANYL;OPRM1;AA;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA
TRAMADOL;OPRM1;AA;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA
FLUOROURACIL;ABCC2;CC;rs717620;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
LEUCOVORIN;ABCC2;CC;rs717620;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
OXALIPLATIN;ABCC2;CC;rs717620;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
BUPRENORPHINE;OPRM1;AA + AG;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
FENTANYL;OPRM1;AA + AG;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
TRAMADOL;OPRM1;AA + AG;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
LENALIDOMIDE;CRBN;CC;rs1705814;DOSAGE;INCREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION | DISCONTINUATION
LENALIDOMIDE;CRBN;CC;rs1705814;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION | DISCONTINUATION
BUPRENORPHINE;COMT;AG;rs4680;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA
FENTANYL;COMT;AG;rs4680;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA
TRAMADOL;COMT;AG;rs4680;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA
FLUOROURACIL;ERCC1;AA;rs11615;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
LEUCOVORIN;ERCC1;AA;rs11615;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
OXALIPLATIN;ERCC1;AA;rs11615;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
FLUOROURACIL;XRCC1;CC;rs25487;TOXICITY;DECREASED_RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
LEUCOVORIN;XRCC1;CC;rs25487;TOXICITY;DECREASED_RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
OXALIPLATIN;XRCC1;CC;rs25487;TOXICITY;DECREASED_RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
RIFAMPIN;NR1I2;T;rs2472677;OTHER;DECREASED_PK;PK:CYP3A4_ACITVITY
RIFAMPIN;NR1I2;T;rs2472677;LADME_PK;DECREASED_PK;PK:CYP3A4_ACITVITY
CARBAMAZEPINE;SCN2A;A;rs2304016;EFFICACY;EFFICACY;EFFICACY:DRUG_RESISTANCE
LAMOTRIGINE;SCN2A;A;rs2304016;EFFICACY;EFFICACY;EFFICACY:DRUG_RESISTANCE
OXCARBAZEPINE;SCN2A;A;rs2304016;EFFICACY;EFFICACY;EFFICACY:DRUG_RESISTANCE
PHENYTOIN;SCN2A;A;rs2304016;EFFICACY;EFFICACY;EFFICACY:DRUG_RESISTANCE
TOPIRAMATE;SCN2A;A;rs2304016;EFFICACY;EFFICACY;EFFICACY:DRUG_RESISTANCE
CAPECITABINE;PTGS2;AA;rs5275;EFFICACY;INCREASED;OTHER:PROGRESSION-FREE_SURVIVAL_AND_OVERALL_SURVIVAL
OXALIPLATIN;PTGS2;AA;rs5275;EFFICACY;INCREASED;OTHER:PROGRESSION-FREE_SURVIVAL_AND_OVERALL_SURVIVAL
NO_DRUG_RELATED;CETP;A;rs708272;nan;nan;OTHER:VARIANCE_IN_LDL | HDL_AND_LDL/HDL
HMG COA REDUCTASE INHIBITORS;CETP;A;rs708272;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:CARDIOVASCULAR_EVENTS
DIURETICS;ADD1;GT + TT;rs4961;EFFICACY;DECREASED_LIKELIHOOD;DISEASE:MYOCARDIAL_INFARCTION
WARFARIN;VKORC1;CT + TT;rs9923231;DOSAGE;EFFICACY;EFFICACY:LOWER_WARFARIN_DOSE_REQUIREMENT
ETHANOL;DRD2;A;rs1076560;OTHER;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
CLOPIDOGREL;P2RY12;AG + GG;rs2046934;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_ACTIVATION_RESPONSE_TO_ADP
METHOTREXATE;ABCC2;CT + TT;rs717620;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
HYDROCHLOROTHIAZIDE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_MEAN_BLOOD_PRESSURE
FLUOROURACIL;MTHFR;AA;rs1801133;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
LEUCOVORIN;MTHFR;AA;rs1801133;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
OXALIPLATIN;MTHFR;AA;rs1801133;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
BROMPERIDOL;DRD2;GG;rs1799732;EFFICACY;INCREASED_EFFICACY;EFFICACY:IMPROVEMENT_IN_ANXIETY-DEPRESSION_SYMPTOMS
NEMONAPRIDE;DRD2;GG;rs1799732;EFFICACY;INCREASED_EFFICACY;EFFICACY:IMPROVEMENT_IN_ANXIETY-DEPRESSION_SYMPTOMS
THIAZIDES;SLC12A3;CC;rs13306673;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_MEAN_BLOOD_PRESSURE
PLAIN;SLC12A3;CC;rs13306673;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_MEAN_BLOOD_PRESSURE
VALPROIC ACID;ABCB1;GG;rs3789243;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
PEGINTERFERON ALFA-2A;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
PEGINTERFERON ALFA-2A;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
RIBAVIRIN;IFNL3;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
RIBAVIRIN;IFNL4;CC;rs12979860;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
AZATHIOPRINE;ITPA;AC;rs1127354;TOXICITY;INCREASED_RISK;DISEASE:LEUKOPENIA
VALPROIC ACID;ABCB1;GG;rs3789243;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA | ALOPECIA | HYPERSENSITIVITY,
ATORVASTATIN;CYP3A5;CC;rs776746;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULAR_DISEASES
ROSUVASTATIN;CYP3A5;CC;rs776746;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULAR_DISEASES
METHOTREXATE;SLCO1B1;CC + CT;rs4149056;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
THIAZIDES;ADRB3;AA;rs4994;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_MEAN_BLOOD_PRESSURE
PLAIN;ADRB3;AA;rs4994;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_MEAN_BLOOD_PRESSURE
TRASTUZUMAB;FCGR2A;AA;rs1801274;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
IRINOTECAN;UGT1A9;T/del + del/del;rs3832043;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
ASPARAGINASE;CPA2;T;rs199695765;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PANCREATITIS
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL3;AA;rs12980275;EFFICACY;INCREASED_EFFICACY;EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE
RIBAVIRIN;IFNL3;AA;rs12980275;EFFICACY;INCREASED_EFFICACY;EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE
DAPSONE;HLA-DRB1;T;rs701829;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
TACROLIMUS;POR;CT + TT;rs1057868;TOXICITY;INCREASED_RISK;DISEASE:DIABETES_MELLITUS
WARFARIN;THBD;CC + CT;rs1042580;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEMORRHAGE
PEGINTERFERON ALFA-2A;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL3;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;IFNL4;TT;rs8099917;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
METHYLPHENIDATE;CES1;AC + CC;rs3815583;TOXICITY;INCREASED_RISK;SIDE_EFFECT:APPETITE_SUPPRESSION
ACE INHIBITORS;BDKRB2;C;rs8012552;TOXICITY;INCREASED_RISK;DISEASE:COUGH
PLAIN;BDKRB2;C;rs8012552;TOXICITY;INCREASED_RISK;DISEASE:COUGH
CORTICOSTEROIDS;BCL2L11;CC;rs724710;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
ACE INHIBITORS;MME;A;rs2016848;TOXICITY;INCREASED_RISK;DISEASE:COUGH
PLAIN;MME;A;rs2016848;TOXICITY;INCREASED_RISK;DISEASE:COUGH
IRINOTECAN;PIN1;CC + CG;rs2233678;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PEGINTERFERON ALFA-2A;nan;GG;rs4273729;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RIBAVIRIN;nan;GG;rs4273729;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
HYDROCHLOROTHIAZIDE;ADD1;GT;rs4961;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_MEAN_ARTERIAL_PRESSURE
ACENOCOUMAROL;VKORC1;AA + AG;rs9934438;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
ASPIRIN;ACE;AT + TT;rs4291;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN_INTOLERANCE
MYCOPHENOLATE MOFETIL;CYP2C8;A;rs11572103;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TIME_TO_ANEMIA_IN_PATIENTS_UNDERGOING_LIVING_OR_DECEASED_DONOR_KIDNEY_TRANSPLANT
HYDROCHLOROTHIAZIDE;ADD1;GT + TT;rs4961;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_MEAN_BLOOD_PRESSURE
MYCOPHENOLATE MOFETIL;CYP2C8;T;rs11572076;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TIME_TO_ANEMIA_IN_PATIENTS_UNDERGOING_LIVING_OR_DECEASED_DONOR_KIDNEY_TRANSPLANT
ACE INHIBITORS;PTGER3;C;rs11209716;TOXICITY;DECREASED_RISK;DISEASE:COUGH
PLAIN;PTGER3;C;rs11209716;TOXICITY;DECREASED_RISK;DISEASE:COUGH
MYCOPHENOLATE MOFETIL;HUS1;T;rs1056663;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TIME_TO_ANEMIA_IN_PATIENTS_UNDERGOING_LIVING_OR_DECEASED_DONOR_KIDNEY_TRANSPLANT
DAPSONE;HLA-DRB1;A;rs17211071;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
TACROLIMUS;PPARA;AA + AG;rs4253728;TOXICITY;INCREASED_RISK;DISEASE:DIABETES_MELLITUS
MYCOPHENOLATE MOFETIL;HUS1;A;rs2037483;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TIME_TO_ANEMIA_IN_PATIENTS_UNDERGOING_LIVING_OR_DECEASED_DONOR_KIDNEY_TRANSPLANT
NO_DRUG_RELATED;ADD1;GT + TT;rs4961;OTHER;INCREASED_LIKELIHOOD;DISEASE:HYPERTENSION
FLUOROURACIL;ABCB1;C;rs2032582;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA
FLUOROURACIL;SLCO1B1;A;rs2306283;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
NO_DRUG_RELATED;ARG1;TT;rs2781666;OTHER;INCREASED_SEVERITY;OTHER:ASTHMA
TACROLIMUS;CYP3A4;TT;rs2740574;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:TRANSPLANT_REJECTION
EPIRUBICIN;ABCC1;CT;rs246221;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEFT_VENTRICULAR_DYSFUNCTION
LEVODOPA;COMT;AA;rs4680;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DYSKINESIA | DRUG-INDUCED
METHOTREXATE;SLC19A1;TT;rs1051266;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
DAUNORUBICIN;ABCC2;A;rs8187710;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DOXORUBICIN;ABCC2;A;rs8187710;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
FOLFOX;DPYD;c.1129-5923C>G, c.1236G>A (HapB3);DPYD c.1129-5923C>G, c.1236G>A (HapB3);EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
DAUNORUBICIN;HFE;G;rs1799945;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DOXORUBICIN;HFE;G;rs1799945;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DAUNORUBICIN;GPR35;T;rs12468485;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DOXORUBICIN;GPR35;T;rs12468485;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DAUNORUBICIN;UGT1A6;T;rs17863783;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DOXORUBICIN;UGT1A6;T;rs17863783;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DAUNORUBICIN;GSTA2;G;rs2180314;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DOXORUBICIN;GSTA2;G;rs2180314;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DAUNORUBICIN;ETFB;A;rs79338777;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DOXORUBICIN;ETFB;A;rs79338777;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DAUNORUBICIN;HNMT;A;rs17583889;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DOXORUBICIN;HNMT;A;rs17583889;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DAUNORUBICIN;ABCC5;AA + AT;rs7627754;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DOXORUBICIN;ABCC5;AA + AT;rs7627754;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
CEFAZOLIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CEFDINIR;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CEFTRIAXONE;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CEFUROXIME;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CEPHALEXIN;HLA-A;*02:01;HLA-A*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TACROLIMUS;CYP2B6;GT;rs3745274;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:TRANSPLANT_REJECTION
CORTICOSTEROIDS;WNT7B;A;rs73175102;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS
CORTICOSTEROIDS;POGK;A;rs115587273;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS
CORTICOSTEROIDS;FAM240C;A;rs78233573;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS
CORTICOSTEROIDS;ZNF37A;A;rs376867011;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS
CODEINE;CYP2D6;INTERMEDIATE_METABOLIZER;CYP2D6;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:EMERGENCIES | PAIN
HYDROCODONE;CYP2D6;INTERMEDIATE_METABOLIZER;CYP2D6;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:EMERGENCIES | PAIN
TRAMADOL;CYP2D6;INTERMEDIATE_METABOLIZER;CYP2D6;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:EMERGENCIES | PAIN
GANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4;nan;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
VALGANCICLOVIR;NUDT15;*2 + *3 + *4;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4;nan;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
VALPROIC ACID;ACOT1;T;rs758109;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
TACROLIMUS;SLCO1B1;AA + AG;rs2306283;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY
AZATHIOPRINE;MOCOS;GT;rs73430958;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
VALPROIC ACID;GABPA;CC;rs59288687;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
VALPROIC ACID;NQO1;GG;rs10517;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
VALPROIC ACID;PPARA;G;rs881740;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
METHOTREXATE;SLCO1B3;AA;rs7311358;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA
METHOTREXATE;SLCO1B3;GG;rs4149117;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA
METHOTREXATE;SLCO1B1;AA + AG;rs2306283;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA
APIXABAN;APOE;C;rs7412;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:INTRACRANIAL_HEMORRHAGES
APIXABAN;APOE;C;rs429358;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:INTRACRANIAL_HEMORRHAGES
PD-1;IFNL3;GG;rs8099917;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS
PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1;IFNL3;GG;rs8099917;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS
DEATH LIGAND 1) INHIBITORS;IFNL3;GG;rs8099917;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS
PD-1;IFNL3;GG;rs12980275;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS
PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1;IFNL3;GG;rs12980275;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS
DEATH LIGAND 1) INHIBITORS;IFNL3;GG;rs12980275;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS
PD-1;IFNL3;TT;rs12979860;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS
PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1;IFNL3;TT;rs12979860;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS
DEATH LIGAND 1) INHIBITORS;IFNL3;TT;rs12979860;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS
TACROLIMUS;ABCB1;TT;rs9282564;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:DEATH
TACROLIMUS;ABCC2;GG;rs2273697;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
TACROLIMUS;SLCO1B1;TT;rs4149056;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:TRANSPLANT_REJECTION
TACROLIMUS;CYP2C19;AA;rs4244285;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY
AZATHIOPRINE;NUDT15;CT;rs116855232;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
AZATHIOPRINE;RRM1;AG + GG;rs1735053;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
AZATHIOPRINE;TPMT;GT + TT;rs9465102;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
CISPLATIN;TRPA1;TT;rs920829;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY
FOLFOX;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
XELOX;DPYD;AG + GG;rs1801265;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
FLUOXETINE;CYP2D6;ULTRARAPID_METABOLIZER;CYP2D6;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TREATMENT_MODIFICATION
FLUOXETINE;CYP2D6;ULTRARAPID_METABOLIZER;CYP2D6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TREATMENT_MODIFICATION
CYCLOSPORINE;SLC29A1;AA;rs693955;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL | RECURRENCE_FREE_SURVIVAL
AFATINIB;AKT1;CC;rs2494750;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ERLOTINIB;AKT1;CC;rs2494750;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
GEFITINIB;AKT1;CC;rs2494750;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SULFAMETHOXAZOLE;HLA-B;*44:03;HLA-B*44:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
TRIMETHOPRIM;HLA-B;*44:03;HLA-B*44:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
SULFAMETHOXAZOLE;HLA-B;*38:01;HLA-B*38:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
TRIMETHOPRIM;HLA-B;*38:01;HLA-B*38:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
SULFAMETHOXAZOLE;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
TRIMETHOPRIM;HLA-C;*04:01;HLA-C*04:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
FOLFOX;GSTP1;GG;rs1695;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES | MYELOSUPPRESSION
XELOX;GSTP1;GG;rs1695;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES | MYELOSUPPRESSION
FOLFOX;TYMS;TTA/TTA + TTA/TTAAAGTTA;rs11280056;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES | MYELOSUPPRESSION
XELOX;TYMS;TTA/TTA + TTA/TTAAAGTTA;rs11280056;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES | MYELOSUPPRESSION
FOLFOX;TYMS;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;rs45445694;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME | EXANTHEMA | DRUG_TOXICITY,
XELOX;TYMS;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;rs45445694;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME | EXANTHEMA | DRUG_TOXICITY,
FOLFOX;GSTP1;GG;rs1695;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
XELOX;GSTP1;GG;rs1695;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
AZATHIOPRINE;HLA-DQA1;*02:01;HLA-DQA1*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PANCREATITIS
AZATHIOPRINE;HLA-DRB1;*07:01;HLA-DRB1*07:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PANCREATITIS
HMG COA REDUCTASE INHIBITORS;ABCG2;T;rs2231142;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY | TOXIC_LIVER_DISEASE
AMITRIPTYLINE;CYP2D6;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
AZATHIOPRINE;TPMT;*3A + *3B + *3C;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
MERCAPTOPURINE;TPMT;*3A + *3B + *3C;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
RISPERIDONE;CYP2D6;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
CODEINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:URINARY_RETENTION | CONSTIPATION | NAUSEA | VOMITING
MORPHINE;OPRM1;AA;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:URINARY_RETENTION | CONSTIPATION | NAUSEA | VOMITING
OXYCODONE;OPRM1;AA;rs1799971;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:URINARY_RETENTION | CONSTIPATION | NAUSEA | VOMITING
